اندوکرینولوژی بالینی زنان و ناباروری اسپیروف

(جلد دوم)

ویرایش نهم

تألیف

هیو تیلور

لوبنا پَل

اِمره سِلی

ترجمه

دکتر مهرناز ولدان

جراح و متخصص زنان و زایمان

عضو هیئت علمی دانشگاه علوم پزشکی تهران

دکتر مینا فتحی کازرونی

دکتر مهشید نیکپور

دکتر سیامک ملکی

با مقدمه

دکتر فیروزه اکبری اسبق

استاد دانشگاه علوم پزشکی تهران

جراح و متخصص زنان و زایمان، فلوشیپ نازایی و IVF

کتاب ارجمند

فهرست جلد دوم

۱۷

دوران‌گذار یائسگی و هورمون‌درمانی یائسگی

یک مرور کلی

در طول تاریخ شرایط جسمی و روحی متعددی به یائسگی نسبت داده شده‌اند. گرچه نویسندگان حوزه پزشکی در گذشته دربارهٔ این موضوع، بسیار نوشته‌اند اما امروزه اطلاعات علمی و داده‌ها نشان داده‌اند که متأسفانه نوشته‌های آنها صحت نداشته است.

یک نمونه خوب از طرز تفکر نادرستی که طی سال‌ها در مورد این موضوع وجود داشته است را می‌توان در نوشتهٔ زیر (نوشته شده به سال ۱۸۸۷) دید (۱):

تخمدان‌ها پس از سال‌ها فعالیت، در سنین بالا از کار نمی‌افتند بلکه تحریک می‌شوند و این تحریک را به گانگلیون‌های عصبی شکم و سپس از آن راه به مغز منتقل می‌کنند. این فرایند باعث ایجاد اختلال در بافت‌های مغزی می‌شود که خود را به شکل عصبی بودن بیش از حد و یا پیدایش ناگهانی جنون نشان می‌دهد.

باور به این‌که اختلالات رفتاری مربوط به تظاهرات سیستم تولید مثل زنان هستند اعتقاد کهنی است که تا به امروز نیز ادامه دارد. این طرز نگاه به پدیده یائسگی را نمی‌توان کاملاً غیرمنطقی دانست؛ دلیلی وجود دارد که به موجب آن می‌توان سال‌های میانی عمر را با تجربیات ناخوشایند همراه دانست. وقایعی که ممکن است به ذهن بیایند وقایع اثرگذاری هستند: شروع بیماری‌ها یا معلولیت‌های عمده (و حتی مرگ) در همسر، اقوام و یا دوستان؛ بازنشسته شدن؛ ناامنی مالی؛ نیاز به مراقبت کردن از والدین یا اقوام بسیار پیر و جدایی از فرزندان. بنابراین جای تعجب نیست که یائسگی، که یکی دیگر از وقایع میانسالی است، در ایجاد این احساسات منفی دخیل باشد.

تأثیر قدرتمند باورهای اجتماعی و فرهنگی و نیز سنت‌ها، پژوهش علمی تمامی جوانب پدیدهٔ قاعدگی را دشوار کرده است. مشکلات ناشی از اتفاقاتی که در زندگی فرد می‌افتند اغلب به اشتباه به یائسگی نسبت داده می‌شوند. اما داده‌ها، به ویژه داده‌هایی که در پژوهش‌های طولی از دل جامعه به دست آمده‌اند این نکته را اثبات کرده‌اند که افزایش اغلب علائم و مشکلات در زنان میانسال بازتاب شرایط اجتماعی و فردی است و نه تغییرات هورمونی مربوط به یائسگی (۱۱ـ۲). تنوع تغییرات ناشی از یائسگی باعث می‌شود که پژوهش‌های مقطعی برای بررسی این پدیده مناسب نباشند. برای پی بردن به آنچه که طبیعی است و واریاسیون‌هایی که نسبت به حالت طبیعی وجود دارند، پژوهش‌های طولی بهتر هستند.

پژوهش سلامت زنان ماساچوست یک پژوهش آینده‌نگر طولی بزرگ و جامع بر روی زنان میانسال است که شواهد قدرتمندی مبنی بر این واقعیت فراهم کرده است که یائسگی یک پدیده منفی نیست و بخش اعظم زنان نباید به آن به عنوان یک تجربه منفی نگاه کنند (۱۲، ۳). زنان وارد شده به این پژوهش (و نیز زنان شرکت‌کننده در سایر پژوهش‌های طولی)، معتقد بودند قطع شدن قاعدگی‌ها تقریباً هیچ آسیبی برای سلامت جسمی و روانی آنها نداشته است، زیرا این زنان،



After E. Cope[1]

شکل ۱-۱۷

احساساتی خنثی و یا مثبت نسبت به یائسگی داشتند. استثنای این موضوع، گروه زنانی بودند که با جراحی یائسه شده بودند. البته در این دسته از زنان نیز کاملاً معقول است که فکر کنیم علل جراحی، برای بیمار از قطع قاعدگی مهمتر بوده‌اند.

تغییراتی که در کارکرد قاعدگی رخ می‌دهند تغییرات ترسناک و تهدیدآمیزی نیستند. در پس تغییرات کارکرد قاعدگی، دلایل فیزیولوژیک موجهی وجود دارند و درک فیزیولوژی این پدیده کمک می‌کند فرد نگرش درستی نسبت به این قضیه داشته باشد. نگرش فرد و انتظارات وی از یائسگی بسیار مهم‌اند. در زنانی که مراجعات بیشتری به مراکز بهداشتی دارند و در آنها که انتظار دوران سختی را دارند علائم بیشتر هستند و افسردگی شدیدتر است (۹، ۸، ۴). علائمی که زنان گزارش می‌کنند به عوامل متعددی در زندگی آنها بستگی دارند و تغییرات هورمونی دوران یائسگی را نمی‌توان مسؤول گرفتاری‌های شایع روانی – اجتماعی و سبک زندگی دانست که همه ما تجربه می‌کنیم. نکته مهم این است که باید بر طبیعی بودن این وقایع فیزیولوژیک تأکید شود. زنان یائسه دچار بیماری (به ویژه یک بیماری ناشی از کمبود هورمونی) نیستند و به هورمون درمانی پس از یائسگی باید به چشم درمان اختصاصی علائم فرد در کوتاه‌مدت و درمان پیشگیرانه در درازمدت نگاه کرد.

نکته دیگری که باید به آن توجه شود این است که پزشکان نگرشی سوگیرانه (منفی) نسبت به این پدیده دارند چرا که اغلب زنانی که سالم و سرحال هستند اصلاً به پزشکان مراجعه نمی‌کنند (۱۴، ۱۳). بنابراین ضرورت دارد که پزشکان نه تنها با واقعیت‌های مرتبط با یائسگی آشنا باشند بلکه دید و نگرش درستی نسبت به این دوره از زندگی داشته باشند. به مداخلات پزشکی که در این دوره صورت می‌گیرد باید به عنوان فرصتی برای ارائه و تقویت یک برنامه مراقبت پیشگیرانه سلامتی نگاه کرد. برنامه‌های مراقبت پیشگیرانه برای زنان، برنامه‌های آشنایی هستند و عبارت‌اند از تنظیم خانواده، ترک سیگار، کنترل وزن بدن و مصرف الکل، پیشگیری از بیماری‌های قلبی عروقی و استئوپروز، حفظ سلامت روانی (شامل سلامت جنسی)، غربالگری برای سرطان و درمان مشکلات مربوط به دستگاه ادراری.

زیاد شدن جمعیت افراد مسن

امروزه با پدیده نسبتاً جدیدی روبرو هستیم: می‌توانیم انتظار داشته باشیم که به سن پیری برسیم. ما در مرز تبدیل به یک جامعه مستطیلی هستیم که در آن تقریباً همه افراد به سن بالا می‌رسند.

در سال ۱۰۰۰ پیش از میلاد میزان امید به زندگی فقط ۱۸ سال بود. تا سال ۱۰۰ پیش از میلاد، در زمان جولیوس سزار، این میزان به ۲۵ سال رسید. در سال ۱۹۰۰، میزان امید به زندگی در ایالات متحده تنها ۴۹ سال بود (شکل ۱-۱۷). در سال ۲۰۰۵



شکل ۲-۱۷

میزان امید به زندگی به طور متوسط برای زنان ۸۰/۷ سال و برای مردان ۷۵/۴ سال بود (۱۵). امروزه هنگامی که به ۶۵ سالگی برسید، اگر مرد باشید می‌توانید امید داشته باشید که به ۸۳ سالگی و اگر زن باشید می‌توانید امید داشته باشید که به ۸۵ سالگی برسید (۱۶). پیش‌بینی می‌شود که در نهایت حدود دوسوم جمعیت به سن ۸۵ یا بیشتر برسند و بیش از ۹۰٪ افراد بیش از ۶۵ سال زندگی کنند –که نزدیک صددرصد نشان‌دهنده یک جامعهٔ مستطیلی خواهد بود **(شکل ۲-۱۷)**. هم‌اکنون سوئد و سوئیس نسبت به سایر کشورها به این ترکیب جمعیتی نزدیکترند.

یک تعریف عمومی خوب برای پیری سن ۶۵ سالگی به بالا است اگرچه درصد قابل توجهی از افراد مسن تا قبل از سن ۷۵ سالگی ضعف‌ها و مشکلات بارز پیری را نشان نمی‌دهند. امروزه، جمعیت مسن علت اصلی بیماری و نیازهای انسانی در ایالات متحده هستند و تعداد افراد مسن (و نیازهای قابل توجهشان) امروزه از هر زمان دیگری بیشتر است (۱۹). در سال ۱۹۰۰ تقریباً ۳ میلیون از آمریکایی‌ها ۶۵ سال و بیش از آن سن داشتند (در حدود ۴٪ از کل جمعیت)، و در سال ۲۰۰۰، این تعداد به ۳۵ میلیون (در حدود ۱۲٪ کل جمعیت) رسید. تا سال ۲۰۳۰ جمعیت افراد مسن در ایالات متحده تقریباً به ۷۰ میلیون نفر خواهد رسید و از هر ۵ آمریکایی، یک نفر مسن خواهد بود (۱۹). جمعیت افراد مسن دنیا از سال ۱۹۹۸ تا ۲۰۲۵ بیش از ۲ برابر خواهد شد و از ۲۶۴ میلیون در سال ۲۰۰۹ به ۴۱۶ میلیون در سال ۲۰۵۰ خواهد رسید (۲۰). علاوه بر رشد جمعیت، پیر شدن جمعیت را نیز باید به عنوان یکی از مشکلات اجتماعی مهم در نظر گرفت.

سرعت تغییر، تحت تأثیر دو پدیدهٔ نوین است. اولین پدیده، تولد تعداد زیادی نوزاد در سال‌های پس از جنگ جهانی دوم (۱۹۶۴-۱۹۴۶) است که پیر شدن جمعیت را موقتاً به تعویق انداخت اما امروزه باعث تسریع پیر شدن جمعیت عمومی شده است. پدیده مهم دیگر، کاهش میزان مرگ‌ومیر افراد مسن است. موفقیت ما در به تعویق انداختن مرگ باعث افزایش تعداد افراد در بخش بالایی منحنی جمعیت‌شناسی شده است **(شکل ۳-۱۷)**. تا سال ۲۰۵۰، جوامع توسعه یافتهٔ فعلی، همگی جوامعی مستطیلی خواهند بود. تعداد افراد بالای ۶۵ سال در چین تا سال ۲۰۵۰ بیش از تعداد کل افرادی (در همهٔ سنین) خواهد بود که در حال حاضر در ایالات متحده زندگی می‌کنند **(جدول ۱-۱۷)**.

این تغییرات، فراگیر هستند و محدود به جوامع مرفه نیستند (۲۱). جمعیت جهان تا سال ۲۱۰۰ یا ۲۱۵۰ به رشد خود ادامه خواهد داد و انتظار می‌رود که در آن هنگام به ۱۱ میلیارد نفر برسد و تثبیت شود. پس از سال ۲۰۲۰ تمام این رشد جمعیت در کشورهای در حال توسعه رخ خواهد داد (۲۰). در سال ۲۰۰۰، ۸۷٪ جمعیت جهان مربوط به فقیرترین کشورها (واقع در آفریقا و آسیا) بوده است. در سال ۱۹۵۰ تنها ۴۰٪ از افراد ۶۰ ساله و بیشتر در کشورهای در حال توسعه زندگی می‌کردند. تا سال ۲۰۵۰ در حدود ۸۰٪ از این افراد در آن کشورها زندگی خواهند کرد زیرا انتظار می‌رود میزان باروری در این کشورها از ۲/۷۳ فرزند به ازای هر زن در سال‌های ۲۰۱۰-۲۰۰۵ به ۲/۰۵ در سال ۲۰۵۰ برسد (۲۰).

در جمعیت‌های مسن یک تفاوت جنسیتی در بقا شناسایی شده است. در سال ۱۹۰۰ تعداد مردان بالای ۶۵ سال در ایالات متحده بیش از زنان بود (۱۰۲ در برابر ۱۰۰). امروزه به ازای هر ۱۰۰ زن بالای ۶۵ سال، تنها ۷۰ مرد وجود دارد (۲۲). در سن ۸۵ سالگی به ازای هر ۱۰۰ زن تنها ۳۹ مرد وجود دارد. نزدیک ۹۰٪ از زنان آمریکایی سفیدپوست می‌توانند امید داشته باشند که تا سن ۷۰ سالگی زنده بمانند. داده‌های آمار حیاتی نشان می‌دهند که این تفاوت جنسیتی در جمعیت سفیدپوستان و سیاه‌پوستان ایالات متحده، مشابه است **(شکل ۴-۱۷)**. نزدیک ۵۵٪ از دختران آنقدر زنده می‌مانند که تولد ۸۵ سالگی‌شان را جشن بگیرند؛ این میزان برای پسران ۳۵٪ است (۲۴). از هر ۵۶۰۰ نفر، یک نفر می‌تواند امید داشته باشد که به ۱۰۰ سالگی برسد (۲۲).



شکل ۳-۱۷

جدول ۱-۱۷ شمارگان کنونی جمعیت جهان

	تولد	مرگ	رشد
سال	۱۴۰,۷۷۳,۰۰۰	۵۱,۳۱۵,۰۰۰	۸۹,۴۵۸,۰۰۰
ماه	۱۱,۷۳۱,۰۸۰	۴,۲۷۶,۲۵۰	۷,۴۵۴,۸۳۴
هفته	۲,۷۰۷,۱۷۳	۱۴۰,۵۸۹	۲۴۵,۰۹۰
ساعت	۱۶,۰۷۰	۵,۸۵۸	۱۰,۲۱۲
دقیقه	۲۶۸	۹۶	۱۷۰
ثانیه	۴/۵	۱/۶	۲/۸

عدد ۱۰ علت اصلی مرگ در ایالات متحده در سال ۲۰۱۶ به ترتیب زیر بوده‌اند (۱۶):

1. **بیماری قلبی**
2. **سرطان**
3. **آسیب‌های ناخواسته**
4. **بیماری‌های مزمن دستگاه تنفسی تحتانی**
5. **سکته مغزی**
6. **بیماری آلزایمر**
7. **دیابت ملیتوس**
8. **آنفلوانزا و پنومونی**
9. **بیماری‌های کلیوی**
10. **خودکشی**

دورنمای سلامتی مردان و زنان در سنین بالا متفاوت است. هورمون‌های جنسی است که باعث تفاوت در نمایه کلسترول – لیپوپروتئین و سایر عوامل مرتبط با قلب و عروق می‌شوند و در نهایت به این می‌انجامد که میزان آترواسکلروز و مرگ‌های زودرس در مردان بیشتر باشد (البته همهٔ اینها جای بحث دارد). از دیدگاه سلامت عمومی، بیشترین میزان تأثیر در این تفاوت

۲

شکل ۴-۱۷

جدول ۲-۱۷ جمعیت زنان مسن ایالات متحده

سن	۱۹۹۰	۲۰۰۰	۲۰۱۰	۲۰۲۰
۵۵–۶۴	۱۰/۸ (٪۸/۶)	۱۲/۱ (٪۹/۰)	۱۷/۱ (٪۱۲/۱)	۱۹/۳ (٪۱۲/۹)
۶۵–۷۴	۱۰/۱ (٪۸/۱)	۹/۸ (٪۷/۳)	۱۱/۰ (٪۷/۸)	۱۵/۶ (٪۱۰/۴)
> ۷۵	۷/۸ (٪۶/۲)	۹/۳ (٪۷/۰)	۹/۸ (٪۶/۹)	۱۱/۰ (٪۷/۳)
مجموع	۲۸/۷	۳۱/۲	۳۷/۹	۴۵/۹

جنسی در میزان مرگ‌ومیر را می‌توان با تغییر سبک زندگی (به منظور کاهش میزان آترواسکلروز) اعمال کرد. این تغییرات عبارت‌اند از: رژیم کم کلسترول، ترک سیگار، حفظ وزن بدن در حد ایده‌آل و ورزش. میزان مرگ‌ومیر در تمامی سنین در مردان بیشتر است، و بنابراین زنان در جمعیت‌های مسن نمایندگان بیشتری دارند (جدول ۱۷.۲). بیماری عروق کرونر (CHD) مسؤول ۴۰٪ از تفاوت مرگ‌ومیر میان مردان و زنان است. یک سوم دیگر از این تفاوت ناشی از سرطان ریه، آمفیزم، سیروز، سوانح و خودکشی است. جالب است بدانید در جامعهٔ آمریکا، تفاوت میزان مرگ‌ومیر در زنان و مردان بیشتر به دلیل تفاوت در شیوهٔ زندگی است. بیشتر بودن میزان مرگ‌ومیر در سن بالای ۶۵ سال در مردان عمدتاً ناشی از کشیدن سیگار، نوشیدن الکل، رفتارهای مستعدکننده ایجاد بیماری‌های کرونر و سوانح است. برآورد می‌شود که تنها سیگار کشیدن، مسؤول دوسوم این

اختلاف در میزان مرگ‌ومیر است، چرا که شیوع کشیدن سیگار در مردان بیشتر است. در زنانی که الگوی سیگار کشیدنشان مشابه مردان است، میزان افزایش خطر مرگ‌ومیر و بیمارمندی همانند مردان است (۲۵).

میزان تفاوت جنسیتی در میزان مرگ‌ومیر از سال ۱۹۷۹ رو به کاهش نهاده است. اداره سرشماری ایالات متحده نشان داده است که میزان تفاوت در امید به زندگی بین زنان و مردان تا سال ۲۰۵۰ افزایش خواهد یافت و سپس به حد ثابتی خواهد رسید. در سال ۲۰۵۰، امید به زندگی در زنان ۸۲ سال و در مردان ۷۶/۷ سال خواهد بود (۲۶). همچنین تعداد زنان ۶۵ ساله و بالاتر ۳۳/۴ میلیون نفر و تعداد مردان ۶۵ ساله و بالاتر ۲۲/۱ میلیون نفر خواهد بود.

علاوه بر افزایش تعداد افراد مسن، خود جمعیت افراد مسن نیز در حال پیرتر شدن است. در سال ۱۹۸۴، جمعیت گروه سنی ۷۴–۶۵ سال در ایالات متحده، ۷ برابر سال ۱۹۰۰ بوده است، اما جمعیت گروه سنی ۸۴–۷۵ سال نسبت به سال ۱۹۰۰، ۱۱ برابر و جمعیت گروه سنی ۸۵ ساله و بالاتر، ۲۱ برابر بیشتر شده است. در دهۀ ۱۹۹۰ جمعیت افراد ۸۵ ساله و بالاتر تا ۳۸٪ افزایش یافت (۲۲). انتظار می‌رود سریعترین افزایش بین سال‌های ۲۰۱۰ و ۲۰۳۰ اتفاق بیفتد چرا که در این سال‌ها، نوزادانی که در انفجار جمعیتی پس از جنگ جهانی دوم به دنیا آمده‌اند، به سنین ۶۵ و بالاتر خواهند رسید. تنها گروه سنی در ایالات متحده که انتظار می‌رود در قرن آینده رشد قابل توجهی داشته باشد گروه سنی بالای ۵۵ سال است. در این گروه سنی، نسبت زنان به مردان، ۲/۶ به ۱ خواهد بود. تا سال ۲۰۴۰ در ایالات متحده ۱۳–۸ میلیون فرد ۸۵ ساله و پیرتر وجود خواهد داشت. تفاوت بین ۸ و ۱۳ اختلاف پیش‌بینی منفی‌نگرانه با خوش‌بینانه درباره پیشگیری و درمان بیماری‌ها است.

در میان جمعیت سالمند، نسبت زنان مجرد افزایش خواهد یافت. احتمال بیوه شدن در زنان مسن بیشتر از مردان مسن است (۵۹٪ در برابر ۲۲٪) (۲۷). نیمی از مردان ۸۵ ساله و مسن‌تر با همسرانشان زندگی می‌کنند در حالی که تنها ۱۰٪ از زنان مسن با شوهرانشان زندگی می‌کنند (۲۸). چون افراد مجرد بیشتر آسیب‌پذیر هستند نیاز به خدمات برای این بخش از جمعیت پیر بیشتر خواهد بود. افراد مسن مجرد آسیب‌پذیرتر هستند، میزان مرگ‌ومیر در آنها بیشتر و میزان رضایت از زندگی کمتر است.

چهارگوش شدن زندگی

طول عمر عبارت است از مرز زندگی از نظر زیست شناختی و بیشترین سنی که اعضای یک گونۀ خاص می‌توانند به آن برسند. باور عمومی بر این است که طول عمر انسان در حال افزایش است در حالی که واقعیت این است که طول عمر ثابت است و در واقع یک ثابت زیست شناختی برای هر گونه است (۲۹). در حقیقت تفاوت‌هایی که در میزان طول عمر گونه‌های مختلف دیده می‌شود نشان‌دهنده زمینه ژنتیکی هر کدام از آنها برای داشتن عمر طولانی است. ثابت نبودن طول عمر به این معنا خواهد بود که جمعیت افراد مسن به صورت نامحدود در حال افزایش است، در حالی که تجزیه و تحلیل درست میزان بقاء نشان می‌دهد که بیشینه سنی که مرگ در آن رخ می‌دهد ثابت است. در حقیقت آنچه که افزایش یافته است امید به زندگی است که نشانگر تعداد سال‌هایی است که انتظار می‌رود فرد از زمان تولد زندگی کند. امید به زندگی نمی‌تواند بیشتر از طول عمر باشد اما می‌تواند تا حد زیادی به آن نزدیک شود. بنا بر آنچه گفته شد تعداد افراد مسن در نهایت از یک حد ثابت فراتر نخواهد رفت اما درصد سال‌هایی از زندگی که در دوران پیری سپری می‌شوند افزایش خواهد یافت **(شکل ۲–۱۷)**.

در جامعۀ آمریکا مرگ‌های پیش از موعد تقریباً دیگر دیده نمی‌شوند. بیماری‌های قلبی عروقی و سرطان‌ها در حال حاضر علل اصلی مرگ‌ومیر هستند. علت این پدیده، افزایش شیوع این بیماری‌ها و یا اپیدمی شدن آنها نیست بلکه در واقع ناشی از موفقیت کامل در از بین بردن بیماری‌های عفونی است. امروزه علل اصلی مرگ‌ومیر بیماری‌های مزمن (که خود تحت تأثیر ژنتیک، سبک زندگی و محیط قرار دارند) و خود کهولت هستند. با این حال حتی اگر بتوان سرطان، دیابت و تمامی بیماری‌های عروقی را به طور کامل از میان برداشت، باز هم امید به زندگی بیش از ۹۰ سال نخواهد بود (۱۷).

جی.اف. فرایز[1] سه دوره تاریخی را در سلامت و بیماری توصیف کرده است (۳۰). دورۀ اول تا سال‌های اولیۀ دهۀ ۱۹۰۰ ادامه داشته و ویژگی آن بیماری‌های عفونی حاد بوده است. دورۀ دوم هم‌اکنون است که ویژگی‌اش بیماری‌های قلبی عروقی و سرطان است. این دوره در حال اتمام است و دوره سوم در حال شروع شدن است که ویژگی آن مشکلات پیری (کاهش دید و شنوایی، اختلال در حافظه و کارکردهای شناختی، کاهش توان و

1- J.F. Fries

اندوخته) است. اغلب رویکردهای پزشکی ما هنوز بر پایه دوره اول است (پیدا کردن بیماری و درمان آن)، اما شرایط کنونی به گونه‌ای است که باید علاوه بر رویکرد پزشکی، رویکردهای روان شناختی و اجتماعی را نیز وارد میدان کرد. تمرکز ما بر روی بیماری‌های مزمن و کشندهٔ وابسته به سن بوده است، اما آنچه چالش‌های جدیدی برانگیخته است مشکلات غیرکشنده و وابسته به پیری مانند بیماری آلزایمر، استئوآرتریت، استئوپروز، چاقی و بی‌اختیاری است. می‌توان گفت که ارزیابی برنامه‌های بهداشتی در سال‌های آینده به جای تأثیر آنها بر میزان مرگ‌ومیر، باید بر پایه توانایی آنها را در ایجاد سال‌هایی بدون معلولیت باشد.

مفهوم کوتاه کردن بیمارمندی

بیماری‌های مزمن، رشد فزاینده‌ای دارند. بهترین راهکار سیستم‌های بهداشتی در برخورد با این بیماری‌ها سعی در تغییر شیب منحنی رشد آنها، کاهش سرعت پیشرفت بیماری و در نتیجه به تعویق انداختن نمود بیماری از لحاظ بالینی و در صورتی که بیماری به حد کافی به تعویق افتاد، پیشگیری مؤثر از آن است. آگاهی عمومی جوامع نسبت به بیماری‌ها به طرز چشمگیری تغییر کرده است. به طور روزافزون به بیماری به چشم مشکلی که بهترین روش برخورد با آن درمان دارویی یا جراحی است نگاه نمی‌شود بلکه بهترین درمان را پیشگیری می‌دانند.

جی.اف. فرایز پیشگیری از بیماری را **کوتاه کردن بیمارمندی** می‌نامد (۳۱ و ۲۹). در صورت پیشگیری از بیماری، انسان‌ها زندگی نسبتاً سالمی خواهند داشت و دوران بیمار بودن آنها به یک دوره کوتاه قبل از مرگ محدود خواهد بود. اما آیا این تغییر واقعاً امکان‌پذیر است؟ مثال خوبی که این مورد را تأیید می‌کند کاهش آترواسکلروز در ایالات متحده است. علل این کاهش عبارت‌اند از کاهش مصرف چربی‌های اشباع شده، کارآمدتر شدن روش‌های تشخیص و درمان پرفشاری خون، افزایش فعالیت بدنی و کاهش میزان سیگار کشیدن (شکل ۵-۱۷).

میزان پزشکان سیگاری از ۷۹٪ به اقلیت ناچیزی رسیده است (۳۲). نکته جالب و قابل تأمل این است که بیشترین میزان کاهش در مصرف سیگار در میان جراحان ریه بوده (که البته جای شگفتی نیست) و کمترین میزان آن در میان متخصصان رکتوم و مقعد مشاهده شده است. از اواسط دهه ۱۹۷۰ تا اوایل دهه ۱۹۹۰، میزان سیگار کشیدن در پزشکان ایالات متحده از ۱۸/۸٪ به ۳/۳٪ رسیده است. متأسفانه همین میزان اندک نیز نمایانگر نزدیک ۱۸۰۰۰ پزشک سیگاری است. از میان آن دسته از جمعیت ایالات متحده که دیپلم دبیرستان ندارند، نزدیک ۳۵ درصد سیگاری هستند. این در حالی است که شیوع مصرف سیگار در میان دارندگان تحصیلات بالاتر ۱۲٪ و در میان دارندگان مدرک دانشگاهی تنها ۵/۷٪ است. در حال حاضر نزدیک ۱۷/۵٪ از مردان و ۱۳/۵٪ از زنان سیگار می‌کشند (۱۶). کشیدن سیگار در میان دانش‌آموزان دبیرستانی در سال ۱۹۹۷ به اوج خود رسید و سپس به حد کنونی خود (۱۵/۵٪) رسید (۱۶). علاوه بر این، ۱۴٪ از دانش‌آموزان دبیرستانی از سیگار برگ و ۸٪ از آنها از تنباکوی جویدنی استفاده می‌کنند. استفاده از تنباکوی جویدنی، پیپ و سیگار برگ به میزان چشمگیری با بیمارمندی و مرگ‌ومیر مرتبط است. به همین دلیل تنباکو یگانه و قابل پیشگیری‌ترین علت بیماری‌های زودهنگام و مرگ در ایالات متحده است. نکته قابل توجه اینجا است که آسیب‌های سیگار کشیدن بر روی زنان بیشتر از مردان است (۳۳). خطر بیماری‌های کشندهٔ عروق کرونر قلب در زنانی که روزانه فقط ۴-۱ نخ سیگار می‌کشند ۲/۵ برابر افزایش می‌یابد (۱۴).

ترک سیگار پس از دهه‌ها سیگار کشیدن سودمند است، و آثار سودمند آن با گذشت یک ماه از ترک پدیدار می‌شوند (۳۵). در پژوهش سلامت پرستاران، با گذشت ۵ سال از ترک سیگار، ۶۱٪ از افزایش خطر مرگ‌ومیر ناشی از بیماری‌های کرونری قلب و ۴۲٪ از میزان مرگ‌ومیر ناشی از سکته‌های مغزی از بین رفته بود (۳۶). از بین رفتن تأثیر سیگار کشیدن بر مرگ‌ومیر ناشی از بیماری‌های تنفسی کندتر است و حتی پس از ۳۰ سال نیز افزایش خطر اندکی در میزان مرگ‌ومیر ناشی از سرطان ریه وجود خواهد داشت. با این حال ۲۰ سال پس از ترک سیگار، میزان خطر مرگ‌ومیر ناشی از بیماری‌های عروقی و مرگ ناشی از بیماری‌های تنفسی (به غیر از سرطان ریه) به حد افراد غیرسیگاری خواهد رسید. حتی در بیماران مسن‌تری که دچار بیماری‌های عروق کرونر هستند در صورت ترک سیگار میزان بقاء افزایش خواهد یافت (۳۷). جدا از این‌که فرد چقدر سن دارد، ادامهٔ سیگار کشیدن باعث افزایش خطر نسبی مرگ خواهد شد. همچنین صرفنظر از سن فرد، ترک سیگار خطر مرگ را کاهش خواهد داد. با این حال حتی در افرادی که قبلاً به مدت



شکل ۵-۱۷ After Fries & Crapo[20]

طولانی سیگار می‌کشیدند ولی مصرف آن را ترک کرده‌اند، خطر سرطان ریه، بالا باقی خواهد ماند (۳۸).

از سال ۱۹۷۰ تاکنون، میزان مرگ ناشی از بیماری‌های کرونری قلب در ایالات متحده، نزدیک ۵۰٪ کاهش یافته است. بین سال‌های ۱۹۷۳ تا ۱۹۸۷ در ایالات متحده میزان مرگ‌ومیر ناشی از بیماری‌های قلبی عروقی تقریباً در تمامی گروه‌های سنی کاهش یافت. مقدار این کاهش در افراد زیر ۵۴ سال، ۴۲٪ و در افراد ۸۴–۵۵ ساله، ۳۳٪ بود (۳۳). علیرغم پیشرفت‌هایی که مشاهده می‌شود، تلاش‌های پیشگیرانه در زمینه عوامل خطرساز بیماری‌های قلبی عروقی، به ویژه چاقی، افزایش فشارخون و کمبود فعالیت جسمی باید افزایش یابد.

تلاش برای بهبود کیفیت زندگی، ارزش ویژه‌ای برای جوامع دارد. این کار باعث کاهش میانگین تعداد سال‌های ناتوانی فرد، که یک مشکل مهم بهداشتی و اجتماعی است، خواهد شد. نکته مهم‌تر این است که این مشکلات چالش‌های مالی بزرگی برای نظام مراقبت‌های بهداشتی و برنامه‌های اجتماعی ایجاد می‌کنند. با مستطیلی شدن جوامع، نسبت افراد مستمری بگیر به افرادی که مالیات می‌پردازند به سرعت افزایش می‌یابد و این مسئله، حمایت‌های مالی برنامه‌های بهداشتی و اجتماعی را به خطر می‌اندازد. کاهش دورهٔ بیمارمندی دستکم یک راه‌حل مناسب برای این مسئله است.

یائسگی به عنوان یک فرصت

یائسگی یک دوره طبیعی از زندگی است؛ نباید آن را غیرطبیعی انگاشت. برای بسیاری از زنان، این تغییر خوشایند است ـ دیگر قاعدگی یا سندرم پیش قاعدگی (PMS) رخ نمی‌دهد و نیاز به جلوگیری از بارداری/ نگرانی از بارداری نیست.

پزشکانی که با زنان در دوران یائسگی سروکار دارند، فرصت جالب توجه و در نتیجه مسؤولیت مهمی دارند. ارائه خدمات پزشکی در این دوره از زندگی می‌تواند از لحاظ پیشگیری از بیماری‌ها بسیار مفید باشد. به همین دلیل این دوران فرصتی است که نباید آن را از دست داد.

با آن‌که اهمیت عادت‌های سالم رفتاری در جوانان را نباید دست‌کم گرفت، اثر آموزش مراقبت‌های پیشگیرانه در سنین میانسالی بیشتر است. در این سنین افراد به کاهش میزان مرگ‌ومیر و بیمارمندی بیماری‌های مزمن با دیدی سرشار از باور، درک و علاقه نگاه می‌کنند. در این سنین احتمال پیدایش بیماری بیشتر است اما اثر تغییر در سبک زندگی نیز بیشتر است.

۲

مرحله‌های پیر شدن باروری: از سال‌های باروری تا آستانه یائسگی (واژه‌شناسی کهنه‌تر) یا از دوران گذار یائسگی (واژه‌شناسی تازه‌تر) تا یائسگی

در سال ۲۰۰۱، کارگاه مرحله‌های پیر شدن باروری[1] (STRAW) نام‌گذاری مرحله‌های دوران گذار یائسگی را استانداردسازی کرد (۳۹). پیش از این کارگاه هیچ روش پذیرفته شده‌ای برای تعریف مرحله‌های پیر شدن باروری منجر به یائسگی وجود نداشت. در سال ۲۰۱۰ در یک کارگاه پیگیری (STRAW + 10)، این معیار به روزرسانی شد تا نشانگر پیشرفت در شناسایی تغییرات کارکرد هیپوتالاموس ـ هیپوفیز که در سراسر پیر شدن باروری رخ می‌دهند، باشد (۴۰). نظام مرحله‌بندی STRAW طول عمر زنان را به سه دوره گسترده تقسیم می‌کند: *دوره باروری*، *دوره گذار به یائسگی*، و *دوره پس از یائسگی*. هر کدام از این سه دوره بر پایه یافته‌های بالینی (الگوی دوره قاعدگی، علائم) و داده‌های پژوهشی (سطوح سرمی هورمون تحریک‌کننده فولیکول [FSH] و هورمون آنتی مولرین [AMH] و شمارش فولیکول آنتروم تخمدان [AFC] با سونوگرافی) به چند مرحله تقسیم می‌شوند. دوران گذار یائسگی یک دوره محدود از تغییرات فیزیولوژی است که در پایان به پیر شدن باروری می‌انجامد. این دوره از زندگی می‌تواند با تغییرات بی‌مانندی همراه باشد که ممکن است اثرهای چشمگیری بر تندرستی جمعیت و بر کیفیت زندگی داشته باشند (۳۹). به یک زن یائسه گفته می‌شود، اگر او یک بازه ۱۲ ماهه پیاپی را بدون قاعدگی سپری کرده باشد و دارای مدرک بیوشیمیایی هیپوگنادیسم (سطوح پایین استرادیول) هیپرگنادوتروپیک (سطوح بالای FSH و هورمون لوتئینیزه‌کننده [LH]) باشد. دوره قاعدگی نهایی یا پایانی[2] (FMP) مرحله «صفر» نامیده می‌شود که نشانگر یک نقطه عطف بین دوره‌های باروری و پس از باروری است. دوره باروری خود به سه مرحله (زودرس [-5]، اوج [-4]، و دیررس [-3]) تقسیم می‌شود. دوران گذار یائسگی به دو مرحله (زودرس [-2] و دیررس [-1]) تقسیم می‌شود. دوره پس از یائسگی نیز به دو مرحله (زودرس [+1] و دیررس [+2]) تقسیم می‌شود (۴۰). **بنابراین *FMP* یک نقطه مرجع برای گزارش باقی مرحله‌ها از میان این سه دوره ویژه پیری باروری است (شکل ۶-۱۷).**

مرحله دیررس باروری (مرحله ۳- *STRAW*)

کاهش آشکار توانایی باروری زودرس‌ترین شاه علامت دوران گذار است که در پی آن گستره‌ای از یک پدیده آشکار بالینی، مانند تغییرات الگوی قاعدگی رخ می‌دهد. چون تغییرات غدد درون‌ریز درست پیش از نمودهای آشکار و چشمگیر بالینی رخ می‌دهند (مانند تغییرات در دوره قاعدگی)، STRAW+ 10 پیشنهاد کرد که مرحله دیررس باروری به دو زیرمرحله 3b- و 3a- تقسیم شود. در مرحله 3b- چرخه‌های قاعدگی به نسبه بدون تغییر هستند، سطوح سرمی FSH دوره زودرس فولیکولی به نسبه پایین اما در بازه طبیعی پیش از یائسگی هستند، اما AMH و AFC (و شاید اینهیبین B) کاهش می‌یابند (۴۱). در مرحله 3a- چرخه‌های قاعدگی کوتاه‌تر می‌شوند و FSH زودرس فولیکولی افزایش می‌یابد، اما AMH، AFC، و اینهیبین B کاهش می‌یابند (۴۱).

دوره گذار زودرس یائسگی (مرحله ۲- *STRAW*)

ویژگی این مرحله افزایش بی‌نظمی در طول چرخه قاعدگی است. این بی‌نظمی با تکرار تفاوت ۷ روزه چرخه قاعدگی که در بیش از ۱۰ چرخه رخ دهد، شناخته می‌شود. ویژگی دیگر این مرحله افزایش متغیر در سطوح FSH دوره زودرس فولیکولی همراه با سطوح پایدار اندک AMH و کاهش AFC است (۴۱).

دوره گذار دیررس یائسگی (مرحله ۱- *STRAW*)

ویژگی این مرحله از دست رفتن برخی قاعدگی‌ها همراه با دوره‌هایی از آمنوره است که ۶۰ روز یا بیشتر طول می‌کشند. طول چرخه‌های قاعدگی نامنظم‌تر می‌شود، سطوح هورمون‌های باروری متغیر است و عدم تخمک‌گذاری بیشتر رخ می‌دهد. سطوح FSH به طور معمول افزایش یافته و در اندازه یائسگی هستند، اگرچه گاهی ممکن است در اندازه پیش از یائسگی و همراه با سطوح بالای استرادیول باشند. سطح سرمی FSH بیشتر از ۲۵ IU/L به طور معمول در این مرحله دیررس گذار دیده می‌شود. این مرحله ۳ـ۱ سال طول می‌کشد و آغاز علامت‌های وازوموتور مانند گرگرفتگی در آن رخ می‌دهد (۴۱).

1. Stages of Reproductive Aging Workshop
2. final menstrual period

Stages	-5	-4	-3b -3a	-2 01	0	+1	+2a	+2b
Phase	*Reproductive*			*Transition*	FMP	*Post Menopause*		
Clinical profile	Fertile	Fertility problems for some	• Fertility problems • Menstrual irregularity • Occasional VMS	• Fertility problems • Menstrual irregularity • VMS are common		• VMS are common • Declining bone density	• Improving VMS in many • Worsening GUSM symptoms • Worsening risk for osteoporosis, cardiovascular disease	
Biochemical finding	• Normal AMH & inhibin • Low FSH	• Normal AMH & inhibin • Low FSH	• Declining AMH • Declining inhibin • Rising FSH	• Low or undetectable AMH & inhibin levels • High FSH		• High FSH • AMH & inhibin undetectable	• Stable FSH • AMH & inhibin undetectable	• Slight decline in FSH • AMH & inhibin undetectable
Ultrasound findings	**Adequate AFC >>8**		**Decline in AFC**	**Few antral follicles**		**Occasional antral follicle**		

AMH: Antimüllerian hormone
FSH: Follicle stimulating hormone
AFC (Antral follicle count)
AMS: Vasomotor symptoms
GUSM: Genitourinary Syndrome of Menopause
FMP: Final menstrual period

شکل ۶-۱۷

دوره زودرس پس از یائسگی (مرحله ۱ STRAW، زیرمرحله‌های 1a+، 1b+، 1c+)

در دوره زودرس پس از یائسگی افزایش سطوح FSH ادامه می‌یابد، اما کاهش سطوح استرادیول تا ۲ سال پس از FMP ادامه دارد تا به سطوح پایدار برسد. هر یک از زیرمرحله‌های 1a+ و 2b+ در دوره زودرس پس از یائسگی یک سال طول می‌کشند و با پایدار شدن نوسان‌های سطوح FSH به پایان می‌رسند. مرحله 1a+ نشانگر تکمیل فاصله ۱۲ ماهه‌ای است که برای تعریف FMP لازم است. این زیرمرحله همچنین نشان‌دهنده پایان دوران آستانه یائسگی (زمان نزدیک یائسگی که با مرحله 2- آغاز می‌شود و ۱۲ ماه پس از FMP پایان می‌یابد) است (۴۱). مرحله 1b+ دربرگیرنده افزایش تغییرات در سطوح FSH و استرادیول است؛ علائم وازوموتور در مرحله‌های 1a+ و 1b+ بسیار شایع هستند. در مرحله 1c+، FSH که افزایش یافته و کاهش سطوح استرادیول اکنون طبیعی شناخته می‌شوند. این زیرمرحله ۶ـ۳ سال به درازا می‌کشد. بدین ترتیب، گستردگی مرحله زودرس پس از یائسگی ۸ـ۵ سال است (۴۱).

دوره دیررس پس از یائسگی (مرحله ۲+)

در این مرحله، سطوح هورمون‌های باروری به طور الزامی پایدار و یکنواخت است. با آن که در این مرحله بار علائم وازوموتور در بسیاری کاهش می‌یابد، علائم بالینی همراه با کاهش استروژن، مانند خشکی مهبل و علائم ادراری تناسلی برجسته‌تر می‌شوند. جالب این‌که ممکن است سطوح FSH دچار کاهش بیشتری شوند، هر چند پژوهش‌های بیشتری برای تأیید این مشاهده لازم است (۴۱).

دوران گذار یائسگی

برای تعریف عینی آنچه که دوران گذار یائسگی خوانده می‌شود تنها یک نشانه وجود دارد و آن نامنظم شدن قاعدگی است. بیمار این بی‌نظمی را به صورت جا افتادن قاعدگی‌ها و یا طولانی شدن فواصل بین قاعدگی‌ها (در حدود ۶۰-۴۰ روز) تجربه می‌کند (۴۲). در عین حال هیچ الگوی جامعی وجود ندارد و هر زن این تغییرات را به صورت تغییر در ویژگی‌های خاص قاعدگی خودش تجربه می‌کند.

یائسگی مقطعی از زمان است که در پی از دست رفتن فعالیت تخمدان‌ها، قاعدگی‌ها برای همیشه قطع می‌شوند. واژه"menopause" از واژه‌های یونانی "men" (به معنی ماه) و "pausis" (به معنی قطع) می‌آید. "climacteric" واژه‌ای

Speroff's Clinical Gynecologic Endocrinology and Infertility

Volume two

Chapter seventeen

REFERENCES

1. **Farnham AM**, Uterine disease as a factor in the production of insanity, Alienist Neurologist 8:532, 1887.
2. **Hällström T**, **Samuelsson S**, Mental health in the climacteric. The longitudinal study of women in Gothenburg, Acta Obstet Gynecol Scand Suppl 130:13, 1985.
3. **McKinlay SM**, **McKinlay JB**, The impact of menopause and social factors on health, In: Hammond CB, Haseltine FP, Schiff I, eds. Menopause: Evaluation, Treatment, and Health Concerns, Alan R. Liss, New York, 1989, pp. 137–161.
4. **Matthews KA**, **Wing RR**, **Kuller LH**, **Meilahn EN**, **Kelsey SF**, **Costello EJ**, **Caggiula AW**, Influences of natural menopause on psychological characteristics and symptoms of middle-aged healthy women, J Consult Clin Psychol 58:345, 1990.
5. **Koster A**, Change-of-life anticipations, attitudes, and experiences among middle-aged Danish women, Health Care Women Int 12:1, 1991.
6. **Holte A**, Influences of natural menopause on health complaints: a prospective study of healthy Norwegian women, Maturitas 14:127, 1992.
7. **Kaufert PA**, **Gilbert P**, **Tate R**, The Manitoba Project: a re-examination of the link between menopause and depression, Maturitas 14:143, 1992.
8. **Dennerstein L**, **Smith AMA**, **Morse C**, **Burger H**, **Green A**, **Hopper J**, **Ryan M**, Menopausal symptoms in Australian women, Med J Aust 159:232, 1993.
9. **Dennerstein L**, **Lehert P**, **Burger HG**, **Dudley E**, Mood and the menopause transition, J Nerv Ment Dis 187:685, 1999.
10. **Smith-DiJulio K**, **Woods NF**, **Mitchell ES**, Well-being during the menopausal transition and early postmenopause: a within-stage analysis, Womens Health Issues 18:310, 2008.
11. **Woods NF**, **Mitchell ES**, **Percival DB**, **Smith-DiJulio K**, Is the menopausal transition stressful? Observations of perceived stress from the Seattle Midlife Women's Health Study, Menopause 16:90, 2009.
12. **Avis NE**, **McKinlay SM**, A longitudinal analysis of women's attitudes toward the menopause: results from the Massachusetts Women's Health Study, Maturitas 13:65, 1991.
13. **Morse CA**, **Smith A**, **Dennerstein L**, **Green A**, **Hopper J**, **Burger H**, The treatment-seeking woman at menopause, Maturitas 18:161, 1994.
14. **Defey D**, **Storch E**, **Cardozo S**, **Diaz O**, **Fernandez G**, The menopause: women's psychology and health care, Soc Sci Med 42:1447, 1996.
15. **Heron MP**, **Hoyert DL**, **Xu J**, **Scott C**, **Tejada-Vera B**, Deaths: preliminary data for 2006, Natl Vital Stat Rep 56(No. 16):1, 2008.
16. **U.S. National Center for Health Statistics**, Health, United States, 2016, http://www.ced.gov,nchs, 2016.
17. **Olshansky SJ**, **Carnes BA**, **Cassel C**, In search of Methuselah: estimating the upper limits to human longevity, Science 250:634, 1990.
18. **Olshansky SJ**, **Carnes BA**, **Cassel C**, The aging of the human species, Sci Am 268(4):46, 1993.
19. **Hobbs FB**, Population Profile of the United States, U.S. Census Bureau, http://www.census.gov/population/www/pop-profile/elderpop.html, 2009.
20. **United Nations**, World population to exceed 9 billion by 2050, http://www.un.org/esa/population/unpop.htm, 2009.
21. **McDevitt TM**, **Stanecki KA**, **Way PO**, Report WP/98, World Population Profile: 1998, Washington, DC: US Census Bureau; 1999.
22. **Hetzel L**, **Smith A**, Census 2000 BriefC2KBR/01-10: The 65 Years and Over Population: 2000, Washington, DC: US Census Bureau; 2004.
23. **Miles TP**, **Bernard MA**, Morbidity, disability, and health status of black American elderly: a new look at the oldest-old, J Am Geriatr Soc 40:1047, 1992.
24. **Day JC**, Bureau of the Census, Current Population Reports, Population Projections of the United States, by Age, Sex, Race, and Hispanic Origin: 1993 to 2050, U.S. Government Printing Office, Washington, 1993.

25. **Centers for Disease Control and Prevention**, **U.S. Department of Health and Human Services**, Women and smoking: a report of the surgeon general, Morb Mortal Wkly Rep 51(RR12):1, 2002.
26. **Annual Report of the Board of Trustees of the Federal Old-Age** and **Survivors Insurance and Disability Insurance Trust Funds**, Report No. Tb1 II.D2, U.S. Government Printing Office, 1995.
27. Centers for Disease Control and Prevention, www.cdc.gov/nchs/data/ad/ad272.pdf, 2003.
28. **Keith PM**, The social context and resources of the unmarried in old age, Int J Aging Hum Dev 23:81, 1986.
29. **Fries JF**, **Crapo LM**, Vitality and Aging, W.H. Freeman and Co., San Francisco, 1981.
30. **Fries JF**, The sunny side of aging, JAMA 263:2354, 1990.
31. **Fries JF**, Strategies for reduction of morbidity, Am J Clin Nutr 55:1257S, 1992.
32. **Nelson DE**, **Giovino GA**, **Emont SL**, **Brackbill R**, **Cameron LL**, **Peddicord J**, **Mowery PD**, Trends in cigarette smoking among US physicians and nurses, JAMA 271:1273, 1994.
33. **Davis DL**, **Dinse GE**, **Hoel DG**, Decreasing cardiovascular disease and increasing cancer among whites in the United States from 1973 through 1987, JAMA 271:431, 1994.
34. **Willett WC**, **Green A**, **Stampfer MJ**, **Speizer FE**, **Colditz GA**, **Rosner B**, **Monson RR**, **Stason W**, **Hennekens CH**, Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes, N Engl J Med 317:1303, 1987.
35. **Jha P**, **Ramasundarahettige C**, **Landsman V**, **Rostron B**, **Thun M**, **Anderson RN**, **McAfee T**, **Peto R**, 21st century hazards of smoking and benefits of cessation in the United States, N Engl J Med 368(4):341, 2013.
36. **Kenfield SA**, **Stampfer MJ**, **Rosner BA**, **Colditz GA**, Smoking and smoking cessation in relation to mortality in women, JAMA 299:2037, 2008.
37. **Hermanson B**, **Omenn GS**, **Kronmal RA**, **Gersh BJ**, Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry, N Engl J Med 319:1365, 1988.
38. **Ebbert JO**, **Yang P**, **Vachon CM**, **Vierkant RA**, **Cerhan JR**, **Folsom AR**, **Sellers TA**, Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women, J Clin Oncol 21:921, 2003.
39. **Soules MR**, **Sherman S**, **Parrott E**, **Rebar R**, **Santoro N**, **Utian W**, **Woods N**, Executive summary: Stages of Reproductive Aging Workshop (STRAW), Climacteric 4(4):267, 2001.
40. **Harlow SD**, **Gass M**, **Hall JE**, **Lobo R**, **Maki P**, **Rebar RW**, **Sherman S**, **Sluss PM**, **de Villiers TJ**; **STRAW + 10 Collaborative Group**, Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging, Climacteric 15(2):105, 2012.
41. **Harlow SD**, **Gass M**, **Hall JE**, **Lobo R**, **Maki P**, **Rebar RW**, **Sherman S**, **Sluss PM**, **de Villiers TJ**; **STRAW + 10 Collaborative Group**, Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging, Fertil Steril 97(4):843, 2012.
42. **Harlow SD**, **Mitchell ES**, **Crawford S**, **Nan B**, **Little R**, **Taffe J**; for the **ReSTAGE Collaboration**, The ReSTAGE Collaboration: defining optimal bleeding criteria for onset of early menopausal transition, Fertil Steril 89:129, 2008.
43. **Vollman RF**, The menstrual cycle, In: Friedman E, ed. Major Problems in Obstetrics and Gynecology, W.B. Saunders Co., Philadelphia, 1977.
44. **Treloar AE**, **Boynton RE**, **Borghild GB**, **Brown BW**, Variation of the human menstrual cycle through reproductive life, Int J Fertil 12:77, 1967.
45. **Cole LA**, **Ladner DG**, **Byrn FW**, The normal variabilities of the menstrual cycle, Fertil Steril 91(2):522, 2009.
46. **Collett ME**, **Wertenberger GE**, **Fiske VM**, The effect of age upon the pattern of the menstrual cycle, Fertil Steril 5:437, 1954.
47. **Chiazze L Jr**, **Brayer FT**, **Macisco JJ Jr**, **Parker MP**, **Duffy BJ**, The length and variability of the human menstrual cycle, JAMA 203:377, 1968.
48. **Munster K**, **Schmidt L**, **Helm P**, Length and variation in the menstrual cycle—a cross-sectional study from a Danish county, Br J Obstet Gynaecol 99:422, 1992.
49. **Belsey EM**, **Pinol APY**; **Task Force on Long-Acting Systemic Agents for Fertility Regulation**, Menstrual bleeding patterns in untreated women, Contraception 55:57, 1997.

50. **Ferrell RJ**, **Simon JA**, **Pincus SM**, **Rodríguez G**, **O'Connor KA**, **Holman DJ**, **Weinstein M**, The length of perimenopausal menstrual cycles increases later and to a greater degree than previously reported, Fertil Steril 86:619, 2006.
51. **Taffe JR**, **Dennerstein L**, Menstrual patterns leading to the final menstrual period, Menopause 9:32, 2002.
52. **den Tonkelaar I**, **te Velde ER**, **Looman CWN**, Menstrual cycle length preceding menopause in relation to age at menopause, Maturitas 29:115, 1998.
53. **Sherman BM**, **West JH**, **Korenman SG**, The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women, J Clin Endocrinol Metab 42:629, 1976.
54. **Lenton EA**, **Landgren B**, **Sexton L**, **Harper R**, Normal variation in the length of the follicular phase of the menstrual cycle: effect of chronological age, Br J Obstet Gynaecol 91:681, 1984.
55. **Buckler HM**, **Evans A**, **Mamlora H**, **Burger HG**, **Anderson DC**, Gonadotropin, steroid and inhibin levels in women with incipient ovarian failure during anovulatory and ovulatory 'rebound' cycles, J Clin Endocrinol Metab 72:116, 1991.
56. **MacNaughton J**, **Bangah M**, **McCloud P**, **Hee J**, **Burger HG**, Age-related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age, Clin Endocrinol 36:339, 1992.
57. **Hee J**, **MacNaughton J**, **Bangah M**, **Burger HG**, Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol and progesterone, Maturitas 18:9, 1993.
58. **Metcalf MG**, **Livesay JH**, Gonadotropin excretion in fertile women: effect of age and the onset of the menopausal transition, J Endocrinol 105:357, 1985.
59. **Rannevik G**, **Jeppsson S**, **Johnell O**, **Bjerre B**, **Yaurell-Borulf Y**, **Svanberg L**, A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density, Maturitas 21:103, 1995.
60. **Burger HG**, **Dudley EC**, **Hopper JL**, **Groome N**, **Guthrie JR**, **Green A**, **Dennerstein L**, Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women, J Clin Endocrinol Metab 84:4025, 1999.
61. **Burger HG**, **Hale GE**, **Dennerstein L**, **Robertson DM**, Cycle and hormone changes during perimenopause: the key role of ovarian function, Menopause 15:603, 2008.
62. **O'Connor KA**, **Ferrell R**, **Brindle E**, **Trumble B**, **Shofer J**, **Holman DJ**, **Weinstein M**, Progesterone and ovulation across stages of the transition to menopause, Menopause 16:1178, 2009.
63. **Treloar AE**, Menstrual cyclicity and the pre-menopause, Maturitas 3:249, 1981.
64. **van Noord PAH**, **Dubas JS**, **Dorland M**, **Boersma H**, **te Velde E**, Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors, Fertil Steril 68:95, 1997.
65. **Burger HG**, **Dudley E**, **Manners P**, **Groome N**, **Robertson DM**, Early follicular phase serum FSH as a function of age: the roles of inhibin B, inhibin A and estradiol, Climacteric 3:17, 2000.
66. **Lasley BL**, **Santoro N**, **Randolph JF**, **Gold EB**, **Crawford S**, **Weiss G**, **McConnell DS**, **Sowers MF**, The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity, J Clin Endocrinol Metab 87:3760, 2002.
67. **Santoro N**, **Brown JR**, **Adel T**, **Skurnick JH**, Characterization of reproductive hormonal dynamics in the perimenopause, J Clin Endocrinol Metab 81:1495, 1996.
68. **Meyer PM**, **Zeger SL**, **Harlow SD**, **Sowers M**, **Crawford S**, **Luborsky JL**, **Janssen I**, **McConnell DS**, **Randolph JF**, **Weiss G**, Characterizing daily urinary hormone profiles for women at midlife using functional data analysis, Am J Epidemiol 165:936, 2007.
69. **Richardson SJ**, **Senikas V**, **Nelson JF**, Follicular depletion during the menopausal transition—evidence for accelerated loss and ultimate exhaustion, J Clin Endocrinol Metab 65:1231, 1987.
70. **Gougeon A**, **Echochard R**, **Thalabard JC**, Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women, Biol Reprod 50:653, 1994.
71. **Faddy MJ**, **Gosden RG**, **Gougeon A**, **Richardson SJ**, **Nelson JF**, Accelerated disappearance of ovarian

follicles in mid-life: implications for forecasting menopause, Hum Reprod 7:1342, 1992.
72. **Klein NA**, **Illingworth PJ**, **Groome NP**, **McNeilly AS**, **Battaglia DE**, **Soules MR**, Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles, J Clin Endocrinol Metab 81:2742, 1996.
73. **Danforth DR**, **Arbogast LK**, **Mroueh J**, **Kim MH**, **Kennard EA**, **Seifer DB**, **Friedman CI**, Dimeric inhibin: a direct marker of ovarian aging, Fertil Steril 70:119, 1998.
74. **Welt CK**, **McNicholl DJ**, **Taylor AE**, **Hall JE**, Female reproductive aging is marked by decreased secretion of dimeric inhibin, J Clin Endocrinol Metab 84:105, 1999.
75. **Seifer DB**, **Gardiner AC**, **Ferreira KA**, **Peluso JJ**, Apoptosis as a function of ovarian reserve in women undergoing in vitro fertilization, Fertil Steril 66:593, 1996.
76. **Klein NA**, **Battaglia DE**, **Miller PB**, **Branigan EF**, **Giudice LC**, **Soules MR**, Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age, J Clin Endocrinol Metab 81:1946, 1996.
77. **Klein NA**, **Battaglia DE**, **Fujimoto VY**, **Davis GS**, **Bremmer WJ**, **Soules MR**, Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women, J Clin Endocrinol Metab 81:1038, 1996.
78. **Klein NA**, **Harper AJ**, **Houmard BS**, **Sluss PM**, **Soules MR**, Is the short follicular phase in older women secondary to advanced or accelerated dominant follicle development?, J Clin Endocrinol Metab 87:5746, 2002.
79. **van Zonneveld P**, **Scheffer GJ**, **Broekmans FJ**, **Blankenstein MA**, **de Jong FH**, **Looman CW**, **Habbema JD**, **te Velde ER**, Do cycle disturbances explain the age-related decline of female fertility? Cycle characteristics of women aged over 40 years compared with a reference population of young women, Hum Reprod 18:495, 2003.
80. **Lass A**, **Silye R**, **Abrams D-C**, **Krausz T**, **Hovatta O**, **Margara R**, **Winston RML**, Follicular density in ovarian biopsy of infertile women: a novel method to assess ovarian reserve, Hum Reprod 12:1028, 1997.
81. **Lass A**, **Skull J**, **McVeigh E**, **Margara R**, **Winston RM**, Measurement of ovarian volume by transvaginal sonography before human menopausal gonadotrophin superovulation for in-vitro fertilization can predict poor response, Hum Reprod 12:294, 1997.
82. **Yong PY**, **Baird DT**, **Thong KJ**, **McNeilly AS**, **Anderson RA**, Prospective analysis of the relationships between the ovarian follicle cohort and basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle number at different stages of the normal menstrual cycle and after pituitary down-regulation, Hum Reprod 18:35, 2003.
83. **Frattarelli JL**, **Lauria-Costab DF**, **Miller BT**, **Bergh PA**, **Scott RT**, Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles, Fertil Steril 74:512, 2000.
84. **Dumesic DA**, **Damario MA**, **Session DR**, **Famuyide A**, **Lesnick TG**, **Thornhill AR**, **McNeilly AS**, Ovarian morphology and serum hormone markers as predictors of ovarian follicle recruitment by gonadotropins for in vitro fertilization, J Clin Endocrinol Metab 86:2538, 2001.
85. **Bancsi LF**, **Broekmans FJ**, **Eijkemans MJ**, **de Jong FH**, **Habbema JD**, **te Velde ER**, Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve, Fertil Steril 77:328, 2002.
86. **Kupesic S**, **Kurjak A**, **Bjelos D**, **Vujisic S**, Three-dimensional ultrasonographic ovarian measurements and in vitro fertilization outcome are related to age, Fertil Steril 79:190, 2003.
87. **Sowers MR**, **Zheng H**, **McConnell D**, **Nan B**, **Harlow S**, **Randolph JF Jr**, Follicle stimulating hormone and its rate of change in defining menopause transition stages, J Clin Endocrinol Metab 93:3958, 2008.
88. **Sowers MR**, **Zheng H**, **McConnell D**, **Nan B**, **Harlow SD**, **Randolph JF Jr**, Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women, J Clin Endocrinol Metab 93:3847, 2008.
89. **Sowers MR**, **Eyvazzadeh AD**, **McConnell D**, **Yosef M**, **Jannausch ML**, **Zhang D**, **Harlow SD**, **Randolph JF Jr**, Anti-müllerian hormone and inhibin B in the definition of ovarian aging and the menopause transition, J Clin Endocrinol Metab 93:3478, 2008.

90. **Depmann M**, **Eijkemans MJ**, **Broer SL**, **Scheffer GJ**, **van Rooij IA**, **Laven JS**, **Broekmans FJ**, Does anti-Mullerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study, Hum Reprod 31(7):1579, 2016.
91. **Visser JA**, **De Jong FH**, **Laven JS**, **Themmen AP**, Anti-müllerian hormone: a new marker for ovarian function, Reproduction 131:1, 2006.
92. **Randolph JF Jr**, **Crawford S**, **Dennerstein L**, **Cain K**, **Harlow SD**, **Little R**, **Mitchell ES**, **Nan B**, **Taffe J**, **Yosef M**, The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition, J Clin Endocrinol Metab 91:3034, 2006.
93. **McKinlay SM**, **Brambilla DJ**, **Posner JG**, The normal menopause transition, Maturitas 14:103, 1992.
94. **McKinlay SM**, **Bigano NL**, **McKinlay JB**, Smoking and age at menopause, Ann Intern Med 103:350, 1985.
95. **Treolar AE**, Menarche, menopause and intervening fecundability, Hum Biol 46:89, 1974.
96. **Meschia M**, **Pansini F**, **Modena AB**, **de Aloysio D**, **Gambacciani M**, **Parazzini F**, **Campagnoli C**, **Maiocchi G**, **Peruzzi E**; On behalf of the **ICARUS Study Group**, Determinants of age at menopause in Italy: results from a large cross-sectional study. ICARUS Study Group. Italian Climacteric Research Group Study, Maturitas 34:119, 2000.
97. **Gold EB**, **Bromberger J**, **Crawford S**, **Samuels S**, **Greendale GA**, **Harlow SD**, **Skurnick J**, Factors associated with age at natural menopause in a multiethnic sample of midlife women, Am J Epidemiol 153:865, 2001.
98. **de Vries E**, **den Tonkelaar I**, **van Noord PAH**, **van der Schouw YT**, **te Velde ER**, **Peeters PHM**, Oral contraceptive use in relation to age at menopause in the DOM cohort, Hum Reprod 16:1657, 2001.
99. **Coulam CB**, **Adamsen SC**, **Annegers JF**, Incidence of premature ovarian failure, Obstet Gynecol 67:604, 1986.
100. **Luborsky JL**, **Meyer P**, **Sowers MF**, **Gold EB**, **Santoro N**, Premature menopause in a multi-ethnic population study of the menopause transition, Hum Reprod 18:199, 2003.
101. **Dratva J**, **Real FG**, **Schindler C**, **Ackermann-Liebrich U**, **Gerbase MW**, **Probst-Hensch NM**, **Svanes C**, **Omenaas ER**, **Neukirch F**, **Wjst M**, **Morabia A**, **Jarvis D**, **Leynaert B**, **Zemp E**, Is age at menopause increasing across Europe? Results on age at menopause and determinants from two population-based studies, Menopause 16:385, 2009.
102. **Kapur P**, **Sinha B**, **Pereira BMJ**, Measuring climacteric symptoms and age at natural menopause in an Indian population using the Greene Climacteric Scale, Menopause 16:378, 2009.
103. **Tibiletti MG**, **Testa G**, **Vegetti W**, **Alagna F**, **Taborelli M**, **Dalpra L**, **Bolis PF**, **Crosignani PG**, The idiopathic forms of premature menopause and early menopause show the same genetic pattern, Hum Reprod 14:2731, 1999.
104. **Vegetti W**, **Marozzi A**, **Manfredini E**, **Testa G**, **Alagna F**, **Nicolosi A**, **Caliari I**, **Taborelli M**, **Tibiletti MG**, **Dalpra L**, **Crosignani PG**, Premature ovarian failure, Mol Cell Endocrinol 161:53, 2000.
105. **Torgerson DJ**, **Avenell A**, **Russell IT**, **Reid DM**, Factors associated with onset of menopause in women aged 45–49, Maturitas 19:83, 1994.
106. **Torgerson DJ**, **Thomas RE**, **Campbell MK**, **Reid DM**, Alcohol consumption and age of maternal menopause are associated with menopause onset, Maturitas 26:21, 1997.
107. **Cramer DW**, **Xu H**, **Harlow BL**, Family history as a predictor of early menopause, Fertil Steril 64:740, 1995.
108. **Nelson LM**, Clinical practice. Primary ovarian insufficiency, N Engl J Med 360(6):606, 2009.
109. **Baird DD**, **Tylavsky FA**, **Anderson JJB**, Do vegetarians have earlier menopause? Proceedings of the Society of Epidemiologic Research, Am J Epidemiol 19:1, 1988.
110. **MacMahon B**, **Worcester J**, Age at menopause U.S. 1960–62, Vital Health Stat 19:1, 1966.
111. **Katsouyanni K**, **Boyle P**, **Trichopoulos D**, Diet and urine estrogens among postmenopausal women, Oncology 48:490, 1991.
112. **Gapstur SM**, **Potter JD**, **Sellers TA**, **Folsom AR**, Increased risk of breast cancer with alcohol consumption in postmenopausal women, Am J Epidemiol 136:1221, 1992.
113. **Gavaler JS**, **Van Thiel DH**, The association between moderate alcoholic beverage consumption and serum estradiol and testosterone levels in normal postmenopausal women: relationship to the literature, Alcohol Clin

Exp Res 16:87, 1992.
114. **Holbrook TC**, **Barrett-Connor E**, A prospective study of alcohol consumption and bone mineral density, Br Med J 306:1506, 1993.
115. **Ginsburg EL**, **Mello NK**, **Mendelson JH**, **Barbieri RL**, **Teoh SK**, **Rothman M**, **Gao X**, **Sholar JW**, Effects of alcohol ingestion on estrogens in postmenopausal women, JAMA 276:1747, 1996.
116. **Snieder H**, **MacGregor AJ**, **Spector TD**, Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause, J Clin Endocrinol Metab 83:1875, 1998.
117. **Rödström K**, **Bengtsson C**, **Milsom I**, **Lissner L**, **Sundh V**, **Bjoürkelund C**, Evidence for a secular trend in menopausal age: a population study of women in Gothenburg, Menopause 10:538, 2003.
118. **Brambila DJ**, **McKinlay SM**, **Johannes CB**, Defining the perimenopause for application in epidemiologic investigations, Am J Epidemiol 140:1091, 1994.
119. **Bromberger JT**, **Matthews KA**, **Kuller LH**, **Wing RR**, **Meilahn EN**, **Plantinga P**, Prospective study of the determinants of age at menopause, Am J Epidemiol 145:124, 1997.
120. **Cassou B**, **Derriennic F**, **Monfort C**, **Dell'Accio P**, **Touranchet A**, Risk factors of early menopause in two generations of gainfully employed French women, Maturitas 26:165, 1997.
121. **Beall CM**, Ages at menopause and menarche in a high-altitude Himalayan population, Ann Hum Biol 10:365, 1983.
122. **Gonzales GF**, **Villena A**, Age at menopause in Central Andean Peruvian women, Menopause 4:32, 1997.
123. **Leidy LF**, Early age at menopause among left-handed women, Obstet Gynecol 76:1111, 1990.
124. **Dane S**, **Reis N**, **Pasinliogu T**, Left-handed women have earlier age of menopause, J Basic Clin Physiol Pharmacol 10:147, 1999.
125. **Cresswell JL**, **Egger P**, **Fall CHD**, **Osmond C**, **Fraser RB**, **Barker DJP**, Is the age of menopause determined in-utero?, Early Hum Dev 49:143, 1997.
126. **Siddle N**, **Sarrel P**, **Whitehead M**, The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review, Fertil Steril 47:94, 1987.
127. **Derksen JGM**, **Brömann HAM**, **Wiegerinck MAHM**, **Vader HL**, **Heintz APM**, The effect of hysterectomy and endometrial ablation on follicle stimulating hormone (FSH) levels up to 1 year after surgery, Maturitas 29:133, 1998.
128. **Chalmers C**, **Lindsay M**, **Usher D**, **Warner P**, **Evans D**, **Ferguson M**, Hysterectomy and ovarian function: levels of follicle stimulating hormone and incidence of menopausal symptoms are not affected by hysterectomy in women under age 45 years, Climacteric 5:366, 2002.
129. **Rustamov O**, **Krishnan M**, **Roberts SA**, **Fitzgerald CT**, Effect of salpingectomy, ovarian cystectomy and unilateral salpingo-oophorectomy on ovarian reserve, Gynecol Surg 13:173, 2016.
130. **Willett W**, **Stampfer MJ**, **Bain C**, **Lipnick R**, **Speizer FE**, **Rosner B**, **Cramer D**, **Hennekens CH**, Cigarette smoking, relative weight, and menopause, Am J Epidemiol 117:651, 1983.
131. **Midgette AS**, **Baron JA**, Cigarette smoking and the risk of natural menopause, Epidemiology 1:474, 1990.
132. **Amundsen DW**, **Diers CJ**, The age of menopause in classical Greece and Rome, Hum Biol 42:79, 1970.
133. **Amundsen DW**, **Diers CJ**, The age of menopause in medieval Europe, Hum Biol 45:605, 1973.
134. **Frommer DJ**, Changing age at menopause, Br Med J 2:349, 1964.
135. **Traupman J**, **Eckels E**, **Hatfield E**, Intimacy in older women's lives, Gerontologist 2:493, 1982.
136. **Pfeiffer E**, **Verwoerdt A**, **Davis GC**, Sexual behavior in middle life, Am J Psychiatr 128:1262, 1972.
137. **Greendale GA**, **Hogan P**, **Shumaker S**; for the **Postmenopausal Estrogen/Progestin Interventions Trial (PEPI) Investigators**, Sexual functioning in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, J Womens Health 5:445, 1996.
138. **Lindau ST**, **Schumm LP**, **Waumann EO**, **Levinson W**, **O'Muircheartaigh CA**, **Waite LJ**, A study of sexuality and health among older adults in the United States, N Engl J Med 357:762, 2007.
139. **Shifren JL**, **Monz BU**, **Russo PA**, **Segreti A**, **Johannes CB**, Sexual problems and distress in United States women. Prevalence and correlates, Obstet Gynecol 112:970, 2008.
140. **Taylor HS**, **Tal A**, **Pal L**, **Li F**, **Black DM**, **Brinton EA**, **Budoff MJ**, **Cedars MI**, **Du W**, **Hodis HN**, **Lobo RA**, **Manson JE**, **Merriam GR**, **Miller VM**, **Naftolin F**, **Neal-Perry G**, **Santoro NF**, **Harman SM**,

Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS), JAMA Intern Med 177(10):1471, 2017.
141. **Dennerstein L**, **Lehert P**, **Burger H**, The relative effects of hormones and relationship factors on sexual function of women through the natural menopause transition, Fertil Steril 84:174, 2005.
142. **Rhodes JC**, **Kjerulff KH**, **Langenberg PW**, **Guzinski GM**, Hysterectomy and sexual function, JAMA 282:20, 1999.
143. **Anderson HD**, **Pace WD**, **Libby AM**, **West DR**, **Valuck RJ**, Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study, Clin Ther 34(1):113, 2012.
144. **DeLamater J**, **Karraker A**, Sexual functioning in older adults, Curr Psychiatry Rep 11:6, 2009.
145. **Martin CE**, Factors affecting sexual functioning in 60–79 year-old married males, Arch Sex Behav 10:399, 1981.
146. **George LK**, **Weiler SJ**, Sexuality in middle and late life, Arch Gen Psychiatr 38:919, 1981.
147. **White CB**, Sexual interest, attitudes, knowledge, and sexual history in relation to sexual behavior in the institutionalized aged, Arch Sex Behav 11:11, 1982.
148. **Renshaw DC**, Sex, intimacy, and the older woman, Women Health 8:43, 1983.
149. **Dennerstein L**, **Lehert P**, **Burger H**, **Dudley E**, Factors affecting sexual functioning of women in the midlife years, Climacteric 2:254, 1999.
150. **Dennerstein L**, **Dudley E**, **Burger H**, Are changes in sexual functioning during midlife due to aging or menopause?, Fertil Steril 76:456, 2001.
151. **Gosden RG**, Follicular status at menopause, Hum Reprod 2:617, 1987.
152. **Chakravarti S**, **Collins WP**, **Forecast JD**, **Newton JR**, **Oram DH**, **Studd JWW**, Hormonal profiles after the menopause, Br Med J 2:784, 1976.
153. **Jiroutek MR**, **Chen M-H**, **Johnston CC**, **Longcope C**, Changes in reproductive hormones and sex hormone-binding globulin in a group of postmenopausal women measured over 10 years, Menopause 5:90, 1998.
154. **Meldrum DR**, **Davidson BJ**, **Tataryn IV**, **Judd HL**, Changes in circulating steroids with aging in postmenopausal women, Obstet Gynecol 57:624, 1981.
155. **Grodin JM**, **Siiteri PK**, **McDonald PC**, Source of estrogen production in postmenopausal women, J Clin Endocrinol Metab 36:207, 1963.
156. **Parker CR Jr**, **Slayden SM**, **Azziz R**, **Crabbe SL**, **Hines GA**, **Boots LR**, **Bae S**, Effects of aging on adrenal function in the human: responsiveness and sensitivity of adrenal androgens and cortisol to adrenocorticotropin in premenopausal and postmenopausal women, J Clin Endocrinol Metab 85:48, 2000.
157. **Labrie F**, **Bélanger A**, **Cusan L**, **Gomez J-L**, **Candas B**, Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging, J Clin Endocrinol Metab 82:2396, 1997.
158. **Burger HG**, **Dudley EC**, **Cui J**, **Dennerstein L**, **Hopper JL**, A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition, J Clin Endocrinol Metab 85:2832, 2000.
159. **Jabara S**, **Christenson LK**, **Wang CY**, **McAllister JM**, **Javitt NB**, **Dunaif A**, **Strauss JF III**, Stromal cells of the human postmenopausal ovary display a distinctive biochemical and molecular phenotype, J Clin Endocrinol Metab 88:484, 2003.
160. **Dowsett M**, **Cantwell B**, **Anshumala L**, **Jeffcoate SL**, **Harris SL**, Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin, J Clin Endocrinol Metab 66:672, 1988.
161. **Andreyko JL**, **Monroe SE**, **Marshall LA**, **Fluker MR**, **Nerenberg CA**, **Jaffe RB**, Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix), J Clin Endocrinol Metab 74:399, 1992.
162. **Sluijmer AV**, **Heineman MJ**, **De Jong FH**, **Evers JL**, Endocrine activity of the postmenopausal ovary: the

effects of pituitary down-regulation and oophorectomy, J Clin Endocrinol Metab 80:2163, 1995.
163. **Longcope C**, **Franz C**, **Morello C**, **Baker RS**, **Johnston CC Jr**, Steroid and gonadotropin levels in women during the peri-menopausal years, Maturitas 8:189, 1986.
164. **Laughlin GA**, **Barrett-Conner E**, **Kritz-Silverstin D**, **von Mühlen D**, Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study, J Clin Endocrinol Metab 85:645, 2000.
165. **Couzinet B**, **Meduri G**, **Lecce MG**, **Young J**, **Brailly S**, **Loosfelt H**, **Milgrom E**, **Schaison G**, The postmenopausal ovary is not a major androgen-producing gland, J Clin Endocrinol Metab 86:5060, 2001.
166. **Judd HL**, **Judd GE**, **Lucas WE**, **Yen SSC**, Endocrine function of the postmenopausal ovary; concentration of androgens and estrogens in ovarian and peripheral vein blood, J Clin Endocrinol Metab 39:1020, 1974.
167. **Judd HL**, **Shamonki IM**, **Frumar AM**, **Lagasse LD**, Origin of serum estradiol in postmenopausal women, Obstet Gynecol 59:680, 1982.
168. **Longcope C**, **Jaffe W**, **Griffing G**, Production rates of androgens and oestrogens in post-menopausal women, Maturitas 3:215, 1981.
169. **Adashi EY**, The climacteric ovary as a functional gonadotropin-driven androgen-producing gland, Fertil Steril 62:20, 1994.
170. **Beyene Y**, From Menarche to Menopause: Reproductive Lives of Peasant Women in Two Cultures, State University of New York Press, Albany, 1989.
171. **Lock M**, Encounters with Aging: Mythologies of Menopause in Japan and North America, University of California Press, Berkeley, 1993.
172. **Lock M**, Menopause in cultural context, Exp Gerontol 29:307, 1994.
173. **Moore B**, **Kombe H**, Climacteric symptoms in a Tanzanian community, Maturitas 13:229, 1991.
174. **Martin MC**, **Block JE**, **Sanchez SD**, **Arnaud CD**, **Beyene Y**, Menopause without symptoms: the endocrinology of menopause among rural Mayan Indians, Am J Obstet Gynecol 168:1839, 1993.
175. **Robinson G**, Cross-cultural perspectives on menopause, J Nerv Ment Dis 184:453, 1996.
176. **Richters JMA**, Menopause in different cultures, J Psychosom Obstet Gynecol 18:73, 1997.
177. **Gold EB**, **Sternfeld B**, **Kelsey JL**, **Brown C**, **Mouton C**, **Reame N**, **Salamone L**, **Stellato R**, Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age, Am J Epidemiol 152:463, 2000.
178. **Obermeyer CM**, Menopause across cultures: a review of the evidence, Menopause 7:184, 2000.
179. **Randolph JF Jr**, **Sowers M**, **Gold EB**, **Morh BA**, **Luborsky J**, **Santoro N**, **McConnell DS**, **Finkelstein JS**, **Kornenman SG**, **Matthews KA**, **Sternfeld B**, **Lasley BL**, Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status, J Clin Endocrinol Metab 88:1516, 2003.
180. **Van Voorhis BJ**, **Santoro N**, **Harlow S**, **Crawford SL**, **Randolph J**, The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause, Obstet Gynecol 112:101, 2008.
181. **Goldstein SR**, **Zeltser I**, **Horan CK**, **Snyder JR**, **Schwartz LB**, Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding, Am J Obstet Gynecol 177:102, 1997.
182. **Smith-Bindman R**, **Kerlikowske K**, **Feldstein VA**, **Subak L**, **Scheidler J**, **Segal M**, **Brand R**, **Grady D**, Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities, JAMA 280:1510, 1998.
183. **Gull B**, **Karlsson B**, **Milsom I**, **Granberg S**, Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer, Am J Obstet Gynecol 188:401, 2003.
184. **Gupta JK**, **Chien PF**, **Voit D**, **Clark TJ**, **Khan KS**, Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis, Acta Obstet Gynecol Scand 81:799, 2002.
185. Practice Bulletin No. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction, Obstet Gynecol 122(1):176, 2013.
186. Practice Bulletin No. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women, Obstet Gynecol

120(1):197, 2012.
187. **Einerth Y**, Vacuum curettage by the Vabra method. A simple procedure for endometrial diagnosis, Acta Obstet Gynecol Scand 61:373, 1982.
188. **Feldman S**, **Shapter A**, **Welch WR**, **Berkowitz RS**, Two-year follow-up of 263 patients with post/perimenopausal vaginal bleeding and negative initial biopsy, Gynecol Oncol 55:56, 1994.
189. **Lin HH**, **Wu MY**, **Shyu MK**, **Chen D**, **Tsai JL**, **Hsieh CY**, Clinical study of 381 postmenopausal bleeding patients, J Formos Med Assoc 92:241, 1993.
190. Practice Bulletin No. 168: cervical cancer screening and prevention, Obstet Gynecol 128(4):e111, 2016.
191. **Royal College of Obstetricians and Gynaecologists (RCOG)** with the **British Society for Gynaecological Endoscopy (BSGE)**, Management of Endometrial Hyperplasia. Green-top Guideline Royal College of Obstetricians and Gynaecologists (RCOG) with the British Society for Gynaecological Endoscopy (BSGE). Management of Endometrial Hyperplasia. Green-top Guideline Royal College of Obstetricians and Gynaecologists (RCOG) with the British Society for Gynaecological Endoscopy (BSGE). Management of Endometrial Hyperplasia. Green-top Guideline No. 67, RCOG/BSGE Joint Guideline, London, 2016.
192. **Reed SD**, **Voigt LF**, **Newton KM**, **Garcia RH**, **Allison K**, **Epplein M**, **Jordan D**, **Swisher E**, **Weiss NS**, Progestin therapy of complex endometrial hyperplasia with and without atypia, Obstet Gynecol 113:655, 2009.
193. **Gebbie AE**, **Glasier A**, **Sweeting V**, Incidence of ovulation in perimenopausal women before and during hormone replacement therapy, Contraception 52:221, 1995.
194. **Casper RF**, **Dodin S**, **Reid RL**; **Study Investigators**, The effect of 20 μg ethinyl estradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women, Menopause 4:139, 1997.
195. **Castracane VD**, **Gimpel T**, **Goldzieher JW**, When is it safe to switch from oral contraceptives to hormonal replacement therapy?, Contraception 52:371, 1995.
196. **Creinin MD**, Laboratory criteria for menopause in women using oral contraceptives, Fertil Steril 66:101, 1996.
197. **Crosignani PG**, **Vercellini P**, **Mosconi P**, **Oldani S**, **Cortesi I**, **De Giorgi O**, Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding, Obstet Gynecol 90:257, 1997.
198. **Kaunitz AM**, **Meredith S**, **Inki P**, **Kubba A**, **Sanchez-Ramos L**, Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding. A systematic review and meta-analysis, Obstet Gynecol 113:1104, 2009.
199. **Irvine GA**, **Campbell-Brown MB**, **Lumsden MA**, **Heikkila A**, **Walker JJ**, **Cameron IT**, Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia, Br J Obstet Gynaecol 105:592, 1998.
200. **Istre O**, **Trolle B**, Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection, Fertil Steril 76:304, 2001.
201. **Romer T**, Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea, Eur J Obstet Gynecol Reprod Biol 90:27, 2000.
202. **Bahamondes L**, **Ribeiro-Huguet P**, **de Andrade KC**, **Leon-Martins O**, **Petta CA**, Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma, Acta Obstet Gynecol Scand 82:580, 2003.
203. **Vereide AB**, **Kaino T**, **Sager G**, **Arnes M**, **Ørbo A**, Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia, Gynecol Oncol 101:214, 2006.
204. **Wildemeersch D**, **Pylyser K**, **De Wever N**, **Dhont M**, Treatment of non atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up, Maturitas 57:210, 2007.
205. **Wheeler DT**, **Bristow RE**, **Kurman RJ**, Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins, Am J Surg Pathol 31:988, 2007.
206. **Varma R**, **Soneja H**, **Bhatia K**, **Ganesan R**, **Rollason T**, **Clark TJ**, **Gupta JK**, The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia—a long-term follow-up study, Eur J Obstet Gynecol Reprod Biol 139:169, 2008.

207. **Haimovich S**, **Checa MA**, **Mancebo G**, **Fusté P**, **Carreras R**, Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device, Menopause 15:1002, 2008.
208. **Ørbo A**, **Arnes M**, **Hancke C**, **Vereide AB**, **Pettersen I**, **Larsen K**, Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only, Gynecol Oncol 111:68, 2008.
209. **Vereide AB**, **Arnes M**, **Straume B**, **Maltau JM**, **Ørbo A**, Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone, Gynecol Oncol 91:526, 2003.
210. **Gallos ID**, **Krishan P**, **Shehmar M**, **Ganesan R**, **Gupta JK**, LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study, Hum Reprod 28(11):2966, 2013.
211. **Inki P**, **Hurskainen R**, **Palo P**, **Ekholm E**, **Grenman S**, **Kivela A**, **Kujansuu E**, **Teperi J**, **Yliskoski M**, **Paavonen J**, Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy, Ultrasound Obstet Gynecol 20:381, 2002.
212. **Kroon E**, **Andolf E**, Diagnosis and follow-up of simple ovarian cysts detected by ultrasound in postmenopausal women, Obset Gynecol 85:211, 1995.
213. **Nardo LG**, **Kroon ND**, **Reginald PW**, Persistent unilocular ovarian cysts in a general population of postmenopausal women: is there a place for expectant management?, Obstet Gynecol 102:589, 2003.
214. **Kronnenberg F**, **Barnard RM**, Modulation of menopausal hot flashes by ambient temperature, J Therm Biol 17:43, 1992.
215. **Hunter M**, The South-East England longitudinal study of the climacteric and postmenopause, Maturitas 14:17, 1992.
216. **Oldenhave A**, **Jaszmann LJB**, **Haspels AA**, **Everaerd WTAM**, Impact of climacteric on well-being, Am J Obstet Gynecol 168:772, 1993.
217. **Hahn PM**, **Wong J**, **Reid RL**, Menopausal-like hot flashes reported in women of reproductive age, Fertil Steril 70:913, 1998.
218. **Guthrie JR**, **Dennerstein L**, **Hopper JL**, **Burger HG**, Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women, Obstet Gynecol 88:437, 1996.
219. **Williams RE**, **Kalilani L**, **DiBenedetti DB**, **Zhou X**, **Granger AL**, **Fehnel SE**, **Levine KB**, **Jordan J**, **Clark RV**, Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States, Climacteric 11:32, 2008.
220. **Rödström K**, **Bengtsson C**, **Lissner L**, **Milsom I**, **Sundh V**, **Bjorkelund C**, A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century, Menopause 9:156, 2002.
221. **Avis NE**, **Stellato R**, **Crawford S**, **Bromberger J**, **Ganz P**, **Cain V**, **Kagawa-Singer M**, Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups, Soc Sci Med 52:345, 2001.
222. **Schwingl PJ**, **Hulka BS**, **Harlow SD**, Risk factors for menopausal hot flashes, Obstet Gynecol 84:29, 1994.
223. **Pham KT**, **Grisso JA**, **Freeman EW**, Ovarian aging and hormone replacement therapy. Hormonal levels, symptoms, and attitudes of African-American and white women, J Gen Intern Med 12:230, 1997.
224. **Thurston RC**, **Sowers MR**, **Chang Y**, **Sternfeld B**, **Gold EB**, **Johnston JM**, **Matthews KA**, Adiposity and reporting of vasomotor symptoms among midlife women: the Study of Women's Health Across the Nation, Am J Epidemiol 167:78, 2008.
225. **Kronnenberg F**, Hot flashes: epidemiology and physiology, Ann N Y Acad Sci 592:52, 1990.
226. **Freeman EW**, **Sherif K**, Prevalence of hot flushes and night sweats around the world: a systematic review, Climacteric 10:197, 2007.
227. **Brown DE**, **Sievert LL**, **Morrison LA**, **Reza AM**, **Mills PS**, Do Japanese American women really have fewer hot flashes than European Americans? The Hilo Women's Health Study, Menopause 16:870, 2009.
228. **Politi MC**, **Schleinitz MD**, **Col NF**, Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis, J Gen Intern Med 23:1507, 2008.

229. **Col NF**, **Guthrie JR**, **Politi M**, **Dennerstein L**, Duration of vasomotor symptoms in middle-aged women: a longitudinal study, Menopause 16:453, 2009.
230. **Avis NE**, **Crawford SL**, **Greendale G**, **Bromberger JT**, **Everson-Rose SA**, **Gold EB**, **Hess R**, **Joffe H**, **Kravitz HM**, **Tepper PG**, **Thurston RC**; **Study of Women's Health Across the Nation**, Duration of menopausal vasomotor symptoms over the menopause transition, JAMA Intern Med 175(4):531, 2015.
231. **Freedman RR**, Hot flashes: behavioral treatments, mechanisms, and relation to sleep, Am J Med 118(Suppl 12B):124, 2005. Figure A.
232. **Freedman RR**, **Benton MD**, **Genik RJ II**, **Graydon FX**, Cortical activation during menopausal hot flashes, Fertil Steril 85:674, 2006.
233. **Wilkin JR**, Flushing reactions: consequences and mechanisms, Ann Intern Med 95:468, 1981.
234. **Aksel S**, **Schomberg DW**, **Tyrey L**, **Hammond CB**, Vasomotor symptoms, serum estrogens and gonadotropin levels in surgical menopause, Am J Obstet Gynecol 126:165, 1976.
235. **Freedman RR**, Physiology of hot flashes, Am J Hum Biol 13:453, 2001.
236. **Freedman RR**, Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes, Fertil Steril 70:332, 1998.
237. **Mohyi D**, **Tabassi K**, **Simon J**, Differential diagnosis of hot flashes, Maturitas 27:203, 1997.
238. **MacLennan AH**, **Henry D**, **Hills S**, **Moore V**, Oral oestrogen replacement therapy versus placebo for hot flushes, Menstrual Disorders Module of the Cochrane Database of Systematic Reviews, 2000.
239. **Pearce J**, **Hawton K**, **Blake F**, **Barlow D**, **Rees M**, **Fagg J**, **Keenan J**, Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study, J Psychosom Res 42:177, 1997.
240. **Raz R**, **Stamm WE**, A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infection, N Engl J Med 329:753, 1993.
241. **Caillouette JC**, **Sharp CF**, **Zimmerman GJ**, **Roy S**, Vaginal pH as a marker for bacterial pathogens and menopausal status, Am J Obstet Gynecol 176:1270, 1997.
242. **Roy S**, **Caillouette JC**, **Roy T**, **Faden JS**, Vaginal pH is similar to FSH for menopause diagnosis, Am J Obstet Gynecol 190:1272, 2004.
243. **Semmens JP**, **Wagner G**, Effects of estrogen therapy on vaginal physiology during menopause, Obstet Gynecol 66:15, 1985.
244. **Wilson PD**, **Faragher B**, **Butler B**, **Bullock D**, **Robinson EL**, **Brown ADG**, Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women, Br J Obstet Gynaecol 94:568, 1987.
245. **Bhatia NN**, **Bergman A**, **Karram MM**, Effects of estrogen on urethral function in women with urinary incontinence, Obstet Gynecol 160:176, 1989.
246. **Goes VR**, **Sartori MG**, **Baracat EC**, **Rodrigues de Lima G**, **Girao MJ**, Urodynamic and clinical evaluation of postmenopausal women with stress urinary incontinence before and after cyclic estrogen therapy, Clin Exp Obstet Gynecol 30:103, 2003.
247. **Al-Badr A**, **Ross S**, **Soroka D**, **Drutz HP**, What is the available evidence for hormone replacement therapy in women with stress urinary incontinence?, J Obstet Gynaecol Can 25:567, 2003.
248. **Fantl JA**, **Bump RC**, **Robinson D**, **McLish DK**, **Wyman JF**, Efficacy of estrogen supplementation in the treatment of urinary incontinence, Obstet Gynecol 88:745, 1996.
249. **Jackson S**, **Shepherd A**, **Brookes S**, **Abrams P**, The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind placebo-controlled trial, Br J Obstet Gynaecol 106:711, 1999.
250. **Steinauer JE**, **Waetjen LE**, **Vittinghoff E**, **Subak LL**, **Hulley SB**, **Grady D**, **Lin F**, **Brown JS**; for the **Heart and Estrogen/Progestin Replacement Study Research Group**, Postmenopausal hormone therapy. Does it cause incontinence?, Obstet Gynecol 106:940, 2005.
251. **Townsend MK**, **GCurhan GC**, **Resnick NM**, **Grodstein F**, Postmenopausal hormone therapy and incident urinary incontinence in middle-aged women, Am J Obstet Gynecol 200:86.e1, 2009.
252. **Waetjen LE**, **Feng W-Y**, **Ye J**, **Johnson WO**, **Greendale GA**, **Sampselle CM**, **Sternfield B**, **Harlow SD**,

Gold EB; for the **Study of Women's Health Across the Nation (SWAN)**, Factors associated with worsening and improving urinary incontinence across the menopausal transition, Obstet Gynecol 111:667, 2008.
253. **Waetjen LE**, **Ye J**, **Feng W-Y**, **Johnson WO**, **Greendale GA**, **Sampselle CM**, **Sternfield B**, **Harlow S**, **Gold EB**; for the **Study of Women's Health Across the Nation (SWAN)**, Association between menopausal transition stages and developing urinary incontinence, Obstet Gynecol 114:989, 2009.
254. **Cody JD**, **Jacobs ML**, **Richardson K**, **Moehrer B**, **Hextall A**, Oestrogen therapy for urinary incontinence in post-menopausal women, Cochrane Database Syst Rev 10:CD001405, 2012.
255. **Tzur T**, **Yohai D**, **Weintraub AY**, The role of local estrogen therapy in the management of pelvic floor disorders, Climacteric 19(2):162, 2016.
256. **Castelo-Branco C**, **Duran M**, **Gonzalez-Merlo J**, Skin collagen changes related to age and hormone replacement therapy, Maturitas 15:113, 1992.
257. **Savvas M**, **Lausrent GB**, Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants, Br J Obstet Gynaecol 100:154, 1993.
258. **Maheux R**, **Naud F**, **Rioux M**, **Grenier R**, **Lemay A**, **Guy J**, **Langevin M**, A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness, Am J Obstet Gynecol 170:642, 1994.
259. **Callens A**, **Vaillant L**, **Lecomte P**, **Berson M**, **Gall Y**, **Lorette G**, Does hormonal skin aging exist? A study of the influence of different hormone therapy regimens on the skin of postmenopausal women using non-invasive measurement techniques, Dermatology 193:289, 1996.
260. **Sator P-G**, **Schmidt JB**, **Sator MO**, **Huber JC**, **Hönigsmann H**, The influence of hormone replacement therapy on skin ageing. A pilot study, Maturitas 39:43, 2001.
261. **Holland EFN**, **Studd JWW**, **Mansell JP**, **Leather AT**, **Bailey AJ**, Changes in collagen composition and cross-links in bone and skin of osteoporotic postmenopausal women treated with percutaneous estradiol implants, Obstet Gynecol 83:180, 1994.
262. **Castelo-Branco C**, **Pons F**, **Gratacøs E**, **Fortuny A**, **Vanrell JA**, **Gonzalez-Merlo J**, Relationship between skin collagen and bone changes during aging, Maturitas 18:199, 1994.
263. **Creidi P**, **Faivre B**, **Agache P**, **Richard E**, **Haudiquet V**, **Sauvanet JP**, Effect of a conjugated oestrogen (Premarin) cream on aging facial skin. A comparative study with a placebo cream, Maturitas 19:211, 1994.
264. **Sator PG**, **Sator MO**, **Schmidt JB**, **Nahavandi H**, **Radakovic S**, **Huber JC**, **Hönigsmann H**, A prospective, randomized, double-blind, placebo-controlled study on the influence of hormone replacement therapy on skin aging in postmenopausal women, Climacteric 10:320, 2007.
265. **Dunn LB**, **Damesyn M**, **Moore AA**, **Reuben DB**, **Greendale GA**, Does estrogen prevent skin aging? Results from the First National Health and Nutrition Examination Survey (NHANES I), Arch Dermatol 133:339, 1997.
266. **Castelo-Branco C**, **Figueras F**, **Martínez de Osaba MJ**, **Vanrell JA**, Facial wrinkling in postmenopausal women. Effects of smoking status and hormone replacement therapy, Maturitas 29:75, 1998.
267. **Phillips TJ**, **Symons J**, **Menon S**; **HT Study Group**, Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women, J Am Acad Dermatol 59:397, 2008.
268. **Cauley JA**, **Petrini AM**, **LaPorte RE**, **Sandler RB**, **Bayles CM**, **Robertson RJ**, **Slemenda CW**, The decline of grip strength in the menopause: relationship to physical activity, estrogen use and anthropometric factors, J Chronic Dis 40:115, 1987.
269. **Phillips SK**, **Rook KM**, **Siddle NC**, **Bruce SA**, **Woldege RC**, Muscle weakness in women occurs at an earlier age than in men but strength is preserved by hormone replacement therapy, Clin Sci (Lond) 84:95, 1993.
270. **Preisinger E**, **Alacamlioglu Y**, **Saradeth T**, **Resch KL**, **Holzer G**, **Metka M**, Forearm bone density and grip strength in women after menopause with and without estrogen replacement therapy, Maturitas 21:57, 1995.
271. **Hammar ML**, **Lindgren R**, **Berg GE**, **Möller CG**, **Niklasson MK**, Effects of hormonal replacement therapy on postural balance among postmenopausal women, Obstet Gynecol 88:955, 1996.

272. **Naessen T**, **Lindmark B**, **Larsen H-C**, Better postural balance in elderly women receiving estrogens, Am J Obstet Gynecol 177:412, 1997.
273. **Ronkainen PHA**, **Kovanen V**, **Alen M**, **Pöllänen E**, **Palonen EM**, **Ankarberg-Lindgren C**, **Hämäläinen E**, **Turpeinen U**, **Kujala UM**, **Puolakka J**, **Kaprio J**, **Sipila S**, Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function: a study with monozygotic twin pairs, J Appl Physiol 107:25, 2009.
274. **Ballinger CB**, Psychiatric aspects of the menopause, Br J Psychiatr 156:773, 1990.
275. **Schmidt PJ**, **Rubinow DR**, Menopause-related affective disorders: a justification for further study, Am J Psychiatr 148:844, 1991.
276. **Gath D**, **Osborn M**, **Bungay G**, **Iles S**, **Day A**, **Bond A**, **Passingham C**, Psychiatric disorder and gynaecological symptoms in middle aged women: a community survey, Br Med J 294:213, 1987.
277. **Everson SA**, **Matthews KA**, **Guzick DS**, **Meilahn EN**, **Wing RR**, **Kuller LH**, Effects of surgical menopause on lipid levels and psychosocial characteristics: the Healthy Women Study, Health Psychol 14:435, 1995.
278. **Avis NE**, **Brambilla D**, **McKinlay SM**, **Vass K**, A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study, Ann Epidemiol 4:214, 1994.
279. **Kessler RC**, **McGonagle KA**, **Swartz M**, **Blazer DG**, **Nelson CB**, Sex and depression in the National Comorbidity Survey I: lifetime prevalence, chronicity and recurrence, J Affect Disord 29:85, 1993.
280. **Busch CM**, **Zonderman AB**, **Costa PT Jr**, Menopausal transition and psychological distress in a nationally representative sample: is menopause associated with psychological distress?, J Aging Health 6:209, 1994.
281. **Dennerstein L**, **Smith AMA**, **Morse C**, Psychological well-being, mid-life and the menopause, Maturitas 20:1, 1994.
282. **Mitchell ES**, **Woods NF**, Symptom experiences of midlife women: observations from the Seattle midlife women's health study, Maturitas 25:1, 1996.
283. **Van Hall EV**, **Verdel M**, **Van Der Velden J**, "Perimenopausal" complaints in women and men: a comparative study, J Womens Health 3:45, 1994.
284. **Calvaresi E**, **Bryan J**, Symptom experience in Australian men and women in midlife, Maturitas 44:225, 2003.
285. **Kim MJ**, **Yim G**, **Park HY**, Vasomotor and physical menopausal symptoms are associated with sleep quality, PLoS One 13(2):e0192934, 2018.
286. **Shaver JL**, **Woods NF**, Sleep and menopause: a narrative review, Menopause 22(8):899, 2015.
287. **Bromberger JT**, **Schott LL**, **Avis NE**, **Crawford SL**, **Harlow SD**, **Joffe H**, **Kravitz HM**, **Matthews KA**, Psychosocial and health-related risk factors for depressive symptom trajectories among midlife women over 15 years: Study of Women's Health Across the Nation (SWAN), Psychol Med 49(2):250, 2018.
288. **Chung HF**, **Pandeya N**, **Dobson AJ**, **Kuh D**, **Brunner EJ**, **Crawford SL**, **Avis NE**, **Gold EB**, **Mitchell ES**, **Woods NF**, **Bromberger JT**, **Thurston RC**, **Joffe H**, **Yoshizawa T**, **Anderson D**, **Mishra GD**, The role of sleep difficulties in the vasomotor menopausal symptoms and depressed mood relationships: an international pooled analysis of eight studies in the InterLACE consortium, Psychol Med 48(15):2550, 2018.
289. **Guthrie KA**, **Larson JC**, **Ensrud KE**, **Anderson GL**, **Carpenter JS**, **Freeman EW**, **Joffe H**, **LaCroix AZ**, **Manson JE**, **Morin CM**, **Newton KM**, **Otte J**, **Reed SD**, **McCurry SM**, Effects of pharmacologic and nonpharmacologic interventions on insomnia symptoms and self-reported sleep quality in women with hot flashes: a pooled analysis of individual participant data from four MsFLASH trials, Sleep 41(1), 2018. doi: 10.1093/sleep/zsx190.
290. **Freeman EW**, **Sammel MD**, **Lin HM**, **Nelson DB**, Associations of hormones and menopausal status with depressed mood in women with no history of depression, Arch Gen Psychiatry 63:375, 2006.
291. **Cohen LS**, **Soares CN**, **Vitonis AF**, **Otto MW**, **Harlow BL**, Risk for new onset of depression during the menopausal transition. The Harvard Study of Moods and Cycles, Arch Gen Psychiatry 63:385, 2006.
292. **Bromberger JT**, **Kravits HM**, **Matthews K**, **Youk A**, **Brown C**, **Feng W**, Predictors of first lifetime episodes of major depression in midlife women, Psychol Med 39:55, 2009.
293. **Kravitz HM**, **Janssen I**, **Bromberger JT**, **Matthews KA Hall MH**, **Ruppert K**, **Joffe H**, Sleep

trajectories before and after the final menstrual period in the Study of Women's Health Across the Nation (SWAN), Curr Sleep Med Rep 3(3):235, 2017.
294. **Prairie BA**, **Wisniewski SR**, **Luther J**, **Hess R**, **Thurston RC**, **Wisner KL**, **Bromberger JT**, Symptoms of depressed mood, disturbed sleep, and sexual problems in midlife women: cross-sectional data from the Study of Women's Health Across the Nation, J Womens Health (Larchmt) 24(2):119, 2015.
295. **Campbell S**, **Whitehead M**, Estrogen therapy and the menopausal syndrome, Clin Obstet Gynecol 4:31, 1977.
296. **Avis NE**, **Crawford S**, **Stellato R**, **Longcope C**, Longitudinal study of hormone levels and depression among women transitioning through menopause, Climacteric 4:243, 2001.
297. **Kuh DL**, **Wadsorth M**, **Hardy R**, Women's health in midlife: the influence of the menopause, social factors and health in earlier life, Br J Obstet Gynaecol 104:923, 1997.
298. **Wiklund I**, **Karlberg J**, **Mattsson L-A**, Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study, Am J Obstet Gynecol 168:824, 1993.
299. **Daly E**, **Gray A**, **Barlow D**, **McPherson K**, **Roche M**, **Vessey M**, Measuring the impact of menopausal symptoms on quality of life, Br Med J 307:836, 1993.
300. **Hlatky MA**, **Boothroyd D**, **Vittinghoff E**, **Sharp P**, **Whooley MA**; for the **HERS Research Group**, Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/progestin Replacement Study (HERS) trial, JAMA 287:591, 2002.
301. **Hays J**, **Ockene JK**, **Brunner RL**, **Kotchen JM**, **Manson JE**, **Patterson RE**, **Aragaki AK**, **Shumaker SA**, **Brzyski RG**, **LaCroix AZ**, **Granek IA**, **Valanis BG**; **Women's Health Initiative Investigators**, Effects of estrogen plus progestin on health-related quality of life, N Engl J Med 348:1839, 2003.
302. **Welton AJ**, **Vickers MR**, **Kim JJ**, **Ford D**, **Lawton BA**, **MacLennan AH**, **Meredith SK**, **Martin J**, **Meade TW**; for the **WISDOM team**, Health related quality of life after combined hormone replacement therapy: randomised controlled trial, Br Med J 337:a119, 2008. doi: 10.1136/bmj.a1190.
303. **Woodward S**, **Freedman RR**, The thermoregulatory effects of menopausal hot flashes on sleep, Sleep 17:497, 1994.
304. **Freedman RR**, **Roehrs TA**, Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance, Menopause 13:576, 2006.
305. **Ensrud KE**, **Stone KL**, **Blackwell TL**, **Sawaya GF**, **Tagliaferri M**, **Diem SJ**, **Grady D**, Frequency and severity of hot flashes and sleep disturbance in postmenopausal women with hot flashes, Menopause 16:286, 2009.
306. **Schiff I**, **Regestein Q**, **Tulchinsky D**, **Ryan KJ**, Effects of estrogens on sleep and psychological state of hypogonadal women, JAMA 242:2405, 1979.
307. **Polo-Kantola P**, **Erkkola R**, **Helenius H**, **Irjala K**, **Polo O**, When does estrogen replacement therapy improve sleep quality?, Am J Obstet Gynecol 178:1002, 1998.
308. **Kravitz HM**, **Ganz PA**, **Bromberger J**, **Powell LH**, **Sutton-Tyrrell K**, **Meyer PM**, Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition, Menopause 10:19, 2003.
309. **Kravitz HM**, **Zhao X**, **Bromberger JT**, **Gold EB**, **Hall MH**, **Matthews KA**, **Sowers MR**, Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women, Sleep 31:979, 2008.
310. **Dennerstein L**, **Burrows GD**, **Hyman GJ**, **Wood C**, Hormone therapy and affect, Maturitas 1:247, 1979.
311. **Sherwin BB**, Affective changes with estrogen and androgen replacement therapy in surgically menopausal women, J Affect Disord 14:177, 1988.
312. **Palinkas LA**, **Barrett-Connor E**, Estrogen use and depressive symptoms in postmenopausal women, Obstet Gynecol 80:30, 1992.
313. **Limouzin-Lamothe M-A**, **Mairon N**, **Joyce CRB**, **Le Gal M**, Quality of life after the menopause: influence of hormonal replacement therapy, Am J Obstet Gynecol 170:618, 1994.
314. **Tosteson AN**, **Gabriel SE**, **Kneeland TS**, **Moncur MM**, **Manganiello PD**, **Schiff I**, **Ettinger B**, **Melton LJ III**, Has the impact of hormone replacement therapy on health-related quality of life been undervalued?, J Womens Health Gend Based Med 9:119, 2000.
315. **Schneider LS**, **Small GW**, **Hamilton SH**, **Bystritsky A**, **Nemeroff CB**, **Meyers BS**; the **Fluoxetine**

Collaborative Study Group, Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial, Am J Geriatr Psychiatry 5:97, 1997.
316. **de Novaes Soares C**, **Almeida OP**, **Joffe H**, **Cohen LS**, Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. A double-blind, randomized, placebo-controlled trial, Arch Gen Psychiatry 58:529, 2001.
317. **Schmidt PJ**, **Nieman LK**, **Danaceau MA**, **Tobin MB**, **Roca CA**, **Murphy JH**, **Rubinow DR**, Estrogen replacement in perimenopause-related depression: a preliminary report, Am J Obstet Gynecol 183:414, 2000.
318. **Gregoire AJ**, **Kumar R**, **Everitt B**, **Henderson AF**, **Studd JW**, Transdermal oestrogen for treatment of severe postnatal depression, Lancet 347:930, 1996.
319. **Ahokas A**, **Kaukoranta J**, **Wahlbeck K**, **Aito M**, Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study, J Clin Psychiatry 62:332, 2001.
320. **Bromberger JT**, **Assmann SF**, **Avis NE**, **Schocken M**, **Kravitzl HM**, **Cordal A**, Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women, Am J Epidemiol 158:347, 2003.
321. **Sherwin BB**, Estrogen effects on cognition in menopausal women, Neurol 48(Suppl 7):S21, 1997.
322. **Rice MM**, **Graves AB**, **Mcurry SM**, **Larson EB**, Estrogen replacement therapy and cognitive function in postmenopausal women without dementia, Am J Med 103(3A):26S, 1997.
323. **Ditkoff EC**, **Crary WG**, **Cristo M**, **Lobo RA**, Estrogen improves psychological function in asymptomatic postmenopausal women, Obstet Gynecol 78:991, 1991.
324. **Polo-Kantola P**, **Portin R**, **Polo O**, **Helenius H**, **Irjala K**, **Erkkola R**, The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women, Obstet Gynecol 91:459, 1998.
325. **Henderson VW**, **Guthrie JR**, **Dudley EC**, **Burger HG**, **Dennerstein L**, Estrogen exposures and memory at midlife: a population-based study of women, Neurology 60:1369, 2003.
326. **Meyer PM**, **Powell LH**, **Wilson RS**, **Everson-Rose SA**, **Kravitz HM**, **Luborsky JL**, **Madden T**, **Pandey D**, **Evans DA**, A population-based longitudinal study of cognitive functioning in the menopausal transition, Neurology 61:801, 2003.
327. **Phillips SM**, **Sherwin BB**, Effects of estrogen on memory function in surgically menopausal women, Psychoneuroendocrinology 17:485, 1992.
328. **Kampen DL**, **Sherwin BB**, Estrogen use and verbal memory in healthy postmenopausal women, Obstet Gynecol 83:979, 1994.
329. **Smith YR**, **Giordani B**, **Lajiness-O'Neill R**, **Zubieta J-K**, Long-term estrogen replacement is associated with improved nonverbal memory and attentional measures in postmenopausal women, Fertil Steril 76:1101, 2001.
330. **Robinson D**, **Friedman L**, **Marcus R**, **Tinklenberg J**, **Yesavage J**, Estrogen replacement therapy and memory in older women, J Am Geriatr Soc 42:919, 1994.
331. **Resnick SM**, **Metter EJ**, **Zonderman AB**, Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect, Neurology 49:1491, 1997.
332. **Maki PM**, **Zonderman AB**, **Resnick SM**, Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy, Am J Psychiatry 158:227, 2001.
333. **Jacobs DM**, **Tang MX**, **Stern Y**, **Sano M**, **Marder K**, **Bell KL**, **Schofield P**, **Dooneief G**, **Gurland B**, **Mayeux R**, Cognitive function in nondemented older women who took estrogen after menopause, Neurology 50:368, 1998.
334. **Matthews K**, **Cauley J**, **Yaffe K**, **Zmuda JM**, Estrogen replacement therapy and cognitive decline in older community women, J Am Geriatr Soc 47:518, 1999.
335. **Shaywitz SE**, **Naftolin F**, **Zelterman D**, **Marchione KE**, **Holahan JM**, **Palter SF**, **Shaywitz BA**, Better oral reading and short-term memory in midlife, postmenopausal women taking estrogen, Menopause 10:420, 2003.
336. **Yaffe K**, **Lui L-Y**, **Grady D**, **Cauley J**, **Kramer J**, **Cummings SR**, Cognitive decline in women in relation to

non-protein-bound oestradiol concentrations, Lancet 356:708, 2000.
337. **Yaffe K**, **Haan M**, **Byers A**, **Tangen C**, **Kuller L**, Estrogen use, APOE, and cognitive decline. Evidence of gene-environment interaction, Neurology 54:1949, 2000.
338. **Behl C**, **Skutella T**, **Lezoualc'h F**, **Post A**, **Widmann M**, **Newton CJ**, **Holsboer F**, Neuroprotection against oxidative stress by estrogens: structure-activity relationship, Mol Pharm 51:535, 1997.
339. **Hashimoto S**, **Katou M**, **Dong Y**, **Murakami K**, **Terada S**, **Inoue M**, Effects of hormone replacement therapy on serum amyloid P component in postmenopausal women, Maturitas 26:113, 1997.
340. **Wooley CS**, **Weiland NG**, **McEwen BS**, **Schwartzkroin PA**, Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density, J Neurosci 17:1848, 1997.
341. **Rhodin JA**, **Thomas TN**, **Clark L**, **Garces A**, **Bryant M**, In vivo cerebrovascular actions of amyloid beta-peptides and the protective effect of conjugated estrogens, J Alzheimers Dis 5:275, 2003.
342. **Zhao L**, **Chen S**, **Brinton RD**, An estrogen replacement therapy containing nine synthetic plant-based conjugated estrogens promotes neuronal survival, Exp Biol Med 228:823, 2003.
343. **Diaz Brinton R**, **Chen S**, **Montoya M**, **Hsieh D**, **Minaya J**, **Kim J**, **Chu HP**, The Women's Health Initiative estrogen replacement therapy is neurotrophic and neuroprotective, Neurobiol Aging 21:475, 2003.
344. **Paganini-Hill A**, **Henderson VW**, Estrogen replacement therapy and risk of Alzheimer disease, Arch Intern Med 156:2213, 1996.
345. **Henderson VW**, The epidemiology of estrogen replacement therapy and Alzheimer's disease, Neurol 48(Suppl 7):S27, 1997.
346. **Waring SC**, **Rocca WA**, **Petersen RC**, **O'Brien PC**, **Tangalos EG**, **Kokmen E**, Postmenopausal estrogen replacement therapy and risk of AD. A population-based study, Neurology 52:965, 1999.
347. **Kawas C**, **Resnick S**, **Morrison A**, **Brookmeyer R**, **Corrada M**, **Zonderman A**, **Bacal C**, **Lingle D**, **Metter E**, A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging, Neurology 48:1517, 1997.
348. **Tang M-X**, **Jacobs D**, **Stern Y**, **Marder K**, **Schofield P**, **Gurland B**, **Andrews H**, **Mayeux R**, Effect of oestrogen during menopause on risk and age of onset of Alzheimer's disease, Lancet 348:429, 1996.
349. **Baldereschi M**, **Di Carlo A**, **Lepore V**, **Bracco L**, **Maggi S**, **Grigoletto F**, **Scarlato G**, **Amaducci L**; for the **ILSA Working Group**, Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging, Neurol 50:996, 1998.
350. **Seshadri S**, **Zornberg GL**, **Derby LE**, **Meyers MW**, **Jick H**, **Drachman DA**, Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease, Arch Neurol 58:435, 2001.
351. **Henderson V**, **Paganini-Hill A**, **Emanuel CK**, **Dunn ME**, **Buckwalter G**, Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects, Arch Neurol 51:896, 1994.
352. **Henderson VW**, **Paganini-Hill A**, **Miller BL**, **Elble RJ**, **Reyes PF**, **Shoupe D**, **McClearly CA**, **Klein RA**, **Hake AM**, **Farlow MR**, Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial, Neurology 54:295, 2000.
353. **Wang PN**, **Liao SQ**, **Liu RS**, **Liu CY**, **Chao HT**, **Lu SR**, **Yu HY**, **Wang SJ**, **Liu HC**, Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study, Neurology 54:2061, 2000.
354. **Mulnard RA**, **Cotman CW**, **Kawas C**, **van Dyck CH**, **Sano M**, **Doody R**, **Koss E**, **Pfeiffer E**, **Jin S**, **Gamst A**, **Grundman M**, **Thomas R**, **Thal LJ**, Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study, JAMA 284:1007, 2000.
355. **Asthani S**, **Craft S**, **Baker LD**, **Raskind MA**, **Birnbaum RS**, **Lofgreen CP**, **Veith RC**, **Plymate SR**, Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study, Psychoneuroendocrinology 24:657, 1999.
356. **Yoon BK**, **Kim DK**, **Kang Y**, **Kim JW**, **Shin MH**, **Na DL**, Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study, Fertil Steril 79:274, 2003.
357. **Schneider LS**, **Farlow MR**, **Henderson VW**, **Pogoda J**, Effects of estrogen replacement therapy on

response to tacrine in patients with Alzheimer's disease, Neurology 46:1580, 1996.
358. **Hogervorst E**, **Yaffe K**, **Richards M**, **Huppert FA**, Hormone replacement therapy to maintain cognitive function in women with dementia, Cochrane Database Syst Rev (1):CD003799, 2009.
359. **Zandi PP**, **Carlson MC**, **Plassman BL**, **Welsh-Bohmer KA**, **Mayer LS**, **Steffens DC**, **Breitner JCS**; for the **Cache County Memory Study Investigators**, Hormone replacement therapy and incidence of Alzheimer disease in older women. The Cache County Study, JAMA 288:2123, 2002.
360. **Steffens DC**, **Norton MC**, **Plassman BL**, **Tschanz JT**, **Wyse BW**, **Welsh-Bohmer KA**, **Anthony JC**, **Breitner JCS**, Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women, J Am Geriatr Soc 47:1171, 1999.
361. **Shumaker SA**, **Legault C**, **Rapp SR**, **Thal L**, **Wallace RB**, **Ockene JK**, **Hendrix SL**, **Jones BN III**, **Assaf AR**, **Jackson RD**, **Kotchen JM**, **Wassertheil-Smoller S**, **Wactawski-Wende J**; for the **WHIMS Investigators**, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial, JAMA 289:2651, 2003.
362. **Rapp SR**, **Espeland MA**, **Shumaker SA**, **Henderson VW**, **Brunner RL**, **Manson JE**, **Gass MLS**, **Stefanick ML**, **Lande DS**, **Hays J**, **Johnson KC**, **Coker LH**, **Dailey M**, **Bowen D**; for the **WHIMS Investigators**, Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial, JAMA 289:2663, 2003.
363. **Espeland MA**, **Rapp SR**, **Shumaker SA**, **Brunner RL**, **Manson JE**, **Sherwin BB**, **Hsia J**, **Margolis KL**, **Hogan PE**, **Wallace R**, **Dailey M**, **Freeman R**, **Hays J**; **Women's Health Initiative Memory Study**, Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study, JAMA 291:2959, 2004.
364. **Resnick SM**, **Espeland MA**, **Jaramillo SA**, **Hirsch C**, **Stefanick ML**, **Murray AM**, **Ockene J**, **Davatzikos C**; for the **Women's Health Initiative Memory Study**, Postmenopausal hormone therapy and regional brain volumes. The WHIMS-MRI study, Neurology 72:135, 2009.
365. **Coker LH**, **Hogan PE**, **Bryan NR**, **Kuller LH**, **Margolis KL**, **Bettermann K**, **Wallace RB**, **Lao Z**, **Freeman R**, **Stefanick ML**, **Shumaker SA**; for the **Women's Health Initiative Memory Study**, Postmenopausal hormone therapy and subclinical cerebrovascular disease. The WHIMS-MRI study, Neurology 72:125, 2009.
366. **Erickson KI**, **Colcombe SJ**, **Raz N**, **Korol DL**, **Scalf P**, **Webb A**, **Cohen NJ**, **McAuley E**, **Kramer AF**, Selective sparing of brain tissue in postmenopausal women receiving hormone replacement therapy, Neurobiol Aging 26:1205, 2005.
367. **Ghidoni R**, **Boccardi M**, **Benussi L**, **Testa C**, **Villa A**, **Pievani M**, **Gigola L**, **Sabattoli F**, **Barbiero L**, **Frisoni GB**, **Binetti G**, Effects of estrogens on cognition and brain morphology: involvement of the cerebellum, Maturitas 54:222, 2006.
368. **Lord C**, **Buss C**, **Lupien SJ**, **Pruessner JC**, Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: a possible window of opportunity effect, Neurobiol Aging 29:95, 2008.
369. **Gleason CE**, **Dowling NM**, **Wharton W**, **Manson JE**, **Miller VM**, **Atwood CS**, **Brinton EA**, **Cedars MI**, **Lobo RA**, **Merriam GR**, **Neal-Perry G**, **Santoro NF**, **Taylor HS**, **Black DM**, **Budoff MJ**, **Hodis HN**, **Naftolin F**, **Harman SM**, **Asthana S**, Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study, PLoS Med 12(6):e1001833, 2015.
370. **Kantarci K**, **Lowe VJ**, **Lesnick TG**, **Tosakulwong N**, **Bailey KR**, **Fields JA**, **Shuster LT**, **Zuk SM**, **Senjem ML**, **Mielke MM**, **Gleason C**, **Jack CR**, **Rocca WA**, **Miller VM**, Early postmenopausal transdermal 17beta-estradiol therapy and amyloid-beta deposition, J Alzheimers Dis 53(2):547, 2016.
371. **Brinton RD**, The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications, Trends Neurosci 31:529, 2008.
372. **National Heart, Lung, and Blood Institute**, Heart Disease in Women, https://www.nhlbi.nih.gov/health-topics/heart-disease-women, 2018.

373. **Clarkson TB**, **Prichard RW**, **Morgan TM**, **Petrick GS**, **Klein KP**, Remodeling of coronary arteries in human and nonhuman primates, JAMA 271:289, 1994.
374. **Galis ZS**, **Khatri JJ**, Matrix metalloproteinases in vascular remodelling and atherogenesis. The good, the bad and the ugly, Circ Res 90:251, 2002.
375. **Umetani M**, **Domoto H**, **Gormley AK**, **Yuhanna IS**, **Cummins CL**, **Javitt NB**, **Korach KS**, **Shaul PW**, **Mangelsdorf DJ**, 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen, Nat Med 13:1185, 2007.
376. **Matthews KA**, **Meilahn E**, **Kuller LH**, **Kelsey SF**, **Caggiula AW**, **Wing RR**, Menopause and risk factors for coronary heart disease, N Engl J Med 321:641, 1989.
377. **Campos H**, **McNamara JR**, **Wilson PW**, **Ordovas JM**, **Schaefer EJ**, Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women, J Clin Endocrinol Metab 67:30, 1988.
378. **Jensen J**, **Nilas L**, **Christiansen C**, Influence of menopause on serum lipids and lipoproteins, Maturitas 12:321, 1990.
379. **Stevenson JC**, **Crook D**, **Godsland IF**, Influence of age and menopause on serum lipids and lipoproteins in healthy women, Atherosclerosis 98:83, 1993.
380. **Matthews KA**, **Crawford SL**, **Chae CU**, **Everson-Rose SA**, **Sowers MF**, **Sternfeld B**, **Sutton-Tyrrell K**, Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?, J Am Coll Cardiol 54:2366, 2009.
381. **van Beresteijn ECH**, **Korevaar JC**, **Huijbregts PCW**, **Schouten EG**, **Burema J**, **Kok FJ**, Perimenopausal increase in serum cholesterol: a 10-year longitudinal study, Am J Epidemiol 137:383, 1993.
382. **Matthews KA**, **Wing RR**, **Kuller LH**, **Meilahn EN**, **Plantinga P**, Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women, Arch Intern Med 154:2349, 1994.
383. **Bruschi F**, **Meschia M**, **Soma M**, **Perotti D**, **Paoletti R**, **Crosignani PG**, Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy, Obstet Gynecol 88:950, 1996.
384. **Brunner D**, **Weisbort J**, **Meshulam N**, **Schwartz S**, **Gross J**, **Saltz-Rennert H**, **Altman S**, **Loebl K**, Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study, Am J Cardiol 59:1271, 1987.
385. **Jacobs DR Jr**, **Mebane IL**, **Bangdiwala SI**, **Criqui MH**, **Tyroler HA**, High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study, Am J Epidemiol 131:32, 1990.
386. **Hulley SB**, **Newman TB**, Cholesterol in the elderly: is it important?, JAMA 272:1372, 1994.
387. **Kannel WB**, Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study, Am Heart J 114:413, 1987.
388. **Downs JR**, **Clearfield M**, **Weis S**, **Whitney E**, **Shapiro DR**, **Beere PA**, **Langendorger A**, **Stein EA**, **Kruyer W**, **Gotto AM Jr**; for the **AFCAPS/TexCAPS Research Group**, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS, JAMA 279:1615, 1998.
389. **Bittner V**, **Simon JA**, **Fong J**, **Blumenthal RS**, **Newby K**, **Stefanick ML**, Correlates of high HDL cholesterol among women with coronary heart disease, Am Heart J 139:288, 2000.
390. **Ford ES**, **Giles WH**, **Dietz WH**, Prevalence of the metabolic syndrome among U.S. adults. Findings from the Third National Health and Nutrition Examination Survey, JAMA 287:356, 2002.
391. **Park YW**, **Zhu S**, **Palaniappan L**, **Heshka S**, **Carnethon MR**, **Heymsfield SB**, The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994, Arch Intern Med 163:427, 2003.
392. **Alberti KG**, **Eckel RH**, **Grundy SM**, **Zimmet PZ**, **Cleeman JI**, **Donato KA**, **Fruchart JC**, **James WP**, **Loria CM**, **Smith SC Jr**; **International Diabetes Federation Task Force on Epidemiology and Prevention**; **National Heart, Lung, and Blood Institute**; **American Heart Association**; **World Heart Federation**; **International Atherosclerosis Society**; **International Association for the Study of**

Obesity, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation 120:1640, 2009.

393. **Janssen I**, **Powell LH**, **Crawford S**, **Lasley B**, **Sutton-Tyrrell K**, Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation (SWAN), Arch Intern Med 168:1568, 2008.
394. **Torréns JI**, **Sutton-Tyrrell K**, **Zhao X**, **Matthews K**, **Brockwell S**, **Sowers M**, **Santoro N**, Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of women's health across the nation, Menopause 16:257, 2009.
395. **Lapidus L**, **Bengtsson C**, **Larsson B**, **Pennert K**, **Rybo E**, **Sjostrom L**, Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Br Med J 289:1257, 1984.
396. **Haarbo J**, **Hassager C**, **Riis BJ**, **Christiansen C**, Relation of body fat distribution to serum lipids and lipoproteins in elderly women, Atherosclerosis 80:57, 1989.
397. **Soler JT**, **Folsom AR**, **Kaye SA**, **Prineas RJ**, Associations of abdominal adiposity, fasting insulin, sex hormone binding globulin and estrogen with lipids and lipoproteins in post-menopausal women, Atherosclerosis 79:21, 1989.
398. **Wing R**, **Matthews K**, **Kuller L**, **Meilahn EN**, **Plantinga PL**, Weight gain at the time of menopause, Arch Intern Med 151:97, 1990.
399. **Expert Panel on Detection Evaluation** and **Treatment of High Blood Cholesterol in Adults**, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA 285:2486, 2001.
400. **LaRosa JC**, **He J**, **Vupputuri S**, Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials, JAMA 282:2340, 1999.
401. **Mostaghel E**, **Waters D**, Women do benefit from lipid lowering: latest clinical trial data, Cardiol Rev 11:4, 2003.
402. **Barker DJP**, **Martyn CN**, **Osmond C**, **Hales CN**, **Fall CHD**, Growth in utero and serum cholesterol concentrations in adult life, Br Med J 307:1524, 1993.
403. **Fall CHD**, **Osmond C**, **Barker DJP**, **Clark PMS**, **Hales CN**, **Stirling Y**, **Meade TW**, Fetal and infant growth and cardiovascular risk factors in women, Br Med J 310:428, 1995.
404. **Ross R**, Atherosclerosis—an inflammatory disease, N Engl J Med 340:115, 1999.
405. **Ridker P**, **Cushman M**, **Stampfer MJ**, **Tracy RP**, **Hennekens CH**, Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men, N Engl J Med 336:973, 1997.
406. **Ridker PM**, **Buring JE**, **Shih J**, **Matias M**, **Hennekens CH**, A prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women, Circulation 98:731, 1998.
407. **Ridker PM**, **Hennekens CH**, **Buring JE**, **Rifai N**, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med 342:836, 2000.
408. **Ridker PM**, **Rifai N**, **Rose L**, **Buring JE**, **Cook NR**, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N Engl J Med 347:1557, 2002.
409. **Albert MA**, **Ridker PM**, The role of C-reactive protein in cardiovascular disease risk, Curr Cardiol Reports 1:99, 1999.
410. **Kaplan RC**, **McGinn AP**, **Baird AE**, **Hendrix SL**, **Kooperberg C**, **Lynch J**, **Rosenbaum DM**, **Johnson KC**, **Strickler HD**, **Wassertheil-Smoller S**, Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study, J Stroke Cerebrovasc Dis 17(6):344, 2008.
411. **Danesh J**, **Whincup P**, **Walker M**, **Lennon L**, **Thomson A**, **Appleby P**, **Gallimore JR**, **Pepys MB**, Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses, Br Med J 321:199, 2000.
412. **Ridker PM**, **Rifai N**, **Pfeffer MA**, **Sacks F**, **Braunwald E**, Long-term effects of pravastatin on plasma

concentration of C-reactive protein, Circulation 100:230, 1999.
413. **Ridker PM**, **Rifai N**, **Pfeffer MA**, **Sacks FM**, **Moye LA**, **Goldman S**, **Flaker GC**, **Braunwald E**; for the **Cholesterol and Recurrent Events (CARE) Investigators**, Inflammation, pravastatin, and the risk of coronary events after myocardial infarction inpatients with average cholesterol levels, Circulation 98:839, 1998.
414. **Walsh BW**, **Paul S**, **Wild RA**, **Dean RA**, **Tracy RP**, **Cox DA**, **Anderson PW**, The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial, J Clin Endocrinol Metab 85:214, 2000.
415. **de Valk-de Roo GW**, **Stehouwer CDA**, **Meijer P**, **Mijatovic V**, **Kluft C**, **Kennemans P**, **Cohen F**, **Watts S**, **Netelenbos C**, Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study, Arterioscler Thromb Vasc Biol 19:2993, 1999.
416. **Prelevic GM**, **Kwong P**, **Byrne DJ**, **Jagroop IA**, **Ginsburg J**, **Mikhailidis DP**, A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women, Fertil Steril 77:945, 2002.
417. **Ridker PM**, **Hennekens CH**, **Rifai N**, **Buring JE**, **Manson JE**, Hormone replacement therapy and increased plasma concentrations of C-reactive protein, Circulation 100:713, 1999.
418. **Cushman M**, **Legault C**, **Barrett-Connor E**, **Stefanick ML**, **Kessler CJ**, **Judd HL**, **Sakkinen PA**, **Tracy RP**, Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study, Circulation 100:717, 1999.
419. **Frohlich M**, **Muhlberger N**, **Hanke H**, **Imhof A**, **Doring A**, **Pepys MB**, **Koenig W**, Markers of inflammation in women on different hormone replacement therapies, Ann Med 35:353, 2003.
420. **Lacut K**, **Oger E**, **Le Gal G**, **Blouch MT**, **Abgrall JF**, **Kerlan V**, **Scarabin PY**, **Mottier D**; **SARAH Investigators**, Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein, Thromb Haemost 90:124, 2003.
421. **Koh KK**, **Ahn JY**, **Jin DK**, **Yoon BK**, **Kim HS**, **Kim DS**, **Shin MS**, **Son JW**, **Choi IS**, **Shin EK**, Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women, Arterioscler Thromb Vasc Biol 22:1459, 2002.
422. **Silvestri A**, **Gebara O**, **Vitale C**, **Wajngarten M**, **Leonardo F**, **Ramieres JA**, **Fini M**, **Mercucro G**, **Rosano GM**, Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response, Circulation 107:3165, 2003.
423. **Pradhan AD**, **Manson JE**, **Rossouw JE**, **Siscovick DS**, **Mouton CP**, **Rifai N**, **Wallace RB**, **Jackson RD**, **Pettinger MB**, **Ridker PM**, Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. Prospective analysis from the Women's Health Initiative Observational Study, JAMA 288:980, 2002.
424. **Shlipak MG**, **Simon JA**, **Vittinghoff E**, **Lin F**, **Barrett-Connor E**, **Knopp RH**, **Levy RI**, **Hulley SB**, Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause, JAMA 283:1845, 2000.
425. **McGill HC Jr**, **McMahan CA**, **Zieske AW**, **Sloop GD**, **Walcott JV**, **Troxclair DA**, **Malcom GT**, **Tracy RE**, **Oalmann MC**, **Strong JP**, Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group, Arterioscler Thromb Vasc Biol 20:1998, 2000.
426. **McGill HC Jr**, **McMahan CA**, **Malcom GT**, **Oalmann MC**, **Strong JP**, Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group, Arterioscler Thromb Vasc Biol 17:95, 1997.
427. **van der Schouw YT**, **van der Graff Y**, **Steyerberg EW**, **Eijkemans JC**, **Banga JD**, Age at menopause as a risk factor for cardiovascular mortality, Lancet 347:714, 1996.
428. **de Kleijn MJ**, **Van der Schouw YT**, **Verbeek AL**, **Peeters PH**, **Banga JD**, **Van der Graff Y**, Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women, Am J Epidemiol 155:339, 2002.
429. **Kalantaridou SN**, **Naka KK**, **Papanikolaou E**, **Kazakos N**, **Kravariti M**, **Calis KA**, **Paraskevaidis EA**, **Sideris DA**, **Tsatsoulis A**, **Chrousos GP**, **Michalis LK**, Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy, J Clin Endocrinol Metab 89:3907, 2004.

430. **Kalantaridou SN**, **Naka KK**, **Bechlioulis A**, **Makrigiannakis A**, **Michalis L**, **Chrousos GP**, Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement, Trends Endocrinol Metab 17:101, 2006.
431. **Chowienczyk PJ**, **Watts GF**, **Cockcroft JR**, **Brett SE**, **Ritter JM**, Sex differences in endothelial function in normal and hypercholesterolaemic subjects, Lancet 344:305, 1994.
432. **Thurston RC**, **Sutton-Tyrrell K**, **Everson-Rose SA**, **Hess R**, **Matthews KA**, Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study, Circulation 118:1234, 2008.
433. **He H**, **Yang F**, **Liu X**, **Zeng X**, **Hu Q**, **Zhu Q**, **Tu B**, Sex hormone ratio changes in men and postmenopausal women with coronary artery disease, Menopause 14:385, 2007.
434. **Hamelin BA**, **Methot J**, **Arsenault M**, **Pilote S**, **Poirier P**, **Plante S**, **Bogaty P**, Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women, Am J Med 114:599, 2003.
435. **Matthews KA**, **Santoro N**, **Lasley B**, **Chang Y**, **Crawford S**, **Pasternak RC**, **Sutton-Tyrrell K**, **Sowers M**, Relation of cardiovascular risk factors in women approaching menopause to menstrual cycle characteristics and reproductive hormones in the follicular and luteal phases, J Clin Endocrinol Metab 91:1789, 2006.
436. **Rickenlund A**, **Eriksson MJ**, **Schenck-Gustafsson K**, **Hirschberg AL**, Amenorrhea in female athletes is associated with endothelial dysfunction and unfavorable lipid profile, J Clin Endocrinol Metab 90:1354, 2005.
437. **Rickenlund A**, **Eriksson MJ**, **Schenck-Gustafsson K**, **Hirschberg AL**, Oral contraceptives improve endothelial function in amenorrheic athletes, J Clin Endocrinol Metab 90:3162, 2005.
438. **Bairey Merz CN**, **Johnson BD**, **Sharaf BL**, **Bittner V**, **Berga SL**, **Braunstein GD**, **Hodgson TK**, **Matthews AE**, **Pepine CJ**, **Reis SE**, **Reichek N**, **Rogers WJ**, **Pohost GM**, **Kelsey SF**, **Sopko G**; for the **WISE Study Group**, Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study, J Am Coll Cardiol 41:413, 2003.
439. **Kaplan JR**, **Adams MR**, **Anthony MS**, **Morgan TM**, **Manuck SB**, **Clarkson TB**, Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys, Arterioscler Thromb Vasc Biol 15:2094, 1995.
440. **Kaplan JR**, **Manuck SB**, **Anthony MS**, **Clarkson TB**, Premenopausal social status and hormone exposure predict postmenopausal atherosclerosis in female monkeys, Am J Obstet Gynecol 99:381, 2002.
441. **Clarkson TB**, **Appt S**, Controversies about HRT—lessons from monkey models, Maturitas 51:64, 2005.
442. **Bairey Merz CN**, **Johnson BD**, **Berga SL**, **Braunstein G**, **Reis SE**, **Bittner V**; the **WISE Study Group**, Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation, Fertil Steril 85:1425, 2006.
443. **Hanke H**, **Hanke S**, **Ickrath O**, **Lange K**, **Bruck B**, **Muck AO**, **Seeger H**, **Zwirner M**, **Voisard R**, **Haasis R**, **Hombach V**, Estradiol concentrations in premenopausal women with coronary heart disease, Coron Artery Dis 8:511, 1997.
444. **Shively CA**, **Register TC**, **Friedman DP**, **Morgan TM**, **Thompson J**, **Lanaier T**, Social stress-associated depression in adult female cynomolgus monkeys (Macaca fascicularis), Biol Psychol 69:67, 2005.
445. **Agatisa PK**, **Matthews KA**, **Bromberger JT**, **Edmundowicz D**, **Chang YF**, **Sutton-Tyrrell K**, Coronary and aortic calcification in women with a history of major depression, Arch Intern Med 165:1229, 2005.
446. **Lewis TT**, **Everson-Rose SA**, **Colvin A**, **Matthews K**, **Bromberger JT**, **Sutton-Tyrrell K**, Interactive effects of race and depressive symptoms on calcification in African-American and white women, Psychosom Med 71:163, 2009.
447. **Clarkson TB**, **Anthony MS**, Hormone replacement therapy and coronary artery atherosclerosis: the monkey model, Br J Obstet Gynaecol 103(Suppl 13):53, 1996.
448. **Karim R**, **Mack WJ**, **Lobo RA**, **Hwang J**, **Liu C**, **Liu C**, **Sevanian A**, **Hodis HN**, Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: estrogen in the prevention of atherosclerosis trial, Menopause 12:366, 2005.
449. **Mendelsohn ME**, **Karas RH**, Molecular and cellular basis of cardiovascular gender differences, Science 308:1583, 2005.

450. **Zhu X**, **Bonet B**, **Knopp RH**, Estradiol 17beta inhibition of LDL oxidation and endothelial cell cytotoxicity is opposed by progestins to different degrees, Atherosclerosis 148:31, 2000.
451. **Wild RA**, **Painter PC**, **Coulson PB**, **Carruth KB**, **Ranney GB**, Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome, J Clin Endocrinol Metab 61:946, 1985.
452. **Wild RA**, **Van Nort JJ**, **Grubb B**, **Bachman W**, **Hartz A**, **Bartholomew M**, Clinical signs of androgen excess as risk factors for coronary artery disease, Fertil Steril 54:255, 1990.
453. **Graf MJ**, **Richards CJ**, **Brown V**, **Meissner L**, **Dunaif A**, The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women, Clin Endocrinol 33:119, 1990.
454. **Conway GS**, **Agrawal R**, **Betteridge DJ**, **Jacobs HS**, Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome, Clin Endocrinol 37:119, 1992.
455. **Wild RA**, **Alaupovic P**, **Parker IJ**, Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance, Am J Obstet Gynecol 166:1191, 1992.
456. **Talbott E**, **Guzick DS**, **Clerici A**, **Berga S**, **Detre K**, **Weimer K**, **Kuller L**, Coronary heart disease risk factors in women with polycystic ovary syndrome, Arterioscler Thromb Vasc Biol 15:821, 1995.
457. **Guzick DS**, **Talbott EO**, **Sutton-Tyrrell K**, **Herzog HC**, **Kuller LH**, **Wolfson SK Jr**, Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study, Am J Obstet Gynecol 174:1224, 1996.
458. **Birdsall MA**, **Farquhar CM**, **White HD**, Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization, Ann Intern Med 126:32, 1997.
459. **Solomon CG**, **Hu FB**, **Dunaif A**, **Rich-Edwards JE**, **Stampfer MJ**, **Willett WC**, **Speizer FE**, **Manson JE**, Menstrual cycle irregularity and risk for future cardiovascular disease, J Clin Endocrinol Metab 87:2013, 2002.
460. **Liu PY**, **Death AK**, **Handelsman DJ**, Androgens and cardiovascular disease, Endocr Rev 24:313, 2003.
461. **Muller M**, **Grobbee DE**, **den Tonkelaar I**, **Lamberts SW**, **Van der Schouw YT**, Endogenous sex hormones and metabolic syndrome in aging men, J Clin Endocrinol Metab 90:2618, 2005.
462. **Kupelian V**, **Page ST**, **Araujo AB**, **Travison TG**, **Bremner WJ**, **McKinlay JB**, Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men, J Clin Endocrinol Metab 91:843, 2006.
463. **Malkin CJ**, **Pugh PJ**, **West JN**, **van Beek EJ**, **Jones TH**, **Channer KS**, Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial, Eur Heart J 27:57, 2006.
464. **Lambrinoudaki I**, **Christodoulakos G**, **Rizos D**, **Economou E**, **Argeitis J**, **Vlachou S**, **Creatsa M**, **Kouskouni E**, **Botsis D**, Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women, Eur J Endocrinol 154:907, 2006.
465. **Mudali S**, **Dobs AS**, **Ding J**, **Cauley JA**, **Szklo M**, **Golden SH**; **Atherosclerosis Risk in Communities Study**, Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study, J Clin Endocrinol Metab 90:1202, 2005.
466. **Bernini GP**, **Moretti A**, **Sgro M**, **Argenio GF**, **Baralascini CO**, **Cristofani R**, **Salvetti A**, Influence of endogenous androgens on carotid wall in postmenopausal women, Menopause 8:43, 2001.
467. **Golden SH**, **Maguire A**, **Ding J**, **Crouse JR**, **Cauley JA**, **Zacur H**, **Szklo M**, Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort, Am J Epidemiol 155:437, 2002.
468. **Clarkson TB**, Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression, Menopause 14:373, 2007.
469. **Salpeter SR**, **Walsh JME**, **Greyber E**, **Salpeter EE**, Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis, J Gen Intern Med 21:363, 2006.
470. **Salpeter SR**, **Walsh JME**, **Greyber E**, **Ormiston TM**, **Salpeter EE**, Mortality associated with hormone replacement therapy in younger and older women. A meta-analysis, J Gen Intern Med 19:791, 2004.
471. **Vartiainen E**, **Puska P**, **Pekkanen J**, **Tuomilehto J**, **Jousilahti P**, Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland, Br Med J 309:23, 1994.
472. **Vartiainen E**, **Sarti C**, **Tuomilehto J**, **Kuulasmaa K**, Do changes in cardiovascular risk factors explain

changes in mortality from stroke in Finland?, Br Med J 310:901, 1995.
473. **Hu FB**, **Stampfer MJ**, **Manson JE**, **Grodstein F**, **Colditz GA**, **Speizer FE**, **Willett WC**, Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women, N Engl J Med 343:530, 2000.
474. **El Khoudary SR**, Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause: a narrative review, Maturitas 104:44, 2017.
475. **Medvei VC**, The History of Clinical Endocrinology, The Parthenon Publishing Group, New York, 1993.
476. **O'Dowd MJ**, **Philipp EE**, The History of Obstetrics and Gynaecology, The Parthenon Publishing Group, New York, 1994.
477. **Speert H**, Obstetric & Gynecologic Milestones Illustrated, The Parthenon Publishing Group, New York, 1996.
478. **Sneader W**, The discovery of oestrogenic hormones, Br Menopause Soc J 6:129, 2000.
479. **Fosbery WHS**, Severe climacteric flushings successfully treated by ovarian extract, Br Med J 1:1039, 1897.
480. **Servinghaus EL**, **Evans J**, Clinical observations on the use of an ovarian hormone: amniotin, Am J Sci 178:638, 1929.
481. **Parkes AS**, The rise of reproductive endocrinology, 1926–1940, J Endocrinol 34:20, 1966.
482. **Maisel AQ**, The Hormone Quest, Random House, New York, 1965, p. 44.
483. **Harding FE**, The oral treatment of ovarian deficiency with conjugated estrogens—equine, West J Surg Obstet Gynecol 52:31, 1944.
484. **Goebelsmann U**, **Mashchak CA**, **Mishell DR Jr**, Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol, Am J Obstet Gynecol 151:868, 1985.
485. **Katzenellenbogen BS**, Biology and receptor interactions of estriol and estriol derivatives in vitro and in vivo, J Steroid Biochem 20:1033, 1984.
486. **Lindsay R**, **Hart DM**, **MacLean A**, **Garwood J**, **Clarkel AC**, **Kraszewski A**, Bone loss during oestriol therapy in postmenopausal women, Maturitas 1:279, 1979.
487. **Devogelaer JP**, **Lecart C**, **Dupret P**, **De Nayer P**, **Nagant De Deuxchaisnes C**, Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women, Maturitas 28:243, 1998.
488. **Lemon HM**, Estriol prevention of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene, Cancer Res 35:1341, 1975.
489. **Melamed M**, **Castraño E**, **Notides AC**, **Sasson S**, Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol, Mol Endocrinol 11:1868, 1997.
490. **Fugh-Berman A**, **Bythrow J**, Bioidentical hormones for menopausal hormone therapy: variation on a theme, J Gen Intern Med 22(7):1030, 2007.
491. **Dusteberg S**, **Nishino Y**, Pharmacokinetic and pharmacological features of oestradiol valerate, Maturitas 4:315, 1982.
492. **Ross D**, **Rees M**, **Godfree V**, **Cooper A**, **Hart D**, **Kingsland C**, **Whitehead M**, Randomised crossover comparison of skin irritation with two transdermal oestradiol patches, Br Med J 315:288, 1997.
493. **Bhathena RK**, **Anklesaria BS**, **Ganatra AM**, Skin reactions with transdermal estradiol therapy in a tropical environment, Int J Gynecol Obstet 60:177, 1998.
494. **Archer DF**; **EstroGel Study Group**, Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women, Menopause 10:516, 2003.
495. **Hedrick RE**, **Ackerman RT**, **Koltun WD**, **Halvorsen MB**, **Lambrecht LJ**, Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women, Menopause 16:132, 2009.
496. **Buster JE**, **Koltun WD**, **Pascual MLG**, **Day WW**, **Peterson C**, Low-dose estradiol spray to treat vasomotor symptoms. A randomized controlled trial, Obstet Gynecol 111:1343, 2008.
497. **Jung-Hoffman C**, **Kuhl H**, Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings, Contraception 42:423, 1990.
498. **Colvin PL Jr**, **Auerbach BJ**, **Koritnik DR**, **Hazzard WR**, **Applebaum-Bowden D**, Differential effects of oral estrogen versus 17b-estradiol on lipoproteins in postmenopausal women, J Clin Endocrinol Metab 70:1568, 1990.

499. **Walsh BW**, **Li H**, **Sacks FM**, Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism, J Lipid Res 35:2083, 1994.
500. **Hillard TC**, **Whicroft SJ**, **Marsh MS**, **Ellerington MC**, **Lees B**, **Whitehead MI**, **Stevenson JC**, Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss, Osteoporos Int 4:341, 1994.
501. **Michaëlsson K**, **Baron JA**, **Farahmand BY**, **Johnell O**, **Magnusson C**, **Persson P-G**, **Persson I**, **Ljunghall S**; On behalf of the **Swedish Hip Fracture Study Group**, Hormone replacement therapy and risk of hip fracture: population based case-control study, Br Med J 316:1858, 1998.
502. **Utian WH**, **Burry KA**, **Archer DF**, **Gallagher JC**, **Boyett RL**, **Guy MP**, **Tachon GJ**, **Chadha-Boreham HK**, **Bouvet AA**, Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group, Am J Obstet Gynecol 181:71, 1999.
503. **Shifren JL**, **Desindes S**, **McIlwain M**, **Doros G**, **Mazer NA**, A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women, Menopause 14:985, 2007.
504. **Kraemer GR**, **Kraemer RR**, **Ogden BW**, **Kilpatrick RE**, **Gimpel TL**, **Castracane VD**, Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin, Fertil Steril 79:534, 2003.
505. **Chen F-P**, **Lee N**, **Soong Y-K**, **Huang K-E**, Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors, Menopause 8:347, 2001.
506. **Vehkavaara S**, **Silveira A**, **Hakala-Ala-Pietilä T**, **Virkamäki A**, **Hovatta O**, **Hamsten A**, **Taskinen M-R**, **Yki-Järvinen H**, Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women, Thromb Haemost 85:619, 2001.
507. **Brynhildsen J**, **Hammar M**, Lipids and clotting factors during low dose transdermal estradiol/norethisterone use, Maturitas 50:344, 2005.
508. **Taner MZ**, **Ozpolat E**, **Taskiran C**, **Onan MA**, **Gursel T**, **Karabulut E**, **Gursoy R**, **Himmetoglu O**, Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study, Maturitas 53:267, 2006.
509. **Lewandoski KC**, **Komorowski J**, **Mikhalidis DP**, **Bienkiewicz M**, **Tan BK**, **O'Callaghan CJ**, **Lewinski A**, **Prelevic G**, **Randeva HS**, Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women, J Clin Endocrinol Metab 91:3123, 2006.
510. **Post MS**, **Christella M**, **Thomassen LG**, **Van Der Mooren MJ**, **Van Baal WM**, **Rosing J**, **Kenemans P**, **Stehouwer CD**, Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women, Arterioscler Thromb Vasc Biol 23:1116, 2003.
511. **Oger E**, **Alhenc-Gelas M**, **Lacut K**, **Blouch MT**, **Roudaut N**, **Kerlan V**, **Collet M**, **Abgrall JF**, **Aiach M**, **Scarabin PY**, **Mottier D**, Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial, Arterioscler Thromb Vasc Biol 23:1671, 2003.
512. **Scarabin PY**, **Oger E**, **Plu-Bureau G**, Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk, Lancet 362:428, 2003.
513. **Straczek C**, **Oger E**, **Beau Yon de Jonage-Canonico M**, **Plu-Bureau G**, **Conard J**, **Meyer G**, **Alhenc-Gelas M**, **Levesque H**, **Trillot N**, **Barrellier MT**, **Wahl D**, **Emmerich J**, **Scarabin PY**, Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration, Circulation 112:3495, 2005.
514. **Canonico M**, **Oger E**, **Plu-Bureau G**, **Conard J**, **Meyer G**, **Lévesque H**, **Trillot N**, **Barrellier MT**, **Wahl D**, **Emmerich J**, **Scarabin PY**; for the **Estrogen and Thromboembolism Risk (ESTHER) Study Group**, Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route

of estrogen administration and progestogens: the ESTHER study, Circulation 115:840, 2007.
515. **Canonico M**, **Fourier A**, **Carcaillon L**, **Olié V**, **Plu-Bureau G**, **Oger E**, **Mesrine S**, **Boutron-Ruault MC**, **Clavel-Chapelon F**, **Scarabin PY**, Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism. Results from the E3N cohort study, Arterioscler Thromb Vasc Biol 30(2):340, 2010.
516. **Rossouw JE**, **Johnson KC**, **Pettinger M**, **Cushman M**, **Sandset PM**, **Kuller L**, **Rosendaal F**, **Rosing J**, **Wasserthal-Smoller S**, **Martin LW**, **Manson JE**, **Lakshminarayan K**, **Merino JG**, **Lynch J**, Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy, Stroke 43(4):952, 2012.
517. **Pradhan AD**, **Manson JE**, **Rossouw JE**, **Siscovick DS**, **Mouton CP**, **Rifai N**, **Wallace RB**, **Jackson RD**, **Pettinger MB**, **Ridker PM**, Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study, JAMA 288(8):980, 2002.
518. **Sendag F**, **Karadadas N**, **Ozsener S**, **Bilgin O**, Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women, Arch Gynecol Obstet 266:38, 2002.
519. **Dansuk R**, **Unal O**, **Karageyim Y**, **Esim E**, **Turan C**, Evaluation of the effect of tibolone and transdermal estradiol on triglyceride level in hypertriglyceridemic and normotriglyceridemic postmenopausal women, Gynecol Endocrinol 18:233, 2004.
520. **Bukowska H**, **Stanosz S**, **Zochowska E**, **Millo B**, **Sieja K**, **Chelstowski K**, **Naruszewicz M**, Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women?, Metabolism 54:72, 2005.
521. **Sanada M**, **Tsuda M**, **Kodama I**, **Sakashita T**, **Nakagawa H**, **Ohama K**, Substitution of transdermal estradiol during oral estrogen-progestin therapy in postmenopausal women: effects on hypertriglyceridemia, Menopause 11:331, 2004.
522. **Simonsen MH**, **Erichsen R**, **Froslev T**, **Rungby J**, **Sorensen HT**, Postmenopausal estrogen therapy and risk of gallstone disease: a population-based case-control study, Drug Saf 36(12):1189, 2013.
523. **Vitale C**, **Gebara O**, **Mercuro G**, **Wajngarten M**, **Silvestri A**, **Rossini P**, **Ramires JA**, **Fiini M**, **Rosano GM**, Value of C-reactive protein levels and IL-6 in predicting events in women at increased cardiovascular risk, Maturitas 50:239, 2005.
524. **Lakoski SG**, **Brosnihan B**, **Herrington DM**, Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial, Am Heart J 150:907, 2005.
525. **Riggs BL**, **Seeman E**, **Hodgson SF**, **Taves DR**, **O'Fallon WM**, Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis, N Engl J Med 306:446, 1982.
526. **DeVries CS**, **Bromley SE**, **Farmer RD**, Myocardial infarction risk and hormone replacement: differences between products, Maturitas 53:343, 2006.
527. **Lovre D**, **Lindsey SH**, **Mauvais-Jarvis F**, Effect of menopausal hormone therapy on components of the metabolic syndrome, Ther Adv Cardiovasc Dis 11(1):33, 2016.
528. **Wild RA**, **Wu C**, **Curb JD**, **Martin LW**, **Phillips L**, **Stefanick M**, **Trevisan M**, **Manson JE**, Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials, Menopause 20(3):254, 2013.
529. **Chu MC**, **Cosper P**, **Nakhuda GS**, **Lobo RA**, A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome, Fertil Steril 86:1669, 2006.
530. **Girdler SS**, **Hinderliter AL**, **Wells EC**, **Sherwood A**, **Grewen KM**, **Light KC**, Transdermal versus oral estrogen therapy in postmenopausal smokers: hemodynamic and endothelial effects, Obstet Gynecol 103:169, 2004.
531. **Mancini F**, **Persico N**, **Genazzani AD**, **Volpe A**, **Battaglia C**, **De Aloysio D**, Effects of hormone replacement therapy on plasma viscosity and Doppler variations in postmenopausal non-smokers and heavy smokers, Gynecol Endocrinol 20:221, 2005.

532. **Araujo DA**, **Farias ML**, **Andrade AT**, Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus, Climacteric 5:286, 2002.
533. **Sztefko K**, **Rogatko I**, **Milewicz T**, **Jozef K**, **Tomasik PJ**, **Szafran Z**, Effect of hormone therapy on the enteroinsular axis, Menopause 12:630, 2005.
534. **Margolis KL**, **Bonds DE**, **Roadabough RJ**, **Tinker L**, **Phillips LS**, **Allen C**, **Bassford T**, **Burke G**, **Torrens J**, **Howard BV**; **Women's Health Initiative Investigators**, Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial, Diabetologia 47:1175, 2004.
535. **Yüksel H**, **Odabasi AR**, **Demircan S**, **Köseoglu K**, **Kizilkaya K**, **Onur E**, Effects of postmenopausal hormone replacement therapy on body fat composition, Gynecol Endocrinol 23:99, 2007.
536. **Saucedo R**, **Basurto L**, **Zarate A**, **Martínez C**, **Hernandez M**, **Galván R**, Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women, Gynecol Obstet Invest 64:61, 2007.
537. **Lobo R**, **March CM**, **Goebelsmann U**, **Krauss RM**, **Mishell DR Jr**, Subdermal estradiol pellets following hysterectomy and oophorectomy, Am J Obstet Gynecol 138:714, 1980.
538. **Suhonen S**, **Sipinen S**, **Lahteenmaki P**, **Laine H**, **Rainio J**, **Arko H**, Postmenopausal oestrogen replacement therapy with subcutaneous oestradiol implants, Maturitas 16:123, 1993.
539. **Notelovitz M**, Estrogen therapy in management of problems associated with urogenital aging: a simple diagnostic test and the effect of the route of hormone administration, Maturitas 22(Suppl):S31, 1995.
540. **Rigg LA**, **Hermann H**, **Yen SSC**, Absorption of estrogens from vaginal creams, N Engl J Med 298:195, 1978.
541. **Pschera H**, **Hjerpe A**, **Carlström K**, Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17b and progesterone in postmenopausal women, Gynecol Obstet Invest 27:204, 1989.
542. **Taechakraichana N**, **Intraragsakul A**, **Panyakhamlerd K**, **Numchaisrika P**, **Limpaphayom K**, Estradiol and follicle-stimulating hormone levels in oophorectomized women using vaginal estrogen, J Med Assoc Thai 80:616, 1997.
543. **Handa VL**, **Bachus KE**, **Johnston WW**, **Robboy SJ**, **Hammond CB**, Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium, Obstet Gynecol 84:215, 1994.
544. **Bachmann G**, **Bouchard C**, **Hoppe D**, **Ranganath R**, **Altomare C**, **Vieweg A**, **Graepel J**, **Helzner E**, Efficacy and safety of low-dose regiments of conjugated estrogens cream administered vaginally, Menopause 16:719, 2009.
545. **Schmidt G**, **Andersson SB**, **Nordle Ö**, **Johansson CJ**, **Gunnarsson PO**, Release of 17-beta-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation, Gynecol Obstet Invest 38:253, 1994.
546. **Johnston A**, Estrogens—pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation—Estring®, Acta Obstet Gynecol Scand 75(Suppl 163):16, 1996.
547. **Henriksson L**, **Stjernquist M**, **Boquist L**, **Cedergren I**, **Selinus I**, A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging, Am J Obstet Gynecol 174:85, 1996.
548. **Naessen T**, **Rodriguez-Macias K**, Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women, Am J Obstet Gynecol 186:944, 2002.
549. **Rioux JE**, **Devlin C**, **Gelfand MM**, **Steinberg WM**, **Hepburn DS**, 17Beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis, Menopause 7:156, 2000.
550. **Dugal R**, **Hesla K**, **Sordal T**, **Aase KH**, **Lilleeidet O**, **Wickstrom E**, Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy, Acta Obstet Gynecol Scand 79:292, 2000.
551. **Mattsson LA**, **Cullberg G**, **Eriksson O**, **Knutsson F**, Vaginal administration of low-dose oestradiol—effects on the endometrium and vaginal cytology, Maturitas 11:217, 1989.
552. **Manonai J**, **Theppisai U**, **Chittacharoen A**, Effect and safety of 17 beta-estradiol tablet in postmenopausal women with urogenital symptoms, J Med Assoc Thai 84:1015, 2001.

553. **Bachmann G**, **Lobo RA**, **Gut R**, **Nachtigall L**, **Notelovitz M**, Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial, Obstet Gynecol 111:67, 2008.
554. **Holmgren PA**, **Lindskog M**, **von Schoultz B**, Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy, Maturitas 11:55, 1989.
555. **Akrivis C**, **Varras M**, **Thodos A**, **Hadjopoulos G**, **Bellou A**, **Antonious N**, Action of 25 microg 17beta-oestradiol vaginal tablets in the treatment of vaginal atrophy in Greek postmenopausal women: clinical study, Clin Exp Obstet Gynecol 30:229, 2003.
556. **Notelovitz M**, **Funk S**, **Nanavati N**, **Mazzeo M**, Estradiol absorption from vaginal tablets in postmenopausal women, Obstet Gynecol 99:556, 2002.
557. **Labrie F**, **Cusan L**, **Gomez J-L**, **Cŏté I**, **Bérubé R**, **Bélanger P**, **Martel C**, **Labrie C**, Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women, Menopause 16:30, 2009.
558. **Naessen T**, **Berglund L**, **Ulmsten U**, Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol, Am J Obstet Gynecol 177:115, 1997.
559. **Naessen T**, **Rodriguez-Macias K**, **Lithell H**, Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women, J Clin Endocrinol Metab 86:2757, 2001.
560. **Santen RJ**, Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels, Climacteric 18(2):121, 2015.
561. The 2017 hormone therapy position statement of The North American Menopause Society, Menopause 24(7):728, 2017.
562. **Le Ray I**, **Dell'Aniello S**, **Bonnetain F**, **Azoulay L**, **Suissa S**, Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study, Breast Cancer Res Treat 135(2):603, 2012.
563. **Speroff L**; for the **United States VR Investigator Group**, Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms, Obstet Gynecol 102:823, 2003.
564. **Al-Azzawi F**, **Buckler HM**; **United Kingdom Vaginal Ring Investigator Group**, Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms, Climacteric 6:118, 2003.
565. **Castelo-Blanco C**, **de Osaba M**, **Vanrezc JA**, **Fortuny A**, **González-Merlo J**, Effects of oophorectomy and hormone replacement therapy on pituitary-gonadal function, Maturitas 17:101, 1993.
566. **Woodruff JD**, **Pickar JH**; for **The Menopause Study Group**, Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone, Am J Obstet Gynecol 170:1213, 1994.
567. **Strickland DM**, **Hammond TL**, Postmenopausal estrogen replacement in a large gynecologic practice, Am J Gynecol Health 2:33, 1988.
568. **Archer DF**, **Pickar JH**, **Bottiglioni F**; for **The Menopause Study Group**, Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate, Obstet Gynecol 83:686, 1994.
569. **The Writing Group for the PEPI Trial**, Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, JAMA 273:199, 1995.
570. **The Writing Group for the PEPI Trial**, Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, JAMA 275:370, 1996.
571. **Speroff L**, **Rowan J**, **Symons J**, **Genant H**, **Wilborn W**; for the **CHART Study Group**, The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study), JAMA 276:1397, 1996.
572. **Pickar JH**, **Yeh IT**, **Wheeler JE**, **Cunnane MF**, **Speroff L**, Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results, Fertil Steril 80:1234, 2003.

573. **King R**, **Whitehead M**, Assessment of the potency of orally administered progestins in women, Fertil Steril 46:1062, 1986.
574. **The Writing Group for the PEPI Trial**, Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, JAMA 276:1389, 1996.
575. **Gillet JY**, **Andre G**, **Faguer B**, **Ernyl R**, **Buvat-Herbaut M**, **Domin MA**, **Kuhn MJM**, **Hedon B**, **Drapier-Faure E**, **Barrat J**, **Lopes P**, **Magnin G**, **Leng JJ**, **Bruhat MA**, **Philippe E**, Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study, Maturitas 19:103, 1994.
576. **Recker RR**, **Davies KM**, **Dowd RM**, **Heaney RP**, The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial, Ann Intern Med 130:897, 1999.
577. **Lindsay R**, **Gallagher JC**, **Kleerekoper M**, **Pickar JH**, Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women, JAMA 287:2668, 2002.
578. **Prestwood KM**, **Thompson DL**, **Kenny AM**, **Seibel MJ**, **Pilbeam CC**, **Raisz LG**, Low dose estrogen and calcium have an additive effect on bone resorption in older women, J Clin Endocrinol Metab 84:179, 1999.
579. **Prestwood KM**, **Kenny AM**, **Kleppinger A**, **Kulldorff M**, Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial, JAMA 290:1042, 2003.
580. **Utian WH**, **Shoupe D**, **Bachmann G**, **Pinkerton JV**, **Pickar JH**, Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate, Fertil Steril 75:1065, 2001.
581. **Gast MJ**, **Freedman MA**, **Vieweg AJ**, **De Melo NR**, **Girão MJBC**, **Zinaman MJ**; for the **Dyspareunia Study Group**, A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women, Menopause 16:247, 2009.
582. **Archer DF**, **Dorin M**, **Lewis V**, **Schneider DL**, **Pickar JH**, Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding, Fertil Steril 75:1080, 2001.
583. **Lobo RA**, **Bush T**, **Carr BR**, **Pickar JH**, Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism, Fertil Steril 76:13, 2001.
584. **Notelovitz M**, **Lenihan JP Jr**, **McDermott MP**, **Kerber IJ**, **Nanavati N**, **Arce J-C**, Initial 17beta-estradiol dose for treating vasomotor symptoms, Obstet Gynecol 95:726, 2000.
585. **Speroff L**, **Symons J**, **Kempfert N**, **Rowan J**; for the **FEMHRT Study Investigators**, The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms, Menopause 7:383, 2000.
586. **Sturdee DW**, **Ulrich LG**, **Barlow DH**, **Wells M**, **Campbell MJ**, **Vessey MP**, **Nielsen B**, **Anderson MC**, **Bragg AJ**, The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy, Br J Obstet Gynaecol 107:1392, 2000.
587. **Wells M**, **Sturdee DW**, **Barlow DH**, **Ulrich LG**, **O'Brien K**, **Campbell MJ**, **Vessey MP**, **Bragg AJ**; for the **UK Continuous Combined Hormone Replacement Therapy Study Investigators**, Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study, Br Med J 325:239, 2002.
588. **Montplaisier J**, **Lorrain J**, **Denesle R**, **Petit D**, Sleep in menopause: differential effects of two forms of hormone replacement therapy, Menopause 8:10, 2001.
589. **Miles RA**, **Press MF**, **Paulson RJ**, **Dahmoush L**, **Lobo RA**, **Sauer MV**, Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study, Fertil Steril 62:485, 1994.
590. **Ross D**, **Cooper AJ**, **Pryse-Davies J**, **Bergeron C**, **Collins WP**, **Whitehead MI**, Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women, Am J Obstet Gynecol 177:937, 1997.
591. **de Ziegler D**, **Ferriani R**, **Moraes L A**, **Bulletti C**, Vaginal progesterone in menopause: crinone 4% in

cyclical and constant combined regimens, Hum Reprod 15(Suppl 1) 149, 2000.
592. **Cicinelli E**, **de Ziegler D**, **Alfonso R**, **Nicoletti R**, **Bellavia M**, **Colafiglio G**, Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study, Fertil Steril 83(6):1859, 2005.
593. **Notelovitz M**, **Cassel D**, **Hille D**, **Furst KW**, **Dain MP**, **VandePol C**, **Skarinsky D**, Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause, Am J Obstet Gynecol 182:7, 2000.
594. **Shulman LP**, **Yankov V**, **Uhl K**, Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized controlled trials, Menopause 9:195, 2002.
595. **Rubinacci A**, **Peruzzi E**, **Modena AB**, **Zanardi E**, **Andrei B**, **De Leo V**, **Pansini FS**, **Quebe-Fehling E**, **de Palacios PI**, Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women, Menopause 10:241, 2003.
596. **Ettinger B**, **Selby J**, **Citron JT**, **Vangessel A**, **Ettinger V**, **Hendrickson MR**, Cyclic hormone replacement therapy using quarterly progestin, Obstet Gynecol 83:693, 1994.
597. **Williams DB**, **Voigt BJ**, **Fu YS**, **Schoenfeld MJ**, **Judd HL**, Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement, Obstet Gynecol 84:787, 1994.
598. **Boerrigter PJ**, **van de Weijer PHM**, **Baak JPA**, **Fox H**, **Haspels AA**, **Kenemans P**, Endometrial response in estrogen replacement therapy quarterly combined with a progestogen, Maturitas 24:63, 1996.
599. **Hirvonen E**, **Salmi T**, **Puolakka J**, **Heikkinen J**, **Granfors E**, **Hulkko S**, **Mäkäräinen L**, **Nummi S**, **Pekonen F**, **Rautio A-M**, **Sundström H**, **Telimaa S**, **Wilen-Rosenqvist G**, **Virkkunen A**, **Wahlström T**, Can progestin be limited to every third month only in postmenopausal women taking estrogen?, Maturitas 21:39, 1995.
600. **Jaakkola S**, **Lyytinen H**, **Pukkala E**, **Ylikorkala O**, Endometrial cancer in postmenopausal women using estradiol-progestin therapy, Obstet Gynecol 114:1197, 2009.
601. **Bjarnason K**, **Cerin Å**, **Lindgren R**, **Weber T**; for the **Scandinavian Long Cycle Study Group**, Adverse endometrial effects during long cycle hormone replacement therapy, Maturitas 32:151, 1999.
602. **Andersson J**, **Rybo G**, Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia, Br J Obstet Gynaecol 97:690, 1990.
603. **Raudaskoski TH**, **Lahti EI**, **Kauppila AJ**, **Apaja-Sarkkinen MA**, **Laatikainen TJ**, Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses, Am J Obstet Gynecol 172:114, 1995.
604. **Wollter-Svensson LO**, **Stadberg E**, **Andersson K**, **Mattsson LA**, **Odlind V**, **Persson I**, Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year, Acta Obstet Gynecol Scand 76:449, 1997.
605. **Raudaskoski T**, **Tapanainen J**, **Tomas E**, **Luotola H**, **Pekonen F**, **Ronni-Sivula H**, **Timonen H**, **Riphagen F**, **Laatikainen T**, Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic responses, Br J Obstet Gynaecol 109:136, 2002.
606. **Varila E**, **Wahlstrom T**, **Rauramo I**, A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy, Fertil Steril 76:969, 2001.
607. **Wollter-Svenson L-O**, **Stadberg E**, **Andersson K**, **Mattsson L-Å**, **Odlind V**, **Persson I**, Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism, Maturitas 22:199, 1995.
608. **McMeekin DS**, **Burger RA**, **Manetta A**, **DiSaia P**, **Berman M**, Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis, Gynecol Oncol 59:81, 1995.
609. **Sherwin BB**, **Gelfand MM**, The role of androgen in the maintenance of sexual functioning in oophorectomized women, Psychosom Med 49:397, 1987.
610. **Myers LS**, **Dixen J**, **Morrissette D**, **Carmichael M**, **Davidson JM**, Effects of estrogen, androgen, and

progestin on sexual psychophysiology and behavior in postmenopausal women, J Clin Endocrinol Metab 70:1124, 1990.

611. **Shifren JL**, **Braunstein GD**, **Simon JA**, **Casson PR**, **Buster JE**, **Redmond GP**, **Burki RE**, **Ginsburg ES**, **Rosen RC**, **Leiblum SR**, **Caramelli KE**, **Mazer NA**, Transdermal testosterone treatment in women with impaired sexual function after oophorectomy, N Engl J Med 343:682, 2000.
612. **Hickok LR**, **Toomey C**, **Speroff L**, A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women, Obstet Gynecol 82:919, 1993.
613. **Watts NB**, **Notelovitz M**, **Timmons MC**, **Addison WA**, **Wiita B**, **Downey LJ**, Comparison of oral estrogens and estrogens plus androgens on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause, Obstet Gynecol 85:529, 1995.
614. **Barrett-Connor E**, **Timmons C**, **Young R**, **Witta B**; for the **Estratest Working Group**, Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women, J Womens Health 5:593, 1996.
615. **Davis SR**, **McCloud P**, **Strauss BJG**, **Burger H**, Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality, Maturitas 21:227, 1995.
616. **Bachmann GA**, **Timmons C**, **Abernethy WD**, Breakthrough bleeding patterns in two continuous combined estrogen/progestogen hormone replacement therapies, one of which included androgens, J Womens Health 5:205, 1996.
617. **Garnett T**, **Studd J**, **Watson N**, **Savvas M**, **Leather A**, The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants, Obstet Gynecol 79:968, 1992.
618. **Barrett-Conner E**, **Young RH**, **Notelovitz M**, **Sullivan J**, **Wiita B**, **Yang HM**, **Nolan J**, A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles, J Reprod Med 44:1012, 1999.
619. **Urman B**, **Pride SM**, **Ho Yuen B**, Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy, Obstet Gynecol 77:595, 1991.
620. **Hameed A**, **Brothwood T**, **Bouloux P**, Delivery of testosterone replacement therapy, Curr Opin Investig Drugs 4:1213, 2003.
621. **Buckler HM**, **Robertson WR**, **Wu FCW**, Which androgen replacement therapy for women?, J Clin Endocrinol Metab 83:3920, 1998.
622. **Davis SR**, **van der Mooren MJ**, **van Lunsen RHW**, **Lopes P**, **Ribot C**, **Rees M**, **Moufarega A**, **Rodenberg C**, **Buch A**, **Purdie DM**, Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial, Menopause 13:387, 2006.
623. **Shifren JL**, **Davis SR**, **Moreau M**, **Waldbaum A**, **Bouchard C**, **DeRogatis L**, **Derzko C**, **Bearnson P**, **Kakos N**, **O'Neill S**, **Levine S**, **Wekselman K**, **Buch A**, **Rodenberg C**, **Kroll R**, Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study, Menopause 13:770, 2007.
624. **Davis SR**, **Moreau M**, **Kroll R**, **Bouchard C**, **Panay N**, **Gass M**, **Braunstein G**, **Hirschberg AL**, **Rodenberg C**, **Pack S**, **Koch H**, **Moufarege A**, **Studd J**; for the **APHRODITE Study Team**, Testosterone for low libido in postmenopausal women not taking estrogen, N Engl J Med 359:2005, 2008.
625. **Tamimi RM**, **Hankinson SE**, **Chen WY**, **Rosner B**, **Colditz GA**, Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women, Arch Intern Med 166:1483, 2006.
626. **Dimitrakakis C**, **Zhou J**, **Wang J**, **Belanger A**, **Labrie F**, **Cheng C**, **Powell D**, **Bondy C**, A physiologic role for testosterone in limiting estrogenic stimulation of the breast, Menopause 10:292, 2003.
627. **Hofling M**, **Hirschberg AL**, **Skoog L**, **Tani E**, **Hägerström T**, **von Schoultz B**, Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women, Menopause 14:183, 2007.
628. **Davis SR**, **Hirschberg AL**, **Wagner LK**, **Lodhi I**, **Von Schoultz B**, The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy, J Clin

Endocrinol Metab 94:4907, 2009.
629. **Sterns EE**, **Zee B**, Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable?, Breast Cancer Res Treat 59:125, 2000.
630. **Davis SR**, **Davison SL**, **Donath S**, **Bell RJ**, Circulating androgen levels and self-reported sexual function in women, JAMA 294:91, 2005.
631. **North American Menopause Society**. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society, Menopause 12(5):496, 2005; quiz 649.
632. **Fooladi E**, **Reuter SE**, **Bell RJ**, **Robinson PJ**, **Davis SR**, Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women, Menopause 22(1):44, 2015.
633. **Huang G**, **Tang E**, **Aakil A**, **Anderson S**, **Jara H**, **Davda M**, **Stroh H**, **Travison TG**, **Bhasin S**, **Basaria S**, Testosterone dose-response relationships with cardiovascular risk markers in androgen-deficient women: a randomized, placebo-controlled trial, J Clin Endocrinol Metab 99(7):E1287, 2014.
634. **Slayden SM**, **Crabbe L**, **Bae S**, **Potter HD**, **Azziz R**, **Parker CR Jr**, The effect of 17b-estradiol on adrenocortical sensitivity, responsiveness, and steroidogenesis in postmenopausal women, J Clin Endocrinol Metab 83:519, 1998.
635. **Baulieu EE**, **Thomas G**, **Legrain S**, **Lahlou N**, **Roger M**, **Debuire B**, **Faucounau V**, **Girard L**, **Hervy MP**, **Latour F**, **Leaud MC**, **Mokrane A**, **Pitti-Ferrandi H**, **Trivalle C**, **de Lacharriere O**, **Nouveau S**, **Rakoto-Arison B**, **Souberbielle JC**, **Raison J**, **Le Bouc Y**, **Raynaud A**, **Girerd X**, **Forette F**, Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue, Proc Natl Acad Sci U S A 97:4279, 2000.
636. **Barnhart KT**, **Freeman E**, **Grisso JA**, **Rader DJ**, **Sammel M**, **Kapoor S**, **Nestler JE**, The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life, J Clin Endocrinol Metab 84:3896, 1999.
637. **Hackbert L**, **Heiman JR**, Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women, J Womens Health Gend Based Med 11:155, 2002.
638. **Johannes CB**, **Stellato RK**, **Feldman HA**, **Longcope C**, **McKinlay JB**, Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women's Health Study, J Clin Epidemiol 52:95, 1999.
639. **Aarlt W**, **Haas J**, **Callies F**, **Reincke M**, **Hubler D**, **Oettel M**, **Ernst M**, **Schulte HM**, **Allolio B**, Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens, J Clin Endocrinol Metab 84:2170, 1999.
640. **Morales A**, **Nolan J**, **Nelson J**, **Yen SSC**, Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age, J Clin Endocrinol Metab 78:1360, 1994.
641. **Casson PR**, **Santoro N**, **Elkind-Hirsch KE**, **Carson SA**, **Hornsby PJ**, **Abraham G**, **Buster J**, Postmenopausal dehydroepiandrosterone (DHEA) administration increases insulin-like growth factor-I (IGF-I) and decreases high density lipoprotein (HDL): a six month trial, Fertil Steril 70:107, 1998.
642. **Thompson RD**, **Carlson M**, Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products, J AOAC Int 83:847, 2000.
643. **Labrie F**, **Archer D**, **Bouchard C**, **Fortier M**, **Cusan L**, **Gomez JL**, **Girard G**, **Baron M**, **Ayotte N**, **Moreau M**, **Dubé R**, **Côté I**, **Labrie C**, **Lavoie L**, **Berger L**, **Gilbert L**, **Martel C**, **Baiser J**, Intravaginal dehydroepiandrosterone (Prasterone), the physiological and a highly efficient treatment of vaginal atrophy, Menopause 16:907, 2009.
644. **Labrie F**, **Archer D**, **Bouchard C**, **Fortier M**, **Cusan L**, **Gomez JL**, **Girard G**, **Baron M**, **Ayotte N**, **Moreau M**, **Dubé R**, **Côté I**, **Labrie C**, **Lavoie L**, **Bérubé R**, **Bélanger P**, **Berger L**, **Gilbert L**, **Martel C**, **Baiser J**, Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration, Menopause 16:897, 2009.
645. **Labrie F**, **Cusan L**, **Gomez JL**, **Côté I**, **Bérubé R**, **Bélanger P**, **Martel C**, **Labrie C**, Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women, J Steroid Biochem Mol Biol 111:178, 2009.
646. **Labrie F**, **Archer D**, **Bouchard C**, **Fortier M**, **Cusan L**, **Gomez JL**, **Girard G**, **Baron M**, **Ayotte N**,

Moreau M, **Dubé R**, **Côte ML**, **Labrie C**, **Lavoie L**, **Berger L**, **Gilbert L**, **Martel C**, **Balser J**, Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women, Menopause 16:923, 2009.

647. **Archer DF**, **Labrie F**, **Montesino M**, **Martel C**, Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy, J Steroid Biochem Mol Biol 174:1, 2017.
648. **Labrie F**, **Archer DF**, **Koltun W**, **Vachon A**, **Young D**, **Frenette L**, **Portman D**, **Montesino M**, **Côté I**, **Parent J**, **Lavoie L**, **Beauregard A**, **Martel C**, **Vaillancourt M**, **Balser J**, **Moyneur É**; **VVA Prasterone Research Group**, Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause, Menopause 23(3):243, 2016.
649. **Draper MW**, **Flowers DE**, **Huster WJ**, **Neild JA**, **Harper KD**, **Arnaud C**, A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women, J Bone Miner Res 11:835, 1996.
650. **Boss SM**, **Huster WJ**, **Neild JA**, **Glant MD**, **Eisenhut CC**, **Draper MW**, Effects of raloxifene hydrochloride on the endometrium of postmenopausal women, Am J Obstet Gynecol 177:1458, 1997.
651. **Delmas PD**, **Bjarnason NH**, **Mitlak BH**, **Ravoux A-C**, **Shah AS**, **Huster WJ**, **Draper M**, **Christiansen C**, Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women, N Engl J Med 337:1641, 1997.
652. **Walsh BW**, **Kuller LH**, **Wild RA**, **Paul S**, **Farmer M**, **Lawrence JB**, **Shah AS**, **Anderson PW**, Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women, JAMA 279:1445, 1998.
653. **Delmas PD**, **Ensrud KE**, **Adachi JD**, **Harper KD**, **Sarkar S**, **Gennari C**, **Reginster JY**, **Pols HA**, **Recker RR**, **Harris ST**, **Wu W**, **Genant HK**, **Black DM**, **Eastell R**; **Multiple Outcomes of Raloxifene Evaluation Investigators**, Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial, J Clin Endocrinol Metab 87:3609, 2002.
654. **Siris ES**, **Harris ST**, **Eastell R**, **Zanchetta JR**, **Goemaere S**, **Diez-Perez A**, **Stock JL**, **Song J**, **Qu Y**, **Kulkarni PM**, **Siddhanti SR**, **Wong M**, **Cummings SR**; for the **Continuing Outcomes Relevant to Evista (CORE) Investigators**, Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) Study, J Bone Miner Res 20:1514, 2005.
655. **Cummings SR**, **Eckert S**, **Krueger KA**, **Grady D**, **Powles TJ**, **Cauley JA**, **Norton L**, **Nickelsen T**, **Bjarnason NH**, **Morrow M**, **Lippman ME**, **Black D**, **Glusman JE**, **Costa A**, **Jordan VC**, The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial, JAMA 281:2189, 1999.
656. **Yaffe K**, **Krueger K**, **Sarkar S**, **Grady D**, **Barrett-Connor E**, **Cox DA**, **Nickelsen T**; for the **Multiple Outcomes of Raloxifene Evaluation Investigators**, Cognitive function in postmenopausal women treated with raloxifene, N Engl J Med 344:1207, 2001.
657. **Martino S**, **Cauley JA**, **Barrett-Connor E**, **Powles TJ**, **Mershon J**, **Disch D**, **Secrest RJ**, **Cummings SR**; for the **CORE Investigators**, Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene, J Natl Cancer Inst 96:1651, 2004.
658. **Vogel VG**, **Costantino JP**, **Wickerham DL**, **Cronin WM**, **Cecchini RS**, **Atkins JN**, **Bevers TB**, **Fehrenbacher L**, **Pajon ER Jr**, **Wade JL III**, **Robidoux A**, **Margolese RG**, **James J**, **Lippman SM**, **Runowicz CD**, **Ganz PA**, **Reis SE**, **McCaskill-Stevens W**, **Ford LG**, **Jordan VC**, **Wolmark N**; **National Surgical Adjuvant Breast and Bowel Project (NSABP)**, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial, JAMA 295:2727, 2006.
659. **Fisher B**, **Costantiho JP**, **Wickerham DL**, **Cecchini RS**, **Cronin WM**, **Robidoux A**, **Bevers TB**, **Kavanah MT**, **Atkins JN**, **Margolese RG**, **Runowicz CD**, **James JM**, **Ford LG**, **Wolmark N**, Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst 97:1652, 2005.

660. **Fisher B**, **Costantino JP**, **Wickerham DL**, **Redmond CK**, **Kavanah M**, **Cronin WM**, **Vogel V**, **Robidoux A**, **Dimitrov N**, **Atkins J**, **Daly M**, **Wieand S**, **Tan-Chiu E**, **Ford L**, **Wolmark N**; other **National Surgical Adjuvant Breast and Bowel Project Investigators**, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst 90:1371, 1998.
661. **Clarkson TB**, **Anthony MS**, **Jerome CP**, Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys, J Clin Endocrinol Metab 83:721, 1998.
662. **Barrett-Connor E**, **Mosca L**, **Collins P**, **Geiger MJ**, **Grady D**, **Kornitzer M**, **McNabb MA**, **Wenger NK**; **Raloxifene Use for the Heart (RUTH) Trial Investigators**, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women, N Engl J Med 355:125, 2006.
663. **Collins P**, **Mosca L**, **Geiger MJ**, **Grady D**, **Kornitzer M**, **Amewou-Atisso MGE**, **Effron MB**, **Dowsett SA**, **Barrett-Connor E**, **Wenger NK**, Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for the Heart Trial. Results of subgroup analyses by age and other factors, Circulation 119:922, 2009.
664. **Gennari L**, **Merlotti D**, **Valleggi F**, **Nuti R**, Ospemifene use in postmenopausal women, Expert Opin Investig Drugs 18:839, 2009.
665. **Simon JA**, **Altomare C**, **Cort S**, **Jiang W**, **Pinkerton JV**, Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials, J Womens Health (Larchmt) 27(1):14, 2018.
666. **Schiavi MC**, **Sciuga V**, **Giannini A**, **Vena F**, **D'oria O**, **Prata G**, **Di Tucci C**, **Savone D**, **Aleksa N**, **Capone C**, **Di Mascio D**, **Meggiorini ML**, **Monti M**, **Zullo MA**, **Muzii L**, **Benedetti Panici P**, Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? Gynecol Endocrinol 34(8):666, 2018.
667. **Berrodin TJ**, **Chang KCN**, **Komm B**, **Freedman LP**, **Nagpal S**, Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination, Mol Endocrinol 23:74, 2009.
668. **Pinkerton JV**, **Archer DA**, **Utian WH**, **Menegoci JC**, **Levine AB**, **Chines AA**, **Constantine GD**, Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis, Menopause 16:1102, 2009.
669. **Archer DA**, **Pinkerton JV**, **Utian WH**, **Menegoci JC**, **de Villiers TJ**, **Kin Yen C**, **Levine AB**, **Chines AA**, **Constantine GD**, Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women, Menopause 16:1109, 2009.
670. **Silverman SL**, **Christiansen C**, **Genant HK**, **Vukicevic S**, **Zanchetta JR**, **de Villiers TJ**, **Constantine GD**, **Chines AA**, Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial, J Bone Miner Res 23:1923, 2008.
671. **Kanis JA**, **Johansson H**, **Oden A**, **McCloskey EV**, Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX, Bone 44(6):1049, 2009. doi: 10.1016/j.bone.2009.02.014.
672. **Harvey JA**, **Hollm MK**, **Ranganath R**, **Guse PA**, **Trott EA**, **Helzner E**, The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis, Menopause 16:1193, 2009.
673. **Pinkerton JV**, **Harvey JA**, **Pan K**, **Thompson JR**, **Ryan KA**, **Chines AA**, **Mirkin S**, **Archer DF**; **SMART-5 Investigators**, Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial, Obstet Gynecol 121(5):959, 2013.
674. **Lobo RA**, **Pinkerton JV**, **Gass ML**, **Dorin MH**, **Ronkin S**, **Pickar JH**, **Constantine G**, Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile, Fertil Steril 92:1025, 2009.
675. **Lindsay R**, **Gallagher JC**, **Kagan R**, **Pickar JH**, **Constantine G**, Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women, Fertil Steril 92:1045, 2009.

676. **Pinkerton JV**, **Utian WH**, **Constantine GD**, **Olivier S**, **Pickar JH**, Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial, Menopause 16:1116, 2009.
677. **Pinkerton JV**, **Pickar JH**, **Racketa J**, **Mirkin S**, Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention, Climacteric 15(5):411, 2012.
678. **Pickar JH**, **Yeh IT**, **Bachmann G**, **Speroff L**, Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy, Fertil Steril 92:1018, 2009.
679. **Archer DF**, **Lewis V**, **Carr BR**, **Olivier S**, **Pickar JH**, Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women, Fertil Steril 92:1039, 2009.
680. **Modelska K**, **Cummings S**, Tibolone for postmenopausal women: systematic review of randomized trials, J Clin Endocrinol Metab 87(1):16, 2002.
681. **Formoso G**, **Perrone E**, **Maltoni S**, **Balduzzi S**, **D'Amico R**, **Bassi C**, **Basevi V**, **Marata AM**, **Magrini N**, **Maestri E**, Short and long term effects of tibolone in postmenopausal women, Cochrane Database Syst Rev (2):Cd008536, 2012.
682. **Kloosterboer HJ**, Tibolone: a steroid with a tissue-specific mode of action, J Steroid Biochem 76:231, 2001.
683. **de Gooyer ME**, **Deckers GH**, **Schoonen WGEJ**, **Verheul HAM**, **Kloosterboer HJ**, Receptor profiling and endocrine interactions of tibolone, Steroids 68:21, 2003.
684. **Timmer CJ**, **Huisman JAM**, Effect of a standardized meal on the bioavailability of a single oral dose of tibolone 2.5 mg in healthy postmenopausal women, Pharmacotherapy 22:310, 2002.
685. **Vos RME**, **Krebbers SFM**, **Verhoeven CHJ**, **Delbressine LPC**, The in vivo human metabolism of tibolone, Drug Metab Dispos 30:106, 2002.
686. **Timmer CJ**, **Houwing NS**, Dose proportionality of three different doses of tibolone, Pharmacotherapy 22:6, 2002.
687. **Markiewicz L**, **Gurpide E**, In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium, J Steroid Biochem 35:535, 1990.
688. **Tang B**, **Markiewicz L**, **Kloosterboer HJ**, **Gurpide E**, Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14), J Steroid Biochem Mol Biol 45:345, 1993.
689. **Punnonen R**, **Liukko P**, **Cortes-Prieto J**, **Eydam F**, **Milojevic S**, **Trevoux R**, **Chryssikopoulos E**, **Franchi F**, **Luisi M**, **Kicovic PM**, Multicentre study of effects of Org OD14 on endometrium, vaginal cytology and cervical mucus in postmenopausal and oophorectomized women, Maturitas 5:281, 1984.
690. **Genazzani AR**, **Benedek Jaszmann L**, **Hart DM**, **Andolsek L**, **Kicovic PM**, **Tax L**, Org OD14 and the endometrium, Maturitas 13:243, 1991.
691. **Trevoux R**, **Dieulangard P**, **Blum A**, Efficacy and safety of Org OD 14 in the treatment of climacteric complaints, Maturitas 5:89, 1983.
692. **Volpe A**, **Facchinetti F**, **Grasso A**, **Petraglia F**, **Campanini D**, **Genazzani AR**, Benefits and risks of different hormonal replacement therapies in postmenopausal women, Maturitas 8:327, 1986.
693. **Siseles NO**, **Halperin H**, **Benencia HJ**, **Berg G**, **Pilnik S**, **Mesch V**, **Arrighi B**, **Wikinski RW**, A comparative study of two hormone replacement therapy regimens on safety and efficacy variables, Maturitas 21:201, 1995.
694. **Nathorst-Böös J**, **Hammar M**, Effect on sexual life—a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen, Maturitas 26:15, 1997.
695. **Hammar M**, **Christau S**, **Nathorst-Böös J**, **Rud T**, **Garre K**, A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms, Br J Obstet Gynaecol 105:904, 1998.
696. **Al-Azzawi F**, **Wahab M**, **Habiba M**, **Akkad A**, **Mason T**, Continuous combined hormone replacement therapy compared with tibolone, Obstet Gynecol 93:258, 1999.
697. **Kökü A**, **Centinkaya MB**, **Yanik F**, **Alper T**, **Malatydlioglu E**, The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women, Maturitas 36:75, 2000.

698. **Landgren MB**, **Coelingh Benink HJT**, **Helmond FA**, **Engelen S**, Dose-response analysis of effects of tibolone on climacteric symptoms, Br J Obstet Gynaecol 109:1109, 2002.
699. **Taskin O**, **Yalcinoglu AI**, **Kucuk S**, **Uryan I**, **Buhur A**, **Burak F**, Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis, Fertil Steril 67:40, 1997.
700. **Crona N**, **Silfverstolpe G**, **Samsioe G**, A double-blind cross-over study on the effects of Org OD 14 compared to estradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women, Acta Endocrinol 102:451, 1983.
701. **Rymer J**, **Chapman MG**, **Fogelman I**, **Wilson POG**, A study of the effect of tibolone on the vagina in postmenopausal women, Maturitas 18:127, 1994.
702. **Botsis D**, **Kassanos D**, **Kalogirous D**, **Antonious G**, **Vitoratos N**, **Karakitsos P**, Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a comparison, Maturitas 26:57, 1997.
703. **Laan E**, **van Lunsen RHW**, **Everaerd W**, The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women, Climacteric 4:28, 2001.
704. **Mendoza N**, **Suárez AM**, **Álamo F**, **Bartual E**, **Vergara F**, **Herruzo A**, Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17b-estradiol for hormonal replacement therapy in women with surgical menopause, Maturitas 37:37, 2000.
705. **Castelo-Branco C**, **Vicente JJ**, **Figueras F**, **Sanjuan A**, **Martinez de Osaba MJ**, **Casals E**, **Pons F**, **Balasch J**, **Vanrell JA**, Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women, Maturitas 34:161, 2000.
706. **Huber J**, **Palacios S**, **Berglund L**, **Hänggi W**, **Sathanandan SM**, **Christau S**, **Helmond F**, Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women, Br J Obstet Gynaecol 109:886, 2002.
707. **Egarter C**, **Topcuoglu AM**, **Vogl S**, **Sator M**, Hormone replacement therapy with tibolone: effects on sexual functioning in postmenopausal women, Acta Obstet Gynecol Scand 81:649, 2002.
708. **Palacios S**, **Menendez C**, **Jurado R**, **Castano JC**, **Vargas JC**, Changes in sex behaviour after menopause: effects of tibolone, Maturitas 22:155, 1995.
709. **Nijland EA**, **Weijmar Schultz WC**, **Nathorst-Böös J**, **Helmond FA**, **Van Lunsen RHW**, **Palacios S**, **Norman RJ**, **Mulder RJ**, **Davis SR**; **LISA Study Investigators Group**, Tibolone and transdermal E2/NETA for the treatment of sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial, J Sex Med 5:646, 2008.
710. **Dören M**, **Rubig A**, **Coelingh Benink HJT**, **Holzgreve W**, Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy, Fertil Steril 75:554, 2001.
711. **Fluck E**, **File SE**, **Rymer J**, Cognitive effects of 10 years of hormone-replacement therapy with tibolone, J Clin Psychopharmacol 22:62, 2002.
712. **Bukulmez O**, **Al A**, **Gurdal H**, **Yarali H**, **Ulug B**, **Gurgan T**, Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores: a prospective randomized trial, Fertil Steril 75:737, 2001.
713. **Clarkson TB**, **Anthony M**, **Wagner JD**, A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys, J Clin Endocrinol Metab 86:5396, 2001.
714. **Clarkson TB**, **Anthony MS**, **Mikkola TS**, **St. Clair RW**, Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys, Stroke 33:2700, 2002.
715. **Fielding CJ**, **Fielding PE**, Molecular physiology of reverse cholesterol transport, J Lipid Res 36:211, 1995.
716. **Pajunen P**, **Syvänne M**, **Castro G**, **Nieminen MS**, **Taskinen MR**, Cholesterol efflux capacity in vitro predicts the severity and extent of coronary artery disease in patients with and without Type 2 diabetes, Scand Cardiovasc J 35:96, 2001.
717. **Mikkola TS**, **Anthony M**, **Clarkson TB**, **St. Clair RW**, Serum cholesterol efflux in postmenopausal

monkeys treated with tibolone or conjugated estrogens, Metabolism 51:523, 2002.
718. **Rymer J**, **Crook D**, **Sidhu M**, **Chapman M**, **Stevenson JC**, Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women, Acta Endocrinol 128:259, 1993.
719. **Milner MH**, **Sinnot MM**, **Cooke TM**, **Kelly A**, **McGill T**, **Harrison RF**, A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin, Obstet Gynecol 87:593, 1996.
720. **Cagnacci A**, **Mallus E**, **Tuveri F**, **Cirillo R**, **Setteneri AM**, **Melis GB**, Effects of tibolone on glucose and lipid metabolism in postmenopausal women, J Clin Endocrinol Metab 82:251, 1997.
721. **Lloyd G**, **McGing E**, **Cooper A**, **Patel N**, **Lumb PJ**, **Wierzbicki AS**, **Jackson G**, A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women, J Hum Hypertens 14:99, 2000.
722. **Ginsburg J**, **Prelevic GM**, Antiatherosclerotic effects of tibolone, Menopause 8:79, 2001.
723. **Gallagher JC**, **Baylink DJ**, **Freeman R**, **McClung M**, Prevention of bone loss with tibolone in postmenopausal women: results of two randomized double-blind, placebo-controlled, dose-finding studies, J Clin Endocrinol Metab 86:4717, 2001.
724. **Barnes JF**, **Farish E**, **Rankin M**, **Hart DM**, A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors, Atherosclerosis 160:185, 2002.
725. **Haenggi W**, **Bersinger NA**, **Mueller MD**, **Bikhaeuser MH**, Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone, Gynecol Endocrinol 13:202, 1999.
726. **Farish E**, **Barnes JF**, **Rolton HA**, **Spowart K**, **Fletcher CD**, **Hart DM**, Effects of tibolone on lipoprotein(a) and HDL subfractions, Maturitas 20:215, 1994.
727. **Lloyd GWL**, **Patel NR**, **McGing EA**, **Cooper AF**, **Kamalvand K**, **Jackson G**, Acute effects of hormone replacement with tibolone on myocardial ischaemia in women with angina, Int J Clin Pract 52:155, 1998.
728. **von Eckardstein A**, **Schmiddem K**, **Hövels A**, **Gülbahce E**, **Schuler-Lüttmann S**, **Elbers J**, **Helmond F**, **Bennink HJ**, **Assmann G**, Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity, Atherosclerosis 159:433, 2001.
729. **Castelo-Branco C**, **Casals E**, **Figueras F**, **Sanjuan A**, **Vicente JJ**, **Balasch J**, **Vanrell JA**, Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins A1 and B, Menopause 6:92, 1999.
730. **Bjarnason NH**, **Bjarnason K**, **Haarbo J**, **Coelingh Bennink HJT**, **Christiansen C**, Tibolone: influence on markers of cardiovascular disease, J Clin Endocrinol Metab 82:1752, 1997.
731. **Kloosterboer HJ**, **Benedek Jaszmann L**, **Kicovic PM**, Long-term effects of OrgOD14 on lipid metabolism in post-menopausal women, Maturitas 12:37, 1990.
732. **Pan H-A**, **Wang S-T**, **Chen C-H**, **Pai M-C**, **Wu M-H**, **Huang K-E**, Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy, Climacteric 5:259, 2002.
733. **Cetinkaya MB**, **Alper T**, **Kökcü A**, **Yanik FF**, **Malatyalioglu E**, Tibolone versus four estrogen replacement therapy protocols and plasma lipid levels in postmenopausal women, Int J Gynaecol Obstet 79:17, 2002.
734. **von Eckardstein A**, **Nofer JR**, **Assmann G**, High density lipoproteins and atherosclerosis. Role of cholesterol efflux and reverse cholesterol transport, Arterioscler Thromb Vasc Biol 21:13, 2001.
735. **von Eckardstein A**, **Crook D**, **Elbers J**, **Ragoobir J**, **Ezeh B**, **Helmonds F**, **Miller N**, **Dieplinger H**, **Coelingh Benink H**, **Assmann A**, Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux, Clin Endocrinol 58:49, 2003.
736. **Morris EP**, **Denton ERE**, **Robinson JG**, **MacDonald LM**, **Rymer JM**, High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure, Climacteric 2:13, 1999.
737. **de Kleijn MJ**, **Wilmink HW**, **Bots ML**, **Bak AA**, **van der Schouw YT**, **Planellas J**, **Engelen S**, **Banga JD**, **Grobbee DE**, Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women, Atherosclerosis 159:357, 2001.
738. **Ceballos C**, **Ribes C**, **Amado JA**, **de Mier I**, **de Rozas LS**, **Berrazueta JR**, Venous endothelial function in

postmenopausal women after six months of tibolone therapy, Maturitas 39:63, 2001.
739. **Manzella D**, **Fornaro F**, **Carbonella M**, **Picardi C**, **Paolisso G**, **Colacurci N**, Effect of tibolone administration on heart rate variability and free fatty acid levels in postmenopausal women, Fertil Steril 78:1005, 2002.
740. **Simoncini T**, **Genazzani AR**, Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells, Mol Cell Endocrinol 162:87, 2000.
741. **Bots ML**, **Evans GW**, **Riley W**, **McBride KH**, **Paskett ED**, **Helmond FA**, **Grobbee DE**; for the **OPAL Investigators**, The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness, Eur Heart J 27:746, 2006.
742. **Renoux C**, **Dell'Aniello S**, **Suissa S**, Hormone replacement therapy and the risk of venous thromboembolism: population-based study, J Thromb Haemost 8:979, 2010.
743. **De Beer F**, **Smelt AHM**, **Van Vark LC**, **Hoogerbrugge N**, **Havekes LM**, **Gevers Leuven JA**, The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia, J Int Med 251:148, 2002.
744. **Prelevic GM**, **Beljic T**, **Balint-Peric L**, **Ginsburg J**, Metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes mellitus, Maturitas 28:271, 1998.
745. **Wiegratz I**, **Starflinger F**, **Tetzloff W**, **Leifels-Fischer B**, **Helmond FA**, **Dericks-Tan JSE**, **Kuhl H**, Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women, Maturitas 41:133, 2002.
746. **Ginsburg J**, **Prelevic G**, **Butler D**, **Okolo S**, Clinical experience with tibolone (Livial) over 8 years, Maturitas 21:71, 1995.
747. **Meuwissen J**, **Wiegerinck M**, **Haverkorn M**, Regression on endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy, Maturitas 21:121, 1995.
748. **Egarter C**, **Sator M**, **Berghammer P**, **Huber J**, Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women, Int J Gynaecol Obstet 64:281, 1999.
749. **Völker W**, **Coelingh Bennink HJT**, **Helmond FA**, Effects of tibolone on the endometrium, Climacteric 4:203, 2001.
750. **Ginsburg J**, **Prelevic GM**, Cause of vaginal bleeding in postmenopausal women taking tibolone, Maturitas 24:1, 1996.
751. **Archer DF**, **Henddrix S**, **Gallagher JC**, **Rymer J**, **Skouby S**, **Ferenczy A**, **den Hollander W**, **Stathopoulos V**, **Helmond FA**; for the **Tibolone Histology of the Endometrium and Breast Endpoints (THEBES) Study Group**, Endometrial effects of tibolone, J Clin Endocrinol Metab 92:911, 2007.
752. **Wu M-H**, **Pan H-A**, **Wang S-T**, **Hsu C-C**, **Chang F-M**, **Huang K-E**, Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy, Climacteric 4:314, 2001.
753. **Nijland EA**, **Nathorst-Böös J**, **Palacios S**, **van de Weijer PW**, **Davis S**, **Stathopoulos VM**, **Birkhäuser MH**, **von Mauw E**, **Mulder RJ**, **Schultz WC**; **LISA Study Investigators Group**, Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction, Climacteric 12:114, 2009.
754. **Rymer J**, **Fogelman I**, **Champman MG**, The incidence of vaginal bleeding with tibolone treatment, Br J Obstet Gynaecol 101:53, 1994.
755. **Berning B**, **van Kuijk C**, **Coelingh Benink HJT**, **Fauser BCJM**, Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women, Maturitas 35:81, 2000.
756. **Hanggi W**, **Lippuner K**, **Riesen W**, **Jaeger P**, **Birkauser MH**, Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised trial, Br J Obstet Gynaecol 104:708, 1997.
757. **Fedele L**, **Bianchi S**, **Raffaelli R**, **Zanconato G**, A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas, Eur J Obstet Gynecol Reprod Biol 88:91, 2000.

758. **Gregoriou O**, **Konidaris S**, **Botsis D**, **Papadias C**, **Makrakis E**, **Creatsas G**, Long term effects of tibolone on postmenopausal women with uterine myomas, Maturitas 40:95, 2001.
759. **Simsek T**, **Karakus C**, **Trak B**, Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period. Tibolone versus transdermal hormonal replacement system, Maturitas 42:243, 2002.
760. **Palomba S**, **Affinito P**, **Tommaselli GA**, **Nappi C**, A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata, Fertil Steril 70:111, 1998.
761. **Santner SJ**, **Feil PD**, **Santen RJ**, In situ estrogen production via estrone sulfatase pathway in breast tumors: relative importance versus aromatase pathway, J Clin Endocrinol Metab 59:29, 1984.
762. **Chetrite GS**, **Cortes-Prieto J**, **Philippe JC**, **Wright F**, **Pasqualini JR**, Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues, J Steroid Biochem Mol Biol 72:23, 2000.
763. **Chetrite G**, **Kloosterboer HJ**, **Pasqualini JR**, Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells, Anticancer Res 17:135, 1997.
764. **Chetrite GS**, **Kloosterboer HJ**, **Philippe JC**, **Pasqualini JR**, Effects of Org OD14 (Livial) and its metabolites on 17-beta-hydroxysteroid dehydrogenase activity in hormone-dependent MDF-7 and T-47D breast cancer cells, Anticancer Res 19:261, 1999.
765. **van de Ven J**, **Donker GH**, **Spsrong M**, **Blankenstein MA**, **Thijssen JHH**, Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells, J Steroid Biochem Mol Biol 81:237, 2002.
766. **Purohit A**, **Malini B**, **Hooymans C**, **Newman SP**, Inhibition of oestrone sulphatase activity by tibolone and its metabolites, Horm Metab Res 1:1, 2002.
767. **Chetrite GS**, **Kloosterboer HJ**, **Philippe JC**, **Pasqualini JR**, Effect of Org OD14 (Livial) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MDF-7 and T-47D, and hormone-independent MDA-MB-231, breast cancer cell lines, Anticancer Res 19:269, 1999.
768. **Kloosterboer HJ**, Endocrine prevention of breast: any role for tibolone?, Eur J Cancer Suppl 6:S24, 2002.
769. **Gompel A**, **Siromachkova M**, **Lombet A**, **Kloosterboer HJ**, **Rostene W**, Tibolone actions on normal and breast cancer cells, Eur J Cancer 36:76, 2000.
770. **de Gooyer ME**, **Overklift Vaupel Kleyn GT**, **Smits KC**, **Ederveen AGH**, **Verheul HAM**, **Kloosterboer HJ**, Tibolone: a compound with tissue specific inhibitory effects on sulfatase, Mol Cell Endocrinol 183:55, 2001.
771. **Valdivia I**, **Ortega D**, Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy, Clin Drug Invest 20:101, 2000.
772. **Colacurci N**, **Fornaro F**, **De Franciscis P**, **Palermo M**, **del Vecchio W**, Effects of different types of hormone replacement therapy on mammographic density, Maturitas 40:159, 2001.
773. **Sendag F**, **Terek MC**, **Õzsener S**, **Öztekin K**, **Bilgin O**, **Bilgen I**, **Memis A**, Mammographic density changes during different postmenopausal hormone replacement therapies, Fertil Steril 76:445, 2001.
774. **Lundström E**, **Christow A**, **Kersemaekers W**, **Svane G**, **Azavedo E**, **Söderqvist G**, **Mol-Arts M**, **Barkfeldt J**, **von Scholutz B**, Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density, Am J Obstet Gynecol 186:717, 2002.
775. **Egarter C**, **Eppel W**, **Vogel S**, **Wolf G**, A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts, Maturitas 40:165, 2001.
776. **Kenemans P**, **Bundred NJ**, **Foidart J-M**, **Kubista E**, **Von Schoultz B**, **Sismondi P**, **Vassilopoulou-Sellin R**, **Yip CH**, **Egberts J**, **Mol-Arts M**, **Mulder R**, **van Os S**, **Beckmann MW**; On behalf of the **LIBERATE Study Group**, Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial, Lancet Oncol 10:135, 2009.
777. **Cummings SR**, **Ettinger B**, **Delmas PD**, **Kenemans P**, **Stathopoulos V**, **Verwij P**, **Mol-Arts M**, **Kloosterboer HJ**, **Mosca L**, **Christiansen C**, **Bilezikian J**, **Kerzberg EM**, **Johnson S**, **Zanchetta JR**, **Grobbee DE**, **Seifert W**, **Eastell R**; **LIFT Trial Investigators**, The effects of tibolone in older postmenopausal women, N Engl J Med 359:697, 2008.

778. **Wierik EJ**, **Hendricks PT**, **Boerstoel-Streefland M**, Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study, Climacteric 7:197, 2004.
779. **Velthuis-Te Wierik EJ**, **Hendricks PT**, **Martinez C**, Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women, Menopause 14:518, 2007.
780. **Lebherz TB**, **French LT**, Nonhormonal treatment of the menopausal syndrome. A double-blind evaluation of an autonomic system stabilizer, Obstet Gynecol 33:795, 1969.
781. **Bergmans MG**, **Merkus JM**, **Corbey RS**, **Schellekens LA**, **Ubachs JM**, Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study, Maturitas 9:227, 1987.
782. **David A**, **Don R**, **Tajchner G**, **Weissglas L**, Veralipride: alternative antidopaminergic treatment for menopausal symptoms, Am J Obstet Gynecol 158:1107, 1988.
783. **Melis GB**, **Bambacciani M**, **Cagnacci A**, **Paoletti AM**, **Mais V**, **Fioretti P**, Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women, Obstet Gynecol 72:688, 1988.
784. **Wesel S**, **Bourguignon RP**, **Bosuma WB**, Veralipride versus conjugated oestrogens: a double-blind study in the management of menopausal hot flushes, Curr Med Res Opin 8:696, 1984.
785. **Barton DL**, **Loprinzi CL**, **Quella SK**, **Sloan JA**, **Veeder MH**, **Egner JR**, **Fidler P**, **Stella PJ**, **Swan DK**, **Vaught NL**, **Novotny P**, Prospective evaluation of vitamin E for hot flashes in breast cancer survivors, J Clin Oncol 16:495, 1998.
786. **Hirata JD**, **Swiersz LM**, **Zell B**, **Small R**, **Ettinger B**, Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial, Fertil Steril 68:981, 1997.
787. **Wiklund IK**, **Mattsson LA**, **Lindgren R**, **Limoni C**, Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group, Int J Clin Pharmacol Res 19:89, 1999.
788. **Jacobson JS**, **Troxel AB**, **Evans J**, **Klaus L**, **Vahdat L**, **Kinne D**, **Lo KM**, **Moore A**, **Rosenman PJ**, **Kaufman EL**, **Neugut AI**, **Grann VR**, Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer, J Clin Oncol 19:2739, 2001.
789. **Quella SK**, **Loprinzi CL**, **Barton DL**, **Knost JA**, **Sloan JA**, **LaVasseur BI**, **Swan D**, **Krupp KR**, **Miller KD**, **Novotny PJ**, Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial, J Clin Oncol 18:1068, 2000.
790. **St. Germain A**, **Peterson CT**, **Robinson JG**, **Alekel DL**, Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment, Menopause 8:17, 2001.
791. **Van Patten CL**, **Olivotto IA**, **Chambers GK**, **Gelmon KA**, **Hislop TG**, **Templeton E**, **Wattie A**, **Prior JC**, Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial, J Clin Oncol 20:1449, 2002.
792. **Pockaj BA**, **Gallagher JG**, **Loprinzi CL**, **Stella PJ**, **Barton DL**, **Sloan JA**, **Lavasseur BI**, **Rao RM**, **Fitch TR**, **Rowland KM**, **Novotny PJ**, **Flynn PJ**, **Richelson E**, **Fauq AH**, Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial NO1CC1, J Clin Oncol 24:2836, 2006.
793. **Krebs E**, **Ensrud KE**, **MacDonald R**, **Wilt T**, Phytoestrogens for treatment of menopausal symptoms: a systematic review, Obstet Gynecol 104:824, 2004.
794. **Vincent A**, **Barton DL**, **Mandrekar JN**, **Cha SS**, **Zais T**, **Wahner-Roedler DL**, **Keppler MA**, **Kreitzer MJ**, **Loprinzi C**, Acupuncture for hot flashes: a randomized, sham-controlled clinical study, Menopause 14:45, 2007.
795. **Deng G**, **Vickers A**, **Yeung S**, **D'Andrea GM**, **Xiao H**, **Heerdt AS**, **Sugarman S**, **Troso-Sandoval T**, **Seidman AD**, **Hudis CA**, **Cassileth B**, Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients, J Clin Oncol 25:5584, 2007.
796. **Lee MS**, **Kim JI**, **Ha JY**, **Boccy K**, **Ernst E**, Yoga for menopausal symptoms: a systematic review, Menopause 16:602, 2009.
797. **Krause MS**, **Nakajima ST**, Hormonal and nonhormonal treatment of vasomotor symptoms, Obstet Gynecol Clin North Am 42(1):163, 2015.

798. **Pandya KJ**, **Raubertas RF**, **Flynn PJ**, **Hynes HE**, **Rosenbluth RJ**, **Kirshner JJ**, **Pierce HI**, **Dragalin V**, **Morrow GR**, Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program Study, Ann Intern Med 132(10):788, 2000.
799. **Lobo RA**, **McCormick W**, **Singer F**, **Roy S**, Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women, Am J Obstet Gynecol 63:1, 1984.
800. **Loprinzi CL**, **Michalak JC**, **Quella SK**, **O'Fallon JR**, **Hatfield AK**, **Nelimark RA**, **Dose AM**, **Fischer T**, **Johnson C**, **Klatt NE**, **Bate WW**, **Rospond RM**, **Oesterling JE**, Megestrol acetate for the prevention of hot flashes, N Engl J Med 331:347, 1994.
801. **Goodwin JW**, **Green SJ**, **Moinpour CM**, **Bearden JD III**, **Giguere JK**, **Jiang CS**, **Lippman SM**, **Martino S**, **Albain KS**, Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626, J Clin Oncol 26:1650, 2008.
802. **Simon JA**, **Portman DJ**, **Kaunitz AM**, **Mekonnen H**, **Kazempour K**, **Bhaskar S**, **Lippman J**, Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials, Menopause 20(10):1027, 2013.
803. **Loprinzi CL**, **Pisansky TM**, **Fonseca R**, **Sloan JA**, **Zahasky KM**, **Quella SK**, **Novotny PJ**, **Rummans TA**, **Dumesic DA**, **Perez EA**, Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors, J Clin Oncol 16:2377, 1998.
804. **Loprinzi CL**, **Kugler JW**, **Sloan JA**, **Malliard JA**, **LaVasseur BI**, **Barton DL**, **Novotny PJ**, **Dakhil SR**, **Rodger K**, **Rummans TA**, **Christensen BJ**, Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial, Lancet 356:2059, 2000.
805. **Evans ML**, **Pritts E**, **Vittinghoff E**, **McClish K**, **Morgan KS**, **Jaffe RB**, Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial, Obstet Gynecol 105(1):161, 2005.
806. **Speroff L**, **Gass M**, **Constantine G**, **Olivier S**; **Study 315 Investigators**, Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial, Obstet Gynecol 111:77, 2008.
807. **Archer DF**, **Dupont CM**, **Constantine GD**, **Pickar JH**, **Olivier S**; for the **Study 319 Investigators**, Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety, Am J Obstet Gynecol 200:238.e1, 2009.
808. **Loprinzi CL**, **Sloan JA**, **Perez EA**, **Quella SK**, **Stella PJ**, **Mailliard JA**, **Halyard MY**, **Pruthi S**, **Novotny PJ**, **Rummans TA**, Phase III evaluation of fluoxetine for treatment of hot flashes, J Clin Oncol 20:1578, 2002.
809. **Kalay AE**, **Demir B**, **Haberal A**, **Kalay M**, **Kandemir O**, Efficacy of citalopram on climacteric symptoms, Menopause 14:223, 2007.
810. **Suvanto-Luukkonen E**, **Koivunen R**, **Sundström H**, **Bioigu R**, **Karjalainen E**, **Häivä-Mällinen L**, **Tapanainen JS**, Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study, Menopause 12:18, 2005.
811. **Kimmick GG**, **Lovato J**, **McQuellon R**, **Robinson E**, **Muss HB**, Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen, Breast J 12:114, 2006.
812. **Grady D**, **Cohen B**, **Tice J**, **Kristof M**, **Olyaie A**, **Sawaya GF**, Ineffectiveness of sertraline for treatment of menopausal hot flushes. A randomized controlled trial, Obstet Gynecol 109:823, 2007.
813. **Guttuso T Jr**, **Kurlan R**, **McDermott MP**, **Kieburtz K**, Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial, Obstet Gynecol 101:337, 2003.
814. **Butt DA**, **Lock M**, **Lewis JE**, **Ross S**, **Moineddin R**, Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial, Menopause 15:310, 2008.
815. **Toulis KA**, **Tzellos T**, **Kouvelas D**, **Goulis DG**, Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis, Clin Ther 31:221, 2009.
816. **Reddy SY**, **Warner H**, **Guttuso T Jr**, **Messing S**, **DiGrazio W**, **Thornburg L**, **Guzick DS**, Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial, Obstet Gynecol 108:41, 2006.

817. **Saadati N**, **Mohammadjafari R**, **Natanj S**, **Abedi P**, The effect of gabapentin on intensity and duration of hot flashes in postmenopausal women: a randomized controlled trial, Glob J Health Sci 5(6):126, 2013.
818. **Loprinzi CL**, **Qin R**, **Baclueva EP**, **Flynn KA**, **Rowland KM Jr**, **Graham DL**, **Erwin NK**, **Dakhil SR**, **Jurgens DJ**, **Burger KN**, Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1, J Clin Oncol 28:641, 2010.
819. **Bardia A**, **Novotny PJ**, **Sloan JA**, **Barton D**, **Loprinzi C**, Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis, Menopause 16:477, 2009.
820. **Stearns V**, **Johnson MD**, **Raae JM**, **Morocho A**, **Novielli A**, **Bhargava P**, **Hayes DF**, **Desta Z**, **Flockhart DA**, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine, J Natl Cancer Inst 95:1758, 2003.
821. **Jin Y**, **Desta Z**, **Stearns V**, **Ward B**, **Ho H**, **Lee KH**, **Skaar T**, **Storniolo AM**, **Li L**, **Araba A**, **Blanchard R**, **Nguyen A**, **Ullmer L**, **Hayden J**, **Lemier S**, **Weinshilboum RM**, **Rae JM**, **Hayes DF**, **Flockhart DA**, CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment, J Natl Cancer Inst 97:30, 2005.
822. **Kelly CM**, **Juurlink DN**, **Gomes T**, **Duong-Hua M**, **Pritchard KI**, **Austin PC**, **Paszat LF**, Risk of death due to breast cancer in women treated with selective serotonin reuptake inhibitor antidepressants and tamoxifen, San Antonio Breast Cancer Symposium, Abstract 2049, December 9–13, 2009.
823. **Stuenkel CA**, Menopausal hormone therapy: current considerations, Endocrinol Metab Clin North Am 44(3):565, 2015.
824. **Gann PH**, **Giovanazzi S**, **Van Horn L**, **Branning A**, **Chatterton RT Jr**, Saliva as a medium for investigating intra- and interindividual differences in sex hormone levels in premenopausal women, Cancer Epidemiol Biomarkers Prev 10:59, 2001.
825. **Chatterton RT Jr**, **Mateo ET**, **Lu D**, **Ling FJ**, Interpopulational differences in the concentrations and ratios of salivary and serum progesterone, Fertil Steril 86:723, 2006.
826. **Flyckt RL**, **Liu J**, **Frasure H**, **Wekselman K**, **Buch A**, **Kinsberg SA**, Comparison of salivary versus serum testosterone levels in postmenopausal women receiving transdermal testosterone supplementation versus placebo, Menopause 16:680, 2009.
827. **American College of Obstetricians** and **Gynecologists Committee on Gynecologic Practice**; **American Society for Reproductive Medicine Practice Committee**, Compounded bioidentical menopausal hormone therapy, Fertil Steril 98(2):308, 2012.
828. **Patsner B**, Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs, Food Drug Law J 63:459, 2008.
829. **Weiderpass E**, **Baron JA**, **Adami HO**, **Magnusson C**, **Lindgren A**, **Bergstrom R**, **Coprreia N**, **Persson I**, Low-potency oestrogen and risk of endometrial cancer: a case-control study, Lancet 353:1824, 1999.
830. **Cole MR**, **Fetrow CW**, Adulteration of dietary supplements, Am J Health Syst Pharm 60:1576, 2003.
831. **Murkies AL**, **Wilcox G**, **Davis SR**, Phytoestrogens, J Clin Endocrinol Metab 83:297, 1998.
832. **Tham DM**, **Gardner CD**, **Haskell WL**, Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence, J Clin Endocrinol Metab 83:2223, 1998.
833. **Kuiper GGJM**, **Carlsson B**, **Grandien K**, **Enmark E**, **Häggblad J**, **Nilsson S**, **Gustafsson J**, Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and b, Endocrinology 138:863, 1997.
834. **Anderson RL**, **Wolf WJ**, Compositional changes in trypsin inhibitors, phytic acid, saponins and isoflavones related to soybean processing, J Nutr 125(Suppl):581S, 1995.
835. **Messina M**, Isoflavone intakes by Japanese were overestimated (letter to the editor), Am J Clin Nutr 62:645, 1995.
836. **Coward L**, **Barnes NC**, **Setchell KDR**, **Barnes S**, The isoflavones genistein and daidzein soybean foods from American and Asian diets, J Agric Food Chem 41:1961, 1993.
837. **Cassidy A**, **Bingham S**, **Setchell KDR**, Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women, Am J Clin Nutr 60:333, 1994.

838. **Lethaby A**, **Marjoribanks J**, **Kronenberg F**, **Roberts H**, **Eden J**, **Brown J**, Phytoestrogens for menopausal vasomotor symptoms, Cochrane Database Syst Rev (12):Cd001395, 2013.
839. **Baber RJ**, **Templeman C**, **Morton T**, **Kelly GE**, **West L**, Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women, Climacteric 2:85, 1999.
840. **Knight DC**, **Howes JB**, **Eden JA**, The effect of Promensil™, an isoflavone extract, on menopausal symptoms, Climacteric 2:79, 1999.
841. **van de Wijer PHM**, **Barentsen R**, Isoflavones form red clover (Promensil®) significantly reduce menopausal hot flush symptoms compared with placebo, Maturitas 42:187, 2002.
842. **Tice JA**, **Ettinger B**, **Ensrud K**, **Wallace R**, **Blackwell T**, **Cummings SR**, Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study. A randomized controlled trial, JAMA 290:207, 2003.
843. **Geller SE**, **Shulman LP**, **van Breemen RB**, **Banuvar S**, **Zhou Y**, **Epstein G**, **Hedayat S**, **Nikolic D**, **Krause EC**, **Piersen CE**, **Bolton JL**, **Pauli GF**, **Farnsworth NR**, Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial, Menopause 16:1156, 2009.
844. **Khoo SK**, **Munro C**, **Battistutta D**, Evening primrose oil and treatment of premenstrual syndrome, Med J Aust 153:189, 1990.
845. **Collins A**, **Cerin A**, **Coleman G**, **Landgren B-M**, Essential fatty acids in the treatment of premenstrual syndrome, Obstet Gynecol 81:93, 1993.
846. **Chenoy R**, **Hussain S**, **Tayob Y**, **O'Brien PM**, **Moss MY**, **Morse PF**, Effect of oral gamolenic acid from evening primrose oil on menopausal flushing, Br Med J 308:501, 1994.
847. **Jiang B**, **Kronenberg F**, **Balick MJ**, **Kennelly EJ**, Analysis of formononetin from black cohosh (Actaea racemosa), Phytomedicine 13:477, 2006.
848. **Newton KM**, **Reed SD**, **Grothaus L**, **Ehrlich K**, **Guiltinan J**, **Ludman E**, **LaCroix AZ**, The Herbal Alternatives for Menopause (HALT) Study: background and study design, Maturitas 52:134, 2005.
849. **Newton KM**, **Reed SD**, **Grothaus L**, **Lee K**, **Ehrlich K**, **LaCroix AZ**, The impact of hormone therapy and herbal remedies for menopause symptoms on sleep quality: the HALT trial (7th European Congress on Menopause, Abstract FCO8.5), Maturitas 54S:S52, 2006.
850. **Maki PM**, **Rugin LH**, **Fornelli D**, **Drogos L**, **Banuvar S**, **Shulman LP**, **Geller SE**, Effects of botanicals and combined hormone therapy on cognition in postmenopausal women, Menopause 16:1167, 2009.
851. **van der Sluijs CP**, **Bensoussan A**, **Chang S**, **Baber R**, A randomized placebo-controlled trial on the effectiveness of an herbal formula to alleviate menopausal vasomotor symptoms, Menopause 16:336, 2009.
852. **Mahady GB**, **Low Dog T**, **Barrett ML**, **Chavez ML**, **Gardiner P**, **Ko R**, **Marles RJ**, **Pellicore LS**, **Giancaspro GI**, **Sarma DN**, United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity, Menopause 15:628, 2008.
853. **Teschke R**, **Bahre R**, **Fuchs J**, **Wolff A**, Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases, Menopause 16:956, 2009.
854. **DeKosky ST**, **Williamson JD**, **Fitzpatrick AL**, **Kronmal RA**, **Ives DG**, **Saxton JA**, **Lopez OL**, **Burke G**, **Carlson MC**, **Fried LP**, **Kuller LH**, **Robbins JA**, **Tracy RP**, **Woolard NF**, **Dunn L**, **Snitz BE**, **Nahin RL**, **Furberg CD**; for the **Ginkgo Evaluation of Memory (GEM) Study Investigators**, Ginkgo biloba for prevention of dementia. A randomized controlled trial, JAMA 300:2253, 2008.
855. **Snitz BE**, **O'Meara ES**, **Carlson MC**, **Arnold AM**, **Ives DG**, **Rapp SR**, **Saxton JA**, **Lopez OL**, **Dunn LO**, **Sink KM**, **DeKosky ST**; for the **Ginkgo Evaluation of Memory (GEM) Study Investigators**, Ginkgo biloba for preventing cognitive decline in older adults. A randomized trial, JAMA 302:2663, 2009.
856. **van Dongen MC**, **van Rossum E**, **Kessels AG**, **Sielhorst HJ**, **Knipschild PG**, The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial, J Am Geriatr Soc 48:1183, 2000.
857. **Solomon PR**, **Adams F**, **Silver A**, **Zimmer J**, **DeVeaux R**, Ginkgo for memory enhancement. A randomized controlled trial, JAMA 288:835, 2002.
858. **Pfister O**, **Sticherling C**, **Schaer B**, **Osswald S**, Electrical storm caused by complementary medication with

Ginkgo biloba extract, Am J Med 121:e3, 2008.
859. **Birks J**, **Grimley Evans J**, Ginkgo biloba for cognitive impairment and dementia, Cochrane Database Syst Rev (1):CD003120, 2007. doi: 10.1002/14651858.CD003120.pub2.
860. **Gaster B**, **Holroyd J**, St. John's wort for depression: a systematic review, Arch Intern Med 160:152, 2000.
861. **Kim HL**, **Streitzer J**, **Goebert D**, St. John's wort for depression: a meta-analysis of well-defined clinical trials, J Nerv Ment Dis 187:532, 1999.
862. **Linde K**, **Mulrow CD**, St John's wort for depression, Cochrane Database Syst Rev (2):CD000448, 2000.
863. **Shelton RC**, **Keller MB**, **Glelenberg A**, **Dunner DL**, **Hirschfeld R**, **Thase ME**, **Russell J**, **Lydiard RB**, **Crits-Cristoph P**, **Gallop R**, **Todd L**, **Hellerstein D**, **Goodnick P**, **Keitner G**, **Stahl SM**, **Halbreich U**, Effectiveness of St John's Wort in major depression. A randomized controlled trial, JAMA 285:1978, 2001.
864. **Hypericum Depression Trial Study Group**, Effect of Hypericum perforatum (St John's Wort) in major depressive disorder. A randomized controlled trial, JAMA 287:1807, 2002.
865. **Food and Drug Administration**, Risk of drug interactions with St. John's wort and indinavir and other drugs, FDA Public Health Advisory, February 10, 2000.
866. **Chen XW**, **Serag ES**, **Sneed KB**, **Liang J**, **Chew H**, **Pan SY**, **Zhou SF**, Clinical herbal interactions with conventional drugs: from molecules to maladies, Curr Med Chem 18(31):4836, 2011.
867. **Moore L**, **Goodwin B**, **Jones SA**, **Wisely GB**, **Serabjit-Singh CJ**, **Willson TM**, **Collins JL**, **Kliewer SA**, St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor, Proc Natl Acad Sci U S A 97:7500, 2000.
868. **Anderson JW**, **Johnstone B**, **Cook-Newell ME**, Meta-analysis of the effects of soy protein intake on serum lipids, N Engl J Med 333:276, 1995.
869. **Clarkson TB**, **Anthony M**, **Morgan TM**, Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens, J Clin Endocrinol Metab 86:41, 2001.
870. **Greaves KA**, **Parks JS**, **Williams JK**, **Wagner JD**, Intact dietary soy protein, but not adding an isoflavone-rich soy extract to casein, improves plasma lipids in ovariectomized cynomolgus monkeys, J Nutr 129:1585, 1999.
871. **Greaves KA**, **Wilson MD**, **Rudel L**, **Williams JK**, **Wagner JD**, Consumption of soy protein reduces cholesterol absorption compared to casein protein alone or supplemented with an isoflavone extract or conjugated equine estrogen in ovariectomized cynomolgus monkeys, J Nutr 130:820, 2000.
872. **Anthony MS**, **Clarkson TB**, **Williams JK**, Effects of soy isoflavones on atherosclerosis: potential mechanisms, Am J Clin Nutr 68:1390S, 1998.
873. **Anthony MS**, **Clarkson TB**, **Hughes CL Jr**, **Morgan TM**, **Burke GL**, Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal Rhesus monkeys, J Nutr 126:43, 1996.
874. **Anthony MS**, **Clarkson TB**, Comparison of soy phytoestrogens and conjugated equine estrogens on atherosclerosis progression in postmenopausal monkeys (abstract), Circulation 90:829, 1998.
875. **Honoré EK**, **Williams JK**, **Anthony MS**, **Clarkson TB**, Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques, Fertil Steril 67:148, 1997.
876. **Williams JK**, **Anthony MS**, **Clarkson TB**, Interactive effects of soy protein and estradiol on coronary artery reactivity in atherosclerotic, ovariectomized monkeys, Menopause 8:307, 2001.
877. **Crouse JR III**, **Morgan T**, **Terry JG**, **Ellis J**, **Vitolins M**, **Burke GL**, A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins, Arch Intern Med 159:2070, 1999.
878. **Potter SM**, **Baum JA**, **Teng H**, **Stillman RJ**, **Shay NF**, **Erdman JW Jr**, Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women, Am J Clin Nutr 68(Suppl):1375S, 1998.
879. **Washburn S**, **Burke GL**, **Morgan T**, **Anthony M**, Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women, Menopause 6:7, 1999.
880. **Merz-Demlow BE**, **Duncan AM**, **Wangen KE**, **Xu X**, **Carr TP**, **Phipps WR**, **Kurzer MS**, Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women, Am J Clin Nutr 71:1462, 2000.

881. **Teixeira SR**, **Potter SM**, **Weigel R**, **Hannum S**, **Erdman JW Jr**, **Hasler CM**, Effects of feeding 4 levels of soy protein for 3 and 6 week on blood lipids and apolipoproteins in moderately hypercholesterolemic men, Am J Clin Nutr 71:1077, 2000.
882. **Simons LA**, **von Konigsmark M**, **Simons J**, **Celermajer DS**, Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women, Am J Cardiol 11:1297, 2000.
883. **Lichtenstein AH**, **Jalbert SM**, **Adlercreutz H**, **Goldin BR**, **Rasmussen H**, **Schaefer EJ**, **Ausman LM**, Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects, Arterioscler Thromb Vasc Biol 22:1852, 2002.
884. **Kreijkamp-Kaspers S**, **Kok L**, **Grobbee DE**, **de Haan EH**, **Aleman A**, **Lampe JW**, **van der Schouw YT**, Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial, JAMA 292:65, 2004.
885. **Jayagopal V**, **Albertazzi P**, **Kilpatrick ES**, **Howarth EM**, **Jennings PE**, **Hepburn DA**, **Atkin SL**, Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes, Diabetes Care 25:1709, 2002.
886. **Jenkens DJA**, **Kendall CW**, **Vidgen E**, **Vuksan V**, **Jackson C**, **Augustin LS**, **Lee B**, **Garsetti M**, **Agarwal S**, **Rao AV**, **Cagampang GB**, **Fulgoni V**, Effect of soy based breakfast cereal on blood lipids and oxidized low density lipoprotein, Metabolism 49:1496, 2000.
887. **Nestel PJ**, **Pomeroy S**, **Kay S**, **Komesaroff P**, **Behrsing J**, **Cameron JD**, **West L**, Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women, J Clin Endocrinol Metab 84:895, 1999.
888. **Food and Drug Administration**, Food labelling: health claims; soy protein and coronary heart disease, Fed Regist 64:57699, 1999.
889. **Upmalis DH**, **Lobo R**, **Bradley L**, **Warren M**, **Cone FL**, **Camia CA**, Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study, Menopause 7:236, 2000.
890. **Hodgson JM**, **Puddey IB**, **Beilin LJ**, **Mori TA**, **Croft KD**, Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentr-ations: a randomized controlled trial in humans, J Nutr 128:728, 1998.
891. **Dewell A**, **Hollenbeck CB**, **Bruce B**, The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women, J Clin Endocrinol Metab 87:118, 2002.
892. **Pan Y**, **Anthony M**, **Clarkson TB**, Effect of estradiol and soy phytoestrogens on choline acetyltransferase and nerve growth factor mRNAs in the frontal cortex and hippocampus of female rats, Proc Soc Exp Biol Med 221:118, 1999.
893. **Pan Y**, **Anthony M**, **Watson S**, **Clarkson TB**, Soy phytoestrogens improve radial arm maze performance in ovariectomized retired breeder rats and do not attenuate benefits of 17beta-estradiol treatment, Menopause 7:230, 2000.
894. **Kritz-Silverstin D**, **Von Muhlen D**, **Barrett-Conner E**, Isoflavones and cognitive function in older women: the SOy and Postmenopausal Health in Aging (SOPHIA) Study, Menopause 10:196, 2003.
895. **Duffy R**, **Wiseman H**, **File SE**, Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones, Pharmacol Biochem Behav 75:721, 2003.
896. **Kreijkamp-Kaspers S**, **Grobbee DE**, **Lampe JW**, **van der Schouw YT**, A randomized, placebo-controlled trial on the effects of soy protein containing isoflavones on quality of life in postmenopausal women, Menopause 12:56, 2005.
897. **Ho SC**, **Chan ASY**, **Ho YP**, **So EKF**, **Sham A**, **Zee B**, **Woo JLF**, Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a double-blind, randomized, controlled trial, Menopause 14:489, 2007.
898. **White LR**, **Petrovitch H**, **Ross GW**, **Masaki K**, **Hardman J**, **Nelson J**, **Davis D**, **Markesbery W**, Brain aging and midlife tofu consumption, J Am Coll Nutr 19:242, 2000.
899. **Adlercreutz H**, **Mazur W**, Phyto-oestrogens and western diseases, Ann Med 29:95, 1997.
900. **Goodman MT**, **Wilkens LR**, **Hankin JH**, **Lyu L-C**, **Wu AH**, **Kolonel LN**, Association of soy and fiber

consumption with the risk of endometrial cancer, Am J Epidemiol 146:294, 1997.
901. **Ingram D**, **Sanders K**, **Kolybaba M**, **Lopez D**, Case-control study of phyto-oestrogens and breast cancer, Lancet 350:990, 1997.
902. **Murkies A**, **Dalais FS**, **Briganti EM**, **Burger HG**, **Healy DL**, **Wahlqvist ML**, **Davis SR**, Phytoestrogens and breast cancer in postmenopausal women: a case control study, Menopause 7:289, 2000.
903. **Lee HP**, **Gourley L**, **Duffy SW**, **Esteve J**, **Lee J**, **Day NE**, Dietary effect on breast cancer risk in Singapore, Lancet 337:1197, 1991.
904. **Wu AH**, **Ziegler RG**, **Horn-Ross PL**, **Nomura AMY**, **West DW**, **Kolonel LN**, **Rosenthal JF**, **Hoover RN**, **Pike MC**, Tofu and risk of breast cancer in Asian-Americans, Cancer Epidemiol Biomarkers Prev 5:901, 1996.
905. **Dai Q**, **Franke AA**, **Jin F**, **Shu XO**, **Hebert JR**, **Custer LJ**, **Cheng J**, **Gao YT**, **Zheng W**, Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai, Cancer Epidemiol Biomarkers Prev 11:815, 2002.
906. **Lee SA**, **Shu XO**, **Li H**, **Yang G**, **Cai H**, **Wen W**, **Ji BT**, **Gao J**, **Gao YT**, **Zheng W**, Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study, Am J Clin Nutr 89:1920, 2009.
907. **Goodman MT**, **Shvetsov YB**, **Wilkens LR**, **Franke AA**, **Le Marchand L**, **Kakazu KK**, **Nomura AM**, **Henderson BE**, **Kolonel LN**, Urinary phytoestrogen excretion and postmenopausal breast cancer risk: the multiethnic cohort study, Cancer Prev Res (Phila) 2:887, 2009.
908. **Messina MJ**, **Persky V**, **Setchell KDR**, **Barnes S**, Soy intake and cancer risk: a review of the in vitro and in vivo data, Nutr Cancer 21:113, 1994.
909. **Petrakis NL**, **Barnes S**, **King EB**, **Lowenstein J**, **Wiencke J**, **Lee MM**, **Miike R**, **Kirk M**, **Coward L**, Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women, Cancer Epidemiol Biomark Prev 5:785, 1996.
910. **Hedelin M**, **Löf M**, **Olsson M**, **Adlercreutz H**, **Sandin S**, **Weiderpass E**, Dietary phytoestrogens are not associated with risk of overall breast cancer but diets rich in coumestrol are inversely associated with risk of estrogen receptor and progesterone receptor negative breast tumors in Swedish women, J Nutr 138:938, 2008.
911. **Ward HA**, **Kuhnle GG**, **Mulligan AA**, **Lentjes MA**, **Luben RN**, **Khaw KT**, Breast, colorectal, and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition-Norfolk in relation to phytoestrogen intake derived from an improved database, Am J Clin Nutr 91:440, 2010.
912. **Lamartiniere CA**, Protection against breast cancer with genistein: a component of soy, Am J Clin Nutr 71(Suppl):1705S, 2000.
913. **Cohen LA**, **Zhao Z**, **Pittman B**, **Scimeca JA**, Effect of intact and isoflavone-depleted soy protein on NMU-induced rat mammary tumorigenesis, Carcinogenesis 21:929, 2000.
914. **Foth D**, **Cline JM**, Effects of mammalian and plant estrogens on mammary glands and uteri of macaques, Am J Clin Nutr 68(Suppl):1413S, 1998.
915. **Foth D**, **Cline JM**, **Romer T**, Effect of isoflavones on mammary gland and endometrium of postmenopausal macaques (Macaca fascicularis), Zentralbl Gynakol 122:96, 2000.
916. **Lu L-JW**, **Anderson KE**, **Grady JJ**, **Nagamani M**, Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction, Cancer Epidemiol Biomark Prev 5:63, 1996.
917. **Wu AH**, **Stancyzk FZ**, **Hendrich S**, **Murphy PA**, **Zhang C**, **Pike MC**, Effects of soy foods on ovarian function in premenopausal women, Br J Cancer 82:1879, 2000.
918. **Lu LW**, **Anderson KE**, **Grady JJ**, **Nagamani M**, Effects of an isoflavone-free soy diet on ovarian hormones in premenopausal women, J Clin Endocrinol Metab 86:3045, 2001.
919. **Martini MC**, **Dancisak BB**, **Haggans CJ**, **Thomas W**, **Slavin JL**, Effects of soy intake on sex hormone metabolism in premenopausal women, Nutr Cancer 34:133, 1999.
920. **Baird DD**, **Umbach DM**, **Lansdell L**, **Hughes CL**, **Setchell KD**, **Weinberg CR**, **Haney AF**, **Wilcox AJ**, **Mclachlan JA**, Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women, J Clin Endocrinol Metab 80:1685, 1995.

921. **Duncan AM**, **Underhill KE**, **Xu X**, **Lavalleur J**, **Phipps WR**, **Kurzer MS**, Modest hormonal effects of soy isoflavones in postmenopausal women, J Clin Endocrinol Metab 84:3479, 1999.
922. **Lu LJ**, **Cree M**, **Josyula S**, **Nagamani M**, **Grady JJ**, **Anderson KE**, Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones, Cancer Res 60:1299, 2000.
923. **Fuhrman BJ**, **Pfeiffer R**, **Xu X**, **Wu AH**, **Korde L**, **Gail MH**, **Keefer LK**, **Veenstra TD**, **Hoover RN**, **Ziegler RG**, Soy intake is associated with increased 2-hydroxylation and decreased 16alpha-hydroxylation of estrogens in Asian-American women, Cancer Epidemiol Biomarkers Prev 18:2751, 2009.
924. **Hargreaves DF**, **Potten CS**, **Harding C**, **Shaw LE**, **Morton MS**, **Roberts SA**, **Howell A**, **Bundred NJ**, Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast, J Clin Endocrinol Metab 84:4017, 1999.
925. **McMichael-Phillips DF**, **Harding C**, **Morton M**, **Roberts SA**, **Howell A**, **Potten CS**, **Bundred NJ**, Effects of soy-protein supplementation on epithelial proliferation in the histologically normal breast, Am J Clin Nutr 68(Suppl):1431S, 1998.
926. **Shu XO**, **Zheng Y**, **Cai H**, **Gu K**, **Chen Z**, **Zheng W**, **Lu W**, Soy food intake and breast cancer survival, JAMA 302:2483, 2009.
927. **Guha N**, **Kwan ML**, **Quesenberry CP Jr**, **Weltzien EK**, **Castillo AL**, **Caan BJ**, Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study, Breast Cancer Res Treat 118:395, 2009.
928. **Scambia G**, **Mango D**, **Signorile PG**, **Angeli RA**, **Palena C**, **Gallo D**, **Bombardelli E**, **Morazzoni P**, **Riva A**, **Manscuso S**, Clinical effects of a standardized soy extract in postmenopausal women: a pilot study, Menopause 7:105, 2000.
929. **Penotti M**, **Fabio E**, **Modena AB**, **Rinaldi M**, **Omodei U**, **Vigano P**, Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries, Fertil Steril 79:1112, 2003.
930. **Komesaroff PA**, **Black C**, **Cable V**, **Sudhir K**, Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women, Climacteric 4:144, 2001.
931. **Stanczyk FZ**, **Paulson RJ**, **Roy S**, Percutaneous administration of progesterone: blood levels and endometrial protection, Menopause 12:232, 2005.
932. **Balk JL**, **Whiteside DA**, **Naus G**, **DeFerrari E**, **Roberts JM**, A pilot study of the effects of phytoestrogen supplementation on postmenopausal endometrium, J Soc Gynecol Investig 9:238, 2002.
933. **Morito K**, **Hirose T**, **Kinjo J**, **Hirakawa T**, **Okawa M**, **Nohara T**, **Ogawa S**, **Inoue S**, **Muramatsu M**, **Masamune Y**, Interaction of phytoestrogens with estrogen receptors alpha and beta, Biol Pharm Bull 24:351, 2001.
934. **Setchell KDR**, **Brown NM**, **Lydeking-Olsen E**, The clinical importance of the metabolite equol—a clue to the effectiveness of soy and its isoflavones, J Nutr 132:3577, 2002.
935. **Lydeking-Olsen, Beck-Jensen JE**, **Setchell KD**, **Holm-Jensen T**, Soymilk or progesterone for prevention of bone loss—a 2 year randomized, placebo-controlled trial, Eur J Nutr 43:246, 2004.
936. **Ishiwata N**, **Melby MK**, **Mizuno S**, **Watanabe S**, New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women, Menopause 16:141, 2009.
937. **Setchell KD**, **Zhao X**, **Jha P**, **Heubi JE**, **Brown NM**, The pharmacokinetic behavior of the soy isoflavone metabolite S-(−)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers, Am J Clin Nutr 90:1029, 2009.
938. **Setchell KD**, **Zhao X**, **Shoaf SE**, **Ragland K**, The pharmacokinetics of S-(−)equol administered as SE5-OH tablets to healthy postmenopausal women, J Nutr 139:2037, 2009.
939. **Lund TD**, **Munson DJ**, **Haldy ME**, **Setchell KD**, **Lephart ED**, **Handa RJ**, Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback, Biol Reprod 70:1188, 2004.
940. **Takahashi K**, **Okada M**, **Ozaki T**, **Kurioka H**, **Manabe A**, **Kanasaki H**, **Miyazaki K**, Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause, Hum Reprod 15:1028, 2000.
941. **Grodstein F**, **Stampfer MJ**, **Falkeborn M**, **Naessen T**, **Persson I**, Postmenopausal hormone therapy and

risk of cardiovascular disease and hip fracture in a cohort of Swedish women, Epidemiology 10:476, 1999.
942. **Cooper A**, **Spencer C**, **Whitehead MI**, **Ross D**, **Barnard GJR**, **Collins WP**, Systemic absorption of progesterone from Progest cream in postmenopausal women, Lancet 351:1255, 1998.
943. **Carey BJ**, **Carey AH**, **Patel S**, **Carter G**, **Studd JWW**, A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women, Br J Obstet Gynaecol 107:722, 2000.
944. **Burry KA**, **Patton PE**, **Hermsmeyer K**, Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen, Am J Obstet Gynecol 180:1504, 1999.
945. **Leonnetti HB**, **Longo S**, **Anasti JN**, Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss, Obstet Gynecol 94:225, 1999.
946. **Benster B**, **Carey A**, **Wadsorth F**, **Vashisht A**, **Domoney C**, **Studd J**, A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women, Menopause Int 15:63, 2009.
947. **Wren BG**, **McFarland K**, **Edwards L**, **O'Shea P**, **Sufi S**, **Gross B**, **Eden JA**, Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women, Climacteric 3:155, 2000.
948. **Wren BG**, **Champion SM**, **Willetts K**, **Manga RZ**, **Eden JA**, Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women, Menopause 10:13, 2003.
949. **O'Leary P**, **Feddema P**, **Chan K**, **Taranto M**, **Smith M**, **Evans S**, Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre- and postmenopausal women, Clin Endocrinol 53:615, 2000.
950. **Lewis JG**, **McGill H**, **Patton V**, **Elder PA**, Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women, Maturitas 41:1, 2002.
951. **Stanczyk FZ**, Treatment of postmenopausal women with topical progesterone creams and gels: are they effective? Climacteric 17(Suppl 2):8, 2014.
952. **Nand S**, **Webster MA**, **Baber R**, **O'Connor V**; for the **Ogen/Provera Study Group**, Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy, Obstet Gynecol 91:678, 1998.
953. **Padwick ML**, **Psryse-Davies J**, **Whitehead MI**, A simple method for determining the optimal dosage of progestin in postmenopausal women receiving estrogens, N Engl J Med 315:930, 1986.
954. **Sturdee DW**, **Barlow DH**, **Ulrich LG**, **Wells M**, **Gydesen H**, **Campbell M**, **O'Brien K**, **Vessey M**; for the **UK Continuous Combined HRT Study Investigators**, Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy?, Lancet 344:979, 1994.
955. **Langer RD**, **Pierce JJ**, **O'Hanlan KA**, **Johnson SR**, **Espeland MA**, **Trabal JF**, **Barnabei VM**, **Merino MJ**, **Scully RE**; for the **Postmenopausal Estrogen/Progestin Interventions Trial**, Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease, N Engl J Med 337:1792, 1997.
956. **American College of Obstetricians and Gynecologists**, The role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Committee Opinion No. 734, Obstet Gynecol 131:e124, 2018.
957. **Botsis D**, **Kassanos D**, **Pyrgiotis E**, **Zourlas PA**, Vaginal sonography of the endometrium in postmenopausal women, Clin Exp Obstet Gynecol 19:189, 1992.
958. **Karlsson B**, **Granberg S**, **Wikland M**, **Ylöstalo P**, **Torvid K**, **Marsal K**, **Valentin L**, Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding—a Nordic Multicenter Study, Am J Obstet Gynecol 172:1488, 1995.
959. **Bakos O**, **Smith P**, **Heimer G**, Transvaginal ultrasonography for identifying endometrial pathology in postmenopausal women, Maturitas 20:181, 1995.
960. **Granberg S**, **Ylöstalo P**, **Wikland M**, **Karlsson B**, Endometrial sonographic and histologic findings in women with and without hormonal replacement therapy suffering from postmenopausal bleeding, Maturitas 27:35, 1997.

961. ACOG Committee Opinion No. 734: the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding, Obstet Gynecol 131(5):e124, 2018.
962. **Hänggi W**, **Bersinger N**, **Altermatt HJ**, **Birkhäuser MH**, Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users, Maturitas 27:133, 1997.
963. **Affinito P**, **Palomba S**, **Sammartino A**, **Bonifacio M**, **Nappi C**, Ultrasonographic endometrial monitoring during continuous-sequential hormonal replacement therapy regimen in postmenopausal women, Maturitas 39:239, 2001.
964. **Van den Bosch T**, **Van Schoubroeck D**, **Ameye L**, **De Brabanter J**, **Van Huffel S**, **Timmerman D**, Ultrasound assessment of endometrial thickness and endometrial polyps in women on hormonal replacement therapy, Am J Obstet Gynecol 188:1249, 2003.
965. **Omodei U**, **Ferrazzia E**, **Ruggeri C**, **Palai N**, **Fallo L**, **Dordoni D**, **Peruginoa G**, Endometrial thickness and histological abnormalities in women on hormonal replacement therapy: a transvaginal ultrasound/hysteroscopic study, Ultrasound Obstet Gynecol 15:317, 2000.
966. **Sladkevicius P**, **Valentin L**, **Marsal K**, Endometrial thickness and Doppler velocimetry of the uterine arteries as discriminators of endometrial status in women with postmenopausal bleeding: a comparative study, Am J Obstet Gynecol 171:722, 1994.
967. **Conoscenti G**, **Meir YJ**, **Fischer-Tamaro L**, **Maieron A**, **Natale R**, **D'Ottavio G**, **Rustico M**, **Mandruzzato G**, Endometrial assessment by transvaginal sonography and histological findings after D & C in women with postmenopausal bleeding, Ultrasound Obstet Gynecol 6:108, 1995.
968. **Symons J**, **Kempfert N**, **Speroff L**, Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators, Obstet Gynecol 96:366, 2000.
969. **Simon JA**, **Symons J**; **femhrt Study Investigators**, Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens, Menopause 8:321, 2001.
970. **Simon JA**, **Liu JH**, **Speroff L**, **Shumel BS**, **Symons JP**, Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate, Am J Obstet Gynecol 188:92, 2003.
971. **Andersson K**, **Mattsson L**, **Rybo G**, **Stadberg E**, Intrauterine release of levonorgestrel—a new way of adding progestogen in hormone replacement therapy, Obstet Gynecol 79:963, 1992.
972. **McGonigle KF**, **Karlan BY**, **Barbuto DA**, **Leuchter RS**, **Lagasse LD**, **Judd HL**, Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy, Gynecol Oncol 55:126, 1994.
973. **Eriksson M**, **Berglund L**, **Rudling M**, **Henriksson P**, **Angelin B**, Effects of estrogen on low density lipoprotein metabolism in males. Short-term and long-term studies during hormonal treatment of prostatic cancer, J Clin Invest 84:802, 1989.
974. **Walsh BW**, **Schiff I**, **Rosner B**, **Greenberg L**, **Ravnikar V**, **Sacks FM**, Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins, N Engl J Med 325:1196, 1991.
975. **Muesing R**, **Miller V**, **LaRosa J**, **Stoy D**, **Phillips E**, Effects of unopposed conjugated equine estrogen on lipoprotein composition and apolipoprotein-E distribution, J Clin Endocrinol Metab 75:1250, 1992.
976. **Manning JM**, **Edwards IJ**, **Wagner WD**, **Wagner JD**, **Adams MR**, **Parks JS**, Effects of contraceptive estrogen and progestin on the atherogenic potential of plasma LDLs in Cynomolgus monkeys, Arterioscler Thromb Vasc Biol 17:1216, 1997.
977. **Campos H**, **Walsh BW**, **Judge H**, **Sacks FM**, Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women, J Clin Endocrinol Metab 82:3955, 1997.
978. **Espeland MA**, **Marcovina SM**, **Miller V**, **Wood PD**, **Wasilauskas C**, **Sherwin R**, **Schrott H**, **Bush TL**, Effect of postmenopausal hormone therapy on lipoprotein(a) concentration, Circulation 97:979, 1998.
979. **Nabulsi A**, **Folsom A**, **White A**, **Patsch W**, **Heiss G**, **Wu K**, **Szklo M**, Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women, N Engl J Med

328:1069, 1993.
980. **Christiansen C**, **Riis BJ**, Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern, Br J Obstet Gynaecol 97:1087, 1990.
981. **Lobo R**, **Pickar J**, **Wild R**, **Walsh B**, **Hirvonen E**, Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group, Obstet Gynecol 84:987, 1994.
982. **Munk-Jensen N**, **Ulrich L**, **Obel E**, **Nielsen S**, **Edwards D**, **Meinertz H**, Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect on plasma lipoproteins in a two-year placebo-controlled trial, Am J Obstet Gynecol 171:132, 1994.
983. **Folsom AR**, **McGovern PG**, **Nabulsi AA**, **Shahar E**, **Kahn ESB**, **Winkhart SP**, **White AD**; for the **Atherosclerosis Risk in Communities Study Investigators**, Changes in plasma lipids and lipoproteins associated with starting or stopping postmenopausal hormone replacement therapy, Am Heart J 132:952, 1996.
984. **Barrett-Connor E**, **Slone S**, **Greendale G**, **Kritz-Silverstein D**, **Espeland M**, **Johnson SR**, **Waclawiw M**, **Fineberg SE**, The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women, Maturitas 27:261, 1997.
985. **Davidson MH**, **Testolin LM**, **Maki KC**, **von Duvillard S**, **Drennan KB**, A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women, Arch Intern Med 157:1186, 1997.
986. **Adams MR**, **Clarkson TB**, **Koritnik DR**, **Nash HA**, Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques, Fertil Steril 47:1010, 1987.
987. **Clarkson TB**, **Adams MR**, **Kaplan JR**, **Shively CA**, **Koritnik DR**, From menarche to menopause: coronary artery atherosclerosis and protection in cynomolgus monkeys, Am J Obstet Gynecol 160:1280, 1989.
988. **Clarkson TB**, **Shively CA**, **Morgan TM**, **Koritnik DR**, **Adams MR**, **Kaplan JR**, Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys, Obstet Gynecol 75:217, 1990.
989. **Kushwaha R**, **Hazzard W**, Exogenous estrogens attenuate dietary hypercholesterolemia and atherosclerosis in the rabbit, Metabolism 30:57, 1981.
990. **Hough JL**, **Zilversmit DB**, Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits, Arteriosclerosis 6:57, 1986.
991. **Henriksson P**, **Stamberger M**, **Eriksson M**, **Rudling M**, **Diczfalusy U**, **Berglund L**, **Angelin B**, Oestrogen-induced changes in lipoprotein metabolism: role in prevention of atherosclerosis in the cholesterol-fed rabbit, Eur J Clin Invest 19:395, 1989.
992. **Haarbo J**, **Leth-Espensen P**, **Stender S**, **Christiansen C**, Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits, J Clin Invest 87:1274, 1991.
993. **Adams MR**, **Kaplan JR**, **Manuck SB**, **Koritnik DR**, **Parks JS**, **Wolfe MS**, **Clarkson TB**, Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone, Arteriosclerosis 10:1051, 1990.
994. **Williams JK**, **Anthony MS**, **Honoré EK**, **Herrington DM**, **Morgan TM**, **Register TC**, **Clarkson TB**, Regression of atherosclerosis in female monkeys, Arterioscler Thromb Vasc Biol 15:827, 1995.
995. **Wagner JD**, **St. Clair RW**, **Schwenke DC**, **Shievely CA**, **Adams MR**, **Clarkson TB**, Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal Cynomolgus monkeys: effects of estrogen and progesterone replacement, Arterioscler Thromb 12:716, 1992.
996. **Shwaery GT**, **Vita JA**, **Keaney JF Jr**, Antioxidant protection of LDL by physiological concentrations of 17 beta-estradiol. Requirement for estradiol modification, Circulation 95:1378, 1997.
997. **Vihma V**, **Vehkavaara S**, **Yki-Järvinen H**, **Hohtari H**, **Tikkanen MJ**, Differential effects of oral and transdermal estradiol treatment on circulating estradiol fatty acid ester concentrations in postmenopausal women, J Clin Endocrinol Metab 88:588, 2003.
998. **Polderman KH**, **Stehouwer DC**, **van Kamp GJ**, **Dekker GA**, **Verheugt FW**, **Gooren LJ**, Influence of sex hormones on plasma endothelin levels, Ann Intern Med 118:429, 1993.
999. **Wilcox JG**, **Hatch IE**, **Gentzschein E**, **Stanczyk FZ**, **Lobo RA**, Endothelin levels decrease after oral and

nonoral estrogen in postmenopausal women with increased cardiovascular risk factors, Fertil Steril 67:273, 1997.

1000. **Bar J**, **Tepper R**, **Fuchs J**, **Pardo Y**, **Goldberger S**, **Ovadia J**, The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women, Obstet Gynecol 81:261, 1993.
1001. **Aune B**, **Øian P**, **Omsjo P**, **Østerud B**, Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood—a beneficial effect on atherogenesis and thrombus formation?, Am J Obstet Gynecol 173:1816, 1995.
1002. **Ganger KF**, **Vyas S**, **Whitehead MI**, **Crook D**, **Miere H**, **Campbell S**, Pulsatility index in the internal carotid artery is influenced by transdermal oestradiol and time since menopause, Lancet 338:839, 1991.
1003. **Hillard TC**, **Bourne TH**, **Whitehead MI**, **Crayford TB**, **Collins WP**, **Campbell S**, Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women, Fertil Steril 58:959, 1992.
1004. **Zegura B**, **Keber I**, **Sebestjen M**, **Borko E**, Orally and transdermally replaced estradiol improves endothelial function in middle-aged women after surgical menopause, Am J Obstet Gynecol 188:1291, 2003.
1005. **Collins P**, **Shay J**, **Jiang C**, **Moss J**, Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal, Circulation 90:1964, 1994.
1006. **Gilligan DM**, **Badar DM**, **Panza JA**, **Quyyumi AA**, **Cannon RO III**, Acute vascular effects of estrogen in postmenopausal women, Circulation 90:786, 1994.
1007. **Gilligan DM**, **Badar DM**, **Panza JL**, **Quyyumi AA**, **Cannon RO III**, Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women, Am J Cardiol 75:264, 1995.
1008. **Mercuro G**, **Vitale C**, **Fini M**, **Zoncu S**, **Leonardo F**, **Rosano GM**, Lipid profiles and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial, Int J Cardiol 89:257, 2003.
1009. **McCrohon JA**, **Adams MR**, **McCredie RJ**, **Robinson J**, **Pike A**, **Abbey M**, **Keech AC**, **Celermajer DS**, Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women, Clin Endocrinol 45:435, 1996.
1010. **Lau TK**, **Wan D**, **Yim SF**, **Sanderson JE**, **Haines CJ**, Prospective, randomized, controlled study of the effect of hormone replacement therapy on peripheral blood flow velocity in postmenopausal women, Fertil Steril 70:284, 1998.
1011. **Koh KK**, **Jin DK**, **Yang SH**, **Lee S-K**, **Hwang HY**, **Kang MH**, **Kim W**, **Kim DS**, **Choi IS**, **Shin EK**, Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women, Circulation 103:1961, 2001.
1012. **Sjorensen KE**, **Dorup I**, **Hermann AP**, **Mosekilde L**, Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function, Circulation 97:1234, 1998.
1013. **Weiner CP**, **Lizasoain I**, **Baylis SA**, **Knowles RG**, **Charles IG**, **Moncada S**, Induction of calcium-dependent nitric oxide synthases by sex hormones, Proc Natl Acad Sci U S A 91:5212, 1994.
1014. **Hayashi T**, **Fukuto JM**, **Ignarro L**, **Chaudhuri G**, Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis, Proc Natl Acad Sci U S A 89:11259, 1992.
1015. **Rosselli M**, **Imthurn B**, **Keller PJ**, **Jackson EK**, **Dubey RK**, Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study, Hypertension 25:848, 1995.
1016. **Imthurn B**, **Rosselli M**, **Jaeger AW**, **Keller PJ**, **Dubey RK**, Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate, J Clin Endocrinol Metab 82:388, 1997.
1017. **Ylikorkala O**, **Cacciatore B**, **Paakkari I**, **Tikkanen MJ**, **Viinikka L**, **Toivonen J**, The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane, Fertil Steril 69:883, 1998.

1018. **Gilligan DM**, **Quyyumi AA**, **Cannon RO III**, Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women, Circulation 89:2545, 1994.
1019. **Roquél M**, **Heras M**, **Roig E**, **Masotti M**, **Rigol M**, **Betriu A**, **Balasch J**, **Sanz G**, Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms, J Am Coll Cardiol 31:139, 1998.
1020. **Guetta V**, **Quyyumi AA**, **Prasad A**, **Panza JA**, **Waclawiw M**, **Cannon III RO**, The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women, Circulation 96:2795, 1997.
1021. **Williams JK**, **Shively CA**, **Clarkson TB**, Determinants of coronary artery reactivity in premenopausal female cynomolgus monkeys with diet-induced atherosclerosis, Circulation 90:983, 1994.
1022. **Chester AH**, **Jiang C**, **Borland JA**, **Yacoub M**, **Collins P**, Oestrogen relaxes human epicardial coronary arteries through non-endothelial-dependent mechanisms, Coron Artery Dis 6:417, 1995.
1023. **Collins P**, **Rosano GM**, **Jiang C**, **Lindsay D**, **Sarrel PM**, **Poole-Wilson PA**, Cardiovascular protection by estrogen—a calcium antagonism effect?, Lancet 341:264, 1993.
1024. **Pines A**, **Fishman EZ**, **Levo Y**, **Auerbuch M**, **Lidor A**, **Drory Y**, **Finkelstein A**, **Hetman-Peri M**, **Moshkowitz M**, **Ben-Ari E**, **Ayalon D**, The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow, Am J Obstet Gynecol 164:806, 1991.
1025. **Pines A**, **Fishman EZ**, **Ayalon D**, **Drory Y**, **Aveerbuch M**, **Levo Y**, Long-term effects of hormone replacement therapy on Doppler-derived parameters of aortic flow in postmenopausal women, Chest 102:1496, 1992.
1026. **Voutilainen S**, **Hippelainen M**, **Hulklo S**, **Karppinen K**, **Ventila M**, **Kupri M**, Left ventricular diastolic function by Doppler echocardiography in relation to hormone replacement therapy in healthy postmenopausal women, Am J Cardiol 71:614, 1993.
1027. **Giraud GD**, **Morton MJ**, **Wilson RA**, **Burry KA**, **Speroff L**, Effects of estrogen and progestin on aortic size and compliance in postmenopausal women, Am J Obstet Gynecol 174:1708, 1996.
1028. **Prelevic GM**, **Beljic T**, The effect of oestrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women, Maturitas 20:37, 1994.
1029. **Liang Y-L**, **Teede H**, **Shiel L**, **Thomas A**, **Craven R**, **Sachithanandan N**, **McNeil JJ**, **Cameron JD**, **Dart A**, **McGrath B**, Effects of oestrogen and progesterone on age-related changes in arteries of postmenopausal women, Clin Exp Pharmacol Physiol 24:457, 1997.
1030. **Pines A**, **Fisman EZ**, **Averbuch M**, **Drory Y**, **Motro M**, **Levo Y**, **Weiss A**, **Rotmensch H**, **Ayalon D**, The long-term effects of transdermal estradiol on left ventricular function and dimensions, Eur J Menopause 2:22, 1995.
1031. **Snabes MC**, **Payne JP**, **Kopelen HA**, **Dunn JK**, **Young RL**, **Zoghbi WA**, Physiologic estradiol replacement therapy and cardiac structure and function in normal postmenopausal women: a randomized, double-blind, placebo-controlled, crossover trial, Obstet Gynecol 89:332, 1997.
1032. **Poehlman ET**, **Goran MI**, **Gardner AW**, **Ades PA**, **Arciero PJ**, **Katzman-Rooks SM**, **Montgovery SM**, **Toth MJ**, **Sutherland PT**, Determinants of decline in resting metabolic rate in aging females, Am J Physiol 264:E450, 1993.
1033. **Trémollieres FA**, **Pouilles J-M**, **Ribot CA**, Relative influence of age and menopause on total and regional body composition changes in postmenopausal women, Am J Obstet Gynecol 175:1594, 1996.
1034. **Walton C**, **Godsland IF**, **Proudler A**, **Wynn V**, **Stevenson JC**, The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women, Eur J Clin Invest 23:466, 1993.
1035. **Proudler AJ**, **Godsland IF**, **Stevenson JC**, Insulin propeptides in conditions associated with insulin resistance in humans and their relevance to insulin measurements, Metabolism 43:46, 1994.
1036. **Haarbo J**, **Marslew U**, **Gotfredsen A**, **Christiansen C**, Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause, Metabolism 40:1323, 1991.
1037. **Ley C**, **Lees B**, **Stevenson J**, Sex- and menopause-associated changes in body-fat distribution, Am J Clin Nutr 55:950, 1992.
1038. **Reubinoff BE**, **Wurtman J**, **Rojansky N**, **Adler D**, **Stein P**, **Schenker JG**, **Brzezinski A**, Effects of

hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study, Fertil Steril 64:963, 1995.

1039. **Gambacciani M**, **Ciaponi M**, **Cappagli B**, **Piaggesi L**, **De Simone L**, **Orlandi R**, **Genazzani AR**, Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women, J Clin Endocrinol Metab 82:414, 1997.
1040. **Chlebowski RT**, **Wactawski-Wende J**, **Ritenbaugh C**, **Hubbell FA**, **Ascensao J**, **Rodabough RJ**, **Rosenberg CA**, **Taylor VM**, **Harris R**, **Chen C**, **Adams-Campbell LL**, **White E**; for the **Women's Health Initiative Investigators**, Estrogen plus progestin and colorectal cancer in postmenopausal women, N Engl J Med 350:991, 2004.
1041. **Ferri C**, **Pittoni V**, **Piccoli A**, **Laurenti O**, **Cassone MR**, **Bellini C**, **Properzi G**, **Valesini G**, **De Mattia G**, **Santucci A**, Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo, J Clin Endocrinol Metab 80:829, 1995.
1042. **Cagnacci A**, **Soldani R**, **Carriero PL**, **Paoletti AM**, **Fioretti P**, **Melis GB**, Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women, J Clin Endocrinol Metab 74:1396, 1992.
1043. **Lindheim S**, **Duffy D**, **Kojima T**, **Vijod M**, **Stancyzk F**, **Lobo R**, The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women, Fertil Steril 62:1176, 1994.
1044. **Salomaa V**, **Rasi V**, **Pekkanen J**, **Vahtera E**, **Jauhiainen M**, **Vartiainen E**, **Ehnholm C**, **Tuomilehto J**, **Myllylä G**, Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors: the FINRISK hemostasis study, Arterioscler Thromb Vasc Biol 15:1549, 1995.
1045. **Kanaya AM**, **Herrington D**, **Vittinghoff E**, **Lin F**, **Grady D**, **Bittner V**, **Cauley JA**, **Barrett-Conner E**, Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled study, Ann Intern Med 138:1, 2003.
1046. **Godsland IF**, **Ganger K**, **Walton C**, **Cust MP**, **Whitehead MI**, **Wynn V**, **Stevenson JC**, Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy, Metabolism 42:846, 1993.
1047. **Cucinelli F**, **Paparella P**, **Soranna L**, **Barini A**, **Cinque B**, **Mancuso S**, **Lanzone A**, Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion, Eur J Endocrinol 140:215, 1999.
1048. **Duncan AC**, **Lyall H**, **Roberts RN**, **Petrie JR**, **Perera MJ**, **Monaghan S**, **Hart DM**, **Connell JMC**, **Lumsden MA**, The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women, J Clin Endocrinol Metab 84:2402, 1999.
1049. **Andersson B**, **Mattsson L**, **Hahn L**, **Mårin P**, **Lapidus L**, **Holm G**, **Bengtsson B**, **Björntorp P**, Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab 82:638, 1997.
1050. **Brussaard HE**, **Gevers Leuven JA**, **Frolich M**, **Kluft C**, **Krans HMJ**, Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM, Diabetologia 40:843, 1997.
1051. **Manson J**, **Rimm E**, **Colditz G**, **Willett W**, **Nathan D**, **Arky R**, **Roxner B**, **Hennekens C**, **Speizer F**, **Stampfer M**, A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin dependent diabetes mellitus, Ann Epidemiol 2:665, 1992.
1052. **Pentti K**, **Tuppurainen M**, **Honkanen R**, **Sandini L**, **Kröger H**, **Alhava E**, **Saarikoski S**, Hormone therapy protects from diabetes: the Kuopio Osteoporosis Risk Factor and Prevention Study, Eur J Endocrinol 160:979, 2009.
1053. **de Lauzon-Guillan B**, **Fournier A**, **Fabre A**, **Simon N**, **Mesrine S**, **Boutron-Ruault MC**, **Balkau B**, **Françoise C-C**, Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l'Education Nationale (E3N) cohort, Diabetologia 52:2092, 2009.
1054. **Bonds DE**, **Lasser N**, **Qi L**, **Brzyski RG**, **Caan B**, **Heiss G**, **Limacher MC**, **Liu JH**, **Mason E**, **Oberman A**, **O'Sullivan MJ**, **Phillips LS**, **Prineas RJ**, **Tinker L**, The effect on conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial, Diabetologia 49:459, 2006.

1055. **Rifici VA**, **Khachadurian AK**, The inhibition of low-density lipoprotein oxidation by 17-beta estradiol, Metabolism 41:1110, 1992.
1056. **Knopp R**, **Zhu X**, **Bonet B**, Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women, Atherosclerosis 110(Suppl 1):S83, 1994.
1057. **Sack MN**, **Rader DJ**, **Cannon RO III**, Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women, Lancet 343:269, 1994.
1058. **Keaney J Jr**, **Shwaery G**, **Xu A**, **Nicholosi R**, **Loscalzo J**, **Foxall T**, **Vita J**, 17 beta-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine, Circulation 89:225, 1994.
1059. **Tranquilli AL**, **Mazzanti L**, **Cugini AM**, **Cester N**, **Garzetti GG**, **Romanini C**, Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants, Gynecol Endocrinol 9:137, 1995.
1060. **Samsioe G**, **Andersson K**, **Mattsson L-Å**, Relative fatty acid composition of serum lecithin in perimenopausal women using combined hormone replacement therapy, Menopause 4:193, 1997.
1061. **Meade TW**, **Dyer S**, **Howarth DJ**, **Imeson JD**, **Stirling Y**, Antithrombin III and procoagulant activity: sex differences and effects of the menopause, Br J Haematol 74:77, 1990.
1062. **Stefanick ML**, **Legault C**, **Tracy RP**, **Howard G**, **Kessler CM**, **Lucas DL**, **Bush TL**, Distribution and correlates of plasma fibrinogen in middle-aged women. Initial findings of the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study, Arterioscler Thromb Vasc Biol 15:2085, 1995.
1063. **Meilahn E**, **Kuller L**, **Matthews K**, **Kiss J**, Hemostatic factors according to menopausal status and use of hormone replacement therapy, Ann Epidemiol 2:445, 1992.
1064. **Scarabin PY**, **Flu-Bureau G**, **Bara L**, **Bonithon-Kopp C**, **Guize L**, **Samama M**, Haemostatic variables and menopausal status: influence of hormone replacement therapy, Thromb Haemost 70:584, 1994.
1065. **Gebara OCE**, **Mittleman MA**, **Sutherland P**, **Lipinska I**, **Matheney T**, **Xu P**, **Welty FK**, **Wilson PW**, **Levy D**, **Muller JE**, **Tofler GH**, Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study, Circulation 91:1952, 1995.
1066. **Conard J**, **Gompel A**, **Pelissier C**, **Mirabel C**, **Basdevant A**, Fibrinogen and plasminogen modifications during oral estradiol replacement therapy, Fertil Steril 68:449, 1997.
1067. **Demirol A**, **Baykal C**, **Kirazli S**, **Ayhan A**, Effects of hormone replacement on hemostasis in spontaneous menopause, Menopause 8:135, 2001.
1068. **De Souza MJ**, **Nulsen JC**, **Sequenzia LC**, **Bona RD**, **Walker FJ**, **Luciano AA**, The effect of medroxyprogesterone acetate on conjugated equine estrogen-induced changes in coagulation parameters in postmenopausal women, J Womens Health 5:121, 1996.
1069. **Bonduki CE**, **Lourenço DM**, **Baracat E**, **Haidar M**, **Noguti MAE**, **da Motta ELA**, **Lima GR**, Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women, Acta Obstet Gynecol Scand 77:330, 1998.
1070. **Meilahn E**, **Cauley J**, **Tracy R**, **Macy E**, **Gutai J**, **Kuller L**, Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women, Am J Epidemiol 143:159, 1996.
1071. **Koh KK**, **Mincemoyer R**, **Bui MN**, **Csako G**, **Pucino F**, **Guetto V**, **Waclawiw M**, **Cannon RO III**, Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women, N Engl J Med 336:683, 1997.
1072. **Boschetti C**, **Corteliaro M**, **Nencioni T**, **Bertolli V**, **Della Volpe A**, **Zanussi C**, Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women, Thromb Res 62:1, 1991.
1073. **Saleh AA**, **Dorey LG**, **Dombrowski MP**, **Ginsburg KA**, **Hirokawa S**, **Kowalczyk C**, **Hirata J**, **Bottoms S**, **Cotton DB**, **Mammen EF**, Thrombosis and hormone replacement therapy in postmenopausal women, Am J Obstet Gynecol 169:1554, 1993.
1074. **Scarabin PY**, **Hemker HC**, **Clement C**, **Soisson V**, **Alhenc-Gelas M**, Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and

progestogens, Menopause 18:873, 2011.
1075. **Pabinger I**, **Ay C**, Biomarkers and venous thromboembolism, Arterioscler Thromb Vasc Biol 29:332, 2009
1076. **Canonico M**, **Plu-Bureau G**, **Lowe GD**, **Scarabin PY**, Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis, Br Med J 336:1227, 2008.
1077. **Kessler CM**, **Szymanski LM**, **Shamsipour Z**, **Muesing RA**, **Miller VT**, **Larosa JC**, Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes, Obstet Gynecol 89:325, 1997.
1078. **Bladbjerg EM**, **Madsen JS**, **Kristensen SR**, **Abrahamsen B**, **Brixen K**, **Mosekilde L**, **Jespersen J**, Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study, J Thromb Haemost 1:1208, 2003.
1079. **Wakatsuki A**, **Ikenouse N**, **Shinohara K**, **Watanabe K**, **Fukaya T**, Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women, Arterioscler Thromb Vasc Biol 23:1948, 2003.
1080. **Suzuki A**, **Mizuno K**, **Ino Y**, **Okada M**, **Kikkawa F**, **Mizutani S**, **Tomoda Y**, Effects of 17 beta-estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro, Cardiovasc Res 32:516, 1996.
1081. **Okada M**, **Suzuki A**, **Mizuno K**, **Asada Y**, **Kuwayama T**, **Tamakoshi K**, **Mizutani S**, **Tomoda Y**, Effects of 17 beta-estradiol and progesterone on migration of human monocytic THP-1 cells stimulated by minimally oxidized low-density lipoprotein in vitro, Cardiovasc Res 34:529, 1997.
1082. **Dubey RK**, **Jackson EK**, **Luscher TF**, Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin 1 receptors, J Clin Invest 96:141, 1995.
1083. **Espeland MA**, **Applegate W**, **Furgerg CD**, **Lefkowitz D**, **Rice L**, **Hunninghake D**; the **ACAPS Investigators**, Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women, Am J Epidemiol 142:1011, 1995.
1084. **Baron YM**, **Galea MB**, Carotid artery wall thickness in women treated with hormone replacement therapy, Maturitas 27:47, 1997.
1085. **Jonas HA**, **Kronmal RA**, **Psaty BM**, **Manolio TA**, **Meilahn EN**, **Tell GS**, **Tracy RP**, **Robbins JA**, **Anton-Culver H**; for the **CHS Collaborative Research Group**, Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis, Ann Epidemiol 6:314, 1996.
1086. **Akkad A**, **Hartshorne T**, **Bell PRF**, **Al-Azzawi F**, Carotid plaque regression on oestrogen replacement: a pilot study, Eur J Vasc Endovasc Surg 11:347, 1996.
1087. **Krasinski K**, **Spyridopoulos I**, **Asahara T**, **van der Zee R**, **Isner JM**, **Losordo DW**, Estradiol accelerates functional endothelial recovery after arterial injury, Circulation 95:1768, 1997.
1088. **Spyridopoulos I**, **Sullivan AB**, **Kearney M**, **Isner JM**, **Losordo DW**, Estrogen-receptor–mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor, Circulation 95:1505, 1997.
1089. **Levine RL**, **Chen SJ**, **Durand J**, **Chen YF**, **Oparil S**, Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery, Circulation 94:2221, 1996.
1090. **Frazier-Jessen MR**, **Kovacs EJ**, Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages, J Immunol 154:1838, 1995.
1091. **Proudler AJ**, **Ahmed AI**, **Crook D**, **Fogelman I**, **Rymer JM**, **Stevenson JC**, Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women, Lancet 346:89, 1995.
1092. **Schunkert H**, **Danser AH**, **Hense HW**, **Derkx FH**, **Kurzinger S**, **Riegger GA**, Effects of estrogen replacement therapy on the renin-angiotensinogen system in postmenopausal women, Circulation 95:39, 1997.
1093. **Nickenig G**, **Bäumer AT**, **Grohè C**, **Kahlert S**, **Strehlow K**, **Rosenkranz S**, **Stäblein A**, **Beckers F**, **Smits JFM**, **Daemen MJAP**, **Vetter H**, **Böhm M**, Estrogen modulates AT1 receptor gene expression in vitro and in vivo, Circulation 97:2197, 1998.
1094. **Nickenig G**, **Jung O**, **Strehlow K**, **Zolk O**, **Linz W**, **Schölkens BA**, **Böhm M**, Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression, Am J Physiol 272(6 Pt 2):H2701, 1997.
1095. **Jilma B**, **Hildebrandt J**, **Kapiotis S**, **Wagner O**, **Kitzweger E**, **Müllner C**, **Monitzer B**, **Krejcy K**, **Eichler H-G**, Effects of estradiol on circulating P-selectin, J Clin Endocrinol Metab 81:2350, 1996.

1096. **Farzati A**, **Espositio K**, **Colacurci N**, **Fornaro F**, **Chiantera V**, **Barzati B**, Effects of transdermal hormone replacement therapy on levels of soluble P- and E-selectin in postmenopausal healthy women, Fertil Steril 77:476, 2002.
1097. **Hak AE**, **Polderman KH**, **Westendorp IC**, **Jakobs C**, **Hofman A**, **Witteman JC**, **Stehouwer CD**, Increased plasma homocysteine after menopause, Atherosclerosis 149:163, 2000.
1098. **Hak AE**, **Bak AA**, **Lindemans J**, **Planellas J**, **Coelingh Benink HJ**, **Hofman A**, **Grobbee DE**, **Witteman JC**, The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trial, Atherosclerosis 158:437, 2001.
1099. **Chiantera V**, **Sarti CD**, **Fornaro F**, **Farzati A**, **De Franciscis P**, **Sepe E**, **Borrelli AL**, **Colacurci N**, Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels, Menopause 10:286, 2003.
1100. **Rosenberg L**, **Armstrong B**, **Jick H**, Myocardial infarction and estrogen therapy in postmenopausal women, N Engl J Med 294:1256, 1976.
1101. **Pfeffer RI**, **Whipple GH**, **Kurosake TT**, **Chapman JM**, Coronary risk and estrogen use in postmenopausal women, Am J Epidemiol 107:479, 1978.
1102. **Jick H**, **Dinan B**, **Rothman KJ**, Noncontraceptive estrogens and non-fatal myocardial infarction, JAMA 239:1407, 1978.
1103. **Rosenberg L**, **Sloane D**, **Shapiro S**, **Kaufman D**, **Stolley PD**, **Miethinen OS**, Noncontraceptive estrogens and myocardial infarction in young women, JAMA 224:339, 1980.
1104. **Ross RK**, **Paganini-Hill A**, **Mack TM**, **Arthur M**, **Henderson BE**, Menopausal oestrogen therapy and protection from death from ischaemic heart disease, Lancet 1:858, 1981.
1105. **Bain C**, **Willett W**, **Hennekens CH**, **Rosner B**, **Belanger C**, **Speizer FE**, Use of postmenopausal hormones and risk of myocardial infarction, Circulation 64:42, 1981.
1106. **Adam S**, **Williams V**, **Vessey MP**, Cardiovascular disease and hormone replacement treatment: a pilot case-control study, Br Med J 282:1277, 1981.
1107. **Szklo M**, **Tonascia J**, **Gordis L**, **Bloom I**, Estrogen use and myocardial infarction risk: a case-control study, Prev Med 13:510, 1984.
1108. **Sullivan JM**, **Vander Zwaag R**, **Lemp GF**, **Hughes JP**, **Maddock V**, **Kroetz FW**, **Ramanathan KB**, **Mirvis DM**, Postmenopausal estrogen use and coronary atherosclerosis, Ann Intern Med 108:358, 1988.
1109. **Gruchow HW**, **Anderson AJ**, **Barboriak JJ**, **Sobocinski KA**, Postmenopausal use of estrogen and occlusion of coronary arteries, Am Heart J 115:954, 1988.
1110. **McFarland K**, **Boniface M**, **Hornung C**, **Earnhardt W**, **Humphries J**, Risk factors and noncontraceptive estrogen use in women with and without coronary disease, Am Heart J 117:1209, 1989.
1111. **Hong MG**, **Romm PA**, **Reagan K**, **Green CE**, **Rackley CE**, Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women, Am J Cardiol 69:176, 1992.
1112. **Psaty BM**, **Heckbart SR**, **Atkins D**, **Lemaitre R**, **Koepsell TD**, **Wahl PN**, **Siscovick DS**, **Wagner EH**, The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women, Arch Intern Med 154:1333, 1994.
1113. **Beard CM**, **Kottke TE**, **Annegers JF**, **Ballard DJ**, The Rochester Coronary Heart Disease Project: effect of cigarette smoking, hypertension, diabetes, and steroidal estrogen use on coronary heart disease among 40- to 59-year-old women, 1960 through 1982, Mayo Clin Proc 64:1471, 1989.
1114. **Newton KM**, **LaCroix AZ**, **McKnight B**, **Knopp RH**, **Siscovick DS**, **Heckbert SR**, **Weiss NS**, Estrogen replacement therapy and prognosis after first myocardial infarction, Am J Epidemiol 145:269, 1997.
1115. **Heckbert SR**, **Weiss NS**, **Koepsell TD**, **Lemaitre RN**, **Smith NL**, **Siscovick DS**, **Lin D**, **Psaty BM**, Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women, Arch Intern Med 157:1330, 1997.
1116. **Varas-Lorenzo C**, **García-Rodríguez LA**, **Perez-Gutthann S**, **Duque-Oliart A**, Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study, Circulation 101:2572, 2000.

1117. **Rodriguez C**, **Calle EE**, **Patel AV**, **Tatham LM**, **Jacobs EJ**, **Thun MJ**, Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women, Am J Epidemiol 153:145, 2001.
1118. **Shlipak MG**, **Angeja BG**, **Go AS**, **Frederick PD**, **Canto JG**, **Grady D**; for the **National Registry of Myocardial Infarction-3 Investigators**, Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women, Circulation 104:2300, 2001.
1119. **Reis SE**, **Holubkov R**, **Young JB**, **White BG**, **Cohn JN**, **Feldman AM**, Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies, J Am Coll Cardiol 36:529, 2000.
1120. **Westendrorp ICD**, **in't Veld BA**, **Grobbee DE**, **Pols HAP**, **Meijer WT**, **Hofman A**, **Witteman JCM**, Hormone replacement therapy and peripheral arterial disease. The Rotterdam Study, Arch Intern Med 160:2498, 2000.
1121. **Burch JC**, **Byrd BF**, **Vaughn WK**, The effects of long-term estrogen on hysterectomized women, Am J Obstet Gynecol 118:778, 1974.
1122. **Gordon T**, **Kannel WB**, **Hjortland MC**, **McNamara PM**, Menopause and coronary heart disease: the Framingham Study, Ann Intern Med 89:37, 1978.
1123. **Hammond CB**, **Jelovsek FR**, **Lee KL**, **Creasman WT**, **Parker RT**, Effects of long-term estrogen replacement therapy: I. Metabolic effects, Am J Obstet Gynecol 133:525, 1979.
1124. **Wilson PWF**, **Garrison RJ**, **Castelli WP**, Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50, N Engl J Med 313:1038, 1985.
1125. **Bush TL**, **Barrett-Connor E**, **Cowan DK**, **Criqui MH**, **Wallace RB**, **Suchindran CM**, **Tyroler HA**, **Rifkind BM**, Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study, Circulation 75:1102, 1987.
1126. **Criqui MH**, **Suarez L**, **Barrett-Connor E**, **McPhillips J**, **Wingard DL**, **Garland C**, Postmenopausal estrogen use and mortality, Am J Epidemiol 128:606, 1988.
1127. **Henderson BE**, **Paganini-Hill A**, **Ross RK**, Estrogen replacement therapy and protection from acute myocardial infarction, Am J Obstet Gynecol 159:312, 1988.
1128. **Perlman J**, **Wolff P**, **Finucane F**, **Madans J**, Menopause and the epidemiology of cardiovascular disease in women, Prog Clin Biol Res 320:283, 1989.
1129. **Lafferty FW**, **Fiske ME**, Postmenopausal estrogen replacement: a long-term cohort study, Am J Med 97:66, 1994.
1130. **Folsom AR**, **Mink PJ**, **Sellers TA**, **Hong C-P**, **Zheng W**, **Potter JD**, Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women, Am J Public Health 85:1128, 1995.
1131. **Grodstein F**, **Stampfer MJ**, **Manson JE**, **Colditz GA**, **Willett WC**, **Rosner B**, **Speizer FE**, **Hennekens CH**, Postmenopausal estrogen and progestin use and risk of cardiovascular disease, N Engl J Med 335:453, 1996.
1132. **Grodstein F**, **Stampfer MJ**, **Colditz GA**, **Willett WC**, **Manson JE**, **Joffe M**, **Rosner B**, **Fuchs C**, **Hankinson SE**, **Hunter DJ**, **Hennekens CH**, **Speizer FE**, Postmenopausal hormone therapy and mortality, N Engl J Med 336:1769, 1997.
1133. **Petitti DB**, **Perlman JA**, **Sidney S**, Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study, Obstet Gynecol 70:289, 1987.
1134. **Ettinger B**, **Friedman GD**, **Bush T**, **Quesenberry CP Jr**, Reduced mortality associated with long-term postmenopausal estrogen therapy, Obstet Gynecol 87:5, 1996.
1135. **Schairer C**, **Adami H-O**, **Hoover R**, **Persson I**, Cause-specific mortality in women receiving hormone replacement therapy, Epidemiology 8:59, 1997.
1136. **Løkkegaard E**, **Andreasen AH**, **Jacobsen RK**, **Nielsen LH**, **Agger C**, **Lidegaard Ø**, Hormone therapy and risk of myocardial infarction: a national register study, Eur Heart J 29:2660, 2008.
1137. **Grodstein F**, **Manson JE**, **Colditz GA**, **Willett WC**, **Speizer FE**, **Stampfer MJ**, A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease, Ann Intern Med 133:933, 2000.

1138. **McLaughlin VV**, **Hoff JA**, **Rich S**, Relation between hormone replacement therapy in women and coronary artery disease estimated by electron beam tomography, Am Heart J 134:1115, 1997.
1139. **Christian RC**, **Harrington S**, **Edwards WD**, **Oberg AL**, **Fitzpatrick LA**, Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women, J Clin Endocrinol Metab 87:1062, 2002.
1140. **Akhrass F**, **Evans AT**, **Wang Y**, **Rich S**, **Kannan CR**, **Fogelfeld L**, **Mazzone T**, Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women, J Clin Endocrinol Metab 88:5611, 2003.
1141. **Manson JE**, **Allison MA**, **Rossouw JE**, **Carr JJ**, **Langer RD**, **Hsia J**, **Kuller LH**, **Cochrane BB**, **Hunt JR**, **Ludlam SE**, **Pettinger MB**, **Gass M**, **Mrgolis KL**, **Nathan L**, **Ockene JK**, **Prentice RL**, **Robbins J**, **Stefanick ML**; for the **WHI and WHI-CACS Investigators**, Estrogen therapy and coronary-artery calcification, N Engl J Med 356:2591, 2007.
1142. **Matthews KA**, **Kuller LH**, **Wing RR**, **Meilahn EN**, **Plantinga P**, Prior to use of estrogen replacement therapy, are users healthier than nonusers?, Am J Epidemiol 143:971, 1997.
1143. **Henderson BE**, **Paganini-Hill A**, **Ross RK**, Decreased mortality in users of estrogen replacement therapy, Arch Intern Med 151:75, 1991.
1144. **Stampfer MJ**, **Colditz GA**, **Willett WC**, **Manson JE**, **Rosner B**, **Speizer FE**, **Hennekens CH**, Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study, N Engl J Med 325:756, 1991.
1145. **Derby CA**, **Hume AL**, **McPhillips JB**, **Barbour MM**, **Carleton RA**, Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared to non-users, Am J Obstet Gynecol 173:544, 1995.
1146. **MacLennan AH**, **Wilson DH**, **Taylor AW**, Hormone replacement therapy: prevalence, compliance and the 'healthy women' notion, Climacteric 1:42, 1998.
1147. **Blumel JE**, **Castelo-Branco C**, **Roncagliolo ME**, **Guanes PP**, **Lavin P**, Do women using hormone replacement treatment have less pre-existing cardiovascular risk, Maturitas 38:315, 2001.
1148. **Petitti DB**, **Wingerd J**, **Pellegrin F**, **Ramcharan S**, Risk of vascular disease in women: smoking, oral contraceptives, non-contraceptive estrogens, and other factors, JAMA 242:1150, 1979.
1149. **Paganini-Hill A**, **Ross RK**, **Henderson BE**, Postmenopausal oestrogen treatment and stroke: a prospective study, Br Med J 297:519, 1988.
1150. **Thompson SG**, **Meade TW**, **Greenberg G**, The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women, J Epidemiol Community Health 43:173, 1989.
1151. **Hunt K**, **Vessey M**, **McPherson K**, Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis, Br J Obstet Gynaecol 97:1080, 1990.
1152. **Finucane FF**, **Mardans JH**, **Bush TL**, **Wolf PH**, **Kleinman JC**, Decreased risk of stroke among postmenopausal hormone users, Arch Intern Med 153:73, 1993.
1153. **Falkeborn M**, **Persson I**, **Terent A**, **Adami HO**, **Lithell H**, **Bergstrom R**, Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden, Arch Intern Med 153:1201, 1993.
1154. **Longstreth WT Jr**, **Nelson LM**, **Koepsell TD**, **van Belle G**, Subarachnoid hemorrhage and hormonal factors in women: a population-based case-control study, Ann Intern Med 121:168, 1994.
1155. **Pedersen AT**, **Lidegaard Ø**, **Kreiner S**, **Ottesen B**, Hormone replacement therapy and risk of non-fatal stroke, Lancet 350:1277, 1997.
1156. **Petitti DB**, **Sidney S**, **Quesenberry CP Jr**, **Bernstein A**, Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy, Stroke 29:23, 1998.
1157. **Lemaitre RN**, **Heckbert SR**, **Psaty BM**, **Smith NL**, **Kaplan RC**, **Longstreth WT Jr**, Hormone replacement therapy and associated risk of stroke in postmenopausal women, Arch Intern Med 162:1954, 2002.
1158. **Løkkegaard E**, **Jovanovic Z**, **Heitmann BL**, **Keiding N**, **Ottesen B**, **Hundrup YA**, **Obel EB**, **Pedersen AT**, Increased risk of stroke in hypertensive women using hormone therapy. Analyses based on the Danish Nurse Study, Arch Neurol 60:1379, 2003.
1159. **Li C**, **Engström G**, **Hedblad B**, **Berglund G**, **Janzon L**, Risk of stroke and hormone replacement therapy. A prospective cohort study, Maturitas 54:11, 2006.

1160. **Lind T**, **Cameron EC**, **Hunter WM**, **Leon C**, **Moran PF**, **Oxley A**, **Gerrard J**, **Lind UCG**, A prospective, controlled trial of six forms of hormone replacement therapy given to postmenopausal women, Br J Obstet Gynaecol 86(Suppl 3):1, 1979.
1161. **Pfeffer RI**, **Kurosaki TT**, **Charlton SK**, Estrogen use and blood pressure in later life, Am J Epidemiol 110:469, 1979.
1162. **Lutola H**, Blood pressure and hemodynamics in postmenopausal women during estradiol-17 substitution, Ann Clin Res 15(Suppl 38):9, 1983.
1163. **Wren BG**, **Routledge AD**, The effect of type and dose of oestrogen on the blood pressure of postmenopausal women, Maturitas 5:135, 1983.
1164. **Hassager C**, **Christiansen C**, Blood pressure during oestrogen/progestogen substitution therapy in healthy post-menopausal women, Maturitas 9:315, 1988.
1165. **Seely EW**, **Walsh BW**, **Gerhard MD**, **Williams GH**, Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women, Hypertension 33:1190, 1999.
1166. **Lip GY**, **Beevers M**, **Churchill D**, **Beevers DG**, Hormone replacement therapy and blood pressure in hypertensive women, J Hum Hypertens 8:491, 1994.
1167. **Sands RH**, **Studd JWW**, **Crook D**, **Warren JB**, **Cruickshank J**, **Coats A**, The effect of estrogen on blood pressure in hypertensive postmenopausal women, Menopause 4:115, 1997.
1168. **Kornhauser C**, **Malacara JM**, **Gray ME**, **Perez-Luque EL**, The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension, J Hum Hypertens 11:405, 1997.
1169. **Mercuro G**, **Zoncu S**, **Piano D**, **Pilia I**, **Lao A**, **Melis GB**, **Cherchi A**, Estradiol-17beta reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension, Am J Hypertens 11:909, 1998.
1170. **Szekacs B**, **Vajo Z**, **Acs N**, **Hada P**, **Csuzi L**, **Bezeredi J**, **Magyar Z**, **Brinton EA**, Hormone replacement therapy reduces mean 24-hour blood pressure and its variability in postmenopausal women with treated hypertension, Menopause 7:31, 2000.
1171. **Affinito P**, **Palomba S**, **Bonifacio M**, **Fontana D**, **Izzo R**, **Trimarco B**, **Nappi C**, Effects of hormonal replacement therapy in postmenopausal hypertensive patients, Maturitas 40:75, 2001.
1172. **Medical Research Council's General Practice Research Framework**, Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy, Br Med J 312:473, 1996.
1173. **Zarifis J**, **Lip GYH**, **Beevers DG**, Effects of discontinuing hormone replacement therapy in patients with uncontrolled hypertension, Am J Hypertens 8:1241, 1995.
1174. **Mercuro G**, **Zoncu S**, **Pilia I**, **Lao A**, **Melis GB**, **Cherchi A**, Effects of acute administration of transdermal estrogen on postmenopausal women with systemic hypertension, Am J Cardiol 80:652, 1997.
1175. **Bérard A**, **Kahn SR**, **Abenhaim L**, Is hormone replacement therapy protective for venous ulcer of the lower limbs?, Pharmacoepidemiol Drug Saf 10:245, 2001.
1176. **Margolis DJ**, **Knauss J**, **Bilker W**, Hormone replacement therapy and prevention of pressure ulcers and venous leg ulcers, Lancet 359:675, 2002.
1177. **The Women's Health Initiative Study Group**, Design of the Women's Health Initiative clinical trial and observational study, Control Clin Trials 19:61, 1998.
1178. **Rossouw JE**, **Anderson GL**, **Prentice RL**, **LaCroix AZ**, **Kooperberg CL**, **Stefanick ML**, **Jackson RD**, **Beresford SA**, **Howard BV**, **Johnson KC**, **Kotchen JM**, **Ockene J**; **Writing Group for the Women's Health Initiative Investigators**, Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial, JAMA 288:321, 2002.
1179. **The Women's Health Initiative Steering Committee**, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial, JAMA 291:1707, 2004.
1180. **Stefanick ML**, **Cochrane BB**, **Hsia J**, **Barad DH**, **Liu JH**, **Johnson SR**, The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants, Ann Epidemiol 13:S78,

2003.

1181. **Manson JE**, **Hsia J**, **Johnson KC**, **Rossouw JE**, **Assaf AR**, **Lasser NL**, **Trevisan M**, **Black HR**, **Heckbert SR**, **Detrano R**, **Strickland OL**, **Wong ND**, **Crouse JR**, **Stein E**, **Cushman M**; for the **Women's Health Initiative Investigators**, Estrogen plus progestin and the risk of coronary heart disease, N Engl J Med 349:523, 2003.

1182. **Chilvers CE**, **Knibb RC**, **Armstrong SJ**, **Woods KL**, **Logan RF**, Post menopausal hormone replacement therapy and risk of acute myocardial infarction—a case control study of women in the East Midlands, UK, Eur Heart J 24:2197, 2003.

1183. **Toh S**, **Hernández-Diaz S**, **Logan RF**, **Rossouw JE**, **Hernán MA**, Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial, Ann Intern Med 152:211, 2010.

1184. **Appt S**, **Clarkson TB**, **Lees CJ**, **Anthony MS**, Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys, Maturitas 55:187, 2006.

1185. **Wassertheil-Smoller S**, **Hendrix SL**, **Limacher M**, **Heiss G**, **Kooperberg C**, **Baird A**, **Kotchen T**, **Curb JD**, **Black H**, **Rossouw JE**, **Aragaki A**, **Safford M**, **Stein E**, **Laowattana S**, **Mysiw WJ**; for the **WHI Investigators**, Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial, JAMA 289:2673, 2003.

1186. **Hendrix SL**, **Wassertheil-Smoller S**, **Johnson KC**, **Howard BV**, **Kooperberg C**, **Rossouw JE**, **Trevisan M**, **Aragaki A**, **Baird AE**, **Bray PF**, **Buring JE**, **Criqui MH**, **Herrington D**, **Lynch JK**, **Rapp SR**, **Torner J**; for the **WHI Investigators**, Effects of conjugated equine estrogen on stroke in the Women's Health Initiative, Circulation 113:2425, 2006.

1187. **Viscoli CM**, **Brass LM**, **Kernan WN**, **Sarrel PM**, **Suissa S**, **Horwitz RL**, A clinical trial of estrogen-replacement therapy after ischemic stroke, N Engl J Med 345:1243, 2001.

1188. **Grodstein F**, **Manson JE**, **Stampfer MJ**, **Rexrode K**, Postmenopausal hormone therapy and stroke. Role of time since menopause and age at initiation of hormone therapy, Arch Intern Med 168:861, 2008.

1189. **Rossouw JE**, **Prentice RL**, **Manson JE**, **LieLing W**, **Barad D**, **Barnabei VM**, **Ko M**, **LaCroix AZ**, **Margolis KL**, **Stefanick ML**, Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause, JAMA 297:1465, 2007.

1190. **Hulley S**, **Grady D**, **Bush T**, **Furberg C**, **Herrington D**, **Riggs B**, **Vittinghoff E**; for the **Heart and Estrogen/progestin Replacement Study (HERS) Research Group**, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women, JAMA 280:605, 1998.

1191. **Grady D**, **Herrington D**, **Bittner V**, **Blumenthal R**, **Davidson M**, **Hlatky M**, **Hsia J**, **Hulley SB**, **Herd A**, **Khan S**, **Newby LK**, **Waters D**, **Vittinghoff E**, **Wenger N**, Heart and Estrogen/progestin Replacement Study Follow-up (HERS II): 1. Cardiovascular outcomes during 6.8 years of hormone therapy, JAMA 288:49, 2002.

1192. **Hulley S**, **Furberg C**, **Barrett-Connor E**, **Cauley J**, **Grady D**, **Haskell W**, **Knopp R**, **Lowery M**, **Satterfield S**, **Schrott H**, **Vittinghoff E**, **Hunninghake D**, Heart and Estrogen/progestin Replacement Study Follow-up (HERS II): 2. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy, JAMA 288:58, 2002.

1193. **Hodis HN**, **Mack WJ**, **Lobo RA**, **Shoupe D**, **Sevanian A**, **Mahrer PR**, **Selzer RH**, **Liu CC**, **Liu CC**, **Azen SP**, Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial, Ann Intern Med 135:939, 2001.

1194. **Herrington DM**, **Reboussin DM**, **Brosnihan KB**, **Sharp PC**, **Shumaker SA**, **Snyder TE**, **Furberg CD**, **Kowalchuk GJ**, **Stuckey TD**, **Rogers WJ**, **Givens DH**, **Waters D**, Effects of estrogen replacement on the progression of coronary-artery atherosclerosis, N Engl J Med 343:522, 2000.

1195. **Hodis HN**, **Mack WJ**, **Azen SP**, **Lobo RA**, **Shoupe D**, **Mahrer PR**, **Faxon DP**, **Cashin-Hemphill L**, **Sanmarco M**, **French WJ**, **Shook TL**, **Gaaarder TD**, **Mehra AO**, **Rabbani R**, **Sevanian A**, **Shil AB**, **Torres M**, **Vogelbach KH**, **Selzer RH**; for the **Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group**, Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women, N Engl J Med 349:535, 2003.

1196. **Clarke SC**, **Kelleher J**, **Lloyd-Jones H**, **Slack M**, **Schofield PM**, A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study, Br J Obstet Gynaecol 109:1056, 2002.
1197. **Waters DD**, **Alderman EL**, **Hsia J**, **Howard BV**, **Cobb FR**, **Rogers WJ**, **Ouyang P**, **Thompson P**, **Tardif JC**, **Higginson L**, **Bittner V**, **Steffes M**, **Gordon DJ**, **Proschan M**, **Younes N**, **Verter JI**, Effects of hormone replacement therapy and antioxidant vitamins supplements on coronary atherosclerosis in postmenopausal women. A randomized controlled trial, JAMA 288:2432, 2002.
1198. **The ESPRIT Team**, Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial, Lancet 360:2001, 2002.
1199. **Hsia J**, **Langer RD**, **Manson JE**, **Kuller L**, **Johnson KC**, **Hendrix SL**, **Pettinger M**, **Hechbert SR**, **Greep N**, **Crawford S**, **Eaton CB**, **Kostis JB**, **Cralis P**, **Prentice R**; for the **Women's Health Initiative Investigators**, Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative, Arch Intern Med 166:357, 2006.
1200. **Salpeter SR**, **Cheng J**, **Thabane L**, **Buckley NS**, **Salpeter EE**, Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women, Am J Med 122:1016, 2009.
1201. **de Kleijn MJ**, **Bots ML**, **Bak AA**, **Westendorp IC**, **Planellas J**, **Coelingh Bennink H**, **Witteman JC**, **Grobbee DE**, Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness, Maturitas 32:195, 1999.
1202. **Angerer P**, **Störk S**, **Kothny W**, **Schmitt P**, **von Schacky C**, Effect of oral postmenopausal hormone replacement on progression of atherosclerosis. A randomized, controlled trial, Atheros Thromb Vasc Biol 21:262, 2001.
1203. **Allison MA**, **Manson JE**, **Langer RD**, **Carr JJ**, **Rossouw JE**, **Pettinger MB**, **Phillips L**, **Cochrane BB**, **Eaton CB**, **Greenland P**, **Hendrix S**, **Hsia J**, **Hunt JR**, **Jackson RD**, **Johnson KC**, **Kuller LH**, **Robinson J**; **Women's Health Initiative and Women's Health Initiative Coronary Artery Calcium Study Investigators**, Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study, Menopause 15:639, 2008.
1204. **Speroff L**, Gonads are the heart of the matter, Menopause 14:385, 2007.
1205. **Rivera CM**, **Grossardt BR**, **Rhodes DJ**, **Rocca WA**, Increased mortality for neurological and mental diseases following early bilateral oophorectomy, Neuroepidemiology 33:32, 2009.
1206. **Rivera CM**, **Grossardt BR**, **Rhodes DJ**, **Brown RD Jr**, **Roger VL**, **Melton LJ III**, **Rocca WA**, Increased cardiovascular mortality after early bilateral oophorectomy, Menopause 16:15, 2009.
1207. **Rocca WA**, **Bower JH**, **Maraganore DM**, **Ahiskog JE**, **Grossardt BR**, **de Andrade M**, **Melton LJ III**, Increased risk of parkinsonism in women who underwent oophorectomy before menopause, Neurology 70:200, 2008.
1208. **Rocca WA**, **Grossardt BR**, **Maraganore DM**, The long-term effects of oophorectomy on cognitive and motor aging are age dependent, Neurodegener Dis 5:257, 2008.
1209. **Rocca WA**, **Grossardt BR**, **Geda YE**, **Gostout BS**, **Bower JH**, **Maraganore DM**, **de Andrade M**, **Melton LJ III**, Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy, Menopause 15:1050, 2008.
1210. **Parker WH**, **Broder MS**, **Chang E**, **Feskanich D**, **Farquhar C**, **Liu Z**, **Shoupe D**, **Berek JS**, **Hankinson S**, **Manson JE**, Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study, Obstet Gynecol 113:1027, 2009.
1211. **Grodstein F**, **Manson JE**, **Stampfer MJ**, Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation, J Womens Health 15:35, 2006.
1212. **Prentice RL**, **Langer R**, **Stefanick ML**, **Howard BV**, **Pettinger M**, **Anderson G**, **Barad D**, **Curb JD**, **Kotchen J**, **Kuller L**, **Limacher MC**, **Wactawski-Wende J**; for the **Women's Health Initiative Investigators**, Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial, Am J Epidemiol 162:404, 2005.
1213. **Harman SM**, **Black DM**, **Naftolin F**, **Brinton EA**, **Budoff MJ**, **Cedars MI**, **Hopkins PN**, **Lobo RA**,

Manson JE, **Merriam GR**, **Miller VM**, **Neal-Perry G**, **Santoro N**, **Taylor HS**, **Vittinghoff E**, **Yan M**, **Hodis HN**, Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial, Ann Intern Med 161(4):249, 2014.

1214. **Miller VM**, **Hodis HN**, **Lahr BD**, **Bailey KR**, **Jayachandran M**, Changes in carotid artery intima-media thickness 3 years after cessation of menopausal hormone therapy: follow-up from the Kronos Early Estrogen Prevention Study, Menopause 26(1):24, 2019.
1215. **Hodis HN**, **Mack WJ**, **Henderson VW**, **Shoupe D**, **Budoff MJ**, **Hwang-Levine J**, **Li Y**, **Feng M**, **Dustin L**, **Kono N**, **Stanczyk FZ**, **Selzer RH**, **Azen SP**; **ELITE Research Group**, Vascular effects of early versus late postmenopausal treatment with estradiol, N Engl J Med 374(13):1221, 2016.
1216. **Mikkola TS**, **Clarkson TB**, Estrogen replacement therapy: atherosclerosis, and vascular function, Cardiovasc Res 53:605, 2002.
1217. **Herrington DM**, **Espeland MA**, **Crouse JR III**, **Robertson J**, **Riley WA**, **McBurnie MA**, **Burke GL**, Estrogen replacement and brachial artery flow-mediated vasodilation in older women, Arterioscler Thromb Vasc Biol 21:1955, 2001.
1218. **Cushman M**, **Kuller LH**, **Prentice R**, **Rodabough RJ**, **Psaty BM**, **Stafford RS**, **Sidney S**, **Rosendaal FR**; for the **Women's Health Initiative Investigators**, Estrogen plus progestin and risk of venous thrombosis, JAMA 292:1573, 2004.
1219. **Curb JD**, **Prentice RL**, **Bray PF**, **Langer RD**, **Van Horn L**, **Barnabei VM**, **Bloch MJ**, **Cyr MG**, **Gass M**, **Lepine L**, **Rodabough RJ**, **Sidney S**, **Uwaifo GI**, **Rosendaal FR**, Venous thrombosis and conjugated equine estrogen in women without a uterus, Arch Intern Med 166:772, 2006.
1220. **Cushman M**, Epidemiology and risk factors for venous thrombosis, Semin Hematol 44(2):62, 2007.
1221. **Herrington DM**, **Vittinghoff E**, **Lin F**, **Fong J**, **Harris F**, **Hunninghake D**, **Bittner V**, **Schrott HG**, **Blumenthal RS**, **Levy R**, Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS), Circulation 105:2962, 2002.
1222. **Pulmonary Embolism Prevention (PEP) Trial Collaborative Group**, Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial, Lancet 355:1295, 2000.
1223. **Toorians AWFT**, **Thomassen MCLGD**, **Zweegman S**, **Magdeleyns EJP**, **Tans G**, **Gooren LJG**, **Rosing J**, Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people, J Clin Endocrinol Metab 88:5723, 2003.
1224. **Canonico M**, **Oger E**, **Conard J**, **Meyer G**, **Lévesque H**, **Trillot N**, **Barrellier MT**, **Wahl D**, **Emmerich J**, **Scarabin PY**; **EStrogen and THromboEmbolism Risk (ESTHER) Study Group**, Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study, J Thromb Haemost 4:1259, 2006.
1225. **Canonico M**, Hormone therapy and risk of venous thromboembolism among postmenopausal women, Maturitas 82(3):304, 2015.
1226. **Lowe GD**, **Upton MN**, **Rumley A**, **McConnachie A**, **O'Reilly DS**, **Watt GC**, Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI, and C-reactive protein—a cross-sectional population survey, Thromb Haemost 86:550, 2001.
1227. **Hoibraaten E**, **Qvigstad E**, **Arnesen H**, **Larsen S**, **Wickstrom E**, **Sandset PM**, Increased risk of recurrent venous thromboembolism during hormone replacement therapy—results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET), Thromb Haemost 84:961, 2000.
1228. **Ridker PM**, **Hennekens CH**, **Lindpaintner K**, **Stampfer MJ**, **Eisenberg PR**, **Miletich JP**, Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men, N Engl J Med 332:912, 1995.
1229. **Cushman M**, **Rosendall FR**, **Psaty BM**, **Cook EF**, **Valliere J**, **Kuller LH**, **Tracy RP**, Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study, Thromb Haemost 79:912, 1998.
1230. **Glueck CJ**, **Wang P**, **Fontaine RN**, **Sieve-Smith L**, **Lang JE**, Estrogen replacement therapy, thrombophilia, and atherothrombosis, Metabolism 51:724, 2002.

1231. **Irani-Hakime N**, **Tamim H**, **Elias G**, **Choueiry S**, **Kreidy R**, **Daccache JL**, **Almawi WY**, **Factor V** R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease, J Thromb Thrombolysis 11:111, 2001.
1232. **American Cancer Society**, Cancer Facts & Figures 2008, http://www.cancer.org/docroot/STT/stt_0.asp, 2009.
1233. **La Vecchia C**, **Negri E**, **Bruzzi P**, **Dardanoni G**, **Decarli A**, **Franceschi S**, **Palli D**, **Talamini R**, The role of age at menarche and at menopause on breast cancer risk: combined evidence from four case-control studies, Ann Oncol 3:625, 1992.
1234. **Potischman N**, **Swanson CA**, **Siiteri P**, **Hoover RN**, Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status, J Natl Cancer Inst 88:756, 1996.
1235. **Yong L-C**, **Brown CC**, **Schatzkin A**, **Schairer C**, Prospective study of relative weight and risk of breast cancer: the Breast Cancer Detection Demonstration Project follow-up study, 1979 to 1987–1989, Am J Epidemiol 43:985, 1996.
1236. **Ziegler RG**, **Hoover RN**, **Nomura AM**, **West DW**, **Wu AH**, **Pike MC**, **Lake AJ**, **Horn-Ross PL**, **Kolonel LN**, **Siiteri PK**, **Fraumeni JF Jr**, Relative weight, weight change, height, and breast cancer risk in Asian-American women, J Natl Cancer Inst 88:650, 1996.
1237. **Sherman B**, **Wallace R**, **Beam J**, **Schlabaugh L**, Relationship of body weight to menarcheal and menopausal age: implication for breast cancer risk, J Clin Endocrinol Metab 52:488, 1981.
1238. **Cauley JA**, **Lucas FL**, **Kuller LH**, **Vogt MT**, **Browner WS**, **Cummings SR**; for the **Study of Osteoporotic Fractures Research Group**, Bone mineral density and risk of breast cancer in older women: the Study of Osteoporotic Fractures, JAMA 276:1404, 1996.
1239. **Zhang Y**, **Kel DP**, **Kreger BE**, **Cupples LA**, **Ellison RC**, **Dorgan JE**, **Schatzkin A**, **Levy D**, **Felson DT**, Bone mass and the risk of breast cancer among postmenopausal women, N Engl J Med 336:611, 1997.
1240. **Chen Z**, **Arendell L**, **Aickin M**, **Cauley J**, **Lewis CE**, **Chlebowski RT**; for the **Women's Health Initiative Program**, Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative, Cancer 113:907, 2008.
1241. **Garland CF**, **Friedlander NJ**, **Barrett-Connor E**, **Khaw K-T**, Sex hormones and postmenopausal breast cancer: a prospective study in an adult community, Am J Epidemiol 135:1220, 1992.
1242. **Helzlsouer KJ**, **Alberg AJ**, **Bush TL**, **Longcope C**, **Gordon GB**, **Comstock GW**, A prospective study of endogenous hormones and breast cancer, Cancer Detect Prev 18:79, 1994.
1243. **Berrino F**, **Muti P**, **Micheli A**, **Bolelli G**, **Krogh V**, **Sciajno R**, **Pisani P**, **Panico S**, **Secreto G**, Serum sex hormone levels after menopause and subsequent breast cancer, J Natl Cancer Inst 88:291, 1996.
1244. **Thomas HV**, **Key TJ**, **Allen DS**, **Moore JW**, **Dowsett M**, **Fentiman IS**, **Wang DY**, A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey, Br J Cancer 76:401, 1997.
1245. **Toniolo PG**, **Levitz M**, **Zeleniuch-Jacquotte A**, **Banerjee S**, **Koenig KL**, **Shore RE**, **Strax P**, **Pasternack BS**, A prospective study of endogenous estrogens and breast cancer in postmenopausal women, J Natl Cancer Inst 87:190, 1995.
1246. **Dorgan JF**, **Longcope C**, **Stephenson HE Jr**, **Falk RT**, **Miller R**, **Franz C**, **Kahle L**, **Campbell WS**, **Tangrea JA**, **Schatzkin A**, Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk, Cancer Epidemiol Biomarkers Prev 5:533, 1996.
1247. **Cuzick J**, **Wang DY**, **Bulbrook RD**, The prevention of breast cancer, Lancet 1:83, 1986.
1248. **Hankinson SE**, **Willett WC**, **Manson JE**, **Colditz GA**, **Hunter DJ**, **Spiegelman D**, **Barbieri RL**, **Speizer FE**, Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women, J Natl Cancer Inst 90:1292, 1998.
1249. **Colditz GA**, **Hankinson SE**, **Hunter DJ**, **Willett WC**, **Manson J**, **Hennekens C**, **Rosner B**, **Speizer FE**, The use of estrogens and progestins and the risk of breast cancer in postmenopausal women, N Engl J Med 332:1589, 1995.
1250. **Persson I**, **Weiderpass E**, **Bergkvist L**, **Bergstrom R**, **Schairer C**, Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement, Cancer Causes Control 10:253, 1999.

1251. **Magnusson C**, **Baron JA**, **Correia N**, **Bergström R**, **Adami HO**, **Persson I**, Breast cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy, Int J Cancer 81:339, 1999.
1252. **Schairer C**, **Lubin J**, **Troisi R**, **Sturgeon S**, **Brinton L**, **Hoover R**, Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk, JAMA 283:485, 2000.
1253. **Ross RK**, **Paganini-Hill A**, **Wan PC**, **Pike MC**, Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin, J Natl Cancer Inst 92:328, 2000.
1254. **Newcomb PA**, **Titus-Ernstoff L**, **Egan KM**, **Trentham-Dietz A**, **Baron JA**, **Storer BE**, **Willett WC**, **Stampfer MJ**, Postmenopausal estrogen and progestin use in relation to breast cancer risk, Cancer Epidemiol Biomarkers Prev 11:593, 2002.
1255. **Porch JV**, **Lee IM**, **Cook NR**, **Rexrode KM**, **Buring JE**, Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States), Cancer Causes Control 13:847, 2002.
1256. **Weiss LK**, **Burkman RT**, **Cushing-Haugen KL**, **Voigt LF**, **Simon MS**, **Daling JR**, **Norman SA**, **Bernstein L**, **Ursin G**, **Marchbanks PA**, **Strom BL**, **Berlin JA**, **Weber AL**, **Doody DR**, **Wingo PA**, **McDonald JA**, **Malone KE**, **Folger SG**, **Spirtas R**, Hormone replacement therapy regimens and breast cancer risk, Obstet Gynecol 100:1148, 2002.
1257. **Li CI**, **Malone KE**, **Porter PL**, **Weiss NS**, **Tang M-T**, **Cushing-Haugen KL**, **Daling JR**, Relationship between long durations and different regimens of hormone therapy and risk of breast cancer, JAMA 289:3254, 2003.
1258. **Olsson HL**, **Ingvar C**, **Bladstrom A**, Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden, Cancer 97:1387, 2003.
1259. **Kerlikowske K**, **Miglioretti DL**, **Ballard-Barbash R**, **Weaver DL**, **Buist DSM**, **Barlow WE**, **Cutter G**, **Geller BM**, **Yankaskas BC**, **Taplin SH**, **Carney PA**, Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population, J Clin Oncol 21:4314, 2003.
1260. **Million Women Study Collaborators**, Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet 362:419, 2003.
1261. **Stahlberg C**, **Pedersen AT**, **Lynge E**, **Andersen ZJ**, **Keiding N**, **Hundrup YA**, **Obel EB**, **Ottesen B**, Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe, Int J Cancer 109:721, 2004.
1262. **Opatrny L**, **Dell'Aniello S**, **Assouline S**, **Suissa S**, Hormone replacement therapy use and variations in the risk of breast cancer, Br J Obstet Gynaecol 115:169, 2008.
1263. **Flesch-Janys D**, **Slanger T**, **Mutschelknauss E**, **Kropp S**, **Obi N**, **Vettorazzi E**, **Braendle W**, **Bastert G**, **Hentschel S**, **Berger J**, **Chang-Claude J**, Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy, Int J Cancer 123:933, 2008.
1264. **Calle EE**, **Feigelson HS**, **Hildebrand JS**, **Teras LR**, **Thun MJ**, **Rodriguez C**, Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype, Cancer 115:936, 2009.
1265. **Jick SS**, **Hagberg KW**, **Kaye JA**, **Jick H**, Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer, Obstet Gynecol 113:74, 2009.
1266. **Collaborative Group on Hormonal Factors in Breast Cancer**, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer, Lancet 350:1047, 1997.
1267. **Gramling R**, **Eaton CB**, **Rothman KJ**, **Cabral H**, **Silliman RA**, **Lash TL**, Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women, Epidemiologiy 20:752, 2009.
1268. **Stahlberg C**, **Lynge E**, **Andersen ZJ**, **Keiding N**, **Ottesen B**, **Rank F**, **Hundrup YA**, **Obel EB**, **Pedersen AT**, Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy—a prospective observational study, Int J Epidemiol 34:931, 2005.
1269. **Li CI**, **Malone KE**, **Porter PL**, **Lawton TJ**, **Voigt LF**, **Cushing-Haugen KL**, **Lin MG**, **Yuan X**, **Daling JR**, Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas, Cancer Epidemiol Biomarkers Prev 17:43, 2008.
1270. **Rosenberg LU**, **Magnusson C**, **Lindström E**, **Wedrén S**, **Hall P**, **Dickman PW**, Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast

cancer: a case-control study, Breast Cancer Res 8:R11, 2006.

1271. **Chlebowski RT**, **Hendrix SL**, **Langer RD**, **Stefanick ML**, **Gass M**, **Lane D**, **Rodabough RJ**, **Gilligan MA**, **Cyr MG**, **Thomson CA**, **Khandekar J**, **Petrovitch H**, **McTiernan A**; for the **WHI Investigators**, Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial, JAMA 289:3243, 2003.
1272. **Anderson GL**, **Chlebowski RT**, **Rossouw JE**, **Rodabough RJ**, **McTiernan A**, **Margolis KL**, **Aggerwal A**, **Curb JD**, **Hendrix SL**, **Hubbell FA**, **Khandekar J**, **Lane DS**, **Lasser N**, **Lopez AM**, **Potter J**, **Ritenbaugh C**, Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin, Maturitas 55:103, 2006.
1273. **LaCroix AZ**, **Chlebowski RT**, **Manson JE**, **Aragaki AK**, **Johnson KC**, **Martin L**, **Margolis KL**, **Stefanick ML**, **Brzyski R**, **Curb JD**, **Howard BV**, **Lewis CE**, **Wactawski-Wende J**; **WHI Investigators**, Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial, JAMA 305(13):1305, 2011.
1274. **Stefanick ML**, **Anderson GL**, **Margolis KL**, **Hendrix SL**, **Rodabough RJ**, **Paskett ED**, **Lane DS**, **Hubbell FA**, **Assaf AR**, **Sarto GE**, **Schenken RS**, **Yasmeen S**, **Lessin L**, **Chlebowski RT**; for the **WHI Investigators**, Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy, JAMA 295:1647, 2006.
1275. **Anderson GL**, **Chlebowski RT**, **Aragaki AK**, **Kuller LH**, **Manson JE**, **Gass M**, **Bluhm E**, **Connelly S**, **Hubbell FA**, **Lane D**, **Martin L**, **Ockene J**, **Rohan T**, **Schenken R**, **Wactawski-Wende J**, Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial, Lancet Oncol 13(5):476, 2012.
1276. **Lyytinen H**, **Pukkala E**, **Ylikorkala O**, Breast cancer risk in postmenopausal women using estrogen-only therapy, Obstet Gynecol 108:1354, 2006.
1277. **Lyytinen H**, **Pukkala E**, **Ylikorkala O**, Breast cancer risk in postmenopausal women using estradiol-progestogen therapy, Obstet Gynecol 113:65, 2009.
1278. **Chen WY**, **Manson JE**, **Hankinson SE**, **Rosner B**, **Holmes MD**, **Willett WC**, **Colditz GA**, Unopposed estrogen therapy and the risk of invasive breast cancer, Arch Intern Med 166:1027, 2006.
1279. **Topo P**, **Luoto R**, **Hemminki E**, **Uutela A**, Declining socioeconomic differences in the use of menopausal and postmenopausal hormone therapy in Finland, Maturitas 32:141, 1999.
1280. **Bergkvist L**, **Adami H-O**, **Persson I**, **Bergstrom R**, **Krusemo UB**, Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy, Am J Epidemiol 130:221, 1989.
1281. **Persson I**, **Yuen J**, **Bergkvist L**, **Schairer C**, Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—long-term follow-up of a Swedish cohort, Int J Cancer 67:327, 1996.
1282. **Willis DB**, **Calle EE**, **Miracle-McMahill HL**, **Heath CW Jr**, Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States, Cancer Causes Control 7:449, 1996.
1283. **Sellers TA**, **Mink PJ**, **Cerhan JR**, **Zheng W**, **Anderson KE**, **Kushi LH**, **Folsom AR**, The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer, Ann Intern Med 127:973, 1997.
1284. **Schairer C**, **Gail M**, **Byrne C**, **Rosenberg PS**, **Sturgeon SR**, **Brinton LA**, **Hoover RN**, Estrogen replacement therapy and breast cancer survival in a large screening study, J Natl Cancer Inst 91:264, 1999.
1285. **Fowble B**, **Hanlon A**, **Greedman G**, **Patchefsky A**, **Kessler H**, **Nicolaou N**, **Hoffman J**, **Sigurdson E**, **Boraas M**, **Goldstein L**, Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation, J Clin Oncol 17:1680, 1999.
1286. **Jernström H**, **Frenander J**, **Fernö M**, **Olsson H**, Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients, Br J Cancer 80:1453, 1999.

1287. **Nanda K**, **Bastian LA**, **Schulz K**, Hormone replacement therapy and the risk of death from breast cancer: a systematic review, Am J Obstet Gynecol 186:325, 2002.
1288. **Schuetz F**, **Diel IJ**, **Pueschel M**, **von Holst T**, **Solomayer EF**, **Lange S**, **Sinn P**, **Bastert G**, **Sohn C**, Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy, Am J Obstet Gynecol 196:342.e1, 2007.
1289. **Christante D**, **Pommier S**, **Garreau J**, **Muller P**, **LaFleur B**, **Pommier R**, Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up, Am J Surg 196:505, 2008.
1290. **Squitieri R**, **Tartter P**, **Ahmed S**, **Brower ST**, Carcinoma of the breast in postmenopausal hormone user and nonuser control groups, J Am Coll Surg 178:167, 1994.
1291. **Bonnier P**, **Romain S**, **Giacalone PL**, **Laffargue F**, **Martin PM**, **Piana L**, Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy, Obstet Gynecol 85:11, 1995.
1292. **Magnusson C**, **Holmberg L**, **Norden T**, **Lindgren A**, **Persson I**, Prognostic characteristics in breast cancers after hormone replacement therapy, Breast Cancer Res Treat 38:325, 1996.
1293. **Harding C**, **Knox WF**, **Faragher EB**, **Baildam A**, **Bundred NJ**, Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit, Br Med J 312:1646, 1996.
1294. **Holli K**, **Isola J**, **Cuzick J**, Low biologic aggressiveness in breast cancer in women using hormone replacement therapy, J Clin Oncol 16:3115, 1998.
1295. **O'Connor IF**, **Shembekar MV**, **Shousha S**, Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study, J Clin Pathol 51:935, 1998.
1296. **Salmon RJ**, **Ansquer Y**, **Asselain B**, **Languille O**, **Lesec G**, **Remvikos Y**, Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause, Oncol Rep 6:699, 1999.
1297. **Bilimoria MM**, **Winchester DJ**, **Sener SF**, **Motykie G**, **Sehgal UL**, **Winchester DP**, Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics, Ann Surg Oncol 6:200, 1999.
1298. **Stallard S**, **Litherland JC**, **Cordiner CM**, **Dobson HM**, **George WD**, **Mallon EA**, **Hole D**, Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study, Br Med J 320:348, 2000.
1299. **Manjer J**, **Malina J**, **Berglund G**, **Bondeson L**, **Garne JP**, **Janzon L**, Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy, Int J Cancer 92:919, 2001.
1300. **Delgado RC**, **Lubian Lopez DM**, Prognosis of breast cancers detected in women receiving hormone replacement therapy, Maturitas 20:147, 2001.
1301. **Sacchini V**, **Zurrida S**, **Andreoni G**, **Luini A**, **Galimberti V**, **Veronesi P**, **Intra M**, **Viale G**, **Veronesi U**, Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users, Ann Surg Oncol 9:266, 2002.
1302. **Cheek J**, **Lacy J**, **Toth-Fejel S**, **Morris K**, **Calhoun K**, **Pommier RF**, The impact of hormone replacement therapy on the detection and stage of breast cancer, Arch Surg 137:1015, 2002.
1303. **Esteve J**, **Seradour B**, **Jacquemier J**, **Remontet L**, Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography, J Med Screen 9:70, 2002.
1304. **Pappo I**, **Meirshon I**, **Karni T**, **Siegelmann-Danielli N**, **Stahl-Kent V**, **Sandbank J**, **Wasserman I**, **Halevy A**, The characteristics of malignant breast tumors in hormone replacement therapy users versus nonusers, Ann Surg Oncol 11:52, 2004.
1305. **Gertig DM**, **Erbas B**, **Fletcher A**, **Amos A**, **Kavanagh AM**, Duration of hormone replacement therapy, breast tumour size and grade in a screening programme, Breast Cancer Res Treat 80:267, 2003.
1306. **Sener SF**, **Winchester DJ**, **Winchester DP**, **Du H**, **Barrera E**, **Bilimoria M**, **Krantz S**, **Rabbitt S**, The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival, Am J Surg

197:403, 2009.
1307. **Fletcher AS**, **Erbas B**, **Kavanagh AM**, **Hart S**, **Rodger A**, **Gertig DM**, Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis, Breast 14:192, 2005.
1308. **Carney PA**, **Miglioretti DL**, **Yankaskas BC**, **Kerlikowske K**, **Rosenberg R**, **Rutter CM**, **Geller BM**, **Abraham LA**, **Taplin SH**, **Dignan M**, **Cutter G**, **Ballard-Barbash R**, Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography, Ann Intern Med 138:168, 2003.
1309. **Carter CL**, **Allen C**, **Henson DE**, Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer 63:181, 1989.
1310. **Port ER**, **Tan LK**, **Borgen PI**, **Van Zee KJ**, Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma, Ann Surg Oncol 5:23, 1998.
1311. **Gajdos C**, **Tartter PI**, **Bleiweiss IJ**, Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers, Ann Surg 230:692, 1999.
1312. **Heimann R**, **Munsell M**, **McBride R**, Mammographically detected breast cancers and the risk of axillary lymph node involvement: is it just the tumor size?, Cancer J 8:276, 2002.
1313. **Heiss G**, **Wallace R**, **Anderson GL**, **Aragaki A**, **Beresford SAA**, **Brzyski R**, **Chlebowski RT**, **Gass M**, **LaCroix AZ**, **Manson JE**, **Prentice RL**, **Rossouw JE**, **Stefanick ML**; for the **WHI Investigators**, Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin, JAMA 299:1036, 2008.
1314. **Crandall CJ**, **Karlamangla A**, **Huang MH**, **Ursin G**, **Guan M**, **Greendale GA**, Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy, Arch Intern Med 166:1578, 2006.
1315. **Crandall CJ**, **Aragaki AK**, **Chlebowski RT**, **McTiernan A**, **Anderson G**, **Hendrix SL**, **Cochrane BB**, **Kuller LH**, **Cauley JA**, New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk, Arch Intern Med 169:1684, 2009.
1316. **Boyd NF**, **Martin LJ**, **Sun L**, **Chiarelli AM**, **Hislop G**, **Yaffe MJ**, **Minkin S**, Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer, Cancer Epidemiol Biomarkers Prev 15:961, 2006.
1317. **Rockhill B**, **Spiegelman D**, **Byrne C**, **Hunter DJ**, **Colditz GA**, Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention, J Natl Cancer Inst 93:358, 2001.
1318. **Elmore JG**, **Barton MB**, **Moceri VM**, **Polk S**, **Arena PJ**, **Fletcher SW**, Ten-year risk of false positive screening mammograms and clinical breast examinations, N Engl J Med 338:1089, 1998.
1319. **Freedman M**, **San Martin J**, **O'Gorman J**, **Eckert S**, **Lippman ME**, **Lo S-CB**, **Walls EL**, **Zeng J**, Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo, J Natl Cancer Inst 93:51, 2001.
1320. **Mandelson MT**, **Oestreicher N**, **Porter PL**, **White D**, **Finder CA**, **Taplin SH**, **White E**, Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers, J Natl Cancer Inst 92:1081, 2000.
1321. **Ong G**, **Austoker J**, **Brett J**, Breast screening: adverse psychological consequences 1 month after placing women on early recall because of a diagnostic uncertainty. A multicentre study, J Med Screen 4:158, 1997.
1322. **El-Bastawissi AY**, **White E**, **Mandelson MT**, **Taplin SH**, Reproductive and hormonal factors associated with mammographic breast density by age (United States), Cancer Causes Control 11:955, 2000.
1323. **Boyd NF**, **Martin LJ**, **Rommens JM**, **Paterson AD**, **Minkin S**, **Yaffe MJ**, **Stone J**, **Hopper JL**, Mammographic density: a heritable risk factor for breast cancer, Methods Mol Biol 472:343, 2009.
1324. **Byrne C**, **Schairer C**, **Wolfe J**, **Parekh N**, **Salane M**, **Brinton LA**, **Hoover R**, **Haile R**, Mammographic features and breast cancer risk: effects with time, age, and menopause status, J Natl Cancer Inst 87:1622, 1995.
1325. **Byng JW**, **Yaffe MJ**, **Jong RA**, **Shumak RS**, **Lockwood GA**, **Tritchler DL**, **Boyd NF**, Analysis of mammographic density and breast cancer risk from digitized mammograms, Radiographics 18:1587, 1998.
1326. **Ursin G**, **Ma H**, **Wu AH**, **Bernstein L**, **Salane M**, **Parisky YR**, **Astrahan M**, **Siozon CC**, **Pike MC**,

Mammographic density and breast cancer in three ethnic groups, Cancer Epidemiol Biomarkers Prev 12:332, 2003.

1327. **Vacek PM**, **Geller BM**, A prospective study of breast cancer risk using routine mammographic breast density measurements, Cancer Epidemiol Biomarkers Prev 13:715, 2004.
1328. **Marugg RC**, **van der Mooren MJ**, **Hendriks JHCL**, **Rolland R**, **Ruijs SHJ**, Mammographic changes in postmenopausal women on hormonal replacement therapy, Eur Radiol 7:749, 1997.
1329. **Persson I**, **Thurfjell E**, **Holmberg L**, Effect of estrogen and estrogen-progestin replacement regimens on mammographic parenchymal density, J Clin Oncol 15:3201, 1997.
1330. **Sala E**, **Warren R**, **McCann J**, **Duffy S**, **Luben R**, **Day N**, High-risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case-control study, Int J Epidemiol 29:629, 2000.
1331. **Rutter CM**, **Mandelson MT**, **Laya MB**, **Seger DJ**, **Taplin S**, Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy, JAMA 285:171, 2001.
1332. **Greendale GA**, **Reboussin BA**, **Sie A**, **Singh HR**, **Olson LK**, **Gatewood O**, **Bassett LW**, **Wasilauskas C**, **Bush T**, **Barrett-Conner E**, Effects of estrogen and estrogen-progestin on mammographic parenchymal density, Ann Intern Med 130:262, 1999.
1333. **McTiernan A**, **Martin CF**, **Peck JD**, **Aragaki A**, **Chlebowski RT**, **Pisano ED**, **Wang CY**, **Brunner RL**, **Johnson KC**, **Manson JE**, **Lewis CE**, **Kotchen JM**, **Hulka BS**, **Women's Health Initiative Mammogram Density Study Investigators**, Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial, J Natl Cancer Inst 97:1366, 2005.
1334. **Lundström E**, **Wilczek B**, **von Palffy Z**, **Söderqvist G**, **von Schoultz B**, Mammographic breast density during hormone replacement therapy: differences according to treatment, Am J Obstet Gynecol 181:348, 1999.
1335. **Lundström E**, **Wilczek B**, **von Palffy Z**, **Söderqvist G**, **von Schoultz B**, Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens, Climacteric 4:42, 2001.
1336. **Erel CT**, **Esen G**, **Seyisoglu H**, **Elter K**, **Uras C**, **Ertungealp E**, **Aksu MF**, Mammographic density increase in women receiving different hormone replacement regimens, Maturitas 40:151, 2001.
1337. **Ziv E**, **Tice J**, **Smith-Bindman R**, **Shepherd J**, **Cummiongs S**, **Kerlikowske K**, Mammographic density and estrogen receptor status of breast cancer, Cancer Epidemiol Biomarkers Prev 13:2090, 2004.
1338. **Roubidoux MA**, **Bailey JE**, **Wray LA**, **Helvie MA**, Invasive cancers detected after breast cancer screening yielded a negative result: relationship of mammographic density to tumor prognostic factors, Radiology 230:42, 2004.
1339. **Ziv E**, **Shepherd J**, **Smith-Bindman R**, **Kerlikowske K**, Mammographic breast density and family history of breast cancer, J Natl Cancer Inst 95:556, 2003.
1340. **Vachon CM**, **Sellers TA**, **Vierkant RA**, **Wu FF**, **Brandt KR**, Case-control study of increased mammographic breast density response to hormone replacement therapy, Cancer Epidemiol Biomarkers Prev 11:1382, 2002.
1341. **Harvey JA**, **Santen RJ**, **Petroni GR**, **Bovbjerg VE**, **Smolkin ME**, **Sheriff FS**, **Russo J**, Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices, Menopause 15:67, 2008.
1342. **Cigler T**, **Tu D**, **Yaffe MJ**, **Findlay B**, **Verma S**, **Johnston D**, **Richardson H**, **Hu H**, **Qi S**, **Goss PE**, A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women, Breast Cancer Res Treat 120(2):427, 2010.
1343. **Berkowitz JE**, **Gatewood OMB**, **Goldblum LE**, **Gayler BW**, Hormonal replacement therapy: mammographic manifestations, Radiology 174:199, 1990.
1344. **Harvey JA**, **Pinkerton JV**, **Herman CR**, Short-term cessation of hormone replacement therapy and improvement of mammographic specificity, J Natl Cancer Inst 89:1623, 1997.
1345. **Colacurci N**, **Fornaro F**, **De Franciscis P**, **Mele D**, **Palermo M**, **del Vecchio W**, Effects of a short-term suspension of hormone replacement therapy on mammographic density, Fertil Steril 76:451, 2001.
1346. **Buist DS**, **Anderson ML**, **Reed SD**, **Aiello Bowles EJ**, **Fitzgibbons ED**, **Gandara JC**, **Seger D**, **Newton KM**, Short-term hormone therapy suspension and mammography recall: a randomized trial, Ann Intern Med

150:752, 2009.
1347. **Weaver K**, **Kataoka M**, **Murray J**, **Muir B**, **Anderson E**, **Warren R**, **Warsi I**, **Highnam R**, **Glasier A**, Does a short cessation of HRT decrease mammographic density?, Maturitas 59:315, 2008.
1348. **Lundström E**, **Bygdeson M**, **Svane G**, **Azavedo E**, **Von Schoultz B**, Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density, Climacteric 10:249, 2007.
1349. **Lundström E**, **Söderqvist G**, **Svane G**, **Azavedo E**, **Olovosson M**, **Skoog L**, **von Schoultz E**, **Von Schoultz B**, Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study, Fertil Steril 85:989, 2006.
1350. **Dinger J**, **Bardenheuer K**, **Minh TD**, Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer, Contraception 83(3):211, 2011.
1351. **Bleyer A**, **Welch HG**, Effect of three decades of screening mammography on breast-cancer incidence, N Engl J Med 367(21):1998, 2012.
1352. **Banks E**, Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review, J Med Screen 8:29, 2001.
1353. **Laya MB**, **Larson EB**, **Taplin SH**, **White E**, Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography, J Natl Cancer Inst 88:643, 1996.
1354. **Rosenberg RD**, **Hunt WC**, **Williamson MR**, **Gilliland FD**, **Wiest PW**, **Kelsey CA**, **Key CR**, **Linver MN**, Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico, Radiology 209:511, 1998.
1355. **Litherland JC**, **Stallard S**, **Hole D**, **Cordiner C**, The effect of hormone replacement therapy on the sensitivity of screening mammograms, Clin Radiol 54:285, 1999.
1356. **Kavanagh AM**, **Mitchell H**, **Giles GG**, Hormone replacement therapy and accuracy of mammographic screening, Lancet 355:270, 2000.
1357. **Salminen TM**, **Saarenmaa IE**, **Heikkilä MM**, **Hakama M**, Is a dense mammographic parenchymal pattern a contraindication to hormonal replacement therapy?, Acta Oncol 39:969, 2000.
1358. **Séradour B**, **Estève J**, **Heid P**, **Jacquemier J**, Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhône programme, J Med Screen 6:99, 1999.
1359. **Moy L**, **Slanetz PJ**, **Yeh ED**, **Moore RH**, **Rafferty EA**, **Kopans DB**, Hormone replacement therapy rarely complicates or alters interpretation on screening mammography: a prospective analysis (abstract), Radiology 217:446, 2000.
1360. **Carney PA**, **Kasales CJ**, **Tosteson AN**, **Weiss JE**, **Goodrich ME**, **Poplack SP**, **Wells WS**, **Titus-Ernstoff L**, Likelihood of additional work-up among women undergoing routine screening mammography: the impact of age, breast density, and hormone therapy use, Prev Med 39:48, 2004.
1361. **Chlebowski RT**, **Anderson G**, **Pettinger M**, **Lane D**, **Langer RD**, **Gilligan MA**, **Walsh BW**, **Chen C**, **McTiernan A**; **Women's Health Initiative Investigators**, Estrogen and progestin and breast cancer detection by means of mammography and breast biopsy, Arch Intern Med 168:370, 2008.
1362. **Berg WA**, **Blume JD**, **Cormack JB**, **Mendelson EB**, **Lehrer D**, **Böhm-Vélez M**, **Pisano ED**, **Jong RA**, **Evans WP**, **Morton MJ**, **Mahoney MC**, **Larsen LH**, **Barr RG**, **Farria DM**, **Marques HS**, **Boparai K**; for the **ACRIN 6666 Investigators**, Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer, JAMA 299:2151, 2008.
1363. **Corsetti V**, **Ferrari A**, **Ghirardi M**, **Bergonzini R**, **Bellarosa S**, **Angelina O**, **Bani C**, **Ciotto S**, Role of ultrasonography in detecting mammographically occult breast carcinoma in women with dense breasts, Radiol Med 111:440, 2006.
1364. **Melnikow J**, **Fenton JJ**, **Whitlock EP**, **Miglioretti DL**, **Weyrich MS**, **Thompson JH**, **Shah K**; **U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews**, Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the US Preventive Service Task Force, Agency for Healthcare Research and Quality (US), Rockville, 2016.

1365. **Pisano ED**, **Hendrick RE**, **Yaffe MJ**, **Baum JK**, **Acharyya S**, **Cormack JB**, **Hanna LA**, **Conant EF**, **Fajardo LL**, **Bassett LW**, **D'Orsi CJ**, **Jong RA**, **Rebner M**, **Tosteson AN**, **Gatsonis CA**, **Group DI**, Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST, Radiology 246:376, 2008.
1366. **Wertheimer MD**, **Costanza ME**, **Dodson TF**, **D'Orsi C**, **Pastides H**, **Zapka JG**, Increasing the effort toward breast cancer detection, JAMA 255:1311, 1986.
1367. **Chen WY**, **Hankinson SE**, **Schnitt SJ**, **Rosner BA**, **Holmes MD**, **Colditz GA**, Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma, Cancer 101:1490, 2004.
1368. **Henderson BE**, **Ross RK**, **Judd HL**, **Krailo MD**, **Pike MC**, Do regular ovulatory cycles increase breast cancer risk?, Cancer 56:1206, 1985.
1369. **Tjønneland A**, **Christensen J**, **Thomsen BL**, **Olsen A**, **Overvad K**, **Ewertz M**, **Mellemkjaer L**, Hormone replacement therapy in relation to breast carcinoma incidence rate ratios. A prospective Danish cohort study, Cancer 100:2328, 2004.
1370. **Stahlberg C**, **Pedersen AT**, **Andersen ZJ**, **Keiding N**, **Hundrup YA**, **Obel EB**, **Møller S**, **Rank F**, **Ottesen B**, **Lynge E**, Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy, Br J Cancer 91:644, 2004.
1371. **Hwang ES**, **Chew T**, **Shiboski S**, **Farren G**, **Benz CC**, **Wrensch M**, Risk factors for estrogen receptor-positive disease, Arch Surg 140:58, 2005.
1372. **Kumar AS**, **Cureton E**, **Shim V**, **Sakata T**, **Moore DH**, **Benz CC**, **Esserman LJ**, **Hwang ES**, Type and duration of exogenous hormone use affects breast cancer histology, Ann Surg Oncol 14:695, 2007.
1373. **Fournier A**, **Berrino F**, **Riboli E**, **Clavel-Chapelon F**, Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, Int J Cancer 114:448, 2005.
1374. **Fournier A**, **Berrino F**, **Clavel-Chapelon F**, Unequal risks for breast cancer associated with different hormone replacement therapies: results from E3N cohort study, Breast Cancer Res Treat 107:103, 2008.
1375. **Fournier A**, **Mesrine S**, **Boutron-Ruault MC**, **Clavel-Chapelon F**, Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?, J Clin Oncol 27:5138, 2009.
1376. **Frasor J**, **Danes JM**, **Komm B**, **Chang KC**, **Lyttle CR**, **Katzenellenbogen BS**, Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype, Endocrinology 144:4562, 2003.
1377. **Hall P**, **Ploner A**, **Bjöhle J**, **Huang F**, **Lin C-Y**, **Liu ET**, **Miller LD**, **Nordgren H**, **Pawitan Y**, **Shaw P**, **Skoog L**, **Smeds J**, **Wedrén S**, **Öhd J**, **Bergh J**, Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study, BMC Med 4:16, 2006.
1378. **Wang X**, **Mori I**, **Tang W**, **Nakamura M**, **Nakamura Y**, **Sato M**, **Sakurai T**, **Kakudo K**, p63 expression in normal, hyperplastic and malignant breast tissues, Breast Cancer 9:216, 2002.
1379. **Conneely OM**, **Jericevic BM**, **Lydon JP**, Progesterone receptors in mammary gland development and tumorigenesis, J Mammary Gland Biol Neoplasia 8:205, 2003.
1380. **Horwitz KB**, **Tung L**, **Takimoto GS**, Novel mechanisms of antiprogestin action, J Steroid Biochem Mol Biol 53:9, 1995.
1381. **Read LD**, **Katzenellenbogen BS**, Characterization and regulation of estrogen and progesterone receptors in breast cancer, Cancer Treat Res 61:277, 1992.
1382. **Kastner P**, **Krust A**, **Turcotte B**, **Stropp U**, **Tora L**, **Gronemeyer H**, **Chambon P**, Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B, EMBO J 9:1603, 1990.
1383. **Feil PD**, **Clarke CL**, **Satyaswaroop PG**, Progestin-mediated changes in progesterone receptor forms in the normal human endometrium, Endocrinology 123:2506, 1988.
1384. **McDonnell DP**, **Goldman ME**, RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism, J Biol Chem 269:11945, 1994.
1385. **McDonnell DP**, **Shahbaz MM**, **Vegeto E**, **O'Malley BW**, The human progesterone receptor A-form

functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity, J Steroid Biochem Mol Biol 48:425, 1994.

1386. **Richer JK**, **Jacobsen BM**, **Manning NG**, **Abel MG**, **Wolf DM**, **Horwitz KB**, Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells, J Biol Chem 277:5209, 2002.
1387. **Giangrande PH**, **Kimbrel EA**, **Edwards DP**, **McDonnell DP**, The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding, Mol Cell Biol 20:3102, 2000.
1388. **Jacobsen BM**, **Schittone SA**, **Richer JK**, **Horwitz KB**, Progesterone-independent effects of human progesterone-receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology, Mol Endocrinol 19:574, 2005.
1389. **Hopp TA**, **Weiss HL**, **Hilsenbeck SG**, **Cui Y**, **Allred DC**, **Horwitz KB**, **Fuqua SA**, Breast cancer patients with progesterone receptor rich PR-A-rich tumors have poorer disease-free survival rates, Clin Cancer Res 10:2751, 2004.
1390. **Mote PA**, **Leary JA**, **Avery KA**, **Sandelin K**, **Chenevix-Trench G**, **Kirk JA**, **Clarke CL**, Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A, Genes Chromosomes Cancer 39:236, 2004.
1391. **Isaksson E**, **Wang H**, **Sahlin L**, **von Schoultz B**, **Cline JM**, **von Schoultz E**, Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue from surgically postmenopausal cynomolgus macaques, Breast Cancer Res Treat 79:233, 2003.
1392. **Toth-Fejel S**, **Cheek J**, **Calhoun K**, **Muller P**, **Pommier RF**, Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool, Arch Surg 139:50, 2004.
1393. **Garreau JR**, **Muller P**, **Pommier R**, **Pommier S**, Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation, Am J Surg 191:576, 2006.
1394. **Russo J**, **Russo IH**, The role of estrogen in the initiation of breast cancer, J Steroid Biochem Mol Biol 102:89, 2006.
1395. **The Endogenous Hormones and Breast Cancer Collaborative Group**, Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies, J Natl Cancer Inst 94:606, 2002.
1396. **Key TJ**, **Appleby PN**, **Reeves GK**, **Roddam A**, **Dorgan JF**, **Longcope C**, **Stanczyk FZ**, **Stephenson HE Jr**, **Falk RT**, **Miller R**, **Schatzkin A**, **Allen DS**, **Fentiman IS**, **Key TJ**, **Wang DY**, **Dowsett M**, **Thomas HV**, **Hankinson SE**, **Toniolo P**, **Akhmedkhanov A**, **Koenig K**, **Shore RE**, **Zeleniuch-Jacquotte A**, **Berrino F**, **Muti P**, **Micheli A**, **Krogh V**, **Sieri S**, **Pala V**, **Venturelli E**, **Secreto G**, **Barrett-Connor E**, **Laughlin GA**, **Kabuto M**, **Akiba S**, **Stevens RG**, **Neriishi K**, **Land CE**, **Cauley JA**, **Kuller LH**, **Cummings SR**, **Helzlsouer KJ**, **Alberg AJ**, **Bush TL**, **Comstock GW**, **Gordon GB**, **Miller SR**, **Longcope C**; **Endogenous Hormones Breast Cancer Collaborative Group**, Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women, J Natl Cancer Inst 95:1218, 2003.
1397. **Key TJA**, **Pike MC**, The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer, Eur J Cancer Clin Oncol 24:29, 1988.
1398. **Anderson TJ**, **Ferguson DJP**, **Raab GM**, Cell turnover in the "resting" human breast: influence of parity, contraceptive pill, age and laterality, Br J Cancer 46:376, 1982.
1399. **Ménard S**, **Casalini P**, **Agresti R**, **Pilotti S**, **Balsari A**, Proliferation of breast carcinoma during menstrual phases, Lancet 352:148, 1998.
1400. **Chang K-J**, **Lee TTY**, **Linarez-Cruz G**, **Fournier S**, **de Ligniéres B**, Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo, Fertil Steril 63:785, 1995.
1401. **Laidlaw IJ**, **Clarke RB**, **Howell A**, **Owen AW**, **Potten CS**, **Anderson E**, The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone, Endocrinology 136:164, 1996.

1402. **Foidart J-M**, **Colin C**, **Denoo X**, **Desreux J**, **Béliard A**, **Fournier S**, **de Ligniéres B**, Estradiol and progesterone regulate the proliferation of human breast epithelial cells, Fertil Steril 69:963, 1998.
1403. **Gompel A**, **Malet C**, **Spritzer P**, **Lalardrie J-P**, **Kuttenn F**, **Mauvais-Jarvis P**, Progestin effect on cell proliferation and 17-hydroxysteroid dehydrogenase activity in normal human breast cells in culture, J Clin Endocrinol Metab 63:1174, 1986.
1404. **Conner P**, **Christow A**, **Kersemaekers W**, **Söderqvist G**, **Skoog L**, **Carlström K**, **Tani E**, **Mol-Arts M**, **von Schoultz B**, A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen-progestogen treatment, Climacteric 7:50, 2004.
1405. **Hofseth LJ**, **Raafat AM**, **Oscuch JR**, **Pathak DR**, **Slomski CA**, **Haslam SZ**, Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast, J Clin Endocrinol Metab 84:4559, 1999.
1406. **Gompel A**, **Somai S**, **Chaouat M**, **Kazem A**, **Kloosterboer HJ**, **Beusman I**, **Forgez P**, **Mimoun M**, **Rostene W**, Hormonal regulation of apoptosis in breast cells and tissues, Steroids 65:593, 2000.
1407. **Stute P**, **Wood CE**, **Kapaln JR**, **Cline JM**, Cyclic changes in the mammary gland of cynomolgus macaques, Fertil Steril 82(Suppl 3):1160, 2004.
1408. **Stanczyk FZ**, **Hapgood JP**, **Winer S**, **Mishell DR Jr**, Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects, Endocr Rev 34(2):171, 2013.
1409. **Courtin A**, **Communal L**, **Vilasco M**, **Cimino D**, **Mourra N**, **de Bortoli M**, **Taverna D**, **Faussat AM**, **Chaouat M**, **Forgez P**, **Gompel A**, Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells, Breast Cancer Res Treat 131(1):49, 2012.
1410. **Sweeney EE**, **Fan P**, **Jordan VC**, Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative study, Cancer Res 74(23):7060, 2014.
1411. **Xu B**, **Kitawaki J**, **Koshiba H**, **Ishihara H**, **Kiyomizu M**, **Teramoto M**, **Kitaoka Y**, **Honjo H**, Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells, Maturitas 56(2):142, 2007.
1412. **Cline JM**, **Soderqvist G**, **von Schoultz E**, **Skoog L**, **von Schoultz B**, Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques, Am J Obstet Gynecol 174:93, 1996.
1413. **Wood CE**, **Sitruk-Ware RL**, **Tsong Y-Y**, **Register TC**, **Lees CJ**, **Cline JM**, Effects of estradiol with oral or intravaginal progesterone on risk markers for breast cancer in a postmenopausal monkey model, Menopause 14:1, 2007.
1414. **Wood CE**, **Sitruk-Ware RL**, **Tsong Y-Y**, **Register TC**, **Lees CJ**, **Cline JM**, Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys, Breast Cancer Res Treat 101:125, 2007.
1415. **Conner P**, **Register TC**, **Skoog L**, **Tani E**, **von Schoultz B**, **Cline JM**, Expression of p53 and markers for apoptosis in breast tissue during long-term hormone therapy in cynomolgus monkeys, Am J Obstet Gynecol 193:58, 2005.
1416. **Micheli A**, **Muti P**, **Secreto G**, **Krogh V**, **Meneghini E**, **Venturelli E**, **Sieri S**, **Pala V**, **Berrino F**, Endogenous sex hormones and subsequent breast cancer in premenopausal women, Int J Cancer 112:312, 2004.
1417. **Eliassen AH**, **Missmer SA**, **Tworoger SS**, **Spiegelman D**, **Barbieri RL**, **Dowsett M**, **Hankinson SE**, Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women, J Natl Cancer Inst 98:1406, 2006.
1418. **Chen W**, **Petitti DB**, **Geiger AM**, Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study, Br J Cancer 93:392, 2005.
1419. **Newcomb PA**, **Egan KM**, **Trentham-Dietz A**, **Titus-Ernstoff L**, **Baron JA**, **Hamptom JM**, **Stampfer MJ**, **Willett WC**, Prediagnostic use of hormone therapy and mortality after breast cancer, Cancer Epidemiol Biomarkers Prev 17:864, 2008.

1420. **Ravdin PM**, **Cronin KA**, **Howlader N**, **Berg CD**, **Chlebowski RT**, **Feuer EJ**, **Edwards BK**, **Berry DA**, The decrease in breast-cancer incidence in 2003 in the United States, N Engl J Med 356:1670, 2007.
1421. **Glass AG**, **Lacey JV**, **Carreon JD**, **Hoover RN**, Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status, J Natl Cancer Inst 99:1152, 2007.
1422. **Clarke CA**, **Glaser SL**, **Uratsu CS**, **Selby JV**, **Kushi LH**, **Herrinton LJ**, Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence, J Clin Oncol 24:e49, 2006.
1423. **Kerlikowske K**, **Miglioretti DL**, **Buist DS**, **Walker R**, **Carney PA**; **National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium**, Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population, J Natl Cancer Inst 99:1335, 2007.
1424. **Fournier A**, **Boutron-Ruault M-C**, **Françoise C-C**, Breast cancer and hormonal therapy in postmenopausal women (Letter to the Editor), N Engl J Med 360:22, 2009.
1425. **Sharpe KH**, **McClements P**, **Clark DI**, **Collins J**, **Springbett A**, **Brewster DH**, Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy, Eur J Cancer 46(5):937, 2010.
1426. **Bouchardy C**, **Usel M**, **Verkooijen HM**, **Fioretta G**, **Benhamou S**, **Neyroud-Caspar I**, **Schaffar R**, **Vlastos G**, **Wespik Y**, **Schàfer P**, **Rapiti E**, Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva, Breast Cancer Res Treat 120(2):519, 2009.
1427. **Canfell K**, **Banks E**, **Moa AM**, **Beral V**, Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia, Med J Aust 188:641, 2008.
1428. **Chlebowski RT**, **Kuller LH**, **Prentice RL**, **Stefanick ML**, **Manson JE**, **Gass M**, **Aragaki A**, **Ockene JK**, **Lane DS**, **Sarto GE**, **Rajkovic A**, **Schenken RS**, **Hendrix SL**, **Ravdin PM**, **Rohan TE**, **Yasmeen S**, **Anderson G**; for the **WHI Investigators**, Breast cancer after use of estrogen plus progestin in postmenopausal women, N Engl J Med 360:573, 2009.
1429. **Bouchardy C**, **Morabia A**, **Verkooijen HM**, **Fioretta G**, **Wespi Y**, **Shäfer P**, Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy, BMC Cancer 6:78, 2006.
1430. **Manson JE**, **Chlebowski RT**, **Stefanick ML**, **Aragaki AK**, **Rossouw JE**, **Prentice RL**, **Anderson G**, **Howard BV**, **Thomson CA**, **LaCroix AZ**, **Wactawski-Wende J**, **Jackson RD**, **Limacher M**, **Margolis KL**, **Wassertheil-Smoller S**, **Beresford SA**, **Cauley JA**, **Eaton CB**, **Gass M**, **Hsia J**, **Johnson KC**, **Kooperberg C**, **Kuller LH**, **Lewis CE**, **Liu S**, **Martin LW**, **Ockene JK**, **O'Sullivan MJ**, **Powell LH**, **Simon MS**, **Van Horn L**, **Vitolins MZ**, **Wallace RB**, Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials, JAMA 310(13):1353, 2013.
1431. **Hsieh RW**, **Rajan SS**, **Sharma SK**, **Greene GL**, Molecular characterization of a B-ring unsaturated estrogen: implications for conjugated equine estrogen components of premarin, Steroids 73(1):59, 2008.
1432. **Heldring N**, **Pike A**, **Andersson S**, **Matthews J**, **Cheng G**, **Hartman J**, **Tujague M**, **Ström A**, **Treuter E**, **Warner M**, **Gustafsson JA**, Estrogen receptors: how do they signal and what are their targets, Physiol Rev 87(3):905, 2000.
1433. **Bhavnani BR**, **Tam SP**, **Lu X**, Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta, Endocrinology 149(10):4857, 2008.
1434. **Lazennec G**, **Bresson D**, **Lucas A**, **Chauveau C**, **Vignon F**, ER beta inhibits proliferation and invasion of breast cancer cells, Endocrinology 142(9):4120, 2001.
1435. **Strom A**, **Hartman J**, **Foster JS**, **Kietz S**, **Wimalasena J**, **Gustafsson JA**, Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D, Proc Natl Acad Sci U S A 101(6):1566, 2004.
1436. **Song Y**, **Santen RJ**, **Wang JP**, **Yue W**, Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro, Endocrinology 154(2):656, 2013.

1437. **Berrodin TJ**, **Chang KC**, **Komm BS**, **Freedman LP**, **Nagpal S**, Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination, Mol Endocrinol 23(1):74, 2009.
1438. **Flores VA**, **Taylor HS**, The effect of menopausal hormone therapies on breast cancer: avoiding the risk, Endocrinol Metab Clin North Am 44(3): 587, 2015.
1439. **Rebbeck TR**, **Levin AM**, **Eisen A**, **Snyder C**, **Watson P**, **Cannon-Albright L**, **Isaacs C**, **Olopade OI**, **Garber JE**, **Godwin AK**, **Daly MB**, **Narod SA**, **Neuhausen SL**, **Lynch HT**, **Weber BL**, Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers, J Natl Cancer Inst 91:1475, 1999.
1440. **Rebbeck TR**, **Friebel T**, **Wagner T**, **Lynch HT**, **Garber JE**, **Daly MB**, **Isaacs C**, **Olopade OI**, **Neuhausen SL**, **van't Veer L**, **Eeles R**, **Evans DG**, **Tomlinson G**, **Matloff E**, **Narod SA**, **Eisen A**, **Domchek S**, **Armstrong K**, **Weber BL**, Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study, J Clin Oncol 23:7804, 2005.
1441. **Eisen A**, **Lubinski J**, **Gronwald J**, **Moller P**, **Lynch HT**, **Kim-Sing C**, **Neuhausen SL**, **Gilbert L**, **Ghadirian P**, **Manoukian S**, **Rennert G**, **Friedman E**, **Isaacs C**, **Rosen E**, **Rosen B**, **Daly M**, **Sun P**, **Narod SA**; **Hereditary Breast Cancer Clinical Study Group**, Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers, J Natl Cancer Inst 100:1361, 2008.
1442. **Kurman RJ**, **Kaminski PF**, **Norris HJ**, The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients, Cancer 56:403, 1985.
1443. **Grady D**, **Gebretsadik T**, **Kerlikowske K**, **Ernster V**, **Petitti D**, Hormone replacement therapy and endometrial cancer risk: a meta-analysis, Obstet Gynecol 85:304, 1995.
1444. **Weiss NS**, **Hill DA**, Postmenopausal estrogen and the incidence of gynecologic cancer, Maturitas 23:235, 1996.
1445. **Shapiro S**, **Kelly JP**, **Rosenberg L**, **Kaufman DW**, **Helmrich SP**, **Rosenshein NB**, **Lewis JL Jr**, **Knapp RC**, **Stolley PD**, **Schottenfeld D**, Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens, N Engl J Med 313:969, 1985.
1446. **Buring JE**, **Bain CJ**, **Ehrmann RL**, Conjugated estrogen use and risk of endometrial cancer, Am J Epidemiol 124:434, 1986.
1447. **Lacey JV Jr**, **Brinton LA**, **Lubin JH**, **Sherman ME**, **Schatzkin A**, **Schairer C**, Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women, Cancer Epidemiol Biomarkers Prev 14:1724, 2005.
1448. **Paganini-Hill A**, **Ross RK**, **Henderson BE**, Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study, Br J Cancer 59:445, 1989.
1449. **Schiff I**, **Sela HK**, **Cramer D**, **Tulchinsky D**, **Ryan KJ**, Endometrial hyperplasia in women on cyclic or continuous estrogen regimens, Fertil Steril 37:79, 1982.
1450. **Notelovitz M**, **Varner RE**, **Rebar RW**, **Fleischmann R**, **McIlwain HH**, **Schwartz SL**, **Sperling M**, **Wilborn W**, **Yang H-M**, **Silfen SL**, Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogens, Menopause 4:80, 1997.
1451. **Johnson SR**, **Ettinger B**, **Macer JL**, **Ensrud KE**, **Quan J**, **Grady D**, Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol, Obstet Gynecol 105:779, 2005.
1452. **Cushing KL**, **Weiss NL**, **Voigt LF**, **McKnight B**, **Beresford SAA**, Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens, Obstet Gynecol 91:35, 1998.
1453. **Thom MH**, **White PJ**, **Williams RM**, **Sturdee PW**, **Paterson MEL**, **Wade-Evans T**, **Studd JWW**, Prevention and treatment of endometrial disease in climacteric women receiving estrogen, Lancet 2:455, 1979.
1454. **Whitehead MI**, **Townsend PT**, **Pryse-Davies J**, **Ryder TA**, **King RJB**, Effects of estrogen and progestins on the biochemistry and morphology of the postmenopausal endometrium, N Engl J Med 305:1599, 1981.
1455. **Gambrell RD Jr**, **Babgnell CA**, **Greenblatt RB**, Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: a review, Am J Obstet Gynecol 146:696, 1983.
1456. **Persson I**, **Adami H-O**, **Bergkvist L**, **Lindgren A**, **Pettersson B**, **Hoover R**, **Schairer C**, Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a

prospective study, Br Med J 298:147, 1989.
1457. **Voigt LF**, **Weiss NS**, **Chu JR**, **Daling J**, **McKnight B**, **van Belle G**, Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer, Lancet 338:274, 1991.
1458. **Strom BL**, **Schinnar R**, **Weber AL**, **Bunin G**, **Berlin JA**, **Baumgarten M**, **DeMichele A**, **Rubin SC**, **Berlin M**, **Troxel AB**, **Rebbeck TR**, Case-control study of postmenopausal hormone replacement therapy and endometrial cancer, Am J Epidemiol 164:775, 2006.
1459. **Varma TR**, Effect of long-term therapy with estrogen and progesterone on the endometrium of postmenopausal women, Acta Obstet Gynecol Scand 64:41, 1985.
1460. **Pike MC**, **Peters RK**, **Cozen W**, **Probst-Hensch NM**, **Felix JC**, **Wan PC**, **Mack TM**, Estrogen-progestin replacement therapy and endometrial cancer, J Natl Cancer Inst 89:1110, 1997.
1461. **Beresford SA**, **Weiss NS**, **Voigt LF**, **McKnight B**, Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women, Lancet 349:458, 1997.
1462. **Weiderpass E**, **Adami HO**, **Baron JA**, **Magnusson C**, **Bergstrom R**, **Lindgren A**, **Correia N**, **Persson I**, Risk of endometrial cancer following estrogen replacement with and without progestins, J Natl Cancer Inst 91:1131, 1999.
1463. **Doherty JA**, **Cushing-Haugen KL**, **Saltzman BS**, **Voigt LF**, **Hill DA**, **Beresford SA**, **Chen C**, **Weiss NS**, Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer, Am J Obstet Gynecol 197:139.e1, 2007.
1464. **Flowers CE**, **Wilborn WH**, **Hyde BM**, Mechanisms of uterine bleeding in postmenopausal patients receiving estrogen alone or with a progestin, Obstet Gynecol 61:135, 1983.
1465. **Hill DA**, **Weiss NS**, **Beresford SA**, **Voigt LF**, **Daling JR**, **Stanford JL**, **Self S**, Continuous combined hormone replacement therapy and risk of endometrial cancer, Am J Obstet Gynecol 183:1456, 2000.
1466. **Anderson GL**, **Judd HL**, **Kaunitz AM**, **Barad DH**, **Beresford SAA**, **Pettinger M**, **Liu J**, **McNeeley SG**, **Lopez AM**; for the **Women's Health Initiative Investigators**, Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. The Women's Health Initiative Randomized Trial, JAMA 290:1739, 2003.
1467. **Fournier A**, **Dossus L**, **Mesrine S**, **Vilier A**, **Boutron-Ruault MC**, **Clavel-Chapelon F**, **Chabbert-Buffet N**, Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992–2008, Am J Epidemiol 180(5):508, 2014.
1468. **Rodriguez C**, **Patel AV**, **Calle EE**, **Jacob EJ**, **Thun MJ**, Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women, JAMA 285:1460, 2001.
1469. **Lacey JV Jr**, **Mink PJ**, **Lubin JH**, **Sherman ME**, **Troisi R**, **Hartge P**, **Schatzkin A**, **Schairer C**, Menopausal hormone replacement therapy and risk of ovarian cancer, JAMA 288:334, 2002.
1470. **Folsom AR**, **Anderson JP**, **Ross JA**, Estrogen replacement therapy and ovarian cancer, Epidemiology 15:100, 2004.
1471. **Lacey JV Jr**, **Brinton LA**, **Letizmann MF**, **Mouw T**, **Hollenbeck A**, **Schatzkin A**, **Hartge P**, Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health—AARP Diet and Health Study Cohort, J Natl Cancer Inst 98:1397, 2006.
1472. **Danforth KN**, **Tworoger SS**, **Hecht JL**, **Rosner BA**, **Colditz GA**, **Hankinson SE**, A prospective study of postmenopausal hormone use and ovarian cancer risk, Br J Cancer 96:151, 2007.
1473. **Million Women Study Collaborators**, Ovarian cancer and hormone replacement therapy in the Million Women Study, Lancet 369:1703, 2007.
1474. **Mørch LS**, **Løkkegaard E**, **Andreasen AH**, **Krüger-Kjaer S**, **Lidegaard Ø**, Hormone therapy and ovarian cancer, JAMA 302:298, 2009.
1475. **Riman T**, **Dickman PW**, **Nilsson S**, **Correia N**, **Nordlinder H**, **Magnusson CM**, **Weiderpass E**, **Persson IR**, Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women, J Natl Cancer Inst 94:497, 2002.
1476. **Whittemore AS**, **Harris R**, **Itnyre J**; the **Collaborative Ovarian Cancer Group**, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II: Invasive epithelial ovarian cancers in white women, Am J Epidemiol 136:1184, 1992.

1477. **Garg PP**, **Kerlikowske K**, **Subak L**, **Grady D**, Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis, Obstet Gynecol 92:472, 1998.
1478. **Coughlin SS**, **Giustozzi A**, **Smith SJ**, **Lee NC**, A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer, J Clin Epidemiol 53:367, 2000.
1479. **Hempling RE**, **Wong C**, **Piver MS**, **Natarajan N**, **Mettlin CJ**, Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study, Obstet Gynecol 89:1012, 1997.
1480. **Risch HA**, Estrogen replacement therapy and risk of epithelial ovarian cancer, Gynecol Oncol 63:254, 1996.
1481. **Sit ASY**, **Modugno F**, **Weissfeld JL**, **Berga SL**, **Ness RB**, Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma, Gynecol Oncol 86:118, 2002.
1482. **Rossing MA**, **Cushing-Haugen KL**, **Wicklund KG**, **Doherty JA**, **Weiss NS**, Menopausal hormone therapy and risk of epithelial ovarian cancer, Cancer Epidemiol Biomarkers Prev 16:2548, 2007.
1483. **Whiteman DC**, **Siskind V**, **Purdie DM**, **Green AC**, Timing of pregnancy and the risk of epithelial ovarian cancer, Cancer Epidemiol Biomarkers Prev 12:42, 2003.
1484. **Yang CY**, **Kuo HW**, **Chiu HF**, Age at first birth, parity, and risk of death from ovarian cancer in Taiwan: a country of low incidence of ovarian cancer, Int J Gynecol Cancer 17:32, 2007.
1485. **Siskind V**, **Green A**, **Bain C**, **Purdie D**, Breastfeeding, menopause, and epithelial ovarian cancer, Epidemiology 8:188, 1997.
1486. **Green A**, **Purdie D**, **Bain C**, **Siskind V**, **Russell P**, **Quinn M**, **Ward B**, Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer, Survey of Women's Health Study Group, Int J Cancer 71:948, 1997.
1487. **Fairfield KM**, **Hunter DJ**, **Fuchs CS**, **Colditz GA**, **Hankinson SE**, Aspirin, other NSAIDs, and ovarian cancer risk (United States), Cancer Causes Control 13:535, 2002.
1488. **Greer JB**, **Modugno F**, **Ness RB**, **Allen GO**, Anthropometry and the risk of epithelial ovarian cancer, Cancer 106:2247, 2006.
1489. **Olsen CM**, **Green AC**, **Whiteman DC**, **Sadeghi S**, **Kolahdooz F**, **Webb PM**, Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis, Eur J Cancer 43:690, 2007.
1490. **Ness RB**, **Cramer DW**, **Goodman MT**, **Kjaer SK**, **Mallin K**, **Mosgaard BJ**, **Purdie DM**, **Risch HA**, **Vergona R**, **Wu AH**, Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies, Am J Epidemiol 155:217, 2002.
1491. **Goodman MT**, **Tung KH**, Alcohol consumption and the risk of borderline and invasive ovarian cancer, Obstet Gynecol 101:1221, 2003.
1492. **Suzuki R**, **Ye W**, **Rylander-Rudqvist T**, **Saji S**, **Colditz GA**, **Wolk A**, Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study, J Natl Cancer Inst 97(21):1601, 2005.
1493. **Green A**, **Purdie D**, **Bain C**, **Siskind V**, **Webb PM**, Cigarette smoking and risk of epithelial ovarian cancer (Australia), Cancer Causes Control 12:713, 2001.
1494. **Goodman MT**, **Tung KH**, Active and passive tobacco smoking and the risk of borderline and invasive ovarian cancer (United States), Cancer Causes Control 14:569, 2003.
1495. **Jordan SJ**, **Whiteman DC**, **Purdie DM**, **Green AC**, **Webb PM**, Does smoking increase risk of ovarian cancer? A systematic review, Gynecol Oncol 103:1122, 2006.
1496. **Modesitt SC**, **Tortolero-Luna G**, **Robinson JB**, **Gershenson DM**, **Wolf JK**, Ovarian and extraovarian endometriosis-associated cancer, Obstet Gynecol 100:788, 2002.
1497. **Purdie DW**, **Bain CJ**, **Siskind V**, **Russell P**, **Hacker NF**, **Ward BG**, **Quinn MA**, **Green AC**, Hormone replacement therapy and risk of epithelial ovarian cancer, Br J Cancer 81:559, 1999.
1498. **Eeles RA**, **Tan S**, **Whitelaw E**, **Fryatt I**, **A'Hern RP**, **Shepherd JH**, **Harmer CL**, **Blake PR**, **Chilvers CED**, Hormone replacement therapy and survival after surgery for ovarian cancer, Br Med J 302:259, 1991.
1499. **Guidozzi F**, **Daponte A**, Estrogen replacement therapy for ovarian carcinoma survivors. A randomized controlled trial, Cancer 86:1013, 1999.
1500. **Ursic-Vrscaj M**, **Bebar S**, **Zakelj MP**, Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival, Menopause 8:70, 2001.
1501. **Hopkins ML**, **Fung MF**, **Le T**, **Shorr R**, Ovarian cancer patients and hormone replacement therapy: a

systematic review, Gynecol Oncol 92:827, 2004.

1502. **Sturdee DW**, **Pines A**; **International Menopause Society Writing Group**; **Archer DF**, **Baber RJ**, **Barlow D**, **Birkhäuser MH**, **Brincat M**, **Cardozo L**, **de Villiers TJ**, **Gambacciani M**, **Gompel AA**, **Henderson VW**, **Kluft C**, **Lobo RA**, **MacLennan AH**, **Marsden J**, **Nappi RE**, **Panay N**, **Pickar JH**, **Robinson D**, **Simon J**, **Sitruk-Ware RL**, **Stevenson JC**, Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health, Climacteric 14(3):302, 2011.
1503. **Chute CG**, **Willett WC**, **Colditz GA**, **Stampfer MJ**, **Rosner B**, **Speizer FE**, A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women, Epidemiology 2:201, 1991.
1504. **Jacobs EJ**, **White E**, **Weiss NS**, Exogenous hormones, reproductive history, and colon cancer, Cancer Causes Control 5:359, 1994.
1505. **Calle EE**, **Miracle-McMahill ML**, **Thun MJ**, **Heath CW Jr**, Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women, J Natl Cancer Inst 87:517, 1995.
1506. **Kampman E**, **Potter JD**, **Slattery ML**, **Caan BJ**, **Edwards S**, Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States, Cancer Causes Control 8:146, 1997.
1507. **Troisi R**, **Schairer C**, **Chow W-H**, **Schatzkin A**, **Brinton LA**, **Fraumeni JF Jr**, A prospective study of menopausal hormones and risk of colorectal cancer (United States), Cancer Causes Control 8:130, 1997.
1508. **Fernandez E**, **La Vecchia C**, **Braga C**, **Talamini R**, **Negri E**, **Parazzini F**, **Franceschi S**, Hormone replacement therapy and risk of colon and rectal cancer, Cancer Epidemiol Biomarkers Prev 7:329, 1998.
1509. **Paganini-Hill A**, Estrogen replacement therapy and colorectal cancer risk in elderly women, Dis Colon Rectum 42:1300, 1999.
1510. **Johnson JR**, **Lacey JV Jr**, **Lazovich D**, **Geller MA**, **Schairer C**, **Schatzkin A**, **Flood A**, Menopausal hormone therapy and risk of colorectal cancer, Cancer Epidemiol Biomarkers Prev 18:196, 2009.
1511. **Rennert G**, **Rennert HS**, **Pinchev M**, **Lavie O**, **Gruber SB**, Use of hormone replacement therapy and the risk of colorectal cancer, J Clin Oncol 27:4542, 2009.
1512. **Grodstein F**, **Martinez E**, **Platz EA**, **Giovannucci E**, **Colditz GA**, **Kautsky M**, **Fuchs C**, **Stampfer MJ**, Postmenopausal hormone use and risk for colorectal cancer and adenoma, Ann Intern Med 128:705, 1998.
1513. **Chan JA**, **Meyerhardt JA**, **Chan AT**, **Giovannucci EL**, **Colditz GA**, **Fuchs CS**, Hormone replacement therapy and survival after colorectal diagnosis, J Clin Oncol 36:5680, 2006.
1514. **Yang G**, **Shu XO**, **Li H**, **Chow WH**, **Cai H**, **Zhang X**, **Gao YT**, **Zheng W**, Prospective cohort study of soy food intake and colorectal cancer risk in women, Am J Clin Nutr 89:577, 2009.
1515. **Ritenbaugh C**, **Stanford JL**, **Wu L**, **Shikany JM**, **Schoen RE**, **Stefanick ML**, **Taylor V**, **Garland C**, **Frank G**, **Lande D**, **Mason E**, **McNeeley SG**, **Ascensao J**, **Chlebowski RT**; **Women's Health Initiative Investigators**, Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trials, Cancer Epidemiol Biomarkers Prev 17:2609, 2008.
1516. **Delellis Henderson K**, **Duan L**, **Sullivan-Halley J**, **Ma H**, **Clarke CA**, **Neuhausen SL**, **Templeman C**, **Bernstein L**, Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study, Am J Epidemiol 171:415, 2010.
1517. **Csizmadi I**, **Collet JP**, **Benedetti A**, **Boivin JF**, **Hanley JA**, The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women, Br J Cancer 90:76, 2004.
1518. **Chlebowski RT**, **Schwartz AG**, **Wakelee H**, **Anderson GL**, **Stefanick ML**, **Manson JE**, **Rodabough RJ**, **Chien JW**, **Wactawski-Wende J**, **Gass M**, **Kotchen JM**, **Johnson KC**, **O'Sullivan MJ**, **Ockene JK**, **Chen C**, **Hubbell FA**; for the **Women's Health Initiative Investigators**, Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative Trial): a post-hoc analysis of a randomised controlled trial, Lancet 374(9697):1243, 2009. doi: 10.1016/S0140-6736(09)61526-9.
1519. **Stabile LP**, **Davis AL**, **Gubish CT**, **Hopkins TM**, **Luketich JD**, **Christie N**, **Finkelstein S**, **Siegfried JM**, Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen, Cancer Res 62:2141, 2002.
1520. **Blackman JA**, **Coogan PF**, **Rosenberg L**, **Strom BL**, **Zauber AG**, **Palmer JR**, **Langenberg P**, **Shapiro**

S, Estrogen replacement therapy and risk of lung cancer, Pharmacoepidemiol Drug Saf 11:561, 2002.
1521. **Schabath MB**, **Wu X**, **Vassilopoulou-Sellin R**, **Vaporciyan AA**, **Spitz MR**, Hormone replacement therapy and lung cancer risk: a case-control analysis, Clin Cancer Res 10:113, 2004.
1522. **Chen KY**, **Hsiao CF**, **Chang GC**, **Tsai YH**, **Su WC**, **Perng RP**, **Huang MS**, **Hsiung CA**, **Chen CJ**, **Yang PC**; **GEFLAC Study Group**, Hormone replacement therapy and lung cancer risk in Chinese, Cancer 110:1768, 2007.
1523. **Rodriguez C**, **Spencer Feigelson H**, **Deka A**, **Patel AV**, **Jacobs EJ**, **Thun MJ**, **Calle EE**, Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort, Cancer Epidemiol Biomarkers Prev 17:655, 2008.
1524. **Schwartz AG**, **Wenzlaff AS**, **Prysak GM**, **Murphy V**, **Cote ML**, **Brooks SC**, **Skafar DF**, **Lonardo F**, Reproductive factors, hormone use, and estrogen receptor expression and risk of non small-cell lung cancer in women, J Clin Oncol 25:5785, 2007.
1525. **Kreuzer M**, **Gerken M**, **Heinrich J**, **Kreienbrock L**, **Wichmann HE**, Hormonal factors and risk of lung cancer among women?, Int J Epidemiol 32:263, 2003.
1526. **Olsson H**, **Bladström A**, **Ingvar C**, Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy?, Obstet Gynecol 102:565, 2003.
1527. **Ganti AK**, **Sahmoun AE**, **Panwalkar AW**, **Tendulkar KK**, **Potti A**, Hormone replacement therapy is associated with decreased survival in women with lung cancer, J Clin Oncol 24:59063, 2006.
1528. **Huang B**, **Carloss H**, **Wyatt SW**, **Riley E**, Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population, Cancer 115:4167, 2009.
1529. **Ayeni O**, **Robinson A**, Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed?, Curr Oncol 16:21, 2009.
1530. **Hershberger PA**, **Vasquez AC**, **Kanterewicz B**, **Land S**, **Siegfried JM**, **Nichols M**, Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands, Cancer Res 65:1598, 2005.
1531. **Márquez-Garbán DC**, **Chen HW**, **Goodglick L**, **Fishbein MC**, **Pietras RJ**, Targeting aromatase and estrogen signaling in human non-small cell lung cancer, Ann N Y Acad Sci 1155:194, 2009.
1532. **Smith JR**, **Barrett-Connor E**, **Kritz-Silverstein D**, **Wingard DL**, **Al-Delaimy WK**, Hormone use and lung cancer incidence: the Rancho Bernardo cohort study, Menopause 16:1044, 2009.
1533. **Adami H-O**, **Persson I**, **Hoover R**, **Schairer C**, **Bergkvist L**, Risk of cancer in women receiving hormone replacement therapy, Int J Cancer 44:833, 1989.
1534. **Parazzini F**, **La Vecchia C**, **Negri E**, **Franceschi S**, **Moroni S**, **Chatenoud L**, **Bolis G**, Case-control study of oestrogen replacement therapy and risk of cervical cancer, Br Med J 315:85, 1997.
1535. **Lacey JV Jr**, **Brinton LA**, **Barnes WA**, **Gravitt PE**, **Greenberg MD**, **Hadjimichael OC**, **Hadjimichael OC**, **McGowen L**, **Mortel R**, **Schwartz PE**, **Kurman RJ**, **Hildesheim A**, Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix, Gynecol Oncol 77:149, 2000.
1536. **Ploch E**, Hormonal replacement therapy in patients after cervical cancer treatment, Gynecol Oncol 26:169, 1987.
1537. **Green A**, Oral contraceptives and skin neoplasia, Contraception 43:653, 1991.
1538. **Hannaford PC**, **Villard-Mackintosh L**, **Vessey MP**, **Kay CR**, Oral contraceptives and malignant melanoma, Br J Cancer 63:430, 1991.
1539. **Osterlind A**, **Tucker MA**, **Stone BJ**, **Jensen OM**, The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women, Int J Cancer 42:821, 1988.
1540. **Holly EA**, **Cress RD**, **Ahn DK**, Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous hormones, Cancer Epidemiol Biomarkers Prev 3:661, 1994.
1541. **White E**, **Kirkpatrick CS**, **Lee JAH**, Case-control study of malignant melanoma in Washington State. I. Constitutional factors and sun exposure, Am J Epidemiol 139:857, 1994.
1542. **Smith MA**, **Fine JA**, **Barnhill RL**, **Berwick M**, Hormonal and reproductive influences and risk of melanoma in women, Int J Epidemiol 27:751, 1998.

1543. **Lea CS**, **Holly EA**, **Hartge P**, **Lee JS**, **Guerry IV D**, **Elder DE**, **Halpern A**, **Sagebiel RW**, **Tucker MA**, Reproductive risk factors for cutaneous melanoma in women: a case-control study, Am J Epidemiol 65:505, 2007.
1544. **Holman CDJ**, **Armstrong BK**, **Heenan PJ**, Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors, Br J Cancer 50:673, 1984.
1545. **Koomen ER**, **Joosse A**, **Herings RM**, **Casparie MK**, **Guchelaar HJ**, **Nijsten T**, Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study, Ann Oncol 20:358, 2009.
1546. **Glueck CJ**, **Lang J**, **Hamer T**, **Tracy T**, Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women, J Lab Clin Med 123:59, 1994.
1547. **Goldenberg NM**, **Wang P**, **Glueck CJ**, An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia, Clin Chim Acta 332:11, 2003.
1548. **Grodstein F**, **Colditz GA**, **Stampfer MJ**, Postmenopausal hormone use and cholecystectomy in a large prospective study, Obstet Gynecol 83:5, 1994.
1549. **Petitti DB**, **Sidney S**, **Perlamn JA**, Increased risk of cholecystectomy in users of supplemental estrogen, Gastroenterolgoy 94:91, 1988.
1550. **La Vecchia C**, **Negri E**, **D'Avanzo B**, **Parazzini F**, **Genitle A**, **Franceschi S**, Oral contraceptives and noncontraceptive oestrogens in the risk of gallstone disease requiring surgery, J Epidemiol Community Health 46:234, 1992.
1551. **Scragg RK**, **McMichael AJ**, **Seamark RF**, Oral contraceptives, pregnancy and endogenous estrogen in gallstone disease—a case-control study, Br Med J 288:1795, 1984.
1552. **Kakar F**, **Weiss NS**, **Strite SA**, Non-contraceptive estrogen use and the risk of gallstone disease in women, Am J Public Health 78:564, 1988.
1553. **Jorgensen T**, Gallstones in a Danish population: fertility, period, pregnancies, and exogenous female sex hormones, Gut 29:433, 1988.
1554. **Simon JA**, **Hunninghake DB**, **Agarwal SK**, **Lin F**, **Cauley JA**, **Ireland CC**, **Pickar JH**; for the **Heart and Estrogen/progestin Replacement Study (HERS) Research Group**, Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease, Ann Intern Med 135:493, 2001.
1555. **Cirillo DJ**, **Wallace RB**, **Rodabough RJ**, **Greenland P**, **LaCroix AZ**, **Limacher MC**, **Larson JC**, Effect of estrogen therapy on gallbladder disease, JAMA 293:330, 2005.
1556. **van Erpecum KJ**, **van Berge Henegouwen GP**, **Verschoor L**, **Stoelwinder B**, **Willekens FLH**, Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women, Gasteroenterology 100:482, 1991.
1557. **Uhler ML**, **Marks JW**, **Voigt BJ**, **Judd HL**, Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women, J Clin Endocrinol Metab 83:410, 1998.
1558. **Liu B**, **Beral V**, **Balkwill A**, **Green JR**, **Sweetland S**, **Reeves G**; **Million Women Study Collaborators**, Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study, Br Med J 337:a386, 2008. doi: 10.1131/bmj.a386.
1559. **Crawford SL**, **Casey VA**, **Avis NE**, **McKinlay SM**, A longitudinal study of weight and the menopause transition: results from the Massachusetts Women's Health Study, Menopause 7:96, 2000.
1560. **Blumel JE**, **Castelo-Branco C**, **Rocangliolo ME**, **Bifa L**, **Tacla X**, **Mamani L**, Changes in body mass index around menopause: a population study of Chilean women, Menopause 8:239, 2001.
1561. **Kritz-Silverstein D**, **Barrett-Connor E**, Long-term postmenopausal hormone use, obesity, and fat distribution in older women, JAMA 27:46, 1996.
1562. **Espeland MA**, **Stefanick ML**, **Kritz-Silverstein D**, **Fineberg SE**, **Waclawiw MA**, **James MK**, **Greendale GA**; for the **Postmenopausal Estrogen/Progestin Interventions Study Investigators**, Effect of postmenopausal hormone therapy on body weight and waist and hip girths, J Clin Endocrinol Metab 82:1549, 1997.

1563. **Thorneycroft IH**, **Lindsay R**, **Pickar JH**, Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the Women's Health, Osteoporosis, Progestin, Estrogen (HOPE) Trial, Am J Obstet Gynecol 197:137.e1, 2007.
1564. **Sowers M**, **Zheng H**, **Tomey K**, **Karvonen-Gutierrez C**, **Jannausch ML**, **Li X**, **Yosef M**, **Symons J**, Changes in body composition in women over six years at midlife: ovarian and chronological aging, J Clin Endocrinol Metab 92:895, 2007.
1565. **Salpeter SR**, **Walsh JME**, **Ormiston TM**, **Greyber E**, **Buckley NS**, **Salpeter EE**, Meta-analysis: effect of hormone therapy on components of the metabolic syndrome in postmenopausal women, Diabetes Obes Metab 8:538, 2006.
1566. **Gambacciani M**, **Ciaponi M**, **Cappagli B**, **De Simone L**, **Orlandi R**, **Genazzani AR**, Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy, Maturitas 39:125, 2001.
1567. **Jensen LB**, **Vestergaard P**, **Hermann AP**, **Gram J**, **Eiken P**, **Abrahamsen B**, **Brot C**, **Kolthoff N**, **Sorensen OH**, **Beck-Nielsen H**, **Nielsen SP**, **Charles P**, **Mosekilde L**, Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized, controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study, J Bone Miner Res 18:333, 2003.
1568. **Chen Z**, **Bassford T**, **Green SB**, **Cauley JA**, **Jackson RD**, **LaCroix AZ**, **Leboff M**, **Stefanick ML**, **Margolis KL**, Postmenopausal hormone therapy and body composition—a substudy of the estrogen plus progestin trial of the Women's Health Initiative, Am J Clin Nutr 82:651, 2005.
1569. **Arabi A**, **Garnero P**, **Porcher R**, **Pelissier C**, **Benhamou CL**, **Roux C**, Changes in body composition during post-menopausal hormone therapy: a 2 year prospective study, Hum Reprod 18:1747, 2003.
1570. **Creasman WT**, Estrogen replacement therapy: is previously treated cancer a contraindication?, Obstet Gynecol 77:308, 1991.
1571. **Lee RB**, **Burke TW**, **Park RC**, Estrogen replacement therapy following treatment for stage 1 endometrial carcinoma, Gynecol Oncol 36:189, 1990.
1572. **Baker DP**, Estrogen-replacement therapy in patients with previous endometrial carcinoma, Compr Ther 16:28, 1990.
1573. **Chapman JA**, **DiSaia PJ**, **Osann K**, **Roth PD**, **Gillotte DL**, **Berman ML**, Estrogen replacement in surgical stage I and II endometrial cancer survivors, Am J Obstet Gynecol 175:1195, 1996.
1574. **Suriano KA**, **McHale M**, **McLaren C**, **Li K-T**, **Re A**, **DiSaia PJ**, Estrogen replacement therapy in endometrial cancer patients: a matched cohort study, Obstet Gynecol 97:555, 2001.
1575. **Ayhan A**, **Taskiran C**, **Simsek S**, **Sever A**, Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?, Int J Gynecol Cancer 16:805, 2006.
1576. **Barakat RR**, **Bundy BN**, **Spirtos NM**, **Bell J**, **Mannel RS**; **Gynecologic Oncology Group Study**, Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study, J Clin Oncol 24:587, 2006.
1577. **Reimnitz C**, **Brand E**, **Nieberg RK**, **Hacker NF**, Malignancy arising in endometriosis associated with unopposed estrogen replacement, Obstet Gynecol 71:444, 1988.
1578. **Heaps JM**, **Nieberg RK**, **Berek JS**, Malignant neoplasms arising in endometriosis, Obstet Gynecol 75:1023, 1990.
1579. **Duun S**, **Roed-Petersen K**, **Michelsen JW**, Endometrioid carcinoma arising from endometriosis of the sigmoid colon during estrogenic treatment, Acta Obstet Gynecol Scand 72:676, 1993.
1580. **Namnoum AB**, **Hickman TN**, **Goodman SB**, **Gehlbach DL**, **Rock JA**, Incidence of symptom recurrence after hysterectomy for endometriosis, Fertil Steril 64:898, 1995.
1581. **Gucer F**, **Pieber D**, **Arikan MG**, Malignancy arising in extraovarian endometriosis during estrogen stimulation, Eur J Gynaecol Oncol 19:39, 1998.
1582. **Leiserowitz GS**, **Gumbs JL**, **Oi R**, **Dalrymple JL**, **Smith LH**, **Ryu J**, **Scudder S**, **Russell AH**, Endometriosis-related malignancies, Int J Gynecol Cancer 13:466, 2003.
1583. **Spicer D**, **Pike MC**, **Henderson BE**, The question of estrogen replacement therapy in patients with a prior

diagnosis of breast cancer, Oncology 4:49, 1990.
1584. **Stoll W**, Phytotherapy influences atrophic vaginal epithelium, Therapeutikon 1:23, 1987.
1585. **Powles TJ**, **Hickish T**, **Casey S**, **O'Brien M**, Hormone replacement after breast cancer, Lancet 342:60, 1993.
1586. **Wile AG**, **Opfell RW**, **Margileth DA**, Hormone replacement therapy in previously treated breast cancer patients, Am J Surg 165:372, 1993.
1587. **DiSaia PJ**, **Odicino F**, **Grosen EA**, **Cowan B**, **Pecorelli S**, **Wile AG**, Hormone replacement therapy in breast cancer (letter), Lancet 342:1232, 1993.
1588. **DiSaia PJ**, **Grosen EA**, **Kurosaki T**, **Gildea M**, **Cowan B**, **Anton-Culver H**, Hormone replacement therapy in breast cancer survivors: a cohort study, Am J Obstet Gynecol 174:1494, 1996.
1589. **Vassilopoulou-Sellin R**, **Theriault R**, **Klein MJ**, Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer, Gynecol Oncol 65:89, 1997.
1590. **Vassilopoulou-Sellin R**, **Asmar L**, **Hortobagyi GN**, **Klein MJ**, **McNeese M**, **Singletary SE**, **Theriault RL**, Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively, J Clin Oncol 17:1482, 1999.
1591. **Decker DA**, **Pettinga JE**, **Cox TC**, **Burdakin JH**, **Jaiyesimi IA**, **Benitez PR**, Hormone replacement therapy in breast cancer survivors, Breast J 3:63, 1997.
1592. **Dew J**, **Eden JA**, **Beller E**, **Magarey C**, **Schwartz P**, **Crea P**, **Wren BG**, A cohort study of hormone replacement therapy given to women previously treated for breast cancer, Climacteric 1:137, 1998.
1593. **Ursic-Vrscaj M**, **Bebar S**, A case-control study of hormone replacement therapy after primary surgical breast cancer treatment, Eur J Surg Oncol 25:146, 1999.
1594. **Guidozzi F**, Estrogen replacement therapy in breast cancer survivors, Int J Gynaecol Obstet 69:101, 2000.
1595. **DiSaia PJ**, **Brewster WR**, **Ziogas A**, **Anton-Culver H**, Breast cancer survival and hormone replacement therapy: a cohort analysis, Am J Clin Oncol 23:541, 2000.
1596. **Marttunen MB**, **Hietanen P**, **Pyrhönen S**, **Tiitinen A**, **Ylikorkala O**, A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy, Maturitas 39:217, 2001.
1597. **Peters GN**, **Fodera T**, **Sabol J**, **Jones S**, **Euhus D**, Estrogen replacement therapy after breast cancer: a 12-year follow-up, Ann Surg Oncol 8:828, 2001.
1598. **Beckmann MW**, **Jap D**, **Djahansouzi S**, **Nestle-Krämling C**, **Kuschel B**, **Dall P**, **Brumm C**, **Bender HG**, Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates, Oncology 60:199, 2001.
1599. **Puthugramam K**, **Gambrell RD Jr**, Estrogen replacement therapy in patients with early breast cancer, Am J Obstet Gynecol 187:289, 2002.
1600. **Decker DA**, **Pettinga JE**, **VanderVelde N**, **Huang RR**, **Kestin L**, **Burdakin JH**, Estrogen replacement therapy in breast cancer survivors: a matched-controlled series, Menopause 10:277, 2003.
1601. **O'Meara ES**, **Rossing MA**, **Daling JR**, **Elmore JG**, **Barlow WE**, **Weiss NS**, Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality, J Natl Cancer Inst 93:754, 2001.
1602. **Vassilopoulou-Sellin R**, **Theriault RL**, Randomized prospective trial of estrogen replacement therapy in women with a history of breast cancer, J Natl Cancer Inst 16:153, 1994.
1603. **Vassilopoulou-Sellin R**, **Cohen DS**, **Hortobagyi GN**, **Klein MJ**, **McNeese M**, **Singletary SE**, **Smith TL**, **Theriault RL**, Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study, Cancer 95:1817, 2002.
1604. **Figueiredo JC**, **Bernstein L**, **Capanu M**, **Malone KE**, **Lynch CF**, **Anton-Culver H**, **Stovall M**, **Bertelsen L**, **Haile RW**, **Bernstein JL**, Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group, J Clin Oncol 26:1411, 2008.
1605. **Holmberg L**, **Anderson H**; for the **HABITS steering and data monitoring committees**, HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomized comparison: trial stopped, Lancet 363:453, 2004.
1606. **Holmberg L**, **Iversen O-E**, **Rudenstam CM**, **Hammar M**, **Kumpulainen E**, **Jaskiewicz J**, **Jassem J**,

Dobaczewska D, **Fjosne HE**, **Peralta O**, **Arriagada R**, **Holmqvist M**, **Maenpa J**; on behalf of the **HABITS Study Group**, Increased risk of recurrence after hormone replacement therapy in breast cancer survivors, J Natl Cancer Inst 100:475, 2008.

1607. **von Schoultz E**, **Rutqvist LE**; **Stockholm Breast Cancer Study Group**, Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial, J Natl Cancer Inst 97:533, 2005.
1608. **Samaras K**, **Kelly RP**, **Hayward CS**, **Campbell LV**, **Sullivan D**, Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes, Diabetes Care 22:1401, 1999.
1609. **Cornu C**, **Mercier C**, **French P**, **Bully C**, **Pugeat M**, **Cousin P**, **Rious JP**, **Bajart L**, **Orgiazzi J**, **Pommet-Nicot C**, **Darsy P**, **Boissel JP**, **Berthezene F**, Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial, Maturitas 37:95, 2000.
1610. **Darko DA**, **Dornhorst A**, **Kennedy G**, **Mandeno RC**, **Seed M**, Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy, Diabetes Res Clin Pract 54:157, 2001.
1611. **Ferrara A**, **Liu JY**, **Karter AJ**, **Selby JV**, **Ackerson LM**, Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes, Diabetes Care 24:1144, 2001.
1612. **Fenkci S**, **Fenkci V**, **Yilmazer M**, **Serteser M**, **Koken T**, Effects of short-term transdermal hormone replacement therapy on glycaemic control, lipid metabolism, C-reactive protein and proteinuria in postmenopausal women with type 2 diabetes or hypertension, Hum Reprod 18:866, 2003.
1613. **Ferrara A**, **Quesenberry CP**, **Karter AJ**, **Njoroge CW**, **Jacobson AS**, **Selby JV**; **Northern California Kaiser Permanente Diabetes Registry,** Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995–1998, Circulation 107:43, 2003.
1614. **Cagnacci A**, **Paoletti AM**, **Zanni A**, **Arangino S**, **Ibba G**, **Orru M**, **Melis GB**, **Volpe A**, Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women, J Clin Endocrinol Metab 87:4117, 2002.
1615. **Cucinelli F**, **Soranna L**, **Romualdi D**, **Muzj G**, **Mancuso S**, **Lanzone A**, The effect of raloxifene on glyco-insulinemic homeostasis in healthy postmenopausal women: a randomized placebo-controlled study, J Clin Endocrinol Metab 87:4186, 2002.
1616. **Crippin JS**, **Jorgensen RA**, **Dickson ER**, **Lindor KD**, Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment, Am J Gastroenterol 89:47, 1994.
1617. **Menon KV**, **Angulo P**, **Boe GM**, **Landor KD**, Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis, Am J Gastroenterol 98:889, 2003.
1618. **Ormarsdóttir S**, **Mallmin H**, **Naessén T**, **Petrén-Mallmin M**, **Broomé U**, **Hultcrantz R**, **Lööf L**, An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis, J Intern Med 256:63, 2004.
1619. **Codes L**, **Asselah T**, **Cazals-Hatem D**, **Tubach F**, **Vidaud D**, **Paraná R**, **Bedossa P**, **Valla D**, **Marcellin P**, Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy, Gut 56:390, 2007.
1620. **Di Martino V**, **Lebray P**, **Myers RP**, **Pannier E**, **Paradis V**, **Charlotte F**, **Moussalli J**, **Thabut D**, **Buffet C**, **Poynard T**, Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure, Hepatology 40:1426, 2004.
1621. **Pietrzak B**, **Cyganek A**, **Jabiry-Zieniewicz Z**, **Bobrowska K**, **Durlik M**, **Oldakowska-Jedynak U**, **Binkowska M**, **Paczek L**, **Kaminski P**, Safety and efficacy of hormonal therapy in menopausal kidney-allograft recipients, Transplant Proc 38:184, 2006.
1622. **Frigo P**, **Eppel W**, **Asseryanis E**, **Sator M**, **Golaszewski T**, **Gruber D**, **Lang C**, **Huber J**, The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women—a vaginosonographic study, Maturitas 21:221, 1995.
1623. **Sener AB**, **Seçkin NC**, **Özmen S**, **Gökmen O**, **Dogu N**, **Ekici E**, The effects of hormone replacement therapy on uterine fibroids in postmenopausal women, Fertil Steril 65:354, 1996.

1624. **Schwartz LB**, **Lazer S**, **Mark M**, **Nachtigall LE**, **Horan C**, **Goldstein SR**, Does the use of postmenopausal hormone replacement therapy influence the size of uterine leiomyomata? A preliminary report, Menopause 3:38, 1996.
1625. **de Aloysio D**, **Altieri P**, **Penacchioni P**, **Salgarello M**, **Ventura V**, Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT, Maturitas 29:261, 1998.
1626. **Palomba S**, **Sena T**, **Noia R**, **Di Carlo C**, **Zullo F**, **Mastrantonio P**, Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas, Obstet Gynecol 98:1053, 2001.
1627. **Palomba S**, **Sammartino A**, **Di Carlo C**, **Affinito P**, **Zullo F**, **Nappi C**, Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women, Fertil Steril 76:38, 2001.
1628. **Palomba S**, **Orio F Jr**, **Morelli M**, **Russo T**, **Pellicano M**, **Zupi E**, **Lombardi G**, **Nappi C**, **Panici PL**, **Zullo F**, Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study, J Clin Endocrinol Metab 87:3603, 2002.
1629. **Siegle JC**, **Cartmell L**, Vulvar leiomyoma associated with estrogen/progestin therapy. A case report, J Reprod Med 40:147, 1995.
1630. **Schwartz SM**, **Weiss NS**, **Daling JR**, **Gammon MD**, **Liff JM**, **Watt J**, **Lynch CF**, **Newcomb PA**, **Armstrong BK**, **Thoompson WD**, Exogenous sex hormone use correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus, Cancer 77:717, 1996.
1631. **Cistulli PA**, **Barnes DJ**, **Grunstein RR**, **Sullivan CE**, Effect of short term hormone replacement in the treatment of obstructive sleep apnea in postmenopausal women, Thorax 46:699, 1994.
1632. **Polo-Kantola P**, **Rauhala E**, **Helenius H**, **Erkkola R**, **Irjala K**, **Polo O**, Breathing during sleep in menopause: a randomized, controlled, crossover trial with estrogen therapy, Obstet Gynecol 102:68, 2003.
1633. **Keefe DL**, **Watson R**, **Naftolin F**, Hormone replacement therapy may alleviate sleep apnea in menopausal women: a pilot study, Menopause 6:196, 1999.
1634. **Manber R**, **Kuo TF**, **Cataldo NA**, **Colrain IM**, The effects of hormone replacement therapy on sleep-disordered breathing in postmenopausal women: a pilot study, Sleep 26:163, 2003.
1635. **Wesström J**, **Ulfberg J**, **Nilsson S**, Sleep apnea and hormone replacement therapy: a pilot study and a literature review, Acta Obstet Gynecol Scand 84:54, 2005.
1636. **Lieberman D**, **Kopernik G**, **Porath A**, **Lazer S**, **Heimer D**, Sub-clinical worsening of bronchial asthma during estrogen replacement therapy in asthmatic post-menopausal women, Maturitas 21:153, 1995.
1637. **Hepburn MJ**, **Dooley DP**, **Morris MJ**, The effects of estrogen replacement therapy on airway function in postmenopausal, asthmatic women, Arch Intern Med 161:2717, 2001.
1638. **Kos-Kudla B**, **Ostrowsksa Z**, **Marek B**, **Ciesielska-Kopacz N**, **Kajdaniuk DK**, **Kudła M**, Effects of hormone replacement therapy on endocrine and spirometric parameters in asthmatic postmenopausal women, Gynecol Endocrinol 15:304, 2001.
1639. **Troisi RJ**, **Speizer FE**, **Willett WC**, **Trichopoulos D**, **Rosner B**, Menopause, postmenopausal estrogen preparations and the risk of adult-onset asthma, Am J Respir Crit Care Med 152:1183, 1995.
1640. **Romieu I**, **Fabre A**, **Fournier A**, **Kauffmann F**, **Varraso R**, **Mesrine S**, **Leynaert B**, **Clavel-Chapelon F**, Postmenopausal hormone therapy and asthma onset in the E3N cohort, Thorax 65(4):292, 2010.
1641. **Barr RG**, **Wentowski CC**, **Grodstein F**, **Somers SC**, **Stampfer MJ**, **Schwartz J**, **Speizer FE**, **Camargo CA Jr**, Prospective study of postmenopausal hormone use and newly diagnosed asthma and chronic obstructive pulmonary disease, Arch Intern Med 164:379, 2004.
1642. **Shumaker SA**, **Legault C**, **Kuller L**, **Rapp SR**, **Thal L**, **Lane DS**, **Fillit H**, **Stefanick ML**, **Hendrix SL**, **Lewis CE**, **Masaki K**, **Coker LH**; **Women's Health Initiative Memory Study**, Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study, JAMA 291:2947, 2004.
1643. **Steiger MJ**, **Quinn NP**, Hormone replacement therapy induced chorea, Br Med J 302:762, 1991.
1644. **Thomas JM**, Hormone-replacement therapy and pulmonary leiomyomatosis (Letter), N Engl J Med 327:1956, 1992.
1645. **Wetterberg L**, **Olsson MB**, **Alm-Agvald I**, Estrogen treatment caused acute attacks of porphyria,

Lakartidningen 92:2197, 1995.
1646. **Gurwood AS**, **Gurwood I**, **Gubman DT**, **Brzezicki LJ**, Idiosyncratic ocular symptoms associated with the estradiol transdermal estrogen replacement patch system, Optom Vis Sci 72:29, 1995.
1647. **Strachan D**, Sudden sensorineural deafness and hormone replacement therapy, J Laryngol Otol 110:1148, 1996.
1648. **Sharma R**, **Pickering J**, **McCormack WM**, Trichomoniasis in a postmenopausal women cured after discontinuation of estrogen replacement therapy, Sex Trans Dis 2:543, 1997.
1649. **Sartore A**, **Grimaldi E**, **Guaschino S**, The treatment of Sjögren's syndrome with tibolone: a case report, Am J Obstet Gynecol 189:894, 2003.
1650. **Vandenbroucke JP**, **Witteman JCM**, **Valkenburg HA**, **Boersma JW**, **Cats A**, **Festen JJM**, **Hartman AP**, **Huber-Bruning O**, **Rasker JJ**, **Weber J**, Noncontraceptive hormones and rheumatoid arthritis in perimenopausal and postmenopausal women, JAMA 255:1299, 1986.
1651. **Spector TD**, **Pregnnan P**, **Harris P**, **Studd JWW**, **Silman AJ**, Does estrogen replacement therapy protect against rheumatoid arthritis?, J Rheumatol 18:1473, 1991.
1652. **Koepsell TD**, **Dugowson CE**, **Nelson JL**, **Voigt LF**, **Daling JR**, Non-contraceptive hormones and the risk of rheumatoid arthritis in menopausal women, Int J Epidemiol 23:1248, 1994.
1653. **Doran MF**, **Crowson CS**, **O'Fallon WM**, **Gabriel SE**, The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study, J Rheumatol 31:207, 2004.
1654. **Hall GM**, **Daniels M**, **Huskisson ES**, **Spector TD**, A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis, Ann Rheum Dis 53:112, 1994.
1655. **Sanchez-Guerro J**, **Liang MH**, **Karlson EW**, **Hunter DJ**, **Colditz GA**, Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus, Ann Intern Med 122:430, 1995.
1656. **Arden NK**, **Lloyd ME**, **Spector TD**, **Hughes GRV**, Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE), Lupus 3:11, 1994.
1657. **Formiga F**, **Moga I**, **Nolla JM**, **Pac M**, **Mitjavila F**, **Roig-Escofet D**, Loss of bone mineral density in premenopausal women with systemic lupus erythematosus, Ann Rheum Dis 54:274, 1995.
1658. **Fernández M**, **Calvo-Alén J**, **Bertoli AM**, **Bastian HM**, **Fessler BJ**, **McGwin G Jr**, **Reveille JD**, **Vilá LM**, **Alarcón GS**, Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women, J Clin Rheumatol 13:261, 2007.
1659. **Sowers MF**, **Hochberg M**, **Crabbe JP**, **Muhich A**, **Crutchfield M**, **Updike S**, Association of bone mineral density and sex hormone levels with osteoarthritis of the hand and knee in premenopausal women, Am J Epidemiol 143:38, 1996.
1660. **Ham KD**, **Loeser RF**, **Lindgren BR**, **Carlson CS**, Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys, Arthritis Rheum 46:1956, 2002.
1661. **Nevitt MC**, **Cummings SR**, **Lane NE**, **Hochberg MC**, **Scott JC**, **Pressman AR**, **Genant HK**, **Cauley JA**; for the **Study of Osteoporotic Fractures Research Group**, Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women, Arch Intern Med 156:2073, 1996.
1662. **Baum M**, **Budzar AU**, **Cuzick J**, **Forbes J**, **Houghton JH**, **Klijn JG**, **Sahmoud T**; **The ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group**, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet 359:2131, 2002.
1663. **Sowers MR**, **McConnell D**, **Jannausch M**, **Buyuktur AG**, **Hochberg MC**, **Jamadar DA**, Estradiol and its metabolites and their association with knee osteoarthritis, Arthritis Rheum 54:2481, 2006.
1664. **Volpe A**, **Lucenti V**, **Forabosco A**, **Boselli F**, **Latessa AM**, **Pozzo P**, **Petraglia F**, **Genazzani AR**, Oral discomfort and hormone replacement therapy in the post-menopause, Maturitas 13:1, 1991.
1665. **Norderyd OM**, **Grossi SG**, **Machtei EE**, **Zambon JJ**, **Hausmann E**, **Dunford RG**, **Genco RJ**, Periodontal status of women taking postmenopausal estrogen supplementation, J Periodontol 64:957, 1993.
1666. **Grossi SG**, Effect of estrogen supplementation on periodontal disease, Compend Contin Educ Dent Suppl 22:S30, 1998.

1667. **Daniell HW**, Postmenopausal tooth loss: contributions to edentulism by osteoporosis and cigarette smoking, Arch Intern Med 143:1678, 1983.
1668. **Krall EA**, **Dawson-Hughes B**, **Papas A**, **Garcia RI**, Tooth loss and skeletal bone density in healthy postmenopausal women, Osteoporos Int 4:104, 1994.
1669. **Paganini-Hill A**, The benefits of estrogen replacement therapy on oral health. The Leisure World Cohort, Arch Intern Med 155:2325, 1995.
1670. **Grodstein F**, **Colditz GA**, **Stampfer MJ**, Post-menopausal hormone use and tooth loss: a prospective study, JAMA 127:372, 1996.
1671. **Harris TM**, The pharmacological treatment of voice disorders, Folia Phoniatr 44:143, 1992.
1672. **Lindholm P**, **Vilkman E**, **Raudaskoski T**, **Suvanto-Luukkonen E**, **Kauppila A**, The effect of postmenopause and postmenopausal HRT on measured voice values and vocal symptoms, Maturitas 28:47, 1997.
1673. **Schneider B**, **van Trotsenburg M**, **Hanke G**, **Bigenzahn W**, **Huber J**, Voice impairment and menopause, Menopause 11:151, 2004.
1674. **Firat Y**, **Engin-Ustun Y**, **Kizilay A**, **Ustun Y**, **Akarcary M**, **Selimoglu E**, **Kafkasli A**, Effect of intranasal estrogen on voice quality, J Voice 23:716, 2009.
1675. **Caruso S**, **Roccasalva L**, **Sapienza G**, **Zappalá M**, **Nuciforo G**, **Biondi S**, Laryngeal cytological aspects in women with surgically induced menopause who were treated with transdermal estrogen replacement therapy, Fertil Steril 74:1073, 2000.
1676. **Metka M**, **Enzelsberger H**, **Knogler W**, **Schurz B**, **Aichmair H**, Ophthalmic complaints as a climacteric symptom, Maturitas 14:3, 1991.
1677. **Altintas O**, **Caglar Y**, **Yüksel N**, **Demirci A**, **Karabas L**, The effects of menopause and hormone replacement therapy on quality and quantity of tear, intraocular pressure and ocular blood flow, Ophthalmologica 218:120, 2004.
1678. **Kramer P**, **Lubkin V**, **Potter W**, **Jacobs M**, **Labay G**, **Silverman P**, Cyclic changes in conjunctival smears from menstruating females, Ophthalmology 97:303, 1990.
1679. **Moss SE**, **Klein R**, **Klein BE**, Prevalence and risk factors for dry eye syndrome, Arch Ophthalmol 118:1264, 2000.
1680. **Sator MO**, **Joura EA**, **Golaszewski T**, **Gruber D**, **Frigo P**, **Metka M**, **Hommer A**, **Huber JC**, Treatment of menopausal keratoconjunctivitis sicca with topical oestradiol, Br J Obstet Gynaecol 105:100, 1998.
1681. **Schaumberg DA**, **Buring JE**, **Sullivan DA**, **Dana MR**, Hormone replacement therapy and dry eye syndrome, JAMA 286:2114, 2001.
1682. **Uncu G**, **Avci R**, **Uncu Y**, **Kaymaz C**, **Develioglu O**, The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity, Gynecol Endocrinol 22:501, 2006.
1683. **Erdem U**, **Ozdegirmenci O**, **Sobaci E**, **Sobaci G**, **Göktolga U**, **Dagli S**, Dry eye in post-menopausal women using hormone replacement therapy, Maturitas 56:257, 2007.
1684. **Klein BEK**, **Klein R**, **Ritter LL**, Is there evidence of an estrogen effect on age-related lens opacities?, Arch Ophthalmol 112:85, 1994.
1685. **Benitez del Castillo JM**, **del Rio T**, **Garcia-Sanchez J**, Effects of estrogen use on lens transmittance in postmenopausal women, Ophthalmology 104:970, 1997.
1686. **Cumming RG**, **Mitchell P**, Hormone replacement therapy, reproductive factors, and cataracts. The Blue Mountains Eye Study, Am J Epidemiol 145:242, 1997.
1687. **Worzala K**, **Hiller R**, **Sperduto R**, **Mutalik K**, **Murabito JM**, **Moskowitz M**, **D'Agostino RB**, **Wilson PW**, Postmenopausal estrogen use, type of menopause, and lens opacities: the Framingham studies, Arch Intern Med 161:1448, 2001.
1688. **Aina FO**, **Smeeth L**, **Hubbard R**, **Hurt LS**, **Fletcher AE**, Hormone replacement therapy and cataract: a population-based case-control study, Eye 20:417, 2006.
1689. **Sator MO**, **Joura EA**, **Frigo P**, **Kurz C**, **Metka M**, **Hommer A**, **Huber JC**, Hormone replacement therapy and intraocular pressure, Maturitas 28:55, 1997.
1690. **Sator MO**, **Akramian J**, **Joura EA**, **Nessmann A**, **Wedrich A**, **Gruber D**, **Metka M**, **Huber JC**,

Reduction of intraocular pressure in a glaucoma patient undergoing hormone replacement therapy, Maturitas 29:93, 1998.
1691. **Tint NL**, **Alexander P**, **Tint KM**, **Vasileiadis GT**, **Yeung AM**, **Azuara-Blanco A**, Hormone therapy and intraocular pressure in nonglaucomatous eyes, Menopause 17:157, 2010.
1692. **Pasqualie LR**, **Rosner BA**, **Hankinson SE**, **Kang JH**, Attributes of female reproductive aging and their relation to primary open-angle glaucoma: a prospective study, J Glaucoma 16:598, 2007.
1693. **Eye Disease Case-Control Study Group**, Risk factors for neovascular age-related macular degeneration, Arch Ophthalmol 110:1702, 1992.
1694. **Klein R**, **Klein BEK**, **Jensen SC**, **Mares-Perlman JA**, **Cruickshanks KF**, **Palta M**, Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III, Ophthalmology 106:1056, 1999.
1695. **Snow KK**, **Cote J**, **Yang W**, **Davis NJ**, **Seddon JM**, Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women, Am J Ophthalmol 134:842, 2002.
1696. **Abramov Y**, **Borik S**, **Yahalom C**, **Fatum M**, **Avgil G**, **Brzezinski A**, **Banin E**, The effect of hormone therapy on the risk for age-related maculopathy in postmenopausal women, Menopause 11:62, 2004.
1697. **Seitzman RL**, **Mangione C**, **Ensrud KE**, **Cauley JA**, **Stone KL**, **Cummings SR**, **Hochberg MC**, **Hillier TA**, **Yu F**, **Coleman AL**, Postmenopausal hormone therapy and age-related maculopathy in older women, Ophthalmic Epidemiol 15:308, 2008.
1698. **Clark K**, **Sowers MR**, **Wallace RB**, **Jannausch ML**, **Lemke J**, **Anderson CV**, Age-related hearing loss and bone mass in a population of rural women aged 60 to 85 years, Ann Epidemiol 5:8, 1995.
1699. **Collin RA**, **Kalay E**, **Tariq M**, **Peters T**, **van der Zwaag B**, **Venselaar H**, **Oostrik J**, **Lee K**, **Ahmed ZM**, **Caylan R**, **Li Y**, **Spierenburg HA**, **Eyupoglu E**, **Heister A**, **Riazuddin S**, **Bahat E**, **Ansar M**, **Arsian S**, **Wollnik B**, **Brunner HG**, **Cremers CW**, **Karaguzel A**, **Ahmad W**, **Cremers FP**, **Vriend G**, **Friedman TB**, **Riazuddin S**, **Leal SM**, **Kremer H**, Mutations of ESRRB encoding estrogen-related receptor beta cause autosomal-recessive nonsyndromic hearing impairment DFNB35, Am J Hum Genet 82:125, 2008.
1700. **Simonoska R**, **Stenberg AE**, **Duan M**, **Yakimchuk K**, **Fridberger A**, **Sahlin L**, **Gustafsson J-A**, **Hultcrantz M**, Inner ear pathology and loss of hearing in estrogen receptor-beta deficient mice, J Endocrinol 201:397, 2009.
1701. **Kilicdag EB**, **Yavuz H**, **Bagis T**, **Tarim E**, **Erkan AN**, **Kazanci F**, Effects of estrogen therapy on hearing in postmenopausal women, Am J Obstet Gynecol 190:77, 2004.
1702. **Guimaraes P**, **Frisina ST**, **Mapes F**, **Tadros SF**, **Frisina DR**, **Frisina RD**, Progestin negatively affects hearing in aged women, Proc Natl Acad Sci U S A 103:14246, 2006.
1703. **Curhan SG**, **Eliassen AH**, **Eavey RD**, **Wang M**, **Lin BM**, **Curhan GC**, Menopause and postmenopausal hormone therapy and risk of hearing loss, Menopause 24(9):1049, 2017.
1704. **Ness J**, **Aronow WS**, **Beck G**, Menopausal symptoms after cessation of hormone replacement therapy, Maturitas 53:356, 2006.
1705. **Lindh-Åstrand L**, **Brynhildsen J**, **Hoffman M**, **Hammar M**, Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study, Menopause 16:1213, 2009.
1706. **Haimov-Kochman R**, **Barak-Glantz E**, **Arbel R**, **Leefsma M**, **Brzezinski A**, **Milwidsky A**, **Hochner-Ceinikier D**, Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study, Menopause 13:370, 2006.
1707. **Asian E**, **Bagis T**, **Kilicdag EB**, **Tarim E**, **Erkanli S**, **Kuscu E**, How best to discontinue postmenopausal hormone therapy: immediate or tapered?, Maturitas 56:78, 2007.
1708. **Lindh-Åstrand L**, **Bixo M**, **Hirschberg AL**, **Sundström-Poromaa I**, **Hammar M**, A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms, Menopause 17:72, 2010.
1709. **Cunha EP**, **Azevedo LH**, **Pompei LM**, **Strufaldi R**, **Steiner ML**, **Ferreira JA**, **Peixoto S**, **Fernandes CE**, Effect of abrupt discontinuation versus gradual dose reduction of postmenopausal hormone therapy on hot flushes, Climacteric 13(4):362, 2010.
1710. **Quigley MET**, **Martin PL**, **Burnier AM**, **Brooks P**, Estrogen therapy arrests bone loss in elderly women,

Am J Obstet Gynecol 156:1516, 1987.
1711. **Cauley JA**, **Seeley DG**, **Enbsrud K**, **Ettinger B**, **Black D**, **Cummings SR**; for the **Study of Osteoporotic Fractures Research Group**, Estrogen replacement therapy and fractures in older women, Ann Intern Med 122:9, 1995.
1712. **Schneider DL**, **Barrett-Connor EL**, **Morton DJ**, Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study, JAMA 277:543, 1997.
1713. **Kiel DP**, **Felson DT**, **Anderson JJ**, **Wilson PWF**, **Moskowitz MA**, Hip fracture and the use of estrogen in postmenopausal women: the Framingham Study, N Engl J Med 317:1169, 1987.
1714. **Schubert W**, **Cullberg G**, **Edgar B**, **Hedner T**, Inhibition of 17b-estradiol metabolism by grapefruit juice in ovariectomized women, Maturitas 20:155, 1995.
1715. **Weber A**, **Jägger R**, **Börmer A**, **Lomger G**, **Vollanth R**, **Matthey K**, **Balogh A**, Can grapefruit juice influence ethinylestradiol bioavailability?, Contraception 63:41, 1996.
1716. **Dorgan JF**, **Reichman ME**, **Judd JT**, **Brown C**, **Longcope C**, **Schatzkin A**, **Campbell WS**, **Franz C**, **Kahle L**, **Taylor PR**, The relation of reported alcohol ingestion to plasma levels of estrogens and androgens in premenopausal women, Cancer Causes Control 5:53, 1994.
1717. **Muti P**, **Trevisan M**, **Micheli A**, **Krogh V**, **Bolelli G**, **Sciajno R**, **Schünemann HJ**, **Berrino F**, Alcohol consumption and total estradiol in premenopausal women, Cancer Epidemiol Biomark Prev 7:189, 1998.
1718. **Chen KL**, **Madak-Erdogan Z**, Estrogen and microbiota crosstalk: should we pay attention? Trends Endocrinol Metab 27(11):752, 2016.
1719. National Osteoporosis Foundation, http://www.nof.org/professionals/
1720. **Lees B**, **Molleson T**, **Arnett TR**, **Stevenson JC**, Differences in proximal femur bone density over two centuries, Lancet 341:673, 1993.
1721. **Eaton SB**, **Nelson DA**, Calcium in evolutionary perspective, Am J Clin Nutr 54:281S, 1991.
1722. **Cooper C**, **Campion G**, **Melton LJ III**, Hip fractures in the elderly: a world-wide projection, Osteoporos Int 2:285, 1992.
1723. **Riis BJ**, **Hansen MA**, **Jensen AM**, **Overgaard K**, **Christiansen C**, Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study, Bone 19:9, 1996.
1724. **Theitz G**, **Buch B**, **Rizzoli R**, **Slosman D**, **Clavien H**, **Sizonko PC**, **Bonjour JPH**, Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects, J Clin Endocrinol Metab 75:1060, 1992.
1725. **Matkovic V**, **Jelic T**, **Wardlaw GM**, **Ilich J**, **Goel PK**, **Wright JK**, **Andon MB**, **Smith KT**, **Heaney RP**, Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model, J Clin Invest 93:799, 1994.
1726. **Sabatier JP**, **Guaydier-Souquieres G**, **Laroche D**, **Benmalek A**, **Fournier L**, **Guillon-Metz F**, **Delavenne J**, **Denis AY**, Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10–24 years of age, Osteoporos Int 6:141, 1996.
1727. **Chevalley T**, **Bonjour JP**, **Ferrari S**, **Rizzoli R**, Deleterious effect of late menarche on distal tibia microstructure in healthy 20-year-old and premenopausal middle-aged women, J Bone Miner Res 24:144, 2009.
1728. **Csermely T**, **Halvax L**, **Vizer M**, **Drozgyik I**, **Tamás P**, **Göcze P**, **Szabó I**, **Jeges S**, **Szilágyi A**, Relationship between adolescent amenorrhea and climacteric osteoporosis, Maturitas 56:368, 2007.
1729. **Bonjour JP**, **Carrie AL**, **Ferrari S**, **Clavien H**, **Slosman D**, **Theintz G**, **Rizzoli R**, Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial, J Clin Invest 15:1287, 1997.
1730. **Bonjour JP**, **Chevalley T**, **Ammann P**, **Slosman D**, **Rizzoli R**, Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study, Lancet 358:1208, 2001.
1731. **Stear SJ**, **Prentice A**, **Jones SC**, **Cole TJ**, Effect of a calcium and exercise intervention on the bone mineral status of 16–18-y-old adolescent girls, Am J Clin Nutr 77:985, 2003.
1732. **Rozen GS**, **Rennert G**, **Dodiuk-Gad RP**, **Rennert HS**, **Ish-Shalom N**, **Diab G**, **Raz B**, **Ish-Shalom S**, Calcium supplementation provides an extended window of opportunity for bone mass accretion after menarche, Am J Clin Nutr 78:993, 2003.

1733. **Recker RR**, **Davies KM**, **Hinders SM**, **Heaney RP**, **Stegman MR**, **Kimmel DB**, Bone gain in young women, JAMA 268:2403, 1992.
1734. **Sirola J**, **Kröger H**, **Honkanen R**, **Jurvelin JS**, **Sandini L**, **Tuppurainen MT**, **Saarikoski S**, Factors affecting bone loss around menopause in women without HRT: a prospective study, Maturitas 45:159, 2003.
1735. **Ettinger B**, Prevention of osteoporosis: treatment of estradiol deficiency, Obstet Gynecol 72:125, 1988.
1736. **Lindsay R**, Prevention and treatment of osteoporosis, Lancet 341:801, 1993.
1737. **Manolagas SC**, Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis, Endocr Rev 21:115, 2000.
1738. **Manolagas SC**, **Kousteni S**, **Jilka RL**, Sex steroids and bone, Recent Prog Horm Res 57:385, 2002.
1739. **Pacifici R**, Cytokines, estrogen, and postmenopausal osteoporosis—the second decade, Endocrinology 130:2659, 1998.
1740. **Canalis E**, **Giustina A**, **Bilezikian JP**, Mechanisms of anabolic therapies for osteoporosis, N Engl J Med 357:905, 2007.
1741. **Hofbauer LC**, **Khosla S**, **Dunstan CR**, **Lacey DL**, **Boyle WJ**, **Riggs BL**, The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption, J Bone Miner Res 15:2, 2000.
1742. **Liel Y**, **Kraus S**, **Levy J**, **Shany S**, Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8), Endocrinology 130:2597, 1992.
1743. **Prince RL**, Counterpoint: estrogen effects on calcitropic hormones and calcium homeostasis, Endocr Rev 15:301, 1994.
1744. **Smith EP**, **Boyd J**, **Frank GR**, **Takahashi H**, **Cohen RM**, **Specker B**, **Williams TC**, **Lubahn DB**, **Korach KS**, Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man, N Engl J Med 331:1056, 1994.
1745. **Carani C**, **Qin K**, **Simoni M**, **Faustini-Fustini M**, **Serpente S**, **Boyd J**, **Korach KS**, **Simpson ER**, Effect of testosterone and estradiol in a man with aromatase deficiency, N Engl J Med 337:91, 1997.
1746. **Khosla S**, **Melton LJ III**, **Atkinson EJ**, **O'Fallon WM**, **Klee GG**, **Riggs BL**, Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen, J Clin Endocrinol Metab 83:2266, 1998.
1747. **Bilezikian JP**, **Morishima A**, **Bell J**, **Grumbach MM**, Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency, N Engl J Med 339:599, 1998.
1748. **Rochira V**, **Faustini-Fustini M**, **Balestrieri A**, **Carani C**, Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters, J Clin Endocrinol Metab 85:1841, 2000.
1749. **Ettinger B**, **Sidney S**, **Cummings SR**, **Libanati C**, **Bikle DD**, **Tekawa IS**, **Tolan K**, **Steiger P**, Racial differences in bone density between young adult black and white subjects persist after adjustment for anthropometric, lifestyle, and biochemical differences, J Clin Endocrinol Metab 82:429, 1997.
1750. **Nelson DA**, **Simpson PM**, **Johnson CC**, **Barondess DA**, **Kleerekopper M**, The accumulation of whole body skeletal mass in third- and fourth-grade children: effects of age, ethnicity, and body composition, Bone 20:73, 1997.
1751. **Hui SL**, **Dimeglio LA**, **Longcope C**, **Peacock M**, **McClintock R**, **Perkins AJ**, **Johnston CC Jr**, Difference in bone mass between black and white American children: attributable to body build, sex hormone levels, or bone turnover?, J Clin Endocrinol Metab 88:642, 2003.
1752. **Bryant RJ**, **Wastney ME**, **Martin BR**, **Wood O**, **McCabe GP**, **Morshidi M**, **Smith DL**, **Peacock M**, **Weaver CM**, Racial differences in bone turnover and calcium metabolism in adolescent females, J Clin Endocrinol Metab 88:1043, 2003.
1753. **Finkelstein JS**, **Lee MT**, **Sowers M**, **Ettinger B**, **Neer RM**, **Kelsey JL**, **Cauley JA**, **Huang M**, **Greendale GA**, Ethnic variation in bone density in premenopausal and early perimenopausal women: effects of anthropometric and lifestyle factors, J Clin Endocrinol Metab 87:3057, 2002.
1754. **Finkelstein JS**, **Brockwell SE**, **Mehta V**, **Greendale GA**, **Sowers MR**, **Ettinger B**, **Lo JC**, **Johnston JM**, **Cauley JA**, **Danielson ME**, **Neer RM**, Bone mineral density changes during the menopause transition in a multiethnic cohort of women, J Clin Endocrinol Metab 93:861, 2008.

1755. **Grisso JA**, **Kelsey JL**, **Strom BL**, **O'Brien LA**, **Maislin G**, **LaPann K**, **Samuelson L**, **Hoffman S**; the **Northeast Hip Fracture Study Group**, Risk factors for hip fracture in black women, N Engl J Med 330:1555, 1994.
1756. **Iki M**, **Kajita E**, **Dohi Y**, **Nishino H**, **Kusaka Y**, **Tsuchida C**, **Yamamoto K**, **Ishii Y**, Age, menopause, bone turnover markers and lumbar bone loss in healthy Japanese women, Maturitas 25:59, 1996.
1757. **Seeman E**, **Hopper JL**, **Bach LA**, **Cooper ME**, **Parkinson E**, **McKay J**, **Jerums G**, Reduced bone mass in daughters of women with osteoporosis, N Engl J Med 320:554, 1989.
1758. **Slemenda CW**, **Christian JC**, **Williams CJ**, **Norton JA**, **Johnston CC Jr**, Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction on heritability estimates, J Bone Miner Res 6:561, 1991.
1759. **Morrison NA**, **Qi JC**, **Tokita A**, **Kelly PJ**, **Crofts L**, **Nguyen TV**, **Sambrook PN**, **Eisman JA**, Prediction of bone density from vitamin D receptor alleles, Nature 367:284, 1994.
1760. **Ferrari S**, **Rizzoli R**, **Chevalley T**, **Slosman D**, **Eisman JA**, **Bonjour J-P**, Vitamin-D-receptor-gene polymorphisms and change in lumbar-spine bone mineral density, Lancet 345:423, 1995.
1761. **Uitterlinden AG**, **Burger H**, **Huang Q**, **Yue F**, **McGuigan FEA**, **Grant SFA**, **Hofman A**, **van Leeuwen JPTM**, **Pols HAP**, **Ralston SH**, Relation of alleles of the collagen type Ia1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women, N Engl J Med 338:1016, 1998.
1762. **Richards JB**, **Rivadeneira F**, **Inouye M**, **Pastinen TM**, **Soranzo N**, **Wilson SG**, **Andrew T**, **Falchi M**, **Gwilliam R**, **Ahmadi KR**, **Valdes AM**, **Arp P**, **Whittaker P**, **Verlaan DJ**, **Jhamai M**, **Kumanduri V**, **Moorhouse M**, **van Meurs JB**, **Hofman A**, **Pols HA**, **Hart D**, **Zhai G**, **Kato BS**, **Mullin BH**, **Zhang F**, **Deloukas P**, **Uitterlinden AG**, **Spector TD**, Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study, Lancet 371:1505, 2008.
1763. **Richelson LS**, **Wahner HW**, **Melton LJ III**, **Riggs BL**, Relative contributions of aging and estrogen deficiency to postmenopausal bone loss, N Engl J Med 311:1273, 1984.
1764. **Nilas L**, **Christiansen C**, Bone mass and its relationship to age and the menopause, J Clin Endocrinol Metab 65:697, 1987.
1765. **Alvioli LV**, Calcium and osteoporosis, Ann Rev Nutr 4:471, 1984.
1766. **Johnston CC Jr**, **Hui SL**, **Witt RM**, **Appledorn R**, **Baker RS**, **Longcope C**, Early menopausal changes in bone mass and sex steroids, J Clin Endocrinol Metab 61:905, 1985.
1767. **Riggs BL**, **Wahner HW**, **Melton LJ III**, **Richelson LS**, **Judd HL**, **Offord KP**, Rates of bone loss in the appendicular and axial skeletons of women, J Clin Invest 77:1487, 1986.
1768. **Riggs BL**, **Wahner HW**, **Dunn WL**, **Mazess RB**, **Offord KP**, **Melton LJ III**, Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis, J Clin Invest 67:328, 1981.
1769. **Baran D**, **Sorensen A**, **Grimes J**, **Lew R**, **Karellas A**, **Johnson B**, **Roche J**, Dietary modification with dairy products for preventing vertebral bone loss in premenopausal women: a three-year prospective study, J Clin Endocrinol Metab 70:264, 1990.
1770. **Elders PJM**, **Lips P**, **Netelenbos C**, **Van Ginkel FC**, **Khoe E**, **Van Der Vijgh WJF**, **Van Der Stelt PF**, Long-term effect of calcium supplementation on bone loss in perimenopausal women, J Bone Miner Res 9:963, 1994.
1771. **Gambacciani M**, **Spinetti A**, **Taponeco F**, **Cappagli B**, **Maffei S**, **Manetti P**, **Piaggesi L**, **Fioretti P**, Bone loss in perimenopausal women: a longitudinal study, Maturitas 18:191, 1994.
1772. **Garton M**, **Martin J**, **New S**, **Lee S**, **Loveridge N**, **Milne J**, **Reid D**, **Reid I**, **Robins S**, Bone mass and metabolism in women aged 45–55, Clin Endocrinol 44:536, 1996.
1773. **Guthrie JR**, **Ebeling PR**, **Hopper JL**, **Barrett-Connor E**, **Dennerstein L**, **Dudley EC**, **Burger HG**, **Wark JD**, A prospective study of bone loss in menopausal Australian-born women, Osteoporos Int 8:282, 1998.
1774. **Sowers M**, **Crutchfield M**, **Bandekar R**, **Randolph JF**, **Shapiro B**, **Schork MA**, **Jannausch M**, Bone mineral density and its change in pre- and perimenopausal white women: the Michigan Bone Health Study, J Bone Miner Res 13:1134, 1998.

1775. **Waller K**, **Reim J**, **Fenster L**, **Swan SH**, **Brumback B**, **Windham GC**, **Lasley B**, **Ettinger B**, **Marcus R**, Bone mass and subtle abnormalities in ovulatory function in healthy women, J Clin Endocrinol Metab 81:663, 1996.
1776. **De Souza MJ**, **Miller BE**, **Sequenzia LC**, **Luciano AA**, **Ulreich S**, **Stier S**, **Prestwood K**, **Lasley BL**, Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners, J Clin Endocrinol Metab 82:2867, 1997.
1777. **NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy**, Osteoporosis prevention, diagnosis and therapy, JAMA 285:785, 2001.
1778. **Cummings SR**, **Melton LJ III**, Epidemiology and outcomes of osteoporotic fractures, Lancet 359:1761, 2002.
1779. **Jacobs RM**, **Himes JH**, **Pihlstrom BL**, Associations of periodontal disease with femoral bone mineral density and estrogen replacement therapy: cross-sectional evaluation of US adults from NHANES III, J Clin Periodontol 27:778, 2000.
1780. **Paganini-Hill A**, Estrogen replacement therapy—something to smile about, Compend Contin Educ Dent Suppl 22:S4, 1998.
1781. **Krall EA**, **Dawson-Hughes B**, **Hannan MT**, **Wilson PW**, **Kiel DP**, Postmenopausal estrogen replacement and tooth retention, Am J Med 102:536, 1997.
1782. **Grodstein F**, **Colditz GA**, **Stampfer MJ**, Tooth loss and hormone use in postmenopausal women, Compend Contin Educ Dent Suppl 22:S9, 1998.
1783. **Lindsay R**, **Silverman SL**, **Cooper C**, **Hanley DA**, **Barton I**, **Broy SB**, **Licata A**, **Benhamou L**, **Geusens P**, **Flowers K**, **Stracke H**, **Seeman E**, Risk of new vertebral fracture in the year following a fracture, JAMA 285:320, 2001.
1784. **Black DM**, **Arden NK**, **Palermo L**, **Pearson J**, **Cummings SR**, Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group, J Bone Miner Res 14:821, 1999.
1785. **Melton LJ III**, **Atkinson EJ**, **Cooper C**, **O'Fallon WM**, **Riggs BL**, Vertebral fractures predict subsequent fractures, Osteoporos Int 10:214, 1999.
1786. **Bliue D**, **Nguyen ND**, **Milch VE**, **Nguyen TV**, **Eisman JA**, **Center JR**, Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women, JAMA 301:513, 2009.
1787. **Silverman SL**, **Shen W**, **Minshall ME**, **Xie S**, **Moses KH**, Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study, J Rheumatol 34:140, 2007.
1788. **Whooley MA**, **Kip KE**, **Cauley JA**, **Ensrud KE**, **Nevitt MC**, **Browner WS**, Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group, Arch Intern Med 159:484, 1999.
1789. **Robbins J**, **Hirsch C**, **Whitmer R**, **Cauley J**, **Harris T**, The association of bone mineral density and depression in an older population, J Am Geriatr Soc 49:732, 2001.
1790. **Milliken LA**, **Wilhelmy J**, **Martin CJ**, **Finkenthal N**, **Cuyssler E**, **Metcalfe L**, **Guido TA**, **Going SB**, **Lohman TG**, Depressive symptoms and changes in body weight exert independent and site-specific effects on bone in postmenopausal women exercising for 1 year, J Gerontol A Biol Sci Med Sci 61:488, 2006.
1791. **Kahl KG**, **Greggersen W**, **Rudolf S**, **Stoeckelhuber BM**, **Bergmann-Koester CU**, **Dibbelt L**, **Schweiger U**, Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder, Psychosom Med 68:669, 2006.
1792. **Yirmiya R**, **Goshen I**, **Bajayo A**, **Kreisel T**, **Feldman S**, **Tam J**, **Trembovler V**, **Csernus V**, **Shohami E**, **Bab I**, Depression induces bone loss through stimulation of the sympathetic nervous system, Proc Natl Acad Sci U S A 103:16876, 2006.
1793. **Richards JB**, **Papaioannou A**, **Adachi JD**, **Joseph L**, **Whitson HE**, **Prior JC**, **Goltzman D**; for the **Canadian Multicentre Osteoporosis Study (CaMos) Research Group**, Effect of selective serotonin reuptake inhibitors on the risk of fracture, Arch Intern Med 167:188, 2007.
1794. **Warden SJ**, **Robling AG**, **Sanders MS**, **Bliziotes MM**, **Turner CH**, Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth, Endocrinology 146:685, 2005.

1795. **Haney EM**, **Chan BK**, **Diem SJ**, **Ensrud KE**, **Cauley JA**, **Barrett-Connor E**, **Orwoll E**, **Bliziotes MM**; for the **Osteoporotic Fractures in Men Study Group**, Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men, Arch Intern Med 167:1246, 2007.
1796. **Diem SJ**, **Blackwell TL**, **Stone KL**, **Yaffe K**, **Haney EM**, **Bliziotes MM**, **Ensrud KE**, Use of antidepressants and rates of hip bone loss in older women: the Study of Osteoporotic Fractures, Arch Intern Med 167:1240, 2007.
1797. **Johnston CC Jr**, **Slemenda CW**, **Melton LJ III**, Clinical use of bone densitometry, N Engl J Med 324:1105, 1991.
1798. **Cummings SR**, **Black DM**, **Nevitt MC**, **Browner W**, **Cauley J**, **Ensrud K**, **Genant KH**, **Palermo L**, **Scott J**, **Vogt TM**, Bone density at various sites for prediction of hip fractures, Lancet 341:72, 1993.
1799. **Johnston CC Jr**, **Slemenda CW**, Identification of patients with low bone mass by single photon absorptiometry and single-energy X-ray absorptiometry, Am J Med 98(Suppl 2A):37S, 1995.
1800. **Rubin SM**, **Cummings SR**, Results of bone densitometry affect women's decisions about taking measures to prevent fractures, Ann Intern Med 116:990, 1992.
1801. **Silverman SL**, **Greenwald M**, **Klein RA**, **Drinkwater BL**, Effect of bone density information on decisions about hormone replacement therapy: a randomized trial, Obstet Gynecol 89:321, 1997.
1802. **Miller PD**, **Bonnick SL**, **Rosen CJ**, Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population, Calcif Tissue Int 58:207, 1996.
1803. **Gregg EW**, **Kriska AM**, **Salamone LM**, **Roberts MM**, **Anderson SJ**, **Ferrell RE**, **Kuller LH**, **Cauley JA**, The epidemiology of quantitative ultrasound: a review of the relationships with bone mass, osteoporosis and fracture risk, Osteoporos Int 7:89, 1997.
1804. **Hans D**, **Dargent-Molina P**, **Schott AM**, **Sebert JL**, **Cormier C**, **Kotzkik PO**, **Delmas PD**, **Pouilles JM**, **Breart G**, **Meunier PJ**; for the **EPIDOS Prospective Study Group**, Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study, Lancet 348:511, 1996.
1805. **Njeh CF**, **Boivin CM**, **Langton CM**, The role of ultrasound in the assessment of osteoporosis: a review, Osteoporos Int 7:7, 1997.
1806. **Faber J**, **Gallow AM**, Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis, Eur J Endocrinol 130:350, 1994.
1807. **Cummings SR**, **Nevitt MC**, **Browner WS**, **Stone K**, **Fox KM**, **Ensrud KE**, **Cauley J**, **Black D**, **Voigt TM**, Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group, N Engl J Med 332:767, 1995.
1808. **Bauer DC**, **Nevitt MC**, **Ettinger B**, **Stone K**, Low thyrotropin levels are not associated with bone loss in older women: a prospective study, J Clin Endocrinol Metab 82:2931, 1997.
1809. **Yang R**, **Yao L**, **Fang Y**, **Sun J**, **Guo T**, **Yang K**, **Tian L**, The relationship between subclinical thyroid dysfunction and the risk of fracture or low bone mineral density: a systematic review and meta-analysis of cohort studies, J Bone Miner Metab 36(2):209, 2018. doi: 10.1007/s00774-017-0828-5.
1810. **Siris ES**, **Miller PD**, **Barrett-Connor E**, **Faulkner KG**, **Wehren LE**, **Abbott TA**, **Berger ML**, **Santora AC**, **Sherwood LM**, Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment, JAMA 286:2815, 2001.
1811. **National Osteoporosis Foundation**, The FRAX Tool, http://www.nof.org/frax_update.htm, 2009.
1812. **WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK**, FRAX, WHO fracture risk assessment tool, http://www.shef.ac.uk/FRAX/, 2009.
1813. **Tosteson AN**, **Melton LJ III**, **Dawson-Hughes B**, **Baim S**, **Favus MJ**, **Khosia S**, **Lindsay RL**; **National Osteoporosis Foundation Guide Committee**, Cost-effective osteoporosis treatment thresholds: the United States perspective, Osteoporos Int 19:437, 2008.
1814. **Dawson-Hughes B**, **Tosteson AN**, **Melton LJ III**, **Baim S**, **Favus MJ**, **Khosia S**, **Lindsay R**, Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA, Osteoporos Int 19:449, 2008.
1815. **Garnero P**, **Gineyts E**, **Rious JP**, **Delmas PD**, Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease, J Clin Endocrinol Metab 79:780, 1994.

1816. **Prestwood KM**, **Pilbeam CC**, **Burleson JA**, **Woodiel FN**, **Delmas PD**, **Deftos LJ**, **Raisz LG**, The short term effects of conjugated estrogen on bone turnover in older women, J Clin Endocrinol Metab 79:366, 1994.
1817. **Chesnut CH III**, **Bell NH**, **Clark GS**, **Drinkwater BL**, **English SC**, **Johnston CC Jr**, **Notelovitz M**, **Rosen M**, **Cain DF**, **Flessland KA**, **Mallinak NJS**, Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density, Am J Med 102:29, 1997.
1818. **Komulainen MH**, **Kröger H**, **Tuppurainen MT**, **Heikkinen A-M**, **Alhava E**, **Honkanen R**, **Saarikoski S**, HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial, Maturitas 31:45, 1998.
1819. **Mosekilde L**, **Beck-Nielsen H**, **Sørensen OH**, **Nielsen SP**, **Charles P**, **Vestergaard P**, **Hermann AP**, **Gram J**, **Hansen TB**, **Abrahamsen B**, **Ebbesen EN**, **Stilgren L**, **Jensen LB**, **Brot C**, **Hansen B**, **Tofteng CL**, **Eiken P**, **Kolthoff N**, Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women—results of the Danish Osteoporosis Prevention Study, Maturitas 36:181, 2000.
1820. **Cauley J**, **Robbins J**, **Chen Z**, **Cummings SR**, **Jackson RD**, **LaCroix AZ**, **LeBoff M**, **Lewis CE**, **McGowan J**, **Neuner J**, **Pettinger M**, **Stefanick ML**, **Wactawski-Wende J**, **Watts NB**; for the **Women's Health Initiative Investigators**, Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative Randomized Trial, JAMA 290:1729, 2003.
1821. **Islam S**, **Liu Q**, **Chines AA**, **Helzner E**, Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000–2005, Menopause 16:77, 2009.
1822. **Weiss NC**, **Ure CL**, **Ballard JH**, **Williams AR**, **Daling JR**, Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen, N Engl J Med 303:1195, 1980.
1823. **Ettinger B**, **Genant HK**, **Cann CE**, Long-term estrogen replacement therapy prevents bone loss and fractures, Ann Intern Med 102:319, 1985.
1824. **Felson DT**, **Zhang Y**, **Hannan MT**, **Kiel DP**, **Wilson PWF**, **Anderson JJ**, The effect of postmenopausal estrogen therapy on bone density in elderly women, N Engl J Med 329:1141, 1993.
1825. **Lindsay R**, **MacLean A**, **Kraszewski A**, **Clark AC**, **Garwood J**, Bone response to termination of estrogen treatment, Lancet 1:1325, 1978.
1826. **Horsman A**, **Nordin BEC**, **Crilly RG**, Effect on bone of withdrawal of estrogen therapy, Lancet 2:33, 1979.
1827. **Christiansen C**, **Christiansen MS**, **Transbol IB**, Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy, Lancet 1:459, 1981.
1828. **Trémollieres FA**, **Pouilles JM**, **Ribot C**, Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women, Osteoporos Int 12:385, 2001.
1829. **Sornay-Rendu E**, **Garnero P**, **Munoz F**, **Duboeuf F**, **Delmas PD**, Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study, Bone 33:159, 2003.
1830. **Greendale GA**, **Espeland M**, **Slone S**, **Marcus R**, **Barrett-Connor E**; **PEPI Safety Follow-up Study (PSFS) Investigators**, Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study, Arch Intern Med 25:665, 2002.
1831. **Gallagher JC**, **Rapuri PB**, **Haynatzki G**, **Detter JR**, Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers, J Clin Endocrinol Metab 87:4914, 2002.
1832. **Bagger YZ**, **Tankó LB**, **Alexandersen P**, **Hansen HB**, **Møllgaard A**, **Ravn P**, **Qvist P**, **Kanis JA**, **Christiansen C**, Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study, Bone 34:728, 2004.
1833. **Middleton ET**, **Steel SA**, The effects of short-term hormone replacement therapy on long-term bone mineral density, Climacteric 10:257, 2007.
1834. **Barrett-Conner E**, **Wehren LE**, **Siris ES**, **Miller P**, **Chen YT**, **Abbott TA III**, **Berger ML**, **Santora AC**, **Sherwood LM**, Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study, Menopause 10:412, 2003.
1835. **Stevenson JC**, **Cust MP**, **Gangar KF**, **Hillard TC**, **Lees B**, **Whitehead MI**, Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women,

Lancet 336:1327, 1990.
1836. **Eiken P**, **Kolthoff N**, **Nielsen SP**, Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women, Bone 19:191S, 1996.
1837. **Nelson HD**, **Rizzo J**, **Harris E**, **Cauley J**, **Ensrud K**, **Bauer DC**, **Orwoll E**; **Study of Osteoporotic Fractures Research Group**, Osteoporosis and fractures in postmenopausal women using estrogens, Arch Intern Med 162:2278, 2002.
1838. **Naessén T**, **Persson I**, **Thor L**, **Mallmin H**, **Ljunghall S**, **Bergstrom R**, Maintained bone density at advanced ages after long-term treatment with low-dose estradiol implants, Br J Obstet Gynaecol 100:454, 1993.
1839. **Armamento-Villareal R**, **Civitelli R**, Estrogen action on the bone mass of postmenopausal women is dependent on body mass and initial bone density, J Clin Endocrinol Metab 80:776, 1995.
1840. **Villareal DT**, **Binder EF**, **Williams DB**, **Schechtman KB**, **Yarasheski KE**, **Kohrt WM**, Bone mineral density response to estrogen replacement in frail elderly women. A randomized controlled trial, JAMA 286:815, 2001.
1841. **Cauley JA**, **Zmuda JM**, **Ensrud KE**, **Bauer DC**, **Ettinger B**; for the **Study of Osteoporotic Fractures Research Group**, Timing of estrogen replacement therapy for optimal osteoporosis prevention, J Clin Endocrinol Metab 86:5700, 2001.
1842. **Lindsay R**, **Hart DM**, **Clark DM**, The minimum effective dose of estrogen for postmenopausal bone loss, Obstet Gynecol 63:759, 1984.
1843. **O'Connell MB**, Pharmacokinetic and pharmacologic variation between different estrogen products, J Clin Pharmacol 35(Suppl 9):18S, 1995.
1844. **Reginster JY**, **Sarlet N**, **Deroisy R**, **Albert A**, **Gaspard U**, **Franchimont P**, Minimal levels of serum estradiol prevent postmenopausal bone loss, Calcif Tissue Int 51:340, 1992.
1845. **Ettinger B**, **Pressman A**, **Sklarin P**, **Bauer DC**, **Cauley JA**, **Cummings SR**, Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures, J Clin Endocrinol Metab 83:2239, 1998.
1846. **Cummings SR**, **Browner WS**, **Bauer D**, **Stone K**, **Ensrud K**, **Jamal S**, **Ettinger B**; for the **Study of Osteoporotic Fractures Research Group**, Endogenous hormones and the risk of hip and vertebral fractures among older women, N Engl J Med 339:733, 1998.
1847. **Ettinger B**, **Genant HK**, **Cann CE**, Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium, Ann Intern Med 106:40, 1987.
1848. **Ettinger B**, **Genant HK**, **Steiger P**, **Madvig P**, Low-dosage micronized 17b-estradiol prevents bone loss in postmenopausal women, Am J Obstet Gynecol 166:479, 1992.
1849. **Genant HK**, **Lucas J**, **Weiss S**, **Akin M**, **Emeky R**, **McNaney-Flint H**, **Downs R**, **Mortola J**, **Watts N**, **Yank HM**, **Banav N**, **Brennan JJ**, **Nolan JC**; for the **Estratab/Osteoporosis Study Group**, Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels, Arch Intern Med 157:2609, 1997.
1850. **Gass M**, **Liu J**, **Rebar RW**, The effect of low-dose conjugated equine estrogens and cyclic MPA on bone density, Maturitas 26:143, 2002.
1851. **Mizunuma H**, **Okano H**, **Soda M**, **Kagami I**, **Miyamoto S**, **Tokizawa T**, **Honjo S**, **Ibuki Y**, Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study, Maturitas 27:69, 1997.
1852. **Prior JC**, **Vigna YM**, **Barr SI**, **Rexworthy C**, **Lentle BC**, Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances, Am J Med 96:521, 1994.
1853. **Selby PL**, **Peacock M**, **Barkworth SA**, **Brown WB**, **Taylor GA**, Early effects of ethinyl oestradiol and norethisterone treatment in postmenopausal women on bone resorption and calcium regulating hormones, Clin Sci 69:265, 1985.
1854. **Christiansen C**, **Nilas L**, **Riis BJ**, **Rodbro P**, **Deftos L**, Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis, Lancet 2:800, 1985.
1855. **Munk-Jensen N**, **Nielsen SP**, **Obel EB**, **Eriksen PB**, Reversal of postmenopausal vertebral bone loss by

oestrogen and progestogen: a double blind placebo controlled study, Br Med J 296:1150, 1988.
1856. **Gallagher JC**, **Kable WT**, **Goldgar D**, Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen, Am J Med 90:171, 1991.
1857. **Grey A**, **Cundy T**, **Evans M**, **Reid I**, Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women, Clin Endocrinol 44:293, 1996.
1858. **Adachi JD**, **Sargeant EJ**, **Sagle MA**, **Lamont D**, **Fawcett PD**, **Bensen WG**, **McQueen M**, **Nazir DJ**, **Goldsmith CH**, A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy, Br J Obstet Gynaecol 104:64, 1997.
1859. **Fuleihan GE**, **Brown EM**, **Curtis K**, **Berger MJ**, **Berger BM**, **Gleason R**, **LeBoff MS**, Effect of sequential and daily continuous hormone replacement therapy on indexes of mineral metabolism, Arch Intern Med 152:1904, 1992.
1860. **Nielsen SP**, **Bärenholdt O**, **Hermansen F**, **Munkin-Jensen NB**, Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment, Br J Obstet Gynaecol 101:319, 1994.
1861. **Heaney RP**, **Draper MW**, Raloxifene and estrogen: comparative bone-remodeling kinetics, J Clin Endocrinol Metab 82:3425, 1997.
1862. **Neele SJ**, **Evertz R**, **De Valk-De Roo GW**, **Roos JC**, **Netelenbos JC**, Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women, Bone 30:599, 2002.
1863. **Meunier PJ**, **Vignot E**, **Garnero P**, **Confavreux E**, **Paris E**, **Liu-Leage S**, **Sarkar S**, **Liu T**, **Wong M**, **Draper MW**, Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group, Osteoporos Int 10:330, 1999.
1864. **Bjarnason NH**, **Sarkar S**, **Duong T**, **Mitlak B**, **Delmas PD**, **Christiansen C**, Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis, Osteoporos Int 12:922, 2001.
1865. **Sambrook PN**, **Geusens P**, **Ribot C**, **Solimano JA**, **Ferrer-Barriendos J**, **Gaines K**, **Verbruggen N**, **Melton ME**, Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX® versus EVISTA® Comparison Trial) International, J Intern Med 255:503, 2004.
1866. **Reid IR**, **Ames RW**, **Evans MC**, **Gamble GD**, **Sharpe SJ**, Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial, Am J Med 98:331, 1995.
1867. **Recker RR**, **Hinders S**, **Davies KM**, **Heaney RP**, **Stegman MR**, **Lappe JM**, **Kimmel DB**, Correcting calcium nutritional deficiency prevents spine fractures in elderly women, J Bone Miner Res 11:1961, 1996.
1868. **Dawson-Hughes B**, **Harris SS**, **Krall EA**, **Dallal GE**, Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older, N Engl J Med 337:670, 1997.
1869. **Baeksgaard L**, **Andersen KP**, **Hyldstrup L**, Calcium and vitamin D supplementation increases spinal BMD in healthy postmenopausal women, Osteoporos Int 8:255, 1998.
1870. **NIH Consensus Development Panel on Optimal Calcium Intake**, Optimal calcium intake, JAMA 272:1942, 1994.
1871. **Tang BM**, **Eslick GD**, **Nowson C**, **Smith C**, **Bensoussan A**, Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis, Lancet 370:657, 2007.
1872. **Hasling C**, **Charles P**, **Jensen FT**, **Mosekilde L**, Calcium metabolism in postmenopausal osteoporosis: the influence of dietary calcium and net absorbed calcium, J Bone Miner Res 5:939, 1990.
1873. **Heaney RP**, **Recker RR**, Distribution of calcium absorption in middle-aged women, Am J Clin Nutr 43:299, 1986.
1874. **Wallace RB**, **Wactawski-Wende J**, **O'Sullivan MJ**, **Larson JC**, **Cochrane B**, **Gass M**, **Masaki K**, Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements, Am J Clin Nutr 94(1):270, 2011.
1875. **Gallagher JC**, **Smith LM**, **Yalamanchili V**, Incidence of hypercalciuria and hypercalcemia during vitamin D

and calcium supplementation in older women, Menopause 21(11):1173, 2014.
1876. **Prince RL**, **Smith M**, **Dick IM**, **Price RI**, **Webb PG**, **Henderson NK**, **Harris MM**, Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormone-replacement therapy, N Engl J Med 325:1189, 1991.
1877. **Heikinheimo RJ**, **Inkovaara JA**, **Harju EJ**, **Haavisto MV**, **Kaarela RH**, **Kataja JM**, **Kokko AM**, **Kolho LA**, **Rajala S**, Annual injection of vitamin D and fractures of aged bones, Calcif Tissue Int 51:105, 1992.
1878. **Aloia JF**, **Vaswani A**, **Yeh JK**, **Ross PL**, **Flaster E**, **Dilmanian FA**, Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss, Ann Intern Med 120:97, 1994.
1879. **Rizzoli R**, **Biver E**, **Bonjour JP**, **Coxam V**, **Goltzman D**, **Kanis JA**, **Lappe J**, **Rejnmark L**, **Sahni S**, **Weaver C**, **Weiler H**, **Reginster JY**, Benefits and safety of dietary protein for bone health-an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation, Osteoporos Int, 2018. doi: 10.1007/s00198-018-4534-5 [Epub ahead of print].
1880. **Lloyd T**, **Andon MB**, **Rollings N**, **Martel JK**, **Landis JR**, **Demers LM**, **Eggli DF**, **Kiesselhorst K**, **Kulin HE**, Calcium supplementation and bone mineral density in adolescent girls, JAMA 270:841, 1993.
1881. **Cadogan J**, **Eastell R**, **Jones N**, **Barker ME**, Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial, Br Med J 315:1255, 1997.
1882. **Ross AC**, **Manson JE**, **Abrams SA**, **Aloia JF**, **Brannon PM**, **Clinton SK**, **Durazo-Arvizu RA**, **Gallagher JC**, **Gallo RL**, **Jones G**, **Kovacs CS**, **Mayne ST**, **Rosen CJ**, **Shapses SA**, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know, J Clin Endocrinol Metab 96(1):53, 2011.
1883. **Ross EA**, **Szabo NJ**, **Tebbett IR**, Lead content of calcium supplements, JAMA 284:1425, 2000.
1884. **Curhan GC**, **Willett WC**, **Speizer FE**, **Spiegelman D**, **Stampfer MJ**, Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women, Ann Intern Med 126:497, 1997.
1885. **Lips P**, Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications, Endocr Rev 22:477, 2001.
1886. **Holick MF**, Vitamin D deficiency, N Engl J Med 357:266, 2007.
1887. **Armas LA**, **Hollis BW**, **Heaney RP**, Vitamin D2 is much less effective than vitamin D3 in humans, J Clin Endocrinol Metab 89:5387, 2004.
1888. **Boonen S**, **Lips P**, **Bouillon R**, **Bischoff-Ferrari HA**, **Vanderschueren D**, **Haentjens P**, Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative meta analysis of randomized controlled trials, J Clin Endocrinol Metab 92:1415, 2007.
1889. **The DIPART (vitamin D individual Patient Analysis of Randomized Trials) Group**, Patient level pooled analysis of 68,500 patients from seven major vitamin D fracture trials in US and Europe, Br Med J 340:b5463, 2010. doi: 10.1136/bmj.b5463.
1890. **Rosen CJ**, **Morrison A**, **Zhou H**, **Storm D**, **Hunter SJ**, **Musgrave K**, **Chen T**, **Wen W**, **Holick MF**, Elderly women in northern New England exhibit seasonal changes in bone mineral density and calciotropic hormones, Bone Miner 25:83, 1994.
1891. **González G**, **Alvarado JN**, **Rojas A**, **Navarrete C**, **Velásquez CG**, **Arteaga E**, High prevalence of vitamin D deficiency in Chilean healthy postmenopausal women with normal sun exposure: additional evidence for a worldwide concern, Menopause 14:455, 2007.
1892. **Ginde AA**, **Liu MC**, **Camargo CA Jr**, Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004, Arch Intern Med 169:626, 2009.
1893. **Thomas MK**, **Lloyd-Jones DM**, **Thadhani RI**, **Shaw AC**, **Deraska DJ**, **Kitch BT**, **Vamvakas EC**, **Dick IM**, **Prince RL**, **Finkelstein JS**, Hypovitaminosis D in medical inpatients, N Engl J Med 338:777, 1998.
1894. **Feskanich D**, **Singh V**, **Willett WC**, **Colditz GA**, Vitamin A intake and hip fractures among postmenopausal women, JAMA 287:47, 2002.
1895. **Whiting SJ**, **Lemke B**, Excess retinol intake may explain the high incidence of osteoporosis in northern

Europe, Nutr Rev 57:191, 1999.

1896. **Jackson RD**, **LaCroix AZ**, **Gass M**, **Wallace RB**, **Robbins J**, **Lewis CE**, **Bassford T**, **Beresford SAA**, **Black HR**, **Blanchette P**, **Bonds DE**, **Brunner RL**, **Brzyski RG**, **Caan B**, **Cauley JA**, **Chlebowski RT**, **Cummings SR**, **Granek I**, **Hays J**, **Heiss G**, **Hendrix SL**, **Howard BV**, **Hsia J**, **Hubbell FA**, **Johnson KC**, **Judd H**, **Kotchen JM**, **Kuller LH**, **Langer RD**, **Lasser NL**, **Limacher MC**, **Ludlam S**, **Manson JE**, **Margolis KL**, **McGowan J**, **Ockene JK**, **O'Sullivan MJ**, **Phillips L**, **Prentice RL**, **Sarto GE**, **Stefanick ML**, **Van Horn L**, **Wactawski-Wende J**, **Whitlock E**, **Anderson GL**, **Assaf AR**, **Barad D**; for the **Women's Health Initiative Investigators**, Calcium plus vitamin D supplementation and the risk of fractures, N Engl J Med 354:669, 2006.

1897. **Chlebowski RT**, **Johnson KC**, **Kooperberg CL**, **Pettinger M**, **Wactawski-Wende J**, **Rohan T**, **Rossouw J**, **Lane D**, **O'Sullivan MJ**, **Yasmeen S**, **Hiatt RA**, **Shikany JM**, **Vitolins M**, **Khandekar J**, **Hubbell FA**; for the **Women's Health Initiative Investigators**, Calcium plus vitamin D supplementation and the risk of breast cancer, J Natl Cancer Inst 100:1581, 2008.

1898. **Brunner RL**, **Cochrane B**, **Jackson RD**, **Larson J**, **Lewis C**, **Limacher M**, **Rosal M**, **Shumaker S**, **Wallace R**; **Women's Health Initiative Investigators**, Calcium, vitamin D supplementation, and physical function in the Women's Health Initiative, J Am Diet Assoc 108:1472, 2008.

1899. **de Boer IH**, **Tinker LF**, **Connelly S**, **Curb JD**, **Howard BV**, **Kestenbaum M**, **Larson JC**, **Manson JE**, **Margolis KL**, **Siscovick DS**, **Weiss NS**; **Women's Health Initiative Investigators**, Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative, Diabetes Care 31:701, 2008.

1900. **Hsia J**, **Heiss G**, **Ren H**, **Allison M**, **Dolan NC**, **Greenland P**, **Heckbert SR**, **Johnson KC**, **Manson JE**, **Sidney S**, **Trevisan M**; **Women's Health Initiative Investigators**, Calcium/vitamin D supplementation and cardiovascular events, Circulation 115:846, 2007.

1901. **Margolis KL**, **Ray RM**, **Van Horn L**, **Manson JE**, **Allison MA**, **Black HR**, **Beresford SA**, **Connelly SA**, **Curb JD**, **Grimm RH Jr**, **Kotchen TA**, **Kuller LH**, **Wassertheil-Smoller S**, **Thomson CA**, **Torner JC**; **Women's Health Initiative Investigators**, Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial, Hypertension 52:847, 2008.

1902. **LaCroix AZ**, **Kotchen J**, **Anderson G**, **Brzyski R**, **Cauley JA**, **Cummings SR**, **Gass M**, **Johnson KC**, **Ko M**, **Larson J**, **Manson JE**, **Stefanick ML**, **Wactawski-Wende J**, Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial, J Gerontol A Biol Sci Med Sci 64(5):559, 2009. doi: 10.1093/gerona/glp006.

1903. **Melamed ML**, **Michos ED**, **Post W**, **Astor B**, 25-Hydroxyvitamin D levels and the risk of mortality in the general population, Arch Intern Med 168:1629, 2008.

1904. **Melamed ML**, **Muntner P**, **Michos ED**, **Uribarri J**, **Weber C**, **Sharma J**, **Raggi P**, Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004, Arterioscler Thromb Vasc Biol 28:1179, 2008.

1905. **Pilz S**, **Dobnig H**, **Nijpels G**, **Heine RJ**, **Stehouwer CD**, **Snijder MB**, **van Dam RM**, **Dekker JM**, Vitamin D and mortality in older men and women, Clin Endocrinol (Oxf) 71(5):666, 2009.

1906. **Garland CF**, **Gorham ED**, **Mohr SB**, **Grant WB**, **Giovannucci EL**, **Lipkin M**, **Newmark HL**, **Holick MF**, **Garland FC**, Vitamin D and prevention of breast cancer: pooled analysis, J Steroid Biochem Mol Biol 103:708, 2007.

1907. **Ginde AA**, **Scragg R**, **Schwartz RS**, **Camargo CA Jr**, Prospective study of serum 25-hydroxyvitamin d level, cardiovascular disease mortality, and all-cause mortality in older U. S. adults, J Am Geriatr Soc 57:1595, 2009.

1908. **Cauley JA**, **Wampler NS**, **Barnhart JM**, **Wu L**, **Allison M**, **Chen Z**, **Hendrix S**, **Robbins J**, **Jackson RD**; **Women's Health Initiative Investigators**, Incidence of fractures compared to cardiovascular disease and breast cancer: the Women's Health Initiative Observational Study, Osteoporos Int 19:1717, 2008.

1909. **Holick MF**, High prevalence of vitamin D inadequacy and implications for health, Mayo Clin Proc 81:353, 2006.

1910. **Cauley JA**, **LaCroix AZ**, **Wu L**, **Horwitz M**, **Danielson ME**, **Bauer DC**, **Lee JS**, **Jackson RD**, **Robbins**

JA, **Wu C**, **Stanczyk FZ**, **LeBoff MS**, **Wactawski-Wende J**, **Sarto G**, **Ockene J**, **Cummings SR**, Serum 25-hydroxyvitamin D concentrations and risk for hip fractures, Ann Intern Med 149:242, 2008.

1911. **Tilyard MW**, **Spears GFS**, **Thomson J**, **Dovey S**, Treatment of postmenopausal osteoporosis with calcitriol or calcium, N Engl J Med 326:357, 1992.
1912. **Chapuy MC**, **Meunier PJ**, Prevention of secondary hyperparathyroidism and hip fracture in elderly women with calcium and vitamin D3 supplements, Osteoporos Int 6(Suppl 3):60, 1996.
1913. **Bischoff-Ferrari HA**, **Dawson-Hughes B**, **Willett W**, **Staehlin H**, **Bazemore M**, **Zee R**, **Wong J**, Fall prevention by vitamin D treatment: a meta-analysis of randomized controlled trials, JAMA 291:1999, 2004.
1914. **Bischoff-Ferrari HA**, **Dietrich T**, **Orav EJ**, **Zhang Y**, **Karlson EW**, **Dawson-Hughes B**, Higher 25-hydroxyvitamin D levels are associated with better lower extremity function in both active and inactive adults 60+ years of age, Am J Clin Nutr 80:752, 2004.
1915. **Dawson-Hughes B**, **Heaney RP**, **Holick MF**, **Lips P**, **Meunier PJ**, **Vieth R**, Estimates of optimal vitamin D status, Osteoporos Int 16:713, 2005.
1916. **de Groen PC**, **Lubbe DF**, **Hirsch LJ**, **Daifotis A**, **Stephenson W**, **Freedholm D**, **Pryor-Tillotson S**, **Seleznick MJ**, **Pinkas H**, **Wang KK**, Esophagitis associated with the use of alendronate, N Engl J Med 335:1016, 1996.
1917. **Bauer DC**, **Black D**, **Ensrud K**, **Thompson D**, **Hochberg M**, **Nevitt M**, **Musliner T**, **Freedholm D**, Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial, Arch Intern Med 28:517, 2000.
1918. **Lowe CE**, **Depew WT**, **Vanner SJ**, **Paterson WG**, **Meddings JB**, Upper gastrointestinal toxicity of alendronate, Am J Gastroenterol 95:634, 2000.
1919. **Mortensen L**, **Charles P**, **Bekker PJ**, **Digennaro J**, **Johnston CC Jr**, Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up, J Clin Endocrinol Metab 83:396, 1998.
1920. **Harris ST**, **Watts NB**, **Genant HK**, **McKeever CD**, **Hangartner T**, **Keller M**, **Chesnut CH III**, **Brown J**, **Eriksen EF**, **Hoseyni MS**, **Axelrod DW**, **Miller PD**, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group, JAMA 282:1344, 1999.
1921. **McClung MR**, **Geusens P**, **Miller PD**, **Zippel H**, **Bensen WG**, **Roux C**, **Adami S**, **Fogelman I**, **Diamond T**, **Eastell R**, **Meunier PJ**, **Reginster J-Y**; for the **Hip Intervention Program Study Group**, Effect of risedronate on the risk of hip fracture in elderly women, N Engl J Med 344:333, 2001.
1922. **Foidart JM**, **Wuttke W**, **Bouw GM**, **Gerlinger C**, **Heithecker R**, A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel, Eur J Contracept Reprod Health Care 5:124, 2000.
1923. **Fogelman I**, **Ribot C**, **Smith R**, **Ethgen D**, **Sod E**, **Reginster J**; for the **BMD-MN Study Group**, Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial, J Clin Endocrinol Metab 85:1895, 2000.
1924. **Grey A**, **Bolland MJ**, **Wattie D**, **Horne A**, **Gamble G**, **Reid IR**, The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women, J Clin Endocrinol Metab 94:538, 2009.
1925. **McClung MR**, **Miller P**, **Recknor C**, **Mesenbrink P**, **Bucci-Rechtweg C**, **Benhamou C-L**, Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass. A randomized controlled trial, Obstet Gynecol 114:999, 2009.
1926. **Schnitzer T**, **Bone HG**, **Crepaldi G**, **Adami S**, **McClung M**, **Kiel D**, **Felsenberg D**, **Recker RR**, **Tonino RP**, **Roux C**, **Pinchera A**, **Foldes AJ**, **Greenspan SL**, **Levine MA**, **Emkey R**, **Santora AC II**, **Kaur A**, **Thompson DE**, **Yates J**, **Orloff JJ**, Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group, Aging 12:1, 2000.
1927. **Brown JP**, **Kendler DL**, **McClung MR**, **Emkey RD**, **Adachi JD**, **Bolognese MA**, **Li Z**, **Balske A**, **Lindsey R**, The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal

osteoporosis, Calcif Tissue Int 71:103, 2002.

1928. **Luckey MM**, **Gilchrist N**, **Bone HG**, **Davie MW**, **de Villiers TJ**, **Wu M**, **Saifotis AG**, **Santora AC**, **Orloff JJ**, Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis, Obstet Gynecol 101:711, 2003.
1929. **Blumel JE**, **Castelo-Branco C**, **de la Cuadra G**, **Maciver L**, **Moreno M**, **Haya J**, Alendronate daily, weekly in conventional tablets and weekly in enteric tablets: preliminary study on the effects in bone turnover markers and incidence of side effects, J Obstet Gynaecol 23:278, 2003.
1930. **Rizzoli R**, **Greenspan SL**, **Bone G II**, **Schnitzer TJ**, **Watts NB**, **Adami S**, **Foldes AJ**, **Roux C**, **Levine MA**, **Uebelhart B**, **Santora AC II**, **Kaur A**, **Peverly CA**, **Orloff JJ**; **Alendronate Once-Weekly Study Group**, Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis, J Bone Miner Res 17:1988, 2002.
1931. **Black DM**, **Cummings SR**, **Karpf DB**, **Cauley JA**, **Thompson DE**, **Nevitt MC**, **Bauer DC**, **Genant HK**, **Haskell WL**, **Marcus R**, **Ott SM**, **Torner JC**, **Quandt SA**, **Reiss TF**, **Ensrud KE**; for the **Fracture Intervention Trial Research Group**, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet 348:1535, 1996.
1932. **Karpf DB**, **Shapiro DR**, **Seeman E**, **Ensrud KE**, **Johnston CC Jr**, **Adami S**, **Harris ST**, **Santora AC II**, **Hirsch LJ**, **Oppenheimer L**, **Thompson D**; for the **Alendronate Osteoporosis Treatment Study Groups**, Prevention of nonvertebral fractures by alendronate, JAMA 277:1159, 1997.
1933. **Black DM**, **Thompson DE**, **Bauer DC**, **Ensrud K**, **Musliner T**, **Hochberg MC**, **Nevitt MC**, **Suryawanshi S**, **Cummings SR**; for the **FIT Research Group**, Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial, J Clin Endocrinol Metab 85:4118, 2000.
1934. **Hosking D**, **Chilvers CED**, **Christiansen C**, **Ravn P**, **Wasnich R**, **Ross P**, **McClung M**, **Balske A**, **Thompson D**, **Daley M**, **Yates AJ**; for the **Early Postmenopausal Intervention Cohort Study Group**, Prevention of bone loss with alendronate in postmenopausal women under 60 years of age, N Engl J Med 338:485, 1998.
1935. **McClung M**, **Clemmesen B**, **Daifotis A**, **Gilchrist NL**, **Eisman J**, **Weinstein RS**, **Fuleihan GEH**, **Reda C**, **Yates AJ**, **Ravn P**; for the **Alendronate Osteoporosis Prevention Study Group**, Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial, Ann Intern Med 128:253, 1998.
1936. **Cummings SR**, **Black DM**, **Thompson DE**, **Applegate WB**, **Barrett-Connor E**, **Musliner TA**, **Palermo L**, **Prineas R**, **Rubin SM**, **Scott JC**, **Vogt T**, **Wallace R**, **Yates AJ**, **LaCroix AZ**; for the **Fracture Intervention Trial Research Group**, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial, JAMA 280:2077, 1998.
1937. **Reginster J**, **Minne HW**, **Sorensen OH**, **Hooper M**, **Roux C**, **Brandi ML**, **Lund B**, **Ethgen D**, **Pack S**, **Roumagnac I**, **Eastell R**, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, Osteoporos Int 11:83, 2000.
1938. **Sorensen OH**, **Crawford GM**, **Mulder H**, **Hosking DJ**, **Gennari C**, **Mellstrom D**, **Pack S**, **Wenderoth D**, **Cooper C**, **Reginster JY**, Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience, Bone 32:120, 2003.
1939. **Chesnut CH III**, **Skag A**, **Christiansen C**, **Recker R**, **Stakkestad JA**, **Hoiseth A**, **Felsenberg D**, **Huss H**, **Gilbride J**, **Schimmer RC**, **Delmas P**; **Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)**, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res 19:1241, 2004.
1940. **Black DM**, **Delmas PD**, **Estell R**, **Reid IR**, **Boonen S**, **Cauley JA**, **Cosman F**, **Lakatos P**, **Leung PC**, **Man Z**, **Mautalen C**, **Mesenbrink P**, **Hu H**, **Caminis J**, **Tong K**, **Rosario-Jansen T**, **Krasnow J**, **Hue TF**, **Sellmeyer D**, **Eriksen EF**, **Cummings SR**; **HORIZON Pivotal Fracture Trial**, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis, N Engl J Med 356:1809, 2007.
1941. **Lindsay R**, **Cosman F**, **Lobo RA**, **Walsh BW**, **Harris ST**, **Reagan JE**, **Liss CL**, **Melton ME**, **Byrnes**

CA, Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial, J Clin Endocrinol Metab 84:3076, 1999.

1942. **Greenspan S**, **Bankhurst A**, **Bell N**, **Bolognese M**, **Bone H**, **Davidson M**, **Downs R**, **Emkey R**, **McKeever C**, **Miller S**, **Mulloy A**, **Weiss S**, **Heyden N**, **Lombardi A**, **Suryawanshi S**, Effects of alendronate and estrogen, alone or in combination, on bone mass and turnover in postmenopausal osteoporosis (abstract), Bone 23(Suppl 5):S174, 1998.
1943. **Harris ST**, **Eriksen EF**, **Davidson M**, **Ettinger MP**, **Moffett AH Jr**, **Baylink DJ**, **Crusan CE**, **Chines AA**, Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women, J Clin Endocrinol Metab 86:1890, 2001.
1944. **Ettinger B**, **Pressman A**, **Schein J**, Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis, Am J Manag Care 4:1377, 1998.
1945. **Faulkner DL**, **Lucy LM**, **Heath H**, **Minshall ME**, **Muchmore DB**, A claims data assessment of patient compliance with alendronate (abstract), Osteoporos Int 8(Suppl 3):21, 1998.
1946. **Siris ES**, **Harris ST**, **Rosen CJ**, **Barr CE**, **Arvesen JN**, **Abbott TA**, **Silverman S**, Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases, Mayo Clin Proc 81:1013, 2006.
1947. **MacLennan AH**, **Wilson DH**, **Taylor AW**, Hormone replacement therapy use over a decade in an Australian population, Climacteric 5:351, 2002.
1948. **Steel SA**, **Albertazzi P**, **Howarth EM**, **Purdie DW**, Factors affecting long-term adherence to hormone replacement therapy after screening for osteoporosis, Climacteric 6:96, 2003.
1949. **Bone HG**, **Hosking D**, **Devogelaer JP**, **Tucci JR**, **Emkey RD**, **Tonino RP**, **Rodriguez-Portales JA**, **Downs RW**, **Gupta JK**, **Santora AC**, **Liberman UA**; for the **Alendronate Phase III Osteoporosis Treatment Study Group**, Ten years' experience with alendronate for osteoporosis in postmenopausal women, N Engl J Med 350:1189, 2004.
1950. **Fleisch H**, Bisphosphonates: mechanisms of action and clinical use in osteoporosis: an update, Horm Metab Res 29:145, 1997.
1951. **Greenspan SL**, **Emkey RD**, **Bone HG**, **Weiss SR**, **Bell NH**, **Downs RW**, **McKeever C**, **Miller SS**, **Davidson M**, **Bolognese MA**, **Mulloy AL**, **Heyden N**, **Wu M**, **Kaur A**, **Lombardi A**, Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial, Ann Intern Med 137:875, 2002.
1952. **Tonino RP**, **Meunier PJ**, **Emkey R**, **Rodriguez-Portales JA**, **Menkes CJ**, **Wasnich RD**, **Bone HG**, **Santora AC**, **Wu M**, **Desai R**, **Ross PD**, Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group, J Clin Endocrinol Metab 85:3109, 2000.
1953. **Bagger YZ**, **Tanko LB**, **Alexandersen P**, **Ravn P**, **Christiansen C**, Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal, Bone 33:301, 2003.
1954. **Black DM**, **Schwartz AV**, **Ensrud KE**, **Cauley JA**, **Levis S**, **Quandt SA**, **Satterfield S**, **Wallace RB**, **Bauer DC**, **Palermo L**, **Wehren LE**, **Lombardi A**, **Santora AC**, **Cummings SR**; for the **FLEX Research Group**, Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial, JAMA 296:2927, 2006.
1955. **Curtis JR**, **Westfall AO**, **Cheng H**, **Deizell E**, **Saag KG**, Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday, Osteoporos Int 19:1613, 2008.
1956. **Neviaser AS**, **Lane JM**, **Lenart BA**, **Edobor-Osula F**, **Lorich DG**, Low-energy femoral shaft fractures associated with alendronate use, J Orthop Trauma 22:346, 2008.
1957. **Khan AA**, **Morrison A**, **Hanley DA**, **Felsenberg D**, **McCauley LK**, **O'Ryan F**, **Reid IR**, **Ruggiero SL**, **Taguchi A**, **Tetradis S**, **Watts NB**, **Brandi ML**, **Peters E**, **Guise T**, **Eastell R**, **Cheung AM**, **Morin SN**, **Masri B**, **Cooper C**, **Morgan SL**, **Obermayer-Pietsch B**, **Langdahl BL**, **Al Dabagh R**, **Davison KS**, **Kendler DL**, **Sándor GK**, **Josse RG**, **Bhandari M**, **El Rabbany M**, **Pierroz DD**, **Sulimani R**, **Saunders DP**, **Brown JP**, **Compston J**; **International Task Force on Osteonecrosis of the Jaw**, Diagnosis and

management of osteonecrosis of the jaw: a systematic review and international consensus, J Bone Miner Res 30(1):3, 2015. doi: 10.1002/jbmr.2405.

1958. **Wilkinson GS**, **Kuo Y-F**, **Freeman JL**, **Goodwin JS**, Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis, J Natl Cancer Inst 99:1016, 2007.
1959. **Zervas K**, **Verrou E**, **Teleioudis E**, **Vahtsevanos K**, **Banti A**, **Mihou D**, **Krikelis D**, **Terpos E**, Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients, Br J Haematol 134:620, 2006.
1960. **Durie BGM**, **Katz M**, **Crowley J**, Osteonecrosis of the jaw and bisphosphonates, N Engl J Med 353:99, 2006.
1961. **Farrugia MC**, **Summerlin D-J**, **Krowiak E**, **Huntley T**, **Freeman S**, **Borrowdale R**, **Tomich C**, Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates, Laryngoscope 116:115, 2006.
1962. **Ruggiero SL**, **Mebrotra B**, **Rosenberg TJ**, **Engroff SL**, Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases, J Oral Maxillofac Surg 62:527, 2004.
1963. **Di Fede O**, **Panzarella V**, **Mauceri R**, **Fusco V**, **Bedogni A**, **Lo Muzio L**; **SIPMO ONJ Board**; **Campisi G**, The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention, Biomed Res Int 2018:2684924, 2018.
1964. **Sharma A**, **Einstein AJ**, **Vallakati A**, **Arbab-Zadeh A**, **Walker MD**, **Mukherjee D**, **Homel P**, **Borer JS**, **Lichstein E**, Risk of atrial fibrillation with use of oral and intravenous bisphosphonates, Am J Cardiol 113:1815, 2014.
1965. **Heckbert SR**, **Li G**, **Cummings SR**, **Smith NL**, **Psaty BM**, Use of alendronate and risk of incident atrial fibrillation in women, Arch Intern Med 168:826, 2008.
1966. **Sørensen HT**, **Christensen S**, **Mehnert F**, **Pedersen L**, **Chapuriat RD**, **Cummings SR**, **Baron JA**, Use of bisphosphonates among women and risk of atrial fibrillation and flutter: a population based case-control study, Br Med J 336:813, 2008.
1967. **Abrahamsen B**, **Eiken P**, **Brixen K**, Atrial fibrillation in fracture patients treated with oral bisphosphonates, J Intern Med 265:581, 2009.
1968. **Bunch TJ**, **Anderson JL**, **May HT**, **Muhlestein JB**, **Horne BD**, **Crandall BG**, **Weiss JP**, **Lappé DL**, **Osborn JS**, **Day JD**, Relation of bisphosphonate therapies and risk of developing atrial fibrillation, Am J Cardiol 103:824, 2009.
1969. **Huang W-F**, **Usai Y-W**, **Wen Y-W**, **Hsiao F-Y**, **Kuo KN**, **Tsai C-R**, Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene, Menopause 17:57, 2010.
1970. **Wysowski D**, Reports of esophageal cancer with oral bisphosphonate use, N Engl J Med 360:89, 2009.
1971. **Solomon DH**, **Patrick A**, **Brookhart MA**, More on reports of esophageal cancer with oral bisphosphonate use, N Engl J Med 360:1790, 2009.
1972. **Abrahamsen B**, **Eiken P**, **Eastell R**, More on reports of esophageal cancer with oral bisphosphonate use, N Engl J Med 360:1789, 2009.
1973. **Wright E**, **Schofield PT**, **Molokhia M**, Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis, Br Med J Open 5(12):e007133, 2015.
1974. **Miller PD**, **Bolognese MA**, **Lewiecki EM**, **McClung MR**, **Ding B**, **Austin M**, **Liu Y**, **San Martin J**; for the **AMG 162 Bone Loss Study Group**, Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial, Bone 43:222, 2008.
1975. **Bone HG**, **Bolognese MA**, **Yuen CK**, **Kendler DL**, **Wang H**, **Liu Y**, **San Martin J**, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women, J Clin Endocrinol Metab 93:2149, 2008.
1976. **Cummings SR**, **San Martin J**, **McClung MR**, **Siris ES**, **Eastell R**, **Reid IR**, **Delmas PD**, **Zoog HB**, **Austin M**, **Wang A**, **Kutilek S**, **Adami S**, **Zanchetta J**, **Libanati C**, **Siddhanti S**, **Christiansen C**; for the **FREEDOM Trial**, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med 361:756, 2009.
1977. **Brown JP**, **Prince RL**, **Deal C**, **Recker RR**, **Kiel DP**, **de Gregorio LH**, **Hadji P**, **Hofbauer LC**, **Alvaro-**

Gracia JM, **Wang H**, **Austin M**, **Wagman RB**, **Newmark R**, **Libanati C**, **San Martin J**, **Bone HG**, Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded phase 3 trial, J Bone Miner Res 24:153, 2009.

1978. **Bone HG**, **Wagman RB**, **Brandi ML**, **Brown JP**, **Chapurlat R**, **Cummings SR**, **Czerwiński E**, **Fahrleitner-Pammer A**, **Kendler DL**, **Lippuner K**, **Reginster JY**, **Roux C**, **Malouf J**, **Bradley MN**, **Daizadeh NS**, **Wang A**, **Dakin P**, **Pannacciulli N**, **Dempster DW**, **Papapoulos S**, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension, Lancet Diabetes Endocrinol 5(7):513, 2017.
1979. **Amgen Manufacturing Limited**, Prolia (denosumab) injection, for subcutaneous use: US prescribing information 2017. http://pi.amgen.com/united_states/prolia/prolia_pi.pdf
1980. **Chesnut CH III**, **Silverman S**, **Andriano K**, **Genant H**, **Gimona A**, **Harris S**, **Kiel D**, **LeBoff M**, **Maricic M**, **Miller P**, **Moniz C**, **Peacock M**, **Richardson P**, **Watts N**, **Baylink D**, A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group, Am J Med 109:267, 2000.
1981. **Ito A**, **Yoshimura M**, Mechanisms of the analgesic effect of calcitonin on chronic pain by alteration of receptor or channel expression, Mol Pain 13:174, 2017.
1982. **Pak CY**, **Sakhaee K**, **Adams-Huet B**, **Piziak V**, **Peterson RD**, **Poindexter JR**, Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final update of a randomized controlled trial, Ann Intern Med 123:401, 1995.
1983. **Pak CYC**, **Sakhaee K**, **Rubin C**, **Rao S**, Update of fluoride in the treatment of osteoporosis, Endocrinologist 8:15, 1998.
1984. **Meunier PJ**, **Roux C**, **Ortolani S**, **Diaz-Curiel M**, **Compston J**, **Marquis P**, **Cormier C**, **Isaia G**, **Badurski J**, **Wark JD**, **Collette, J**, **Reginster JY**, Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis, Osteoporos Int 20:1663, 2009.
1985. **Reginster JY**, **Felsenberg D**, **Boonen S**, **Diez-Perez A**, **Rizzoli R**, **Brandi ML**, **Spector TD**, **Brixen K**, **Goemaere S**, **Cormier C**, **Balogh A**, **Delmas PD**, **Meunier PJ**, Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial, Arthritis Rheum 58:1687, 2009.
1986. **Deeks ED**, **Dhillon S**, Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis, Drugs 70(6):733, 2010.
1987. **Berning B**, **Kuijk CV**, **Kuper JW**, **Bennink HJ**, **Kicovic PM**, **Fauser BC**, Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized placebo-controlled study, Bone 19:395, 1996.
1988. **Lippuner K**, **Haenggi W**, **Birkhaeuser MH**, **Casez J-P**, **Jaeger P**, Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17b-estradiol and dihydrogesterone, J Bone Miner Res 12:806, 1997.
1989. **Studd J**, **Arnala I**, **Kicovic PM**, **Zamblera D**, **Kröger H**, **Holland N**, A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures, Obstet Gynecol 92:574, 1998.
1990. **Milner M**, **Harrison RF**, **Gilligan E**, **Kelly A**, Bone density changes during two years' treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women, Menopause 7:327, 2000.
1991. **Rymer J**, Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss, Osteoporos Int 12:478, 2001.
1992. **Ederveen AGH**, **Kloosterboer HJ**, Tibolone exerts an estrogenic effect on bone leading to prevention of bone loss and reduction in bone resorption in ovariectomized rats, Osteoporos Int 8:95, 1999.
1993. **Palomba S**, **Morelli M**, **Di Carlo C**, **Noia R**, **Pellicano M**, **Zullo F**, Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone, Fertil Steril 78:63, 2002.
1994. **Cosman F**, **Nieves J**, **Woelfert L**, **Formica C**, **Gordon S**, **Shen V**, **Lindsay R**, Parathyroid hormone added

to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal, J Bone Miner Res 16:925, 2001.

1995. **Body JJ**, **Gaich GA**, **Scheele WH**, **Kulkarni PM**, **Miller PD**, **Peretz A**, **Dore RK**, **Correa-Rotter R**, **Papaioanou A**, **Cumming DC**, **Hodsman AB**, A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone, 1–34) with alendronate in postmenopausal women with osteoporosis, J Clin Endocrinol Metab 87:4528, 2002.

1996. **Rittmaster RS**, **Bolognese MA**, **Ettinger MP**, **Hanley DA**, **Hodsman AB**, **Kendler DL**, **Rosen CG**, Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate, J Clin Endocrinol Metab 85:2129, 2000.

1997. **Eastell R**, **Nickelsen T**, **Marin F**, **Barker C**, **Hadji P**, **Farrerons J**, **Audran M**, **Boonen S**, **Brixen K**, **Melo Gomes J**, **Obermayer-Pietsch B**, **Avramidis A**, **Sigurdsson G**, **Glüer CC**, Sequential treatment of severe postmenopausal osteoporosis following teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS), J Bone Miner Res 24:726, 2009.

1998. **Díez-Pérez A**, **Marin F**, **Eriksen EF**, **Kendler DL**, **Krege JH**, **Delgado-Rodríguez M**, Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis, Bone 120:1, 2018.

1999. **Cosman F**, Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches, Curr Osteoporos Rep 12(4):385, 2014.

2000. **Niimi R**, **Kono T**, **Nishihara A**, **Hasegawa M**, **Kono T**, **Sudo A**, Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial, JBMR Plus 2(5):289, 2018.

2001. **Arjmandi BH**, **Birnbaum R**, **Goyal NV**, **Getlinger MJ**, **Juma S**, **Alekel L**, **Hasler CM**, **Drum ML**, **Hollis BW**, **Kukreja SC**, Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content, Am J Clin Nutr 68(Suppl):1364S, 1998.

2002. **Lees CJ**, **Ginn TA**, Soy protein isolate diet does not prevent increased cortical bone turnover in ovariectomized macaques, Calcif Tissue Int 62:557, 1998.

2003. **Register TC**, **Jayo MJ**, **Anthony MS**, Soy phytoestrogens do not prevent bone loss in postmenopausal monkeys, J Clin Endocrinol Metab 88:4362, 2003.

2004. **Alekel DL**, **Peterson C**, **St. Germain A**, **Hanson K**, Isoflavone-rich soy isolate exerts significant bone-sparing in the lumbar spine of perimenopausal women (abstract), Am Soc Bone Miner Res, Annual Meeting, 1999.

2005. **Gallagher JC**, **Satpathy R**, **Rafferty K**, **Haynatzka V**, The effect of soy protein on bone metabolism, Menopause 11:290, 2004.

2006. **Vupadhyayula PM**, **Gallagher JC**, **Templin T**, **Logsdon SM**, **Smith LM**, Effects of soy protein isolate on bone mineral density and physical performance indices in postmenopausal women—a 2-year randomized, double-blind, placebo-controlled trial, Menopause 16:320, 2009.

2007. **Lucas EA**, **Wild RD**, **Hammond LJ**, **Khalil DA**, **Juma S**, **Daggy BP**, **Stoecker BJ**, **Arjmandi BH**, Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women, J Clin Endocrinol Metab 87:1527, 2002.

2008. **Nakamura T**, **Turner CH**, **Yoshikawa T**, **Slemenda CW**, **Peacock M**, **Burr DB**, **Mizuno Y**, **Orimo H**, **Ouchi Y**, **Johnston CC Jr**, Do variations in hip geometry explain differences in hip fracture risk between Japanese and white Americans?, J Bone Miner Res 9:1071, 1994.

2009. **Melis GB**, **Paoletti AM**, **Cagnacci A**, Ipriflavone prevents bone loss in postmenopausal women, Menopause 3:27, 1996.

2010. **Gennari C**, **Agnusdei D**, **Crepaldi G**, **Isaia G**, **Mazzuoli G**, **Ortolani S**, **Bufalino L**, **Passeri M**, Effect of ipriflavone—a synthetic derivative of natural isoflavones—on bone mass loss in the early years after menopause, Menopause 5:9, 1998.

2011. **de Aloysio D**, **Gambacciani M**, **Altieri P**, **Ciaponi M**, **Ventura V**, **Mura M**, **Genazzani AR**, **Bottiglioni F**, Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT, Gynecol Endocrinol 11:289, 1997.

2012. **Gambacciani M**, **Ciaponi M**, **Cappagli B**, **Piaggesi L**, **Genazzani AR**, Effects of combined low dose of the

isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women, Maturitas 28:75, 1997.

2013. **Alexandersen P**, **Toussaint A**, **Christiansen C**, **Devogelaer J-P**, **Roux C**, **Fechtenbaum J**, **Gennari C**, **Reginster JY**; for the **Ipriflavone Multicenter European Fracture Study**, Ipriflavone in the treatment of postmenopausal osteoporosis. A randomized controlled trial, JAMA 285:1482, 2001.
2014. **Morito K**, **Hirose T**, **Kinjo J**, **Hirakawa T**, **Okawa M**, **Nohara T**, **Ogawa S**, **Inoue S**, **Muramatsu M**, **Masamune Y**, Interaction of phytoestrogens with estrogen receptors a and b, Biol Pharm Bull 24:351, 2001.
2015. **Wu J**, **Oka J**, **Ezaki J**, **Ohtomo T**, **Ueno T**, **Uchiyama S**, **Toda T**, **Uehara M**, **Ishimi Y**, Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial, Menopause 14:866, 2007.
2016. **Meier CR**, **Schlienger RG**, **Kraenzlin ME**, **Schlegel B**, **Jick H**, HMG-CoA reductase inhibitors and the risk of fractures, JAMA 283:3205, 2000.
2017. **Wang PS**, **Solomon DH**, **Mogun H**, **Avorn J**, HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients, JAMA 283:3211, 2000.
2018. **Reid IR**, **Hague W**, **Emberson J**, **Baker J**, **Tonkin A**, **Hunt D**, **MacMahon S**, **Sharpe N**, Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease, Lancet 357:1887, 2001.
2019. **Ray WA**, **Daugherty JR**, **Griffin MR**, Lipid-lowering agents and the risk of hip fracture in a Medicaid population, Inj Prev 8:276, 2002.
2020. **LaCroix AZ**, **Cauley JA**, **Pettinger M**, **Hsia J**, **Bauer DC**, **McGowan J**, **Chen Z**, **Lewis CE**, **McNeeley SG**, **Passaro MD**, **Jackson RD**, Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study, Ann Intern Med 139:97, 2003.
2021. **An T**, **Hao J**, **Sun S**, **Li R**, **Yang M**, **Cheng G**, **Zou M**, Efficacy of statins for osteoporosis: a systematic review and meta-analysis, Osteoporos Int 28(1):47, 2017.
2022. **Morton DJ**, **Barrett-Connor EL**, **Edelstein SL**, Thiazides and bone mineral density in elderly men and women, Am J Epidemiol 139:1107, 1994.
2023. **Xiao X**, **Xu Y**, **Wu Q**, Thiazide diuretic usage and risk of fracture: a metaanalysis of cohort studies, Osteoporos Int 29(7):1515, 2018.
2024. **Chow RK**, **Harrison JE**, **Brown CF**, **Hajek V**, Physical fitness effect on bone mass in postmenopausal women, Arch Phys Med Rehabil 67:231, 1986.
2025. **Dalsky G**, **Stocke KS**, **Ehsani AA**, **Slatopolsky E**, **Lee WC**, **Birjes J Jr**, Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women, Ann Intern Med 108:824, 1988.
2026. **Cavanagh DJ**, **Cann CE**, Brisk walking does not stop bone loss in postmenopausal women, Bone 9:201, 1988.
2027. **Brooke-Wavell K**, **Jones PRM**, **Hardman AE**, Brisk walking reduces calcaneal bone loss in post-menopausal women, Clin Sci 92:75, 1997.
2028. **Ebrahim S**, **Thompson PW**, **Baskaran V**, **Evans K**, Randomized placebo-controlled trial of brisk walking in the prevention of postmenopausal osteoporosis, Age Ageing 26:253, 1997.
2029. **Kohrt WM**, **Snead DB**, **Slatopolsky E**, **Birge SJ Jr**, Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women, J Bone Miner Res 10:1303, 1995.
2030. **Feskanich D**, **Willett W**, **Colditz GA**, Walking and leisure-time activity and risk of hip fracture in postmenopausal women, JAMA 288:2300, 2002.
2031. **Hopper JL**, **Seeman E**, The bone density of female twins discordant for tobacco use, N Engl J Med 330:387, 1994.
2032. **Krall EA**, **Dawson-Hughes B**, Smoking and bone loss among postmenopausal women, J Bone Miner Res 6:331, 1991.
2033. **Kiel DP**, **Felson DT**, **Hannan MT**, **Anderson JJ**, **Wilson PW**, Caffeine and the risk of hip fracture: the Framingham Study, Am J Epidemiol 132:675, 1990.
2034. **Barrett-Connor E**, **Chang JC**, **Edelstein SL**, Coffee-associated osteoporosis offset by daily milk consumption, JAMA 271:280, 1994.
2035. **Greenspan SL**, **Myers ER**, **Maitland LA**, **Resnick NM**, **Hayes WC**, Fall severity and bone mineral

density as risk factors for hip fracture in ambulatory elderly, JAMA 271:128, 1994.
2036. **Armstrong AL**, **Oborne J**, **Coupland CAC**, **MacPherson MB**, **Bassey EJ**, **Wallace WA**, Effects of hormone replacement therapy on muscle performance and balance in post-menopausal women, Clin Sci 91:685, 1996.
2037. **Ekblad S**, **Lönnberg B**, **Berg G**, **Ödkvist L**, **Ledin T**, **Hammar M**, Estrogen effects on postural balance in postmenopausal women without vasomotor symptoms: a randomized masked trial, Obstet Gynecol 95:278, 2000.
2038. **Bemben DA**, **Langdon DB**, Relationship between estrogen use and musculoskeletal function in postmenopausal women, Maturitas 42:119, 2002.
2039. **Ribom EL**, **Piehl-Aulin K**, **Ljunghall S**, **Ljunggren O**, **Naessén T**, Six months of hormone replacement therapy does not influence muscle strength in postmenopausal women, Maturitas 42:225, 2002.
2040. **Brown M**, **Birge SJ**, **Kohrt WM**, Hormone replacement therapy does not augment gains in muscle strength or fat-free mass in response to weight-bearing exercise, J Gerontol 52A:B166, 1997.
2041. **Randell KM**, **Honkanen RJ**, **Komulainen MH**, **Tuppurainen MT**, **Kroger H**, **Saarikoski S**, Hormone replacement therapy and risk of falling in early postmenopausal women—a population-based study, Clin Endocrinol 54:769, 2001.
2042. **Parker MJ**, **Gillespie LD**, **Gillespie WJ**, Hip protectors for preventing hip fractures in the elderly, Cochrane Database Syst Rev (3):CD001255, 2003.
2043. **Lukert BP**, **Johnson BE**, **Robinson RG**, Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss, J Bone Miner Res 7:1063, 1992.
2044. **Hall GM**, **Daniels M**, **Doyle DV**, **Spector TD**, Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids, Arthritis Rheum 37:1499, 1994.
2045. **Adachi JD**, **Saag KG**, **Delmas PD**, **Liberman UA**, **Emkey RD**, **Seeman E**, **Lane NE**, **Kaufman JM**, **Poubelle PE**, **Hawkins F**, **Correa-Rotter R**, **Menkes CJ**, **Rodriguez-Portales JA**, **Schnitzer TJ**, **Block JA**, **Wing J**, **McIlwain HH**, **Westhovens R**, **Brown J**, **Melo-Gomes JA**, **Gruber BL**, **Yanover MJ**, **Leite MO**, **Siminoski KG**, **Nevitt MC**, **Sharp JT**, **Malice MP**, **Dumortier T**, **Czachur M**, **Carofano W**, **Daifotis A**, Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial, Arthritis Rheum 44:202, 2001.
2046. **Reid DM**, **Devogelaer J-P**, **Saag KG**, **Roux C**, **Lau C-S**, **Regionster J-Y**, **Papanastasiou P**, **Ferreira A**, **Hartl F**, **Fashola T**, **Mesenbrink P**, **Sambrook PN**; for the **HORIZON Investigators**, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, Lancet 373:1253, 2009.
2047. **Yang YX**, **Lewis JD**, **Epstein S**, **Metz DC**, Long-term proton pump inhibitor therapy and risk of hip fracture, JAMA 296:2947, 2006.
2048. **Vestergaard P**, **Rejnmark L**, **Mosekilde L**, Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture, Calcif Tissue Int 79:76, 2006.
2049. **Kahn S**, **Haffner SM**, **Heise MA**, **Herman WH**, **Holman RR**, **Jones NP**, **Kravitz BG**, **Lachin JM**, **O'Neill MC**, **Zinman B**, **Viberti G**; **ADOPT Study Group**, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, N Engl J Med 355:2427, 2006.
2050. **Grey A**, **Bolland M**, **Gamble G**, **Wattie D**, **Horne A**, **Davidson J**, **Reid JR**, The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial, J Clin Endocrinol Metab 92:1305, 2007.
2051. **Cummings SR**, **Palermo L**, **Browner W**, **Marcus R**, **Wallace R**, **Pearson J**, **Blackwell T**, **Eckert S**, **Black D**, Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group, JAMA 283:1318, 2000.
2052. **Adami S**, **Giannini S**, **Bianchi G**, **Sinigaglia L**, **Di Munno O**, **Fiore CE**, **Minisola S**, **Rossini M**, Vitamin D status and response to treatment in post-menopausal osteoporosis, Osteoporos Int 20:239, 2009.
2053. **Komulainen M**, **Kroger H**, **Tuppurainen MT**, **Heikkinen AM**, **Honkanen RJ**, **Saarikoski S**, Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical

trial, Osteoporos Int 11:211, 2000.
2054. **Gavaler JS**, Thoughts on individualizing hormone replacement therapy based on the postmenopausal health disparities study data, J Womens Health 12:757, 2003.

Chapter eighteen

REFERENCES

1. **Tyldesley JA**, Hatchepsut: The Female Pharaoh, Penguins Group, London, 1996, pp. 99–129.
2. **Benjamin H**, The transsexual phenomenon, Trans N Y Acad Sci 29(4):428, 1967.
3. **Hembree WC**, **Cohen-Kettenis PT**, **Gooren L**, **Hannema SE**, **Meyer WJ**, **Murad MH**, **Rosenthal SM**, **Safer JD**, **Tangpricha V**, **T'Sjoen GG**, Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice guideline, J Clin Endocrinol Metab 102(11):1, 2017.
4. **David KG**, **Dingemanse E**, **Freud JL**, On crystalline male hormone from testicles (testosterone) effective as from urine or from cholesterol, Hoppe-Seyler's Z Physiol Chem 233(5–6):261, 1935 (in German) Translated.
5. **Freeman ER**, **Bloom DA**, **McGuire EJ**, A brief history of testosterone, J Urol 165(2):371, 2001.
6. **Dodds EC**, **Goldberg L**, **Lawson W**, **Robinson R**, Estrogenic activity of certain synthetic compounds, Nature 141(3562):247, 1938.
7. **Magnus H**, Chirurgische Eingriffe bei Anomalien des Sexuallebens, Therap Ggw 67:451, 1933.
8. **Grant JM**, **Mottet LA**, **Tanis J**, **With DM**, **Henman JL**, **Harrison J**, et al., National transgender discrimination survey report on health and healthcare: findings of a study by the National Center for Transgender Equality and National Gay and Lesbian Task Force, 2010. http://www.thetaskforce.org/static_html/downloads/resources_and_tools/ntds_reort_on_health.pdf (Accessed March 18, 2018).
9. **Puckett JA**, **Cleary P**, **Rossman K**, **Newcomb ME**, **Mustanski B**, Barriers to gender-affirming care of transgender and gender nonconforming individuals, Sex Res Social Policy 15(1):48, 2018.
10. **World Professional Association for Transgender Health**, Standards of care for the health of transsexual, transgender, and gender nonconforming people. http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1351&pk_association_webpage=3926 (Accessed March 14, 2018).
11. **Lee PA**, **Houk CP**, **Ahmed SF**, **Hughes IA**, Consensus statement on management of intersex disorders, Pediatrics 118(2):488, 2006.
12. **Flores AR**, **Herman JL**, **Gates GJ**, **Brown TNT**, How Many Adults Identify as Transgender in the United States, The Williams Institute, UCLA School of Law, 2016. https://williamsinstitute.law.ucla.edu/wp-content/uploads/How-Many-Adults-Identify-as-Transgender-in-the-United-States.pdf
13. **Van Kesteren PJ**, **Gooran LJ**, **Megens JA**, An epidemiologic and demographic study of transsexuals in the Netherlands, Arch Sex Behav 25:589, 1996.
14. **DeCuypere G**, **Van Hemelrijck M**, **Michel A**, **Carael B**, **Heylens G**, **Rubens R**, **Hoebeke H**, **Monstery S**, Prevalence and demography of transsexualism in Belgium, Eur Psychol 22(3):137, 2007.
15. **Chapkin SR**, **Kim F**, Ten most important things to know about caring for transgender patients, Am J Med 130:1238, 2017.
16. **American Psychiatric Association**, Diagnostic and statistic manual of mental disorders: DSM-IV- TR. Washington, DC, 2000.
17. **Cohen-Kettenis PT**, Gender change in 46, XY persons with 5α-reductase-2 deficiency and 17β-hydrozysteroid dehydrogenase-3 deficiency, Arch Sex Behav 34(4):399, 2005.
18. **Barenbaum SA**, Effects of early androgen on sex-typed activities and interests in adolescents with congenital adrenal hyperplasia, Horm Behav 35:102, 1999.
19. **Ediati A**, **Juniarto AZ**, **Birnie E**, **Drop SLS**, **Faradz SMH**, **Dessens AB**, Gender development in Indonesian children, adolescents, and adults with disorders of sex development, Arch Sex Behav 44(5):1339, 2015.
20. **Dessens AB**, **Slijper FME**, **Drop SLS**, Gender dysphoria and gender change in chromosomal females with congenital adrenal hyperplasia, Arch Sex Behav 34(4):389, 2005.
21. **Gangaher A**, **Jyostna VP**, **Chauhan V**, **Hohn J**, **Mehta M**, Gender of rearing and psychosocial aspect of 46 XX congenital adrenal hyperplasia, Ind J Endocrin Metab 20(6):870, 2016.
22. **Reiner WG**, **Gearhart JP**, Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth, N Engl J Med 350:333, 2004.

23. **Gooren L**, The biology of human psychosexual differentiation, Horm Behav 50(4):589, 2006.
24. **Chung WCJ**, **De Vries GJ**, **Swaab D**, Sexual differentiation of the bed nucleus of the stria terminalis in humans may extend into adulthood, J Neurosci 22(3):1027, 2002.
25. **Swaab DF**, **Fliers E**, A sexually dimorphic nucleus in the human brain, Science 228:1112, 1985.
26. **Cooke BM**, **Hegstrom CD**, **Villeneuve LS**, **Breedlove SM**, Sexual differentiation of the vertebrate brain: principles and mechanisms, Front Neuroendocrinol 19:323, 1998.
27. **Zhou JN**, **Hofman MA**, **Gooren LJG**, **Swaab DF**, A sex difference in the human brain and its relation to transsexuality, Nature 378:68, 1995.
28. **Kruijver FP**, **Zhou JN**, **Pool CW**, **Hofman MA**, **Gooren LJG**, **Swaab DF**, Male-to-female transsexuals have female neuron numbers in a limbic nucleus, J Clin Endocrinol Metab 85(5):2034, 2000.
29. **Coolidge FL**, **Thede LL**, **Young SE**, The heritability of gender identity disorder in a child and adolescent twin sample, Behav Genet 32(4):251, 2002.
30. **Heylens G**, **De Cuypere G**, **Zucker KJ**, **Schelfaut C**, **Elaut E**, **Vanden Bossche H**, **De Baere E**, **T'Sjoen G**, Gender identity disorder in twins: a review of the case report literature, J Sex Med 9(3):751, 2012.
31. **Gómez-Gil E**, **Trilla-García A**, **Godás-Sieso T**, **Halperin-Rabinovich I**, **Puig Domingo M**, **Vidal Hagemeijer A**, **Peri Nogués JM**, Estimación de la prevalencia, incidencia y razón de sexos del transexualismo en Cataluña según la demanda asistencial [Estimation of prevalence, incidence and sex ratio of transsexualism in Catalonia according to health care demand]. Actas Esp Psiquiatr 34:295, 2006.
32. **Unger CA**, Care of the transgender patient: the role of the gynecologist, Obstet Gynecol 211(1):16, 2014.
33. **Owen-Smith AA**, **Sineath C**, **Sanchez T**, **Dea R**, **Giammettei S**, **Gillespie T**, **Helms MF**, **Hunkeler EM**, **Quinn VP**, **Roblin D**, **Slovis J**, **Stephenson R**, **Sullivan PS**, **Tangpricha V**, **Woodyatt C**, **Goodman M**, Perception of community tolerance and prevalence of depression among transgender persons, J Gay Lesbian Ment Health 21(1):64, 2017.
34. **Su D**, **Irwin JA**, **Fischer C**, **Ramos A**, **Kelley M**, **Mendoza DAR**, **Coleman JD**, Mental health disparities within the LGBT population: a comparison between transgender and nontransgender individuals, Transgend Health 1(1):12, 2016.
35. **Haas AP**, **Rodgers PL**, **Herman JL**, Suicide Attempts among Transgender and Gender Nonconforming Adults, The Williams Institute, UCLA Law School, 2014, https://williamsinstitute.law.ucla.edu/wp-content/uploads/AFSP-Williams-Suicide-Report-Final.pdf
36. **American Psychiatric Association**, Diagnostic and Statistical Manual of Mental Disorders, 5th ed., American Psychiatric Association Publishing, Arlington, 2013.
37. **World Health Organization**, International Statistical Classification of Diseases and Related Health Problems, 10th Revision, WHO Publishing, Geneva, 2011.
38. **Gómez-Gil E**, **Zubiaurre-Elorza L**, **Esteva I**, **Guillamon A**, **Godás T**, **Cruz Almaraz M**, **Halperin I**, **Salamero M**, Hormone-treated transsexuals report less social distress, anxiety and depression, Psychoneuroendocrinology 37(5):662, 2012.
39. **Gorin-Lazard A**, **Baumstarck K**, **Boyer L**, **Maquigneau A**, **Gebleuz S**, **Penochet J**, Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals, J Nerv Ment Dis 201(11):996, 2013.
40. **Colizzi M**, **Costa R**, **Todarello O**, Transsexual patients' psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study, Psychoneuroendocrinology 39:65, 2014.
41. **Murad MH**, **Elmin MB**, **Garcia MZ**, **Mullan RJ**, **Murad A**, **Erwin PJ**, **Montori VM**, Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes, Clin Endocrinol 72:214, 2010.
42. **Irwig M**, Testosterone therapy for transgender men, Lancet Diabetes Endocrinol 5(4):301, 2017.
43. **Deutsch MB**, Overview of feminizing hormone therapy, In: Madeline B Deutsch, ed., Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People, 2nd ed., Center of Excellence for Transgender Health, Department of Family and Community Medicine, University of California San Francisco, 2016. www.transhealth.ucsf.edu/guidelines (Accessed March 8, 2018).

44. **Ahmad S**, **Leinung M**, The response of the menstrual cycle to initiation of hormone therapy in transgender men, Transgend Health 2(1):176, 2017.
45. **Deutsch MB**, **Bhakri V**, **Kubicek K**, Effects of cross-sex hormone treatment on transgender women and men, Obstet Gynecol 125:605, 2015.
46. **Nakamura A**, **Watanabe M**, **Sugimoto M**, **Sako T**, **Mahmood S**, **Kaku M**, **Nasu Y**, **Ishii K**, **Nagai A**, **Kumon H**, Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder, Endocr J 60:275, 2013.
47. **Velho I**, **Fighera TM**, **Ziegelmann PK**, **Spritzer PM**, Effects of testosterone therapy on BMI, blood pressure and laboratory profile of transgender men: a systematic review, Andrology 5:881, 2017.
48. **Wierckx K**, **Van Caenegem E**, **Schreiner T**, **Haraldsen I**, **Fisher A**, **Toye K**, **Kaufman JM**, **T'Sjoen G**, Cross-sex hormone therapy in trans person is safe and effective at short-time follow-up: results from European Network for the Investigation of Gender incongruence, J Sex Med 11(8):1999, 2014.
49. **Elamin MB**, **Garcia MZ**, **Murad MH**, **Erwin PJ**, **Montori VM**, Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analysis, Clin Endocrinol 71(1):1, 2010.
50. **Weinand JD**, **Safer JD**, Hormone therapy in transgender adults is safe with provider supervision: a review of hormone therapy sequelae for transgender individuals, J Clin Transl Endocrinol 2:55, 2015.
51. **Shatzel JJ**, **Connellly KJ**, **DeLoughery TG**, Thrombotic Issues in transgender medicine: a review, Am J Hematol 92(2):204, 2016.
52. **Lehrman K**, Pulmonary embolism in a transsexual man taking diethylstilbestrol, JAMA 235(2):532, 1976.
53. **Asscheman H**, **Tsjoen G**, **Lemaire A**, **Mas M**, **Meriggiola M**, **Mueller A**, **Kuhn A**, **Dhejne C**, **Morel-Journel N**, **Gooren LJ**, Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review, Andrologia 46(7):791, 2013.
54. **Wierckx K**, **Elaut E**, **Declercq E**, **Heylens G**, **De Cuypere G**, **Taes Y**, **Kaufman JM**, **T'Sjoen G**, Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study, Eur J Endocrinol 169(4):471, 2013.
55. **Wierckx K**, **Mueller S**, **Weyers S**, **Van Caenegem E**, **Roef G**, **Heylens G**, **T'Sjoen G**, Long-term evaluation of cross-sex hormone treatment in transsexual persons, J Sex Med 9(10):2641, 2012.
56. **Drummond KD**, **Bradley SJ**, **Peterson-Badali M**, **Zucker KJ**, A follow-up study of girls with gender identity disorder, Dev Psychol 44(1):34, 2008.
57. **Wallien MSC**, **Swaab H**, **Cohen-Kettenis PT**, Psychiatric comorbidity among children with gender identity disorder, J Am Acad Child Adolesc Physiatry 46(10):1307, 2007.
58. **Lynch MM**, **Khandheria MM**, **Meyer WJ**, Retrospective study of the management of childhood and adolescent gender identity disorder using medroxyprogesterone acetate, Int J Transgenderism 16:201, 2015.
59. **Paulson RJ**, At last, an orally active gonadotropin-releasing hormone antagonist, Fertil Steril 111(1):30-31, 2019. doi: 10.1016/j.fertnstert.2018.11.024. No abstract available. PMID: 30611410
60. **deVries ALC**, **Steensma TD**, **Doreleijers TAH**, **Cohen-Kettenis PT**, Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study, J Sex Med 8(8):2276, 2011.
61. **Mann L**, **Harmoni R**, **Power C**, Adolescent decision-making: the development of competence, J Adolesc 12(3):265, 1989.
62. **Stultiens L**, **Goddin T**, **Borry P**, **Dierickx K**, **Nys H**, Minors and informed consent: a comparative approach, Eur J Health Law 14(1):21, 2007.
63. **Goldman RH**, **Kaser DJ**, **Missmer SA**, **Farland LV**, **Scout**, **Ashby RK**, **Ginsberg ES**, Fertility treatment for the transgender community: a public opinion study, J Assist Reprod Genet 34:1457, 2017.
64. **Wierckx K**, **Van Caenegem E**, **Pennings G**, **Elaut E**, **Dedecker D**, **Van De Peer F**, **Weyers S**, **De Sutter P**, **T'Sjoen G**, Reproductive wish in transsexual men, Hum Reprod 27(2):483, 2012.
65. **De Sutter P**, **Kira K**, **Verschoor A**, **Hotimsky A**, The desire to have children and the preservation of fertility in transsexual women: a survey, Int J Transgenderism 6(3):215, 2002.
66. **Light AD**, **Obedin-Maliver J**, **Sevelius JM**, **Kerns JL**, Transgender men who experience pregnancy after female-to-male gender transitioning, Obstet Gynecol 124(6):1120, 2014.
67. **Maxwell S**, **Noyes N**, **Keefe D**, **Berkeley AS**, **Goldman KN**, Pregnancy outcomes after fertility

preservation in transgender men, Obstet Gynecol 129(6):1031, 2017.
68. **Schneider F**, **Kliesch S**, **Shlatt S**, **Neuhaus N**, Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function, Andrology 5(5):873, 2017.
69. **Hamada A**, **Kingsberg S**, **Wierckx K**, **T'Sjoen G**, **De Sutter P**, **Knudson G**, **Agarwal A**, Semen characteristics of transwomen referred for sperm banking before sex transition: a case series, Andrologia 47(7):832, 2015.
70. **Bentsianov S**, **Gordon L**, **Goldman A**, **Jacobs A**, **Steever J**, Use of copper intrauterine device in transgender male adolescents, Contraception 98(1):74, 2018.
71. **American College of Obstetricians-Gynecologists**, Practice bulletin no. 122: breast cancer screening, Obstet Gynecol 118(2 Pt 1):372, 2011.
72. **Siu AL**; **U.S. Preventative Services Task Force**, Screening for breast cancer: U.S. Preventative Services Task Force Recommendation Statement, Ann Intern Med 164(4):279, 2016.
73. **Gynberg M**, **Fanchin R**, **Dubost G**, **Colau JC**, **Bremont-Weil C**, **Frydman R**, **Ayoubi JM**, Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population, Reprod Biomed Online 20:553, 2010.
74. **Weyers S**, **Villeirs G**, **Vanherreweghe E**, **Verstraelen H**, **Monstrey S**, **Van den Broecke R**, **Gerris J**, Mammography and breast sonography in transsexual women, Eur J Radiol 74(3):508, 2010.
75. **Gooren LJ**, **van Trotsenburg MAA**, **Giltay EJ**, **van Diest PJ**, Breast cancer development in transsexual subjects receiving cross-sex hormone treatment, J Sex Med 10(12):3129, 2013.
76. **Anderson GL**, **Limacher M**, **Assaf AR**, **Bassford T**, **Beresford SA**, **Black H**, **Bonds D**, **Brunner R**, **Brzyski R**, **Caan B**, **Chlebowski R**, **Curb D**, **Gass M**, **Hays J**, **Heiss G**, **Hendrix S**, **Howard BV**, **Hsia J**, **Hubbell A**, **Jackson R**, **Johnson KC**, **Judd H**, **Kotchen JM**, **Kuller L**, **LaCroix AZ**, **Lane D**, **Langer RD**, **Lasser N**, **Lewis CE**, **Manson J**, **Margolis K**, **Ockene J**, **O'Sullivan MJ**, **Phillips L**, **Prentice RL**, **Ritenbaugh C**, **Robbins J**, **Rossouw JE**, **Sarto G**, **Stefanick ML**, **Van Horn L**, **Wactawski-Wende J**, **Wallace R**, **Wassertheil-Smoller S**; **Women's Health Initiative Steering Committee**, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trail, JAMA 291(14):1701, 2004.
77. **Saslow D**, **Solomon D**, **Lawson HW**, **Killackey M**, **Kulasingam SL**, **Cain J**, **Garcia FA**, **Moriarty AT**, **Waxman AG**, **Wilbur DC**, **Wentzensen N**, **Downs LS Jr**, **Spitzer M**, **Moscicki AB**, **Franco EL**, **Stoler MH**, **Schiffman M**, **Castle PE**, **Myers ER**, **Chelmow D**, **Herzig A**, **Kim JJ**, **Kinney W**, **Herschel WL**, **Waldman J**, American Cancer Society, American Society for Colposcopy and Cervical Pathology and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer, J Low Genit Tract Dis 16(3):175, 2012.
78. **Irwg M**, Clinical dilemmas in the management of transgender men, Curr Opin 24(3):233, 2017.
79. **Miksad RA**, **Bubley G**, **Church P**, **Sanda M**, **Rofsky N**, **Kaplan I**, **Cooper A**, Prostate cancer in a transgender woman 41 years after initiation of feminization, JAMA 296(19):2316, 2006.
80. **Wolf AM**, **Wender RC**, **Etzioni RB**, **Thompson IM**, **D'Amico AV**, **Volk RJ**, **Brooks DD**, **Dash C**, **Guessous I**, **Andrews K**, **DeSantis C**, **Smith RA**; **American Cancer Society Prostate Cancer Advisory Committee**, American Cancer Society guidelines for the early detection of prostate cancer: update 2010, CA Cancer J Clin 60(2):70, 2010.
81. **Weyers S**, **De Sutter P**, **Hoebeke S**, **Monstrey G**, **T'Sjoen G**, **Verstraelen H**, **Gerris J**, Gynaecological aspects of the treatment and follow-up of transsexual men and women, Facts Views Vis Obgyn 2(1):35, 2010.
82. **Trum HW**, **Hoebeke P**, **Gooren LJ**, Sex reassignment of transsexual people from a gynecologist's and urologist's perspective, Acta Obstet Gynecol Scand 94(6):563, 2015.
83. **Gooren L**, Hormone treatment of the adult transsexual patient, Horm Res 64:31, 2005.
84. **Morrison SD**, **Shakir A**, **Vyas KS**, **Kirby J**, **Crane CN**, **Lee GK**, Paloplasty: a review of technique and outcomes, Plast Reconstr Surg 138(3):594, 2016.
85. **Morrison SD**, **Chen ML**, **Crane CN**, An overview of female-to-male gender-confirming surgery, Nat Rev Urol 14(8):486, 2017.
86. **Lista F**, **Ahmad J**, Evidence-based medicine: augmentation mammaplasty, Plast Reconstr Surg 132(6):1684,

2013.
87. **Bizic MR**, **Stojanovic V**, **Djordjevic ML**, Genital reconstruction for the transgendered individual, J Pediatr Urol 13(5):446, 2017.
88. **Horbach SER**, **Bouman M**, **Smit JM**, **Ozer M**, **Buncamper ME**, **Mullender MG**, Outcome of vaginoplasty in male-to-female transgenders: a systematic review of surgical techniques, J Sex Med 12:1499, 2015.

Chapter nineteen

REFERENCES

1. Prevalence of obesity among adults and youth: United States, 2015–2016, https://www.cdc.gov/nchs/data/databriefs/db288.pdf
2. **National Center for Health Statistics**, Health, United States, 2016: With Chartbook on Long-Term Trends in Health, National Center for Health Statistics, Hyattsville, 2017.
3. **Flegal KM**, **Kruszon-Moran D**, **Carroll MD**, **Fryar CD**, **Ogden CL**, Trends in obesity among adults in the United States, 2005 to 2014, JAMA 315:2284, 2016.
4. **Ogden C**, **Carroll MD**, **Lawman, HG**, **Fryar CD**, **Kruszon-Moran D**, **Kit BK**, **Flegal BM**, Trends in obesity among children and adolescents in the United States, 1988–1994 through 2013–2014, JAMA 315:2292, 2016.
5. **Fryar CD**, **Carroll MD**, **Ogden CL**, Prevalence of overweight, obesity, and extreme obesity among adults aged 20 and over: United States, 1960–1962 through 2011–2014, National Center for Health Statistics Data, Health E-Stats, July 2016.
6. **Fryar CD**, **Carroll MD**, **Ogden CL**, Prevalence of overweight and obesity among children and adolescents aged 2–19 years: United States, 1963–1965 through 2013–2014, National Center for Health Statistics Data, Health E-Stats, July 2016.
7. **Harlan WR**, **Landis JR**, **Flegal KM**, **Davis CS**, **Miller ME**, Secular trends in body mass in the United States, 1960–1980, Am J Epidemiol 128:1065, 1988.
8. **Kuczmarski RJ**, **Flegal KM**, **Campbell SM**, **Johnson CL**, Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991, JAMA 272:205, 1994.
9. **Prentice AM**, **Jebb SA**, Obesity in Britain: gluttony or sloth?, Br Med J 311: 437, 1995.
10. **Flegal KM**, **Carroll MD**, **Ogden CL**, **Johnson CL**, Prevalence and trends in obesity among US adults, 1999–2000, JAMA 288:1723, 2002.
11. **Centers for Disease Control and Prevention**, State Indicator Report on Physical Activity, 2010. U.S. Department of Health and Human Services, Atlanta, 2010.
12. **Ogden CL**, **Carroll MD**, **Curtin LR**, **Lamb MM**, **Flegal KM**, Prevalence of high body mass index in US children and adolescents, 2007–2008, JAMA 303:242, 2010.
13. **Adams KF**, **Schatzkin A**, **Harris TB**, **Kipnis V**, **Mouw T**, **Ballard-Barbash R**, **Hollenbeck A**, **Leitzmann MF**, Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old, N Engl J Med 355:763, 2006.
14. **Manson JE**, **Willett WC**, **Stampfer MJ**, **Coditz GA**, **Hunter DJ**, **Hankinson SE**, **Hennekens CH**, **Speizer FE**, Body weight and mortality among women, N Engl J Med 333:677, 1995.
15. **Park YW**, **Zhu S**, **Palaniappan L**, **Heshka S**, **Carnethon MR**, **Heymsfield SB**, The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994, Arch Intern Med 163:427, 2003.
16. **Calle EE**, **Rodriguez C**, **Walker-Thurmond K**, **Thun MJ**, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med 348:1625, 2003.
17. **Renehan AG**, **Tyson M**, **Egger M**, **Heller RF**, **Zwahlen M**, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet 371:569, 2008.
18. **Must A**, **Jacques PF**, **Dallal GE**, **Bajema CJ**, **Dietz WH**, Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study of 1922 to 1935, N Engl J Med 327:1350, 1992.
19. **Peeters A**, **Barendregt JJ**, **Willekens F**, **Mackenbach JP**, **Al Mamun A**, **Bonneux L**; **for NEDCOM, the Netherlands Epidemiology and Demography, Compression of Morbidity Research Group**, Obesity in adulthood and its consequences for life expectancy: a life-table analysis, Ann Intern Med 138:24, 2003.
20. **Stewart ST**, **Cutler DM**, **Rosen AB**, Forecasting the effects of obesity and smoking on U.S. life expectancy, N Engl J Med 361:2252, 2009.
21. **Ravussin E**, **Swinburn BA**, Pathophysiology of obesity, Lancet 340:404, 1992.

22. **Thomas AE**, **McKay DA**, **Cutlip MB**, A nomograph method for assessing body weight, Am J Clin Nutr 29:302, 1976.
23. **Prospective Studies Collaboration**; **Whitlock G**, **Lewington S**, **Sherliker P**, **Clarke RB**, **Emberson J**, **Halsey J**, **Qizilbash N**, **Collins R**, **Peto R**, Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies, Lancet 373:1083, 2009.
24. **Field AE**, **Coakley EH**, **Must A**, **Spadano JL**, **Laird N**, **Dietz WH**, **Rimm E**, **Colditz GA**, Impact of overweight on the risk of developing common chronic diseases during a 10-year period, Arch Intern Med 161:1581, 2001.
25. **Colditz GA**, **Willett WC**, **Rotnitzky A**, **Manson JE**, Weight gain as a risk factor for clinical diabetes mellitus in women, Ann Intern Med 122:481, 1995.
26. **Willett WC**, **Manson JE**, **Stampfer MJ**, **Colditz GA**, **Rosner B**, **Speizer FE**, **Hennekens CH**, Weight change and coronary heart disease in women: risk within the "normal" range, JAMA 273:461, 1995.
27. **Ferraro R**, **Lillioja S**, **Fontvieille A-M**, **Rising R**, **Bogardus C**, **Ravussin E**, Lower sedentary metabolic rate in women compared with men, J Clin Invest 90:780, 1992.
28. **Fukagawa NA**, **Bandini LG**, **Young JB**, Effect of age on body composition and resting metabolic rate, Am J Physiol 259:E233, 1990.
29. **Vaughan L**, **Zurlo F**, **Ravussin E**, Aging and energy expenditure, Am J Clin Nutr 53:821, 1991.
30. **Van Pelt RE**, **Jones PP**, **Davy KP**, **Desouza CA**, **Tanaka H**, **Davy BM**, **Seals DR**, Regular exercise and the age-related decline in resting metabolic rate in women, J Clin Endocrinol Metab 82:3208, 1997.
31. **Suter PM**, **Schutz Y**, **Jequier E**, The effect of ethanol on fat storage in healthy subjects, N Engl J Med 326:983, 1992.
32. **Fabry P**, **Hejda S**, **Cerny K**, Effects of meal frequency in school children. Changes in weight-height proportion and skinfold thickness, Am J Clin Nutr 18:358, 1966.
33. **Gold RM**, Hypothalamic obesity: the myth of the ventromedial nucleus, Science 182:488, 1973.
34. **Leibowitz SF**, Brain peptides and obesity: pharmacologic treatment, Obes Res 3(Suppl 4):573S, 1995.
35. **Wilber JF**, Neuropeptides, appetite regulation, and human obesity, JAMA 266:257, 1991.
36. **Sabatier N**, **Rowe I**, **Leng G**, Central release of oxytocin and the ventromedial hypothalamus, Biochem Soc Trans 35:1247, 2007.
37. **Kennedy GC**, The role of depot fat in the hypothalamic control of food intake in the rat, Proc R Soc Lond B Biol Sci 140:578, 1953.
38. **Hervey GR**, The effects of lesions in the hypothalamus in parabiotic rats, J Physiol 145:336, 1958.
39. **Zhang Y**, **Proenca R**, **Maffei M**, **Barone M**, **Leopold L**, **Friedman J**, Positional cloning of the mouse obese gene and its human homologue, Nature 372:425, 1994.
40. **Rossi J**, **Balthasar N**, **Olson D**, **Scott M**, **Berglund E**, **Lee CE**, **Choi MJ**, **Lauzon D**, **Lowell BB**, **Elmquist JK**, Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis, Cell Metab 13(2): 195, 2011.
41. **Campfield LA**, **Smith FJ**, **Burn P**, The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks, Horm Metab Res 28:619, 1996.
42. **Tartaglia LA**, The leptin receptor, J Biol Chem 272:6093, 1997.
43. **Fan W**, **Boston BA**, **Kesterson RA**, **Hruby VJ**, **Cone RD**, Role of melanocortinergic neurons in feeding and the agouti obesity syndrome, Nature 385:165, 1997.
44. **Huszar D**, **Lynch CA**, **Fairchild-Huntress V**, **Dunmore JH**, **Fang Q**, **Berkemeier LR**, **Gu W**, **Kesterson RA**, **Boston BA**, **Cone RD**, **Smith FJ**, **Campfield LA**, **Burn P**, **Lee F**, Targeted disruption of the melanocortin-4 receptor results in obesity in mice, Cell 88(1):131, 1997.
45. **Krude H**, **Biebermann H**, **Luck W**, **Horn R**, **Brabant G**, **Gruters A**, Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans, Nat Genet 19:155, 1998.
46. **Yeo GS**, **Lank EJ**, **Farooqi IS**, **Keogh J**, **Challis BG**, **O'Rahilly S**, Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms, Hum Mol Genet 12:561, 2003.
47. **Caro JF**, **Sinha MK**, **Kolaczynski JW**, **Zhang PL**, **Considine RV**, Leptin: the tale of an obesity gene,

Diabetes 45:1455, 1996.
48. **Stephens TW**, **Basinski M**, **Bristow PK**, **Bue-Valleskey JM**, **Burgett SG**, **Craft L**, **Hale J**, **Hoffman J**, **Hsiung HM**, **Kriauciunas A**, **et al.,** The role of neuropeptide Y in the antiobesity action of the obesity gene product, Nature 377:530, 1995.
49. **Mercer JG**, **Hoggard N**, **Williams LM**, **Lawrence CB**, **Hannah LT**, **Trayburn P**, Localization of leptin receptor mRNA and the long form splice variant (Ob-Rb) in mouse hypothalamus and adjacent brain regions by in situ hybridization, FEBS Lett 387:113, 1996.
50. **Devos R**, **Richards JG**, **Campfield LA**, **Tartaglia LA**, **Guisez Y**, **Van der Heyden J**, **Travernier J**, **Plaetinck G**, **Burn P**, OB protein binds specifically to the chorioid plexus of mice and rats, Proc Natl Acad Sci U S A 93:5668, 1996.
51. **Cusin I**, **Rohner-Jeanrenaud F**, **Stricker-Krongrad A**, **Jeanrenaud B**, The weight-reducing effect of an intracerebroventricular bolus injection of leptin in genetically obese fa/fa rats. Reduced sensitivity compared with lean animals, Diabetes 45:1446, 1996.
52. **Muccioli G**, **Tschöp M**, **Papotti M**, **Deghenghi R**, **Hieman M**, **Ghigo E**, Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity, Eur J Pharmacol 440:235, 2002.
53. **Tena-Sempere M**, Ghrelin as a pleotrophic modulator of gonadal function and reproduction, Nat Clin Pract 4:666, 2008.
54. **Fernández-Fernández R**, **Tena-Sempere M**, **Navarro VM**, **Barreiro ML**, **Castellano JM**, **Aguilar E**, **Pinilla L**, Effects of ghrelin upon gonadotropin-releasing hormone and gonadotropin secretion in adult female rats: in vivo and in vitro studies, Neuroendocrinology 82(5–6):245, 2005.
55. **Müller TD**, **Nogueiras R**, **Andermann ML**, **Andrews ZB**, **Anker SD**, **Argente J**, **Batterham RL**, **Benoit SC**, **Bowers CY**, **Broglio F**, **Casanueva FF**, **D'Alessio D**, **Depoortere I**, **Geliebter A**, **Ghigo E**, **Cole PA**, **Cowley M**, **Cummings DE**, **Dagher A**, **Diano S**, **Dickson SL**, **Diéguez C**, **Granata R**, **Grill HJ**, **Grove K**, **Habegger KM**, **Heppner K**, **Heiman ML**, **Holsen L**, **Holst B**, **Inui A**, **Jansson JO**, **Kirchner H**, **Korbonits M**, **Laferrère B**, **LeRoux CW**, **Lopez M**, **Morin S**, **Nakazato M**, **Nass R**, **Perez-Tilve D**, **Pfluger PT**, **Schwartz TW**, **Seeley RJ**, **Sleeman M**, **Sun Y**, **Sussel L**, **Tong J**, **Thorner MO**, **van der Lely AJ**, **van der Ploeg LH**, **Zigman JM**, **Kojima M**, **Kangawa K**, **Smith RG**, **Horvath T**, **Tschöp MH**, Ghrelin, Mol Metab 21:437, 2015.
56. **Kojima M**, **Hosoda H**, **Date Y**, **Nakazato M**, **Matsuo H**, **Kangawa K**, Ghrelin is a growth hormone-releasing acylated peptide from stomach, Nature 402:656, 1999.
57. **Arvat E**, **Maccario M**, **Di Vito L**, **Broglio F**, **Benso kA**, **Gottero C**, **Papotti M**, **Muccioli G**, **Dieguez C**, **Casanueva FF**, **Deghenghi R**, **Camanni F**, **Ghigo E**, Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS) in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS and GH-releasing hormone, J Clin Endocrinol Metab 86:1169, 2001.
58. **Batterham RL**, **Cohen MA**, **Ellis SM**, **Le Roux CW**, **Withers DJ**, **Frost GS**, **Ghatei MA**, **Bloom SR**, Inhibition of food intake in obese subjects by peptide YY3–36, N Engl J Med 349:941, 2003.
59. **Wren AM**, **Seal IJ**, **Cohen MA**, **Brynes AE**, **Frost GS**, **Murphy KG**, **Dhillo WS**, **Ghatei MA**, **Bloom SR**, Ghrelin enhances appetite and increases food intake in humans, J Clin Endocrinol Metab 86:5992, 2001.
60. **Neary NM**, **Small CJ**, **Wren AM**, **Lee JL**, **Druce MR**, **Palmieri C**, **Frost GS**, **Ghatei MA**, **Coombes RC**, **Bloom SR**, Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial, J Clin Endocrinol Metab 89:2832, 2004.
61. **Miljic D**, **Pekic S**, **Djurovic M**, **Doknic M**, **Milic N**, **Casanueva FF**, **Ghatei M**, **Popovic V**, Ghrelin has partial or no effect on appetite, growth hormone, prolactin and cortisol release in patients with anorexia nervosa, J Clin Endocrinol Metab 91:1491, 2006.
62. **Tena-Sempere M**, Roles of ghrelin and leptin in the control of reproductive function, Neuroendocrinology 86:229, 2007.
63. **Dietrich MO**, **Horvath TL**, Feeding signals and brain circuitry, Eur J Neurosci 30(9):1688, 2009.
64. **Broberger C**, **Johansen J**, **Johansson C**, **Schalling M**, **Hokfelt T**, The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice, Proc Natl Acad Sci U S A 95(25):15043, 1998.

65. **Horvath TL**, **Bechmann I**, **Naftolin F**, **Kalra SP**, **Leranth C**, Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate nucleus: GABAergic and non-GABAergic subpopulations, Brain Res 756(1–2):283, 1997.
66. **Ollmann MM**, **Wilson BD**, **Yang YK**, **Kerns JA**, **Chen Y**, **Gantz I**, **Barsh GS**, Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein, Science (New York, NY) 278(5335):135, 1997.
67. **Chen HY**, **Trumbauer ME**, **Chen AS**, **Weingarth DT**, **Adams JR**, **Frazier EG**, **Shen Z**, **Marsh DJ**, **Feighner SD**, **Guan XM**, **Ye Z**, **Nargund RP**, **Smith RG**, **Van der Ploeg LH**, **Howard AD**, **MacNeil DJ**, **Qian S**, Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein, Endocrinology 145(6):2607, 2004.
68. **Clark JT**, **Kalra PS**, **Crowley WR**, **Kalra SP**, Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats, Endocrinology 115(1):427, 1984.
69. **Zarjevski N**, **Cusin I**, **Vettor R**, **Rohner-Jeanrenaud F**, **Jeanrenaud B**, Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity, Endocrinology 133(4):1753, 1993.
70. **Schwartz MW**, **Seeley RJ**, The new biology of body weight regulation, J Am Diet Assoc 97:54, 1997.
71. **Bäckberg M**, **Madjid N**, **Ogren SO**, **Meister B**, Down-regulated expression of agouti-related protein (AGRP) mRNA in the hypothalamic arcuate nucleus of hyperphagic and obese tub/tub mice, Mol Brain Res 125:129, 2004.
72. **Shutter JR**, **Graham M**, **Kinsey AC**, **Scully S**, **Lüthy R**, **Stark KL**, Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice, Genes Dev 11(5):593, 1997.
73. **Ollmann MM**, **Wilson BD**, **Yang YK**, **Kerns JA**, **Chen Y**, **Gantz I**, **Barsh GS**, Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein, Science 278:135, 1997.
74. **Hahn TM**, **Breininger JF**, **Baskin DG**, **Schwartz MW**, Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons, Nat Neurosci 1(4):271, 1998.
75. **Kohno D**, **Sone H**, **Minokoshi Y**, **Yada T**, Ghrelin raises [Ca2+]i via AMPK in hypothalamic arcuate nucleus NPY neurons, Biochem Biophys Res Commun 366(2):388, 2008.
76. **Sternson SM**, **Shepherd GM**, **Friedman JM**, Topographic mapping of VMH → arcuate nucleus microcircuits and their reorganization by fasting, Nat Neurosci 8(10):1356, 2005.
77. **Takahashi KA**, **Cone RD**, Fasting induces a large, leptin-dependent increase in the intrinsic action potential frequency of orexigenic arcuate nucleus neuropeptide Y/Agouti-related protein neurons, Endocrinology 146(3):1043, 2005.
78. **Yang Y**, **Atasoy D**, **Su HH**, **Sternson SM**, Hunger states switch a flip-flop memory circuit via a synaptic AMPK-dependent positive feedback loop, Cell 146(6):992, 2011.
79. **Fioramonti X**, **Contie S**, **Song Z**, **Routh VH**, **Lorsignol A**, **Penicaud L**, Characterization of glucosensing neuron subpopulations in the arcuate nucleus: integration in neuropeptide Y and pro-opio melanocortin networks? Diabetes 56(5):1219, 2007.
80. **Enriori PJ**, **Evans AE**, **Sinnayah P**, **Jobst EE**, **Tonelli-Lemos L**, **Billes SK**, **Glavas MM**, **Grayson BE**, **Perello M**, **Nillni EA**, **Grove KL**, **Cowley MA**, Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons, Cell Metab 5:181, 2007.
81. **Creemers JW**, **Pritchard LE**, **Gyte A**, **Le Rouzic P**, **Meulemans S**, **Wardlaw SL**, **Zhu X**, **Steiner DF**, **Davies N**, **Armstrong D**, **Lawrence CB**, **Luckman SM**, **Schmitz CA**, **Davies RA**, **Brennand JC**, **White A**, Agouti-related protein is posttranslationally cleaved by proprotein convertase 1 to generate agouti-related protein (AGRP)83-132: interaction between AGRP83-132 and melanocortin receptors cannot be influenced by syndecan-3, Endocrinology 147:1621, 2006.
82. **Aponte Y**, **Atasoy D**, **Sternson SM**, AGRP neurons are sufficient to orchestrate feeding behavior rapidly and without training, Nat Neurosci 14(3):351, 2011.
83. **Cone RD**, Anatomy and regulation of the central melanocortin system, Nat Neurosci 8(5):571, 2005.
84. **Ibrahim N**, **Bosch MA**, **Smart JL**, **Qiu J**, **Rubinstein M**, **Ronnekleiv OK**, **Low MJ**, **Kelly MJ**, Hypothalamic proopiomelanocortin neurons are glucose responsive and express K(ATP) channels,

Endocrinology 144(4):1331, 2003.
85. **Parton LE**, **Ye CP**, **Coppari R**, **Enriori PJ**, **Choi B**, **Zhang CY**, **Xu C**, **Vianna CR**, **Balthasar N**, **Lee CE**, **Elmquist JK**, **Cowley MA**, **Lowell BB**, Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity, Nature 449(7159):228, 2007.
86. **Wang R**, **Liu X**, **Hentges ST**, **Dunn-Meynell AA**, **Levin BE**, **Wang W**, **Routh VH**, The regulation of glucose-excited neurons in the hypothalamic arcuate nucleus by glucose and feeding-relevant peptides, Diabetes 53(8):1959, 2004.
87. **Cowley MA**, **Smart JL**, **Rubinstein M**, **Cerdan MG**, **Diano S**, **Horvath TL**, **Cone RD**, **Low MJ**, Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus, Nature 411(6836):480, 2001.
88. **Elias CF**, **Aschkenasi C**, **Lee C**, **Kelly J**, **Ahima RS**, **Bjorbaek C**, **Flier JS**, **Saper CB**, **Elmquist JK**, Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area, Neuron 23(4):775, 1999.
89. **Krashes MJ**, **Koda S**, **Ye C**, **Rogan SC**, **Adams AC**, **Cusher DS**, **Maratos-Flier E**, **Roth BL**, **Lowell BB**, Rapid, reversible activation of AgRP neurons drives feeding behavior in mice, J Clin Invest 121(4):1424, 2011.
90. **Dietrich MO**, **Antunes C**, **Geliang G**, **Liu ZW**, **Borok E**, **Nie Y**, **Xu AW**, **Souza DO**, **Gao Q**, **Diano S**, **Gao XB**, **Horvath TL**, Agrp neurons mediate Sirt1's action on the melanocortin system and energy balance: roles for Sirt1 in neuronal firing and synaptic plasticity, J Neurosci 30(35):11815, 2010.
91. **Tong Q**, **Ye CP**, **Jones JE**, **Elmquist JK**, **Lowell BB**, Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance, Nat Neurosci 11(9):998, 2008.
92. **Wu Q**, **Howell MP**, **Cowley MA**, **Palmiter RD**, Starvation after AgRP neuron ablation is independent of melanocortin signaling, Proc Natl Acad Sci U S A 105(7):2687, 2008.
93. **Atasoy D**, **Betley JN**, **Su HH**, **Sternson SM**, Deconstruction of a neural circuit for hunger, Nature 488(7410):172, 2012.
94. **Horvath TL**, **Naftolin F**, **Kalra SP**, **Leranth C**, Neuropeptide-Y innervation of beta-endorphin-containing cells in the rat mediobasal hypothalamus: a light and electron microscopic double immunostaining analysis, Endocrinology, 131(5):2461, 1992.
95. **Wu Q**, **Howell MP**, **Palmiter RD**, Ablation of neurons expressing agouti-related protein activates fos and gliosis in postsynaptic target regions, J Neurosci 28(37):9218, 2008.
96. **Halaas JL**, **Gajiwala KS**, **Maffei M**, **Cohen SL**, **Chait BT**, **Rabinowitz D**, **Lallone RL**, **Burley SK**, **Friedman JM**, Weight-reducing effects of the plasma protein encoded by the obese gene, Science (New York, NY) 269(5223): 543, 1995.
97. **van den Top M**, **Lee K**, **Whyment AD**, **Blanks AM**, **Spanswick D**, Orexigen-sensitive NPY/AgRP pacemaker neurons in the hypothalamic arcuate nucleus, Nat Neurosci 7(5):493, 2004.
98. **Pinto S**, **Roseberry AG**, **Liu H**, **Diano S**, **Shanabrough M**, **Cai X**, **Friedman JM**, **Horvath TL**, Rapid rewiring of arcuate nucleus feeding circuits by leptin, Science 304:110, 2004.
99. **Schwartz MW**, **Baskin DG**, **Bukowski TR**, **Kuijper JL**, **Foster D**, **Lasser G**, **Prunkard DE**, **Porte D**, **Woods SC**, **Seeley RJ**, **Weigle DS**, Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice, Diabetes 45:531, 1996.
100. **Wiegle DS**, **Duell PB**, **Connor WE**, **Steiner RA**, **Soules MR**, **Kuijper JL**, Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels, J Clin Endocrinol Metab 82:561, 1997.
101. **Rohner-Jeanrenaud F**, A neuroendocrine reappraisal of the dual-centre hypothesis: its implications for obesity and insulin resistance, Int J Obes Relat Metab Disord 19:517, 1995.
102. **Cowley MA**, **Smith RG**, **Diano S**, **Tschop M**, **Pronchuk N**, **Grove KL**, **Strasburger CJ**, **Bidlingmaier M**, **Esterman M**, **Heiman ML**, **Garcia-Segura LM**, **Nillni EA**, **Mendez P**, **Low MJ**, **Sotonyi P**, **Friedman JM**, **Liu H**, **Pinto S**, **Colmers WF**, **Cone RD**, **Horvath TL**, The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis, Neuron 37(4):649, 2003.
103. **Andrews ZB**, **Liu ZW**, **Walllingford N**, **Erion DM**, **Borok E**, **Friedman JM**, **Tschöp MH**, **Shanabrough**

M, **Cline G**, **Shulman GI**, **Coppola A**, **Gao XB**, **Horvath TL**, **Diano S**, UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals, Nature 454:846, 2008.

104. **Spanswick D**, **Smith MA**, **Mirshamsi S**, **Routh VH**, **Ashford ML**, Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats, Nat Neurosci 3(8):757, 2000.
105. **Yaswen L**, **Diehl N**, **Brennan MB**, **Hochgeschwender U**, Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin, Nat Med 5(9):1066, 1999.
106. **Balthasar N**, **Dalgaard LT**, **Lee CE**, **Yu J**, **Funahashi H**, **Williams T**, **Ferreira M**, **Tang V**, **McGovern RA**, **Kenny CD**, **Christiansen LM**, **Edelstein E**, **Choi B**, **Boss O**, **Aschkenasi C**, **Zhang CY**, **Mountjoy K**, **Kishi T**, **Elmquist JK**, **Lowell BB**, Divergence of melanocortin pathways in the control of food intake and energy expenditure, Cell 123(3):493, 2005.
107. **Sutton GM**, **Trevaskis JL**, **Hulver MW**, **McMillan RP**, **Markward NJ**, **Babin MJ**, **Meyer EA**, **Butler AA**, Diet-genotype interactions in the development of the obese, insulin-resistant phenotype of C57BL/6J mice lacking melanocortin-3 or -4 receptors, Endocrinology 147(5):2183, 2006.
108. **Butler AA**, **Kesterson RA**, **Khong K**, **Cullen MJ**, **Pelleymounter MA**, **Dekoning J**, **Baetscher M**, **Cone RD**, A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse, Endocrinology 141(9):3518, 2000.
109. **Erickson JC**, **Clegg KE**, **Palmiter RD**, Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y, Nature 381(6581):415, 1996.
110. **Qian S**, **Chen H**, **Weingarth D**, **Trumbauer ME**, **Novi DE**, **Guan X**, **Yu H**, **Shen Z**, **Feng Y**, **Frazier E**, **Chen A**, **Camacho RE**, **Shearman LP**, **Gopal-Truter S**, **MacNeil DJ**, **Van der Ploeg LH**, **Marsh DJ**, Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice, Mol Cell Biol 22(14):5027, 2002.
111. **Luquet S**, **Perez FA**, **Hnasko TS**, **Palmiter RD**, NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates, Science (New York, NY) 310(5748):683, 2005.
112. **Wu Q**, **Boyle MP**, **Palmiter RD**, Loss of GABAergic signaling by AgRP neurons to the parabrachial nucleus leads to starvation, Cell 137(7):1225, 2009.
113. **Ingalls AM**, **Dickie MM**, **Snell GD**, Obese, a new mutation in the house mouse, Obes Res 4(1):101, 1996.
114. **Cohen P**, **Zhao C**, **Cai X**, **Montez JM**, **Rohani SC**, **Feinstein P**, **Mombaerts P**, **Friedman JM**, Selective deletion of leptin receptor in neurons leads to obesity, J Clin Invest 108(8):1113, 2001.
115. **McMinn JE**, **Liu SM**, **Dragatsis I**, **Dietrich P**, **Ludwig T**, **Eiden S**, **Chua SC Jr**, An allelic series for the leptin receptor gene generated by CRE and FLP recombinase, Mamm Genome 15(9):677, 2004.
116. **Dezaki K**, **Sone H**, **Koizumi M**, **Nakata M**, **Kakei M**, **Nagai H**, **Hosoda H**, **Kangawa K**, **Yada T**, Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose intolerance, Diabetes 55(12):3486, 2006.
117. **Wortley KE**, **Anderson KD**, **Garcia K**, **Murray JD**, **Malinova L**, **Liu R**, **Moncrieffe M**, **Thabet K**, **Cox HJ**, **Yancopoulos GD**, **Wiegand SJ**, **Sleeman MW**, Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference, Proc Natl Acad Sci U S A 101(21):8227, 2004.
118. **Saladin R**, **Staels B**, **Auwerx J**, **Briggs M**, Regulation of ob gene expression in rodents and humans, Horm Metab Res 28:638, 1996.
119. **Kolaczynski JW**, **Ohannesian J**, **Considine RV**, **Marco CC**, **Caro JF**, Response of leptin to short-term and prolonged overfeeding in humans, J Clin Endocrinol Metab 81:4162, 1996.
120. **Malmstrom R**, **Taskinen MR**, **Karonen SL**, **Ykijarvinen H**, Insulin increases plasma leptin concentrations in normals and patients with NIDDM, Diabetologia 39:993, 1996.
121. **Kolaczynski JW**, **Nyce MR**, **Considine RV**, **Boden G**, **Nolan JJ**, **Henry R**, **Mudaliar SR**, **Olefsky J**, **Caro JF**, Acute and chronic effect of insulin on leptin production in humans: studies in vivo and in vitro, Diabetes 45:699, 1996.
122. **Schwartz MW**, **Seeley RJ**, Neuroendocrine responses to starvation and weight loss, N Engl J Med 336:1802, 1997.
123. **Considine RV**, **Sinha MK**, **Heiman ML**, **Krauciunas A**, **Stephens TW**, **Nyce MR**, **Ohannesian JP**, **Marco CC**, **McKee LJ**, **Bauer TL**, **Caro JF**, Serum immunoreactive-leptin concentrations in normal-weight

and obese humans, N Engl J Med 334:292, 1995.
124. **Lonnqvist F**, **Arner P**, **Norfors L**, **Schalling M**, Overexpression of the obese (ob) gene in adipose tissue of human obese subjects, Nat Med 9:950, 1995.
125. **Hamilton B**, **Paglia D**, **Kwan A**, **Deitel M**, Increased obese mRNA expression in omental fat cells from massively obese humans, Nat Med 9:953, 1995.
126. **Kennedy A**, **Gettys TW**, **Watson P**, **Wallace P**, **Ganaway E**, **Pan Q**, **Garvey WT**, The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure, J Clin Endocrinol Metab 82:1293, 1997.
127. **Saad MF**, **Damani S**, **Gingerich RL**, **Riad-Gabriel MG**, **Khan A**, **Boyadjian R**, **Jinagouda SD**, **El-Tawil K**, **Rude RK**, **Kamdar V**, Sexual dimorphism in plasma leptin concentration, J Clin Endocrinol Metab 82:579, 1997.
128. **Nicklas BJ**, **Toth MJ**, **Goldberg AP**, **Poehlman ET**, Racial differences in plasma leptin concentrations in obese postmenopausal women, J Clin Endocrinol Metab 82:315, 1997.
129. **Considine RV**, **Considine EL**, **Williams CJ**, **Nyce MR**, **Zhang PL**, **Opentanova I**, **Ohannesian JP**, **Koaczynsi JW**, **Bauer TL**, **Moore JH**, **Caro JF**, Mutation screening and identification of a sequence variation in the human Ob gene coding, Biochem Biophys Res Commun 220:735, 1996.
130. **Schwartz MH**, **Peskind E**, **Raskind M**, **Boyko EJ**, **Porte D Jr**, Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans, Nat Med 2:589, 1996.
131. **Caro JF**, **Kolaczynski JW**, **Nyce MR**, **Ohannesian JP**, **Opentanova I**, **Goldman WH**, **Lynn RB**, **Zhang P-L**, **Sinha MK**, **Considine RV**, Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance, Lancet 348:159, 1996.
132. **Van Heek M**, **Compton DS**, **France CF**, **Tedesco RP**, **Fawzi AB**, **Graziano MP**, **Sybertz EJ**, **Strader CD**, **Davis HR Jr**, Diet-induced obese mice develop peripheral, but not central, resistance to leptin, J Clin Invest 99:385, 1997.
133. **Sinha MK**, **Opentanova I**, **Ohannesian JP**, **Kolaczynski JW**, **Heiman ML**, **Hale J**, **Becker GW**, **Bowsher RR**, **Stephens TW**, **Caro JF**, Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting, J Clin Invest 98:1277, 1996.
134. **National Task Force on the Prevention and Treatment of Obesity**, Long-term pharmacotherapy in the management of obesity, JAMA 276:1907, 1996.
135. **Wing RR**, **Sinha MK**, **Considine RV**, **Lang W**, **Caro JF**, Relationship between weight loss maintenance and changes in serum leptin levels, Horm Metab Res 28:698, 1996.
136. **Saris WHM**, **Kempen KR**, **Campfield LA**, **Tenenbaum R**, Responses of plasma OB protein concentration to weight cycling in obese women, Obes Res 4(Suppl 1):40s, 1996.
137. **Considine RV**, **Considine EL**, **Williams CJ**, **Hyde TM**, **Caro JF**, The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the ob/ob mouse and fa/fa rat mutations, Diabetes 45:992, 1996.
138. **Montague CT**, **Farooqi IS**, **Whitehead JP**, **Soos MA**, **Rau H**, **Wareham NJ**, **Sewter CP**, **Digby JE**, **Mohammed SN**, **Hurst JA**, **Cheetham CH**, **Earley AR**, **Barnett AH**, **Prins JB**, **O'Rahilly SO**, Congenital leptin deficiency is associated with severe early-onset obesity in humans, Nature 387:903, 1997.
139. **Strobel A**, **Issad T**, **Camoin M**, **Ozata M**, **Strosberg AD**, A leptin mutation associated with hypogonadism and morbid obesity, Nat Genet 18:213, 1998.
140. **Mazen I**, **El-Gammal M**, **Abdel-Hamid M**, **Amr K**, A novel homozygous missense mutaitonof the leptin gene (N103K) in an obese Egyptian patient, Mol Genet Metab 97:305, 2009.
141. **Wang TN**, **Huang MC**, **Chang WT**, **Ko AM**, **Tsai EM**, **Liu CS**, **Lee CH**, **Ko YC**, G-2548A polymorphism of the leptin gene is correlated with extreme obesity in Taiwanese aborigines, Obesity 14:183, 2006.
142. **Jackson RS**, **Creemers JWM**, **Ohagi S**, **Raffin-Sanson ML**, **Sanders L**, **Montague CT**, **Hutton JC**, **O'Rahilly S**, Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene, Nat Genet 16:303, 1997.
143. **Chagnon YC**, **Perusse L**, **Lamothe M**, **Chagnon M**, **Nadeau A**, **Dionne FT**, **Gagnon J**, **Cheung WK**, **Leibel RL**, **Bouchard G**, Suggestive linkages between markers on human 1p32-p22 and body fat and insulin

levels in the Quebec Family Study, Obes Res 5:115, 1997.
144. **Calton MA**, **Ersoy BA**, **Zhang S**, **Kane JP**, **Malloy MJ**, **Pullinger CR**, **Bromberg Y**, **Pennacchio LA**, **Dent R**, **McPherson R**, **Ahituv N**, **Vaisee C**, Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study, Hum Mol Genet 18:1140, 2009.
145. **Wangensteen T**, **Kolsgaard ML**, **Mattingsdal M**, **Joner G**, **Tonstad S**, **Undlien D**, **Retterstol L**, Mutations in the melanocrotin 4 receptor (MCR4) gene in obese patients in Norway, Exp Clin Endocrinol Diabetes 117:266, 2009.
146. **Reinehr T**, **Hebebrand J**, **Friedel S**, **Toschke AM**, **Brumm H**, **Biebermann H**, **Hinney A**, Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene, Obesity 17:382, 2009.
147. **Chehab FF**, **Mounzih K**, **Lu R**, **Lim ME**, Early onset of reproductive function in normal female mice treated with leptin, Science 275:88, 1997.
148. **Mantzoros CS**, **Flier JS**, **Rogol AD**, A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of puberty, J Clin Endocrinol Metab 82:1066, 1997.
149. **Suter KJ**, **Phol CR**, **Wilson ME**, Circulating concentrations of nocturnal leptin, growth hormone, and insulin-like growth factor-I increase before the onset of puberty in agonadal male monkeys: potential signals for the initiation of puberty, J Clin Endocrinol Metab 85:808, 2000.
150. **Holtkamp K**, **Herpertz-Dahlmann B**, **Mika C**, **Heer M**, **Heussen N**, **Fichter M**, **Herpertz S**, **Senf W**, **Blum WF**, **Schweiger U**, **Warnke A**, **Ballauff A**, **Remschmidt H**, **Hebebrand J**, Elevated physical activity and low leptin levels co-occur in patients with anorexia nervosa, J Clin Endocrinol Metab 88:5169, 2003.
151. **Farooqi IS**, **Jebb SA**, **Langmack G**, **Lawrence E**, **Cheetham CH**, **Prentice AM**, **Hughes IA**, **McCamish MA**, **O'Rahilly S**, Effects of recombinant leptin therapy in a child with congenital leptin deficiency, N Engl J Med 341:879, 1999.
152. **Rosenbaum M**, **Nicolson M**, **Hirsch J**, **Heymsfield SB**, **Gallagher D**, **Chu F**, **Leibel R**, Effects of gender, body composition, and menopause on plasma concentrations of leptin, J Clin Endocrinol Metab 81:3424, 1996.
153. **Hassink SG**, **Sheslow DV**, **de Lancey E**, **Opentanova I**, **Considine RV**, **Caro JF**, Serum leptin in children with obesity: relationship to gender and development, Pediatrics 98:201, 1996.
154. **Ahima RS**, **Prabakren D**, **Mantzoros C**, **Ou D**, **Lowell B**, **Maratzoros-Flier E**, **Flier J**, Role of leptin in the neuroendocrine response to fasting, Nature 382:250, 1996.
155. **Laughlin GA**, **Yen SSC**, Hypoleptinemia in women athletes: absence of a diurnal rhythm with amenorrhea, J Clin Endocrinol Metab 82:318, 1997.
156. **Kohrt WM**, **Landt M**, **Birge Jr SJ**, Serum leptin levels are reduced in response to exercise training, but not hormone replacement therapy in older women, J Clin Endocrinol Metab 81:3980, 1996.
157. **Laughlin GA**, **Yen SSC**, Serum leptin levels in women with polycystic ovary syndrome: the role of insulin resistance/hyperinsulinemia, J Clin Endocrinol Metab 82:1692, 1997.
158. **Mantzoros CS**, **Dunaif A**, **Flier JS**, Leptin concentrations in the polycystic ovary syndrome, J Clin Endocrinol Metab 82:1687, 1997.
159. **Rouru J**, **Anttila L**, **Koskinen P**, **Penttilä T-A**, **Irjala K**, **Huupponen R**, **Koulu M**, Serum leptin concentrations in women with polycystic ovary syndrome, J Clin Endocrinol Metab 82:1697, 1997.
160. **Sahin I**, **Serter R**, **Karakurt F**, **Demirbas B**, **Guler S**, **Culha C**, **Taskapan C**, **Aral Y**, Leptin levels increase during flutamide therapy in women with polycystic ovary syndrome, Horm Res 60:232, 2003.
161. **Nolan JJ**, **Olefsky JM**, **Nyce MR**, **Considine RV**, **Caro JF**, Effect of troglitazone on leptin production: studies in vitro and in human subjects, Diabetes 45:1276, 1996.
162. **Cioffi JA**, **Shafer AW**, **Zupancic TJ**, **Smith-Gbur J**, **Mikhail A**, **Platika D**, **Snodgress HR**, Novel B219/OB receptor isoforms: possible role of leptin in hemapoiesis and reproduction, Nat Med 2:585, 1996.
163. **Zachow RJ**, **Magoffin DA**, Direct intraovarian effects of leptin: impairment of the synergistic action of insulin-like growth factor-I on follicle-stimulating hormone-dependent estradiol-17b production by rat ovarian granulosa cells, Endocrinology 138:847, 1997.

164. **Cioffi JA**, **Van Blerkom J**, **Antczak M**, **Shafer A**, **Wittmer S**, **Snodgrass HR**, The expression of leptin and its receptors in pre-ovulatory human follicles, Mol Hum Reprod 3:467, 1997.
165. **Frisch RE**, **Revelle R**, Menstrual cycles: fatness as a determinant of minimum weight-for-height for their maintenance or onset, Science 185:949, 1974.
166. **Frisch RE**, Body fat, menarche, and reproductive ability, Semin Reprod Endocrinol 3:45, 1985.
167. **Welt CK**, **Chan JL**, **Bullen J**, **Murphy R**, **Smith P**, **DePaoli AM**, **Karalis A**, **Mantzoros CS**, Recombinant human leptin in women with hypothalamic amenorrhea, N Engl J Med 351:987, 2004.
168. **Germain N**, **Galusca B**, **Le Roux CW**, **Bossu C**, **Ghatel MA**, **Lang F**, **Bloom SR**, **Estour B**, Constitutional thinness and lean anorexia nervosa display opposite concentraitons of petide YY, glucagon-like peptide 1, ghrelin, and leptin, Am J Clin Nutr 85:967, 2007.
169. **Dorn LD**, **Chrousos GP**, The neurobiology of stress: understanding regulation of affect during female biological transitions, Semin Reprod Endocrinol 15:19, 1997.
170. **Vulliémoz NR**, **Xiao E**, **Xia-Zhang L**, **Rivier J**, **Ferin M**, Astressin B, a nonselective corticotropin-releasing hormone receptor antagonist, prevents the inhibitory effect of ghrelin on luteinizing hormone pulse frequency in the ovariectomized rhesus monkey, Endocrinology 149:869, 2008.
171. **Vulliémoz NR**, **Xiao E**, **Xia-Zhang L**, **Wardlaw SL**, **Ferin M**, Central infusion of agouti-related peptide suppresses pulsatile luteinizing hormone release in the ovariectomized rhesus monkey, Endocrinology 146:784, 2005.
172. **Miller KK**, **Parulekar MS**, **Schoenfeld E**, **Anderson E**, **Hubbard J**, **Klibanski A**, **Grinspoon SK**, Decreased leptin levels in normal weight women with hypothalamic amenorrea: the effects of body composition and nutritional intake, J Clin Endocrinol Metab 83:2309, 1998.
173. **Wade GN**, **Schneider JE**, **Li H-Y**, Control of fertility by metabolic cues, Am J Physiol 270(Endocrinol Metab 33):E1, 1996.
174. **Charney E**, **Goodman HC**, **McBride M**, **Lyon B**, **Pratt R**, Childhood antecedents of adult obesity, N Engl J Med 295:6, 1976.
175. **Garn SM**, **LaVelle M**, **Rosenberg KR**, **Hawthorne VM**, Maturational timing as a factor in female fatness and obesity, Am J Clin Nutr 43:879, 1986.
176. **Stunkard AJ**, **Sorensen TIA**, **Teasdale TW**, **Chakraborty R**, **Schull WJ**, **Schulsinger F**, An adoptive study of human obesity, N Engl J Med 314:193, 1986.
177. **Ravussin E**, **Lillioja S**, **Knowler WC**, **Christin L**, **Freymond D**, **Abbott WGH**, **Boyce V**, **Howard BV**, **Bogardus C**, Reduced rate of energy expenditure as a risk factor for body-weight gain, N Engl J Med 318:467, 1988.
178. **Stunkard AJ**, **Harris JR**, **Pederson NL**, **McClearn GE**, The body-mass index of twins who have been reared apart, N Engl J Med 322:1483, 1990.
179. **Whitaker RC**, **Wright JA**, **Pepe MS**, **Seidel KD**, **Dietz WH**, Predicting obesity in young adulthood from childhood and parental obesity, N Engl J Med 337:869, 1997.
180. **Rissanen AM**, **Heliovaara M**, **Knekt P**, **Reunanen A**, **Aromaa A**, Determinants of weight gain and overweight in adult Finns, Eur J Clin Nutr 45:419, 1991.
181. **Ogden CL**, **Fakhouri TH**, **Carroll MD**, **Hales CM**, **Fryar CD**, **Li X**, **Freedman DS**, Prevalence of obesity among adults, by household income and education—United States, 2011–2014, MMWR Morb Mortal Wkly Rep 66:1369, 2017.
182. **Ogden CL**, **Carroll MD**, **Fakhouri TH**, **Hales CM**, **Fryar CD**, **Li X**, **Freedman DS**, Prevalence of obesity among youths, by household income and education—United States, 2011–2014, MMWR Morb Mortal Wkly Rep 67:186, 2018.
183. **Alberti KG**, **Eckel RH**, **Grundy SM**, **Zimmet PZ**, **Cleeman JL**, **Donato KA**, **Fruchaart JC**, **James WP**, **Loria CM**, **Smith SC Jr**; **International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity**, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American

Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation 120:1640, 2009.
184. **Hewing R**, **Liebermeister H**, **Daweke H**, **Gries FA**, **Gruneklee D**, Weight regain after low calorie diet: long term pattern of blood sugar, serum lipids, ketone bodies, and serum insulin levels, Diabetologia 9:197, 1973.
185. **Stern MP**, **Haffner SM**, Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease, Arteriosclerosis 6:123, 1986.
186. **Peiris AN**, **Sothmann MS**, **Aiman EJ**, **Kissebah AH**, The relationship of insulin to sex hormone binding globulin: role of adiposity, Fertil Steril 52:69, 1989.
187. **Kirschner MA**, **Samojlik E**, **Drejda M**, **Szmal E**, **Schneider G**, **Ertel N**, Androgen-estrogen metabolism in women with upper body versus lower body obesity, J Clin Endocrinol Metab 70:473, 1990.
188. **Pasquali R**, **Cantobelli S**, **Casimirri F**, **Capelli M**, **Bortoluzzi L**, **Flamia R**, **Labate AMM**, **Barbara L**, The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution, J Clin Endocrinol Metab 77:341, 1993.
189. **Wabitsch M**, **Hauner H**, **Heinze E**, **Bockmann A**, **Benz R**, **Mayer H**, **Teller W**, Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction, J Clin Endocrinol Metab 80:3469, 1995.
190. **Lapidus L**, **Bengtsson C**, **Larsson B**, **Pennert K**, **Rybo E**, **Sjostrom L**, Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Br Med J 289:1257, 1984.
191. **Ostlund Jr RE**, **Staten M**, **Kohrt W**, **Schultz J**, **Malley M**, The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors for the HDL2 cholesterol level in older adults, N Engl J Med 322:229, 1990.
192. **Deutsch MI**, **Mueller WH**, **Malina RM**, Androgyny in fat patterning is associated with obesity in adolescents and young adults, Ann Hum Biol 12:275, 1985.
193. **Ashwell M**, **Chinn S**, **Stalley S**, **Garrow JS**, Female fat distribution—a simple classification based on two circumference measurements, Int J Obes Relat Metab Disord 6:143, 1982.
194. **Ashwell M**, **Cole TJ**, **Dixon AK**, Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography, Br Med J 290:1692, 1985.
195. **Pouliot MC**, **Despres JP**, **Lemieux S**, **Moorjani S**, **Bouchard C**, **Tremblay A**, **Nadeau A**, **Lupren PJ**, Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women, Am J Cardiol 73:460, 1994.
196. **Lean MEJ**, **Han TS**, **Durenberg P**, Predicting body composition by densitometry from simple anthropometric measurements, Am J Clin Nutr 63:4, 1996.
197. **Janssen I**, **Katzmarzyk PT**, **Ross R**, Waist circumference and not body mass index explains obesity-related health risk, Am J Clin Nutr 79:379, 2004.
198. **de Koning L**, **Merchant AT**, **Pogue J**, **Anand SS**, Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies, Eur Heart J 28:850, 2007.
199. **Manson JE**, **Colditz GA**, **Stampfer MJ**, **Willett WC**, **Rosner B**, **Monson RR**, **Speizer FE**, **Hennekens CH**, A prospective study of obesity and risk of coronary heart disease in women, N Engl J Med 322:882, 1990.
200. **Williamson DF**, **Pamuk E**, **Thun M**, **Flanders D**, **Byers T**, **Heath C**, Prospective study of intentional weight-loss and mortality in never-smoking overweight US white women aged 40–64, Am J Epidemiol 141:1128, 1995.
201. **Garrow JS**, Treatment of obesity, Lancet 340:409, 1992.
202. **Foster GD**, **Wyatt HR**, **Hill JO**, **McGuckin BG**, **Brill C**, **Mohammed BS**, **Szapary PO**, **Rader DJ**, **Edman JS**, **Klein S**, A randomized trial of a low-carbohydrate diet for obesity, N Engl J Med 348:2082, 2003.
203. **Yancy Jr WS**, **Olsen MK**, **Guyton JR**, **Bakst RP**, **Westman EC**, A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial, Ann Intern Med 140:769, 2004.
204. **Gordon ES**, Metabolic aspects of obesity, Adv Metab Disord 4:229, 1970.
205. **National Institutes of Health (NIH) and National Heart Lung and Blood Institute (NHLBI)**, Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity The Evidence Report,

U.S. Government Printing Office, Washington, 1998.
206. **Wadden TA**, **Stunkard AJ**, **Brownell KD**, Very low calorie diets: their efficacy, safety, and future, Ann Intern Med 99:675, 1983.
207. **Lichtman SW**, **Pisarska K**, **Berman ER**, **Pestone M**, **Dowling H**, **Offenbacher E**, **Weisel H**, **Heshka S**, **Matthews DE**, **Heymsfield SB**, Discrepancy between self-reported and actual caloric intake and exercise in obese subjects, N Engl J Med 327:1893, 1992.
208. **Volkmar FR**, **Stunkard AJ**, **Woolston J**, **Bailey RA**, High attrition rates in commercial weight reduction programs, Arch Intern Med 141:426, 1981.
209. **Grodstein F**, **Levine R**, **Troy L**, **Spencer T**, **Colditz GA**, **Stampfer MJ**, Three-year follow-up of participants in a commercial weight loss program. Can you keep it off?, Arch Intern Med 156:1302, 1996.
210. **Heshka S**, **Anderson JW**, **Atkinson RL**, **Greenway FL**, **Hill JO**, **Phinney SD**, **Kolotkin RL**, **Miller-Kovach K**, **Pi-Sunyer FX**, Weight loss with self-help compared with a structured commercial program. A randomized trial, JAMA 289:1792, 2003.
211. **Dansinger ML**, **Gleason JA**, **Griffith JL**, **Selker HP**, **Schaefer EJ**, Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial, JAMA 293:43, 2005.
212. **Wadden TA**, **Berkowitz RI**, **Womble LG**, **Sarwer DB**, **Phelan S**, **Cato RK**, **Hesson LA**, **Osel SY**, **Kaplan RC**, **Stunkard AJ**, Randomized trial of lifestyle modification and pharmacotherapy for obesity, N Engl J Med 353:2111, 2005.
213. **Truby H**, **Baic S**, **deLooy A**, **Fox KR**, **Livingstone MB**, **Logan CM**, **Macdonald IA**, **Morgan LM**, **Taylor MA**, **Millward DJ**, Randomised controlled trial of four commercial weight loss programmes in the UK: initial findings from the BBC "diet trials," Br Med J 332:1309, 2006.
214. **Gardner CD**, **Kiazand A**, **Alhassan S**, **Kim SH**, **Stafford RS**, **Balise RR**, **Kraemer HC**, **King AC**, Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A to Z Weight Loss Study: a randomized trial, JAMA 297:969, 2007.
215. **Sjöström CD**, **Lissner L**, **Sjöström L**, Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study, Obes Res 5:519, 1997.
216. **Diabetes Prevention Program Research Council**, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med 346: 393, 2002.
217. **Diabetes Prevention Program Research Group**, 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study, Lancet 374:1677, 2009.
218. **Flegal KM**, **Troiano RP**, **Pamuk ER**, **Kuczmarski RJ**, **Campbell SM**, The influence of smoking cessation on the prevalence of overweight in the United States, N Engl J Med 333:1165, 1995.
219. **Sjöström L**, **Rissanen A**, **Andersen T**, **Boldrin M**, **Golay A**, **Koppeschaar HPF**, **Krempf M**; for the **European Multicentre Orlistat Study Group**, Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients, Lancet 352:167, 1998.
220. **Larsen PJ**, **Fledelius C**, **Knudsen LB**, **Tang-Christensen M**, Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats, Diabetes 50:2530, 2001.
221. **Astrup A**, **Rössner S**, **Van Gaal L**, **Rissanen A**, **Niskanen L**, **Al Hakim M**, **Madsen J**, **Rasmussen MF**, **Lean ME**; **NN8022-1807 Study Group**, Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study, Lancet 374:1606, 2009.
222. **Thomsen WJ**, **Grottick AJ**, **Menzaghi F**, **Reyes-Saldana H**, **Espitia S**, **Yuskin D**, **Whelan K**, **Martin M**, **Morgan M**, **Chen W**, **Al-Shamma H**, **Smith B**, **Chalmers D**, **Behan D**, Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization, J Pharmacol Exp Ther 325:577, 2008.
223. **Abenhaim L**, **Moride Y**, **Brenot F**, **Rich S**, **Benichou J**, **Kurz X**, **Higenbottom T**, **Oakley C**, **Wouters E**, **Aubier M**, **Simonneau G**, **Begaud B**, Appetite-suppressant drugs and the risk of primary pulmonary hypertension, N Engl J Med 335:609, 1996.

224. **Connolly HM**, **Crary JL**, **McGoon MD**, **Hensrud DD**, **Edwards BS**, **Edwards WD**, **Schaff HV**, Valvular heart disease associated with fenfluramine-phentermine, N Engl J Med 337:581, 1997.
225. **Graham DJ**, **Green L**, Further cases of valvular heart disease associated with fenfluramine-phentermine, N Engl J Med 337:635, 1997.
226. **Goldstein DJ**, **Rampey Jr AH**, **Enas GG**, **Potvin JH**, **Fludzinski LA**, **Levine LR**, Fuoxetine: a randomized clinical trial in the treatment of obesity, Int J Obes Relat Metab Disord 18:129, 1994.
227. **Michelson D**, **Amsterdam JD**, **Quitkin FM**, **Reimherr FW**, **Rosenbaum JF**, **Zajecka J**, **Sundell KL**, **Kim Y**, **Beasley CM Jr**, Changes in weight during a 1-year trial of fluoxetine, Am J Psychiatry 156:1170, 1999.
228. **Bray GA**, **Blackburn GL**, **Ferguson JM**, **Greenway FL**, **Jain AK**, **Mendel CM**, **Mendels J**, **Ryan DH**, **Schwartz SL**, **Scheinbaum ML**, **Seaton TB**, Sibutramine produces dose-related weight loss, Obes Res 7:189, 1999.
229. **Van Gaal LF**, **Rissanen AM**, **Scheen AJ**, **Ziegler O**, **Rössner S**; **RIO-Europe Study Group**, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, Lancet 365:1389, 2005.
230. **Pi-Sunyer FX**, **Aronne LJ**, **Heshmati HM**, **Devin J**, **Rosenstock J**; **RIO-North America Study Group**, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial, JAMA 295:761, 2006.
231. **Sam AH**, **Salem V**, **Ghatei MA**, Rimonabant: from RIO to Ban, J Obes 2011:432607, 2011.
232. **Khera R**, **Murad MH**, **Chandar AK**, **Dulai PS**, **Wang Z**, **Prokop LJ**, **Loomba R**, **Camilleri M**, **Singh S**, Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis, JAMA 315:2424, 2016.
233. **Li Z**, **Maglione M**, **Tu W**, **Mojica W**, **Arterburn D**, **Hugarman LR**, **Hilton L**, **Suttorp M**, **Solomon V**, **Shekelle PG**, **Morton SC**, Meta-analysis: pharmacologic treatment of obesity, Ann Intern Med 142:532, 2005.
234. **Sjöström L**, **Narbro K**, **Sjöström CD**, **Karason K**, **Larsson B**, **Wedel H**, **Lystig T**, **Sullivan M**, **Bouchard C**, **Carlsson B**, **Bengtsson C**, **Dahlgren S**, **Gummesson A**, **Jacobson P**, **Karlsson J**, **Lindross AK**, **Lönroth H**, **Näslund I**, **Olbers T**, **Stenlöf K**, **Torgerson J**, **Agren G**, **Carlsson LM**; **Swedish Obese Subjects Study**, Effects of bariatric surgery on mortality in Swedish obese subjects, N Engl J Med 357:741, 2007.
235. **Cunneen SA**, Review of meta-analytic comparisons of bariatric surgery with a focus on laparoscopic adjustable gastric banding, Surg Obes Relat Dis 4: S47, 2008.
236. **Treadwell JR**, **Sun F**, **Schoelles K**, Systematic review and meta-analysis of bariatric surgery for pediatric obesity, Ann Surg 248:763, 2008.
237. **Buchwald H**, **Estok R**, **Fahrbach K**, **Banel D**, **Jensen MD**, **Pories WJ**, **Bantie JP**, **Sledge I**, Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis, Am J Med 122:248, 2009.
238. **Longitudinal Assessment of Bariatric Surgery (LABS) Consortium**; **Flum DR**, **Belle SH**, **King WC**, **Wahed AS**, **Berk P**, **Chapman W**, **Pories W**, **Courcoulas A**, **McCloskey C**, **Mitchell J**, **Patterson E**, **Pomp A**, **Staten MA**, **Yanovski SZ**, **Thirlby R**, **Wolfe B**, Perioperative safety in the longitudinal assessment of bariatric surgery, N Engl J Med 361:445, 2009.
239. **Rivlin RS**, Drug therapy: therapy of obesity with hormones, N Engl J Med 292:26, 1975.
240. **Paffenbarge RS Jr**, **Wing AL**, **Hyde RT**, Physical activity as an index of heart attack risk in college alumni, Am J Epidemiol 108:161, 1978.
241. **Weisweiler P**, Plasma lipoproteins and lipase and lecithin: cholesterol acyltransferase activities in obese subjects before and after weight reduction, J Clin Endocrinol Metab 65:969, 1987.
242. **Jakicic JM**, **Marcus BH**, **Gallagher KI**, **Napolitano M**, **Lang W**, Effect of exercise duration and intensity on weight loss in overweight, sedentary women, JAMA 290:1323, 2003.
243. **Safer DJ**, Diet, behavior modification, and exercise: a review of obesity treatments from a long-term perspective, South Med J 84:1470, 1991.
244. **Skender ML**, Comparison of a 2-year weight loss trends in behavioral treatments of obesity: diet, exercise,

and combination interventions, J Am Diet Assoc 96:342, 1996.
245. **Jensen MK**, **Chiuve SE**, **Rimm EB**, **Dethlefsen C**, **Tjønneland A**, **Joensen AM**, **Overvad K**, Obesity, behavioral lifestyle factors, and risk of acute coronary events, Circulation 117:3062, 2008.
246. **Konishi F**, Food energy equivalents of various activities, J Am Diet Assoc 46: 186, 1965.
247. **Sims EAH**, **Danforth E Jr**, **Horton ES**, **Bray GA**, **Glennon JA**, **Salans LB**, Endocrine and metabolic effects of experimental obesity in man, Recent Prog Horm Res 29:457, 1973.
248. **Welle SL**, **Amatruda JM**, **Forbes GB**, **Lockwood DH**, Resting metabolic rates of obese women after rapid weight loss, J Clin Endocrinol Metab 59:41, 1984.
249. **Leibel RL**, **Rosenbaum M**, **Hirsch J**, Changes in energy expenditure resulting from altered body weight, N Engl J Med 332:621, 1995.

Chapter twenty

REFERENCES

1. **Medvei VC**, The History of Clinical Endocrinology, The Parthenon Publishing Group, New York, 1993.
2. **Heuer H**, **Visser TJ**, Minireview: pathophysiological importance of thyroid hormone transporters, Endocrinology 150:1078, 2009.
3. **Brent GA**, The molecular basis of thyroid hormone action, N Engl J Med 331:847, 1994.
4. **Melmed S**, **Hershman J**, The thyroid and aging, In: Korenman SG, ed. Endocrine Aspects of Aging, Elsevier Science Publishing, New York, 1982, p. 33.
5. **Surks MI**, **Hollowell JG**, Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism, J Clin Endocrinol Metab 92:4575, 2007.
6. **Boucai L**, **Surks MI**, Reference limits for serum TSH differ significantly between races and with age, potentially causing erroneous diagnosis in a substantial number of patients, Clin Endocrinol 70:788, 2009.
7. **Roberts CGP**, **Ladenson PW**, Hypothyroidism, Lancet 363:793, 2004.
8. **Hollowell JG**, **Staehling NW**, **Flanders WD**, **Hannon WH**, **Gunter EW**, **Spencer CA**, **Braverman LE**, **Serum TSH**, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III), J Clin Endocrinol Metab 87:489, 2002.
9. **Felicetta JV**, Thyroid changes with aging: significance and management, Geriatrics 42:86, 1987.
10. **Danese MD**, **Powe NR**, **Sawin CT**, **Ladenson PW**, Screening for mild thyroid failure at the periodic health examination. A decision and cost-effectiveness analysis, JAMA 276:285, 1996.
11. **Gharib H**, **Tuttle RM**, **Baskin HJ**, **Fish LH**, **Singer PA**, **McDermott MT**, Consensus Statement #1: Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society, Thyroid 15(1):24, 2005.
12. **Hansen KA**, **Tho SPT**, **Hanly M**, **Moretuzzo RW**, **McDonough PG**, Massive ovarian enlargement in primary hypothyroidism, Fertil Steril 67:169, 1997.
13. **Wiseman SA**, **Powell JT**, **Humphries SE**, **Press M**, The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene, J Clin Endocrinol Metab 77:108, 1993.
14. **Golden SH**, **Robinson KA**, **Saldanha I**, **Anton B**, **Ladenson PW**, Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review, J Clin Endocrinol Metab 94:1853, 2009.
15. **Huber G**, **Staub J-J**, **Meier C**, **Mitrache C**, **Guglielmetti M**, **Huber P**, **Braverman LE**, Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies, J Clin Endocrinol Metab 87:3221, 2002.
16. **Surks MI**, **Ortiz E**, **Daniels GH**, **Sawin CT**, **Col NF**, **Cobin RH**, **Franklyn JA**, **Hershman JM**, **Burman KD**, **Denke MA**, **Gorman C**, **Cooper RS**, **Weissman NJ**, Subclinical thyroid disease: scientific review and guidelines for diagnosis and management, JAMA 291:228, 2004.
17. **Monzani F**, **Caraccio N**, **Siciliano G**, **Manca L**, **Murri L**, **Ferrannini E**, Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism, J Clin Endocrinol Metab 82:3315, 1997.
18. **Monzani F**, **Del Guerra P**, **Caraccio N**, **Pruneti CA**, **Pucci E**, **Luisi M**, **Baschieri L**, Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment, Clin Investig 71:367, 1993.
19. **Kinlaw WB III**, Thyroid disorders and cholesterol: identifying the realm of clinical relevance, Endocrinologist 5:147, 1995.
20. **Danese MD**, **Ladenson PW**, **Meinert CL**, **Powe NR**, Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature, J Clin Endocrinol Metab 85:2993, 2000.
21. **Caraccio N**, **Ferrannini E**, **Monzani F**, Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study, J Clin Endocrinol Metab 87:1533, 2002.
22. **Hak AE**, **Pols HA**, **Visser TJ**, **Drexhage HA**, **Hofman A**, **Witteman JC**, Subclinical hypothyroidism is an

independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study, Ann Intern Med 132:270, 2000.
23. **Cinemre H**, **Bilir C**, **Gokosmanoglu F**, **Bahcebasi T**, Iron deficiency anemia in patients with subclinical hypothyroidism benefits substantially by the addition of low-dose levothyroxine to iron replacement, as compared with iron replacement alone, J Clin Endocrinol Metab 94:1511, 2009.
24. **Abalovich M**, **Gutierrez S**, **Alcaraz G**, **Maccallini G**, **Garcia A**, **Levalle O**, Overt and subclinical hypothyroidism complicating pregnancy, Thyroid 12:63, 2002.
25. **Cooper DS**, Thyroid hormone treatment: new insights into an old therapy, JAMA 261:2694, 1989.
26. **Toft AD**, Thyroxine therapy, N Engl J Med 331:174, 1994.
27. **Walsh JP**, **Shiels L**, **Lim EM**, **Bhagat CI**, **Ward LC**, **Stuckey BGA**, **Dhaliwal SS**, **Chew GT**, **Bhagat MC**, **Cussons AJ**, Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism, J Clin Endocrinol Metab 88:4543, 2003.
28. **Sawka AM**, **Gerstein HC**, **Marriott MJ**, **MacQueen GM**, **Joffe RT**, Does a combination regimen of thyroxine (T4) and 3,5,3'-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial, J Clin Endocrinol Metab 88:4551, 2003.
29. **Clyde PW**, **Harari AE**, **Getka EJ**, **Shakir KMM**, Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial, JAMA 290:2952, 2003.
30. **Rosenbaum RL**, **Barzel US**, Levothyroxine replacement dose for primary hypothyroidism decreases with age, Ann Intern Med 96:53, 1982.
31. **Demers LM**, **Spencer CA**, Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease, Thyroid 13:2, 2003.
32. **Watts NB**, Use of a sensitive thyrotropin assay for monitoring treatment with levothyroxine, Arch Intern Med 149:309, 1989.
33. **Lazarus JH**, Hyperthyroidism, Lancet 349:339, 1997.
34. **Wallaschofski H**, **Kuwert T**, **Lohmann T**, TSH-receptor autoantibodies—differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre, Exp Clin Endocrinol Diabetes 112:171, 2004.
35. **Sawin CT**, **Geller A**, **Wolf PA**, **Belanger AJ**, **Baker E**, **Bacharach P**, **Wilson PWF**, **Benjamin EJ**, **D'Agostino RB**, Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons, N Engl J Med 331:1249, 1994.
36. **Sgarbi JA**, **Villaça FG**, **Garbeline B**, **Villar HE**, **Romaldini JH**, The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities, J Clin Endocrinol Metab 88:1672, 2003.
37. **Cooper DS**, Approach to the patient with subclinical hyperthyroidism, J Clin Endocrinol Metab 92:3, 2007.
38. **Franklyn JA**, The management of hyperthyroidism, N Engl J Med 330:1731, 1994.
39. **Cooper DS**, Thyroid hormone and the skeleton, JAMA 259:3175, 1988.
40. **Wartofsky L**, Osteoporosis and therapy with thyroid hormone, Endocrinologist 1:57, 1991.
41. **Diamond T**, **Nery L**, **Hales I**, A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma, J Clin Endocrinol Metab 72:1184, 1991.
42. **Solomon BL**, **Wartofsky L**, **Burman KD**, Prevalence of fractures in postmenopausal women with thyroid disease, Thyroid 3:17, 1993.
43. **Vestergaard P**, **Rejnmark L**, **Weeke J**, **Mosekilde L**, Fracture risk in patients treated for hyperthyroidism, Thyroid 10:341, 2000.
44. **Foldes J**, **Tarjan G**, **Szathmary M**, **Varga F**, **Krasznai I**, **Horvath C**, Bone mineral density in patients with endogenous subclinical hyperthyroidism: is the thyroid status a risk factor for osteoporosis? Clin Endocrinol 39:521, 1993.
45. **Bauer DC**, **Ettinger B**, **Nevitt MC**, **Stone KL**; for the **Osteoporotic Fractures Research Group**, Risk for fracture in women with low serum levels of thyroid-stimulating hormone, Ann Intern Med 134:561, 2001.
46. **Barsony J**, **Lakatos P**, **Foldes J**, **Feher T**, Effect of vitamin D3 loading and thyroid hormone replacement

therapy on the decreased serum 25-hydroxyvitamin D level in patients with hypothyroidism, Acta Endocrinol 113:329, 1986.
47. **Ross DS**, **Neer RM**, **Ridgway EC**, **Daniels GH**, Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with l-thyroxine, Am J Med 82:1167, 1987.
48. **Faber J**, **Gallow AM**, Changes in bone mass during prolonged subclinical hyperthyroidism due to l-thyroxine treatment: a meta-analysis, Eur J Endocrinol 130:350, 1994.
49. **Leese GP**, **Jung RT**, **Guthrie C**, **Waugh N**, **Browing MCK**, Morbidity in patients on l-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH, Clin Endocrinol 37:500, 1992.
50. **Sheppard MC**, **Holder R**, **Fraklyn JA**, Levothyroxine treatment and occurrence of fracture of the hip, Arch Intern Med 162:338, 2002.
51. **van den Eeden SK**, **Barzilay JI**, **Ettinger B**, **Minkoff J**, Thyroid hormone use and the risk of hip fracture in women ≥65 years: a case-control study, J Womens Health (Larchmt) 12:27, 2003.
52. **Schneider DL**, **Barrett-Connor EL**, **Morton DJ**, Thyroid hormone use and bone mineral density in elderly women: effects of estrogen, JAMA 271:1245, 1994.
53. **Mazzaferri EL**, Management of a solitary thyroid nodule, N Engl J Med 328:553, 1993.
54. **Smith JJ**, **Chen X**, **Schneider DF**, **Broome JT**, **Sippel RS**, **Chen H**, **Solórzano CC**, Cancer after thyroidectomy: a multi-institutional experience with 1,523 patients, J Am Coll Surg 216(4):571, 2013.
55. **Pacini F**, **Fontanelli M**, **Fugazzola L**, **Elisei R**, **Romei C**, **Di Coscio G**, **Miccoli P**, **Pinchera A**, Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma, J Clin Endocrinol Metab 78:826, 1994.
56. **Abalovich M**, **Amino N**, **Barbour LA**, **Cobin RH**, **De Groot LJ**, **Glinoer D**, **Mandel SJ**, **Stagnaro-Green A**, Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab 92(Suppl):S1, 2007.
57. **Gharib H**, **Goellner JR**, Fine-needle aspiration biopsy of the thyroid: an appraisal, Ann Intern Med 118:282, 1993.
58. **Glinoer D**, The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology, Endocr Rev 18:404, 1997.
59. **Smyth PPA**, **Hetherton AMT**, **Smith DF**, **Radcliff M**, **O'Herlihy C**, Maternal iodine status and thyroid volume during pregnancy: correlation with neonatal iodine intake, J Clin Endocrinol Metab 82:2840, 1997.
60. **Kennedy RL**, **Darne J**, The role of hCG in regulation of the thyroid gland in normal and abnormal pregnancy, Obstet Gynecol 78:298, 1991.
61. **Ballabio M**, **Poshyachinda M**, **Ekins RP**, Pregnancy-induced changes in thyroid function: role of human chorionic gonadotropin as putative regulator of maternal thyroid, J Clin Endocrinol Metab 73:824, 1991.
62. **Glinoer D**, **DeNayer P**, **Bourdoux P**, **Lemone M**, **Robyn C**, **Van Steirteghem A**, **Kinthaert J**, **Lejeune B**, Regulation of maternal thyroid during pregnancy, J Clin Endocrinol Metab 71:276, 1990.
63. **Kimura M**, **Amino N**, **Tamaki H**, **Mitsuda N**, **Miyai K**, **Tanizawa O**, Physiologic thyroid activation in normal early pregnancy is induced by circulating hCG, Obstet Gynecol 75:775, 1990.
64. **Kimura M**, **Amino N**, **Tamaki H**, **Ito E**, **Mitsuda N**, **Miyai K**, **Tanizawa O**, Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of hCG with higher stimulating activity, Clin Endocrinol 38:345, 1993.
65. **Berghout A**, **Ended E**, **Ross A**, **Hogerzeil HV**, **Smits NJ**, **Wiersinga WM**, Thyroid function and thyroid size in normal pregnant women living in an iodine replete area, Clin Endocrinol 41:375, 1994.
66. **Dashe JS**, **Casey BM**, **Wells CE**, **McIntire DD**, **Byrd EW**, **Leveno KJ**, **Cunningham FG**, Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific ranges, Obstet Gynecol 106:753, 2006.
67. **American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum**; **Stagnaro-Green A**, **Abalovich M**, **Alexander E**, **Azizi F**, **Mestman J**, **Negro R**, **Nixon A**, **Pearce EN**, **Soldin OP**, **Sullivan S**, **Wiersinga W**, Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum, Thyroid 21:1081, 2011.
68. **De Groot L**, **Abalovich M**, **Alexander EK**, **Amino N**, **Barbour L**, **Cobin RH**, **Eastman CJ**, **Lazarus JH**, **Luton D**, **Mandel SJ**, **Mestman J**, **Rovet J**, **Sullivan S**, Management of thyroid dysfunction during

pregnancy and postpartum: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab 97:2543, 2012.
69. **Calvo RM**, **Jauniaux E**, **Gulbis B**, **Asuncion M**, **Gervy C**, **Contempre B**, **Morreale de Escobar G**, Fetal tissues are exposed to biologically relevant free thyroxine concentrations during early phases of development, J Clin Endocrinol Metab 87:1768, 2002.
70. **Davis LE**, **Leveno KL**, **Cunningham FG**, Hypothyroidism complicating pregnancy, Obstet Gynecol 72:108, 1988.
71. **Leung AS**, **Millar LK**, **Koonings PP**, **Montoro M**, **Mestman JH**, Perinatal outcome in hypothyroid pregnancies, Obstet Gynecol 81:349, 1993.
72. **Wasserstrum N**, **Anania CA**, Perinatal consequences of maternal hypothyroidism in early pregnancy and inadequate replacement, Clin Endocrinol 42:353, 1995.
73. **Casey BM**, **Dashe JS**, **Wells CE**, **McIntire DD**, **Byrd W**, **Leveno KJ**, **Cunningham FG**, Subclinical hypothyroidism and pregnancy outcomes, Obstet Gynecol 105:239, 2005.
74. **Negro R**, **Formoso G**, **Mangieri T**, **Pezzarossa A**, **Dazzi D**, **Hassan H**, Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications, J Clin Endocrinol Metab 91:2587, 2006.
75. **Goodwin TM**, **Montoro M**, **Mestman JH**, Transient hyperthyroidism and hyperemesis gravidarum: clinical aspects, Am J Obstet Gynecol 167:648, 1992.
76. **Goodwin TM**, **Montoro M**, **Mestman JH**, **Pekary AE**, **Hershman JM**, The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum, J Clin Endocrinol Metab 75:1333, 1992.
77. **Yamazaki K**, **Sato K**, **Shizume K**, **Kanaji Y**, **Ito Y**, **Obara T**, **Nakagawa T**, **Koizumi T**, **Nishimura R**, Potent thyrotropic activity of human chorionic gonadotropin variants in terms of 125I incorporation and de novo synthesized thyroid hormone release in human thyroid follicles, J Clin Endocrinol Metab 80:473, 1995.
78. **Tsuruta E**, **Tada H**, **Tamaki H**, **Kashiwai T**, **Asahio K**, **Takeoka K**, **Mitsuda N**, **Amino N**, Pathogenic role of asialo human chorionic gonadotropin in gestational thyrotoxicosis, J Clin Endocrinol Metab 80:350, 1995.
79. **Thorpe-Beeston JG**, **Nicolaides KH**, **McGregor AM**, Fetal thyroid function, Thyroid 2:207, 1992.
80. **Burrow GN**, **Fisher DA**, **Larsen PR**, Maternal and fetal thyroid function, N Engl J Med 331:1072, 1994.
81. **Hume R**, **Simpson JL**, **Delahunty C**, **van Toor H**, **Wu SY**, **Williams FL**, **Visser TJ**; **Scottish Preterm Thyroid Group**, Human fetal and cord serum thyroid hormones: developmental trends and interrelationships, J Clin Endocrinol Metab 89:4097, 2004.
82. **Leonard JL**, Non-genomic actions of thyroid hormone in brain development, Steroids 73:1008, 2008.
83. **Hallengren B**, **Lantz M**, **Andreasson B**, **Grennert L**, Pregnant women on thyroxine substitution are often dysregulated in early pregnancy, Thyroid 19:391, 2009.
84. **Benhadi N**, **Wiersinga WM**, **Reitsma JB**, **Vrijkotte TGM**, **Bonsel GJ**, Higher TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death, Eur J Endocrinol 160:985, 2009.
85. **Maruo T**, **Katayama K**, **Matuso H**, **Anwar M**, **Mochizuki M**, The role of maternal thyroid hormones in maintaining early pregnancy in threatened abortion, Acta Endocrinol 127:118, 1992.
86. **Haddow JE**, **Palomaki GE**, **Allan WC**, **Williams JR**, **Knight GJ**, **Gagnon J**, **O'Heir CE**, **Mitchell ML**, **Hermos RJ**, **Waisbren SE**, **Faix JD**, **Klein RZ**, Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child, N Engl J Med 341:549, 1999.
87. **Klein RZ**, **Sargent JD**, **Larsen PR**, **Waisbren SE**, **Haddow JE**, **Mitchell ML**, Relation of severity of maternal hypothyroidism to cognitive development of offspring, J Med Screen 8:18, 2001.
88. **Pop VJ**, **Kuijpens JL**, **van Baar AL**, **Verkerk G**, **van Son MM**, **de Vijlder JJ**, **Vuisma T**, **Wiersinga WM**, **Drexhage HA**, **Vader HL**, Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy, Clin Endocrinol 50:149, 1999.
89. **Pop VJ**, **Brouwers EP**, **Vader HL**, **Vulsma T**, **Van Baar AL**, **de Vijlder JJ**, Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study, Clin Endocrinol 59:282, 2003.
90. **Kooistra L**, **Crawford S**, **Van Baar AL**, **Brouwers EP**, **Pop VJ**, Neonatal effects of maternal hypothyroxinemia during early pregnancy, Pediatrics 117:161, 2006.

91. **American College of Obstetricians and Gynecologists**, ACOG Practice Bulletin No. 148: thyroid disease in pregnancy, Obstet Gynecol 125:996, 2015.
92. **American Society for Reproductive Medicine Practice Committee**, Subclinical hypothyroidism in the infertile female population: a guideline, Fertil Steril 104:545, 2015.
93. **Vaidya B**, **Anthony S**, **Bilous M**, **Shields B**, **Drury J**, **Hutchison S**, **Bilous R**, Detection of thyroid dysfunction in early pregnancy: universal screening or target high-risk case finding? J Clin Endocrinol Metab 92:203, 2007.
94. **Clearly-Goldman J**, **Malone FD**, **Lambert-Messerlian G**, **Sullivan L**, **Canick J**, **Porter TF**, **Luthy D**, **Gross S**, **Bianchi DW**, **D'Alton ME**; **for the FASTER Consortium**, Maternal thyroid hypofunction and pregnancy outcome, Obstet Gynecol 112:85, 2008.
95. **Glinoer D**, **Riahi M**, **Grun JP**, **Kinthaert J**, Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders, J Clin Endocrinol Metab 79:197, 1994.
96. **Poppe K**, **Gilnoer D**, **Tournaye H**, **Devroey P**, **van Steirteghem A**, **Kaufman L**, **Velkeniers B**, Assisted reproduction and thyroid autoimmunity: an unfortunate combination? J Clin Endocrinol Metab 88:4149, 2003.
97. **Wolfberg A**, **Lee-Parritz A**, **Peller AJ**, **Lieberman E**, Obstetric and neonatal outcomes associated with maternal hypothyroid disease, J Matern Fetal Neonatal Med 17:35, 2005.
98. **Wikner BN**, **Sparre LS**, **Stiller C-O**, **Källén B**, **Asker C**, Maternal use of thyroid hormones in pregnancy and neonatal outcome, Acta Obstet Gynecol Scand 87:617, 2008.
99. **Mandel SJ**, **Larsen PR**, **Seely EW**, **Brent GA**, Increased need for thyroxine during pregnancy in women with primary hypothyroidism, N Engl J Med 323:91, 1990.
100. **Kaplan MM**, Monitoring thyroxine treatment during pregnancy, Thyroid 2:147, 1992.
101. **Alexander EK**, **Marqusee E**, **Lawrence J**, **Jarolim P**, **Fischer GA**, **Larsen PR**, Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism, N Engl J Med 351:241, 2004.
102. **Mandel SJ**, **Spencer CA**, **Hollowell JG**, Are detection and treatment of thyroid insufficiency in pregnancy feasible? Thyroid 15:44, 2005.
103. **McClain MR**, **Lambert-Messerlian G**, **Haddow JE**, **Palomaki GE**, **Canick JA**, **Clearly-Goldman J**, **Malone FD**, **Porter TF**, **Nyberg DA**, **Bernstein P**, **D'Alton ME**, **FaSTER Research Consortium**, Sequential first- and second-trimester TSH, free thyroxine, and thyroid antibody measurements in women with known hypothyroidism: a FaSTER trial study, Am J Obstet Gynecol 199:129.e1, 2008.
104. **LaFranchi S**, Congenital hypothyroidism: etiologies, diagnosis, and management, Thyroid 9:735, 1999.
105. **Salerno M**, **Militerni R**, **Bravaccio C**, **Micillo M**, **Capalbo D**, **Di MS**, **Tenore A**, Effect of different starting doses of levothyroxine on growth and intellectual outcome at four years of age in congenital hypothyroidism, Thyroid 12:45, 2002.
106. **Rovet JF**, **Ehrlich R**, Psychoeducational outcome in children with early-treated congenital hypothyroidism, Pediatrics 105:515, 2000.
107. **Rovet JF**, Children with congenital hypothyroidism and their siblings: do they really differ? Pediatrics 115:e52, 2005.
108. **Dimitropoulos A**, **Molinari L**, **Etter K**, **Torresani T**, **Lang-Muritano M**, **Jenni OG**, **Largo RH**, **Latal B**, Children with congenital hypothyroidism: long-term intellectual outcome after early high-dose treatment, Pediatr Res 65:2420248, 2009.
109. **Grüters A**, **Krude H**, **Biebermann H**, Molecular genetic defects in congenital hypothyroidism, Eur J Endocrinol 151(Suppl 3):U39, 2004.
110. **Al Taji E**, **Biebermann H**, **Limanová Z**, **Hniková O**, **Zikmund J**, **Dame C**, **Grüters A**, **Lebl J**, **Krude H**, Screening for mutations in transcription factors in a Czech cohort of 170 patients with congenital and early-onset hypothyroidism: identification of a novel PAX8 mutation in dominantly inherited early-onset non-autoimmune hypothyroidism, Eur J Endocrinol 156:521, 2007.
111. **Perelman AH**, **Johnson RL**, **Clemons RD**, **Finberg HJ**, **Clewell WH**, **Trujillo L**, Intrauterine diagnosis and treatment of fetal goitrous hypothyroidism, J Clin Endocrinol Metab 71:618, 1990.
112. **Shoham I**, **Aricha-Tamir A**, **Weintraub AY**, **Mazor M**, **Wiznitzer A**, **Holcberg G**, **Sheiner E**, Fetal heart

rate tracing patterns associated with congenital hypothyroidism, Am J Obstet Gynecol 201:48.e1, 2009.
113. **Klein AH**, **Murphy BEP**, **Artal R**, **Oddie TH**, **Fisher DA**, Amniotic fluid thyroid hormone concentrations during human gestation, Am J Obstet Gynecol 136:626, 1980.
114. **Davidson KM**, **Richards DS**, **Schatz DA**, **Fisher DA**, Successful in utero treatment of fetal goiter and hypothyroidism, N Engl J Med 324:543, 1991.
115. **Glinoer D**, The importance of iodine nutrition during pregnancy, Public Health Nutr 10:1541, 2007.
116. **Miyata I**, **Abe-Gotyo N**, **Tajima A**, **Yoshikawa H**, **Teramoto S**, **Seo M**, **Kanno K**, **Sugiura K**, **Tanaka T**, **Eto Y**, Successful intrauterine therapy for fetal goitrous hypothyroidism during late gestation, Endocr J 54:813, 2007.
117. **Roti E**, **Emerson CH**, Clinical review 29: postpartum thyroiditis, J Clin Endocrinol Metab 74:3, 1992.
118. **Stagnaro-Green A**, Postpartum thyroiditis, J Clin Endocrinol Metab 87:4042, 2002.
119. **Vargas MT**, **Bariones-Urbina R**, **Gladman D**, **Papsin FR**, **Walfish PG**, Antithyroid microsomal autoantibodies and HLA-DR5 are associated with postpartum thyroid dysfunction: evidence supporting an autoimmune pathogenesis, J Clin Endocrinol Metab 67:327, 1988.
120. **Ando T**, **Davies TF**, Postpartum autoimmune thyroid disease: the potential role of fetal microchimerism, J Clin Endocrinol Metab 88:2965, 2003.
121. **Alvarez-Marfany M**, **Roman SH**, **Drexler AZ**, **Robertson C**, **Stagnaro-Green A**, Long-term prospective study of postpartum thyroid dysfunction in women with insulin dependent diabetes mellitus, J Clin Endocrinol Metab 79:10, 1994.
122. **Marqusee E**, **Hill JA**, **Mandel SJ**, Thyroiditis after pregnancy loss, J Clin Endocrinol Metab 82:2455, 1997.
123. **Walfish PG**, **Chan YYC**, Postpartum hyperthyroidism, Clin Endocrinol Metab 14:417, 1985.
124. **Kita M**, **Goulis DG**, **Avramides A**, Post-partum thyroiditis in a Mediterranean population: a prospective study of a large cohort of thyroid antibody positive women at the time of delivery, J Endocrinol Invest 25:513, 2002.
125. **Davis LE**, **Lucas MJ**, **Hankins GDV**, **Roark ML**, **Cunningham FG**, Thyrotoxicosis complicating pregnancy, Am J Obstet Gynecol 160:63, 1989.
126. **Millar LK**, **Wing DA**, **Leung AS**, **Koonings PP**, **Montoro MN**, **Mestman JH**, Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism, Obstet Gynecol 84:946, 1994.
127. **Easterling TR**, **Chmucker BC**, **Carlson KL**, **Millard SP**, **Benedetti TJ**, Maternal hemodynamics in pregnancies complicated by hyperthyroidism, Obstet Gynecol 78:348, 1991.
128. **Casey BM**, **Dashe JS**, **Wells CE**, **McIntire DD**, **Leveno KJ**, **Cunningham FG**, Subclinical hyperthyroidism and pregnancy outcomes, Obstet Gynecol 107:337, 2006.
129. **Männistö T**, **Vaarasmaki M**, **Pouta A**, **Hartikainen AL**, **Ruokonen A**, **Surcel HM**, **Bloigu A**, **Järvelin MR**, **Suvanto-Luukkonen E**, Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: a prospective population-based cohort study, J Clin Endocrinol Metab 94:772, 2009.
130. **Cheron RG**, **Kaplan MM**, **Larsen PR**, **Selenkow HA**, **Crigler JF Jr**, Neonatal thyroid function after propylthiouracil therapy for maternal Graves' disease, N Engl J Med 304:525, 1981.
131. **Burrow GN**, **Klatskin EH**, **Genel M**, Intellectual development in children whose mothers received propylthiouracil during pregnancy, Yale J Biol Med 51:151, 1978.
132. **Mitsuda N**, **Tamaki H**, **Amino N**, **Hosono T**, **Miyaki K**, **Tanizasa O**, Risk factors for developmental disorders in infants born to women with Graves' disease, Obstet Gynecol 80:359, 1992.
133. **Wing DA**, **Millar LK**, **Koonings PP**, **Montoro MN**, **Mestman JH**, A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy, Am J Obstet Gynecol 170:90, 1994.
134. **Wenstrom KD**, **Weinger CP**, **Williamson RA**, **Grant SS**, Prenatal diagnosis of fetal hyperthyroidism using funipuncture, Obstet Gynecol 76:513, 1990.
135. **Cohen O**, **Pinhas-Hamiel O**, **Sivan E**, **Dolitski M**, **Lipitz S**, **Achiron R**, Serial in utero ultrasonographic measurements of the fetal thyroid: a new complementary tool in the management of maternal hyperthyroidism in pregnancy, Prenat Diagn 23:740, 2003.
136. **Luton D**, **Le Gac I**, **Vuillard E**, **Castanet M**, **Guibourdenche J**, **Noel M**, **Toubert ME**, **Léger J**, **Boissinot C**, **Schlageter MH**, **Garel C**, **Tébeka B**, **Oury JF**, **Czernichow P**, **Polak M**, Management of Graves' disease during pregnancy: the key role of fetal thyroid gland monitoring, J Clin Endocrinol Metab

90:6093, 2005.

Chapter twenty one

REFERENCES

1. **Sedgh G**, **Singh S**, **Hussain R**, Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann 45:301, 2014.
2. **Sedgh G**, **Finer LB**, **Bankole A**, **Eilers MA**, **Singh S**, Adolescent pregnancy, birth, and abortion rates across countries, J Adolesc Health 56:223, 2015.
3. **Finer LB**, **Zolna MR**, Declines in unintended pregnancy in the United States, 2008–2011, N Engl J Med 374:9, 2016.
4. **Lesesne CA**, **Lewis K**, **Fisher D**, Promoting Science-Based Approaches to Teen Pregnancy Prevention Using Getting to Outcomes for Teen Pregnancy Prevention (PSBA-GTO), Centers for Disease Control and Prevention, Atlanta, 2006.
5. **Martin JA**, **Hamilton BE**, **Osterman MJK**, **Driscoll AK**, **Mathews TJ**, Births: final data for 2015, Natl Vital Stat Rep 66:1, 2017.
6. **Santelli JS**, **Lindberg LD**, **Finer LB**, **Singh S**, Explaining recent declines in adolescent pregnancy in the United States: the contribution of abstinence and improved contraceptive use, Am J Public Health 97:150, 2007.
7. **Lindberg LD**, Changes in formal sex education: 1995–2002, Persp Sexual Reprod Health 38:182, 2006.
8. **Kirby D**, Emerging Answers 2007. Research Findings on Programs to Reduce Teen Pregnancy and Sexually Transmitted Diseases, The National Campaign to Prevent Teen and Unplanned Pregnancy, http://www.thenationalcampaign.org/EA2007/EA2007_full.pdf, 2007.
9. **Mueller TE**, **Gavin LE**, **Kulkarni A**, The association between sex education and youth's engagement in sexual intercourse, age at first intercourse, and birth control use at first sex, J Adolesc Health 42:89, 2008.
10. **Kavanaugh ML**, **Jerman J**, **Finer LB**, Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009–2012, Obstet Gynecol 126(5):917, 2015.
11. **Guttmacher Institute**, Fact sheet: contraceptive use in the United States, https://www.guttmacher.org/fact-sheet/contraceptive-use-united-states, 2016.
12. **Daniels K**, **Daugherty J**, **Jones J**, **Mosher W**, Current contraceptive use and variation by selected characteristics among women aged 15–44 in the United States, 2011–2013, Natl Health Stat Rep 86(1):1, 2015.
13. **Alkema L**, **Kantorova V**, **Menozzi C**, **Biddlecorn A**, National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis, Lancet 381:1642, 2013.
14. **Trussell J**, **Hatcher RA**, **Cates Jr W**, **Stewart FH**, **Kost K**, A guide to interpreting contraceptive efficacy studies, Obstet Gynecol 76:558, 1990.
15. **Trussell J**, Contraceptive failure in the United States, Contraception 83:397, 2011.
16. **Trussell J**, Contraceptive efficacy of the reality female condom, Contraception 58:147, 1998.
17. **Trussell J**, **Vaughan B**, Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth, Fam Plann Perspect 31:64, 1999.
18. **Pearl R**, Factors in human fertility and their statistical evaluation, Lancet 222:607, 1933.
19. **Chandra A**, **Martinez GM**, **Mosher WD**, **Abma JC**, **Jones J**, Fertility, Family Planning, and Reproductive Health of U.S. Women: Data from the 2002 National Survey of Family Growth, National Center for Health Statistics Series 23: No. 25, 2005.
20. **Mosher WD**, **Martinez GM**, **Chandra A**, **Abma JC**, **Willson SJ**, Use of Contraception and Use of Family Planning Services in the United States: 1982–2002, Advance Data from Vital and Health Statistics, Report No. 350, National Center for Health Statistics, 2004.
21. **Mosher WD**, **Pratt WF**, Contraceptive Use in the United States, 1973–88, Advance data from vital and health statistics, Report No. 182, National Center for Health Statistics, Washington, 1990.
22. **Mosher WD**, Use of family planning services in the United States: 1982 and 1988, Advance data from vital and health statistics. Report No. 184, National Center for Health Statistics, Washington, 1990.
23. **Abma JC**, **Chandra A**, **Mosher WD**, **Peterson L**, **Piccinino L**, Fertility, Family Planning, and Women's Health: New Data from the 1995 National Survey of Family Growth, Report No. 19, Series 23, National Center

for Health Statistics, Washington, 1997.
24. **Jones J**, **Mosher W**, **Daniels K**, Current Contraceptive Use in the United States, 2006–2010, and Changes in Patterns of Use Since 1995, Report No. 60, National Center for Health Statistics, Washington, 2012.
25. **Polaneczky M**, **Slap G**, **Forke C**, **Rappaport A**, **Sondheimer S**, The use of levonorgestrel implants (Norplant) for contraception in adolescent mothers, New Engl J Med 331:1201, 1994.
26. **Polaneczky M**, **Guarnaccia M**, **Alon J**, **Wiley J**, Early experience with the contraceptive use of depo-medroxyprogesterone acetate in an inner-city population, Fam Plann Perspect 28:174, 1996.
27. **Abraham M**, **Zhao Q**, **Peipert JF**, Young age, nulliparity, and continuation of long-acting reversible contraceptive methods, Obstet Gynecol 126:823, 2015.
28. **Diedrich JT**, **Zhao Q**, **Madden T**, **Secura GM**, **Peipert JF**, Three-year continuation of reversible contraception, Am J Obstet Gynecol 662, 2015.
29. **Canada Contraception Consensus**, Contraception in Canada, J Obstet Gynecol Canada, 2015.
30. **Office for National Statistics**, Contraception and Sexual Health 2007/2008, http://www.statistics.gov.uk/downloads/theme_health/contra2007–8.pdf, July 1, 2009.
31. **Bajos N**, **Bohet A**, **Le Guen M**, **Moreau C**, Contraception in France: new contexts, new practices? Popul Soc 492:1, 2012.
32. **United Nations**, The world at six billion, http://www.un.org/esa/population/publications/sixbillion/sixbilpart1.pdf, 2009.
33. **Population Reference Bureau**, 2017 World Population Data Sheet, U.S. Agency of International Development, Washington, 2017.
34. **Guttmacher Institute**, Unmet need for contraception in developing countries: examining women's reasons for not using a method, http://www.guttmacher.org/report/unmet-needs-for-contraception-in-developing-countries, 2016.
35. **UNICEF**, Current status + progress: maternal mortality, https://data.unicef.org/topic/maternal-health/maternal-mortality, 2017.
36. **Bernabé-Ortiz A**, **White PJ**, **Carcamo CP**, **Hughes JP**, **Gonzales MA**, **Garcia PJ**, **Garnett GP**, **Holmes KK**, Clandestine induced abortion: prevalence, incidence and risk factors among women in a Latin American country, Can Med Assoc J 180:298, 2009.
37. **Jones RK**, **Darroch JE**, **Henshaw SK**, Contraceptive use among U.S. women having abortions in 2000–2001, Perspect Sex Reprod Health 34:294, 2002.
38. **Frost JJ**, **Sonfield A**, **Zolna MR**, **Finer LB**, Return on investment: a fuller assessment of the benefits and cost savings of the US publicly funded family planning program, Milbank Q 92:696, 2014.
39. **Forrest JD**, **Singh S**, Public-sector savings resulting from expenditures for contraceptive services, Fam Plann Perspect 22:6, 1990.
40. **Meier KJ**, **McFarlane DR**, State family planning and abortion expenditures: their effect on public health, Am J Public Health 84:1468, 1994.
41. **Peipert JF**, **Gutmann J**, Oral contraceptive risk assessment: a survey of 247 educated women, Obstet Gynecol 82:112, 1993.
42. **Murphy P**, **Kirkman A**, **Hale RW**, A national survey of women's attitudes toward oral contraception and other forms of birth control, Womens Health Issues 5:94, 1995.
43. **Picardo CM**, **Nichols MD**, **Edelman A**, **Jensen JT**, Women's knowledge and sources of information on the risks and benefits of oral contraception, J Am Med Women's Assoc 58:112, 2003.
44. **Grossman D**, **Fernandez L**, **Hopkins K**, **Amastae J**, **Potter JE**, Perceptions of the safety of oral contraceptives among a predominantly Latina population in Texas, Contraception 81:254, 2010.
45. **EngenderHealth**. Contraceptive sterilization: global issues and trends. Chapter 2: Sterilization Incidence and Prevalence. EngenderHealth, New York, 2002.
46. **Speert H**, Obstetric & Gynecologic Milestones Illustrated, The Parthenon Publishing Group, New York, 1996.
47. **Lungren SS**, A case of cesarean section twice successfully performed on the same patient, with remarks on the time, indications, and details of the operation, Am J Obstet 14:78, 1881.
48. **Baird D**, The fifth freedom, Br Med J i:234, 1966.

49. **Giovannucci E**, **Tosteson TD**, **Speizer FE**, **Vessey MP**, **Colditz GA**, A long-term study of mortality in men who have undergone vasectomy, New Engl J Med 326:1392, 1992.
50. **Layde PM**, **Ory HW**, **Peterson HB**, **Scally MJ**, **Greenspan JR**, **Smith JC**, **Fleming D**, The declining lengths of hospitalization for tubal sterilizations, JAMA 245:714, 1981.
51. **Escobedo LG**, **Peterson HB**, **Grubb GS**, **Franks AL**, Case fatality rates for tubal sterilization in U.S. hospitals, Am J Obstet Gynecol 160:147, 1989.
52. **U.S. National Center for Health Statistics**, Vital Stat US, https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pregnancy-mortality-surveillance-system.htm, 2014.
53. **Peterson HB**, **Huber DH**, **Belker AM**, Vasectomy: an appraisal for the obstetrician-gynecologist, Obstet Gynecol 76:568, 1990.
54. **Barone MA**, **Nazerali H**, **Cortes M**, **Chen-Mok M**, **Pollack AE**, **Sokal D**, A prospective study of time and number of ejaculations to azoospermia after vasectomy by ligation and excision, J Urol 170:892, 2003.
55. **Griffin T**, **Tooher R**, **Nowakowski K**, **Lloyd M**, **Maddern G**, How little is enough? The evidence for post-vasectomy testing, J Urol 174:29, 2005.
56. **Peterson HB**, **Xia Z**, **Hughes JM**, **Wilcox LS**, **Tylor LR**, **Trussell J**, The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization, Am J Obstet Gynecol 174:1161, 1996.
57. **Peterson HB**, Sterilization, Am J Obstet Gynecol 111: 189, 2008.
58. **Lichterg E**, **Laff S**, **Friedman E**, Value of routine dilatation and curettage at the time of interval sterilization, Obstet Gynecol 67:763, 1986.
59. **Peterson HB**, **Xia Z**, **Hughes JM**, **Wilcox LS**, **Tylor LR**, **Trussell J**; **for the U.S. Collaborative Review of Sterilization Working Group**, The risk of ectopic pregnancy after tubal sterilization, New Engl J Med 336:762, 1997.
60. **Miesfeld R**, **Gaarontans R**, **Moyers T**, Vaginal tubal sterilization. Is infection a significant risk? Am J Obstet Gynecol 137:183, 1980.
61. **Levanon K**, **Crum C**, **Drapkin R**, New insights into the pathogenesis of serous ovarian cancer and its clinical impact, J Clin Oncol 26:5284, 2008.
62. **Dubeau L**, The cell of origin of ovarian epithelial tumours, Lancet Oncol 9:1191, 2008.
63. **Salvador S**, **Gilks B**, **Köbel M**, **Huntsman D**, **Rosen B**, **Miller D**, The fallopian tube: primary site of most pelvic high-grade serous carcinomas, Int J Gynecol Cancer 19:58, 2009.
64. **Hankinson SE**, **Hunter DJ**, **Colditz GA**, **Willett WC**, **Stampfer MJ**, **Rosner B**, **Hennekens CH**, **Speizer FE**, Tubal sterilization, hysterectomy, and risk of ovarian cancer. A prospective study, JAMA 270:2813, 1993.
65. **Miracle-McMahill HL**, **Calle EE**, **Kosinski AS**, **Rodriguez C**, **Wingo PA**, **Thun MJ**, **Heath CW JR**, Tubal ligation and fatal ovarian cancer in a large prospective cohort study, Am J Epidemiol 145:349, 1997.
66. **Mori M**, **Harabuchi I**, **Miyake H**, **Casagrande JT**, **Henderson BE**, **Ross RK**, Reproductive, genetic, and dietary risk factors for ovarian cancer, Am J Epidemiol 128:771, 1988.
67. **Irwin KL**, **Weiss NS**, **Lee NC**, **Peterson HB**, Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer, Am J Epidemiol 134:362, 1991.
68. **Whittemore AS**, **Harris R**, **Itnyre J**; **the Collaborative Ovarian Cancer Group**, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II: Invasive epithelial ovarian cancers in white women, Am J Epidemiol 136:1184, 1992.
69. **Powell CB**, **Alabaster A**, **Simmons S**, **Garcia C**, et al., Salpingectomy for sterilization: change in practice in a large integrate health care system, 2011–2016, Obstet Gynecol 130:961, 2017.
70. **Castellano T**, **Zerden M**, **Marsh L**, **Boggess K**, Risks and benefits of salpingectomy at the time of sterilization, Obstet Gynecol Surv 72:663, 2017.
71. **Peterson HB**, **Xia Z**, **Wilcox LS**, **Tylor LR**, **Trussell J**; **for the U.S. Collaborative Review of Sterilization Working Group**, Pregnancy after tubal sterilization with bipolar electrocoagulation, Obstet Gynecol 94:163, 1999.
72. **Penfield AJ**, The Filshie clip for female sterilization: a review of world experience, Am J Obstet Gynecol

182:485, 2000.
73. **Centers for Disease Control and Prevention**, Deaths following female sterilization with unipolar electrocoagulating devices, MMWR 30:150, 1981.
74. **Soderstrom RM**, **Levy BS**, **Engel T**, Reducing bipolar sterilization failures, Obstet Gynecol 74:60, 1989.
75. **Trussell J**, **Guilbert E**, **Hedley A**, Sterilization failure, sterilization reversal, and pregnancy after sterilization reversal in Quebec, Obstet Gynecol 101:677, 2003.
76. **Ruminjo JK**, **Lynam PF**, A fifteen-year review of female sterilization by minilaparotomy under local anesthesia in Kenya, Contraception 55:249, 1997.
77. **Layde PM**, **Peterson HB**, **Dicker RC**, **DeStefano F**, **Ruben GL**, **Ory HW**, Risk factors for complications of interval tubal sterilization by laparotomy, Obstet Gynecol 62:180, 1983.
78. **Lippes J**, Quinacrine sterilization: time for reconsideration, Contraception 92: 91, 2015
79. **Cooper JM**, **Carignan CS**, **Cher D**, **Kerin JF**; **Group STOPI**, Microinsert nonincisional hysteroscopic sterilization, Obstet Gynecol 102:59, 2003.
80. **Mino M**, **Arjona JE**, **Cordon J**, **Pelegrin B**, **Povedano B**, **Chacon E**, Success rate and patient satisfaction with the Essure sterilization in an outpatient setting: a prospective study of 857 women, Br J Obstet Gynaecol 114:763, 2007.
81. **Savage UK**, **Masters SJ**, **Smid M**, **Hung Y-Y**, **Jacobson GF**, Hysteroscopic sterilization in a large group practice. Experience and effectivenss, Obstet Gynecol 114:1227, 2009.
82. **Levy B**, **Levie MD**, **Childers ME**, A summary of reported pregnancies after hysteroscopic sterilization, J Minim Invasive Gynecol 14:271, 2007.
83. **Vancaillie TG**, **Anderson TL**, **Johns DA**, A 12-month prospective evaluation of transcervical sterilization using implantable polymer matrices, Obstet Gynecol 112:1270, 2008.
84. **Hillis SD**, **Marchbanks PA**, **Tylor LR**, **Peterson HB**; **for the U.S. Collaborative Review of Sterilization Working Group**, Higher hysterectomy risk for sterilized than nonsterilized women: findings from the U.S. Collaborative Review of Sterilization, Obstet Gynecol 91:241, 1998.
85. **Kjer J**, Sexual adjustment to tubal sterilization, Eur J Obstet Gynecol 35:211, 1990.
86. **Costello C**, **Hillis SD**, **Marchbanks PA**, **Jamieson DJ**, **Peterson HB**; **US Collaborative Review of Sterilization Working Group**, The effect of interval tubal sterilization on sexual interest and pleasure, Obstet Gynecol 100:511, 2002.
87. **Rulin MC**, **Davidson AR**, **Philliber SG**, **Graves WL**, **Cushman LF**, Changes in menstrual symptoms among sterilized and comparison women: a prospective study, Obstet Gynecol 79:749, 1989.
88. **DeStefano F**, **Perlman J**, **Peterson HB**, **Diamond E**, Long-term risk of menstrual disturbances after tubal sterilization, Am J Obstet Gynecol 152:835, 1985.
89. **Shy KK**, **Stergachis A**, **Grothaus LG**, **Wagner EH**, **Hecht J**, **Anderson G**, Tubal sterilization and risk of subsequent hospital admission for menstrual disorders, Am J Obstet Gynecol 166:1698, 1992.
90. **Thranov I**, **Hertz JB**, **Kjer JJ**, **Andresen A**, **Micic S**, **Nielsen J**, **Hancke S**, Hormonal and menstrual changes after laparoscopic sterilization by Falope-rings or Filshie-clips, Fertil Steril 57:751, 1992.
91. **Wilcox LS**, **Martinez-Schnell B**, **Peterson HB**, **Ware JH**, **Hughes JM**, Menstrual function after tubal sterilization, Am J Epidemiol 135:1368, 1992.
92. **Rulin MC**, **Davidson AR**, **Philliber SG**, **Graves WL**, **Cushman LF**, Long-term effect of tubal sterilization on menstrual indices and pelvic pain, Obstet Gynecol 82:118, 1993.
93. **Carmona F**, **Cristóbal P**, **Casamitjana R**, **Balasch J**, Effect of tubal sterilization on ovarian follicular reserve and function, Am J Obstet Gynecol 189:447, 2003.
94. **Fagundes ML**, **Mendes MC**, **Patta MC**, **Rodrigues R**, **Berezowski AT**, **de Moura MD**, **Yazille ME**, Hormonal assessment of women submitted to tubal ligation, Contraception 71:309, 2005.
95. **Gentile GP**, **Helbig DW**, **Zacur H**, **Park T**, **Lee YJ**, **Westhoff CL**, Hormone levels before and after tubal sterilization, Contraception 73:507, 2006.
96. **Dede FS**, **Dilbaz B**, **Akyuz O**, **Caliskan E**, **Kurtaran V**, **Dilbaz S**, Changes in menstrual pattern and ovarian function following bipolar electrocauterization of the fallopian tubes for voluntary surgical contraception, Contraception 73:88, 2006.

97. **Carney PI**, **Yao J**, **Lin J**, **Law A**, Occurrence of chronic pelvic pain, abnormal uterine bleeding, and hysterectomy post procedure among women who have undergone female sterilization procedures—a retrospective claims analysis of commercially insured women in the US, J Minim Invasive Gynecol, 17:31265, 2017.
98. **Peterson HB**, **Jeng G**, **Folger SG**, **Hillis SA**, **Marchbanks PA**, **Wilcox LS**; **for the U.S. Collaborative Review of Sterilization Working Group**, The risk of menstrual abnormalities after tubal sterilization. U.S. Collaborative Review of Sterilization Working Group, New Engl J Med 343:1724, 2000.
99. **Miller WB**, **Shain RN**, **Pasta DJ**, Tubal sterilization or vasectomy: how do married couples make the decision? Fertil Steril 56:278, 1991.
100. **Grubb G**, **Refoser H**, **Layde PM**, **Rubin GL**, Regret after decision to have a tubal sterilization, Fertil Steril 44:248, 1985.
101. **Hillis SD**, **Marchbanks PA**, **Tylor LR**, **Peterson HB**, Poststerilization regret: findings from the United States Collaborative Review of Sterilization, Obstet Gynecol 93:889, 1999.
102. **Chandra A**, Surgical Sterilization in the United States: Prevalence and Characteristics, 1965–95, Vital and Health Statistics, Series 23: No. 20, National Center for Health Statistics, Hyattsville, 1998.
103. **Schmidt JE**, **Hillis SD**, **Marchbanks PA**, **Jeng G**, **Peterson HB**, Requesting information about and obtaining reversal after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization, Fertil Steril 74:892, 2000.
104. **Curtis KM**, **Mohllajee AP**, **Peterson HB**, Regret following female sterilization at a young age: a systematic review, Contraception 73:205, 2006.
105. **Jamieson DJ**, **Kaufman SC**, **Cosstello C**, **Hillis SD**, **Marchbanks PA**, **Peterson HB**; **US Collaborative Review of Sterilization Working Group**, A comparison of women's regret after vasectomy versus tubal sterilization, Obstet Gynecol 99:1073, 2002.
106. **Vemer HM**, **Colla P**, **Schoot DC**, **Willensen WN**, **Bierkens PB**, **Rolland R**, Women regretting their sterilization, Fertil Steril 46:724, 1986.
107. **Wilcox LS**, **Chu SY**, **Peterson HB**, Characteristics of women who considered or obtained tubal reanastomosis: results from a prospective study of tubal sterilization, Obstet Gynecol 75:661, 1990.
108. **Vessey M**, **Huggins G**, **Lawless M**, **McPherson K**, **Yeates D**, Tubal sterilization: findings in a large prospective study, Br J Obstet Gynaecol 90:203, 1983.
109. **WHO**, Mental health and female sterilization: report of a WHO collaborative study, J Biosoc Sci 16:1, 1984.
110. **Berger GS**, **Thorp JM**, **Weaver MA**, Effectiveness of bilateral tubotubal anastomosis in a large outpatient population, Hum Reprod 31:1120, 2016.
111. **Smith GL**, **Taylor GP**, **Smith KF**, Comparative risks and costs of male and female sterilization, Am J Public Health 75:370, 1985.
112. **Marquette CM**, **Koonin LM**, **Antarsh L**, **Gargiullo PM**, **Smith JC**, Vasectomy in the United States, 1991, Am J Public Health 85:644, 1995.
113. **Kendrick JS**, **Gonzales B**, **Huber DH**, **Grubb GS**, **Rubin G**, Complications of vasectomies in the United States, J Fam Pract 25:245, 1987.
114. **Goldacre MJ**, **Wotton CJ**, **Seagroatt V**, **Yeates D**, Cancer and cardiovascular disease after vasectomy: an epidemiological database study, Fertil Steril 84:1438, 2005.
115. **Goldacre MJ**, **Wotton CJ**, **Seagroatt V**, **Yeates D**, Immune-related disease before and after vasectomy: an epidemiological database study, Hum Reprod 22:1273, 2007.
116. **Bertero E**, **Hallak J**, **Gromatzky C**, **Lucon AM**, **Arap S**, Assessment of sexual function in patients undergoing vasectomy using the international index of erectile function, Int Braz J Urol 31:452, 2005.
117. **Giovanucci E**, **Ascherio A**, **Rimm EB**, **Colditz GA**, **Stampfer MJ**, **Willett WC**, A prospective cohort study of vasectomy and prostate cancer in US men, JAMA 269:873, 1993.
118. **Giovanucci E**, **Tosteson TD**, **Speizer FE**, **Ascherio A**, **Vessey MP**, **Colditz GA**, A retrospective cohort study of vasectomy and prostate cancer in US men, JAMA 269:878, 1993.
119. **Hayes RB**, **Pottern LM**, **Greenberg R**, **Schoenberg J**, **Swanson GM**, **Liff J**, **Schwartz AG**, **Brown LM**, **Hoover RN**, Vasectomy and prostate cancer in US blacks and whites, Am J Epidemiol 137:263, 1993.

120. **Hsing AW**, **Wang RT**, **Gu FL**, **Lee M**, **Wang T**, **Leng TJ**, **Spitz M**, **Blot WJ**, Vasectomy and prostate cancer risk in China, Cancer Epidemiol Biomark Prev 3:285, 1994.
121. **Sidney S**, **Quesenberry Jr CP**, **Sadler MC**, **Guess HA**, **Lydick EG**, **Cattolica EV**, Vasectomy and the risk of prostate cancer in a cohort of multiphasic health-checkup examinees: second report, Cancer Causes Control 2:113, 1991.
122. **Moller H**, **Knudsen LB**, **Lynge E**, Risk of testicular cancer after vasectomy: cohort study of over 73,000 men, Br Med J 309:295, 1994.
123. **Rosenberg L**, **Palmer JR**, **Zauber AG**, **Warshauer E**, **Strom BL**, **Harlap S**, **Shapiro S**, The relation of vasectomy to risk of cancer, Am J Epidemiol 140:431, 1994.
124. **Zhu K**, **Stanford JL**, **Daling JR**, **McKnight B**, **Stergachis A**, **Brawer MK**, **Weiss NS**, Vasectomy and prostate cancer: a case-control study in a health maintenance organization, Am J Epidemiol 144:717, 1996.
125. **Holt SK**, **Salinas CA**, **Stanford JL**, Vasectomy and the risk of prostate cancer, J Urol 180:2565, 2008.
126. **Schwingle PJ**, **Meirik O**, **Kapp N**, **Farley TM**; **HRP Multicenter Study of Prostate Cancer and Vasectomy**, Prostate cancer and vasectomy: a hospital-based case-control study in China, Nepal and the Republic of Korea, Contraception 79:363, 2009.
127. **John EM**, **Whittemore AS**, **Wu AH**, **Kolonel LN**, **Hislop TG**, **Howe GR**, **West DW**, **Hankin J**, **Dreon DM**, **The C-Z**, **Burch JD**, **Paffenbarger RS Jr**, Vasectomy and prostate cancer: results from a multiethnic case-control study, J Natl Cancer Inst 87:662, 1995.
128. **Lynge E**, **Knudsen LB**, **Müller H**, Vasectomy and testis and prostate cancer, Fertil Control Rev 3:8, 1994.
129. **Healey B**, Does vasectomy cause prostate cancer? JAMA 269:2620, 1993.
130. **Bernal-Delgado E**, **Latour-Pérez J**, **Pradas-Arnal F**, **Gómez-López LI**, The association between vasectomy and prostate cancer: a systematic review of the literature, Fertil Steril 70:191, 1998.
131. **Cox B**, **Sneyd MJ**, **Paul C**, **Delahunt B**, **Skegg DC**, Vasectomy and risk of prostate cancer, JAMA 287:3110, 2002.
132. **Manson JE**, **Ridker PM**, **Spelsberg A**, **Ajani U**, **Lotufo PA**, **Hennekens CH**, Vasectomy and subsequent cardiovascular disease in US physicians, Contraception 59:181, 1999.
133. **Krieger JN**, **Nirapathpongporn A**, **Chaiyaporn M**, **Peterson G**, **Nikolaeva I**, **Akridge R**, **Ross SO**, **Coombs RW**, Vasectomy and human immunodeficiency virus type 1 in semen, J Urol 159:820, 1998.
134. **Hendry WF**, Vasectomy and vasectomy reversal, Br J Urol 73:337, 1994.
135. **Belker AM**, **Thomas AJ**, **Fuchs EF**, **Konnak JM**, **Sharlip ID**, Results of 1,469 microsurgical vasectomy reversals by the vasovasostomy group, J Urol 145:505, 1991.
136. **Winters SJ**, **Marshall GR**, Hormonally-based male contraceptives: will they ever be a reality? J Clin Endocrinol Metab 73:464A, 1991.
137. **Waites GMH**, Development of methods of male contraception: impact of the World Health Organization Task Force, Fertil Steril 80:1, 2003.
138. **Wang C**, **Swerdloff RS**, Male hormonal contraception, Am J Obstet Gynecol 190:S60, 2004.
139. **Grimes DA**, **Lopez LM**, **Gallo MF**, **Halpern V**, **Nanda K**, **Schulz KF**, Steroid hormones for contraception in men, Cochrane Database Syst Rev CD004316, 2012.
140. **Waites GMH**, **Wang C**, **Griffin PD**, Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug, Int J Androl 21:8, 1998.
141. **Atrash HK**, **Strauss LT**, **Kendrick JS**, **Skjeldestad FE**, **Ahn YW**, The relation between induced abortion and ectopic pregnancy, Obstet Gynecol 89:512, 1997.
142. **Jerman J**, **Jones RK**, **Onda T**, Characteristics of U.S. Abortion Patients in 2014 and Changes Since 2008, Guttmacher Institute, New York, 2016.
143. **Grimes DA**, **Benson J**, **Singh S**, **Romero M**, **Ganatra B**, **Okonofua FE**, **Shah IH**, Unsafe abortion: the preventable pandemic, Lancet 368:1908, 2006.
144. **Jatlaoui TC**, **Shah J**, **Mandel M**, **Krashin JW**, **Suchdev DB**, **Jamieson DJ**; **Centers for Disease Control and Prevention**, Abortion surveillance: United States, 2014, MMWR Surveill Summ 66:1, 2017.
145. **Creanga AA**, **Syverson C**, **Seed K**, **Callaghan WM**, Pregnancy-related mortality in the United States, 2011–2013, Obstet Gynecol 130:366, 2017.

146. **Grimes DA**, **Schulz KF**, **Cates W Jr**, **Tyler CW Jr**, Local versus general anesthesia: which is safer for performing suction curettage abortions, Am J Obstet Gynecol 135:1030, 1979.
147. **Peterson HB**, **Grimes DA**, **Cates W Jr**, **Rubin GL**, Comparative risk of death from induced abortion at 12 weeks' gestation performed with local versus general anesthesia, Am J Obstet Gynecol 141:763, 1981.
148. **Buehler J**, **Schulz K**, **Grimes D**, **Mogue C**, The risk of serious complications from induced abortion: do personal characteristics make a difference?, Am J Obstet Gynecol 153:14, 1985.
149. **Hakim-Elahi E**, **Tovell H**, **Burnhill M**, Complications of first trimester abortions: a report of 170,000 cases, Obstet Gynecol 76:129, 1990.
150. **Hogue C**, Impact of abortion on subsequent fertility, Clin Obstet Gynecol 13:96, 1986.
151. **Stubblefield PG**, **Monson RR**, **Schoenbaum SC**, **Wolfson CE**, **Cookson DJ**, **Ryan KJ**, Fertility after induced abortion: a prospective follow-up study, Obstet Gynecol 63:186, 1984.
152. **Daling J**, **Weiss N**, **Voigt I**, **Spadoni LR**, **Soderstrom R**, **Moore DE**, **Stadel BV**, Tubal infertility in relation to prior induced abortion, Fertil Steril 43:389, 1985.
153. **Daling J**, **Chow W**, **Weiss N**, **Metch BT**, **Soderstrom R**, Ectopic pregnancy in relation to previous induced abortion, JAMA 253:1005, 1985.
154. **Kalish RB**, **Chasen ST**, **Rosenzweig LB**, **Rashbaum WK**, **Chervenak FA**, Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome, Am J Obstet Gynecol 187:882, 2002.
155. **Debby A**, **Glezerman M**, **Sagiv R**, **Sadan O**, **Malinger G**, **Golan A**, Reproductive performance following midtrimester termination of pregnancy, Gynecol Obstet Invest 56:168, 2003.
156. **Skjeldestad FE**, **Gargiullo PM**, **Kendrick JS**, Multiple induced abortions as risk factor for ectopic pregnancy. A prospective study, Acta Obstet Gynecol Scand 76:691, 1997.
157. **Shah PS**, **Zao J**, Induced termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-anlayses, BJOG 116:1425, 2009.
158. **Swingle HM**, **Colaizy TT**, **Zimmerman MB**, **Morriss FH**, Abortion and the risk of subsequent preterm birth: a systematic review with meta-analysis, J Reprod Med 54:95, 2009.
159. **Saccone G**, **Perriera L**, **Berghella V**, Prior uterine evacuation of pregnancy as independent risk factor for preterm birth: a systematic review and metaanalysis, Am J Obstet Gynecol 214:572, 2016.
160. **Day JC**, Bureau of the Census, Current population reports. Population projections of the United States, by age, sex, race, and Hispanic origin: 1993 to 2050, U.S. Government Printing Office, Washington, DC, 1993.
161. **Tharaux-Deneux C**, **Bouyer J**, **Job-Spira N**, **Coste J**, **Spira A**, Risk of ectopic pregnancy and previous induced abortion, Am J Public Health 88:401, 1998.
162. **Sun Y**, **Che Y**, **Gao E**, **Olsen J**, **Zhou W**, Induced abortion and risk of subsequent miscarriage, Int J Epidemiol 32:449, 2003.
163. **Zhou W**, **Olsen J**, Are complications after an induced abortion associated with reproductive failures in a subsequent pregnancy? Acta Obstet Gynecol Scand 82:177, 2003.
164. **Biggs MA**, **Upadhyay UD**, **McCulloch CE**, **Foster DG**, Women's mental health and well-being 5 years after receiving or being denied an abortion: a prospective, longitudinal cohort study, JAMA Psychiat 74:169, 2017.
165. **Charles VE**, **Polis CB**, **Sridhara SK**, **Blum RW**, Abortion and long-term mental health outcomes: a systematic review of the evidence, Contraception 78:436, 2008.
166. **American Psychological Association**, Report of the APA Task Force on Mental Health and Abortion, http://www.apa.org/releases/abortion-report.pdf, 2008.
167. **Andrieu N**, **Clavel F**, **Gairard B**, **Piana L**, **Bremond A**, **Lansac JH**, **Flamant R**, **Renaud R**, Familial risk of breast cancer and abortion, Cancer Detect Prev 18:51, 1994.
168. **Daling JR**, **Malone KE**, **Voigt LF**, **White E**, **Weiss NS**, Risk of breast cancer among young women: relationship to induced abortion, J Natl Cancer Inst 86:1584, 1994.
169. **Rookus MA**, **van Leeuwen FE**, Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case-control study, J Natl Cancer Inst 88:1759, 1996.
170. **Melbye M**, **Wohlfahrt J**, **Olsen JH**, **Frisch M**, **Westergaard T**, **Helweg-Larsen K**, **Andersen PK**, Induced abortion and the risk of breast cancer, New Engl J Med 336:81, 1997.

171. **Ye Z**, **Gao DL**, **Qin Q**, **Ray RM**, **Thomas DB**, Breast cancer in relation to induced abortion in a cohort of Chinese women, Br J Cancer 87:977, 2002.
172. **Mahue-Giangreco M**, **Ursin G**, **Sullivan-Halley J**, **Berstein L**, Induced abortion, miscarriage, and breast cancer of young women, Cancer Epidemiol Biomarkers Prev 12:209, 2003.
173. **Brewster DH**, **Stockton DL**, **Dobbie R**, **Bull D**, **Beral V**, Risk of breast cancer after miscarriage or induced abortion: a Scottish record linkage case-control study, J Epidemiol Community Health 59:283, 2005.
174. **Michels KB**, **Xue F**, **Colditz GA**, **Willett WC**, Induced and spontaneous abortion and incidence of breast cancer among young women. A prospective cohort study, Arch Intern Med 167:814, 2007.
175. **Ganatra B**, **Gerdts C**, **Rossier C**, et al., Global, regional and subregional classification of abortions by safety, 2010–14: estimates from a Bayesian hierarchical model, Lancet 390:2372, 2017.
176. **Jerman J**, **Jones RK**, Secondary measures of access to abortion services in the United States, 2011 and 2012: gestational age limits, cost, and harassment, Womens Health Issues 24:e419, 2014.
177. **Jones RK**, **Jerman J**, Abortion incidence and service availability in the United States, 2014, Perspect Sex Reprod Health 49:17, 2017.
178. **Landy U**, Abortion counseling—a new component of medical care, Clin Obstet Gynecol 13:33, 1986.
179. **Prager SW**, **Steinauer JE**, **Foster DG**, **Darney PD**, **Drey EA**, Risk factors for repeat elective abortions, Am J Obstet Gynecol 197:575.e1, 2007.
180. **Darney PD**, **Atkinson E**, **Hirabayashi K**, Uterine perforation during second trimester abortion by cervical dilation and instrumental extraction: a review of 15 cases, Obstet Gynecol 75:441, 1990.
181. **World Health Organization Task Force on Postovulatory Methods of Fertility Regulation,** Cervical ripening with mifepristone (RU-486) in late first trimester abortion, Contraception 50:461, 1994.
182. **MacIsaac L**, **Grossman D**, **Balistreri E**, **Darney P**, A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion, Obstet Gynecol 93:766, 1999.
183. **Virk J**, **Zhang J**, **Olsen J**, Medical abortion and the risk of subsequent adverse pregnancy outcomes, New Engl J Med 357:648, 2007.
184. **Jensen JT**, **Astley SJ**, **Morgan E**, **Nichols M**, Outcomes of suction curettage and mifepristone abortion in the United States. A prospective comparison study, Contraception 59:153, 1999.
185. **Niinimäki M**, **Pouta A**, **Bloigu A**, **Gissler M**, **Hemminki E**, **Suhonen S**, **Heikinheimo O**, Immediate complications after medical compared with surgical termination of pregnancy, Obstet Gynecol 114:795, 2009.
186. **El-Rafaey HJ**, **Rajasekar D**, **Abdalla M**, **Calder L**, **Templeton A**, Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol, New Engl J Med 332:983, 1995.
187. **Silvestre L**, **Dubois C**, **Renault M**, **Rezvani Y**, **Baulieu EE**, **Ulmann A**, Voluntary interruption of pregnancy with Mifepristone (RU 486) and a prostaglandin analogue, New Engl J Med 322:645, 1990.
188. **Fiala C**, **Gemzell-Danielsson K**, Review of medical abortion using mifepristone in combination with a prostaglandin analogue, Contraception 74:66, 2006.
189. **Thong KJ**, **Baird DT**, Induction of abortion with mifepristone and misoprostol in early pregnancy, Br J Obstet Gynaecol 99:1004, 1992.
190. **Peyron R**, **Aubeny E**, **Targosz V**, **Silvestre L**, **Renault M**, **Elkik F**, **Leclerc P**, **Ulmann A**, **Baulieu EE**, Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol, New Engl J Med 328:1509, 1993.
191. **Schaff EA**, **Eisinger SH**, **Stadalius LS**, **Franks P**, **Gore BZ**, **Poppema S**, Low-dose mifepristone 200 mg and vaginal misoprostol for abortion, Contraception 59:1, 1999.
192. **Schaff EA**, **Fielding SL**, **Westhoff C**, **Ellertson C**, **Eisinger SH**, **Stadalius LS**, **Fuller L**, Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial, JAMA 284:1948, 2000.
193. **Ashok PW**, **Penney GC**, **Flett GMM**, **Templeton A**, An effective regimen for early medical abortion: a report of 2000 consecutive cases, Hum Reprod 13:2962, 1998.
194. **Schaff EA**, **Fielding SL**, **Westhoff C**, Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy, Contraception 66:247, 2002.
195. **Hamoda H**, **Ashok PW**, **Flett GMM**, **Templeton A**, Medical abortion at 64 to 91 days of gestation: a

review of 483 consecutive cases, Am J Obstet Gynecol 188:1315, 2003.
196. **von Hertzen H**, **Honkanen H**, **Piaggio G**, **Bartfai G**, **Erdenetungalag R**, **Gemzell-Danielsson K**, **Gopalan S**, **Horga M**, **Jerve F**, **Mittal S**, **Ngoc NT**, **Peregoudov A**, **Prasad RN**, **Pretnar-Darovec A**, **Shah RS**, **Song S**, **Tang OS**, **Wu SC**; **WHO Research Group on Post-ovulatory Methods of Fertility Regulation**, WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy, Br J Obstet Gynaecol 110:808, 2003.
197. **Fischer M**, **Bhatnagar J**, **Guarner J**, **Reagan S**, **Hacker JK**, **Van Meter SH**, **Poukens V**, **Whiteman DB**, **Iton A**, **Cheung M**, **Dassey DE**, **Shieh W-J**, **Zaki SR**, Fatal toxic shock syndrome associated with Clostridium sordelli after medical abortion, New Engl J Med 353:2352, 2005.
198. **Fjerstad M**, **Trussell J**, **Sivin I**, **Lichtenberg ES**, **Cullins V**, Rates of serious infection after changes in regimens for medical abortion, New Engl J Med 361:145, 2009.
199. **Meckstroth K**, **Whitaker A**, **Bertisch S**, **Goldberg A**, **Darney P**, Misoprostol administered by epithelial routes: drug absorption and uterine response, Obstet Gynecol 108:582, 2006.
200. **Winikoff B**, **Dzuba IG**, **Creinin MD**, **Crowden WA**, **Goldberg AB**, **Gonzales J**, **Howe M**, **Moskowitz J**, **Prine L**, **Shannon CS**, Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial, Obstet Gynecol 112:1303, 2008.
201. **Kapp N**, **Baldwin MK**, **Rodriguez MI**, Efficacy of medical abortion prior to 6 gestational weeks: a systematic review, Contraception 2018;97(2):90–99.
202. **Cohen AL**, **Bhatnagar J**, **Reagan S**, **Zane SB**, **D'Angeli MA**, **Fischer M**, **Killgore G**, **Dwan-Gett TS**, **Blossom DB**, **Shieh WJ**, **Guarner J**, **Jernigan J**, **Duchin JSZ**, **Zaki SR**, **McDonald LC**, Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion, Obstet Gynecol 110:1027, 2007.
203. **Ashok PW**, **Flett GM**, **Templeton A**, Termination of pregnancy at 9–13 weeks' amenorrhoea with mifepristone and misoprostol, Lancet 352:542, 1998.
204. **Baird DT**, **Brown A**, **Cheng L**, **Critchley HO**, **Lin S**, **Narvekar N**, **Williams AR**, Mifepristone: a novel estrogen-free daily contraceptive pill, Steroids 68:1099, 2003.
205. **Lakha F**, **Ho PC**, **Van der Spuy ZM**, **Dada K**, **Elton R**, **Glasier AF**, **Critchley HO**, **Williams AR**, **Baird DT**, A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel), Hum Reprod 22:2428, 2007.
206. **Creinin MD**, **Vittinghoff E**, **Keder L**, **Darney PD**, **Tiller G**, Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy, Contraception 53:321, 1996.
207. **Creinin MD**, Medical abortion with methotrexate 75 mg intramuscularly and vaginal misoprostol, Contraception 56:367, 1997.
208. **Creinin MD**, Oral methotrexate and vaginal misoprostol for early abortion, Contraception 54:15, 1996.
209. **Creinin M**, **Darney P**, Methotrexate and misoprostol for early abortion, Contraception 48:339, 1993.
210. **Creinin MD**, **Vittinghoff E**, Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial, JAMA 272:1190, 1994.
211. **Creinin MD**, **Park M**, Acceptablility of medical abortion with methotrexate and misoprostol, Contraception 52:41, 1995.
212. **Hauskenecht RU**, Methotrexate and misoprostol to terminate early pregnancy, New Engl J Med 333:538, 1995.
213. **Mishell Jr DR**, **Jain JK**, **Byrne JD**, **Lacarra MDC**, A medical method of early pregnancy termination using tamoxifen and misoprostol, Contraception 58:1, 1998.
214. **Wiebe ER**, Tamoxifen compared to methotrexate when used with misoprostol for abortion, Contraception 59:265, 1999.
215. **Koopersmith TB**, **Mishell DR Jr**, The use of misoprostol for termination of early pregnancy, Contraception 53:237, 1996.
216. **Carbonell JLL**, **Rodríguez J**, **Velazco A**, **Tanda R**, **Sánchez C**, **Barambio S**, **Chami S**, **Valero F**, **Marí J**, **de Vargas F**, **Salvador I**, Oral and vaginal misoprostol 800 μg every 8 h for early abortion, Contraception 67:457, 2003.

217. **Blanchard K**, **Winikoff B**, **Ellertson C**, Misoprostol used alone for the termination of early pregnancy. A review of the evidence, Contraception 59:209, 1999.
218. **Carbonell Esteve JL**, **Varela L**, **Velazco A**, **Cabezas E**, **Tanda R**, **Cabezas E**, **Sánchez C**, Early abortion with 800 mg of misoprostol by the vaginal route, Contraception 59:219, 1999.
219. **Jain JK**, **Meckstroth KR**, **Mishell DR Jr**, Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol, Am J Obstet Gynecol 181:1386, 1999.
220. **Pastuszak AL**, **Schüler L**, **Speck-Martins CE**, **Coelho K-EFA**, **Cordello SM**, **Vargas F**, **Brunoni D**, **Schwarz IVD**, **Larrandaburu M**, **Safattle H**, **Meloni VFA**, **Koren G**, Use of misoprostol during pregnancy and Möbius' syndrome in infants, New Engl J Med 338:1881, 1998.
221. **Gonzalez CH**, **Marques-Dias MJ**, **Kim CA**, **Sugayama SMM**, **Da Paz JA**, **Huson SM**, **Holmes LB**, Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy, Lancet 351:1624, 1998.
222. **Bos-Thompson MA**, **Hillaire-Buys D**, **Roux C**, **Faillie JL**, **Amram D**, Möbious syndrome in a neonate after mifepristone and misoprostol elective abortion failure, Ann Pharmacother 42:888, 2008.
223. **Howie FL**, **Henshaw RC**, **Naji SA**, **Russell IT**, **Templeton AA**, Medical abortion or vacuum aspiration? Two year follow-up of a patient preference trial, Br J Obstet Gynaecol 104:829, 1997.
224. **Elul B**, **Ellertson C**, **Winikoff B**, **Coyaji K**, Side effects of mifepristone-misoprostol abortion versus surgical abortion. Data from a trial in China, Cuba, and India, Contraception 59:107, 1999.
225. **Brewer C**, Prevention of infection after abortion with a supervised single dose of doxycycline, Br Med J 281:780, 1980.
226. **Hodgson JE**, **Major B**, **Portmann K**, **Quattlebaum FW**, Prophylactic use of tetracycline for first trimester abortions, Obstet Gynecol 45:574, 1975.
227. **Park T-X**, **Flock M**, **Schulz KF**, **Grimes DA**, Preventing febrile complications of suction curettage abortion, Am J Obstet Gynecol 152:252, 1985.
228. **Darj E**, **Stralin E**, **Nilsson S**, The prophylactic effect of doxycycline on postoperative infection rate after first trimester abortion, Obstet Gynecol 70:755, 1987.
229. **Sawaya GF**, **Grady D**, **Kerlikowske K**, **Grimes DA**, Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis, Obstet Gynecol 87:884, 1996.
230. **Levallois P**, **Rioux J**, Prophylactic antibiotics for suction curettage abortion: results of a clinical controlled trial, Am J Obstet Gynecol 158:100, 1988.
231. **Heisterberg L**, **Petersen K**, Metronidazole prophylaxis in elective first trimester abortion, Obstet Gynecol 65:371, 1985.
232. **Larsson PG**, **Platz-Christensen JJ**, **Thejls H**, **Forsum U**, **Pahlson C**, Incidence of pelvic inflammatory disease after first trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study, Am J Obstet Gynecol 166:100, 1992.
233. Hooker
234. **Jones RK**, **Finer LB**, Who has second-trimester abortions in the United States? Contraception 85:544, 2012.
235. **Foster DG**, **Jackson RA**, **Cosby K**, **Weitz TA**, **Darney PD**, **Drey EA**, Predictors of delay in each step leading to an abortion, Contraception 77:289, 2008.
236. **Peterson WF**, **Berry FN**, **Grace MR**, **Gulbranson CL**, Second trimester abortion by dilatation and evacuation: an analysis of 11,747 cases, Obstet Gynecol 62:185, 1983.
237. **Kafrissen M**, **Schulz K**, **Grimes D**, **Cates W Jr**, Midtrimester abortion: intra amniotic instillation of hyperosmolar urea and prostaglandin F2a v dilatation and evacuation, JAMA 251:916, 1984.
238. **Ferris LE**, **McMain-Klein M**, **Colodny N**, **Fellows GF**, **Lamont J**, Factors associated with immediate abortion complications, Can Med Assoc J 154:1677, 1996.
239. **Lohr PA**, **Hayes JL**, **Gemzell-Danielsson K**, Surgical versus medical methods for second trimester induced abortion, Cochrane Database Syst Rev (1):CD006714, 2008.
240. **Grossman D**, **Blanchard K**, **Blumenthal P**, Complications after second trimester surgical and medical abortion, Reprod Health Matters 15(31 Suppl):173, 2008.

241. **Mackay T**, **Schulz K**, **Grimes D**, Safety of local versus general anesthesia for second trimester dilatation and evacuation abortion, Obstet Gynecol 66:661, 1985.
242. **Atrash H**, **Chelk T**, **Hogue C**, Legal abortion and general anesthesia, Am J Obstet Gynecol 158:420, 1988.
243. **Ashok PW**, **Templeton A**, **Wagaarachi PT**, **Flett GMM**, Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases, Contraception 69:51, 2004.
244. **Esteve JL**, **Gallego FG**, **Llorente MP**, **Bermúdez SB**, **Sala ES**, **Gopnzález LV**, **Texidó CS**, Late second-trimester abortions induced with mifepristone, misoprostol and oxytocin: a report of 428 consecutive cases, Contraception 78:52, 2008.
245. **Borgatta L**, **Kapp N**, Clinical guidelines: labor induction abortion in the second trimester, Contraception 84:4, 2011.
246. **Jones RK**, **Kost K**, **Singh S**, **Henshaw SK**, **Finer LB**, Trends in abortion in the United States, Clin Obstet Gynecol 52:119, 2009.
247. **Truong HM**, **Kellogg T**, **McFarland W**, **Kang MS**, **Darney P**, **Drey EA**, Contraceptive intentions among adolescents after abortion, J Adolesc Health 39:283, 2006.
248. **Ceylan A**, **Ertem M**, **Saka G**, **Akdeniz N**, Post abortion family planning counseling as a tool to increase contraception use, BMC Public Health 9:20, 2009.
249. **Becker S**, **Bazant ES**, **Meyers C**, Couples counseling at an abortion clinic: a pilot study, Contraception 78:424, 2008.
250. **Heikinheimo O**, **Gissler M**, **Suhonen S**, Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion, Contraception 78:149, 2008.
251. **Madden T**, **Westhoff C**, Rates of follow-up and repeat pregnancy in the 12 months after first-trimester induced abortion, Obstet Gynecol 113:663, 2009.
252. **World Health Organization**, Medical eligibility for contraceptive use, http://apps.who.int/rhl/fertility/contraception/mec_story/en/index.html, 2009.
253. **Drey EA**, **Reeves MF**, **Ogawa DD**, **Sokoloff A**, **Darney PD**, **Steinauer JE**, Insertion of intrauterine contraceptives immediately following first- and second-trimester abortions, Contraception 79:397, 2009.
254. **Grimes DA**, **Schulz K**, **Stanwood N**, Immediate postabortal insertion of intrauterine devices, Cochrane Database Syst Rev (4):CD001777, 2004.
255. **Bednarek PH**, **Creinin MD**, **Reeves MF**, **Cwiak C**, **Espey E**, **Jensen JT**, Immediate intrauterine device insertion following suction aspiration between 5–12 weeks gestation is safe and does not significantly increase expulsion, FIGO Meeting, Capetown, South Africa Abstract, 2009.
256. **Cwiak CA**, **Bednarek PH**, **Reeves MF**, **Espey E**, **Creinin MD**, Uterine infection following immediate or delayed postaspiration intrauterine device insertion, Contraception 80:210 (Abstract), 2009.
257. **Niinimaki M**, **Pouta A**, **Bloigu A**, **Gissler M**, **Hemminki E**, **Suhonen S**, **Heikinheimo O**, Frequency and risk factors for repeat abortions after surgical compared with medical termination of pregnancy, Obstet Gynecol 113:845, 2009.
258. **Hognert H**, **Kopp Kallner H**, **Cameron S**, **Nyreli C**, **Jawad I**, et al., Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion—a randomized controlled equivalence trial, Hum Reprod 31:2484, 2016.
259. **Raymond EG**, **Weaver MA**, **Tan YL**, **Louie KS**, **Bousiequez M**, et al., Effect of immediate compared with delayed insertion of etonogestrel implants on medical abortion efficacy and repeat pregnancy: a randomized clinical trial, Obstet Gynecol 127:306, 2016.
260. **Bowman J**, Thirty-five years of Rh prophylaxis, Transfusion 43:1661–1666, 2003.

Chapter twenty two

REFERENCES

1. **Simmer HH**, On the history of hormonal contraception. I. Ludwig Haberlandt (1885–1932) and his concept of "hormonal sterilization", Contraception 1:3, 1970.
2. **Simmer HH**, On the history of hormonal contraception. II. Otfried Otto Fellner (1873–19??) and estrogens as antifertility hormones, Contraception 3:1, 1971.
3. **Marker RE**, The early production of steroid hormones, CHOC News, The Center for History of Medicine, University of Pennsylvania, 4:3, 1987.
4. **Marker RE**, Interview by Jeffrey L. Sturchio at Pennsylvania State University, Chemical Heritage Foundation, Philadelphia, Oral History: Transcript No. 0068, April 17, 1987.
5. **Applezweig N**, The big steroid treasure hunt, Chemical Week January 31, 38, 1959.
6. **Lehman FPA**, Early history of steroid chemistry in Mexico: the story of three remarkable men, Steroids 57:403, 1992.
7. **Djerassi C**, Problems of manufacture and distribution. The manufacture of steroidal contraceptives: technical versus political aspects, Proc Roy Soc 195:175, 1976.
8. **Djerassi C**, The Pill, Pygmy Chimps, and Degas' Horse, Basic Books, New York, 1992.
9. **Djerassi C**, Steroid research at Syntex: "the Pill" and cortisone, Steroids 57:631, 1992.
10. **Hench PS**, **Kendall EC**, **Slocumb CH**, **Polley HF**, The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone, compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis, Proc Staff Meet Mayo Clin 24:181, 1949.
11. **Rosenkranz G**, **Pataki J**, **Djerassi C**, Synthesis of cortisone, J Am Chem Soc 76:4055, 1951.
12. **Djerassi C**, **Miramontes L**, **Rosenkranz G**, **Sondheimer F**, Synthesis of 19-nor-17alpha-ethynyltestosterone and 19-nor-17alpha-methyltestosterone, J Am Chem Soc 76:4092, 1954.
13. **Colton FB**, Steroids and "the Pill:" early steroid research at Searle, Steroids 57:624, 1992.
14. **Hechter O**, **Jacobsen RP**, **Jeanloz R**, **Levy H**, **Pincus G**, **Schenker V**, Pathways of corticosteroid synthesis, J Clin Endocrinol Metab 10:827, 1950.
15. **Speroff L**, A Good Man. Gregory Goodwin Pincus, Arnica Publishing, Portland, Oregon, 2009, 158.
16. **Ehrenstein M**, Investigations on steroids. VIII. Lower homologs of hormones of the pregnane series: 10-nor–11-desoxycorticosterone acetate and 10-norprogesterone, J Org Chem 9:435, 1944.
17. **Tullner WW**, **Herz R**, High progestational activity of 19-norprogesterone, Endocrinology 52:359, 1953.
18. **Herz R**, **Waite JH**, **Thomas LB**, Progestational effectiveness of 19-nor-ethinyl-testosterone by oral route in women, Proc Soc Exp Biol Med 91:418, 1956.
19. **Tullner WW**, **Hertz R**, Progestational activity of 19-norprogesterone and 19-nor-ethisterone in the Rhesus monkey, Proc Soc Exp Biol Med 94:298, 1957.
20. **Tyler ET**, Comparative evaluation of various types of administration of progesterone, J Clin Endocrinol Metab 15:881, 1955.
21. **Zaffaroni A**, Life after Syntex, Chemical Heritage 12:2,10,12, 2004.
22. **Pincus GC**, **Chang MC**, **Hafez ESE**, **Zarrow MX**, **Merrill A**, Effects of certain 19-nor steroids on reproductive processes in animals, Science 124:890, 1956.
23. **Rock J**, **Pincus G**, **Garcia C-R**, Effects of certain 19-nor steroids on the normal human menstrual cycle, Science 124:891, 1956.
24. **Pincus G**, The hormonal control of ovulation and early development, Postgrad Med 24:654, 1958.
25. **Pincus G**, The Control of Fertility, Academic Press, New York, 1965.
26. **Goldzieher JW**, Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications, Am J Obstet Gynecol 163: 318, 1990.
27. **Goldzieher J**, **Stanczyk FZ**, Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins, Contraception 78:4, 2008.
28. **Stanczyk FZ**, **Roy S**, Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids, Contraception 42:67, 1990.

29. **Edgren RA**, Progestagens, In: Givens J, ed. Clinical Uses of Steroids, Yearbook, Chicago, 1980, p 1.
30. **Kuhnz W**, **Blode H**, **Maher M**, Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women, Contraception 49:255, 1994.
31. **Stanczyk FZ**, Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism, Contraception 55: 273, 1997.
32. **Hammond GL**, **Abrams LS**, **Creasy GW**, **Natarajan J**, **Allen JG**, **Siiteri PK**, Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties, Contraception 67:93, 2003.
33. **Speroff L**, **DeCherney A**, Evaluation of a new generation of oral contraceptives, Obstet Gynecol 81:1034, 1993.
34. **Breitkopf DM**, **Rosen MP**, **Young SL**, **Nagamani M**, Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism, Contraception 67:349, 2003.
35. **Kriplani A**, **Periyasamy AJ**, **Agarwal N**, **Kulshrestha V**, **Kumar A**, **Ammini AC**, Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome, Contraception 82:139, 2010.
36. **Foster RH**, **Wilde MI**, Dienogest, Drugs 56:825, 1998.
37. **Wiegratz I**, **Stahlberg S**, **Mantehy T**, **Sänger N**, **Mittmann K**, **Lange E**, **Mellinger U**, **Kuhl H**, Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters, Contraception 78:384, 2008.
38. **Endrikat J**, **Parke S**, **Trummer D**, **Schmidt W**, **Duijkers I**, **Klipping C**, Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies, Contraception 78:218, 2008.
39. **Ahrendt H-J**, **Makalová D**, **Parke S**, **Mellinger U**, **Mansour D**, Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel, Contraception 80:436, 2009.
40. **Palacios S**, **Wildt L**, **Parke S**, **Machlitt A**, **Römer T**, **Bitzer J**, Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A phase III trial, Eur J Obstet Gynecol Reprod Biol 149:57, 2009.
41. **Fuhrmann U**, **Krattenmacher R**, **Slater EP**, **Fritzemeier K-H**, The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential, Contraception 54:243, 1996.
42. **Oelkers W**, **Helmerhorst FM**, **Wuttke W**, **Heithecker R**, Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers, Gynecol Endocrinol 14:204, 2000.
43. **Loughlin J**, **Seeger JD**, **Eng PM**, **Foegh M**, **Clifford CR**, **Cutone J**, **Walker AM**, Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives, Contraception 78:377, 2008.
44. **Freeman EW**, **Kroll R**, **Rapkin A**, **Pearlstein T**, **Brown C**, **Parsey K**, **Zhang P**, **Patel H**, **Foegh M**; **PMS/PMDD Research Group**, Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder, J Womens Health Gend Based Med 10:561, 2001.
45. **Foidart JM**, **Wuttke W**, **Bouw GM**, **Gerlinger C**, **Heithecker R**, A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel, Eur J Contracept Reprod Health Care 5:124, 2000.
46. **Yonkers KA**, **Brown C**, **Pearlstein TB**, **Foegh M**, **Sampson-Landers C**, **Rapkin A**, Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder, Obstet Gynecol 106:492, 2005.
47. **Due I**, **Botella J**, **Bonnet P**, **Frabol F**, **Delansorne R**, **Paris J**, Antiandrogenic properties of nomegestrol acetate, Drug Res 45:70, 1995.
48. **Sitruik-Ware RL**, New progestagens for contraceptive use, Hum Reprod Update 12:169, 2006.
49. **Rowan JP**, "Estrophasic" dosing: a new concept in oral contraceptive therapy, Am J Obstet Gynecol 180:S302, 1999.
50. **Boyd RA**, **Zegarac EA**, **Posvar EL**, **Flack MR**, Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol, Contraception 63:71, 2001.

51. **Gilliam M**, **Elam G**, **Maloney JM**, **Flack MR**, **Sevilla CL**, **McLaughlin-Derman R**, Acne treatment with a low-dose oral contraceptive, Obstet Gynecol 97(Suppl 1):S9, 2001.
52. **Wiebe ER**, **Trussell J**, Contraceptive failure related to estimated cycle day of conception relative to the start of the last bleeding episode, Contraception 79:178, 2009.
53. **van Heusden AM**, **Fauser BCJM**, Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives, Contraception 59:237, 1999.
54. **Endrikat J**, **Müller U**, **Düsterberg B**, A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 mg ethinylestradiol/75 mg gestodene and 30 mg ethinylestradiol/75 mg gestodene, with respect to efficacy, cycle control, and tolerance, Contraception 55:131, 1997.
55. **Rosenberg MJ**, **Meyers A**, **Roy V**, Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations, Contraception 60:321, 1999.
56. **Sulak P**, **Lippman J**, **Siu C**, **Massaro J**, **Goodwin A**, Clinical comparison of triphasic norgestimate/35 mg ethinylestradiol and monophasic norethindrone acetate/20 mg ethinylestradiol: cycle control, lipid effects, and user satisfaction, Contraception 59:161, 1999.
57. **Rosenberg MJ**, **Waugh MS**, **Stevens CM**, Smoking and cycle control among oral contraceptive users, Am J Obstet Gynecol 174:628, 1996.
58. **Rosenberg MJ**, **Waugh MS**, Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons, Am J Obstet Gynecol 179:577, 1998.
59. **Jung-Hoffman C**, **Kuhl H**, Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings, Contraception 42:423, 1990.
60. **Willis SA**, **Kuehl TJ**, **Spiekerman AM**, **Sulak P**, Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval, Contraception 74:100, 2006.
61. **Baerwald AR**, **Adams G**, **Pierson R**, Characteristics of ovarian follicular wave dynamics in women, Biol Reprod 69:1023, 2003.
62. **Goodman AL**, **Hodgen GD**, The ovarian triad of the primate menstrual cycle, Recent Prog Horm Res 39:1, 1983.
63. **Ginther OJ**, **Beg MA**, **Bergfelt DR**, **Danadeu FX**, **Kot K**, Follicle selection in monovular species, Biol Reprod 65:638, 2001.
64. **Killick SR**, Ovarian follicles during oral contraceptive cycles: their potential for ovulation, Fertil Steril 52:580, 1989.
65. **Crosignani PG**, **Testa G**, **Vegetti W**, **Parazzini F**, Ovarian activity during regular oral contraceptive use, Contraception 54:271, 1996.
66. **Baerwald AR**, **Olatunbosun OA**, **Pierson RA**, Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use, Contraception 70:371, 2004.
67. **Pierson RA**, **Archer DF**, **Moreau M**, **Shangold GA**, **Fisher AC**, **Creasy GW**; **for the Ortho Evra™/Evra™ 008 Study Group**, Ortho Evra™/Evra™ versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error, Fertil Steril 80:34, 2003.
68. **Nakajima ST**, **Archer DF**, **Ellman H**, Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mg (Loestrin® 24 Fe), Contraception 75:16, 2007.
69. **Spona J**, **Elstein M**, **Feichtinger W**, **Sullivan H**, **Lüdicke F**, **Müller U**, **Düsterberg B**, Shorter pill-free interval in combined oral contraceptives decreases follicular development, Contraception 54:71, 1996.
70. **Endrikat J**, **Cronin M**, **Gerlinger C**, **Ruebig A**, **Schmidt W**, **Dusterberg B**, Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel, Contraception 64:201, 2001.
71. **Endrikat J**, **Cronin M**, **Gerlinger C**, **Ruebig A**, **Schmidt W**, **Dusterberg B**, Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene, Contraception 64:99, 2001.
72. **Sullivan H**, **Furniss H**, **Spona J**, **Elstein M**, Effect of 21-day and 24-day oral contraceptive regimens

containing gestodene (60 mg) and ethinyl estradiol (15 mg) on ovarian activity, Fertil Steril 72:115, 1999.
73. **Gestodene Study Group 324**, Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg, Eur J Contracept Reprod Health Care 4(Suppl 2):17, 1999.
74. **Fruzzetti F**, **Genazzani AR**, **Ricci C**, **De Negri F**, **Bersi C**, **Carmassi F**, A 12-month clinical investigation with a 24-day regimen containing 15 microg ethinylestradiol plus 60 microg gestodene with respect to hemostasis and cycle control, Contraception 63:303, 2001.
75. **Klipping C**, **Marr J**, **Korner P**, Ovulation inhibition effects of two low-dose oral contraceptive dosing regimens following intentional dosing errors (abstract), Obstet Gynecol 107(Suppl):495, 2006.
76. **Miller L**, **Notter KM**, Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial, Obstet Gynecol 98:771, 2001.
77. **Kwiecien M**, **Edelman A**, **Nichols MD**, **Jensen JT**, Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial, Contraception 67:9, 2003.
78. **Miller L**, **Hughes JP**, Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial, Obstet Gynecol 101:653, 2003.
79. **Elomaa K**, **Rolland R**, **Brosens I**, **Moorrees M**, **Deprest J**, **Tuominen J**, **Lähteenmäki P**, Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation, Am J Obstet Gynecol 179:41, 1998.
80. **Creinin MD**, **Lippman JS**, **Eder SE**, **Godwin AJ**, **Olson W**, The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 mg ethinyl estradiol versus monophasic levonorgestrel/20 mg ethinyl estradiol, Contraception 66:147, 2002.
81. **Baerwald AR**, **Olatunbosun OA**, **Pierson RA**, Effects of oral contraceptives administered at defined stages of ovarian follicular development, Fertil Steril 86:27, 2006.
82. **Anderson FD**, **Hait H**; **the Seasonale-301 Study Group**, A multicenter, randomized study of an extended cycle oral contraceptive, Contraception 68:89, 2003.
83. **Vandever MA**, **Kuehl TJ**, **Sulak PJ**, **Witt I**, **Coffee A**, **Wincek TJ**, **Reape KZ**, Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens, Contraception 77:162, 2008.
84. **Kaunitz AM**, **Portman DJ**, **Hait H**, **Reape KZ**, Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive, Contraception 79:350, 2009.
85. **Kroll R**, **Reape KZ**, **Margolis M**, The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol, Contraception 81:41, 2010.
86. **Edelman AB**, **Koontz SL**, **Nichols MD**, **Jensen JT**, Continuous oral contraceptives. Are bleeding patterns dependent on the hormones given?, Obstet Gynecol 107:657, 2006.
87. **Archer DF**, **Jensen JT**, **Johnson JV**, **Borisute H**, **Grubb GS**, **Coinstantine GD**, Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results, Contraception 74:439, 2006.
88. **Teichmann A**, **Apter D**, **Emerich J**, **Greven K**, **Klasa-Mazurkiewicz D**, **Melis GB**, **Spaczynski M**, **Grubb GS**, **Constantine G**, **Spielmann D**, Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial, Contraception 80:504, 2009.
89. **Coffee AL**, **Kuehl TJ**, **Willis S**, **Sulak PJ**, Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen, Am J Obstet Gynecol 195:1311, 2006.
90. **Coffee AL**, **Sulak PJ**, **Kuehl TJ**, Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen, Contraception 75:444, 2007.
91. **Sulak P**, **Willis S**, **Kuehl TJ**, **Coffee A**, **Clark J**, Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval, Headache 47:27, 2007.
92. **Archer DF**, **Kovalevsky G**, **Ballagh SA**, **Grubb GS**, Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen, Contraception 80:245, 2009.
93. **Davis AR**, **Kroll R**, **Soltes B**, **Zhang N**, **Grubb GS**, **Constantine GD**, Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive, Fertil Steril 89:1059, 2008.

94. **Alexander NJ**, **Baker E**, **Kaptein M**, **Karck U**, **Miller L**, **Zampaglione E**, Why consider vaginal drug administration?, Fertil Steril 82:1, 2004.
95. **Timmer CJ**, **Mulders TM**, Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring, Clin Pharmacokinet 39:233, 2000.
96. **Weisberg E**, **Brache V**, **Alvarez F**, **Massai R**, **Mishell Jr DR**, **Apter D**, **Gale J**, **Sivin I**, **Tsong Y-Y**, **Fraser IS**, Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen, Contraception 72:46, 2005.
97. **Rad M**, **Kluft C**, **Ménard J**, **Burggraaf J**, **de Kam ML**, **Meijer P**, **Sivin I**, **Sitruik-Ware RL**, Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables, Am J Obstet Gynecol 195:72, 2006.
98. **Jensen JT**, **Edelman AB**, **Chen BA**, **Archer DF**, **Barnhart KT**, et al., Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone and estradiol: pharmacokinetics from a dose-finding study, Contraception 97:422, 2018.
99. **Roumen FJME**, **Apter D**, **Mulders TMT**, **Dieben TOM**, Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol, Hum Reprod 16:469, 2001.
100. **Miller L**, **Verhoeven CH**, **Hout J**, Extended regimens of the contraceptive vaginal ring: a randomized trial, Obstet Gynecol 106:473, 2005.
101. **Mulders TM**, **Dieben TO**, Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition, Fertil Steril 75:865, 2001.
102. **Sulak PJ**, **Smith V**, **Coffee A**, **Witt I**, **Kuehl AL**, **Kuehl TJ**, Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial, Obstet Gynecol 112:563, 2008.
103. **Dieben TOM**, **Roumen FJME**, **Apter D**, Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring, Obstet Gynecol 100: 585, 2002.
104. **Oddsson K**, **Leifels-Fischer B**, **de Melo NR**, **Wiel-Masson D**, **Benedetto C**, **Verhoeven CH**, **Dieben TO**, Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial, Contraception 71:176, 2005.
105. **Szarewski A**, High acceptability and satisfaction with NuvaRing use, Eur J Contracept Reprod Health Care 7:31, 2002.
106. **Merki-Feld GS**, **Hund M**, Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages, Eur J Contracept Reprod Health Care 12:240, 2007.
107. **Brucker C**, **Karck U**, **Merkle E**, Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany, Eur J Contracept Reprod Health Care 13:31, 2008.
108. **Dittrich R**, **Parker L**, **Rosen JB**, **Shangold G**, **Creasy GW**, **Fisher AC**; **for the Ortho Evra/Evra 001 Study Group**, Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized multicenter, dose-response study, Am J Obstet Gynecol 186:15, 2002.
109. **Zacur HA**, **Hedon B**, **Mansour D**, **Shangold GA**, **Fisher AC**, **Creasy GW**, Integrated summary of Ortho Evra™/Evra™ contraceptive patch adhesion in varied climates and conditions, Fertil Steril 77(Suppl 2):S32, 2002.
110. **Audet M-C**, **Moreau M**, **Koltun WD**, **Waldbaum AS**, **Shangold G**, **Fisher AC**, **Creasy GW**; **for the ORTHO EVRA/EVRA 004 Study Group**, Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. A randomized controlled trial, JAMA 285:2347, 2001.
111. **Smallwood GH**, **Meador ML**, **Lenihan JP Jr**, **Shangold GA**, **Fisher AC**, **Creasy GW**; **for the ORTHO EVRA/EVRA 002 Study Group**, Efficacy and safety of a transdermal contraceptive system, Obstet Gynecol 98:799, 2001.
112. **Abrams LS**, **Skee DM**, **Natarajan J**, **Wong FA**, Pharmacokinetic overview of Ortho Evra™/Evra™, Fertil Steril 77(Suppl 2):S3, 2002.

113. **Abrams LS**, **Skee DM**, **Natarajan J**, **Wong FA**, **Lasseter KC**, Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants, Contraception 64:287, 2001.
114. **Abrams LS**, **Skee DM**, **Natarajan J**, **Wong FA**, **Anderson BD**, Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites, Br J Clin Pharmacol 53:141, 2002.
115. **Abrams LS**, **Skee DM**, **Wong FA**, **Anderson NJ**, **Leese PT**, Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches, J Clin Pharmacol 41:1232, 2001.
116. **Abrams LS**, **Skee DM**, **Natarajan J**, **Wong FA**, **Leese PT**, **Creasy GW**, **Shangold MM**, Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise, J Clin Pharmacol 41:1301, 2001.
117. **Foster DG**, **Parvateneni R**, **de Bocanegra HT**, **Lewis C**, **Bradsberry M**, **Darney P**, Number of oral contraceptive pill packages dispensed, method continuation, and costs, Obstet Gynecol 108:1107, 2006.
118. **Bylander A**, **Lind K**, **Goksor M**, **Billig H**, **Larsson DG**, The classical progesterone receptor mediates the rapid reduction of fallopian tube ciliary beat frequency by progesterone, Reprod Biol Endocrinol 11:33, 2013.
119. **Bylander A**, **Gunnarsson L**, **Shao R**, **Billig H**, **Larsson DG**, Progesterone-mediated effects on gene expression and oocyte-cumulus complex transport in the mouse fallopian tube, Reprod Biol Endocrinol 13:40, 2015.
120. **Rossmanith WG**, **Steffens D**, **Schramm G**, A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity, Contraception 56:23, 1997.
121. **Sparrow MJ**, Pill method failures, N Z Med J 100:102, 1987.
122. **Hansen TH**, **Lundvall F**, Factors influencing the reliability of oral contraceptives, Acta Obstet Gynecol Scand 76:61, 1997.
123. **Fu H**, **Darroch JE**, **Haas T**, **Ranjit N**, Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth, Fam Plann Perspect 31:58, 1999.
124. **Kost K**, **Singh S**, **Vaughan B**, **Trussell J**, **Bankole A**, Estimates of contraceptive failure from the 2002 National Survey of Family Growth, Contraception 77:10, 2008.
125. **Archer DF**, **Bigrigg A**, **Smallwood GH**, **Shangold GA**, **Creasy GW**, **Fisher AC**, Assessment of compliance with a weekly contraceptive patch (Ortho Evra™/Evra™) among North American women, Fertil Steril 77(Suppl 2):S27, 2002.
126. **Urdl W**, **Apter D**, **Alperstein A**, **Koll P**, **Schönian S**, **Bringer J**, **Fisher AC**, **Preik M**; **ORTHO EVRA/EVRA 003 Study Group**, Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception, Eur J Obstet Gynecol Reprod Biol 121:202, 2005
127. **Gilliam ML**, **Neustadt A**, **Kozloski M**, **Mistretta S**, **Tilmon S**, **Godfrey E**, Adherence and acceptability of the randomized contraceptive ring compared with the pill among students: a randomized clinical trial, Obstet Gynecol 115:503, 2010.
128. **Jain S**, **Vaqid NB**, **Narang Y**, **Suneja A**, **Guleria K**, A randomised controlled trial comparing the efficacy and side-effects of intravaginal ring (NuvaRing®) with combined oral hormonal preparation in dysfunctional uterine bleeding, J Clin Diagn Res 10:1, 2016.
129. **Martinelli I**, **Sacchi E**, **Landi G**, **Taioli E**, **Duca F**, **Mannucci PM**, High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives, N Engl J Med 338:1793, 1998.
130. **Hajjar KA**, Factor V Leiden: an unselfish gene?, N Engl J Med 331:1585, 1994.
131. **Svensson PJ**, **Dahlbäck B**, Resistance to activated protein C as a basis for venous thrombosis, N Engl J Med 330:517, 1994.
132. **Zöller B**, **Hillarp A**, **Berntorp E**, **Dahlbäck B**, Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis, Annu Rev Med 48:45, 1997.
133. **Rees DC**, **Cox M**, **Clegg JB**, World distribution of factor V Leiden, Lancet 346:1133, 1995.
134. **Zivelin A**, **Griffin JH**, **Xu X**, **Pabinger I**, **Samama M**, **Conard J**, **Brenner B**, **Eldor A**, **Seligsohn U**, A single genetic origin for a common Caucasian risk factor for venous thrombosis, Blood 89:397, 1997.

135. **Poort SR**, **Rosendaal FR**, **Reitsma PH**, **Bertina RM**, A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis, Blood 88:3698, 1996.
136. **Rosendaal FR**, **Doggen CJM**, **Zivelin A**, **Arruda VR**, **Aiach M**, **Siscovick DS**, **Hillarp H**, **Watzke HH**, **Bernardi F**, **Cumming AM**, **Preston FE**, **Reitsma PH**, Geographic distribution of the 20210 G to A prothrombin variant, Thromb Haemost 79:706, 1998.
137. **Martinelli I**, **Taioli E**, **Bucciarelli P**, **Akhavan S**, **Mannucci PM**, Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis, Arterioscler Thromb Vasc Biol 19:700, 1999.
138. **Legnani C**, **Cosmi B**, **Valdre L**, **Boggian O**, **Bernardi F**, **Coccheri S**, **Palareti G**, Venous thromboembolism, oral contraceptives and high prothrombin levels, J Thromb Haemost 1:112, 2003.
139. **Meade TW**, Oral contraceptives, clotting factors, and thrombosis, Am J Obstet Gynecol 142:758, 1982.
140. **The Oral Contraceptive and Hemostasis Study Group**, The effect of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study, Contraception 67:173, 2003.
141. **Jespersen J**, **Petersen KR**, **Skouby SO**, Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid, Am J Obstet Gynecol 163:396, 1990.
142. **Notelovitz M**, **Kitchens CS**, **Khan FY**, Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial, Am J Obstet Gynecol 167:1255, 1992.
143. **Schlit AF**, **Grandjean P**, **Donnez J**, **Lavenne E**, Large increase in plasmatic 11-dehydro-TXB2 levels due to oral contraceptives, Contraception 51:53, 1995.
144. **Fruzzetti F**, **Ricci C**, **Fioretti P**, Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives, Contraception 49:579, 1994.
145. **Kluft C**, **Meijer P**, **Laguardia KD**, **Fisher AC**, Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables, Contraception 77:77, 2008.
146. **Basdevant A**, **Conard J**, **Pelissier C**, **Guyene T-T**, **Lapousterle C**, **Mayer M**, **Guy-Grand B**, **Degrelle H**, Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel, Contraception 48:193, 1993.
147. **Winkler UH**, **Schindler AE**, **Endrikat J**, **Düsterberg B**, A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 mg and 30 mg ethinylestradiol, Contraception 53:75, 1996.
148. **Croft P**, **Hannaford PC**, Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study, Br Med J 298:165, 1989.
149. **Rosenberg L**, **Palmer JR**, **Lesko SM**, **Shapiro S**, Oral contraceptive use and the risk of myocardial infarction, Am J Epidemiol 131:1009, 1990.
150. **Stampfer MJ**, **Willett WC**, **Colditz GA**, **Speizer FE**, **Hennekens CH**, Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study, Am J Obstet Gynecol 163:285, 1990.
151. **Colditz GA**; **the Nurses' Health Study Research Group**, Oral contraceptive use and mortality during 12 years of follow-up: the Nurses' Health Study, Ann Intern Med 120:821, 1994.
152. **Beral V**, **Hermon C**, **Kay C**, **Hannaford P**, **Darby S**, **Reeves G**, Mortality associated with oral contraceptive use: 25-year follow-up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study, Br Med J 318:96, 1999.
153. **Vessey M**, **Painter R**, **Yeates D**, Mortality in relation to oral contraceptive use and cigarette smoking, Lancet 362:185, 2003.
154. **Böttiger LE**, **Boman G**, **Eklund G**, **Westerholm B**, Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content, Lancet 1:1097, 1980.
155. **Gerstman BB**, **Piper JM**, **Tomita DK**, **Ferguson WJ**, **Stadel BV**, **Lundin FE**, Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease, Am J Epidemiol 133:32, 1991.

156. **Vessey M**, **Mant D**, **Smith A**, **Yeates D**, Oral contraceptives and venous thromboembolism: findings in a large prospective study, Br Med J 292:526, 1986.
157. **Helmrich SP**, **Rosenberg L**, **Kaufman DW**, **Strom B**, **Shapiro S**, Venous thromboembolism in relation to oral contraceptive use, Obstet Gynecol 69:91, 1987.
158. **Thorogood M**, **Mann J**, **Murphy M**, **Vessey M**, Risk factors for fatal venous thromboembolism in young women: a case-control study, Int J Epidemiol 21:48, 1992.
159. **Rosenberg L**, **Hennekens CH**, **Rosner B**, **Belanger C**, **Rothman KH**, **Speizer FE**, Oral contraceptive use in relation to nonfatal myocardial infarction, Am J Epidemiol 11:59, 1980.
160. **Royal College of General Practitioners' Oral Contraceptive Study**, Incidence of arterial disease among oral contraceptive users, J Roy Coll Gen Pract 33:75, 1983.
161. **Lidegaard Ø**, Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study, Br Med J 306:956, 1993.
162. **Lawson DH**, **Davidson JF**, **Jick H**, Oral contraceptive use and venous thromboembolism: absence of an effect of smoking, Br Med J 2:729, 1977.
163. **Petitti DB**, **Wingerd J**, **Pellegrin F**, **Ramcharan S**, Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease, Am J Epidemiol 108:480, 1978.
164. **Royal College of General Practitioners**, Oral contraceptive study: oral contraceptives, venous thrombosis, and varicose veins, J Roy Coll Gen Pract 28:393, 1978.
165. **Porter JB**, **Hershel J**, **Walker AM**, Mortality among oral contraceptive users, Obstet Gynecol 70:29, 1987.
166. **WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception**, Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study, Lancet 346:1575, 1995.
167. **WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception**, Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease, Lancet 346:1582, 1995.
168. **Spitzer WO**, **Lewis MA**, **Heinemann LAJ**, **Thorogood M**, **MacRae KD**; **on behalf of the Transnational Research Group on Oral Contraceptives and the Health of Young Women**, Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study, Br Med J 312:83, 1996.
169. **Jick H**, **Jick SS**, **Gurewich V**, **Myers MW**, **Vasilakis C**, Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components, Lancet 348:1589, 1995.
170. **Jick H**, **Kaye JA**, **Vasilakis-Scaramozza C**, **Jick SS**, Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis, Br Med J 321:1190, 2000.
171. **Jick SJ**, **Kaye JA**, **Russmann S**, **Jick H**, Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel, Contraception 73:566, 2006.
172. **Bloemenkammp KWM**, **Rosendaal FR**, **Helmerhorst FM**, **Büller HR**, **Vandenbroucke JP**, Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen, Lancet 348:1593, 1995.
173. **Lidegaard Ø**, **Edström B**, **Kreiner S**, Oral contraceptives and venous thromboembolism. A case-control study, Contraception 5:291, 1998.
174. **Lidegaard Ø**, **Edström B**, **Kreiner S**, Oral contraceptives and venous thromboembolism: a five-year national case-control study, Contraception 65:187, 2002.
175. **Farmer RDT**, **Lawrenson RA**, **Thompson CR**, **Kennedy JG**, **Hambleton IR**, Population-based study of risk of venous thromboembolism associated with various oral contraceptives, Lancet 349:83, 1997.
176. **Farmer RD**, **Lawrenson RA**, **Todd JC**, **Williams TJ**, **MacRae KD**, **Tyrer F**, **Leydon GM**, A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives, Br J Clin Pharmacol 49:580, 2000.

177. **Farmer RDT**, **Todd J-C**, **Lewis MA**, **MacRae KD**, **Williams TJ**, The risks of venous thromboembolic disease among German women using oral contraceptives: a database study, Contraception 57:67, 1998.
178. **Farmer RDT**, **Williams TJ**, **Simpson EL**, **Nightingale AL**, Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database, Br Med J 321:477, 2000.
179. **Suissa S**, **Blais L**, **Spitzer WO**, **Cusson J**, **Lewis M**, **Heinemann L**, First-time use of newer oral contraceptives and the risk of venous thromboembolism, Contraception 56:141, 1997.
180. **Suissa S**, **Spitzer WO**, **Rainville B**, **Cusson J**, **Lewis M**, **Heinemann L**, Recurrent use of newer oral contraceptives and the risk of venous thromboembolism, Hum Reprod 15:817, 2000.
181. **Todd J**, **Lawrenson R**, **Farmer RD**, **Williams TJ**, **Leydon GM**, Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database, Hum Reprod 14:1500, 1999.
182. **Heinemann LAJ**, **Lewis MA**, **Assmann A**, **Thiel C**, Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use, Contraception 65:207, 2002.
183. **Heinemann LAJ**, **Lewis MA**, **Assman A**, **Gravens L**, **Guggenmoos-Holzmann I**, Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives?, Pharmacoepidemiol Drug Saf 5:285, 1996.
184. **Jamin C**, **de Mouzon J**, Selective prescribing of third generation oral contraceptives (OCs), Contraception 54:55, 1996.
185. **Van Lunsen WH**, Recent oral contraceptive use patterns in four European countries: evidence for selective prescribing of oral contraceptives containing third generation progestogens, Eur J Contracept Reprod Health Care 1:39, 1996.
186. **Lewis MA**, **Heinemann LAJ**, **MacRae KD**, **Bruppacher R**, **Spitzer WO**, The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research, Contraception 54:5, 1996.
187. **Sheldon T**, Dutch GPs warned against new contraceptive pill, Br Med J 324:869, 2002.
188. **Pearce HM**, **Layton DW**, **Wilton LV**, **Shakir SA**, Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin, Br J Clin Pharmacol 60:98, 2005.
189. **Dinger JC**, **Heinemann LA**, **Kühl-Habich D**, The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives based on 142,475 women-years of observation, Contraception 75:344, 2007.
190. **Seeger JD**, **Loughlin J**, **Eng PM**, **Clifford CR**, **Cutone J**, **Walker AM**, Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives, Obstet Gynecol 110:587, 2007.
191. **Lidegaard Ø**, **Lokkegaard E**, **Svendsen AL**, **Agger C**, Hormonal contraception and risk of venous thromboembolism: national follow-up study, Br Med J 339:b2890, 2009. doi:10.1136/bmj.b2890.
192. **van Hylckama Vlieg A**, **Helmerhorst FM**, **Vandenbroucke JP**, **Doggen CJM**, **Rosendaal FR**, The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study, Br Med J 339, 2009.
193. **Dinger JC**, **Bardenheuer K**, **Assmann A**, International active surveillance study of women taking oral contraceptives (INAS-OC study), BMC Med Res Methodol 9:77, 2009.
194. **Dinger JC**, **Bardenheuer K**, **Heinemann K**, Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives, Contraception 89:253, 2014.
195. **Heinemann LA**, **Dinger JC**, Range of published estimates of venous thromboembolism incidence in young women, Contraception 75:328, 2007.
196. **Pomp ER**, **le Cessie S**, **Rosendaal FR**, **Doggen CJ**, Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations, Br J Haematol 139:289, 2007.
197. **Pomp ER**, **Rosendaal FR**, **Doggen CJ**, Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use, Am J Hematol 83:97, 2008.
198. **van den Heuvel MW**, **van Bragt AJ**, **Ainabawy AK**, **Kaptein MC**, Comparison of ethinylestradiol

pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive, Contraception 72:168, 2005.
199. **Jick SS**, **Kaye JA**, **Russmann S**, **Jick H**, Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 mg of ethinyl estradiol, Contraception 73:223, 2006.
200. **Jick S**, **Kaye JA**, **Li L**, **Jick H**, Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 mg of ethinyl estradiol, Contraception 76:4, 2007.
201. **Cole JA**, **Norman H**, **Doherty M**, **Walker AM**, Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive users, Obstet Gynecol 109:339, 2007.
202. **Jick SS**, **Hagberg KW**, **Hernandez RK**, **Kaye JA**, Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to non-fatal venous thromboembolism, Contraception 81:16, 2010.
203. **Vensson PJ**, **Dahlbäck B**, Resistance to activated protein C as a basis for venous thrombosis, N Engl J Med 330:517, 1994.
204. **Hellgren M**, **Svensson PJ**, **Dahlbäck B**, Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives, Am J Obstet Gynecol 173:210, 1995.
205. **Vandenbroucke JP**, **Koster T**, **Briët E**, **Reitsma PH**, **Bertina RM**, **Rosendaal FR**, Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation, Lancet 344:1453, 1994.
206. **Spannagl M**, **Heinemann AJ**, **Schramm W**, Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?, Eur J Contracept Reprod Health Care 5:105, 2000.
207. **Bloemenkamp KW**, **Rosendaal FR**, **Helmerhorst FM**, **Vandenbroucke JP**, Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects, Arch Intern Med 160:49, 2000.
208. **Ridker PM**, **Miletich JP**, **Hennekens CH**, **Buring JE**, Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening, JAMA 277:1305, 1997.
209. **Winkler UH**, Blood coagulation and oral contraceptives. A critical review, Contraception 57:203, 1998.
210. **Reich LM**, **Bower M**, **Key NS**, Role of the geneticist in testing and counseling for inherited thrombophilia, Genet Med 5:133, 2003.
211. **Lidegaard Ø**, **Kreiner S**, Cerebral thrombosis and oral contraceptives. A case-control study, Contraception 57:303, 1998.
212. **Lidegaard Ø**, **Edström B**, Oral contraceptives and myocardial infarction. A case-control study (abstract), Eur J Contracept Reprod Health Care 1(Suppl):72, 1996.
213. **Sidney S**, **Petitti DB**, **Quesenberry CP**, **Klatsky AL**, **Ziel HK**, **Wolf S**, Myocardial infarction in users of low-dose oral contraceptives, Obstet Gynecol 88:939, 1996.
214. **Lewis MA**, **Heinemann LAJ**, **Spitzer WO**, **MacRae KD**, **Bruppacher R**; **for the Transnational Research Group on Oral Contraceptives and the Health of Young Women**, The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women, Contraception 56: 129, 1997.
215. **Lewis MA**, **Spitzer WO**, **Heinemann LAJ**, **MacRae KD**, **Bruppacher R**, Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism, Br Med J 315:679, 1997.
216. **Dunn N**, **Thorogood M**, **Garagher B**, **de Caestecker L**, **MacDonald TM**, **McCollum C**, **Thomas S**, **Mann R**, Oral contraceptives and myocardial infarction: results of the MICA case-control study, Br Med J 318:1579, 1999.
217. **Rosenberg L**, **Palmer JR**, **Rao RS**, **Shapiro S**, Low-dose contraceptive use and the risk of myocardial infarction, Arch Intern Med 161:1065, 2001.
218. **WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception**, Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study, Lancet 349:1202, 1997.

219. **Tanis BC**, **van den Bosch MA**, **Kemmeren JM**, **Cats VM**, **Helmerhorst FM**, **Algra A**, **van der Graaf Y**, **Rosendaal FR**, Oral contraceptives and the risk of myocardial infarction, N Engl J Med 345:1787, 2001.
220. **Margolis KL**, **Adami H-O**, **Luo J**, **Ye W**, **Weiderpass E**, A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women, Fertil Steril 88:310, 2007.
221. **Stampfer MJ**, **Willett WC**, **Colditz GA**, **Speizer FE**, **Hennekens CH**, A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases, N Engl J Med 319:1313, 1988.
222. **Mant J**, **Painter R**, **Vessey M**, Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study, Br J Obstet Gynaecol 105:890, 1998.
223. **Salonen JT**, Oral contraceptives, smoking and risk of myocardial infarction in young women: a longitudinal population study in eastern Finland, Acta Med Scand 212:141, 1982.
224. **Jick SS**, **Jick H**, The contraceptive patch in relation to ischemic stroke and acute myocardial infarction, Pharmacotherapy 27:218, 2007.
225. **Petitti DB**, **Sidney S**, **Quesenberry CP Jr**, **Bernstein A**, Incidence of stroke and myocardial infarction in women of reproductive age, Stroke 28:280, 1997.
226. **Jick H**, **Porter J**, **Rothman KJ**, Oral contraceptives and nonfatal stroke in healthy young women, Ann Intern Med 89:58, 1978.
227. **Vessey MP**, **Lawless M**, **Yeates D**, Oral contraceptives and stroke: findings in a large prospective study, Br Med J 289:530, 1984.
228. **Hannaford PC**, **Croft PR**, **Kay CR**, Oral contraception and stroke: evidence from the Royal College of General Practitioners' Oral Contraception Study, Stroke 25:935, 1994.
229. **Petitti DB**, **Sidney S**, **Bernstein A**, **Wolf S**, **Quesenberry C**, **Ziel HK**, Stroke in users of low-dose oral contraceptives, N Engl J Med 335:8, 1996.
230. **Heinemann LAJ**, **Lewis MA**, **Spitzer WO**, **Thorogood M**, **Guggenmoos-Holzmann I**, **Bruppacher R**; **the Transnational Research Group on Oral Contraceptives and the Health of Young Women**, Thromboembolic stroke in young women. A European case-control study on oral contraceptives, Contraception 57:29, 1998.
231. **Kemmeren JM**, **Tanis BC**, **van den Bosch MA**, **Bollen EL**, **Helmerhorst FM**, **van der Graaf Y**, **Rosendaal FR**, **Algra A**, Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke, Stroke 33:1202, 2002.
232. **Schwartz SM**, **Siscovick DS**, **Longstreth WT Jr**, **Psaty BM**, **Beverly RK**, **Raghunathan TE**, **Lin D**, **Koepsell TD**, Use of low-dose oral contraceptives and stroke in young women, Ann Intern Med 127:596, 1997.
233. **Schwartz SM**, **Petitti DB**, **Siscovick DS**, **Longstreth NT Jr**, **Sidney S**, **Raghunathan TE**, **Quesenberry CP Jr**, **Kelaghan J**, Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies, Stroke 29:2277, 1998.
234. **WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception**, Ischaemic stroke and combined oral contraceptives: results of an international, multicentre case-control study, Lancet 348:498, 1996.
235. **WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception**, Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study, Lancet 348:505, 1996.
236. **Lidegaard Ø**, **Kreiner S**, Contraceptives and cerebral thrombosis: a five-year national case-control study, Contraception 65:197, 2002.
237. **Yang L**, **Kuper H**, **Sandin S**, **Margolis KL**, **Chen Z**, **Adami HO**, **Weiderpass E**, Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stroke in a cohort study of middle-aged Swedish women, Stroke 40:1050, 2009.
238. **Sidney S**, **Cooper WO**, Recent combined hormonal contraceptives and the risk of thromboembolism and other cardiovascular events in new users, Contraception 87:505, 2013.
239. **Barrett DH**, **Anda RF**, **Escobedo LG**, **Croft JB**, **Williamson DF**, **Marks JS**, Trends in oral contraceptive use and cigarette smoking, Arch Fam Med 3: 438, 1994.

240. **Juster HR**, **Loomis BR**, **Hinman TM**, **Farrelly MC**, **Hyland A**, **Bauer UE**, **Birkhead GS**, Declines in hospital admissions for acute myocardial infarction in New York state after implementation of a comprehensive smoking ban, Am J Public Health 97:2035, 2007.
241. **Seo DC**, **Torabi MR**, Reduced admissions for acute myocardial infarction associated with a public smoking ban: matched controlled study, J Drug Educ 37: 217, 2007.
242. **Wahl P**, **Walden C**, **Knopp R**, **Hoover J**, **Wallace R**, **Heiss R**, **Refkind B**, Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol, N Engl J Med 308:862, 1983.
243. **Burkman RT**, **Robinson JC**, **Kruszon-Moran D**, **Kimball AW**, **Kwiterovich P**, **Burford RG**, Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial, Obstet Gynecol 71:33, 1988.
244. **Patsch W**, **Brown SA**, **Grotto AM Jr**, **Young RL**, The effect of triphasic oral contraceptives on plasma lipids and lipoproteins, Am J Obstet Gynecol 161: 1396, 1989.
245. **Gevers Leuven JA**, **Dersjant-Roorda MC**, **Helmerhorst FM**, **de Boer R**, **Neymeyer-Leloux A**, **Havekes L**, Estrogenic effect of gestodene-desogestrel-containing oral contraceptives on lipoprotein metabolism, Am J Obstet Gynecol 163:358, 1990.
246. **Kloosterboer HJ**, **Rekers H**, Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations, Am J Obstet Gynecol 163: 370, 1990.
247. **Notelovitz M**, **Feldmand EB**, **Gillespy M**, **Gudat J**, Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial, Am J Obstet Gynecol 160:1269, 1989.
248. **Young RL**, **DelConte A**, Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: a twenty-four-month clinical trial, Am J Obstet Gynecol 181:S59, 1999.
249. **Sibai BM**, **Odlind V**, **Meador ML**, **Shangold GA**, **Fisher AC**, **Creasy GW**, A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra™/Evra™), Fertil Steril 77(Suppl 2):S19, 2002.
250. **Adams MR**, **Clarkson TB**, **Koritnik DR**, **Nash HA**, Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques, Fertil Steril 47: 1010, 1987.
251. **Clarkson TB**, **Adams MR**, **Kaplan JR**, **Shively CA**, **Koritnik DR**, From menarche to menopause: coronary artery atherosclerosis and protection in cynomolgus monkeys, Am J Obstet Gynecol 160:1280, 1989.
252. **Clarkson TB**, **Shively CA**, **Morgan TM**, **Koritnik DR**, **Adams MR**, **Kaplan JR**, Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys, Obstet Gynecol 75:217, 1990.
253. **Kushwaha R**, **Hazzard W**, Exogenous estrogens attenuate dietary hypercholesterolemia and atherosclerosis in the rabbit, Metabolism 30:57, 1981.
254. **Hough JL**, **Zilversmit DB**, Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits, Arteriosclerosis 6:57, 1986.
255. **Henriksson P**, **Stamberger M**, **Eriksson M**, **Rudling M**, **Diczfalusy U**, **Berglund L**, **Angelin B**, Oestrogen-induced changes in lipoprotein metabolism: role in prevention of atherosclerosis in the cholesterol-fed rabbit, Eur J Clin Invest 19:395, 1989.
256. **Engel JH**, **Engel E**, **Lichtlen PR**, Coronary atherosclerosis and myocardial infarction in young women—role of oral contraceptives, Eur Heart J 4:1, 1983.
257. **Jugdutt BI**, **Stevens GF**, **Zacks DJ**, **Lee SJK**, **Taylor RF**, Myocardial infarction, oral contraception, cigarette smoking, and coronary artery spasm in young women, Am Heart J 106:757, 1983.
258. **Kovacs L**, **Bartfai G**, **Apro G**, **Annus J**, **Bulpitt C**, **Belsey E**, **Pinol A**, The effect of the contraceptive pill on blood pressure: a randomized controlled trial of three progestogen-oestrogen combinations in Szeged, Hungary, Contraception 33:69, 1986.
259. **Giribela CR**, **Consolim-Colombo FM**, **Nisenbaum MG**, **Moraes TL**, **Giribela AH**, **Baracat EC**, **Melo NR**, Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol 31(11), 912–915, 2015.

260. **Nisenbaum MG**, **de Melo NR**, **Giribela CR**, **de Morais TL**, **Guerra GM**, **de Angelis K**, **Mostarda C**, **Baracat EC**, **Consolim-Colombo FM**, Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial, Eur J Obstet Gynecol Reprod Biol 175:62–66, 2014.
261. **Nichols M**, **Robinson G**, **Bounds W**, **Newman B**, **Guillebaud J**, Effect of four combined oral contraceptives on blood pressure in the pill-free interval, Contraception 47:367, 1993.
262. **Qifang S**, **Deliang L**, **Ziurong J**, **Haifang L**, **Zhongshu Z**, Blood pressure changes and hormonal contraceptives, Contraception 50:131, 1994.
263. **Darney P**, Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials, Contraception 48:323, 1993.
264. **Farahmand M**, **Ramezani Tehrani F**, **Rostami Dovom M**, **Hashemi S**, **Azizi F**, The impact of oral contraceptives on cardiometabolic parameters, J Endocrinol Invest 39:277, 2016.
265. **Chasan-Taber L**, **Willett WC**, **Manson JE**, **Spiegelman D**, **Hunter DJ**, **Curhan G**, **Colditz GA**, **Stampfer MJ**, Prospective study of oral contraceptives and hypertension among women in the United States, Circulation 94:483, 1996.
266. **Brady WA**, **Kritz-Silverstein D**, **Barrett-Connor E**, **Morales AJ**, Prior oral contraceptive use is associated with higher blood pressure in older women, J Womens Health 7:221, 1998.
267. **Pritchard JA**, **Pritchard SA**, Blood pressure response to estrogen-progestin oral contraceptives after pregnancy-induced hypertension, Am J Obstet Gynecol 129:733, 1977.
268. **Braken MB**, **Srisuphan W**, Oral contraception as a risk factor for preeclampsia, Am J Obstet Gynecol 142:191, 1982.
269. **Gratacos E**, **Torres P**, **Cararach V**, **Quinto L**, **Alonso PL**, **Fortuny A**, Does the use of contraception reduce the risk of pregnancy-induced hypertension?, Hum Reprod 11:2138, 1996.
270. **Thadhani R**, **Stampfer MJ**, **Chasan-Taber L**, **Willett WC**, **Curhan GC**, A prospective study of pregravid oral contraceptive use and risk of hypertensive disorders of pregnancy, Contraception 60:145, 1999.
271. **Lubianca JN**, **Faccin CS**, **Fuchs FD**, Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women, Contraception 67:19, 2003.
272. **Cosmi B**, **Legnani C**, **Bernardi F**, **Coccheri S**, **Palareti G**, Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception, Arch Intern Med 163:1105, 2003.
273. **Baglin T**, **Luddington R**, **Brown K**, **Baglin C**, Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study, Lancet 362:523, 2003.
274. **de Bruijn SFTM**, **Stam J**, **Koopman MMW**, **Vandenbroucke JP**; **for the Cerebral Venous Sinus Thrombosis Study Group**, Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions, Br Med J 316:589, 1998.
275. **Jick SS**, **Jick H**, Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch, Contraception 74:290, 2006.
276. **Pabinger I**, **Schneider B**; **the GTH Study Group**, Thrombotic risk of women with hereditary antithrombin III, protein C, and protein S deficiency taking oral contraceptive medication, Thromb Haemost 5:548, 1994.
277. **Godsland IF**, **Crook D**, **Simpson R**, **Proudler T**, **Gelton C**, **Lees B**, **Anyaoku V**, **Devenport M**, **Wynn V**, The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism, N Engl J Med 323: 1375, 1990.
278. **van der Vange N**, **Kloosterboer HJ**, **Haspels AA**, Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism, Am J Obstet Gynecol 156:918, 1987.
279. **Bowes WA**, **Katta LR**, **Droegemueller W**, **Braight TG**, Triphasic randomized clinical trial: comparison of effects on carbohydrate metabolism, Am J Obstet Gynecol 161:1402, 1989.
280. **Gaspard UJ**, **Lefebvre PJ**, Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease, Am J Obstet Gynecol 163:334, 1990.
281. **Troisi RJ**, **Cowie CC**, **Harris MI**, Oral contraceptive use and glucose metabolism in a national sample of

women in the United States, Am J Obstet Gynecol 183:389, 2000.
282. **Hannaford PC**, **Kay CR**, Oral contraceptives and diabetes mellitus, Br Med J 299:315, 1989.
283. **Rimm EB**, **Manson JE**, **Stampfer MJ**, **Colditz GA**, **Willett WC**, **Rosner B**, **Hennekens CH**, **Speizer FE**, Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women, Diabetologia 35:967, 1992.
284. **Duffy TJ**, **Ray R**, Oral contraceptive use: prospective follow-up of women with suspected glucose intolerance, Contraception 30:197, 1984.
285. **Chasan-Taber L**, **Colditz GA**, **Willett WC**, **Stampfer MJ**, **Hunter DJ**, **Colditz GA**, **Spiegelman D**, **Manson JE**, A prospective study of oral contraceptives and NIDDM among U.S. women, Diabetes Care 20:330, 1997.
286. **Kjos SL**, **Shoupe D**, **Douyan S**, **Friedman RL**, **Bernstein GS**, **Mestman JH**, **Mishell DR Jr**, Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study, Am J Obstet Gynecol 163:1822, 1990.
287. **Kjos SL**, **Peters RK**, **Xiang A**, **Thomas D**, **Schaefer U**, **Buchanan TA**, Contraception and the risk of type 2 diabetes in Latino women with prior gestational diabetes, JAMA 280:533, 1998.
288. **Skouby SO**, **Malsted-Pedersen L**, **Kuhl C**, **Bennet P**, Oral contraceptives in diabetic women: metabolic effects of compounds with different estrogen/progestogen profiles, Fertil Steril 46:858, 1986.
289. **Garg SK**, **Chase HP**, **Marshall G**, **Hoops SL**, **Holmes DL**, **Jackson WE**, Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus, JAMA 271:1099, 1994.
290. **Petersen KR**, **Skouby SO**, **Sidelmann J**, **Mølsted-Petersen L**, **Jespersen J**, Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus, Am J Obstet Gynecol 171:400, 1994.
291. **Klein BE**, **Klein R**, **Moss SE**, Mortality and hormone-related exposures in women with diabetes, Diabetes Care 22:248, 1999.
292. **Grigoryan OR**, **Grodnitskaya EE**, **Andreeva EN**, **Chebotnikova TV**, **Melnichenko GA**, Use of the NuvaRing hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus, Gynecol Endocrinol 24:99, 2008.
293. **Hannaford PC**, **Kay CR**, **Vessey MP**, **Painter R**, **Mant J**, Combined oral contraceptives and liver disease, Contraception 55:145, 1997.
294. **Royal College of General Practitioners' Oral Contraception Study**, Oral contraceptives and gallbladder disease, Lancet ii:957, 1982.
295. **Bennion LJ**, **Ginsberg RL**, **Garnick MB**, **Bennett PH**, Effects of oral contraceptives on the gallbladder bile of normal women, N Engl J Med 294:189, 1976.
296. **Grodstein F**, **Colditz GA**, **Hunter DJ**, **Manson JE**, **Willett WC**, **Stampfer MJ**, A prospective study of symptomatic gallstones in women: relation with oral contraceptives and other risk factors, Obstet Gynecol 84:207, 1994.
297. **La Vecchia C**, **Negri E**, **D'Avanzo B**, **Parazzini F**, **Genitle A**, **Franceschi S**, Oral contraceptives and noncontraceptive oestrogens in the risk of gallstone disease requiring surgery, J Epidemiol Community Health 46:234, 1992.
298. **Vessey M**, **Painter R**, Oral contraceptive use and benign gallbladder disease; revisited, Contraception 50:167, 1994.
299. **Cherqui D**, **Rahmouni A**, **Charlotte F**, **Boulahdour H**, **Metreau JM**, **Meignan M**, **Fagniez PL**, **Zafrani ES**, **Mathieu D**, **Dhumeaux C**, Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical radiological and pathological correlations, Hepatology 22:1674, 1995.
300. **Côté C**, Regression of focal nodular hyperplasia of the liver after oral contraceptive discontinuation, Clin Nucl Med 9:587, 1997.
301. **Heinemann LA**, **Weimann A**, **Gerken G**, **Thiel C**, **Schlaud M**, **Do Minh T**, Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study, Eur J Contracept Reprod Health Care 3:194, 1998.

302. **Scalori A**, **Tavani A**, **Gallus S**, **La Vecchia C**, **Colombo M**, Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study, Am J Obstet Gynecol 186:195, 2002.
303. **Lucky AW**, **Henderson TA**, **Olson WH**, **Robisch DM**, **Lebwohl M**, **Swinyer LJ**, Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris, J Am Acad Dermatol 37:746, 1997.
304. **Redmond GP**, **Olson WH**, **Lippman JS**, **Kafrissen ME**, **Jones TM**, **Jorizzo JL**, Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial, Obstet Gynecol 89:615, 1997.
305. **Redmond G**, **Godwin AJ**, **Olson W**, **Lippman JS**, Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence, Contraception 60:81, 1999.
306. **Carpenter S**, **Neinstein LS**, Weight gain in adolescent and young adult oral contraceptive users, J Adolesc Health Care 7:342, 1986.
307. **Reubinoff BE**, **Wurtman J**, **Rojansky N**, **Adler D**, **Stein P**, **Schenker JG**, **Brzezinski A**, Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study, Fertil Steril 64:963, 1995.
308. **Moore LL**, **Valuck R**, **McDougall C**, **Fink W**, A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives, Contraception 52:215, 1995.
309. **Rosenberg M**, Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. Contraception 58:345, 1998.
310. **Risser WL**, **Gefter L**, **Barratt MS**, **Risser JM**, Weight change in adolescents who used hormonal contraception, J Adolesc Health 24:433, 1999.
311. **Gupta S**, Weight gain on the combined pill—is it real?, Hum Reprod Update 6:427, 2000.
312. **Thiboutot D**, **Archer DF**, **Lemay A**, **Washenik K**, **Roberts J**, **Harrison DD**, A randomized, controlled trial of a low-dose contraceptive containing 20 mg of ethinyl estradiol and 100 mg of levonorgestrel for acne treatment, Fertil Steril 76:461, 2001.
313. **Coney P**, **Washenik K**, **Langley RGB**, **DiGiovanna JJ**, **Harrison DD**, Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials, Contraception 63:297, 2001.
314. **Vessey MP**, **Villard-Mackintosh L**, **Painter R**, Oral contraceptives and pregnancy in relation to peptic ulcer, Contraception 46:349, 1992.
315. **Lashner BA**, **Kane SV**, **Hanauer SB**, Lack of association between oral contraceptive use and ulcerative colitis, Gastroenterology 99:1032, 1990.
316. **Torok HM**, A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream, Am J Clin Dermatol 7:223, 2006.
317. **Milman N**, **Kirchhoff M**, **Jorgensen T**, Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment, Ann Hematol 65:96, 1992.
318. **Galan P**, **Yoon HC**, **Preziosi P**, **Viteri P**, **Fieux B**, **Briancon S**, **Malvy D**, **Roussel AM**, **Favier A**, **Hercberg S**, Determining factors in the iron status of adult women in the SU.VI.MAX study, Eur J Clin Nutr 52:383, 1998.
319. **Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction**, Effects of contraceptives on hemoglobin and ferritin, Contraception 58:261, 1998.
320. **Mooij PN**, **Thomas CMG**, **Doesburg WH**, **Eskes TK**, Multivitamin supplementation in oral contraceptive users, Contraception 44:277, 1991.
321. **Skovlund CW**, **Morch LS**, **Kessing LV**, **Lidegaard O**, Association of hormonal contraception with depression, JAMA Psychiat 73:1154, 2016.
322. **Skovlund CW**, **Morch LS**, **Kessing LV**, **Lange T**, **Lidegaard O**, Association of hormonal contraception with suicide attempts and suicides, Am J Psychiatry 175:336, 2018.
323. **Keyes KM**, **Cheslack-Postava K**, **Westhoff C**, **Heim CM**, **Haloossim M**, **Walsh K**, **Koenen K**, Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of

sexually active women in the United States, Am J Epidemiol 178:1378, 2013.
324. **Toffol E**, **Heikinheimo O**, **Koponen P**, **Luoto R**, **Partonen T**, Hormonal contraception and mental health: results of a population-based study, Hum Reprod 26:3085, 2011.
325. **Worly BL**, **Gur TL**, **Schaffir J**, The relationship between progestin hormonal contraception and depression: a systemic review, Contraception 97:478, 2018.
326. **Pagano HP**, **Zapata LB**, **Berry-Bibee EN**, **Nanda K**, **Curtis KM**, Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review, Contraception 94:641, 2016.
327. **Schaffir J**, **Worly BL**, **Gur TL**, Combined hormonal contraception and its effects on mood: a critical review, Eur J Contracept Reprod Health Care 21:347, 2016.
328. **Lundin C**, **Danielsson KG**, **Bixo M**, **Moby L**, **Bengtsdotter H**, et al., Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle—a double blind, placebo-controlled randomized trial, Psychoneuroendocrinology 76:135, 2017.
329. **Davis AR**, **Castaño PM**, Oral contraceptives and libido in women, Annu Rev Sex Res 15:297, 2004.
330. **Oranratanaphan S**, **Taneepanichskul S**, A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido, J Med Assoc Thai 89(Suppl 4):S17, 2006.
331. **Greco T**, **Graham CA**, **Bancroft J**, **Tanner A**, **Doll HA**, The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 mg of ethinyl estradiol, Contraception 76:8, 2007.
332. **Wendler J**, **Siegert C**, **Schelhorn P**, **Klinger G**, **Gurr S**, **Kaufmann J**, **Aydinlik S**, **Braunschweig T**, The influence of Microgynon® and Diane-35®, two sub-fifty ovulation inhibitors, on voice function in women, Contraception 52:343, 1995.
333. **The Cancer and Steroid Hormone Study of the CDC and NICHD**, Combination oral contraceptive use and the risk of endometrial cancer, JAMA 257:796, 1987.
334. **Schlesselman JJ**, Oral contraceptives and neoplasia of the uterine corpus, Contraception 43:557, 1991.
335. **Vessey MP**, **Painte R**, Endometrial and ovarian cancer and oral contraceptives—findings in a large cohort study, Br J Cancer 71:1340, 1995.
336. **Schlesselman JJ**, Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis, Hum Reprod 12: 1851, 1997.
337. **Salazar-Martinez E**, **Lazcano-Ponce EC**, **Gonzalez Lira-Lira G**, **Escudero-De los Rios P**, **Salmeron-Castro J**, **Hernandez-Avila M**, Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico, Cancer Res 59:3658, 1999.
338. **Weiderpass E**, **Adami HO**, **Baron JA**, **Magnusson C**, **Lindgren A**, **Persson I**, Use of oral contraceptives and endometrial cancer risk (Sweden), Cancer Causes Control 10:277, 1999.
339. **Jick SS**, **Walker AM**, **Jick H**, Oral contraceptives and endometrial cancer, Obstet Gynecol 82:931, 1993.
340. **Sherman ME**, **Sturgeon S**, **Brinton LA**, **Potischman N**, **Kurman RJ**, **Berman ML**, **Mortel R**, **Twiggs LB**, **Barrett RJ**, **Wilbanks GD**, Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas, Mod Pathol 10:963, 1997.
341. **Mant JWF**, **Vessey MP**, Ovarian and endometrial cancers, Cancer Surv 19: 287, 1994.
342. **Adami HO**, **Bergstrom R**, **Persson I**, **Sparen P**, The incidence of ovarian cancer in Sweden, 1960–1984, Am J Epidemiol 132:446, 1990.
343. **Silva IS**, **Swerdlow AJ**, Recent trends in incidence of and mortality from breast, ovarian and endometrial cancer in England and Wales and their relation to changing fertility and oral contraceptive use, Br J Cancer 72:485, 1995.
344. **Oriel KA**, **Hartenbach EM**, **Remington PL**, Trends in United States ovarian cancer mortality, 1979–1995, Obstet Gynecol 93:30, 1999.
345. **Lurie G**, **Thompson P**, **McDuffie KE**, **Carney ME**, **Terada KY**, **Goodman MT**, Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk, Obstet Gynecol 109:597, 2007.
346. **The Cancer and Steroid Hormone Study of the CDC and NICHD**, The reduction in risk of ovarian cancer associated with oral-contraceptive use, N Engl J Med 316:650, 1987.

347. **Hankinson SE**, **Colditz GA**, **Hunter DJ**, **Spencer TL**, **Rosner B**, **Stampfer MJ**, A quantitative assessment of oral contraceptive use and risk of ovarian cancer, Obstet Gynecol 80:708, 1992.
348. **Whittemore AS**, **Harris R**, **Itnyre J**; **the Collaborative Ovarian Cancer Group**, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II: Invasive epithelial ovarian cancers in white women, Am J Epidemiol 136:1184, 1992.
349. **Wittenberg L**, **Cook LS**, **Rossing MA**, **Weiss NS**, Reproductive risk factors for mucinous and non-mucinous epithelial ovarian cancer, Epidemiology 10: 761, 1999.
350. **Ness RB**, **Grisso JA**, **Klapper J**, **Schlesselman JJ**, **Silberzweig S**, **Vergona R**, **Morgan M**, **Wheeler JE**; **the SHARE Study Group**, Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives, Am J Epidemiol 152:233, 2000.
351. **Royar J**, **Becher H**, **Chang-Claude J**, Low-dose oral contraceptives: protective effect on ovarian cancer risk, Int J Cancer 95:370, 2001.
352. **Collaborative Group on Epidemiological Studies of Ovarian Cancer**, **Beral V**, **Doll R**, **Hermon C**, **Peto R**, **Reeves G**, Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls, Lancet 371:303, 2008.
353. **Tworoger SS**, **Fairfield KM**, **Colditz GA**, **Rosner BA**, **Hankinson SE**, Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk, Am J Epidemiol 166:894, 2007.
354. **Rosenberg L**, **Palmer JR**, **Zauber AG**, **Warshauer ME**, **Lewis JL Jr**, **Strom BL**, **Harlap S**, **Shapiro S**, A case-control study of oral contraceptive use and invasive epithelial ovarian cancer, Am J Epidemiol 139:654, 1994.
355. **Gross TP**, **Schlesselman JJ**, The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer, Obstet Gynecol 83:419, 1994.
356. **Walker GR**, **Schlesselman J**, **Ness RB**, Family history of cancer, oral contraceptive use, and ovarian cancer risk, Am J Obstet Gynecol 186:8, 2002.
357. **Narod SA**, **Risch H**, **Moslehi R**, **Dørum A**, **Neuhausen S**, **Olsson H**, **Provencher D**, **Radice P**, **Evans G**, **Bishop S**, **Brunet J-S**, **Ponder BAJ**; **for the Hereditary Ovarian Cancer Clinical Study Group**, Oral contraceptives and the risk of hereditary ovarian cancer, N Engl J Med 339:424, 1998.
358. **Whittemore AS**, **Balise RR**, **Pharoah PD**, **Dicioccio RA**, **Oakley-Girvan I**, **Ramus SJ**, **Daly M**, **Usinowicz MB**, **Garlinghouse-Jones K**, **Ponder BA**, **Buys SS**, **Senie RT**, **Andrulis IL**, **John EM**, **Hopper JL**, **Piver MS**, Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations, Br J Cancer 91:1911, 2004.
359. **McLaughlin JR**, **Risch HA**, **Lubinski J**, **Moller P**, **Ghadirian P**, **Lynch H**, **Karlan B**, **Fishman D**, **Rosen B**, **Neuhausen SL**, **Offit K**, **Kauff N**, **Domchek S**, **Tung N**, **Friedman E**, **Foulkes W**, **Sun P**, **Narod SA**; **Hereditary Ovarian Cancer Clinical Study Group**, Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study, Lancet Oncol 8:26, 2007.
360. **Brinton LA**, Oral contraceptives and cervical neoplasia, Contraception 43:581, 1991.
361. **Delgado-Rodriguez M**, **Sillero-Arenas M**, **Martin-Moreno JM**, **Galvez-Vargas R**, Oral contraceptives and cancer of the cervix uteri. A meta-analysis, Acta Obstet Gynecol Scand 71:368, 1992.
362. **Gram IT**, **Macaluso M**, **Stalsberg H**, Oral contraceptive use and the incidence of cervical intraepithelial neoplasia, Am J Obstet Gynecol 167:40, 1992.
363. **Irwin KL**, **Rosero-Bixby L**, **Oberle MW**, **Lee NC**, **Whatley AS**, **Fortney JA**, **Bonhomme MG**, Oral contraceptives and cervical cancer risk in Costa Rica: detection bias or causal association?, JAMA 259:59, 1988.
364. **Ye Z**, **Thomas DB**, **Ray RM**; **the WHO Collaborative Study of Neoplasia and Steroid Contraceptives**, Combined oral contraceptives and risk of cervical carcinoma in situ, Int J Epidemiol 24:19, 1995.
365. **Iversen L**, **Sivasubramaniam S**, **Lee AJ**, **Fielding S**, **Hannaford PC**, Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' oral contraceptive study, Am J Obstet Gynecol 216:580, 2017.
366. **Ylitalo N**, **Sorensen P**, **Josefsson A**, **Frisch M**, **Sparen P**, **Ponten J**, **Gyllensten U**, **Melbye M**, **Adami HO**, Smoking and oral contraceptives as risk factors for cervical carcinoma in situ, Int J Cancer 81:357, 1999.

367. **Brinton LA**, **Reeves WC**, **Brenes MM**, **Herrero R**, **de Britton RC**, **Gaitan E**, **Tenorio F**, **Garcia M**, **Rawls WE**, Oral contraceptive use and risk of invasive cervical cancer, Int J Epidemiol 19:4, 1990.
368. **Ursin G**, **Peters RK**, **Hendeson BE**, **d'Ablaing G III**, **Monroe KR**, **Pike MC**, Oral contraceptive use and adenocarcinoma of cervix, Lancet 344:1390, 1994.
369. **Thomas DB**, **Ray RM**; **the World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives**, Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix, Am J Epidemiol 144:281, 1996.
370. **Smith JS**, **Green J**, **de Gonzalez AB**, **Appleby P**, **Peto J**, **Plummer M**, **Franceschi S**, **Beral V**, Cervical cancer and use of hormonal contraceptives: a systematic review, Lancet 361:1159, 2003.
371. **Moreno V**, **Bosch FX**, **Muñoz N**, **Meijer CJLM**, **Shah KV**, **Walboomers JMM**, **Herrero R**, **Franceschi S**; **for the International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group**, Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study, Lancet 359:1085, 2002.
372. **International Collaboration of Epidemiological Studies of Cervical Cancer**, Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16573 women with cervical cancer and 35509 women without cervical cancer from 24 epidemiological studies, Lancet 370:1609, 2007.
373. **Neuberger J**, **Forman D**, **Doll R**, **Williams R**, Oral contraceptives and hepatocellular carcinoma, Br Med J 292:1355, 1986.
374. **Palmer JR**, **Rosenberg L**, **Kaufman DW**, **Warshauer ME**, **Stolley P**, **Shapiro S**, Oral contraceptive use and liver cancer, Am J Epidemiol 130:878, 1989.
375. **WHO Collaborative Study of Neoplasia and Steroid Contraceptives**, Combined oral contraceptives and liver cancer, Int J Cancer 43:254, 1989.
376. **The Collaborative MILTS Project Team**, Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS), Contraception 56:275, 1997.
377. **Mant JW**, **Vessey MP**, Trends in mortality from primary liver cancer in England and Wales 1975–92: influence of oral contraceptives, Br J Cancer 72:800, 1995.
378. **Waetjen LE**, **Grimes DA**, Oral contraceptives and primary liver cancer: temporal trends in three countries, Obstet Gynecol 88:945, 1996.
379. **El-Serag HB**, **Mason AC**, Rising incidence of hepatocellular carcinoma in the United States, N Engl J Med 340:745, 1999.
380. **McPherson K**, **Neil A**, **Vessey MP**, Oral contraceptives and breast cancer, Lancet ii:414, 1983.
381. **La Vecchia C**, **Decarli A**, **Fasoli M**, **Franceschi S**, **Gentile A**, **Negri E**, **Parazzini F**, **Tognomi G**, Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study, Br J Cancer 54:311, 1986.
382. **Meirik O**, **Dami H**, **Christoffersen T**, **Lund E**, **Bergstrom R**, **Bergsjo P**, Oral contraceptive use and breast cancer in young women, Lancet ii:650, 1986.
383. **Kay CR**, **Hannaford PC**, Breast cancer and the pill — further report from the Royal College of General Practitioners' oral contraceptive study, Br J Cancer 58:675, 1988.
384. **Miller DR**, **Rosenberg L**, **Kaufman DW**, **Stolley P**, **Warshauer ME**, **Shapiro S**, Breast cancer before age 45 and oral contraceptive use: new findings, Am J Epidemiol 129:269, 1989.
385. **UK National Case-Control Study Group**, Oral contraceptive use and breast cancer risk in young women, Lancet i:973, 1989.
386. **WHO Collaborative Study of Neoplasia and Steroid Contraceptives**, Breast cancer and combined oral contraceptives: results from a multinational study, Br J Cancer 61:110, 1990.
387. **La Vecchia C**, **Negri E**, **Franceschi S**, **Talamini R**, **Amadori D**, **Filiberti R**, **Conti E**, **Montella M**, **Veronesi A**, **Parazzini F**, **Ferraroni M**, **Decarli A**, Oral contraceptives and breast cancer: a cooperative Italian study, Int J Cancer 60: 163, 1995.
388. **Del Pup L**, **Codacci-Pisanelli G**, **Peccatori F**, Breast cancer risk of hormonal contraception: Counselling considering new evidence, Crit Rev Oncol Hematol 137:123–130, 2019.
389. **Rosenberg L**, **Palmer JR**, **Rao RS**, **Zauber AG**, **Strom BL**, **Warshauer ME**, **Harlap S**, **Shapiro S**, Case-

control study of oral contraceptive use and risk of breast cancer, Am J Epidemiol 143:25, 1996.
390. **Hennekens CH**, **Speizer FE**, **Lipnik RJ**, **Rosner B**, **Bain C**, **Belanger C**, **Stampfer MJ**, **Willett W**, **Peto R**, Case-control study of oral contraceptive use and breast cancer, J Natl Cancer Inst 72:39, 1984.
391. **Rosenberg L**, **Miller DR**, **Kaufman DW**, **Helmrich SP**, **Stolley PD**, **Schoffenfeld D**, **Shapiro S**, Breast cancer and oral contraceptive use, Am J Epidemiol 119:167, 1984.
392. **Stadel BV**, **Rubin GL**, **Webster LA**, **Schlesselmann JJ**, **Wingo PA**, Oral contraceptives and breast cancer in young women, Lancet ii:970, 1985.
393. **Mørch LS**, **Skovlund CW**, **Hannaford PC**, **Iversen L**, **Fielding S**, **Lidegaard Ø**, Contemporary hormonal contraception and the risk of breast cancer, N Engl J Med 377:2228, 2017.
394. **Pike MC**, **Krailo MD**, **Henderson BE**, **Duke A**, **Roy S**, Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use, Lancet ii:926, 1983.
395. **Wingo PA**, **Lee NC**, **Ory HW**, **Beral V**, **Peterson HB**, **Rhodes P**, Age-specific differences in the relationship between oral contraceptive use and breast cancer, Obstet Gynecol 78:161, 1991.
396. **Ursin G**, **Aragaki CC**, **Paganini-Hill A**, **Siemiatycki J**, **Thompson WD**, **Haile RW**, Oral contraceptives and premenopausal bilateral breast cancer: a case-control study, Epidemiology 3:414, 1992.
397. **Rookus MA**, **Leeuwen FE**; **for the Netherlands Oral Contraceptives and Breast Cancer Study Group**, Oral contraceptives and risk of breast cancer in women aged 20–54 years, Lancet 344:844, 1994.
398. **White E**, **Malone KE**, **Weiss NS**, **Daling JR**, Breast cancer among young U.S. women in relation to oral contraceptive use, J Natl Cancer Inst 86:505, 1994.
399. **Brinton LA**, **Daling JR**, **Liff JM**, **Schoenberg JB**, **Malone KE**, **Stanford JL**, **Coates RJ**, **Gammon MD**, **Hanson L**, **Hoover RN**, Oral contraceptives and breast cancer risk among younger women, J Natl Cancer Inst 87:827, 1995.
400. **Collaborative Group on Hormonal Factors in Breast Cancer**, Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies, Lancet 347:1713, 1996.
401. **Collaborative Group on Hormonal Factors in Breast Cancer**, Breast cancer and hormonal contraceptives: further results, Contraception 54:1S, 1996.
402. **Kumle M**, **Weiderpass E**, **Braaten T**, **Persson I**, **Adami H-O**, **Lund E**, Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study, Cancer Epidemiol Biomarkers Prev 11:1375, 2002.
403. **Cancer and Steroid Hormone Study, CDC and NICHD**, Oral contraceptive use and the risk of breast cancer, N Engl J Med 315:405, 1986.
404. **Schlesselman JJ**, **Stadel BV**, **Murray P**, **Shenghan L**, Breast cancer risk in relation to type of estrogen contained in oral contraceptives, Contraception 36: 595, 1987.
405. **Stanford JL**, **Brinton LA**, **Hoover RN**, Oral contraceptives and breast cancer: results from an expanded case-control study, Br J Cancer 60:375, 1989.
406. **Murray P**, **Schlesselman JJ**, **Stadel BV**, **Shenghan L**, Oral contraceptives and breast cancer risk in women with a family history of breast cancer, Am J Obstet Gynecol 73:977, 1989.
407. **Schildkraut JM**, **Hulka BS**, **Wilkinson WE**, Oral contraceptives and breast cancer: a case-control study with hospital and community controls, Obstet Gynecol 76:395, 1990.
408. **Lambe M**, **Hsieh C**, **Trichopoulos D**, **Ekbom A**, **Pavia M**, **Adami H-O**, Transient increase in the risk of breast cancer after giving birth, N Engl J Med 331:5, 1994.
409. **Guinee VF**, **Olsson H**, **Moller T**, **Hess KR**, **Taylor SH**, **Fahey T**, **Gladikov JV**, **van den Blink JW**, **Bonichon F**, **Dische S**, et al., Effect of pregnancy on prognosis for young women with breast cancer, Lancet 343:1587, 1994.
410. **Kroman N**, **Wohlfart J**, **Andersen KW**, **Mouriudsen HT**, **Westergaard U**, **Melbye M**, Time since childbirth and prognosis in primary breast cancer: population based study, Br Med J 315:851, 1997.
411. **Narod S**, **Dube MP**, **Klijn J**, **Lubinski J**, **Lynch HT**, **Ghadirian P**, **Provencher D**, et al., Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst 94:1773, 2002.

412. **Haile RW**, **Thomas DC**, **McGuire V**, **Felberg A**, **John EM**, **Milne R**, **Hopper JL**, **Jenkins MA**, **Levine AJ**, **Daly MM**, **Buys SS**, **Senie RT**, **Andrulis IL**, **Knight JA**, **Godwin AK**, **Southey M**, **McCredie MR**, **Giles GG**, **Andrews L**, **Tucker K**, **Miron A**, **Apicella C**, **Tesoriero A**, **Bane A**, **Pike MC**; **ConFab Investigators, Ontario Cancer Genetics Network Investigators**, **Whittemore AS**, BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50, Cancer Epidemiol Biomarkers Prev 15:1863, 2006.
413. **Brohet RM**, **Goldgar DE**, **Easton DF**, **Antonious AC**, **Andrieu N**, **Chang-Claude J**, **Peock S**, **Eeles RA**, **Cook M**, **Chu C**, **Noguès C**, **Lasset C**, **Berthet P**, **Meijers-Heijboer H**, **Gerdes AM**, **Olsson H**, **Caldes T**, **van Leeuwen FE**, **Rookus MA**, Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group, J Clin Oncol 25:3831, 2007.
414. **Lee E**, **Ma H**, **McKean-Cowdin R**, **Van Den Berg D**, **Bernstein L**, **Henderson BE**, **Ursin G**, Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population based study, Cancer Epidemiol Biomarkers Prev 17:3170, 2008.
415. **Figueiredo JC**, **Haile RW**, **Bernstein L**, **Malone KE**, **Largent J**, **Langholz B**, **Lynch CF**, **Bertelsen L**, **Capanu M**, **Concannon P**, **Borg A**, **Børresen-Dale AL**, **Diep A**, **Teraoka S**, **Torngren T**, **Xue S**, **Berstein JL**, Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study, Breast Cancer Res Treat 120:175, 2010.
416. **Nyante SJ**, **Gammon MD**, **Malone KE**, **Daling JR**, **Brinton LA**, The association between oral contraceptive use and lobular and ductal breast cancer in young women, Int J Cancer 122:936, 2007.
417. **Martinez ME**, **Grodstein F**, **Giovannucci E**, **Colditz GA**, **Speizer FE**, **Hennekens C**, **Rosner B**, **Willett WC**, **Stampfer MJ**, A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer, Cancer Epidemiol Biomarkers Prev 6:1, 1997.
418. **Fernandez E**, **La Vecchia C**, **Balducci A**, **Chatenoud L**, **Franceschi S**, **Negri E**, Oral contraceptives and colorectal cancer risk: a meta-analysis, Br J Cancer 84:722, 2001.
419. **Levi F**, **Pasche C**, **Lucchini F**, **La Vecchia C**, Oral contraceptives and colorectal cancer, Dig Liver Dis 35:85, 2003.
420. **Nichols HB**, **Trentham-Dietz A**, **Hampton JM**, **Newcomb PA**, Oral contraceptive use, reproductive factors, and colorectal cancer risk: findings from Wisconsin, Cancer Epidemiol Biomarkers Prev 14:1212, 2005.
421. **Hannaford P**, **Elliott A**, Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study, Contraception 71:95, 2005.
422. **Green A**, Oral contraceptives and skin neoplasia, Contraception 43:653, 1991.
423. **Hannaford PC**, **Villard-Mackintosh L**, **Vessey MP**, **Kay CR**, Oral contraceptives and malignant melanoma, Br J Cancer 63:430, 1991.
424. **Vessey MP**, **Painter R**, **Powell J**, Skin disorders in relation to oral contraception and other factors, including age, social class, smoking and body mass index, Br J Dermatol 143:815, 2000.
425. **Milne R**, **Vessey M**, The association of oral contraception with kidney cancer, colon cancer, gallbladder cancer (including extrahepatic bile duct cancer) and pituitary tumors, Contraception 43:667, 1991.
426. **Berkowitz RS**, **Bernstein MR**, **Harlow BL**, **Rice LW**, **Lage JM**, **Goldstein DP**, **Cramer DW**, Case-control study of risk factors for partial molar pregnancy, Am J Obstet Gynecol 173:788, 1995.
427. **Palmer JR**, **Driscoll SG**, **Rosenberg L**, **Berkowitz RS**, **Lurain JR**, **Soper J**, **Twiggs LB**, **Gershenson DM**, **Kohorn EI**, **Berman M**, **Shapiro S**, **Rao RS**, Oral contraceptive use and risk of gestational trophoblastic tumors, J Natl Cancer Inst 91:635, 1999.
428. **Parazzini F**, **Cipriani S**, **Mangili G**, **Garavaglia E**, **Guarnerio P**, **Ricci E**, **Benzi G**, **Salerio B**, **Polverino G**, **La Vecchia C**, Oral contraceptives and risk of gestational trophoblastic disease, Contraception 65:425, 2002.
429. **Horn-Ross PL**, **Morrow M**, **Ljung BM**, Menstrual and reproductive factors for salivary gland cancer risk in women, Epidemiology 10:528, 1999.
430. **Wiegratz I**, **Kutschera E**, **Lee JH**, **Moore C**, **Mellinger U**, **Winkler UH**, **Kuhl H**, Effect of four oral

contraceptives on thyroid hormones, adrenal and blood pressure parameters, Contraception 67:361, 2003.
431. **Janerich DT**, **Dugan JM**, **Standfast SJ**, **Strite L**, Congenital heart disease and prenatal exposure to exogenous sex hormones, Br Med J i:1058, 1977.
432. **Nora JJ**, **Nora AH**, **Blu J**, **Ingram J**, **Foster D**, Exogenous progestogen and estrogen implicated in birth defects, JAMA 240:837, 1978.
433. **Heinonen OP**, **Slone D**, **Monson RR**, **Hook ER**, **Shapiro S**, Cardiovascular birth defects in antenatal exposure to female sex hormones, N Engl J Med 296:67, 1976.
434. **Simpson JL**, **Phillips OP**, Spermicides, hormonal contraception and congenital malformations, Adv Contracept 6:141, 1990.
435. **Michaelis J**, **Michaelis H**, **Gluck E**, **Koller S**, Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations, Teratology 27:57, 1983.
436. **Bracken MB**, Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies, Obstet Gynecol 76: 552, 1990.
437. **Raman-Wilms L**, **Tseng AL**, **Wighardt S**, **Einarson TR**, **Koren G**, Fetal genital effects of first trimester sex hormone exposure: a meta-analysis, Obstet Gynecol 85:141, 1995.
438. **Ressequie LJ**, **Hick JF**, **Bruen JA**, **Noller KL**, **O'Fallon WM**, **Kurland LT**, Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936–1974, Fertil Steril 43:514, 1985.
439. **Katz Z**, **Lancet M**, **Skornik J**, **Chemke J**, **Mogilemer B**, **Klinberg M**, Teratogenicity of progestogens given during the first trimester of pregnancy, Obstet Gynecol 65:775, 1985.
440. **Vessey MP**, **Smith MA**, **Yates D**, Return of fertility after discontinuation of oral contraceptives: influence of age and parity, Br J Fam Plann 11:120, 1986.
441. **Linn S**, **Schoenbaum SC**, **Monson RR**, **Rosner B**, **Ryan KJ**, Delay in conception for former 'pill' users, JAMA 247:629, 1982.
442. **Bracken MB**, **Hellenbrand KG**, **Holford TR**, Conception delay after oral contraceptive use: the effect of estrogen dose, Fertil Steril 53:21, 1990.
443. **Bagwell MA**, **Coker AL**, **Thompson SJ**, **Baker ER**, **Addy CL**, Primary infertility and oral contraceptive steroid use, Fertil Steril 63:1161, 1995.
444. **Farrow A**, **Hull MGR**, **Northstone K**, **Taylor H**, **Ford WCL**, **Golding J**, Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception, Hum Reprod 17:2754, 2002.
445. **Cronin M**, **Schellschmidt I**, **Dinger J**, Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives, Obstet Gynecol 114:616, 2009.
446. **Rothman KJ**, Fetal loss, twinning, and birth weight after oral-contraceptive use, N Engl J Med 297:468, 1977.
447. **Ford JH**, **MacCormac L**, Pregnancy and lifestyle study: the long-term use of the contraceptive pill and the risk of age-related miscarriage, Hum Reprod 10:1397, 1995.
448. **Rothman KJ**, **Liess J**, Gender of offspring after oral-contraceptive use, N Engl J Med 295:859, 1976.
449. **Magidor S**, **Poalti H**, **Harlap S**, **Baras M**, Long-term follow-up of children whose mothers used oral contraceptives prior to contraception, Contraception 29:203, 1984.
450. **Vessey M**, **Doll R**, **Peto R**, **Johnson B**, **Wiggins P**, A long-term follow-up study of women using different methods of contraception—an interim report, J Biosoc Sci 8:373, 1976.
451. **Royal College of General Practitioners**, The outcome of pregnancy in former oral contraceptive users, Br J Obstet Gynaecol 83:608, 1976.
452. **Gray RH**, **Campbell OM**, **Zacur HA**, **Labbok MH**, **MacRae SL**, Postpartum return of ovarian activity in nonbreastfeeding women monitored by urinary assays, J Clin Endocrinol Metab 64:645, 1987.
453. **Campbell OM**, **Gray RH**, Characteristics and determinants of postpartum ovarian function in women in the United States, Am J Obstet Gynecol 169:55, 1993.
454. **Kolata G**, Kung hunter-gatherers: feminism, diet and birth control, Science 185:932, 1974.
455. **Short RV**, Lactation. The central control of reproduction, Ciba Found Sympos 45:73, 1976.
456. **Thapa S**, **Short RV**, **Potts M**, Breastfeeding, birth spacing and their effects on child survival, Nature 335:679,

1988.
457. **Miller JE**, Birth intervals and perinatal health: an investigation of three hypotheses, Fam Plann Perspect 23:62, 1991.
458. **Wasalathanthri S**, **Tennekoon KH**, Lactational amenorrhea/anovulation and some of their determinants: a comparison of well-nourished and undernourished women, Fertil Steril 76:317, 2001.
459. **Labbok MH**, **Hight-Laukaran V**, **Peterson AE**, **Fletcher V**, **von Hertzen H**, **Van Look PFA**, Multicenter study of the lactational amenorrhea method (LAM): I. Efficacy, duration, and implications for clinical application, Contraception 55:327, 1997.
460. **Visness CM**, **Kennedy KI**, **Gross BA**, **Parenteau-Carreau S**, **Flynn AM**, **Brown JB**, Fertility of fully breast-feeding women in the early postpartum period, Obstet Gynecol 89:164, 1997.
461. **Perez A**, **Vela P**, **Masnick GS**, **Potter RG**, First ovulation after childbirth: the effect of breastfeeding, Am J Obstet Gynecol 114:1041, 1972.
462. **Diaz S**, **Peralta O**, **Juez G**, **Salvatierra AM**, **Casado ME**, **Duran E**, **Croxatto HB**, Fertility regulation in nursing women. I. The probability of conception in full nursing women living in an urban setting, J Biosoc Sci 14:329, 1982.
463. **McNeilly AS**, **Glasier A**, **Howie PW**, Endocrine control of lactational infertility, In: Dobbing J, ed. Maternal Nutrition and Lactational Infertility, Nevey/Raven Press, New York, 1985, p. 177.
464. **Rivera R**, **Kennedy KI**, **Ortiz E**, **Barrera M**, **Bhiwandiwala PP**, Breast-feeding and the return to ovulation in Durango, Mexico, Fertil Steril 49:780, 1988.
465. **Lewis PR**, **Brown JB**, **Renfree MB**, **Short RV**, The resumption of ovulation and menstruation in a well-nourished population of women breastfeeding for an extended period of time, Fertil Steril 55:529, 1991.
466. **Robson KM**, **Brant HA**, **Kumar R**, Maternal sexuality during first pregnancy and after childbirth, Br J Obstet Gynaecol 88:881, 1981.
467. **Glazener CMA**, Sexual function after childbirth: women's experiences, persistent morbidity and lack of professional recognition, Br J Obstet Gynaecol 104:330, 1997.
468. **Elliott SA**, **Watson JP**, Sex during pregnancy and the first postnatal year, J Psychosom Res 29:541, 1985.
469. **Connolly A**, **Thorp J**, **Pahel L**, Effects of pregnancy and childbirth on postpartum sexual function: a longitudinal prospective study, Int Urogynecol J Pelvic Floor Dysfunct 16:263, 2005.
470. **Woranitat W**, **Taneepanichskul S**, Sexual function during the postpartum period, J Med Assoc Thai 90:1744, 2007.
471. **Rowland M**, **Foxcroft L**, **Hopman WM**, **Patel R**, Breastfeeding and sexuality immediately post partum, Can Fam Physician 51:1366, 2005.
472. **Grudzinskas JG**, **Atkinson L**, Sexual function during the puerperium, Arch Sex Behav 13:85, 1984.
473. **Egbuonu I**, **Ezechukwu CC**, **Chukwuka JO**, **Ikechebelu JI**, Breast-feeding, return of menses, sexual activity and contraceptive practices among mothers in the first six months of lactation in Onitsha, South Eastern Nigeria, J Obstet Gynaecol 25:500, 2005.
474. **Short RV**, **Lewis PR**, **Renfree MB**, **Shaw G**, Contraceptive effects of extended lactational amenorrhoea: beyond the Bellagio Consensus, Lancet 337:715, 1991.
475. **Pérez A**, **Labbok MH**, **Queenan JT**, Clinical study of the lactational amenorrhoea method for family planning, Lancet 339:968, 1992.
476. **Diaz S**, **Aravena R**, **Cardenas H**, **Casado ME**, **Miranda P**, **Schiappacasse V**, **Croxatto HB**, Contraceptive efficacy of lactational amenorrhea in urban Chilean women, Contraception 43:335, 1991.
477. **Kazi A**, **Kennedy KI**, **Visness CM**, **Khan T**, Effectiveness of the lactational amenorrhea method in Pakistan, Fertil Steril 64:717, 1995.
478. **Kennedy KI**, **Rivera R**, **McNeilly AS**, Consensus statement on the use of breastfeeding as a family planning method, Bellagio, Italy, Contraception 39:477, 1989.
479. **Ramos R**, **Kennedy KI**, **Visness CM**, Effectiveness of lactational amenorrhoea in preventing pregnancy in Manila, The Philippines, Br Med J 313:909, 1996.
480. **World Health Organization Task Force on Methods for the Natural Regulation of Fertility**, The World Health Organization multinational study of breast-feeding and lactational amenorrhea. I. Description of infant

feeding patterns and the return of menses, Fertil Steril 70:448, 1998.
481. **World Health Organization Task Force on Methods for the Natural Regulation of Fertility**, The World Health Organization multinational study of breast-feeding and lactational amenorrhea. II. Factors associated with the length of amenorrhea, Fertil Steril 70:461, 1998.
482. **World Health Organization Task Force on Methods for the Natural Regulation of Fertility**, The World Health Organization multinational study of breast-feeding and lactational amenorrhea. III. Pregnancy during breast-feeding, Fertil Steril 72:431, 1999.
483. **World Health Organization Task Force on Methods for the Natural Regulation of Fertility**, The World Health Organization multinational study of breast-feeding and lactational amenorrhea. IV. Postpartum bleeding and lochia in breast-feeding women, Fertil Steril 72:441, 1999.
484. **Gray RH**, **Campbell OM**, **Apelo R**, **Eslami SS**, **Zacur H**, **Ramos RM**, **Gehret JC**, **Labbok MH**, Risk of ovulation during lactation, Lancet 335:25, 1990.
485. **Gross BA**, Natural family planning indicators of ovulation, Clin Reprod Fertil 5:91, 1987.
486. **Kremer JAM**, **Thomas CMG**, **Rolland R**, **van der Heijden PF**, **Thomas CM**, **Lancranjan I**, Return of gonadotropic function in postpartum women during bromocriptine treatment, Fertil Steril 51:622, 1989.
487. **Haartsen JE**, **Heineman MJ**, **Elings M**, **Evers JLH**, **Lancranjan I**, Resumption of pituitary and ovarian activity post-partum: endocrine and ultrasonic observations in bromocriptine-treated women, Hum Reprod 7:746, 1992.
488. **Shikary ZK**, **Bertrabet S**, **Patel ZM**, **Paytel S**, **Joshi JV**, **Toddywala VA**, **Toddywala SP**, **Patel DM**, **Jhaveri K**, **Saxena BN**, ICMR task force study on hormonal contraception. Transfer of levonorgestrel administered through different drug delivery systems from the maternal circulation into the newborn's circulation via breast milk, Contraception 35:477, 1987.
489. **Betrabet SS**, **Shikary ZK**, **Toddywalla VS**, **Toddywalla SP**, **Patel D**, **Saxena BN**, Transfer of norethisterone (NET) and levonorgestrel (LNG) from a single tablet into the infant's circulation through the mother's milk, Contraception 35:517, 1987.
490. **Dorea JG**, **Miazaki ES**, The effects of oral contraceptive use on iron and copper concentrations in breast milk, Fertil Steril 72:297, 1999.
491. **Diaz S**, **Peralta O**, **Juez G**, **Herreros C**, **Casado ME**, **Salvatierra AM**, **Miranda P**, **Durn E**, **Croxatto HB**, Fertility regulation in nursing women: III. Short-term influence of a low-dose combined oral contraceptive upon lactation and infant growth, Contraception 27:1, 1982.
492. **Croxatto HB**, **Diaz S**, **Peralta O**, **Juez G**, **Herreros C**, **Casado ME**, **Salvatierra AM**, **Miranda P**, **Durn E**, Fertility regulation in nursing women: IV. Long-term influence of a low-dose combined oral contraceptive initiated at day 30 postpartum upon lactation and child growth, Contraception 27:13, 1983.
493. **Peralta O**, **Diaz S**, **Juez G**, **Herreros C**, **Casado ME**, **Salvatierra AM**, **Miranda P**, **Durn E**, **Croxatto HB**, Fertility regulation in nursing women: V. Long-term influence of a low-dose combined oral contraceptive initiated at day 90 postpartum upon lactation and infant growth, Contraception 27:27, 1983.
494. **WHO, Special Programme of Research, Development, and Research Training in Human Reproduction, Task Force on Oral Contraceptives**, Effects of hormonal contraceptives on milk volume and infant growth, Contraception 30:505, 1984.
495. **WHO Task Force for Epidemiological Research on Reproductive Health, Special Programme of Research, Development and Research Training in Human Reproduction**, Progestogen-only contraceptives during lactation. I. Infant growth, Contraception 50:35, 1994.
496. **WHO Task Force for Epidemiological Research on Reproductive Health, Special Programme of Research, Development and Research Training in Human Reproduction**, Progestogen-only contraceptives during lactation. II. Infant development, Contraception 50:55, 1994.
497. **Nilsson S**, **Melbin T**, **Hofvander Y**, **Sundelin C**, **Valentin J**, **Nygren KG**, Long-term follow-up of children breast-fed by mothers using oral contraceptives, Contraception 34:443, 1986.
498. **McCann MF**, **Moggia AV**, **Hibbins JE**, **Potts M**, **Becker C**, The effects of a progestin-only oral contraceptive (levonorgestrel 0.03 mg) on breast-feeding, Contraception 40:635, 1989.
499. **Moggia AV**, **Harris GS**, **Dunson TR**, **Diaz R**, **Moggia MS**, **Ferrer MA**, **McMullen SL**, A comparative

study of a progestin-only oral contraceptive versus non-hormonal methods in lactating women in Buenos Aires, Argentina, Contraception 44:31, 1991.
500. **Caird LE**, **Reid-Thomas V**, **Hannan WJ**, **Gow S**, **Glasier AF**, Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women, Clin Endocrinol 41:739, 1994.
501. **Halderman LD**, **Nelson AL**, Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns, Am J Obstet Gynecol 186: 1250, 2002.
502. **World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception**, Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study, Contraception 57:315, 1998.
503. **Heinemann LA**, **Assmann A**, **Do Minh T**, **Garbe E**, Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women, Eur J Contracept Reprod Health Care 4:67, 1999.
504. **Heit JA**, **Kobbervig CE**, **James AH**, **Petterson TM**, **Bailey KR**, **Melton LJI**, Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study, Ann Intern Med 143: 697, 2005.
505. **James AH**, **Jamison MG**, **Brancazio LR**, **Myers ER**, Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality, Am J Obstet Gynecol 194:1311, 2006.
506. **Blanco-Molina A**, **Trujillo-Santos J**, **Criado J**, **Lopez L**, **Lecumberri R**, **Gutierrez R**, **Monreal M**; **RIETE Investigators**, Venous thromboembolism during pregnancy or postpartum: findings from the RIETE registry, Thromb Haemost 97:186, 2007.
507. **James AH**, **Tapson VG**, **Goldhaber SZ**, Thrombosis during pregnancy and the postpartum period, Am J Obstet Gynecol 193:216, 2005.
508. **Samuelsson E**, **Hedenmalm K**, **Persson I**, Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives—an approach to specifying rates, Eur J Epidemiol 20:509, 2005.
509. **Samuelsson E**, **Hellgren M**, **Högberg U**, Pregnancy-related deaths due to pulmonary embolism in Sweden, Acta Obstet Gynecol Scand 86:435, 2007.
510. **Huerta C**, **Johansson S**, **Wallander MA**, **García Rodríguez LA**, Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom, Arch Intern Med 167: 935, 2007.
511. **Pituitary Adenoma Study Group**, Pituitary adenomas and oral contraceptives: a multicenter case-control study, Fertil Steril, 39:753, 1983.
512. **Shy FKK**, **McTiernan AM**, **Daling JR**, **Weiss NS**, Oral contraceptive use and the occurrence of pituitary prolactinomas, JAMA 249:2204, 1983.
513. **Wingrave SJ**, **Kay CR**, **Vessey MP**, Oral contraceptives and pituitary adenomas, Br Med J 280:685, 1980.
514. **Hulting A-L**, **Werner S**, **Hagenfeldt K**, Oral contraceptives do not promote the development or growth of prolactinomas, Contraception 27:69, 1983.
515. **Corenblum B**, **Donovan L**, The safety of physiological estrogen plus progestin replacement therapy and oral contraceptive therapy in women with pathological hyperprolactinemia, Fertil Steril 59:671, 1993.
516. **Testa G**, **Vegetti W**, **Motta T**, **Alagna F**, **Bianchedi D**, **Carlucci C**, **Bianchi M**, **Parazzini F**, **Crosignani PG**, Two-year treatment with oral contraceptives in hyperprolactinemic patients, Contraception 58:69, 1998.
517. **Furuhjelm M**, **Carlstrom K**, Amenorrhea following use of combined oral contraceptives, Acta Obstet Gynecol Scand 52:373, 1973.
518. **Shearman RP**, **Smith ID**, Statistical analysis of relationship between oral contraceptives, secondary amenorrhea and galactorrhea, J Obstet Gynaecol Br Commonw 79:654, 1972.
519. **Jacobs HS**, **Knuth UA**, **Hull MGR**, **Franks S**, Post "pill" amenorrhea—cause or coincidence?, Br Med J ii:940, 1977.
520. **Vessey MP**, **Hannaford P**, **Mant J**, **Painter R**, **Frith P**, **Chappel D**, Oral contraception and eye disease:

findings in two large cohort studies, Br J Ophthalmol 82(5):538–542, 1998.
521. **Vessey MP**, **Hannaford P**, **Mant J**, **Painter R**, **Frith P**, **Chappel D**, Oral contraception and eye disease: findings in two large cohort studies, Br Med J 82:538, 1998.
522. **Villard-Mackintosh L**, **Vessey MP**, Oral contraceptives and reproductive factors in multiple sclerosis incidence, Contraception 47:161, 1993.
523. **Thorogood M**, **Hannaford PC**, The influence of oral contraceptives on the risk of multiple sclerosis, Br J Obstet Gynaecol 105:1296, 1998.
524. **Hernan MA**, **Hohol MJ**, **Olek MJ**, **Spiegelman D**, **Ascherio A**, Oral contraceptives and the incidence of multiple sclerosis, Neurology 55:848, 2000.
525. **Alonso A**, **Jick SS**, **Olek MJ**, **Ascherio A**, **Jick H**, **Hernan MA**, Recent use of oral contraceptives and the risk of multiple sclerosis, Arch Neurol 62: 1362, 2005.
526. **Holmqvist P**, **Hammar M**, **Landtblom AM**, **Brynhildsen J**, Symptoms of multiple sclerosis in women in relation to cyclical hormone changes, Eur J Contracept Reprod Health Care 14:365, 2009.
527. **Costello Daly C**, **Helling-Giese GE**, **Mati JK**, **Hunter DJ**, Contraceptive methods and the transmission of HIV: implications for family planning, Genitourin Med 70:110, 1994.
528. **Taneepanichskul S**, **Phuapradit W**, **Chaturachinda K**, Association of contraceptives and HIV-1 infection in Thai female commercial sex workers, Aust N Z J Obstet Gynaecol 37:86, 1997.
529. **Kapiga SH**, **Lyamuya EF**, **Lwihula GK**, **Hunter DJ**, The incidence of HIV infection among women using family planning methods in Dar-es-Salaam, Tanzania, AIDS 12:75, 1998.
530. **Cejtin HE**, **Jacobson L**, **Springer G**, **Watts DH**, **Levine AJ**, **Greenblatt R**, **Anastos K**, **Minkoff HL**, **Massad LS**, **Schmidt JB**, Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women, AIDS 17:1702, 2003.
531. **Richardson BA**, **Otieno PA**, **Mbori-Ngacha D**, **Overbaugh J**, **Farquhar C**, **John-Stewart GC**, Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women, AIDS 21:749, 2007.
532. **El-Ibiary SY**, **Cocohoba JM**, Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives, Eur J Contracept Reprod Health Care 13:123, 2008.
533. **Westrom I**, Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries, Am J Obstet Gynecol 138:880, 1980.
534. **Eschenbach DA**, **Harnisch JP**, **Holmes KK**, Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors, Am J Obstet Gynecol 128:838, 1977.
535. **Rubin GL**, **Ory WH**, **Layde PM**, Oral contraceptives and pelvic inflammatory disease, Am J Obstet Gynecol 140:630, 1980.
536. **Senanayake P**, **Kramer DG**, Contraception and the etiology of pelvic inflammatory diseases: new perspectives, Am J Obstet Gynecol 138:852, 1980.
537. **Panser LA**, **Phipps WR**, Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease, Contraception 43:91, 1991.
538. **Svensson L**, **Westrom L**, **Mardh P**, Contraceptives and acute salpingitis, JAMA 251:2553, 1984.
539. **Wolner-Hanssen P**, Oral contraceptive use modifies the manifestations of pelvic inflammatory disease, Br J Obstet Gynaecol 93:619, 1986.
540. **Cates W Jr**, **Washington AE**, **Rubin GL**, **Peterson HB**, The pill, chlamydia and PID, Fam Plann Perspect 17:175, 1985.
541. **Cottingham J**, **Hunter D**, Chlamydia trachomatis and oral contraceptive use: a quantitative review, Genitourin Med 68:209, 1992.
542. **Critchlow CW**, **Wölner-Hanssen P**, **Eschenbach DA**, **Kiviat NB**, **Koutsky LA**, **Stevens CE**, **Holmes KK**, Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking, and douching, Am J Obstet Gynecol 173:534, 1995.
543. **Cramer DW**, **Goldman MB**, **Schiff I**, **Belisla S**, **Albrecht B**, **Stadel B**, **Gibson M**, **Wilson E**, **Stillman R**, **Thompson I**, The relationship of tubal infertility to barrier method and oral contraceptive use, JAMA 257:2446, 1987.
544. **Wolner-Hanssen P**, **Eschenbach DA**, **Paavonen J**, **Kiviat N**, **Stevens CE**, **Critchlow C**, **DeRouen T**,

Holmes KK, Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use, JAMA 263:54, 1990.

545. **Spinillo A**, **Gorini G**, **Piazzi G**, **Balataro F**, **Monaco A**, **Zara F**, The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease, Contraception 54:163, 1996.
546. **Ness RB**, **Keder LM**, **Soper DE**, **Amortegui AJ**, **Gluck J**, **Wiesenfeld H**, **Sweet RL**, **Rice PA**, **Peipert JF**, **Donegan SP**, **Kanbour-Shakir A**, Oral contraception and the recognition of endometritis, Am J Obstet Gynecol 176:580, 1997.
547. **Ness RB**, **Soper DE**, **Holley RL**, **Peipert J**, **Randall H**, **Sweet RL**, **Sondheimer SJ**, et al.; for the **PID Evaluation and Clinical health (PEACH) Study Investigators**, Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study, Am J Obstet Gynecol 185:121, 2001.
548. **Barbone F**, **Austin H**, **Louv WC**, **Alexander WJ**, A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis, Am J Obstet Gynecol 163:510, 1990.
549. **Shoubnikova M**, **Hellberg D**, **Nilsson S**, **Mårdh P-A**, Contraceptive use in women with bacterial vaginosis, Contraception 55:355, 1997.
550. **Baeten JM**, **Nyange PM**, **Richardson BA**, **Lavreys L**, **Chohan B**, **Martin HL, Jr**, **Mandaliya K**, **Ndinya-Achola JO**, **Bwayo JJ**, **Kreiss JK**, Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study, Am J Obstet Gynecol 185:380, 2001.
551. **Rifkin SB**, **Smith MR**, **Brotman RM**, **Gindi RM**, **Erbelding EJ**, Hormonal contraception and risk of bacterial vaginosis diagnosis in an observational study of women attending STD clinics in Baltimore, MD, Contraception 80:63, 2009.
552. **Roumen FJME**, **Boon ME**, **van Velzen D**, **Dieben TOM**, **Coelingh Bennink HJT**, The cervico-vaginal epithelium during 20 cycles' use of a combined contraceptive vaginal ring, Hum Reprod 11:2443, 1996.
553. **Davies GC**, **Feng LX**, **Newton JR**, **Dieben TO**, **Coelingh Bennink HJ**, The effects of a combined contraceptive vaginal ring releasing ethinyloestradiol and 3-keto-desogestrel on vaginal flora, Contraception 45:511, 1992.
554. **Veres S**, **Miller L**, **Burington B**, A comparison between the vaginal ring and oral contraceptives, Obstet Gynecol 104:555, 2004.
555. **Stewart FH**, **Harper CC**, **Ellertson CE**, **Grimes DA**, **Sawaya GF**, **Trussell J**, Clinical breast and pelvic examination requirements for hormonal contraception, Current practice vs evidence, JAMA 285:2231, 2001.
556. **Milsom I**, **Sundell G**, **Andersch B**, A longitudinal study of contraception and pregnancy outcome in a representative sample of young Swedish women, Contraception 43:111, 1991.
557. **Letterie GS**, **Chow GE**, Effect of "missed" pills on oral contraceptive effectiveness, Obstet Gynecol 79:979, 1992.
558. **Westhoff CL**, **Kerns J**, **Morroni C**, **Tiezzi L**, **Aikins-Murphy P**, Quick-start: a novel oral contraceptive initiation method, Contraception 66:141, 2002.
559. **Westhoff C**, **Morroni C**, **Kerns J**, **Murphy PA**, Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial, Fertil Steril 79:322, 2003.
560. **Potter L**, **Oakley D**, **de Leon-Wong E**, **Cañamar R**, Measuring compliance among oral contraceptive users, Fam Plann Perspect 28:154, 1996.
561. **Killick SR**, **Bancroft K**, **Oelbaum S**, **Morris J**, **Elstein M**, Extending the duration of the pill-free interval during combined oral contraception, Adv Contracept 6:33, 1990.
562. **Rosenberg MJ**, **Waugh MS**, **Higgins JE**, The effect of desogestrel, gestodene, and other factors on spotting and bleeding, Contraception 53:85, 1996.
563. **Westhoff C**, **Jones K**, **Robilotto C**, **Heartwell S**, **Edwards S**, **Zieman M**, **Cushman L**, Smoking and oral contraceptive continuation, Contraception 79:375, 2009.
564. **Krettek SE**, **Arkin SI**, **Chaisilwattana P**, **Monif GR**, Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting, Obstet Gynecol 81:728, 1993.
565. **Sulak PJ**, **Kuehl TJ**, **Coffee A**, **Willis S**, Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen, Am J Obstet Gynecol 195:935, 2006.

566. **Lemay A**, **Dewailly SD**, **Grenier R**, **Huard J**, Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d, l-norgestrel, J Clin Endocrinol Metab 71:8, 1990.
567. **Mango D**, **Ricci S**, **Manna P**, **Miggiano GAD**, **Serra GB**, Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris, Contraception 53:163, 1996.
568. **Thorneycroft IH**, **Stanczyk FZ**, **Bradshaw KD**, **Ballagh SA**, **Nichols M**, **Weber ME**, Effect of low-dose oral contraceptives on androgenic markers and acne, Contraception 60:255, 1999.
569. **Rosen MP**, **Breitkopf DM**, **Nagamani M**, A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris, Am J Obstet Gynecol 188:1158, 2003.
570. **Maloney JM**, **Dietze P Jr**, **Watson D**, **Niknian M**, **Lee-Rugh S**, **Sampson-Landers C**, **Korner P**, Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen. A randomized controlled trial, Obstet Gynecol 112:773, 2008.
571. **Palombo-Kinne E**, **Schellschmidt I**, **Schumacher U**, **Gräser T**, Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate, Contraception 79:282, 2009.
572. **Cassidenti DL**, **Paulson RJ**, **Serafini P**, **Stanczyk FZ**, **Lobo RA**, Effects of sex steroids on skin 5a-reductase activity in vitro, Obstet Gynecol 78:103, 1991.
573. **Grimes DA**, **Hughes JM**, Use of multiphasic oral contraceptives and hospitalizations of women with functional ovarian cysts in the United States, Obstet Gynecol 73:1037, 1989.
574. **Holt VL**, **Cushing-Haugen KL**, **Daling JR**, Oral contraceptives, tubal sterilization, and functional ovarian cyst risk, Obstet Gynecol 102:252, 2003.
575. **Vessey M**, **Metcalfe A**, **Wells C**, **McPherson K**, **Westhoff C**, **Yeates C**, Ovarian neoplasms, functional ovarian cysts, and oral contraceptives, Br Med J 294:1518, 1987.
576. **Lanes SF**, **Birmann B**, **Walker AM**, **Singer S**, Oral contraceptive type and functional ovarian cysts, Am J Obstet Gynecol 166:956, 1992.
577. **Holt VL**, **Daling JR**, **McKnight B**, **Moore D**, **Stergachis A**, **Weiss NS**, Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives, Obstet Gynecol 79:529, 1992.
578. **Young RL**, **Snabes MC**, **Frank ML**, **Reilly M**, A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development, Am J Obstet Gynecol 167:678, 1992.
579. **Grimes DA**, **Godwin AJ**, **Rubin A**, **Smith JA**, **Lacarra M**, Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial, Obstet Gynecol 83:29, 1994.
580. **Neely JL**, **Abate M**, **Swinker M**, **D'Angio R**, The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone, Obstet Gynecol 77:416, 1991.
581. **Murphy AA**, **Zacur HA**, **Charache P**, **Burkman RT**, The effect of tetracycline on levels of oral contraceptives, Am J Obstet Gynecol 164:28, 1991.
582. **Back DJ**, **Tija J**, **Martin C**, **Millar E**, **Mant T**, **Morrison P**, **Orme P**, The lack of interaction between temafloxacin and combined oral contraceptive steroids, Contraception 43:317, 1991.
583. **Csemiczky G**, **Alvendal C**, **Landgren BM**, Risk for ovulation in women taking a low-dose oral contraceptive (Microgynon) when receiving antibacterial treatment with a fluoroquinolone (ofloxacin), Adv Contracept 12:101, 1996.
584. **Dogterom P**, **van den Heuvel MW**, **Thomsen T**, Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials, Clin Pharmacokinet 44:429, 2005.
585. **Helms SE**, **Bredle DL**, **Zajic J**, **Jarjoura D**, **Brodell RT**, **Krishnarao I**, Oral contraceptive failure rates and oral antibiotics, J Am Acad Dermatol 36: 705, 1997.
586. **Schöller-Gyüre M**, **Kakuda TN**, **Woodfall B**, **Aharchi F**, **Peeters M**, **Vandermeulen K**, **Hoetelmans RMW**, Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone, Contraception 80:44, 2009.
587. **Markowitz JS**, **Donovan JL**, **DeVane CL**, **Taylor RM**, **Ruan Y**, **Wang J-S**, **Chavin KD**, Effect of St

John's Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme, JAMA 290:1500, 2003.
588. **Szoka PR**, **Edgren RA**, Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database, Fertil Steril 49(Suppl):31S, 1988.
589. **Mitchell MC**, **Hanew T**, **Meredith CG**, **Schenker S**, Effects of oral contraceptive steroids on acetaminophen metabolism and elimination, Clin Pharmacol Ther 34:48, 1983.
590. **Gupta KC**, **Joshi JV**, **Hazari K**, **Pohujani SM**, **Satoskjar RS**, Effect of low estrogen combination oral contraceptives on metabolism of aspirin and phenylbutazone, Int J Clin Pharmacol Ther Toxicol 20:511, 1982.
591. **Lipton RB**, **Vigal ME**, **Diamond MP**, **Freitag F**, **Reed ML**, **Stewart WF**, Migraine prevalence, disease burden, and the need for preventive therapy, Neurology 68:343, 2007.
592. **Curtis KM**, **Chrisman CE**, **Peterson HB**, Contraception for women in selected circumstances, Obstet Gynecol 99:1100, 2002.
593. **Tietjen GE**, The relationship of migraine and stroke, Neuroepidemiology 19:13, 2000.
594. **Chang CL**, **Donaghy M**, **Poulter N**, Migraine and stroke in young women: case-control study, Br Med J 318:13, 1999.
595. **Donaghy M**, **Chang CL**, **Poulter N**, Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age, J Neurol Neurosurg Psychiatry 73:747, 2002.
596. **Tzourio C**, **Tehindrazanarierelo A**, **Iglésias S**, **Alpérovitch A**, **Chgedru F**, **d'Anglejan-Chatillon J**, **Bousser M-G**, Case-control study of migraine and risk of ischaemic stroke in young women, Br Med J 310:830, 1995.
597. **Lidegaard Ø**, Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease, Br J Obstet Gynaecol 102:153, 1995.
598. **MacClellan LR**, **Giles W**, **Cole J**, **Wozniak M**, **Stern B**, **Mitchell BD**, **Kittner SJ**, Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study, Stroke 38:2438, 2007.
599. **Friedman AJ**, **Thomas PP**, Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas?, Obstet Gynecol 85:631, 1995.
600. **Mattson RH**, **Cramer JA**, **Darney PD**, **Naftolin F**, Use of oral contraceptives by women with epilepsy, JAMA 256:238, 1986.
601. **Vessey M**, **Painter R**, **Yeates D**, Oral contraception and epilepsy: findings in a large cohort study, Contraception 66:77, 2002.
602. **Klosterskov Jensen P**, **Saano V**, **Haring P**, **Svenstrup B**, **Menge GP**, Possible interaction between oxcarbazepine and an oral contraceptive, Epilepsia 33:1149, 1992.
603. **Rosenfeld WE**, **Doose DR**, **Walker SA**, **Nayak RK**, Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy, Epilepsia 38:317, 1997.
604. **Fattore C**, **Cipolla G**, **Gatti G**, **Limido GL**, **Sturm Y**, **Bernasconi C**, **Perucca E**, Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women, Epilepsia 40:783, 1999.
605. **Sidhu J**, **Job S**, **Singh S**, **Philipson R**, The pharmacokinetic and pharmacodynamic consequences of the coadministration of lamotrigine and a combined oral contraceptive in healthy female subjects, Br J Clin Pharmacol 61:191, 2006.
606. **Galimberti CA**, **Mazzucchelli I**, **Arbasino C**, **Canevini MP**, **Fattore C**, **Petrucca E**, Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy, Epilepsia 47:1569, 2006.
607. **Montouris G**, Importance of monotherapy in women across the reproductive cycle, Neurology 69:S10, 2007.
608. **Wegner I**, **Edelbroek PM**, **Bulk S**, **Lindhout D**, Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives, Neurology 73:1388, 2009.
609. **Bounds W**, **Guillebaud J**, Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs, J Fam Plann Reprod Health Care 28:78, 2002.
610. **Lutcher CL**, **Milner PF**, Contraceptive-induced vascular occlusive events in sickle cell disorders—fact or fiction? (abstract), Clin Res 34:217A, 1986.
611. **Yoong WC**, **Tuck SM**, **Yardumian A**, Red cell deformability in oral contraceptive pill users with sickle cell

anemia, Br J Haematol 104:868, 1999.
612. **DeCeular K**, **Gruber C**, **Hayes R**, **Serjeant GR**, Medroxyprogesterone acetate and homozygous sickle-cell disease, Lancet ii:229, 1982.
613. **Jungers P**, **Dougados M**, **Pelissier L**, **Kuttenn F**, **Tron F**, **Lesavre P**, **Bach JF**, Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus, Arthritis Rheum 25:618, 1982.
614. **Bernier M-O**, **Mikaeloff Y**, **Hudson M**, **Suissa S**, Combined oral contraceptive use and the risk of systemic lupus erythematosus, Arthritis Rheum 61:476, 2009.
615. **Petri M**, **Robinson C**, Oral contraceptives and systemic lupus erythematosus, Arthritis Rheum 40:797, 1997.
616. **Sánchez-Guerrero J**, **Uribe AG**, **Jiménez-Santana L**, **Mestanza-Peralta M**, **Lara-Reyes P**, **Seuc AH**, **Cravioto M**, A trial of contraceptive methods in women with systemic lupus erythematosus, N Engl J Med 353:2539, 2005.
617. **Petri M**, **Kim MY**, **Kalunian KC**, **Grossman J**, **Hahn BH**, **Sammaritano LR**, **Lockshin M**, **Merrill JT**, **Belmont HM**, **Askanase AD**, **McCune WJ**, **Hearth-Holmes M**, **Dooley MA**, **Von Feldt J**, **Friedman A**, **Tan M**, **Davis J**, **Cronin M**, **Diamond B**, **Mackay M**, **Sigler L**, **Fillius M**, **Rupel A**, **Licciardi F**, **Buyon JP**; for the **OC-SELENA Trial**, Combined oral contraceptives in women with systemic lupus erythematosus, N Engl J Med 353:2550, 2005.
618. **Knopp RH**, **LaRosa JC**, **Burkman RT Jr**, Contraception and dyslipidemia, Am J Obstet Gynecol 168:1994, 1993.
619. **Abdollahi M**, **Cushman M**, **Rosendaal FR**, Obesity: risk of venous thromboembolism and the interaction with coagulation factor levels and oral contraceptive use, Thromb Haemost 89:493, 2003.
620. **Nightingale AL**, **Lawrenson RA**, **Simpson EL**, **Williams TJ**, **MacRae KD**, **Farmer RD**, The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives, Eur J Contracept Reprod Health Care 5:265, 2000.
621. **Larsen TB**, **Sorensen HT**, **Gislum M**, **Johnson SP**, Maternal smoking, obesity, and the risk of thromboembolism during pregnancy and the puerperium: a population-based nested control study, Thromb Res 120:505, 2007.
622. **Holt VL**, **Cushing-Haugen KL**, **Daling JR**, Body weight and risk of oral contraceptive failure, Obstet Gynecol 99:820, 2002.
623. **Zieman M**, **Guillebaud J**, **Weisberg E**, **Shangold GA**, **Fisher AC**, **Creasy GW**, Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system: the analysis of pooled data, Fertil Steril 77(Suppl 2):S13, 2002.
624. **Norris PM**, **Kamat A**, **Estes C**, Contraceptive failure in overweight patients taking combination oral contraceptive pills, Contraception, 68:Abstract 16, 2003.
625. **Holt VL**, **Scholes D**, **Wicklund KG**, **Cushing-Haugen KL**, **Daling JR**, Body mass index, weight, and oral contraceptive failure risk, Obstet Gynecol 105:46, 2005.
626. **Brunner LR**, **Hogue CJ**, The role of body weight in oral contraceptive failure: results from the 1995 National Survey of Family Growth, Ann Epidemiol 15:492, 2005.
627. **Brunner LR**, **Hogue CJ**, The association between body weight, unintended pregnancy resulting in a livebirth, and contraception at the time of conception, Matern Child Health J 9:413, 2005.
628. **Dinger JC**, **Cronin M**, **Möhner S**, **Schellschmidt I**, **Minh TD**, **Westhoff C**, Oral contraceptive effectiveness according to body mass index, weight, age, and other factors, Am J Obstet Gynecol 201:263.e1, 2009.
629. **Archer DF**, **Maheux R**, **DelConte A**, **O'Brien FB**; **North American Levonorgestrel Study Group**, Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 mg levonorgestrel and 20 mg ethinyl estradiol (Alesse), Am J Obstet Gynecol 181:S39, 1999.
630. **Edelman AB**, **Carlson NE**, **Cherala G**, **Munar MY**, **Stouffer RL**, **Cameron JL**, **Stanczyk FZ**, **Jensen JT**, Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity, Contraception 80:119, 2009.
631. **Victor A**, **Odlind V**, **Kral JG**, Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass, Gastroenterol Clin North Am 16:483, 1987.

632. **Gerrits EG**, **Ceulemans R**, **van Hee R**, **Hendrickx L**, **Totté E**, Contraceptive treatment after biliopancreatic diversion needs consensus, Obes Surg 13:378, 2003.
633. **Azziz R**, The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome: therapeutic response, Fertil Steril 61:570, 1994.
634. **Nader S**, **Riad-Gabriel MG**, **Saad M**, The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women, J Clin Endocrinol Metab 82:3074, 1997.
635. **Pasquali R**, **Gambineri A**, **Anconetani B**, **Vicennati V**, **Colitta D**, **Caramelli E**, **Casimirri F**, **Morselli-Labate AM**, The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestogen treatment, Clin Endocrinol 50:517, 1999.
636. **Klibanski A**, **Biller BMK**, **Schoenfeld DA**, **Herzog DB**, **Saxe VC**, The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa, J Clin Endocrinol Metab 80:898, 1995.
637. **Drinkwater BL**, **Bruemmer B**, **Chesnut CH III**, Menstrual history as a determinant of current bone density in young athletes, JAMA 263:545, 1990.
638. **Jonnavithula S**, **Warren MP**, **Fox RP**, **Lazaro MI**, Bone density is compromised in amenorrheic women despite return of menses: a 2-year study, Obstet Gynecol 81:669, 1993.
639. **Grimmer SF**, **Back DJ**, **Orme ML**, **Cowie A**, **Gilmore I**, **Tjia J**, The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy, Contraception 33:51, 1986.
640. **Nilsson LO**, **Victor A**, **Kral JG**, **Johansson ED**, **Kock NG**, Absorption of an oral contraceptive gestagen in ulcerative colitis before and after proctocolectomy and construction of a continent ileostomy, Contraception 31:195, 1985.
641. **Sandler RS**, **Wurzelmann JI**, **Lyles CM**, Oral contraceptive use and the risk of inflammatory bowel disease, Epidemiology 3:374, 1992.
642. **Timmer A**, **Sutherland LR**, **Martin F**, Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group, Gastroenterology 114:1143, 1998.
643. **Katschinski B**, **Fingerie D**, **Scherbaum B**, **Goebell H**, Oral contraceptive use and cigarette smoking in Crohn's disease, Dig Dis Sci 38:1596, 1993.
644. **Lashner BA**, **Kane SV**, **Hanauer SB**, Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study, Gastroenterology 97:1442, 1989.
645. **Cosnes J**, **Carbonnel F**, **Carrat F**, **Beaugerie L**, **Gendre JP**, Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study, Gut 45:218, 1999.
646. **Pietrzak B**, **Bobrowska K**, **Jabiry-Zieniewicz Z**, **Kaminski P**, **Wielgos M**, **Pazik J**, **Durlik M**, Oral and transdermal hormonal contraception in women after kidney transplantation, Transplant Proc 39:2759, 2007.
647. **Jabiry-Zieniewicz Z**, **Bobrowska K**, **Kaminski P**, **Wielgos M**, **Zieniewicz K**, **Krawczyk M**, Low-dose hormonal contraception after liver transplantation, Transplant Proc 39:1530, 2007.
648. **Coutinho EM**, **de Souza JC**, **da Silva AR**, **de Acosta OM**, **Flores JG**, **Gu ZP**, **Ladipo OA**, **Adekunle AO**, **Otolorin EO**, **Shaaban MM**, **Abul Oyoom M**, et al., Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial, Clin Pharmacol Ther 53:65, 1993.
649. **Ziaei S**, **Rajaei L**, **Faghihzadeh S**, **Lamyian M**, Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route, Contraception 65:329, 2002.
650. **Bryner RW**, **Toffle RC**, **Ullrich IH**, **Yeater RA**, Effect of low dose oral contraceptives on exercise performance, Br J Sports Med 30:36, 1996.
651. **Redman LM**, **Scroop GC**, **Westlander G**, **Norman RJ**, Effect of a synthetic progestin on the exercise status of sedentary young women, J Clin Endocrinol Metab 90:3830, 2005.
652. **Thompson HS**, **Hyatt JP**, **De Souza MJ**, **Clarkson PM**, The effects of oral contraceptives on delayed onset muscle soreness following exercise, Contraception 56:59, 1997.
653. **Brynhildsen J**, **Lennartsson H**, **Klemetz M**, **Dahlquist P**, **Hedin B**, **Hammar M**, Oral contraceptive use among female elite athletes and age-matched controls and its relation to low back pain, Acta Obstet Gynecol Scand 76:873, 1997.

654. **Milsom I**, **Sundell G**, **Andersch B**, The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea, Contraception 42:497, 1990.
655. **Larsson G**, **Milsom I**, **Lindstedt G**, **Rybo G**, The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status, Contraception 46:327, 1992.
656. **Davis A**, **Goodwin A**, **Lippman J**, **Olson W**, **Kafrissen M**, Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding, Obstet Gynecol 96:913, 2000.
657. **Vessey MP**, **Villard-Mackintosh L**, **Painter R**, Epidemiology of endometriosis in women attending family-planning clinics, Br Med J 306:182, 1993.
658. **Parazzini F**, **Ferraroni M**, **Bocciolone L**, **Tozzi L**, **Rubessa S**, **La Vecchia C**, Contraceptive methods and risk of pelvic endometriosis, Contraception 49:47, 1994.
659. **Sangi-Haghpeykar H**, **Poindexter AN III**, Epidemiology of endometriosis among parous women, Obstet Gynecol 85:983, 1995.
660. **Harada T**, **Momoeda M**, **Taketani Y**, **Hoshiai H**, **Terakawa N**, Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial, Fertil Steril 90:1583, 2008.
661. **Davis AR**, **Westhoff C**, **O'Connell K**, **Gallagher N**, Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial, Obstet Gynecol 106: 97, 2005.
662. **Vercellini P**, **Frontino G**, **De Giorgi O**, **Pietropaolo G**, **Pasin R**, **Crosignani PG**, Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen, Fertil Steril 80:560, 2003.
663. **Seracchioli R**, **Mabrouk M**, **Frascà C**, **Manuzzi L**, **Montanari G**, **Keramyda A**, **Venturoli S**, Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial, Fertil Steril 93:52, 2010.
664. **Modugno F**, **Ness RB**, **Allen GO**, **Schildkraut JM**, **Davis FG**, **Goodman MT**, Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis, Am J Obstet Gynecol 191: 733, 2004.
665. **Enzelsberger H**, **Metka M**, **Heytmanek G**, **Schurz B**, **Kurz C**, **Kusztrich M**, Influence of oral contraceptive use on bone density in climacteric women, Maturitas 9:375, 1988.
666. **Lindsay R**, **Tohme J**, **Kanders B**, The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women, Contraception 34:333, 1986.
667. **Enzelberger H**, **Metka M**, **Heytmanek G**, **Schurz B**, **Kurz C**, **Kusztrich M**, Influence of oral contraceptive use on bone density in climacteric women, Maturitas 9:375, 1988.
668. **Kleerekoper M**, **Brienza RS**, **Schultz LR**, **Johnson CC**, Oral contraceptive use may protect against low bone mass, Arch Intern Med 151:1971, 1991.
669. **Kritz-Silverstein D**, **Barrett-Connor E**, Bone mineral density in postmenopausal women as determined by prior oral contraceptive use, Am J Public Health 83:100, 1993.
670. **Tuppurrainen M**, **Kröger H**, **Saarikoski S**, **Honkanen R**, **Alhava E**, The effect of previous oral contraceptive use on bone mineral density in perimenopausal women, Osteoporos Int 4:93, 1994.
671. **Gambacciani M**, **Spinetti A**, **Taponeco F**, **Cappagli B**, **Piaggesi L**, **Fioretti P**, Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism, Obstet Gynecol 83:392, 1994.
672. **Pasco JA**, **Kotowicz MA**, **Henry MJ**, **Panahi S**, **Seeman E**, **Nicholson GC**, Oral contraceptives and bone mineral density: a population-based study, Am J Obstet Gynecol 182:265, 2000.
673. **Mais V**, **Fruzzetti F**, **Aiossa S**, **Paoletti AM**, **Guerriero S**, **Melis GB**, Bone metabolism in young women taking a monophasic pill containing 20 mg ethinylestradiol, Contraception 48:445, 1993.
674. **Polatti F**, **Perotti F**, **Filippa N**, **Gallina D**, **Nappi RE**, Bone mass and long-term monophasic oral contraceptive treatment in young women, Contraception 51:221, 1995.
675. **Hartard M**, **Bottermann P**, **Bartenstein P**, **Jeschke D**, **Schwaiger M**, Effects on bone mineral density of low-dosed oral contraceptives compared to and combined with physical activity, Contraception 55:87, 1997.
676. **Mallmin H**, **Ljunghall S**, **Persson I**, **Bergstrom R**, Risk factors for fractures of the distal forearm: a

population-based case-control study, Osteoporos Int 4:97, 1994.
677. **Johansson C**, **Mellström D**, An earlier fracture as a risk factor for new fracture and its association with smoking and menopausal age in women, Maturitas 24:97, 1996.
678. **O'Neill TW**, **Marsden D**, **Adams JE**, **Silman AJ**, Risk factors, falls, and fracture of the distal forearm in Manchester, UK, J Epidemiol Community Health 50:288, 1996.
679. **O'Neill TW**, **Silman AJ**, **Naves Diaz M**, **Cooper C**, **Kanis J**, **Felsenberg D**, Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women, Osteoporos Int 7:72, 1997.
680. **Cooper C**, **Hannaford P**, **Croft P**, **Kay CR**, Oral contraceptive pill use and fractures in women: a prospective study, Bone 14:41, 1993.
681. **Vessey M**, **Mant J**, **Painter R**, Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study, Contraception 57:231, 1998.
682. **Michaëlsson K**, **Baron JA**, **Farahmand BY**, **Persson I**, **Ljunghall S**, Oral contraceptive use and risk of hip fracture: a case-control study, Lancet 353:1481, 1999.
683. **Hazes JMW**, **Dijkmans BAC**, **Vandenbroucke JP**, **De Vries RRP**, **Cats A**, Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives, Arthritis Rheum 33:173, 1990.
684. **Spector TD**, **Hochberg MC**, The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytical epidemiological studies using meta-analysis, J Clin Epidemiol 43:1221, 1990.
685. **Pladevall-Vila M**, **Delclos GL**, **Varas C**, **Guyer H**, **Brugués-Tarradellas J**, **Anglada-Arisa A**, Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity, Am J Epidemiol 144:1, 1996.
686. **Drossaers-Bakker KW**, **Zwinderman AH**, **van Zeben D**, **Breedveld FC**, **Hazes JM**, Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis, Ann Rheum Dis 61:405, 2002.
687. **van der Vange N**, **Blankenstein MA**, **Kloosterboer HJ**, **Haspels AA**, **Thijssen JHH**, Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone, Contraception 41:345, 1990.
688. **Coenen CMH**, **Thomas CMG**, **Borm GF**, **Rolland R**, Changes in androgens during treatment with four low-dose contraceptives, Contraception 53:171, 1996.
689. **Palatsi R**, **Hirvensalo E**, **Liukko P**, **Malmiharju T**, **Mattila L**, **Riihiluoma P**, **Ylöstalo P**, Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives, Acta Derm Venereol 64:517, 1984.
690. **Steinkampf MP**, **Hammond KR**, **Blackwell RE**, Hormonal treatment of functional ovarian cysts: a randomized, prospective study, Fertil Steril 54:775, 1990.
691. **Ben-Ami M**, **Geslevich Y**, **Battino S**, **Matilsky M**, **Shalev E**, Management of functional ovarian cysts after induction of ovulation. A randomized prospective study, Acta Obstet Gynecol Scand 72:396, 1993.
692. **MacKenna A**, **Fabres C**, **Alam V**, **Morales V**, Clinical management of functional ovarian cysts: a prospective and randomized study, Hum Reprod 15:2567, 2000.
693. **Turan C**, **Zorlu CG**, **Ugur M**, **Ozcan T**, **Kaleli B**, **Gokmen O**, Expectant management of functional ovarian cysts: an alternative to hormonal therapy, Int J Gynaecol Obstet 47:257, 1994.
694. **Nezhat CH**, **Nezhat F**, **Borhan S**, **Seidman DS**, **Nezhat CR**, Is hormonal treatment efficacious in the management of ovarian cysts in women with histories of endometriosis?, Hum Reprod 11:874, 1996.
695. **Rosenberg MJ**, **Waugh MS**, **Meehan TE**, Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation, Contraception 51: 283, 1995.
696. **Villegas-Salas E**, **Ponce de León R**, **Juárez-Perez MA**, **Grubb GS**, Effect of vitamin B6 on the side effects of a low-dose combined oral contraceptive, Contraception 55:245, 1997.
697. **Peterson LS**, **Oakley D**, **Potter LS**, **Darroch JE**, Women's efforts to prevent pregnancy: consistency of oral contraceptive use, Fam Plann Perspect 30:19, 1998.
698. **Chi I**, The safety and efficacy issues of progestin-only oral contraceptives — an epidemiologic perspective, Contraception 47:1, 1993.

699. **McCann MF**, **Potter LS**, Progestin-only oral contraception: a comprehensive review, Contraception 50(Suppl 1):S9, 1994.
700. **Moghissi KS**, **Marks C**, Effects of microdose progestogens on endogenous gonadotrophic and steroid hormones, cervical mucus properties, vaginal cytology and endometrium, Fertil Steril 22:424, 1971.
701. **Moghissi KS**, **Syner FN**, **McBride LC**, Contraceptive mechanism of microdose norethindrone, Obstet Gynecol 4:585, 1973.
702. **Collaborative Study Group on the Desogestrel-Containing Progestogen-Only Pill**, A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day, Eur J Contracept Reprod Health Care 3:169, 1998.
703. **Fotherby K**, The progestogen-only pill and thrombosis, Br J Fam Plann 15: 83, 1989.
704. **Ball MJ**, **Gillmer AE**, Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone, Contraception 44: 223, 1991.
705. **Trussell J**, **Kost K**, Contraceptive failure in the United States: a critical review of the literature, Stud Fam Plann 18:237, 1987.
706. **Vessey MP**, **Lawless M**, **Yeates D**, **McPherson K**, Progestogen-only contraception: findings in a large prospective study with special reference to effectiveness, Br J Fam Plann 10:117, 1985.
707. **Bisset AM**, **Dingwall-Fordyce I**, **Hamilton MJK**, The efficacy of the progestogen-only pill as a contraceptive method, Br J Fam Plann 16:84, 1990.
708. **Broome M**, **Fotherby K**, Clinical experience with the progestogen-only pill, Contraception 42:489, 1990.
709. **Li R**, **Luo X**, **Archer DF**, **Chegini N**, Doxycycline alters the expression of matrix metalloproteases in the endometrial cells exposed to ovarian steroids and pro-inflammatory cytokine, J Reprod Immunol 73:118, 2007.
710. **Tayob Y**, **Adams J**, **Jacobs HS**, **Guillebaud J**, Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception, Br J Obstet Gynaecol 92:1003, 1985.
711. **Pakarinen P**, **Lahteenmaki P**, **Rutanen EM**, The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1, Acta Obstet Gynecol Scand 78:423, 1999.
712. **Dunson TR**, **McLaurin VL**, **Grubb GS**, **Rosman AW**, A multicenter clinical trial of a progestin-only oral contraceptive in lactating women, Contraception 47:23, 1993.
713. **Mintz G**, **Gutierrez G**, **Deleze M**, **Rodriguez E**, Contraception with progestogens in systemic lupus erythematosus, Contraception 30:29, 1984.
714. **Winkler UH**, **Howie H**, **Bühler K**, **Korver T**, **Geurts TBP**, **Coelingh Bennink HJT**, A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 mg desogestrel or 30 mg levonorgestrel, Contraception 57:385, 1998.
715. **Weiderpass E**, **Adami HO**, **Baron JA**, **Magnusson C**, **Bergstrom R**, **Lindgren A**, **Correia N**, **Persson I**, Risk of endometrial cancer following estrogen replacement with and without progestins, J Natl Cancer Inst 91:1131, 1999.
716. **Burton R**, **Savage W**, **Reader F**, The "morning after pill." Is this the wrong name for it?, Br J Fam Plann 15:119, 1990.
717. **Young L**, **McCowan LM**, **Roberts HE**, **Farquhar CM**, Emergency contraception—why women don't use it, N Z Med J 108:145, 1995.
718. **Harper CC**, **Ellerton CE**, The emergency contraceptive pill: a survey of knowledge and attitudes among students at Princeton, Am J Obstet Gynecol 173:1438, 1995.
719. **Hu X**, **Cheng L**, **Hua X**, **Glasier A**, Advanced provision of emergency contraception to postnatal women in China makes no difference in abortion rates: a randomized controlled trial, Contraception 72:111, 2005.
720. **Raymond EG**, **Stewart F**, **Weaver M**, **Monteith C**, **Van Der Pol B**, Impact of increased access to emergency contraceptive pills: a randomized controlled trial, Obstet Gynecol 108:1098, 2006.
721. **Rocca CH**, **Schwartz EB**, **Stewart FH**, **Darney PD**, **Raine TR**, **Harper CC**, Beyond access: acceptability, use, and nonuse of emergency contraception among young women, Am J Obstet Gynecol 196:29, 2007.

722. **Sambol NC**, **Harper CC**, **Kim L**, **Liu CY**, **Darney P**, **Raine TR**, Pharmacokinetics of single-dose levonorgestrel in adolescents, Contraception 74:104, 2006.
723. **Delbanco SF**, **Mauldon J**, **Smith MD**, Little knowledge and limited practice: emergency contraceptive pills, the public, and the obstetrician-gynecologist, Obstet Gynecol 89:1006, 1997.
724. **Trussell J**, **Stewart F**, **Guest F**, **Hatcher RA**, Emergency contraceptive pills: a simple proposal to reduce unintended pregnancies, Fam Plann Perspect 24:269, 1992.
725. **Harvey SM**, **Beckman LJ**, **Sherman C**, **Petitti D**, Women's experience and satisfaction with emergency contraception, Fam Plann Perspect 31:237, 1999.
726. **Raine T**, **Harper C**, **Rocca C**, **Fisher R**, **Darney PD**, Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial, JAMA 193:54, 2005.
727. **Morris JM**, **van Wagenen G**, Compounds interfering with ovum implantation and development. III. The role of estrogens, Am J Obstet Gynecol 96:804, 1966.
728. **Yuzpe AA**, **Smith RP**, **Rademaker AW**, A multicenter clinical investigation employing ethinyl estradiol combined with DL-norgestrel as a postcoital contraceptive agent, Fertil Steril 37:508, 1982.
729. **Ho PC**, **Kwan MSW**, A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception, Hum Reprod 8:389, 1993.
730. **Task Force on Postovulatory Methods of Fertility Regulation**, Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception, Lancet 352:428, 1998.
731. **von Hertzen H**, **Piaggio G**, **Ding J**, **Chen J**, **Song S**, **Bartfai G**, **Ng E**, **Gemzell-Danielsson K**, **Oyunbileg A**, **Wu S**, **Cheng W**, **Ludicke F**, **Pretnar-Darovec A**, **Kirkman R**, **Mittal S**, **Khomassuridze A**, **Apter D**, **Peregoudov A**; **WHO Research Group on Post-Ovulatory Methods of Fertility Regulation**, Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial, Lancet 360:1803, 2002.
732. **Arowojoulu AO**, **Okewole IA**, **Adekunie AO**, Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians, Contraception 66:269, 2002.
733. **Glasier A**, **Baird D**, The effects of self-administering emergency contraception, N Engl J Med 339:1, 1998.
734. **Raine T**, **Harper C**, **Leon K**, **Darney P**, Emergency contraception: advance provision in a young, high-risk clinic population, Obstet Gynecol 96:1, 2000.
735. **Jackson RD**, **Bimla Schwarz E**, **Freedman L**, **Darney P**, Advance supply of emergency contraception: effect on use and usual contraception—a randomized trial, Obstet Gynecol 102:8, 2003.
736. **Gainer E**, **Blum J**, **Toverud E-L**, **Portugal N**, **Tyden T**, **Nesheim B-I**, **Larsson M**, **Vilar D**, **Nymoen P**, **Aneblom G**, **Lutwick A**, **Winikoff B**, Bringing emergency contraception over the counter: experiences of nonprescription users in France, Norway, Sweden and Portugal, Contraception 68:117, 2003.
737. **Young DC**, **Wiehle RD**, **Joshi SG**, **Poindexter AN III**, Emergency contraception alters progesterone-associated endometrial protein in serum and uterine luminal fluid, Obstet Gynecol 84:266, 1994.
738. **Swahn ML**, **Westlund P**, **Johannisson E**, **Bygdeman M**, Effect of postcoital contraceptive methods on the endometrium and the menstrual cycle, Acta Obstet Gynecol Scand 75:738, 1996.
739. **Trussell J**, **Raymond EG**, Statistical evidence about the mechanism of action of the Yuzpe regimen of emergency contraception, Obstet Gynecol 93:872, 1999.
740. **Marions L**, **Hultenby K**, **Lindell I**, **Sun X**, **Stabi B**, **Gemzell Danielsson K**, Emergency contraception with mifepristone and levonorgestrel: mechanism of action, Obstet Gynecol 100:65, 2002.
741. **Croxatto HB**, **Fuentealba B**, **Brache V**, **Salvatierra AM**, **Alvarez G**, **Massai R**, **Cochon L**, **Faundes A**, Effects of the Yuzpe regimen, given during the follicular phase, on ovarian function, Contraception 65:121, 2002.
742. **Novikova N**, **Weisberg E**, **Stanczyk FZ**, **Croxatto HB**, **Fraser IS**, Effectiveness of levonorgestrel emergency contraception given before or after ovulation—a pilot study, Contraception 75:112, 2007.
743. **Lalitkumar PG**, **Lalitkumar S**, **Meng CX**, **Stavreus-Evers A**, **Hambiliki F**, **Bentin-Ley U**, **Gemzell-Danielsson K**, Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model, Hum Reprod 22:3031, 2007.

744. **Meng CX**, **Cheng LN**, **Lalitkumar PG**, **Zhang L**, **Zhang HJ**, **Gemzell-Danielsson K**, Expressions of steroid receptors and Ki67 in first-trimester decidua and chorionic villi exposed to levonorgestrel used for emergency contraception, Fertil Steril 91(Suppl 4):1420, 2009.
745. **Ortiz ME**, **Ortiz RE**, **Fuentes MA**, **Parraguez VH**, **Croxatto HB**, Post-coital administration of levonorgestrel does not interfere with post-fertilization events in the new-world monkey Cebus apella, Hum Reprod 19:1352, 2004.
746. **Muller AL**, **Llados CM**, **Croxatto HB**, Postcoital treatment with levonorgestrel does not disrupt postfertilization events in the rat, Contraception 67:415, 2003.
747. **Trussell J**, **Ellertson C**, **Dorflinger L**, Effectiveness of the Yuzpe regimen of emergency contraception by cycle day of intercourse: implications for mechanism of action, Contraception 67:167, 2003.
748. **Okewole IA**, **Arowojolu AO**, **Odusoga OL**, **Oloyede OA**, **Adeleye OA**, **Salu J**, **Dada OA**, Effect of single administration of levonorgestrel on the menstrual cycle, Contraception 75:372, 2007.
749. **Fasoli M**, **Parazzini F**, **Cecchetti G**, **La Vecchia C**, Post-coital contraception: an overview of published studies, Contraception 39:459, 1989.
750. **Haspels AA**, Emergency contraception: a review, Contraception 50:101, 1994.
751. **Glasier A**, Emergency postcoital contraception, N Engl J Med 337:1058, 1997.
752. **Wilcox AJ**, **Weinberg CR**, **Baird DD**, Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 333:1517, 1995.
753. **Trussell J**, **Ellertson C**, **Stewart F**, The effectiveness of the Yuzpe regimen of emergency contraception, Fam Plann Perspect 28:58, 1996.
754. **Trussell J**, **Rodríguez G**, **Ellertson C**, New estimates of the effectiveness of the Yuzpe regimen of emergency contraception, Contraception 57:363, 1998.
755. **Trussell J**, **Rodríguez C**, **Ellertson C**, Updated estimates of the effectiveness of the Yuzpe regimen of emergency contraception, Contraception 59: 147, 1999.
756. **Trussell J**, **Ellertson C**, **Rodriguez G**, The Yuzpe regimen of emergency contraception: how long after the morning after?, Obstet Gynecol 88:150, 1996.
757. **Rodrigues I**, **Grou F**, **Joly J**, Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse, Am J Obstet Gynecol 184:531, 2001.
758. **Piaggio G**, **von Hertzen H**, **Grimes DA**, **Van Look PFA**; **on behalf of the Task Force on Postovulatory Methods of Fertility Regulation**, Timing of emergency contraception with levonorgestrel or the Yuzpe regimen, Lancet 353:721, 1999.
759. **Vasilakis C**, **Jick SS**, **Jick H**, The risk of venous thromboembolism in users of postcoital contraceptive pills, Contraception 59:79, 1999.
760. **Webb A**, **Taberner D**, Clotting factors after emergency contraception, Adv Contracept 9:75, 1993.
761. **Ellertson C**, **Webb A**, **Blanchard K**, **Bigrigg A**, **Haskell S**, **Shochet T**, **Trussell J**, Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial, Obstet Gynecol 101:1160, 2003.
762. **Webb AMC**, **Russell J**, **Elstein M**, Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception, Br Med J 305:927, 1992.
763. **Glasier A**, **Thong KJ**, **Dewar M**, **Mackie M**, **Baird DT**, Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception, N Engl J Med 327:1041, 1992.
764. **Task Force on Postovulatory Methods of Fertility Regulation**, Comparison of three single doses of mifepristone as emergency contraception: a randomised trial, Lancet 353:697, 1999.
765. **Xiao BL**, **von Hertzen H**, **Zhao H**, **Piaggio G**, A randomized double-blind comparison of two single doses of mifepristone for emergency contraception, Hum Reprod 17:3084, 2002.
766. **Hamoda H**, **Ashok PW**, **Stalder C**, **Flett GM**, **Kennedy E**, **Templeton A**, A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception, Obstet Gynecol 104:1307, 2004.
767. **Creinin MD**, **Schlaff W**, **Archer DF**, **Wan L**, **Frezieres R**, **Thomas M**, **Rosenberg M**, **Higgins J**, Progesterone receptor modulator for emergency contraception: a randomized controlled trial, Obstet Gynecol 108:1089, 2006.
768. **Glasier AF**, **Cameron ST**, **Fine PM**, **Logan SJS**, **Casale W**, **Van Horn J**, **Sogor L**, **Blithe DL**, **Scherrer**

B, **Mathe H**, **Jaspart A**, **Ulmann A**, **Gainer E**, Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis, Lancet 375:555, 2010.

769. **Henshaw SK**, **Kost K**, Trends in the Characteristics of Women Obtaining Abortions, 1974 to 2004, Guttmacher Institute, New York, 2008.
770. **Paul C**, **Skegg DC**, **Spears GF**, Oral contraceptive use and risk of breast cancer in older women, Cancer Causes Control 6:485, 1995.
771. **Kirkman RJE**, **Pedersen JH**, **Fioretti P**, **Roberts HE**, Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age, Contraception 49:33, 1994.
772. **Fioretti P**, **Fruzzetti F**, **Navalesi R**, **Ricci C**, **Moccoli R**, **Cerri FM**, **Orlandi MC**, **Melis GB**, Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel, Contraception 35:229, 1987.
773. **Steffensen K**, Evaluation of an oral contraceptive containing 0.150 mg desogestrel and 0.020 mg ethinylestradiol in women aged 30 years or older, Acta Obstet Gynecol Scand Suppl 144:23, 1987.
774. **Melis GB**, **Fruzzetti F**, **Nicoletti I**, **Ricci C**, **Lammers P**, **Atsma WJ**, **Fioretti P**, A comparative study on the effects of a monophasic pill containing desogestrel plus 20 mg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors, Contraception 43:23, 1991.
775. **Gordon EM**, **Williams SR**, **Frenchek B**, **Mazur CH**, **Speroff L**, Dose-dependent effects of postmenopausal estrogen/progestin on antithrombin III and factor XII, J Lab Clin Med 111:52, 1988.
776. **Poulter NR**, **Chang CL**, **Farley TMM**, **Meirik O**, Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications, Lancet 354:1610, 1999.
777. **Vasilakis C**, **Jick H**, **del Mar Melero-Montes M**, Risk of idiopathic venous thromboembolism in users of progestagens alone, Lancet 354:1610, 1999.
778. **Gebbie AE**, **Glasier A**, **Sweeting V**, Incidence of ovulation in perimenopausal women before and during hormone replacement therapy, Contraception 52:221, 1995.
779. **Casper RF**, **Dodin S**, **Reid RL**; **Study Investigators**, The effect of 20 mg ethinyl estradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women, Menopause 4:139, 1997.
780. **Castracane VD**, **Gimpel T**, **Goldzieher JW**, When is it safe to switch from oral contraceptives to hormonal replacement therapy?, Contraception 52:371, 1995.
781. **Creinin MD**, Laboratory criteria for menopause in women using oral contraceptives, Fertil Steril 66:101, 1996.

Chapter twenty three

REFERENCES

1. **United Nations, Department of Economic and Social Affairs**, Trends in Contraceptive Use Worldwide, 2015.
2. **Kost K**, **Singh S**, **Vaughan B**, **Trussell J**, **Bankole A**, Estimates of contraceptive failure from the 2002 National Survey of Family Growth, Contraception 77:10, 2008.
3. **Darney PD**, **Elizabeth A**, **Tanner S**, **MacPherson S**, **Hellerstein S**, **Alvardo A**, Acceptance and perceptions of Norplant among users in San Francisco, USA, Stud Fam Plann 21:152, 1990.
4. **Hubacher D**, **Spector H**, **Monteith C**, **Chen PL**, **Hart C**, Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial, Am J Obstet Gynecol 216:101, 2017.
5. **Sivin I**, **Lähteenmäki P**, **Ranta S**, **Darney P**, **Klaisle C**, **Wan L**, **Mishell DR Jr**, **Lacarra M**, **Viegas OAC**, **Bilhareus P**, **Koetsawang S**, **Piya-Anant M**, **Diaz S**, **Pavez M**, **Alvarez F**, **Brache V**, **LaGuardia K**, **Nash H**, **Stern J**, Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants, Contraception 55:81, 1997.
6. **Sivin I**, **Alvarez F**, **Mishell DR Jr**, **Darney P**, **Wan L**, **Brache V**, **Lacarra M**, **Klaisle C**, **Stern J**, Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic, Contraception 58:275, 1998.
7. **Wan LS**, **Stiber A**, **Lam LY**, The levonorgestrel two-rod implant for long-acting contraception: 10 years of clinical experience, Obstet Gynecol 102:24, 2003.
8. **Shastri PV**, Toxicology of polymers for implant contraceptives in women, Contraception 65:9, 2002.
9. **Schnabel P**, **Merki-Feld GS**, **Malvy A**, **Duijkers I**, **Mommers E**, **van den Heuvel MW**, Bioequivalence and x-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: a 3-year, randomized, double-blind study, Clin Drug Investig 32:413, 2012.
10. **Huber J**, **Wenzl R**, Pharmacokinetics of Implanon. An integrated analysis, Contraception 58(Suppl):85S, 1998.
11. **Egberg N**, **van Beek A**, **Gunnervik C**, **Hulkko S**, **Hirvonen E**, **Larsson-Cohn U**, **Bennink HC**, Effects on the hemostatic system and liver function in relation to Implanon® and Norplant®, Contraception 58:93, 1998.
12. **Affandi B**, An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon®, Contraception 58:99S, 1998.
13. **Urbancsek J**, An integrated analysis of nonmenstrual adverse events with Implanon®, Contraception 58(Suppl):109S, 1998.
14. **Zheng S-R**, **Zheng H-M**, **Qian S-Z**, **Sang G-W**, **Kaper RF**, A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon®) and a six-capsule (Norplant®) hormonal contraceptive implant, Contraception 60:1, 1999.
15. **Haukkamaa M**, Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment, Contraception 33:559, 1986.
16. **Sivin I**, International experience with Norplant and Norplant-2 contraceptives, Stud Fam Plann 19:81, 1988.
17. **Faculty of Family Planning and Reproductive Healthcare**, Drug interactions with hormonal contraception, J Fam Plann Reprod Health Care 31:139, 2005.
18. **Mäkäräinen L**, **van Beek A**, **Tuomivaara L**, **Asplund B**, **Coelingh Bennink H**, Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant, Fertil Steril 69:714, 1998.
19. **Brache V**, **Faundes A**, **Johansson E**, **Alvarez F**, Anovulation, inadequate luteal phase, and poor sperm penetration in cervical mucus during prolonged use of Norplant implants, Contraception 31:261, 1985.
20. **Dunson TR**, **Blumenthal PD**, **Alvarez F**, **Brache V**, **Cochon L**, **Dalberth B**, **Glover L**, **Remsburg R**, **Vu K**, **Katz D**, Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus, Fertil Steril 69:258, 1998.
21. **Brache V**, **Alvarez-Sanchez F**, **Faundes A**, **Tejada AS**, **Cochon L**, Ovarian endocrine function through five years of continuous treatment with Norplant subdermal contraceptive implants, Contraception 41:169, 1990.

22. **Darney P**, **Patel A**, **Rosen K**, **Shapiro LS**, **Kaunitz AM**, Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials, Fertil Steril 91:1646, 2009.
23. **Morrell, KM**, **Cremers S**, **Westhoff CL**, **Davis AR**, Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year, Contraception 93:263, 2016.
24. **Affandi B**, **Cekan S**, **Boonkasemanti R**, **Samil RS**, **Diczfalusy E**, The interaction between sex hormone binding globulin and levonorgestrel released from Norplant, an implantable contraceptive, Contraception 35:135, 1987.
25. **Alvarez F**, **Brache V**, **Tejada AS**, **Faundes A**, Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use, Contraception 33:111, 1986.
26. **Croxatto HB**, **Mäkäräinen L**, The pharmacodynamics and efficacy of Implanon®, Contraception 58:91S, 1998.
27. **Croxatto HB**, **Diaz S**, **Salvatierra AM**, **Morales P**, **Ebensperger C**, **Brandeis A**, Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro, Contraception 36:193, 1987.
28. **Croxatto HB**, Mechanisms that explain the contraceptive action of progestin implants for women, Contraception 65:21, 2002.
29. **Segal SJ**, **Alvarez-Sanchez F**, **Brache V**, **Faundes A**, **Vilja P**, **Tuohimaa P**, Norplant implants: the mechanism of contraceptive action, Fertil Steril 56:273, 1991.
30. **Shaaban MM**, **Salem HT**, **Abdullah KA**, Influence of levonorgestrel contraceptive implants, Norplant, initiated early postpartum, upon lactation and infant growth, Contraception 32:623, 1985.
31. **Diaz S**, **Herreros C**, **Juez G**, **Casado ME**, **Salvatierra AM**, **Miranda P**, **Peralta O**, **Croxatto HB**, Fertility regulation in nursing women: influence of Norplant levonorgestrel implants upon lactation and infant growth, Contraception 32:53, 1985.
32. **Braga GC**, **Ferriolli E**, **Quintana SM**, **Ferriani RA**, **Pfrimer K**, **Vieira CS**, Immediate postpartum initiation of etonogestrel-releasing implant: a randomized controlled trial on breastfeeding impact, Contraception 92:536, 2015.
33. **Brito MB**, **Ferriani RA**, **Quintana SM**, **Yazlle MEH**, **Silva de Sá MF**, **Vieira CS**, Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study, Contraception 80:519, 2009.
34. **Sivin I**, **Stern J**, **Diaz S**, **Pavez M**, **Alvarez F**, **Brache V**, **Mishell DR Jr**, **Lacarra M**, **McCarthy T**, **Holma P**, **Darney P**, **Klaisle C**, **Olsson S-E**, **Odlind V**, Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices, Am J Obstet Gynecol 166:1208, 1992.
35. **Diaz S**, **Pavez M**, **Cardenas H**, **Croxatto HB**, Recovery of fertility and outcome of planned pregnancies after the removal of Norplant subdermal implants or copper-T IUDs, Contraception 35:569, 1987.
36. **Croxatto HB**, Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant, Eur J Contracept Reprod Health Care 5(Suppl 2):21, 2000.
37. **Lockhat FB**, **Emembolu JO**, **Konje JC**, The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease, Hum Reprod 19:179, 2004.
38. **Bahamondes L**, **Petta CA**, **Fernandes A**, **Monteiro I**, Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea, Contraception 75:S134, 2007.
39. **Vercellini P**, **Frontino G**, **De Giorgi O**, **Aimi G**, **Zaina B**, **Crosignani PG**, Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study, Fertil Steril 80:305, 2003.
40. **Crosignani PG**, **Luciano A**, **Ray A**, **Bergqvist A**, Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain, Hum Reprod 21:248, 2006.
41. **Walch K**, **Unfried G**, **Huber J**, **Kurz C**, **van Trotsenburg M**, **Pernicka E**, **Wenzl R**, Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis—a pilot study, Contraception 79:29, 2009.

42. **Dunson TR**, **Amatya RN**, **Krueger SL**, Complications and risk factors associated with the removal of Norplant implants, Obstet Gynecol 85:543, 1995.
43. **Brache V**, **Faundes A**, **Alvarez F**, **Cochon L**, Non-menstrual adverse events during use of implantable contraceptives for women: data from clinical trials, Contraception 65:63, 2002.
44. **Darney PD**, **Callegari LS**, **Swift A**, **Atkinson ES**, **Robert AM**, Condom practices of urban teens using Norplant contraceptive implants, oral contraceptives, and condoms for contraception, Am J Obstet Gynecol 180:929, 1999.
45. **Lipetz C**, **Phillips CJ**, **Fleming CF**, The cost-effectiveness of a long-acting reversible contraceptive (Implanon) relative to oral contraception in a community setting, Contraception 79:304, 2009.
46. **Crespi S**, **Kerrigan M**, **Sood V**, Budget impact analysis of 8 hormonal contraceptive options, Am J Manag Care 19:e249, 2013.
47. **Trussell J**, **Hassan F**, **Lowin J**, **Law A**, **Filonenko A**, Achieving cost-neutrality with long-acting reversible contraceptive methods, Contraception 91:49, 2015.
48. **Berenson AB**, **Wiemann CM**, **Rickerr VI**, **McCombs SL**, Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of use, Am J Obstet Gynecol 176:586, 1997.
49. **Zibners A**, **Cromer BA**, **Hayes J**, Comparison of continuation rates for hormonal contraception among adolescents, J Pediatr Adolesc Gynecol 12:90, 1999.
50. **Diedrich JT**, **Klein DA**, **Peipert JF**, Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Obstet Gynecol 216:364, 2017.
51. **Affandi B**, **Korver T**, **Geurts TB**, **Coelingh Bennink JH**, A pilot efficacy study with a single-rod contraceptive implant (Implanon) in 200 Indonesian women treated for < or = 4 years, Contraception 59:167, 1999.
52. **Croxatto HB**, **Urbancsek J**, **Massai R**, **Coelingh Bennink H**, **van Beek A**, A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group, Hum Reprod 14:976, 1999.
53. **Harrison-Woolrych M**, **Hill R**, Unintended pregnancies with the etonogestrel implant (Implanon): a case series from post-marketing experience in Australia, Contraception 71:306, 2005.
54. **Brache V**, **Blumenthal PD**, **Alvarez F**, **Dunson TR**, **Cochon L**, **Faundes A**, Timing of onset of contraceptive effectiveness in Norplant® implant users. II. Effect on the ovarian function in the first cycle of use, Contraception 59:245, 1999.
55. **Callahan R**, **Yacobson I**, **Halpern V**, **Nanda K**, Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: a systematic review, Contraception 92:514, 2015.
56. **Sivin I**, **Alvarez-Sanchez F**, **Diaz S**, **Holma P**, **Coutinho E**, **McDonald O**, **Robertson DN**, **Stern J**, Three-year experience with Norplant subdermal contraception, Fertil Steril 39:799, 1983.
57. **Shoupe D**, **Mishell DR Jr**, **Bopp B**, **Fiedling M**, The significance of bleeding patterns in Norplant implant users, Obstet Gynecol 77:256, 1991.
58. **Sivin I**, **Diaz S**, **Holma P**, **Alvarez-Sanchez F**, **Robertson DN**, A four-year clinical study of Norplant implants, Stud Fam Plann 14:184, 1983.
59. **Pasquale SA**, **Knuppel RA**, **Owens AG**, **Bachmann GA**, Irregular bleeding, body mass index and coital frequency in Norplant contraceptive users, Contraception 50:109, 1994.
60. **Runic R**, **Schatz F**, **Krey L**, **Demopoulos R**, **Thung S**, **Wan L**, **Lockwood CJ**, Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception, J Clin Endocrinol Metab 82:1983, 1997.
61. **Hickey M**, **Simbar M**, **Young L**, **Markham R**, **Russell P**, **Fraser IS**, A longitudinal study of changes in endometrial microvascular density in Norplant® implant users, Contraception 59:123, 1999.
62. **Nilsson C**, **Holma P**, Menstrual blood loss with contraceptive subdermal levonorgestrel implants, Fertil Steril 35:304, 1981.
63. **Fakeye O**, **Balogh S**, Effect of Norplant contraceptive use on hemoglobin, packed cell volume, and menstrual bleeding patterns, Contraception 39:265, 1989.
64. **Fraser IS**, **Weisberg E**, **Minehan E**, **Johansson ED**, A detailed analysis of menstrual blood loss in women

using Norplant® and Nestorone® progestin-only contraceptive implants or vaginal rings, Contraception 61:241, 2000.

65. **International Collaborative Post-Marketing Surveillance of Norplant**, Post-marketing surveillance of Norplant® contraceptive implants: I. Contraceptive efficacy and reproductive health, Contraception 63:167, 2001.
66. **Abdel-Aleem H**, **d'Arcangues C**, **Vogelsong KK**, **Gülmezoglu AM**, Treatment of vaginal bleeding irregularities induced by progestin only contraceptives, Cochrane Database Syst Rev (4):CD003449, 2007. doi:10.1002/14651858.CD003449.pub3.
67. **Alvarez-Sanchez F**, **Brache V**, **Thevenin F**, **Cochon L**, **Faundes A**, Hormonal treatment for bleeding irregularities in Norplant implant users, Am J Obstet Gynecol 174:919, 1996.
68. **Shaaban MM**, **Elwan SI**, **El-Sharkawy MM**, **Farghaly AS**, Effect of subdermal levonorgestrel contraceptive implants, Norplant, on liver functions, Contraception 30:407, 1984.
69. **Singh K**, **Viegas OAC**, **Liew D**, **Singh P**, **Ratnam SS**, Two-year follow-up of changes in clinical chemistry in Singaporean Norplant acceptors: metabolic changes, Contraception 39:129, 1989.
70. **Shaaban MM**, **Elwan SI**, **El-Kabsh MY**, **Farghaly SA**, **Thabet N**, Effect of levonorgestrel contraceptive implants, Norplant, on bleeding and coagulation, Contraception 30:421, 1984.
71. **Singh K**, **Viegas OAC**, **Koh SCL**, **Ratnam SS**, Effect of long-term use of Norplant implants on haemostatic function, Contraception 45:203, 1992.
72. **Viegas OAC**, **Koh SLC**, **Ratnam SS**, The effects of reformulated 2-rod Norplant implant on haemostasis after three years, Contraception 54:219, 1996.
73. **Croxatto HB**, **Diaz S**, **Robertson D**, **Pavez M**, Clinical chemistries in women treated with levonorgestrel implant (Norplant) or a TCu 200 IUD, Contraception 27:281, 1983.
74. **Abdulla K**, **Elwan SI**, **Salem HS**, **Shaaban MM**, Effect of early postpartum use of the contraceptive implants, Norplant, on the serum levels of immunoglobulin of the mothers and their breastfed infants, Contraception 32:261, 1985.
75. **Bayad M**, **Ibrahim I**, **Fayad M**, **Hassanein AA**, **Hafez ES**, **Abdalla MI**, Serum cortisol in women users of subdermal levonorgestrel implants, Contracept Deliv Syst 4:133, 1983.
76. **Roy S**, **Mishell DR Jr**, **Robertson D**, **Krauss RM**, **Lacarra M**, **Duda MJ**, Long-term reversible contraception with levonorgestrel-releasing Silastic rods, Am J Obstet Gynecol 148:1006, 1984.
77. **Otubu JAM**, **Towobola OA**, **Aisien AO**, **Ogunkeye OO**, Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins, Contraception 47:149, 1993.
78. **Konje JC**, **Otolorin EO**, **Ladipo OA**, Changes in carbohydrate metabolism during 30 months on Norplant, Contraception 44:163, 1991.
79. **Koopersmith TB**, **Lobo RA**, Insulin sensitivity is unaltered by the use of the Norplant subdermal implant contraceptive, Contraception 51:197, 1995.
80. **Harper MA**, **Meis PJ**, **Steele L**, A prospective study of insulin sensitivity and glucose metabolism in women using a continuous subdermal levonorgestrel implant system, J Soc Gynecol Investig 4:86, 1997.
81. **Meirik O**, **Farley TMM**, **Sivin I**; **International Collaborative Post-Marketing Surveillance of Norplant**, Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization, Am J Obstet Gynecol 97:539, 2001.
82. **International Collaborative Post-Marketing Surveillance of Norplant**, Post-marketing surveillance of Norplant® contraceptive implants: II. Non-reproductive health, Contraception 63:187, 2001.
83. **Suherman SK**, **Affandi B**, **Korver T**, The effects of Implanon on lipid metabolism in comparison with Norplant, Contraception 60:281, 1999.
84. **Oderich CL**, **Wender MC**, **Lubianca JN**, **Santos LM**, **de Mello GC**, Impact of etonogestrel-releasing implant and copper intrauterine device on carbohydrate metabolism: a comparative study, Contraception 85:173, 2012.
85. **Villas-Boas J**, **Vilodre LC**, **Malerba H**, **Salcedo MP**, **Jimenez MF**, **El Beitune P**, Metabolic safety of the etonogestrel contraceptive implant in healthy women over a 3-year period, Eur J Obstet Gynecol Reprod Biol 202:51, 2016.

86. **Bender NM**, **Segall-Gutierrez P**, **Lopez Najera SO**, **Stanczyk FZ**, **Montoro M**, **Mishell DR**, Effects of progestin-only long-acting contraception on metabolic markers in obese women, Contraception 88:418, 2013.
87. **Biswas A**, **Viegas OA**, **Bennink HJ**, **Korver T**, **Ratnam SS**, Effect of Implanon use on selected parameters of thyroid and adrenal function, Contraception 62:247, 2000.
88. **Cromer BA**, **Blair JM**, **Mahan JD**, **Zibners L**, **Naumovski Z**, A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives, J Pediatr 129:671, 1996.
89. **Beerthuizen R**, **van Beek A**, **Massai R**, **Mäkäräinen L**, **Hout J**, **Bennink HJ**, Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception, Hum Reprod 15:118, 2000.
90. **Naessen T**, **Olsson SE**, **Gudmundson J**, Differential effects on bone density of progestogen-only methods for contraception in premenopausal women, Contraception 52:35, 1995.
91. **Di X**, **Li Y**, **Zhang C**, **Jiang J**, **Gu S**, Effects of levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism, Contraception 60:161, 1999.
92. **Petitti DB**, **Piaggio G**, **Mehta S**, **Cravioto MC**, **Meirik O**; **WHO Study of Hormonal Contraception and Bone Health**, Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population, Obstet Gynecol 95:736, 2000.
93. **Westhoff C**, **Truman C**, **Kalmuss D**, **Cushman L**, **Rulin M**, **Heartwell S**, **Davidson A**, Depressive symptoms and Norplant® contraceptive implants, Contraception 57:241, 1998.
94. **Wysowski DK**, **Green L**, Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System, Obstet Gynecol 85:538, 1995.
95. **Fraser IS**, **Tiitinen A**, **Affandi B**, **Brache V**, **Croxatto HB**, **Diaz S**, **Ginsburg J**, **Gu S**, **Holma P**, **Johansson E**, **Meirik O**, **Mishell DR Jr**, **Nash HA**, **von Schoultz B**, **Sivin I**, Norplant® consensus statement and background review, Contraception 57:1, 1998.
96. **Lopez LM**, **Ramesh S**, **Chen M**, **Edelman A**, **Otterness C**, **Trussell J**, **Helmerhorst FM**, Progestin-only contraceptives: effects on weight, Cochrane Database Syst Rev (8):CD008815, 2016. doi:10.1002/14651858.CD008815.pub4.
97. **Faundes A**, **Brache V**, **Tejada AS**, **Cochon L**, **Alvarez-Sanchez F**, Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants, Fertil Steril 56:27, 1991.
98. **Darney PD**, **Taylor RN**, **Klaisle C**, **Bottles K**, **Zaloudek C**, Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant implant users, Contraception 53:97, 1996.
99. **Strom BL**, **Berlin JA**, **Weber AL**, **Norman SA**, **Bernstein L**, **Burkman RT**, **Daling JR**, **Deapen D**, **Folger SG**, **Malone KE**, **Marchbanks PA**, **Simon MS**, **Ursin G**, **Weiss LK**, **Spirtas R**, Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer, Contraception 69:353, 2004.
100. **Phemister DA**, **Lauarent S**, **Harrison FNH Jr**, Use of Norplant contraceptive implants in the immediate postpartum period: safety and tolerance, Am J Obstet Gynecol 172:175, 1995.
101. **Darney PD**, **Klaisle CM**, **Tanner S**, **Alvarado AM**, Sustained-release contraceptives, Curr Probl Obstet Gynecol Fertil 13:95, 1990.
102. **Zimmerman M**, **Haffey J**, **Crane E**, **Szumowski D**, **Alvarez F**, **Bhiromrut P**, **Brache V**, **Lubis F**, **Salah M**, **Shaaban MM**, **Shawly B**, **Sidiip S**, Assessing the acceptability of Norplant implants in four countries: findings from focus group research, Stud Fam Plann 21:92, 1990.
103. **Mascarenhas L**, Insertion and removal of Implanon: practical considerations, Eur J Contracept Reprod Health Care 5(Suppl 2):29, 2000.
104. **Lantz A**, **Nosher JL**, **Pasquale S**, **Siegel RL**, Ultrasound characteristics of subdermally implanted Implanon contraceptive rods, Contraception 56:323, 1997.
105. **Zieman M**, **Klaisle C**, **Walker D**, **Bahisteri E**, **Darney P**, Fingers versus instruments for removing levonorgestrel contraceptive implants (Norplant), J Gynecol Tech 3:213, 1997.
106. **Bromham DR**, **Davey A**, **Gaffikin L**, **Ajello CA**, Materials, methods and results of the Norplant training

program, Br J Fam Plann 10:256, 1995.
107. **Creinin MD**, **Kaunitz AM**, **Darney PD**, **Schwartz L**, **Hampton T**, **Gordon K**, **Rekers H**, The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience, Contraception 95:205, 2017.
108. **Levine JP**, **Sinofsky FE**, **Christ MF**, Assessment of Implanon insertion and removal, Contraception 78:409, 2008.
109. **Nelson AL**, Neutralizing pH of lidocaine reduces pain during Norplant system insertion procedures, Contraception 51:299, 1995.
110. **Ismail H**, **Mansour D**, **Singh M**, Migration of Implanon, J Fam Plann Reprod Health Care 32:157, 2006.
111. **Klavon SL**, **Grubb G**, Insertion site complications during the first year of Norplant use, Contraception 41:27, 1990.
112. **Blain S**, **Oloto E**, **Meyrick I**, **Bromham D**, Skin reactions following Norplant® insertion and removal—possible causative factors, Br J Fam Plann 21:130, 1996.
113. **Darney PD**, **Klaisle CM**, **Walker DM**, The pop-out method of Norplant removal, Adv Contracept 8:188, 1992.
114. **Glauser SJ**, **Scharling ES**, **Stovall TG**, **Zagoria RJ**, Ultrasonography: usefulness in localization of the Norplant contraceptive implant system, J Ultrasound Med 14:411, 1995.
115. **Diedrich JT**, **Zhao Q**, **Madden T**, **Secura GM**, **Peipert JF**, Three-year continuation of reversible contraception, Am J Obstet Gynecol 215:662, 2015.
116. **Abraham M**, **Zhao Q**, **Peipert JF**, Young age, nulliparity, and continuation of long-acting reversible contraceptive methods, Obstet Gynecol 126:823, 2015.
117. **Smith A**, **Reuter S**, An assessment of the use of Implanon in three community services, J Fam Plann Reprod Health Care 28:193, 2002.
118. **Gu S**, **Sivin I**, **Du M**, **Zhang L**, **Ying-Lin L**, **Meng F**, **Wu S**, **Wang P**, **Gao Y**, **He X**, **Qi L**, **Chen C**, **Liu Y**, **Wang D**, Effectiveness of Norplant implants through seven years: a large-scale study in China, Contraception 52:99, 1995.
119. **Reuter S**, **Smith A**, Implanon: user views in the first year across three family planning services in the Trent Region, UK, Eur J Contracept Reprod Health Care 8:27, 2003.
120. **Dugoff L**, **Jones OW III**, **Allen-Davis J**, **Hurst BS**, **Schlaff WD**, Assessing the acceptability of Norplant contraceptive in four patient populations, Contraception 52:45, 1995.
121. **Cromer BA**, **Smith RD**, **Blair JM**, **Dwyer J**, **Brown RT**, A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception, Pediatrics 94:687, 1994.
122. **Cullins VE**, **Remsburg RE**, **Blumenthal PD**, **Huggins GR**, Comparison of adolescent and adult experience with Norplant levonorgestrel contraceptive implants, Obstet Gynecol 83:1026, 1994.
123. **Polaneczky M**, **Slap G**, **Forke C**, **Rappaport A**, **Sondheimer S**, The use of levonorgestrel implants (Norplant) for contraception in adolescent mothers, N Engl J Med 331:1201, 1994.
124. **Berenson AB**, **Wiemann CM**, Use of levonorgestrel implants versus oral contraceptives in adolescence: a case-control study, Am J Obstet Gynecol 172:1128, 1995.
125. **Coutinho EM**, One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant), Contraception 47:94, 1993.
126. **Haukkamaa M**, **Laurikka-Routti M**, **Heikinheimo O**, **Moo-Young A**, Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study, Contraception 45:49, 1992.
127. **Diaz S**, **Schiappacasse V**, **Pavez M**, **Zepeda A**, **Moo-Young AJ**, **Brandeis A**, **Lahteenmaki P**, **Croxatto HB**, Clinical trial with Nestorone subdermal contraceptive implants, Contraception 51:33, 1995.
128. **Rosenfield A**, **Maine D**, **Rochat R**, **Shelton J**, **Hatcher R**, The Food and Drug Administration and medroxyprogesterone acetate: what are the issues? JAMA 249:2922, 1983.
129. **WHO**, A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: I. Contraceptive efficacy and side effects, Contraception 34:223, 1986.
130. **WHO**, Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids:

norethisterone enanthate and medroxyprogesterone acetate. Final report, Contraception 28:1, 1983.
131. **Jain J**, **Dutton C**, **Nicosia A**, **Wajszeczuk C**, **Bode FR**, **Mishell DR Jr**, Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera, Contraception 70:11, 2004.
132. **Jain J**, **Jakimiuk AJ**, **Bode FR**, **Ross D**, **Kaunitz AM**, Contraceptive efficacy and safety of DMPA-SC, Contraception 70:269, 2004.
133. **Kaunitz AM**, **Darney PD**, **Ross D**, **Wolter KD**, **Speroff L**, Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density, Contraception 80:7, 2009.
134. **Mishell DR Jr**, Effect of 6 methyl-17-hydroxyprogesterone on urinary excretion of luteinizing hormone, Am J Obstet Gynecol 99:86, 1967.
135. **Fraser IS**, **Weisberg EA**, A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate, Med J Aust 1(Suppl):3, 1981.
136. **Pardthaisong T**, **Gray RH**, In utero exposure to steroid contraceptives and outcome of pregnancy, Am J Epidemiol 134:795, 1991.
137. **Gray RH**, **Pardthaisong T**, In utero exposure to steroid contraceptives and survival during infancy, Am J Epidemiol 134:804, 1991.
138. **Siriwongse T**, **Snidvonga W**, **Tantayaporn P**, **Leepipalboon S**, Effect of depot-medroxyprogesterone acetate on serum progesterone levels, when administered on various cycle days, Contraception 26:487, 1982.
139. **Petta C**, **Faúndes A**, **Dunson TR**, **Ramos M**, **DeLucio M**, **Faúndes D**, **Bahamondes L**, Timing of onset of contraceptive effectiveness in Depo-Provera users. I. Changes in cervical mucus, Fertil Steril 69:252, 1998.
140. **Petta CA**, **Faúndes A**, **Dunson TR**, **Ramos M**, **DeLucio M**, **Faúndes D**, **Bahamondes L**, Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function, Fertil Steril 70:817, 1998.
141. **Nelson AL**, **Katz T**, Initiation and continuation rates seen in 2-year experience with Same Day injections of DMPA, Contraception 75:84, 2007.
142. **Rickert VI**, **Tiezzi L**, **Lipshutz J**, **León J**, **Vaughan RD**, **Westhoff C**, Depo Now: preventing unintended pregnancies among adolescents and young adults, J Adolesc Health 40:22, 2007.
143. **Steiner MJ**, **Kwok C**, **Stanback J**, **Byamugisha JK**, **Chipato T**, **Magwali T**, **Mmiro F**, **Rugpao S**, **Sriplienchan S**, **Morrison C**, Injectable contraception: what should the longest interval be for reinjections? Contraception 77:410, 2008.
144. **Harlap S**, **Kost K**, **Forrest JD**, Preventing Pregnancy, Protecting Health: A New Look at Birth Control Choices in the United States, The Alan Guttmacher Institute, New York, 1991.
145. **Darney P**, **Jain J**, **Jakimiuk AJ**, Zero pregnancies with new low dose depot medroxyprogesterone acetate subcutaneous injection for contraception (abstract), Fertil Steril 82:S105, 2004.
146. **O'Dell CM**, **Forke CM**, **Polaneczky MM**, **Sondheimer SJ**, **Slap GB**, Depot medroxyprogesterone acetate or oral contraception in postpartum adolescents, Obstet Gynecol 91:609, 1998.
147. **Polaneczky M**, **Guarnaccia M**, **Alon J**, **Wiley J**, Early experience with the contraceptive use of depot-medroxyprogesterone acetate in an inner-city population, Fam Plann Perspect 28:174, 1996.
148. **Tepper NK**, **Whiteman MK**, **Marchbanks PA**, **James AH**, **Curtis KM**, Progestin-only contraception and thromboembolism: a systematic review, Contraception 94:678, 2016.
149. **World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception**, Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study, Contraception 57:315, 1998.
150. **Poulter NR**, **Chang CL**, **Farley TMM**, **Meirik O**, Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications, Lancet 354:1610, 1999.
151. **Vasilakis C**, **Jick H**, **del Mar Melero-Montes M**, Risk of idiopathic venous thromboembolism in users of progestagens alone, Lancet 354:1610, 1999.
152. **DeCeular K**, **Gruber C**, **Hayes R**, **Serjeant GR**, Medroxyprogesterone acetate and homozygous sickle-cell disease, Lancet ii:229, 1982.
153. **de Abood M**, **de Castillo Z**, **Guerrero F**, **Espino M**, **Austin KL**, Effect of Depo-Provera® or

Microgynon® on the painful crises of sickle-cell anemia patients, Contraception 56:313, 1997.
154. **Jimenez J**, **Ochoa M**, **Soler MP**, **Portales P**, Long-term follow-up of children breast-fed by mothers receiving depot-medroxyprogesterone acetate, Contraception 30:523, 1984.
155. **Zacharias S**, **Aguilena J**, **Assanzo JR**, **Zanatu J**, Effects of hormonal and non-hormonal contraceptives on lactation and incidence of pregnancy, Contraception 33:203, 1986.
156. **Pardthaisong T**, **Yenchit C**, **Gray R**, The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation, Contraception 45:313, 1992.
157. **Virutamasen P**, **Leepipatpaiboon S**, **Kriengsinyot R**, **Vichaidith P**, **Muia PN**, **Sekadde-Kigondu CB**, **Mati JKG**, **Forest MG**, **Dikkeschei LD**, **Wolthers BG**, **d'Arcangues C**, Pharmacodynamic effects of depot-medroxyprogesterone acetate (DMPA) administered to lactating women on their male infants, Contraception 54:153, 1996.
158. **Halderman LD**, **Nelson AL**, Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns, Am J Obstet Gynecol 186: 1250, 2002.
159. **Xiang AH**, **Kawakubo M**, **Kjos SL**, **Buchanan TA**, Long-acting injectable progestin contraception and risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus, Diabetes Care 29:613, 2006.
160. **Mattson RH**, **Cramer JA**, **Caldwell BV**, **Siconolfi BC**, Treatment of seizures with medroxyprogesterone acetate: preliminary report, Neurology 34:1255, 1984.
161. **Sönmezer M**, **Atabekoglu C**, **Cengiz B**, **Dökmeci F**, **Cengiz SD**, Depot-medroxyprogesterone acetate in anticoagulated patients with previous hemorrhagic corpus luteum, Eur J Contracept Reprod Health Care 10:9, 2005.
162. **WHO Collaborative Study of Neoplasia and Steroid Contraceptives**, Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer, Int J Cancer 49:186, 1991.
163. **Wilailak S**, **Vipupinyo C**, **Suraseranivong V**, **Chotivanich K**, **Kietpeerakool C**, et al, Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicenter case-control study, Br J Obstet Gynaecol 119:672, 2012.
164. **WHO Collaborative Study of Neoplasia and Steroid Contraceptives**, Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer, Int J Cancer 49:191, 1991.
165. **Lumbiganon P**, **Rugpao S**, **Phandhu-fung S**, **Laopaiboon M**, **Vudhikamraksa N**, **Werawatkul Y**, Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study, Br J Obstet Gynaecol 103:909, 1996.
166. **Gray RH**, Reduced risk of pelvic inflammatory disease with injectable contraceptives, Lancet i:1046, 1985.
167. **Gardner JM**, **Mishell DR Jr**, Analysis of bleeding patterns and resumption of fertility following discontinuation of a long-acting injectable contraceptive, Fertil Steril 21:286, 1970.
168. **Arias RD**, **Jain JK**, **Brucker C**, **Ross D**, **Ray A**, Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg, Contraception 74:234, 2006.
169. **Harel Z**, **Biro FM**, **Kollar LM**, Depo-Provera in adolescents: effects of early second injection or prior oral contraception, J Adolesc Health 16:379, 1995.
170. **Goldberg AB**, **Cardenas LH**, **Hubbard AE**, **Darney PD**, Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol, Contraception 66:215, 2002.
171. **Thurman AR**, **Livengood CH**, **Soper DE**, Chronic endometritis in DMPA users and Chlamydia trachomatis endometritis, Contraception 76:49, 2007.
172. **Westhoff C**, **Wieland D**, **Tiezzi L**, Depression in users of depot-medroxyprogesterone acetate, Contraception 51:351, 1995.
173. **Westhoff C**, **Truman C**, **Kalmuss D**, **Cushman L**, **Davidson A**, **Rulin M**, **Heartwell S**, Depressive symptoms and Depo-Provera, Contraception 57:237, 1998.
174. **Gupta N**, **O'Brien R**, **Jacobsen LJ**, **Davis A**, **Zuckerman A**, **Supran S**, **Kulig J**, Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: a prospective study, J Pediatr Adolesc Gynecol 14:71, 2001.
175. **Singata-Madliki M**, **Hofmeyr GJ**, **Lawrie TA**, The effect of depot medroxyprogesterone acetate on

postnatal depression: a randomized controlled trial, J Fam Plann Reprod Health Care 42:171, 2016.
176. **Moore LL**, **Valuck R**, **McDougall C**, **Fink W**, A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives, Contraception 52:215, 1995.
177. **Mainwaring R**, **Hales HA**, **Stevenson K**, **Hatasaka HH**, **Poulson AM**, **Jones KP**, **Peterson CM**, Metabolic parameters, bleeding, and weight changes in U.S. women using progestin only contraceptives, Contraception 51:149, 1995.
178. **Taneepanichskul S**, **Reinprayoon D**, **Khaosaad P**, Comparative study of weight change between long-term DMPA and IUD acceptors, Contraception 58:149, 1998.
179. **Bahamondes L**, **Del Castillo S**, **Tabares G**, **Arce XE**, **Perrotti M**, **Petta C**, Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years, Contraception 64:223, 2001.
180. **Berenson AB**, **Rahman M**, Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use, Am J Obstet Gynecol 200:329.e1, 2009.
181. **Westhoff C**, **Jain JK**, **Milsom I**, **Ray A**, Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104mg/0.65 mL, Contraception 75:261, 2007.
182. **Bonny AE**, **Ziegler J**, **Harvey R**, **Debanne SM**, **Secic M**, **Cromer BA**, Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method, Arch Pediatr Adolesc Med 160:40, 2006.
183. **Beksinska ME**, **Smit JA**, **Keleinschmidt I**, **Milford C**, **Farley T**, Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception, Contraception 81:30, 2010.
184. **Espey E**, **Steinhart J**, **Ogburn T**, **Qualls C**, Depo-provera associated with weight gain in Navajo women, Contraception 62:55, 2000.
185. **Kim C**, **Seidel KW**, **Begier EA**, **Kwok YS**, Diabetes and depot medroxyprogesterone contraception in Navajo women, Arch Intern Med 161:1766, 2001.
186. **Le Y-CL**, **Rahman M**, **Berenson AB**, Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users, Obstet Gynecol 114:279, 2009.
187. **Jacobson DL**, **Peralta L**, **Farmer M**, **Graham NM**, **Gaydos C**, **Zenilman J**, Relationship of hormonal contraception and cervical ectopy as measured by computerized planimetry to chlamydial infection in adolescents, Sex Transm Dis 27:313, 2000.
188. **Baeten JM**, **Nyange PM**, **Richardson BA**, **Lavreys L**, **Chohan B**, **Martin HL**, **Mandaliya K**, **Nidinya-Achola JO**, **Bwayo JJ**, **Kreiss JK**, Hormonal contraception and risk of sexually transmitted disease acquisition: results form a prospective study, Am J Obstet Gynecol 185:380, 2001.
189. **Morrison CS**, **Bright P**, **Wong EL**, **Kwok C**, **Yacobson I**, **Gaydos CA**, **Tucker HT**, **Blumenthal PD**, Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections, Sex Transm Dis 31:561, 2004.
190. **Pettifor A**, **Delany S**, **Kleinschmidt I**, **Miller WC**, **Atashili J**, **Rees H**, Use of injectable progestin contraception and risk of STI among South African women, Contraception 80:555, 2009.
191. **Kleinschmidt I**, **Rees H**, **Delany S**, **Smith D**, **Dinat N**, **Nkala B**, **McIntyre JA**, Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort, Contraception 75:461, 2007.
192. **Myer L**, **Denny L**, **Wright TC**, **Kuhn L**, Prospective study of hormonal contraception and women's risk of HIV infection in South Africa, Int J Epidemiol 36:166, 2007.
193. **Brooks G**, Anaphylactoid shock with medroxyprogesterone acetate: a case report, J La State Med Soc 126:397, 1974.
194. **Rajapaksa DS**, Anaphylaxis to Depo-Provera?, Ceylon Med J 38:158, 1993.
195. **Selo-Ojeme DO**, **Tillisi A**, **Welch CC**, Anaphylaxis from medroxyprogesterone acetate, Obstet Gynecol 103:1045, 2004.
196. **Lestishock L**, **Pariseau C**, **Rooholamini S**, **Ammerman S**, Anaphylaxis from depot medroxyprogesterone acetate in an adolescent girl, Obstet Gynecol 118:443, 2011.

197. **WHO Collaborative Study of Neoplasia and Steroid Contraceptives**, Breast cancer and depot-medroxyprogesterone acetate: a multinational study, Lancet 338:833, 1991.
198. **Lee NC**, **Rosero-Bixby L**, **Oberle MW**, **Grimaldo C**, **Whatley AS**, **Rovira EZ**, A case-control study of breast cancer and hormonal contraception in Costa Rica, J Natl Cancer Inst 79:1247, 1987.
199. **Paul C**, **Skegg DCG**, **Spears GFS**, Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer, Br Med J 299:7591, 1989.
200. **Skegg DCG**, **Noonan EA**, **Paul C**, **Spears GFS**, **Meirik O**, **Thomas DB**, Depot medroxyprogesterone acetate and breast cancer: a pooled analysis of the World Health Organization and the New Zealand studies, JAMA 273:799, 1995.
201. **Shapiro S**, **Rosenberg L**, **Hoffman M**, **Truter H**, **Cooper D**, **Rao S**, **Dent D**, **Gudgeon A**, **van Zyl J**, **Katzenellenbogen J**, **Bailie R**, Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives, Am J Epidemiol 151:396, 2000.
202. **The New Zealand Contraception and Health Study Group**, History of long-term use of depot-medroxyprogesterone acetate in patients with cervical dysplasia; case-control analysis nested in a cohort study, Contraception 50:443, 1994.
203. **Thomas DB**, **Ray RM**; **WHO Collaborative Study of Neoplasia and Steroid Contraceptives**, Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix, Contraception 52:307, 1995.
204. **WHO Collaborative Study of Neoplasia and Steroid Contraception**, Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer, Contraception 45:299, 1992.
205. **Thomas DB**, **Ye Z**, **Ray RM**; **WHO Collaborative Study of Neoplasia and Steroid Contraception**, Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA), Contraception 51:25, 1995.
206. **Valente PT**, **Schantz HD**, **Trabal JF**, Cytologic changes in cervical smears associated with prolonged use of depot-medroxyprogesterone acetate, Cancer 84:328, 1998.
207. **WHO**, Depo-medroxyprogesterone acetate (DMPA) and cancer; memorandum from a WHO meeting, Bull World Health Organ 64:375, 1986.
208. **Garza-Fores J**, **De la Cruz DL**, **Valles de Bourges V**, **Sanchez-Nuncio R**, **Martinez M**, **Fuziwara JL**, **Perez-Palacios G**, Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism, Contraception 44:61, 1991.
209. **Enk L**, **Landgren BM**, **Lindberg U-B**, **Silverstolpe G**, **Crona N**, A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone enanthate) on serum and lipoprotein lipids, Horm Metab Res 24:85, 1992.
210. **Berenson AB**, **Rahman M**, **Wilkinson G**, Effect of injectable and oral contraceptives on serum lipids, Obstet Gynecol 114:786, 2009.
211. **WHO**, A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users, Contraception 47:177, 1993.
212. **Fahmy K**, **Khairy M**, **Allam G**, **Gobran F**, **Allush M**, Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women, Contraception 44:431, 1991.
213. **Fahmy K**, **Abdel-Razik M**, **Shaaraway M**, **Al-Kholy G**, **Saad S**, **Wagdi A**, **Al-Azzony M**, Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile, Contraception 44:419, 1991.
214. **Cromer VA**, **Lazebnik R**, **Rome E**, **Stager M**, **Bonny AE**, **Ziegler J**, **Debanne SM**, Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception, Am J Obstet Gynecol 192:42, 2005.
215. **Cundy T**, **Evans M**, **Roberts H**, **Wattie D**, **Ames R**, **Reid IR**, Bone density in women receiving depot medroxyprogesterone acetate for contraception, Br Med J 303:13, 1991.
216. **Cundy T**, **Cornish J**, **Roberts H**, **Elder H**, **Reid IR**, Spinal bone density in women using depot medroxyprogesterone contraception, Obstet Gynecol 92:569, 1998.
217. **Berenson AB**, **Breitkopf CR**, **Grady JJ**, **Rickert VI**, **Thomas A**, Effects of hormonal contraception on bone mineral density after 24 months of use, Obstet Gynecol 103:899, 2004.

218. **Clark MK**, **Sowers MR**, **Nichols S**, **Levy B**, Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate, Fertil Steril 82:1580, 2004.
219. **Scholes D**, **LaCroix AZ**, **Ichikawa LE**, **Barlow WE**, **Ott SM**, Injectable hormone contraception and bone density: results from a prospective study, Epidemiology 13:581, 2002.
220. **Cundy T**, **Farquhar CM**, **Cornish J**, **Reid IR**, Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women, J Clin Endocrinol Metab 81:1014, 1996.
221. **Paiva LC**, **Pinto-Neto AM**, **Faúndes A**, Bone density among long-term users of medroxyprogesterone acetate as a contraceptive, Contraception 58:351, 1998.
222. **Scholes D**, **Lacroix AZ**, **Ott SM**, **Ichikawa LE**, **Barlow WE**, Bone mineral density in women using depot medroxyprogesterone acetate for contraception, Obstet Gynecol 93:233, 1999.
223. **Rahman M**, **Berenson AB**, Predictors of higher bone mineral density loss and use of depot medroxyprogesterone acetate, Obstet Gynecol 115:35, 2010.
224. **Cundy T**, **Ames R**, **Horne A**, **Clearwater J**, **Roberts H**, **Gamble G**, **Reid IR**, A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate, J Clin Endocrinol Metab 88:78, 2003.
225. **Theitz G**, **Buch B**, **Rizzoli R**, **Slosman D**, **Clavien H**, **Sizonko PC**, **Bonjour JPH**, Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects, J Clin Endocrinol Metab 75:1060, 1992.
226. **Matkovic V**, **Jelic T**, **Wardlaw GM**, **Ilich J**, **Goel PK**, **Wright JK**, **Andon MB**, **Smith KT**, **Heaney RP**, Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis: inference from a cross-sectional model, J Clin Invest 93:799, 1994.
227. **Lara-Torre E**, **Edwards CP**, **Perlaman S**, **Hertweck SP**, Bone mineral density in adolescent females using depot medroxyprogesterone acetate, J Pediatr Adolesc Gynecol 17:17, 2004.
228. **Cromer BA**, **Bonny AE**, **Stager M**, **Lazebnik R**, **Rome E**, **Ziegler J**, **Camin-Shingler K**, **Secic M**, Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study, Fertil Steril 90:2060, 2008.
229. **Kumar R**, **Cohen WR**, **Epstein FH**, Vitamin D and calcium hormones in pregnancy, N Engl J Med 302:1143, 1980.
230. **Sowers M**, **Corton G**, **Shapiro B**, **Jannausch ML**, **Crutchfield M**, **Smith ML**, **Randolph JF**, **Hollis B**, Changes in bone density with lactation, JAMA 269:3130, 1993.
231. **Kalkwarf HJ**, **Specker BL**, Bone mineral loss during lactation and recovery after weaning, Obstet Gynecol 86:26, 1995.
232. **Laskey MA**, **Prentice A**, Bone mineral changes during and after lactation, Obstet Gynecol 94:608, 1999.
233. **Kovacs CS**, Calcium and bone metabolism in pregnancy and lactation, J Clin Endocrinol Metab 86:2344, 2001.
234. **Kalkwarf HJ**, **Specker BL**, **Bianchi DC**, **Ranz J**, **Ho M**, The effect of calcium supplementation on bone density during lactation and after weaning, N Engl J Med 337:523, 1997.
235. **Laskey MA**, **Prentice A**, **Hanratty LA**, **Jarjou LM**, **Dibba B**, **Beavan SR**, **Cole TJ**, Bone changes after 3 mo of lactation: influence of calcium intake, breast-milk output, and vitamin D-receptor genotype, Am J Clin Nutr 67:685, 1998.
236. **Ritchie LD**, **Fung EB**, **Halloran BP**, **Turnlund JR**, **Van Loan MD**, **Cann CE**, **King JC**, A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses, Am J Clin Nutr 67:693, 1998.
237. **Polatti F**, **Capuzzo E**, **Viazzo F**, **Colleoni R**, **Klersy C**, Bone mineral changes during and after lactation, Obstet Gynecol 94:52, 1999.
238. **Karlsson C**, **Obrant KJ**, **Karlsson M**, Pregnancy and lactation confer reversible bone loss in humans, Osteoporos Int 12:828, 2001.
239. **Kojima N**, **Douchi T**, **Kosha S**, **Nagata Y**, Cross-sectional study of the effects of parturition and lactation on bone mineral density later in life, Maturitas 41:203, 2002.
240. **Cundy T**, **Cornish J**, **Evans MC**, **Roberts H**, **Reid IR**, Recovery of bone density in women who stop using medroxyprogesterone acetate, Br Med J 308:247, 1994.

241. **Clark MK**, **Sowers M**, **Levy B**, **Nichols S**, Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate, Fertil Steril 86:1466, 2006.
242. **Kaunitz AM**, **Miller PD**, **Rice VM**, **Ross D**, **McClung MR**, Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation, Contraception 74:90, 2006.
243. **Scholes D**, **LaCroix AZ**, **Ichikawa LE**, **Barlow WE**, **Ott SM**, Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception, Arch Pediatr Adolesc Med 159:139, 2005.
244. **Berenson AB**, **Rahman M**, **Breitkopf CR**, **Bi LX**, Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density, Obstet Gynecol 112:788, 2008.
245. **Orr-Walker BJ**, **Evans MC**, **Ames RW**, **Clearwater JM**, **Cundy T**, **Reid IR**, The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women, Clin Endocrinol (Oxf) 49:615, 1998.
246. **Murphy LJ**, **Murphy LC**, **Stead B**, **Sutherland RL**, **Lazarus L**, Modulation of lactogenic receptors by progestins in cultured human breast cancer cells, J Clin Endocrinol Metab 62:280, 1986.
247. **Simon WE**, **Pahnke VG**, **Holzel F**, In vitro modulation of prolactin binding to human mammary carcinoma cells by steroid hormones and prolactin, J Clin Endocrinol Metab 60:1243, 1985.
248. **Kelly PA**, **Kjiane J**, **Postel-Vinay M-C**, **Edery M**, The prolactin/growth hormone receptor family, Endocr Rev 12:235, 1991.
249. **Garza-Flores J**, **Cardenas S**, **Rodriguez V**, **Cravioto MC**, **Diaz-Sanchez V**, **Perez-Palacios G**, Return to ovulation following the use of long-acting injectable contraceptives: a comparative study, Contraception 31:361, 1985.
250. **Pardthaisong T**, Return of fertility after use of the injectable contraceptive Depo Provera: up-dated analysis, J Biosoc Sci 16:23, 1984.
251. **Schwallie P**, **Assenze J**, The effect of depo medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation. A review, Contraception 10:181, 1974.
252. **Beksinska ME**, **Smit JA**, **Kleinschmidt I**, **Rees H**, **Farley TMM**, **Guidozzi F**, Detection of raised FSH levels among older women using depomedroxyprogesterone acetate and norethisterone enanthate, Contraception 68:339, 2003.
253. **Juliato CT**, **Fernandes A**, **Marchi NM**, **Castro S**, **Olivotti B**, **Bahamondes L**, Usefulness of FSH measurements for determining menopause in long-term users of depot-medroxyprogesterone acetate over 40 years of age, Contraception 76:282, 2007.
254. **Newton JR**, **d'Arcangues C**, **Hall PE**, A review of 'once-a-month' combined injectable contraceptives, J Obstet Gynaecol 14(Suppl 1):S1, 1994.
255. **Rosenblatt KA**, **Gao DL**, **Ray RM**, **Nelson ZC**, **Wernli KJ**, **Li W**, **Thomas DB**, Monthly injectable contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai, Contraception 76:40, 2007.
256. **WHO Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation**, A multicentered phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection, Contraception 40:531, 1989.
257. **Cuong DT**, **Huong M**, Comparative phase III clinical trial of two injectable contraceptive preparations, depot-medroxyprogesterone acetate and Cyclofem in Vietnamese women, Contraception 54:169, 1996.
258. **Hall P**, **Bahamondes L**, **Diaz J**, **Petta C**, Introductory study of the once-a-month, injectable contraceptive Cyclofem® in Brazil, Chile, Columbia, and Peru, Contraception 56:353, 1997.
259. **Garza-Flores J**, **Morales del Olmo A**, **Fuziwara JL**, **Figueroa JG**, **Alonso A**, **Monroy J**, **Perez M**, **Urbina-Fuentes M**, **Guevara SJ**, **Cedeno E**, **Barrios R**, **Ferman JJ**, **Medina LM**, **Velezquez E**, **Perez-Palacios G**, Introduction of Cyclofem® once-a-month injectable contraceptive in Mexico, Contraception 58:7, 1998.
260. **Kaunitz AM**, **Garceau RJ**, **Cromie MA**; **Lunelle Study Group**, Comparative safety, efficacy, and cycle

control of Lunelle™ monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum® 7/7/7 oral contraceptive (Norethindrone/ethinyl estradiol triphasic), Contraception 60:179, 1999.

261. **Garceau RJ**, **Wajszczuk CJ**, **Kaunitz AM**; **Lunelle Study Group**, Bleeding patterns of women using Lunelle™ monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum™ 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives, Contraception 62:289, 2000.
262. **Bahamondes L**, **Lavín P**, **Ojeda G**, **Petta C**, **Diaz J**, **Maradiegue E**, **Monteiro I**, Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem®, Contraception 55:307, 1997.
263. **Bahamondes L**, **Marchi NM**, **Nakagava HM**, **de Melo MLR**, **de Lourdes Cristofoletti M**, **Pellini E**, **Scozzafave RH**, **Petta C**, Self-administration with UniJect® of the once-a-month injectable contraceptive Cyclofem®, Contraception 56:301, 1997.
264. **Piya-Anant M**, **Koetsawang S**, **Patrasupapong N**, **Dinchuen P**, **d'Arcangues C**, **Piaggio G**, **Pinol A**, Effectiveness of Cyclofem® in the treatment of depot medroxyprogesterone acetate induced amenorrhea, Contraception 57:23, 1998.
265. **Kesseru EV**, **Aydinlik S**, **Etchepareborda JJ**, Multicentered, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive; final three-year report, Contraception 50:329, 1994.
266. **Sang GW**, **Shao QX**, **Ge RS**, **Chen JK**, **Song S**, **Fang KJ**, **He ML**, **Luo SY**, **Chen SF**, **Chen XB**, **Li MX**, **Wu SC**, **Sun GL**, **Zhou HE**, **Zhang SF**, **Zhu LL**, **Ye BL**, **Zhang JH**, **Ma FL**, **Jiang BY**, **Zhou ZQ**, **Dong QH**, **Shenm HC**, **Liu YX**, **Shao JY**, **Wang SX**, **Ming HD**, **Zhu ZR**, **Cheng HZ**, **Chen SH**, **Yu HY**, **Zhang ZY**, **Qing YN**, **Wang XY**, **Hall PE**, **d'Arcangues C**, **Snow RC**, A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem, and injectable no. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and side effects, Contraception 51:167, 1995.
267. **Martínez GH**, **Castañeda A**, **Correa JE**, Vaginal bleeding patterns in users of Perlutal®, a once-a-month injectable contraceptive consisting of 10 mg estradiol enanthate combined with 150 mg dihydroxyprogesterone acetophenide. A trial of 5462 woman-months, Contraception 58:21, 1998.
268. **Coutinho EM**, **Spinola P**, **Barbosa I**, **Gatto M**, **Tomaz G**, **Morais K**, **Yazlle ME**, **de Souza RN**, **Neto JSP**, **de Barros Leal W**, **Leal C**, **Hippolito SB**, **Abranches AD**, Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate, Contraception 55:175, 1997.
269. **Huber SC**, **Piotrow PT**, **Orlans B**, **Dommer G**, Intrauterine devices, Popul Rep B (2), 1975.
270. **Richter R**, Ein mittel zur verhutung der konzeption, Deutsche Med Wochenschrift 35:1525, 1909.
271. **Pust K**, Ein brauchbarer frauenschutz, Deutsche Med Wochenschrift 49:952, 1923.
272. **Gräfenberg E**, An intrauterine contraceptive method, In: Sanger M, Stone HM, eds. The Practice of Contraception: Proceedings of the 7th International Birth Control Conference, Zurich, Switzerland, Williams & Wilkins, Baltimore, 1930, p. 33.
273. **Ota T**, A study on birth control with an intra-uterine instrument, Jpn J Obstet Gynecol 17:210, 1934.
274. **Ishihama A**, Clinical studies on intrauterine rings, especially the present state of contraception in Japan and the experiences in the use of intra-uterine rings, Yokohama Med Bull 10:89, 1959.
275. **Oppenheimer W**, Prevention of pregnancy by the Graefenberg ring method: a re-evaluation after 28 years' experience, Am J Obstet Gynecol 78:446, 1959.
276. **Tietze C**, Evaluation of intrauterine devices. Ninth progress report of the cooperative statistical program, Stud Fam Plann 1:1, 1970.
277. **Tatum HJ**, **Schmidt FH**, **Phillips DM**, **McCarty M**, **O'Leary WM**, The Dalkon shield controversy, structural and bacteriologic studies of IUD tails, JAMA 231:711, 1975.
278. **Kessel E**, Pelvic inflammatory disease with intrauterine device use: a reassessment, Fertil Steril 51:1, 1989.
279. **Eschenbach DA**, **Harnisch JP**, **Holmes KK**, Pathogenesis of acute pelvic inflammatory disease: role of

contraception and other risk factors, Am J Obstet Gynecol 128:838, 1977.
280. **Kaufman DW**, **Shapiro S**, **Rosenberg L**, **Monson RR**, **Miettinen OS**, **Stolley PD**, **Slone D**, Intrauterine contraceptive device use and pelvic inflammatory disease, Am J Obstet Gynecol 136:159, 1980.
281. **Kaufman DW**, **Watson J**, **Rosenberg L**, **Helmrich SP**, **Miller DR**, **Miettinen OS**, **Stolley PD**, **Shapiro S**, The effect of different types of intrauterine devices on the risk of pelvic inflammatory disease, JAMA 250:759, 1983.
282. **Lee NC**, **Rubin GL**, **Ory HW**, **Burkman RT**, Type of intrauterine device and the risk of pelvic inflammatory disease, Obstet Gynecol 62:1, 1983.
283. **Daling JR**, **Weiss NS**, **Metch BJ**, **Chow WH**, **Soderstrom RM**, **Moore DE**, **Spadoni LR**, **Stadel BV**, Primary tubal infertility in relation to the use of an intrauterine device, N Engl J Med 312:937, 1985.
284. **Cramer DW**, **Schiff I**, **Schoenbaum SC**, **Gibson M**, **Belisle S**, **Albrecht B**, **Stillman RJ**, **Berger MJ**, **Wilson E**, **Stadel BV**, **Seible M**, Tubal infertility and the intrauterine device, N Engl J Med 312:941, 1985.
285. **Lee NC**, **Rubin GL**, **Borucki R**, The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study, Obstet Gynecol 72:1, 1988.
286. **Piccinino LJ**, **Mosher WD**, Trends in contraceptive use in the United States: 1982–1995, Fam Plann Perspect 30:4, 1998.
287. **Alan Guttmacher Institute**, Contraceptive use in the United States, Guttmacher Institute Fact Sheet: September 2016, https://www.guttmacher.org/sites/default/files/factsheet/fb_contr_use_0.pdf
288. **Zipper JA**, **Medel M**, **Prage R**, Suppression of fertility by intrauterine copper and zinc in rabbits: a new approach to intrauterine contraception, Am J Obstet Gynecol 105:529, 1969.
289. **Tatum HJ**, Milestones in intrauterine device development, Fertil Steril 39:141, 1983.
290. **Sivin I**, **Tatum HJ**, Four years of experience with the TCu 380A intrauterine contraceptive device, Fertil Steril 36:159, 1981.
291. **Sujuan G**, **Liuqu Z**, **Yuhao W**, **Feng L**, Chinese IUDs, In: Bardin CW, Mishell DR Jr, eds. Proceedings from the Fourth International Conference on IUDs, Butterworth-Heinemann, Boston, 1994, p. 308.
292. **Bilian X**, Chinese experience with intrauterine devices, Contraception 75:S31, 2007.
293. **Siving I**, Utility and drawbacks of continuous use of a copper T IUD for 20 years, Contraception 75:S70, 2007.
294. **Sivin I**, **Diaz S**, **Pavéz M**, **Alvarez F**, **Brache V**, **Diaz J**, **Odlind V**, **Olsson S-E**, **Stern J**, Two-year comparative trial of the gyne T 380 slimline and gyne T 380 intrauterine copper devices, Contraception 44:481, 1991.
295. **Sivin I**, **Stern J**; **International Committee for Contraception Research**, Health during prolonged use of levonorgestrel 20 mg/d and the copper TCu 380 Ag intrauterine contraceptive devices: a multicenter study, Fertil Steril 61: 70, 1994.
296. **Chi I-C**, The TCu-380A (AG), MLCu375, and Nova-T IUDs and the IUD daily releasing 20 mg levonorgestrel—four pillars of IUD contraception for the nineties and beyond?, Contraception 47:325, 1993.
297. **Kurz KM**, **Meier-Oehlke PA**, The Cu SAFE 300 IUD, a new concept in intrauterine contraception: first year results of a large study with follow-up of 1017 acceptors, Adv Contracept 7:291, 1991.
298. **Luukkainen T**, **Allonen H**, **Haukkamaa M**, **Lahteenmake P**, **Nilsson CG**, **Toivonen J**, Five years' experience with levonorgestrel-releasing IUDs, Contraception 33:139, 1986.
299. **Sivin I**, **Stern J**, **Coutinho E**, **Mattos CER**, **El Mahgoub S**, **Diaz S**, **Pavéz M**, **Alvarez F**, **Brache V**, **Thevinin F**, **Diaz J**, **Faundes A**, **Diaz MM**, **McCarthy T**, **Mishell DR Jr**, **Shoupe D**, Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the copper T380 Ag IUDs, Contraception 44:473, 1991.
300. **Toivonen J**, **Luukkainen T**, **Alloven H**, Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel and copper-releasing intrauterine devices, Obstet Gynecol 77:261, 1991.
301. **Bilian X**, **Liying Z**, **Xuling Z**, **Mengchun J**, **Luukkainen T**, **Allonen H**, Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device, Contraception 41:353, 1990.
302. **Crosignani PG**, **Vercellini P**, **Mosconi P**, **Oldani S**, **Cortesi I**, **De Giorgi O**, Levonorgestrel-releasing

intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding, Obstet Gynecol 90:257, 1997.
303. **Kaunitz AM**, **Meredith S**, **Inki P**, **Kubba A**, **Sanchez-Ramos L**, Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding. A systematic review and meta-analysis, Obstet Gynecol 113: 1104, 2009.
304. **Gardner FJE**, **Konje JC**, **Abrams KR**, **Brown LJR**, **Khanna S**, **Al-Azzawi F**, **Bell SC**, **Taylor DJ**, Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial, Lancet 356:1711, 2000.
305. **Vercellini P**, **Aimi G**, **Panazza S**, **De Giorgi O**, **Pesole A**, **Crosignani PG**, A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study, Fertil Steril 72:505, 1999.
306. **Raudaskoski TH**, **Lahti EI**, **Kauppila AJ**, **Apaja-Sarkkinen MA**, **Laatikainen TJ**, Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses, Am J Obstet Gynecol 172:114, 1995.
307. **Suhonen S**, **Holmstrom T**, **Lahteenmaki P**, Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy, Acta Obstet Gynecol Scand 76:145, 1997.
308. **Suvanto-Luukkonen E**, **Kauppila A**, The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience, Fertil Steril 72:161, 1999.
309. **Varila E**, **Wahlstrom T**, **Rauramo I**, A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy, Fertil Steril 76:969, 2001.
310. **Raudaskoski T**, **Tapanainen J**, **Tomas E**, **Luotola H**, **Pekonen F**, **Ronni-Sivula H**, **Timonen H**, **Riphagen F**, **Laatikainen T**, Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic responses, Br J Obstet Gynaecol 109:136, 2002.
311. **Hampton NR**, **Rees MC**, **Lowe DG**, **Rauramo I**, **Barlow D**, **Guillebaud J**, Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women, Hum Reprod 20:2653, 2005.
312. **Crenin MD**, **Jansen R**, **Starr RM**, **Gobburu J**, **Gopalakrishnan M**, **Olariu A**, Levonorgestrel release rates over 5 years with the Liletta 52-mg intrauterine system, Contraception 94:353, 2016.
313. **Apter D**, **Gemzell-Danielsson K**, **Hauck B**, **Rosen K**, **Zurth C**, Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies, Fertil Steril 101:1656, 2014.
314. **Wildemeersch D**, **Janssens D**, **Andrade A**, The Femilis LNG-IUS: contraceptive performance—an interim analysis, Eur J Contracept Reprod Health Care 14:103, 2009.
315. **Van Kets H**, **Van der Pas H**, **Thiery M**, **Wildemeersch D**, **Vrijens M**, **Van Trappen Y**, **Temmerman M**, **DePypere H**, **Delbarge W**, **Dhont M**, **Defoort P**, **Schacht EH**, **Bátárl I**, **Barri P**, **Martinez F**, **Iglesias Cortit LH**, **Creatsas G**, **Shangchun W**, **Xiaoming C**, **Zuan-chong F**, **Yu-ming W**, **Andrade A**, **Reinprayoon D**, **Pizarro E**, The GyneFix® implant system for interval, postabortal and postpartum contraception: a significant advance in long-term reversible contraception, Eur J Contracept Reprod Health Care 2:1, 1997.
316. **Wildemeersch D**, **Batar I**, **Webb A**, **Gbolade BA**, **Delbarge W**, **Temmerman M**, **Dhont M**, **Gillebaud J**, GyneFIX. The frameless intrauterine contraceptive implant—an update for interval, emergency and postabortal contraception, Br J Fam Plann 24:149, 1999.
317. **Wu S**, **Hu J**, **Wildemeersch D**, Performance of the frameless GyneFix and the TCu380A IUDs in a 3-year multicenter, randomized, comparative trial in parous women, Contraception 61:91, 2000.
318. **Wildemeersch D**, **Dhont M**, **Temmerman M**, **Delbarge W**, **Schacht E**, **Thiery M**, GyneFix-LNG: preliminary clinical experience with a copper and levonorgestrel-releasing intrauterine system, Eur J Contracept Reprod Health Care 4:15, 1999.
319. **Wildemeersch D**, **Schacht E**, **Wildemeersch P**, Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment

in peri and postmenopausal women, Maturitas 44:237, 2003.
320. **Wildemeersch D**, **Rowe PJ**, Assessment of menstrual blood loss in women with idiopathic menorrhagia using the frameless levonorgestrel-releasing intrauterine system, Contraception 70:165, 2004.
321. **Wildemeersch D**, **Pylyser K**, **De Wever N**, **Dhont M**, Treatment of non atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up, Maturitas 57:210, 2007.
322. **Sivin I**, IUDs are contraceptives, not abortifacients: a comment on research and belief, Stud Fam Plann 20:355, 1989.
323. **Ortiz ME**, **Croxatto HB**, The mode of action of IUDs, Contraception 36:37, 1987.
324. **Ortiz ME**, **Croxatto HB**, Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action, Contraception 75:S16, 2007.
325. **Croxatto HB**, **Devoto L**, **Durand M**, **Ezcurra E**, **Larrea F**, **Nagle C**, **Ortiz ME**, **Vantman D**, **Vega M**, **von Hertzen H**, Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature, Contraception 63: 112.
326. **Alvarez F**, **Guiloff E**, **Brache V**, **Hess R**, **Fernandez E**, **Salvatierra AM**, **Guerrero B**, **Zacharias S**, New insights on the mode of action of intrauterine contraceptive devices in women, Fertil Steril 49:768, 1988.
327. **Segal SJ**, **Alvarez-Sanchez F**, **Adejuwon CA**, **Brache De Mejla V**, **Leon P**, **Faundes A**, Absence of chorionic gonadotropin in sera of women who use intrauterine devices, Fertil Steril 44:214, 1985.
328. **Wilcox AJ**, **Weinberg CR**, **Armstrong EG**, **Canfield RE**, Urinary human chorionic gonadotropin among intrauterine device users: detection with a highly specific and sensitive assay, Fertil Steril 47:265, 1987.
329. **Ämmälä M**, **Nyman T**, **Strengell L**, **Rutanen E-M**, Effect of intrauterine contraceptive devices on cytokine messenger ribonucleic acid expression in the human endometrium, Fertil Steril 63:773, 1995.
330. **Critchley HO**, **Wang H**, **Jones RL**, **Kelly RW**, **Drudy TA**, **Gebbie AE**, **Buckley CH**, **McNeilly AS**, **Glasier AF**, Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery, Hum Reprod 13:1218, 1998.
331. **Barbosa I**, **Olsson SE**, **Odlind V**, **Goncalves T**, **Coutinho E**, Ovarian function after seven years' use of levonorgestrel IUD, Adv Contracept 11:85, 1995.
332. **Vessey MP**, **Lawless M**, **McPherson K**, **Yeates D**, Fertility after stopping use of intrauterine contraceptive device, Br Med J 283:106, 1983.
333. **Belhadj H**, **Sivin I**, **Diaz S**, **Pavéz M**, **Tejada A-S**, **Brache V**, **Alvarez F**, **Shoupe D**, **Breaux H**, **Mishell DR Jr**, **McCarthy T**, **Yo V**, Recovery of fertility after use of the levonorgestrel 20 mcg/day or copper T 380Ag intrauterine device, Contraception 34:261, 1986.
334. **Skjeldestadt FE**, **Bratt H**, Fertility after complicated and non-complicated use of IUDs. A controlled prospective study, Adv Contracept 4:179, 1988.
335. **Wilson JC**, A prospective New Zealand study of fertility after removal of copper intrauterine devices for conception and because of complications: a four-year study, Am J Obstet Gynecol 160:391, 1989.
336. **Inki P**, **Hurskainen R**, **Palo P**, **Ekholm E**, **Grenman S**, **Kivela A**, **Kujansuu E**, **Teperi J**, **Yliskoski M**, **Paavonen J**, Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy, Ultrasound Obstet Gynecol 20:381, 2002.
337. **Lidegaard Ø**, **Lokkegaard E**, **Svendsen AL**, **Agger C**, Hormonal contraception and risk of venous thromboembolism: national follow-up study, Br Med J 339:b2890, 2009. doi:10.1136/bmj.b2890.
338. **Milsom I**, **Andersson K**, **Andersch B**, **Rybo G**, A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia, Am J Obstet Gynecol 164:879, 1991.
339. **Tang GW**, **Lo SS**, Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability, Contraception 51: 231, 1995.
340. **Irvine GA**, **Campbell-Brown MB**, **Lumsden MA**, **Heikkila A**, **Walker JJ**, **Cameron IT**, Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia, Br J Obstet Gynaecol 105:592, 1998.
341. **Istre O**, **Trolle B**, Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection, Fertil Steril 76:304, 2001.

342. **Romer T**, Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea, Eur J Obstet Gynecol Reprod Biol 90:27, 2000.
343. **Hurskainen R**, **Teperi J**, **Rissanen P**, **Aalto A-M**, **Grenman S**, **Kivelä A**, **Kujansuu E**, **Vuorma S**, **Yliskoski M**, **Paavonen J**, Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia. Randomized trial 5-year follow-up, JAMA 291:1456, 2004.
344. **Reid PC**, **Virtanen-Karl S**, Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts, Br J Obstet Gynaecol 112:1121, 2005.
345. **Busfield RA**, **Farquhar CM**, **Sowter MC**, **Lethaby A**, **Sprecher M**, **Yu Y**, **Sadler LC**, **Brown J**, **Johnson N**, A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding, Br J Obstet Gynaecol 113:257, 2006.
346. **Brown PM**, **Farquhar CM**, **Lethaby A**, **Sadler LC**, **Johnson NP**, Cost-effectiveness analysis of levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding, Br J Obstet Gynaecol 113:797, 2006.
347. **Shaw RW**, **Symonds IM**, **Tamizian O**, **Chaplain J**, **Mukhopadhyay S**, Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia, Aust N Z J Obstet Gynaecol 47:335, 2007.
348. **Andersson J**, **Rybo G**, Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia, Br J Obstet Gynaecol 97:690, 1990.
349. **Baldszti E**, **Wimmer-Puchinger B**, **Loschke K**, Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study, Contraception 67:87, 2003.
350. **Gemzell-Danielsson K**, **Apter D**, **Dermout S**, **Faustmann T**, **Rosen K**, **Schmelter T**, **Merz M**, **Nelson A**, Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use, Eur J Obstet Gynecol Reprod Biol 210:22, 2017.
351. **Fan G**, **Kang S**, **Ren M**, **Weisberg E**, **Lukkari-Lax E**, **Roth K**, **Shin S**, A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg), in an Asia-Pacific population, Contraception 95:371, 2017.
352. **Hidalgo M**, **Bahamondes L**, **Perrotti M**, **Diaz J**, **Dantas-Monteiro C**, **Petta C**, Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years, Contraception 65:129, 2002.
353. **Grigorieva V**, **Chen-Mok M**, **Tarasova M**, **Mikhailov A**, Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas, Fertil Steril 79:1194, 2003.
354. **Mercorio F**, **De Simone R**, **Di Spiezio Sardo A**, **Cerrota G**, **Bifulco G**, **Vancore F**, **Nappi C**, The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia, Contraception 67:277, 2003.
355. **Soysal S**, **Soysal M**, The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial, Gynecol Obstet Invest 59:29, 2005.
356. **Magalães J**, **Aldrighi JM**, **De Lima GR**, Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas, Contraception 75:193, 2007.
357. **Tasci Y**, **Caglar GS**, **Kayikcioglu F**, **Cengiz H**, **Yagci B**, **Gunes M**, Treatment of menorrhagia with the levonorgestrel releasing intrauterine system: effects on ovarian function and uterus, Arch Gynecol Obstet 280:39, 2009.
358. **Rizkalla HF**, **Higgins M**, **Kelehan P**, **O'Herlihy C**, Pathological findings associated with the presence of a Mirena intrauterine system at hysterectomy, Int J Gynecol Pathol 27:74, 2008.
359. **Fedele L**, **Bianchi S**, **Raffaelli R**, **Portuese A**, **Dorta M**, Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device, Fertil Steril 68:426, 1997.
360. **Cho S**, **Nam A**, **Kim H**, **Chay D**, **Park K**, **Cho DJ**, **Park Y**, **Lee B**, Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis, Am J Obstet Gynecol 198:373.e1, 2008.
361. **Sheng J**, **Zhang WY**, **Zhang JP**, **Lu D**, The LNG-IUS study on adenomyosis: a 3-year follow-up study on the

efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis, Contraception 79:189, 2009.
362. **Kingman CE**, **Kadir R**, **Lee CA**, **Economides DL**, The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders, Br J Obstet Gynaecol 111:1425, 2004.
363. **Schaedel ZE**, **Dolan G**, **Powell MC**, The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders, Am J Obstet Gynecol 193:1361, 2005.
364. **Pisoni CN**, **Cuadrado MJ**, **Khamashta MA**, **Hunt BJ**, Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel-releasing intrauterine device (Mirena coil), Lupus 15:877, 2006.
365. **Lukes AS**, **Reardon B**, **Arepally G**, Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders, Fertil Steril 90:673, 2007.
366. **Kilic S**, **Yuksel B**, **Doganay M**, **Bardakci H**, **Akinsu F**, **Uzunlar O**, **Mollamahutoglu L**, The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement, Contraception 80:152, 2009.
367. **Andersson K**, **Odlind V**, **Rybo G**, Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial, Contraception 49:56, 1994.
368. **Petta CA**, **Ferriani RA**, **Abrao MS**, **Hassan D**, **Rosa e Silva JC**, **Podgaec S**, **Bahamondes L**, Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis, Hum Reprod 20:1993, 2005.
369. **Lockhat FB**, **Emembolu JO**, **Konje JC**, The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3-year follow-up, Hum Reprod 20:789, 2005.
370. **Gomes MK**, **Ferriani RA**, **Rosa e Silva JC**, **Japur de Sá Rosa e Silva AC**, **Vieira CS**, **Câdido dos Reis FJ**, The levonorgestrel-releasing intrauterine system and endometriosis staging, Fertil Steril 87:1231, 2007.
371. **Petta CA**, **Ferriani RA**, **Abrão MS**, **Hassan D**, **Rosa e Silva JC**, **Podgaec S**, **Bahamondes L**, A 3-year follow-up of women with endometriosis and pelvic pain users of the levonorgestrel-releasing intrauterine system, Eur J Obstet Gynecol Reprod Biol 143:128, 2009.
372. **Kesim MD**, **Aydin Y**, **Atis A**, **Mandiraci G**, Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen, Climacteric 11:252, 2008.
373. **Chan SS**, **Tam WH**, **Yeo W**, **Yu MM**, **Ng DP**, **Wong AW**, **Kwan WH**, **Yuen PM**, A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women, Br J Obstet Gynaecol 114:1510, 2007.
374. **Gardner FJ**, **Konje JC**, **Bell SC**, **Abrams KR**, **Brown LJ**, **Taylor DJ**, **Habiba M**, Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system: long-term follow-up of a randomised control trial, Gynecol Oncol 114:452, 2009.
375. **Bahamondes L**, **Ribeiro-Huguet P**, **de Andrade KC**, **Leon-Martins O**, **Petta CA**, Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma, Acta Obstet Gynecol Scand 82: 580, 2003.
376. **Vereide AB**, **Kaino T**, **Sager G**, **Arnes M**, **Ørbo A**, Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia, Gynecol Oncol 101:214, 2006.
377. **Wheeler DT**, **Bristow RE**, **Kurman RJ**, Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins, Am J Surg Pathol 31:988, 2007.
378. **Varma R**, **Soneja H**, **Bhatia K**, **Ganesan R**, **Rollason T**, **Clark TJ**, **Gupta JK**, The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia—a long-term follow-up study, Eur J Obstet Gynecol Reprod Biol 139:169, 2008.
379. **Haimovich S**, **Checa MA**, **Mancebo G**, **Fusté P**, **Carreras R**, Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device, Menopause 15:1002, 2008.

380. **Ørbo A**, **Arnes M**, **Hancke C**, **Vereide AB**, **Pettersen I**, **Larsen K**, Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only, Gynecol Oncol 111:68, 2008.
381. **Vereide AB**, **Arnes M**, **Straume B**, **Maltau JM**, **Ørbo A**, Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone, Gynecol Oncol 91:526, 2003.
382. **Abu J**, **Brown L**, **Ireland D**, Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (Mirena) in a 36-year-old woman, Int J Gynecol Cancer 16:1445, 2006.
383. **Kresowik J**, **Ryan GL**, **Van Voorhis BJ**, Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system, Obstet Gynecol 111: 547, 2008.
384. **Laurelli G**, **Falcone F**, **Gallo MS**, **Scala F**, **Losito S**, **Granata V**, **Cascella M**, **Greggi S**, Long-term oncologic and reproductive outcomes in young women with early endometrial cancer conservatively treated: a prospective study and literature update, Int J Gynecol Cancer 26:1650, 2016.
385. **United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction**, Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C, Contraception 56:341, 1997.
386. **Hidalgo MM**, **Hidalgo-Regina C**, **Bahamondes V**, **Monteiro I**, **Petta CA**, **Bahamondes L**, Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system, Contraception 80:84, 2009.
387. **Sivin I**, **Stern J**, **Diaz J**, **Diaz MM**, **Faundes A**, **Mahgoub SE**, **Diaz S**, **Pavéz M**, **Coutinho E**, **Mattos CER**, **McCarthy T**, **Mishell DR Jr**, **Shoupe D**, **Alvarez F**, **Brache V**, **Jimenez E**, Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices, Contraception 35:245, 1987.
388. **Sivin I**, **Schmidt F**, Effectiveness of IUDs: a review, Contraception 36:55, 1987.
389. **Petta CA**, **Amatya R**, **Farr G**, Clinical evaluation of the TCu 380A IUD at six Latin American centers, Contraception 50:17, 1994.
390. **WHO Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on the Safety and Efficacy of Fertility Regulating Methods**, The TCu 380A, TCu 220C, Multiload 250, and Nova T IUDs at 3, 5, and 7 years of use, Contraception 42:141, 1990.
391. **Farr G**, **Amatya R**, Contraceptive efficacy of the copper T 380A and copper T 200 intrauterine devices: results from a comparative clinical trial in six developing countries, Contraception 49:231, 1994.
392. **Rivera R**, **Chen-Mok M**, **McMullen S**, Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD, Contraception 60:155, 1999.
393. **Paterson H**, **Ashton J**, **Harrison-Woolrych M**, A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents, Contraception 79:433, 2009.
394. **Thonneau P**, **Almont T**, **de La Rochebrochard E**, **Maria B**, Risk factors for IUD failure: results of a large multicentre case-control study, Hum Reprod 21: 2612, 2006.
395. **WHO Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Intrauterine Devices for Fertility Regulation**, A multinational case-control study of ectopic pregnancy, Clin Reprod Fertil 3:131, 1985.
396. **Marchbanks PA**, **Annegers JE**, **Coulam CB**, **Strathy JH**, **Kurland LT**, Risk factors for ectopic pregnancy. A population based study, JAMA 259:1823, 1988.
397. **Ory HW**, Ectopic pregnancy and intrauterine contraceptive devices: new perspectives, Obstet Gynecol 57:2, 1981.
398. **Edelman DA**, **Porter CW**, The intrauterine device and ectopic pregnancy, Contraception 36:85, 1987.
399. **Makinen JL**, **Erkkola RU**, **Laippala PJ**, Causes of the increase in incidence of ectopic pregnancy—a study on 1017 patients from 1966 to 1985 in Turku, Finland, Am J Obstet Gynecol 160:642, 1989.
400. **Skjeldestad FE**, How effectively do copper intrauterine devices prevent ectopic pregnancy? Acta Obstet

Gynecol Scand 76:684, 1997.
401. **Sivin I**, Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception, Obstet Gynecol 78:291, 1991.
402. **Borgatta L**, **Buhling KJ**, **Rybowski S**, **Roth K**, **Rosen K**, A multicenter, open-label, randomized phase III study comparing a new levonorgestrel intrauterine device system (LNG-IUS 8) with combined oral contraception in young women of reproductive age, Eur J Contracept Reprod Health Care, 21:372, 2016.
403. **Eisenberg DL**, **Schreiber CA**, **Turok DK**, **Teal SB**, **Westhoff CL**, **Creinin MD**, Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system, Contraception 92:10, 2015.
404. **Backman T**, **Rauramo I**, **Huhtala S**, **Koskenvuo M**, Pregnancy during the use of levonorgestrel intrauterine system, Am J Obstet Gynecol 190:50, 2004.
405. **Hov GG**, **Skjeldestad FE**, **Hilstad T**, Use of IUD and subsequent fertility—follow-up after participation in a randomized clinical trial, Contraception 75:88, 2007.
406. **Cameron IT**, **Haining R**, **Lumsden M-A**, **Thomas VR**, **Smith SK**, The effects of mefenamic acid and norethisterone on measured menstrual blood loss, Obstet Gynecol 76:85, 1990.
407. **Zhao G**, **Minshi L**, **Pengdi Z**, **Ruhua X**, **Jiedong W**, **Renqing X**, A preliminary morphometric study on the endometrium from patients treated with indomethacin-releasing copper intrauterine device, Hum Reprod 12:1563, 1997.
408. **Milsom I**, **Andersson K**, **Jonasson K**, **Lindstedt G**, **Rybo G**, The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status, Contraception 52:175, 1995.
409. **Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction**, Effects of contraceptives on hemoglobin and ferritin, Contraception 58:261, 1998.
410. **Hassan EO**, **El-Husseini M**, **El-Nahal N**, The effect of 1-year use of the CuT 380A and oral contraceptive pills on hemoglobin and ferritin levels, Contraception 60:101, 1999.
411. **Backman T**, **Huhtala S**, **Blom T**, **Luoto R**, **Rauramo I**, **Markku K**, Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users, Br J Obstet Gynaecol 107:335, 2000.
412. **Pakarinen P**, **Lahteenmaki P**, **Rutanen EM**, The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1, Acta Obstet Gynecol Scand 78:423, 1999.
413. **Morin-Papunen L**, **Martikainen H**, **McCarthy MI**, **Franks S**, **Sovio U**, **Hartikainen A-L**, **Ruokonen A**, **Leinonen M**, **Laitinen J**, **Järvelin M-R**, **Pouta A**, Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population, Am J Obstet Gynecol 199:529.e1, 2008.
414. **Backman T**, **Rauramo I**, **Jaakkola K**, **Inki P**, **Vaahtera K**, **Launonen A**, **Koskenvuo M**, Use of the levonorgestrel-releasing intrauterine system and breast cancer, Obstet Gynecol 106:813, 2005.
415. **Lundström E**, **Söderqvist G**, **Svane G**, **Azavedo E**, **Olovosson M**, **Skoog L**, **von Schoultz E**, **von Schoultz B**, Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study, Fertil Steril 85:989, 2006.
416. **Castellsague X**, **Thompson WD**, **Dubrow R**, Intra-uterine contraception and the risk of endometrial cancer, Int J Cancer 54:911, 1993.
417. **Lassise DL**, **Savitz DA**, **Hamman RF**, **Baron AE**, **Brinton LA**, **Levines RS**, Invasive cervical cancer and intrauterine device use, Int J Epidemiol 20:865, 1991.
418. **Parazzini F**, **La Vecchia C**, **Negri E**, Use of intrauterine device and risk of invasive cervical cancer, Int J Epidemiol 21:1030, 1992.
419. **Hill DA**, **Weiss NS**, **Voigt LF**, **Beresford SAA**, Endometrial cancer in relation to intra-uterine device use, Int J Cancer 70:278, 1997.
420. **Sturgeon SR**, **Brinton LA**, **Berman ML**, **Mortel R**, **Twiggs LB**, **Barrett RJ**, **Wilbanks GD**, **Lurain JR**,

Intrauterine device use and endometrial cancer risk, Int J Epidemiol 26:496, 1997.
421. **Benshushan A**, **Paltiel O**, **Rojansky N**, **Brzezinski A**, **Laufer N**, IUD use and the risk of endometrial cancer, Eur J Obstet Gynecol Reprod Biol 105:166, 2002.
422. **Mark AS**, **Hricak H**, Intrauterine contraceptive devices: MR imaging, Radiology 162:311, 1987.
423. **Pasquale SA**, **Russer TJ**, **Foldesy R**, **Mezrich RS**, Lack of interaction between magnetic resonance imaging and the copper-T380A IUD, Contraception 55:169, 1997.
424. **Mishell DR Jr**, **Bell JH**, **Good RG**, **Moyer DL**, The intrauterine device: a bacteriologic study of the endometrial cavity, Am J Obstet Gynecol 96:119, 1966.
425. **Farley MM**, **Rosenberg MJ**, **Rowe PJ**, **Chen J-H**, **Meirik O**, Intrauterine devices and pelvic inflammatory disease: an international perspective, Lancet 339: 785, 1992.
426. **Skouby SO**, **Molsted-Pedersen L**, **Kosonen A**, Consequences of intrauterine contraception in diabetic women, Fertil Steril 42:568, 1984.
427. **Faundes A**, **Telles E**, **Cristofoletti MI**, **Faundes D**, **Castro S**, **Hardy E**, The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis, Contraception 58:105, 1998.
428. **Jatlaoui TC**, **Simmons KB**, **Curtis KM**, The safety of intrauterine initiation among women with current asymptomatic cervical infections or at increased risk of sexually transmitted infections, Contraception 94:701, 2016.
429. **Mehanna MTR**, **Rizk MA**, **Ramadan M**, **Schachter J**, Chlamydial serologic characteristics among intrauterine contraceptive device users: does copper inhibit chlamydial infection in the female genital tract? Am J Obstet Gynecol 171:691, 1994.
430. **Kleinman D**, **Insler V**, **Sarov I**, Inhibition of Chlamydia trachomatis growth in endometrial cells by copper: possible relevance for the use of copper IUDs, Contraception 39:665, 1989.
431. **Drake RW**, **Martins SL**, **Whitaker AK**, Intrauterine device use in an urban university clinic: safety of use in a population at high risk for sexually transmitted infections, Contraception 92:319, 2015.
432. **Kronmal RA**, **Whitney CW**, **Mumford SD**, The intrauterine device and pelvic inflammatory disease: the Women's Health Study reanalyzed, J Clin Epidemiol 44:109, 1991.
433. **Lee NC**, **Rubin GL**, **Grimes DA**, Measures of sexual behavior and the risk of pelvic inflammatory disease, Obstet Gynecol 77:425, 1991.
434. **Murray S**, **Hickey JB**, **Houang E**, Significant bacteremia associated with replacement of intrauterine contraceptive device, Am J Obstet Gynecol 156:698, 1987.
435. **Vu Q**, **Micks E**, **McCoy E**, **Prager S**, Efficacy and safety of long-acting reversible contraception in women with cardiovascular conditions, Am J Cardiol, 117:302, 2016.
436. **Suri V**, **Aggarwal N**, **Kaur R**, **Chaudhary N**, **Ray P**, **Grover A**, Safety of intrauterine contraceptive device (copper T 200 B) in women with cardiac disease, Contraception 78:315, 2008.
437. **Shoubnikova M**, **Hellberg D**, **Nilsson S**, **Mårdh P-A**, Contraceptive use in women with bacterial vaginosis, Contraception 55:355, 1997.
438. **Jossens MOR**, **Schachter J**, **Sweet RL**, Risk factors associated with pelvic inflammatory disease of differing microbial etiologies, Obstet Gynecol 83: 989, 1994.
439. **European Study Group**, Risk factors for male to female transmission of HIV, Br Med J 298:411, 1989.
440. **Musicco M**, **Nicolosi A**, **Saracco A**, **Lazzarin A**, IUD use and man to woman sexual transmission of HIV-1, In: Bardin CW, Mishell DR Jr, eds. Proceedings from the Fourth International Conference on IUDs, Butterworth-Heinemann, Boston, 1994, p. 179.
441. **Kapiga SH**, **Lyamuya EF**, **Lwihula GK**, **Hunter DJ**, The incidence of HIV infection among women using family planning methods in Dar-es-Salaam, Tanzania, AIDS 12:75, 1998.
442. **European Study Group on Heterosexual Transmission of HIV**, Comparison of female to male and male to female transmission of HIV in 563 stable couples, Br Med J 304:809, 1992.
443. **Sinei SK**, **Morrison CS**, **Sekadde-Kigondu C**, **Allen M**, **Kokonya D**, Complications of use of intrauterine devices among HIV-1-infected women, Lancet 351:1238, 1998.
444. **Heikinheimo O**, **Lehtovirta P**, **Suni J**, **Paavonen J**, The levonorgestrel-releasing intrauterine system (LNG-

IUS) in HIV-infected women—effects on bleeding patterns, ovarian function and genital shedding of HIV, Hum Reprod 21: 2857, 2006.
445. **Lehtovirta P**, **Paavonen J**, **Heikinheimo O**, Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women, Contraception 75: 37, 2007.
446. **Stringer EM**, **Kaseba C**, **Levy J**, **Sinkala M**, **Goldenberg RL**, **Chi BH**, **Matongo I**, **Vermund SH**, **Mwanahamuntu M**, **Stringer JSA**, A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus, Am J Obstet Gynecol 197: 144.e1, 2007.
447. **Phillips SJ**, **Curtis KM**, **Polis CB**, Effect of hormonal contraceptive methods on HIV disease progression, AIDS 13:787, 2013.
448. **Ozgun MT**, **Batukan C**, **Mazicioglu MM**, **Serin IS**, **Baskol M**, **Ozturk A**, Intrauterine device use does not increase the incidence of anti-hepatitis C seropositivity among monogamous women in Turkey, Contraception 80: 261, 2009.
449. **Sawtelle AL**, **Chappell NP**, **Miller CR**, Actinomyces-related tubo-ovarian abscess in a poorly controlled type II diabetic with a copper intrauterine device, Mil Med 182:1874, 2017.
450. **Chapin DS**, **Sullinger JC**, A 43-year old woman with left buttock pain and a presacral mass, N Engl J Med 323:183, 1990.
451. **Keebler C**, **Chatwani A**, **Schwartz R**, Actinomycosis infection associated with intrauterine contraceptive devices, Am J Obstet Gynecol 145:596, 1983.
452. **Fiorino AS**, Intrauterine contraceptive device-associated actinomycotic abscess and Actinomyces detection on cervical smear, Obstet Gynecol 87:142, 1996.
453. **Duguid HLD**, Actinomycosis and IUDs, IPPF Med Bull 17:3, 1983.
454. **Petitti DB**, **Yamamoto D**, **Morgenstern N**, Factors associated with actinomyces-like organisms on Papanicolaou smear in users of IUDs, Am J Obstet Gynecol 145:338, 1983.
455. **Merki-Feld GS**, **Lebeda E**, **Hogg B**, **Keller PJ**, The incidence of actinomyces-like organisms in Papanicolaou-stained smears of copper- and levonorgestrel-releasing intrauterine devices, Contraception 61:365, 2000.
456. **Westhoff C**, IUDs and colonization or infection with Actinomyces, Contraception 75:S48, 2007.
457. **Persson E**, **Holmberg K**, **Dahlgren S**, **Nielsson L**, Actinomyces israelii in genital tract of women with and without intrauterine contraception devices, Acta Obstet Gynecol Scand 62:563, 1983.
458. **Yeo JK**, **Youm J**, **Kim JH**, **Jee BC**, Actinomyces-like organisms in cervical smears: the association with intrauterine device and pelvic inflammatory disease, Obstet Gynecol Sci 57:393, 2014.
459. **Merki-Feld GS**, **Rosselli M**, **Imthurn B**, Comparison of two procedures for routine IUD exchange in women with positive Pap smears for actinomyces-like organisms, Contraception 77:177, 2008.
460. **Hill GB**, Eubacterium nodatum mimics Actinomyces in intrauterine device-associated infections and other settings within the female genital tract, Obstet Gynecol 79:534, 1992.
461. **Stubblefield P**, **Fuller A**, **Foster S**, Ultrasound-guided intrauterine removal of intrauterine contraceptive devices in pregnancy, Obstet Gynecol 72:961, 1988.
462. **Lewit S**, Outcome of pregnancy with intrauterine device, Contraception 2:47, 1970.
463. **Alvior GT Jr**, Pregnancy outcome with removal of intrauterine device, Obstet Gynecol 41:894, 1973.
464. **Assaf A**, **Gohar M**, **Saad S**, **El-Nashar A**, **Abdel Aziz A**, Removal of intrauterine devices with missing tails during early pregnancy, Contraception 45:541, 1992.
465. **Cohen SB**, **Bouaziz J**, **Bar-on A**, **Schiff E**, **Goldenberg M**, **Mashiach R**, In-office hysteroscopic extraction of intrauterine devices in pregnant patients who underwent prior ultrasound-guided extraction failure, J Minim Invasive Gynecol, 24:833, 2017.
466. **Foreman H**, **Stadel BV**, **Schlesselman S**, Intrauterine device usage and fetal loss, Obstet Gynecol 58:669, 1981.
467. **United Kingdom Family Planning Research Network**, Pregnancy outcome associated with the use of IUDs, Br J Fam Plann 15:7, 1989.
468. **Williams P**, **Johnson B**, **Vessey M**, Septic abortion in women using intrauterine devices, Br Med J iv:263,

1975.
469. **Schaeffer SF**, **Gimovsky AC**, **Aly H**, **Mohamed MA**, Pregnancy and delivery with an intrauterine device in situ: outcomes in the National Inpatient Sample Database, J Matern Fetal Neonatal Med 26:1, 2017.
470. **Guillebaud J**, IUD and congenital malformation, Br Med J i:1016, 1975.
471. **Layde PM**, **Goldberg MF**, **Safra MJM**, **Oakley GP**, Failed intrauterine device contraception and limb reduction deformities: a case-control study, Fertil Steril 31:18, 1979.
472. **Suhonen S**, **Haukkamaa M**, **Jakobsson T**, **Rauramo I**, Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study, Contraception 69:407, 2004.
473. **Veldhuis HM**, **Vos AG**, **Lagro-Janssen ALM**, Complications of the intrauterine device in nulliparous and parous women, Eur J Contracept Reprod Health Care 10:82, 2004.
474. **Newton J**, **Tacchi D**, Long-term use of copper intrauterine devices, Br J Fam Plann 16:116, 1990.
475. **Haimov-Kochman R**, **Ackerman Z**, **Anteby EY**, The contraceptive choice for a Wilson's disease patient with chronic liver disease, Contraception 56:241, 1997.
476. **Kjos SL**, **Ballagh SA**, **La Cour M**, **Xiang A**, **Mishell DR Jr**, The copper T380A intrauterine device in women with Type II diabetes mellitus, Obstet Gynecol 84:1006, 1994.
477. **Sanders JN**, **Turok DK**, **Gawron LM**, **Law A**, **Wen L**, **Lynen R**, Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review, Am J Obstet Gynecol 216:590e1, 2017.
478. **Diedrich JT**, **Madden T**, **Zhao Q**, **Peipert JF**, Long-term utilization and continuation of intrauterine devices, Am J Obstet Gynecol 213:822, 2015.
479. **Duenas JL**, **Albert A**, **Carrasco F**, Intrauterine contraception in nulligravid vs parous women, Contraception 53:23, 1996.
480. **Hubacher D**, **Lara-Ricalde R**, **Taylor DJ**, **Guerra-Infante F**, **Guzman-Rodriguez R**, Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women, N Engl J Med 345:561, 2001.
481. **Doll H**, **Vessey M**, **Painter R**, Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception, Br J Obstet Gynaecol 108:304, 2001.
482. **Andersson K**, **Batar I**, **Rybo G**, Return to fertility after removal of a levonorgestrel-releasing intra-uterine device and Nova T, Contraception 46:575, 1992.
483. **Bastianelli C**, **Farris M**, **Lippa A**, **Lucantoni V**, **Valente A**, [Use of intrauterine device by nulliparous women. Prospective study and preliminary data], Minerva Ginecol 50:231, 1998.
484. **Edelman D**, **Van Os W**, Safety of intrauterine contraception, Adv Contracept 6:207, 1990.
485. **Mishell DR Jr**, **Roy S**, Copper intrauterine contraceptive device event rates following insertion 4 to 8 weeks post partum, Am J Obstet Gynecol 143:29, 1982.
486. **Zhuang L**, **Wang H**, **Yang P**, Observations of the clinical efficacies and side effects of six different timings of IUD insertions, Chin J Obstet Gynecol 22:350, 1987.
487. **Chi I-C**, **Farr G**, Postpartum IUD contraception—a review of an international experience, Adv Contracept 5:127, 1989.
488. **Celen S**, **Möröy P**, **Sucak A**, **Aktulay A**, **Danisman N**, Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices, Contraception 69:279, 2004.
489. **Zhou S**, **Chi I-C**, Immediate postpartum IUD insertions in a Chinese hospital—a two-year follow-up, Int J Gynaecol Obstet 35:157, 1991.
490. **Chi I-C**, **Potts M**, **Wilkens L**, **Champion C**, Performance of the TCu-380A device in breastfeeding and non-breastfeeding women, Contraception 39:603, 1989.
491. **Andersson K**, **Ryde-Blomqvist E**, **Lindell K**, **Odlind V**, **Milsom I**, Perforations with intrauterine devices. Report from a Swedish survey, Contraception 57:251, 1998.
492. **White MK**, **Ory HW**, **Rooks JB**, **Rochat RW**, Intrauterine device termination rates and the menstrual cycle day of insertion, Obstet Gynecol 55:220, 1980.
493. **Korjamo R**, **Mentula M**, **Heikinheimo O**, Expulsions and adverse events following immediate and later

insertion of a levonorgestrel-releasing intrauterine system after medical termination of late first- and second-trimester pregnancy: a randomized controlled trial, BJOG 124:1965, 2017.
494. **Querido L**, **Ketting E**, **Haspels AA**, IUD insertion following induced abortion, Contraception 31:603, 1985.
495. **Reeves MF**, **Smith KJ**, **Creinin MD**, Contraceptive effectiveness of immediate compared with delayed insertion of intrauterine devices after abortion: a decision analysis, Obstet Gynecol 110:1286, 2007.
496. **Rabin JM**, **Spitzer M**, **Dwyer AT**, **Kaiser IM**, Topical anesthesia for gynecologic procedures, Obstet Gynecol 73:1040, 1984.
497. **Anteby E**, **Revel A**, **Ben-Chetrit A**, **Rosen B**, **Tadmor O**, **Yagel S**, Intrauterine device failure: relation to its location within the uterine cavity, Obstet Gynecol 81:112, 1993.
498. **Stanback J**, **Grimes D**, Can intrauterine device removals for bleeding or pain be predicted at a one-month follow-up visit? A multivariate analysis, Contraception 58:357, 1998.
499. **Grimes DA**, **Schulz KF**, Antibiotic prophylaxis for intrauterine contraceptive device insertion, Cochrane Database Syst Rev (2):CD001327, 2000.
500. **Sachs BP**, **Gregory K**, **McArdle C**, **Pinshaw A**, Removal of retained intrauterine contraceptive devices in pregnancy, Am J Perinatol 9:139, 1992.
501. **Gorsline J**, **Osborne N**, Management of the missing intrauterine contraceptive device: report of a case, Am J Obstet Gynecol 153:228, 1985.
502. **Adoni A**, **Chetrit AB**, The management of intrauterine devices following uterine perforation, Contraception 43:77, 1991.
503. **Markovitch O**, **Klein Z**, **Gidoni Y**, **Holzinger M**, **Beyth Y**, Extrauterine mislocated IUD: is surgical removal mandatory? Contraception 66:105, 2002.
504. **Gronlund B**, **Blaabjerg J**, Serious intestinal complication five years after insertion of a Nova-T, Contraception 44:517, 1991.

Chapter twenty four

REFERENCES

1. **Himes NE**, Medical History of Contraception, Williams & Wilkins, Baltimore, 1936.
2. **Gamble CJ**, Spermicidal times as aids to the clinician's choice of contraceptive materials, Fertil Steril 8:174, 1957.
3. **Trussell J**, **Vaughan B**, Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth, Fam Plann Perspect 31:64, 1999.
4. **Fu H**, **Darroch JE**, **Haas T**, **Ranjit N**, Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth, Fam Plann Perspect 31:58, 1999.
5. **Kost K**, **Singh S**, **Vaughan B**, **Trussell J**, **Bankole A**, Estimates of contraceptive failure from the 2002 National Survey of Family Growth, Contraception 77:10, 2008.
6. **Grimes DA**, **Cates W Jr**, Family planning and sexually transmitted diseases, In: Holmes KK, Mardh P-A, Sparling PF, eds. Sexually Transmitted Diseases, 2nd ed, McGraw-Hill, New York, 1990, p. 1087.
7. **Cramer DW**, **Goldman MB**, **Schiff I**, **Belisla S**, **Albrecht B**, **Stadel B**, **Gibson M**, **Wilson E**, **Stillman R**, **Thompson I**, The relationship of tubal infertility to barrier method and oral contraceptive use, JAMA 257:2446, 1987.
8. **Rosenberg MJ**, **Davidson AJ**, **Chen J-H**, **Judson FN**, **Douglas JM**, Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms, Am J Pub Health 82:669, 1992.
9. **Rowe PJ**, You win some and you lose some—contraception and infections, Aust N Z Obstet Gynaecol 34:299, 1994.
10. **Cates W Jr**, **Stone K**, Family planning, sexually transmitted diseases and contraceptive choice: a literature update: part I, Fam Plann Perspect 24:75, 1992.
11. **Kost K**, **Forrest JD**, **Harlap S**, Comparing the health risks and benefits of contraceptive choices, Fam Plann Perspect 23:54, 1991.
12. **Feldblum PJ**, **Kuyoh MA**, **Bwayo JJ**, **Omari M**, **Wong EL**, **Tweedy KG**, **Welsh MJ**, Female condom introduction and sexually transmitted infection prevalence: results of a community intervention trial in Kenya, AIDS 15:1037, 2001.
13. **French PP**, **Latka M**, **Gollub EL**, **Rogers C**, **Hoover DR**, **Stein ZA**, Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women, Sex Transm Dis 30:433, 2003.
14. **Coker AL**, **Hulka BS**, **McCann MF**, **Walton LA**, Barrier methods of contraception and cervical intraepithelial neoplasia, Contraception 45:1, 1992.
15. **Schwartz B**, **Gaventa S**, **Broome CV**, **Reingold AL**, **Hightower AW**, **Perlman JA**, **Wolf PH**, Nonmenstrual toxic shock syndrome associated with barrier contraceptives: report of a case-control study, Rev Infect Dis 11(Suppl):S43, 1989.
16. **Klonoff-Cohen HS**, **Savitz DA**, **Cefalo RC**, **McCann MF**, An epidemiologic study of contraception and preeclampsia, JAMA 262:3143, 1989.
17. **Mills JL**, **Klebanoff MA**, **Graubard BI**, **Carey JC**, **Berendes HW**, Barrier contraceptive methods and preeclampsia, JAMA 265:70, 1991.
18. **Guttmacher Institute**, Contraceptive Use in the United States, Fact Sheet, September 2016.
19. **Cook L**, **Nanda K**, **Grimes D**, The diaphragm with and without spermicide for contraception: a Cochrane review, Hum Reprod 17:867, 2002.
20. **Fihn SD**, **Latham RH**, **Roberts P**, **Running K**, **Stamm WE**, Association between diaphragm use and urinary tract infection, JAMA 254:240, 1985.
21. **Hooton TM**, **Scholes D**, **Hughes JP**, **Winter C**, **Roberts PL**, **Stapleton AE**, **Stergachis A**, **Stamm WE**, A prospective study of risk factors for symptomatic urinary tract infection in young women, New Engl J Med 335:468, 1996.
22. **Hooton TM**, **Hillier S**, **Johnson C**, **Roberts P**, **Stamm WE**, Escherichia coli bacteriuria and contraceptive method, JAMA 265:64, 1991.

23. **Centers for Disease Control and Prevention**, Toxic shock syndrome, United States, 1970–1982, MMWR 31:201, 1982.
24. **Keith L**, **Berger G**, **Moss W**, Prevalence of gonorrhea among women using various methods of contraception, Br J Venereal Dis 51:307, 1975.
25. **Kelaghan J**, **Rubin GL**, **Ory HW**, **Layde PM**, Barrier method contraceptives and pelvic inflammatory disease, JAMA 248:184, 1982.
26. **Padian NS**, **van der Straten A**, **Ramjee G**, **Chipato T**, **de Bruyn G**, **Blanchard K**, **Shiboski S**, **Montgomery ET**, **Fancher H**, **Cheng H**, **Rosenblum M**, **van der Laan M**, **Jewell N**, **McIntyre J**; **MIRA Team**, Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomized controlled trial, Lancet 370:251, 2007.
27. **Coffey PS**, **Kilbourne-Brook M**, **Brache V**, **Cochón L**, Comparative acceptability of the SILCS and Ortho ALL-FLEX diaphragms among couples in the Dominican Republic, Contraception 78:418, 2008.
28. **Shihata AA**, The FemCap: a new contraceptive choice, Eur J Contracept Reprod Health Care 3:160, 1998.
29. **Mauck C**, **Callahan M**, **Weiner DH**, **Dominik R**; the **FemCap® Investigators Group**, A comparative study of the safety and efficacy of FemCap®, a new vaginal barrier contraceptive, and the Ortho All-Flex® diaphragm, Contraception 60:71, 1999.
30. **Bernstein G**, **Kilzer LH**, **Coulson AH**, **Nakamara RM**, **Smith GC**, **Bernstein R**, **Frezieres R**, **Clark VA**, **Coan C**, Studies of cervical caps, Contraception 26:443, 1982.
31. **Richwald GA**, **Greenland S**, **Gerber MM**, **Potik R**, **Kersey L**, **Comas MA**, Effectiveness of the cavity-rim cervical cap: results of a large clinical study, Obstet Gynecol 74:143, 1989.
32. **Gollub EL**, **Sivin I**, The Prentif cervical cap and pap smear results: a critical appraisal, Contraception 40:343, 1989.
33. **Hunt WL**, **Gabbay L**, **Potts M**, Lea's Shield®, a new barrier contraceptive; preliminary clinical evaluations, three-day tolerance study, Contraception 50:551, 1994.
34. **Archer DF**, **Mauck CK**, **Viniegra-Sibal A**, **Anderson FD**, Lea's Shield®: a phase I postcoital study of a new contraceptive barrier device, Contraception 52: 167, 1995.
35. **Mauck C**, **Glover LH**, **Miller E**, **Allen S**, **Archer DF**, **Blumenthal P**, **Rosenzweig BA**, **Dominik R**, **Sturgen K**, **Cooper J**, **Fingerhut F**, **Peacock L**, **Gabelnick HL**, Lea's Shield®: a study of the safety and efficacy of a new vaginal barrier contraceptive used with and without spermicide, Contraception 53:329, 1996.
36. **Roizen J**, **Richardson S**, **Tripp J**, **Hardwicke H**, **Lam TQ**, Oves contraceptive cap: short-term acceptability, aspects of use and user satisfaction, J Fam Plann Reprod Health Care 28:188, 2002.
37. **Courtot AM**, **Nikas G**, **Gravanis A**, **Psychoyos A**, Effects of cholic acid and "Protectaid" formulations on human sperm motility and ultrastructure, Hum Reprod 9:1999, 1994.
38. **Psychoyos A**, **Creatsas G**, **Hassan E**, Spermicidal and antiviral properties of cholic acid: contraceptive efficacy of a new vaginal sponge (Protectaid®) containing sodium cholate, Hum Reprod 8:866, 1993.
39. **Trussell J**, **Hatcher RA**, **Cates W Jr**, **Stewart FH**, **Kost K**, Contraceptive failure in the United States: an update, Stud Fam Plann 21:51, 1990.
40. **Edelman DA**, **McIntyre SL**, **Harper J**, A comparative trial of the Today contraceptive sponge and diaphragm: a preliminary report, Am J Obstet Gynecol 150:869, 1984.
41. **Creatsas G**, **Guerrero E**, **Guilbert E**, **Drouin J**, **Serfaty D**, **Lemieux L**, **Suissa S**, **Colin P**, A multinational evaluation of the efficacy, safety and acceptability of the Protectaid contraceptive sponge, Eur J Contracept Reprod Health Care 6:172, 2001.
42. **McIntyre SL**, **Higgins JE**, Parity and use-effectiveness with the contraceptive sponge, Am J Obstet Gynecol 155:796, 1986.
43. **Costello Daly C**, **Helling-Giese GE**, **Mati JK**, **Hunter DJ**, Contraceptive methods and the transmission of HIV: implications for family planning, Genitourin Med 70:110, 1994.
44. **Hicks DR**, **Martin LS**, **Getchell JP**, **Health JL**, **Francis DP**, **McDougal JS**, **Curran JW**, **Voeller B**, Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro, Lancet ii:1422, 1985.
45. **Kreiss J**, **Ngugi E**, **Holmes K**, **Ndinya-Achola J**, **Waiyaki P**, **Roberts PL**, **Ruminjo I**, **Sajabi R**, **Kimata**

J, **Fleming TR**, **Anzala A**, **Holton D**, **Plummer F**, Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes, JAMA 268:477, 1992.
46. **Mendez F**, **Castro A**, Prevention of sexual transmission of AIDS/STD by a spermicide containing benzalkonium chloride, Arch AIDS Res 4:115, 1990.
47. **Zekeng L**, **Feldblum PJ**, **Oliver RM**, **Kaptue L**, Barrier contraceptive use and HIV infection among high risk women in Cameroon, AIDS 7:725, 1993.
48. **Wittkowski KM**, **Susser E**, **Kietz K**, The protective effect of condoms and nonoxynol-9 against HIV infection, Am J Public Health 88:590, 1998.
49. **Centers for Disease Control and Prevention**, Nonoxynol-9 spermicide contraception use—United States, 1999, MMWR 51:389, 2002.
50. **Van Damme L**, **Ramjee G**, **Alary M**, **Vuylsteke B**, **Chandeying V**, **Rees H**, **Sirivongrangson P**, **Mukenge-Tshibaka L**, **Ettiegne-Traore V**, **Uaheowitchai C**, **Karim SS**, **Masee B**, **Perriens J**, **Laga M**; for the **COL-1492 Study Group**, Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial, Lancet 360:971, 2002.
51. **Louv WC**, **Austin H**, **Alexander WJ**, **Stagno S**, **Cheeks J**, A clinical trial of nonoxynol-9 as a prophylaxis for cervical Neisseria gonorrhoeae and Chlamydia trachomatis infections, J Infect Dis 158:518, 1988.
52. **Austin H**, **Louv WC**, **Alexander WJ**, A case-control study of spermicides and gonorrhea, JAMA 251:2822, 1984.
53. **Niruthisard S**, **Roddy RE**, **Chutivongse S**, Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections, Lancet 339:1371, 1992.
54. **Roddy RE**, **Zekeng L**, **Ryan KA**, **Tamoufém U**, **Weir SS**, **Wong EL**, A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases, New Engl J Med 339:504, 1998.
55. **Roddy RE**, **Zekeng L**, **Ryan KA**, **Tamoufe U**, **Tweedy KG**, Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial, JAMA 287:1117, 2002.
56. **Richardson BA**, **Lavreys L**, **Martin HL** Jr, **Stevens CE**, **Ngugi E**, **Mandaliya K**, **Bwayo J**, **Ndinya-Achola J**, **Kreiss JK**, Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial, Sex Transm Dis 28:394, 2001.
57. **Barbone F**, **Austin H**, **Louv WC**, **Alexander WJ**, A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis, Am J Obstet Gynecol 163:510, 1990.
58. **Raymond E**, **Dominik R**; **The Spermicide Trial Group**, Contraceptive effectiveness of two spermicides: a randomized trial, Obstet Gynecol 93:896, 1999.
59. **Raymond EG**, **Chen PL**, **Luoto J**; for the **Spermicide Trial Group**, Contraceptive effectiveness and safety of five nonoxynol-9 spermicides: a randomized trial, Obstet Gynecol 103:430, 2004.
60. **Louik C**, **Mitchell AA**, **Werler MM**, **Hanson JW**, **Shapiro S**, Maternal exposure to spermicides in relation to certain birth defects, New Engl J Med 317:474, 1987.
61. **Bracken MB**, **Vita K**, Frequency of non-hormonal contraception around conception and association with congenital malformations in offspring, Am J Epidemiol 117:281, 1983.
62. **Einarson TR**, **Koren G**, **Mattice D**, **Schechter-Tsafiri O**, Maternal spermicide use and adverse reproductive outcome: a meta-analysis, Am J Obstet Gynecol 162:655, 1990.
63. **Malyk B**, Preliminary results: serum chemistry values before and after the intravaginal administration of 5% nonoxynol-9 cream, Fertil Steril 35:647, 1981.
64. **Niruthisard S**, **Roddy RE**, **Chutivonge S**, The effects of frequent nonoxynol-9 use on vaginal and cervical mucosa, Sex Transm Dis 268:521, 1991.
65. **Roddy RE**, **Cordero M**, **Cordero C**, **Fortney JA**, A dosing study of nonoxynol-9 and genital irritation, AIDS 4:165, 1993.
66. **Hooton TM**, **Fennell CL**, **Clark AM**, **Stamm WE**, Nonoxynol-9: differential antibacterial activity and enhancement of bacterial adherence to vaginal epithelial cells, J Infect Dis 164:1216, 1991.
67. **Skoler-Karpoff S**, **Ramjee G**, **Ahmed K**, **Altini L**, **Plagianos MG**, **Friedland B**, **Govender S**, **De Kock A**, **Cassim N**, **Palanee T**, **Dozier G**, **Maguire R**, **Lahteenmaki P**, Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial, Lancet 372:1977,

2008.
68. **Ballagh SA**, **Brache V**, **Mauck C**, **Callahan MM**, **Cochon L**, **Wheeless A**, **Moench TR**, **A Phase I study of the functional performance, safety and acceptability of the BufferGel® Duet™**, Contraception 77:130, 2008.
69. **Mayer KH**, **Abdool Karim SS**, **Kelly C**, **Maslankowski L**, **Rees H**, **Profy AT**, et al., Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women, AIDS 17:321, 2003.
70. **Abdool Karim SS**, **Richardson BA**, **Ramjee G**, **Hoffman IF**, **Chirenje ZM**, et al., Safety and effectiveness of BufferGel and 0.5%PRO2000 Gel for the prevention of HIV infection in women, AIDS 25:957, 2011.
71. **Williams DL**, **Newman DR**, **Ballagh SA**, **Creinin MD**, **Barnhart K**, **Weiner DH**, **Bell AJ**, **Jamieson DJ**, Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY jelly used with a diaphragm, Sex Transm Dis 34:977, 2007.
72. **Stone KM**, **Grimes DA**, **Magder LS**, Primary prevention of sexually transmitted diseases. A primer for clinicians, JAMA 255:1763, 1986.
73. **Van de Perre P**, **Jacobs D**, **Sprecher-Goldberger S**, The latex condom, an efficient barrier against sexual transmission of AIDS-related viruses, AIDS 1:49, 1987.
74. **Winer RL**, **Hughes JP**, **Feng Q**, **O'Reilly S**, **Kiviat NB**, **Holmes KK**, **Koutsky LA**, Condom use and the risk of genital human papillomavirus infection in young women, New Engl J Med 354:2645, 2006.
75. **Fihn SD**, **Boyko EJ**, **Normand EH**, **Chen C-L**, **Grafton JR**, **Hunt M**, **Yarbro P**, **Scholes D**, **Stergachis A**, Association between use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women, Am J Epidemiol 144:512, 1996.
76. **DeVincenzi I**; for the **European Study Group on Heterosexual Transmission of HIV**, A longitudinal study of human immunodeficiency virus transmission by heterosexual partners, New Engl J Med 331:341, 1994.
77. **Davis KR**, **Weller SC**, The effectiveness of condoms in reducing heterosexual transmission of HIV, Fam Plann Perspect 31:272, 1999.
78. **Diaz T**, **Schable B**, **Chu SY**; the **Supplement to HIV and AIDS Surveillance Project Group**, Relationship between use of condoms and other forms of contraception among human immunodeficiency virus-infected women, Obstet Gynecol 86:277, 1995.
79. **Wald A**, **Langenberg AG**, **Link K**, **Izu AE**, **Ashley R**, **Warren T**, **Tyring S**, **Douglas JM Jr**, **Corey L**, Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women, JAMA 285:3100, 2001.
80. **Frezieres RG**, **Walsh TL**, **Nelson AL**, **Clark VA**, **Coulson AH**, Breakage and acceptability of a polyurethane condom: a randomized, controlled study, Fam Plann Perspect 30:73, 1998.
81. **Steiner MJ**, **Dominik R**, **Rountree RW**, **Nanda K**, **Dorflinger L**, Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial, Obstet Gynecol 101:539, 2003.
82. **Grady WR**, **Klepinger DH**, **Billy JOG**, **Tanfer K**, Condom characteristics: the perceptions and preferences of men in the United States, Fam Plann Perspect 25:67, 1993.
83. **Trussell J**, **Warner DL**, **Hatcher RA**, Condom slippage and breakage rates, Fam Plann Perspect 24:20, 1992.
84. **Martinez GM**, **Abma JC**, Sexual activity, contraceptive use, and childbearing of teenagers aged 15–19 in the United States, NCHS Data Brief 209, July 2015.
85. **Sparrow MJ**, **Lavill K**, Breakage and slippage of condoms in family planning clients, Contraception 50:117, 1994.
86. **Rosenberg MJ**, **Waugh MS**, Latex condom breakage and slippage in a controlled clinical trial, Contraception 56:17, 1997.
87. **Population Information Program**, Population Reports, Condoms, Now More than Ever, The Johns Hopkins University, Baltimore, Report No. H-81, 1990.
88. **Walsh TL**, **Frezieres RG**, **Peacock K**, **Nelson AL**, **Clark VA**, **Bernstein L**, **Wraxall BGD**, Use of prostate-specific antigen (PSA) to measure semen exposure resulting from male condom failures: implications

for contraceptive efficacy and the prevention of sexually transmitted disease, Contraception 67: 139, 2003.
89. **Platt R**, **Rice PA**, **McCormack WM**, Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea, JAMA 250:3205, 1983.
90. **Hooper RR**, **Reynolds GM**, **Jones OG**, **Zaidi A**, **Wiesner RJ**, **Latimer KP**, **Lester A**, **Campbell AF**, **Harrison WO**, **Karney WW**, **Holmes KK**, Cohort study of venereal disease. I. The risk of gonorrhea transmission from infected women to men, Am J Epidemiol 108:136, 1978.
91. **Donnell, D**, **Baeten JM**, **Kiarie J**, **Thomas KK**, **Stevens W**, et al., Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis, Lancet 375:2092, 2010.
92. **Quinn TC**, **Wawer MJ**, **Sewankambo N**, **Serwadda D**, **Li C**, **Wabwire-Mangen F**, **Meehan MO**, **Lutalo T**, **Gray RH**, Viral load and heterosexual transmission of human immunodeficiency virus type 1, N Engl J Med 342:921, 2000.
93. **Anderson RM**, **Medley GF**, Epidemiology of HIV infection and AIDS: incubation and infectious periods, survival and vertical transmissions, AIDS 2 (Suppl 1):557, 1988.
94. **Cameron DW**, **Simonsen JN**, **D'Costa LJ**, **Ronald AR**, **Maitha GM**, **Gakinya MN**, **Cheang M**, et al., Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men, Lancet ii:403, 1989.
95. **Soper DE**, **Brockwell NJ**, **Dalton JP**, Evaluation of the effects of a female condom on the female lower genital tract, Contraception 44:21, 1991.
96. **Drew WL**, **Blair M**, **Miner RC**, **Conant M**, Evaluation of the virus permeability of a new condom for women, Sex Transm Dis 17:110, 1990.
97. **Beksinska M**, **Rees HV**, **Dickson-Tetteh KE**, **Mqoqi N**, **Kleinschmidt I**, **McIntyre JA**, Structural integrity of the female condom after multiple uses, washing, drying, and re-lubrication, Contraception 63:33, 2001.
98. **Bounds W**, **Guillebaud J**, **Newman GB**, Female condom (Femidom). A clinical study of its use-effectiveness and patient acceptability, Br J Fam Plann 18:36, 1992.
99. **Trussell J**, **Sturgen K**, **Strickler J**, **Dominik R**, Comparative contraceptive efficacy of the female condom and other barrier methods, Fam Plann Perspect 26:66, 1994.
100. **Farr G**, **Gabelnick H**, **Sturgen K**, **Dorflinger L**, Contraceptive efficacy and acceptability of the female condom, Am J Public Health 84:1960, 1994.
101. **Trussell J**, Contraceptive efficacy of the Reality® female condom, Contraception 58:147, 1998.
102. **Zukerman Z**, **Weiss DB**, **Orvieto R**, Does preejaculatory penile secretion originating from Cowper's gland contain sperm?, J Assist Reprod Genet 20:157, 2003.
103. **Ilaria G**, **Jacobs JL**, **Polsky B**, **Koll B**, **Baron P**, **MacLow C**, **Armstrong DK**, **Schlegel PN**, Detection of HIV-1 DNA sequences in pre-ejaculatory fluid, Lancet 340:1469, 1992.
104. **Pudney J**, **Oneta M**, **Mayer K**, **Seage 3rd G**, **Anderson D**, Pre-ejaculatory fluid as potential vector for sexual transmission of HIV-1, Lancet 340:1470, 1992.
105. **Killick, SR**, **Leary C**, **Trussell J**, **Guthrie KA**, Sperm content of pre-ejaculatory fluid, Hum Fertil 14:48, 2011.
106. **Jones RK**, **Fennell J**, **Higgins JA**, **Blanchard K**, Better than nothing or savvy risk-reduction practice? The importance of withdrawal, Contraception 79:407, 2009.
107. **Sznitman SR**, **Romer D**, **Brown LK**, **DiClemente RJ**, **Valois RF**, **Vanable PA**, **Carey MP**, **Stanton B**, Prevalence, correlates, and sexually transmitted infection risk related to coitus interruptus among African-American adolescents, Sex Transm Dis 36:218, 2009.
108. **Woods JL**, **Hensel DJ**, **Fortenberry JD**, Contraceptive withdrawal in adolescents: a complex picture of usage, J Pediatr Adolesc Gynecol 22:233, 2009.

Chapter twenty five

REFERENCES

1. **Practice Committee of the American Society for Reproductive Medicine**, Definitions of infertility and recurrent pregnancy loss, Fertil Steril 99(1):63, 2013.
2. **Wang X**, **Chen C**, **Wang L**, **Chen D**, **Guang W**, **French J**, Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study, Fertil Steril 79:577, 2003.
3. **Gnoth C**, **Godehardt D**, **Godehardt E**, **Frank-Herrmann P**, **Freundl G**, Time to pregnancy: results of the German prospective study and impact on the management of infertility, Hum Reprod 18:1959, 2003.
4. **Thoma ME**, **McLain AC**, **Louis JF**, **King RB**, **Trumble AC**, **Sundaram R**, **Buck Louis GM**, Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach, Fertil Steril 99(5):1324.e1, 2013.
5. **Centers for Disease Control and Prevention**, National Survey of Family Growth, https://www.cdc.gov/nchs/nsfg/key_statistics/i.htm#infertility. Accessed on January 16, 2018.
6. **Martin JA**, **Hamilton BE**, **Osterman MJK**, **Driscoll AK**, **Mathews TJ**, Births: final data for 2015, Natl Vital Stat Rep 66:1, 2017.
7. **Ventura SJ**, **Martin JA**, **Curtin SC**, **Mathews TJ**, Report of final natality statistics, 1996, Mon Vital Stat Rep 46:1, 1998.
8. **Ventura SJ**, **Hamilton BE**, **Sutton PD**, Revised birth and fertility rates for the United States, 2000 and 2001, Natl Vital Stat Rep 51:1, 2003.
9. **Ryan CL**, **Bauman K**, Educational Attainment in the United States: 2015, in Current Population Reports, U.S. Census Bureau, Washington, D.C., 2016.
10. **Bureau of Labor Statistics, Employment Projections**, Civilian Labor Force Participation Rate by Age, Sex, Race and Ethnicity, October 24, 2017, https://www.bls.gov/emp/ep_table_303.htm
11. **Norton AJ**, **Miller L**, United States Bureau of the Census, Marriage, divorce, and remarriage in the 1990's, U.S. Census Bureau, Washington, D.C., 1992.
12. **Kreider RM**, **Ellis R**, Number, Timing, and Duration of Marriages and Divorces: 2009. Current Population Reports, U.S. Census Bureau, Washington, D.C., 2011, pp. 70–125.
13. **Kreider R**, **Fields J**, Number, Timing, and Duration of Marriages and Divorces, 1996, U.S. Dept. of Commerce Economics and Statistics Administration, U.S. Census Bureau, Washington, D.C., 2002.
14. **National Center for Health Statistics (U.S.)**, Vital Statistics of the United States: Marriage and Divorce for 1989 to 1995, U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, MD; Washington, D.C., 1997.
15. **National Center for Health Statistics (U.S.)**, Advance report of final marriage statistics, 1989 and 1990, MVSR 43, 1995.
16. **Martin JA**, **Hamilton BE**, **Sutton PD**, **Ventura SJ**, **Menacker F**, **Munson ML**, Births: final data for 2002, Natl Vital Stat Rep 52:1, 2003.
17. **The World Factbook**, https://www.cia.gov/library/publications/the-world- factbook/
18. **Abma JC**, **Chandra A**, **Mosher WD**, **Peterson LS**, **Piccinino LJ**, Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth, Vital Health Stat 23:1, 1997.
19. **Chandra A**, **Stephen EH**, Impaired fecundity in the United States: 1982–1995, Fam Plann Perspect 30:34, 1998.
20. **Stephen EH**, **Chandra A**, Declining estimates of infertility in the United States: 1982–2002, Fertil Steril 86:516, 2006.
21. Key Statistics from the National Survey of Family Growth 2011–2015, https://www.cdc.gov/nchs/fastats/infertility.htm
22. **Mascarenhas MN**, **Flaxman SR**, **Boerma T**, **Vanderpoel S**, **Stevens GA**, National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys, PLoS Med 9(12):e1001356, 2012. doi:10.1371/journal.pmed.1001356.
23. **Stephen EH**, **Chandra A**, Use of infertility services in the United States: 1995, Fam Plann Perspect 32:132,

2000.
24. **Chandra A**, **Stephen EH**, Infertility service use among U.S. women: 1995 and 2002, Fertil Steril 93:725, 2010.
25. Key Statistics from the National Survey of Family Growth 2011–2015, https://www.cdc.gov/nchs/nsfg/key_statistics/i.htm#infertilityservices
26. **Menken J**, **Trussell J**, **Larsen U**, Age and infertility, Science 233:1389, 1986.
27. **Tietze C**, Reproductive span and rate of reproduction among Hutterite women, Fertil Steril 8:89, 1957.
28. **Maroulis GB**, Effect of aging on fertility and pregnancy, Semin Reprod Endocrinol 9:165, 1991.
29. **van Noord-Zaadstra BM**, **Looman CW**, **Alsbach H**, **Habbena JDF**, **te Velde ER**, **Karbaat J**, Delaying child-bearing: effect of age on fecundity and outcome of pregnancy, Br Med J 302:1361, 1991.
30. **Schwartz D**, **Mayaux MJ**, Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. Federation CECOS, N Engl J Med 306:404, 1982.
31. **Virro MS**, **Shewchuk AB**, Pregnancy outcome in 242 conceptions after artificial insemination with donor sperm and effects of maternal age on the prognosis for successful pregnancy, Am J Obstet Gynecol 148:518, 1984.
32. **Shenfield F**, **Doyle P**, **Valentine A**, **Steele SJ**, **Tan S-L**, Effects of age, gravidity and male infertility status on cumulative conception rates following artificial insemination with cryopreserved donor semen: analysis of 2998 cycles of treatment in one centre over 10 years, Hum Reprod 8:60, 1993.
33. **Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology**, 2015 Assisted Reproductive Technology National Summary Report, US Dept of Health and Human Services, Atlanta, GA, 2017.
34. **Stein ZA**, A woman's age: childbearing and child rearing, Am J Epidemiol 121:327, 1985.
35. **Hassold T**, **Chiu D**, Maternal age-specific rates of numerical chromosome abnormalities with special reference to trisomy, Hum Genet 70:11, 1985.
36. **Warburton D**, **Kline J**, **Stein Z**, **Strobino B**, Cytogenetic abnormalities in spontaneous abortions of recognized conceptions, In: Porter IH, ed. Perinatal Genetics: Diagnosis and Treatment, Academic Press, New York, 1986.
37. **Gosden RG**, Maternal age: a major factor affecting the prospects and outcome of pregnancy, Ann N Y Acad Sci 442:45, 1985.
38. **Wilcox AJ**, **Weiberg CR**, **O'Connor JF**, **Baird DD**, **Schlatterer JP**, **Canfield RE**, **Armstrong EG**, **Nisula BC**, Incidence of early loss of pregnancy, N Engl J Med 319:189, 1988.
39. **Zinaman MJ**, **Clegg ED**, **Brown CC**, **O'Connor J**, **Selevan SG**, Estimates of human fertility and pregnancy loss, Fertil Steril 65:503, 1996.
40. **Warburton D**, Reproductive loss: how much is preventable? N Engl J Med 316:158, 1987.
41. **Block E**, Quantitative morphological investigations of the follicular system in women, Acta Anat 14:108, 1952.
42. **Block E**, A quantitative morphological investigation of the follicular system in newborn female infants, Acta Anat (Basel) 17:201, 1953.
43. **Baker TG**, A quantitative and cytological study of germ cells in human ovaries, Proc R Soc Lond B Biol Sci 158:417, 1963.
44. **Vaskivuo TE**, **Anttonen M**, **Herva R**, **Billig H**, **Dorland M**, **te Velde ER**, **Stenback F**, **Heikinheimo M**, **Tapanainen JS**, Survival of human ovarian follicles from fetal to adult life: apoptosis, apoptosis-related proteins, and transcription factor GATA-4, J Clin Endocrinol Metab 86:3421, 2001.
45. **Markstrom E**, **Svensson E**, **Shao R**, **Svanberg B**, **Billig H**, Survival factors regulating ovarian apoptosis—dependence on follicle differentiation, Reproduction 123:23, 2002.
46. **te Velde ER**, **Pearson PL**, The variability of female reproductive ageing, Hum Reprod Update 8:141, 2002.
47. **Richardson SJ**, **Senikas V**, **Nelson JF**, Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion, J Clin Endocrinol Metab 65:1231, 1987.
48. **Faddy MJ**, **Gosden RG**, A model conforming the decline in follicle numbers to the age of menopause in women, Hum Reprod 11:1484, 1996.
49. **Battaglia DE**, **Goodwin P**, **Klein NA**, **Soules MR**, Influence of maternal age on meiotic spindle assembly in oocytes from naturally cycling women, Hum Reprod 11:2217, 1996.

50. **Gougeon A**, **Echochard R**, **Thalabard JC**, Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women, Biol Reprod 50:653, 1994.
51. **Coxworth JE**, **Hawkes K**, Ovarian follicle loss in humans and mice: lessons from statistical model comparison, Hum Reprod 25(7):1796, 2010.
52. **Gougeon A**, **Chainy GB**, Morphometric studies of small follicles in ovaries of women at different ages, J Reprod Fertil 81:433, 1987.
53. **Faddy MJ**, **Gosden RG**, **Gougeon A**, **Richardson SJ**, **Nelson JF**, Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause, Hum Reprod 7:1342, 1992.
54. **Kirkwood TB**, Ovarian ageing and the general biology of senescence, Maturitas 30:105, 1998.
55. **Leidy LE**, **Godfrey LR**, **Sutherland MR**, Is follicular atresia biphasic? Fertil Steril 70:851, 1998.
56. **Cant MA**, **Johnstone RA**, Reproductive conflict and the separation of reproductive generations in humans, Proc Natl Acad Sci U S A 105:5332, 2008.
57. **Tilly JL**, **Telfer EE**, Purification of germline stem cells from adult mammalian ovaries: a step closer towards control of the female biological clock? Mol Hum Reprod 15:393, 2009.
58. **Faddy MJ**, Follicle dynamics during ovarian ageing, Mol Cell Endocrinol 163:43, 2000.
59. **Hansen KR**, **Knowlton NS**, **Thyer AC**, **Charleston JS**, **Soules MR**, **Klein NA**, A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause, Hum Reprod 23:699, 2008.
60. **Da Silva-Buttkus P**, **Marcelli G**, **Franks S**, **Stark J**, **Hardy K**, Inferring biological mechanisms from spatial analysis: prediction of a local inhibitor in the ovary, Proc Natl Acad Sci U S A 106:456, 2009.
61. **Nilsson E**, **Rogers N**, **Skinner MK**, Actions of anti-Mullerian hormone on the ovarian transcriptome to inhibit primordial to primary follicle transition, Reproduction 134:209, 2007.
62. **Adhikari D**, **Liu K**, Molecular mechanisms underlying the activation of mammalian primordial follicles, Endocr Rev 30:438, 2009.
63. **Klein NA**, **Battaglia DE**, **Fujimoto VY**, **Davis GS**, **Bremmer WJ**, **Soules MR**, Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women, J Clin Endocrinol Metab 81:1038, 1996.
64. **Burger HG**, **Dudley EC**, **Hopper JL**, **Groome N**, **Guthrie JR**, **Green A**, **Dennerstein L**, Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women, J Clin Endocrinol Metab 84:4025, 1999.
65. **Wise PM**, **Smith MJ**, **Dubal DB**, **Wilson ME**, **Rau SW**, **Cashion AB**, **Bottner M**, **Rosewell KL**, Neuroendocrine modulation and repercussions of female reproductive aging, Recent Prog Horm Res 57:235, 2002.
66. **Bellino FL**, **Wise PM**, Nonhuman primate models of menopause workshop, Biol Reprod 68:10, 2003.
67. **Rehman HU**, **Masson EA**, Neuroendocrinology of female aging, Gend Med 2:41, 2005.
68. **Yin W**, **Gore AC**, Neuroendocrine control of reproductive aging: roles of GnRH neurons, Reproduction 131:403, 2006.
69. **Nozaki M**, **Mitsunaga F**, **Shimizu K**, Reproductive senescence in female Japanese monkeys (Macaca fuscata): age- and season-related changes in hypothalamic-pituitary-ovarian functions and fecundity rates, Biol Reprod 52:1250, 1995.
70. **van Look PF**, **Lothian H**, **Hunter WM**, **Michie EA**, **Baird DT**, Hypothalamic-pituitary-ovarian function in perimenopausal women, Clin Endocrinol (Oxf) 7:13, 1977.
71. **Weiss G**, **Skurnick JH**, **Goldsmith LT**, **Santoro NF**, **Park SJ**, Menopause and hypothalamic-pituitary sensitivity to estrogen, JAMA 292:2991, 2004.
72. **Gill S**, **Sharpless JL**, **Rado K**, **Hall JE**, Evidence that GnRH decreases with gonadal steroid feedback but increases with age in postmenopausal women, J Clin Endocrinol Metab 87:2290, 2002.
73. **Hall JE**, **Lavoie HB**, **Marsh EE**, **Martin KA**, Decrease in gonadotropin-releasing hormone (GnRH) pulse frequency with aging in postmenopausal women, J Clin Endocrinol Metab 85:1794, 2000.
74. **Rossmanith WG**, Gonadotropin secretion during aging in women: review article, Exp Gerontol 30:369, 1995.

75. **Kwekkeboom DJ**, **de Jong FH**, **van Hemert AM**, **Vandenbroucke JP**, **Valkenburg HA**, **Lamberts SW**, Serum gonadotropins and alpha-subunit decline in aging normal postmenopausal women, J Clin Endocrinol Metab 70:944, 1990.
76. **de Koning CH**, **Popp-Snijders C**, **Schoemaker J**, **Lambalk CB**, Elevated FSH concentrations in imminent ovarian failure are associated with higher FSH and LH pulse amplitude and response to GnRH, Hum Reprod 15:1452, 2000.
77. **Matt DW**, **Kauma SW**, **Pincus SM**, **Veldhuis JD**, **Evans WS**, Characteristics of luteinizing hormone secretion in younger versus older premenopausal women, Am J Obstet Gynecol 178:504, 1998.
78. **Klein NA**, **Battaglia DE**, **Clifton DK**, **Bremner WJ**, **Soules MR**, The gonadotropin secretion pattern in normal women of advanced reproductive age in relation to the monotropic FSH rise, J Soc Gynecol Investig 3:27, 1996.
79. **Reame NE**, **Kelche RP**, **Beitins IZ**, **Yu MY**, **Zawacki CM**, **Padmanabhan V**, Age effects of follicle-stimulating hormone and pulsatile luteinizing hormone secretion across the menstrual cycle of premenopausal women, J Clin Endocrinol Metab 81:1512, 1996.
80. **Randolph JF**, **Ginsburg KA**, **Leach RE**, **Blacker CM**, **Moghissi KS**, **Diamond MP**, **Reame NE**, Elevated early follicular gonadotropin levels in women with unexplained infertility do not provide evidence for disordered gonadotropin-releasing hormone secretion as assessed by luteinizing hormone pulse characteristics, Fertil Steril 80:320, 2003.
81. **Eshkol A**, **Lunenfeld B**, **Insler V**, The effect of sex steroids on pituitary responsiveness to gonadotropin releasing hormone, J Steroid Biochem 6:1061, 1975.
82. **Fujimoto VY**, **Klein NA**, **Battaglia DE**, **Bremner WJ**, **Soules MR**, The anterior pituitary response to a gonadotropin-releasing hormone challenge test in normal older reproductive-age women, Fertil Steril 65:539, 1996.
83. **Klein NA**, **Battaglia DE**, **Miller PB**, **Branigan EF**, **Giudice LC**, **Soules MR**, Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age, J Clin Endocrinol Metab 81:1946, 1996.
84. **Hofmann GE**, **Danforth DR**, **Seifer DB**, Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening, Fertil Steril 69:474, 1998.
85. **Welt CK**, **McNicholl DJ**, **Taylor AE**, **Hall JE**, Female reproductive aging is marked by decreased secretion of dimeric inhibin, J Clin Endocrinol Metab 84:105, 1999.
86. **Seifer DB**, **Scott RT Jr**, **Bergh PA**, **Abrogast LK**, **Friedman CI**, **Mack CK**, **Danforth DR**, Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone, Fertil Steril 72:63, 1999.
87. **Klein NA**, **Houmard BS**, **Hansen KR**, **Woodruff TK**, **Sluss PM**, **Bremner WJ**, **Soules MR**, Age-related analysis of inhibin A, inhibin B, and activin a relative to the intercycle monotropic follicle-stimulating hormone rise in normal ovulatory women, J Clin Endocrinol Metab 89:2977, 2004.
88. **Hale GE**, **Zhao X**, **Hughes CL**, **Burger HG**, **Robertson DM**, **Fraser IS**, Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system, J Clin Endocrinol Metab 92:3060, 2007.
89. **Knauff EA**, **Eijkemans MJ**, **Lambalk CB**, **ten Kate-Booij MJ**, **Hoek A**, **Beerendonk CC**, **Laven JS**, **Goverde AJ**, **Broekmans FJ**, **Themmen AP**, **de Jong FH**, **Fauser BC**, Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure, J Clin Endocrinol Metab 94:786, 2009.
90. **Burger HG**, **Hale GE**, **Dennerstein L**, **Robertson DM**, Cycle and hormone changes during perimenopause: the key role of ovarian function, Menopause 15:603, 2008.
91. **Welt CK**, **Smith ZA**, **Pauler DK**, **Hall JE**, Differential regulation of inhibin A and inhibin B by luteinizing hormone, follicle-stimulating hormone, and stage of follicle development, J Clin Endocrinol Metab 86:2531, 2001.
92. **Burger HG**, **Dudley EC**, **Hopper JL**, **Shelley JM**, **Green A**, **Smith A**, **Dennerstein L**, **Morse C**, The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample, J Clin Endocrinol Metab 80:3537, 1995.

93. **Burger HG**, **Groome NP**, **Robertson DM**, Both inhibin A and B respond to exogenous follicle-stimulating hormone in the follicular phase of the human menstrual cycle, J Clin Endocrinol Metab 83:4167, 1998.
94. **Landgren BM**, **Collins A**, **Csemiczky G**, **Burger HG**, **Baksheev L**, **Robertson DM**, Menopause transition: annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause, J Clin Endocrinol Metab 89:2763, 2004.
95. **Seifer DB**, **Gardiner AC**, **Ferreira KA**, **Peluso JJ**, Apoptosis as a function of ovarian reserve in women undergoing in vitro fertilization, Fertil Steril 66:593, 1996.
96. **Santoro N**, **Brown JR**, **Adel T**, **Skurnick JH**, Characterization of reproductive hormonal dynamics in the perimenopause, J Clin Endocrinol Metab 81:1495, 1996.
97. **Shideler SE**, **DeVane GW**, **Kalra PS**, **Benirschke K**, **Lasley BL**, Ovarian-pituitary hormone interactions during the perimenopause, Maturitas 11:331, 1989.
98. **de Koning CH**, **McDonnell J**, **Themmen AP**, **de Jong FH**, **Homburg R**, **Lambalk CB**, The endocrine and follicular growth dynamics throughout the menstrual cycle in women with consistently or variably elevated early follicular phase FSH compared with controls, Hum Reprod 23:1416, 2008.
99. **Miro F**, **Parker SW**, **Aspinall LJ**, **Coley J**, **Perry PW**, **Ellis JE**, Sequential classification of endocrine stages during reproductive aging in women: the FREEDOM study, Menopause 12:281, 2005.
100. **Mersereau JE**, **Evans ML**, **Moore DH**, **Liu JH**, **Thomas MA**, **Rebar RW**, **Pennington E**, **Cedars MI**, Luteal phase estrogen is decreased in regularly menstruating older women compared with a reference population of younger women, Menopause 15:482, 2008.
101. **Pal L**, **Zhang K**, **Zeitlian G**, **Santoro N**, Characterizing the reproductive hormone milieu in infertile women with diminished ovarian reserve, Fertil Steril 93:1074, 2010.
102. **Burger H**, The menopausal transition—endocrinology, J Sex Med 5:2266, 2008.
103. **Treloar AE**, **Boynton RE**, **Borghild GB**, **Brown BW**, Variation of the human menstrual cycle through reproductive life, Int J Fertil 12:77, 1967.
104. **Klein NA**, **Harper AJ**, **Houmard BS**, **Sluss PM**, **Soules MR**, Is the short follicular phase in older women secondary to advanced or accelerated dominant follicle development? J Clin Endocrinol Metab 87:5746, 2002.
105. **Hansen KR**, **Thyer AC**, **Sluss PM**, **Bremner WJ**, **Soules MR**, **Klein NA**, Reproductive ageing and ovarian function: is the early follicular phase FSH rise necessary to maintain adequate secretory function in older ovulatory women? Hum Reprod 20:89, 2005.
106. **van Zonneveld P**, **Scheffer GJ**, **Broekmans FJ**, **Blankenstein MA**, **de Jong FH**, **Looman CW**, **Habbema JD**, **te Velde ER**, Do cycle disturbances explain the age-related decline of female fertility? Cycle characteristics of women aged over 40 years compared with a reference population of young women, Hum Reprod 18:495, 2003.
107. **Beemsterboer SN**, **Homburg R**, **Gorter NA**, **Schats R**, **Hompes PG**, **Lambalk CB**, The paradox of declining fertility but increasing twinning rates with advancing maternal age, Hum Reprod 21:1531, 2006.
108. **Lenton EA**, **Landgren BM**, **Sexton L**, Normal variation in the length of the luteal phase of the menstrual cycle: identification of the short luteal phase, Br J Obstet Gynaecol 91:685, 1984.
109. **Miro F**, **Aspinall LJ**, The onset of the initial rise in follicle-stimulating hormone during the human menstrual cycle, Hum Reprod 20:96, 2005.
110. **Hoekstra C**, **Zhao ZZ**, **Lambalk CB**, **Willemsen G**, **Martin NG**, **Boomsma DI**, **Montgomery GW**, Dizygotic twinning, Hum Reprod Update 14:37, 2008.
111. **Vollman RF**, The menstrual cycle, In: Friedman E, ed. Major Problems in Obstetrics and Gynecology, W.B. Saunders Co., Philadelphia, 1977.
112. **Soules MR**, **Sherman S**, **Parrott E**, **Rebar R**, **Santoro N**, **Utian W**, **Woods N**, Executive summary: stages of reproductive aging workshop (STRAW), Fertil Steril 76:874, 2001.
113. **den Tonkelaar I**, **te Velde ER**, **Looman CW**, Menstrual cycle length preceding menopause in relation to age at menopause, Maturitas 29:115, 1998.
114. **Weinstein M**, **Gorrindo T**, **Riley A**, **Mormino J**, **Niedfeldt J**, **Singer B**, **Rodriguez G**, **Simon J**, **Pincus S**, Timing of menopause and patterns of menstrual bleeding, Am J Epidemiol 158:782, 2003.
115. **Treloar AE**, Menstrual cyclicity and the pre-menopause, Maturitas 3:249, 1981.

116. **Lisabeth L**, **Harlow S**, **Qaqish B**, A new statistical approach demonstrated menstrual patterns during the menopausal transition did not vary by age at menopause, J Clin Epidemiol 57:484, 2004.
117. **Broekmans FJ**, **Faddy MJ**, **Scheffer G**, **te Velde ER**, Antral follicle counts are related to age at natural fertility loss and age at menopause, Menopause 11: 607, 2004.
118. **Magursky V**, **Mesko M**, **Sokolik L**, Age at the menopause and onset of the climacteric in women of Martin District, Czechoslovakia. Statistical survey and some biological and social correlations, Int J Fertil 20:17, 1975.
119. **Bengtsson C**, **Lindquist O**, **Redvall L**, Menstrual status and menopausal age of middle-aged Swedish women. A population study of women in Goteborg 1968–69 and 1974–75, Acta Obstet Gynecol Scand 60:269, 1981.
120. **Hagstad A**, **Johansson S**, **Wilhelmsson C**, **Janson PO**, Gynaecology of middle-aged women—menstrual and reproductive histories, Maturitas 7:99, 1985.
121. **Luoto R**, **Kaprio J**, **Uutela A**, Age at natural menopause and sociodemographic status in Finland, Am J Epidemiol 139:64, 1994.
122. **van Noord PA**, **Dubas JS**, **Dorland M**, **Boersma H**, **te Velde E**, Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors, Fertil Steril 68:95, 1997.
123. **de Vries E**, **den Tonkelaar I**, **van Noord PA**, **van der Schouw YT**, **te Velde ER**, **Peeters PH**, Oral contraceptive use in relation to age at menopause in the DOM cohort, Hum Reprod 16:1657, 2001.
124. **Lawlor DA**, **Ebrahim S**, **Smith GD**, The association of socio-economic position across the life course and age at menopause: the British Women's Heart and Health Study, Br J Obstet Gynaecol 110:1078, 2003.
125. **Cramer DW**, **Xu H**, **Harlow BL**, Family history as a predictor of early menopause, Fertil Steril 64:740, 1995.
126. **Torgerson DJ**, **Avenell A**, **Russell IT**, **Reid DM**, Factors associated with onset of menopause in women aged 45–49, Maturitas 19:83, 1994.
127. **Snieder H**, **MacGregor AJ**, **Spector TD**, Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause, J Clin Endocrinol Metab 83:1875, 1998.
128. **Treloar SA**, **Do KA**, **Martin NG**, Genetic influences on the age at menopause, Lancet 352:1084, 1998.
129. **de Bruin JP**, **Bovenhuis H**, **van Noord PA**, **Pearson PL**, **van Arendonk JA**, **te Velde ER**, **Kuurman WW**, **Dorland M**, The role of genetic factors in age at natural menopause, Hum Reprod 16:2014, 2001.
130. **Thomas F**, **Renaud F**, **Benefice E**, **de Meeus T**, **Guegan JF**, International variability of ages at menarche and menopause: patterns and main determinants, Hum Biol 73:271, 2001.
131. **Parazzini F**, Determinants of age at menopause in women attending menopause clinics in Italy, Maturitas 56:280, 2007.
132. **Soares SR**, **Melo MA**, Cigarette smoking and reproductive function, Curr Opin Obstet Gynecol 20:281, 2008.
133. **van Asselt KM**, **Kok HS**, **Pearson PL**, **Dubas JS**, **Peeters PH**, **Te Velde ER**, **van Noord PA**, Heritability of menopausal age in mothers and daughters, Fertil Steril 82:1348, 2004.
134. **Murabito JM**, **Yang Q**, **Fox C**, **Wilson PW**, **Cupples LA**, Heritability of age at natural menopause in the Framingham Heart Study, J Clin Endocrinol Metab 90:3427, 2005.
135. **Torgerson DJ**, **Thomas RE**, **Reid DM**, Mothers and daughters menopausal ages: is there a link? Eur J Obstet Gynecol Reprod Biol 74:63, 1997.
136. **Tibiletti MG**, **Testa G**, **Vegetti W**, **Alagna F**, **Taborelli M**, **Dalpra L**, **Bolis PF**, **Crosignani PG**, The idiopathic forms of premature menopause and early menopause show the same genetic pattern, Hum Reprod 14:2731, 1999.
137. **Vegetti W**, **Marozzi A**, **Manfredini E**, **Testa G**, **Alagna F**, **Nicolosi A**, **Caliari I**, **Taborelli M**, **Tibiletti MG**, **Dalpra L**, **Crosignani PG**, Premature ovarian failure, Mol Cell Endocrinol 161:53, 2000.
138. **Nikolaou D**, **Templeton A**, Early ovarian ageing: a hypothesis: detection and clinical relevance, Hum Reprod 18:1137, 2003.
139. **Farhi J**, **Homburg R**, **Ferber A**, **Orvieto R**, **Ben Rafael Z**, Non-response to ovarian stimulation in normogonadotrophic, normogonadal women: a clinical sign of impending onset of ovarian failure pre-empting the rise in basal follicle stimulating hormone levels, Hum Reprod 12:241, 1997.
140. **de Boer EJ**, **den Tonkelaar I**, **te Velde ER**, **Burger CW**, **Klip H**, **van Leeuwen FE**, A low number of retrieved oocytes at in vitro fertilization treatment is predictive of early menopause, Fertil Steril 77:978, 2002.

141. **Lawson R**, **El-Toukhy T**, **Kassab A**, **Taylor A**, **Braude P**, **Parsons J**, **Seed P**, Poor response to ovulation induction is a stronger predictor of early menopause than elevated basal FSH: a life table analysis, Hum Reprod 18:527, 2003.
142. **Kok HS**, **van Asselt KM**, **van der Schouw YT**, **Peeters PH**, **Wijmenga C**, Genetic studies to identify genes underlying menopausal age, Hum Reprod Update 11:483, 2005.
143. **Skillern A**, **Rajkovic A**, Recent developments in identifying genetic determinants of premature ovarian failure, Sex Dev 2:228, 2008.
144. **Guzeloglu-Kayisli O**, **Lalioti MD**, **Sasson I**, **Aydiner F**, **Sakkas D**, **Seli E**, Embryonic poly(A) binding protein (EPAB) is required for oocyte maturation and female fertility in mouse, Biochem J 446:47, 2012.
145. **Esencan E**, **Kallen A**, **Zhang M**, **Seli E**, Translational activation of maternally-derived mRNAs in oocytes and early embryos and the role of embryonic poly(A) binding protein (EPAB), Biol Reprod, 2019 Feb 26. pii: ioz034. doi: 10.1093/biolre/ioz034.
146. **Knauff EA**, **Franke L**, **van Es MA**, **van den Berg LH**, **van der Schouw YT**, **Laven JS**, **Lambalk CB**, **Hoek A**, **Goverde AJ**, **Christin-Maitre S**, **Hsueh AJ**, **Wijmenga C**, **Fauser BC**, Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene, Hum Reprod 24:2372, 2009.
147. **Laissue P**, **Lakhal B**, **Benayoun BA**, **Dipietromaria A**, **Braham R**, **Elghezal H**, **Philibert P**, **Saad A**, **Sultan C**, **Fellous M**, **Veitia RA**, Functional evidence implicating FOXL2 in non-syndromic premature ovarian failure and in the regulation of the transcription factor OSR2, J Med Genet 46:455, 2009.
148. **Kevenaar ME**, **Themmen AP**, **Rivadeneira F**, **Uitterlinden AG**, **Laven JS**, **van Schoor NM**, **Lips P**, **Pols HA**, **Visser JA**, A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity, Hum Reprod 22:2382, 2007.
149. **He C**, **Kraft P**, **Chen C**, **Buring JE**, **Paré G**, **Hankinson SE**, **Chanock SJ**, **Ridker PM**, **Hunter DJ**, **Chasman DI**, Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet 41:724, 2009.
150. **Stolk L**, **Zhai G**, **van Meurs JB**, **Verbiest MM**, **Visser JA**, **Estrada K**, **Rivadeneira F**, **Williams FM**, **Cherkas L**, **Deloukas P**, **Soranzo N**, **de Keyzer JJ**, **Pop VJ**, **Lips P**, **Lebrun CE**, **van der Schouw YT**, **Grobbee DE**, **Witteman J**, **Hofman A**, **Pols HA**, **Laven JS**, **Spector TD**, **Uitterlinden AG**, Loci at chromosomes 13, 19 and 20 influence age at natural menopause, Nat Genet 41:645, 2009.
151. **Chen CT**, **Liu CT**, **Chen GK**, **Andrews JS**, **Arnold AM**, **Dreyfus J**, **Franceschini N**, **Garcia ME**, **Kerr KF**, **Li G**, **Lohman KK**, **Musani SK**, **Nalls MA**, **Raffel LJ**, **Smith J**, **Ambrosone CB**, **Bandera EV**, **Bernstein L**, **Britton A**, **Brzyski RG**, **Cappola A**, **Carlson CS**, **Couper D**, **Deming SL**, **Goodarzi MO**, **Heiss G**, **John EM**, **Lu X**, **Le Marchand L**, **Marciante K**, **Mcknight B**, **Millikan R**, **Nock NL**, **Olshan AF**, **Press MF**, **Vaiyda D**, **Woods NF**, **Taylor HA**, **Zhao W**, **Zheng W**, **Evans MK**, **Harris TB**, **Henderson BE**, **Kardia SL**, **Kooperberg C**, **Liu Y**, **Mosley TH**, **Psaty B**, **Wellons M**, **Windham BG**, **Zonderman AB**, **Cupples LA**, **Demerath EW**, **Haiman C**, **Murabito JM**, **Rajkovic A**, Meta-analysis of loci associated with age at natural menopause in African-American women, Hum Mol Genet 23:3327, 2014.
152. **Shen C**, **Delahanty RJ**, **Gao YT**, **Shen C**, **Delahanty RJ**, **Gao YT**, **Lu W**, **Xiang YB**, **Zheng Y**, **Cai Q**, **Zheng W**, **Shu XO**, **Long J**, Evaluating GWAS-identified SNPs for age at natural menopause among Chinese women, PLoS One 8:e58766, 2013.
153. **Murray A**, **Bennett CE**, **Perry JR**, **Weedon MN**, **Jacobs PA**, **Morris DH**, **Orr N**, **Schoemaker MJ**, **Jones M**, **Ashworth A**, **Swerdlow AJ**; **ReproGen Consortium**, Common genetic variants are significant risk factors for early menopause: results from the Breakthrough Generations Study, Hum Mol Genet 20:186, 2011.
154. **Stolk L**, **Perry JR**, **Chasman DI**, **He C**, **Mangino M**, **Sulem P**, **Barbalic M**, **Broer L**, **Byrne EM**, **Ernst F**, **Esko T**, **Franceschini N**, **Gudbjartsson DF**, **Hottenga JJ**, **Kraft P**, **McArdle PF**, **Porcu E**, **Shin SY**, **Smith AV**, **van Wingerden S**, **Zhai G**, **Zhuang WV**, **Albrecht E**, **Alizadeh BZ**, **Aspelund T**, **Bandinelli S**, **Lauc LB**, **Beckmann JS**, **Boban M**, **Boerwinkle E**, **Broekmans FJ**, **Burri A**, **Campbell H**, **Chanock SJ**, **Chen C**, **Cornelis MC**, **Corre T**, **Coviello AD**, **d'Adamo P**, **Davies G**, **de Faire U**, **de Geus EJ**,

Deary IJ, **Dedoussis GV**, **Deloukas P**, **Ebrahim S**, **Eiriksdottir G**, **Emilsson V**, **Eriksson JG**, **Fauser BC**, **Ferreli L**, **Ferrucci L**, **Fischer K**, **Folsom AR**, **Garcia ME**, **Gasparini P**, **Gieger C**, **Glazer N**, **Grobbee DE**, **Hall P**, **Haller T**, **Hankinson SE**, **Hass M**, **Hayward C**, **Heath AC**, **Hofman A**, **Ingelsson E**, **Janssens AC**, **Johnson AD**, **Karasik D**, **Kardia SL**, **Keyzer J**, **Kiel DP**, **Kolcic I**, **Kutalik Z**, **Lahti J**, **Lai S**, **Laisk T**, **Laven JS**, **Lawlor DA**, **Liu J**, **Lopez LM**, **Louwers YV**, **Magnusson PK**, **Marongiu M**, **Martin NG**, **Klaric IM**, **Masciullo C**, **McKnight B**, **Medland SE**, **Melzer D**, **Mooser V**, **Navarro P**, **Newman AB**, **Nyholt DR**, **Onland-Moret NC**, **Palotie A**, **Paré G**, **Parker AN**, **Pedersen NL**, **Peeters PH**, **Pistis G**, **Plump AS**, **Polasek O**, **Pop VJ**, **Psaty BM**, **Räikkönen K**, **Rehnberg E**, **Rotter JI**, **Rudan I**, **Sala C**, **Salumets A**, **Scuteri A**, **Singleton A**, **Smith JA**, **Snieder H**, **Soranzo N**, **Stacey SN**, **Starr JM**, **Stathopoulou MG**, **Stirrups K**, **Stolk RP**, **Styrkarsdottir U**, **Sun YV**, **Tenesa A**, **Thorand B**, **Toniolo D**, **Tryggvadottir L**, **Tsui K**, **Ulivi S**, **van Dam RM**, **van der Schouw YT**, **van Gils CH**, **van Nierop P**, **Vink JM**, **Visscher PM**, **Voorhuis M**, **Waeber G**, **Wallaschofski H**, **Wichmann HE**, **Widen E**, **Wijnands-van Gent CJ**, **Willemsen G**, **Wilson JF**, **Wolffenbuttel BH**, **Wright AF**, **Yerges-Armstrong LM**, **Zemunik T**, **Zgaga L**, **Zillikens MC**, **Zygmunt M**; **LifeLines Cohort Study**, **Arnold AM**, **Boomsma DI**, **Buring JE**, **Crisponi L**, **Demerath EW**, **Gudnason V**, **Harris TB**, **Hu FB**, **Hunter DJ**, **Launer LJ**, **Metspalu A**, **Montgomery GW**, **Oostra BA**, **Ridker PM**, **Sanna S**, **Schlessinger D**, **Spector TD**, **Stefansson K**, **Streeten EA**, **Thorsteinsdottir U**, **Uda M**, **Uitterlinden AG**, **van Duijn CM**, **Völzke H**, **Murray A**, **Murabito JM**, **Visser JA**, **Lunetta KL**, Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet 44:260, 2012.

155. **AlAsiri S**, **Basit S**, **Wood-Trageser MA**, **Yatsenko SA**, **Jeffries EP**, **Surti U**, **Ketterer DM**, **Afzal S**, **Ramzan K**, **Faiyaz-Ul Haque M**, **Jiang H**, **Trakselis MA**, **Rajkovic A**, Exome sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability, J Clin Invest 125(1):258, 2015.
156. **Desai S**, **Wood-Trageser M**, **Matic J**, **Chipkin J**, **Jiang H**, **Bachelot A**, **Dulon J**, **Sala C**, **Barbieri C**, **Cocca M**, **Toniolo D**, **Touraine P**, **Witchel S**, **Rajkovic A**, MCM8 and MCM9 nucleotide variants in women with primary ovarian insufficiency, J Clin Endocrinol Metab 102:576, 2017.
157. **Jacobs SL**, **Metzger DA**, **Dodson WC**, **Haney AF**, Effect of age on response to human menopausal gonadotropin stimulation, J Clin Endocrinol Metab 71:1525, 1990.
158. **Piltonen T**, **Koivunen R**, **Ruokonen A**, **Tapanainen JS**, Ovarian age-related responsiveness to human chorionic gonadotropin, J Clin Endocrinol Metab 88:3327, 2003.
159. **Kuliev A**, **Cieslak J**, **Verlinsky Y**, Frequency and distribution of chromosome abnormalities in human oocytes, Cytogenet Genome Res 111:193, 2005.
160. **Hunt PA**, **Hassold TJ**, Human female meiosis: what makes a good egg go bad? Trends Genet 24:86, 2008.
161. **Pellestor F**, **Anahory T**, **Hamamah S**, Effect of maternal age on the frequency of cytogenetic abnormalities in human oocytes, Cytogenet Genome Res 111:206, 2005.
162. **Pellestor F**, **Andreo B**, **Arnal F**, **Humeau C**, **Demaille J**, Maternal aging and chromosomal abnormalities: new data drawn from in vitro unfertilized human oocytes, Hum Genet 112:195, 2003.
163. **Pellestor F**, **Andreo B**, **Anahory T**, **Hamamah S**, The occurrence of aneuploidy in human: lessons from the cytogenetic studies of human oocytes, Eur J Med Genet 49:103, 2006.
164. **Angell R**, First-meiotic-division nondisjunction in human oocytes, Am J Hum Genet 61:23, 1997.
165. **Angell R**, Mechanism of chromosome nondisjunction in human oocytes, Prog Clin Biol Res 393:13, 1995.
166. **Kuliev A**, **Cieslak J**, **Ilkevitch Y**, **Verlinsky Y**, Chromosomal abnormalities in a series of 6,733 human oocytes in preimplantation diagnosis for age-related aneuploidies, Reprod Biomed Online 6:54, 2003.
167. **Geraedts J**, **Montag M**, **Magli MC**, **Repping S**, **Handyside A**, **Staessen C**, **Harper J**, **Schmutzler A**, **Collins J**, **Goossens V**, **van der Ven H**, **Vesela K**, **Gianaroli L**, Polar body array CGH for prediction of the status of the corresponding oocyte. Part I: clinical results, Hum Reprod 26:3173, 2011.
168. **Franasiak JM**, **Forman EJ**, **Hong KH**, **Werner MD**, **Upham KM**, **Treff NR**, **Scott RT**, Aneuploidy across individual chromosomes at the embryonic level in trophectoderm biopsies: changes with patient age and chromosome structure, J Assist Reprod Genet 31:1501, 2014.
169. **Lamb NE**, **Feingold E**, **Savage A**, **Avramopoulos D**, **Freeman S**, **Gu Y**, **Hallberg A**, **Hersey J**,

Karadima G, **Pettay D**, **Saker D**, **Shen J**, **Taft L**, **Mikkelsen M**, **Petersen MB**, **Hassold T**, **Sherman SL**, Characterization of susceptible chiasma configurations that increase the risk for maternal nondisjunction of chromosome 21, Hum Mol Genet 6:1391, 1997.

170. **Lamb NE**, **Freeman SB**, **Savage-Austin A**, **Pettay D**, **Taft L**, **Hersey J**, **Gu Y**, **Shen J**, **Saker D**, **May KM**, **Avramopoulos D**, **Petersen MB**, **Hallberg A**, **Mikkelsen M**, **Hassold TJ**, **Sherman SL**, Susceptible chiasmate configurations of chromosome 21 predispose to non-disjunction in both maternal meiosis I and meiosis II, Nat Genet 14:400, 1996.
171. **Nasmyth K**, Disseminating the genome: joining, resolving, and separating sister chromatids during mitosis and meiosis, Annu Rev Genet 35:673, 2001.
172. **Michaelis C**, **Ciosk R**, **Nasmyth K**, Cohesins: chromosomal proteins that prevent premature separation of sister chromatids, Cell 91:35, 1997.
173. **Nicklas BJ**, **Toth MJ**, **Goldberg AP**, **Poehlman ET**, Racial differences in plasma leptin concentrations in obese postmenopausal women, J Clin Endocrinol Metab 82:315, 1997.
174. **Nicklas RB**, How cells get the right chromosomes, Science 275:632, 1997.
175. **Nasmyth K**, **Peters JM**, **Uhlmann F**, Splitting the chromosome: cutting the ties that bind sister chromatids, Science 288:1379, 2000.
176. **Mahmood R**, **Brierley CH**, **Faed MJ**, **Mills JA**, **Delhanty JD**, Mechanisms of maternal aneuploidy: FISH analysis of oocytes and polar bodies in patients undergoing assisted conception, Hum Genet 106:620, 2000.
177. **Sandalinas M**, **Marquez C**, **Munne S**, Spectral karyotyping of fresh, non-inseminated oocytes, Mol Hum Reprod 8:580, 2002.
178. **Volarcik K**, **Sheean L**, **Goldfarb J**, **Woods L**, **Abdul-Karim FW**, **Hunt P**, The meiotic competence of in-vitro matured human oocytes is influenced by donor age: evidence that folliculogenesis is compromised in the reproductively aged ovary, Hum Reprod 13:154, 1998.
179. **Nagele F**, **O'Connor H**, **Davies A**, **Badawy A**, **Mohamed H**, **Magos A**, 2500 Outpatient diagnostic hysteroscopies, Obstet Gynecol 88:87, 1996.
180. **Day Baird D**, **Dunson DB**, **Hill MC**, **Cousins D**, **Schectman JM**, High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence, Am J Obstet Gynecol 188:100, 2003.
181. **DeWaay DJ**, **Syrop CH**, **Nygaard IE**, **Davis WA**, **Van Voorhis BJ**, Natural history of uterine polyps and leiomyomata, Obstet Gynecol 100:3, 2002.
182. **Donnez J**, **Jadoul P**, What are the implications of myomas on fertility? A need for a debate? Hum Reprod 17:1424, 2002.
183. **Olive DL**, **Pritts EA**, Fibroids and reproduction, Semin Reprod Med 28(3):218, 2010.
184. **Varasteh NN**, **Neuwirth RS**, **Levin B**, **Keltz MD**, Pregnancy rates after hysteroscopic polypectomy and myomectomy in infertile women, Obstet Gynecol 94:168, 1999.
185. **Mastrominas M**, **Pistofidis GA**, **Dimitropoulos K**, Fertility outcome after outpatient hysteroscopic removal of endometrial polyps and submucous fibroids, J Am Assoc Gynecol Laparosc 3:S29, 1996.
186. **Noci I**, **Borri P**, **Chieffi O**, **Scarselli G**, **Biagiotti R**, **Moncini D**, **Paglierani M**, **Taddei G**, I. Aging of the human endometrium: a basic morphological and immunohistochemical study, Eur J Obstet Gynecol Reprod Biol 63:181, 1995.
187. **Yaron Y**, **Botchan A**, **Amit A**, **Kogosowski A**, **Yovel I**, **Lessing JB**, Endometrial receptivity: the age-related decline in pregnancy rates and the effect of ovarian function, Fertil Steril 60:314, 1993.
188. **Meldrum DR**, Female reproductive aging—ovarian and uterine factors, Fertil Steril 59:1, 1993.
189. **Pellicer A**, **Simon C**, **Remohi J**, Effects of aging on the female reproductive system, Hum Reprod 10(Suppl 2):77, 1995.
190. **Centers for Disease Control and Prevention**, 2007 assisted reproductive technology success rates, National Summary and Fertility Clinic Reports, Atlanta, GA, 2009.
191. **Sauer MV**, **Paulson RJ**, **Lobo RA**, Pregnancy in women 50 or more years of age: outcomes of 22 consecutively established pregnancies from oocyte donation, Fertil Steril 64:11, 1995.
192. **Abdalla HI**, **Burton G**, **Kirkland A**, **Johnson MR**, **Leonard T**, **Brooks AA**, **Studd JW**, Age, pregnancy and miscarriage: uterine versus ovarian factors, Hum Reprod 8:1512, 1993.

193. **Taylor HS**, Role of the uterus in fertility, pregnancy, and developmental programming, Fertil Steril 110(5):849, 2018.
194. **Segal TR**, **Kim K**, **Mumford SL**, **Goldfarb JM**, **Weinerman RS**, How much does the uterus matter? Perinatal outcomes are improved when donor oocyte embryos are transferred to gestational carriers compared to intended parent recipients Fertil Steril 110:888, 2018.
195. **Kidd SA**, **Eskenazi B**, **Wyrobek AJ**, Effects of male age on semen quality and fertility: a review of the literature, Fertil Steril 75:237, 2001.
196. **Eskenazi B**, **Wyrobek AJ**, **Sloter E**, **Kidd SA**, **Moore L**, **Young S**, **Moore D**, The association of age and semen quality in healthy men, Hum Reprod 18(2):447, 2003.
197. **Kumar N**, **Singh AK**, **Choudhari AR**, Impact of age on semen parameters in male partners of infertile couples in a rural tertiary care center of central India: a cross-sectional study, Int J Reprod Biomed (Yazd), 15(8):497, 2017.
198. **Girsh E**, **Katz N**, **Genkin L**, **Girtler O**, **Bocker J**, **Bezdin S**, **Barr I**. Male age influences oocyte-donor program results, J Assist Reprod Genet 25(4):137, 2008.
199. **Nankin HR**, Fertility in aging men, Maturitas 7:259, 1985.
200. **Bujan L**, **Mieusset R**, **Mondinat C**, **Mansat A**, **Pontonnier F**, Sperm morphology in fertile men and its age related variation, Andrologia 20:121, 1988.
201. **Rolf C**, **Behre HM**, **Nieschlag E**, Reproductive parameters of older compared to younger men of infertile couples, Int J Androl 19:135, 1996.
202. **Chia SE**, **Lim ST**, **Tay SK**, Factors associated with male infertility: a case-control study of 218 infertile and 240 fertile men, Br J Obstet Gynaecol 107:55, 2000.
203. **Tennekoon KH**, **Karunanayake EH**, **Serum FSH**, LH, and testosterone concentrations in presumably fertile men: effect of age, Int J Fertil 38:108, 1993.
204. **Vermeulen A**, **Kaufman JM**, Ageing of the hypothalamo-pituitary-testicular axis in men, Horm Res 43:25, 1995.
205. **Hassan MA**, **Killick SR**, Effect of male age on fertility: evidence for the decline in male fertility with increasing age, Fertil Steril 79(Suppl 3):1520, 2003.
206. **Faber BM**, **Mercan R**, **Hamacher P**, **Muasher SJ**, **Toner JP**, The impact of an egg donor's age and her prior fertility on recipient pregnancy outcome, Fertil Steril 68:370, 1997.
207. **Dunson DB**, **Colombo B**, **Baird DD**, Changes with age in the level and duration of fertility in the menstrual cycle, Hum Reprod 17:1399, 2002.
208. **Paulson RJ**, **Milligan RC**, **Sokol RZ**, The lack of influence of age on male fertility, Am J Obstet Gynecol 184(5):818; discussion 822–824, 2001.
209. **Egozcue J**, **Blanco J**, **Anton E**, **Egozcue S**, **Sarrate Z**, **Vidal F**, Genetic analysis of sperm and implications of severe male infertility—a review, Placenta 24(Suppl 2): S62, 2003.
210. **Slama R**, **Werwatz A**, **Boutou O**, **Ducot B**, **Spira A**, **Hardle W**, Does male age affect the risk of spontaneous abortion? An approach using semiparametric regression, Am J Epidemiol 157:815, 2003.
211. **Jenkins TG**, **Aston KI**, **Pflueger C**, **Cairns BR**, **Carrell DT**, Age-associated sperm DNA methylation alterations: possible implications in offspring disease susceptibility, Plos Genet 10:e1004458, 2014.
212. **Zumoff B**, **Strain GW**, **Kream J**, **O'Connor J**, **Rosenfeld RS**, **Levin J**, **Fukushima DK**, Age variation of the 24-hour mean plasma concentrations of androgens, estrogens, and gonadotropins in normal adult men, J Clin Endocrinol Metab 54:534, 1982.
213. **Veldhuis JD**, Recent insights into neuroendocrine mechanisms of aging of the human male hypothalamic-pituitary-gonadal axis, J Androl 20:1, 1999.
214. **Hermann M**, **Untergasser G**, **Rumpold H**, **Berger P**, Aging of the male reproductive system, Exp Gerontol 35:1267, 2000.
215. **Muasher SJ**, **Oehninger S**, **Simonetti S**, **Matta J**, **Ellis LM**, **Liu HC**, **Jones GS**, **Rosenwaks Z**, The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome, Fertil Steril 50:298, 1988.
216. **Scott RT**, **Toner JP**, **Muasher SJ**, **Oehninger S**, **Robinson S**, **Rosenwaks Z**, Follicle-stimulating hormone

levels on cycle day 3 are predictive of in vitro fertilization outcome, Fertil Steril 51:651, 1989.
217. **Toner JP**, **Philput CB**, **Jones GS**, **Muasher SJ**, Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age, Fertil Steril 55:784, 1991.
218. **Pearlstone AC**, **Fournet N**, **Gambone JC**, **Pang SC**, **Buyalos RP**, Ovulation induction in women age 40 and older: the importance of basal follicle-stimulating hormone level and chronological age, Fertil Steril 58:674, 1992.
219. **Scott RT Jr**, **Hofmann GE**, Prognostic assessment of ovarian reserve, Fertil Steril 63:1, 1995.
220. **Bukman A**, **Heineman MJ**, Ovarian reserve testing and the use of prognostic models in patients with subfertility, Hum Reprod Update 7:581, 2001.
221. **Barroso G**, **Oehninger S**, **Monzo A**, **Kolm P**, **Gibbons WE**, **Muasher SJ**, High FSH:LH ratio and low LH levels in basal cycle day 3: impact on follicular development and IVF outcome, J Assist Reprod Genet 18:499, 2001.
222. **Broekmans FJ**, **Kwee J**, **Hendriks DJ**, **Mol BW**, **Lambalk CB**, A systematic review of tests predicting ovarian reserve and IVF outcome, Hum Reprod Update 12:685, 2006.
223. **Roberts JE**, **Spandorfer S**, **Fasouliotis SJ**, **Kashyap S**, **Rosenwaks Z**, Taking a basal follicle-stimulating hormone history is essential before initiating in vitro fertilization, Fertil Steril 83:37, 2005.
224. **Abdalla H**, **Thum MY**, Repeated testing of basal FSH levels has no predictive value for IVF outcome in women with elevated basal FSH, Hum Reprod 21:171, 2006.
225. **Scott RT Jr**, **Hofmann GE**, **Oehninger S**, **Muasher SJ**, Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization, Fertil Steril 54:297, 1990.
226. **Hazout A**, **Bouchard P**, **Seifer DB**, **Aussage P**, **Junca AM**, **Cohen-Bacrie P**, Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol, Fertil Steril 82:1323, 2004.
227. **Eldar-Geva T**, **Ben-Chetrit A**, **Spitz IM**, **Rabinowitz R**, **Markowitz E**, **Mimoni T**, **Gal M**, **Zylber-Haran E**, **Margalioth EJ**, Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome, Hum Reprod 20:3178, 2005.
228. **McIlveen M**, **Skull JD**, **Ledger WL**, Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population, Hum Reprod 22:778, 2007.
229. **Phophong P**, **Ranieri DM**, **Khadum I**, **Meo F**, **Serhal P**, Basal 17beta-estradiol did not correlate with ovarian response and in vitro fertilization treatment outcome, Fertil Steril 74:1133, 2000.
230. **Evers JL**, **Slaats P**, **Land JA**, **Dumoulin JC**, **Dunselman GA**, Elevated levels of basal estradiol-17beta predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization, Fertil Steril 69:1010, 1998.
231. **Smotrich DB**, **Widra EA**, **Gindoff PR**, **Levy MJ**, **Hall JL**, **Stillman RJ**, Prognostic value of day 3 estradiol on in vitro fertilization outcome, Fertil Steril 64:1136, 1995.
232. **Licciardi FL**, **Liu HC**, **Rosenwaks Z**, Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization, Fertil Steril 64:991, 1995.
233. **Buyalos RP**, **Daneshmand S**, **Brzechffa PR**, Basal estradiol and follicle-stimulating hormone predict fecundity in women of advanced reproductive age undergoing ovulation induction therapy, Fertil Steril 68:272, 1997.
234. **Navot D**, **Rosenwaks Z**, **Margalioth EJ**, Prognostic assessment of female fecundity, Lancet ii:645, 1987.
235. **Yong PY**, **Baird DT**, **Thong KJ**, **McNeilly AS**, **Anderson RA**, Prospective analysis of the relationships between the ovarian follicle cohort and basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle number at different stages of the normal menstrual cycle and after pituitary down-regulation, Hum Reprod 18:35, 2003.
236. **Yanushpolsky EH**, **Hurwitz S**, **Tikh E**, **Racowsky C**, Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in women younger than 40 years of age, Fertil Steril 80:111, 2003.

237. **Csemiczky G**, **Harlin J**, **Fried G**, Predictive power of clomiphene citrate challenge test for failure of in vitro fertilization treatment, Acta Obstet Gynecol Scand 81:954, 2002.
238. **Kwee J**, **Schats R**, **McDonnell J**, **Lambalk CB**, **Schoemaker J**, Intercycle variability of ovarian reserve tests: results of a prospective randomized study, Hum Reprod 19:590, 2004.
239. **Hannoun A**, **Abu Musa A**, **Awwad J**, **Kaspar H**, **Khalil A**, Clomiphene citrate challenge test: cycle to cycle variability of cycle day 10 follicle stimulating hormone level, Clin Exp Obstet Gynecol 25:155, 1998.
240. **Hendriks DJ**, **Broekmans FJ**, **Bancsi LF**, **de Jong FH**, **Looman CW**, **Te Velde ER**, Repeated clomiphene citrate challenge testing in the prediction of outcome in IVF: a comparison with basal markers for ovarian reserve, Hum Reprod 20:163, 2005.
241. **Hendriks DJ**, **Mol BW**, **Bancsi LF**, **te Velde ER**, **Broekmans FJ**, The clomiphene citrate challenge test for the prediction of poor ovarian response and nonpregnancy in patients undergoing in vitro fertilization: a systematic review, Fertil Steril 86:807, 2006.
242. **Muttukrishna S**, **McGarrigle H**, **Wakim R**, **Khadum I**, **Ranieri DM**, **Serhal P**, Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? Br J Obstet Gynaecol 112:1384, 2005.
243. **Muttukrishna S**, **Suharjono H**, **McGarrigle H**, **Sathanandan M**, Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? Br J Obstet Gynaecol 111:1248, 2004.
244. **Balasch J**, **Creus M**, **Fabregues F**, **Carmona F**, **Casamitjana R**, **Ascaso C**, **Vanrell JA**, Inhibin, follicle-stimulating hormone, and age as predictors of ovarian response in in vitro fertilization cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment, Am J Obstet Gynecol 175: 1226, 1996.
245. **Seifer DB**, **MacLaughlin DT**, **Christian BP**, **Feng B**, **Shelden RM**, Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles, Fertil Steril 77:468, 2002.
246. **Hall JE**, **Welt CK**, **Cramer DW**, Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome, Hum Reprod 14:409, 1999.
247. **Creus M**, **Penarrubia J**, **Fabregues F**, **Vidal E**, **Carmona F**, **Casamitjana R**, **Vanrell JA**, **Balasch J**, Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome, Hum Reprod 15:2341, 2000.
248. **Smeenk JM**, **Sweep FC**, **Zielhuis GA**, **Kremer JA**, **Thomas CM**, **Braat DD**, Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracytoplasmic sperm injection, Fertil Steril 87:223, 2007.
249. **Vigier B**, **Tran D**, **Legeai L**, **Bezard J**, **Josso N**, Origin of anti-Mullerian hormone in bovine freemartin fetuses, J Reprod Fertil 70:473, 1984.
250. **Durlinger AL**, **Kramer P**, **Karels B**, **de Jong FH**, **Uilenbroek JT**, **Grootegoed JA**, **Themmen AP**, Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary, Endocrinology 140:5789, 1999.
251. **Durlinger AL**, **Gruijters MJ**, **Kramer P**, **Karels B**, **Kumar TR**, **Matzuk MM**, **Rose UM**, **de Jong FH**, **Uilenbroek JT**, **Grootegoed JA**, **Themmen AP**, Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary, Endocrinology 142:4891, 2001.
252. **Weenen C**, **Laven JS**, **Von Bergh AR**, **Cranfield M**, **Groome NP**, **Visser JA**, **Kramer P**, **Fauser BC**, **Themmen AP**, Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment, Mol Hum Reprod 10:77, 2004.
253. **Durlinger AL**, **Visser JA**, **Themmen APN**, Regulation of ovarian function: the role of anti-Müllerian hormone, Reproduction 124:601, 2002.
254. **Fanchin R**, **Schonauer LM**, **Righini C**, **Frydman N**, **Frydman R**, **Taieb J**, Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation, Hum Reprod 18:328, 2003.
255. **Catteau-Jonard S**, **Pigny P**, **Reyss AC**, **Decanter C**, **Poncelet E**, **Dewailly D**, Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome, J Clin Endocrinol Metab 92:4138, 2007.
256. **Kevenaar ME**, **Meerasahib MF**, **Kramer P**, **van de Lang-Born BM**, **de Jong FH**, **Groome NP**,

Themmen AP, **Visser JA**, Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice, Endocrinology 147:3228, 2006.
257. **Sowers MR**, **Eyvazzadeh AD**, **McConnell D**, **Yosef M**, **Jannausch ML**, **Zhang D**, **Harlow S**, **Randolph JF Jr**, Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition, J Clin Endocrinol Metab 93:3478, 2008.
258. **van Rooij IA**, **Tonkelaar I**, **Broekmans FJ**, **Looman CW**, **Scheffer GJ**, **de Jong FH**, **Themmen AP**, **te Velde ER**, Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition, Menopause 11:601, 2004.
259. **van Rooij IA**, **Broekmans FJ**, **Scheffer GJ**, **Looman CW**, **Habbema JD**, **de Jong FH**, **Fauser BJ**, **Themmen AP**, **te Velde ER**, Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study, Fertil Steril 83:979, 2005.
260. **de Vet A**, **Laven JS**, **de Jong FH**, **Themmen AP**, **Fauser BC**, Antimullerian hormone serum levels: a putative marker for ovarian aging, Fertil Steril 77:357, 2002.
261. **Fanchin R**, **Taieb J**, **Lozano DH**, **Ducot B**, **Frydman R**, **Bouyer J**, High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status, Hum Reprod 20:923, 2005.
262. **Tsepelidis S**, **Devreker F**, **Demeestere I**, **Flahaut A**, **Gervy C**, **Englert Y**, Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women, Hum Reprod 22:1837, 2007.
263. **Hehenkamp WJ**, **Looman CW**, **Themmen AP**, **de Jong FH**, **Te Velde ER**, **Broekmans FJ**, Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation, J Clin Endocrinol Metab 91:4057, 2006.
264. **Broer SL**, **Broekmans FJM**, **Laven JSE**, **Fauser BCJM**, Anti-Müllerian hormone: ovarian reserve testing and its potential implications, Hum Reprod Update 20:688, 2014.
265. **Freour T**, **Mirallie S**, **Bach-Ngohou K**, **Denis M**, **Barriere P**, **Masson D**, Measurement of serum anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART), Clin Chim Acta 375:162, 2007.
266. **Dorgan JF**, **Spittle CS**, **Egleston BL**, **Shaw CM**, **Kahle LL**, **Brinton LA**, Assay reproducibility and within-person variation of Mullerian inhibiting substance, Fertil Steril 94:301, 2010.
267. **van Rooij IA**, **Broekmans FJ**, **te Velde ER**, **Fauser BC**, **Bancsi LF**, **de Jong FH**, **Themmen AP**, Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve, Hum Reprod 17:3065, 2002.
268. **Silberstein T**, **MacLaughlin DT**, **Shai I**, **Trimarchi JR**, **Lambert-Messerlian G**, **Seifer DB**, **Keefe DL**, **Blazar AS**, Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology, Hum Reprod 21:159, 2006.
269. **Ebner T**, **Sommergruber M**, **Moser M**, **Shebl O**, **Schreier-Lechner E**, **Tews G**, Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles, Hum Reprod 21:2022, 2006.
270. **Morin SJ**, **Patounakis G**, **Juneau CR**, **Neal SA**, **Scott RT Jr**, **Seli E**, Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance, Hum Reprod, 2018. doi: 10.1093/humrep/dey238.
271. **Pacheco A**, **Cruz M**, **Iglesias C**, **García-Velasco JA**, Very low anti-müllerian hormone concentrations are not an independent predictor of embryo quality and pregnancy rate. Reprod Biomed Online 37(1):113, 2018.
272. **Ficicioglu C**, **Kutlu T**, **Baglam E**, **Bakacak Z**, Early follicular antimullerian hormone as an indicator of ovarian reserve, Fertil Steril 85:592, 2006.
273. **Gnoth C**, **Schuring AN**, **Friol K**, **Tigges J**, **Mallmann P**, **Godehardt E**, Relevance of anti-Mullerian hormone measurement in a routine IVF program, Hum Reprod 23:1359, 2008.
274. **Penarrubia J**, **Fabregues F**, **Manau D**, **Creus M**, **Casals G**, **Casamitjana R**, **Carmona F**, **Vanrell JA**, **Balasch J**, Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist–gonadotropin treatment, Hum Reprod 20:915, 2005.
275. **Gougeon A**, Regulation of ovarian follicular development in primates: facts and hypotheses, Endocr Rev

17:121, 1996.
276. **Pache TD**, **Wladimiroff JW**, **de Jong FH**, **Hop WC**, **Fauser BC**, Growth patterns of nondominant ovarian follicles during the normal menstrual cycle, Fertil Steril 54:638, 1990.
277. **Ruess ML**, **Kline J**, **Santos R**, **Levin B**, **Timor-Tritsch I**, Age and the ovarian follicle pool assessed with transvaginal ultrasonography, Am J Obstet Gynecol 174:624, 1996.
278. **Scheffer GJ**, **Broekmans FJ**, **Dorland M**, **Habbema JD**, **Looman CW**, **te Velde ER**, Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility, Fertil Steril 72:845, 1999.
279. **Meldrum DR**, **Chetkowski RJ**, **Steingold KA**, **Randle D**, Transvaginal ultrasound scanning of ovarian follicles, Fertil Steril 42:803, 1984.
280. **Bancsi LF**, **Broekmans FJ**, **Looman CW**, **Habbema JD**, **te Velde ER**, Impact of repeated antral follicle counts on the prediction of poor ovarian response in women undergoing in vitro fertilization, Fertil Steril 81:35, 2004.
281. **Hansen KR**, **Morris JL**, **Thyer AC**, **Soules MR**, Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting, Fertil Steril 80:577, 2003.
282. **Scheffer GJ**, **Broekmans FJ**, **Bancsi LF**, **Habbema JD**, **Looman CW**, **Te Velde ER**, Quantitative transvaginal two- and three-dimensional sonography of the ovaries: reproducibility of antral follicle counts, Ultrasound Obstet Gynecol 20:270, 2002.
283. **Broekmans FJ**, **Soules MR**, **Fauser BC**, Ovarian aging: mechanisms and clinical consequences, Endocr Rev 30:465, 2009.
284. **Hendriks DJ**, **Mol BW**, **Bancsi LF**, **Te Velde ER**, **Broekmans FJ**, Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level, Fertil Steril 83:291, 2005.
285. **Hirshfield AN**, Rescue of atretic follicles in vitro and in vivo, Biol Reprod 40:181, 1989.
286. **Bancsi LF**, **Broekmans FJ**, **Eijkemans MJ**, **de Jong FH**, **Habbema JD**, **te Velde ER**, Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve, Fertil Steril 77:328, 2002.
287. **Frattarelli JL**, **Lauria-Costab DF**, **Miller BT**, **Bergh PA**, **Scott RT**, Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles, Fertil Steril 74:512, 2000.
288. **Frattarelli JL**, **Levi AJ**, **Miller BT**, **Segars JH**, A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles, Fertil Steril 80:350, 2003.
289. **Chang MY**, **Chiang CH**, **Hsieh TT**, **Soong YK**, **Hsu KH**, Use of the antral follicle count to predict the outcome of assisted reproductive technologies, Fertil Steril 69:505, 1998.
290. **Ng EH**, **Tang OS**, **Ho PC**, The significance of the number of antral follicles prior to stimulation in predicting ovarian responses in an IVF programme, Hum Reprod 15:1937, 2000.
291. **Kupesic S**, **Kurjak A**, **Bjelos D**, **Vujisic S**, Three-dimensional ultrasonographic ovarian measurements and in vitro fertilization outcome are related to age, Fertil Steril 79:190, 2003.
292. **Lass A**, **Silye R**, **Abrams D-C**, **Krausz T**, **Hovatta O**, **Margara R**, **Winston RML**, Follicular density in ovarian biopsy of infertile women: a novel method to assess ovarian reserve, Hum Reprod 12:1028, 1997.
293. **Lass A**, **Skull J**, **McVeigh E**, **Margara R**, **Winston RM**, Measurement of ovarian volume by transvaginal sonography before human menopausal gonadotrophin superovulation for in-vitro fertilization can predict poor response, Hum Reprod 12:294, 1997.
294. **Jayaprakasan K**, **Campbell B**, **Hopkisson J**, **Clewes J**, **Johnson I**, **Raine-Fenning N**, Establishing the intercycle variability of three-dimensional ultrasonographic predictors of ovarian reserve, Fertil Steril 90:2126, 2008.
295. **Elter K**, **Sismanoglu A**, **Durmusoglu F**, Intercycle variabilities of basal antral follicle count and ovarian volume in subfertile women and their relationship to reproductive aging: a prospective study, Gynecol Endocrinol 20:137, 2005.
296. **Merce LT**, **Gomez B**, **Engels V**, **Bau S**, **Bajo JM**, Intraobserver and interobserver reproducibility of ovarian

volume, antral follicle count, and vascularity indices obtained with transvaginal 3-dimensional ultrasonography, power Doppler angiography, and the virtual organ computer-aided analysis imaging program, J Ultrasound Med 24:1279, 2005.

297. **Jarvela IY**, **Sladkevicius P**, **Kelly S**, **Ojha K**, **Campbell S**, **Nargund G**, Quantification of ovarian power Doppler signal with three-dimensional ultrasonography to predict response during in vitro fertilization, Obstet Gynecol 102:816, 2003.
298. **Schild RL**, **Knobloch C**, **Dorn C**, **Fimmers R**, **van der Ven H**, **Hansmann M**, The role of ovarian volume in an in vitro fertilization programme as assessed by 3D ultrasound, Arch Gynecol Obstet 265:67, 2001.
299. **Kwee J**, **Elting ME**, **Schats R**, **McDonnell J**, **Lambalk CB**, Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization, Reprod Biol Endocrinol 5:9, 2007.
300. **Merce LT**, **Barco MJ**, **Bau S**, **Troyano JM**, Prediction of ovarian response and IVF/ICSI outcome by three-dimensional ultrasonography and power Doppler angiography, Eur J Obstet Gynecol Reprod Biol 132:93, 2007.
301. **Fanchin R**, **de Ziegler D**, **Olivennes F**, **Taieb J**, **Dzik A**, **Frydman R**, Exogenous follicle stimulating hormone ovarian reserve test (EFORT): a simple and reliable screening test for detecting 'poor responders' in in-vitro fertilization, Hum Reprod 9:1607, 1994.
302. **Seifer DB**, **Lambert-Messerlian G**, **Hogan JW**, **Gardiner AC**, **Blazar AS**, **Berk CA**, Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome, Fertil Steril 67:110, 1997.
303. **Corson SL**, **Gutmann J**, **Batzer FR**, **Wallace H**, **Klein N**, **Soules MR**, Inhibin-B as a test of ovarian reserve for infertile women, Hum Reprod 14:2818, 1999.
304. **Dzik A**, **Lambert-Messerlian G**, **Izzo VM**, **Soares JB**, **Pinotti JA**, **Seifer DB**, Inhibin B response to EFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle, Fertil Steril 74:1114, 2000.
305. **Kwee J**, **Elting MW**, **Schats R**, **Bezemer PD**, **Lambalk CB**, **Schoemaker J**, Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study, Hum Reprod 18:1422, 2003.
306. **Winslow KL**, **Toner JP**, **Brzyski RG**, **Oehninger SC**, **Acosta AA**, **Muasher SJ**, The gonadotropin-releasing hormone agonist stimulation test–a sensitive predictor of performance in the flare-up in vitro fertilization cycle, Fertil Steril 56:711, 1991.
307. **Galtier-Dereure F**, **De Bouard V**, **Picto MC**, **Vergnes C**, **Humeau C**, **Bringer J**, **Hedon B**, Ovarian reserve test with the gonadotrophin-releasing hormone agonist buserelin: correlation with in-vitro fertilization outcome, Hum Reprod 11:1393, 1996.
308. **Ranieri DM**, **Phophong P**, **Khadum I**, **Meo F**, **Davis C**, **Serhal P**, Simultaneous evaluation of basal FSH and oestradiol response to GnRH analogue (F-G-test) allows effective drug regimen selection for IVF, Hum Reprod 16:673, 2001.
309. **Verhagen TE**, **Hendriks DJ**, **Bancsi LF**, **Mol BW**, **Broekmans FJ**, The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis, Hum Reprod Update 14:95, 2008.
310. **van Tilborg TC**, **Oudshoorn SC**, **Eijkemans MJC**, **Mochtar MH**, **van Golde RJT**, **Hoek A**, **Kuchenbecker WKH**, **Fleischer K**, **de Bruin JP**, **Groen H**, **van Wely M**, **Lambalk CB**, **Laven JSE**, **Mol BWJ**, **Broekmans FJM**, **Torrance HL**; **OPTIMIST study group**, Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis, Hum Reprod 32:2485, 2017.
311. **van Tilborg TC**, **Torrance HL**, **Oudshoorn SC**, **Eijkemans MJC**, **Koks CAM**, **Verhoeve HR**, **Nap AW**, **Scheffer GJ**, **Manger AP**, **Schoot BC**, **Sluijmer AV**, **Verhoeff A**, **Groen H**, **Laven JSE**, **Mol BWJ**, **Broekmans FJM**; **OPTIMIST study group**, Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder, Hum Reprod 32:2496, 2017.
312. **Oudshoorn SC**, **van Tilborg TC**, **Eijkemans MJC**, **Oosterhuis GJE**, **Friederich J**, **van Hooff MHA**, **van Santbrink EJP**, **Brinkhuis EA**, **Smeenk JMJ**, **Kwee J**, **de Koning CH**, **Groen H**, **Lambalk CB**, **Mol BWJ**, **Broekmans FJM**, **Torrance HL**; **OPTIMIST study group**, Individualized versus standard

FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder, Hum Reprod 32:2506; 2017.
313. **Harrison RF**, **Jacob S**, **Spillane H**, **Mallon E**, **Hennelly B**, A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles, Fertil Steril 75:23, 2001.
314. **Klinkert ER**, **Broekmans FJ**, **Looman CW**, **Habbema JD**, **te Velde ER**, Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial, Hum Reprod 20:611, 2005.
315. **Popovic-Todorovic B**, **Loft A**, **Ziebe S**, **Andersen AN**, Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in "standard" patients treated with 150 IU/day during the first cycle, Acta Obstet Gynecol Scand 83:842, 2004.
316. **Tarlatzis BC**, **Zepiridis L**, **Grimbizis G**, **Bontis J**, Clinical management of low ovarian response to stimulation for IVF: a systematic review, Hum Reprod Update 9:61, 2003.
317. **Kyrou D**, **Kolibianakis EM**, **Venetis CA**, **Papanikolaou EG**, **Bontis J**, **Tarlatzis BC**, How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis, Fertil Steril 91:749, 2009.
318. **Barrenetxea G**, **Agirregoikoa JA**, **Jimenez MR**, **de Larruzea AL**, **Ganzabal T**, **Carbonero K**, Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles, Fertil Steril 89:546, 2008.
319. **Scott RT Jr**, **Elkind-Hirsch KE**, **Styne-Gross A**, **Miller KA**, **Frattarelli JL**, The predictive value for in vitro fertility delivery rates is greatly impacted by the method used to select the threshold between normal and elevated basal follicle-stimulating hormone, Fertil Steril 89:868, 2008.
320. **van Rooij IA**, **de Jong E**, **Broekmans FJ**, **Looman CW**, **Habbema JD**, **te Velde ER**, High follicle-stimulating hormone levels should not necessarily lead to the exclusion of subfertile patients from treatment, Fertil Steril 81:1478, 2004.
321. **Lashen H**, **Ledger W**, **Lopez-Bernal A**, **Barlow D**, Poor responders to ovulation induction: is proceeding to in-vitro fertilization worthwhile? Hum Reprod 14:964, 1999.
322. **Zhen XM**, **Qiao J**, **Li R**, **Wang LN**, **Liu P**, The clinical analysis of poor ovarian response in in-vitro-fertilization embryo-transfer among Chinese couples, J Assist Reprod Genet 25:17, 2008.
323. **Scott RT Jr**, **Leonardi MR**, **Hofmann GE**, **Illions EH**, **Neal GS**, **Navot D**, A prospective evaluation of clomiphene citrate challenge test screening of the general infertility population, Obstet Gynecol 82:539, 1993.
324. **Scott RT**, **Opsahl MS**, **Leonardi MR**, **Neall GS**, **Illions EH**, **Navot D**, Life table analysis of pregnancy rates in a general infertility population relative to ovarian reserve and patient age, Hum Reprod 10:1706, 1995.
325. **Leach RE**, **Moghissi KS**, **Randolph JF**, **Reame NE**, **Blacker CM**, **Ginsburg KA**, **Diamond MP**, Intensive hormone monitoring in women with unexplained infertility: evidence for subtle abnormalities suggestive of diminished ovarian reserve, Fertil Steril 68:413, 1997.
326. **Hofmann GE**, **Sosnowski J**, **Scott RT**, **Thie J**, Efficacy of selection criteria for ovarian reserve screening using the clomiphene citrate challenge test in a tertiary fertility center population, Fertil Steril 66:49, 1996.
327. Prevalence of obesity among adults and youth: United States, 2015-2016. https://www.cdc.gov/nchs/data/databriefs/db288.pdf
328. **Practice Committee of the American Society for Reproductive Medicine**, Obesity and reproduction, Fertil Steril 90(Suppl 5):S21, 2008.
329. **Practice Committee of the American Society for Reproductive Medicine**, Smoking and infertility, Fertil Steril 90(Suppl 5):S254, 2008.
330. **Stillman RJ**, **Rosenberg MJ**, **Sachs BP**, Smoking and reproduction, Fertil Steril 46:545, 1986.
331. **Laurent SL**, **Thompson SJ**, **Addy C**, **Garrison CZ**, **Moore EE**, An epidemiologic study of smoking and primary infertility in women, Fertil Steril 57:565, 1992.
332. **Hughes EG**, **Brennan BG**, Does cigarette smoking impair natural or assisted fecundity, Fertil Steril 66:679, 1996.
333. **Augood C**, **Duckitt K**, **Templeton AA**, Smoking and female infertility: a systematic review and meta-

analysis, Hum Reprod 13:1532, 1998.
334. **Hakim RB**, **Gray RH**, **Zacur H**, Alcohol and caffeine consumption and decreased fertility, Fertil Steril 70:632, 1998.
335. **Hull MG**, **North K**, **Taylor H**, **Farrow A**, **Ford WC**, Delayed conception and active and passive smoking. The Avon Longitudinal Study of Pregnancy and Childhood Study Team, Fertil Steril 74:725, 2000.
336. **Baird DD**, **Wilcox AJ**, Cigarette smoking associated with delayed conception, JAMA 253:2979, 1985.
337. **Suonio S**, **Saarikoski S**, **Kauhanen O**, **Metsapelto A**, **Terho J**, **Vohlonen I**, Smoking does affect fecundity, Eur J Obstet Gynecol Reprod Biol 34:89, 1990.
338. **Howe G**, **Westhoff C**, **Vessey M**, **Yeates D**, Effects of age, cigarette smoking, and other factors on fertility: findings in a large prospective study, Br Med J (Clin Res Ed) 290:1697, 1985.
339. **Cooper GS**, **Baird DD**, **Hulka BS**, **Weinberg CR**, **Savitz DA**, **Hughes CL Jr**, Follicle-stimulating hormone concentrations in relation to active and passive smoking, Obstet Gynecol 85:407, 1995.
340. **El-Nemr A**, **Al-Shawaf T**, **Sabatini L**, **Wilson C**, **Lower AM**, **Grudzinskas JG**, Effect of smoking on ovarian reserve and ovarian stimulation in in-vitro fertilization and embryo transfer, Hum Reprod 13:2192, 1998.
341. **Sharara FI**, **Beatse SN**, **Leonardi MR**, **Navot D**, **Scott RT Jr**, Cigarette smoking accelerates the development of diminished ovarian reserve as evidenced by the clomiphene citrate challenge test, Fertil Steril 62:257, 1994.
342. **Rowland AS**, **Baird DD**, **Long S**, **Wegienka G**, **Harlow SD**, **Alavanja M**, **Sandler DP**, Influence of medical conditions and lifestyle factors on the menstrual cycle, Epidemiology 13:668, 2002.
343. **Zenzes MT**, **Wang P**, **Casper RF**, Cigarette smoking may affect meiotic maturation of human oocytes, Hum Reprod 10:3213, 1995.
344. **Zenzes MT**, **Reed TE**, **Wang P**, **Klein J**, Cotinine, a major metabolite of nicotine, is detectable in follicular fluids of passive smokers in in vitro fertilization therapy, Fertil Steril 66:614, 1996.
345. **Zenzes MT**, **Krishnan S**, **Krishnan B**, **Zhang H**, **Casper RF**, Cadmium accumulation in follicular fluid of women in in vitro fertilization-embryo transfer is higher in smokers, Fertil Steril 64:599, 1995.
346. **Zenzes MT**, **Bielecki R**, **Reed TE**, Detection of benzo(a)pyrene diol epoxide-DNA adducts in sperm of men exposed to cigarette smoke, Fertil Steril 72:330, 1999.
347. **Zenzes MT**, **Puy LA**, **Bielecki R**, **Reed TE**, Detection of benzo[a]pyrene diol epoxide-DNA adducts in embryos from smoking couples: evidence for transmission by spermatozoa, Mol Hum Reprod 5:125, 1999.
348. **Center for Disease Control (CDC)**, Preconception and interconception health status of women who recently gave birth to a live-born infant—Pregnancy Risk Assessment Monitoring System (PRAMS)—United States, 26 reporting areas, 2004, MMWR Morb Mortal Wkly Rep 56(10):1, 2007.
349. **Center for Disease Control (CDC)**, State-specific prevalence of cigarette smoking among adults and quitting among persons aged 18–35 years—United States, 2006, MMWR Morb Mortal Wkly Rep 56(38):993, 2007.
350. **Fiore MC**, US public health service clinical practice guideline: treating tobacco use and dependence, Respir Care 45:1200, 2000.
351. **Smith CG**, **Asch RH**, Drug abuse and reproduction, Fertil Steril 48:355, 1987.
352. **Mueller BA**, **Daling JR**, **Weiss NS**, **Moore DE**, Recreational drug use and the risk of primary infertility, Epidemiology 1:195, 1990.
353. **Bracken MB**, **Eskenazi B**, **Sachse K**, **McSharry J-E**, **Hellenbrand K**, **Leon-Summers L**, Association of cocaine use with sperm concentration, motility, and morphology, Fertil Steril 53:315, 1990.
354. **Grodstein F**, **Goldman MB**, **Cramer DW**, Infertility in women and moderate alcohol use, Am J Public Health 84:1429, 1994.
355. **Tolstrup JS**, **Kjaer SK**, **Holst C**, **Sharif H**, **Munk C**, **Osler M**, **Schmidt L**, **Andersen AM**, **Gronbaek M**, Alcohol use as predictor for infertility in a representative population of Danish women, Acta Obstet Gynecol Scand 82:744, 2003.
356. **Greenlee AR**, **Arbuckle TE**, **Chyou PH**, Risk factors for female infertility in an agricultural region, Epidemiology 14:429, 2003.
357. **Nagy F**, **Pendergrass PB**, **Bowen DC**, **Yeager JC**, A comparative study of cytological and physiological

parameters of semen obtained from alcoholics and non-alcoholics, Alcohol 21:17, 1986.
358. **Jensen TK**, **Hjollund NH**, **Henriksen TB**, **Scheike T**, **Kolstad H**, **Giwercman A**, **Ernst E**, **Bonde JP**, **Skakkebaek NE**, **Olsen J**, Does moderate alcohol consumption affect fertility? Follow up study among couples planning first pregnancy, Br Med J 317:505, 1998.
359. **Juhl M**, **Nyboe Andersen AM**, **Gronbaek M**, **Olsen J**, Moderate alcohol consumption and waiting time to pregnancy, Hum Reprod 16:2705, 2001.
360. **Klonoff-Cohen H**, **Lam-Kruglick P**, **Gonzalez C**, Effects of maternal and paternal alcohol consumption on the success rates of in vitro fertilization and gamete intrafallopian transfer, Fertil Steril 79:330, 2003.
361. **Bolumar F**, **Olsen J**, **Rebagliato M**, **Bisanti L**, Caffeine intake and delayed conception: a European multicenter study on infertility and subfecundity. European Study Group on Infertility and Subfecundity, Am J Epidemiol 145:324, 1997.
362. **Caan B**, **Quesenberry CP Jr**, **Coates AO**, Differences in fertility associated with caffeinated beverage consumption, Am J Public Health 88:270, 1998.
363. **Cnattingius S**, **Signorello LB**, **Anneren G**, **Clausson B**, **Ekbom A**, **Ljunger E**, **Blot WJ**, **McLaughlin JK**, **Petersson G**, **Rane A**, **Granath F**, Caffeine intake and the risk of first-trimester spontaneous abortion, N Engl J Med 343:1839, 2000.
364. **American College of Obstetrics and Gynecology**, Frequently asked questions FAQ001 pregnancy, 2018.
365. **Hruska KS**, **Furth PA**, **Seifer DB**, **Sharara FI**, **Flaws JA**, Environmental factors in infertility, Clin Obstet Gynecol 43:821, 2000.
366. **Stevens VC**, Some reproductive studies in the baboon, Hum Reprod Update 3:533, 1997.
367. **Wilcox AJ**, **Weinberg CR**, **Baird DD**, Timing of sexual intercourse in relation to ovulation—effects on the probability of conception, survival of the pregnancy, and sex of the baby, N Engl J Med 333:1517, 1995.
368. **Guttmacher AF**, Factors affecting normal expectancy of conception, JAMA 161:855, 1956.
369. **Evers JL**, Female subfertility, Lancet 360:151, 2002.
370. **Wilcox AJ**, **Weinberg CR**, **Baird DD**, Post-ovulatory ageing of the human oocyte and embryo failure, Hum Reprod 13:394, 1998.
371. **Dunson DB**, **Baird DD**, **Wilcox AJ**, **Weinberg CR**, Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation, Hum Reprod 14:1835, 1999.
372. **Miller PB**, **Soules MR**, The usefulness of a urinary LH kit for ovulation prediction during menstrual cycles of normal women, Obstet Gynecol 87: 13, 1996.
373. **Nielsen MS**, **Barton SD**, **Hatasaka HH**, **Stanford JB**, Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick, Fertil Steril 76:384, 2001.
374. **Manders M**, **McLindon L**, **Schulze B**, **Beckmann MM**, **Kremer JA**, **Farquhar C**, Timed intercourse for couples trying to conceive, Cochrane Database Syst Rev, (3):CD011345, 2015. doi: 10.1002/14651858.CD011345.pub2.
375. **Agarwal SK**, **Haney AF**, Does recommending timed intercourse really help the infertile couple? Obstet Gynecol 84:307, 1994.
376. **Miller JH**, **Weinberg RK**, **Canino NL**, **Klein NA**, **Soules MR**, The pattern of infertility diagnoses in women of advanced reproductive age, Am J Obstet Gynecol 181:952, 1999.
377. **Maheshwari A**, **Hamilton M**, **Bhattacharya S**, Effect of female age on the diagnostic categories of infertility, Hum Reprod 23:538, 2008.
378. **Snick HK**, **Snick TS**, **Evers JL**, **Collins JA**, The spontaneous pregnancy prognosis in untreated subfertile couples: the Walcheren primary care study, Hum Reprod 12:1582, 1997.
379. **Hull MG**, **Glazener CM**, **Kelly NJ**, **Conway DI**, **Foster PA**, **Hinton RA**, **Coulson C**, **Lambert PA**, **Watt EM**, **Desai KM**, Population study of causes, treatment, and outcome of infertility, Br Med J (Clin Res Ed) 291:1693, 1985.
380. **Collins JA**, **Burrows EA**, **Wilan AR**, The prognosis for live birth among untreated infertile couples, Fertil Steril 64:22, 1995.
381. **Sundstrom I**, **Ildgruben A**, **Hogberg U**, Treatment-related and treatment-independent deliveries among infertile couples, a long-term follow-up, Acta Obstet Gynecol Scand 76:238, 1997.

382. **Eimers JM**, **te Velde ER**, **Gerritse R**, **Vogelzang ET**, **Looman CW**, **Habbema JD**, The prediction of the chance to conceive in subfertile couples, Fertil Steril 61:44, 1994.
383. **Bostofte E**, **Bagger P**, **Michael A**, **Stakemann G**, Fertility prognosis for infertile couples, Fertil Steril 59:102, 1993.
384. **Practice Committee of the American Society for Reproductive Medicine**, Diagnostic evaluation of the infertile female: a committee opinion, Fertil Steril 103(6):e44, 2015.
385. **Stubblefield P**, **Monson R**, **Schoenbaum S**, **Wolfson CE**, **Cookson DJ**, **Ryan KJ**, Fertility after induced abortion: a prospective follow-up study, Obstet Gynecol 62:186, 1984.
386. **Frank P**, **McNamee R**, **Hannaford PC**, **Kay CR**, **Hirsch S**, The effect of induced abortion on subsequent fertility, Br J Obstet Gynaecol 100:575, 1993.
387. **U.S. Preventive Services Task Force**, Cervical Cancer: Screening, https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cervical-cancer-screening
388. **American College of Obstetricians and Gynecologists**, ACOG Committee Opinion. Number 690, March 2017. Carrier screening in the age of genomic medicine, Obstet Gynecol 129(3):e35, 2017.
389. **Practice Committee of American Society for Reproductive Medicine**, Vaccination guidelines for female infertility patients: a committee opinion, Fertil Steril 99(2):337, 2013.
390. **Soares RC**, **Siqueira MM**, **Toscano CM**, **Maia Mde L**, **Flannery B**, et al., Follow-up study of unknowingly pregnant women vaccinated against rubella in Brazil, 2001-2002, J Infect Dis 204:S729, 2011.
391. **Workowski KA**, **Bolan GA**, Sexually transmitted diseases treatment guidelines, 2015, MMWR Recomm Rep 64:3, 2015.
392. **Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Assisted Reproductive Technology**, Recommendations for gamete and embryo donation: a committee opinion, Fertil Steril 99(1):47, 2013.
393. **Practice Committee of the American Society for Reproductive Medicine**, Diagnostic evaluation of the infertile male, Fertil Steril 103(3):e18, 2015.
394. **Bates GW**, **Garza DE**, **Garza MM**, Clinical manifestations of hormonal changes in the menstrual cycle, Obstet Gynecol Clin North Am 17:299, 1990.
395. **Quagliarello J**, **Arny M**, Inaccuracy of basal body temperature charts in predicting urinary luteinizing hormone surges, Fertil Steril 45:334, 1986.
396. **Luciano AA**, **Peluso J**, **Koch E**, **Maier D**, **Kuslis S**, **Davison E**, Temporal relationship and reliability of the clinical, hormonal, and ultrasonographic indices of ovulation in infertile women, Obstet Gynecol 75:412, 1990.
397. **Abraham GE**, **Maroulis GB**, **Marshall JR**, Evaluation of ovulation and corpus luteum function using measurements of plasma progesterone, Obstet Gynecol 44:522, 1974.
398. **Wathen NC**, **Perry L**, **Lilford RJ**, **Chard T**, Interpretation of single progesterone measurement in diagnosis of anovulation and defective luteal phase: observations on analysis of the normal range, Br Med J 288:7, 1984.
399. **Soules MR**, **McLachlan RI**, **Ek M**, **Dahl KD**, **Cohen NL**, **Bremmer WJ**, Luteal phase deficiency: characterization of reproductive hormones over the menstrual cycle, J Clin Endocrinol Metab 69:804, 1989.
400. **Soules MR**, **Clifton DK**, **Cohen NL**, **Bremner WJ**, **Steiner RA**, Luteal phase deficiency: abnormal gonadotropin and progesterone secretion patterns, J Clin Endocrinol Metab 69:813, 1989.
401. **Li TC**, **Lenton EA**, **Dockery P**, **Cooke ID**, A comparison of some clinical and endocrinological features between cycles with normal and defective luteal phases in women with unexplained infertility, Hum Reprod 5:805, 1990.
402. **Cooke ID**, **Morgan CA**, **Parry TE**, Correlation of endometrial biopsy and plasma progesterone levels in infertile women, J Obstet Gynaecol Br Commonw 79:647, 1972.
403. **Shepard MK**, **Senturia YD**, Comparison of serum progesterone and endometrial biopsy for confirmation of ovulation and evaluation of luteal function, Fertil Steril 28:541, 1977.
404. **Rosenfeld DL**, **Chudow S**, **Bronson RA**, Diagnosis of luteal phase inadequacy, Obstet Gynecol 56:193, 1980.
405. **Cumming DC**, **Honore LH**, **Scott JZ**, **Williams KP**, The late luteal phase in infertile women: comparison of

simultaneous endometrial biopsy and progesterone levels, Fertil Steril 43:715, 1985.
406. **Li T-C**, **Lenton EA**, **Dockery P**, **Rogers AW**, **Cooke ID**, The relation between daily salivary progesterone profile and endometrial development in the luteal phase of fertile and infertile women, Br J Obstet Gynaecol 96:445, 1989.
407. **Jordan J**, **Craig K**, **Clifton DK**, **Soules MJ**, Luteal phase defect: the sensitivity and specificity of diagnostic methods in common use, Fertil Steril 62: 54, 1994.
408. **Hull MG**, **Savage PE**, **Bromham DR**, **Ismail AA**, **Morris AF**, The value of a single serum progesterone measurement in the midluteal phase as a criterion of a potentially fertile cycle ("ovulation") derived from treated and untreated conception cycles, Fertil Steril 37:355, 1982.
409. **Ellinwood WE**, **Norman RL**, **Spies HG**, Changing frequency of pulsatile luteinizing hormone and progesterone secretion during the luteal phase of the menstrual cycle of rhesus monkeys, Biol Reprod 31:714, 1984.
410. **Filicori M**, **Butler JP**, **Crowley WF**, Neuroendocrine regulation of the corpus luteum in the human: evidence for pulsatile progesterone secretion, J Clin Invest 73:1638, 1984.
411. **McGovern PG**, **Myers ER**, **Silva S**, **Coutifaris C**, **Carson SA**, **Legro RS**, **Schlaff WD**, **Carr BR**, **Steinkampf MP**, **Giudice LC**, **Leppert PC**, **Diamond MP**, Absence of secretory endometrium after false-positive home urine luteinizing hormone testing, Fertil Steril 82:1273, 2004.
412. **Martinez AR**, **Bernardus RE**, **Vermeiden JP**, **Schoemaker J**, Reliability of home urinary LH tests for timing of insemination: a consumer's study, Hum Reprod 7:751, 1992.
413. **Johnson S**, **Ellis J**, **Godbert S**, **Ali S**, **Zinaman M**, Comparison of a digital ovulation test with three popular line ovulation tests to investigate user accuracy and certainty, Expert Opin Med Diagn 5(6):467, 2011.
414. **Martinez AR**, **Bernardus RE**, **Vermeiden JP**, **Schoemaker J**, Time schedules of intrauterine insemination after urinary luteinizing hormone surge detection and pregnancy results, Gynecol Endocrinol 8:1, 1994.
415. **Meyer WR**, **Smith PM**, **Clark MR**, **Cusmano LL**, **Fritz MA**, Therapeutic cup insemination with cryopreserved donor sperm: prognostic value of cervical mucus score at insemination and the number of motile sperm in mucus at 24 hours, Fertil Steril 66:435, 1996.
416. **Tiplady S**, **Jones G**, **Campbell M**, **Johnson S**, **Ledger W**, Home ovulation tests and stress in women trying to conceive: a randomized controlled trial, Hum Reprod 28(1):138, 2013. doi:10.1093/humrep/des372. Epub 2012 Oct 18.
417. **Jones G**, **Carlton J**, **Weddell S**, **Johnson S**, **Ledger WL**, Women's experiences of ovulation testing: a qualitative analysis, Reprod Health 12:116, 2015.
418. **Jones GS**, Some newer aspects of the management of infertility, JAMA 1411:1123, 1949.
419. **Jones GS**, The luteal phase defect, Fertil Steril 27:351, 1976.
420. **Hertig AT**, **Rock J**, **Adams EC**, A description of 34 human ova within the first 17 days of development, Am J Anat 98:435, 1956.
421. **Navot RW**, **Scott RT**, **Doresch K**, **Veeck LL**, **Liu HC**, **Rosenwaks Z**, The window of embryo transfer and the efficiency of human conception in vitro, Fertil Steril 55:114, 1991.
422. **Bergh PA**, **Navot D**, The impact of embryonic development and endometrial maturity on the timing of implantation, Fertil Steril 58:537, 1992.
423. **Fritz MA**, **Hess DL**, **Patton PE**, Influence of corpus luteum age on the steroidogenic response to exogenous human chorionic gonadotropin in normal cycling women, Am J Obstet Gynecol 167:709, 1992.
424. **Lessey BA**, **Fritz MA**, Defective luteal function, In: Fraser IS, et al., eds. Estrogen and Progestogens in Clinical Practice, Churchill Livingstone, London, 1998.
425. **Tay PY**, **Lenton EA**, The optimum time for exogenous human chorionic gonadotropin to rescue the corpus luteum, J Assist Reprod Genet 16:495, 1999.
426. **Wilcox AJ**, **Baird DD**, **Weinberg CR**, Time of implantation of the conceptus and loss of pregnancy, N Engl J Med 340:1796, 1999.
427. **Noyes RW**, **Hertig AW**, **Rock J**, Dating the endometrial biopsy, Fertil Steril 1:3, 1950.
428. **Shoupe D**, **Mishell DR Jr**, **Lacarra M**, **Lobo R**, **Horenstein J**, **d'Ablaing G**, **Moyer D**, Correlation of endometrial maturation with four methods of estimating day of ovulation, Obstet Gynecol 73:88, 1989.

429. **Noyes RW**, **Haman JO**, Accuracy of endometrial dating: correlation of endometrial dating with basal body temperature and menses, Fertil Steril 4:504, 1953.
430. **Andrews WC**, Luteal phase defects, Fertil Steril 32:501, 1979.
431. **Duggan MA**, **Brashert P**, **Ostor A**, **Scurry J**, **Billson V**, **Kneafsey P**, **Difrancesco L**, The accuracy and interobserver reproducibility of endometrial dating, Pathology 33:292, 2001.
432. **Aksel S**, Sporadic and recurrent luteal phase defects in cyclic women: comparison with normal cycles, Fertil Steril 33:372, 1980.
433. **Wentz AC**, **Kossoy L**, **Parker RA**, The impact of luteal phase inadequacy in an infertile population, Am J Obstet Gynecol 162:937, 1990.
434. **Li TC**, **Dockery P**, **Cooke ID**, Endometrial development in the luteal phase of women with various types of infertility: comparison with women of normal fertility, Hum Reprod 6:325, 1991.
435. **Balasch J**, **Fabreques F**, **Creus M**, **Vanrell JA**, The usefulness of endometrial biopsy for luteal phase evaluation in infertility, Hum Reprod 7:973, 1992.
436. **Peters AJ**, **Lloyd RP**, **Coulam CP**, Prevalence of out-of-phase endometrial biopsy specimens, Am J Obstet Gynecol 166:1738, 1992.
437. **Batista MC**, **Cartledge TP**, **Merino MJ**, **Axiotis C**, **Platia MP**, **Merriam GR**, **Loriaux DL**, **Nieman LK**, Midluteal phase endometrial biopsy does not accurately predict luteal function, Fertil Steril 59:294, 1993.
438. **Davis OK**, **Berkeley AS**, **Naus GJ**, **Cholst IN**, **Freedman KS**, The incidence of luteal phase defect in normal, fertile women, determined by serial endometrial biopsies, Fertil Steril 51:582, 1989.
439. **Johannisson E**, **Parker RA**, **Landgren BM**, **Diczfalusy E**, Morphometric analysis of the human endometrium in relation to peripheral hormone levels, Fertil Steril 38:564, 1982.
440. **Munster K**, **Schmidt L**, **Helm P**, Length and variation in the menstrual cycle–a cross-sectional study from a Danish county, Br J Obstet Gynaecol 99: 422, 1992.
441. **Guermandi E**, **Vegetti W**, **Bianchi MM**, **Uglietti A**, **Ragni G**, **Crosignani P**, Reliability of ovulation tests in infertile women, Obstet Gynecol 97:92, 2001.
442. **Lenton EA**, **Landgren B**, **Sexton L**, **Harper R**, Normal variation in the length of the follicular phase of the menstrual cycle: effect of chronological age, Br J Obstet Gynaecol 91:681, 1984.
443. **Scott RT**, **Snyder RR**, **Strickland DM**, **Tyburski CC**, **Bagnall JA**, **Reed KR**, **Adair CA**, **Hensley SB**, The effect of interobserver variation in dating endometrial histology on the diagnosis of luteal phase defects, Fertil Steril 50: 888, 1988.
444. **Gibson M**, **Badger GJ**, **Byrn F**, **Lee KR**, **Korson R**, **Trainer TD**, Error in histologic dating of secretory endometrium: variance component analysis, Fertil Steril 56:242, 1991.
445. **Scott RT**, **Snyder RR**, **Bagnall JW**, **Reed KD**, **Adair CF**, **Hensley SD**, Evaluation of the impact of intraobserver variability on endometrial dating and the diagnosis of luteal phase defects, Fertil Steril 60:652, 1993.
446. **Smith S**, **Hosid S**, **Scott L**, Endometrial biopsy dating. Interobserver variation and its impact on clinical practice, J Reprod Med 40:1, 1995.
447. **Murray MJ**, **Meyer WR**, **Zaino RJ**, **Lessey BA**, **Novotny DB**, **Ireland I**, **Fritz MA**, A critical reanalysis of the accuracy, reproducibility, and clinical utility of histologic endometrial dating: a systematic study of the secretory phase in normally cycling, fertile women, Fertil Steril 81:1333, 2004.
448. **Coutifaris C**, **Myers ER**, **Guzick DS**, **Diamond MP**, **Carson SA**, **Legro RS**, **McGovern PG**, **Schlaff WD**, **Carr BR**, **Steinkampf MP**, **Silva S**, **Vogel DL**, **Leppert PC**, Histological dating of timed endometrial biopsy tissue is not related to fertility status, Fertil Steril 82:1264, 2004.
449. **Usadi RS**, **Groll JM**, **Lessey BA**, **Lininger RA**, **Zaino RJ**, **Fritz MA**, **Young SL**, Endometrial development and function in experimentally induced luteal phase deficiency, J Clin Endocrinol Metab 93:4058, 2008.
450. **Groll JM**, **Usadi RS**, **Lessey BA**, **Lininger R**, **Young SL**, **Fritz MA**, Effects of variations in serum estradiol concentrations on secretory endometrial development and function in experimentally induced cycles in normal women, Fertil Steril 92:2058, 2009.
451. **Young SL**, **Lessey BA**, Progesterone function in human endometrium: clinical perspectives, Semin Reprod

Med 28:5, 2010.
452. **Talbi S**, **Hamilton AE**, **Vo KC**, **Tulac S**, **Overgaard MT**, **Dosiou C**, **Le Shay N**, **Nezhat CN**, **Kempson R**, **Lessey BA**, **Nayak NR**, **Giudice LC**, Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women, Endocrinology 147:1097, 2006.
453. **Eun Kwon H**, **Taylor HS**, The role of HOX genes in human implantation [Review], Ann N Y Acad Sci 1034:1, 2004.
454. **Taylor HS**, **Arici A**, **Olive D**, **Igarashi P**, HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium, J Clin Invest 101(7):1379, 1998.
455. **Taylor HS**, The role of HOX genes in human implantation, Hum Reprod Update 6(1):75, 2000.
456. **Taylor HS**, **Igarashi P**, **Olive DL**, **Arici A**, Sex steroids mediate HOXA11 expression in the human peri-implantation endometrium, J Clin Endocrinol Metab 84(3):1129, 1999.
457. **Lessey BA**, Endometrial integrins and the establishment of uterine receptivity, Hum Reprod 13(Suppl 3):247, 1998.
458. **Lindhard A**, **Bentin-Ley U**, **Ravn V**, **Islin H**, **Hviid T**, **Rex S**, **Bangsboll S**, **Sorensen S**, Biochemical evaluation of endometrial function at the time of implantation, Fertil Steril 78:221, 2002.
459. **Apparao KB**, **Murray MJ**, **Fritz MA**, **Meyer WR**, **Chambers AF**, **Truong PR**, **Lessey BA**, Osteopontin and its receptor alphavbeta(3) integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differentially, J Clin Endocrinol Metab 86:4991, 2001.
460. **Carson DD**, **Lagow E**, **Thathiah A**, **Al-Shami R**, **Farach-Carson MC**, **Vernon M**, **Yuan L**, **Fritz MA**, **Lessey B**, Changes in gene expression during the early to mid-luteal (receptive phase) transition in human endometrium detected by high-density microarray screening, Mol Hum Reprod 8:871, 2002.
461. **Allan G**, **Campen C**, **Hodgen G**, **Williams R**, **Charnock-Jones DS**, **Wan J**, **Erlander M**, **Palmer S**, Identification of genes with differential regulation in primate endometrium during the proliferative and secretory phases of the cycle, Endocr Res 29:53, 2003.
462. **Kao LC**, **Germeyer A**, **Tulac S**, **Lobo S**, **Yang JP**, **Taylor RN**, **Osteen K**, **Lessey BA**, **Giudice LC**, Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility, Endocrinology 144:2870, 2003.
463. **Genbacev OD**, **Prakobphol A**, **Foulk RA**, **Krtolica AR**, **Ilic D**, **Singer MS**, **Yang ZQ**, **Kiessling LL**, **Rosen SD**, **Fisher SJ**, Trophoblast L-selectin-mediated adhesion at the maternal-fetal interface, Science 299:405, 2003.
464. **Díaz-Gimeno P**, **Horcajadas JA**, **Martínez-Conejero JA**, **Esteban FJ**, **Alamá P**, **Pellicer A**, **Simon C**, A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature, Fertil Steril 95:50, 2011.
465. **Ruiz-Alonso M**, **Blesa D**, **Díaz-Gimeno P**, **Gomez E**, **Fernandez-Sanchez M**, **Carranza F**, **Carrera J**, **Vilella F**, **Pellicer A**, **Simon C**, The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure, Fertil Steril 100:818, 2013.
466. **Koot YE**, **van Hooff SR**, **Boomsma CM**, **van Leenen D**, **Groot Koerkamp MJ**, **Goddijn M**, **Eijkemans MJ**, **Fauser BC**, **Holstege FC**, **Macklon NS**, An endometrial gene expression signature accurately predicts recurrent implantation failure after IVF, Sci Rep 6:19411, 2016. doi: 10.1038/srep19411.
467. **de Crespigny LC**, **O'Herlihy C**, **Robinson HP**, Ultrasonic observation of the mechanism of human ovulation, Am J Obstet Gynecol 139:636, 1981.
468. **Ecochard R**, **Marret H**, **Rabilloud M**, **Bradai R**, **Boehringer H**, **Girotto S**, **Barbato M**, Sensitivity and specificity of ultrasound indices of ovulation in spontaneous cycles, Eur J Obstet Gynecol Reprod Biol 91:59, 2000.
469. **Petsos P**, **Chandler C**, **Oak M**, **Ratcliffe WA**, **Wood R**, **Anderson DC**, The assessment of ovulation by a combination of ultrasound and detailed serial hormone profiles in 35 women with long-standing unexplained infertility, Clin Endocrinol (Oxf) 22:739, 1985.
470. **Daly DC**, **Soto-Albors C**, **Walters C**, **Ying YK**, **Riddick DH**, Ultrasonographic assessment of luteinized unruptured follicle syndrome in unexplained infertility, Fertil Steril 43:62, 1985.

471. **Priddy AR**, **Killick SR**, **Elstein M**, **Morris J**, **Sullivan M**, **Patel L**, **Elder M**, The effect of prostaglandin synthetase inhibitors on human preovulatory follicular fluid prostaglandin, thromboxane, and leukotriene concentrations, J Clin Endocrinol Metab 71:235, 1990.
472. **Smith G**, **Roberts R**, **Hall C**, **Nuki G**, Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis, Br J Rheumatol 35:458, 1996.
473. **Eggert-Kruse W**, **Reimann-Andersen J**, **Rohr G**, **Pohl S**, **Tilgen W**, **Runnebaum B**, Clinical relevance of sperm morphology assessment using strict criteria and relationship with sperm-mucus interaction in vivo and in vitro, Fertil Steril 63:612, 1995.
474. **Bonilla-Musoles F**, Scanner electron microscopy of the cervical mucus, Clin Exp Obstet Gynecol 10:151, 1983.
475. **Overstreet JW**, **Katz DF**, **Yudin AI**, Cervical mucus and sperm transport in reproduction, Semin Perinatol 15:149, 1991.
476. **Yudin AI**, **Hanson FW**, **Katz DF**, Human cervical mucus and its interaction with sperm: fine structural view, Biol Reprod 40:661, 1989.
477. **Katz DF**, Human cervical mucus: research update, Am J Obstet Gynecol 165:1984, 1991.
478. **Chretien FC**, Involvement of the glycoproteic meshwork of cervical mucus in the mechanism of sperm orientation, Acta Obstet Gynecol Scand 82:449, 2003.
479. **Katz DF**, **Slade DA**, **Nakajima ST**, Analysis of pre-ovulatory changes in cervical mucus hydration and sperm penetrability, Adv Contracept 13:143, 1997.
480. **Oei SG**, **Keirse MJ**, **Bloemenkamp KW**, **Helmerhorst FM**, European postcoital tests: opinions and practice, Br J Obstet Gynaecol 102:621, 1995.
481. **Franken DR**, **Pretorius E**, **Grobler S**, **De Wet JI**, Important semen parameters during postcoital testing, Arch Androl 14:213, 1985.
482. **Hull MG**, **Savage PE**, **Bromham DR**, Prognostic value of the postcoital test: prospective study based on time-specific conception rates, Br J Obstet Gynaecol 89:299, 1982.
483. **Quagliarello J**, **Arny M**, Intracervical versus intrauterine insemination: correlation of outcome with antecedent postcoital testing, Fertil Steril 46:870, 1986.
484. **Glazener CM**, **Coulson C**, **Lambert PA**, **Watt EM**, **Hinton RA**, **Kelly NJ**, **Hull MG**, The value of artificial insemination with husband's semen in infertility due to failure of postcoital sperm-mucus penetration—controlled trial of treatment, Br J Obstet Gynaecol 94:774, 1987.
485. **Eimers JM**, **te Velde ER**, **Gerritse R**, **van Kooy RJ**, **Kremer J**, **Habbema JD**, The validity of the postcoital test for estimating the probability of conceiving, Am J Obstet Gynecol 171:65, 1994.
486. **Glazener CM**, **Ford WC**, **Hull MG**, The prognostic power of the post-coital test for natural conception depends on duration of infertility, Hum Reprod 15:1953, 2000.
487. **Collins JA**, **So Y**, **Wilson EH**, **Wrixon W**, **Casper RF**, The postcoital test as a predictor of pregnancy among 355 infertile couples, Fertil Steril 41:703, 1984.
488. **Oei SG**, **Helmerhorst FM**, **Keirse MJ**, When is the post-coital test normal? A critical appraisal, Hum Reprod 10:1711, 1995.
489. **Fehring RJ**, Accuracy of the peak day of cervical mucus as a biological marker of fertility, Contraception 66:231, 2002.
490. **Hamilton CJ**, **Evers JL**, **de Haan J**, Ultrasound increases the prognostic value of the postcoital test, Gynecol Obstet Invest 21:80, 1986.
491. **Kovacs GT**, **Newman GB**, **Henson GL**, The postcoital test: What is normal? Br Med J 1:818, 1978.
492. **Cimino C**, **Borruso AR**, **Napoli P**, **Cittadini E**, Evaluation of the importance of Chlamydia T. and/or Mycoplasma H. and/or Ureaplasma U. genital infections and of antisperm antibodies in couples affected by muco-semen incompatibility and in couples with unexplained infertility Acta Eur Fertil 24:13, 1993.
493. **Critchlow CW**, **Wölner-Hanssen P**, **Eschenbach DA**, **Kiviat NB**, **Koutsky LA**, **Stevens CE**, **Holmes KK**, Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking, and douching, Am J Obstet Gynecol 173:534, 1995.
494. **Manhart LE**, **Critchlow CW**, **Holmes KK**, **Dutro SM**, **Eschenbach DA**, **Stevens CE**, **Totten PA**,

Mucopurulent cervicitis and Mycoplasma genitalium, J Infect Dis 187:650, 2003.
495. **Tredway DR**, **Wortham JW Jr**, **Condon-Mahony M**, **Baker D**, **Shane JM**, Correlation of postcoital evaluation with in vitro sperm cervical mucus determinations and ureaplasma cultures, Fertil Steril 43:286, 1985.
496. **Farhi J**, **Valentine A**, **Bahadur G**, **Shenfield F**, **Steele SJ**, **Jacobs HS**, In-vitro cervical mucus-sperm penetration tests and outcome of infertility treatments in couples with repeatedly negative post-coital tests, Hum Reprod 10: 85, 1995.
497. **Keel BA**, **Schalue TK**, Correlation of the bovine cervical mucus penetration test with human sperm characteristics in 1,406 ejaculates, Arch Androl 44:109, 2000.
498. **Bateman BG**, **Nunley WC Jr**, **Kolp LA**, Exogenous estrogen therapy for the treatment of clomiphene citrate-induced cervical mucus abnormalities: Is it effective? Fertil Steril 54:577, 1990.
499. **Check JH**, **Adelson HG**, **Wu CH**, Improvement of cervical factor with guaifenesin, Fertil Steril 37:707, 1982.
500. **Ansari AH**, **Gould KG**, **Ansari VM**, Sodium bicarbonate douching for improvement of the postcoital test, Fertil Steril 33:608, 1980.
501. **Friedman A**, **Haas S**, **Kredentser J**, **Stewart E**, **Schiff I**, A controlled trial of intrauterine insemination for cervical factor and male factor: a preliminary report, Int J Fertil 34:199, 1989.
502. **Kirby CA**, **Flaherty SP**, **Godfrey BM**, **Warnes GM**, **Matthews CD**, A prospective trial of intrauterine insemination of motile spermatozoa versus timed intercourse, Fertil Steril 56:102, 1991.
503. **te Velde ER**, **van Kooy RJ**, **Waterreus JJ**, Intrauterine insemination of washed husband's spermatozoa: a controlled study, Fertil Steril 51:182, 1989.
504. **Mol BW**, Diagnostic potential of the postcoital test, In: Heineman MJ, ed. Evidence-Based Medicine in Clinical Practice, American Society for Reproductive Medicine, Birmingham, AL, 2001.
505. **Glatstein IZ**, **Harlow BL**, **Hornstein MD**, Practice patterns among reproductive endocrinologists: the infertility evaluation, Fertil Steril 67:443, 1997.
506. **Griffith CS**, **Grimes DA**, The validity of the postcoital test, Am J Obstet Gynecol 162:615, 1990.
507. **Oei SG**, **Bloemenkamp KW**, **Helmerhorst FM**, **Naaktgeboren N**, **Keirse MJ**, Evaluation of the postcoital test for assessment of 'cervical factor' infertility, Eur J Obstet Gynecol Reprod Biol 64:217, 1996.
508. **Oei SG**, **Helmerhorst FM**, **Bloemenkamp KW**, **Hollants FA**, **Meerpoel DE**, **Keirse MJ**, Effectiveness of the postcoital test: randomised controlled trial, Br Med J 317:502, 1998.
509. **Reuter KL**, **Daly DC**, **Cohen SM**, Septate versus bicornuate uteri: errors in imaging diagnosis, Radiology 172:749, 1989.
510. **Pellerito JS**, **McCarthy SM**, **Doyle MB**, **Glickman MG**, **DeCherney AH**, Diagnosis of uterine anomalies: relative accuracy of MR imaging, endovaginal sonography, and hysterosalpingography, Radiology 183:795, 1992.
511. **Homer HA**, **Li TC**, **Cooke ID**, The septate uterus: a review of management and reproductive outcome, Fertil Steril 73:1, 2000.
512. **Preutthipan S**, **Linasmita V**, A prospective comparative study between hysterosalpingography and hysteroscopy in the detection of intrauterine pathology in patients with infertility, J Obstet Gynaecol Res 29:33, 2003.
513. **Soares SR**, **Barbosa dos Reis MM**, **Camargos AF**, Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases, Fertil Steril 73:406, 2000.
514. **Breitkopf D**, **Goldstein SR**, **Seeds JW**, ACOG technology assessment in obstetrics and gynecology. Number 3, September 2003. Saline infusion sonohysterography, Obstet Gynecol 102:659, 2003.
515. **Sladkevicius P**, **Valentin L**, **Marsal K**, Blood flow velocity in the uterine and ovarian arteries during the normal menstrual cycle, Ultrasound Obstet Gynecol 3:199, 1993.
516. **Tan SL**, **Zaidi J**, **Campbell S**, **Doyle P**, **Collins W**, Blood flow changes in the ovarian and uterine arteries during the normal menstrual cycle, Am J Obstet Gynecol 175:625, 1996.
517. **Gonen Y**, **Casper RF**, Prediction of implantation by the sonographic appearance of the endometrium during controlled ovarian stimulation for in vitro fertilization (IVF), J In Vitro Fert Embryo Transf 7:146, 1990.

518. **Khalifa E**, **Brzyski RG**, **Oehninger S**, **Acosta AA**, **Muasher SJ**, Sonographic appearance of the endometrium: the predictive value for the outcome of in-vitro fertilization in stimulated cycles, Hum Reprod 7:677, 1992.
519. **Friedler S**, **Schenker JG**, **Herman A**, **Lewin A**, The role of ultrasonography in the evaluation of endometrial receptivity following assisted reproductive treatments: a critical review, Hum Reprod Update 2:323, 1996.
520. **Rashidi BH**, **Sadeghi M**, **Jafarabadi M**, **Tehrani Nejad ES**, Relationships between pregnancy rates following in vitro fertilization or intracytoplasmic sperm injection and endometrial thickness and pattern, Eur J Obstet Gynecol Reprod Biol 120:179, 2005.
521. **Merce LT**, **Barco MJ**, **Bau S**, **Troyano J**, Are endometrial parameters by three-dimensional ultrasound and power Doppler angiography related to in vitro fertilization/embryo transfer outcome? Fertil Steril 89:111, 2008.
522. **Chen SL**, **Wu FR**, **Luo C**, **Chen X**, **Shi XY**, **Zheng HY**, **Ni YP**, Combined analysis of endometrial thickness and pattern in predicting outcome of in vitro fertilization and embryo transfer: a retrospective cohort study, Reprod Biol Endocrinol 24:30, 2010.
523. **Steer CV**, **Tan SL**, **Mason BA**, **Campbell S**, Midluteal-phase vaginal color Doppler assessment of uterine artery impedance in a subfertile population, Fertil Steril 61:53, 1994.
524. **Tinkanen H**, **Kujansuu E**, **Laippala P**, Vascular resistance in uterine and ovarian arteries: its association with infertility and the prognosis of infertility, Eur J Obstet Gynecol Reprod Biol 57:111, 1994.
525. **Isaksson R**, **Tiitinen A**, **Reinikainen LM**, **Cacciatore B**, Comparison of uterine and spiral artery blood flow in women with unexplained and tubal infertility, Ultrasound Obstet Gynecol 21:174, 2003.
526. **Kelly SM**, **Sladkevicius P**, **Campbell S**, **Nargund G**, Investigation of the infertile couple: a one-stop ultrasound-based approach, Hum Reprod 16:2481, 2001.
527. **Benacerraf BR**, **Shipp TD**, **Bromley B**, Which patients benefit from a 3D reconstructed coronal view of the uterus added to standard routine 2D pelvic sonography? AJR Am J Roentgenol 190(3):626, 2008.
528. **Faivre E**, **Fernandez H**, **Deffieux X**, **Gervaise A**, **Frydman R**, **Levaillant JM**, Accuracy of three-dimensional ultrasonography in differential diagnosis of septate and bicornuate uterus compared with office hysteroscopy and pelvic magnetic resonance imaging, J Minim Invasive Gynecol 19(1):101, 2012.
529. **Ghi T**, **Casadio P**, **Kuleva M**, **Perrone AM**, **Savelli L**, **Giunchi S**, **et al**, Accuracy of three-dimensional ultrasound in diagnosis and classification of congenital uterine anomalies, Fertil Steril 92(2):808, 2009.
530. **Moini A**, **Mohammadi S**, **Hosseini R**, **Eslami B**, **Ahmadi F**, Accuracy of 3-dimensional sonography for diagnosis and classification of congenital uterine anomalies, J Ultrasound Med 32(6):923, 2013.
531. **Becker E Jr**, **Lev-Toaff AS**, **Kaufman EP**, **Halpern EJ**, **Edelweiss MI**, **Kurtz AB**, The added value of transvaginal sonohysterography over transvaginal sonography alone in women with known or suspected leiomyoma, J Ultrasound Med 21:237, 2002.
532. **Leone FP**, **Lanzani C**, **Ferrazzi E**, Use of strict sonohysterographic methods for preoperative assessment of submucous myomas, Fertil Steril 79:998, 2003.
533. **Sylvestre C**, **Child TJ**, **Tulandi T**, **Tan SL**, A prospective study to evaluate the efficacy of two- and three-dimensional sonohysterography in women with intrauterine lesions, Fertil Steril 79:1222, 2003.
534. **Makris N**, **Kalmantis K**, **Skartados N**, **Papadimitriou A**, **Mantzaris G**, **Antsaklis A**, Three-dimensional hysterosonography versus hysteroscopy for the detection of intracavitary uterine abnormalities, Int J Gynaecol Obstet 97:6, 2007.
535. **Kupesic S**, **Kurjak A**, **Skenderovic S**, **Bjelos D**, Screening for uterine abnormalities by three-dimensional ultrasound improves perinatal outcome, J Perinat Med 30(1):9, 2002.
536. **La Torre R**, **De Felice C**, **De Angelis C**, **Coacci F**, **Mastrone M**, **Cosmi EV**, Transvaginal sonographic evaluation of endometrial polyps: a comparison with two dimensional and three dimensional contrast sonography, Clin Exp Obstet Gynecol 26(3–4):171, 1999.
537. **Stadtmauer L**, **Shah A**, Gynecologic surgery: preoperative assessment with ultrasound, Clin Obstet Gynecol 60(1):82, 2017.
538. **Fedele L**, **Bianchi S**, **Dorta M**, **Vignali M**, Intrauterine adhesions: detection with transvaginal US, Radiology 199:757, 1996.
539. **Salle B**, **Gaucherand P**, **de Saint Hilaire P**, **Rudigoz RC**, Transvaginal sonohysterographic evaluation of

intrauterine adhesions, J Clin Ultrasound 27:131, 1999.
540. **Davis PC**, **O'Neill MJ**, **Yoder IC**, **Lee SI**, **Mueller PR**, Sonohysterographic findings of endometrial and subendometrial conditions, Radiographics 22:803, 2002.
541. **Karayalcin R**, **Ozcan S**, **Moraloglu O**, **Ozyer S**, **Mollamahmutoglu L**, **Batioglu S**, Results of 2500 office-based diagnostic hysteroscopies before IVF, Reprod Biomed Online 20:689, 2010.
542. **Simon C**, **Martinez L**, **Pardo F**, **Tortajada M**, **Pellicer A**, Mullerian defects in women with normal reproductive outcome, Fertil Steril 56:1192, 1991.
543. **Acién P**, Incidence of Müllerian defects in fertile and infertile women, Hum Reprod 12:1372, 1997.
544. **Ashton D**, **Amin HK**, **Richart RM**, **Neuwirth RS**, The incidence of asymptomatic uterine anomalies in women undergoing transcervical tubal sterilization, Obstet Gynecol 72:28, 1988.
545. **Raga F**, **Bauset C**, **Remohi J**, **Bonilla-Musoles F**, **Simón C**, **Pellicer A**, Reproductive impact of congenital Müllerian anomalies, Hum Reprod 12:2277, 1997.
546. **Jurkovic D**, **Gruboeck K**, **Tailor A**, **Nicolaides KH**, Ultrasound screening for congenital uterine anomalies, Br J Obstet Gynaecol 104:1320, 1997.
547. **Grimbizis GF**, **Camus M**, **Tarlatzis BC**, **Bontis JN**, **Devroey P**, Clinical implications of uterine malformations and hysteroscopic treatment results, Hum Reprod Update 7:161, 2001.
548. **Chan YY**, **Jayaprakasan K**, **Zamora J**, **Thornton JG**, **Raine-Fenning N**, **Coomarasamy A**, The prevalence of congenital uterine anomalies in unselected and high-risk populations: a systematic review, Hum Reprod Update 17:761, 2011.
549. **Practice Committee of the American Society of Reproductive Medicine**, Uterine septum: a guideline, Fertil Steril 106:530, 2016.
550. **Venetis CA**, **Papadopoulos SP**, **Campo R**, **Gordts S**, **Tarlatzis BC**, **Grimbizis GF**, Clinical implications of congenital uterine anomalies: a meta-analysis of comparative studies, Reprod Biomed Online 29:665, 2014.
551. **Burchell RC**, **Creed F**, **Rasoulpour M**, **Whitcomb M**, Vascular anatomy of the human uterus and pregnancy wastage, Br J Obstet Gynaecol 85:698, 1978.
552. **Candiani GB**, **Fedele L**, **Zamberletti D**, **De Virgiliis D**, **Carinelli S**, Endometrial patterns in malformed uteri, Acta Eur Fertil 14:311, 1983.
553. **Rock JA**, **Murphy AA**, Anatomic abnormalities, Clin Obstet Gynecol 29:886, 1986.
554. **Fedele L**, **Bianchi S**, **Marchini M**, **Franchi D**, **Tozzi L**, **Dorta M**, Ultrastructural aspects of endometrium in infertile women with septate uterus, Fertil Steril 65:750, 1996.
555. **Valle RF**, **Ekpo GE**, Hysteroscopic metroplasty for the septate uterus: a review and meta-analysis, J Minim Invasive Gynecol 20:22, 2013.
556. **Colacurci N**, **De Franciscis P**, **Fornaro F**, **Fortunato N**, **Perino A**, The significance of hysteroscopic treatment of congenital uterine malformations, Reprod Biomed Online 4(Suppl 3):52, 2002.
557. **Baird DD**, **Dunson DB**, **Hill MC**, **Cousins D**, **Schetman JM**, High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence, Am J Obstet Gynecol 188:100, 2003.
558. **Cramer SF**, **Patel A**, The frequency of uterine leiomyomas, Am J Clin Pathol 94:435, 1990.
559. **Practice Committee of the American Society of Reproductive Medicine**, Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate: a guideline, Fertil Steril 108:416, 2017.
560. **Practice Committee of the American Society for Reproductive Medicine**, Myomas and reproductive function, Fertil Steril 90(Suppl 5):125, 2008.
561. **Deligdish L**, **Loewenthal M**, Endometrial changes associated with myomata of the uterus, J Clin Pathol 23:676, 1970.
562. **Sharma SP**, **Misra SD**, **Mittal VP**, Endometrial changes–a criterion for the diagnosis of submucous uterine leiomyoma, Indian J Pathol Microbiol 22:33, 1979.
563. **Maguire M**, **Segars J**, Benign uterine disease: leiomyomata and benign polyps, In: April JD, et al., eds. The Endometrium: Molecular, Cellular and Clinical Perspectives, Informa HealthCare, London, UK, 2008, p. 797.
564. **Rackow BW**, **Taylor HS**, Submucosal uterine leiomyomas have a global effect on molecular determinants of endometrial receptivity, Fertil Steril 93:2027, 2010.

565. **Horcajadas JA**, **Goyri E**, **Higon MA**, **Martinez-Conejero JA**, **Gambadauro P**, **Garcia G**, **Meseguer M**, **Simon C**, **Pellicer A**, Endometrial receptivity and implantation are not affected by the presence of uterine intramural leiomyomas: a clinical and functional genomics analysis, J Clin Endocrinol Metab 93(9):3490, 2008.
566. **Farhi J**, **Ashkenazi J**, **Feldberg D**, **Dicker D**, **Orvieto R**, **Ben Rafael Z**, Effect of uterine leiomyomata on the results of in-vitro fertilization treatment, Hum Reprod 10:2576, 1995.
567. **Eldar-Geva T**, **Meagher S**, **Healy DL**, **MacLachlan V**, **Breheny S**, **Wood C**, Effect of intramural, subserosal, and submucosal uterine fibroids on the outcome of assisted reproductive technology treatment, Fertil Steril 70:687, 1998.
568. **Stovall DW**, **Parrish SB**, **Van Voorhis BJ**, **Hahn SJ**, **Sparks AE**, **Syrop CH**, Uterine leiomyomas reduce the efficacy of assisted reproduction cycles: results of a matched follow-up study, Hum Reprod 13:192, 1998.
569. **Hart R**, **Khalaf Y**, **Yeong CT**, **Seed P**, **Taylor A**, **Braude P**, A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception, Hum Reprod 16:2411, 2001.
570. **Khalaf Y**, **Ross C**, **El-Toukhy T**, **Hart R**, **Seed P**, **Braude P**, The effect of small intramural uterine fibroids on the cumulative outcome of assisted conception, Hum Reprod 21:2640, 2006.
571. **Somigliana E**, **De Benedictis S**, **Vercellini P**, **Nicolosi AE**, **Benaglia L**, **Scarduelli C**, **Ragni C**, **Fedele L**, Fibroids not encroaching the endometrial cavity and IVF success rate: a prospective study, Hum Reprod 26:834, 2011.
572. **Christopoulos G**, **Vlismas A**, **Salim R**, **Islam R**, **Trew G**, **Lavery S**, Fibroids that do not distort the uterine cavity and IVF success rates: an observational study using extensive matching criteria, BJOG 124:615, 2017.
573. **Ezzati M**, **Norian JM**, **Segars JH**, Management of uterine fibroids in the patient pursuing assisted reproductive technologies, Womens Health (Lond) 5:413, 2009.
574. **Benecke C**, **Kruger TF**, **Siebert TI**, **Van der Merwe JP**, **Steyn DW**, Effect of fibroids on fertility in patients undergoing assisted reproduction. A structured literature review, Gynecol Obstet Invest 59:225, 2005.
575. **Somigliana E**, **Vercellini P**, **Daguati R**, **Pasin R**, **De Giorgi O**, **Crosignani PG**, Fibroids and female reproduction: a critical analysis of the evidence, Hum Reprod Update 13:465, 2007.
576. **Klatsky PC**, **Tran ND**, **Caughey AB**, **Fujimoto VY**, Fibroids and reproductive outcomes: a systematic literature review from conception to delivery, Am J Obstet Gynecol 198:357, 2008.
577. **Pritts EA**, **Parker WH**, **Olive DL**, Fibroids and infertility: an updated systematic review of the evidence, Fertil Steril 91:1215, 2009.
578. **Hartmann KE**, **Velez Edwards DR**, **Savitz DA**, **Jonsson-Funk ML**, **Wu P**, **Sundermann AC**, **Baird DD**, Prospective cohort study of uterine fibroids and miscarriage risk, Am J Epidemiol 186:1140, 2017.
579. **Healy DL**, Impact of uterine fibroids on ART outcome, Environ Health Perspect 108(Suppl 5):845, 2000.
580. **Dietterich C**, **Check JH**, **Choe JK**, **Nazari A**, **Fox F**, The presence of small uterine fibroids not distorting the endometrial cavity does not adversely affect conception outcome following embryo transfer in older recipients, Clin Exp Obstet Gynecol 27:168, 2000.
581. **Jun SH**, **Ginsburg ES**, **Racowsky C**, **Wise LA**, **Hornstein MD**, Uterine leiomyomas and their effect on in vitro fertilization outcome: a retrospective study, J Assist Reprod Genet 18:139, 2001.
582. **Surrey ES**, **Lietz AK**, **Schoolcraft WB**, Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization-embryo transfer cycle outcome, Fertil Steril 75:405, 2001.
583. **Check JH**, **Choe JK**, **Lee G**, **Dietterich C**, The effect on IVF outcome of small intramural fibroids not compressing the uterine cavity as determined by a prospective matched control study, Hum Reprod 17:1244, 2002.
584. **Oliveira FG**, **Abdelmassih VG**, **Diamond MP**, **Dozortsev D**, **Melo NR**, **Abdelmassih R**, Impact of subserosal and intramural uterine fibroids that do not distort the endometrial cavity on the outcome of in vitro fertilization-intracytoplasmic sperm injection, Fertil Steril 81:582, 2004.
585. **Sunkara SK**, **Khairy M**, **El-Toukhy T**, **Khalaf Y**, **Coomarassamy A**, The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis, Hum Reprod 25:418, 2010.
586. **Casini ML**, **Rossi F**, **Agostini R**, **Unfer V**, Effects of the position of fibroids on fertility, Gynecol Endocrinol 22:106, 2006.

587. **Bulletti C**, **De Ziegler D**, **Polli V**, **Flamigni C**, The role of leiomyomas in infertility, J Am Assoc Gynecol Laparosc 6:441, 1999.
588. **Aboulghar MM**, **Al-Inany HG**, **Aboulghar MA**, **Serour GI**, **Mansour RT**, The effect of intramural fibroids on the outcome of IVF, Middle East Fertil Soc J 9:263, 2004.
589. **Seoud M**, **Patterson R**, **Musher S**, **Coddington C**, Effects of myoma or prior myomectomy on In Vitro Fertilization (IVF) performance, J Assist Reprod Genet 9:217, 1992.
590. **Bulletti C**, **DE Ziegler D**, **Levi Setti P**, **Cicinelli E**, **Polli V**, **Stefanetti M**, Myomas, pregnancy outcome, and in vitro fertilization, Ann N Y Acad Sci 1034:84, 2004.
591. **Fauconnier A**, **Dubuisson JB**, **Ancel PY**, **Chapron C**, Prognostic factors of reproductive outcome after myomectomy in infertile patients, Hum Reprod 15:1751, 2000.
592. **Dubuisson JB**, **Fauconnier A**, **Chapron C**, **Kreiker G**, **Norgaard C**, Second look after laparoscopic myomectomy, Hum Reprod 13:2102, 1998.
593. **Lieng M**, **Istre O**, **Langebrekke A**, Uterine rupture after laparoscopic myomectomy, J Am Assoc Gynecol Laparosc 11:92, 2004.
594. **Banas T**, **Klimek M**, **Fugiel A**, **Skotniczny K**, Spontaneous uterine rupture at 35 weeks' gestation, 3 years after laparoscopic myomectomy, without signs of fetal distress, J Obstet Gynaecol Res 31:527, 2005.
595. **Grande N**, **Catalano GF**, **Ferrari S**, **Marana R**, Spontaneous uterine rupture at 27 weeks of pregnancy after laparoscopic myomectomy, J Minim Invasive Gynecol 12:301, 2005.
596. **Parker WH**, **Iacampo K**, **Long T**, Uterine rupture after laparoscopic removal of a pedunculated myoma, J Minim Invasive Gynecol 14:362, 2007.
597. **Taylor HS**, Fibroids: when should they be removed to improve in vitro fertilization success? Fertil Steril 109(5):784, 2018.
598. **Advincula AP**, **Song A**, The role of robotic surgery in gynecology, Curr Opin Obstet Gynecol 19:331, 2007.
599. **Palomba S**, **Zupi E**, **Falbo A**, **Russo T**, **Marconi D**, **Tolino A**, **Manguso F**, **Mattei A**, **Zullo F**, A multicenter randomized, controlled study comparing laparoscopic versus minilaparotomic myomectomy: reproductive outcomes, Fertil Steril 88:933, 2007.
600. **Holloway RW**, **Patel SD**, **Ahmad S**, Robotic surgery in gynecology, Scand J Surg 98:96, 2009.
601. **Luciano AA**, Myomectomy, Clin Obstet Gynecol 52:362, 2009.
602. **Agdi M**, **Tulandi T**, Minimally invasive approach for myomectomy, Semin Reprod Med 28:228, 2010.
603. **Al-Inany H**, Intrauterine adhesions. An update, Acta Obstet Gynecol Scand 80:986, 2001.
604. **Yu D**, **Wong YM**, **Cheong Y**, **Xia E**, **Li TC**, Asherman syndrome–one century later, Fertil Steril 89:759, 2008.
605. **Berman JM**, Intrauterine adhesions, Semin Reprod Med 26:349, 2008.
606. **Thomson AJ**, **Abbott JA**, **Deans R**, **Kingston A**, **Vancaillie TG**, The management of intrauterine synechiae, Curr Opin Obstet Gynecol 21:335, 2009.
607. **Jensen PA**, **Stromme WB**, Amenorrhea secondary to puerperal curettage (Asherman's syndrome), Am J Obstet Gynecol 113:150, 1972.
608. **Romer T**, Post-abortion-hysteroscopy—a method for early diagnosis of congenital and acquired intrauterine causes of abortions, Eur J Obstet Gynecol Reprod Biol 57:171, 1994.
609. **Taylor PJ**, **Cumming DC**, **Hill PJ**, Significance of intrauterine adhesions detected hysteroscopically in eumenorrheic infertile women and role of antecedent curettage in their formation, Am J Obstet Gynecol 139:239, 1981.
610. **Shaffer W**, Role of uterine adhesions in the cause of multiple pregnancy losses, Clin Obstet Gynecol 29:912, 1986.
611. **Schenker JG**, Etiology of and therapeutic approach to synechia uteri, Eur J Obstet Gynecol Reprod Biol 65:109, 1996.
612. **Tripathy SN**, Infertility and pregnancy outcome in female genital tuberculosis, Int J Gynaecol Obstet 76:159, 2002.
613. **Westendorp IC**, **Ankum WM**, **Mol BW**, **Vonk J**, Prevalence of Asherman's syndrome after secondary removal of placental remnants or a repeat curettage for incomplete abortion, Hum Reprod 13:3347, 1998.

614. **Friedler S**, **Margalioth EJ**, **Kafka I**, **Yaffe H**, Incidence of post-abortion intra-uterine adhesions evaluated by hysteroscopy—a prospective study, Hum Reprod 8:442, 1993.
615. **Roma Dalfo A**, **Ubeda B**, **Ubeda A**, **Monzon M**, **Rotger R**, **Ramos R**, **Palacio A**, Diagnostic value of hysterosalpingography in the detection of intrauterine abnormalities: a comparison with hysteroscopy, AJR Am J Roentgenol 183:1405, 2004.
616. **Schenker JG**, **Margalioth EJ**, Intrauterine adhesions: an updated appraisal, Fertil Steril 37:593, 1982.
617. **Practice Committee of the American Association of Gynecological Laparoscopists**, Practice guidelines on intrauterine adhesions developed in collaboration with the European Society of Gynaecological Endoscopy (ESGE), J Minim Invasive Gynecol 24:695, 2017.
618. **Kresowik JD**, **Syrop CH**, **Van Voorhis BJ**, **Ryan GL**, Ultrasound is the optimal choice for guidance in difficult hysteroscopy, Ultrasound Obstet Gynecol 39:715, 2012.
619. **Tasma ML**, **Louwerse MD**, **Hehenkamp WJ**, **Geomini PM**, **Bongers MY**, **Veersema S**, **van Kesteren PJ**, **Tromp E**, **Huirne JA**, **Graziosi GC**, Misoprostol for cervical priming prior to hysteroscopy in postmenopausal and premenopausal nulliparous women; a multicentre randomised placebo controlled trial, BJOG 125:81, 2018.
620. **Cooper JM**, **Brady RM**, Late complications of operative hysteroscopy, Obstet Gynecol Clin North Am 27:367, 2000.
621. **American Association of Gynecologic Laparoscopists**, Practice guidelines for management of intrauterine synechiae, J Minim Invasive Gynecol 17:1, 2010.
622. **Coccia ME**, **Becattini C**, **Bracco GL**, **Pampaloni F**, **Bargelli G**, **Scarselli G**, Pressure lavage under ultrasound guidance: a new approach for outpatient treatment of intrauterine adhesions, Fertil Steril 75:601, 2001.
623. **Karande V**, **Levrant S**, **Hoxsey R**, **Rinehart J**, **Gleicher N**, Lysis of intrauterine adhesions using gynecoradiologic techniques, Fertil Steril 68:658, 1997.
624. **March CM**, Intrauterine adhesions, Obstet Gynecol Clin North Am 22:491, 1995.
625. **Pistofidis GA**, **Dimitropoulos K**, **Mastrominas M**, Comparison of operative and fertility outcome between groups of women with intrauterine adhesions after adhesiolysis, J Am Assoc Gynecol Laparosc 3:S40, 1996.
626. **Lindheim SR**, **Kavic S**, **Shulman SV**, **Sauer MV**, Operative hysteroscopy in the office setting, J Am Assoc Gynecol Laparosc 7:65, 2000.
627. **Goldenberg M**, **Sivan E**, **Sharabi Z**, **Bider D**, **Rabinovici J**, **Seidman DS**, Outcome of hysteroscopic resection of submucous myomas for infertility, Fertil Steril 64:714, 1995.
628. **Katz Z**, **Ben-Arie A**, **Lurie S**, **Manor M**, **Insler V**, Reproductive outcome following hysteroscopic adhesiolysis in Asherman's syndrome, Int J Fertil Menopausal Stud 41:462, 1996.
629. **Capella-Allouc S**, **Morsad F**, **Rongieres-Bertrand C**, **Taylor S**, **Fernandez H**, Hysteroscopic treatment of severe Asherman's syndrome and subsequent fertility, Hum Reprod 14:1230, 1999.
630. **Zikopoulos KA**, **Kolibianakis EM**, **Platteau P**, **de Munck L**, **Tournaye H**, **Devroey P**, **Camus M**, Live delivery rates in subfertile women with Asherman's syndrome after hysteroscopic adhesiolysis using the resectoscope or the Versapoint system, Reprod Biomed Online 8:720, 2004.
631. **Kodaman PH**, Hysteroscopic polypectomy for women undergoing IVF treatment: when is it necessary? Curr Opin Gynecol Obstet 28:184, 2016.
632. **Lass A**, **Williams G**, **Abusheikha N**, **Brinsden P**, The effect of endometrial polyps on outcomes of in vitro fertilization (IVF) cycles, J Assist Reprod Genet 16:410, 1999.
633. **Shokeir TA**, **Shalan HM**, **El-Shafei MM**, Significance of endometrial polyps detected hysteroscopically in eumenorrheic infertile women, J Obstet Gynaecol Res 30:84, 2004.
634. **Jovanovic AS**, **Boynton KA**, **Mutter GL**, Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability, Cancer Res 56:1917, 1996.
635. **Pal L**, **Niklaus AL**, **Kim M**, **Pollack S**, **Santoro N**, Heterogeneity in endometrial expression of aromatase in polyp-bearing uteri, Hum Reprod 23:80, 2008.
636. **Dal Cin P**, **Vanni R**, **Marras S**, **Moerman P**, **Kools P**, **Andria M**, **Valdes E**, **Deprest J**, **Van de Ven W**,

Van den Berghe H, Four cytogenetic subgroups can be identified in endometrial polyps, Cancer Res 55:1565, 1995.
637. **Kamel HS**, **Darwish AM**, **Mohamed SA**, Comparison of transvaginal ultrasonography and vaginal sonohysterography in the detection of endometrial polyps, Acta Obstet Gynecol Scand 79:60, 2000.
638. **Lindheim SR**, **Morales AJ**, Comparison of sonohysterography and hysteroscopy: lessons learned and avoiding pitfalls, J Am Assoc Gynecol Laparosc 9:223, 2002.
639. **Mittal K**, **Schwartz L**, **Goswami S**, **Demopoulos R**, Estrogen and progesterone receptor expression in endometrial polyps, Int J Gynecol Pathol 15:345, 1996.
640. **Spiewankiewicz B**, **Stelmachow J**, **Sawicki W**, **Cendrowski K**, **Wypych P**, **Swiderska K**, The effectiveness of hysteroscopic polypectomy in cases of female infertility, Clin Exp Obstet Gynecol 30:23, 2003.
641. **Perez-Medina T**, **Bajo-Arenas J**, **Salazar F**, **Redondo T**, **Sanfrutos L**, **Alvarez P**, **Engels V**, Endometrial polyps and their implication in the pregnancy rates of patients undergoing intrauterine insemination: a prospective, randomized study, Hum Reprod 20:1632, 2005.
642. **Isikoglu M**, **Berkkanoglu M**, **Senturk Z**, **Coetzee K**, **Ozgur K**, Endometrial polyps smaller than 1.5 cm do not affect ICSI outcome, Reprod Biomed Online 12:199, 2006.
643. **Shohayeb A Shaltout A**, Persistent endometrial polyps may affect the pregnancy rate in patients undergoing intrauterine insemination, Middle East Fertil Soc J 16:259, 2011.
644. **Bosteels J**, **Kasius J**, **Weyers S**, **et al.**, Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities, Cochrane Database Syst Rev (2):CD009461, 2015.
645. **Mouhayar Y**, **Yin O**, **Mumford SL**, **Segars JH**, Hysteroscopic polypectomy prior to infertility treatment: a cost analysis and systematic review, Eur J Obstet Gynecol Reprod Biol 213:107, 2017.
646. **Afifi K**, **Anand S**, **Nallapeta S**, **Gelbaya TA**, Management of endometrial polyps in subfertile women: a systematic review, Eur J Obstet Gynecol Reprod Biol 151:117, 2010.
647. **Lieng M**, **Istre O**, **Qvigstad E**, Treatment of endometrial polyps: a systematic review, Acta Obstet Gynecol Scand 89:992, 2010.
648. **Czernobilsky B**, Endometritis and infertility, Fertil Steril 30:119, 1978.
649. **Paavonen J**, **Kiviat N**, **Brunham RC**, **Stevens CE**, **Kuo CC**, **Stamm WE**, **Miettinen A**, **Soules M**, **Eschenbach DA**, **Holmes KK**, Prevalence and manifestations of endometritis among women with cervicitis, Am J Obstet Gynecol 152:280, 1985.
650. **Korn AP**, **Hessol N**, **Padian N**, **Bolan G**, **Muzsnai D**, **Donegan E**, **Jonte J**, **Schachter J**, **Landers DV**, Commonly used diagnostic criteria for pelvic inflammatory disease have poor sensitivity for plasma cell endometritis, Sex Transm Dis 22:335, 1995.
651. **Korn AP**, **Bolan G**, **Padian N**, **Ohm-Smith M**, **Schachter J**, **Landers DV**, Plasma cell endometritis in women with symptomatic bacterial vaginosis, Obstet Gynecol 85:387, 1995.
652. **Wiesenfeld HC**, **Hillier SL**, **Krohn MA**, **Amortegui AJ**, **Heine RP**, **Landers DV**, **Sweet RL**, Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease, Obstet Gynecol 100:456, 2002.
653. **Polisseni F**, **Bambirra EA**, **Camargos AF**, Detection of chronic endometritis by diagnostic hysteroscopy in asymptomatic infertile patients, Gynecol Obstet Invest 55:205, 2003.
654. **Paukku M**, **Puolakkainen M**, **Paavonen T**, **Paavonen J**, Plasma cell endometritis is associated with Chlamydia trachomatis infection, Am J Clin Pathol 112:211, 1999.
655. **Mount S**, **Mead P**, **Cooper K**, Chlamydia trachomatis in the endometrium: can surgical pathologists identify plasma cells? Adv Anat Pathol 8:327, 2001.
656. **Taylor-Robinson D**, Mycoplasma genitalium—an up-date, Int J STD AIDS 13:145, 2002.
657. **Cicinelli E**, **Matteo M**, **Trojano G**, **Mitola PC**, **Tinelli R**, **Vitagliano A**, **Crupano FM**, **Lepera A**, **Miragliotta G**, **Resta L**, Chronic endometritis in patients with unexplained infertility: prevalence and effects of antibiotic treatment on spontaneous conception, Am J Reprod Immunol 79:e12782, 2018.
658. **Cicinelli E**, **Matteo M**, **Tinelli R**, **Lepera A**, **Alfonso R**, **Indraccolo U**, **Marrocchella S**, **Greco P**, **Resta L**, Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy, Hum Reprod 30:323, 2015.

659. **Kasius JC**, **Fatemi HM**, **Bourgain C**, **Sie-Go DM**, **Eijkemans RJ**, **Fauser BC**, **Devroey P**, **Broekmans FJ**, The impact of chronic endometritis on reproductive outcome, Fertil Steril 96:1451, 2011.
660. **Honore GM**, **Holden AE**, **Schenken RS**, Pathophysiology and management of proximal tubal blockage, Fertil Steril 71:785, 1999.
661. **Westrom L**, Effect of acute pelvic inflammatory disease on fertility, Am J Obstet Gynecol 121:707, 1975.
662. **Westrom I**, Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries, Am J Obstet Gynecol 138:880, 1980.
663. **Westrom L**, **Joesoef R**, **Reynolds G**, **Hagdu A**, **Thompson SE**, Pelvic inflammatory disease and fertility, Sex Trans Dis 19:185, 1992.
664. **Westrom LV**, Sexually transmitted diseases and infertility, Sex Transm Dis 21:S32, 1994.
665. **Westrom L**, Effect of pelvic inflammatory disease on fertility, Venereology 8:219, 1995.
666. **Mohiyiddeen L**, **Hardiman A**, **Fitzgerald C**, **Hughes E**, **Mol BW**, **Johnson N**, **Watson A**, Tubal flushing for subfertility, Cochrane Database Syst Rev (5):CD003718, 2015.
667. **Forsey JP**, **Caul EO**, **Paul ID**, **Hull MG**, Chlamydia trachomatis, tubal disease and the incidence of symptomatic and asymptomatic infection following hysterosalpingography, Hum Reprod 5:444, 1990.
668. **Uzun O**, **Findik S**, **Danaci M**, **Katar D**, **Erkan L**, Pulmonary and cerebral oil embolism after hysterosalpingography with oil soluble contrast medium, Respirology 9:134, 2004.
669. **Ma G**, **Mao R**, **Zhai H**, Hyperthyroidism secondary to hysterosalpingography: an extremely rare complication: a case report, Medicine (Baltimore) 95:e5588, 2016.
670. **Dabekausen YA**, **Evers JL**, **Land JA**, **Stals FS**, Chlamydia trachomatis antibody testing is more accurate than hysterosalpingography in predicting tubal factor infertility, Fertil Steril 61:833, 1994.
671. **Mol BW**, **Dijkman B**, **Wertheim P**, **Lijmer J**, **van der Veen F**, **Bossuyt PM**, The accuracy of serum chlamydial antibodies in the diagnosis of tubal pathology: a meta-analysis, Fertil Steril 67:1031, 1997.
672. **Thomas K**, **Coughlin L**, **Mannion PT**, **Haddad NG**, The value of Chlamydia trachomatis antibody testing as part of routine infertility investigations, Hum Reprod 15:1079, 2000.
673. **Veenemans LM**, **van der Linden PJ**, The value of Chlamydia trachomatis antibody testing in predicting tubal factor infertility, Hum Reprod 17:695, 2002.
674. **Hindocha A**, **Beere L**, **O'Flynn H**, **Watson A**, **Ahmad G**, Pain relief in hysterosalpingography, Cochrane Database Syst Rev (9):CD006106, 2015.
675. **Karaman E**, **Cim N**, **Alkis I**, **Yildirim A**, **Yildizhan R**, Rectal indomethacin use in pain relief during hysterosalpingography: a randomized placebo controlled trial, J Obstet Gynaecol Res 42:195, 2016.
676. **Stumpf PG**, **March CM**, Febrile morbidity following hysterosalpingography: identification of risk factors and recommendations for prophylaxis, Fertil Steril 33:487, 1980.
677. **Pittaway DE**, **Winfield AC**, **Maxson W**, **Daniell J**, **Herbert C**, **Wentz AC**, Prevention of acute pelvic inflammatory disease after hysterosalpingography: efficacy of doxycycline prophylaxis, Am J Obstet Gynecol 147:623, 1983.
678. **Perisinakis K**, **Damilakis J**, **Grammatikakis J**, **Theocharopoulos N**, **Gourtsoyiannis N**, Radiogenic risks from hysterosalpingography, Eur Radiol 13:1522, 2003.
679. **Tur-Kaspa I**, **Seidman DS**, **Soriano D**, **Greenberg I**, **Dor J**, **Bider D**, Hysterosalpingography with a balloon catheter versus a metal cannula: a prospective, randomized, blinded comparative study, Hum Reprod 13:75, 1998.
680. **Ricci G**, **Guastalla P**, **Ammar L**, **Cervi G**, **Guarnieri S**, **Sartore A**, Balloon catheter vs. cervical vacuum cup for hysterosalpingography: a prospective, randomized, single-blinded study, Fertil Steril 87:1458, 2007.
681. **Cohen SB**, **Wattiez A**, **Seidman DS**, **Lidor AL**, **Hendler**, **Rabinovichi J**, **Goldenberg M**, Comparison of cervical vacuum cup cannula with metal cannula for hysterosalpingography, BJOG 108:1031, 2001.
682. **Lindequist S**, **Justesen P**, **Larsen C**, **Rasmussen F**, Diagnostic quality and complications of hysterosalpingography: oil- versus water-soluble contrast media—a randomized prospective study, Radiology 179:69, 1991.
683. **Moore DE**, **Segars JH Jr**, **Winfield AC**, **Page DL**, **Eisenberg AD**, **Holburn GE**, Effects of contrast agents on the fallopian tube in a rabbit model, Radiology 176:721, 1990.

684. **Grosskinsky CM**, **Clark RL**, **Wilson PA**, **Novotny DB**, Pelvic granulomata mimicking endometriosis following the administration of oil-based contrast media for hysterosalpingography, Obstet Gynecol 83:890, 1994.
685. **Nunley WC Jr**, **Bateman BG**, **Kitchin JD III**, **Pope TL Jr**, Intravasation during hysterosalpingography using oil-base contrast medium—a second look, Obstet Gynecol 70:309, 1987.
686. **Dreyer K**, **van Rijswijk J**, **Mijatovic V**, **Goddijn M**, **Verhoeve HR**, **van Rooij IAJ**, **Hoek A**, **Bourdrez P**, **Nap AW**, **Rijnsaardt-Lukassen HGM**, **Timmerman CCM**, **Kaplan M**, **Hooker AB**, **Gijsen AP**, **van Golde R**, **van Heteren CF**, **Sluijmer AV**, **de Bruin JP**, **Smeenk JMJ**, **de Boer JAM**, **Scheenjes E**, **Duijn AEJ**, **Mozes A**, **Pelinck MJ**, **Traas MAF**, **van Hooff MHA**, **van Unnik GA**, **de Koning CH**, **van Geloven N**, **Twisk JWR**, **Hompes PGA**, **Mol BWJ**, Oil-based or water-based contrast for hysterosalpingography in infertile women, N Engl J Med 25:2043, 2017.
687. **Mol BW**, **Swart P**, **Bossuyt PM**, **van der Veen F**, Is hysterosalpingography an important tool in predicting fertility outcome? Fertil Steril 67:663, 1997.
688. **Mol BW**, **Collins JA**, **Burrows EA**, **van der Veen F**, **Bossuyt PM**, Comparison of hysterosalpingography and laparoscopy in predicting fertility outcome, Hum Reprod 14:1237, 1999.
689. **Maheux-Lacroix S**, **Boutin A**, **Moore L**, **Bergeron ME**, **Bujold E**, **Laberge P**, **Lemyre M**, **Dodin S**, Hysterosalpingosonography for diagnosing tubal occlusion in subfertile women: a systematic review with meta-analysis, Hum Reprod 29:953, 2014.
690. **Evers JLH**, **Land JA**, **Mol BW**, Evidence-based medicine for diagnostic questions, Semin Reprod Med 21:9, 2003.
691. **Dessole S**, **Meloni GB**, **Capobianco G**, **Manzoni MA**, **Ambrosini G**, **Canalis GC**, A second hysterosalpingography reduces the use of selective technique for treatment of a proximal tubal obstruction, Fertil Steril 73:1037, 2000.
692. **Swart P**, **Mol BW**, **van der Veen F**, **van Beurden M**, **Redekop WK**, **Bossuyt PM**, The accuracy of hysterosalpingography in the diagnosis of tubal pathology: a meta-analysis, Fertil Steril 64:486, 1995.
693. **Coppus SF**, **Opmeer BC**, **Logan S**, **van der Veen F**, **Bhattacharya S**, **Mol BW**, The predictive value of medical history taking and Chlamydia IgG ELISA anti- body testing (CAT) in the selection of subfertile women for diagnostic laparoscopy: a clinical prediction model approach, Hum Reprod 22:1353, 2007.
694. **Mol BW**, **Swart P**, **Bossuyt PM**, **van Beurden M**, **van der Veen F**, Reproducibility of the interpretation of hysterosalpingography in the diagnosis of tubal pathology, Hum Reprod 11:1204, 1996.
695. **Glatstein IZ**, **Sleeper LA**, **Lavy Y**, **Simon A**, **Adoni A**, **Palti Z**, **Hurwitz A**, **Laufer N**, Observer variability in the diagnosis and management of the hysterosalpingogram, Fertil Steril 67:233, 1997.
696. **Bilgin H**, **Ozcan B**, **Bilgin T**, Methemoglobinemia induced by methylene blue perturbation during laparoscopy, Acta Anaesthesiol Scand 42:594, 1998.
697. **Mhaskar R**, **Mhaskar AM**, Methemoglobinemia following chromopertubation in treated pelvic tuberculosis, Int J Gynaecol Obstet 77:41, 2002.
698. **Maas JW**, **Evers JL**, **ter Riet G**, **Kessels AG**, Pregnancy rate following normal versus abnormal hysterosalpingography findings: a meta-analysis, Gynecol Obstet Invest 43:79, 1997.
699. **Lim SL**, **Jung JJ**, **Yu SL**, **Rajesh H**, A comparison of hysterosalpingo-foam sonography (HyFoSy) and hysterosalpingo-contrast sonography with saline medium (HyCoSy) in the assessment of tubal patency, Eur J Obstet Gynecol Reprod Biol 195:168, 2015.
700. **Alcázar JL**, **Martinez-Astorquiza Corral T**, **Orozco R**, **Dominguez-Piriz J**, **Juez L**, **Errasti T**, Three-dimensional hysterosalpingo-contrast-sonography for the assessment of tubal patency in women with infertility: a systematic review with meta-analysis, Gynecol Obstet Invest 81:289, 2016.
701. **Piccioni MG**, **Riganelli L**, **Filippi V**, **Fuggetta E**, **Colagiovanni V**, **Imperiale L**, **Caccetta J**, **Panici PB**, **Porpora MG**, Sonohysterosalpingography: comparison of foam and saline solution, J Clin Ultrasound 45:67, 2017.
702. **He Y**, **Ma X**, **Xu J**, **Li S**, **Wu H**, **Liu Q**, **Kong L**, **Luo J**, **Liu H**, Comparison of assessment methods for fallopian tubal patency and peritubal adhesion between transvaginal 4-dimensional hysterosalpingo-contrast sonography and laparoscopic chromopertubation, J Ultrasound Med 36:547, 2017.

703. **Land JA**, **Evers JL**, **Goossens VJ**, How to use Chlamydia antibody testing in subfertility patients, Hum Reprod 13:1094, 1998.
704. **Jones CS**, **Maple PA**, **Andrews NJ**, **Paul ID**, **Caul EO**, Measurement of IgG antibodies to Chlamydia trachomatis by commercial enzyme immunoassays and immunofluorescence in sera from pregnant women and patients with infertility, pelvic inflammatory disease, ectopic pregnancy, and laboratory diagnosed Chlamydia psittaci/Chlamydia pneumoniae infection, J Clin Pathol 56: 225, 2003.
705. **Land JA**, **Gijsen AP**, **Kessels AG**, **Slobbe ME**, **Bruggeman CA**, Performance of five serological chlamydia antibody tests in subfertile women, Hum Reprod 18:2621, 2003.
706. **Johnson NP**, **Taylor K**, **Nadgir AA**, **Chinn DJ**, **Taylor PJ**, Can diagnostic laparoscopy be avoided in routine investigation for infertility? Br J Obstet Gynaecol 107:174, 2000.
707. **Akande VA**, **Hunt LP**, **Cahill DJ**, **Caul EO**, **Ford WC**, **Jenkins JM**, Tubal damage in infertile women: prediction using chlamydia serology, Hum Reprod 18:1841, 2003.
708. **The Practice Committee of the American Society for Reproductive Medicine**, Role of tubal surgery in the era of assisted reproductive technology: a committee opinion, Fertil Steril 103:e37, 2015.
709. **Broeze KA**, **Opmeer BC**, **Coppus SF**, **Van Geloven N**, **Den Hartog JE**, **Land JA**, **Van der Linden PJ**, **Ng EH**, **Van der Steeg JW**, **Steures P**, **Van der Veen F**, **Mol BW**, Integration of patient characteristics and the results of Chlamydia antibody testing and hysterosalpingography in the diagnosis of tubal pathology: an individual patient data meta-analysis, Hum Reprod 27:2979, 2012.
710. **Turkgeldi E**, **Yagmur H**, **Seyhan A**, **Urman B**, **Ata B**, Short and long term outcomes of children conceived with assisted reproductive technology, Eur J Obstet Gynecol Reprod Biol 207:129, 2016.
711. **Borrero SB**, **Reeves MF**, **Schwarz EB**, **Bost JE**, **Creinin MD**, **Ibrahim SA**, Race, insurance status, and desire for tubal sterilization reversal, Fertil Steril 90:272, 2008
712. **Schmidt JE**, **Hillis SD**, **Marchbanks PA**, **Jeng G**, **Peterson HB**, Requesting information about and obtaining reversal after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization, Fertil Steril 74:892, 2000.
713. **Chi IC**, **Jones DB**, Incidence, risk factors, and prevention of poststerilization regret in women: an updated international review from an epidemiological perspective, Obstet Gynecol Surv 49:722, 1994.
714. **Neuhaus W**, **Bolte A**, Prognostic factors for preoperative consultation of women desiring sterilization: findings of a retrospective analysis, J Psychosom Obstet Gynaecol 16:45, 1995.
715. **Hardy E**, **Bahamondes L**, **Osis MJ**, **Costa RG**, **Faundes A**, Risk factors for tubal sterilization regret, detectable before surgery, Contraception 54:159, 1996.
716. **Curtis KM**, **Mohllajee AP**, **Peterson HB**, Regret following female sterilization at a young age: a systematic review, Contraception 73:205, 2006.
717. **Opsahl MS**, **Klein TA**, The role of laparoscopy in the evaluation of candidates for sterilization reversal, Fertil Steril 48:546, 1987.
718. **Henderson SR**, The reversibility of female sterilization with the use of microsurgery: a report on 102 patients with more than one year of follow-up, Am J Obstet Gynecol 149:57, 1984.
719. **Rock JA**, **Chang YS**, **Limpaphayom K**, **Koetswang S**, **Moeloek FA**, **Guzick DS**, **Burkman RT**, **King TM**, Microsurgical tubal anastomosis: a controlled trial in four Asian centers, Microsurgery 5:95, 1984.
720. **Boeckx W**, **Gordts S**, **Buysse K**, **Brosens I**, Reversibility after female sterilization, Br J Obstet Gynaecol 93:839, 1986.
721. **te Velde ER**, **Boer ME**, **Looman CW**, **Habbema JD**, Factors influencing success or failure after reversal of sterilization: a multivariate approach, Fertil Steril 54:270, 1990.
722. **Winston RM**, Tubal surgery or in vitro fertilization (IVF)? J Assist Reprod Genet 9:309, 1992.
723. **Dubuisson JB**, **Chapron C**, **Nos C**, **Morice P**, **Aubriot FX**, **Garnier P**, Sterilization reversal: fertility results, Hum Reprod 10:1145, 1995.
724. **Rouzi AA**, **Mackinnon M**, **McComb PF**, Predictors of success of reversal of sterilization, Fertil Steril 64:29, 1995.
725. **Glock JL**, **Kim AH**, **Hulka JF**, **Hunt RB**, **Trad FS**, **Brumsted JR**, Reproductive outcome after tubal reversal in women 40 years of age or older, Fertil Steril 65:863, 1996.

726. **Penzias AS**, **DeCherney AH**, Is there ever a role for tubal surgery? Am J Obstet Gynecol 174:1218, 1996.
727. **Van Voorhis BJ**, Comparison of tubal ligation reversal procedures, Clin Obstet Gynecol 43:641, 2000.
728. **Yoon TK**, **Sung HR**, **Kang HG**, **Cha SH**, **Lee CN**, **Cha KY**, Laparoscopic tubal anastomosis: fertility outcome in 202 cases, Fertil Steril 72:1121, 1999.
729. **Falcone T**, **Goldberg JM**, **Margossian H**, **Stevens L**, Robotic-assisted laparoscopic microsurgical tubal anastomosis: a human pilot study, Fertil Steril 73:1040, 2000.
730. **Cha SH**, **Lee MH**, **Kim JH**, **Lee CN**, **Yoon TK**, **Cha KY**, Fertility outcome after tubal anastomosis by laparoscopy and laparotomy, J Am Assoc Gynecol Laparosc 8:348, 2001.
731. **Rodgers AK**, **Goldberg JM**, **Hammel JP**, **Falcone T**, Tubal anastomosis by robotic compared with outpatient minilaparotomy, Obstet Gynecol 109:1375, 2007.
732. **Dharia Patel SP**, **Steinkampf MP**, **Whitten SJ**, **Malizia BA**, Robotic tubal anastomosis: surgical technique and cost effectiveness, Fertil Steril 90:1175, 2008.
733. **Boer-Meisel ME**, **te Velde ER**, **Habbema JD**, **Kardaun JW**, Predicting the pregnancy outcome in patients treated for hydrosalpinx: a prospective study, Fertil Steril 45:23, 1986.
734. **Canis M**, **Mage G**, **Pouly JL**, **Manhes H**, **Wattiez A**, **Bruhat MA**, Laparoscopic distal tuboplasty: report of 87 cases and a 4-year experience, Fertil Steril 56:616, 1991.
735. **Diamond E**, Lysis of postoperative pelvic adhesions in infertility, Fertil Steril 31:287, 1979.
736. **Gomel V**, Salpingo-ovariolysis by laparoscopy in infertility, Fertil Steril 40:607, 1983.
737. **Donnez J**, **Casanas-Roux F**, Prognostic factors of fimbrial microsurgery, Fertil Steril 46:200, 1986.
738. **Dubuisson JB**, **Bouquet de Joliniere J**, **Aubriot FX**, **Darai E**, **Foulot H**, **Mandelbrot L**, Terminal tuboplasties by laparoscopy: 65 consecutive cases, Fertil Steril 54:401, 1990.
739. **Dlugi AM**, **Reddy S**, **Saleh WA**, **Mersol-Barg MS**, **Jacobsen G**, Pregnancy rates after operative endoscopic treatment of total (neosalpingostomy) or near total (salpingostomy) distal tubal occlusion, Fertil Steril 62:913, 1994.
740. **Taylor RC**, **Berkowitz J**, **McComb PF**, Role of laparoscopic salpingostomy in the treatment of hydrosalpinx, Fertil Steril 75:594, 2001.
741. **Kitchin JD III**, **Nunley WC Jr**, **Bateman BG**, Surgical management of distal tubal occlusion, Am J Obstet Gynecol 155:524, 1986.
742. **Daniell JF**, **Diamond MP**, **McLaughlin DS**, **Martin DC**, **Feste J**, **Surrey MW**, **Friedman S**, **Vaughn WK**, Clinical results of terminal salpingostomy with the use of the CO2 laser: report of the Intraabdominal Laser Study Group, Fertil Steril 45:175, 1986.
743. **Audebert AJ**, **Pouly JL**, **Von Theobald P**, Laparoscopic fimbrioplasty: an evaluation of 35 cases, Hum Reprod 13:1496, 1998.
744. **Marana R**, **Quagliarello J**, Distal tubal occlusion: microsurgery versus in vitro fertilization—a review, Int J Fertil 33:107, 1988.
745. **Zeyneloglu HB**, **Arici A**, **Olive D**, Adverse effects of hydrosalpinx on pregnancy rates after in vitro fertilization—embryo transfer, Fertil Steril 70:492, 1998.
746. **Camus E**, **Poncelet C**, **Goffinet F**, **Wainer B**, **Meriet F**, **Nisand I**, et al., Pregnancy rates after in-vitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta-analysis of published comparative studies, Hum Reprod 14:1243, 1999.
747. **Beyler SA**, **James KP**, **Fritz MA**, **Meyer WR**, Hydrosalpingeal fluid inhibits in-vitro embryonic development in a murine model, Hum Reprod 12:2724, 1997.
748. **Meyer WR**, **Castelbaum AJ**, **Somkuti S**, **Sagoskin AW**, **Doyle M**, **Harris JE**, **Lessey BA**, Hydrosalpinges adversely affect markers of endometrial receptivity, Hum Reprod 12:1393, 1997.
749. **Strandell A**, **Lindhard A**, **Waldenstrom U**, **Thorburn J**, Hydrosalpinx and IVF outcome: cumulative results after salpingectomy in a randomized controlled trial, Hum Reprod 16:2403, 2001.
750. **Johnson N**, **van Voorst S**, **Sowter MC**, **Strandell A**, **Mol BW**, Surgical treatment for tubal disease in women due to undergo in vitro fertilisation, Cochrane Database Syst Rev (1):CD002125, 2010.
751. **Sagoskin AW**, **Lessey BA**, **Mottla GL**, **Richter KS**, **Chetkowski RJ**, **Chang AS**, et al., Salpingectomy or proximal tubal occlusion of unilateral hydrosalpinx increases the potential for spontaneous pregnancy, Hum

Reprod 18:2634, 2003.
752. **Aboulghar MA**, **Mansour RT**, **Serour GI**, Spontaneous intrauterine pregnancy following salpingectomy for a unilateral hydrosalpinx, Hum Reprod 17:1099, 2002.
753. **Choe J**, **Check JH**, Salpingectomy for unilateral hydrosalpinx may improve in vivo fecundity, Gynecol Obstet Invest 48:285, 1999.
754. **Kotlyar A**, **Gingold J**, **Shue S**, **Falcone T**, The effect of salpingectomy on ovarian function, J Minim Invasive Gynecol 24:563, 2017.
755. **Mohamed AA**, **Yosef AH**, **James C**, **Al-Hussaini TK**, **Bedaiwy MA**, **Amer SAKS**, Ovarian reserve after salpingectomy: a systematic review and meta-analysis, Acta Obstet Gynecol Scand 96:795, 2017.
756. **Zhang Y**, **Sun Y**, **Guo Y**, **Li TC**, **Duan H**, Salpingectomy and proximal tubal occlusion for hydrosalpinx prior to in vitro fertilization: a meta-analysis of randomized controlled trials, Obstet Gynecol Surv 70:33, 2015.
757. **Van Voorhis BJ**, **Sparks AE**, **Syrop CH**, **Stovall DW**, Ultrasound-guided aspiration of hydrosalpinges is associated with improved pregnancy and implantation rates after in-vitro fertilization cycles, Hum Reprod 13:736, 1998.
758. **Tsiami A**, **Chaimani A**, **Mavridis D**, **Siskou M**, **Assimakopoulos E**, **Sotiriadis A**, Surgical treatment for hydrosalpinx prior to in-vitro fertilization embryo transfer: a network meta-analysis, Ultrasound Obstet Gynecol 48:434, 2016.
759. **Bloechle M**, **Schreiner T**, **Lisse K**, Recurrence of hydrosalpinges after transvaginal aspiration of tubal fluid in an IVF cycle with development of a serometra, Hum Reprod 12:703, 1997.
760. **Xu B**, **Zhang Q**, **Zhao J**, **Wang Y**, **Xu D**, **Li Y**, Pregnancy outcome of in vitro fertilization after Essure and laparoscopic management of hydrosalpinx: a systematic review and meta-analysis, Fertil Steril 108:84, 2017.
761. **Barbosa MW**, **Sotiriadis A**, **Papatheodorou SI**, **Mijatovic V**, **Nastri CO**, **Martins WP**, High miscarriage rate in women treated with Essure® for hydrosalpinx before embryo transfer: a systematic review and meta-analysis, Ultrasound Obstet Gynecol 48:556, 2016.
762. **Al-Jaroudi D**, **Herba MJ**, **Tulandi T**, Reproductive performance after selective tubal catheterization, J Minim Invasive Gynecol 12:150, 2005.
763. **Fortier KJ**, **Haney AF**, The pathologic spectrum of uterotubal junction obstruction, Obstet Gynecol 65:93, 1985.
764. **De Silva PM**, **Chu JJ**, **Gallos ID**, **Vidyasagar AT**, **Robinson L**, **Coomarasamy A**, Fallopian tube catheterization in the treatment of proximal tubal obstruction: a systematic review and meta-analysis, Hum Reprod 32:836, 2017.
765. **Farhi J**, **Ben-Haroush A**, **Lande Y**, **Fisch B**, Role of treatment with ovarian stimulation and intrauterine insemination in women with unilateral tubal occlusion diagnosed by hysterosalpingography, Fertil Steril 88:396, 2007.
766. **Patton PE**, **Williams TJ**, **Coulam CB**, Microsurgical reconstruction of the proximal oviduct, Fertil Steril 47:35, 1987.
767. **Patton PE**, **Williams TJ**, **Coulam CB**, Results of microsurgical reconstruction in patients with combined proximal and distal tubal occlusion: double obstruction, Fertil Steril 48:670, 1987.
768. **Marana R**, **Quagliarello J**, Proximal tubal occlusion: microsurgery versus IVF–a review, Int J Fertil 33:338, 1988.
769. **Gleicher N**, **Confino E**, **Corfman R**, **Coulam C**, **DeCherney A**, **Haas G**, **Katz E**, **Robinson E**, **Tur-Kaspa I**, **Vermesh M**, The multicentre transcervical balloon tuboplasty study: conclusions and comparison to alternative technologies, Hum Reprod 8:1264, 1993.
770. **Wiedemann R**, **Hepp H**, Selection of patients for IVF therapy or alternative therapy methods, Hum Reprod 4:23, 1989.
771. **Dodson WC**, **Whitesides DB**, **Hughes CL Jr**, **Easley HA III**, **Haney AF**, Superovulation with intrauterine insemination in the treatment of infertility: a possible alternative to gamete intrafallopian transfer and in vitro fertilization, Fertil Steril 48:441, 1987.
772. **Crosignani PG**, **Collins J**, **Cooke ID**, **Diczfalusy E**, **Rubin B**, Recommendations of the ESHRE workshop on 'Unexplained Infertility'. Anacapri, August 28–9, 1992, Hum Reprod 8:977, 1993.

773. **Crosignani PG**, **Collins J**, **Cooke ID**, **Diczfaluzy E**, **Rubin B**, Unexplained infertility, Hum Reprod 8:977, 1993.
774. **Somigliana E**, **Paffoni A**, **Busnelli A**, **Filippi F**, **Pagliardini L**, **Vigano P**, **Vercellini P**, Age-related infertility and unexplained infertility: an intricate clinical dilemma, Hum Reprod 31:1390, 2016.
775. **ESHRE Capri Workshop Group**, A prognosis-based approach to infertility: understanding the role of time Hum Reprod 32:1556, 2017.
776. **Conner SJ**, **Lefievre L**, **Hughes DC**, **Barratt CL**, Cracking the egg: increased complexity in the zona pellucida, Hum Reprod 20:1148, 2005.
777. **Chatzimeletiou K**, **Morrison EE**, **Prapas N**, **Prapas Y**, **Handyside AH**, The centrosome and early embryogenesis: clinical insights, Reprod Biomed Online 16:485, 2008.
778. **Moomjy M**, **Sills ES**, **Rosenwaks Z**, **Palermo GD**, Implications of complete fertilization failure after intracytoplasmic sperm injection for subsequent fertilization and reproductive outcome, Hum Reprod 13:2212, 1998.
779. **Liu J**, **Nagy Z**, **Joris H**, **Tournaye H**, **Smitz J**, **Camus M**, **Devroey P**, **Van Steirteghem A**, Analysis of 76 total fertilization failure cycles out of 2732 intracytoplasmic sperm injection cycles, Hum Reprod 10:2630, 1995.
780. **Gurgan T**, **Urman B**, **Yarali H**, **Kisnisci HA**, The results of in vitro fertilization-embryo transfer in couples with unexplained infertility failing to conceive with superovulation and intrauterine insemination, Fertil Steril 64:93, 1995.
781. **Ruiz A**, **Remohi J**, **Minguez Y**, **Guanes PP**, **Simon C**, **Pellicer A**, The role of in vitro fertilization and intracytoplasmic sperm injection in couples with unexplained infertility after failed intrauterine insemination, Fertil Steril 68: 171, 1997.
782. **Takeuchi S**, **Minoura H**, **Shibahara T**, **Shen X**, **Futamura N**, **Toyoda N**, In vitro fertilization and intracytoplasmic sperm injection for couples with unexplained infertility after failed direct intraperitoneal insemination, J Assist Reprod Genet 17:515, 2000.
783. **Martin JS**, **Nisker JA**, **Parker JI**, **Kaplan B**, **Tummon IS**, **Yuzpe AA**, The pregnancy rates of cohorts of idiopathic infertility couples gives insights into the underlying mechanism of infertility, Fertil Steril 64:98, 1995.
784. **Boklage CE**, Survival probability of human conceptions from fertilization to term, Int J Fertil 35:75, 1990.
785. **Macklon NS**, **Geraedts JP**, **Fauser BC**, Conception to ongoing pregnancy: the 'black box' of early pregnancy loss, Hum Reprod Update 8:333, 2002.
786. **Staessen C**, **Platteau P**, **Van Assche E**, **Michiels A**, **Tournaye H**, **Camus M**, **Devroey P**, **Liebaers I**, **Van Steirteghem A**, Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial, Hum Reprod 19:2849, 2004.
787. **Mastenbroek S**, **Twisk M**, **van Echten-Arends J**, **Sikkema-Raddatz B**, **Korevaar JC**, **Verhoeve HR**, **Vogel NE**, **Arts EG**, **de Vries JW**, **Bossuyt PM**, **Buys CH**, **Heineman MJ**, **Repping S**, **van der Veen F**, In vitro fertilization with preimplantation genetic screening, N Engl J Med 357:9, 2007.
788. **Mardon H**, **Grewal S**, **Mills K**, Experimental models for investigating implantation of the human embryo, Semin Reprod Med 25:410, 2007.
789. **Fazleabas AT**, Physiology and pathology of implantation in the human and nonhuman primate, Semin Reprod Med 25:405, 2007.
790. **Tapia A**, **Gangi LM**, **Zegers-Hochschild F**, **Balmaceda J**, **Pommer R**, **Trejo L**, **Pacheco IM**, **Salvatierra AM**, **Henriquez S**, **Quezada M**, **Vargas M**, **Rios M**, **Munroe DJ**, **Croxatto HB**, **Velasquez L**, Differences in the endometrial transcript profile during the receptive period between women who were refractory to implantation and those who achieved pregnancy, Hum Reprod 23:340, 2008.
791. **Collins JA**, **Van Steirteghem A**, Overall prognosis with current treatment of infertility, Hum Reprod Update 10:309, 2004.
792. **Lenton EA**, **Weston GA**, **Cooke ID**, Long-term follow-up of the apparently normal couple with a complaint of infertility, Fertil Steril 28:913, 1977.
793. **Hunault CC**, **Habbema JD**, **Eijkemans MJ**, **Collins JA**, **Evers JL**, **te Velde ER**, Two new prediction rules for spontaneous pregnancy leading to live birth among subfertile couples, based on the synthesis of three

previous models, Hum Reprod 19:2019, 2004.
794. **Guzick DS**, **Sullivan MW**, **Adamson GD**, **Cedars MI**, **Falk RJ**, **Peterson EP**, **Steinkampf MP**, Efficacy of treatment for unexplained infertility, Fertil Steril 70:207, 1998.
795. **Collins J**, **Rowe T**, Age of the female partner is a prognostic factor in prolonged unexplained infertility: a multicenter study, Fertil Steril 52:15, 1989.
796. **Zikopoulos K**, **West CP**, **Thong PW**, **Kalser EM**, **Morrison J**, **Wu FCW**, Homologous intra-uterine insemination has no advantage over timed natural intercourse when used in combination with ovulation induction for the treatment of unexplained infertility, Hum Reprod 8:563, 1993.
797. **Martinez AR**, **Bernardus RE**, **Voorhorst FJ**, **Vermeiden JP**, **Schoemaker J**, Intrauterine insemination does and clomiphene citrate does not improve fecundity in couples with infertility due to male or idiopathic factors: a prospective, randomized, controlled study, Fertil Steril 53:847, 1990.
798. **Verhulst SM**, **Cohlen BJ**, **Hughes E**, **Te Velde E**, **Heineman MJ**, Intra-uterine insemination for unexplained subfertility, Cochrane Database Syst Rev (2):CD001838, 2006.
799. **Bhattacharya S**, **Harrild K**, **Mollison J**, **Wordsworth S**, **Tay C**, **Harrold A**, **McQueen D**, **Lyall H**, **Johnston L**, **Burrage J**, **Grossett S**, **Walton H**, **Lynch J**, **Johnstone A**, **Kini S**, **Raja A**, **Templeton A**, Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial, Br Med J 337:a716, 2008.
800. **Steures P**, **van der Steeg JW**, **Hompes PG**, **Bossuyt PM**, **Habbema JD**, **Eijkemans MJ**, **Schols WA**, **Burggraaff JM**, **van der Veen F**, **Mol BW**, Effectiveness of intrauterine insemination in subfertile couples with an isolated cervical factor: a randomized clinical trial, Fertil Steril 88:1692, 2007.
801. **Randall JM**, **Templeton A**, The effects of clomiphene citrate upon ovulation and endocrinology when administered to patients with unexplained infertility, Hum Reprod 6:659, 1991.
802. **Glazener CMA**, **Coulson C**, **Lambert PA**, **Watt EM**, **Hinton RA**, **Kelly NG**, **Hull MGR**, Clomiphene treatment for women with unexplained infertility: placebo-controlled study of hormonal responses and conception rates, Gynecol Endocrinol 4:75, 1990.
803. **Harrison RF**, **O'Moore RR**, The use of clomiphene citrate with and without human chorionic gonadotropin, Ir Med J 76:273, 1983.
804. **Fujii S**, **Fukui A**, **Fukushi Y**, **Kagiya A**, **Sato S**, **Saito Y**, The effects of clomiphene citrate on normal ovulatory women, Fertil Steril 68:997, 1997.
805. **Fisch P**, **Casper RF**, **Brown SE**, **Wrixon W**, **Collins JA**, **Reid RL**, **Simpson C**, Unexplained infertility: evaluation of treatment with clomiphene citrate and human chorionic gonadotropin, Fertil Steril 51:828, 1989.
806. **Deaton JL**, **Gibson N**, **Blackmer KM**, **Nakajima ST**, **Badger GJ**, **Brumsted JR**, A randomized, controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility, Fertil Steril 54:1083, 1990.
807. **Farquhar CM**, **Liu E**, **Armstrong S**, **Arroll N**, **Lensen S**, **Brown J**, Intrauterine insemination with ovarian stimulation versus expectant management for unexplained infertility (TUI): a pragmatic, open-label, randomised, controlled, two-centre trial, Lancet 391:441, 2018.
808. **Arici A**, **Byrd W**, **Bradshaw K**, **Kutteh WH**, **Marshburn P**, **Carr BR**, Evaluation of clomiphene citrate and human chorionic gonadotropin treatment: a prospective, randomized, crossover study during intrauterine insemination cycles, Fertil Steril 61:314, 1994.
809. **Karlstrom P-O**, **Bergh T**, **Lundkvist O**, A prospective randomized trial of artificial insemination versus intercourse in cycles stimulated with human menopausal gonadotropin or clomiphene citrate, Fertil Steril 59:554, 1993.
810. **Agarwal S**, **Mittal S**, A randomised prospective trial of intrauterine insemination versus timed intercourse in superovulated cycles with clomiphene, Indian J Med Res 120:519, 2004.
811. **Reindollar RH**, **Regan MM**, **Neumann PJ**, **Levine BS**, **Thornton KL**, **Alper MM**, **Goldman MB**, A randomized clinical trial to evaluate optimal treatment for unexplained infertility; the fast track and standard treatment (FASTT) trial, Fertil Steril 94:888, 2010.
812. **Custers IM**, **Steures P**, **Hompes P**, **Flierman P**, **van Kasteren Y**, **van Dop PA**, **van der Veen F**, **Mol BW**, Intrauterine insemination: how many cycles should we perform? Hum Reprod 23:885, 2008.

813. **Dovey S**, **Sneeringer RM**, **Penzias AS**, Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles, Fertil Steril 90:2281, 2008.
814. **Guzick DS**, **Carson SA**, **Coutifaris C**, **Overstreet JW**, **Factor-Litvak P**, **Steinkampf MP**, **Hill JA**, **Mastroianni L Jr**, **Buster JE**, **Nakajimi ST**, **Vogel DL**, **Canfield RE**; for the **National Cooperative Reproductive Medicine Network**, Efficacy of superovulation and intrauterine insemination in the treatment of infertility, N Engl J Med 340:177, 1999.
815. **Gregoriou O**, **Vitoratos N**, **Papadias C**, **Konidaris S**, **Gargaropoulos A**, **Louridas C**, Controlled ovarian hyperstimulation with or without intrauterine insemination for the treatment of unexplained infertility, Int J Gynaecol Obstet 48:55, 1995.
816. **Steures P**, **van der Steeg JW**, **Hompes PG**, **Habbema JD**, **Eijkemans MJ**, **Broekmans FJ**, **Verhoeve HR**, **Bossuyt PM**, **van der Veen F**, **Mol BW**, Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis: a randomised clinical trial, Lancet 368:216, 2006.
817. **Diamond MP**, **Legro RS**, **Coutifaris C**, **Alvero R**, **Robinson RD**, **Casson P**, **Christman GM**, **Ager J**, **Huang H**, **Hansen KR**, **Baker V**, **Usadi R**, **Seungdamrong A**, **Bates GW**, **Rosen RM**, **Haisenleder D**, **Krawetz SA**, **Barnhart K**, **Trussell JC**, **Ohl D**, **Jin Y**, **Santoro N**, **Eisenberg E**, **Zhang H**; **NICHD Reproductive Medicine Network**, Letrozole, gonadotropin, or clomiphene for unexplained infertility, New Engl J Med 373:1230, 2015.
818. **Peeraer K**, **Debrock S**, **De Loecker P**, **Tomassetti C**, **Laenen A**, **Welkenhuysen M**, **Meeuwis L**, **Pelckmans S**, **Mol BW**, **Spiessens C**, **De Neubourg D**, **D'Hooghe TM**, Low-dose human menopausal gonadotrophin versus clomiphene citrate in subfertile couples treated with intrauterine insemination: a randomized controlled trial, Hum Reprod 30(5):1079, 2015.
819. **Cantineau AE**, **Cohlen BJ**, **Heineman MJ**, Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility, Cochrane Database Syst Rev (2):CD005356, 2007.
820. **Luo S**, **Li S**, **Jin S**, **Li Y**, **Zhang Y**, Effectiveness of GnRH antagonist in the management of subfertile couples undergoing controlled ovarian stimulation and intrauterine insemination: a meta-analysis, PLoS One 9:e109133, 2014.
821. **Crosignani PG**, **Walters DE**, **Soliani A**, The ESHRE multicentre trial on the treatment of unexplained infertility: a preliminary report. European Society of Human Reproduction and Embryology, Hum Reprod 6:953, 1991.
822. **Goverde AJ**, **McDonnell J**, **Vermeiden JP**, **Schats R**, **Rutten FF**, **Schoemaker J**, Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomised trial and cost-effectiveness analysis, Lancet 355:13, 2000.
823. **Custers IM**, **König TE**, **Broekmans FJ**, **Hompes PG**, **Kaaijk E**, **Oosterhuis J**, **Mochtar MH**, **Repping S**, **van Wely M**, **Steures P**, **van der Veen F**, **Mol BW**, Couples with unexplained subfertility and unfavorable prognosis: a randomized pilot trial comparing the effectiveness of in vitro fertilization with elective single embryo transfer versus intrauterine insemination with controlled ovarian stimulation, Fertil Steril 96:1107, 2011.
824. **Bensdorp AJ**, **Tjon-Kon-Fat RI**, **Bossuyt PM**, **Koks CA**, **Oosterhuis GJ**, **Hoek A**, **Hompes PG**, **Broekmans FJ**, **Verhoeve HR**, **de Bruin JP**, **van Golde R**, **Repping S**, **Cohlen BJ**, **Lambers MD**, **van Bommel PF**, **Slappendel E**, **Perquin D**, **Smeenk JM**, **Pelinck MJ**, **Gianotten J**, **Hoozemans DA**, **Maas JW**, **Eijkemans MJ**, **van der Veen F**, **Mol BW**, **van Wely M**, Prevention of multiple pregnancies in couples with unexplained or mild male subfertility: randomised controlled trial of in vitro fertilisation with single embryo transfer or in vitro fertilisation in modified natural cycle compared with intrauterine insemination with controlled ovarian hyperstimulation, BMJ 350:g7771, 2015.
825. **Nandi A**, **Bhide P**, **Hooper R**, **Gudi A**, **Shah A**, **Khan K**, **Homburg R**, Intrauterine insemination with gonadotropin stimulation or in vitro fertilization for the treatment of unexplained subfertility: a randomized controlled trial, Fertil Steril 107:1329, 2017.
826. **Tjon-Kon-Fat RI**, **Tajik P**, **Zafarmand MH**, **Bensdorp AJ**, **Bossuyt PMM**, **Oosterhuis GJE**, **van Golde R**, **Repping S**, **Lambers MDA**, **Slappendel E**, **Perquin D**, **Pelinck MJ**, **Gianotten J**, **Maas JWM**,

Eijkemans MJC, **van der Veen F**, **Mol BW**, **van Wely M**; **INeS study group**, IVF or IUI as first-line treatment in unexplained subfertility: the conundrum of treatment selection markers, Hum Reprod 32:1028, 2017.

827. **van Peperstraten AM**, **Nelen WL**, **Hermens RP**, **Jansen L**, **Scheenjes E**, **Braat DD**, **Grol RP**, **Kremer JA**, Why don't we perform elective single embryo transfer? A qualitative study among IVF patients and professionals, Hum Reprod 23:2036, 2008.
828. **Elit L**, **Charles C**, **Dimitry S**, **Tedford-Gold S**, **Gafni A**, **Gold I**, **Whelan T**, It's a choice to move forward: women's perceptions about treatment decision making in recurrent ovarian cancer, Psychooncology 19:318, 2010.
829. **Vahratian A**, Utilization of fertility-related services in the United States, Fertil Steril 90:1317, 2008.
830. **Elgindy EA**, **El-Haieg DO**, **El-Sebaey A**, Anti-Mullerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients, Fertil Steril 89:1670, 2008.
831. **Maia H Jr**, **Pimentel K**, **Silva TM**, **Freitas LA**, **Zausner B**, **Athayde C**, **Coutinho EM**, Aromatase and cyclooxygenase-2 expression in endometrial polyps during the menstrual cycle, Gynecol Endocrinol 22:219, 2006.
832. **Papaioannou S**, **Afnan M**, **Girling AJ**, **Coomarasamy A**, **Ola B**, **Olufowobi O**, **McHugo JM**, **Hammadieh N**, **Sharif K**, The effect on pregnancy rates of tubal perfusion pressure reductions achieved by guide-wire tubal catheterization, Hum Reprod 17:2174, 2002.
833. **Athaullah N**, **Proctor M**, **Johnson NP**, Oral versus injectable ovulation induction agents for unexplained subfertility, Cochrane Database Syst Rev (3):CD003052, 2002.
834. **Bureau of Labor Statistics, News Release**. Employment Characteristics of Families–2016, Released April 20, 2017.
835. **Marshall LM**, **Spiegelman D**, **Barbieri RL**, **Goldman MB**, **Manson JE**, **Colditz GA**, **Willett WC**, **Hunter DJ**, Variation in the incidence of uterine leiomyoma among premenopausal women by age and race, Obstet Gynecol 90(6):967, 1997.
836. **Ferraretti AP**, **La Marca A**, **Fauser BCJM**, **Tarlatzis B**, **Nargund G**, **Gianaroli L**, ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria, Hum Reprod 26:1616, 2011.
837. **Humaidan P**, **Alvigg C**, **Fischer R**, **Esteves SC**, The novel POSEIDON stratification of low prognosis patients in assisted reproductive technology and its proposed marker of successful outcome, F100 Research 5:2911, 2016.
838. **Zinaman M**, **Johnson S**, **Ellis J**, **Ledger W**, Accuracy of perception of ovulation day in women trying to conceive, Curr Med Res Opin 28(5):749, 2012.
839. **Hua Y**, **Zhang W**, **Hu X**, **Yang A**, **Zhu X**, The use of misoprostol for cervical priming prior to hysteroscopy: a systematic review and analysis, Drug Des Devel Ther 10:2789, 2016.
840. **Yanaihara A**, **Yorimitsu T**, **Motoyama H**, **Iwasaki S**, **Kawamura T**, Location of endometrial polyp and pregnancy rate in infertility patients, Fertil Steril 90:180, 2008.
841. **Zagoria RJ**, **Regan SW**, **Dyer RB**, Nonsurgical fallopian tube recanalization for treatment of infertility, N C Med J 52:491, 1991.

Chapter twenty six

REFERENCES

1. **Thonneau P**, **Marchand S**, **Tallec A**, **Ferial ML**, **Ducot B**, **Lansac J**, **Lopes P**, **Tabaste JM**, **Spira A**, Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988–1989), Hum Reprod 6:811, 1991.
2. **Wong CH**, **Cheng CY**, The blood-testis barrier: its biology, regulation, and physiological role in spermatogenesis, Curr Top Dev Biol 71:263, 2005.
3. **Vogel F**, **Rathenberg R**, Spontaneous mutation in man, Adv Hum Genet 5:223, 1975.
4. **Buaas FW**, **Kirsh AL**, **Sharma M**, **McLean DJ**, **Morris JL**, **Griswold MD**, **de Rooij DG**, **Braun RE**, Plzf is required in adult male germ cells for stem cell self-renewal, Nat Genet 36:647, 2004.
5. **Costoya JA**, **Hobbs RM**, **Barna M**, **Cattoretti G**, **Manova K**, **Sukhwani M**, **Orwig KE**, **Wolgemuth DJ**, **Pandolfi PP**, Essential role of Plzf in maintenance of spermatogonial stem cells, Nat Genet 36:653, 2004.
6. **Johnson L**, **Petty CS**, **Neaves WB**, Further quantification of human spermatogenesis: germ cell loss during postprophase of meiosis and its relationship to daily sperm production, Biol Reprod 29:207, 1983.
7. **Lie PP**, **Cheng CY**, **Mruk DD**, Coordinating cellular events during spermatogenesis: a biochemical model, Trends Biochem Sci 34:366, 2009.
8. **Burgoyne PS**, The role of the mammalian Y chromosome in spermatogenesis, Development 101(Suppl):133, 1987.
9. **Heller CG**, **Clermont Y**, Spermatogenesis in man: an estimate of its duration, Science 140:184, 1963.
10. **Rowley MJ**, **Teshima F**, **Heller CG**, Duration of transit of spermatozoa through the human male ductular system, Fertil Steril 21:390, 1970.
11. **Hinrichsen MJ**, **Blaquier JA**, Evidence supporting the existence of sperm maturation in the human epididymis, J Reprod Fertil 60:291, 1980.
12. **Wang C**, **McDonald V**, **Leung A**, **Superlano L**, **Berman N**, **Hull L**, **Swerdloff RS**, Effect of increased scrotal temperature on sperm production in normal men, Fertil Steril 68:334, 1997.
13. **Ketelslegers JM**, **Hetzel WD**, **Sherins RJ**, **Catt KJ**, Developmental changes in testicular gonadotropin receptors: plasma gonadotropins and plasma testosterone in the rat, Endocrinology 103:212, 1978.
14. **Wahlstrom T**, **Huhtaniemi I**, **Hovatta O**, **Seppala M**, Localization of luteinizing hormone, follicle-stimulating hormone, prolactin, and their receptors in human and rat testis using immunohistochemistry and radioreceptor assay, J Clin Endocrinol Metab 57:825, 1983.
15. **Morse HC**, **Horike N**, **Rowley MJ**, **Heller CG**, Testosterone concentrations in testes of normal men: effects of testosterone propionate administration, J Clin Endocrinol Metab 37:882, 1973.
16. **McLachlan RI**, **O'Donnell L**, **Meachem SJ**, **Stanton PG**, **de K**, **Pratis K**, **Robertson DM**, Hormonal regulation of spermatogenesis in primates and man: insights for development of the male hormonal contraceptive, J Androl 23:149, 2002.
17. **Matsumoto AM**, **Bremner WJ**, Modulation of pulsatile gonadotropin secretion by testosterone in man, J Clin Endocrinol Metab 58:609, 1984.
18. **Plant TM**, **Dubey AK**, Evidence from the rhesus monkey (Macaca mulatta) for the view that negative feedback control of luteinizing hormone secretion by the testis is mediated by a deceleration of hypothalamic gonadotropin-releasing hormone pulse frequency, Endocrinology 115:2145, 1984.
19. **Veldhuis JD**, **Rogol AD**, **Samojlik E**, **Ertel NH**, Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man, J Clin Invest 74:47, 1984.
20. **Sheckter CB**, **Matsumoto AM**, **Bremner WJ**, Testosterone administration inhibits gonadotropin secretion by an effect directly on the human pituitary, J Clin Endocrinol Metab 68:397, 1989.
21. **Santen RJ**, Is aromatization of testosterone to estradiol required for inhibition of luteinizing hormone secretion in men? J Clin Invest 56:1555, 1975.
22. **Winters SJ**, **Troen P**, Evidence for a role of endogenous estrogen in the hypothalamic control of gonadotropin secretion in men, J Clin Endocrinol Metab 61:842, 1985.

23. **Lacroix A**, **McKenna TJ**, **Rabinowitz D**, Sex steroid modulation of gonadotropins in normal men and in androgen insensitivity syndrome, J Clin Endocrinol Metab 48:235, 1979.
24. **Bagatell CJ**, **Dahl KD**, **Bremner WJ**, The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol, J Androl 15:15, 1994.
25. **Morishima A**, **Grumbach MM**, **Simpson ER**, **Fisher C**, **Qin K**, Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens, J Clin Endocrinol Metab 80:3689, 1995.
26. **Hayes FJ**, **Seminara SB**, **Decruz S**, **Boepple PA**, **Crowley WF Jr**, Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback, J Clin Endocrinol Metab 85:3027, 2000.
27. **Plymate SR**, **Paulsen CA**, **McLachlan RI**, Relationship of serum inhibin levels to serum follicle stimulating hormone and sperm production in normal men and men with varicoceles, J Clin Endocrinol Metab 74:859, 1992.
28. **Anderson RA**, **Wallace EM**, **Groome NP**, **Bellis AJ**, **Wu FC**, Physiological relationships between inhibin B, follicle stimulating hormone secretion and spermatogenesis in normal men and response to gonadotrophin suppression by exogenous testosterone, Hum Reprod 12:746, 1997.
29. **Illingworth PJ**, **Groome NP**, **Byrd W**, **Rainey WE**, **McNeilly AS**, **Mather JP**, **Bremmer WJ**, Inhibin-B: a likely candidate for the physiologically important form of inhibin in men, J Clin Endocrinol Metab 81:1321, 1996.
30. **Majumdar SS**, **Mikuma N**, **Ishwad PC**, **Winters SJ**, **Attardi BJ**, **Perera AD**, **Plant TM**, Replacement with recombinant human inhibin immediately after orchidectomy in the hypophysiotropically clamped male rhesus monkey (Macaca mulatta) maintains follicle-stimulating hormone (FSH) secretion and FSH beta messenger ribonucleic acid levels at precastration values, Endocrinology 136:1969, 1995.
31. **Ramaswamy S**, **Marshall GR**, **Pohl CR**, **Friedman RL**, **Plant TM**, Inhibitory and stimulatory regulation of testicular inhibin B secretion by luteinizing hormone and follicle-stimulating hormone, respectively, in the rhesus monkey (Macaca mulatta), Endocrinology 144:1175, 2003.
32. **Saez JM**, Leydig cells: endocrine, paracrine, and autocrine regulation, Endocr Rev 15:574, 1994.
33. **Gnessi L**, **Fabbri A**, **Spera G**, Gonadal peptides as mediators of development and functional control of the testis: an integrated system with hormones and local environment, Endocr Rev 18:541, 1997.
34. **Nieschlag E**, **Simoni M**, **Gromoll J**, **Weinbauer GF**, Role of FSH in the regulation of spermatogenesis: clinical aspects, Clin Endocrinol (Oxf) 51:139, 1999.
35. **Huleihel M**, **Abuelhija M**, **Lunenfeld E**, In vitro culture of testicular germ cells: regulatory factors and limitations, Growth Factors 25:236, 2007.
36. **Sofikitis N**, **Giotitsas N**, **Tsounapi P**, **Baltogiannis D**, **Giannakis D**, **Pardalidis N**, Hormonal regulation of spermatogenesis and spermiogenesis, J Steroid Biochem Mol Biol 109:323, 2008.
37. **Weiss J**, **Axelrod L**, **Whitcomb RW**, **Harris PE**, **Crowley WF**, **Jameson JL**, Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone, N Engl J Med 326:179, 1992.
38. **Levalle O**, **Zylbersztein C**, **Aszpis S**, **Aquilano D**, **Terradas C**, **Colombani M**, **Aranda C**, **Scaglia H**, Recombinant human follicle-stimulating hormone administration increases testosterone production in men, possibly by a Sertoli cell-secreted nonsteroid factor, J Clin Endocrinol Metab 83:3973, 1998.
39. **Tapanainen JS**, **Aittomäki K**, **Min J**, **Vaskivuo T**, **Huhtaniemi I**, Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility, Nat Genet 15:205, 1997.
40. **Mozaffarian GA**, **Higley M**, **Paulsen CA**, Clinical studies in an adult male patient with "isolated follicle stimulating hormone (FSH) deficiency", J Androl 4:393, 1983.
41. **Al-Ansari AA**, **Khalil TH**, **Kelani Y**, **Mortimer CH**, Isolated follicle-stimulating hormone deficiency in men: successful long-term gonadotropin therapy, Fertil Steril 42:618, 1984.
42. **Marshall GR**, **Wickings EJ**, **Nieschlag E**, Testosterone can initiate spermatogenesis in an immature nonhuman primate, Macaca fascicularis, Endocrinology 114:2228, 1984.
43. **Phillip M**, **Arbelle JE**, **Segev Y**, **Parvari R**, Male hypogonadism due to a mutation in the gene for the beta-subunit of follicle-stimulating hormone, N Engl J Med 338:1729, 1998.
44. **Lindstedt G**, **Nystrom E**, **Matthews C**, **Ernest I**, **Janson PO**, **Chatterjee K**, Follitropin (FSH) deficiency in an infertile male due to FSH beta gene mutation. A syndrome of normal puberty and virilization but

underdeveloped testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations, Clin Chem Lab Med 36:663, 1998.
45. **Finkel DM**, **Phillips JL**, **Snyder PJ**, Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism, N Engl J Med 313:651, 1985.
46. **Weinbauer GF**, **Behre HM**, **Fingscheidt U**, **Nieschlag E**, Human follicle-stimulating hormone exerts a stimulatory effect on spermatogenesis, testicular size, and serum inhibin levels in the gonadotropin-releasing hormone antagonist-treated nonhuman primate (Macaca fascicularis), Endocrinology 129:1831, 1991.
47. **Weinbauer GF**, **Schlatt S**, **Walter V**, **Nieschlag E**, Testosterone-induced inhibition of spermatogenesis is more closely related to suppression of FSH than to testicular androgen levels in the cynomolgus monkey model (Macaca fascicularis), J Endocrinol 168:25, 2001.
48. **Simoni M**, **Gromoll J**, **Nieschlag E**, The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology, Endocr Rev 18:739, 1997.
49. **Gromoll J**, **Simoni M**, **Nieschlag E**, An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man, J Clin Endocrinol Metab 81:1367, 1996.
50. **Vicari E**, **Mongioi A**, **Calogero AE**, **Moncada ML**, **Sidoti G**, **Polosa P**, **D'Agata R**, Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism —long-term follow-up, Int J Androl 15:320, 1992.
51. **Srinath BR**, **Wickings EJ**, **Witting C**, **Nieschlag E**, Active immunization with follicle-stimulating hormone for fertility control: a 4 1/2-year study in male rhesus monkeys, Fertil Steril 40:110, 1983.
52. **Moudgal NR**, **Ravindranath N**, **Murthy GS**, **Dighe RR**, **Aravindan GR**, **Martin F**, Long-term contraceptive efficacy of vaccine of ovine follicle-stimulating hormone in male bonnet monkeys (Macaca radiata), J Reprod Fertil 96:91, 1992.
53. **Moudgal NR**, **Sairam MR**, Is there a true requirement for follicle stimulating hormone in promoting spermatogenesis and fertility in primates? Hum Reprod 13:916, 1998.
54. **Moudgal NR**, **Murthy GS**, **Prasanna Kumar KM**, **Martin F**, **Suresh R**, **Medhamurthy R**, **Patil S**, **Sehgal S**, **Saxena BN**, Responsiveness of human male volunteers to immunization with ovine follicle stimulating hormone vaccine: results of a pilot study, Hum Reprod 12:457, 1997.
55. **Matsumoto AM**, **Karpas AE**, **Bremner WJ**, Chronic human chorionic gonadotropin administration in normal men: evidence that follicle-stimulating hormone is necessary for the maintenance of quantitatively normal spermatogenesis in man, J Clin Endocrinol Metab 62:1184, 1986.
56. **Behre HM**, **Baus S**, **Kliesch S**, **Keck C**, **Simoni M**, **Nieschlag E**, Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders, J Clin Endocrinol Metab 80:2394, 1995.
57. **Buchter D**, **von Eckardstein S**, **von Eckardstein A**, **Kamischke A**, **Simoni M**, **Behre HM**, **Nieschlag E**, Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception, J Clin Endocrinol Metab 84:1244, 1999.
58. **Arslan M**, **Weinbauer GF**, **Schlatt S**, **Shahab M**, **Nieschlag E**, FSH and testosterone, alone or in combination, initiate testicular growth and increase the number of spermatogonia and Sertoli cells in a juvenile non-human primate (Macaca mulatta), J Endocrinol 136:235, 1993.
59. **Schlatt S**, **Arslan M**, **Weinbauer GF**, **Behre HM**, **Nieschlag E**, Endocrine control of testicular somatic and premeiotic germ cell development in the immature testis of the primate Macaca mulatta, Eur J Endocrinol 133:235, 1995.
60. **Whitcomb RW**, **Crowley WF Jr**, Clinical review 4: Diagnosis and treatment of isolated gonadotropin-releasing hormone deficiency in men, J Clin Endocrinol Metab 70:3, 1990.
61. **Burgues S**, **Calderon MD**, Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorionic gonadotrophin for the treatment of male hypogonadotrophic hypogonadism. Spanish Collaborative Group on Male Hypogonadotropic Hypogonadism, Hum Reprod 12:980, 1997.
62. **Buchter D**, **Behre HM**, **Kliesch S**, **Nieschlag E**, Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases, Eur J Endocrinol 139:298, 1998.

63. **Schaison G**, **Young J**, **Pholsena M**, **Nahoul K**, **Couzinet B**, Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism, J Clin Endocrinol Metab 77:1545, 1993.
64. **Ventura SJ**, **Martin JA**, **Curtin SC**, **Matthew MS**, Report of final natality statistics, 1995, Mon Vital Stat Rep 45(Suppl 11), 1997.
65. **Ventura SJ**, **Hamilton BE**, **Sutton PD**, Revised birth and fertility rates for the United States, 2000 and 2001, Natl Vital Stat Rep 51:1, 2003.
66. **Kidd SA**, **Eskenazi B**, **Wyrobek AJ**, Effects of male age on semen quality and fertility: a review of the literature, Fertil Steril 75:237, 2001.
67. **Eskenazi B**, **Wyrobek AJ**, **Sloter E**, **Kidd SA**, **Moore L**, **Young S**, **Moore D**, The association of age and semen quality in healthy men, Hum Reprod 18:447, 2003.
68. **Nankin HR**, Fertility in aging men, Maturitas 7:259, 1985.
69. **Bujan L**, **Mieusset R**, **Mondinat C**, **Mansat A**, **Pontonnier F**, Sperm morphology in fertile men and its age related variation, Andrologia 20:121, 1988.
70. **Rolf C**, **Behre HM**, **Nieschlag E**, Reproductive parameters of older compared to younger men of infertile couples, Int J Androl 19:135, 1996.
71. **Chia SE**, **Lim ST**, **Tay SK**, Factors associated with male infertility: a case-control study of 218 infertile and 240 fertile men, Br J Obstet Gynaecol 107:55, 2000.
72. **Tennekoon KH**, **Karunanayake EH**, Serum FSH, LH, and testosterone concentrations in presumably fertile men: effect of age, Int J Fertil 38:108, 1993.
73. **Vermeulen A**, **Kaufman JM**, Ageing of the hypothalamo-pituitary-testicular axis in men, Horm Res 43:25, 1995.
74. **Paulson RJ**, **Milligan RC**, **Sokol RZ**, The lack of influence of age on male fertility, Am J Obstet Gynecol 184:818, 2001.
75. **Hassan MA**, **Killick SR**, Effect of male age on fertility: evidence for the decline in male fertility with increasing age, Fertil Steril 79(Suppl 3):1520, 2003.
76. **ESHRE Capri workshop group**, Social determinants of human reproduction, Hum Reprod 16:1518, 2001.
77. **Ford WC**, **North K**, **Taylor H**, **Farrow A**, **Hull MG**, **Golding J**, Increasing paternal age is associated with delayed conception in a large population of fertile couples: evidence for declining fecundity in older men. The ALSPAC Study Team (Avon Longitudinal Study of Pregnancy and Childhood), Hum Reprod 15:1703, 2000.
78. **Dunson DB**, **Colombo B**, **Baird DD**, Changes with age in the level and duration of fertility in the menstrual cycle, Hum Reprod 17:1399, 2002.
79. **Klonoff-Cohen HS**, **Natarajan L**, The effect of advancing paternal age on pregnancy and live birth rates in couples undergoing in vitro fertilization or gamete intrafallopian transfer, Am J Obstet Gynecol 191:507, 2004.
80. **de La Rochebrochard E**, **de Mouzon J**, **Thepot F**, **Thonneau P**, Fathers over 40 and increased failure to conceive: the lessons of in vitro fertilization in France, Fertil Steril 85:1420, 2006.
81. **de La Rochebrochard E**, **Thonneau P**, Paternal age >or=40 years: an important risk factor for infertility, Am J Obstet Gynecol 189:901, 2003.
82. **Faber BM**, **Mercan R**, **Hamacher P**, **Muasher SJ**, **Toner JP**, The impact of an egg donor's age and her prior fertility on recipient pregnancy outcome, Fertil Steril 68:370, 1997.
83. **Gallardo E**, **Simon C**, **Levy M**, **Guanes PP**, **Remohi J**, **Pellicer A**, Effect of age on sperm fertility potential: oocyte donation as a model, Fertil Steril 66:260, 1996.
84. **Bellver J**, **Garrido N**, **Remohi J**, **Pellicer A**, **Meseguer M**, Influence of paternal age on assisted reproduction outcome, Reprod Biomed Online 17:595, 2008.
85. **Frattarelli JL**, **Miller KA**, **Miller BT**, **Elkind-Hirsch K**, **Scott RT Jr**, Male age negatively impacts embryo development and reproductive outcome in donor oocyte assisted reproductive technology cycles, Fertil Steril 90:97, 2008.
86. **Luna M**, **Finkler E**, **Barritt J**, **Bar-Chama N**, **Sandler B**, **Copperman AB**, **Grunfeld L**, Paternal age and assisted reproductive technology outcome in ovum recipients, Fertil Steril 92:1772, 2009.
87. **Hermann M**, **Untergasser G**, **Rumpold H**, **Berger P**, Aging of the male reproductive system, Exp Gerontol

35:1267, 2000.
88. **Bishop MW**, Ageing and reproduction in the male, J Reprod Fertil 12 (Suppl):65, 1970.
89. **Johnson L**, Spermatogenesis and aging in the human, J Androl 7:331, 1986.
90. **Zumoff B**, **Strain GW**, **Kream J**, **O'Connor J**, **Rosenfeld RS**, **Levin J**, **Fukushima DK**, Age variation of the 24-hour mean plasma concentrations of androgens, estrogens, and gonadotropins in normal adult men, J Clin Endocrinol Metab 54:534, 1982.
91. **Veldhuis JD**, Recent insights into neuroendocrine mechanisms of aging of the human male hypothalamic-pituitary-gonadal axis, J Androl 20:1, 1999.
92. **Goldman N**, **Montgomery M**, Fecundability and husband's age, Soc Biol 36:146, 1989.
93. **Martin RH**, **Spriggs E**, **Ko E**, **Rademaker AW**, The relationship between paternal age, sex ratios, and aneuploidy frequencies in human sperm, as assessed by multicolor FISH, Am J Hum Genet 57:1395, 1995.
94. **Egozcue J**, **Blanco J**, **Anton E**, **Egozcue S**, **Sarrate Z**, **Vidal F**, Genetic analysis of sperm and implications of severe male infertility—a review, Placenta 24(Suppl 2):S62, 2003.
95. **McInnes B**, **Rademaker A**, **Martin R**, Donor age and the frequency of disomy for chromosomes 1, 13, 21 and structural abnormalities in human spermatozoa using multicolour fluorescence in-situ hybridization, Hum Reprod 13:2489, 1998.
96. **Sartorelli EM**, **Mazzucatto LF**, **de Pina-Neto JM**, Effect of paternal age on human sperm chromosomes, Fertil Steril 76:1119, 2001.
97. **Bosch M**, **Rajmil O**, **Egozcue J**, **Templado C**, Linear increase of structural and numerical chromosome 9 abnormalities in human sperm regarding age, Eur J Hum Genet 11:754, 2003.
98. **Singh NP**, **Muller CH**, **Berger RE**, Effects of age on DNA double-strand breaks and apoptosis in human sperm, Fertil Steril 80:1420, 2003.
99. **Glaser RL**, **Broman KW**, **Schulman RL**, **Eskenazi B**, **Wyrobek AJ**, **Jabs EW**, The paternal-age effect in Apert syndrome is due, in part, to the increased frequency of mutations in sperm, Am J Hum Genet 73:939, 2003.
100. **Slama R**, **Werwatz A**, **Boutou O**, **Ducot B**, **Spira A**, **Hardle W**, Does male age affect the risk of spontaneous abortion? An approach using semiparametric regression, Am J Epidemiol 157:815, 2003.
101. **McIntosh GC**, **Olshan AF**, **Baird PA**, Paternal age and the risk of birth defects in offspring, Epidemiology 6:282, 1995.
102. **Olshan AF**, **Schnitzer PG**, **Baird PA**, Paternal age and the risk of congenital heart defects, Teratology 50:80, 1994.
103. **Olson JM**, **Breslow NE**, **Beckwith JB**, Wilms' tumour and parental age: a report from the National Wilms' Tumour Study, Br J Cancer 67:813, 1993.
104. **Zhu JL**, **Madsen KM**, **Vestergaard M**, **Olesen AV**, **Basso O**, **Olsen J**, Paternal age and congenital malformations, Hum Reprod 20:3173, 2005.
105. **Lian ZH**, **Zack MM**, **Erickson JD**, Paternal age and the occurrence of birth defects, Am J Hum Genet 39:648, 1986.
106. **Yang Q**, **Wen SW**, **Leader A**, **Chen XK**, **Lipson J**, **Walker M**, Paternal age and birth defects: how strong is the association? Hum Reprod 22:696, 2007.
107. **Auroux M**, [Age of the father and development], Contracept Fertil Sex 21:382, 1993.
108. **Tarin JJ**, **Brines J**, **Cano A**, Long-term effects of delayed parenthood, Hum Reprod 13:2371, 1998.
109. **Friedman JM**, Genetic disease in the offspring of older fathers, Obstet Gynecol 57:745, 1981.
110. **Malaspina D**, **Harlap S**, **Fennig S**, **Heiman D**, **Nahon D**, **Feldman D**, **Susser ES**, Advancing paternal age and the risk of schizophrenia, Arch Gen Psychiatry 58:361, 2001.
111. **Sipos A**, **Rasmussen F**, **Harrison G**, **Tynelius P**, **Lewis G**, **Leon DA**, **Gunnell D**, Paternal age and schizophrenia: a population based cohort study, Br Med J 329:1070, 2004.
112. **Tsuchiya KJ**, **Takagai S**, **Kawai M**, **Matsumoto H**, **Nakamura K**, **Minabe Y**, **Mori N**, **Takei N**, Advanced paternal age associated with an elevated risk for schizophrenia in offspring in a Japanese population, Schizophr Res 76:337, 2005.
113. **Perrin MC**, **Brown AS**, **Malaspina D**, Aberrant epigenetic regulation could explain the relationship of

paternal age to schizophrenia, Schizophr Bull 33:1270, 2007.
114. **Reichenberg A**, **Gross R**, **Weiser M**, **Bresnahan M**, **Silverman J**, **Harlap S**, **Rabinowitz J**, **Shulman C**, **Malaspina D**, **Lubin G**, **Knobler HY**, **Davidson M**, **Susser E**, Advancing paternal age and autism, Arch Gen Psychiatry 63:1026, 2006.
115. **Tsuchiya KJ**, **Matsumoto K**, **Miyachi T**, **Tsujii M**, **Nakamura K**, **Takagai S**, **Kawai M**, **Yagi A**, **Iwaki K**, **Suda S**, **Sugihara G**, **Iwata Y**, **Matsuzaki H**, **Sekine Y**, **Suzuki K**, **Sugiyama T**, **Mori N**, **Takei N**, Paternal age at birth and high-functioning autistic-spectrum disorder in offspring, Br J Psychiatry 193:316, 2008.
116. **Durkin MS**, **Maenner MJ**, **Newschaffer CJ**, **Lee LC**, **Cunniff CM**, **Daniels JL**, **Kirby RS**, **Leavitt L**, **Miller L**, **Zahorodny W**, **Schieve LA**, Advanced parental age and the risk of autism spectrum disorder, Am J Epidemiol 168:1268, 2008.
117. **Croen LA**, **Najjar DV**, **Fireman B**, **Grether JK**, Maternal and paternal age and risk of autism spectrum disorders, Arch Pediatr Adolesc Med 161:334, 2007.
118. **Lauritsen MB**, **Pedersen CB**, **Mortensen PB**, Effects of familial risk factors and place of birth on the risk of autism: a nationwide register-based study, J Child Psychol Psychiatry 46:963, 2005.
119. **American College of Obstetricians and Gynecologists**, ACOG committee opinion. Advanced paternal age: risks to the fetus. Number 189, October 1997. Committee on Genetics. American College of Obstetricians and Gynecologists, Int J Gynaecol Obstet 59:271, 1997.
120. **Erickson JD**, Paternal age and Down syndrome, Am J Hum Genet 31:489, 1979.
121. **Stene J**, **Fischer G**, **Stene E**, **Mikkelsen M**, **Petersen E**, Paternal age effect in Down's syndrome, Ann Hum Genet 40:299, 1977.
122. **Roth MP**, **Feingold J**, **Baumgarten A**, **Bigel P**, **Stoll C**, Reexamination of paternal age effect in Down's syndrome, Hum Genet 63:149, 1983.
123. **Hook EB**, **Regal RR**, A search for a paternal-age effect upon cases of 47, +21 in which the extra chromosome is of paternal origin, Am J Hum Genet 36:413, 1984.
124. **Sloter E**, **Nath J**, **Eskenazi B**, **Wyrobek AJ**, Effects of male age on the frequencies of germinal and heritable chromosomal abnormalities in humans and rodents, Fertil Steril 81:925, 2004.
125. **Yip BH**, **Pawitan Y**, **Czene K**, Parental age and risk of childhood cancers: a population-based cohort study from Sweden, Int J Epidemiol 35:1495, 2006.
126. **Slama R**, **Bouyer J**, **Windham G**, **Fenster L**, **Werwatz A**, **Swan SH**, Influence of paternal age on the risk of spontaneous abortion, Am J Epidemiol 161:816, 2005.
127. **Nybo Andersen AM**, **Hansen KD**, **Andersen PK**, **Davey Smith G**, Advanced paternal age and risk of fetal death: a cohort study, Am J Epidemiol 160:1214, 2004.
128. **Hatch M**, **Kline J**, **Levin B**, **Hutzler M**, **Warburton D**, Paternal age and trisomy among spontaneous abortions, Hum Genet 85:355, 1990.
129. **de la Rochebrochard E**, **Thonneau P**, Paternal age and maternal age are risk factors for miscarriage; results of a multicentre European study, Hum Reprod 17:1649, 2002.
130. **Olshan AF**, **Ananth CV**, **Savitz DA**, Intrauterine growth retardation as an endpoint in mutation epidemiology: an evaluation based on paternal age, Mutat Res 344:89, 1995.
131. **Chen XK**, **Wen SW**, **Krewski D**, **Fleming N**, **Yang Q**, **Walker MC**, Paternal age and adverse birth outcomes: teenager or 40+, who is at risk? Hum Reprod 23:1290, 2008.
132. **Astolfi P**, **De Pasquale A**, **Zonta LA**, Late paternity and stillbirth risk, Hum Reprod 19:2497, 2004.
133. **Harman SM**, **Metter EJ**, **Tobin JD**, **Pearson J**, **Blackman MR**, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging, J Clin Endocrinol Metab 86:724, 2001.
134. **Purifoy FE**, **Koopmans LH**, **Mayes DM**, Age differences in serum androgen levels in normal adult males, Hum Biol 53:499, 1981.
135. **Bremner WJ**, **Vitiello MV**, **Prinz PN**, Loss of circadian rhythmicity in blood testosterone levels with aging in normal men, J Clin Endocrinol Metab 56:1278, 1983.
136. **Wu FC**, **Tajar A**, **Pye SR**, **Silman AJ**, **Finn JD**, **O'Neill TW**, **Bartfai G**, **Casanueva F**, **Forti G**, **Giwercman A**, **Huhtaniemi IT**, **Kula K**, **Punab M**, **Boonen S**, **Vanderschueren D**, Hypothalamic-

pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study, J Clin Endocrinol Metab 93:2737, 2008.
137. **Travison TG**, **Araujo AB**, **Kupelian V**, **O'Donnell AB**, **McKinlay JB**, The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men, J Clin Endocrinol Metab 92:549, 2007.
138. **Morley JE**, **Kaiser FE**, **Perry HM III**, **Patrick P**, **Morley PM**, **Stauber PM**, **Vellas B**, **Baumgartner RN**, **Garry PJ**, Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men, Metabolism 46:410, 1997.
139. **Feldman HA**, **Longcope C**, **Derby CA**, **Johannes CB**, **Araujo AB**, **Coviello AD**, **Bremner WJ**, **McKinlay JB**, Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study, J Clin Endocrinol Metab 87:589, 2002.
140. **Couillard C**, **Gagnon J**, **Bergeron J**, **Leon AS**, **Rao DC**, **Skinner JS**, **Wilmore JH**, **Despres JP**, **Bouchard C**, Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study, J Clin Endocrinol Metab 85:1026, 2000.
141. **Araujo AB**, **Esche GR**, **Kupelian V**, **O'Donnell AB**, **Travison TG**, **Williams RE**, **Clark RV**, **McKinlay JB**, Prevalence of symptomatic androgen deficiency in men, J Clin Endocrinol Metab 92:4241, 2007.
142. **Davidson JM**, **Chen JJ**, **Crapo L**, **Gray GD**, **Greenleaf WJ**, **Catania JA**, Hormonal changes and sexual function in aging men, J Clin Endocrinol Metab 57:71, 1983.
143. **Kwan M**, **Greenleaf WJ**, **Mann J**, **Crapo L**, **Davidson JM**, The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men, J Clin Endocrinol Metab 57:557, 1983.
144. **Korenman SG**, **Morley JE**, **Mooradian AD**, **Davis SS**, **Kaiser FE**, **Silver AJ**, **Viosca SP**, **Garza D**, Secondary hypogonadism in older men: its relation to impotence, J Clin Endocrinol Metab 71:963, 1990.
145. **van den Beld AW**, **de Jong FH**, **Grobbee DE**, **Pols HA**, **Lamberts SW**, Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men, J Clin Endocrinol Metab 85:3276, 2000.
146. **Sternbach H**, Age-associated testosterone decline in men: clinical issues for psychiatry, Am J Psychiatry 155:1310, 1998.
147. **Janowsky JS**, **Oviatt SK**, **Orwoll ES**, Testosterone influences spatial cognition in older men, Behav Neurosci 108:325, 1994.
148. **Moffat SD**, **Zonderman AB**, **Metter EJ**, **Blackman MR**, **Harman SM**, **Resnick SM**, Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men, J Clin Endocrinol Metab 87:5001, 2002.
149. **Greendale GA**, **Edelstein S**, **Barrett-Connor E**, Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study, J Bone Miner Res 12:1833, 1997.
150. **Vermeulen A**, **Goemaere S**, **Kaufman JM**, Testosterone, body composition and aging, J Endocrinol Invest 22:110, 1999.
151. **Turner HE**, **Wass JA**, Gonadal function in men with chronic illness, Clin Endocrinol (Oxf) 47:379, 1997.
152. **Kupelian V**, **Page ST**, **Araujo AB**, **Travison TG**, **Bremner WJ**, **McKinlay JB**, Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men, J Clin Endocrinol Metab 91:843, 2006.
153. **Laaksonen DE**, **Niskanen L**, **Punnonen K**, **Nyyssonen K**, **Tuomainen TP**, **Valkonen VP**, **Salonen R**, **Salonen JT**, Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men, Diabetes Care 27:1036, 2004.
154. **Oh JY**, **Barrett-Connor E**, **Wedick NM**, **Wingard DL**, Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study, Diabetes Care 25:55, 2002.
155. **Laughlin GA**, **Barrett-Connor E**, **Bergstrom J**, Low serum testosterone and mortality in older men, J Clin Endocrinol Metab 93:68, 2008.
156. **Morley JE**, **Charlton E**, **Patrick P**, **Kaiser FE**, **Cadeau P**, **McCready D**, **Perry HM III**, Validation of a screening questionnaire for androgen deficiency in aging males, Metabolism 49:1239, 2000.
157. **Smith KW**, **Feldman HA**, **McKinlay JB**, Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men, Clin Endocrinol (Oxf) 53:703, 2000.

158. **T'Sjoen G**, **Goemaere S**, **De Meyere M**, **Kaufman JM**, Perception of males' aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels, Psychoneuroendocrinology 29:201, 2004.
159. **Tancredi A**, **Reginster JY**, **Schleich F**, **Pire G**, **Maassen P**, **Luyckx F**, **Legros JJ**, Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers, Eur J Endocrinol 151:355, 2004.
160. **Morley JE**, **Perry HM III**, **Kevorkian RT**, **Patrick P**, Comparison of screening questionnaires for the diagnosis of hypogonadism, Maturitas 53:424, 2006.
161. **Lin YC**, **Hwang TI**, **Chiang HS**, **Yang CR**, **Wu HC**, **Wu TL**, **Huang SP**, Correlations of androgen deficiency with clinical symptoms in Taiwanese males, Int J Impot Res 18:343, 2006.
162. **Bhasin S**, **Cunningham GR**, **Hayes FJ**, **Matsumoto AM**, **Snyder PJ**, **Swerdloff RS**, **Montori VM**, Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab 91:1995, 2006.
163. **Nilsson PM**, **Moller L**, **Solstad K**, Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males, J Intern Med 237:479, 1995.
164. **Vermeulen A**, **Verdonck L**, **Kaufman JM**, A critical evaluation of simple methods for the estimation of free testosterone in serum, J Clin Endocrinol Metab 84:3666, 1999.
165. **Swerdloff RS**, Proceedings of the Endocrine Society Andropause Consensus Conferences 2000–2001, In: The Endocrine Society Continuing Medical Education Series, January 31, 2002.
166. **Advisory Panel on Testosterone Replacement in Men**, Report of National Institute on aging advisory panel on testosterone replacement in men, J Clin Endocrinol Metab 86:4611, 2001.
167. **Morales A**, **Nolan J**, **Nelson J**, **Yen SS**, Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age, J Clin Endocrinol Metab 78:1360, 1994.
168. **Snyder PJ**, **Peachey H**, **Hannoush P**, **Berlin JA**, **Loh L**, **Lenrow DA**, **Holmes JH**, **Dlewati A**, **Santanna J**, **Rosen CJ**, **Strom BL**, Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age, J Clin Endocrinol Metab 84:2647, 1999.
169. **Kenny AM**, **Prestwood KM**, **Gruman CA**, **Marcello KM**, **Raisz LG**, Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, J Gerontol A Biol Sci Med Sci 56:M266, 2001.
170. **Amory JK**, **Watts NB**, **Easley KA**, **Sutton PR**, **Anawalt BD**, **Matsumoto AM**, **Bremner WJ**, **Tenover JL**, Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone, J Clin Endocrinol Metab 89:503, 2004.
171. **Page ST**, **Amory JK**, **Bowman FD**, **Anawalt BD**, **Matsumoto AM**, **Bremner WJ**, **Tenover JL**, Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T, J Clin Endocrinol Metab 90:1502, 2005.
172. **Bhasin S**, **Singh AB**, **Mac RP**, **Carter B**, **Lee MI**, **Cunningham GR**, Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan, J Androl 24:299, 2003.
173. **Calof OM**, **Singh AB**, **Lee ML**, **Kenny AM**, **Urban RJ**, **Tenover JL**, **Bhasin S**, Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials, J Gerontol A Biol Sci Med Sci 60:1451, 2005.
174. **Marks LS**, **Mazer NA**, **Mostaghel E**, **Hess DL**, **Dorey FJ**, **Epstein JI**, **Veltri RW**, **Makarov DV**, **Partin AW**, **Bostwick DG**, **Macairan ML**, **Nelson PS**, Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial, JAMA 296:2351, 2006.
175. **Matsumoto AM**, **Sandblom RE**, **Schoene RB**, **Lee KA**, **Giblin EC**, **Pierson DJ**, **Bremner WJ**, Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep, Clin Endocrinol (Oxf) 22:713, 1985.
176. **Schneider BK**, **Pickett CK**, **Zwillich CW**, **Weil JV**, **McDermott MT**, **Santen RJ**, **Varano LA**, **White DP**, Influence of testosterone on breathing during sleep, J Appl Physiol 61:618, 1986.
177. **Liu PY**, **Yee B**, **Wishart SM**, **Jimenez M**, **Jung DG**, **Grunstein RR**, **Handelsman DJ**, The short-term

effects of high-dose testosterone on sleep, breathing, and function in older men, J Clin Endocrinol Metab 88:3605, 2003.
178. **Hajjar RR**, **Kaiser FE**, **Morley JE**, Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis, J Clin Endocrinol Metab 82:3793, 1997.
179. **Whitsel EA**, **Boyko EJ**, **Matsumoto AM**, **Anawalt BD**, **Siscovick DS**, Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis, Am J Med 111:261, 2001.
180. **Spratt DI**, **Carr DB**, **Merriam GR**, **Scully RE**, **Rao PN**, **Crowley WF Jr**, The spectrum of abnormal patterns of gonadotropin-releasing hormone secretion in men with idiopathic hypogonadotropic hypogonadism: clinical and laboratory correlations, J Clin Endocrinol Metab 64:283, 1987.
181. **Santen RJ**, **Paulsen CA**, Hypogonadotropic eunuchoidism. I. Clinical study of the mode of inheritance, J Clin Endocrinol Metab 36:47, 1973.
182. **Lieblich JM**, **Rogol AD**, **White BJ**, **Rosen SW**, Syndrome of anosmia with hypogonadotropic hypogonadism (Kallmann syndrome): clinical and laboratory studies in 23 cases, Am J Med 73:506, 1982.
183. **Duke V**, **Quinton R**, **Gordon I**, **Bouloux PM**, **Woolf AS**, Proteinuria, hypertension and chronic renal failure in X-linked Kallmann's syndrome, a defined genetic cause of solitary functioning kidney, Nephrol Dial Transplant 13:1998, 1998.
184. **Bick D**, **Franco B**, **Sherin RJ**, **Heye B**, **Pike L**, **Crawford J**, **Maddalena A**, **Incerti B**, **Pragliola A**, **Meitinger T**, **Ballabio A**, Brief report: intragenic deletion of the KALIG-1 gene in Kallmann's syndrome, N Engl J Med 326:1752, 1992.
185. **Hardelin J-P**, **Levilliers J**, **Young J**, **Pholsena M**, **Legouis R**, **Kirk J**, **Boulooux P**, **Petit C**, **Schaison G**, Xp22.3 deletions in isolated familial Kallmann's syndrome, J Clin Endocrinol Metab 76:827, 1993.
186. **Sato N**, **Katsumata N**, **Kagami M**, **Hasegawa T**, **Hori N**, **Kawakita S**, **Minowada S**, **Shimotsuka A**, **Shishiba Y**, **Yokozawa M**, **Yasuda T**, **Nagasaki K**, **Hasegawa D**, **Hasegawa Y**, **Tachibana K**, **Naiki Y**, **Horikawa R**, **Tanaka T**, **Ogata T**, Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients, J Clin Endocrinol Metab 89:1079, 2004.
187. **Dode C**, **Levilliers J**, **Dupont JM**, **De Paepe A**, **Le Du N**, **Soussi-Yanicostas N**, **Coimbra RS**, **Delmaghani S**, **Compain-Nouaille S**, **Baverel F**, **Pecheux C**, **Le Tessier D**, **Cruaud C**, **Delpech M**, **Speleman F**, **Vermeulen S**, **Amalfitano A**, **Bachelot Y**, **Bouchard P**, **Cabrol S**, **Carel JC**, **Delemarre-van de Waal H**, **Goulet-Salmon B**, **Kottler ML**, **Richard O**, **Sanchez-Franco F**, **Saura R**, **Young J**, **Petit C**, **Hardelin JP**, Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome, Nat Genet 33:463, 2003.
188. **de Roux N**, **Young J**, **Brailly-Tabard S**, **Misrahi M**, **Milgrom E**, **Schaison G**, The same molecular defects of the gonadotropin-releasing hormone receptor determine a variable degree of hypogonadism in affected kindred, J Clin Endocrinol Metab 84:567, 1999.
189. **Valdes-Socin H**, **Salvi R**, **Daly AF**, **Gaillard RC**, **Quatresooz P**, **Tebeu PM**, **Pralong FP**, **Beckers A**, Hypogonadism in a patient with a mutation in the luteinizing hormone beta-subunit gene, N Engl J Med 351:2619, 2004.
190. **Lofrano-Porto A**, **Barra GB**, **Giacomini LA**, **Nascimento PP**, **Latronico AC**, **Casulari LA**, **da Rocha Neves Fde A**, Luteinizing hormone beta mutation and hypogonadism in men and women, N Engl J Med 357:897, 2007.
191. **Bhangoo AP**, **Hunter CS**, **Savage JJ**, **Anhalt H**, **Pavlakis S**, **Walvoord EC**, **Ten S**, **Rhodes SJ**, Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency, J Clin Endocrinol Metab 91:747, 2006.
192. **Cohen RN**, **Cohen LE**, **Botero D**, **Yu C**, **Sagar A**, **Jurkiewicz M**, **Radovick S**, Enhanced repression by HESX1 as a cause of hypopituitarism and septooptic dysplasia, J Clin Endocrinol Metab 88:4832, 2003.
193. **Wu W**, **Cogan JD**, **Pfaffle RW**, **Dasen JS**, **Frisch H**, **O'Connell SM**, **Flynn SE**, **Brown MR**, **Mullis PE**, **Parks JS**, **Phillips JA III**, **Rosenfeld MG**, Mutations in PROP1 cause familial combined pituitary hormone deficiency, Nat Genet 18:147, 1998.
194. **Siemons LJ**, **Mahler CH**, Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive

function after iron depletion, J Clin Endocrinol Metab 65:585, 1987.
195. **Cundy T**, **Butler J**, **Bomford A**, **Williams R**, Reversibility of hypogonadotropic hypogonadism associated with genetic haemochromatosis, Clin Endocrinol (Oxf) 38:617, 1993.
196. **Carter JN**, **Tyson JE**, **Tolis G**, **Van Vliet S**, **Faiman C**, **Friesen HG**, Prolactin-screening tumors and hypogonadism in 22 men, N Engl J Med 299:847, 1978.
197. **World Health Organization**, Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men, Fertil Steril 65:821, 1996.
198. **MacAdams MR**, **White RH**, **Chipps BE**, Reduction of serum testosterone levels during chronic glucocorticoid therapy, Ann Intern Med 104:648, 1986.
199. **Abs R**, **Verhelst J**, **Maeyaert J**, **Van Buyten JP**, **Opsomer F**, **Adriaensen H**, **Verlooy J**, **Van Havenbergh T**, **Smet M**, **Van Acker K**, Endocrine consequences of long-term intrathecal administration of opioids, J Clin Endocrinol Metab 85:2215, 2000.
200. **Finch PM**, **Roberts LJ**, **Price L**, **Hadlow NC**, **Pullan PT**, Hypogonadism in patients treated with intrathecal morphine, Clin J Pain 16:251, 2000.
201. **Bliesener N**, **Albrecht S**, **Schwager A**, **Weckbecker K**, **Lichtermann D**, **Klingmuller D**, Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence, J Clin Endocrinol Metab 90:203, 2005.
202. **Spratt DI**, **Cox P**, **Orav J**, **Moloney J**, **Bigos T**, Reproductive axis suppression in acute illness is related to disease severity, J Clin Endocrinol Metab 76:1548, 1993.
203. **Schneider HJ**, **Kreitschmann-Andermahr I**, **Ghigo E**, **Stalla GK**, **Agha A**, Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review, JAMA 298:1429, 2007.
204. **Flannery MT**, **Pattani S**, **Wallach PM**, **Warner E**, Case report: hypothalamic tuberculoma associated with secondary panhypopituitarism, Am J Med Sci 306:101, 1993.
205. **Isidori AM**, **Caprio M**, **Strollo F**, **Moretti C**, **Frajese G**, **Isidori A**, **Fabbri A**, Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels, J Clin Endocrinol Metab 84:3673, 1999.
206. **Allen NE**, **Appleby PN**, **Davey GK**, **Key TJ**, Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men, Cancer Causes Control 13:353, 2002.
207. **Gapstur SM**, **Gann PH**, **Kopp P**, **Colangelo L**, **Longcope C**, **Liu K**, Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study, Cancer Epidemiol Biomarkers Prev 11:1041, 2002.
208. **Jensen TK**, **Andersson AM**, **Jorgensen N**, **Andersen AG**, **Carlsen E**, **Petersen JH**, **Skakkebaek NE**, Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men, Fertil Steril 82:863, 2004.
209. **Tsai EC**, **Matsumoto AM**, **Fujimoto WY**, **Boyko EJ**, Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat, Diabetes Care 27:861, 2004.
210. **Schwartz ID**, **Root AW**, The Klinefelter syndrome of testicular dysgenesis, Endocrinol Metab Clin North Am 20:153, 1991.
211. **Bojesen A**, **Juul S**, **Gravholt CH**, Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study, J Clin Endocrinol Metab 88:622, 2003.
212. **Paulsen CA**, **Gordon DL**, **Carpenter RW**, **Gandy HM**, **Drucker WD**, Klinefelter's syndrome and its variants: a hormonal and chromosomal study, Recent Prog Horm Res 24:321, 1968.
213. **Zitzmann M**, **Depenbusch M**, **Gromoll J**, **Nieschlag E**, X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients, J Clin Endocrinol Metab 89:6208, 2004.
214. **Zinn AR**, **Ramos P**, **Elder FF**, **Kowal K**, **Samango-Sprouse C**, **Ross JL**, Androgen receptor CAGn repeat length influences phenotype of 47,XXY (Klinefelter) syndrome, J Clin Endocrinol Metab 90:5041, 2005.
215. **Wang C**, **Baker HW**, **Burger HG**, **De Kretser DM**, **Hudson B**, Hormonal studies in Klinefelter's

syndrome, Clin Endocrinol (Oxf) 4:399, 1975.
216. **Ferlin A**, **Zuccarello D**, **Zuccarello B**, **Chirico MR**, **Zanon GF**, **Foresta C**, Genetic alterations associated with cryptorchidism, JAMA 300:2271, 2008.
217. **Bender BG**, **Linden MG**, **Robinson A**, Neuropsychological impairment in 42 adolescents with sex chromosome abnormalities, Am J Med Genet 48:169, 1993.
218. **Simm PJ**, **Zacharin MR**, The psychosocial impact of Klinefelter syndrome—a 10 year review, J Pediatr Endocrinol Metab 19:499, 2006.
219. **Ross JL**, **Roeltgen DP**, **Stefanatos G**, **Benecke R**, **Zeger MP**, **Kushner H**, **Ramos P**, **Elder FF**, **Zinn AR**, Cognitive and motor development during childhood in boys with Klinefelter syndrome, Am J Med Genet A 146A:708, 2008.
220. **Weiss JR**, **Moysich KB**, **Swede H**, Epidemiology of male breast cancer, Cancer Epidemiol Biomarkers Prev 14:20, 2005.
221. **Volkl TM**, **Simm D**, **Beier C**, **Dorr HG**, Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, Pediatrics 117:e98, 2006.
222. **Campbell WA**, **Newton MS**, **Price WH**, Hypostatic leg ulceration and Klinefelter's syndrome, J Ment Defic Res 24:115, 1980.
223. **Scofield RH**, **Bruner GR**, **Namjou B**, **Kimberly RP**, **Ramsey-Goldman R**, **Petri M**, **Reveille JD**, **Alarcon GS**, **Vila LM**, **Reid J**, **Harris B**, **Li S**, **Kelly JA**, **Harley JB**, Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome, Arthritis Rheum 58:2511, 2008.
224. **Bojesen A**, **Juul S**, **Birkebaek NH**, **Gravholt CH**, Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses, J Clin Endocrinol Metab 91:1254, 2006.
225. **Simpson JL**, Male pseudohermaphroditism: genetics and clinical delineation, Hum Genet 44:1, 1978.
226. **Ferlin A**, **Arredi B**, **Speltra E**, **Cazzadore C**, **Selice R**, **Garolla A**, **Lenzi A**, **Foresta C**, Molecular and clinical characterization of Y chromosome microdeletions in infertile men: a 10-year experience in Italy, J Clin Endocrinol Metab 92:762, 2007.
227. **Mascarenhas M**, **Thomas S**, **Kamath MS**, **Ramalingam R**, **Kongari AM**, **Yuvarani S**, **Srivastava VM**, **George K**, Prevalence of chromosomal abnormalities and Y chromosome microdeletion among men with severe semen abnormalities and its correlation with successful sperm retrieval, J Hum Reprod Sci 9:187, 2016.
228. **Kuroda-Kawaguchi T**, **Skaletsky H**, **Brown LG**, **Minx PJ**, **Cordum HS**, **Waterston RH**, **Wilson RK**, **Silber S**, **Oates R**, **Rozen S**, **Page DC**, The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men, Nat Genet 29:279, 2001.
229. **Krausz C**, **Degl'Innocenti S**, Y chromosome and male infertility: update, 2006, Front Biosci 11:3049, 2006.
230. **Luddi A**, **Margollicci M**, **Gambera L**, **Serafini F**, **Cioni M**, **De Leo V**, **Balestri P**, **Piomboni P**, Spermatogenesis in a man with complete deletion of USP9Y, N Engl J Med 360:881, 2009.
231. **Tyler-Smith C**, **Krausz C**, The will-o'-the-wisp of genetics–hunting for the azoospermia factor gene, N Engl J Med 360:925, 2009.
232. **Krausz C**, **Quintana-Murci L**, **Barbaux S**, **Siffroi JP**, **Rouba H**, **Delafontaine D**, **Souleyreau-Therville N**, **Arvis G**, **Antoine JM**, **Erdei E**, **Taar JP**, **Tar A**, **Jeandidier E**, **Plessis G**, **Bourgeron T**, **Dadoune JP**, **Fellous M**, **McElreavey K**, A high frequency of Y chromosome deletions in males with nonidiopathic infertility, J Clin Endocrinol Metab 84:3606, 1999.
233. **Foresta C**, **Moro E**, **Garolla A**, **Onisto M**, **Ferlin A**, Y chromosome microdeletions in cryptorchidism and idiopathic infertility, J Clin Endocrinol Metab 84:3660, 1999.
234. **McLachlan RI**, **Aitken RJ**, **Cram D**, **Krausz C**, **O'Bryan M**, Need for standardization and confirmation of STS deletions on the Y chromosome, Fertil Steril 90:463, 2008.
235. **Aiman J**, **Griffin JE**, **Gazak JM**, **Wilson JD**, **MacDonald PC**, Androgen insensitivity as a cause of infertility in otherwise normal men, N Engl J Med 300:223, 1979.
236. **Griffin JE**, Androgen resistance—the clinical and molecular spectrum, N Engl J Med 326:611, 1992.
237. **von Eckardstein S**, **Syska A**, **Gromoll J**, **Kamischke A**, **Simoni M**, **Nieschlag E**, Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men, J Clin Endocrinol

Metab 86:2585, 2001.
238. **Wallerand H**, **Remy-Martin A**, **Chabannes E**, **Bermont L**, **Adessi GL**, **Bittard H**, Relationship between expansion of the CAG repeat in exon 1 of the androgen receptor gene and idiopathic male infertility, Fertil Steril 76:769, 2001.
239. **Casella R**, **Maduro MR**, **Misfud A**, **Lipshultz LI**, **Yong EL**, **Lamb DJ**, Androgen receptor gene polyglutamine length is associated with testicular histology in infertile patients, J Urol 169:224, 2003.
240. **Dowsing AT**, **Yong EL**, **Clark M**, **McLachlan RI**, **de Kretser DM**, **Trounson AO**, Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene, Lancet 354:640, 1999.
241. **Rajpert-De Meyts E**, **Leffers H**, **Petersen JH**, **Andersen AG**, **Carlsen E**, **Jorgensen N**, **Skakkebaek NE**, CAG repeat length in androgen-receptor gene and reproductive variables in fertile and infertile men, Lancet 359:44, 2002.
242. **Davis-Dao CA**, **Tuazon ED**, **Sokol RZ**, **Cortessis VK**, Male infertility and variation in CAG repeat length in the androgen receptor gene: a meta-analysis, J Clin Endocrinol Metab 92:4319, 2007.
243. **Hess RA**, **Bunick D**, **Lee KH**, **Bahr J**, **Taylor JA**, **Korach KS**, **Lubahn DB**, A role for oestrogens in the male reproductive system, Nature 390:509, 1997.
244. **Smith EP**, **Boyd J**, **Frank GR**, **Takahashi H**, **Cohen RM**, **Specker B**, **Williams TC**, **Lubahn DB**, **Korach KS**, Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man, N Engl J Med 331:1056, 1994.
245. **Robertson KM**, **O'Donnell L**, **Jones ME**, **Meachem SJ**, **Boon WC**, **Fisher CR**, **Graves KH**, **McLachlan RI**, **Simpson ER**, Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene, Proc Natl Acad Sci U S A 96:7986, 1999.
246. **Nuti F**, **Krausz C**, Gene polymorphisms/mutations relevant to abnormal spermatogenesis, Reprod Biomed Online 16:504, 2008.
247. **Simoni M**, **Gromoll J**, **Hoppner W**, **Kamischke A**, **Krafft T**, **Stahle D**, **Nieschlag E**, Mutational analysis of the follicle-stimulating hormone (FSH) receptor in normal and infertile men: identification and characterization of two discrete FSH receptor isoforms, J Clin Endocrinol Metab 84:751, 1999.
248. **Takeda R**, **Ueda M**, Pituitary-gonadal function in male patients with myotonic dystrophy- serum luteinizing hormone, follicle stimulating hormone and testosterone levels and histological damage of the testis, Acta Endocrinol (Copenh) 84:382, 1977.
249. **Teng YN**, **Lin YM**, **Lin YH**, **Tsao SY**, **Hsu CC**, **Lin SJ**, **Tsai WC**, **Kuo PL**, Association of a single-nucleotide polymorphism of the deleted-in-azoospermia-like gene with susceptibility to spermatogenic failure, J Clin Endocrinol Metab 87:5258, 2002.
250. **Teng YN**, **Lin YM**, **Sun HF**, **Hsu PY**, **Chung CL**, **Kuo PL**, Association of DAZL haplotypes with spermatogenic failure in infertile men, Fertil Steril 86:129, 2006.
251. **Becherini L**, **Guarducci E**, **Degl'Innocenti S**, **Rotondi M**, **Forti G**, **Krausz C**, DAZL polymorphisms and susceptibility to spermatogenic failure: an example of remarkable ethnic differences, Int J Androl 27:375, 2004.
252. **Tung JY**, **Rosen MP**, **Nelson LM**, **Turek PJ**, **Witte JS**, **Cramer DW**, **Cedars MI**, **Pera RA**, Variants in Deleted in AZoospermia-Like (DAZL) are correlated with reproductive parameters in men and women, Hum Genet 118:730, 2006.
253. **Tung JY**, **Rosen MP**, **Nelson LM**, **Turek PJ**, **Witte JS**, **Cramer DW**, **Cedars MI**, **Reijo-Pera RA**, Novel missense mutations of the Deleted-in-AZoospermia-Like (DAZL) gene in infertile women and men, Reprod Biol Endocrinol 4:40, 2006.
254. **Tal R**, **Holland R**, **Belenky A**, **Konichezky M**, **Baniel J**, Incidental testicular tumors in infertile men, Fertil Steril 82:469, 2004.
255. **Raman JD**, **Nobert CF**, **Goldstein M**, Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis, J Urol 174:1819, 2005.
256. **Rajfer J**, **Handelsman DJ**, **Swerdloff RS**, **Hurwitz R**, **Kaplan H**, **Vandergast T**, **Ehrlich RM**, Hormonal therapy of cryptorchidism. A randomized, double-blind study comparing human chorionic gonadotropin and gonadotropin-releasing hormone, N Engl J Med 314:466, 1986.
257. **Lee PA**, **Coughlin MT**, **Bellinger MF**, Inhibin B: comparison with indexes of fertility among formerly

cryptorchid and control men, J Clin Endocrinol Metab 86:2576, 2001.
258. **Romeo C**, **Santoro G**, Varicocele and infertility: why a prevention? J Endocrinol Invest 32:559, 2009.
259. **Pryor JL**, **Howards SS**, Varicocele, Urol Clin North Am 14:499, 1987.
260. **Saypol DC**, **Howards SS**, **Turner TT**, **Miller ED Jr**, Influence of surgically induced varicocele on testicular blood flow, temperature, and histology in adult rats and dogs, J Clin Invest 68:39, 1981.
261. **Mieusset R**, **Bujan L**, **Mondinat C**, **Mansat A**, **Pontonnier F**, **Grandjean H**, Association of scrotal hyperthermia with impaired spermatogenesis in infertile men, Fertil Steril 48:1006, 1987.
262. **Beard CM**, **Benson RC Jr**, **Kelalis PP**, **Elveback LR**, **Kurland LT**, The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974, Mayo Clin Proc 52:3, 1977.
263. **Adamopoulos DA**, **Lawrence DM**, **Vassilopoulos P**, **Contoyiannis PA**, **Swyer GI**, Pituitary-testicular interrelationships in mumps orchitis and other viral infections, Br Med J 1:1177, 1978.
264. **Morley JE**, **Distiller LA**, **Sagel J**, **Kok SH**, **Kay G**, **Carr P**, **Katz M**, Hormonal changes associated with testicular atrophy and gynaecomastia in patients with leprosy, Clin Endocrinol (Oxf) 6:299, 1977.
265. **Krieger JN**, **Coombs RW**, **Collier AC**, **Koehler JK**, **Ross SO**, **Chaloupka K**, **Murphy VL**, **Corey L**, Fertility parameters in men infected with human immunodeficiency virus, J Infect Dis 164:464, 1991.
266. **Umapathy E**, STD/HIV association: effects on semen characteristics, Arch Androl 51:361, 2005.
267. **Gazvani MR**, **Buckett W**, **Luckas MJM**, **Aird IA**, **Hipkin LJ**, **Lewis-Jones DI**, Conservative management of azoospermia following steroid abuse, Hum Reprod 12:1706, 1997.
268. **Rowley MJ**, **Leach DR**, **Warner GA**, **Heller CG**, Effect of graded doses of ionizing radiation on the human testis, Radiat Res 59:665, 1974.
269. **Kandeel FR**, **Swerdloff RS**, Role of temperature in regulation of spermatogenesis and the use of heating as a method for contraception, Fertil Steril 49:1, 1988.
270. **Smith CG**, **Asch RH**, Drug abuse and reproduction, Fertil Steril 48:355, 1987.
271. **Bracken MB**, **Eskenazi B**, **Sachse K**, **McSharry J-E**, **Hellenbrand K**, **Leon-Summers L**, Association of cocaine use with sperm concentration, motility, and morphology, Fertil Steril 53:315, 1990.
272. **Kunzle R**, **Mueller MD**, **Hanggi W**, **Birkhauser MH**, **Drescher H**, **Bersinger NA**, Semen quality of male smokers and nonsmokers in infertile couples, Fertil Steril 79:287, 2003.
273. **Spratt DI**, **Bigos ST**, **Beitins I**, **Cox P**, **Longcope C**, **Orav J**, Both hyper- and hypogonadotropic hypogonadism occur transiently in acute illness: bio- and immunoactive gonadotropins, J Clin Endocrinol Metab 75:1562, 1992.
274. **Handelsman DJ**, **Dong Q**, Hypothalamo-pituitary gonadal axis in chronic renal failure, Endocrinol Metab Clin North Am 22:145, 1993.
275. **Smith SR**, **Chhetri MK**, **Johanson J**, **Radfar N**, **Migeon CJ**, The pituitary-gonadal axis in men with protein-calorie malnutrition, J Clin Endocrinol Metab 41:60, 1975.
276. **Stillman RJ**, In utero exposure to diethylstilbestrol: adverse effects on the reproductive tract and reproductive performance in male and female offspring, Am J Obstet Gynecol 142:905, 1982.
277. **Patrizio P**, **Asch RH**, **Handelin B**, **Silber SJ**, Aetiology of congenital absence of vas deferens: genetic study of three generations, Hum Reprod 8:215, 1993.
278. **Munro NC**, **Currie DC**, **Lindsay KS**, **Ryder TA**, **Rutman A**, **Dewar A**, **Greenstone MA**, **Hendry WF**, **Cole PJ**, Fertility in men with primary ciliary dyskinesia presenting with respiratory infection, Thorax 49:684, 1994.
279. **Zariwala MA**, **Knowles MR**, **Omran H**, Genetic defects in ciliary structure and function, Annu Rev Physiol 69:423, 2007.
280. **Wilton LJ**, **Teichtahl H**, **Temple-Smith PD**, **Johnson JL**, **Southwick GJ**, **Burger HG**, **de Kretser DM**, Young's syndrome (obstructive azoospermia and chronic sinobronchial infection): a quantitative study of axonemal ultrastructure and function, Fertil Steril 55:144, 1991.
281. **Ichioka K**, **Kohei N**, **Okubo K**, **Nishiyama H**, **Terai A**, Obstructive azoospermia associated with chronic sinopulmonary infection and situs inversus totalis, Urology 68:204.e5, 2006.
282. **American Society for Reproductive Medicine**, Report on optimal evaluation of the infertile male, Fertil Steril 86:S202, 2006.

283. **Lee PA**, Fertility in cryptorchidism. Does treatment make a difference? Endocrinol Metab Clin North Am 22:479, 1993.
284. **Sheynkin YR**, **Hendin BN**, **Schlegel PN**, **Goldstein M**, Microsurgical repair of iatrogenic injury to the vas deferens, J Urol 159:139, 1998.
285. **Poland ML**, **Moghissi KS**, **Giblin PT**, **Ager JW**, **Olson JM**, Variation of semen measures within normal men, Fertil Steril 44:396, 1985.
286. **Mallidis C**, **Howard EJ**, **Baker HW**, Variation of semen quality in normal men, Int J Androl 14:99, 1991.
287. **Sherins RJ**, **Brightwell D**, **Sternthal PM**, Longitudinal analysis of semen of fertile and infertile men, In: Troen P, Nankin R, eds. The Testis in Normal and Infertile Men, Raven Press, New York, 1977, p. 473.
288. **Tielemans E**, **Heederik D**, **Burdorf A**, **Loomis D**, **Habbema DF**, Intraindividual variability and redundancy of semen parameters, Epidemiology 8:99, 1997.
289. **Chen Z**, **Toth T**, **Godfrey-Bailey L**, **Mercedat N**, **Schiff I**, **Hauser R**, Seasonal variation and age-related changes in human semen parameters, J Androl 24:226, 2003.
290. **Gyllenborg J**, **Skakkebaek NE**, **Nielsen NC**, **Keiding N**, **Giwercman A**, Secular and seasonal changes in semen quality among young Danish men: a statistical analysis of semen samples from 1927 donor candidates during 1977–1995, Int J Androl 22:28, 1999.
291. **Andolz P**, **Bielsa MA**, **Andolz A**, Circannual variation in human semen parameters, Int J Androl 24:266, 2001.
292. **Tyler JP**, **Crockett NG**, **Driscoll GL**, Studies of human seminal parameters with frequent ejaculation. I. Clinical characteristics, Clin Reprod Fertil 1:273, 1982.
293. **Pellestor F**, **Girardet A**, **Andreo B**, Effect of long abstinence periods on human sperm quality, Int J Fertil Menopausal Stud 39:278, 1994.
294. **MacLeod J**, **Gold RA**, The male factor in fertility and infertility. II. Spermatozoan counts in 1000 cases of known fertility and 1000 cases of infertile marriage, J Urol 66:436, 1951.
295. **MacLeod J**, **Gold RZ**, The male factor in fertility and infertility. III. An analysis of motile activity in the spermatozoa of 1,000 fertile men and 1,000 men in infertile marriage, Fertil Steril 2:187, 1951.
296. **MacLeod J**, **Gold RZ**, The male factor in fertility and infertility. IV. Sperm morphology in fertile and infertile marriage, Fertil Steril 2:394, 1951.
297. **Guzick DS**, **Overstreet JW**, **Factor-Litvak P**, **Brazil CK**, **Nakajima ST**, **Coutifaris C**, **Carson SA**, **Cisneros P**, **Steinkampf MP**, **Hill JA**, **Xu D**, **Vogel DL**, Sperm morphology, motility, and concentration in fertile and infertile men, N Engl J Med 345:1388, 2001.
298. **Bonde JP**, **Ernst E**, **Jensen TK**, **Hjollund NH**, **Kolstad H**, **Henriksen TB**, **Scheike T**, **Giwercman A**, **Olsen J**, **Skakkebaek NE**, Relation between semen quality and fertility: a population-based study of 430 first-pregnancy planners, Lancet 352:1172, 1998.
299. **Jorgensen N**, **Andersen AG**, **Eustache F**, **Irvine DS**, **Suominen J**, **Petersen JH**, **Andersen AN**, **Auger J**, **Cawood EH**, **Horte A**, **Jensen TK**, **Jouannet P**, **Keiding N**, **Vierula M**, **Toppari J**, **Skakkebaek NE**, Regional differences in semen quality in Europe, Hum Reprod 16:1012, 2001.
300. **Swan SH**, **Brazil C**, **Drobnis EZ**, **Liu F**, **Kruse RL**, **Hatch M**, **Redmon JB**, **Wang C**, **Overstreet JW**, Geographic differences in semen quality of fertile U.S. males, Environ Health Perspect 111:414, 2003.
301. **Cooper TG**, **Neuwinger J**, **Bahrs S**, **Nieschlag E**, Internal quality control of semen analysis, Fertil Steril 58:172, 1992.
302. **McLachlan RI**, **Baker HW**, **Clarke GN**, **Harrison KL**, **Matson PL**, **Holden CA**, **de Kretser DM**, Semen analysis: its place in modern reproductive medical practice, Pathology 35:25, 2003.
303. **World Health Organization**, Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 2nd ed, Cambridge University Press, Cambridge, 1987.
304. **World Health Organization**, Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 3rd ed, Cambridge University Press, Cambridge, 1992.
305. **World Health Organization**, Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 4th ed, Cambridge University Press, Cambridge, 1999.
306. **Cooper TG**, **Noonan E**, **von Eckardstein S**, **Auger J**, **Baker HW**, **Behre HM**, **Haugen TB**, **Kruger T**,

Wang C, **Mbizvo MT**, **Vogelsong KM**, World Health Organization reference values for human semen characteristics, Hum Reprod Update 16:231, 2010.

307. **Sharlip ID**, **Jarow JP**, **Belker AM**, **Lipshultz LI**, **Sigman M**, **Thomas AJ**, **Schlegel PN**, **Howards SS**, **Nehra A**, **Damewood MD**, **Overstreet JW**, **Sadovsky R**, Best practice policies for male infertility, Fertil Steril 77:873, 2002.
308. **Weiske WH**, **Salzler N**, **Schroeder-Printzen I**, **Weidner W**, Clinical findings in congenital absence of the vasa deferentia, Andrologia 32:13, 2000.
309. **Daudin M**, **Bieth E**, **Bujan L**, **Massat G**, **Pontonnier F**, **Mieusset R**, Congenital bilateral absence of the vas deferens: clinical characteristics, biological parameters, cystic fibrosis transmembrane conductance regulator gene mutations, and implications for genetic counseling, Fertil Steril 74:1164, 2000.
310. **Dohle GR**, Inflammatory-associated obstructions of the male reproductive tract, Andrologia 35:321, 2003.
311. **Ozgok Y**, **Tan MO**, **Kilciler M**, **Tahmaz L**, **Kibar Y**, Diagnosis and treatment of ejaculatory duct obstruction in male infertility, Eur Urol 39:24, 2001.
312. **Paick J**, **Kim SH**, **Kim SW**, Ejaculatory duct obstruction in infertile men, BJU Int 85:720, 2000.
313. **Willott GM**, Frequency of azoospermia, Forensic Sci Int 20:9, 1982.
314. **Jarow JP**, **Espeland MA**, **Lipshultz LI**, Evaluation of the azoospermic patient, J Urol 142:62, 1989.
315. **Silber SJ**, **Nagy Z**, **Devroey P**, **Tournaye H**, **Van Steirteghem AC**, Distribution of spermatogenesis in the testicles of azoospermic men: the presence or absence of spermatids in the testes of men with germinal failure, Hum Reprod 12:2422, 1997.
316. **Ron-El R**, **Strassburger D**, **Friedler S**, **Komarovski D**, **Bern O**, **Soffer Y**, **Raziel A**, Extended sperm preparation: an alternative to testicular sperm extraction in non-obstructive azoospermia, Hum Reprod 12:1222, 1997.
317. **Ombelet W**, **Bosmans E**, **Janssen M**, **Cox A**, **Vlasselaer J**, **Gyselaers W**, **Vandeput H**, **Gielen J**, **Pollet H**, **Maes M**, **Steeno O**, **Kruger T**, Semen parameters in a fertile versus subfertile population: a need for change in the interpretation of semen testing, Hum Reprod 12:987, 1997.
318. **Carlsen E**, **Giwercman A**, **Keidin N**, **Skakkebaek NE**, Evidence for decreasing quality of semen during past 50 years, Br Med J 305:609, 1992.
319. **Auger J**, **Kunstmann JM**, **Czyglik F**, **Jouannet P**, Decline in semen quality among fertile men in Paris during the last 20 years, N Engl J Med 332:281, 1995.
320. **Sherins RJ**, Are semen quality and male infertility changing? N Engl J Med 332:327, 1995.
321. **Fisch H**, **Goluboff ET**, **Olson JH**, **Feldshuh J**, **Broder SH**, **Barad DH**, Semen analysis in 1283 men from the United States over a 25-year period: no decline in quality, Fertil Steril 65:1009, 1996.
322. **Paulsen CA**, **Berman NG**, **Wang C**, Data from men in greater Seattle area reveals no downward trend in semen quality: further evidence that deterioration of semen quality is not geographically uniform, Fertil Steril 65:1015, 1996.
323. **Rasmussen PE**, **Erb K**, **Westergaard LG**, **Laursen ST**, No evidence for decreasing semen quality in four birth cohorts of 1,055 Danish men born between 1950 and 1970, Fertil Steril 68:1059, 1997.
324. **Benshushan A**, **Shoshani O**, **Paltiel O**, **Schenker JG**, **Lewin A**, Is there really a decrease in sperm parameters among healthy young men? A survey of sperm donations during 15 years, J Assist Reprod Genet 14:347, 1997.
325. **Andolz P**, **Bielsa MA**, **Vila J**, Evolution of semen quality in North-eastern Spain: a study in 22,759 infertile men over a 36 year period, Hum Reprod 14: 731, 1999.
326. **Miller DC**, **Hollenbeck BK**, **Smith GD**, **Randolph JF**, **Christman GM**, **Smith YR**, **Lebovic DI**, **Ohl DA**, Processed total motile sperm count correlates with pregnancy outcome after intrauterine insemination, Urology 60:497, 2002.
327. **Pasqualotto EB**, **Daitch JA**, **Hendin BN**, **Falcone T**, **Thomas AJ Jr**, **Nelson DR**, **Agarwal A**, Relationship of total motile sperm count and percentage motile sperm to successful pregnancy rates following intrauterine insemination, J Assist Reprod Genet 16:476, 1999.
328. **Van Voorhis BJ**, **Barnett M**, **Sparks AE**, **Syrop CH**, **Rosenthal G**, **Dawson J**, Effect of the total motile sperm count on the efficacy and cost-effectiveness of intrauterine insemination and in vitro fertilization, Fertil

Steril 75:661, 2001.
329. **Berg U**, **Brucker C**, **Berg FD**, Effect of motile sperm count after swim-up on outcome of intrauterine insemination, Fertil Steril 67:747, 1997.
330. **Branigan EF**, **Estes MA**, **Muller CH**, Advanced semen analysis: a simple screening test to predict intrauterine insemination success, Fertil Steril 71:547, 1999.
331. **Casper RF**, **Meriano JS**, **Jarvi KA**, **Cowen L**, **Lucato ML**, The hypo-osmotic swelling test for selection of viable sperm for intracytoplasmic sperm injection in men with complete asthenozoospermia, Fertil Steril 65:972, 1996.
332. **Kruger TF**, **Acosta AA**, **Simmons KF**, **Swanson RJ**, **Matta JF**, **Oehninger S**, Predictive value of abnormal sperm morphology in in vitro fertilization, Fertil Steril 49:112, 1988.
333. **Menkveld R**, **Stander FS**, **Kotze TJ**, **Kruger TF**, **van Zyl JA**, The evaluation of morphological characteristics of human spermatozoa according to stricter criteria, Hum Reprod 5:586, 1990.
334. **Kruger TF**, **Acosta AA**, **Simmons KF**, **Swanson RJ**, **Matta JF**, **Veeck LL**, **Morshedi M**, **Brugo S**, New method of evaluating sperm morphology with predictive value for human in vitro fertilization, Urology 30:248, 1987.
335. **Kruger TF**, **Menkveld R**, **Stander FS**, **Lombard CJ**, **Van der Merwe JP**, **van Zyl JA**, **Smith K**, Sperm morphologic features as a prognostic factor in in vitro fertilization, Fertil Steril 46:1118, 1986.
336. **Hernandez M**, **Molina R**, **Olmedo J**, **Olmedo SB**, **Coetzee K**, **Estofan D**, Prognostic value of the strict criteria: an Argentinian experience, Arch Androl 37:87, 1996.
337. **Vawda AI**, **Gunby J**, **Younglai EV**, Semen parameters as predictors of in-vitro fertilization: the importance of strict criteria sperm morphology, Hum Reprod 11:1445, 1996.
338. **Ombelet W**, **Fourie FL**, **Vandeput H**, **Bosmans E**, **Cox A**, **Janssen M**, **Kruger T**, Teratozoospermia and in-vitro fertilization: a randomized prospective study, Hum Reprod 9:1479, 1994.
339. **Menkveld R**, **Kruger TF**, Advantages of strict (Tygerberg) criteria for evaluation of sperm morphology, Int J Androl 18(Suppl 2):36, 1995.
340. **Coetzee K**, **Kruge TF**, **Lombard CJ**, Predictive value of normal sperm morphology: a structured literature review, Hum Reprod Update 4:73, 1998.
341. **Gunalp S**, **Onculoglu C**, **Gurgan T**, **Kruger TF**, **Lombard CJ**, A study of semen parameters with emphasis on sperm morphology in a fertile population: an attempt to develop clinical thresholds, Hum Reprod 16:110, 2001.
342. **Pisarska MD**, **Casson PR**, **Cisneros PL**, **Lamb DJ**, **Lipshultz LI**, **Buster JE**, **Carson SA**, Fertilization after standard in vitro fertilization versus intracytoplasmic sperm injection in subfertile males using sibling oocytes, Fertil Steril 71:627, 1999.
343. **Kihaile PE**, **Misumi J**, **Hirotsuru K**, **Kumasako Y**, **Kisanga RE**, **Utsunomiya T**, Comparison of sibling oocyte outcomes after intracytoplasmic sperm injection and in vitro fertilization in severe teratozoospermic patients in the first cycle, Int J Androl 26:57, 2003.
344. **Hall J**, **Fishel S**, **Green S**, **Fleming S**, **Hunter A**, **Stoddart N**, **Dowell K**, **Thornton S**, Intracytoplasmic sperm injection versus high insemination concentration in-vitro fertilization in cases of very severe teratozoospermia, Hum Reprod 10:493, 1995.
345. **Mansour RT**, **Aboulghar MA**, **Serour GI**, **Amin YM**, **Ramzi AM**, The effect of sperm parameters on the outcome of intracytoplasmic sperm injection, Fertil Steril 64:982, 1995.
346. **Robinson JN**, **Lockwood GM**, **Dokras A**, **Egan DM**, **Nicholson SC**, **Ross C**, **Barlow DH**, Does isolated teratozoospermia affect performance in in-vitro fertilization and embryo transfer?, Hum Reprod 9:870, 1994.
347. **Keegan BR**, **Barton S**, **Sanchez X**, **Berkeley AS**, **Krey LC**, **Grifo J**, Isolated teratozoospermia does not affect in vitro fertilization outcome and is not an indication for intracytoplasmic sperm injection, Fertil Steril 88:1583, 2007.
348. **Zinaman MJ**, **Brown CC**, **Selevan SG**, **Clegg ED**, Semen quality and human fertility: a prospective study with healthy couples, J Androl 21:145, 2000.
349. **Menkveld R**, **Wong WY**, **Lombard CJ**, **Wetzels AM**, **Thomas CM**, **Merkus HM**, **Steegers-Theunissen RP**, Semen parameters, including WHO and strict criteria morphology, in a fertile and subfertile

population: an effort towards standardization of in-vivo thresholds, Hum Reprod 16:1165, 2001.
350. **Lee RK**, **Hou JW**, **Ho HY**, **Hwu YM**, **Lin MH**, **Tsai YC**, **Su JT**, Sperm morphology analysis using strict criteria as a prognostic factor in intrauterine insemination, Int J Androl 25:277, 2002.
351. **Hauser R**, **Yogev L**, **Botchan A**, **Lessing JB**, **Paz G**, **Yavetz H**, Intrauterine insemination in male factor subfertility: significance of sperm motility and morphology assessed by strict criteria, Andrologia 33:13, 2001.
352. **Toner JP**, **Mossad H**, **Grow DR**, **Morshedi M**, **Swanson RJ**, **Oehninger S**, Value of sperm morphology assessed by strict criteria for prediction of the outcome of artificial (intrauterine) insemination, Andrologia 27:143, 1995.
353. **Van Waart J**, **Kruger TF**, **Lombard CJ**, **Ombelet W**, Predictive value of normal sperm morphology in intrauterine insemination (IUI): a structured literature review, Hum Reprod Update 7:495, 2001.
354. **Karabinus DS**, **Gelety TJ**, The impact of sperm morphology evaluated by strict criteria on intrauterine insemination success, Fertil Steril 67:536, 1997.
355. **Matorras R**, **Corcostegui B**, **Perez C**, **Mandiola M**, **Mendoza R**, **Rodriguez-Escudero FJ**, Sperm morphology analysis (strict criteria) in male infertility is not a prognostic factor in intrauterine insemination with husband's sperm, Fertil Steril 63:608, 1995.
356. **Hofmann GE**, **Santilli BA**, **Kindig S**, **Scott RT Jr**, **Johnson CA**, Intraobserver, interobserver variation of sperm critical morphology: comparison of examiner and computer-assisted analysis, Fertil Steril 65:1021, 1996.
357. **Franken DR**, **Barendsen R**, **Kruger TF**, A continuous quality control program for strict sperm morphology, Fertil Steril 74:721, 2000.
358. **Franken DR**, **Menkveld R**, **Kruger TF**, **Sekadde-Kigondu C**, **Lombard C**, Monitoring technologist reading skills in a sperm morphology quality control program, Fertil Steril 79(Suppl 3):1637, 2003.
359. **Wolff H**, **Anderson DJ**, Immunohistologic characterization and quantitation of leukocyte subpopulations in human semen, Fertil Steril 49:497, 1988.
360. **Eggert-Krause W**, **Bellmann A**, **Rohr G**, **Tilgen W**, **Runnenbaum B**, Differentiation of round cells in semen by means of monoclonal antibodies and relationship with male fertility, Fertil Steril 58:1046, 1992.
361. **Wolff H**, **Politch JA**, **Martinez A**, **Haimovici F**, **Hill JA**, **Anderson DJ**, Leukocytospermia is associated with poor semen quality, Fertil Steril 53:528, 1990.
362. **Ludwig M**, **Vidal A**, **Huwe P**, **Diemer T**, **Pabst W**, **Weidner W**, Significance of inflammation on standard semen analysis in chronic prostatitis/chronic pelvic pain syndrome, Andrologia 35:152, 2003.
363. **Randall JM**, **Evans DH**, **Bird VG**, **Aballa TC**, **Lynne CM**, **Brackett NL**, Leukocytospermia in spinal cord injured patients is not related to histological inflammatory changes in the prostate, J Urol 170:897, 2003.
364. **Siciliano L**, **Tarantino P**, **Longobardi F**, **Rago V**, **De Stefano C**, **Carpino A**, Impaired seminal antioxidant capacity in human semen with hyperviscosity or oligoasthenozoospermia, J Androl 22:798, 2001.
365. **Curi SM**, **Ariagno JI**, **Chenlo PH**, **Mendeluk GR**, **Pugliese MN**, **Sardi Segovia LM**, **Repetto HE**, **Blanco AM**, Asthenozoospermia: analysis of a large population, Arch Androl 49:343, 2003.
366. **Munuce MJ**, **Bregni C**, **Carizza C**, **Mendeluk G**, Semen culture, leukocytospermia, and the presence of sperm antibodies in seminal hyperviscosity, Arch Androl 42:21, 1999.
367. **Gonzales GF**, **Kortebani G**, **Mazzolli AB**, Hyperviscosity and hypofunction of the seminal vesicles, Arch Androl 30:63, 1993.
368. **ESHRE (European Society of Human Reproduction and Embryology) Andrology Special Interest Group**, Consensus workshop on advanced diagnostic andrology techniques, Hum Reprod 11:1463, 1996.
369. **Turek PJ**, Infections, immunology, and male infertility, Infertil Reprod Med Clin North Am 10:435, 1999.
370. **Eggert-Kruse W**, **Christmann M**, **Gerhard I**, **Pohl S**, **Klinga K**, **Runnebaum B**, Circulating antisperm antibodies and fertility prognosis: a prospective study, Hum Reprod 4:513, 1989.
371. **Collins JA**, **Burrows EA**, **Yeo J**, **Younglai EV**, Frequency and predictive value of antisperm antibodies among infertile couples, Hum Reprod 8:592, 1993.
372. **Haas GG Jr**, The inhibitory effect of sperm-associated immunoglobulins on cervical mucus penetration, Fertil Steril 46:334, 1986.
373. **Mahony MC**, **Blackmore PF**, **Bronson RA**, **Alexander NJ**, Inhibition of human sperm-zona pellucida tight binding in the presence of antisperm antibody positive polyclonal patient sera, J Reprod Immunol 19:287, 1991.

374. **Haas GG Jr**, **Manganiello P**, A double-blind placebo-controlled study of the use of methylprednisolone in infertile men with sperm-associated immunoglobulins, Fertil Steril 47:295, 1987.
375. **Bohring C**, **Krause W**, Immune infertility: towards a better understanding of sperm (auto)-immunity. The value of proteomic analysis, Hum Reprod 18:915, 2003.
376. **Ayvaliotis B**, **Bronson R**, **Rosenfeld D**, **Cooper G**, Conception rates in couples where autoimmunity to sperm is detected, Fertil Steril 43:739, 1985.
377. **Ombelet W**, **Vandeput H**, **Janssen M**, **Cox A**, **Vossen C**, **Pollet H**, **Steeno O**, **Bosmans E**, Treatment of male infertility due to sperm surface antibodies: IUI or IVF?, Hum Reprod 12:1165, 1997.
378. **McLachlan RI**, Basis, diagnosis and treatment of immunological infertility in men, J Reprod Immunol 57:35, 2002.
379. **Yanagimachi R**, Zona-free hamster eggs: their use in assessing fertilizing capacity and examining chromosomes of human spermatozoa, Gamete Res 10:187, 1984.
380. **Smith RG**, **Johnson A**, **Lamb D**, **Lipshultz LI**, Functional tests of spermatozoa. Sperm penetration assay, Urol Clin North Am 14:451, 1987.
381. **Aitken RJ**, **Buckingham DW**, **Fang HG**, Analysis of the responses of human spermatozoa to A23187 employing a novel technique for assessing the acrosome reaction, J Androl 14:132, 1993.
382. **Rogers BJ**, **Perreault SD**, **Bentwood BJ**, **McCarville C**, **Hale RW**, **Soderdahl DW**, Variability in the human-hamster in vitro assay for fertility evaluation, Fertil Steril 39:204, 1983.
383. **Aitken RJ**, Diagnostic value of the zona-free hamster oocyte penetration test and sperm movement characteristics in oligozoospermia, Int J Androl 8:348, 1985.
384. **Mao C**, **Grimes DA**, The sperm penetration assay: can it discriminate between fertile and infertile men? Am J Obstet Gynecol 159:279, 1988.
385. **Margalioth EJ**, **Feinmesser M**, **Navot D**, **Mordel N**, **Bronson RA**, The long-term predictive value of the zona-free hamster ova sperm penetration assay, Fertil Steril 52:490, 1989.
386. **O'Shea DL**, **Odem RR**, **Cholewa C**, **Gast MJ**, Long-term follow-up of couples after hamster egg penetration testing, Fertil Steril 60:1040, 1993.
387. **Kruger TF**, **Swanson RJ**, **Hamilton M**, **Simmons KF**, **Acosta AA**, **Matta JF**, **Oehniger S**, **Morshedi M**, Abnormal sperm morphology and other semen parameters related to the outcome of the hamster oocyte human sperm penetration assay, Int J Androl 11:107, 1988.
388. **Soffer Y**, **Golan A**, **Herman A**, **Pansky M**, **Caspi E**, **Ron-El R**, Prediction of in vitro fertilization outcome by sperm penetration assay with TEST-yolk buffer preincubation, Fertil Steril 58:556, 1992.
389. **Zahalsky MP**, **Zoltan E**, **Medley N**, **Nagler HM**, Morphology and the sperm penetration assay, Fertil Steril 79:39, 2003.
390. **Burkman LJ**, **Coddington CC**, **Franken DR**, **Kruger TF**, **Rosenwaks Z**, **Hodgen GD**, The hemizona assay (HZA): development of a diagnostic test for the binding of human spermatozoa to the human hemizona pellucida to predict fertilization potential, Fertil Steril 49:688, 1988.
391. **Oehninger S**, **Coddington CC**, **Scott R**, **Franken DA**, **Burkman LJ**, **Acosta AA**, **Hodgen GD**, Hemizona assay: assessment of sperm dysfunction and prediction of in vitro fertilization outcome, Fertil Steril 51:665, 1989.
392. **Franken DR**, **Oehninger S**, **Burkman LJ**, **Coddington CC**, **Kruger TF**, **Rosenwaks Z**, **Acosta AA**, **Hodgen GD**, The hemizona assay (HZA): a predictor of human sperm fertilizing potential in in vitro fertilization (IVF) treatment, J In Vitro Fert Embryo Transf 6:44, 1989.
393. **Coddington CC III**, The hemizona assay (HZA) and considerations for its use in assisted reproductive technology, Semin Reprod Endocrinol 10:1, 1992.
394. **Davis RO**, **Rothmann SA**, **Overstreet JW**, Accuracy and precision of computer-aided sperm analysis in multicenter studies, Fertil Steril 57:648, 1992.
395. **Davis RO**, **Katz DF**, Standardization and comparability of CASA instruments, J Androl 13:81, 1992.
396. **Barratt CL**, **Tomlinson MJ**, **Cooke ID**, Prognostic significance of computerized motility analysis for in vivo fertility, Fertil Steril 60:520, 1993.
397. **Krause W**, Computer-assisted semen analysis systems: comparison with routine evaluation and prognostic

value in male fertility and assisted reproduction, Hum Reprod 10(Suppl 1):60, 1995.
398. **Macleod IC**, **Irvine DS**, The predictive value of computer-assisted semen analysis in the context of a donor insemination programme, Hum Reprod 10:580, 1995.
399. **Liu DY**, **Baker HWG**, Inhibition of acrosin activity with a trypsin inhibitor blocks human sperm penetration of the zona pellucida, Biol Reprod 48:340, 1993.
400. **Fenichel P**, **Donzeau M**, **Farahifar D**, **Basteris B**, **Ayraud N**, **Hsi BL**, Dynamics of human sperm acrosome reaction: relation with in vitro fertilization, Fertil Steril 55:994, 1991.
401. **Huszar G**, **Vigue L**, **Oehninger S**, Creatine kinase immunocytochemistry of human sperm-hemizona complexes: selective binding of sperm with mature creatine kinase-staining pattern, Fertil Steril 61:136, 1994.
402. **Rolf C**, **Behre HM**, **Cooper TG**, **Koppers B**, **Nieschlag E**, Creatine kinase activity in human spermatozoa and seminal plasma lacks predictive value for male fertility in in vitro fertilization, Fertil Steril 69:727, 1998.
403. **Iwasaki A**, **Gagnon C**, Formation of reactive oxygen species in spermatozoa of infertile patients, Fertil Steril 57:409, 1992.
404. **de Lamirande E**, **Gagnon C**, Human sperm hyperactivation in whole semen and its association with low superoxide scavenging capacity in seminal plasma, Fertil Steril 59:1291, 1993.
405. **Aitken RJ**, **Buckingham D**, **West K**, **Wu FC**, **Zikopoulos K**, **Richardson DW**, Differential contribution of leucocytes and spermatozoa to the generation of reactive oxygen species in the ejaculates of oligozoospermic patients and fertile donors, J Reprod Fertil 94:451, 1992.
406. **Kim JG**, **Parthasarathy S**, Oxidation and the spermatozoa, Semin Reprod Endocrinol 16:235, 1998.
407. **Irvine DS**, **Twigg JP**, **Gordon EL**, **Fulton N**, **Milne PA**, **Aitken RJ**, DNA integrity in human spermatozoa: relationships with semen quality, J Androl 21:33, 2000.
408. **Evenson DP**, **Jost LK**, **Marshall D**, **Zinaman MJ**, **Clegg E**, **Purvis K**, **de Angelis P**, **Claussen OP**, Utility of the sperm chromatin structure assay as a diagnostic and prognostic tool in the human fertility clinic, Hum Reprod 14:1039, 1999.
409. **Larson KL**, **DeJonge CJ**, **Barnes AM**, **Jost LK**, **Evenson DP**, Sperm chromatin structure assay parameters as predictors of failed pregnancy following assisted reproductive techniques, Hum Reprod 15:1717, 2000.
410. **Morris ID**, **Ilott S**, **Dixon L**, **Brison DR**, The spectrum of DNA damage in human sperm assessed by single cell gel electrophoresis (Comet assay) and its relationship to fertilization and embryo development, Hum Reprod 17:990, 2002.
411. **Zini A**, **Fischer MA**, **Sharir S**, **Shayegan B**, **Phang D**, **Jarvi K**, Prevalence of abnormal sperm DNA denaturation in fertile and infertile men, Urology 60:1069, 2002.
412. **Duran EH**, **Morshedi M**, **Taylor S**, **Oehninger S**, Sperm DNA quality predicts intrauterine insemination outcome: a prospective cohort study, Hum Reprod 17:3122, 2002.
413. **Spano M**, **Bonde JP**, **Hjollund HI**, **Kolstad HA**, **Cordelli E**, **Leter G**, Sperm chromatin damage impairs human fertility. The Danish First Pregnancy Planner Study Team, Fertil Steril 73:43, 2000.
414. **Saleh RA**, **Agarwal A**, **Nelson DR**, **Nada EA**, **El-Tonsy MH**, **Alvarez JG**, **Thomas AJ Jr**, **Sharma RK**, Increased sperm nuclear DNA damage in normozoospermic infertile men: a prospective study, Fertil Steril 78:313, 2002.
415. **Lopes S**, **Sun JG**, **Jurisicova A**, **Meriano J**, **Casper RF**, Sperm deoxyribonucleic acid fragmentation is increased in poor-quality semen samples and correlates with failed fertilization in intracytoplasmic sperm injection, Fertil Steril 69:528, 1998.
416. **Zini A**, **Bielecki R**, **Phang D**, **Zenzes MT**, Correlations between two markers of sperm DNA integrity, DNA denaturation and DNA fragmentation, in fertile and infertile men, Fertil Steril 75:674, 2001.
417. **Tomlinson MJ**, **Moffatt O**, **Manicardi GC**, **Bizzaro D**, **Afnan M**, **Sakkas D**, Interrelationships between seminal parameters and sperm nuclear DNA damage before and after density gradient centrifugation: implications for assisted conception, Hum Reprod 16:2160, 2001.
418. **Larson-Cook KL**, **Brannian JD**, **Hansen KA**, **Kasperson KM**, **Aamold ET**, **Evenson DP**, Relationship between the outcomes of assisted reproductive techniques and sperm DNA fragmentation as measured by the sperm chromatin structure assay, Fertil Steril 80:895, 2003.

419. **Collins JA**, **Barnhart KT**, **Schlegel PN**, Do sperm DNA integrity tests predict pregnancy with in vitro fertilization? Fertil Steril 89:823, 2008.
420. **Sigman M**, **Jarow JP**, Endocrine evaluation of infertile men, Urology 50:659, 1997.
421. **Sokol RZ**, Endocrinology of male infertility: evaluation and treatment, Semin Reprod Med 27:149, 2009.
422. **Pavlovich CP**, **King P**, **Goldstein M**, **Schlegel PN**, Evidence of a treatable endocrinopathy in infertile men, J Urol 165:837, 2001.
423. **Raman JD**, **Schlegel PN**, Aromatase inhibitors for male infertility, J Urol 167:624, 2002.
424. **Honig SC**, **Lipshultz LI**, **Jarow J**, Significant medical pathology uncovered by a comprehensive male infertility evaluation, Fertil Steril 62:1028, 1994.
425. **Kolettis PN**, Is physical examination useful in predicting epididymal obstruction? Urology 57:1138, 2001.
426. **Gorelick JI**, **Goldstein M**, Loss of fertility in men with varicocele, Fertil Steril 59:613, 1993.
427. **World Health Organization**, The influence of varicocele on parameters of fertility in a large group of men presenting to infertility clinics. World Health Organization, Fertil Steril 57:1289, 1992.
428. **Carter SS**, **Shinohara K**, **Lipshultz LI**, Transrectal ultrasonography in disorders of the seminal vesicles and ejaculatory ducts, Urol Clin North Am 16:773, 1989.
429. **Belker AM**, **Steinbock GS**, Transrectal prostate ultrasonography as a diagnostic and therapeutic aid for ejaculatory duct obstruction, J Urol 144:356, 1990.
430. **Jarow JP**, Seminal vesicle aspiration in the management of patients with ejaculatory duct obstruction, J Urol 152:899, 1994.
431. **Jarow JP**, Transrectal ultrasonography in the diagnosis and management of ejaculatory duct obstruction, J Androl 17:467, 1996.
432. **Schlegel PN**, **Shin D**, **Goldstein M**, Urogenital anomalies in men with congenital absence of the vas deferens, J Urol 155:1644, 1996.
433. **Anguiano A**, **Oates RD**, **Amos JA**, **Dean M**, **Gerrard B**, **Stewart C**, **Maher TA**, **White MB**, **Milunsky A**, Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis, JAMA 267:1794, 1992.
434. **Oates RD**, **Amos JA**, The genetic basis of congenital bilateral absence of the vas deferens and cystic fibrosis, J Androl 15:1, 1994.
435. **Shin D**, **Gilbert F**, **Goldstein M**, **Schlegel PN**, Congenital absence of the vas deferens: incomplete penetrance of cystic fibrosis gene mutations, J Urol 158:1794, 1997.
436. **Foresta C**, **Garolla A**, **Bartoloni L**, **Bettella A**, **Ferlin A**, Genetic abnormalities among severely oligospermic men who are candidates for intracytoplasmic sperm injection, J Clin Endocrinol Metab 90:152, 2005.
437. **Ravel C**, **Berthaut I**, **Bresson JL**, **Siffroi JP**, Prevalence of chromosomal abnormalities in phenotypically normal and fertile adult males: large-scale survey of over 10,000 sperm donor karyotypes, Hum Reprod 21:1484, 2006.
438. **De Braekeleer M**, **Dao TN**, Cytogenetic studies in male infertility: a review, Hum Reprod 6:245, 1991.
439. **Rucker GB**, **Mielnik A**, **King P**, **Goldstein M**, **Schlegel PN**, Preoperative screening for genetic abnormalities in men with nonobstructive azoospermia before testicular sperm extraction, J Urol 160:2068, 1998.
440. **Tournaye H**, **Staessen C**, **Liebaers I**, **Van Assche E**, **Devroey P**, **Bonduelle M**, **Van Steirteghem A**, Testicular sperm recovery in nine 47,XXY Klinefelter patients, Hum Reprod 11:1644, 1996.
441. **Pryor JL**, **Kent-First M**, **Muallem A**, **Van Bergen AH**, **Nolten WE**, **Meisner L**, **Roberts KP**, Microdeletions in the Y chromosome of infertile men, N Engl J Med 336:534, 1997.
442. **Vogt PH**, **Edelmann A**, **Kirsch S**, **Henegrin O**, **Hirschmann P**, **Kiesewetter F**, **Kohn FM**, **Schill WB**, **Farah S**, **Ramos C**, **Hartmann M**, **Hartschuh W**, **Meschede D**, **Behre HM**, **Castel A**, **Nieshlag E**, **Weidner W**, **Grone HJ**, **Jung A**, **Engel W**, **Haidl G**, Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11, Hum Mol Genet 5:933, 1996.
443. **Mulhall JP**, **Reijo R**, **Alagappan R**, **Brown L**, **Page D**, **Carson R**, **Oates RD**, Azoospermic men with deletion of the DAZ gene cluster are capable of completing spermatogenesis: fertilization, normal embryonic

development and pregnancy occur when retrieved testicular spermatozoa are used for intracytoplasmic sperm injection, Hum Reprod 12:503, 1997.

444. **Oates RD**, **Silber S**, **Brown LG**, **Page DC**, Clinical characterization of 42 oligospermic or azoospermic men with microdeletion of the AZFc region of the Y chromosome, and of 18 children conceived via ICSI, Hum Reprod 17:2813, 2002.
445. **Kamp C**, **Huellen K**, **Fernandes S**, **Sousa M**, **Schlegel PN**, **Mielnik A**, **Kleiman S**, **Yavetz H**, **Krause W**, **Kupker W**, **Johannisson R**, **Schulze W**, **Weidner W**, **Barros A**, **Vogt PH**, High deletion frequency of the complete AZFa sequence in men with Sertoli-cell-only syndrome, Mol Hum Reprod 7:987, 2001.
446. **Krausz C**, **Quintana-Murci L**, **McElreavey K**, Prognostic value of Y deletion analysis: what is the clinical prognostic value of Y chromosome microdeletion analysis? Hum Reprod 15:1431, 2000.
447. **Brandell RA**, **Mielnik A**, **Liotta D**, **Ye Z**, **Veeck LL**, **Palermo GD**, **Schlegel PN**, AZFb deletions predict the absence of spermatozoa with testicular sperm extraction: preliminary report of a prognostic genetic test, Hum Reprod 13:2812, 1998.
448. **Kent-First M**, **Muallem A**, **Shultz J**, **Pryor J**, **Roberts K**, **Nolten W**, **Meisner L**, **Chandley A**, **Gouchy G**, **Jorgensen L**, **Havighurst T**, **Grosch J**, Defining regions of the Y-chromosome responsible for male infertility and identification of a fourth AZF region (AZFd) by Y-chromosome microdeletion detection, Mol Reprod Dev 53:27, 1999.
449. **Silber SJ**, **Repping S**, Transmission of male infertility to future generations: lessons from the Y chromosome, Hum Reprod Update 8:217, 2002.
450. **Cram DS**, **Ma K**, **Bhasin S**, **Arias J**, **Pandjaitan M**, **Chu B**, **Audrins MS**, **Saunders D**, **Quinn F**, **deKretser D**, **McLachlan R**, Y chromosome analysis of infertile men and their sons conceived through intracytoplasmic sperm injection: vertical transmission of deletions and rarity of de novo deletions, Fertil Steril 74:909, 2000.
451. **Chang PL**, **Sauer MV**, **Brown S**, Y chromosome microdeletion in a father and his four infertile sons, Hum Reprod 14:2689, 1999.
452. **Nathanson KL**, **Kanetsky PA**, **Hawes R**, **Vaughn DJ**, **Letrero R**, **Tucker K**, **Friedlander M**, **Phillips KA**, **Hogg D**, **Jewett MA**, **Lohynska R**, **Daugaard G**, **Richard S**, **Chompret A**, **Bonaiti-Pellie C**, **Heidenreich A**, **Olah E**, **Geczi L**, **Bodrogi I**, **Ormiston WJ**, **Daly PA**, **Oosterhuis JW**, **Gillis AJ**, **Looijenga LH**, **Guilford P**, **Fossa SD**, **Heimdal K**, **Tjulandin SA**, **Liubchenko L**, **Stoll H**, **Weber W**, **Rudd M**, **Huddart R**, **Crockford GP**, **Forman D**, **Oliver DT**, **Einhorn L**, **Weber BL**, **Kramer J**, **McMaster M**, **Greene MH**, **Pike M**, **Cortessis V**, **Chen C**, **Schwartz SM**, **Bishop DT**, **Easton DF**, **Stratton MR**, **Rapley EA**, The Y deletion gr/gr and susceptibility to testicular germ cell tumor, Am J Hum Genet 77:1034, 2005.
453. **Kallmann FJ**, **Schoenfeld WA**, **Barrera SE**, The genetic aspects of primary eunuchoidism, Am J Ment Defic 48:203, 1944.
454. **Nachtigall LB**, **Boepple PA**, **Pralong FP**, **Crowley WF Jr**, Adult-onset idiopathic hypogonadotropic hypogonadism—a treatable form of male infertility, N Engl J Med 336:410, 1997.
455. **Nishimura K**, **Matsumiya K**, **Tsuboniwa N**, **Yamanaka M**, **Koga M**, **Miura H**, **Tsujimura A**, **Uchida K**, **Kondoh N**, **Kitamura M**, **Okuyama A**, Bromocriptine for infertile males with mild hyperprolactinemia: hormonal and spermatogenic effects, Arch Androl 43:207, 1999.
456. **Arafah BM**, **Manni A**, **Brodkey JS**, **Kaufman B**, **Velasco M**, **Pearson OH**, Cure of hypogonadism after removal of prolactin-secreting adenomas in men, J Clin Endocrinol Metab 52:91, 1981.
457. **Winters SJ**, **Troen P**, Altered pulsatile secretion of luteinizing hormone in hypogonadal men with hyperprolactinaemia, Clin Endocrinol (Oxf) 21:257, 1984.
458. **De Rosa M**, **Colao A**, **Di Sarno A**, **Ferone D**, **Landi ML**, **Zarrilli S**, **Paesano L**, **Merola B**, **Lombardi G**, Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine, Eur J Endocrinol 138:286, 1998.
459. **Murray FT**, **Cameron DF**, **Ketchum C**, Return of gonadal function in men with prolactin-secreting pituitary tumors, J Clin Endocrinol Metab 59:79, 1984.
460. **Merino G**, **Carranza-Lira S**, **Martinez-Chequer JC**, **Barahona E**, **Moran C**, **Bermudez JA**,

Hyperprolactinemia in men with asthenozoospermia, oligozoospermia, or azoospermia, Arch Androl 38:201, 1997.
461. **Vandekerckhove P**, **Lilford R**, **Vail A**, **Hughes E**, Bromocriptine for idiopathic oligo/asthenospermia, Cochrane Database Syst Rev (2):CD000152, 2000.
462. **Matsumoto AM**, **Paulsen CA**, **Bremner WJ**, Stimulation of sperm production by human luteinizing hormone in gonadotropin-suppressed normal men, J Clin Endocrinol Metab 59:882, 1984.
463. **Matsumoto AM**, **Bremner WJ**, Stimulation of sperm production by human chorionic gonadotropin after prolonged gonadotropin suppression in normal men, J Androl 6:137, 1985.
464. **Burris AS**, **Rodbard HW**, **Winters SJ**, **Sherins RJ**, Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size, J Clin Endocrinol Metab 66:1144, 1988.
465. **Burris AS**, **Clark RV**, **Vantman DJ**, **Sherins RJ**, A low sperm concentration does not preclude fertility in men with isolated hypogonadotropic hypogonadism after gonadotropin therapy, Fertil Steril 50:343, 1988.
466. **Bouloux PM**, **Nieschlag E**, **Burger HG**, **Skakkebaek NE**, **Wu FC**, **Handelsman DJ**, **Baker GH**, **Ochsenkuehn R**, **Syska A**, **McLachlan RI**, **Giwercman A**, **Conway AJ**, **Turner L**, **van Kuijk JH**, **Voortman G**, Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone, J Androl 24:604, 2003.
467. **Depenbusch M**, **von Eckardstein S**, **Simoni M**, **Nieschlag E**, Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone, Eur J Endocrinol 147:617, 2002.
468. **Crowley WF**, **Whitcomb RW**, Gonadotropin-releasing hormone deficiency in men: diagnosis and treatment with exogenous gonadotropin-releasing hormone, Am J Obstet Gynecol 163:1752, 1990.
469. **Christiansen P**, **Skakkebaek NE**, Pulsatile gonadotropin-releasing hormone treatment of men with idiopathic hypogonadotropic hypogonadism, Horm Res 57:32, 2002.
470. **Giusti M**, **Cavagnaro P**, **Torre R**, Role of pulsatile luteinizing hormone releasing-hormone therapy in males with idiopathic hypogonadotropic hypogonadism and delayed puberty, Recenti Prog Med 82:47, 1991.
471. **Spratt DI**, **Finkelstein JS**, **O'Dea LS**, **Badger TM**, **Rao PN**, **Campbell JD**, **Crowley WF Jr**, Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism. A model for studies of the hormone's physiologic effects, Ann Intern Med 105:848, 1986.
472. **Hoffman AR**, **Crowley WF Jr**, Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone, N Engl J Med 307:1237, 1982.
473. **Aulitzky W**, **Frick J**, **Galvan G**, Pulsatile luteinizing hormone-releasing hormone treatment of male hypogonadotropic hypogonadism, Fertil Steril 50:480, 1988.
474. **Pitteloud N**, **Hayes FJ**, **Dwyer A**, **Boepple PA**, **Lee H**, **Crowley WF Jr**, Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism, J Clin Endocrinol Metab 87:4128, 2002.
475. **Liu L**, **Banks SM**, **Barnes KM**, **Sherins RJ**, Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism, J Clin Endocrinol Metab 67:1140, 1988.
476. **Kliesch S**, **Behre HM**, **Nieschlag E**, High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men, Eur J Endocrinol 131:347, 1994.
477. **Hershlag A**, **Schiff SF**, **DeCherney AH**, Retrograde ejaculation, Hum Reprod 6:255, 1991.
478. **Yavetz H**, **Yogev L**, **Hauser R**, **Lessing JB**, **Paz G**, **Homonnai ZT**, Retrograde ejaculation, Hum Reprod 9:381, 1994.
479. **Gerig NE**, **Meacham RB**, **Ohl DA**, Use of electroejaculation in the treatment of ejaculatory failure secondary to diabetes mellitus, Urology 49:239, 1997.
480. **Yanushpolsky EH**, **Politch JA**, **Hill JA**, **Anderson DJ**, Is leukocytospermia clinically relevant? Fertil Steril 66:822, 1996.
481. **Yanushpolsky EH**, **Politch JA**, **Hill JA**, **Anderson DJ**, Antibiotic therapy and leukocytospermia: a prospective, randomized, controlled study, Fertil Steril 63:142, 1995.

482. **Erel CT**, **Senturk LM**, **Demir F**, **Irez T**, **Ertungealp E**, Antibiotic therapy in men with leukocytospermia, Int J Fertil Womens Med 42:206, 1997.
483. **Hua VN**, **Schaeffer AJ**, Acute and chronic prostatitis, Med Clin North Am 88:483, 2004.
484. **Trum JW**, **Mol BW**, **Pannekoek Y**, **Spanjaard L**, **Wertheim P**, **Bleker OP**, **van der Veen F**, Value of detecting leukocytospermia in the diagnosis of genital tract infection in subfertile men, Fertil Steril 70:315, 1998.
485. **Tomlinson MJ**, **Barratt CL**, **Cooke ID**, Prospective study of leukocytes and leukocyte subpopulations in semen suggests they are not a cause of male infertility, Fertil Steril 60:1069, 1993.
486. **Vandekerckhove P**, **Lilford R**, **Vail A**, **Hughes E**, Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia, Cochrane Database Syst Rev (2):CD000150, 2000.
487. **Liu PY**, **Handelsman DJ**, The present and future state of hormonal treatment for male infertility, Hum Reprod Update 9:9, 2003.
488. **Kamischke A**, **Behre HM**, **Bergmann M**, **Simoni M**, **Schafer T**, **Nieschlag E**, Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial, Hum Reprod 13:596, 1998.
489. **Matorras R**, **Perez C**, **Corcostegui B**, **Pijoan JI**, **Ramon O**, **Delgado P**, **Rodriguez-Escudero FJ**, Treatment of the male with follicle-stimulating hormone in intrauterine insemination with husband's spermatozoa: a randomized study, Hum Reprod 12:24, 1997.
490. **Foresta C**, **Bettella A**, **Merico M**, **Garolla A**, **Ferlin A**, **Rossato M**, Use of recombinant human follicle-stimulating hormone in the treatment of male factor infertility, Fertil Steril 77:238, 2002.
491. **Foresta C**, **Bettella A**, **Garolla A**, **Ambrosini G**, **Ferlin A**, Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study, Fertil Steril 84:654, 2005.
492. **Attia AM**, **Al-Inany HG**, **Farquhar C**, **Proctor M**, Gonadotrophins for idiopathic male factor subfertility, Cochrane Database Syst Rev (1):CD005071, 2007.
493. **World Health Organization**, A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. World Health Organization, Int J Androl 15:299, 1992.
494. **Vandekerckhove P**, **Lilford R**, **Vail A**, **Hughes E**, Clomiphene or tamoxifen for idiopathic oligo/asthenospermia, Cochrane Database Syst Rev (2):CD000151, 2000.
495. **Gorrill MJ**, **Burry KA**, **Patton PE**, Pregnancy outcomes using donor sperm insemination after failed in vitro fertilization with intracytoplasmic sperm injection cycles in couples with complex infertility disorders, Fertil Steril 80:936, 2003.
496. **O'Brien P**, **Vandekerckhove P**, Intra-uterine versus cervical insemination of donor sperm for subfertility, Cochrane Database Syst Rev (2):CD000317, 2000.
497. **Goldberg JM**, **Mascha E**, **Falcone T**, **Attaran M**, Comparison of intrauterine and intracervical insemination with frozen donor sperm: a meta-analysis, Fertil Steril 72:792, 1999.
498. **van der Westerlaken LA**, **Naaktgeboren N**, **Helmerhorst FM**, Evaluation of pregnancy rates after intrauterine insemination according to indication, age, and sperm parameters, J Assist Reprod Genet 15:359, 1998.
499. **Campana A**, **Sakkas D**, **Stalberg A**, **Bianchi PG**, **Comte I**, **Pache T**, **Walker D**, Intrauterine insemination: evaluation of the results according to the woman's age, sperm quality, total sperm count per insemination and life table analysis, Hum Reprod 11:732, 1996.
500. **Guzick DS**, **Carson SA**, **Coutifaris C**, **Overstreet JW**, **Factor-Litvak P**, **Steinkampf MP**, **Hill JA**, **Mastroianni L Jr**, **Buster JE**, **Nakajimi ST**, **Vogel DL**, **Canfield RE**; for the **National Cooperative Reproductive Medicine Network**, Efficacy of superovulation and intrauterine insemination in the treatment of infertility, N Engl J Med 340:177, 1999.
501. **Ford WC**, **Mathur RS**, **Hull MG**, Intrauterine insemination: is it an effective treatment for male factor infertility? Baillieres Clin Obstet Gynaecol 11:691, 1997.
502. **Byrd W**, **Edman C**, **Bradshaw K**, **Odom J**, **Carr B**, **Ackerman G**, A prospective randomized study of pregnancy rates following intrauterine and intracervical insemination using frozen donor sperm, Fertil Steril 53:521, 1990.

503. **Botchan A**, **Hauser R**, **Gamzu R**, **Yogev L**, **Paz G**, **Yavetz H**, Results of 6139 artificial insemination cycles with donor spermatozoa, Hum Reprod 16:2298, 2001.
504. **Wolf DP**, **Patton PE**, **Burry KA**, **Kaplan PF**, Intrauterine insemination-ready versus conventional semen cryopreservation for donor insemination: a comparison of retrospective results and a prospective, randomized trial, Fertil Steril 76:181, 2001.
505. **Williams RS**, **Alderman J**, Predictors of success with the use of donor sperm, Am J Obstet Gynecol 185:332, 2001.
506. **Ferrara I**, **Balet R**, **Grudzinskas JG**, Intrauterine insemination with frozen donor sperm. Pregnancy outcome in relation to age and ovarian stimulation regime, Hum Reprod 17:2320, 2002.
507. **Pittrof RU**, **Shaker A**, **Dean N**, **Bekir JS**, **Campbell S**, **Tan SL**, Success of intrauterine insemination using cryopreserved donor sperm is related to the age of the woman and the number of preovulatory follicles, J Assist Reprod Genet 13:310, 1996.
508. **Kerin J**, **Byrd W**, Supracervical placement of spermatozoa, In: Soules MR, ed. Controversies in Reproductive Endocrinology and Infertility, Elsevier, Amsterdam, 1989.
509. **Nulsen JC**, **Walsh S**, **Dumez S**, **Metzger DA**, A randomized and longitudinal study of human menopausal gonadotropin with intrauterine insemination in the treatment of infertility, Obstet Gynecol 82:780, 1993.
510. **Tur-Kaspa I**, **Dudkiewicz A**, **Confino E**, **Gleicher N**, Pooled sequential ejaculates: a way to increase the total number of motile sperm from oligospermic men, Fertil Steril 54:906, 1990.
511. **Lindheim SR**, **Barad DH**, **Zinger M**, **Witt B**, **Amin H**, **Cohen B**, **Fisch H**, **Barg P**, Abnormal sperm morphology is highly predictive of pregnancy outcome during controlled ovarian hyperstimulation and intrauterine insemination, J Assist Reprod Genet 13:569, 1996.
512. **Chauhan M**, **Barratt CL**, **Cooke SM**, **Cooke ID**, Differences in the fertility of donor insemination recipients—a study to provide prognostic guidelines as to its success and outcome, Fertil Steril 51:815, 1989.
513. **Ahmed Ebbiary N**, **Martin K**, **Gibbs A**, **D'Arcy Y**, **Afnan M**, **Newton JR**, Spontaneous ovulatory cycle donor insemination programme: prognostic indicators of a successful pregnancy, Hum Reprod 9:1852, 1994.
514. **Shenfield F**, **Doyle P**, **Valentine A**, **Steele SJ**, **Tan S-L**, Effects of age, gravidity and male infertility status on cumulative conception rates following artificial insemination with cryopreserved donor semen: analysis of 2998 cycles of treatment in one centre over 10 years, Hum Reprod 8:60, 1993.
515. **Kang BM**, **Wu TC**, Effect of age on intrauterine insemination with frozen donor sperm, Obstet Gynecol 88:93, 1996.
516. **Corson SL**, Factors affecting donor artificial insemination success rates, Fertil Steril 33:415, 1980.
517. **Smith KD**, **Rodriguez-Rigau LJ**, **Steinberger E**, The influence of ovulatory dysfunction and timing of insemination on the success of artificial insemination donor (AID) with fresh or cryopreserved semen, Fertil Steril 36:496, 1981.
518. **Bradshaw KD**, **Guzick DS**, **Grun B**, **Johnson N**, **Ackerman G**, Cumulative pregnancy rates for donor insemination according to ovulatory function and tubal status, Fertil Steril 48:1051, 1987.
519. **Nash D**, **Haning RV Jr**, **Shapiro SS**, The value of hysterosalpingography prior to donor artificial insemination, Fertil Steril 31:378, 1979.
520. **Guzick DS**, **Sullivan MW**, **Adamson GD**, **Cedars MI**, **Falk RJ**, **Peterson EP**, **Steinkampf MP**, Efficacy of treatment of unexplained infertility, Fertil Steril 70:207, 1998.
521. **American Society for Reproductive Medicine**, Effectiveness and Treatment for Unexplained Infertility. A Practice Committee Report, American Society for Reproductive Medicine, Birmingham, 2000.
522. **Depypere HT**, **Gordts S**, **Campo R**, **Comhaire F**, Methods to increase the success rate of artificial insemination with donor semen, Hum Reprod 9:661, 1994.
523. **Lashen H**, **Afnan M**, **Kennefik A**, Early resort to ovarian stimulation improves the cost-effectiveness of a donor insemination programme, Hum Reprod 14:1983, 1999.
524. **Matorras R**, **Diaz T**, **Corcostegui B**, **Ramon O**, **Pijoan JI**, **Rodriguez-Escudero FJ**, Ovarian stimulation in intrauterine insemination with donor sperm: a randomized study comparing clomiphene citrate in fixed protocol versus highly purified urinary FSH, Hum Reprod 17:2107, 2002.
525. **Carrell DT**, **Kuneck PH**, **Peterson CM**, **Hatasaka HH**, **Jones KP**, **Campbell BF**, A randomized,

prospective analysis of five sperm preparation techniques before intrauterine insemination of husband sperm, Fertil Steril 69:122, 1998.
526. **Morshedi M**, **Duran HE**, **Taylor S**, **Oehninger S**, Efficacy and pregnancy outcome of two methods of semen preparation for intrauterine insemination: a prospective randomized study, Fertil Steril 79(Suppl 3):1625, 2003.
527. **Boomsma CM**, **Heineman MJ**, **Cohlen BJ**, **Farquhar C**, Semen preparation techniques for intrauterine insemination, Cochrane Database Syst Rev (4):CD004507, 2007.
528. **Aitken RJ**, **Clarkson JS**, Significance of reactive oxygen species and antioxidants in defining the efficacy of sperm preparation techniques, J Androl 9:367, 1988.
529. **Mortimer D**, Sperm preparation techniques and iatrogenic failures of in-vitro fertilization, Hum Reprod 6:173, 1991.
530. **Henkel RR**, **Schill WB**, Sperm preparation for ART, Reprod Biol Endocrinol 1:108, 2003.
531. **Mahadevan M**, **Baker G**, Assessment and preparation of semen for in vitro fertilization, In: Wood C, Trounson AO, eds. Clinical In Vitro Fertilization, Springer-Verlag, Berlin, 1984, p. 83.
532. **Pousette A**, **Akerlof E**, **Rosenborg L**, **Fredricsson B**, Increase in progressive motility and improved morphology of human spermatozoa following their migration through Percoll gradients, Int J Androl 9:1, 1986.
533. **Prakash P**, **Leykin L**, **Chen Z**, **Toth T**, **Sayegh R**, **Schiff I**, **Isaacson K**, Preparation by differential gradient centrifugation is better than swim-up in selecting sperm with normal morphology (strict criteria), Fertil Steril 69:722, 1998.
534. **Lim CC**, **Lewis SE**, **Kennedy M**, **Donnelly ET**, **Thompson W**, Human sperm morphology and in vitro fertilization: sperm tail defects are prognostic for fertilization failure, Andrologia 30:43, 1998.
535. **Wilcox AJ**, **Weinberg CR**, **Baird DD**, Post-ovulatory ageing of the human oocyte and embryo failure, Hum Reprod 13:394, 1998.
536. **Wilcox AJ**, **Weinberg CR**, **Baird DD**, Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby, N Engl J Med 333:1517, 1995.
537. **Dunson DB**, **Baird DD**, **Wilcox AJ**, **Weinberg CR**, Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation, Hum Reprod 14:1835, 1999.
538. **Nijs M**, **Ombelet W**, Cryopreservation of human sperm, Hum Fertil (Camb) 4:158, 2001.
539. **Miller PB**, **Soules MR**, The usefulness of a urinary LH kit for ovulation prediction during menstrual cycles of normal women, Obstet Gynecol 87:13, 1996.
540. **Nielsen MS**, **Barton SD**, **Hatasaka HH**, **Stanford JB**, Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick, Fertil Steril 76:384, 2001.
541. **Ragni G**, **Maggioni P**, **Guermandi E**, **Testa A**, **Baroni E**, **Colombo M**, **Crosignani PG**, Efficacy of double intrauterine insemination in controlled ovarian hyperstimulation cycles, Fertil Steril 72:619, 1999.
542. **Ransom MX**, **Blotner MB**, **Bohrer M**, **Corsan G**, **Kemmann E**, Does increasing frequency of intrauterine insemination improve pregnancy rates significantly during ovulation induction cycles? Fertil Steril 61:303, 1994.
543. **Alborzi S**, **Motazedian S**, **Parsanezhad ME**, **Jannati S**, Comparison of the effectiveness of single intrauterine insemination (IUI) versus double IUI per cycle in infertile patients, Fertil Steril 80:595, 2003.
544. **Osuna C**, **Matorras R**, **Pijoan JI**, **Rodriguez-Escudero FJ**, One versus two inseminations per cycle in intrauterine insemination with sperm from patients' husbands: a systematic review of the literature, Fertil Steril 82:17, 2004.
545. **Cantineau AE**, **Heineman MJ**, **Cohlen BJ**, Single versus double intrauterine insemination in stimulated cycles for subfertile couples: a systematic review based on a Cochrane review, Hum Reprod 18:941, 2003.
546. **Lincoln SR**, **Long CA**, **Cowan BD**, One artificial insemination per cycle with donor sperm is as efficacious as two inseminations, J Assist Reprod Genet 12:67, 1995.
547. **Meyer WR**, **Smith PM**, **Clark MR**, **Cusmano LL**, **Fritz MA**, Therapeutic cup insemination with cryopreserved donor sperm: prognostic value of cervical mucus score at insemination and the number of motile sperm in mucus at 24 hours, Fertil Steril 66:435, 1996.
548. **Patton PE**, **Burry KA**, **Thurmond A**, **Novy MJ**, **Wolf DP**, Intrauterine insemination outperforms intracervical insemination in a randomized, controlled study with frozen, donor semen, Fertil Steril 57:559, 1992.

549. **Hurd WW**, **Menge AC**, **Randolph JF Jr**, **Ohl DA**, **Ansbacher R**, **Brown AN**, Comparison of intracervical, intrauterine, and intratubal techniques for donor insemination, Fertil Steril 59:339, 1993.
550. **Khalil MR**, **Rasmussen PE**, **Erb K**, **Laursen SB**, **Rex S**, **Westergaard LG**, Intrauterine insemination with donor semen. An evaluation of prognostic factors based on a review of 1131 cycles, Acta Obstet Gynecol Scand 80:342, 2001.
551. **Practice Committee of the American Society for Reproductive Medicine**, 2008 Guidelines for gamete and embryo donation: a Practice Committee report, Fertil Steril 90:S30, 2008.
552. **Marshburn PB**, **McIntire D**, **Carr BR**, **Byrd W**, Spermatozoal characteristics from fresh and frozen donor semen and their correlation with fertility outcome after intrauterine insemination, Fertil Steril 58:179, 1992.
553. **Stewart GJ**, **Tyler JP**, **Cunningham AL**, **Barr JA**, **Driscoll GL**, **Gold J**, **Lamont BJ**, Transmission of human T-cell lymphotropic virus type III (HTLV-III) by artificial insemination by donor, Lancet 2:581, 1985.
554. **Thyer AC**, **Patton PE**, **Burry KA**, **Mixon BA**, **Wolf DP**, Fecundability trends among sperm donors as a measure of donor performance, Fertil Steril 71: 891, 1999.
555. **Carrell DT**, **Cartmill D**, **Jones KP**, **Hatasaka HH**, **Peterson CM**, Prospective, randomized, blinded evaluation of donor semen quality provided by seven commercial sperm banks, Fertil Steril 78:16, 2002.
556. **Kolettis PN**, **Thomas AJ Jr**, Vasoepididymostomy for vasectomy reversal: a critical assessment in the era of intracytoplasmic sperm injection, J Urol 158: 467, 1997.
557. **Pavlovich CP**, **Schlegel PN**, Fertility options after vasectomy: a cost-effectiveness analysis, Fertil Steril 67:133, 1997.
558. **Schlegel PN**, Is assisted reproduction the optimal treatment for varicocele-associated male infertility? A cost-effectiveness analysis, Urology 49:83, 1997.
559. **Donovan JF Jr**, **DiBaise M**, **Sparks AE**, **Kessler J**, **Sandlow JI**, Comparison of microscopic epididymal sperm aspiration and intracytoplasmic sperm injection/in-vitro fertilization with repeat microscopic reconstruction following vasectomy: is second attempt vas reversal worth the effort? Hum Reprod 13:387, 1998.
560. **Kolettis PN**, **D'Amico AM**, **Box L**, **Burns JR**, Outcomes for vasovasostomy with bilateral intravasal azoospermia, J Androl 24:22, 2003.
561. **Matthews GJ**, **Schlegel PN**, **Goldstein M**, Patency following microsurgical vasoepididymostomy and vasovasostomy: temporal considerations, J Urol 154:2070, 1995.
562. **Goldstein M**, **Li PS**, **Matthews GJ**, Microsurgical vasovasostomy: the microdot technique of precision suture placement, J Urol 159:188, 1998.
563. **Kolettis PN**, **Woo L**, **Sandlow JI**, Outcomes of vasectomy reversal performed for men with the same female partners, Urology 61:1221, 2003.
564. **Kolettis PN**, **Sabanegh ES**, **D'Amico AM**, **Box L**, **Sebesta M**, **Burns JR**, Outcomes for vasectomy reversal performed after obstructive intervals of at least 10 years, Urology 60:885, 2002.
565. **Fuchs EF**, **Burt RA**, Vasectomy reversal performed 15 years or more after vasectomy: correlation of pregnancy outcome with partner age and with pregnancy results of in vitro fertilization with intracytoplasmic sperm injection, Fertil Steril 77:516, 2002.
566. **Paick JS**, **Park JY**, **Park DW**, **Park K**, **Son H**, **Kim SW**, Microsurgical vasovasostomy after failed vasovasostomy, J Urol 169:1052, 2003.
567. **Hibi H**, **Yamada Y**, **Honda N**, **Fukatsu H**, **Katsuno S**, **Ohshima S**, **Yamamoto M**, Microsurgical vasoepididymostomy with sperm cryopreservation for future assisted reproduction, Int J Urol 7:435, 2000.
568. **Chan PT**, **Brandell RA**, **Goldstein M**, Prospective analysis of outcomes after microsurgical intussusception vasoepididymostomy, BJU Int 96:598, 2005.
569. **Schiff J**, **Chan P**, **Li PS**, **Finkelberg S**, **Goldstein M**, Outcome and late failures compared in 4 techniques of microsurgical vasoepididymostomy in 153 consecutive men, J Urol 174:651, 2005.
570. **Glazier DB**, **Marmar JL**, **Mayer E**, **Gibbs M**, **Corson SL**, The fate of cryopreserved sperm acquired during vasectomy reversals, J Urol 161:463, 1999.
571. **Pryor JP**, **Hendry WF**, Ejaculatory duct obstruction in subfertile males: analysis of 87 patients, Fertil Steril 56:725, 1991.

572. **Turek PJ**, Seminal vesicle and ejaculatory duct surgery, In: Graham SD Jr, ed. Glenn's Urologic Surgery, Lippincott-Raven, Philadelphia, 1998, p. 477.
573. **Cornel EB**, **Dohle GR**, **Meuleman EJ**, Transurethral deroofing of midline prostatic cyst for subfertile men, Hum Reprod 14:2297, 1999.
574. **Schroeder-Printzen I**, **Ludwig M**, **Kohn F**, **Weidner W**, Surgical therapy in infertile men with ejaculatory duct obstruction: technique and outcome of a standardized surgical approach, Hum Reprod 15:1364, 2000.
575. **Purohit RS**, **Wu DS**, **Shinohara K**, **Turek PJ**, A prospective comparison of 3 diagnostic methods to evaluate ejaculatory duct obstruction, J Urol 171:232, 2004.
576. **Kadioglu A**, **Cayan S**, **Tefekli A**, **Orhan I**, **Engin G**, **Turek PJ**, Does response to treatment of ejaculatory duct obstruction in infertile men vary with pathology? Fertil Steril 76:138, 2001.
577. **Paduch DA**, **Niedzielski J**, Repair versus observation in adolescent varicocele: a prospective study, J Urol 158:1128, 1997.
578. **Sigman M**, **Jarow JP**, Ipsilateral testicular hypotrophy is associated with decreased sperm counts in infertile men with varicoceles, J Urol 158:605, 1997.
579. **Chehval MJ**, **Purcell MH**, Deterioration of semen parameters over time in men with untreated varicocele: evidence of progressive testicular damage, Fertil Steril 57:174, 1992.
580. **Witt MA**, **Lipshultz LI**, Varicocele: a progressive or static lesion? Urology 42:541, 1993.
581. **Matthews GJ**, **Matthews ED**, **Goldstein M**, Induction of spermatogenesis and achievement of pregnancy after microsurgical varicocelectomy in men with azoospermia and severe oligoasthenospermia, Fertil Steril 70:71, 1998.
582. **Kim ED**, **Leibman BB**, **Grinblat DM**, **Lipshultz LI**, Varicocele repair improves semen parameters in azoospermic men with spermatogenic failure, J Urol 162:737, 1999.
583. **Goldstein M**, **Gilbert BR**, **Dicker AP**, **Dwosh J**, **Gnecco C**, Microsurgical inguinal varicocelectomy with delivery of the testis: an artery and lymphatic sparing technique, J Urol 148:1808, 1992.
584. **Schlesinger MH**, **Wilets IF**, **Nagler HM**, Treatment outcome after varicocelectomy. A critical analysis, Urol Clin North Am 21:517, 1994.
585. **Steckel J**, **Dicker AP**, **Goldstein M**, Relationship between varicocele size and response to varicocelectomy, J Urol 149:769, 1993.
586. **Evers JL**, **Collins JA**, **Vandekerckhove P**, Surgery or embolisation for varicocele in subfertile men, Cochrane Database Syst Rev (1):CD000479, 2001.
587. **Evers JL**, **Collins JA**, Assessment of efficacy of varicocele repair for male subfertility: a systematic review, Lancet 361:1849, 2003.
588. **Grasso M**, **Lania C**, **Castelli M**, **Galli L**, **Franzoso F**, **Rigatti P**, Low-grade left varicocele in patients over 30 years old: the effect of spermatic vein ligation on fertility, BJU Int 85:305, 2000.
589. **Madgar I**, **Weissenberg R**, **Lunenfeld B**, **Karasik A**, **Goldwasser B**, Controlled trial of high spermatic vein ligation for varicocele in infertile men, Fertil Steril 63:120, 1995.
590. **Nieschlag E**, **Hertle L**, **Fischedick A**, **Abshagen K**, **Behre HM**, Update on treatment of varicocele: counselling as effective as occlusion of the vena spermatica, Hum Reprod 13:2147, 1998.
591. **Cayan S**, **Erdemir F**, **Ozbey I**, **Turek PJ**, **Kadioglu A**, **Tellaloglu S**, Can varicocelectomy significantly change the way couples use assisted reproductive technologies? J Urol 167:1749, 2002.
592. **Shin D**, **Lemack GE**, **Goldstein M**, Induction of spermatogenesis and pregnancy after adult orchiopexy, J Urol 158:2242, 1997.
593. **Ohl DA**, **Sonksen J**, **Menge AC**, **McCabe M**, **Keller LM**, Electroejaculation versus vibratory stimulation in spinal cord injured men: sperm quality and patient preference, J Urol 157:2147, 1997.
594. **Palermo G**, **Joris H**, **Devroey P**, **Van Steirteghem AC**, Pregnancies after intracytoplasmic injection of a single spermatozoon into an oocyte, Lancet 340:17, 1992.
595. **Van Steirteghem AC**, **Nagy Z**, **Joris H**, **Liu J**, **Staessen C**, **Smitz J**, **Wisanto A**, **Devroey P**, High fertilization and implantation rates after intracytoplasmic sperm injection, Hum Reprod 8:1061, 1993.
596. **Centers for Disease Control and Prevention**, 2015 Assisted Reproductive Technology Success Rates. National Summary and Fertility Clinic Reports, U.S. Department of Health and Human Services, Atlanta, 2017.

597. **Matthews GJ**, **Goldstein M**, A simplified method of epididymal sperm aspiration, Urology 47:123, 1996.
598. **Nudell DM**, **Conaghan J**, **Pedersen RA**, **Givens CR**, **Schriock ED**, **Turek PJ**, The mini-micro-epididymal sperm aspiration for sperm retrieval: a study of urological outcomes, Hum Reprod 13:1260, 1998.
599. **Janzen N**, **Goldstein M**, **Schlegel PN**, **Palermo GD**, **Rosenwaks Z**, **Hariprashad J**, Use of electively cryopreserved microsurgically aspirated epididymal sperm with IVF and intracytoplasmic sperm injection for obstructive azoospermia, Fertil Steril 74:696, 2000.
600. **Shrivastav P**, **Nadkarni P**, **Wensvoort S**, **Craft I**, Percutaneous epididymal sperm aspiration for obstructive azoospermia, Hum Reprod 9:2058, 1994.
601. **Craft IL**, **Khalifa Y**, **Boulos A**, **Pelekanos M**, **Foster C**, **Tsirigotis M**, Factors influencing the outcome of in-vitro fertilization with percutaneous aspirated epididymal spermatozoa and intracytoplasmic sperm injection in azoospermic men, Hum Reprod 10:1791, 1995.
602. **Tournaye H**, **Camus M**, **Goossens A**, **Liu J**, **Nagy P**, **Silber S**, **Van Steirteghem AC**, **Devroey P**, Recent concepts in the management of infertility because of non-obstructive azoospermia, Hum Reprod 10(Suppl 1):115, 1995.
603. **Schlegel PN**, **Palermo GD**, **Goldstein M**, **Menendez S**, **Zaninovic N**, **Veeck LL**, **Rosenwaks Z**, Testicular sperm extraction with intracytoplasmic sperm injection for nonobstructive azoospermia, Urology 49:435, 1997.
604. **Craft I**, **Tsirigotis M**, Simplified recovery, preparation and cryopreservation of testicular spermatozoa, Hum Reprod 10:1623, 1995.
605. **Schlegel PN**, Testicular sperm extraction: microdissection improves sperm yield with minimal tissue excision, Hum Reprod 14:131, 1999.
606. **Dardashti K**, **Williams RH**, **Goldstein M**, Microsurgical testis biopsy: a novel technique for retrieval of testicular tissue, J Urol 163:1206, 2000.
607. **Silber SJ**, **van Steirteghem A**, **Nagy Z**, **Liu J**, **Tournaye H**, **Devroey P**, Normal pregnancies resulting from testicular sperm extraction and intracytoplasmic sperm injection for azoospermia due to maturation arrest, Fertil Steril 66:110, 1996.
608. **Chen SU**, **Ho HN**, **Chen HF**, **Tsai TC**, **Lee TY**, **Yang YS**, Fertilization and embryo cleavage after intracytoplasmic spermatid injection in an obstructive azoospermic patient with defective spermiogenesis, Fertil Steril 66:157, 1996.
609. **Su LM**, **Palermo GD**, **Goldstein M**, **Veeck LL**, **Rosenwaks Z**, **Schlegel PN**, Testicular sperm extraction with intracytoplasmic sperm injection for nonobstructive azoospermia: testicular histology can predict success of sperm retrieval, J Urol 161:112, 1999.
610. **Chan PT**, **Palermo GD**, **Veeck LL**, **Rosenwaks Z**, **Schlegel PN**, Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy, Cancer 92:1632, 2001.
611. **Damani MN**, **Master V**, **Meng MV**, **Burgess C**, **Turek P**, **Oates RD**, Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection, J Clin Oncol 20:930, 2002.
612. **Revel A**, **Haimov-Kochman R**, **Porat A**, **Lewin A**, **Simon A**, **Laufer N**, **Gino H**, **Meirow D**, In vitro fertilization-intracytoplasmic sperm injection success rates with cryopreserved sperm from patients with malignant disease, Fertil Steril 84:118, 2005.
613. **Palermo GD**, **Schlegel PN**, **Sills ES**, **Veeck LL**, **Zaninovic N**, **Menendez S**, **Rosenwaks Z**, Births after intracytoplasmic injection of sperm obtained by testicular extraction from men with nonmosaic Klinefelter's syndrome, N Engl J Med 338:588, 1998.
614. **Kurinczuk JJ**, **Bower C**, Birth defects in infants conceived by intracytoplasmic sperm injection: an alternative interpretation, Br Med J 315:1260, 1997.
615. **Hansen M**, **Bower C**, **Milne E**, **de Klerk N**, **Kurinczuk JJ**, Assisted reproductive technologies and the risk of birth defects—a systematic review, Hum Reprod 20:328, 2005.
616. **Fraga CG**, **Motchnik PA**, **Wyrobek AJ**, **Rempel DM**, **Ames BN**, Smoking and low antioxidant levels increase oxidative damage to sperm DNA, Mutat Res 351:199, 1996.

617. **Ji BT**, **Shu XO**, **Linet MS**, **Zheng W**, **Wacholder S**, **Gao YT**, **Ying DM**, **Jin F**, Paternal cigarette smoking and the risk of childhood cancer among offspring of nonsmoking mothers, J Natl Cancer Inst 89:238, 1997.
618. **Sun JG**, **Jurisicova A**, **Casper RF**, Detection of deoxyribonucleic acid fragmentation in human sperm: correlation with fertilization in vitro, Biol Reprod 56:602, 1997.
619. **Bonduelle M**, **Wilikens A**, **Buysse A**, **Van Assche E**, **Wisanto A**, **Devroey P**, **Van Steirteghem AC**, **Liebaers I**, Prospective follow-up study of 877 children born after intracytoplasmic sperm injection (ICSI), with ejaculated epididymal and testicular spermatozoa and after replacement of cryopreserved embryos obtained after ICSI, Hum Reprod 11(Suppl 4):131, 1996.
620. **Bonduelle M**, **Legein J**, **Buysse A**, **Van Assche E**, **Wisanto A**, **Devroey P**, **Van Steirteghem AC**, **Liebaers I**, Prospective follow-up study of 423 children born after intracytoplasmic sperm injection, Hum Reprod 11:1558, 1996.
621. **Van Golde R**, **Boada M**, **Veiga A**, **Evers J**, **Geraedts J**, **Barri P**, A retrospective follow-up study on intracytoplasmic sperm injection, J Assist Reprod Genet 16:227, 1999.
622. **Hansen M**, **Kurinczuk JJ**, **Bower C**, **Webb S**, The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization, N Engl J Med 346:725, 2002.
623. **Lie RT**, **Lyngstadaas A**, **Orstavik KH**, **Bakketeig LS**, **Jacobsen G**, **Tanbo T**, Birth defects in children conceived by ICSI compared with children conceived by other IVF-methods; a meta-analysis, Int J Epidemiol 34:696, 2005.
624. **Wennerholm UB**, **Bergh C**, **Hamberger L**, **Lundin K**, **Nilsson L**, **Wikland M**, **Kallen B**, Incidence of congenital malformations in children born after ICSI, Hum Reprod 15:944, 2000.
625. **Allen VM**, **Wilson RD**, **Cheung A**, Pregnancy outcomes after assisted reproductive technology, J Obstet Gynaecol Can 28:220, 2006.

Chapter twenty seven

REFERENCES

1. **Hull MG**, **Glazener CM**, **Kelly NJ**, **Conway DI**, **Foster PA**, **Hinton RA**, **Coulson C**, **Lambert PA**, **Watt EM**, **Desai KM**, Population study of causes, treatment, and outcome of infertility, Br Med J (Clin Res Ed) 291:1693, 1985.
2. **Bates GW**, **Garza DE**, **Garza MM**, Clinical manifestations of hormonal changes in the menstrual cycle, Obstet Gynecol Clin North Am 17:299, 1990.
3. **Practice Committee of the American Society for Reproductive Medicine**, Diagnostic evaluation of the infertile female: a committee opinion, Fertil Steril 103:e44, 2015.
4. **Abraham GE**, **Maroulis GB**, **Marshall JR**, Evaluation of ovulation and corpus luteum function using measurements of plasma progesterone, Obstet Gynecol 44:522, 1974.
5. **Wathen NC**, **Perry L**, **Lilford RJ**, **Chard T**, Interpretation of single progesterone measurement in diagnosis of anovulation and defective luteal phase: observations on analysis of the normal range, Br Med J (Clin Res Ed) 288:7, 1984.
6. **Filicori M**, **Butler JP**, **Crowley WF Jr**, Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion, J Clin Invest 73:1638, 1984.
7. Agents stimulating gonadal function in the human. Report of a WHO scientific group, World Health Organ Tech Rep Ser 514:1, 1973.
8. **Laven JS**, **Imani B**, **Eijkemans MJ**, **Fauser BC**, New approach to polycystic ovary syndrome and other forms of anovulatory infertility, Obstet Gynecol Surv 57:755, 2002.
9. **Teede HJ**, **Misso ML**, **Costello MF**, **Dokras A**, **Laven J**, **Moran L**, **Piltonen T**, **Norman RJ; International PCOS Network**, Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome, Fertil Steril 110:364, 2018.
10. **Lincoln SR**, **Ke RW**, **Kutteh WH**, Screening for hypothyroidism in infertile women, J Reprod Med 44:455, 1999.
11. **Webster J**, **Piscitelli G**, **Polli A**, **Ferrari CI**, **Ismail I**, **Scanlon MF**, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group, N Engl J Med 331:904, 1994.
12. **Cuellar FG**, Bromocriptine mesylate (Parlodel) in the management of amenorrhea/galactorrhea associated with hyperprolactinemia, Obstet Gynecol 55:278, 1980.
13. **Thonneau P**, **Marchand S**, **Tallec A**, **Ferial ML**, **Ducot B**, **Lansac J**, **Lopes P**, **Tabaste JM**, **Spira A**, Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988-1989), Hum Reprod 6:811, 1991.
14. **Pasquali R**, **Antenucci D**, **Casimirri F**, **Venturoli S**, **Paradisi R**, **Fabbri R**, **Balestra V**, **Melchionda N**, **Barbara L**, Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss, J Clin Endocrinol Metab 68:173, 1989.
15. **Kiddy DS**, **Hamilton-Fairley D**, **Seppala M**, **Koistinen R**, **James VH**, **Reed MJ**, **Franks S**, Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I, Clin Endocrinol (Oxf) 31:757, 1989.
16. **Guzick DS**, **Wing R**, **Smith D**, **Berga SL**, **Winters SJ**, Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women, Fertil Steril 61:598, 1994.
17. **Andersen P**, **Seljeflot I**, **Abdelnoor M**, **Arnesen H**, **Dale PO**, **Lovik A**, **Birkeland K**, Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome, Metabolism 44:611, 1995.
18. **Jakubowicz DJ**, **Nestler JE**, 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss, J Clin Endocrinol Metab 82:556, 1997.
19. **Clark AM**, **Ledger W**, **Galletly C**, **Tomlinson L**, **Blaney F**, **Wang X**, **Norman RJ**, Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women, Hum Reprod 10:2705,

1995.
20. **Hollmann M**, **Runnebaum B**, **Gerhard I**, Effects of weight loss on the hormonal profile in obese, infertile women, Hum Reprod 11:1884, 1996.
21. **Legro RS**, **Dodson WC**, **Kris-Etherton PM**, **Kunselman AR**, **Stetter CM**, **Williams NI**, **Gnatuk CL**, **Estes SJ**, **Fleming J**, **Allison KC**, **Sarwer DB**, **Coutifaris C**, **Dokras A**, Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome, J Clin Endocrinol Metab 100:4048, 2015.
22. **Legro RS**, **Brzyski RG**, **Diamond MP**, **Coutifaris C**, **Schlaff WD**, **Casson P**, **Christman GM**, **Huang H**, **Yan Q**, **Alvero R**, **Haisenleder DJ**, **Barnhart KT**, **Bates GW**, **Usadi R**, **Lucidi S**, **Baker V**, **Trussell JC**, **Krawetz SA**, **Snyder P**, **Ohl D**, **Santoro N**, **Eisenberg E**, **Zhang H; NICHD Reproductive Medicine Network**, Letrozole versus clomiphene for infertility in the polycystic ovary syndrome, N Engl J Med 371:119, 2014.
23. **Legro RS**, **Dodson WC**, **Kunselman AR**, **Stetter CM**, **Kris-Etherton PM**, **Williams NI**, **Gnatuk CL**, **Estes SJ**, **Allison KC**, **Sarwer DB**, **Diamond MP**, **Schlaff WD**, **Casson PR**, **Christman GM**, **Barnhart KT**, **Bates GW**, **Usadi R**, **Lucidi S**, **Baker V**, **Zhang H**, **Eisenberg E**, **Coutifaris C**, **Dokras A**, Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS, J Clin Endocrinol Metab 101:2658, 2016.
24. **Kominiarek MA**, **Jungheim ES**, **Hoeger KM**, **Rogers AM**, **Kahan S**, **Kim JJ**, American Society for Metabolic and Bariatric Surgery position statement on the impact of obesity and obesity treatment on fertility and fertility therapy Endorsed by the American College of Obstetricians and Gynecologists and the Obesity Society, Surg Obes Relat Dis 13:750, 2017.
25. **Skubleny D**, **Switzer NJ**, **Gill RS**, **Dykstra M**, **Shi X**, **Sagle MA**, **de Gara C**, **Birch DW**, **Karmali S**, The impact of bariatric surgery on polycystic ovary syndrome: a systematic review and meta-analysis, Obes Surg 26:169, 2016.
26. **Christ JP**, **Falcone T**, Bariatric surgery improves hyperandrogenism, menstrual irregularities, and metabolic dysfunction among women with polycystic ovary syndrome (PCOS), Obes Surg 28:2171, 2018.
27. **Escobar-Morreale HF**, **Santacruz E**, **Luque-Ramirez M**, **Botella Carretero JI**, Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis, Hum Reprod Update 23:390, 2017.
28. **Greenblatt RB**, **Barfield WE**, **Jungck EC**, **Ray AW**, Induction of ovulation with MRL/41. Preliminary report, JAMA 178:101, 1961.
29. **Dickey RP**, **Holtkamp DE**, Development, pharmacology and clinical experience with clomiphene citrate, Hum Reprod Update 2:483, 1996.
30. **Palomba S**, **Orio F Jr**, **Falbo A**, **Manguso F**, **Russo T**, **Cascella T**, **Tolino A**, **Carmina E**, **Colao A**, **Zullo F**, Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome, J Clin Endocrinol Metab 90:4068, 2005.
31. **Clark JH**, **Markaverich BM**, The agonistic-antagonistic properties of clomiphene: a review, Pharmacol Ther 15:467, 1981.
32. **Mikkelson TJ**, **Kroboth PD**, **Cameron WJ**, **Dittert LW**, **Chungi V**, **Manberg PJ**, Single-dose pharmacokinetics of clomiphene citrate in normal volunteers, Fertil Steril 46:392, 1986.
33. **Ernst S**, **Hite G**, **Cantrell JS**, **Richardson A Jr**, **Benson HD**, Stereochemistry of geometric isomers of clomiphene: a correction of the literature and a reexamination of structure-activity relationships, J Pharm Sci 65:148, 1976.
34. **Van Campenhout J**, **Borreman E**, **Wyman H**, **Antaki A**, Induction of ovulation with cisclomiphene, Am J Obstet Gynecol 115:321, 1973.
35. **Young SL**, **Opsahl MS**, **Fritz MA**, Serum concentrations of enclomiphene and zuclomiphene across consecutive cycles of clomiphene citrate therapy in anovulatory infertile women, Fertil Steril 71:639, 1999.
36. **Hsueh AJ**, **Erickson GF**, **Yen SS**, Sensitisation of pituitary cells to luteinising hormone releasing hormone by clomiphene citrate in vitro, Nature 273:57, 1978.

37. **Kerin JF**, **Liu JH**, **Phillipou G**, **Yen SS**, Evidence for a hypothalamic site of action of clomiphene citrate in women, J Clin Endocrinol Metab 61:265, 1985.
38. **Kettel LM**, **Roseff SJ**, **Berga SL**, **Mortola JF**, **Yen SS**, Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome, Fertil Steril 59:532, 1993.
39. **Wu CH**, **Prazak LM**, Endocrine basis for ovulation induction, Clin Obstet Gynecol 17:65, 1974.
40. **Adashi EY**, Clomiphene citrate: mechanism(s) and site(s) of action—a hypothesis revisited, Fertil Steril 42:331, 1984.
41. **Butzow TL**, **Kettel LM**, **Yen SS**, Clomiphene citrate reduces serum insulin-like growth factor I and increases sex hormone-binding globulin levels in women with polycystic ovary syndrome, Fertil Steril 63:1200, 1995.
42. **Thompson LA**, **Barratt CL**, **Thornton SJ**, **Bolton AE**, **Cooke ID**, The effects of clomiphene citrate and cyclofenil on cervical mucus volume and receptivity over the periovulatory period, Fertil Steril 59:125, 1993.
43. **Marchini M**, **Dorta M**, **Bombelli F**, **Ruspa M**, **Campana A**, **Dolcetta G**, **Radici E**, Effects of clomiphene citrate on cervical mucus: analysis of some influencing factors, Int J Fertil 34:154, 1989.
44. **Roumen FJ**, [Decreased quality of cervix mucus under the influence of clomiphene: a meta-analysis], Ned Tijdschr Geneeskd 141:2401, 1997.
45. **Tepper R**, **Lunenfeld B**, **Shalev J**, **Ovadia J**, **Blankstein J**, The effect of clomiphene citrate and tamoxifen on the cervical mucus, Acta Obstet Gynecol Scand 67:311, 1988.
46. **Elstein M**, **Fawcett GM**, Effects of the anti-oestrogens, clomiphene and tamoxifen, on the cervical factor in female infertility, Ciba Found Symp 109:173, 1984.
47. **Griffith CS**, **Grimes DA**, The validity of the postcoital test, Am J Obstet Gynecol 162:615, 1990.
48. **Oei SG**, **Helmerhorst FM**, **Bloemenkamp KW**, **Hollants FA**, **Meerpoel DE**, **Keirse MJ**, Effectiveness of the postcoital test: randomised controlled trial, BMJ 317:502, 1998.
49. **Guzick DS**, **Carson SA**, **Coutifaris C**, **Overstreet JW**, **Factor-Litvak P**, **Steinkampf MP**, **Hill JA**, **Mastroianni L**, **Buster JE**, **Nakajima ST**, **Vogel DL**, **Canfield RE**, Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network, N Engl J Med 340:177, 1999.
50. **Guzick DS**, **Sullivan MW**, **Adamson GD**, **Cedars MI**, **Falk RJ**, **Peterson EP**, **Steinkampf MP**, Efficacy of treatment for unexplained infertility, Fertil Steril 70:207, 1998.
51. **Asante A**, **Coddington CC**, **Schenck L**, **Stewart EA**, Thin endometrial stripe does not affect likelihood of achieving pregnancy in clomiphene citrate/intrauterine insemination cycles, Fertil Steril 100:1610.e1, 2013.
52. **Kolibianakis EM**, **Zikopoulos KA**, **Fatemi HM**, **Osmanagaoglu K**, **Evenpoel J**, **Van Steirteghem A**, **Devroey P**, Endometrial thickness cannot predict ongoing pregnancy achievement in cycles stimulated with clomiphene citrate for intrauterine insemination, Reprod Biomed Online 8:115, 2004.
53. **Eden JA**, **Place J**, **Carter GD**, **Jones J**, **Alaghband-Zadeh J**, **Pawson ME**, The effect of clomiphene citrate on follicular phase increase in endometrial thickness and uterine volume, Obstet Gynecol 73:187, 1989.
54. **Randall JM**, **Templeton A**, Transvaginal sonographic assessment of follicular and endometrial growth in spontaneous and clomiphene citrate cycles, Fertil Steril 56:208, 1991.
55. **Haritha S**, **Rajagopalan G**, Follicular growth, endometrial thickness, and serum estradiol levels in spontaneous and clomiphene citrate-induced cycles, Int J Gynaecol Obstet 81:287, 2003.
56. **Check JH**, **Dietterich C**, **Lurie D**, The effect of consecutive cycles of clomiphene citrate therapy on endometrial thickness and echo pattern, Obstet Gynecol 86:341, 1995.
57. **Bonhoff AJ**, **Naether OG**, **Johannisson E**, Effects of clomiphene citrate stimulation on endometrial structure in infertile women, Hum Reprod 11:844, 1996.
58. **Sereepapong W**, **Suwajanakorn S**, **Triratanachat S**, **Sampatanukul P**, **Pruksananonda K**, **Boonkasemsanti W**, **Reinprayoon D**, Effects of clomiphene citrate on the endometrium of regularly cycling women, Fertil Steril 73:287, 2000.
59. **Sgarlata CS**, **Mikhail G**, **Hertelendy F**, Clomiphene and tamoxifen inhibit progesterone synthesis in granulosa cells: comparison with estradiol, Endocrinology 114:2032, 1984.
60. **Opsahl MS**, **Fitz TA**, **Rexroad CE Jr**, **Fritz MA**, Effects of enclomiphene and zuclomiphene on basal and gonadotrophin-stimulated progesterone secretion by isolated subpopulations of small and large ovine luteal cells,

Hum Reprod 11:1250, 1996.
61. **Olsson JH**, **Nilsson L**, **Hillensjo T**, Effect of clomiphene isomers on progestin synthesis in cultured human granulosa cells, Hum Reprod 2:463, 1987.
62. **Schmidt GE**, **Kim MH**, **Mansour R**, **Torello L**, **Friedman CI**, The effects of enclomiphene and zuclomiphene citrates on mouse embryos fertilized in vitro and in vivo, Am J Obstet Gynecol 154:727, 1986.
63. **Practice Committee of the American Society for Reproductive Medicine**, Use of clomiphene citrate in infertile women: a committee opinion, Fertil Steril 100:341, 2013.
64. **Practice Committee of the American Society for Reproductive Medicine**, Use of clomiphene citrate in women, Fertil Steril 86:S187, 2006.
65. **Bhattacharya S**, **Harrild K**, **Mollison J**, **Wordsworth S**, **Tay C**, **Harrold A**, **McQueen D**, **Lyall H**, **Johnston L**, **Burrage J**, **Grossett S**, **Walton H**, **Lynch J**, **Johnstone A**, **Kini S**, **Raja A**, **Templeton A**, Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial, BMJ 337:a716, 2008.
66. **Glazener CM**, **Coulson C**, **Lambert PA**, **Watt EM**, **Hinton RA**, **Kelly NG**, **Hull MG**, Clomiphene treatment for women with unexplained infertility: placebo-controlled study of hormonal responses and conception rates, Gynecol Endocrinol 4:75, 1990.
67. **Meyer WR**, **Fritz MA**, Empiric clomiphene treatment: when and why, Contemp OB/GYN 40:13, 1995.
68. **Deaton JL**, **Clark RR**, **Pittaway DE**, **Herbst P**, **Bauguess P**, Clomiphene citrate ovulation induction in combination with a timed intrauterine insemination: the value of urinary luteinizing hormone versus human chorionic gonadotropin timing, Fertil Steril 68:43, 1997.
69. **Strott CA**, **Cargille CM**, **Ross GT**, **Lipsett MB**, The short luteal phase, J Clin Endocrinol Metab 30:246, 1970.
70. **Sherman BM**, **Korenman SG**, Measurement of serum LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the inadequate luteal phase, J Clin Endocrinol Metab 39:145, 1974.
71. **Quagliarello J**, **Weiss G**, Clomiphene citrate in the management of infertility associated with shortened luteal phases, Fertil Steril 31:373, 1979.
72. **Downs KA**, **Gibson M**, Clomiphene citrate therapy for luteal phase defect, Fertil Steril 39:34, 1983.
73. **Huang KE**, The primary treatment of luteal phase inadequacy: progesterone versus clomiphene citrate, Am J Obstet Gynecol 155:824, 1986.
74. **Murray DL**, **Reich L**, **Adashi EY**, Oral clomiphene citrate and vaginal progesterone suppositories in the treatment of luteal phase dysfunction: a comparative study, Fertil Steril 51:35, 1989.
75. **Guzick DS**, **Zeleznik A**, Efficacy of clomiphene citrate in the treatment of luteal phase deficiency: quantity versus quality of preovulatory follicles, Fertil Steril 54:206, 1990.
76. **Deaton JL**, **Gibson M**, **Blackmer KM**, **Nakajima ST**, **Badger GJ**, **Brumsted JR**, A randomized, controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility or surgically corrected endometriosis, Fertil Steril 54:1083, 1990.
77. **Abu Hashim H**, **Ombar O**, **Abd Elaal I**, Intrauterine insemination versus timed intercourse with clomiphene citrate in polycystic ovary syndrome: a randomized controlled trial, Acta Obstet Gynecol Scand 90:344, 2011.
78. **Wu CH**, **Winkel CA**, The effect of therapy initiation day on clomiphene citrate therapy, Fertil Steril 52:564, 1989.
79. **Diamond MP**, **Kruger M**, **Santoro N**, **Zhang H**, **Casson P**, **Schlaff W**, **Coutifaris C**, **Brzyski R**, **Christman G**, **Carr BR**, **McGovern PG**, **Cataldo NA**, **Steinkampf MP**, **Gosman GG**, **Nestler JE**, **Carson S**, **Myers EE**, **Eisenberg E**, **Legro RS**; **Eunice Kennedy Shriver National Institute of Child Health, Human Development Cooperative Reproductive Medicine Network**, Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome, Obstet Gynecol 119:902, 2012.
80. **Jones CA**, **Garbedian K**, **Dixon M**, **Murphy K**, **Shapiro H**, Randomized trial comparing the effect of endometrial shedding with medroxyprogesterone acetate with random start of clomiphene citrate for ovulation induction in oligo-ovulatory and anovulatory women, J Obstet Gynaecol Can 38:458, 2016.
81. **Lobo RA**, **Gysler M**, **March CM**, **Goebelsmann U**, **Mishell DR Jr**, Clinical and laboratory predictors of clomiphene response, Fertil Steril 37:168, 1982.

82. **Lobo RA**, **Granger LR**, **Davajan V**, **Mishell DR Jr**, An extended regimen of clomiphene citrate in women unresponsive to standard therapy, Fertil Steril 37:762, 1982.
83. **Hammond MG**, **Halme JK**, **Talbert LM**, Factors affecting the pregnancy rate in clomiphene citrate induction of ovulation, Obstet Gynecol 62:196, 1983.
84. **Tiitinen AE**, **Laatikainen TJ**, **Seppala MT**, Serum levels of insulin-like growth factor binding protein-1 and ovulatory responses to clomiphene citrate in women with polycystic ovarian disease, Fertil Steril 60:58, 1993.
85. **Gysler M**, **March CM**, **Mishell DR Jr**, **Bailey EJ**, A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test, Fertil Steril 37:161, 1982.
86. **Gorlitsky GA**, **Kase NG**, **Speroff L**, Ovulation and pregnancy rates with clomiphene citrate, Obstet Gynecol 51:265, 1978.
87. **Dodge ST**, **Strickler RC**, **Keller DW**, Ovulation induction with low doses of clomiphene citrate, Obstet Gynecol 67:63S, 1986.
88. **Fluker MR**, **Wang IY**, **Rowe TC**, An extended 10-day course of clomiphene citrate (CC) in women with CC-resistant ovulatory disorders, Fertil Steril 66:761, 1996.
89. **Isaacs JD Jr**, **Lincoln SR**, **Cowan BD**, Extended clomiphene citrate (CC) and prednisone for the treatment of chronic anovulation resistant to CC alone, Fertil Steril 67:641, 1997.
90. **Miller PB**, **Soules MR**, The usefulness of a urinary LH kit for ovulation prediction during menstrual cycles of normal women, Obstet Gynecol 87:13, 1996.
91. **Opsahl MS**, **Robins ED**, **O'Connor DM**, **Scott RT**, **Fritz MA**, Characteristics of gonadotropin response, follicular development, and endometrial growth and maturation across consecutive cycles of clomiphene citrate treatment, Fertil Steril 66:533, 1996.
92. **Zreik TG**, **Garcia-Velasco JA**, **Habboosh MS**, **Olive DL**, **Arici A**, Prospective, randomized, crossover study to evaluate the benefit of human chorionic gonadotropin-timed versus urinary luteinizing hormone-timed intrauterine inseminations in clomiphene citrate-stimulated treatment cycles, Fertil Steril 71:1070, 1999.
93. **McGovern PG**, **Myers ER**, **Silva S**, **Coutifaris C**, **Carson SA**, **Legro RS**, **Schlaff WD**, **Carr BR**, **Steinkampf MP**, **Giudice LC**, **Leppert PC**, **Diamond MP; NICHD National Cooperative Reproductive Medicine Network**, Absence of secretory endometrium after false-positive home urine luteinizing hormone testing, Fertil Steril 82:1273, 2004.
94. **Noyes RW**, **Hertig AT**, **Rock J**, Dating the endometrial biopsy, Am J Obstet Gynecol 122:262, 1975.
95. **de Crespigny LC**, **O'Herlihy C**, **Robinson HP**, Ultrasonic observation of the mechanism of human ovulation, Am J Obstet Gynecol 139:636, 1981.
96. **Ecochard R**, **Marret H**, **Rabilloud M**, **Bradai R**, **Boehringer H**, **Girotto S**, **Barbato M**, Sensitivity and specificity of ultrasound indices of ovulation in spontaneous cycles, Eur J Obstet Gynecol Reprod Biol 91:59, 2000.
97. **Kousta E**, **White DM**, **Franks S**, Modern use of clomiphene citrate in induction of ovulation, Hum Reprod Update 3:359, 1997.
98. **Smith YR**, **Randolph JF Jr**, **Christman GM**, **Ansbacher R**, **Howe DM**, **Hurd WW**, Comparison of low-technology and high-technology monitoring of clomiphene citrate ovulation induction, Fertil Steril 70:165, 1998.
99. **Hurst BS**, **Hickman JM**, **Matthews ML**, **Usadi RS**, **Marshburn PB**, Novel clomiphene "stair-step" protocol reduces time to ovulation in women with polycystic ovarian syndrome, Am J Obstet Gynecol 200:510.e1, 2009.
100. **Imani B**, **Eijkemans MJ**, **te Velde ER**, **Habbema JD**, **Fauser BC**, A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility, Fertil Steril 77:91, 2002.
101. **Deveci CD**, **Demir B**, **Sengul O**, **Dilbaz B**, **Goktolga U**, Clomiphene citrate 'stair-step' protocol vs. traditional protocol in patients with polycystic ovary syndrome: a randomized controlled trial, Arch Gynecol Obstet 291:179, 2015.
102. **Imani B**, **Eijkemans MJ**, **te Velde ER**, **Habbema JD**, **Fauser BC**, Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility, J Clin Endocrinol Metab 83:2361, 1998.

103. **Homburg R**, Clomiphene citrate—end of an era? A mini-review, Hum Reprod 20:2043, 2005.
104. **Imani B**, **Eijkemans MJ**, **te Velde ER**, **Habbema JD**, **Fauser BC**, Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility, J Clin Endocrinol Metab 84:1617, 1999.
105. **ACOG Committee on Practice Bulletins-Gynecology**, ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists number 34, February 2002. Management of infertility caused by ovulatory dysfunction. American College of Obstetricians and Gynecologists, Obstet Gynecol 99:347, 2002.
106. **Purvin VA**, Visual disturbance secondary to clomiphene citrate, Arch Ophthalmol 113:482, 1995.
107. **Schenker JG**, **Yarkoni S**, **Granat M**, Multiple pregnancies following induction of ovulation, Fertil Steril 35:105, 1981.
108. **Ahlgren M**, **Kallen B**, **Rannevik G**, Outcome of pregnancy after clomiphene therapy, Acta Obstet Gynecol Scand 55:371, 1976.
109. **Correy JF**, **Marsden DE**, **Schokman FC**, The outcome of pregnancy resulting from clomiphene-induced ovulation, Aust N Z J Obstet Gynaecol 22:18, 1982.
110. **Reindollar RH**, **Regan MM**, **Neumann PJ**, **Levine BS**, **Thornton KL**, **Alper MM**, **Goldman MB**, A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial, Fertil Steril 94:888, 2010.
111. **Kurachi K**, **Aono T**, **Minagawa J**, **Miyake A**, Congenital malformations of newborn infants after clomiphene-induced ovulation, Fertil Steril 40:187, 1983.
112. **Reefhuis J**, **Honein MA**, **Schieve LA**, **Rasmussen SA; National Birth Defects Prevention Study**, Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997-2005, Hum Reprod 26:451, 2011.
113. **Whiteman D**, **Murphy M**, **Hey K**, **O'Donnell M**, **Goldacre M**, Reproductive factors, subfertility, and risk of neural tube defects: a case-control study based on the Oxford Record Linkage Study Register, Am J Epidemiol 152:823, 2000.
114. **Lammer EJ**, Clomiphene-induced ovulation and the risk of neural tube defects, Reprod Toxicol 9:491, 1995.
115. **Carlier P**, **Choulika S**, **Efthymiou ML**, [Clomiphene-exposed pregnancies—analysis of 39 information requests including 25 cases with known outcome], Therapie 51:532, 1996.
116. **Hack M**, **Brish M**, **Serr DM**, **Insler V**, **Salomy M**, **Lunenfeld B**, Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after clomiphene therapy, JAMA 220:1329, 1972.
117. **Dickey RP**, **Taylor SN**, **Curole DN**, **Rye PH**, **Pyrzak R**, Incidence of spontaneous abortion in clomiphene pregnancies, Hum Reprod 11:2623, 1996.
118. **Legro RS**, **Barnhart HX**, **Schlaff WD**, **Carr BR**, **Diamond MP**, **Carson SA**, **Steinkampf MP**, **Coutifaris C**, **McGovern PG**, **Cataldo NA**, **Gosman GG**, **Nestler JE**, **Giudice LC**, **Leppert PC**, **Myers ER; Cooperative Multicenter Reproductive Medicine Network**, Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome, N Engl J Med 356:551, 2007.
119. **Tung KH**, **Wilkens LR**, **Wu AH**, **McDuffie K**, **Nomura AM**, **Kolonel LN**, **Terada KY**, **Goodman MT**, Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis, Am J Epidemiol 161:321, 2005.
120. **Whittemore AS**, **Harris R**, **Itnyre J**, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group, Am J Epidemiol 136:1184, 1992.
121. **Rossing MA**, **Daling JR**, **Weiss NS**, **Moore DE**, **Self SG**, Ovarian tumors in a cohort of infertile women, N Engl J Med 331:771, 1994.
122. **Venn A**, **Watson L**, **Lumley J**, **Giles G**, **King C**, **Healy D**, Breast and ovarian cancer incidence after infertility and in vitro fertilisation, Lancet 346:995, 1995.
123. **Modan B**, **Ron E**, **Lerner-Geva L**, **Blumstein T**, **Menczer J**, **Rabinovici J**, **Oelsner G**, **Freedman L**, **Mashiach S**, **Lunenfeld B**, Cancer incidence in a cohort of infertile women, Am J Epidemiol 147:1038, 1998.
124. **Potashnik G**, **Lerner-Geva L**, **Genkin L**, **Chetrit A**, **Lunenfeld E**, **Porath A**, Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study, Fertil Steril 71:853, 1999.

125. **Mosgaard BJ**, **Lidegaard O**, **Kjaer SK**, **Schou G**, **Andersen AN**, Infertility, fertility drugs, and invasive ovarian cancer: a case-control study, Fertil Steril 67:1005, 1997.
126. **Unkila-Kallio L**, **Tiitinen A**, **Wahlstrom T**, **Lehtovirta P**, **Leminen A**, Reproductive features in women developing ovarian granulosa cell tumour at a fertile age, Hum Reprod 15:589, 2000.
127. **Rossing MA**, **Tang MT**, **Flagg EW**, **Weiss LK**, **Wicklund KG**, A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs, Am J Epidemiol 160:1070, 2004.
128. **Brinton L**, Long-term effects of ovulation-stimulating drugs on cancer risk, Reprod Biomed Online 15:38, 2007.
129. **Kashyap S**, **Moher D**, **Fung MF**, **Rosenwaks Z**, Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis, Obstet Gynecol 103:785, 2004.
130. **Calderon-Margalit R**, **Friedlander Y**, **Yanetz R**, **Kleinhaus K**, **Perrin MC**, **Manor O**, **Harlap S**, **Paltiel O**, Cancer risk after exposure to treatments for ovulation induction, Am J Epidemiol 169:365, 2009.
131. **Rizzuto I**, **Behrens RF**, **Smith LA**, Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility, Cochrane Database Syst Rev (8):CD008215, 2013.
132. **Bjornholt SM**, **Kjaer SK**, **Nielsen TS**, **Jensen A**, Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study, Hum Reprod 30:222, 2015.
133. **Ness RB**, **Cramer DW**, **Goodman MT**, **Kjaer SK**, **Mallin K**, **Mosgaard BJ**, **Purdie DM**, **Risch HA**, **Vergona R**, **Wu AH**, Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies, Am J Epidemiol 155:217, 2002.
134. **Trabert B**, **Lamb EJ**, **Scoccia B**, **Moghissi KS**, **Westhoff CL**, **Niwa S**, **Brinton LA**, Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort, Fertil Steril 100:1660, 2013.
135. **Brinton LA**, **Scoccia B**, **Moghissi KS**, **Westhoff CL**, **Niwa S**, **Ruggieri D**, **Trabert B**, **Lamb EJ**, Long-term relationship of ovulation-stimulating drugs to breast cancer risk, Cancer Epidemiol Biomarkers Prev 23:584, 2014.
136. **Skalkidou A**, **Sergentanis TN**, **Gialamas SP**, **Georgakis MK**, **Psaltopoulou T**, **Trivella M**, **Siristatidis CS**, **Evangelou E**, **Petridou E**, Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility, Cochrane Database Syst Rev (3):CD010931, 2017.
137. **Lobo RA**, **Paul W**, **March CM**, **Granger L**, **Kletzky OA**, Clomiphene and dexamethasone in women unresponsive to clomiphene alone, Obstet Gynecol 60:497, 1982.
138. **Daly DC**, **Walters CA**, **Soto-Albors CE**, **Tohan N**, **Riddick DH**, A randomized study of dexamethasone in ovulation induction with clomiphene citrate, Fertil Steril 41:844, 1984.
139. **Trott EA**, **Plouffe L Jr**, **Hansen K**, **Hines R**, **Brann DW**, **Mahesh VB**, Ovulation induction in clomiphene-resistant anovulatory women with normal dehydroepiandrosterone sulfate levels: beneficial effects of the addition of dexamethasone during the follicular phase, Fertil Steril 66:484, 1996.
140. **Vital Reyes VS**, **Tellez Velasco S**, **Hinojosa Cruz JC**, **Reyes Fuentes A**, [Clomiphene acetate and prednisone: alternative approach for the management of patients with chronic anovulation and clomiphene treatment failure], Ginecol Obstet Mex 68:266, 2000.
141. **Parsanezhad ME**, **Alborzi S**, **Motazedian S**, **Omrani G**, Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial, Fertil Steril 78:1001, 2002.
142. **Elnashar A**, **Abdelmageed E**, **Fayed M**, **Sharaf M**, Clomiphene citrate and dexamethasone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study, Hum Reprod 21:1805, 2006.
143. **Keay SD**, **Jenkins JM**, Adjunctive use of dexamethasone in Clomid resistant patients, Fertil Steril 80:230; author reply 231, 2003.
144. **O'Herlihy C**, **Pepperell RJ**, **Robinson HP**, Ultrasound timing of human chorionic gonadotropin administration in clomiphene-stimulated cycle, Obstet Gynecol 59:40, 1982.
145. **Martinez AR**, **Bernadus RE**, **Voorhorst FJ**, **Vermeiden JP**, **Schoemaker J**, A controlled study of human

chorionic gonadotrophin induced ovulation versus urinary luteinizing hormone surge for timing of intrauterine insemination, Hum Reprod 6:1247, 1991.
146. **Palatnik A**, **Strawn E**, **Szabo A**, **Robb P**, What is the optimal follicular size before triggering ovulation in intrauterine insemination cycles with clomiphene citrate or letrozole? An analysis of 988 cycles, Fertil Steril 97:1089.e1, 2012.
147. **Martinez AR**, **Bernardus RE**, **Kucharska D**, **Schoemaker J**, Urinary luteinizing hormone testing and prediction of ovulation in spontaneous, clomiphene citrate and human menopausal gonadotropin-stimulated cycles. A clinical evaluation, Acta Endocrinol (Copenh) 124:357, 1991.
148. **Andersen AG**, **Als-Nielsen B**, **Hornnes PJ**, **Franch Andersen L**, Time interval from human chorionic gonadotrophin (HCG) injection to follicular rupture, Hum Reprod 10:3202, 1995.
149. **George K**, **Kamath MS**, **Nair R**, **Tharyan P**, Ovulation triggers in anovulatory women undergoing ovulation induction, Cochrane Database Syst Rev (1):CD006900, 2014.
150. **Kosmas IP**, **Tatsioni A**, **Fatemi HM**, **Kolibianakis EM**, **Tournaye H**, **Devroey P**, Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis, Fertil Steril 87:607, 2007.
151. **Fritz MA**, **Hess DL**, **Patton PE**, Influence of corpus luteum age on the steroidogenic response to exogenous human chorionic gonadotropin in normal cycling women, Am J Obstet Gynecol 167:709, 1992.
152. **Agarwal SK**, **Buyalos RP**, Corpus luteum function and pregnancy rates with clomiphene citrate therapy: comparison of human chorionic gonadotrophin-induced versus spontaneous ovulation, Hum Reprod 10:328, 1995.
153. **Nestler JE**, **Jakubowicz DJ**, **Reamer P**, **Gunn RD**, **Allan G**, Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome, N Engl J Med 340:1314, 1999.
154. **Azziz R**, **Ehrmann D**, **Legro RS**, **Whitcomb RW**, **Hanley R**, **Fereshetian AG**, **O'Keefe M**, **Ghazzi MN; PCOS/Troglitazone Study Group**, Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial, J Clin Endocrinol Metab 86:1626, 2001.
155. **Creanga AA**, **Bradley HM**, **McCormick C**, **Witkop CT**, Use of metformin in polycystic ovary syndrome: a meta-analysis, Obstet Gynecol 111:959, 2008.
156. **Morley LC**, **Tang T**, **Yasmin E**, **Norman RJ**, **Balen AH**, Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility, Cochrane Database Syst Rev (11):CD003053, 2017.
157. **Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org, Practice Committee of the American Society for Reproductive Medicine**, Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline, Fertil Steril 108:426, 2017.
158. **Baillargeon JP**, **Jakubowicz DJ**, **Iuorno MJ**, **Jakubowicz S**, **Nestler JE**, Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity, Fertil Steril 82:893, 2004.
159. **Rouzi AA**, **Ardawi MS**, A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome, Fertil Steril 85:428, 2006.
160. **Kaul S**, **Bolger AF**, **Herrington D**, **Giugliano RP**, **Eckel RH**, **American Heart A**; **American College Of Cardiology Foundation**, Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation, J Am Coll Cardiol 55:1885, 2010.
161. **Abu Hashim H**, **Shokeir T**, **Badawy A**, Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial, Fertil Steril 94:1405, 2010.
162. **Moghetti P**, **Castello R**, **Negri C**, **Tosi F**, **Perrone F**, **Caputo M**, **Zanolin E**, **Muggeo M**, Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical

evaluation, J Clin Endocrinol Metab 85:139, 2000.
163. **Ng EH**, **Wat NM**, **Ho PC**, Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial, Hum Reprod 16:1625, 2001.
164. **Fleming R**, **Hopkinson ZE**, **Wallace AM**, **Greer IA**, **Sattar N**, Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial, J Clin Endocrinol Metab 87:569, 2002.
165. **Yarali H**, **Yildiz B**, Metformin and FSH for induction of ovulation in women with polycystic ovary syndrome, Hum Reprod 17:3007, 2002.
166. **Salpeter SR**, **Greyber E**, **Pasternak GA**, **Salpeter EE**, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis, Arch Intern Med 163:2594, 2003.
167. **Stades AM**, **Heikens JT**, **Erkelens DW**, **Holleman F**, **Hoekstra JB**, Metformin and lactic acidosis: cause or coincidence? A review of case reports, J Intern Med 255:179, 2004.
168. **Homburg R**, Pregnancy complications in PCOS, Best Pract Res Clin Endocrinol Metab 20:281, 2006.
169. **Palomba S**, **Falbo A**, **Orio F Jr**, **Manguso F**, **Russo T**, **Tolino A**, **Annamaria C**, **Dale B**, **Zullo F**, A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination, Hum Reprod 20:2879, 2005.
170. **Palomba S**, **Orio F Jr**, **Nardo LG**, **Falbo A**, **Russo T**, **Corea D**, **Doldo P**, **Lombardi G**, **Tolino A**, **Colao A**, **Zullo F**, Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial, J Clin Endocrinol Metab 89:4801, 2004.
171. **Glueck CJ**, **Goldenberg N**, **Wang P**, **Loftspring M**, **Sherman A**, Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy, Hum Reprod 19:510, 2004.
172. **Dodd JM**, **Grivell RM**, **Deussen AR, Hague WM**, Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes, Cochrane Database Syst Rev, 7:CD010564, 2018. doi: 10.1002/14651858.CD010564.pub2.
173. **Hellmuth E**, **Damm P**, **Molsted-Pedersen L**, Oral hypoglycaemic agents in 118 diabetic pregnancies, Diabet Med 17:507, 2000.
174. **Hughes RC**, **Rowan JA**, Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? Diabet Med 23:318, 2006.
175. **Kalafat E**, **Sukur YE**, **Abdi A**, **Thilaganathan B**, **Khalil A**, Metformin for the prevention of hypertensive disorders of pregnancy in women with gestational diabetes and obesity: a systematic review and meta-analysis, Ultrasound Obstet Gynecol 52(6):706, 2018.
176. **Gilbert C**, **Valois M**, **Koren G**, Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis, Fertil Steril 86:658, 2006.
177. **Branigan EF**, **Estes MA**, Treatment of chronic anovulation resistant to clomiphene citrate (CC) by using oral contraceptive ovarian suppression followed by repeat CC treatment, Fertil Steril 71:544, 1999.
178. **Branigan EF**, **Estes MA**, A randomized clinical trial of treatment of clomiphene citrate-resistant anovulation with the use of oral contraceptive pill suppression and repeat clomiphene citrate treatment, Am J Obstet Gynecol 188:1424; discussion 1429, 2003.
179. **Genazzani AD**, **Battaglia C**, **Gamba O**, **Petraglia F**, **Malavasi B**, **Genazzani AR**, The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycystic ovary disease after discontinuation of treatment, J Assist Reprod Genet 17:269, 2000.
180. **Genazzani AD**, **Petraglia F**, **Battaglia C**, **Gamba O**, **Volpe A**, **Genazzani AR**, A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the

ovulatory function in patients with polycystic ovary syndrome, Fertil Steril 67:463, 1997.
181. **De Leo V**, **Fulghesu AM**, **la Marca A**, **Morgante G**, **Pasqui L**, **Talluri B**, **Torricelli M**, **Caruso A**, Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism, Gynecol Endocrinol 14:411, 2000.
182. **Mitwally MF**, **Casper RF**, Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate, Fertil Steril 75:305, 2001.
183. ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice, Obstet Gynecol 131:e194, 2018.
184. **Franik S**, **Eltrop SM**, **Kremer JA**, **Kiesel L**, **Farquhar C**, Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome, Cochrane Database Syst Rev (5):CD010287, 2018.
185. **Buzdar A**, **Howell A**, Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer, Clin Cancer Res 7:2620, 2001.
186. **Winer EP**, **Hudis C**, **Burstein HJ**, **Chlebowski RT**, **Ingle JN**, **Edge SB**, **Mamounas EP**, **Gralow J**, **Goldstein LJ**, **Pritchard KI**, **Braun S**, **Cobleigh MA**, **Langer AS**, **Perotti J**, **Powles TJ**, **Whelan TJ**, **Browman GP**, American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002, J Clin Oncol 20:3317, 2002.
187. **Naftolin F**, Brain aromatization of androgens, J Reprod Med 39:257, 1994.
188. **Naftolin F**, **MacLusky NJ**, **Leranth CZ**, **Sakamoto HS**, **Garcia-Segura LM**, The cellular effects of estrogens on neuroendocrine tissues, J Steroid Biochem 30:195, 1988.
189. **Kamat A**, **Hinshelwood MM**, **Murry BA**, **Mendelson CR**, Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans, Trends Endocrinol Metab 13:122, 2002.
190. **Amer SA**, **Smith J**, **Mahran A**, **Fox P**, **Fakis A**, Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome, Hum Reprod 32:1631, 2017.
191. **Vendola KA**, **Zhou J**, **Adesanya OO**, **Weil SJ**, **Bondy CA**, Androgens stimulate early stages of follicular growth in the primate ovary, J Clin Invest 101:2622, 1998.
192. **Weil S**, **Vendola K**, **Zhou J**, **Bondy CA**, Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development, J Clin Endocrinol Metab 84:2951, 1999.
193. **Vendola K**, **Zhou J**, **Wang J**, **Famuyiwa OA**, **Bievre M**, **Bondy CA**, Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary, Biol Reprod 61:353, 1999.
194. **Giudice LC**, Insulin-like growth factors and ovarian follicular development, Endocr Rev 13:641, 1992.
195. **Adashi EY**, Intraovarian regulation: the proposed role of insulin-like growth factors, Ann N Y Acad Sci 687:10, 1993.
196. **Gadalla MA**, **Huang S**, **Wang R**, **Norman RJ**, **Abdullah SA**, **El Saman AM**, **Ismail AM**, **van Wely M**, **Mol BWJ**, Effect of clomiphene citrate on endometrial thickness, ovulation, pregnancy and live birth in anovulatory women: systematic review and meta-analysis, Ultrasound Obstet Gynecol 51:64, 2018.
197. **Mehdinejadiani S**, **Amidi F**, **Mehdizadeh M**, **Barati M**, **Safdarian L**, **Aflatoonian R**, **Alyasin A**, **Aghahosseini M**, **Pazhohan A**, **Hayat P**, **Mohammadzadeh Kazorgah F**, **Sobhani A**, The effects of letrozole and clomiphene citrate on ligands expression of Wnt3, Wnt7a, and Wnt8b in proliferative endometrium of women with Polycystic ovarian syndrome, Gynecol Endocrinol 34:775, 2018.
198. **Mehdinejadiani S**, **Amidi F**, **Mehdizadeh M**, **Barati M**, **Pazhohan A**, **Alyasin A**, **Mehdinejadiani K**, **Sobhani A**, Effects of letrozole and clomiphene citrate on Wnt signaling pathway in endometrium of polycystic ovarian syndrome and healthy women, Biol Reprod, 100(3):641–648, 2019. doi: 10.1093/biolre/ioy187.
199. **Miller PB**, **Parnell BA**, **Bushnell G**, **Tallman N**, **Forstein DA**, **Higdon HL III**, **Kitawaki J**, **Lessey BA**, Endometrial receptivity defects during IVF cycles with and without letrozole, Hum Reprod 27:881, 2012.
200. **Ganesh A**, **Chauhan N**, **Das S**, **Chakravarty B**, **Chaudhury K**, Endometrial receptivity markers in infertile women stimulated with letrozole compared with clomiphene citrate and natural cycles, Syst Biol Reprod Med 60:105, 2014.
201. **Ganesh A**, **Chattopadhyay R**, **Narendra Babu K**, **Chakravarty B**, **Chaudhury K**, Analysis of spindle characteristics and embryo quality in mice stimulated with letrozole using Polscope imaging, Fertil Steril

93:1477, 2010.
202. **Diamond MP**, **Legro RS**, **Coutifaris C**, **Alvero R**, **Robinson RD**, **Casson P**, **Christman GM**, **Ager J**, **Huang H**, **Hansen KR**, **Baker V**, **Usadi R**, **Seungdamrong A**, **Bates GW**, **Rosen RM**, **Haisenleder D**, **Krawetz SA**, **Barnhart K**, **Trussell JC**, **Ohl D**, **Jin Y**, **Santoro N**, **Eisenberg E**, **Zhang H; NICHD Reproductive Medicine Network**, Letrozole, gonadotropin, or clomiphene for unexplained infertility, N Engl J Med 373:1230, 2015.
203. **Tredway D**, **Schertz JC**, **Bock D**, **Hemsey G**, **Diamond MP**, Anastrozole single-dose protocol in women with oligo- or anovulatory infertility: results of a randomized phase II dose-response study, Fertil Steril 95:1725.e1, 2011.
204. **Ghomian N**, **Khosravi A**, **Mousavifar N**, A randomized clinical trial on comparing the cycle characteristics of two different initiation days of letrozole treatment in clomiphene citrate resistant PCOS patients in IUI cycles, Int J Fertil Steril 9:17, 2015.
205. **Badawy A**, **Mosbah A**, **Tharwat A**, **Eid M**, Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol, Fertil Steril 92:236, 2009.
206. **Dehbashi S**, **Dehbashi S**, **Kazerooni T**, **Robati M**, **Alborzi S**, **Parsanezhad ME**, **Shadman A**, Comparison of the effects of letrozole and clomiphene citrate on ovulation and pregnancy rate in patients with polycystic ovary syndrome, Iran J Med Sci 34:23, 2009.
207. **Warraich G**, **Vause TD**, First reported case of sextuplets conceived via letrozole for ovulation induction, Fertil Steril 103:535, 2015.
208. **Tulandi T**, **Martin J**, **Al-Fadhli R**, **Kabli N**, **Forman R**, **Hitkari J**, **Librach C**, **Greenblatt E**, **Casper RF**, Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate, Fertil Steril 85:1761, 2006.
209. **Forman R**, **Gill S**, **Moretti M**, **Tulandi T**, **Koren G**, **Casper R**, Fetal safety of letrozole and clomiphene citrate for ovulation induction, J Obstet Gynaecol Can 29:668, 2007.
210. **Stein IF**, **Leventhal ML**, Amenorrhea associated with bilateral polycystic ovaries, Am J Obstet Gynecol 29:247.e1, 1935.
211. **Donesky BW**, **Adashi EY**, Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy, Fertil Steril 63:439, 1995.
212. **Daniell JF**, **Miller W**, Polycystic ovaries treated by laparoscopic laser vaporization, Fertil Steril 51:232, 1989.
213. **Gjonnaess H**, Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope, Fertil Steril 41:20, 1984.
214. **Zahiri Sorouri Z**, **Sharami SH**, **Tahersima Z**, **Salamat F**, Comparison between unilateral and bilateral ovarian drilling in clomiphene citrate resistance polycystic ovary syndrome patients: a randomized clinical trial of efficacy, Int J Fertil Steril 9:9, 2015.
215. **El-Sayed MLM**, **Ahmed MA**, **Mansour MAA**, **Mansour SAA**, Unilateral versus bilateral laparoscopic ovarian drilling using thermal dose adjusted according to ovarian volume in CC-resistant PCOS, a randomized study, J Obstet Gynaecol India 67:356, 2017.
216. **Farquhar C**, **Brown J**, **Marjoribanks J**, Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome, Cochrane Database Syst Rev (6):CD001122, 2012.
217. **Seow KM**, **Juan CC**, **Hwang JL**, **Ho LT**, Laparoscopic surgery in polycystic ovary syndrome: reproductive and metabolic effects, Semin Reprod Med 26:101, 2008.
218. **Greenblatt E**, **Casper RF**, Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome, Am J Obstet Gynecol 156:279, 1987.
219. **Armar NA**, **McGarrigle HH**, **Honour J**, **Holownia P**, **Jacobs HS**, **Lachelin GC**, Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome, Fertil Steril 53:45, 1990.
220. **Lemieux S**, **Lewis GF**, **Ben-Chetrit A**, **Steiner G**, **Greenblatt EM**, Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels, J Clin Endocrinol Metab 84:4278, 1999.
221. **Kovacs G**, **Buckler H**, **Bangah M**, **Outch K**, **Burger H**, **Healy D**, **Baker G**, **Phillips S**, Treatment of

anovulation due to polycystic ovarian syndrome by laparoscopic ovarian electrocautery, Br J Obstet Gynaecol 98:30, 1991.
222. **Lockwood GM**, **Muttukrishna S**, **Groome NP**, **Matthews DR**, **Ledger WL**, Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle, J Clin Endocrinol Metab 83:1730, 1998.
223. **Naether OG**, **Fischer R**, Adhesion formation after laparoscopic electrocoagulation of the ovarian surface in polycystic ovary patients, Fertil Steril 60:95, 1993.
224. **Naether OG**, **Fischer R**, **Weise HC**, **Geiger-Kotzler L**, **Delfs T**, **Rudolf K**, Laparoscopic electrocoagulation of the ovarian surface in infertile patients with polycystic ovarian disease, Fertil Steril 60:88, 1993.
225. **Gurgan T**, **Kisnisci H**, **Yarali H**, **Develioglu O**, **Zeyneloglu H**, **Aksu T**, Evaluation of adhesion formation after laparoscopic treatment of polycystic ovarian disease, Fertil Steril 56:1176, 1991.
226. **Greenblatt EM**, **Casper RF**, Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate, Fertil Steril 60:766, 1993.
227. **Gurgan T**, **Urman B**, **Aksu T**, **Yarali H**, **Develioglu O**, **Kisnisci HA**, The effect of short-interval laparoscopic lysis of adhesions on pregnancy rates following Nd-YAG laser photocoagulation of polycystic ovaries, Obstet Gynecol 80:45, 1992.
228. **Farquhar C**, **Vandekerckhove P**, **Lilford R**, Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome, Cochrane Database Syst Rev (4):CD001122, 2001.
229. **Dabirashrafi H**, Complications of laparoscopic ovarian cauterization, Fertil Steril 52:878, 1989.
230. **Giampaolino P**, **Morra I**, **De Rosa N**, **Cagnacci A**, **Pellicano M**, **Di Carlo C**, **Nappi C**, **Bifulco G**, Impact of transvaginal hydrolaparoscopy ovarian drilling on ovarian stromal blood flow and ovarian volume in clomiphene citrate-resistant PCOS patients: a case-control study, Gynecol Endocrinol 33:690, 2017.
231. **Melica F**, **Chiodi S**, **Cristoforoni PM**, **Ravera GB**, Reductive surgery and ovarian function in the human—can reductive ovarian surgery in reproductive age negatively influence fertility and age at onset of menopause? Int J Fertil Menopausal Stud 40:79, 1995.
232. **Armar NA**, **Lachelin GC**, Laparoscopic ovarian diathermy: an effective treatment for anti-oestrogen resistant anovulatory infertility in women with the polycystic ovary syndrome, Br J Obstet Gynaecol 100:161, 1993.
233. **Farhi J**, **Soule S**, **Jacobs HS**, Effect of laparoscopic ovarian electrocautery on ovarian response and outcome of treatment with gonadotropins in clomiphene citrate-resistant patients with polycystic ovary syndrome, Fertil Steril 64:930, 1995.
234. **Balen AH**, **Braat DD**, **West C**, **Patel A**, **Jacobs HS**, Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients, Hum Reprod 9:1563, 1994.
235. **Farquhar CM**, **Williamson K**, **Gudex G**, **Johnson NP**, **Garland J**, **Sadler L**, A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome, Fertil Steril 78:404, 2002.
236. **Gjonnaess H**, Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results, Acta Obstet Gynecol Scand 73:407, 1994.
237. **Gjonnaess H**, The course and outcome of pregnancy after ovarian electrocautery in women with polycystic ovarian syndrome: the influence of body-weight, Br J Obstet Gynaecol 96:714, 1989.
238. **Gjonnaess H**, A simple treatment for polycystic ovarian syndrome, World Health Forum 11:214, 1990.
239. **Lunenfeld B**, Historical perspectives in gonadotrophin therapy, Hum Reprod Update 10:453, 2004.
240. **Casper RF**, Are recombinant gonadotrophins safer, purer and more effective than urinary gonadotrophins? Reprod Biomed Online 11:539, 2005.
241. **Practice Committee of American Society for Reproductive Medicine, Birmingham, Alabama**, Gonadotropin preparations: past, present, and future perspectives, Fertil Steril 90:S13, 2008.
242. **Stokman PG**, **de Leeuw R**, **van den Wijngaard HA**, **Kloosterboer HJ**, **Vemer HM**, **Sanders AL**, Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations, Fertil Steril

60:175, 1993.
243. **Rosenberg E**, **Coleman J**, **Damani M**, **Garcia CR**, Clinical effect of postmenopausal gonadotropin, J Clin Endocrinol Metab 23:181–190, 1963.
244. **Lunenfeld B**, Treatment of anovulation by human gonadotropins, J Int Fed Gynaecol Obstet 1:153–167, 1963. doi: https://doi.org/10.1002/j.1879-3479.1963.tb00335.x.
245. **van de Weijer BH**, **Mulders JW**, **Bos ES**, **Verhaert PD**, **van den Hooven HW**, Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities, Reprod Biomed Online 7:547, 2003.
246. **Gocial B**, **Keye WR**, **Fein SH**, **Nardi RV**, Subcutaneously administered Repronex in female patients undergoing in vitro fertilization is as effective and well tolerated as intramuscular menotropin treatment. Repronex SC, IVF Study Group, Fertil Steril 74:73, 2000.
247. **Giudice E**, **Crisci C**, **Eshkol A**, **Papoian R**, Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins, Hum Reprod 9:2291, 1994.
248. **Filicori M**, **Cognigni GE**, **Pocognoli P**, **Tabarelli C**, **Ferlini F**, **Perri T**, **Parmegiani L**, Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone, Fertil Steril 80:390, 2003.
249. **Olijve W**, **de Boer W**, **Mulders JW**, **van Wezenbeek PM**, Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon), Mol Hum Reprod 2:371, 1996.
250. **Steelman SL**, **Pohley FM**, Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin, Endocrinology 53:604, 1953.
251. **Fauser BC**, **Mannaerts BM**, **Devroey P**, **Leader A**, **Boime I**, **Baird DT**, Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency, Hum Reprod Update 15:309, 2009.
252. **Loutradis D**, **Drakakis P**, **Vlismas A**, **Antsaklis A**, Corifollitropin alfa, a long-acting follicle-stimulating hormone agonist for the treatment of infertility, Curr Opin Investig Drugs 10:372, 2009.
253. **Olsson H**, **Sandstrom R**, **Grundemar L**, Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line, J Clin Pharmacol 54:1299, 2014.
254. **le Cotonnec JY**, **Loumaye E**, **Porchet HC**, **Beltrami V**, **Munafo A**, Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone, Fertil Steril 69:201, 1998.
255. **le Cotonnec JY**, **Porchet HC**, **Beltrami V**, **Munafo A**, Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay, Fertil Steril 69:195, 1998.
256. **Porchet HC**, **Le Cotonnec JY**, **Neuteboom B**, **Canali S**, **Zanolo G**, Pharmacokinetics of recombinant human luteinizing hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone, J Clin Endocrinol Metab 80:667, 1995.
257. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group, J Clin Endocrinol Metab 83:1507, 1998.
258. **Kolibianakis EM**, **Kalogeropoulou L**, **Griesinger G**, **Papanikolaou EG**, **Papadimas J**, **Bontis J**, **Tarlatzis BC**, Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis, Hum Reprod Update 13:445, 2007.
259. **Mochtar MH**, **Van der Veen F**, **Ziech M**, **van Wely M**, Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles, Cochrane Database Syst Rev (2):CD005070, 2007.
260. **Ludwig M**, **Doody KJ**, **Doody KM**, Use of recombinant human chorionic gonadotropin in ovulation induction,

Fertil Steril 79:1051, 2003.
261. **Youssef MA**, **Abou-Setta AM**, **Lam WS**, Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles, Cochrane Database Syst Rev (4):CD003719, 2016.
262. **Butler SA**, hCG—mass units, molar conversions, and the standardization of biologic units, Fertil Steril 80:1533; author reply 1533, 2003.
263. **McDonough PG**, hCG—mass units, molar conversions, and the standardization of biologic units, Fertil Steril 80:1534, 2003.
264. **Chang P**, **Kenley S**, **Burns T**, **Denton G**, **Currie K**, **DeVane G**, **O'Dea L**, Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer, Fertil Steril 76:67, 2001.
265. **International Recombinant Human Chorionic Gonadotropin Study Group**, Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG, Fertil Steril 75:1111, 2001.
266. **Fauser BC**, Follicular development and oocyte maturation in hypogonadotrophic women employing recombinant follicle-stimulating hormone: the role of oestradiol, Hum Reprod Update 3:101, 1997.
267. **Filicori M**, The role of luteinizing hormone in folliculogenesis and ovulation induction, Fertil Steril 71:405, 1999.
268. **Levy DP**, **Navarro JM**, **Schattman GL**, **Davis OK**, **Rosenwaks Z**, The role of LH in ovarian stimulation: exogenous LH: let's design the future, Hum Reprod 15:2258, 2000.
269. **Danforth DR**, Endocrine and paracrine control of oocyte development, Am J Obstet Gynecol 172:747, 1995.
270. **Couzinet B**, **Lestrat N**, **Brailly S**, **Forest M**, **Schaison G**, Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency, J Clin Endocrinol Metab 66:552, 1988.
271. **Strauss JF III**, **Steinkampf MP**, Pituitary-ovarian interactions during follicular maturation and ovulation, Am J Obstet Gynecol 172:726, 1995.
272. **Schoot DC**, **Harlin J**, **Shoham Z**, **Mannaerts BM**, **Lahlou N**, **Bouchard P**, **Bennink HJ**, **Fauser BC**, Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women, Hum Reprod 9:1237, 1994.
273. **Shoham Z**, **Balen A**, **Patel A**, **Jacobs HS**, Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients, Fertil Steril 56:1048, 1991.
274. **Carone D**, **Caropreso C**, **Vitti A**, **Chiappetta R**, Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols, J Endocrinol Invest 35:996, 2012.
275. **Keenan JA**, **Moghissi KS**, Luteal phase support with hCG does not improve fecundity rate in human menopausal gonadotropin-stimulated cycles, Obstet Gynecol 79:983, 1992.
276. **Messinis IE**, **Bergh T**, **Wide L**, The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility, Fertil Steril 50:31, 1988.
277. **Hamilton CJ**, **Jaroudi KA**, **Sieck UV**, The value of luteal support with progesterone in gonadotropin-induced cycles, Fertil Steril 60:786, 1993.
278. **Blumenfeld Z**, **Nahhas F**, Luteal dysfunction in ovulation induction: the role of repetitive human chorionic gonadotropin supplementation during the luteal phase, Fertil Steril 50:403, 1988.
279. **Noci I**, **Biagiotti R**, **Maggi M**, **Ricci F**, **Cinotti A**, **Scarselli G**, Low day 3 luteinizing hormone values are predictive of reduced response to ovarian stimulation, Hum Reprod 13:531, 1998.
280. **Farine D**, **Dor J**, **Lupovici N**, **Lunenfeld B**, **Mashiach S**, Conception rate after gonadotropin therapy in hyperprolactinemia and normoprolactinemia, Obstet Gynecol 65:658, 1985.
281. **Weiss NS**, **Nahuis M**, **Bayram N**, **Mol BW**, **Van der Veen F**, **van Wely M**, Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome, Cochrane Database Syst Rev (1):CD010290, 2015.

282. **Dodson WC**, **Hughes CL Jr**, **Yancy SE**, **Haney AF**, Clinical characteristics of ovulation induction with human menopausal gonadotropins with and without leuprolide acetate in polycystic ovary syndrome, Fertil Steril 52:915, 1989.
283. **Whelan JG III**, **Vlahos NF**, The ovarian hyperstimulation syndrome, Fertil Steril 73:883, 2000.
284. **Green KA**, **Zolton JR**, **Schermerhorn SM**, **Lewis TD**, **Healy MW**, **Terry N**, **DeCherney AH**, **Hill MJ**, Progesterone luteal support after ovulation induction and intrauterine insemination: an updated systematic review and meta-analysis, Fertil Steril 107:924.e5, 2017.
285. **Thompson CR**, **Hansen LM**, Pergonal (menotropins): a summary of clinical experience in the induction of ovulation and pregnancy, Fertil Steril 21:844, 1970.
286. **Olive DL**, The role of gonadotropins in ovulation induction, Am J Obstet Gynecol 172:759, 1995.
287. **Chong AP**, **Rafael RW**, **Forte CC**, Influence of weight in the induction of ovulation with human menopausal gonadotropin and human chorionic gonadotropin, Fertil Steril 46:599, 1986.
288. **Van Der Meer M**, **Hompes PG**, **De Boer JA**, **Schats R**, **Schoemaker J**, Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome, J Clin Endocrinol Metab 83:423, 1998.
289. **Homburg R**, **Levy T**, **Ben-Rafael Z**, A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome, Fertil Steril 63:729, 1995.
290. **White DM**, **Polson DW**, **Kiddy D**, **Sagle P**, **Watson H**, **Gilling-Smith C**, **Hamilton-Fairley D**, **Franks S**, Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women, J Clin Endocrinol Metab 81:3821, 1996.
291. **Hedon B**, **Hugues JN**, **Emperaire JC**, **Chabaud JJ**, **Barbereau D**, **Boujenah A**, **Howles CM**, **Truong F**, A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women, Hum Reprod 13:2688, 1998.
292. **Homburg R**, **Howles CM**, Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements, Hum Reprod Update 5:493, 1999.
293. **Calaf Alsina J**, **Ruiz Balda JA**, **Romeu Sarrio A**, **Caballero Fernandez V**, **Cano Trigo I**, **Gomez Parga JL**, **Gonzalez Batres C**, **Rodriguez Escudero FJ**, Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial, BJOG 110:1072, 2003.
294. **Dale PO**, **Tanbo T**, **Haug E**, **Abyholm T**, The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome, Hum Reprod 13:567, 1998.
295. **De Leo V**, **la Marca A**, **Ditto A**, **Morgante G**, **Cianci A**, Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome, Fertil Steril 72:282, 1999.
296. **Filicori M**, **Cognigni GE**, **Tabarelli C**, **Pocognoli P**, **Taraborrelli S**, **Spettoli D**, **Ciampaglia W**, Stimulation and growth of antral ovarian follicles by selective LH activity administration in women, J Clin Endocrinol Metab 87:1156, 2002.
297. **Filicori M**, **Cognigni GE**, **Taraborrelli S**, **Spettoli D**, **Ciampaglia W**, **de Fatis CT**, **Pocognoli P**, Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome, J Clin Endocrinol Metab 84:2659, 1999.
298. **Zeleznik AJ**, **Hillier SG**, The role of gonadotropins in the selection of the preovulatory follicle, Clin Obstet Gynecol 27:927, 1984.
299. **Zeleznik AJ**, **Midgley AR Jr**, **Reichert LE Jr**, Granulosa cell maturation in the rat: increased binding of human chorionic gonadotropin following treatment with follicle-stimulating hormone in vivo, Endocrinology 95:818, 1974.
300. **Shima K**, **Kitayama S**, **Nakano R**, Gonadotropin binding sites in human ovarian follicles and corpora lutea during the menstrual cycle, Obstet Gynecol 69:800, 1987.
301. **Rani CS**, **Salhanick AR**, **Armstrong DT**, Follicle-stimulating hormone induction of luteinizing hormone

receptor in cultured rat granulosa cells: an examination of the need for steroids in the induction process, Endocrinology 108:1379, 1981.
302. **Filicori M**, **Cognigni GE**, **Taraborrelli S**, **Spettoli D**, **Ciampaglia W**, **de Fatis CT**, Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea, Fertil Steril 72:1118, 1999.
303. **Hillier SG**, **Whitelaw PF**, **Smyth CD**, Follicular oestrogen synthesis: the 'two-cell, two-gonadotrophin' model revisited, Mol Cell Endocrinol 100:51, 1994.
304. **Egbase PE**, **Al Sharhan M**, **Berlingieri P**, **Grudzinskas JG**, Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment, Hum Reprod 15:2082, 2000.
305. **Sullivan MW**, **Stewart-Akers A**, **Krasnow JS**, **Berga SL**, **Zeleznik AJ**, Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation, J Clin Endocrinol Metab 84:228, 1999.
306. **Loumaye E**, **Engrand P**, **Shoham Z**, **Hillier SG**, **Baird DT**, Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation, Hum Reprod 18:314, 2003.
307. **Filicori M**, **Flamigni C**, **Cognigni GE**, **Falbo A**, **Arnone R**, **Capelli M**, **Pavani A**, **Mandini M**, **Calderoni P**, **Brondelli L**, Different gonadotropin and leuprorelin ovulation induction regimens markedly affect follicular fluid hormone levels and folliculogenesis, Fertil Steril 65:387, 1996.
308. **Filicori M**, **Cognigni GE**, **Pocognoli P**, **Tabarelli C**, **Spettoli D**, **Taraborrelli S**, **Ciampaglia W**, Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration, Hum Reprod 17:2009, 2002.
309. **Loumaye E**, **Engrand P**, **Shoham Z**, **Hillier SG**, **Baird DT**, Clinical evidence for an LH ceiling? Hum Reprod 18:2719, 2003.
310. **Filicori M**, **Cognigni GE**, **Ciampaglia W**, What clinical evidence for an LH ceiling? Hum Reprod 18:1556, 2003.
311. **March CM**, **Tredway DR**, **Mishell DR Jr**, Effect of clomiphene citrate upon amount and duration of human menopausal gonadotropin therapy, Am J Obstet Gynecol 125:699, 1976.
312. **Ron-el R**, **Soffer Y**, **Langer R**, **Herman A**, **Weintraub Z**, **Caspi E**, Low multiple pregnancy rate in combined clomiphene citrate—human menopausal gonadotrophin treatment for ovulation induction or enhancement, Hum Reprod 4:495, 1989.
313. **Lu PY**, **Chen AL**, **Atkinson EJ**, **Lee SH**, **Erickson LD**, **Ory SJ**, Minimal stimulation achieves pregnancy rates comparable to human menopausal gonadotropins in the treatment of infertility, Fertil Steril 65:583, 1996.
314. **Ransom MX**, **Doughman NC**, **Garcia AJ**, Menotropins alone are superior to a clomiphene citrate and menotropin combination for superovulation induction among clomiphene citrate failures, Fertil Steril 65:1169, 1996.
315. **Dodson WC**, **Hughes CL**, **Whitesides DB**, **Haney AF**, The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome, J Clin Endocrinol Metab 65:95, 1987.
316. **Manzi DL**, **Dumez S**, **Scott LB**, **Nulsen JC**, Selective use of leuprolide acetate in women undergoing superovulation with intrauterine insemination results in significant improvement in pregnancy outcome, Fertil Steril 63:866, 1995.
317. **Sagle M**, **Bishop K**, **Ridley N**, **Alexander FM**, **Michel M**, **Bonney RC**, **Beard RW**, **Franks S**, Recurrent early miscarriage and polycystic ovaries, BMJ 297:1027, 1988.
318. **Regan L**, **Owen EJ**, **Jacobs HS**, Hypersecretion of luteinising hormone, infertility, and miscarriage, Lancet 336:1141, 1990.
319. **Homburg R**, **Armar NA**, **Eshel A**, **Adams J**, **Jacobs HS**, Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome, BMJ 297:1024, 1988.
320. **Tulppala M**, **Palosuo T**, **Ramsay T**, **Miettinen A**, **Salonen R**, **Ylikorkala O**, A prospective study of 63

couples with a history of recurrent spontaneous abortion: contributing factors and outcome of subsequent pregnancies, Hum Reprod 8:764, 1993.
321. **Fleming R**, **Coutts JR**, LHRH analogues for ovulation induction, with particular reference to polycystic ovary syndrome, Baillieres Clin Obstet Gynaecol 2:677, 1988.
322. **Bachus KE**, **Hughes CL Jr**, **Haney AF**, **Dodson WC**, The luteal phase in polycystic ovary syndrome during ovulation induction with human menopausal gonadotropin with and without leuprolide acetate, Fertil Steril 54:27, 1990.
323. **Gagliardi CL**, **Emmi AM**, **Weiss G**, **Schmidt CL**, Gonadotropin-releasing hormone agonist improves the efficiency of controlled ovarian hyperstimulation/intrauterine insemination, Fertil Steril 55:939, 1991.
324. **Homburg R**, **Eshel A**, **Kilborn J**, **Adams J**, **Jacobs HS**, Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries, Hum Reprod 5:32, 1990.
325. **Hughes E**, **Collins J**, **Vandekerckhove P**, Gonadotrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome, Cochrane Database Syst Rev (2):CD000097, 2000.
326. **Dodson WC**, **Walmer DK**, **Hughes CL Jr**, **Yancy SE**, **Haney AF**, Adjunctive leuprolide therapy does not improve cycle fecundity in controlled ovarian hyperstimulation and intrauterine insemination of subfertile women, Obstet Gynecol 78:187, 1991.
327. **Muechler EK**, **Kohler D**, **Huang KE**, Monitoring of ovulation induction with HMG-HCG therapy by plasma estrogen and progesterone, Int J Fertil 26:273, 1981.
328. **Reuter KL**, **Cohen S**, **Furey L**, **Baker S**, Sonographic appearance of the endometrium and ovaries during cycles stimulated with human menopausal gonadotropin, J Reprod Med 41:509, 1996.
329. **Haning RV Jr**, **Levin RM**, **Behrman HR**, **Kase NG**, **Speroff L**, Plasma estradiol window and urinary estriol glucuronide determinations for monitoring menotropin induction of ovulation, Obstet Gynecol 54:442, 1979.
330. **Diamond MP**, **Wentz AC**, Ovulation induction with human menopausal gonadotropins, Obstet Gynecol Surv 41:480, 1986.
331. **Navot D**, **Margalioth EJ**, **Laufer N**, **Brzezinski A**, **Birkenfeld A**, **Schenker JG**, Periovulatory 17 beta-estradiol pattern in conceptional and nonconceptional cycles during menotropin treatment of anovulatory infertility, Fertil Steril 47:234, 1987.
332. **Silverberg KM**, **Olive DL**, **Burns WN**, **Johnson JV**, **Groff TR**, **Schenken RS**, Follicular size at the time of human chorionic gonadotropin administration predicts ovulation outcome in human menopausal gonadotropin-stimulated cycles, Fertil Steril 56:296, 1991.
333. **Navot D**, **Relou A**, **Birkenfeld A**, **Rabinowitz R**, **Brzezinski A**, **Margalioth EJ**, Risk factors and prognostic variables in the ovarian hyperstimulation syndrome, Am J Obstet Gynecol 159:210, 1988.
334. **Diamond MP**, **DeCherney AH**, **Baretto P**, **Lunenfeld B**, Multiple consecutive cycles of ovulation induction with human menopausal gonadotropins, Gynecol Endocrinol 3:237, 1989.
335. **Silverberg KM**, **Klein NA**, **Burns WN**, **Schenken RS**, **Olive DL**, Consecutive versus alternating cycles of ovarian stimulation using human menopausal gonadotrophin, Hum Reprod 7:940, 1992.
336. **Akin JW**, **Shepard MK**, The effects of baseline ovarian cysts on cycle fecundity in controlled ovarian hyperstimulation, Fertil Steril 59:453, 1993.
337. **Shoham Z**, **Di Carlo C**, **Patel A**, **Conway GS**, **Jacobs HS**, Is it possible to run a successful ovulation induction program based solely on ultrasound monitoring? The importance of endometrial measurements, Fertil Steril 56:836, 1991.
338. **Weiss NS**, **van Vliet MN**, **Limpens J**, **Hompes PGA**, **Lambalk CB**, **Mochtar MH**, **van der Veen F**, **Mol BWJ**, **van Wely M**, Endometrial thickness in women undergoing IUI with ovarian stimulation. How thick is too thin? A systematic review and meta-analysis, Hum Reprod 32:1009, 2017.
339. **Isaacs JD Jr**, **Wells CS**, **Williams DB**, **Odem RR**, **Gast MJ**, **Strickler RC**, Endometrial thickness is a valid monitoring parameter in cycles of ovulation induction with menotropins alone, Fertil Steril 65:262, 1996.
340. **Dickey RP**, **Olar TT**, **Taylor SN**, **Curole DN**, **Matulich EM**, Relationship of endometrial thickness and

pattern to fecundity in ovulation induction cycles: effect of clomiphene citrate alone and with human menopausal gonadotropin, Fertil Steril 59:756, 1993.
341. **Schwartz M**, **Jewelewicz R**, **Dyrenfurth I**, **Tropper P**, **Vande Wiele RL**, The use of human menopausal and chorionic gonadotropins for induction of ovulation, Sixteen years' experience at the Sloane Hospital for Women, Am J Obstet Gynecol 138:801, 1980.
342. **Ho YB**, **Pride SM**, Induction of ovulation with exogenous gonadotropins in anovulatory infertile women, Semin Reprod Med 8:186–197, 1990.
343. **Fluker MR**, **Urman B**, **Mackinnon M**, **Barrow SR**, **Pride SM**, **Yuen BH**, Exogenous gonadotropin therapy in World Health Organization groups I and II ovulatory disorders, Obstet Gynecol 83:189, 1994.
344. **Dor J**, **Itzkowic DJ**, **Mashiach S**, **Lunenfeld B**, **Serr DM**, Cumulative conception rates following gonadotropin therapy, Am J Obstet Gynecol 136:102, 1980.
345. **Hall JG**, Twinning, Lancet 362:735, 2003.
346. **Gleicher N**, **Oleske DM**, **Tur-Kaspa I**, **Vidali A**, **Karande V**, Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins, N Engl J Med 343:2, 2000.
347. **Peeraer K**, **Debrock S**, **De Loecker P**, **Tomassetti C**, **Laenen A**, **Welkenhuysen M**, **Meeuwis L**, **Pelckmans S**, **Mol BW**, **Spiessens C**, **De Neubourg D**, **D'Hooghe TM**, Low-dose human menopausal gonadotrophin versus clomiphene citrate in subfertile couples treated with intrauterine insemination: a randomized controlled trial, Hum Reprod 30:1079, 2015.
348. **Danhof NA**, **van Wely M**, **Repping S**, **Koks C**, **Verhoeve HR**, **de Bruin JP**, **Verberg MFG**, **van Hooff MHA**, **Cohlen BJ**, **van Heteren CF**, **Fleischer K**, **Gianotten J**, **van Disseldorp J**, **Visser J**, **Broekmans FJM**, **Mol BWJ**, **van der Veen F**, **Mochtar MH**; **SUPER study group**, Follicle stimulating hormone versus clomiphene citrate in intrauterine insemination for unexplained subfertility: a randomized controlled trial, Hum Reprod 33:1866, 2018.
349. **Derom C**, **Vlietinck R**, **Derom R**, **Van den Berghe H**, **Thiery M**, Increased monozygotic twinning rate after ovulation induction, Lancet 1:1236, 1987.
350. **Bohrer M**, **Kemmann E**, Risk factors for spontaneous abortion in menotropin-treated women, Fertil Steril 48:571, 1987.
351. **Shoham Z**, **Zosmer A**, **Insler V**, Early miscarriage and fetal malformations after induction of ovulation (by clomiphene citrate and/or human menotropins), in vitro fertilization, and gamete intrafallopian transfer, Fertil Steril 55:1, 1991.
352. **Martin JA**, **Hamilton BE**, **Osterman MJK**, **Driscoll AK**, **Drake P**, Births: final data for 2016, Natl Vital Stat Rep 67:1, 2018.
353. **Centers for Disease Control and Prevention (CDC)**, Contribution of assisted reproductive technology and ovulation-inducing drugs to triplet and higher-order multiple births—United States, 1980-1997, MMWR Morb Mortal Wkly Rep 49:535, 2000.
354. **Smith LK**, **Manktelow BN**, **Draper ES**, **Boyle EM**, **Johnson SJ**, **Field DJ**, Trends in the incidence and mortality of multiple births by socioeconomic deprivation and maternal age in England: population-based cohort study, BMJ Open 4:e004514, 2014.
355. **Santana DS**, **Cecatti JG**, **Haddad SM**, **Parpinelli MA**, **Costa ML**, **Surita FG**, **Sousa MH**; **Brazilian Network for the Surveillance of Severe Maternal Morbidity Study Group**, Severe maternal morbidity and perinatal outcomes of multiple pregnancy in the Brazilian Network for the Surveillance of Severe Maternal Morbidity, Int J Gynaecol Obstet 139:230, 2017.
356. [1995 FIVNAT evaluation], Contracept Fertil Sex 24:694, 1996.
357. **Martin JA**, **MacDorman MF**, **Mathews TJ**, Triplet births: trends and outcomes, 1971-94, Vital Health Stat 21 21:1, 1997.
358. **Bromer JG**, **Ata B**, **Seli M**, **Lockwood CJ**, **Seli E**, Preterm deliveries that result from multiple pregnancies associated with assisted reproductive technologies in the USA: a cost analysis, Curr Opin Obstet Gynecol 23:168, 2011.
359. Multiple gestation pregnancy. The ESHRE Capri Workshop Group, Hum Reprod 15:1856, 2000.
360. **Bryan E**, The impact of multiple preterm births on the family, BJOG 110(Suppl 20):24, 2003.

361. **Practice Committee of American Society for Reproductive Medicine**, Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion, Fertil Steril 97:825, 2012.
362. **Kulkarni AD**, **Jamieson DJ**, **Jones HW Jr**, **Kissin DM**, **Gallo MF**, **Macaluso M**, **Adashi EY**, Fertility treatments and multiple births in the United States, N Engl J Med 369:2218, 2013.
363. **Gleicher N**, **Vidail A**, **Karande V**, Risks of multiple pregnancy—the decision belongs to whom? Fertil Steril 76:423; author reply 424, 2001.
364. **Grobman WA**, **Milad MP**, **Stout J**, **Klock SC**, Patient perceptions of multiple gestations: an assessment of knowledge and risk aversion, Am J Obstet Gynecol 185:920, 2001.
365. **Dickey RP**, A year of inaction on high-order multiple pregnancies due to ovulation induction, Fertil Steril 79:14, 2003.
366. **Fritz MA**, **Ory SJ**, Practice guidelines cannot be justified in the absence of sufficient evidence: inaction is far more appropriate than indefensible action, Fertil Steril 79:22, 2003.
367. **Dickey RP**, **Taylor SN**, **Lu PY**, **Sartor BM**, **Rye PH**, **Pyrzak R**, Relationship of follicle numbers and estradiol levels to multiple implantation in 3,608 intrauterine insemination cycles, Fertil Steril 75:69, 2001.
368. **Tur R**, **Barri PN**, **Coroleu B**, **Buxaderas R**, **Martinez F**, **Balasch J**, Risk factors for high-order multiple implantation after ovarian stimulation with gonadotrophins: evidence from a large series of 1878 consecutive pregnancies in a single centre, Hum Reprod 16:2124, 2001.
369. **Ragni G**, **Maggioni P**, **Guermandi E**, **Testa A**, **Baroni E**, **Colombo M**, **Crosignani PG**, Efficacy of double intrauterine insemination in controlled ovarian hyperstimulation cycles, Fertil Steril 72:619, 1999.
370. **Dickey RP**, **Pyrzak R**, Prevention of high order multiple pregnancy, Hum Reprod 17:1411; author reply 1411, 2002.
371. **Haydardedeoglu B**, **Bagis T**, **Simsek E**, **Cok T**, **Hacivelioglu SO**, **Erkanli S**, The impact of rescue in vitro fertilization converted from high-response gonadotropin intrauterine insemination cycles in terms of implantation and pregnancy rates as compared with matched controls, Fertil Steril 92:137, 2009.
372. **Many A**, **Azem F**, **Lessing JB**, **Yovel I**, **Yavetz H**, **Amit A**, Pregnancy rate in IVF rescue in high responders to human menopausal gonadotropin, J Assist Reprod Genet 16:520, 1999.
373. **Balayla J**, **Granger L**, **St-Michel P**, **Villeneuve M**, **Fontaine JY**, **Desrosiers P**, **Dahdouh EM**, Rescue in vitro fertilization using a GnRH antagonist in hyper-responders from gonadotropin intrauterine insemination (IUI) cycles, J Assist Reprod Genet 30:773, 2013.
374. **De Geyter C**, **De Geyter M**, **Nieschlag E**, Low multiple pregnancy rates and reduced frequency of cancellation after ovulation induction with gonadotropins, if eventual supernumerary follicles are aspirated to prevent polyovulation, J Assist Reprod Genet 15:111, 1998.
375. **Albano C**, **Platteau P**, **Nogueira D**, **Cortvrindt R**, **Smitz J**, **Devroey P**, Avoidance of multiple pregnancies after ovulation induction by supernumerary preovulatory follicular reduction, Fertil Steril 76:820, 2001.
376. **Britt DW**, **Risinger ST**, **Mans M**, **Evans MI**, Anxiety among women who have undergone fertility therapy and who are considering multifetal pregnancy reduction: trends and implications, J Matern Fetal Neonatal Med 13:271, 2003.
377. **Berkowitz RL**, **Lynch L**, **Stone J**, **Alvarez M**, The current status of multifetal pregnancy reduction, Am J Obstet Gynecol 174:1265, 1996.
378. **Landy HJ**, **Keith LG**, The vanishing twin: a review, Hum Reprod Update 4:177, 1998.
379. **Lipitz S**, **Shulman A**, **Achiron R**, **Zalel Y**, **Seidman DS**, A comparative study of multifetal pregnancy reduction from triplets to twins in the first versus early second trimesters after detailed fetal screening, Ultrasound Obstet Gynecol 18:35, 2001.
380. **Dodd JM**, **Crowther CA**, Reduction of the number of fetuses for women with triplet and higher order multiple pregnancies, Cochrane Database Syst Rev (2):CD003932, 2003.
381. **Evans MI**, **Berkowitz RL**, **Wapner RJ**, **Carpenter RJ**, **Goldberg JD**, **Ayoub MA**, **Horenstein J**, **Dommergues M**, **Brambati B**, **Nicolaides KH**, **Holzgreve W**, **Timor-Tritsch IE**, Improvement in outcomes of multifetal pregnancy reduction with increased experience, Am J Obstet Gynecol 184:97, 2001.
382. **Yaron Y**, **Bryant-Greenwood PK**, **Dave N**, **Moldenhauer JS**, **Kramer RL**, **Johnson MP**, **Evans MI**,

Multifetal pregnancy reductions of triplets to twins: comparison with nonreduced triplets and twins, Am J Obstet Gynecol 180:1268, 1999.

383. **Lipitz S**, **Reichman B**, **Uval J**, **Shalev J**, **Achiron R**, **Barkai G**, **Lusky A**, **Mashiach S**, A prospective comparison of the outcome of triplet pregnancies managed expectantly or by multifetal reduction to twins, Am J Obstet Gynecol 170:874, 1994.
384. **Sebire NJ**, **D'Ercole C**, **Sepulveda W**, **Hughes K**, **Nicolaides KH**, Effects of embryo reduction from trichorionic triplets to twins, Br J Obstet Gynaecol 104:1201, 1997.
385. **Ziadeh SM**, Perinatal outcome in 41 sets of triplets in Jordan, Birth 27:185, 2000.
386. **Ata B**, **Rasillo LJ**, **Sukhdeo S**, **Son WY**, **Tan SL**, **Dahan MH**, Obstetric outcomes of IVF trichorionic triamniotic triplets which are spontaneously or electively reduced to twins, J Assist Reprod Genet 28:1217, 2011.
387. **Wimalasundera RC**, Selective reduction and termination of multiple pregnancies, Semin Fetal Neonatal Med 15:327, 2010.
388. **Anthoulakis C**, **Dagklis T**, **Mamopoulos A**, **Athanasiadis A**, Risks of miscarriage or preterm delivery in trichorionic and dichorionic triplet pregnancies with embryo reduction versus expectant management: a systematic review and meta-analysis, Hum Reprod 32:1351, 2017.
389. **Dodd J**, **Crowther C**, Multifetal pregnancy reduction of triplet and higher-order multiple pregnancies to twins, Fertil Steril 81:1420, 2004.
390. **Stone J**, **Ferrara L**, **Kamrath J**, **Getrajdman J**, **Berkowitz R**, **Moshier E**, **Eddleman K**, Contemporary outcomes with the latest 1000 cases of multifetal pregnancy reduction (MPR), Am J Obstet Gynecol 199:406.e1, 2008.
391. **Razaz N**, **Avitan T**, **Ting J**, **Pressey T**, **Joseph KS**, Perinatal outcomes in multifetal pregnancy following fetal reduction, CMAJ 189:E652, 2017.
392. **van de Mheen L**, **Everwijn SM**, **Knapen MF**, **Haak MC**, **Engels MA**, **Manten GT**, **Zondervan HA**, **Wirjosoekarto SA**, **van Vugt JM**, **Erwich JJ**, **Bilardo CM**, **van Pampus MG**, **de Groot CJ**, **Mol BW**, **Pajkrt E**, Pregnancy outcome after fetal reduction in women with a dichorionic twin pregnancy, Hum Reprod 30:1807, 2015.
393. **Mai Q**, **Hu X**, **Yang G**, **Luo Y**, **Huang K**, **Yuan Y**, **Zhou C**, Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial, Am J Obstet Gynecol 216:42.e1, 2017.
394. **Vasseur C**, **Rodien P**, **Beau I**, **Desroches A**, **Gerard C**, **de Poncheville L**, **Chaplot S**, **Savagner F**, **Croue A**, **Mathieu E**, **Lahlou N**, **Descamps P**, **Misrahi M**, A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome, N Engl J Med 349:753, 2003.
395. **Smits G**, **Olatunbosun O**, **Delbaere A**, **Pierson R**, **Vassart G**, **Costagliola S**, Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor, N Engl J Med 349:760, 2003.
396. **Montanelli L**, **Delbaere A**, **Di Carlo C**, **Nappi C**, **Smits G**, **Vassart G**, **Costagliola S**, A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome, J Clin Endocrinol Metab 89:1255, 2004.
397. **Goldsman MP**, **Pedram A**, **Dominguez CE**, **Ciuffardi I**, **Levin E**, **Asch RH**, Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome, Fertil Steril 63:268, 1995.
398. **Bergh PA**, **Navot D**, Ovarian hyperstimulation syndrome: a review of pathophysiology, J Assist Reprod Genet 9:429, 1992.
399. **Levin ER**, **Rosen GF**, **Cassidenti DL**, **Yee B**, **Meldrum D**, **Wisot A**, **Pedram A**, Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome, J Clin Invest 102:1978, 1998.
400. **Geva E**, **Jaffe RB**, Role of vascular endothelial growth factor in ovarian physiology and pathology, Fertil Steril 74:429, 2000.
401. **Pellicer A**, **Albert C**, **Mercader A**, **Bonilla-Musoles F**, **Remohi J**, **Simon C**, The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular

endothelial growth factor, Fertil Steril 71:482, 1999.
402. **Revel A**, **Barak V**, **Lavy Y**, **Anteby E**, **Abramov Y**, **Schenker JJ**, **Amit A**, **Finci-Yeheskel Z**, **Mayer M**, **Simon A**, **Laufer N**, **Hurwitz A**, Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome, Fertil Steril 66:66, 1996.
403. **Delbaere A**, **Bergmann PJ**, **Gervy-Decoster C**, **Deschodt-Lanckman M**, **de Maertelaer V**, **Staroukine M**, **Camus M**, **Englert Y**, Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation, Fertil Steril 67:1038, 1997.
404. **Buyalos RP**, **Lee CT**, Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization, Fertil Steril 65:1, 1996.
405. **Golan A**, **Ron-el R**, **Herman A**, **Soffer Y**, **Weinraub Z**, **Caspi E**, Ovarian hyperstimulation syndrome: an update review, Obstet Gynecol Surv 44:430, 1989.
406. **Ashrafi M**, **Bahmanabadi A**, **Akhond MR**, **Arabipoor A**, Predictive factors of early moderate/severe ovarian hyperstimulation syndrome in non-polycystic ovarian syndrome patients: a statistical model, Arch Gynecol Obstet 292:1145, 2015.
407. **Lee TH**, **Liu CH**, **Huang CC**, **Wu YL**, **Shih YT**, **Ho HN**, **Yang YS**, **Lee MS**, Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles, Hum Reprod 23:160, 2008.
408. **Nakhuda GS**, **Chu MC**, **Wang JG**, **Sauer MV**, **Lobo RA**, Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization, Fertil Steril 85:1541, 2006.
409. **Ocal P**, **Sahmay S**, **Cetin M**, **Irez T**, **Guralp O**, **Cepni I**, Serum anti-Mullerian hormone and antral follicle count as predictive markers of OHSS in ART cycles, J Assist Reprod Genet 28:1197, 2011.
410. **Tal R**, **Seifer DB**, **Khanimov M**, **Malter HE**, **Grazi RV**, **Leader B**, Characterization of women with elevated antimullerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes, Am J Obstet Gynecol 211:59.e1, 2014.
411. **Jayaprakasan K**, **Chan Y**, **Islam R**, **Haoula Z**, **Hopkisson J**, **Coomarasamy A**, **Raine-Fenning N**, Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women, Fertil Steril 98:657, 2012.
412. **Forman RG**, **Frydman R**, **Egan D**, **Ross C**, **Barlow DH**, Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention, Fertil Steril 53:502, 1990.
413. **Delvigne A**, **Demoulin A**, **Smitz J**, **Donnez J**, **Koninckx P**, **Dhont M**, **Englert Y**, **Delbeke L**, **Darcis L**, **Gordts S**, **Puttemans P**, **Gerris J**, **Schoysman R**, **Leroy F**, The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features, Hum Reprod 8:1353, 1993.
414. **Enskog A**, **Henriksson M**, **Unander M**, **Nilsson L**, **Brannstrom M**, Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization, Fertil Steril 71:808, 1999.
415. **Practice Committee of the American Society for Reproductive Medicine. Electronic address ASRM@asrm.org, Practice Committee of the American Society for Reproductive Medicine**, Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline, Fertil Steril 106:1634, 2016.
416. **Practice Committee of American Society for Reproductive Medicine**, Ovarian hyperstimulation syndrome, Fertil Steril 90:S188, 2008.
417. **Mashiach S**, **Bider D**, **Moran O**, **Goldenberg M**, **Ben-Rafael Z**, Adnexal torsion of hyperstimulated ovaries in pregnancies after gonadotropin therapy, Fertil Steril 53:76, 1990.
418. **Zosmer A**, **Katz Z**, **Lancet M**, **Konichezky S**, **Schwartz-Shoham Z**, Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome, Fertil Steril 47:524, 1987.
419. **Borenstein R**, **Elhalah U**, **Lunenfeld B**, **Schwartz ZS**, Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach, Fertil Steril 51:791, 1989.

420. **Navot D**, **Bergh PA**, **Laufer N**, Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment, Fertil Steril 58:249, 1992.
421. **Abramov Y**, **Elchalal U**, **Schenker JG**, Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study, Fertil Steril 71:645, 1999.
422. **Wilson CA**, **Keye WR Jr**, A survey of adolescent dysmenorrhea and premenstrual symptom frequency. A model program for prevention, detection, and treatment, J Adolesc Health Care 10:317, 1989.
423. **Lincoln SR**, **Opsahl MS**, **Blauer KL**, **Black SH**, **Schulman JD**, Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization, J Assist Reprod Genet 19:159, 2002.
424. **Qublan HS**, **Al-Taani MI**, **Megdadi MF**, **Metri RM**, **Al-Ahmad N**, Multiple transvaginal ascitic fluid aspirations improves the clinical and reproductive outcome in patients undergoing in vitro fertilisation treatment complicated by severe early ovarian hyperstimulation syndrome, J Obstet Gynaecol 32:379, 2012.
425. **Aboulghar MA**, **Mansour RT**, **Serour GI**, **Amin Y**, Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome, Fertil Steril 53:933, 1990.
426. **Rizk B**, **Aboulghar M**, Modern management of ovarian hyperstimulation syndrome, Hum Reprod 6:1082, 1991.
427. **Rinaldi ML**, **Spirtos NJ**, Chest tube drainage of pleural effusion correcting abdominal ascites in a patient with severe ovarian hyperstimulation syndrome: a case report, Fertil Steril 63:1114, 1995.
428. **Eshre Capri Workshop Group**, Venous thromboembolism in women: a specific reproductive health risk, Hum Reprod Update 19:471, 2013.
429. **Rova K**, **Passmark H**, **Lindqvist PG**, Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles, Fertil Steril 97:95, 2012.
430. **Reed AP**, **Tausk H**, **Reynolds H**, Anesthetic considerations for severe ovarian hyperstimulation syndrome, Anesthesiology 73:1275, 1990.
431. **Grochowski D**, **Wolczynski S**, **Kuczynski W**, **Domitrz J**, **Szamatowicz J**, **Szamatowicz M**, Correctly timed coasting reduces the risk of ovarian hyperstimulation syndrome and gives good cycle outcome in an in vitro fertilization program, Gynecol Endocrinol 15:234, 2001.
432. **Al-Shawaf T**, **Zosmer A**, **Hussain S**, **Tozer A**, **Panay N**, **Wilson C**, **Lower AM**, **Grudzinskas JG**, Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound for identification of high-risk patients, Hum Reprod 16:24, 2001.
433. **Ulug U**, **Bahceci M**, **Erden HF**, **Shalev E**, **Ben-Shlomo I**, The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles, Hum Reprod 17:310, 2002.
434. **Sher G**, **Zouves C**, **Feinman M**, **Maassarani G**, 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization, Hum Reprod 10:3107, 1995.
435. **Waldenstrom U**, **Kahn J**, **Marsk L**, **Nilsson S**, High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: a multicentre study, Hum Reprod 14:294, 1999.
436. **Kol S**, **Muchtar M**, Recombinant gonadotrophin-based, ovarian hyperstimulation syndrome-free stimulation of the high responder: suggested protocol for further research, Reprod Biomed Online 10:575, 2005.
437. **Lewit N**, **Kol S**, **Manor D**, **Itskovitz-Eldor J**, Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study, Hum Reprod 11:1399, 1996.
438. **Fatemi HM**, **Popovic-Todorovic B**, **Humaidan P**, **Kol S**, **Banker M**, **Devroey P**, **Garcia-Velasco JA**, Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol, Fertil Steril 101:1008, 2014.
439. **Alvarez C**, **Marti-Bonmati L**, **Novella-Maestre E**, **Sanz R**, **Gomez R**, **Fernandez-Sanchez M**, **Simon C**, **Pellicer A**, Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction, J Clin Endocrinol Metab 92:2931, 2007.

440. **Taheripanah R**, **Balash F**, **Anbiaee R**, **Mahmoodi M**, **Akbari Sene A**, Breast Cancer and Ovulation Induction Treatments, Clin Breast Cancer 18:395, 2018.
441. **Burkman RT**, **Tang MT**, **Malone KE**, **Marchbanks PA**, **McDonald JA**, **Folger SG**, **Norman SA**, **Strom BL**, **Bernstein L**, **Ursin G**, **Weiss LK**, **Daling JR**, **Simon MS**, **Spirtas R**, Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study, Fertil Steril 79:844, 2003.
442. **Crowley WF Jr**, **McArthur JW**, Simulation of the normal menstrual cycle in Kallman's syndrome by pulsatile administration of luteinizing hormone-releasing hormone (LHRH), J Clin Endocrinol Metab 51:173, 1980.
443. **Leyendecker G**, **Wildt L**, **Hansmann M**, Pregnancies following chronic intermittent (pulsatile) administration of Gn-RH by means of a portable pump ("Zyklomat")—a new approach to the treatment of infertility in hypothalamic amenorrhea, J Clin Endocrinol Metab 51:1214, 1980.
444. **Crowley WF Jr**, **Filicori M**, **Spratt DI**, **Santoro NF**, The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women, Recent Prog Horm Res 41:473, 1985.
445. **Filicori M**, **Flamigni C**, **Meriggiola MC**, **Cognigni G**, **Valdiserri A**, **Ferrari P**, **Campaniello E**, Ovulation induction with pulsatile gonadotropin-releasing hormone: technical modalities and clinical perspectives, Fertil Steril 56:1, 1991.
446. **Martin K**, **Santoro N**, **Hall J**, **Filicori M**, **Wierman M**, **Crowley WF Jr**, Clinical review 15: Management of ovulatory disorders with pulsatile gonadotropin-releasing hormone, J Clin Endocrinol Metab 71:1081A, 1990.
447. **Filicori M**, **Flamigni C**, **Dellai P**, **Cognigni G**, **Michelacci L**, **Arnone R**, **Sambataro M**, **Falbo A**, Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles, J Clin Endocrinol Metab 79:1215, 1994.
448. **Gill S**, **Taylor AE**, **Martin KA**, **Welt CK**, **Adams JM**, **Hall JE**, Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome, J Clin Endocrinol Metab 86:2428, 2001.
449. **Braat DD**, **Schoemaker R**, **Schoemaker J**, Life table analysis of fecundity in intravenously gonadotropin-releasing hormone-treated patients with normogonadotropic and hypogonadotropic amenorrhea, Fertil Steril 55:266, 1991.
450. **Timmerman-van Kessel EC**, **Cikot RJ**, **Dargel-Donkers EJ**, **Zwertbroek W**, **van Dop PA**, **Schoot DC**, A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome, Fertil Steril 73:1145, 2000.
451. **Braat DD**, **Ayalon D**, **Blunt SM**, **Bogchelman D**, **Coelingh Bennink HJ**, **Handelsman DJ**, **Heineman MJ**, **Lappohn RE**, **Lorijn RH**, **Rolland R**, **Willemsen WMP**, **Schoemaker J**, Pregnancy outcome in luteinizing hormone-releasing hormone induced cycles: a multicentre study, Gynecol Endocrinol 3:35, 1989.
452. **Filicori M**, **Flamigni C**, **Meriggiola MC**, **Ferrari P**, **Michelacci L**, **Campaniello E**, **Valdiserri A**, **Cognigni G**, Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders, J Clin Endocrinol Metab 72:965, 1991.
453. **Jansen RP**, Pulsatile intravenous gonadotrophin releasing hormone for ovulation induction: determinants of follicular and luteal phase responses, Hum Reprod 8(Suppl 2):193, 1993.
454. **Santoro N**, **Wierman ME**, **Filicori M**, **Waldstreicher J**, **Crowley WF Jr**, Intravenous administration of pulsatile gonadotropin-releasing hormone in hypothalamic amenorrhea: effects of dosage, J Clin Endocrinol Metab 62:109, 1986.
455. **Filicori M**, **Campaniello E**, **Michelacci L**, **Pareschi A**, **Ferrari P**, **Bolelli G**, **Flamigni C**, Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH, J Clin Endocrinol Metab 66:327, 1988.
456. **Louvet JP**, **Harman SM**, **Schrieber JR**, **Ross GT**, Evidence of a role of androgens in follicular maturation, Endocrinology 97:366, 1975.
457. **Filicori M**, **Flamigni C**, **Campaniello E**, **Valdiserri A**, **Ferrari P**, **Meriggiola MC**, **Michelacci L**, **Pareschi A**, The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management, J Clin Endocrinol Metab 69:825, 1989.

458. **Tranoulis A**, **Laios A**, **Pampanos A**, **Yannoukakos D**, **Loutradis D**, **Michala L**, Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis, Fertil Steril 109:708.e8, 2018.
459. **Homburg R**, **Eshel A**, **Armar NA**, **Tucker M**, **Mason PW**, **Adams J**, **Kilborn J**, **Sutherland IA**, **Jacobs HS**, One hundred pregnancies after treatment with pulsatile luteinising hormone releasing hormone to induce ovulation, BMJ 298:809, 1989.
460. **Martin KA**, **Hall JE**, **Adams JM**, **Crowley WF Jr**, Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea, J Clin Endocrinol Metab 77:125, 1993.
461. **Carr JS**, **Reid RL**, Ovulation induction with gonadotropin-releasing hormone (GnRH), Semin Reprod Endocrinol 8:174, 1990.
462. **Schran HF**, **Bhuta SI**, **Schwarz HJ**, **Thorner MO**, The pharmacokinetics of bromocriptine in man, Adv Biochem Psychopharmacol 23:125, 1980.
463. **Bankowski BJ**, **Zacur HA**, Dopamine agonist therapy for hyperprolactinemia, Clin Obstet Gynecol 46:349, 2003.
464. **Ferrari C**, **Barbieri C**, **Caldara R**, **Mucci M**, **Codecasa F**, **Paracchi A**, **Romano C**, **Boghen M**, **Dubini A**, Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients, J Clin Endocrinol Metab 63:941, 1986.
465. **Friedman E**, **Adams EF**, **Hoog A**, **Gejman PV**, **Carson E**, **Larsson C**, **De Marco L**, **Werner S**, **Fahlbusch R**, **Nordenskjold M**, Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors, J Clin Endocrinol Metab 78:568, 1994.
466. **Padilla SL**, **Person GK**, **McDonough PG**, **Reindollar RH**, The efficacy of bromocriptine in patients with ovulatory dysfunction and normoprolactinemic galactorrhea, Fertil Steril 44:695, 1985.
467. **Yamaguchi M**, **Aono T**, **Koike K**, **Nishikawa Y**, **Ikegami H**, **Miyake A**, **Tanizawa O**, Effects of nocturnal hyperprolactinemia on ovarian luteal function and galactorrhea, Eur J Obstet Gynecol Reprod Biol 39:187, 1991.
468. **Asukai K**, **Uemura T**, **Minaguchi H**, Occult hyperprolactinemia in infertile women, Fertil Steril 60:423, 1993.
469. **Fujimoto VY**, **Clifton DK**, **Cohen NL**, **Soules MR**, Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting, Obstet Gynecol 76:71, 1990.
470. **Suginami H**, **Hamada K**, **Yano K**, **Kuroda G**, **Matsuura S**, Ovulation induction with bromocriptine in normoprolactinemic anovulatory women, J Clin Endocrinol Metab 62:899, 1986.
471. **Isik AZ**, **Gulekli B**, **Zorlu CG**, **Ergin T**, **Gokmen O**, Endocrinological and clinical analysis of hyperprolactinemic patients with and without ultrasonically diagnosed polycystic ovarian changes, Gynecol Obstet Invest 43:183, 1997.
472. **Papaleo E**, **Doldi N**, **De Santis L**, **Marelli G**, **Marsiglio E**, **Rofena S**, **Ferrari A**, Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome, Hum Reprod 16:2263, 2001.
473. **Falaschi P**, **Rocco A**, **del Pozo E**, Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome, J Clin Endocrinol Metab 62:348, 1986.
474. **Verhelst J**, **Abs R**, **Maiter D**, **van den Bruel A**, **Vandeweghe M**, **Velkeniers B**, **Mockel J**, **Lamberigts G**, **Petrossians P**, **Coremans P**, **Mahler C**, **Stevenaert A**, **Verlooy J**, **Raftopoulos C**, **Beckers A**, Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients, J Clin Endocrinol Metab 84:2518, 1999.
475. **Factor SA**, Dopamine agonists, Med Clin North Am 83:415, vi, 1999.
476. **Wang AT**, **Mullan RJ**, **Lane MA**, **Hazem A**, **Prasad C**, **Gathaiya NW**, **Fernandez-Balsells MM**, **Bagatto A**, **Coto-Yglesias F**, **Carey J**, **Elraiyah TA**, **Erwin PJ**, **Gandhi GY**, **Montori VM**, **Murad MH**, Treatment of hyperprolactinemia: a systematic review and meta-analysis, Syst Rev 1:33, 2012.
477. **Ciccarelli E**, **Giusti M**, **Miola C**, **Potenzoni F**, **Sghedoni D**, **Camanni F**, **Giordano G**, Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic

patients, J Clin Endocrinol Metab 69:725, 1989.
478. **Katz E**, **Schran HF**, **Adashi EY**, Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy, Obstet Gynecol 73:517, 1989.
479. **Ginsburg J**, **Hardiman P**, **Thomas M**, Vaginal bromocriptine—clinical and biochemical effects, Gynecol Endocrinol 6:119, 1992.
480. **Motta T**, **de Vincentiis S**, **Marchini M**, **Colombo N**, **D'Alberton A**, Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics, Fertil Steril 65:440, 1996.
481. **Turkalj I**, **Braun P**, **Krupp P**, Surveillance of bromocriptine in pregnancy, JAMA 247:1589, 1982.
482. **Weil C**, The safety of bromocriptine in long-term use: a review of the literature, Curr Med Res Opin 10:25, 1986.
483. **Czeizel A**, **Kiss R**, **Racz K**, **Mohori K**, **Glaz E**, Case-control cytogenetic study in offspring of mothers treated with bromocriptine during early pregnancy, Mutat Res 210:23, 1989.
484. **Raymond JP**, **Goldstein E**, **Konopka P**, **Leleu MF**, **Merceron RE**, **Loria Y**, Follow-up of children born of bromocriptine-treated mothers, Horm Res 22:239, 1985.
485. **Schade R**, **Andersohn F**, **Suissa S**, **Haverkamp W**, **Garbe E**, Dopamine agonists and the risk of cardiac-valve regurgitation, N Engl J Med 356:29, 2007.
486. **Zanettini R**, **Antonini A**, **Gatto G**, **Gentile R**, **Tesei S**, **Pezzoli G**, Valvular heart disease and the use of dopamine agonists for Parkinson's disease, N Engl J Med 356:39, 2007.
487. **Roth BL**, Drugs and valvular heart disease, N Engl J Med 356:6, 2007.

Chapter twenty eight

REFERENCES

1. **Steptoe PC**, **Edwards RG**, Reimplantation of a human embryo with subsequent tubal pregnancy, Lancet 1:880, 1976.
2. **Steptoe PC**, **Edwards RG**, Birth after the reimplantation of a human embryo, Lancet 2:366, 1978.
3. **Sunderam S**, **Kissin DM**, **Crawford SB**, **Folger SG**, **Boulet SL**, **Warner L**, **Barfield WD**, Assisted reproductive technology surveillance—United States, 2015, MMWR Surveill Summ 67:1, 2018.
4. **Pinter B**, **da Silva MO**, **Bloemenkamp K**, **Fronteira I**, **Karro H**, Assisted Reproductive Technologies in European Union: Findings of the Reproductive Health Report, 2018. https://webgate.ec.europa.eu/chafea_pdb/assets/files/pdb/2007110/2007110_d12-01_en_ps.pdf
5. **Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology**, 2015 Assisted Reproductive Technology National Summary Report, 2017.
6. **Diamond E**, Lysis of postoperative pelvic adhesions in infertility, Fertil Steril 31(3):287, 1979.
7. **Gomel V**, Salpingo-ovariolysis by laparoscopy in infertility, Fertil Steril 40(5): 607, 1983.
8. **Donnez J**, **Casanas-Roux F**, Prognostic factors of fimbrial microsurgery, Fertil Steril 46:200, 1986.
9. **Dubuisson JB**, **Bouquet de Joliniere J**, **Aubriot FX**, **Darai E**, **Foulot H**, **Mandelbrot L**, Terminal tuboplasties by laparoscopy: 65 consecutive cases, Fertil Steril 54:401, 1990.
10. **Canis M**, **Mage G**, **Pouly JL**, **Manhes H**, **Wattiez A**, **Bruhat MA**, Laparoscopic distal tuboplasty: report of 87 cases and a 4-year experience, Fertil Steril 56:616, 1991.
11. **Dlugi AM**, **Reddy S**, **Saleh WA**, **Mersol-Barg MS**, **Jacobsen G**, Pregnancy rates after operative endoscopic treatment of total (neosalpingostomy), Fertil Steril 62:913, 1994.
12. **Taylor RC**, **Berkowitz J**, **McComb PF**, Role of laparoscopic salpingostomy in the treatment of hydrosalpinx, Fertil Steril 75:594, 2001.
13. **Beyler SA**, **James KP**, **Fritz MA**, **Meyer WR**, Hydrosalpingeal fluid inhibits in-vitro embryonic development in a murine model, Hum Reprod 12:2724, 1997.
14. **Meyer WR**, **Castelbaum AJ**, **Somkuti S**, **Sagoskin AW**, **Doyle M**, **Harris JE**, **Lessey BA**, Hydrosalpinges adversely affect markers of endometrial receptivity, Hum Reprod 12:1393, 1997.
15. **Cohen MA**, **Lindheim SR**, **Sauer MV**, Hydrosalpinges adversely affect implantation in donor oocyte cycles, Hum Reprod 14:1087, 1999.
16. **Strandell A**, **Lindhard A**, Why does hydrosalpinx reduce fertility? The importance of hydrosalpinx fluid, Hum Reprod 17:1141, 2002.
17. **Daftary GS**, **Taylor HS**, Hydrosalpinx fluid diminishes endometrial cell HOXA10 expression, Fertil Steril 78(3):577, 2002.
18. **Daftary GS**, **Kayisli U**, **Seli E**, **Bukulmez O**, **Arici A**, **Taylor HS**, Salpingectomy increases peri-implantation endometrial HOXA10 expression in women with hydrosalpinx, Fertil Steril 87(2):367, 2007.
19. **Johnson N**, **van Voorst S**, **Sowter MC**, **Strandell A**, **Mol BW**, Surgical treatment for tubal disease in women due to undergo in vitro, Cochrane Database Syst Rev (1):CD002125, 2010.
20. **Aboulghar MA**, **Mansour RT**, **Serour GI**, Spontaneous intrauterine pregnancy following salpingectomy for a unilateral hydrosalpinx, Hum Reprod 17:1099, 2002.
21. **Choe J**, **Check JH**, Salpingectomy for unilateral hydrosalpinx may improve in vivo fecundity, Gynecol Obstet Invest 48:285, 1999.
22. **Al-Jaroudi D**, **Herba MJ**, **Tulandi T**, Reproductive performance after selective tubal catheterization, J Minim Invasive Gynecol 12:150, 2005.
23. **Flood JT**, **Grow DR**, Transcervical tubal cannulation: a review, Obstet Gynecol Surv 48:768, 1993.
24. **Confino E**, **Tur-Kaspa I**, **DeCherney A**, **Corfman R**, **Coulam C**, **Robinson E**, **Haas G**, **Katz E**, **Vermesh M**, **Gleicher N**, Transcervical balloon tuboplasty. A multicenter study, JAMA 264:2079, 1990.
25. **Woolcott R**, **Fisher S**, **Thomas J**, **Kable W**, A randomized, prospective, controlled study of laparoscopic dye studies and selective salpingography as diagnostic tests of fallopian tube patency, Fertil Steril 72:879, 1999.

26. **Valle RF**, Tubal cannulation, Obstet Gynecol Clin North Am 22:519, 1995.
27. **Thurmond AS**, Selective salpingography and fallopian tube recanalization, Am J Roentgenol 156:33, 1991.
28. **Sankpal RS**, **Confino E**, **Matzel A**, **Cohen LS**, Investigation of the uterine cavity and fallopian tubes using three-dimensional saline sonohysterosalpingography, Int J Gynaecol Obstet 73:125, 2001.
29. **Papaioannou S**, **Afnan M**, **Girling AJ**, **Coomarasamy A**, **Ola B**, **Olufowobi O**, **McHugo JM**, **Hammadieh N**, **Sharif K**, Long-term fertility prognosis following selective salpingography and tubal catheterization in women with proximal tubal blockage, Hum Reprod 17:2325, 2002.
30. **Papaioannou S**, **Afnan M**, **Girling AJ**, **Coomarasamy A**, **Ola B**, **Olufowobi O**, **McHugo JM**, **Hammadieh N**, **Sharif K**, The effect on pregnancy rates of tubal perfusion pressure reductions achieved by guide-wire tubal catheterization, Hum Reprod 17:2174, 2002.
31. **Patton PE**, **Williams TJ**, **Coulam CB**, Microsurgical reconstruction of the proximal oviduct, Fertil Steril 47:35, 1987.
32. **Patton PE**, **Williams TJ**, **Coulam CB**, Results of microsurgical reconstruction in patients with combined proximal and distal tubal occlusion: double obstruction, Fertil Steril 48:670, 1987.
33. **Marana R**, **Quagliarello J**, Proximal tubal occlusion: microsurgery versus IVF—a review, Int J Fertil 33:338, 1988.
34. **Honore GM**, **Holden AE**, **Schenken RS**, Pathophysiology and management of proximal tubal blockage, Fertil Steril 71:785, 1999.
35. **Stephen EH**, **Chandra A**, Use of infertility services in the United States: 1995, Fam Plann Perspect 32:132, 2000.
36. **Borrero SB**, **Reeves MF**, **Schwarz EB**, **Bost JE**, **Creinin MD**, **Ibrahim SA**, Race, insurance status, and desire for tubal sterilization reversal, Fertil Steril 90:272, 2008.
37. **Schmidt JE**, **Hillis SD**, **Marchbanks PA**, **Jeng G**, **Peterson HB**, Requesting information about and obtaining reversal after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization, Fertil Steril 74:892, 2000.
38. **Chi IC**, **Jones DB**, Incidence, risk factors, and prevention of poststerilization regret in women: an updated international review from an epidemiological perspective, Obstet Gynecol Surv 49:722, 1994.
39. **Neuhaus W**, **Bolte A**, Prognostic factors for preoperative consultation of women desiring sterilization: findings of a retrospective analysis, J Psychosom Obstet Gynaecol 16:45, 1995.
40. **Hardy E**, **Bahamondes L**, **Osis MJ**, **Costa RG**, **Faundes A**, Risk factors for tubal sterilization regret, detectable before surgery, Contraception 54:159, 1996.
41. **Curtis KM**, **Mohllajee AP**, **Peterson HB**, Regret following female sterilization at a young age: a systematic review, Contraception 73:205, 2006.
42. **Henderson SR**, The reversibility of female sterilization with the use of microsurgery: a report on 102 patients with more than one year of follow-up, Am J Obstet Gynecol 149:57, 1984.
43. **Rock JA**, **Chang YS**, **Limpaphayom K**, **Koetswang S**, **Moeloek FA**, **Guzick DS**, **Burkman RT**, **King TM**, Microsurgical tubal anastomosis: a controlled trial in four Asian centers, Microsurgery 5:95, 1984.
44. **Boeckx W**, **Gordts S**, **Buysse K**, **Brosens I**, Reversibility after female sterilization, Br J Obstet Gynaecol 93:839, 1986.
45. **te Velde ER**, **Boer ME**, **Looman CW**, **Habbema JD**, Factors influencing success or failure after reversal of sterilization: a multivariate approach, Fertil Steril 54:270, 1990.
46. **Winston RM**, Tubal surgery or in vitro fertilization (IVF)? J Assist Reprod Genet 9:309, 1992.
47. **Dubuisson JB**, **Chapron C**, **Nos C**, **Morice P**, **Aubriot FX**, **Garnier P**, Sterilization reversal: fertility results, Hum Reprod 10:1145, 1995.
48. **Rouzi AA**, **Mackinnon M**, **McComb PF**, Predictors of success of reversal of sterilization, Fertil Steril 64:29, 1995.
49. **Glock JL**, **Kim AH**, **Hulka JF**, **Hunt RB**, **Trad FS**, **Brumsted JR**, Reproductive outcome after tubal reversal in women 40 years of age or older, Fertil Steril 65:863, 1996.
50. **Schenken RS**, **Asch RH**, **Williams RF**, **Hodgen GD**, Etiology of infertility in monkeys with endometriosis: luteinized unruptured follicles, luteal phase defects, pelvic adhesions, and spontaneous abortions, Fertil Steril 41:

122, 1984.
51. **Toya M**, **Saito H**, **Ohta N**, **Saito T**, **Kaneko T**, **Hiroi M**, Moderate and severe endometriosis is associated with alterations in the cell cycle of granulosa cells in patients undergoing in vitro fertilization and embryo transfer, Fertil Steril 73:344, 2000.
52. **Oral E**, **Arici A**, **Olive DL**, **Huszar G**, Peritoneal fluid from women with moderate or severe endometriosis inhibits sperm motility: the role of seminal fluid components, Fertil Steril 66:787, 1996.
53. **Lyons RA**, **Djahanbakhch O**, **Saridogan E**, **Naftalin AA**, **Mahmood T**, **Weekes A**, **Chenoy R**, Peritoneal fluid, endometriosis, and ciliary beat frequency in the human fallopian tube, Lancet 360:1221, 2002.
54. **Lessey BA**, **Castelbaum AJ**, **Sawin SW**, **Buck CA**, **Schinnar R**, **Bilker W**, **Strom BL**, Aberrant integrin expression in the endometrium of women with endometriosis, J Clin Endocrinol Metab 79:643, 1994.
55. **Illera MJ**, **Juan L**, **Stewart CL**, **Cullinan E**, **Ruman J**, **Lessey BA**, Effect of peritoneal fluid from women with endometriosis on implantation in the mouse model, Fertil Steril 74:41, 2000.
56. **Macer ML**, **Taylor HS**, Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility, Obstet Gynecol Clin North Am 39(4):535, 2012.
57. **Bromer JG**, **Aldad TS**, **Taylor HS**, Defining the proliferative phase endometrial defect, Fertil Steril 91(3):698, 2009.
58. **Taylor HS**, **Bagot C**, **Kardana A**, **Olive D**, **Arici A**, HOX gene expression is altered in the endometrium of women with endometriosis, Hum Reprod 14(5):1328, 1999.
59. **Vercellini P**, **Vigano P**, **Frattaruolo MP**, **Borghi A**, **Somigliana E**, Bowel surgery as a fertility-enhancing procedure in patients with colorectal endometriosis: methodological, pathogenic and ethical issues, Hum Reprod 33:1205, 2018.
60. **Centini G**, **Afors K**, **Murtada R**, **Argay IM**, **Lazzeri L**, **Akladios CY**, **Zupi E**, **Petraglia F**, **Wattiez A**, Impact of laparoscopic surgical management of deep endometriosis on pregnancy rate, J Minim Invasive Gynecol 23:113, 2016.
61. **Adamson GD**, **Pasta DJ**, Surgical treatment of endometriosis-associated infertility: meta-analysis compared with survival analysis, Am J Obstet Gynecol 171:1488; discussion 1504–1505, 1994.
62. **Olive DL**, **Lee KL**, Analysis of sequential treatment protocols for endometriosis-associated infertility, Am J Obstet Gynecol 154:613, 1986.
63. **Ata B**, **Turkgeldi E**, **Seyhan A**, **Urman B**, Effect of hemostatic method on ovarian reserve following laparoscopic endometrioma excision; comparison of suture, hemostatic sealant, and bipolar desiccation. A systematic review and meta-analysis, J Minim Invasive Gynecol 22:363, 2015.
64. **Muzii L**, **Bellati F**, **Palaia I**, **Plotti F**, **Manci N**, **Zullo MA**, **Angioli R**, **Panici PB**, Laparoscopic stripping of endometriomas: a randomized trial on different surgical techniques. Part I: clinical results, Hum Reprod 20:1981, 2005.
65. **Reich H**, **Abrao MS**, Post-surgical ovarian failure after laparoscopic excision of bilateral endometriomas: is this rare problem preventable? Am J Obstet Gynecol 195:339, 2006.
66. **Adamson GD**, **Pasta DJ**, Endometriosis fertility index: the new, validated endometriosis staging system, Fertil Steril 94:1609, 2010.
67. **Tomassetti C**, **Geysenbergh B**, **Meuleman C**, **Timmerman D**, **Fieuws S**, **D'Hooghe T**, External validation of the endometriosis fertility index (EFI) staging system for predicting non-ART pregnancy after endometriosis surgery, Hum Reprod 28:1280, 2013.
68. **Hobo R**, **Nakagawa K**, **Usui C**, **Sugiyama R**, **Ino N**, **Motoyama H**, **Kuribayashi Y**, **Inoue M**, **Sugiyama R**, The endometriosis fertility index is useful for predicting the ability to conceive without assisted reproductive technology treatment after laparoscopic surgery, regardless of endometriosis, Gynecol Obstet Invest 83:493, 2018.
69. **Maheux-Lacroix S**, **Nesbitt-Hawes E**, **Deans R**, **Won H**, **Budden A**, **Adamson D**, **Abbott JA**, Endometriosis fertility index predicts live births following surgical resection of moderate and severe endometriosis, Hum Reprod 32:2243, 2017.
70. **Zhang X**, **Liu D**, **Huang W**, **Wang Q**, **Feng X**, **Tan J**, Prediction of Endometriosis Fertility Index in patients with endometriosis-associated infertility after laparoscopic treatment, Reprod Biomed Online 37:53, 2018.

71. **Hamdan M**, **Dunselman G**, **Li TC**, **Cheong Y**, The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis, Hum Reprod Update 21:809, 2015.
72. **Seyhan A**, **Urman B**, **Turkgeldi E**, **Ata B**, Do endometriomas grow during ovarian stimulation for assisted reproduction? A three-dimensional volume analysis before and after ovarian stimulation, Reprod Biomed Online 36:239, 2018.
73. **Benaglia L**, **Busnelli A**, **Biancardi R**, **Vegetti W**, **Reschini M**, **Vercellini P**, **Somigliana E**, Oocyte retrieval difficulties in women with ovarian endometriomas, Reprod Biomed Online 37:77, 2018.
74. **Padilla SL**, Ovarian abscess following puncture of an endometrioma during ultrasound-guided oocyte retrieval, Hum Reprod 8:1282, 1993.
75. **Younis JS**, **Ezra Y**, **Laufer N**, **Ohel G**, Late manifestation of pelvic abscess following oocyte retrieval, for in vitro fertilization, in patients with severe endometriosis and ovarian endometriomata, J Assist Reprod Genet 14:343, 1997.
76. **Moini A**, **Riazi K**, **Amid V**, **Ashrafi M**, **Tehraninejad E**, **Madani T**, **Owj M**, Endometriosis may contribute to oocyte retrieval-induced pelvic inflammatory disease: report of eight cases, J Assist Reprod Genet 22:307, 2005.
77. **Seyhan A**, **Ata B**, **Son WY**, **Dahan MH**, **Tan SL**, Comparison of complication rates and pain scores after transvaginal ultrasound-guided oocyte pickup procedures for in vitro maturation and in vitro fertilization cycles, Fertil Steril 101:705, 2014.
78. **Benaglia L**, **Somigliana E**, **Iemmello R**, **Colpi E**, **Nicolosi AE**, **Ragni G**, Endometrioma and oocyte retrieval-induced pelvic abscess: a clinical concern or an exceptional complication? Fertil Steril 89:1263, 2008.
79. **Sallam HN**, **Garcia-Velasco JA**, **Dias S**, **Arici A**, Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis, Cochrane Database Syst Rev (1):CD004635, 2006.
80. **Drakopoulos P**, **Rosetti J**, **Pluchino N**, **Blockeel C**, **Santos-Ribeiro S**, **de Brucker M**, **Drakakis P**, **Camus M**, **Tournaye H**, **Polyzos NP**, Does the type of GnRH analogue used, affect live birth rates in women with endometriosis undergoing IVF/ICSI treatment, according to the rAFS stage? Gynecol Endocrinol 34:884, 2018.
81. **Rodriguez-Purata J**, **Coroleu B**, **Tur R**, **Carrasco B**, **Rodriguez I**, **Barri PN**, Endometriosis and IVF: are agonists really better? Analysis of 1180 cycles with the propensity score matching, Gynecol Endocrinol 29:859, 2013.
82. **Thonneau P**, **Marchand S**, **Tallec A**, **Ferial ML**, **Ducot B**, **Lansac J**, **Lopes P**, **Tabaste JM**, **Spira A**, Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988-1989), Hum Reprod 6:811, 1991.
83. **Schlegel PN**, **Girardi SK**, Clinical review 87: in vitro fertilization for male factor infertility, J Clin Endocrinol Metab 82:709, 1997.
84. **Cooper TG**, **Noonan E**, **von Eckardstein S**, **Auger J**, **Baker HW**, **Behre HM**, **Haugen TB**, **Kruger T**, **Wang C**, **Mbizvo MT**, **Vogelsong KM**, World Health Organization reference values for human semen characteristics, Hum Reprod Update 16:231, 2010.
85. **Guzick DS**, **Overstreet JW**, **Factor-Litvak P**, **Brazil CK**, **Nakajima ST**, **Coutifaris C**, **Carson SA**, **Cisneros P**, **Steinkampf MP**, **Hill JA**, **Xu D**, **Vogel DL; National Cooperative Reproductive Medicine Network**, Sperm morphology, motility, and concentration in fertile and infertile men, N Engl J Med 345:1388, 2001.
86. **van der Westerlaken LA**, **Naaktgeboren N**, **Helmerhorst FM**, Evaluation of pregnancy rates after intrauterine insemination according to indication, age, and sperm parameters, J Assist Reprod Genet 15:359, 1998.
87. **Miller DC**, **Hollenbeck BK**, **Smith GD**, **Randolph JF**, **Christman GM**, **Smith YR**, **Lebovic DI**, **Ohl DA**, Processed total motile sperm count correlates with pregnancy outcome after intrauterine insemination, Urology 60:497, 2002.
88. **Van Voorhis BJ**, **Barnett M**, **Sparks AE**, **Syrop CH**, **Rosenthal G**, **Dawson J**, Effect of the total motile sperm count on the efficacy and cost-effectiveness of intrauterine insemination and in vitro fertilization, Fertil Steril 75: 661, 2001.

89. **Campana A**, **Sakkas D**, **Stalberg A**, **Bianchi PG**, **Comte I**, **Pache T**, **Walker D**, Intrauterine insemination: evaluation of the results according to the woman's age, sperm quality, total sperm count per insemination and life table analysis, Hum Reprod 11:732, 1996.
90. **Nulsen JC**, **Walsh S**, **Dumez S**, **Metzger DA**, A randomized and longitudinal study of human menopausal gonadotropin with intrauterine insemination in the treatment of infertility, Obstet Gynecol 82:780, 1993.
91. **Erdem M**, **Erdem A**, **Mutlu MF**, **Ozisik S**, **Yildiz S**, **Guler I**, **Karakaya C**, The impact of sperm morphology on the outcome of intrauterine insemination cycles with gonadotropins in unexplained and male subfertility, Eur J Obstet Gynecol Reprod Biol 197:120, 2016.
92. **Ombelet W**, **Dhont N**, **Thijssen A**, **Bosmans E**, **Kruger T**, Semen quality and prediction of IUI success in male subfertility: a systematic review, Reprod Biomed Online 28:300, 2014.
93. **Deveneau NE**, **Sinno O**, **Krause M**, **Eastwood D**, **Sandlow JI**, **Robb P**, **Granlund A**, **Strawn EY Jr**, Impact of sperm morphology on the likelihood of pregnancy after intrauterine insemination, Fertil Steril 102:1584.e2, 2014.
94. **Kashanian JA**, **Brannigan RE**, Sperm morphology and reproductive outcomes: a perplexing relationship, Fertil Steril 102:1561, 2014.
95. **Lee J**, **Hwang S**, **Lee J**, **Yoo J**, **Jang D**, **Hwang K**, **Kim M**, Effect of insemination timing on pregnancy outcome in association with female age, sperm motility, sperm morphology and sperm concentration in intrauterine insemination, J Obstet Gynaecol Res 44:1100, 2018.
96. **Lemmens L**, **Kos S**, **Beijer C**, **Brinkman JW**, **van der Horst FA**, **van den Hoven L**, **Kieslinger DC**, **van Trooyen-van Vrouwerff NJ**, **Wolthuis A**, **Hendriks JC**, **Wetzels AM; Semen Section of the Dutch Foundation for Quality Assessment in Medical Laboratories**, Predictive value of sperm morphology and progressively motile sperm count for pregnancy outcomes in intrauterine insemination, Fertil Steril 105:1462, 2016.
97. **Kruger TF**, **Acosta AA**, **Simmons KF**, **Swanson RJ**, **Matta JF**, **Oehninger S**, Predictive value of abnormal sperm morphology in in vitro fertilization, Fertil Steril 49:112, 1988.
98. **Van Uem JF**, **Acosta AA**, **Swanson RJ**, **Mayer J**, **Ackerman S**, **Burkman LJ**, **Veeck L**, **McDowell JS**, **Bernardus RE**, **Jones HW Jr**, Male factor evaluation in in vitro fertilization: norfolk experience, Fertil Steril 44:375, 1985.
99. **Hernandez M**, **Molina R**, **Olmedo J**, **Olmedo SB**, **Coetzee K**, **Estofan D**, Prognostic value of the strict criteria: an Argentinian experience, Arch Androl 37:87, 1996.
100. **Vawda AI**, **Gunby J**, **Younglai EV**, Semen parameters as predictors of in-vitro fertilization: the importance of strict criteria sperm morphology, Hum Reprod 11:1445, 1996.
101. **Ombelet W**, **Fourie FL**, **Vandeput H**, **Bosmans E**, **Cox A**, **Janssen M**, **Kruger T**, Teratozoospermia and in-vitro fertilization: a randomized prospective study, Hum Reprod 9:1479, 1994.
102. **Menkveld R**, **Kruger TF**, Advantages of strict (Tygerberg) criteria for evaluation of sperm morphology, Int J Androl 18(Suppl 2):36, 1995.
103. **Hall J**, **Fishel S**, **Green S**, **Fleming S**, **Hunter A**, **Stoddart N**, **Dowell K**, **Thornton S**, Intracytoplasmic sperm injection versus high insemination concentration in-vitro fertilization in cases of very severe teratozoospermia, Hum Reprod 10:493, 1995.
104. **Mansour RT**, **Aboulghar MA**, **Serour GI**, **Amin YM**, **Ramzi AM**, The effect of sperm parameters on the outcome of intracytoplasmic sperm injection, Fertil Steril 64:982, 1995.
105. **Robinson JN**, **Lockwood GM**, **Dokras A**, **Egan DM**, **Nicholson SC**, **Ross C**, **Barlow DH**, Does isolated teratozoospermia affect performance in in-vitro fertilization and embryo transfer? Hum Reprod 9:870, 1994.
106. **Keegan BR**, **Barton S**, **Sanchez X**, **Berkeley AS**, **Krey LC**, **Grifo J**, Isolated teratozoospermia does not affect in vitro fertilization outcome and is not an indication for intracytoplasmic sperm injection, Fertil Steril 88:1583, 2007.
107. **Dodson WC**, **Whitesides DB**, **Hughes CLJ**, **Easley HA III**, **Haney AF**, Superovulation with intrauterine insemination in the treatment of infertility: a possible alternative to gamete intrafallopian transfer and in vitro fertilization, Fertil Steril 48:441, 1987.
108. **Crosignani PG**, **Collins J**, **Cooke ID**, **Diczfalusy E**, **Rubin B**, Unexplained infertility, Hum Reprod 8:977,

1993.
109. **Crosignani PG**, **Collins J**, **Cooke ID**, **Diczfalusy E**, **Rubin B**, Recommendations of the ESHRE workshop on "Unexplained Infertility". Anacapri, August 28-9, 1992, Hum Reprod 8:977, 1993.
110. **Guzick DS**, **Sullivan MW**, **Adamson GD**, **Cedars MI**, **Falk RJ**, **Peterson EP**, **Steinkampf MP**, Efficacy of treatment for unexplained infertility, Fertil Steril 70:207, 1998.
111. **Reindollar RH**, **Regan MM**, **Neumann PJ**, **Levine BS**, **Thornton KL**, **Alper MM**, **Goldman MB**, A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial, Fertil Steril 94:888, 2010.
112. **Custers IM**, **Steures P**, **Hompes P**, **Flierman P**, **van Kasteren Y**, **van Dop PA**, **van der Veen F**, **Mol BW**, Intrauterine insemination: how many cycles should we perform? Hum Reprod 23:885, 2008.
113. **Dovey S**, **Sneeringer RM**, **Penzias AS**, Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles, Fertil Steril 90:2281, 2008.
114. **Guzick DS**, **Carson SA**, **Coutifaris C**, **Overstreet JW**, **Factor-Litvak P**, **Steinkampf MP**, **Hill JA**, **Mastroianni L**, **Buster JE**, **Nakajima ST**, **Vogel DL**, **Canfield RE**, Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network, N Engl J Med 340:177, 1999.
115. **Steures P**, **van der Steeg JW**, **Hompes PG**, **Habbema JD**, **Eijkemans MJ**, **Broekmans FJ**, **Verhoeve HR**, **Bossuyt PM**, **van der Veen F**, **Mol BW**, **Collaborative Effort on the Clinical Evaluation in Reproductive Medicine**, Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis: a randomised clinical trial, Lancet 368:216, 2006.
116. **Hughes EG**, **Beecroft ML**, **Wilkie V**, **Burville L**, **Claman P**, **Tummon I**, **Greenblatt E**, **Fluker M**, **Thorpe K**, A multicentre randomized controlled trial of expectant management versus IVF in women with Fallopian tube patency, Hum Reprod 19:1105, 2004.
117. **Gurgan T**, **Urman B**, **Yarali H**, **Kisnisci HA**, The results of in vitro fertilization-embryo transfer in couples with unexplained infertility failing to conceive with superovulation and intrauterine insemination, Fertil Steril 64:93, 1995.
118. **Ruiz A**, **Remohi J**, **Minguez Y**, **Guanes PP**, **Simon C**, **Pellicer A**, The role of in vitro fertilization and intracytoplasmic sperm injection in couples with unexplained infertility after failed intrauterine insemination, Fertil Steril 68:171, 1997.
119. **Takeuchi S**, **Minoura H**, **Shibahara T**, **Shen X**, **Futamura N**, **Toyoda N**, In vitro fertilization and intracytoplasmic sperm injection for couples with unexplained infertility after failed direct intraperitoneal insemination, J Assist Reprod Genet 17:515, 2000.
120. **Martin JS**, **Nisker JA**, **Parker JI**, **Kaplan B**, **Tummon IS**, **Yuzpe AA**, The pregnancy rates of cohorts of idiopathic infertility couples gives insights into the underlying mechanism of infertility, Fertil Steril 64:98, 1995.
121. **Boulet SL**, **Mehta A**, **Kissin DM**, **Warner L**, **Kawwass JF**, **Jamieson DJ**, Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection, JAMA 313:255, 2015.
122. **Kushnir VA**, **Barad DH**, **Gleicher N**, Intracytoplasmic sperm injection and reproductive outcomes, JAMA 313:1672, 2015.
123. **Li Z**, **Wang AY**, **Bowman M**, **Hammarberg K**, **Farquhar C**, **Johnson L**, **Safi N**, **Sullivan EA**, ICSI does not increase the cumulative live birth rate in non-male factor infertility, Hum Reprod 33:1322, 2018.
124. **Navot D**, **Laufer N**, **Kopolovic J**, **Rabinowitz R**, **Birkenfeld A**, **Lewin A**, **Granat M**, **Margalioth EJ**, **Schenker JG**, Artificially induced endometrial cycles and establishment of pregnancies in the absence of ovaries, N Engl J Med 314:806, 1986.
125. **Oktay K**, **Rodriguez-Wallberg K**, **Schover L**, Preservation of fertility in patients with cancer, N Engl J Med 360:2681; author reply 2682, 2009.
126. **Grifo JA**, **Noyes N**, Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients, Fertil Steril 93:391, 2010.
127. **Practice Committees of American Society for Reproductive Medicine; Society for Assisted**

Reproductive Technology, Mature oocyte cryopreservation: a guideline, Fertil Steril 99:37, 2013.
128. **Cobo A**, **Kuwayama M**, **Perez S**, **Ruiz A**, **Pellicer A**, **Remohi J**, Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method, Fertil Steril 89:1657, 2008.
129. **Brinsden PR**, Gestational surrogacy, Hum Reprod Update 9:483, 2003.
130. **Utian WH**, **Sheean L**, **Goldfarb JM**, **Kiwi R**, Successful pregnancy after in vitro fertilization and embryo transfer from an infertile woman to a surrogate, N Engl J Med 313:1351, 1985.
131. **Practice Committee of Society for Assisted Reproductive Technology; Practice Committee of American Society for Reproductive Medicine**, Preimplantation genetic testing: a Practice Committee opinion, Fertil Steril 90:S136, 2008.
132. **Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology**, The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion, Fertil Steril 109:429, 2018.
133. **Malizia BA**, **Hacker MR**, **Penzias AS**, Cumulative live-birth rates after in vitro fertilization, N Engl J Med 360:236, 2009.
134. **Ata B**, **Kaplan B**, **Danzer H**, **Glassner M**, **Opsahl M**, **Tan SL**, **Munne S**, Array CGH analysis shows that aneuploidy is not related to the number of embryos generated, Reprod Biomed Online 24:614, 2012.
135. **Sauer MV**, **Paulson RJ**, **Lobo RA**, Reversing the natural decline in human fertility. An extended clinical trial of oocyte donation to women of advanced reproductive age, JAMA 268:1275, 1992.
136. **Hull MG**, **Fleming CF**, **Hughes AO**, **McDermott A**, The age-related decline in female fecundity: a quantitative controlled study of implanting capacity and survival of individual embryos after in vitro fertilization, Fertil Steril 65:783, 1996.
137. **Ziebe S**, **Loft A**, **Petersen JH**, **Andersen AG**, **Lindenberg S**, **Petersen K**, **Andersen AN**, Embryo quality and developmental potential is compromised by age, Acta Obstet Gynecol Scand 80:169, 2001.
138. **van Rooij IA**, **Bancsi LF**, **Broekmans FJ**, **Looman CW**, **Habbema JD**, **te Velde ER**, Women older than 40 years of age and those with elevated follicle-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization, Fertil Steril 79:482, 2003.
139. **Hull MG**, Effectiveness of infertility treatments: choice and comparative analysis, Int J Gynaecol Obstet 47:99, 1994.
140. **Munne S**, **Held KR**, **Magli CM**, **Ata B**, **Wells D**, **Fragouli E**, **Baukloh V**, **Fischer R**, **Gianaroli L**, Intra-age, intercenter, and intercycle differences in chromosome abnormalities in oocytes, Fertil Steril 97:935, 2012.
141. **Pellestor F**, **Andreo B**, **Arnal F**, **Humeau C**, **Demaille J**, Maternal aging and chromosomal abnormalities: new data drawn from in vitro unfertilized human oocytes, Hum Genet 112:195, 2003.
142. **Nasmyth K**, Disseminating the genome: joining, resolving, and separating sister chromatids during mitosis and meiosis, Annu Rev Genet 35:673, 2001.
143. **Battaglia DE**, **Goodwin P**, **Klein NA**, **Soules MR**, Influence of maternal age on meiotic spindle assembly in oocytes from naturally cycling women, Hum Reprod 11:2217, 1996.
144. **Spandorfer SD**, **Bendikson K**, **Dragisic K**, **Schattman G**, **Davis OK**, **Rosenwaks Z**, Outcome of in vitro fertilization in women 45 years and older who use autologous oocytes, Fertil Steril 87:74, 2007.
145. **Sunkara SK**, **Rittenberg V**, **Raine-Fenning N**, **Bhattacharya S**, **Zamora J**, **Coomarasamy A**, Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles, Hum Reprod 26:1768, 2011.
146. **Richardson SJ**, **Senikas V**, **Nelson JF**, Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion, J Clin Endocrinol Metab 65:1231, 1987.
147. **Faddy MJ**, **Gosden RG**, A model conforming the decline in follicle numbers to the age of menopause in women, Hum Reprod 11:1484, 1996.
148. **Gougeon A**, **Ecochard R**, **Thalabard JC**, Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women, Biol Reprod 50:653, 1994.
149. **Nilsson E**, **Rogers N**, **Skinner MK**, Actions of anti-Mullerian hormone on the ovarian transcriptome to

inhibit primordial to primary follicle transition, Reproduction 134:209, 2007.
150. **Adhikari D**, **Liu K**, Molecular mechanisms underlying the activation of mammalian primordial follicles, Endocr Rev 30:438, 2009.
151. **Da Silva-Buttkus P**, **Marcelli G**, **Franks S**, **Stark J**, **Hardy K**, Inferring biological mechanisms from spatial analysis: prediction of a local inhibitor in the ovary, Proc Natl Acad Sci U S A 106:456, 2009.
152. **Coxworth JE**, **Hawkes K**, Ovarian follicle loss in humans and mice: lessons from statistical model comparison, Hum Reprod 25:1796, 2010.
153. **Klein NA**, **Battaglia DE**, **Fujimoto VY**, **Davis GS**, **Bremner WJ**, **Soules MR**, Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women, J Clin Endocrinol Metab 81:1038, 1996.
154. **Klein NA**, **Battaglia DE**, **Miller PB**, **Branigan EF**, **Giudice LC**, **Soules MR**, Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age, J Clin Endocrinol Metab 81:1946, 1996.
155. **Hofmann GE**, **Danforth DR**, **Seifer DB**, Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening, Fertil Steril 69:474, 1998.
156. **Welt CK**, **McNicholl DJ**, **Taylor AE**, **Hall JE**, Female reproductive aging is marked by decreased secretion of dimeric inhibin, J Clin Endocrinol Metab 84:105, 1999.
157. **Seifer DB**, **Scott RT Jr**, **Bergh PA**, **Abrogast LK**, **Friedman CI**, **Mack CK**, **Danforth DR**, Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone, Fertil Steril 72:63, 1999.
158. **Klein NA**, **Houmard BS**, **Hansen KR**, **Woodruff TK**, **Sluss PM**, **Bremner WJ**, **Soules MR**, Age-related analysis of inhibin A, inhibin B, and activin a relative to the intercycle monotropic follicle-stimulating hormone rise in normal ovulatory women, J Clin Endocrinol Metab 89:2977, 2004.
159. **Hale GE**, **Zhao X**, **Hughes CL**, **Burger HG**, **Robertson DM**, **Fraser IS**, Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system, J Clin Endocrinol Metab 92:3060, 2007.
160. **Knauff EA**, **Eijkemans MJ**, **Lambalk CB**, **ten Kate-Booij MJ**, **Hoek A**, **Beerendonk CC**, **Laven JS**, **Goverde AJ**, **Broekmans FJ**, **Themmen AP**, **de Jong FH**, **Fauser BC; Dutch Premature Ovarian Failure Consortium**, Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure, J Clin Endocrinol Metab 94:786, 2009.
161. **Burger HG**, **Hale GE**, **Dennerstein L**, **Robertson DM**, Cycle and hormone changes during perimenopause: the key role of ovarian function, Menopause 15:603, 2008.
162. **Klein NA**, **Harper AJ**, **Houmard BS**, **Sluss PM**, **Soules MR**, Is the short follicular phase in older women secondary to advanced or accelerated dominant follicle development? J Clin Endocrinol Metab 87:5746, 2002.
163. **van Zonneveld P**, **Scheffer GJ**, **Broekmans FJ**, **Blankenstein MA**, **de Jong FH**, **Looman CW**, **Habbema JD**, **te Velde ER**, Do cycle disturbances explain the age-related decline of female fertility? Cycle characteristics of women aged over 40 years compared with a reference population of young women, Hum Reprod 18:495, 2003.
164. **de Koning CH**, **McDonnell J**, **Themmen AP**, **de Jong FH**, **Homburg R**, **Lambalk CB**, The endocrine and follicular growth dynamics throughout the menstrual cycle in women with consistently or variably elevated early follicular phase FSH compared with controls, Hum Reprod 23:1416, 2008.
165. **Muasher SJ**, **Oehninger S**, **Simonetti S**, **Matta J**, **Ellis LM**, **Liu HC**, **Jones GS**, **Rosenwaks Z**, The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome, Fertil Steril 50:298, 1988.
166. **Scott RT**, **Toner JP**, **Muasher SJ**, **Oehninger S**, **Robinson S**, **Rosenwaks Z**, Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome, Fertil Steril 51:651, 1989.
167. **Toner JP**, **Philput CB**, **Jones GS**, **Muasher SJ**, Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age, Fertil Steril 55:784, 1991.
168. **Pearlstone AC**, **Fournet N**, **Gambone JC**, **Pang SC**, **Buyalos RP**, Ovulation induction in women age 40 and older: the importance of basal follicle-stimulating hormone level and chronological age, Fertil Steril 58:674,

1992.
169. **Scott RT Jr**, **Hofmann GE**, Prognostic assessment of ovarian reserve, Fertil Steril 63:1, 1995.
170. **Broekmans FJ**, **Kwee J**, **Hendriks DJ**, **Mol BW**, **Lambalk CB**, A systematic review of tests predicting ovarian reserve and IVF outcome, Hum Reprod Update 12:685, 2006.
171. **Barroso G**, **Oehninger S**, **Monzo A**, **Kolm P**, **Gibbons WE**, **Muasher SJ**, High FSH:LH ratio and low LH levels in basal cycle day 3: impact on follicular development and IVF outcome, J Assist Reprod Genet 18:499, 2001.
172. **Hazout A**, **Bouchard P**, **Seifer DB**, **Aussage P**, **Junca AM**, **Cohen-Bacrie P**, Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol, Fertil Steril 82:1323, 2004.
173. **Eldar-Geva T**, **Ben-Chetrit A**, **Spitz IM**, **Rabinowitz R**, **Markowitz E**, **Mimoni T**, **Gal M**, **Zylber-Haran E**, **Margalioth EJ**, Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome, Hum Reprod 20:3178, 2005.
174. **McIlveen M**, **Skull JD**, **Ledger WL**, Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population, Hum Reprod 22:778, 2007.
175. **Phophong P**, **Ranieri DM**, **Khadum I**, **Meo F**, **Serhal P**, Basal 17beta-estradiol did not correlate with ovarian response and in vitro fertilization treatment outcome, Fertil Steril 74:1133, 2000.
176. **Evers JL**, **Slaats P**, **Land JA**, **Dumoulin JC**, **Dunselman GA**, Elevated levels of basal estradiol-17beta predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization, Fertil Steril 69:1010, 1998.
177. **Smotrich DB**, **Widra EA**, **Gindoff PR**, **Levy MJ**, **Hall JL**, **Stillman RJ**, Prognostic value of day 3 estradiol on in vitro fertilization outcome, Fertil Steril 64:1136, 1995.
178. **Licciardi FL**, **Liu HC**, **Rosenwaks Z**, Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization, Fertil Steril 64:991, 1995.
179. **Buyalos RP**, **Daneshmand S**, **Brzechffa PR**, Basal estradiol and follicle-stimulating hormone predict fecundity in women of advanced reproductive age undergoing ovulation induction therapy, Fertil Steril 68:272, 1997.
180. **Sowers MR**, **Eyvazzadeh AD**, **McConnell D**, **Yosef M**, **Jannausch ML**, **Zhang D**, **Harlow S**, **Randolph JF Jr**, Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition, J Clin Endocrinol Metab 93:3478, 2008.
181. **van Rooij IA**, **Tonkelaar I**, **Broekmans FJ**, **Looman CW**, **Scheffer GJ**, **de Jong FH**, **Themmen AP**, **te Velde ER**, Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition, Menopause 11:601, 2004.
182. **van Rooij IA**, **Broekmans FJ**, **Scheffer GJ**, **Looman CW**, **Habbema JD**, **de Jong FH**, **Fauser BJ**, **Themmen AP**, **te Velde ER**, Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study, Fertil Steril 83:979, 2005.
183. **de Vet A**, **Laven JS**, **de Jong FH**, **Themmen AP**, **Fauser BC**, Antimullerian hormone serum levels: a putative marker for ovarian aging, Fertil Steril 77:357, 2002.
184. **Muttukrishna S**, **McGarrigle H**, **Wakim R**, **Khadum I**, **Ranieri DM**, **Serhal P**, Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG 112:1384, 2005.
185. **Muttukrishna S**, **Suharjono H**, **McGarrigle H**, **Sathanandan M**, Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? BJOG 111:1248, 2004.
186. **van Rooij IA**, **Broekmans FJ**, **te Velde ER**, **Fauser BC**, **Bancsi LF**, **de Jong FH**, **Themmen AP**, Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve, Hum Reprod 17:3065, 2002.
187. **Silberstein T**, **MacLaughlin DT**, **Shai I**, **Trimarchi JR**, **Lambert-Messerlian G**, **Seifer DB**, **Keefe DL**, **Blazar AS**, Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology, Hum Reprod 21:159, 2006.

188. **Ebner T**, **Sommergruber M**, **Moser M**, **Shebl O**, **Schreier-Lechner E**, **Tews G**, Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles, Hum Reprod 21:2022, 2006.
189. **Kedem A**, **Haas J**, **Geva LL**, **Yerushalmi G**, **Gilboa Y**, **Kanety H**, **Hanochi M**, **Maman E**, **Hourvitz A**, Ongoing pregnancy rates in women with low and extremely low AMH levels. A multivariate analysis of 769 cycles, PLoS One 8:e81629, 2013.
190. **Lin WQ**, **Yao LN**, **Zhang DX**, **Zhang W**, **Yang XJ**, **Yu R**, The predictive value of anti-Mullerian hormone on embryo quality, blastocyst development, and pregnancy rate following in vitro fertilization-embryo transfer (IVF-ET), J Assist Reprod Genet 30:649, 2013.
191. **Mutlu MF**, **Erdem M**, **Erdem A**, **Yildiz S**, **Mutlu I**, **Arisoy O**, **Oktem M**, Antral follicle count determines poor ovarian response better than anti-Mullerian hormone but age is the only predictor for live birth in in vitro fertilization cycles, J Assist Reprod Genet 30:657, 2013.
192. **Reichman DE**, **Goldschlag D**, **Rosenwaks Z**, Value of antimullerian hormone as a prognostic indicator of in vitro fertilization outcome, Fertil Steril 101:1012.e1, 2014.
193. **Broer SL**, **van Disseldorp J**, **Broeze KA**, **Dolleman M**, **Opmeer BC**, **Bossuyt P**, **Eijkemans MJ**, **Mol BW**, **Broekmans FJ; IMPORT study group**, Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach, Hum Reprod Update 19:26, 2013.
194. **Iliodromiti S**, **Kelsey TW**, **Wu O**, **Anderson RA**, **Nelson SM**, The predictive accuracy of anti-Mullerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature, Hum Reprod Update 20:560, 2014.
195. **Tal R**, **Tal O**, **Seifer BJ**, **Seifer DB**, Antimullerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis, Fertil Steril 103:119.e3, 2015.
196. **Broer SL**, **Dolleman M**, **van Disseldorp J**, **Broeze KA**, **Opmeer BC**, **Bossuyt PM**, **Eijkemans MJ**, **Mol BW**, **Broekmans FJ**, **Group I-ES**, Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis, Fertil Steril 100:420.e7, 2013.
197. **Seifer DB**, **MacLaughlin DT**, **Christian BP**, **Feng B**, **Shelden RM**, Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles, Fertil Steril 77:468, 2002.
198. **Morin SJ**, **Patounakis G**, **Juneau CR**, **Neal SA**, **Scott RT Jr**, **Seli E**, Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance, Hum Reprod, 2018 Jul 11. doi: 10.1093/humrep/dey238.
199. **Ficicioglu C**, **Kutlu T**, **Baglam E**, **Bakacak Z**, Early follicular antimullerian hormone as an indicator of ovarian reserve, Fertil Steril 85:592, 2006.
200. **Gnoth C**, **Schuring AN**, **Friol K**, **Tigges J**, **Mallmann P**, **Godehardt E**, Relevance of anti-Mullerian hormone measurement in a routine IVF program, Hum Reprod 23:1359, 2008.
201. **Penarrubia J**, **Fabregues F**, **Manau D**, **Creus M**, **Casals G**, **Casamitjana R**, **Carmona F**, **Vanrell JA**, **Balasch J**, Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist—gonadotropin treatment, Hum Reprod 20:915, 2005.
202. **Elgindy EA**, **El-Haieg DO**, **El-Sebaey A**, Anti-Mullerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients, Fertil Steril 89:1670, 2008.
203. **Pache TD**, **Wladimiroff JW**, **de Jong FH**, **Hop WC**, **Fauser BC**, Growth patterns of nondominant ovarian follicles during the normal menstrual cycle, Fertil Steril 54:638, 1990.
204. **Meldrum DR**, **Chetkowski RJ**, **Steingold KA**, **Randle D**, Transvaginal ultrasound scanning of ovarian follicles, Fertil Steril 42:803, 1984.
205. **Bancsi LF**, **Broekmans FJ**, **Looman CW**, **Habbema JD**, **te Velde ER**, Impact of repeated antral follicle counts on the prediction of poor ovarian response in women undergoing in vitro fertilization, Fertil Steril 81:35, 2004.

206. **Hansen KR**, **Morris JL**, **Thyer AC**, **Soules MR**, Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting, Fertil Steril 80:577, 2003.
207. **Scheffer GJ**, **Broekmans FJ**, **Bancsi LF**, **Habbema JD**, **Looman CW**, **Te Velde ER**, Quantitative transvaginal two- and three-dimensional sonography of the ovaries: reproducibility of antral follicle counts, Ultrasound Obstet Gynecol 20:270, 2002.
208. **Bancsi LF**, **Broekmans FJ**, **Eijkemans MJ**, **de Jong FH**, **Habbema JD**, **te Velde ER**, Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve, Fertil Steril 77:328, 2002.
209. **Frattarelli JL**, **Lauria-Costab DF**, **Miller BT**, **Bergh PA**, **Scott RT**, Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles, Fertil Steril 74:512, 2000.
210. **Frattarelli JL**, **Levi AJ**, **Miller BT**, **Segars JH**, A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles, Fertil Steril 80:350, 2003.
211. **Hendriks DJ**, **Mol BW**, **Bancsi LF**, **Te Velde ER**, **Broekmans FJ**, Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level, Fertil Steril 83:291, 2005.
212. **Chang MY**, **Chiang CH**, **Hsieh TT**, **Soong YK**, **Hsu KH**, Use of the antral follicle count to predict the outcome of assisted reproductive technologies, Fertil Steril 69:505, 1998.
213. **Ng EH**, **Tang OS**, **Ho PC**, The significance of the number of antral follicles prior to stimulation in predicting ovarian responses in an IVF programme, Hum Reprod 15:1937, 2000.
214. **Kupesic S**, **Kurjak A**, **Bjelos D**, **Vujisic S**, Three-dimensional ultrasonographic ovarian measurements and in vitro fertilization outcome are related to age, Fertil Steril 79:190, 2003.
215. **La Marca A**, **Sighinolfi G**, **Radi D**, **Argento C**, **Baraldi E**, **Artenisio AC**, **Stabile G**, **Volpe A**, Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART), Hum Reprod Update 16:113, 2010.
216. **Lukaszuk K**, **Kunicki M**, **Liss J**, **Lukaszuk M**, **Jakiel G**, Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization, Eur J Obstet Gynecol Reprod Biol 168:173, 2013.
217. **Polyzos NP**, **Nelson SM**, **Stoop D**, **Nwoye M**, **Humaidan P**, **Anckaert E**, **Devroey P**, **Tournaye H**, Does the time interval between antimullerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study, Fertil Steril 100:438, 2013.
218. **Scott RT Jr**, **Elkind-Hirsch KE**, **Styne-Gross A**, **Miller KA**, **Frattarelli JL**, The predictive value for in vitro fertility delivery rates is greatly impacted by the method used to select the threshold between normal and elevated basal follicle-stimulating hormone, Fertil Steril 89:868, 2008.
219. **van Rooij IA**, **de Jong E**, **Broekmans FJ**, **Looman CW**, **Habbema JD**, **te Velde ER**, High follicle-stimulating hormone levels should not necessarily lead to the exclusion of subfertile patients from treatment, Fertil Steril 81:1478, 2004.
220. **Lashen H**, **Ledger W**, **Lopez-Bernal A**, **Barlow D**, Poor responders to ovulation induction: is proceeding to in-vitro fertilization worthwhile? Hum Reprod 14:964, 1999.
221. **Zhen XM**, **Qiao J**, **Li R**, **Wang LN**, **Liu P**, The clinical analysis of poor ovarian response in in-vitro-fertilization embryo-transfer among Chinese couples, J Assist Reprod Genet 25:17, 2008.
222. **Broekmans FJ**, **Soules MR**, **Fauser BC**, Ovarian aging: mechanisms and clinical consequences, Endocr Rev 30:465, 2009.
223. **Strandell A**, **Lindhard A**, **Eckerlund I**, Cost–effectiveness analysis of salpingectomy prior to IVF, based on a randomized controlled trial, Hum Reprod 20:3284, 2005.
224. **Kotlyar A**, **Gingold J**, **Shue S**, **Falcone T**, The effect of salpingectomy on ovarian function, J Minim Invasive Gynecol 24:563, 2017.
225. **Mohamed AA**, **Yosef AH**, **James C**, **Al-Hussaini TK**, **Bedaiwy MA**, **Amer S**, Ovarian reserve after salpingectomy: a systematic review and meta-analysis, Acta Obstet Gynecol Scand 96:795, 2017.
226. **Zhang Y**, **Sun Y**, **Guo Y**, **Li TC**, **Duan H**, Salpingectomy and proximal tubal occlusion for hydrosalpinx prior

to in vitro fertilization: a meta-analysis of randomized controlled trials, Obstet Gynecol Surv 70:33, 2015.
227. **Van Voorhis BJ**, **Sparks AE**, **Syrop CH**, **Stovall DW**, Ultrasound-guided aspiration of hydrosalpinges is associated with improved pregnancy and implantation rates after in-vitro fertilization cycles, Hum Reprod 13:736, 1998.
228. **Tsiami A**, **Chaimani A**, **Mavridis D**, **Siskou M**, **Assimakopoulos E**, **Sotiriadis A**, Surgical treatment for hydrosalpinx prior to in-vitro fertilization embryo transfer: a network meta-analysis, Ultrasound Obstet Gynecol 48:434, 2016.
229. **Bloechle M**, **Schreiner T**, **Lisse K**, Recurrence of hydrosalpinges after transvaginal aspiration of tubal fluid in an IVF cycle with development of a serometra, Hum Reprod 12:703, 1997.
230. **Xu B**, **Zhang Q**, **Zhao J**, **Wang Y**, **Xu D**, **Li Y**, Pregnancy outcome of in vitro fertilization after Essure and laparoscopic management of hydrosalpinx: a systematic review and meta-analysis, Fertil Steril 108:84.e5, 2017.
231. **Barbosa MW**, **Sotiriadis A**, **Papatheodorou SI**, **Mijatovic V**, **Nastri CO**, **Martins WP**, High miscarriage rate in women treated with Essure(R) for hydrosalpinx before embryo transfer: a systematic review and meta-analysis, Ultrasound Obstet Gynecol 48:556, 2016.
232. **Rackow BW**, **Taylor HS**, Submucosal uterine leiomyomas have a global effect on molecular determinants of endometrial receptivity, Fertil Steril 93(6):2027, 2010.
233. **Sinclair DC**, **Mastroyannis A**, **Taylor HS**, Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3, J Clin Endocrinol Metab 96(2):412, 2011.
234. **Doherty LF**, **Taylor HS**, Leiomyoma-derived transforming growth factor-β impairs bone morphogenetic protein-2-mediated endometrial receptivity, Fertil Steril 103(3):845, 2015.
235. **Olive DL**, **Pritts EA**, Fibroids and reproduction, Semin Reprod Med 28:218, 2010.
236. **Ezzati M**, **Norian JM**, **Segars JH**, Management of uterine fibroids in the patient pursuing assisted reproductive technologies, Womens Health (Lond) 5:413, 2009.
237. **Benecke C**, **Kruger TF**, **Siebert TI**, **Van der Merwe JP**, **Steyn DW**, Effect of fibroids on fertility in patients undergoing assisted reproduction. A structured literature review, Gynecol Obstet Invest 59:225, 2005.
238. **Somigliana E**, **Vercellini P**, **Daguati R**, **Pasin R**, **De Giorgi O**, **Crosignani PG**, Fibroids and female reproduction: a critical analysis of the evidence, Hum Reprod Update 13:465, 2007.
239. **Klatsky PC**, **Tran ND**, **Caughey AB**, **Fujimoto VY**, Fibroids and reproductive outcomes: a systematic literature review from conception to delivery, Am J Obstet Gynecol 198:357, 2008.
240. **Pritts EA**, **Parker WH**, **Olive DL**, Fibroids and infertility: an updated systematic review of the evidence, Fertil Steril 91:1215, 2009.
241. **Hartmann KE**, **Velez Edwards DR**, **Savitz DA**, **Jonsson-Funk ML**, **Wu P**, **Sundermann AC**, **Baird DD**, Prospective cohort study of uterine fibroids and miscarriage risk, Am J Epidemiol 186:1140, 2017.
242. **Eldar-Geva T**, **Meagher S**, **Healy DL**, **MacLachlan V**, **Breheny S**, **Wood C**, Effect of intramural, subserosal, and submucosal uterine fibroids on the outcome, Fertil Steril 70:687, 1998.
243. **Stovall DW**, **Parrish SB**, **Van Voorhis BJ**, **Hahn SJ**, **Sparks AE**, **Syrop CH**, Uterine leiomyomas reduce the efficacy of assisted reproduction cycles: results, Hum Reprod 13:192, 1998.
244. **Healy DL**, Impact of uterine fibroids on ART outcome, Environ Health Perspect 108(Suppl 5):845, 2000.
245. **Hart R**, **Khalaf Y**, **Yeong CT**, **Seed P**, **Taylor A**, **Braude P**, A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception, Hum Reprod 16:2411, 2001.
246. **Khalaf Y**, **Ross C**, **El-Toukhy T**, **Hart R**, **Seed P**, **Braude P**, The effect of small intramural uterine fibroids on the cumulative outcome of assisted conception, Hum Reprod 21:2640, 2006.
247. **Farhi J**, **Ashkenazi J**, **Feldberg D**, **Dicker D**, **Orvieto R**, **Ben Rafael Z**, Effect of uterine leiomyomata on the results of in-vitro fertilization treatment, Hum Reprod 10:2576, 1995.
248. **Dietterich C**, **Check JH**, **Choe JK**, **Nazari A**, **Fox F**, The presence of small uterine fibroids not distorting the endometrial cavity does not adversely affect conception outcome following embryo transfer in older recipients, Clin Exp Obstet Gynecol 27:168, 2000.
249. **Jun SH**, **Ginsburg ES**, **Racowsky C**, **Wise LA**, **Hornstein MD**, Uterine leiomyomas and their effect on in vitro fertilization outcome: a retrospective study, J Assist Reprod Genet 18:139, 2001.

250. **Surrey ES**, **Lietz AK**, **Schoolcraft WB**, Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization-embryo transfer cycle outcome, Fertil Steril 75:405, 2001.
251. **Check JH**, **Choe JK**, **Lee G**, **Dietterich C**, The effect on IVF outcome of small intramural fibroids not compressing the uterine cavity as determined by a prospective matched control study, Hum Reprod 17:1244, 2002.
252. **Oliveira FG**, **Abdelmassih VG**, **Diamond MP**, **Dozortsev D**, **Melo NR**, **Abdelmassih R**, Impact of subserosal and intramural uterine fibroids that do not distort the endometrial cavity on the outcome of in vitro fertilization-intracytoplasmic sperm injection, Fertil Steril 81:582, 2004.
253. **Sunkara SK**, **Khairy M**, **El-Toukhy T**, **Khalaf Y**, **Coomarasamy A**, The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis, Hum Reprod 25:418, 2010.
254. **Taylor HS**, Fibroids: when should they be removed to improve in vitro fertilization success? Fertil Steril 109(5):784, 2018.
255. **Hornstein MD**, Lifestyle and IVF outcomes, Reprod Sci 23:1626, 2016.
256. **Firns S**, **Cruzat VF**, **Keane KN**, **Joesbury KA**, **Lee AH**, **Newsholme P**, **Yovich JL**, The effect of cigarette smoking, alcohol consumption and fruit and vegetable consumption on IVF outcomes: a review and presentation of original data, Reprod Biol Endocrinol 13:134, 2015.
257. **Waylen AL**, **Metwally M**, **Jones GL**, **Wilkinson AJ**, **Ledger WL**, Effects of cigarette smoking upon clinical outcomes of assisted reproduction: a meta-analysis, Hum Reprod Update 15:31, 2009.
258. **Schachter-Safrai N**, **Karavani G**, **Levitas E**, **Friger M**, **Zeadna A**, **Lunenfeld E**, **Har-Vardi I**, Does cryopreservation of sperm affect fertilization in nonobstructive azoospermia or cryptozoospermia? Fertil Steril 107:1148, 2017.
259. **Morshedi M**, **Oehninger S**, **Veeck LL**, **Ertunc H**, **Bocca S**, **Acosta AA**, Cryopreserved/thawed semen for in vitro fertilization: results from fertile donors and infertile patients, Fertil Steril 54:1093, 1990.
260. **Yavetz H**, **Lessing JB**, **Niv Y**, **Amit A**, **Barak Y**, **Yovel I**, **David MP**, **Peyser MR**, **Yogev L**, **Homonnai Z**, et al., The efficiency of cryopreserved semen versus fresh semen for in vitro fertilization/embryo transfer, J In Vitro Fert Embryo Transf 8:145, 1991.
261. **Karayalcin R**, **Ozcan S**, **Moraloglu O**, **Ozyer S**, **Mollamahmutoglu L**, **Batioglu S**, Results of 2500 office-based diagnostic hysteroscopies before IVF, Reprod Biomed Online 20:689, 2010.
262. **El-Mazny A**, **Abou-Salem N**, **El-Sherbiny W**, **Saber W**, Outpatient hysteroscopy: a routine investigation before assisted reproductive techniques? Fertil Steril 95:272, 2011.
263. **Fatemi HM**, **Kasius JC**, **Timmermans A**, **van Disseldorp J**, **Fauser BC**, **Devroey P**, **Broekmans FJ**, Prevalence of unsuspected uterine cavity abnormalities diagnosed by office hysteroscopy prior to in vitro fertilization, Hum Reprod 25:1959, 2010.
264. **Smit JG**, **Kasius JC**, **Eijkemans MJC**, **Koks CAM**, **van Golde R**, **Nap AW**, **Scheffer GJ**, **Manger PAP**, **Hoek A**, **Schoot BC**, **van Heusden AM**, **Kuchenbecker WKH**, **Perquin DAM**, **Fleischer K**, **Kaaijk EM**, **Sluijmer A**, **Friederich J**, **Dykgraaf RHM**, **van Hooff M**, **Louwe LA**, **Kwee J**, **de Koning CH**, **Janssen I**, **Mol F**, **Mol BWJ**, **Broekmans FJM**, **Torrance HL**, Hysteroscopy before in-vitro fertilisation (inSIGHT): a multicentre, randomised controlled trial, Lancet 387:2622, 2016.
265. **El-Toukhy T**, **Campo R**, **Khalaf Y**, **Tabanelli C**, **Gianaroli L**, **Gordts SS**, **Gordts S**, **Mestdagh G**, **Mardesic T**, **Voboril J**, **Marchino GL**, **Benedetto C**, **Al-Shawaf T**, **Sabatini L**, **Seed PT**, **Gergolet M**, **Grimbizis G**, **Harb H**, **Coomarasamy A**, Hysteroscopy in recurrent in-vitro fertilisation failure (TROPHY): a multicentre, randomised controlled trial, Lancet 387:2614, 2016.
266. **Becker E Jr**, **Lev-Toaff AS**, **Kaufman EP**, **Halpern EJ**, **Edelweiss MI**, **Kurtz AB**, The added value of transvaginal sonohysterography over transvaginal sonography alone in women with known or suspected leiomyoma, J Ultrasound Med 21:237, 2002.
267. **Leone FP**, **Lanzani C**, **Ferrazzi E**, Use of strict sonohysterographic methods for preoperative assessment of submucous myomas, Fertil Steril 79:998, 2003.
268. **Sylvestre C**, **Child TJ**, **Tulandi T**, **Tan SL**, A prospective study to evaluate the efficacy of two- and three-dimensional sonohysterography in women with intrauterine lesions, Fertil Steril 79:1222, 2003.

269. **Henne MB**, **Milki AA**, Uterine position at real embryo transfer compared with mock embryo transfer, Hum Reprod 19:570, 2004.
270. **Miller KL**, **Frattarelli JL**, The pre-cycle blind mock embryo transfer is an inaccurate predictor of anticipated embryo transfer depth, J Assist Reprod Genet 24:77, 2007.
271. **Sallam HN**, Embryo transfer: factors involved in optimizing the success, Curr Opin Obstet Gynecol 17:289, 2005.
272. **Mansour RT**, **Aboulghar MA**, Optimizing the embryo transfer technique, Hum Reprod 17:1149, 2002.
273. **Aboulghar MA**, **Mansour RT**, **Serour GA**, **Amin YM**, **Sattar MA**, **Ramzy AM**, In vitro fertilization in a spontaneous cycle: a successful simple protocol, J Obstet Gynaecol (Tokyo 1995) 21:337, 1995.
274. **Nargund G**, **Waterstone J**, **Bland J**, **Philips Z**, **Parsons J**, **Campbell S**, Cumulative conception and live birth rates in natural (unstimulated) IVF cycles, Hum Reprod 16:259, 2001.
275. **Pelinck MJ**, **Hoek A**, **Simons AH**, **Heineman MJ**, Efficacy of natural cycle IVF: a review of the literature, Hum Reprod Update 8:129, 2002.
276. **Castelo-Branco A**, **Frydman N**, **Kadoch J**, **Le Du A**, **Fernandez H**, **Fanchin R**, **Frydman R**, [The role of the semi natural cycle as option of treatment of patients with a poor prognosis for successful in vitro fertilization], J Gynecol Obstet Biol Reprod (Paris) 33:518, 2004.
277. **Kolibianakis E**, **Zikopoulos K**, **Camus M**, **Tournaye H**, **Van Steirteghem A**, **Devroey P**, Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation, Hum Reprod 19:2545, 2004.
278. **Weghofer A**, **Margreiter M**, **Bassim S**, **Sevelda U**, **Beilhack E**, **Feichtinger W**, Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age, Fertil Steril 81:1002, 2004.
279. **Elizur SE**, **Aslan D**, **Shulman A**, **Weisz B**, **Bider D**, **Dor J**, Modified natural cycle using GnRH antagonist can be an optional treatment in poor responders undergoing IVF, J Assist Reprod Genet 22:75, 2005.
280. **Pelinck MJ**, **Vogel NE**, **Hoek A**, **Simons AH**, **Arts EG**, **Mochtar MH**, **Beemsterboer S**, **Hondelink MN**, **Heineman MJ**, Cumulative pregnancy rates after three cycles of minimal stimulation IVF and results according to subfertility diagnosis: a multicentre cohort study, Hum Reprod 21:2375, 2006.
281. **Verberg MF**, **Macklon NS**, **Nargund G**, **Frydman R**, **Devroey P**, **Broekmans FJ**, **Fauser BC**, Mild ovarian stimulation for IVF, Hum Reprod Update 15:13, 2009.
282. **Trounson AO**, **Leeton JF**, **Wood C**, **Webb J**, **Wood J**, Pregnancies in humans by fertilization in vitro and embryo transfer in the controlled ovulatory cycle, Science 212:681, 1981.
283. **Quigley MM**, **Schmidt CL**, **Beauchamp PJ**, **Pace-Owens S**, **Berkowitz AS**, **Wolf DP**, Enhanced follicular recruitment in an in vitro fertilization program: clomiphene alone versus a clomiphene/human menopausal gonadotropin combination, Fertil Steril 42:25, 1984.
284. **Macklon NS**, **Stouffer RL**, **Giudice LC**, **Fauser BC**, The science behind 25 years of ovarian stimulation for in vitro fertilization, Endocr Rev 27:170, 2006.
285. **Dickey RP**, **Taylor SN**, **Rye PH**, **Lu PY**, Future use of clomiphene in ovarian stimulation. A role for clomiphene in the 21st century? Hum Reprod 13:2361, 1998.
286. **Messinis IE**, **Milingos SD**, Future use of clomiphene in ovarian stimulation. Clomiphene in the 21st century, Hum Reprod 13:2362, 1998.
287. **Ingerslev HJ**, **Hojgaard A**, **Hindkjaer J**, **Kesmodel U**, A randomized study comparing IVF in the unstimulated cycle with IVF following clomiphene citrate, Hum Reprod 16:696, 2001.
288. **Branigan EF**, **Estes MA**, Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression, Fertil Steril 73:587, 2000.
289. **MacDougall MJ**, **Tan SL**, **Hall V**, **Balen A**, **Mason BA**, **Jacobs HS**, Comparison of natural with clomiphene citrate-stimulated cycles in in vitro fertilization: a prospective, randomized trial, Fertil Steril 61:1052, 1994.
290. **Diamond MP**, **Hill GA**, **Webster BW**, **Herbert CM**, **Rogers BJ**, **Osteen KG**, **Maxson WS**, **Vaughn WK**, **Wentz AC**, Comparison of human menopausal gonadotropin, clomiphene citrate, and combined human menopausal gonadotropin-clomiphene citrate stimulation protocols for in vitro fertilization, Fertil Steril 46:1108,

1986.
291. **Corfman RS**, **Milad MP**, **Bellavance TL**, **Ory SJ**, **Erickson LD**, **Ball GD**, A novel ovarian stimulation protocol for use with the assisted reproductive technologies, Fertil Steril 60:864, 1993.
292. **Dor J**, **Ben-Shlomo I**, **Levran D**, **Rudak E**, **Yunish M**, **Mashiach S**, The relative success of gonadotropin-releasing hormone analogue, clomiphene citrate, and gonadotropin in 1,099 cycles of in vitro fertilization, Fertil Steril 58:986, 1992.
293. **Weigert M**, **Krischker U**, **Pohl M**, **Poschalko G**, **Kindermann C**, **Feichtinger W**, Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study, Fertil Steril 78:34, 2002.
294. **Dhont M**, **Onghena A**, **Coetsier T**, **De Sutter P**, Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction, Hum Reprod 10:791, 1995.
295. **Lin YH**, **Hwang JL**, **Seow KM**, **Huang LW**, **Hsieh BC**, **Tzeng CR**, Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol—a randomized study, Gynecol Endocrinol 22:297, 2006.
296. **Fiedler K**, **Ludwig M**, Use of clomiphene citrate in in vitro fertilization (IVF) and IVF/intracytoplasmic sperm injection cycles, Fertil Steril 80:1521, 2003.
297. **Williams SC**, **Gibbons WE**, **Muasher SJ**, **Oehninger S**, Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist, Fertil Steril 78:1068, 2002.
298. **Mansour R**, **Aboulghar M**, **Serour GI**, **Al-Inany HG**, **Fahmy I**, **Amin Y**, The use of clomiphene citrate/human menopausal gonadotrophins in conjunction with GnRH antagonist in an IVF/ICSI program is not a cost effective protocol, Acta Obstet Gynecol Scand 82:48, 2003.
299. **Kawachiya SST**, **Kato K**, **Takehara Y**, **Teramoto S**, **Kato O**, The effectiveness of clomiphene citrate in suppressing the LH surge in the minimal stimulation IVF protocol, Fertil Steril 86:S412, 2006.
300. **Kato K**, **Takehara Y**, **Segawa T**, **Kawachiya S**, **Okuno T**, **Kobayashi T**, **Bodri D**, **Kato O**, Minimal ovarian stimulation combined with elective single embryo transfer policy; age-specific results of a large, single-centre, Japanese cohort, Reprod Biol Endocrinol 27:35, 2012.
301. **Bodri D**, **Kawachiya S**, **De Brucker M**, **Tournaye H**, **Kondo M**, **Kato R**, **Matsumoto T**, Cumulative success rates following mild IVF in unselected infertile patients: a 3-year, single-centre cohort study, Reprod Biomed Online 28: 572, 2014.
302. **Zhang J**, **Chang L**, **Sone Y**, **Silber S**, Minimal ovarian stimulation (mini-IVF) for IVF utilizing vitrification and cryopreserved embryo transfer, Reprod Biomed Online 21:485, 2010.
303. **Meldrum D**, GnRH agonists as adjuncts for in vitro fertilization, Obstet Gynecol Surv 44:314, 1989.
304. **Edwards RG**, **Lobo R**, **Bouchard P**, Time to revolutionize ovarian stimulation, Hum Reprod 11:917, 1996.
305. **Janssens RM**, **Lamballk CB**, **Vermeiden JP**, **Schats R**, **Bernards JM**, **Rekers-Mombarg LT**, **Schoemaker J**, Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study, Hum Reprod 15:2333, 2000.
306. **Hughes EG**, **Fedorkow DM**, **Daya S**, **Sagle MA**, **Van de Koppel P**, **Collins JA**, The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials, Fertil Steril 58:888, 1992.
307. **Daya S**, Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles, Cochrane Database Syst Rev (2):CD001299, 2000.
308. **Meldrum DR**, **Wisot A**, **Hamilton F**, **Gutlay AL**, **Huynh D**, **Kempton W**, Timing of initiation and dose schedule of leuprolide influence the time course of ovarian suppression, Fertil Steril 50:400, 1988.
309. **Urbancsek J**, **Witthaus E**, Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization, Fertil Steril 65:966, 1996.
310. **El-Nemr A**, **Bhide M**, **Khalifa Y**, **Al-Mizyen E**, **Gillott C**, **Lower AM**, **Al-Shawaf T**, **Grudzinskas JG**,

Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study, Eur J Obstet Gynecol Reprod Biol 103:140, 2002.
311. **Albuquerque LE**, **Saconato H**, **Maciel MC**, Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles, Cochrane Database Syst Rev (3):CD002808, 2002.
312. **Thatcher SS**, **Jones E**, **DeCherney AH**, Ovarian cysts decrease the success of controlled ovarian stimulation and in vitro fertilization, Fertil Steril 52:812, 1989.
313. **Keltz MD**, **Jones EE**, **Duleba AJ**, **Polcz T**, **Kennedy K**, **Olive DL**, Baseline cyst formation after luteal phase gonadotropin-releasing hormone agonist administration is linked to poor in vitro fertilization outcome, Fertil Steril 64:568, 1995.
314. **Segal S**, **Shifren JL**, **Isaacson KB**, **Leykin L**, **Chang Y**, **Pal L**, **Toth TL**, Effect of a baseline ovarian cyst on the outcome of in vitro fertilization-embryo transfer, Fertil Steril 71:274, 1999.
315. **Zeyneloglu HB**, **Isik AZ**, **Kara S**, **Senoz S**, **Ozcan U**, **Gokmen O**, Impact of baseline cysts at the time of administration of gonadotropin-releasing hormone analog for in vitro fertilization, Int J Fertil Womens Med 43:300, 1998.
316. **Penzias AS**, **Jones EE**, **Seifer DB**, **Grifo JA**, **Thatcher SS**, **DeCherney AH**, Baseline ovarian cysts do not affect clinical response to controlled ovarian hyperstimulation for in vitro fertilization, Fertil Steril 57:1017, 1992.
317. **Goldberg JM**, **Miller FA**, **Friedman CI**, **Dodds WG**, **Kim MH**, Effect of baseline ovarian cysts on in vitro fertilization and gamete intrafallopian transfer cycles, Fertil Steril 55:319, 1991.
318. **Hornstein MD**, **Barbieri RL**, **Ravnikar VA**, **McShane PM**, The effects of baseline ovarian cysts on the clinical response to controlled ovarian hyperstimulation in an in vitro fertilization program, Fertil Steril 52:437, 1989.
319. **Karande VC**, **Scott RT**, **Jones GS**, **Muasher SJ**, Non-functional ovarian cysts do not affect ipsilateral or contralateral ovarian performance during in-vitro fertilization, Hum Reprod 5:431, 1990.
320. **McDonnell R**, **Marjoribanks J**, **Hart RJ**, Ovarian cyst aspiration prior to in vitro fertilization treatment for subfertility, Cochrane Database Syst Rev (12):CD005999, 2014.
321. **Oudshoorn SC**, **van Tilborg TC**, **Eijkemans MJC**, **Oosterhuis GJE**, **Friederich J**, **van Hooff MHA**, **van Santbrink EJP**, **Brinkhuis EA**, **Smeenk JMJ**, **Kwee J**, **de Koning CH**, **Groen H**, **Lambalk CB**, **Mol BWJ**, **Broekmans FJM**, **Torrance HL; OPTIMIST study group**, Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder, Hum Reprod 32:2506, 2017.
322. **van Tilborg TC**, **Oudshoorn SC**, **Eijkemans MJC**, **Mochtar MH**, **van Golde RJT**, **Hoek A**, **Kuchenbecker WKH**, **Fleischer K**, **de Bruin JP**, **Groen H**, **van Wely M**, **Lambalk CB**, **Laven JSE**, **Mol BWJ**, **Broekmans FJM**, **Torrance HL; OPTIMIST study group**, Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis, Hum Reprod 32:2485, 2017.
323. **van Tilborg TC**, **Torrance HL**, **Oudshoorn SC**, **Eijkemans MJC**, **Koks CAM**, **Verhoeve HR**, **Nap AW**, **Scheffer GJ**, **Manger AP**, **Schoot BC**, **Sluijmer AV**, **Verhoeff A**, **Groen H**, **Laven JSE**, **Mol BWJ**, **Broekmans FJM; OPTIMIST study group**, Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder, Hum Reprod 32:2496, 2017.
324. **van Tilborg TC**, **Torrance HL**, **Oudshoorn SC**, **Eijkemans MJC**, **Mol BW**, **Broekmans FJM; OPTIMIST study group**, The end for individualized dosing in IVF ovarian stimulation? Reply to letters-to-the-editor regarding the OPTIMIST papers, Hum Reprod 33:984, 2018.
325. **La Marca A**, **Blockeel C**, **Bosch E**, **Fanchin R**, **Fatemi HM**, **Fauser BC**, **Garcia-Velasco JA**, **Humaidan P**, **Tarlatzis BC**, **Nelson SM**, Individualized FSH dosing improves safety and reduces iatrogenic poor response while maintaining live-birth rates, Hum Reprod 33:982, 2018.
326. **Nelson SM**, **Anderson RA**, Derailing individualized ovarian stimulation, Hum Reprod 33:980, 2018.
327. **Sunkara SK**, **Polyzos NP**, OPTIMIST trial: optimistic evidence? Hum Reprod 33:983, 2018.
328. **Daya S**, Methodologic pitfalls in assessing the efficacy of recombinant follicle-stimulating hormone versus human menopausal gonadotropin in assisted reproduction, Fertil Steril 80:1100, 2003.

329. **van Wely M**, **Westergaard LG**, **Bossuyt PM**, **van der Veen F**, Human menopausal gonadotropin and recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles, Fertil Steril 80:1121, 2003.
330. **Filicori M**, **Cognigni GE**, **Pocognoli P**, **Ciampaglia W**, Choice of ovarian stimulation regimens in assisted reproduction: finding the thread in the gonadotropin maze, Fertil Steril 80:1114, 2003.
331. **Collins J**, A turbulent arena, Fertil Steril 80:1117, 2003.
332. **van Wely M**, **Kwan I**, **Burt AL**, **Thomas J**, **Vail A**, **Van der Veen F**, **Al-Inany HG**, Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles, Cochrane Database Syst Rev (2):CD005354, 2011.
333. **Mannaerts B**, **Shoham Z**, **Schoot D**, **Bouchard P**, **Harlin J**, **Fauser B**, **Jacobs H**, **Rombout F**, **Coelingh Bennink H**, Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers, Fertil Steril 59:108, 1993.
334. **Duijkers IJ**, **Klipping C**, **Boerrigter PJ**, **Machielsen CS**, **De Bie JJ**, **Voortman G**, Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females, Hum Reprod 17:1987, 2002.
335. **Seyhan A**, **Ata B**, The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist, Int J Womens Health 3:243, 2011.
336. **Pouwer AW**, **Farquhar C**, **Kremer JA**, Long-acting FSH versus daily FSH for women undergoing assisted reproduction, Cochrane Database Syst Rev (7): CD009577, 2015.
337. **Balasch J**, **Vidal E**, **Penarrubia J**, **Casamitjana R**, **Carmona F**, **Creus M**, **Fabregues F**, **Vanrell JA**, Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH, Hum Reprod 16:1636, 2001.
338. **Chappel SC**, **Howles C**, Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process, Hum Reprod 6:1206, 1991.
339. **Laml T**, **Obruca A**, **Fischl F**, **Huber JC**, Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropic women, Gynecol Endocrinol 13:98, 1999.
340. **Filicori M**, **Cognigni GE**, **Taraborrelli S**, **Spettoli D**, **Ciampaglia W**, **de Fatis CT**, **Pocognoli P**, Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome, J Clin Endocrinol Metab 84:2659, 1999.
341. **Fleming R**, **Chung CC**, **Yates RW**, **Coutts JR**, Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity, Hum Reprod 11:1854, 1996.
342. **Fleming R**, **Rehka P**, **Deshpande N**, **Jamieson ME**, **Yates RW**, **Lyall H**, Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH, Hum Reprod 15:1440, 2000.
343. **Westergaard LG**, **Erb K**, **Laursen S**, **Rasmussen PE**, **Rex S**, The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women, Hum Reprod 11:1209, 1996.
344. **Westergaard LG**, **Erb K**, **Laursen SB**, **Rex S**, **Rasmussen PE**, Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study, Fertil Steril 76:543, 2001.
345. **Gordon UD**, **Harrison RF**, **Fawzy M**, **Hennelly B**, **Gordon AC**, A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome, Fertil Steril 75:324, 2001.
346. **Sills ES**, **Levy DP**, **Moomjy M**, **McGee M**, **Rosenwaks Z**, A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization, Hum Reprod 14:2230, 1999.
347. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian

stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group, Hum Reprod 13:3023, 1998.
348. **Westergaard LG**, **Laursen SB**, **Andersen CY**, Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction, Hum Reprod 15:1003, 2000.
349. **Esposito MA**, **Barnhart KT**, **Coutifaris C**, **Patrizio P**, Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone, Fertil Steril 75:519, 2001.
350. **Lehert P**, **Kolibianakis EM**, **Venetis CA**, **Schertz J**, **Saunders H**, **Arriagada P**, **Copt S**, **Tarlatzis B**, Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis, Reprod Biol Endocrinol 12:17, 2014.
351. **Pandian Z**, **McTavish AR**, **Aucott L**, **Hamilton MP**, **Bhattacharya S**, Interventions for "poor responders" to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF), Cochrane Database Syst Rev (1):CD004379, 2010.
352. **Konig TE, van der Houwen LE**, **Overbeek A**, **Hendriks ML**, **Beutler-Beemsterboer SN**, **Kuchenbecker WK**, **Renckens CN**, **Bernardus RE**, **Schats R**, **Homburg R**, **Hompes PG**, **Lambalk CB**, Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study, Hum Reprod 28:2804, 2013.
353. **Vuong TN**, **Phung HT**, **Ho MT**, Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial, Hum Reprod 30:1188, 2015.
354. **Bosch E**, **Labarta E**, **Crespo J**, **Simon C**, **Remohi J**, **Pellicer A**, Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis, Fertil Steril 95:1031, 2011.
355. **Humaidan P**, **Chin W**, **Rogoff D**, **D'Hooghe T**, **Longobardi S**, **Hubbard J**, **Schertz J; ESPART Study Investigators**, Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders, Hum Reprod 32:544, 2017.
356. **Ata B**, **Seli E**, Strategies for controlled ovarian stimulation in the setting of ovarian aging, Semin Reprod Med 33:436, 2015.
357. **Coomarasamy A**, **Afnan M**, **Cheema D**, **van der Veen F**, **Bossuyt PM**, **van Wely M**, Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis, Hum Reprod 23:310, 2008.
358. **Ata B**, **Tulandi T**, Ultrasound automated volume calculation in reproduction and in pregnancy, Fertil Steril 95:2163, 2011.
359. **Chen SL**, **Wu FR**, **Luo C**, **Chen X**, **Shi XY**, **Zheng HY**, **Ni YP**, Combined analysis of endometrial thickness and pattern in predicting outcome of in vitro fertilization and embryo transfer: a retrospective cohort study, Reprod Biol Endocrinol 8:30, 2010.
360. **Kuc P**, **Kuczynska A**, **Topczewska M**, **Tadejko P**, **Kuczynski W**, The dynamics of endometrial growth and the triple layer appearance in three different controlled ovarian hyperstimulation protocols and their influence on IVF outcomes, Gynecol Endocrinol 27:867, 2011.
361. **Zhao J**, **Zhang Q**, **Li Y**, The effect of endometrial thickness and pattern measured by ultrasonography on pregnancy outcomes during IVF-ET cycles, Reprod Biol Endocrinol 10:100, 2012.
362. **Gonen Y**, **Casper RF**, Prediction of implantation by the sonographic appearance of the endometrium during controlled ovarian stimulation for in vitro fertilization (IVF), J In Vitro Fert Embryo Transf 7:146, 1990.
363. **Noyes N**, **Liu HC**, **Sultan K**, **Schattman G**, **Rosenwaks Z**, Endometrial thickness appears to be a significant factor in embryo implantation in in-vitro fertilization, Hum Reprod 10:919, 1995.
364. **Fanchin R**, **Righini C**, **Ayoubi JM**, **Olivennes F**, **de Ziegler D**, **Frydman R**, New look at endometrial echogenicity: objective computer-assisted measurements predict endometrial receptivity in in vitro fertilization-embryo transfer, Fertil Steril 74:274, 2000.

365. **Check JH**, **Lurie D**, **Dietterich C**, **Callan C**, **Baker A**, Adverse effect of a homogeneous hyperechogenic endometrial sonographic pattern, despite adequate endometrial thickness on pregnancy rates following in-vitro fertilization, Hum Reprod 8:1293, 1993.
366. **Check JH**, **Nowroozi K**, **Choe J**, **Lurie D**, **Dietterich C**, The effect of endometrial thickness and echo pattern on in vitro fertilization outcome in donor oocyte-embryo transfer cycle, Fertil Steril 59:72, 1993.
367. **Dechaud H**, **Bessueille E**, **Bousquet PJ**, **Reyftmann L**, **Hamamah S**, **Hedon B**, Optimal timing of ultrasonographic and Doppler evaluation of uterine receptivity to implantation, Reprod Biomed Online 16:368, 2008.
368. **Kinay T**, **Tasci Y**, **Dilbaz S**, **Cinar O**, **Demir B**, **Haberal A**, The relationship between endometrial thickness and pregnancy rates in GnRH antagonist down-regulated ICSI cycles, Gynecol Endocrinol 26:833, 2010.
369. **Basir GS**, **O WS**, **So WW**, **Ng EH**, **Ho PC**, Evaluation of cycle-to-cycle variation of endometrial responsiveness using transvaginal sonography in women undergoing assisted reproduction, Ultrasound Obstet Gynecol 19:484, 2002.
370. **Al-Ghamdi A**, **Coskun S**, **Al-Hassan S**, **Al-Rejjal R**, **Awartani K**, The correlation between endometrial thickness and outcome of in vitro fertilization and embryo transfer (IVF-ET) outcome, Reprod Biol Endocrinol 6:37, 2008.
371. **Bozdag G**, **Esinler I**, **Yarali H**, The impact of endometrial thickness and texture on intracytoplasmic sperm injection outcome, J Reprod Med 54:303, 2009.
372. **Richter KS**, **Bugge KR**, **Bromer JG**, **Levy MJ**, Relationship between endometrial thickness and embryo implantation, based on 1,294 cycles of in vitro fertilization with transfer of two blastocyst-stage embryos, Fertil Steril 87:53, 2007.
373. **Yang W**, **Zhang T**, **Li Z**, **Ren X**, **Huang B**, **Zhu G**, **Jin L**, Combined analysis of endometrial thickness and pattern in predicting clinical outcomes of frozen embryo transfer cycles with morphological good-quality blastocyst: A retrospective cohort study, Medicine (Baltimore) 97:e9577, 2018.
374. **Bergh C**, **Hillensjo T**, **Nilsson L**, Sonographic evaluation of the endometrium in in vitro fertilization IVF cycles. A way to predict pregnancy? Acta Obstet Gynecol Scand 71:624, 1992.
375. **Oliveira JB**, **Baruffi RL**, **Mauri AL**, **Petersen CG**, **Borges MC**, **Franco JG Jr**, Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins, Hum Reprod 12:2515, 1997.
376. **Ueno J**, **Oehninger S**, **Brzyski RG**, **Acosta AA**, **Philput CB**, **Muasher SJ**, Ultrasonographic appearance of the endometrium in natural and stimulated in-vitro fertilization cycles and its correlation with outcome, Hum Reprod 6:901, 1991.
377. **Zaidi J**, **Campbell S**, **Pittrof R**, **Tan SL**, Endometrial thickness, morphology, vascular penetration and velocimetry in predicting implantation in an in vitro fertilization program, Ultrasound Obstet Gynecol 6:191, 1995.
378. **Khalifa E**, **Brzyski RG**, **Oehninger S**, **Acosta AA**, **Muasher SJ**, Sonographic appearance of the endometrium: the predictive value for the outcome of in-vitro fertilization in stimulated cycles, Hum Reprod 7:677, 1992.
379. **Bassil S**, Changes in endometrial thickness, width, length and pattern in predicting pregnancy outcome during ovarian stimulation in in vitro fertilization, Ultrasound Obstet Gynecol 18:258, 2001.
380. **Dickey RP**, **Olar TT**, **Curole DN**, **Taylor SN**, **Rye PH**, Endometrial pattern and thickness associated with pregnancy outcome after assisted reproduction technologies, Hum Reprod 7:418, 1992.
381. **Weissman A**, **Gotlieb L**, **Casper RF**, The detrimental effect of increased endometrial thickness on implantation and pregnancy rates and outcome in an in vitro fertilization program, Fertil Steril 71:147, 1999.
382. **Dietterich C**, **Check JH**, **Choe JK**, **Nazari A**, **Lurie D**, Increased endometrial thickness on the day of human chorionic gonadotropin injection does not adversely affect pregnancy or implantation rates following in vitro fertilization-embryo transfer, Fertil Steril 77:781, 2002.
383. **Yakin K**, **Akarsu C**, **Kahraman S**, Cycle lumping or—sampling a witches' brew? Fertil Steril 73:175, 2000.
384. **Sundstrom P**, Establishment of a successful pregnancy following in-vitro fertilization with an endometrial thickness of no more than 4 mm, Hum Reprod 13:1550, 1998.

385. **Amin B**, **Cho M**, **Shamonki M**, Establishment of a successful pregnancy and term delivery following ovulation induction with a maximum endometrial thickness of 3 mm, J Fertil In Vitro IVF Worldw Reprod Med Genet Stem Cell Biol 2:114, 2012.
386. **Kasius A**, **Smit JG**, **Torrance HL**, **Eijkemans MJ**, **Mol BW**, **Opmeer BC**, **Broekmans FJ**, Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis, Hum Reprod Update 20:530, 2014.
387. **De Geyter C**, **Schmitter M**, **De Geyter M**, **Nieschlag E**, **Holzgreve W**, **Schneider HP**, Prospective evaluation of the ultrasound appearance of the endometrium in a cohort of 1,186 infertile women, Fertil Steril 73:106, 2000.
388. **Youssef MA**, **Abou-Setta AM**, **Lam WS**, Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles, Cochrane Database Syst Rev (4):CD003719, 2016.
389. **Humaidan P**, **Kol S**, **Papanikolaou EG; Copenhagen GnRH Agonist Triggering Workshop Group**, GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 17:510, 2011.
390. **Turkgeldi E**, **Turkgeldi L**, **Seyhan A**, **Ata B**, Gonadotropin-releasing hormone agonist triggering of oocyte maturation in assisted reproductive technology cycles, Turk J Obstet Gynecol 12:96, 2015.
391. **Lamb JD**, **Shen S**, **McCulloch C**, **Jalalian L**, **Cedars MI**, **Rosen MP**, Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial, Fertil Steril 95:1655, 2011.
392. **Vermeiden JP**, **Roseboom TJ**, **Goverde AJ**, **Suchartwatnachai C**, **Schoute E**, **Braat DD**, **Schats R**, An artificially induced follicle stimulating hormone surge at the time of human chorionic gonadotrophin administration in controlled ovarian stimulation cycles has no effect on cumulus expansion, fertilization rate, embryo quality and implantation rate, Hum Reprod 12:1399, 1997.
393. **Zhou X**, **Guo P**, **Chen X**, **Ye D**, **Liu Y**, **Chen S**, Comparison of dual trigger with combination GnRH agonist and hCG versus hCG alone trigger of oocyte maturation for normal ovarian responders, Int J Gynaecol Obstet 141:327, 2018.
394. **Lin MH**, **Wu FS**, **Lee RK**, **Li SH**, **Lin SY**, **Hwu YM**, Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles, Fertil Steril 100:1296, 2013.
395. **Li S**, **Zhou D**, **Yin T**, **Xu W**, **Xie Q**, **Cheng D**, **Yang J**, Dual trigger of triptorelin and HCG optimizes clinical outcome for high ovarian responder in GnRH-antagonist protocols, Oncotarget 9:5337, 2018.
396. **Lu X**, **Hong Q**, **Sun L**, **Chen Q**, **Fu Y**, **Ai A**, **Lyu Q**, **Kuang Y**, Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist, Fertil Steril 106:1356, 2016.
397. **Zhang J**, **Wang Y**, **Mao X**, **Chen Q**, **Hong Q**, **Cai R**, **Zhang S**, **Kuang Y**, Dual trigger of final oocyte maturation in poor ovarian responders undergoing IVF/ICSI cycles, Reprod Biomed Online 35:701, 2017.
398. **Oliveira SA**, **Calsavara VF**, **Cortes GC**, Final oocyte maturation in assisted reproduction with human chorionic gonadotropin and gonadotropin-releasing hormone agonist (Dual Trigger), JBRA Assist Reprod 20:246, 2016.
399. **Seval MM**, **Ozmen B**, **Atabekoglu C**, **Sukur YE**, **Simsir C**, **Kan O**, **Sonmezer M**, Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles, J Obstet Gynaecol Res 42:1146, 2016.
400. **Youssef MA**, **Van der Veen F**, **Al-Inany HG**, **Mochtar MH**, **Griesinger G**, **Nagi Mohesen M**, **Aboulfoutouh I**, **van Wely M**, Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology, Cochrane Database Syst Rev (10):CD008046, 2014.
401. **Venetis CA**, **Kolibianakis EM**, **Bosdou JK**, **Lainas GT**, **Sfontouris IA**, **Tarlatzis BC**, **Lainas TG**, Estimating the net effect of progesterone elevation on the day of hCG on live birth rates after IVF: a cohort analysis of 3296 IVF cycles, Hum Reprod 30:684, 2015.
402. **Venetis CA**, **Kolibianakis EM**, **Bosdou JK**, **Tarlatzis BC**, Progesterone elevation and probability of

pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles, Hum Reprod Update 19:433, 2013.

403. **Esteves SC**, **Khastgir G**, **Shah J**, **Murdia K**, **Gupta SM**, **Rao DG**, **Dash S**, **Ingale K**, **Patil M**, **Moideen K**, **Thakor P**, **Dewda P**, Association between progesterone elevation on the day of human chronic gonadotropin trigger and pregnancy outcomes after fresh embryo transfer in in vitro fertilization/intracytoplasmic sperm injection cycles, Front Endocrinol (Lausanne) 9:201, 2018.
404. **Xu B**, **Li Z**, **Zhang H**, **Jin L**, **Li Y**, **Ai J**, **Zhu G**, Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles, Fertil Steril 97:1321.e1, 2012.
405. **Racca A**, **Santos-Ribeiro S**, **De Munck N**, **Mackens S**, **Drakopoulos P**, **Camus M**, **Verheyen G**, **Tournaye H**, **Blockeel C**, Impact of late-follicular phase elevated serum progesterone on cumulative live birth rates: is there a deleterious effect on embryo quality? Hum Reprod 33:860, 2018.
406. **Ata B**, **Seli E**, A universal freeze all strategy: why it is not warranted, Curr Opin Obstet Gynecol 29:136, 2017.
407. **Smitz J**, **Camus M**, **Devroey P**, **Erard P**, **Wisanto A**, **Van Steirteghem AC**, Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization, Hum Reprod 5:933, 1990.
408. **MacDougall MJ**, **Tan SL**, **Jacobs HS**, In-vitro fertilization and the ovarian hyperstimulation syndrome, Hum Reprod 7:597, 1992.
409. **Rizk B**, **Smitz J**, Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures, Hum Reprod 7:320, 1992.
410. **Chen ZJ**, **Shi Y**, **Sun Y**, **Zhang B**, **Liang X**, **Cao Y**, **Yang J**, **Liu J**, **Wei D**, **Weng N**, **Tian L**, **Hao C**, **Yang D**, **Zhou F**, **Shi J**, **Xu Y**, **Li J**, **Yan J**, **Qin Y**, **Zhao H**, **Zhang H**, **Legro RS**, Fresh versus frozen embryos for infertility in the polycystic ovary syndrome, N Engl J Med 375:523, 2016.
411. **Shapiro BS**, **Daneshmand ST**, **Garner FC**, **Aguirre M**, **Hudson C**, **Thomas S**, Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed embryo transfers in high responders, Fertil Steril 96:516, 2011.
412. **Dahan MH**, **Tannus S**, **Seyhan A**, **Tan SL**, **Ata B**, Combined modalities for the prevention of ovarian hyperstimulation syndrome following an excessive response to stimulation, Gynecol Endocrinol 34:252, 2018.
413. **Ferraretti AP**, **La Marca A**, **Fauser BC**, **Tarlatzis B**, **Nargund G**, **Gianaroli L; ESHRE working group on Poor Ovarian Response Definition**, ESHRE consensus on the definition of "poor response" to ovarian stimulation for in vitro fertilization: the Bologna criteria, Hum Reprod 26:1616, 2011.
414. **Ferraretti AP**, **Gianaroli L**, The Bologna criteria for the definition of poor ovarian responders: is there a need for revision? Hum Reprod 29:1842, 2014.
415. **Venetis CA**, The Bologna criteria for poor ovarian response: the good, the bad and the way forward, Hum Reprod 29:1839, 2014.
416. **Boza A**, **Oguz SY**, **Misirlioglu S**, **Yakin K**, **Urman B**, Utilization of the Bologna criteria: a promise unfulfilled? A review of published and unpublished/ongoing trials, Fertil Steril 109:104.e2, 2018.
417. **Kyrou D**, **Kolibianakis EM**, **Venetis CA**, **Papanikolaou EG**, **Bontis J**, **Tarlatzis BC**, How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis, Fertil Steril 91:749, 2009.
418. **Hill MJ**, **McWilliams GD**, **Miller KA**, **Scott RT, Jr.**, **Frattarelli JL**, A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates, Fertil Steril 91:739, 2009.
419. **Arslan M**, **Bocca S**, **Mirkin S**, **Barroso G**, **Stadtmauer L**, **Oehninger S**, Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr, Fertil Steril 84:555, 2005.
420. **Padilla SL**, **Dugan K**, **Maruschak V**, **Shalika S**, **Smith RD**, Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders, Fertil Steril 65:796, 1996.
421. **Garcia JE**, **Padilla SL**, **Bayati J**, **Baramki TA**, Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization, Fertil Steril 53:302,

1990.
422. **San Roman GA**, **Surrey ES**, **Judd HL**, **Kerin JF**, A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization, Fertil Steril 58:744, 1992.
423. **Gelety TJ**, **Pearlstone AC**, **Surrey ES**, Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women, Fertil Steril 64:1074, 1995.
424. **Blockeel C**, **Baumgarten M**, **De Vos M**, **Verheyen G**, **Devroey P**, Administration of GnRH antagonists in case of elevated progesterone at initiation of the cycle: a prospective cohort study, Curr Pharm Biotechnol 12:423, 2011.
425. **Kolibianakis EM**, **Zikopoulos K**, **Smitz J**, **Camus M**, **Tournaye H**, **Van Steirteghem AC**, **Devroey P**, Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists, Hum Reprod 19:1525, 2004.
426. **Loumaye E**, **Vankrieken L**, **Depreester S**, **Psalti I**, **de Cooman S**, **Thomas K**, Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development, Fertil Steril 51:105, 1989.
427. **Surrey ES**, **Bower J**, **Hill DM**, **Ramsey J**, **Surrey MW**, Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization, Fertil Steril 69:419, 1998.
428. **Gonen Y**, **Jacobson W**, **Casper RF**, Gonadotropin suppression with oral contraceptives before in vitro fertilization, Fertil Steril 53:282, 1990.
429. **Cedrin-Durnerin I**, **Bulwa S**, **Herve F**, **Martin-Pont B**, **Uzan M**, **Hugues JN**, The hormonal flare-up following gonadotrophin-releasing hormone agonist administration is influenced by a progestogen pretreatment, Hum Reprod 11:1859, 1996.
430. **Xiao J**, **Chang S**, **Chen S**, The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis, Fertil Steril 100:1594.e1, 2013.
431. **Pu D**, **Wu J**, **Liu J**, Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF, Hum Reprod 26:2742, 2011.
432. **Matikainen T**, **Ding YQ**, **Vergara M**, **Huhtaniemi I**, **Couzinet B**, **Schaison G**, Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women, J Clin Endocrinol Metab 75:820, 1992.
433. **Reissmann T**, **Felberbaum R**, **Diedrich K**, **Engel J**, **Comaru-Schally AM**, **Schally AV**, Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview, Hum Reprod 10:1974, 1995.
434. **Olivennes F**, **Cunha-Filho JS**, **Fanchin R**, **Bouchard P**, **Frydman R**, The use of GnRH antagonists in ovarian stimulation, Hum Reprod Update 8:279, 2002.
435. **Albano C**, **Felberbaum RE**, **Smitz J**, **Riethmuller-Winzen H**, **Engel J**, **Diedrich K**, **Devroey P**, Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group, Hum Reprod 15:526, 2000.
436. **Akman MA**, **Erden HF**, **Tosun SB**, **Bayazit N**, **Aksoy E**, **Bahceci M**, Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial, Hum Reprod 16:868, 2001.
437. **Felberbaum RE**, **Albano C**, **Ludwig M**, **Riethmuller-Winzen H**, **Grigat M**, **Devroey P**, **Diedrich K**, Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study, Hum Reprod 15:1015, 2000.
438. **Ludwig M**, **Felberbaum RE**, **Devroey P**, **Albano C**, **Riethmuller-Winzen H**, **Schuler A**, **Engel W**,

Diedrich K, Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction, Arch Gynecol Obstet 264:29, 2000.

439. **de Jong D**, **Macklon NS**, **Eijkemans MJ**, **Mannaerts BM**, **Coelingh Bennink HJ**, **Fauser BC; Ganirelix Dose-Finding Study Group**, Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon), Fertil Steril 75:688, 2001.
440. **Toftager M**, **Bogstad J**, **Bryndorf T**, **Lossl K**, **Roskaer J**, **Holland T**, **Praetorius L**, **Zedeler A**, **Nilas L**, **Pinborg A**, Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles, Hum Reprod 31:1253, 2016.
441. **Al-Inany HG**, **Youssef MA**, **Aboulghar M**, **Broekmans F**, **Sterrenburg M**, **Smit J**, **Abou-Setta AM**, Gonadotrophin-releasing hormone antagonists for assisted reproductive technology, Cochrane Database Syst Rev (5):CD001750, 2011.
442. **Toftager M**, **Bogstad J**, **Lossl K**, **Praetorius L**, **Zedeler A**, **Bryndorf T**, **Nilas L**, **Pinborg A**, Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols, Hum Reprod 32: 556, 2017.
443. **Al-Inany HG**, **Abou-Setta AM**, **Aboulghar M**, Gonadotrophin-releasing hormone antagonists for assisted conception, Cochrane Database Syst Rev (3):CD001750, 2006.
444. **Albano C**, **Smitz J**, **Camus M**, **Riethmuller-Winzen H**, **Van Steirteghem A**, **Devroey P**, Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation, Fertil Steril 67:917, 1997.
445. **Diedrich K**, **Diedrich C**, **Santos E**, **Zoll C**, **al-Hasani S**, **Reissmann T**, **Krebs D**, **Klingmuller D**, Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation, Hum Reprod 9:788, 1994.
446. **Ludwig M**, **Katalinic A**, **Banz C**, **Schroder AK**, **Loning M**, **Weiss JM**, **Diedrich K**, Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study, Hum Reprod 17:2842, 2002.
447. **Klipstein S**, **Reindollar RH**, **Regan MM**, **Alper MM**, Initiation of the gonadotropin-releasing hormone antagonist ganirelix for in vitro fertilization cycles in which the lead follicle is >14 mm, Fertil Steril 81:714, 2004.
448. **Olivennes F**, **Belaisch-Allart J**, **Emperaire JC**, **Dechaud H**, **Alvarez S**, **Moreau L**, **Nicollet B**, **Zorn JR**, **Bouchard P**, **Frydman R**, Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin), Fertil Steril 73:314, 2000.
449. **Olivennes F**, **Diedrich K**, **Frydman R**, **Felberbaum RE**, **Howles CM; Cerotide Multiple Dose International Study Group; Cetrotide Single Dose International Study Group**, Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences, Reprod Biomed Online 6:432, 2003.
450. **Olivennes F**, **Alvarez S**, **Bouchard P**, **Fanchin R**, **Salat-Baroux J**, **Frydman R**, The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg, Hum Reprod 13:2411, 1998.
451. **Fanchin R**, **Cunha-Filho JS**, **Schonauer LM**, **Kadoch IJ**, **Cohen-Bacri P**, **Frydman R**, Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens, Fertil Steril 79:316, 2003.
452. **Griesinger G**, **Kolibianakis EM**, **Venetis C**, **Diedrich K**, **Tarlatzis B**, Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis, Fertil Steril 94:2382, 2010.
453. **Farquhar C**, **Rombauts L**, **Kremer JA**, **Lethaby A**, **Ayeleke RO**, Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques, Cochrane Database Syst Rev (5):CD006109, 2017.
454. **Aslan K**, **Avci B**, **Uncu G**, **Saribal S**, **Ata B**, Scheduling GnRH antagonist cycles by a short course of oral

estradiol administration during early follicular phase: a comparative study with non-scheduled cycles, Gynecol Endocrinol 31:465, 2015.

455. **Fanchin R**, **Salomon L**, **Castelo-Branco A**, **Olivennes F**, **Frydman N**, **Frydman R**, Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists, Hum Reprod 18:2698, 2003.
456. **de Ziegler D**, **Jaaskelainen AS**, **Brioschi PA**, **Fanchin R**, **Bulletti C**, Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH), Hum Reprod 13:561, 1998.
457. **Fanchin R**, **Cunha-Filho JS**, **Schonauer LM**, **Righini C**, **de Ziegler D**, **Frydman R**, Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulating hormone and inhibin B levels and ovarian follicular status, Fertil Steril 79:585, 2003.
458. **Itskovitz-Eldor J**, **Kol S**, **Mannaerts B**, Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication, Hum Reprod 15:1965, 2000.
459. **Fauser BC**, **de Jong D**, **Olivennes F**, **Wramsby H**, **Tay C**, **Itskovitz-Eldor J**, **van Hooren HG**, Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization, J Clin Endocrinol Metab 87:709, 2002.
460. **Kolibianakis E**, **Bourgain C**, **Albano C**, **Osmanagaoglu K**, **Smitz J**, **Van Steirteghem A**, **Devroey P**, Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up, Fertil Steril 78:1025, 2002.
461. **Kolibianakis EM**, **Albano C**, **Kahn J**, **Camus M**, **Tournaye H**, **Van Steirteghem AC**, **Devroey P**, Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy, Fertil Steril 79:873, 2003.
462. **Kolibianakis EM**, **Albano C**, **Camus M**, **Tournaye H**, **Van Steirteghem AC**, **Devroey P**, Relationship between LH and oestradiol in IVF cycles before GnRH antagonist initiation, Reprod Biomed Online 7:190, 2003.
463. **Kolibianakis E**, **Zikopoulos K**, **Albano C**, **Camus M**, **Tournaye H**, **Van Steirteghem A**, **Devroey P**, Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI, Reprod Biomed Online 7:313, 2003.
464. **Sunkara SK**, **Tuthill J**, **Khairy M**, **El-Toukhy T**, **Coomarasamy A**, **Khalaf Y**, **Braude P**, Pituitary suppression regimens in poor responders undergoing IVF treatment: a systematic review and meta-analysis, Reprod Biomed Online 15:539, 2007.
465. **Gonen Y**, **Balakier H**, **Powell W**, **Casper RF**, Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization, J Clin Endocrinol Metab 71:918, 1990.
466. **Imoedemhe DA**, **Chan RC**, **Sigue AB**, **Pacpaco EL**, **Olazo AB**, A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme, Hum Reprod 6:1088, 1991.
467. **Pellicer A**, **Albert C**, **Mercader A**, **Bonilla-Musoles F**, **Remohi J**, **Simon C**, The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor, Fertil Steril 71:482, 1999.
468. **Wang TH**, **Horng SG**, **Chang CL**, **Wu HM**, **Tsai YJ**, **Wang HS**, **Soong YK**, Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor, J Clin Endocrinol Metab 87:3300, 2002.
469. **Yamamoto S**, **Konishi I**, **Tsuruta Y**, **Nanbu K**, **Mandai M**, **Kuroda H**, **Matsushita K**, **Hamid AA**, **Yura Y**, **Mori T**, Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary, Gynecol Endocrinol 11:371, 1997.
470. **Scotti L**, **Irusta G**, **Abramovich D**, **Tesone M**, **Parborell F**, Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat

model of ovarian hyperstimulation syndrome, Mol Cell Endocrinol 335:116, 2011.
471. **Borgbo T**, **Povlsen BB**, **Andersen CY**, **Borup R**, **Humaidan P**, **Grondahl ML**, Comparison of gene expression profiles in granulosa and cumulus cells after ovulation induction with either human chorionic gonadotropin or a gonadotropin-releasing hormone agonist trigger, Fertil Steril 100:994, 2013.
472. **Humaidan P**, **Bredkjaer HE**, **Bungum L**, **Bungum M**, **Grondahl ML**, **Westergaard L**, **Andersen CY**, GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study, Hum Reprod 20:1213, 2005.
473. **Kolibianakis EM**, **Schultze-Mosgau A**, **Schroer A**, **van Steirteghem A**, **Devroey P**, **Diedrich K**, **Griesinger G**, A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists, Hum Reprod 20:2887, 2005.
474. **Acevedo B**, **Gomez-Palomares JL**, **Ricciarelli E**, **Hernandez ER**, Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates, Fertil Steril 86:1682, 2006.
475. **Griesinger G**, **Berndt H**, **Schultz L**, **Depenbusch M**, **Schultze-Mosgau A**, Cumulative live birth rates after GnRH-agonist triggering of final oocyte maturation in patients at risk of OHSS:a prospective, clinical cohort study, Eur J Obstet Gynecol Reprod Biol 149:190, 2010.
476. **Herrero L**, **Pareja S**, **Losada C**, **Cobo AC**, **Pellicer A**, **Garcia-Velasco JA**, Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome, Fertil Steril 95:1137, 2011.
477. **Babayof R**, **Margalioth EJ**, **Huleihel M**, **Amash A**, **Zylber-Haran E**, **Gal M**, **Brooks B**, **Mimoni T**, **Eldar-Geva T**, Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial, Hum Reprod 21:1260, 2006.
478. **Engmann L**, **Siano L**, **Schmidt D**, **Nulsen J**, **Maier D**, **Benadiva C**, GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS, Reprod Biomed Online 13:639, 2006.
479. **Chen SL**, **Ye DS**, **Chen X**, **Yang XH**, **Zheng HY**, **Tang Y**, **He YX**, **Guo W**, Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol, Hum Reprod 27:1351, 2012.
480. **Kummer NE**, **Feinn RS**, **Griffin DW**, **Nulsen JC**, **Benadiva CA**, **Engmann LL**, Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger, Hum Reprod 28:152, 2013.
481. **Humaidan P**, **Bungum L**, **Bungum M**, **Yding Andersen C**, Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study, Reprod Biomed Online 13:173, 2006.
482. **Humaidan P**, **Ejdrup Bredkjaer H**, **Westergaard LG**, **Yding Andersen C**, 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study, Fertil Steril 93:847, 2010.
483. **Humaidan P**, **Polyzos NP**, **Alsbjerg B**, **Erb K**, **Mikkelsen AL**, **Elbaek HO**, **Papanikolaou EG**, **Andersen CY**, GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients, Hum Reprod 28:2511, 2013.
484. **Humaidan P**, Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study, Reprod Biomed Online 18:630, 2009.
485. **Radesic B**, **Tremellen K**, Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates, Hum Reprod 26:3437, 2011.
486. **Fatemi HM**, **Popovic-Todorovic B**, **Humaidan P**, **Kol S**, **Banker M**, **Devroey P**, **Garcia-Velasco JA**, Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol, Fertil Steril 101:1008, 2014.
487. **Gurbuz AS**, **Gode F**, **Ozcimen N**, **Isik AZ**, Gonadotrophin-releasing hormone agonist trigger and freeze-all

strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases, Reprod Biomed Online 29:541, 2014.
488. **Seyhan A**, **Ata B**, **Polat M**, **Son WY**, **Yarali H**, **Dahan MH**, Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG, Hum Reprod 28:2522, 2013.
489. **Oktay K**, **Turkcuoglu I**, **Rodriguez-Wallberg KA**, GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation, Reprod Biomed Online 20:783, 2010.
490. **Baerwald AR**, **Adams GP**, **Pierson RA**, Ovarian antral folliculogenesis during the human menstrual cycle: a review, Hum Reprod Update 18:73, 2012.
491. **Sonmezer M**, **Turkcuoglu I**, **Coskun U**, **Oktay K**, Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles, Fertil Steril 95:2125.e9, 2011.
492. **Cakmak H**, **Rosen MP**, Random-start ovarian stimulation in patients with cancer, Curr Opin Obstet Gynecol 27:215, 2015.
493. **Kim JH**, **Kim SK**, **Lee HJ**, **Lee JR**, **Jee BC**, **Suh CS**, **Kim SH**, Efficacy of random-start controlled ovarian stimulation in cancer patients, J Korean Med Sci 30:290, 2015.
494. **Kuang Y**, **Chen Q**, **Hong Q**, **Lyu Q**, **Ai A**, **Fu Y**, **Shoham Z**, Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol), Reprod Biomed Online 29:684, 2014.
495. **Kuang Y**, **Hong Q**, **Chen Q**, **Lyu Q**, **Ai A**, **Fu Y**, **Shoham Z**, Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles, Fertil Steril 101:105, 2014.
496. **Boots CE**, **Meister M**, **Cooper AR**, **Hardi A**, **Jungheim ES**, Ovarian stimulation in the luteal phase: systematic review and meta-analysis, J Assist Reprod Genet 33:971, 2016.
497. **Liu C**, **Jiang H**, **Zhang W**, **Yin H**, Double ovarian stimulation during the follicular and luteal phase in women ≥38 years: a retrospective case-control study, Reprod Biomed Online 35:678, 2017.
498. **Ubaldi FM**, **Capalbo A**, **Vaiarelli A**, **Cimadomo D**, **Colamaria S**, **Alviggi C**, **Trabucco E**, **Venturella R**, **Vajta G**, **Rienzi L**, Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation, Fertil Steril 105:1488.e1, 2016.
499. **Chen H**, **Wang Y**, **Lyu Q**, **Ai A**, **Fu Y**, **Tian H**, **Cai R**, **Hong Q**, **Chen Q**, **Shoham Z**, **Kuang Y**, Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles, Fertil Steril 103:1194.e2, 2015.
500. **Dimitry ES**, **Oskarsson T**, **Conaghan J**, **Margara R**, **Winston RM**, Beneficial effects of a 24 h delay in human chorionic gonadotrophin administration during in-vitro fertilization treatment cycles, Hum Reprod 6:944, 1991.
501. **Tan SL**, **Balen A**, **el Hussein E**, **Mills C**, **Campbell S**, **Yovich J**, **Jacobs HS**, A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization, Fertil Steril 57:1259, 1992.
502. **Jamieson ME**, **Fleming R**, **Kader S**, **Ross KS**, **Yates RW**, **Coutts JR**, In vivo and in vitro maturation of human oocytes: effects on embryo development and polyspermic fertilization, Fertil Steril 56:93, 1991.
503. **Tarlatzis BC**, Oocyte collection and quality, Assist Reprod Rev 2:16, 1992.
504. **Mansour RT**, **Aboulghar MA**, **Serour GI**, Study of the optimum time for human chorionic gonadotropin-ovum pickup interval in in vitro fertilization, J Assist Reprod Genet 11:478, 1994.
505. **Kwan I**, **Bhattacharya S**, **Knox F**, **McNeil A**, Conscious sedation and analgesia for oocyte retrieval during in vitro fertilisation procedures, Cochrane Database Syst Rev (3):CD004829, 2005.
506. **Dicker D**, **Ashkenazi J**, **Feldberg D**, **Levy T**, **Dekel A**, **Ben-Rafael Z**, Severe abdominal complications after transvaginal ultrasonographically guided retrieval of oocytes for in vitro fertilization and embryo transfer, Fertil Steril 59:1313, 1993.
507. **Bennett SJ**, **Waterstone JJ**, **Cheng WC**, **Parsons J**, Complications of transvaginal ultrasound-directed follicle aspiration: a review of 2670 consecutive procedures, J Assist Reprod Genet 10:72, 1993.

508. **van Os HC**, **Roozenburg BJ**, **Janssen-Caspers HA**, **Leerentveld RA**, **Scholtes MC**, **Zeilmaker GH**, **Alberda AT**, Vaginal disinfection with povidon iodine and the outcome of in-vitro fertilization, Hum Reprod 7:349, 1992.
509. **Waterstone JJ**, **Parsons JH**, A prospective study to investigate the value of flushing follicles during transvaginal ultrasound-directed follicle aspiration, Fertil Steril 57:221, 1992.
510. **Levy G**, **Hill MJ**, **Ramirez CI**, **Correa L**, **Ryan ME**, **DeCherney AH**, **Levens ED**, **Whitcomb BW**, The use of follicle flushing during oocyte retrieval in assisted reproductive technologies: a systematic review and meta-analysis, Hum Reprod 27:2373, 2012.
511. **Georgiou EX**, **Melo P**, **Brown J**, **Granne IE**, Follicular flushing during oocyte retrieval in assisted reproductive techniques, Cochrane Database Syst Rev (4):CD004634, 2018.
512. **Tan SL**, **Waterstone J**, **Wren M**, **Parsons J**, A prospective randomized study comparing aspiration only with aspiration and flushing for transvaginal ultrasound-directed oocyte recovery, Fertil Steril 58:356, 1992.
513. **Haydardedeoglu B**, **Gjemalaj F**, **Aytac PC**, **Kilicdag EB**, Direct aspiration versus follicular flushing in poor responders undergoing intracytoplasmic sperm injection: a randomised controlled trial, BJOG 124:1190, 2017.
514. **Wisanto A**, **Bollen N**, **Camus M**, **De Grauwe E**, **Devroey P**, **Van Steirteghem AC**, Effect of transuterine puncture during transvaginal oocyte retrieval on the results of human in-vitro fertilization, Hum Reprod 4:790, 1989.
515. **Ben-Shlomo I**, **Schiff E**, **Levran D**, **Ben-Rafael Z**, **Mashiach S**, **Dor J**, Failure of oocyte retrieval during in vitro fertilization: a sporadic event rather than a syndrome, Fertil Steril 55:324, 1991.
516. **Quintans CJ**, **Donaldson MJ**, **Blanco LA**, **Pasqualini RS**, Empty follicle syndrome due to human errors: its occurrence in an in-vitro fertilization programme, Hum Reprod 13:2703, 1998.
517. **Aktas M**, **Beckers NG**, **van Inzen WG**, **Verhoeff A**, **de Jong D**, Oocytes in the empty follicle: a controversial syndrome, Fertil Steril 84:1643, 2005.
518. **Khalaf Y**, **Braude P**, "Curing" empty follicle syndrome, Hum Reprod 12:1601, 1997.
519. **Zegers-Hochschild F**, **Fernandez E**, **Mackenna A**, **Fabres C**, **Altieri E**, **Lopez T**, The empty follicle syndrome: a pharmaceutical industry syndrome, Hum Reprod 10:2262, 1995.
520. **Ndukwe G**, **Thornton S**, **Fishel S**, **Dowell K**, **al-Hassan S**, **Hunter A**, Predicting empty follicle syndrome, Fertil Steril 66:845, 1996.
521. **Uygur D**, **Alkan RN**, **Batuoglu S**, Recurrent empty follicle syndrome, J Assist Reprod Genet 20:390, 2003.
522. **Castillo JC**, **Garcia-Velasco J**, **Humaidan P**, Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS, J Assist Reprod Genet 29:249, 2012.
523. **Kasapoglu I**, **Turk P**, **Dayan A**, **Uncu G**, Does the presence of endometriosis cause a challenge for transvaginal oocyte retrieval procedure? A comparison between patients with endometriosis and without endometriosis, J Turk Ger Gynecol Assoc 19:151, 2018.
524. **Tureck RW**, **Garcia CR**, **Blasco L**, **Mastroianni L Jr**, Perioperative complications arising after transvaginal oocyte retrieval, Obstet Gynecol 81:590, 1993.
525. **Yaron Y**, **Peyser MR**, **Samuel D**, **Amit A**, **Lessing JB**, Infected endometriotic cysts secondary to oocyte aspiration for in-vitro fertilization, Hum Reprod 9:1759, 1994.
526. **Levi-Setti PE**, **Cirillo F**, **Scolaro V**, **Morenghi E**, **Heilbron F**, **Girardello D**, **Zannoni E**, **Patrizio P**, Appraisal of clinical complications after 23,827 oocyte retrievals in a large assisted reproductive technology program, Fertil Steril 109:1038.e1, 2018.
527. **Coccia ME**, **Becattini C**, **Bracco GL**, **Scarselli G**, Acute abdomen following dermoid cyst rupture during transvaginal ultrasonographically guided retrieval of oocytes, Hum Reprod 11:1897, 1996.
528. **Azem F**, **Wolf Y**, **Botchan A**, **Amit A**, **Lessing JB**, **Kluger Y**, Massive retroperitoneal bleeding: a complication of transvaginal ultrasonography-guided oocyte retrieval for in vitro fertilization-embryo transfer, Fertil Steril 74:405, 2000.
529. **Almog B**, **Rimon E**, **Yovel I**, **Bar-Am A**, **Amit A**, **Azem F**, Vertebral osteomyelitis: a rare complication of transvaginal ultrasound-guided oocyte retrieval, Fertil Steril 73:1250, 2000.
530. **El-Shawarby S**, **Margara R**, **Trew G**, **Lavery S**, A review of complications following transvaginal oocyte retrieval for in-vitro fertilization, Hum Fertil (Camb) 7:127, 2004.

531. **Mehri S**, **Levi Setti PE**, **Greco K**, **Sakkas D**, **Martinez G**, **Patrizio P**, Correlation between follicular diameters and flushing versus no flushing on oocyte maturity, fertilization rate and embryo quality, J Assist Reprod Genet 31:73, 2014.
532. **Rosen MP**, **Shen S**, **Dobson AT**, **Rinaudo PF**, **McCulloch CE**, **Cedars MI**, A quantitative assessment of follicle size on oocyte developmental competence, Fertil Steril 90:684, 2008.
533. **Gilchrist RB**, **Nayudu PL**, **Nowshari MA**, **Hodges JK**, Meiotic competence of marmoset monkey oocytes is related to follicle size and oocyte-somatic cell associations, Biol Reprod 52:1234, 1995.
534. **Veeck LL**, Oocyte assessment and biological performance, Ann N Y Acad Sci 541:259, 1988.
535. **Lin YC**, **Chang SY**, **Lan KC**, **Huang HW**, **Chang CY**, **Tsai MY**, **Kung FT**, **Huang FJ**, Human oocyte maturity in vivo determines the outcome of blastocyst development in vitro, J Assist Reprod Genet 20:506, 2003.
536. **Moor RM**, **Dai Y**, **Lee C**, **Fulka J Jr**, Oocyte maturation and embryonic failure, Hum Reprod Update 4:223, 1998.
537. **Borghol N**, **Lornage J**, **Blachere T**, **Sophie Garret A**, **Lefevre A**, Epigenetic status of the H19 locus in human oocytes following in vitro maturation, Genomics 87:417, 2006.
538. **Bromfield J**, **Messamore W**, **Albertini DF**, Epigenetic regulation during mammalian oogenesis, Reprod Fertil Dev 20:74, 2008.
539. **Dahan MH**, **Tan SL**, **Chung J**, **Son WY**, Clinical definition paper on in vitro maturation of human oocytes, Hum Reprod 31:1383, 2016.
540. **Cha KY**, **Koo JJ**, **Ko JJ**, **Choi DH**, **Han SY**, **Yoon TK**, Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program, Fertil Steril 55:109, 1991.
541. **Baker SJ**, **Spears N**, The role of intra-ovarian interactions in the regulation of follicle dominance, Hum Reprod Update 5:153, 1999.
542. **Trounson A**, **Anderiesz C**, **Jones G**, Maturation of human oocytes in vitro and their developmental competence, Reproduction 121:51, 2001.
543. **Child TJ**, **Abdul-Jalil AK**, **Gulekli B**, **Tan SL**, In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome, Fertil Steril 76:936, 2001.
544. **Soderstrom-Anttila V**, **Makinen S**, **Tuuri T**, **Suikkari AM**, Favourable pregnancy results with insemination of in vitro matured oocytes from unstimulated patients, Hum Reprod 20:1534, 2005.
545. **Mikkelsen AL**, **Andersson AM**, **Skakkebaek NE**, **Lindenberg S**, Basal concentrations of oestradiol may predict the outcome of in-vitro maturation in regularly menstruating women, Hum Reprod 16:862, 2001.
546. **Mikkelsen AL**, **Smith S**, **Lindenberg S**, Impact of oestradiol and inhibin A concentrations on pregnancy rate in in-vitro oocyte maturation, Hum Reprod 15:1685, 2000.
547. **Mikkelsen AL**, **Smith SD**, **Lindenberg S**, In-vitro maturation of human oocytes from regularly menstruating women may be successful without follicle stimulating hormone priming, Hum Reprod 14:1847, 1999.
548. **Cha KY**, **Han SY**, **Chung HM**, **Choi DH**, **Lim JM**, **Lee WS**, **Ko JJ**, **Yoon TK**, Pregnancies and deliveries after in vitro maturation culture followed by in vitro fertilization and embryo transfer without stimulation in women with polycystic ovary syndrome, Fertil Steril 73:978, 2000.
549. **Siristatidis C**, **Sergentanis TN**, **Vogiatzi P**, **Kanavidis P**, **Chrelias C**, **Papantoniou N**, **Psaltopoulou T**, In vitro maturation in women with vs. without polycystic ovarian syndrome: a systematic review and meta-analysis, PLoS One 10:e0134696, 2015.
550. **Cha KY**, **Chung HM**, **Lee DR**, **Kwon H**, **Chung MK**, **Park LS**, **Choi DH**, **Yoon TK**, Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer, Fertil Steril 83: 1461, 2005.
551. **Chian RC**, **Buckett WM**, **Tulandi T**, **Tan SL**, Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome, Hum Reprod 15:165, 2000.
552. **Child TJ**, **Phillips SJ**, **Abdul-Jalil AK**, **Gulekli B**, **Tan SL**, A comparison of in vitro maturation and in vitro

fertilization for women with polycystic ovaries, Obstet Gynecol 100:665, 2002.
553. **Le Du A**, **Kadoch IJ**, **Bourcigaux N**, **Doumerc S**, **Bourrier MC**, **Chevalier N**, **Fanchin R**, **Chian RC**, **Tachdjian G**, **Frydman R**, **Frydman N**, In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience, Hum Reprod 20:420, 2005.
554. **Lin YH**, **Hwang JL**, **Huang LW**, **Mu SC**, **Seow KM**, **Chung J**, **Hsieh BC**, **Huang SC**, **Chen CY**, **Chen PH**, Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes, Hum Reprod 18:1632, 2003.
555. **Mikkelsen AL**, **Lindenberg S**, Benefit of FSH priming of women with PCOS to the in vitro maturation procedure and the outcome: a randomized prospective study, Reproduction 122:587, 2001.
556. **Fadini R**, **Dal Canto MB**, **Mignini Renzini M**, **Brambillasca F**, **Comi R**, **Fumagalli D**, **Lain M**, **Merola M**, **Milani R**, **De Ponti E**, Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study, Reprod Biomed Online 19:343, 2009.
557. **Reavey J**, **Vincent K**, **Child T**, **Granne IE**, Human chorionic gonadotrophin priming for fertility treatment with in vitro maturation, Cochrane Database Syst Rev (11):CD008720, 2016.
558. **Yoon HG**, **Yoon SH**, **Son WY**, **Lee SW**, **Park SP**, **Im KS**, **Lim JH**, Pregnancies resulting from in vitro matured oocytes collected from women with regular menstrual cycle, J Assist Reprod Genet 18:325, 2001.
559. **Cobo AC**, **Requena A**, **Neuspiller F**, **Aragon s M**, **Mercader A**, **Navarro J**, **Simon C**, **Remohi J**, **Pellicer A**, Maturation in vitro of human oocytes from unstimulated cycles: selection of the optimal day for ovum retrieval based on follicular size, Hum Reprod 14:1864, 1999.
560. **Jurema MW**, **Nogueira D**, In vitro maturation of human oocytes for assisted reproduction, Fertil Steril 86:1277, 2006.
561. **Wynn P**, **Picton HM**, **Krapez JA**, **Rutherford AJ**, **Balen AH**, **Gosden RG**, Pretreatment with follicle stimulating hormone promotes the numbers of human oocytes reaching metaphase II by in-vitro maturation, Hum Reprod 13:3132, 1998.
562. **Hashimoto S**, **Fukuda A**, **Murata Y**, **Kikkawa M**, **Oku H**, **Kanaya H**, **Sonoda M**, **Sugihara K**, **Murata T**, **Nagata F**, **Nakaoaka Y**, **Morimoto Y**, Effect of aspiration vacuum on the developmental competence of immature human oocytes retrieved using a 20-gauge needle, Reprod Biomed Online 14:444, 2007.
563. **Walls M**, **Junk S**, **Ryan JP**, **Hart R**, IVF versus ICSI for the fertilization of in-vitro matured human oocytes, Reprod Biomed Online 25:603, 2012.
564. **Centers for Disease Control and Prevention**, 2015 Assisted Reproductive Technology Success Rates. National Summary and Fertility Clinic Reports, Centers for Disease Control and Prevention, Atlanta, 2017.
565. **Zhang XY**, **Ata B**, **Son WY**, **Buckett WM**, **Tan SL**, **Ao A**, Chromosome abnormality rates in human embryos obtained from in-vitro maturation and IVF treatment cycles, Reprod Biomed Online 21:552, 2010.
566. **Spits C**, **Guzman L**, **Mertzanidou A**, **Jacobs K**, **Ortega-Hrepich C**, **Gilchrist RB**, **Thompson JG**, **De Vos M**, **Smitz J**, **Sermon K**, Chromosome constitution of human embryos generated after in vitro maturation including 3-isobutyl-1-methylxanthine in the oocyte collection medium, Hum Reprod 30:653, 2015.
567. **Walls ML**, **Hunter T**, **Ryan JP**, **Keelan JA**, **Nathan E**, **Hart RJ**, In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes, Hum Reprod 30:88, 2015.
568. **Chian RC**, **Xu CL**, **Huang JY**, **Ata B**, Obstetric outcomes and congenital abnormalities in infants conceived with oocytes matured in vitro, Facts Views Vis Obgyn 6:15, 2014.
569. **Son WY**, **Tan SL**, Laboratory and embryological aspects of hCG-primed in vitro maturation cycles for patients with polycystic ovaries, Hum Reprod Update 16:675, 2010.
570. **Prakash P**, **Leykin L**, **Chen Z**, **Toth T**, **Sayegh R**, **Schiff I**, **Isaacson K**, Preparation by differential gradient centrifugation is better than swim-up in selecting sperm with normal morphology (strict criteria), Fertil Steril 69:722, 1998.
571. **Lim CC**, **Lewis SE**, **Kennedy M**, **Donnelly ET**, **Thompson W**, Human sperm morphology and in vitro fertilization: sperm tail defects are prognostic for fertilization failure, Andrologia 30:43, 1998.
572. **Sapienza F**, **Verheyen G**, **Tournaye H**, **Janssens R**, **Pletincx I**, **Derde M**, **Van Steirteghem A**, An auto-controlled study in in-vitro fertilization reveals the benefit of Percoll centrifugation to swim-up in the preparation

of poor-quality semen, Hum Reprod 8:1856, 1993.
573. **Van der Zwalmen P**, **Bertin-Segal G**, **Geerts L**, **Debauche C**, **Schoysman R**, Sperm morphology and IVF pregnancy rate: comparison between Percoll gradient centrifugation and swim-up procedures, Hum Reprod 6:581, 1991.
574. **Yamanaka M**, **Tomita K**, **Hashimoto S**, **Matsumoto H**, **Satoh M**, **Kato H**, **Hosoi Y**, **Inoue M**, **Nakaoka Y**, **Morimoto Y**, Combination of density gradient centrifugation and swim-up methods effectively decreases morphologically abnormal sperms, J Reprod Dev 62:599, 2016.
575. **Quinn MM**, **Jalalian L**, **Ribeiro S**, **Ona K**, **Demirci U**, **Cedars MI**, **Rosen MP**, Microfluidic sorting selects sperm for clinical use with reduced DNA damage compared to density gradient centrifugation with swim-up in split semen samples, Hum Reprod, 2018 Jul 10. doi: 10.1093/humrep/dey239.
576. **Shirota K**, **Yotsumoto F**, **Itoh H**, **Obama H**, **Hidaka N**, **Nakajima K**, **Miyamoto S**, Separation efficiency of a microfluidic sperm sorter to minimize sperm DNA damage, Fertil Steril 105:315.e1, 2016.
577. **Rappa KL**, **Rodriguez HF**, **Hakkarainen GC**, **Anchan RM**, **Mutter GL**, **Asghar W**, Sperm processing for advanced reproductive technologies: where are we today? Biotechnol Adv 34:578, 2016.
578. **Van Blerkom J**, **Henry G**, **Porreco R**, Preimplantation human embryonic development from polypronuclear eggs after in vitro fertilization, Fertil Steril 41:686, 1984.
579. **van der Ven HH**, **Al-Hasani S**, **Diedrich K**, **Hamerich U**, **Lehmann F**, **Krebs D**, Polyspermy in in vitro fertilization of human oocytes: frequency and possible causes, Ann N Y Acad Sci 442:88, 1985.
580. **McFadden DE**, **Langlois S**, Parental and meiotic origin of triploidy in the embryonic and fetal periods, Clin Genet 58:192, 2000.
581. **McFadden DE**, **Pantzar JT**, Placental pathology of triploidy, Hum Pathol 27:1018, 1996.
582. **Society for Assisted Reproductive Technology; American Society for Reproductive Medicine**, Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry, Fertil Steril 87: 1253, 2007.
583. **Bhattacharya S**, **Hamilton MP**, **Shaaban M**, **Khalaf Y**, **Seddler M**, **Ghobara T**, **Braude P**, **Kennedy R**, **Rutherford A**, **Hartshorne G**, **Templeton A**, Conventional in-vitro fertilisation versus intracytoplasmic sperm injection for the treatment of non-male-factor infertility: a randomised controlled trial, Lancet 357:2075, 2001.
584. **van Rumste MM**, **Evers JL**, **Farquhar CM**, Intra-cytoplasmic sperm injection versus conventional techniques for oocyte insemination during in vitro fertilisation in patients with non-male subfertility, Cochrane Database Syst Rev (2):CD001301, 2003.
585. **Jow WW**, **Steckel J**, **Schlegel PN**, **Magid MS**, **Goldstein M**, Motile sperm in human testis biopsy specimens, J Androl 14:194, 1993.
586. **Silber SJ**, **Nagy Z**, **Devroey P**, **Tournaye H**, **Van Steirteghem AC**, Distribution of spermatogenesis in the testicles of azoospermic men: the presence or absence of spermatids in the testes of men with germinal failure, Hum Reprod 12:2422, 1997.
587. **Practice Committee of American Society for Reproductive Medicine; Practice Committee of Society for Assisted Reproductive Technology**, Round spermatid nucleus injection (ROSNI), Fertil Steril 90:S199, 2008.
588. **Anguiano A**, **Oates RD**, **Amos JA**, **Dean M**, **Gerrard B**, **Stewart C**, **Maher TA**, **White MB**, **Milunsky A**, Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis, JAMA 267:1794, 1992.
589. **Oates RD**, **Amos JA**, The genetic basis of congenital bilateral absence of the vas deferens and cystic fibrosis, J Androl 15:1, 1994.
590. **Male Infertility Best Practice Policy Committee of the American Urological Association; Practice Committee of the American Society for Reproductive Medicine**, Report on optimal evaluation of the infertile male, Fertil Steril 86:S202, 2006.
591. **Hershlag A**, **Schiff SF**, **DeCherney AH**, Retrograde ejaculation, Hum Reprod 6:255, 1991.
592. **Yavetz H**, **Yogev L**, **Hauser R**, **Lessing JB**, **Paz G**, **Homonnai ZT**, Retrograde ejaculation, Hum Reprod 9:381, 1994.

593. **Gerig NE**, **Meacham RB**, **Ohl DA**, Use of electroejaculation in the treatment of ejaculatory failure secondary to diabetes mellitus, Urology 49:239, 1997.
594. **Ohl DA**, **Sonksen J**, **Menge AC**, **McCabe M**, **Keller LM**, Electroejaculation versus vibratory stimulation in spinal cord injured men: sperm quality and patient preference, J Urol 157:2147, 1997.
595. **Matthews GJ**, **Goldstein M**, A simplified method of epididymal sperm aspiration, Urology 47:123, 1996.
596. **Nudell DM**, **Conaghan J**, **Pedersen RA**, **Givens CR**, **Schriock ED**, **Turek PJ**, The mini-micro-epididymal sperm aspiration for sperm retrieval: a study of urological outcomes, Hum Reprod 13:1260, 1998.
597. **Janzen N**, **Goldstein M**, **Schlegel PN**, **Palermo GD**, **Rosenwaks Z**, **Hariprashad J**, Use of electively cryopreserved microsurgically aspirated epididymal sperm with IVF and intracytoplasmic sperm injection for obstructive azoospermia, Fertil Steril 74:696, 2000.
598. **Shrivastav P**, **Nadkarni P**, **Wensvoort S**, **Craft I**, Percutaneous epididymal sperm aspiration for obstructive azoospermia, Hum Reprod 9:2058, 1994.
599. **Craft IL**, **Khalifa Y**, **Boulos A**, **Pelekanos M**, **Foster C**, **Tsirigotis M**, Factors influencing the outcome of in-vitro fertilization with percutaneous aspirated epididymal spermatozoa and intracytoplasmic sperm injection in azoospermic men, Hum Reprod 10:1791, 1995.
600. **Craft I**, **Tsirigotis M**, Simplified recovery, preparation and cryopreservation of testicular spermatozoa, Hum Reprod 10:1623, 1995.
601. **Friedler S**, **Raziel A**, **Strassburger D**, **Soffer Y**, **Komarovsky D**, **Ron-El R**, Testicular sperm retrieval by percutaneous fine needle sperm aspiration compared with testicular sperm extraction by open biopsy in men with non-obstructive azoospermia, Hum Reprod 12:1488, 1997.
602. **Schlegel PN**, Testicular sperm extraction: microdissection improves sperm yield with minimal tissue excision, Hum Reprod 14:131, 1999.
603. **Dardashti K**, **Williams RH**, **Goldstein M**, Microsurgical testis biopsy: a novel technique for retrieval of testicular tissue, J Urol 163:1206, 2000.
604. **Su LM**, **Palermo GD**, **Goldstein M**, **Veeck LL**, **Rosenwaks Z**, **Schlegel PN**, Testicular sperm extraction with intracytoplasmic sperm injection for nonobstructive azoospermia: testicular histology can predict success of sperm retrieval, J Urol 161:112, 1999.
605. **Chan PT**, **Palermo GD**, **Veeck LL**, **Rosenwaks Z**, **Schlegel PN**, Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy, Cancer 92:1632, 2001.
606. **Palermo GD**, **Schlegel PN**, **Sills ES**, **Veeck LL**, **Zaninovic N**, **Menendez S**, **Rosenwaks Z**, Births after intracytoplasmic injection of sperm obtained by testicular extraction from men with nonmosaic Klinefelter's syndrome, N Engl J Med 338:588, 1998.
607. **Ron-El R**, **Strassburger D**, **Friedler S**, **Komarovski D**, **Bern O**, **Soffer Y**, **Raziel A**, Extended sperm preparation: an alternative to testicular sperm extraction in non-obstructive azoospermia, Hum Reprod 12:1222, 1997.
608. **Schlegel PN**, **Su LM**, Physiological consequences of testicular sperm extraction, Hum Reprod 12:1688, 1997.
609. **Ostad M**, **Liotta D**, **Ye Z**, **Schlegel PN**, Testicular sperm extraction for nonobstructive azoospermia: results of a multibiopsy approach with optimized tissue dispersion, Urology 52:692, 1998.
610. **Friedler S**, **Raziel A**, **Schachter M**, **Strassburger D**, **Bern O**, **Ron-El R**, Outcome of first and repeated testicular sperm extraction and ICSI in patients with non-obstructive azoospermia, Hum Reprod 17:2356, 2002.
611. **Podsiadly BT**, **Woolcott RJ**, **Stanger JD**, **Stevenson K**, Pregnancy resulting from intracytoplasmic injection of cryopreserved spermatozoa recovered from testicular biopsy, Hum Reprod 11:1306, 1996.
612. **Gil-Salom M**, **Romero J**, **Minguez Y**, **Rubio C**, **De los Santos MJ**, **Remohi J**, **Pellicer A**, Pregnancies after intracytoplasmic sperm injection with cryopreserved testicular spermatozoa, Hum Reprod 11:1309, 1996.
613. **Friedler S**, **Raziel A**, **Strassburger D**, **Schachter M**, **Soffer Y**, **Ron-El R**, Factors influencing the outcome of ICSI in patients with obstructive and non-obstructive azoospermia: a comparative study, Hum Reprod 17:3114, 2002.
614. **Levran D**, **Bider D**, **Yonesh M**, **Yemini Z**, **Seidman DS**, **Mashiach S**, **Dor J**, A randomized study of intracytoplasmic sperm injection (ICSI) versus subzonal insemination (SUZI) for the management of severe

male-factor infertility, J Assist Reprod Genet 12:319, 1995.
615. **Tarlatzis BC**, **Bili H**, Intracytoplasmic sperm injection. Survey of world results, Ann N Y Acad Sci 900:336, 2000.
616. **Gordon JW**, **Grunfeld L**, **Garrisi GJ**, **Talansky BE**, **Richards C**, **Laufer N**, Fertilization of human oocytes by sperm from infertile males after zona pellucida drilling, Fertil Steril 50:68, 1988.
617. **Strohmer H**, **Feichtinger W**, Successful clinical application of laser for micromanipulation in an in vitro fertilization program, Fertil Steril 58:212, 1992.
618. **Malter HE**, **Cohen J**, Partial zona dissection of the human oocyte: a nontraumatic method using micromanipulation to assist zona pellucida penetration, Fertil Steril 51:139, 1989.
619. **Fishel S**, **Antinori S**, **Jackson P**, **Johnson J**, **Rinaldi L**, Presentation of six pregnancies established by sub-zonal insemination (SUZI), Hum Reprod 6:124, 1991.
620. **Palermo G**, **Joris H**, **Devroey P**, **Van Steirteghem AC**, Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte, Lancet 340:17, 1992.
621. **Tesarik J**, **Sousa M**, **Testart J**, Human oocyte activation after intracytoplasmic sperm injection, Hum Reprod 9:511, 1994.
622. **Tesarik J**, **Sousa M**, Key elements of a highly efficient intracytoplasmic sperm injection technique: Ca2+ fluxes and oocyte cytoplasmic dislocation, Fertil Steril 64:770, 1995.
623. **Gearon CM**, **Taylor AS**, **Forman RG**, Factors affecting activation and fertilization of human oocytes following intracytoplasmic injection, Hum Reprod 10:896, 1995.
624. **Gerris J**, **Mangelschots K**, **Van Royen E**, **Joostens M**, **Eestermans W**, **Ryckaert G**, ICSI and severe male-factor infertility: breaking the sperm tail prior to injection, Hum Reprod 10:484, 1995.
625. **Dozortsev D**, **Rybouchkin A**, **De Sutter P**, **Dhont M**, Sperm plasma membrane damage prior to intracytoplasmic sperm injection: a necessary condition for sperm nucleus decondensation, Hum Reprod 10:2960, 1995.
626. **Hewitson L**, **Dominko T**, **Takahashi D**, **Martinovich C**, **Ramalho-Santos J**, **Sutovsky P**, **Fanton J**, **Jacob D**, **Monteith D**, **Neuringer M**, **Battaglia D**, **Simerly C**, **Schatten G**, Unique checkpoints during the first cell cycle of fertilization after intracytoplasmic sperm injection in rhesus monkeys, Nat Med 5:431, 1999.
627. **Hardarson T**, **Lundin K**, **Hamberger L**, The position of the metaphase II spindle cannot be predicted by the location of the first polar body in the human oocyte, Hum Reprod 15:1372, 2000.
628. **Wang WH**, **Meng L**, **Hackett RJ**, **Odenbourg R**, **Keefe DL**, The spindle observation and its relationship with fertilization after intracytoplasmic sperm injection in living human oocytes, Fertil Steril 75:348, 2001.
629. **Hershlag A**, **Paine T**, **Kvapil G**, **Feng H**, **Napolitano B**, In vitro fertilization-intracytoplasmic sperm injection split: an insemination method to prevent fertilization failure, Fertil Steril 77:229, 2002.
630. **Jaroudi K**, **Al-Hassan S**, **Al-Sufayan H**, **Al-Mayman H**, **Qeba M**, **Coskun S**, Intracytoplasmic sperm injection and conventional in vitro fertilization are complementary techniques in management of unexplained infertility, J Assist Reprod Genet 20:377, 2003.
631. **Barnes FL**, **Crombie A**, **Gardner DK**, **Kausche A**, **Lacham-Kaplan O**, **Suikkari AM**, **Tiglias J**, **Wood C**, **Trounson AO**, Blastocyst development and birth after in-vitro maturation of human primary oocytes, intracytoplasmic sperm injection and assisted hatching, Hum Reprod 10:3243, 1995.
632. **Nagy ZP**, **Cecile J**, **Liu J**, **Loccufier A**, **Devroey P**, **Van Steirteghem A**, Pregnancy and birth after intracytoplasmic sperm injection of in vitro matured germinal-vesicle stage oocytes: case report, Fertil Steril 65:1047, 1996.
633. **Chian RC**, **Gulekli B**, **Buckett WM**, **Tan SL**, Priming with human chorionic gonadotropin before retrieval of immature oocytes in women with infertility due to the polycystic ovary syndrome, N Engl J Med 341:1624, 1626, 1999.
634. **Tucker MJ**, **Wright G**, **Morton PC**, **Massey JB**, Birth after cryopreservation of immature oocytes with subsequent in vitro maturation, Fertil Steril 70:578, 1998.
635. **Kuleshova L**, **Gianaroli L**, **Magli C**, **Ferraretti A**, **Trounson A**, Birth following vitrification of a small number of human oocytes: case report, Hum Reprod 14:3077, 1999.
636. **Schroeder AC**, **Schultz RM**, **Kopf GS**, **Taylor FR**, **Becker RB**, **Eppig JJ**, Fetuin inhibits zona pellucida

hardening and conversion of ZP2 to ZP2f during spontaneous mouse oocyte maturation in vitro in the absence of serum, Biol Reprod 43:891, 1990.
637. **Zhang X**, **Rutledge J**, **Armstrong DT**, Studies on zona hardening in rat oocytes that are matured in vitro in a serum-free medium, Mol Reprod Dev 28:292, 1991.
638. **Vincent C**, **Pickering SJ**, **Johnson MH**, The hardening effect of dimethylsulphoxide on the mouse zona pellucida requires the presence of an oocyte and is associated with a reduction in the number of cortical granules present, J Reprod Fertil 89:253, 1990.
639. **Manna C**, **Rienzi L**, **Greco E**, **Sbracia M**, **Rahman A**, **Poverini R**, **Siracusa G**, **De Felici M**, Zona pellucida solubility and cortical granule complements in human oocytes following assisted reproductive techniques, Zygote 9:201, 2001.
640. **Mahadevan MM**, Optimization of culture conditions for human in vitro fertilization and embryo transfer, Semin Reprod Endocrinol 16:197, 1998.
641. **Gardner DK**, **Lane M**, Embryo culture, In: Gardner DK, Weissman A, Howles CM, Shoham Z, eds. Textbook of Assisted Reproductive Techniques: Laboratory and Clinical Perspectives, Martin Dunitz, London, 2001.
642. **Boiso I**, **Veiga A**, **Edwards RG**, Fundamentals of human embryonic growth in vitro and the selection of high-quality embryos for transfer, Reprod Biomed Online 5:328, 2002.
643. **Gardner DK**, **Pool TB**, **Lane M**, Embryo nutrition and energy metabolism and its relationship to embryo growth, differentiation, and viability, Semin Reprod Med 18:205, 2000.
644. **Gardner DK**, **Lane M**, **Calderon I**, **Leeton J**, Environment of the preimplantation human embryo in vivo: metabolite analysis of oviduct and uterine fluids and metabolism of cumulus cells, Fertil Steril 65:349, 1996.
645. **Gardner DK**, Changes in requirements and utilization of nutrients during mammalian preimplantation embryo development and their significance in embryo culture, Theriogenology 49:83, 1998.
646. **Sfontouris IA**, **Martins WP**, **Nastri CO**, **Viana IG**, **Navarro PA**, **Raine-Fenning N**, **van der Poel S**, **Rienzi L**, **Racowsky C**, Blastocyst culture using single versus sequential media in clinical IVF: a systematic review and meta-analysis of randomized controlled trials, J Assist Reprod Genet 33:1261, 2016.
647. **Hardarson T**, **Bungum M**, **Conaghan J**, **Meintjes M**, **Chantilis SJ**, **Molnar L**, **Gunnarsson K**, **Wikland M**, Noninferiority, randomized, controlled trial comparing embryo development using media developed for sequential or undisturbed culture in a time-lapse setup, Fertil Steril 104:1452.e1, 2015.
648. **Costa-Borges N**, **Belles M**, **Meseguer M**, **Galliano D**, **Ballesteros A**, **Calderon G**, Blastocyst development in single medium with or without renewal on day 3: a prospective cohort study on sibling donor oocytes in a time-lapse incubator, Fertil Steril 105:707, 2016.
649. **Cimadomo D**, **Scarica C**, **Maggiulli R**, **Orlando G**, **Soscia D**, **Albricci L**, **Romano S**, **Sanges F**, **Ubaldi FM**, **Rienzi L**, Continuous embryo culture elicits higher blastulation but similar cumulative delivery rates than sequential: a large prospective study, J Assist Reprod Genet 35:1329, 2018.
650. **Werner MD**, **Hong KH**, **Franasiak JM**, **Forman EJ**, **Reda CV**, **Molinaro TA**, **Upham KM**, **Scott RT Jr**, Sequential versus Monophasic Media Impact Trial (SuMMIT): a paired randomized controlled trial comparing a sequential media system to a monophasic medium, Fertil Steril 105:1215, 2016.
651. **Braude P**, **Bolton V**, **Moore S**, Human gene expression first occurs between the four- and eight-cell stages of preimplantation development, Nature 332:459, 1988.
652. **Taylor DM**, **Ray PF**, **Ao A**, **Winston RM**, **Handyside AH**, Paternal transcripts for glucose-6-phosphate dehydrogenase and adenosine deaminase are first detectable in the human preimplantation embryo at the three- to four-cell stage, Mol Reprod Dev 48:442, 1997.
653. **Janny L**, **Menezo YJ**, Evidence for a strong paternal effect on human preimplantation embryo development and blastocyst formation, Mol Reprod Dev 38:36, 1994.
654. **Miller JE**, **Smith TT**, The effect of intracytoplasmic sperm injection and semen parameters on blastocyst development in vitro, Hum Reprod 16:918, 2001.
655. **Edwards LJ**, **Williams DA**, **Gardner DK**, Intracellular pH of the mouse preimplantation embryo: amino acids act as buffers of intracellular pH, Hum Reprod 13:3441, 1998.
656. **Lane M**, Mechanisms for managing cellular and homeostatic stress in vitro, Theriogenology 55:225, 2001.

657. **Hammer MA**, **Kolajova M**, **Leveille M**, **Claman P**, **Baltz JM**, Glycine transport by single human and mouse embryos, Hum Reprod 15:419, 2000.
658. **Lane M**, **Gardner DK**, Amino acids and vitamins prevent culture-induced metabolic perturbations and associated loss of viability of mouse blastocysts, Hum Reprod 13:991, 1998.
659. **Pellicer A**, **Valbuena D**, **Cano F**, **Remohi J**, **Simon C**, Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period, Fertil Steril 65:1190, 1996.
660. **Simon C**, **Garcia Velasco JJ**, **Valbuena D**, **Peinado JA**, **Moreno C**, **Remohi J**, **Pellicer A**, Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen, Fertil Steril 70:234, 1998.
661. **Fanchin R**, **Righini C**, **Olivennes F**, **Taylor S**, **de Ziegler D**, **Frydman R**, Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization, Hum Reprod 13:1968, 1998.
662. **Fanchin R**, **Ayoubi JM**, **Righini C**, **Olivennes F**, **Schonauer LM**, **Frydman R**, Uterine contractility decreases at the time of blastocyst transfers, Hum Reprod 16:1115, 2001.
663. **Gardner DK**, **Lane M**, Culture of viable human blastocysts in defined sequential serum-free media, Hum Reprod 13(Suppl 3):148; discussion 160, 1998.
664. **Wilson M**, **Hartke K**, **Kiehl M**, **Rodgers J**, **Brabec C**, **Lyles R**, Integration of blastocyst transfer for all patients, Fertil Steril 77:693, 2002.
665. **Patton PE**, **Sadler-Fredd K**, **Burry KA**, **Gorrill MJ**, **Johnson A**, **Larson JM**, **Wolf DP**, Development and integration of an extended embryo culture program, Fertil Steril 72:418, 1999.
666. **Langley MT**, **Marek DM**, **Gardner DK**, **Doody KM**, **Doody KJ**, Extended embryo culture in human assisted reproduction treatments, Hum Reprod 16:902, 2001.
667. **Schoolcraft WB**, **Gardner DK**, Blastocyst culture and transfer increases the efficiency of oocyte donation, Fertil Steril 74:482, 2000.
668. **Glujovsky D**, **Farquhar C**, **Quinteiro Retamar AM**, **Alvarez Sedo CR**, **Blake D**, Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology, Cochrane Database Syst Rev (6):CD002118, 2016.
669. **Yang L**, **Cai S**, **Zhang S**, **Kong X**, **Gu Y**, **Lu C**, **Dai J**, **Gong F**, **Lu G**, **Lin G**, Single embryo transfer by Day 3 time-lapse selection versus Day 5 conventional morphological selection: a randomized, open-label, non-inferiority trial, Hum Reprod 33:869, 2018.
670. **Seli E**, **Robert C**, **Sirard MA**, OMICS in assisted reproduction: possibilities and pitfalls, Mol Hum Reprod 16:513, 2010.
671. **Schoolcraft WB**, **Fragouli E**, **Stevens J**, **Munne S**, **Katz-Jaffe MG**, **Wells D**, Clinical application of comprehensive chromosomal screening at the blastocyst stage, Fertil Steril 94:1700, 2010.
672. **Thomas MR**, **Sparks AE**, **Ryan GL**, **Van Voorhis BJ**, Clinical predictors of human blastocyst formation and pregnancy after extended embryo culture and transfer, Fertil Steril 94:543, 2010.
673. **Dessolle L**, **Freour T**, **Barriere P**, **Darai E**, **Ravel C**, **Jean M**, **Coutant C**, A cycle-based model to predict blastocyst transfer cancellation, Hum Reprod 25:598, 2010.
674. **Racowsky C**, **Jackson KV**, **Cekleniak NA**, **Fox JH**, **Hornstein MD**, **Ginsburg ES**, The number of eight-cell embryos is a key determinant for selecting day 3 or day 5 transfer, Fertil Steril 73:558, 2000.
675. **Neuber E**, **Rinaudo P**, **Trimarchi JR**, **Sakkas D**, Sequential assessment of individually cultured human embryos as an indicator of subsequent good quality blastocyst development, Hum Reprod 18:1307, 2003.
676. **Shoukir Y**, **Chardonnens D**, **Campana A**, **Bischof P**, **Sakkas D**, The rate of development and time of transfer play different roles in influencing the viability of human blastocysts, Hum Reprod 13:676, 1998.
677. **Gardner DK**, **Schoolcraft WB**, **Wagley L**, **Schlenker T**, **Stevens J**, **Hesla J**, A prospective randomized trial of blastocyst culture and transfer in in-vitro fertilization, Hum Reprod 13:3434, 1998.
678. **Armstrong S**, **Bhide P**, **Jordan V**, **Pacey A**, **Farquhar C**, Time-lapse systems for embryo incubation and assessment in assisted reproduction, Cochrane Database Syst Rev (5):CD011320, 2018.
679. **Goto K**, **Kumasako Y**, **Koike M**, **Kanda A**, **Kido K**, **Nagaki M**, **Otsu E**, **Kawabe F**, **Kai Y**, **Utsunomiya T**, Prediction of the in vitro developmental competence of early-cleavage-stage human embryos with time-lapse imaging and oxygen consumption rate measurement, Reprod Med Biol 17:289, 2018.

680. **Kirkegaard K**, **Kesmodel US**, **Hindkjaer JJ**, **Ingerslev HJ**, Time-lapse parameters as predictors of blastocyst development and pregnancy outcome in embryos from good prognosis patients: a prospective cohort study, Hum Reprod 28:2643, 2013.
681. **Milewski R**, **Kuc P**, **Kuczynska A**, **Stankiewicz B**, **Lukaszuk K**, **Kuczynski W**, A predictive model for blastocyst formation based on morphokinetic parameters in time-lapse monitoring of embryo development, J Assist Reprod Genet 32:571, 2015.
682. **Motato Y**, **de los Santos MJ**, **Escriba MJ**, **Ruiz BA**, **Remohi J**, **Meseguer M**, Morphokinetic analysis and embryonic prediction for blastocyst formation through an integrated time-lapse system, Fertil Steril 105:376.e9, 2016.
683. **Desai N**, **Goldberg JM**, **Austin C**, **Falcone T**, Are cleavage anomalies, multinucleation, or specific cell cycle kinetics observed with time-lapse imaging predictive of embryo developmental capacity or ploidy? Fertil Steril 109: 665, 2018.
684. **Reignier A**, **Lammers J**, **Barriere P**, **Freour T**, Can time-lapse parameters predict embryo ploidy? A systematic review, Reprod Biomed Online 36:380, 2018.
685. **Stillman RJ**, **Richter KS**, **Banks NK**, **Graham JR**, Elective single embryo transfer: a 6-year progressive implementation of 784 single blastocyst transfers and the influence of payment method on patient choice, Fertil Steril 92:1895, 2009.
686. **Mullin CM**, **Fino ME**, **Talebian S**, **Krey LC**, **Licciardi F**, **Grifo JA**, Comparison of pregnancy outcomes in elective single blastocyst transfer versus double blastocyst transfer stratified by age, Fertil Steril 93:1837, 2010.
687. **Gardner DK**, **Lane M**, **Stevens J**, **Schlenker T**, **Schoolcraft WB**, Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer, Fertil Steril 73:1155, 2000.
688. **Damario MA**, **Phy JL**, **Tummon IS**, Successful elective single blastocyst transfer in a patient with prior repetitive high-order multiple gestations, J Assist Reprod Genet 19:205, 2002.
689. **Gardner DK**, **Surrey E**, **Minjarez D**, **Leitz A**, **Stevens J**, **Schoolcraft WB**, Single blastocyst transfer: a prospective randomized trial, Fertil Steril 81:551, 2004.
690. **Vitthala S**, **Gelbaya TA**, **Brison DR**, **Fitzgerald CT**, **Nardo LG**, The risk of monozygotic twins after assisted reproductive technology: a systematic review and meta-analysis, Hum Reprod Update 15:45, 2009.
691. **Chang HJ**, **Lee JR**, **Jee BC**, **Suh CS**, **Kim SH**, Impact of blastocyst transfer on offspring sex ratio and the monozygotic twinning rate: a systematic review and meta-analysis, Fertil Steril 91:2381, 2009.
692. **Papanikolaou EG**, **Fatemi H**, **Venetis C**, **Donoso P**, **Kolibianakis E**, **Tournaye H**, **Tarlatzis B**, **Devroey P**, Monozygotic twinning is not increased after single blastocyst transfer compared with single cleavage-stage embryo transfer, Fertil Steril 93:592, 2010.
693. **Behr B**, **Fisch JD**, **Racowsky C**, **Miller K**, **Pool TB**, **Milki AA**, Blastocyst-ET and monozygotic twinning, J Assist Reprod Genet 17:349, 2000.
694. **da Costa AA**, **Abdelmassih S**, **de Oliveira FG**, **Abdelmassih V**, **Abdelmassih R**, **Nagy ZP**, **Balmaceda JP**, Monozygotic twins and transfer at the blastocyst stage after ICSI, Hum Reprod 16:333, 2001.
695. **Tarlatzis BC**, **Qublan HS**, **Sanopoulou T**, **Zepiridis L**, **Grimbizis G**, **Bontis J**, Increase in the monozygotic twinning rate after intracytoplasmic sperm injection and blastocyst stage embryo transfer, Fertil Steril 77:196, 2002.
696. **Weston G**, **Osianlis T**, **Catt J**, **Vollenhoven B**, Blastocyst transfer does not cause a sex-ratio imbalance, Fertil Steril 92:1302, 2009.
697. **Menezo YJ**, **Chouteau J**, **Torello J**, **Girard A**, **Veiga A**, Birth weight and sex ratio after transfer at the blastocyst stage in humans, Fertil Steril 72:221, 1999.
698. **Milki AA**, **Jun SH**, **Hinckley MD**, **Behr B**, **Giudice LC**, **Westphal LM**, Incidence of monozygotic twinning with blastocyst transfer compared to cleavage-stage transfer, Fertil Steril 79:503, 2003.
699. **Luna M**, **Duke M**, **Copperman A**, **Grunfeld L**, **Sandler B**, **Barritt J**, Blastocyst embryo transfer is associated with a sex-ratio imbalance in favor of male offspring, Fertil Steril 87:519, 2007.
700. **Kausche A**, **Jones GM**, **Trounson AO**, **Figueiredo F**, **MacLachlan V**, **Lolatgis N**, Sex ratio and birth weights of infants born as a result of blastocyst transfers compared with early cleavage stage embryo transfers, Fertil Steril 76:688, 2001.

701. **Alfarawati S**, **Fragouli E**, **Colls P**, **Stevens J**, **Gutierrez-Mateo C**, **Schoolcraft WB**, **Katz-Jaffe MG**, **Wells D**, The relationship between blastocyst morphology, chromosomal abnormality, and embryo gender, Fertil Steril 95:520, 2011.
702. **Mittwoch U**, Blastocysts prepare for the race to be male, Hum Reprod 8:1550, 1993.
703. **Alviggi C**, **Conforti A**, **Carbone IF**, **Borrelli R**, **de Placido G**, **Guerriero S**, Influence of cryopreservation on perinatal outcome after blastocyst- vs cleavage-stage embryo transfer: systematic review and meta-analysis, Ultrasound Obstet Gynecol 51:54, 2018.
704. **Cox GF**, **Burger J**, **Lip V**, **Mau UA**, **Sperling K**, **Wu BL**, **Horsthemke B**, Intracytoplasmic sperm injection may increase the risk of imprinting defects, Am J Hum Genet 71:162, 2002.
705. **DeBaun MR**, **Niemitz EL**, **Feinberg AP**, Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19, Am J Hum Genet 72:156, 2003.
706. **Gicquel C**, **Gaston V**, **Mandelbaum J**, **Siffroi JP**, **Flahault A**, **Le Bouc Y**, In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene, Am J Hum Genet 72:1338, 2003.
707. **Maher ER**, **Brueton LA**, **Bowdin SC**, **Luharia A**, **Cooper W**, **Cole TR**, **Macdonald F**, **Sampson JR**, **Barratt CL**, **Reik W**, **Hawkins MM**, Beckwith-Wiedemann syndrome and assisted reproduction technology (ART), J Med Genet 40:62, 2003.
708. **Moll AC**, **Imhof SM**, **Cruysberg JR**, **Schouten-van Meeteren AY**, **Boers M**, **van Leeuwen FE**, Incidence of retinoblastoma in children born after in-vitro fertilisation, Lancet 361:309, 2003.
709. **Lidegaard O**, **Pinborg A**, **Andersen AN**, Imprinting diseases and IVF: Danish National IVF cohort study, Hum Reprod 20:950, 2005.
710. **Santos F**, **Hyslop L**, **Stojkovic P**, **Leary C**, **Murdoch A**, **Reik W**, **Stojkovic M**, **Herbert M**, **Dean W**, Evaluation of epigenetic marks in human embryos derived from IVF and ICSI, Hum Reprod 25:2387, 2010.
711. **Watkins AJ**, **Fleming TP**, Blastocyst environment and its influence on offspring cardiovascular health: the heart of the matter, J Anat 215:52, 2009.
712. **Amor DJ**, **Halliday J**, A review of known imprinting syndromes and their association with assisted reproduction technologies, Hum Reprod 23:2826, 2008.
713. **Confino E**, **Rawlins R**, **Binor Z**, **Radwanska E**, The effect of the oviduct, uterine, and in vitro environments on zona thinning in the mouse embryo, Fertil Steril 68:164, 1997.
714. **Garside WT**, **Loret de Mola JR**, **Bucci JA**, **Tureck RW**, **Heyner S**, Sequential analysis of zona thickness during in vitro culture of human zygotes: correlation with embryo quality, age, and implantation, Mol Reprod Dev 47:99, 1997.
715. **Loret De Mola JR**, **Garside WT**, **Bucci J**, **Tureck RW**, **Heyner S**, Analysis of the human zona pellucida during culture: correlation with diagnosis and the preovulatory hormonal environment, J Assist Reprod Genet 14:332, 1997.
716. **Palmstierna M**, **Murkes D**, **Csemiczky G**, **Andersson O**, **Wramsby H**, Zona pellucida thickness variation and occurrence of visible mononucleated blastomers in preembryos are associated with a high pregnancy rate in IVF treatment, J Assist Reprod Genet 15:70, 1998.
717. **Gabrielsen A**, **Lindenberg S**, **Petersen K**, The impact of the zona pellucida thickness variation of human embryos on pregnancy outcome in relation to suboptimal embryo development. A prospective randomized controlled study, Hum Reprod 16:2166, 2001.
718. **Keltz MD**, **Skorupski JC**, **Bradley K**, **Stein D**, Predictors of embryo fragmentation and outcome after fragment removal in in vitro fertilization, Fertil Steril 86:321, 2006.
719. **Cohen J**, **Alikani M**, **Trowbridge J**, **Rosenwaks Z**, Implantation enhancement by selective assisted hatching using zona drilling of human embryos with poor prognosis, Hum Reprod 7:685, 1992.
720. **Lanzendorf SE**, **Nehchiri F**, **Mayer JF**, **Oehninger S**, **Muasher SJ**, A prospective, randomized, double-blind study for the evaluation of assisted hatching in patients with advanced maternal age, Hum Reprod 13:409, 1998.
721. **Hurst BS**, **Tucker KE**, **Awoniyi CA**, **Schlaff WD**, Assisted hatching does not enhance IVF success in good-prognosis patients, J Assist Reprod Genet 15:62, 1998.

722. **Magli MC**, **Gianaroli L**, **Ferraretti AP**, **Fortini D**, **Aicardi G**, **Montanaro N**, Rescue of implantation potential in embryos with poor prognosis by assisted zona hatching, Hum Reprod 13:1331, 1998.
723. **Hellebaut S**, **De Sutter P**, **Dozortsev D**, **Onghena A**, **Qian C**, **Dhont M**, Does assisted hatching improve implantation rates after in vitro fertilization or intracytoplasmic sperm injection in all patients? A prospective randomized study, J Assist Reprod Genet 13:19, 1996.
724. **Chao KH**, **Chen SU**, **Chen HF**, **Wu MY**, **Yang YS**, **Ho HN**, Assisted hatching increases the implantation and pregnancy rate of in vitro fertilization (IVF)-embryo transfer (ET), but not that of IVF-tubal ET in patients with repeated IVF failures, Fertil Steril 67:904, 1997.
725. **Obruca A**, **Strohmer H**, **Sakkas D**, **Menezo Y**, **Kogosowski A**, **Barak Y**, **Feichtinger W**, Use of lasers in assisted fertilization and hatching, Hum Reprod 9:1723, 1994.
726. **Mantoudis E**, **Podsiadly BT**, **Gorgy A**, **Venkat G**, **Craft IL**, A comparison between quarter, partial and total laser assisted hatching in selected infertility patients, Hum Reprod 16:2182, 2001.
727. **Hsieh YY**, **Huang CC**, **Cheng TC**, **Chang CC**, **Tsai HD**, **Lee MS**, Laser-assisted hatching of embryos is better than the chemical method for enhancing the pregnancy rate in women with advanced age, Fertil Steril 78:179, 2002.
728. **Fong CY**, **Bongso A**, **Ng SC**, **Kumar J**, **Trounson A**, **Ratnam S**, Blastocyst transfer after enzymatic treatment of the zona pellucida: improving in-vitro fertilization and understanding implantation, Hum Reprod 13:2926, 1998.
729. **Balaban B**, **Urman B**, **Alatas C**, **Mercan R**, **Mumcu A**, **Isiklar A**, A comparison of four different techniques of assisted hatching, Hum Reprod 17:1239, 2002.
730. **Nakayama T**, **Fujiwara H**, **Yamada S**, **Tastumi K**, **Honda T**, **Fujii S**, Clinical application of a new assisted hatching method using a piezo-micromanipulator for morphologically low-quality embryos in poor-prognosis infertile patients, Fertil Steril 71:1014, 1999.
731. **Cohen J**, **Inge KL**, **Suzman M**, **Wiker SR**, **Wright G**, Videocinematography of fresh and cryopreserved embryos: a retrospective analysis of embryonic morphology and implantation, Fertil Steril 51:820, 1989.
732. **Edirisinghe WR**, **Ahnonkitpanit V**, **Promviengchai S**, **Suwajanakorn S**, **Pruksananonda K**, **Chinpilas V**, **Virutamasen P**, A study failing to determine significant benefits from assisted hatching: patients selected for advanced age, zonal thickness of embryos, and previous failed attempts, J Assist Reprod Genet 16:294, 1999.
733. **Carney SK**, **Das S**, **Blake D**, **Farquhar C**, **Seif MM**, **Nelson L**, Assisted hatching on assisted conception (in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), Cochrane Database Syst Rev (12):CD001894, 2012.
734. **Das S**, **Blake D**, **Farquhar C**, **Seif MM**, Assisted hatching on assisted conception (IVF and ICSI), Cochrane Database Syst Rev (2):CD001894, 2009.
735. **Alteri A**, **Vigano P**, **Maizar AA**, **Jovine L**, **Giacomini E**, **Rubino P**, Revisiting embryo assisted hatching approaches: a systematic review of the current protocols, J Assist Reprod Genet 35:367, 2018.
736. **He F**, **Zhang CY**, **Wang LS**, **Li SL**, **Hu LN**, Assisted hatching in couples with advanced maternal age: a systematic review and meta-analysis, Curr Med Sci 38:552, 2018.
737. **Zeng M**, **Su S**, **Li L**, The effect of laser-assisted hatching on pregnancy outcomes of cryopreserved-thawed embryo transfer: a meta-analysis of randomized controlled trials, Lasers Med Sci 33:655, 2018.
738. **Li D**, **Yang DL**, **An J**, **Jiao J**, **Zhou YM**, **Wu QJ**, **Wang XX**, Effect of assisted hatching on pregnancy outcomes: a systematic review and meta-analysis of randomized controlled trials, Sci Rep 6:31228, 2016.
739. **Hershlag A**, **Paine T**, **Cooper GW**, **Scholl GM**, **Rawlinson K**, **Kvapil G**, Monozygotic twinning associated with mechanical assisted hatching, Fertil Steril 71:144, 1999.
740. **Schieve LA**, **Meikle SF**, **Peterson HB**, **Jeng G**, **Burnett NM**, **Wilcox LS**, Does assisted hatching pose a risk for monozygotic twinning in pregnancies conceived through in vitro fertilization? Fertil Steril 74:288, 2000.
741. **Sheen TC**, **Chen SR**, **Au HK**, **Chien YY**, **Wu KY**, **Tzeng CR**, Herniated blastomere following chemically assisted hatching may result in monozygotic twins, Fertil Steril 75:442, 2001.
742. **Skiadas CC**, **Missmer SA**, **Benson CB**, **Gee RE**, **Racowsky C**, Risk factors associated with pregnancies containing a monochorionic pair following assisted reproductive technologies, Hum Reprod 23:1366, 2008.
743. **Verlinsky Y**, **Ginsberg N**, **Lifchez A**, **Valle J**, **Moise J**, **Strom CM**, Analysis of the first polar body:

preconception genetic diagnosis, Hum Reprod 5:826, 1990.
744. **Angell RR**, Possible pitfalls in preimplantation diagnosis of chromosomal disorders based on polar body analysis, Hum Reprod 9:181, 1994.
745. **Geraedts J**, **Montag M**, **Magli MC**, **Repping S**, **Handyside A**, **Staessen C**, **Harper J**, **Schmutzler A**, **Collins J**, **Goossens V**, **van der Ven H**, **Vesela K**, **Gianaroli L**, Polar body array CGH for prediction of the status of the corresponding oocyte. Part I: clinical results, Hum Reprod 26:3173, 2011.
746. **Nikas G**, **Ao A**, **Winston RM**, **Handyside AH**, Compaction and surface polarity in the human embryo in vitro, Biol Reprod 55:32, 1996.
747. **Scott KL**, **Hong KH**, **Scott RT Jr**, Selecting the optimal time to perform biopsy for preimplantation genetic testing, Fertil Steril 100:608, 2013.
748. **Goossens V**, **De Rycke M**, **De Vos A**, **Staessen C**, **Michiels A**, **Verpoest W**, **Van Steirteghem A**, **Bertrand C**, **Liebaers I**, **Devroey P**, **Sermon K**, Diagnostic efficiency, embryonic development and clinical outcome after the biopsy of one or two blastomeres for preimplantation genetic diagnosis, Hum Reprod 23:481, 2008.
749. **Scott RT Jr**, **Upham KM**, **Forman EJ**, **Zhao T**, **Treff NR**, Cleavage-stage biopsy significantly impairs human embryonic implantation potential while blastocyst biopsy does not: a randomized and paired clinical trial, Fertil Steril 100:624, 2013.
750. **Damario MA**, **Barmat L**, **Liu HC**, **Davis OK**, **Rosenwaks Z**, Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients, Hum Reprod 12:2359, 1997.
751. **De Vos A**, **Staessen C**, **De Rycke M**, **Verpoest W**, **Haentjens P**, **Devroey P**, **Liebaers I**, **Van de Velde H**, Impact of cleavage-stage embryo biopsy in view of PGD on human blastocyst implantation: a prospective cohort of single embryo transfers, Hum Reprod 24:2988, 2009.
752. **Dokras A**, **Sargent IL**, **Gardner RL**, **Barlow DH**, Human trophectoderm biopsy and secretion of chorionic gonadotrophin, Hum Reprod 6:1453, 1991.
753. **Carson SA**, **Gentry WL**, **Smith AL**, **Buster JE**, Trophectoderm microbiopsy in murine blastocysts: comparison of four methods, J Assist Reprod Genet 10:427, 1993.
754. **Wilton L**, **Voullaire L**, **Sargeant P**, **Williamson R**, **McBain J**, Preimplantation aneuploidy screening using comparative genomic hybridization or fluorescence in situ hybridization of embryos from patients with recurrent implantation failure, Fertil Steril 80:860, 2003.
755. **Jericho H**, **Wilton L**, **Gook DA**, **Edgar DH**, A modified cryopreservation method increases the survival of human biopsied cleavage stage embryos, Hum Reprod 18:568, 2003.
756. **Coates A**, **Kung A**, **Mounts E**, **Hesla J**, **Bankowski B**, **Barbieri E**, **Ata B**, **Cohen J**, **Munne S**, Optimal euploid embryo transfer strategy, fresh versus frozen, after preimplantation genetic screening with next generation sequencing: a randomized controlled trial, Fertil Steril 107:723.e3, 2017.
757. **Verlinsky Y**, **Rechitsky S**, **Verlinsky O**, **Masciangelo C**, **Lederer K**, **Kuliev A**, Preimplantation diagnosis for early-onset Alzheimer disease caused by V717L mutation, JAMA 287:1018, 2002.
758. **Ao A**, **Wells D**, **Handyside AH**, **Winston RM**, **Delhanty JD**, Preimplantation genetic diagnosis of inherited cancer: familial adenomatous polyposis coli, J Assist Reprod Genet 15:140, 1998.
759. **Verlinsky Y**, **Rechitsky S**, **Verlinsky O**, **Xu K**, **Schattman G**, **Masciangelo C**, **Ginberg N**, **Strom C**, **Rosenwaks Z**, **Kuliev A**, Preimplantation diagnosis for p53 tumour suppressor gene mutations, Reprod Biomed Online 2:102, 2001.
760. **Verlinsky Y**, **Rechitsky S**, **Schoolcraft W**, **Strom C**, **Kuliev A**, Preimplantation diagnosis for Fanconi anemia combined with HLA matching, JAMA 285:3130, 2001.
761. **Handyside AH**, **Harton GL**, **Mariani B**, **Thornhill AR**, **Affara N**, **Shaw MA**, **Griffin DK**, Karyomapping: a universal method for genome wide analysis of genetic disease based on mapping crossovers between parental haplotypes, J Med Genet 47:651, 2010.
762. **Lee VCY**, **Chow JFC**, **Yeung WSB**, **Ho PC**, Preimplantation genetic diagnosis for monogenic diseases, Best Pract Res Clin Obstet Gynaecol 44:68, 2017.
763. **Treff NR**, **Fedick A**, **Tao X**, **Devkota B**, **Taylor D**, **Scott RT Jr**, Evaluation of targeted next-generation

sequencing-based preimplantation genetic diagnosis of monogenic disease, Fertil Steril 99:1377.e6, 2013.
764. **Goldman KN**, **Nazem T**, **Berkeley A**, **Palter S**, **Grifo JA**, Preimplantation Genetic Diagnosis (PGD) for monogenic disorders: the value of concurrent aneuploidy screening, J Genet Couns 25:1327, 2016.
765. **Iews M**, **Tan J**, **Taskin O**, **Alfaraj S**, **AbdelHafez FF**, **Abdellah AH**, **Bedaiwy MA**, Does preimplantation genetic diagnosis improve reproductive outcome in couples with recurrent pregnancy loss owing to structural chromosomal rearrangement? A systematic review, Reprod Biomed Online 36:677, 2018.
766. **Ikuma S**, **Sato T**, **Sugiura-Ogasawara M**, **Nagayoshi M**, **Tanaka A**, **Takeda S**, Preimplantation genetic diagnosis and natural conception: a comparison of live birth rates in patients with recurrent pregnancy loss associated with translocation, PLoS One 10:e0129958, 2015.
767. **Bedaiwy MA**, **Maithripala SI**, **Durland US**, **Havelock J**, **Kashyap S**, **Hitkari J**, **Lisonkova S**, Reproductive outcomes of couples with recurrent pregnancy loss due to parental chromosome rearrangement, Fertil Steril 106:e343, 2016.
768. **Goddijn M**, **Joosten JH**, **Knegt AC**, **van derVeen F**, **Franssen MT**, **Bonsel GJ**, **Leschot NJ**, Clinical relevance of diagnosing structural chromosome abnormalities in couples with repeated miscarriage, Hum Reprod 19:1013, 2004.
769. **Stephenson MD**, **Sierra S**, Reproductive outcomes in recurrent pregnancy loss associated with a parental carrier of a structural chromosome rearrangement, Hum Reprod 21:1076, 2006.
770. **Sugiura-Ogasawara M**, **Ozaki Y**, **Sato T**, **Suzumori N**, **Suzumori K**, Poor prognosis of recurrent aborters with either maternal or paternal reciprocal translocations, Fertil Steril 81:367, 2004.
771. **Menezo YJ**, **Bellec V**, **Zaroukian A**, **Benkhalifa M**, Embryo selection by IVF, co-culture and transfer at the blastocyst stage in case of translocation, Hum Reprod 12:2802, 1997.
772. **Magli MC**, **Gianaroli L**, **Ferraretti AP**, Chromosomal abnormalities in embryos, Mol Cell Endocrinol 183(Suppl 1):S29, 2001.
773. **Mastenbroek S**, **Twisk M**, **van der Veen F**, **Repping S**, Preimplantation genetic screening: a systematic review and meta-analysis of RCTs, Hum Reprod Update 17:454, 2011.
774. **Rubio C**, **Bellver J**, **Rodrigo L**, **Castillon G**, **Guillen A**, **Vidal C**, **Giles J**, **Ferrando M**, **Cabanillas S**, **Remohi J**, **Pellicer A**, **Simon C**, In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study, Fertil Steril 107:1122, 2017.
775. **Hardarson T**, **Hanson C**, **Lundin K**, **Hillensjo T**, **Nilsson L**, **Stevic J**, **Reismer E**, **Borg K**, **Wikland M**, **Bergh C**, Preimplantation genetic screening in women of advanced maternal age caused a decrease in clinical pregnancy rate: a randomized controlled trial, Hum Reprod 23:2806, 2008.
776. **Mastenbroek S**, **Twisk M**, **van Echten-Arends J**, **Sikkema-Raddatz B**, **Korevaar JC**, **Verhoeve HR**, **Vogel NE**, **Arts EG**, **de Vries JW**, **Bossuyt PM**, **Buys CH**, **Heineman MJ**, **Repping S**, **van der Veen F**, In vitro fertilization with preimplantation genetic screening, N Engl J Med 357:9, 2007.
777. **Verpoest W**, **Staessen C**, **Bossuyt PM**, **Goossens V**, **Altarescu G**, **Bonduelle M**, **Devesa M**, **Eldar-Geva T**, **Gianaroli L**, **Griesinger G**, **Kakourou G**, **Kokkali G**, **Liebenthron J**, **Magli MC**, **Parriego M**, **Schmutzler AG**, **Tobler M**, **van der Ven K**, **Geraedts J**, **Sermon K**, Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial, Hum Reprod 33:1767, 2018.
778. **Yang Z**, **Liu J**, **Collins GS**, **Salem SA**, **Liu X**, **Lyle SS**, **Peck AC**, **Sills ES**, **Salem RD**, Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study, Mol Cytogenet 5:24, 2012.
779. **Forman EJ**, **Hong KH**, **Ferry KM**, **Tao X**, **Taylor D**, **Levy B**, **Treff NR**, **Scott RT Jr**, In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial, Fertil Steril 100:100.e1, 2013.
780. **Forman EJ**, **Hong KH**, **Franasiak JM**, **Scott RT Jr**, Obstetrical and neonatal outcomes from the BEST Trial: single embryo transfer with aneuploidy screening improves outcomes after in vitro fertilization without compromising delivery rates, Am J Obstet Gynecol 210:157.e1, 2014.
781. **Scott RT Jr**, **Upham KM**, **Forman EJ**, **Hong KH**, **Scott KL**, **Taylor D**, **Tao X**, **Treff NR**, Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilization implantation and delivery rates: a randomized controlled trial, Fertil Steril 100:697, 2013.

782. **Munne S**, **Kaplan B**, **Frattarelli JL**, **Gysler M**, **Child TJ**, **Nakhuda G**, **Shamma FN**, **Silverberg K**, **Kalista T**, **Oliver K**, **Katz-Jaffe MG**, **Wells D**, **Gordon T**, **Willman S**, Global multicenter randomized controlled trial comparing single embryo transfer with embryo selected by preimplantation genetic screening using next-generation sequencing versus morphologic assessment, Fertil Steril 108:e19, 2017.
783. **Greco E**, **Minasi MG**, **Fiorentino F**, Healthy babies after intrauterine transfer of mosaic aneuploid blastocysts, N Engl J Med 373:2089, 2015.
784. **Edwards RG**, **Fishel SB**, **Cohen J**, **Fehilly CB**, **Purdy JM**, **Slater JM**, **Steptoe PC**, **Webster JM**, Factors influencing the success of in vitro fertilization for alleviating human infertility, J In Vitro Fert Embryo Transf 1:3, 1984.
785. **Kovacs GT**, Which factors are important for successful embryo transfer after in-vitro fertilization? Hum Reprod 14:2679, 1999.
786. **Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org; Practice Committee of the American Society for Reproductive Medicine**, Performing the embryo transfer: a guideline, Fertil Steril 107:882, 2017.
787. **Karande VC**, **Morris R**, **Chapman C**, **Rinehart J**, **Gleicher N**, Impact of the "physician factor" on pregnancy rates in a large assisted reproductive technology program: do too many cooks spoil the broth? Fertil Steril 71:1001, 1999.
788. **Hearns-Stokes RM**, **Miller BT**, **Scott L**, **Creuss D**, **Chakraborty PK**, **Segars JH**, Pregnancy rates after embryo transfer depend on the provider at embryo transfer, Fertil Steril 74:80, 2000.
789. **Angelini A**, **Brusco GF**, **Barnocchi N**, **El-Danasouri I**, **Pacchiarotti A**, **Selman HA**, Impact of physician performing embryo transfer on pregnancy rates in an assisted reproductive program, J Assist Reprod Genet 23:329, 2006.
790. **Toth TL**, **Lee MS**, **Bendikson KA**, **Reindollar RH; American Society for Reproductive Medicine Embryo Transfer Advisory Panel**, Embryo transfer techniques: an American Society for Reproductive Medicine survey of current Society for Assisted Reproductive Technology practices, Fertil Steril 107:1003, 2017.
791. **Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org**, **Penzias A**, **Bendikson K**, **Butts S**, **Coutifaris C**, **Falcone T**, **Fossum G**, **Gitlin S**, **Gracia C**, **Hansen K**, **Mersereau J**, **Odem R**, **Rebar R**, **Reindollar R**, **Rosen M**, **Sandlow J**, **Vernon M**, ASRM standard embryo transfer protocol template: a committee opinion, Fertil Steril 107:897, 2017.
792. **Mansour R**, **Aboulghar M**, **Serour G**, Dummy embryo transfer: a technique that minimizes the problems of embryo transfer and improves the pregnancy rate in human in vitro fertilization, Fertil Steril 54:678, 1990.
793. **Visser DS**, **Fourie FL**, **Kruger HF**, Multiple attempts at embryo transfer: effect on pregnancy outcome in an in vitro fertilization and embryo transfer program, J Assist Reprod Genet 10:37, 1993.
794. **Abusheikha N**, **Lass A**, **Akagbosu F**, **Brinsden P**, How useful is cervical dilatation in patients with cervical stenosis who are participating in an in vitro fertilization-embryo transfer program? The Bourn Hall experience, Fertil Steril 72:610, 1999.
795. **Yanushpolsky EH**, **Ginsburg ES**, **Fox JH**, **Stewart EA**, Transcervical placement of a Malecot catheter after hysteroscopic evaluation provides for easier entry into the endometrial cavity for women with histories of difficult intrauterine inseminations and/or embryo transfers: a prospective case series, Fertil Steril 73:402, 2000.
796. **Groutz A**, **Lessing JB**, **Wolf Y**, **Yovel I**, **Azem F**, **Amit A**, Cervical dilatation during ovum pick-up in patients with cervical stenosis: effect on pregnancy outcome in an in vitro fertilization-embryo transfer program, Fertil Steril 67: 909, 1997.
797. **Glatstein IZ**, **Pang SC**, **McShane PM**, Successful pregnancies with the use of laminaria tents before embryo transfer for refractory cervical stenosis, Fertil Steril 67:1172, 1997.
798. **Schoolcraft WB**, **Surrey ES**, **Gardner DK**, Embryo transfer: techniques and variables affecting success, Fertil Steril 76:863, 2001.
799. **Woolcott R**, **Stanger J**, Potentially important variables identified by transvaginal ultrasound-guided embryo transfer, Hum Reprod 12:963, 1997.
800. **Sundstrom P**, **Wramsby H**, **Persson PH**, **Liedholm P**, Filled bladder simplifies human embryo transfer, Br J

Obstet Gynaecol 91:506, 1984.
801. **Lewin A**, **Schenker JG**, **Avrech O**, **Shapira S**, **Safran A**, **Friedler S**, The role of uterine straightening by passive bladder distension before embryo transfer in IVF cycles, J Assist Reprod Genet 14:32, 1997.
802. **Teixeira DM**, **Dassuncao LA**, **Vieira CV**, **Barbosa MA**, **Coelho Neto MA**, **Nastri CO**, **Martins WP**, Ultrasound guidance during embryo transfer: a systematic review and meta-analysis of randomized controlled trials, Ultrasound Obstet Gynecol 45:139, 2015.
803. **Brown J**, **Buckingham K**, **Buckett W**, **Abou-Setta AM**, Ultrasound versus "clinical touch" for catheter guidance during embryo transfer in women, Cochrane Database Syst Rev (3):CD006107, 2016.
804. **Goudas VT**, **Hammitt DG**, **Damario MA**, **Session DR**, **Singh AP**, **Dumesic DA**, Blood on the embryo transfer catheter is associated with decreased rates of embryo implantation and clinical pregnancy with the use of in vitro fertilization-embryo transfer, Fertil Steril 70:878, 1998.
805. **Mansour RT**, **Aboulghar MA**, **Serour GI**, **Amin YM**, Dummy embryo transfer using methylene blue dye, Hum Reprod 9:1257, 1994.
806. **Fanchin R**, **Harmas A**, **Benaoudia F**, **Lundkvist U**, **Olivennes F**, **Frydman R**, Microbial flora of the cervix assessed at the time of embryo transfer adversely affects in vitro fertilization outcome, Fertil Steril 70:866, 1998.
807. **Moini A**, **Kiani K**, **Bahmanabadi A**, **Akhoond M**, **Akhlaghi A**, Improvement in pregnancy rate by removal of cervical discharge prior to embryo transfer in ICSI cycles: a randomised clinical trial, Aust N Z J Obstet Gynaecol 51:315, 2011.
808. **Eskandar MA**, **Abou-Setta AM**, **El-Amin M**, **Almushait MA**, **Sobande AA**, Removal of cervical mucus prior to embryo transfer improves pregnancy rates in women undergoing assisted reproduction, Reprod Biomed Online 14: 308, 2007.
809. **Visschers BA**, **Bots RS**, **Peeters MF**, **Mol BW**, **van Dessel HJ**, Removal of cervical mucus: effect on pregnancy rates in IVF/ICSI, Reprod Biomed Online 15: 310, 2007.
810. **Lavie O**, **Margalioth EJ**, **Geva-Eldar T**, **Ben-Chetrit A**, Ultrasonographic endometrial changes after intrauterine insemination: a comparison of two catheters, Fertil Steril 68:731, 1997.
811. **Ata B**, **Isiklar A**, **Balaban B**, **Urman B**, Prospective randomized comparison of Wallace and Labotect embryo transfer catheters, Reprod Biomed Online 14: 471, 2007.
812. **Abdelmassih VG**, **Neme RM**, **Dozortsev D**, **Abdelmassih S**, **Diamond MP**, **Abdelmassih R**, Location of the embryo-transfer catheter guide before the internal uterine os improves the outcome of in vitro fertilization, Fertil Steril 88:499, 2007.
813. **Kato O**, **Takatsuka R**, **Asch RH**, Transvaginal-transmyometrial embryo transfer: the Towako method; experiences of 104 cases, Fertil Steril 59:51, 1993.
814. **Sharif K**, **Afnan M**, **Lenton W**, **Bilalis D**, **Hunjan M**, **Khalaf Y**, Transmyometrial embryo transfer after difficult immediate mock transcervical transfer, Fertil Steril 65:1071, 1996.
815. **Groutz A**, **Lessing JB**, **Wolf Y**, **Azem F**, **Yovel I**, **Amit A**, Comparison of transmyometrial and transcervical embryo transfer in patients with previously failed in vitro fertilization-embryo transfer cycles and/or cervical stenosis, Fertil Steril 67:1073, 1997.
816. **Biervliet FP**, **Lesny P**, **Maguiness SD**, **Robinson J**, **Killick SR**, Transmyometrial embryo transfer and junctional zone contractions, Hum Reprod 17:347, 2002.
817. **Coroleu B**, **Barri PN**, **Carreras O**, **Martinez F**, **Parriego M**, **Hereter L**, **Parera N**, **Veiga A**, **Balasch J**, The influence of the depth of embryo replacement into the uterine cavity on implantation rates after IVF: a controlled, ultrasound-guided study, Hum Reprod 17:341, 2002.
818. **Kwon H**, **Choi DH**, **Kim EK**, Absolute position versus relative position in embryo transfer: a randomized controlled trial, Reprod Biol Endocrinol 13: 78, 2015.
819. **Pacchiarotti A**, **Mohamed MA**, **Micara G**, **Tranquilli D**, **Linari A**, **Espinola SM**, **Aragona C**, The impact of the depth of embryo replacement on IVF outcome, J Assist Reprod Genet 24:189, 2007.
820. **Oliveira JB**, **Martins AM**, **Baruffi RL**, **Mauri AL**, **Petersen CG**, **Felipe V**, **Contart P**, **Pontes A**, **Franco Junior JG**, Increased implantation and pregnancy rates obtained by placing the tip of the transfer catheter in the central area of the endometrial cavity, Reprod Biomed Online 9:435, 2004.

821. **Tiras B**, **Polat M**, **Korucuoglu U**, **Zeyneloglu HB**, **Yarali H**, Impact of embryo replacement depth on in vitro fertilization and embryo transfer outcomes, Fertil Steril 94:1341, 2010.
822. **Cenksoy PO**, **Ficicioglu C**, **Yesiladali M**, **Akcin OA**, **Kaspar C**, The importance of the length of uterine cavity, the position of the tip of the inner catheter and the distance between the fundal endometrial surface and the air bubbles as determinants of the pregnancy rate in IVF cycles, Eur J Obstet Gynecol Reprod Biol 172:46, 2014.
823. **Yovich JL**, **Turner SR**, **Murphy AJ**, Embryo transfer technique as a cause of ectopic pregnancies in in vitro fertilization, Fertil Steril 44:318, 1985.
824. **Nazari A**, **Askari HA**, **Check JH**, **O'Shaughnessy A**, Embryo transfer technique as a cause of ectopic pregnancy in in vitro fertilization, Fertil Steril 60:919, 1993.
825. **Bennett S**, **Waterstone J**, **Parsons J**, **Creighton S**, Two cases of cervical pregnancy following in vitro fertilization and embryo transfer to the lower uterine cavity, J Assist Reprod Genet 10:100, 1993.
826. **Poindexter AN, III**, **Thompson DJ**, **Gibbons WE**, **Findley WE**, **Dodson MG**, **Young RL**, Residual embryos in failed embryo transfer, Fertil Steril 46:262, 1986.
827. **Meldrum DR**, **Chetkowski R**, **Steingold KA**, **de Ziegler D**, **Cedars MI**, **Hamilton M**, Evolution of a highly successful in vitro fertilization-embryo transfer program, Fertil Steril 48:86, 1987.
828. **Khan I**, **Staessen C**, **Devroey P**, **Van Steirteghem AC**, Human serum albumin versus serum: a comparative study on embryo transfer medium, Fertil Steril 56:98, 1991.
829. **Menezo Y**, **Arnal F**, **Humeau C**, **Ducret L**, **Nicollet B**, Increased viscosity in transfer medium does not improve the pregnancy rates after embryo replacement, Fertil Steril 52:680, 1989.
830. **Bontekoe S**, **Heineman MJ**, **Johnson N**, **Blake D**, Adherence compounds in embryo transfer media for assisted reproductive technologies, Cochrane Database Syst Rev (2):CD007421, 2014.
831. **Urman B**, **Yakin K**, **Ata B**, **Isiklar A**, **Balaban B**, Effect of hyaluronan-enriched transfer medium on implantation and pregnancy rates after day 3 and day 5 embryo transfers: a prospective randomized study, Fertil Steril 90:604, 2008.
832. **Fancsovits P**, **Lehner A**, **Murber A**, **Kaszas Z**, **Rigo J**, **Urbancsek J**, Effect of hyaluronan-enriched embryo transfer medium on IVF outcome: a prospective randomized clinical trial, Arch Gynecol Obstet 291:1173, 2015.
833. **Safari S**, **Razi MH**, **Safari S**, **Razi Y**, Routine use of EmbryoGlue(®) as embryo transfer medium does not improve the ART outcomes, Arch Gynecol Obstet 291:433, 2015.
834. **Nishihara T**, **Morimoto Y**, Evaluation of transfer media containing different concentrations of hyaluronan for human in vitro fertilization, Reprod Med Biol 16:349, 2017.
835. **Fu W**, **Yu M**, **Zhang XJ**, Effect of hyaluronic acid-enriched transfer medium on frozen-thawed embryo transfer outcomes, J Obstet Gynaecol Res 44:747, 2018.
836. **Eytan O**, **Elad D**, **Jaffa AJ**, Evaluation of the embryo transfer protocol by a laboratory model of the uterus, Fertil Steril 88:485, 2007.
837. **Eytan O**, **Elad D**, **Jaffa AJ**, Bioengineering studies of the embryo transfer procedure, Ann N Y Acad Sci 1101:21, 2007.
838. **Eytan O**, **Zaretsky U**, **Jaffa AJ**, **Elad D**, In vitro simulations of embryo transfer in a laboratory model of the uterus, J Biomech 40:1073, 2007.
839. **Yaniv S**, **Jaffa AJ**, **Elad D**, Modeling embryo transfer into a closed uterine cavity, J Biomech Eng 134:111003, 2012.
840. **Alvero R**, **Hearns-Stokes RM**, **Catherino WH**, **Leondires MP**, **Segars JH**, The presence of blood in the transfer catheter negatively influences outcome at embryo transfer, Hum Reprod 18:1848, 2003.
841. **Awonuga A**, **Nabi A**, **Govindbhai J**, **Birch H**, **Stewart B**, Contamination of embryo transfer catheter and treatment outcome in in vitro fertilization, J Assist Reprod Genet 15:198, 1998.
842. **Ebner T**, **Yaman C**, **Moser M**, **Sommergruber M**, **Polz W**, **Tews G**, The ineffective loading process of the embryo transfer catheter alters implantation and pregnancy rates, Fertil Steril 76:630, 2001.
843. **Listijono DR**, **Boylan T**, **Cooke S**, **Kilani S**, **Chapman MG**, An analysis of the impact of embryo transfer difficulty on live birth rates, using a standardised grading system, Hum Fertil (Camb) 16:211, 2013.

844. **Moragianni VA**, **Cohen JD**, **Smith SE**, **Schinfeld JS**, **Somkuti SG**, **Lee A**, **Barmat LI**, Effect of macroscopic or microscopic blood and mucus on the success rates of embryo transfers, Fertil Steril 93:570, 2010.
845. **Nabi A**, **Awonuga A**, **Birch H**, **Barlow S**, **Stewart B**, Multiple attempts at embryo transfer: does this affect in-vitro fertilization treatment outcome? Hum Reprod 12:1188, 1997.
846. **Phillips JA**, **Martins WP**, **Nastri CO**, **Raine-Fenning NJ**, Difficult embryo transfers or blood on catheter and assisted reproductive outcomes: a systematic review and meta-analysis, Eur J Obstet Gynecol Reprod Biol 168:121, 2013.
847. **Munoz M**, **Meseguer M**, **Lizan C**, **Ayllon Y**, **Perez-Cano I**, **Garrido N**, Bleeding during transfer is the only parameter of patient anatomy and embryo quality that affects reproductive outcome: a prospective study, Fertil Steril 92:953, 2009.
848. **Rhodes TL**, **McCoy TP**, **Higdon HL III**, **Boone WR**, Factors affecting assisted reproductive technology (ART) pregnancy rates: a multivariate analysis, J Assist Reprod Genet 22:335, 2005.
849. **Sallam HN**, **Agameya AF**, **Rahman AF**, **Ezzeldin F**, **Sallam AN**, Ultrasound measurement of the uterocervical angle before embryo transfer: a prospective controlled study, Hum Reprod 17:1767, 2002.
850. **El-Shawarby SA**, **Ravhon A**, **Skull J**, **Ellenbogen A**, **Trew G**, **Lavery S**, A prospective randomized controlled trial of Wallace and Rocket embryo transfer catheters, Reprod Biomed Online 17:549, 2008.
851. **Oraif A**, **Hollet-Caines J**, **Feyles V**, **Rebel M**, **Abduljabar H**, Do multiple attempts at embryo transfer affect clinical pregnancy rates? J Obstet Gynaecol Can 36:406, 2014.
852. **Lee HC**, **Seifer DB**, **Shelden RM**, Impact of retained embryos on the outcome of assisted reproductive technologies, Fertil Steril 82:334, 2004.
853. **Tur-Kaspa I**, **Yuval Y**, **Bider D**, **Levron J**, **Shulman A**, **Dor J**, Difficult or repeated sequential embryo transfers do not adversely affect in-vitro fertilization pregnancy rates or outcome, Hum Reprod 13:2452, 1998.
854. **Vicdan K**, **Isik AZ**, **Akarsu C**, **Sozen E**, **Caglar G**, **Dingiloglu B**, **Tuncay G**, The effect of retained embryos on pregnancy outcome in an in vitro fertilization and embryo transfer program, Eur J Obstet Gynecol Reprod Biol 134: 79, 2007.
855. **Yi HJ**, **Koo HS**, **Cha SH**, **Kim HO**, **Park CW**, **Song IO**, Reproductive outcomes of retransferring retained embryos in blastocyst transfer cycles, Clin Exp Reprod Med 43:133, 2016.
856. **Silberstein T**, **Trimarchi JR**, **Shackelton R**, **Weitzen S**, **Frankfurter D**, **Plosker S**, Ultrasound-guided miduterine cavity embryo transfer is associated with a decreased incidence of retained embryos in the transfer catheter, Fertil Steril 84:1510, 2005.
857. **Gaikwad S**, **Garrido N**, **Cobo A**, **Pellicer A**, **Remohi J**, Bed rest after embryo transfer negatively affects in vitro fertilization: a randomized controlled clinical trial, Fertil Steril 100:729, 2013.
858. **Li B**, **Zhou H**, **Li W**, Bed rest after embryo transfer, Eur J Obstet Gynecol Reprod Biol 155:125, 2011.
859. **Craciunas L**, **Tsampras N**, Bed rest following embryo transfer might negatively affect the outcome of IVF/ICSI: a systematic review and meta-analysis, Hum Fertil (Camb) 19:16, 2016.
860. **Templeton A**, **Morris JK**, Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization, N Engl J Med 339:573, 1998.
861. **Schieve LA**, **Peterson HB**, **Meikle SF**, **Jeng G**, **Danel I**, **Burnett NM**, **Wilcox LS**, Live-birth rates and multiple-birth risk using in vitro fertilization, JAMA 282:1832, 1999.
862. **Engmann L**, **Maconochie N**, **Tan SL**, **Bekir J**, Trends in the incidence of births and multiple births and the factors that determine the probability of multiple birth after IVF treatment, Hum Reprod 16:2598, 2001.
863. **Santana DS**, **Cecatti JG**, **Surita FG**, **Silveira C**, **Costa ML**, **Souza JP**, **Mazhar SB**, **Jayaratne K**, **Qureshi Z**, **Sousa MH**, **Vogel JP**; **WHO Multicountry Survey on Maternal and Newborn Health Research Network**, Twin pregnancy and severe maternal outcomes: the World Health Organization multicountry survey on maternal and newborn health, Obstet Gynecol 127:631, 2016.
864. **Bromer JG**, **Ata B**, **Seli M**, **Lockwood CJ**, **Seli E**, Preterm deliveries that result from multiple pregnancies associated with assisted reproductive technologies in the USA: a cost analysis, Curr Opin Obstet Gynecol 23:168, 2011.
865. **Ata B**, **Seli E**, Economics of assisted reproductive technologies, Curr Opin Obstet Gynecol 22:183, 2010.

866. **Jain T**, **Harlow BL**, **Hornstein MD**, Insurance coverage and outcomes of in vitro fertilization, N Engl J Med 347:661, 2002.
867. **Provost MP**, **Thomas SM**, **Yeh JS**, **Hurd WW**, **Eaton JL**, State insurance mandates and multiple birth rates after in vitro fertilization, Obstet Gynecol 128:1205, 2016.
868. **Styer AK**, **Luke B**, **Vitek W**, **Christianson MS**, **Baker VL**, **Christy AY**, **Polotsky AJ**, Factors associated with the use of elective single-embryo transfer and pregnancy outcomes in the United States, 2004-2012, Fertil Steril 106:80, 2016.
869. **Cabello Y**, **Gomez-Palomares JL**, **Castilla JA**, **Hernandez J**, **Marqueta J**, **Pareja A**, **Luceno F**, **Hernandez E**, **Coroleu B**, Impact of the Spanish Fertility Society guidelines on the number of embryos to transfer, Reprod Biomed Online 21:667, 2010.
870. **Bissonnette F**, **Phillips SJ**, **Gunby J**, **Holzer H**, **Mahutte N**, **St-Michel P**, **Kadoch IJ**, Working to eliminate multiple pregnancies: a success story in Quebec, Reprod Biomed Online 23:500, 2011.
871. **Urman B**, **Yakin K**, New Turkish legislation on assisted reproductive techniques and centres: a step in the right direction? Reprod Biomed Online 21:729, 2010.
872. **Mancuso AC**, **Boulet SL**, **Duran E**, **Munch E**, **Kissin DM**, **Van Voorhis BJ**, Elective single embryo transfer in women less than age 38 years reduces multiple birth rates, but not live birth rates, in United States fertility clinics, Fertil Steril 106:1107, 2016.
873. **American Society for Reproductive Medicine**, Guidelines on Number of Embryos Transferred, American Society for Reproductive Medicine, Birmingham, 1998.
874. **Combelles CM**, **Orasanu B**, **Ginsburg ES**, **Racowsky C**, Optimum number of embryos to transfer in women more than 40 years of age undergoing treatment with assisted reproductive technologies, Fertil Steril 84:1637, 2005.
875. **Stern JE**, **Goldman MB**, **Hatasaka H**, **MacKenzie TA**, **Surrey ES**, **Racowsky C; Society for Assisted Reproductive Technology Writing Group**, Optimizing the number of cleavage stage embryos to transfer on day 3 in women 38 years of age and older: a Society for Assisted Reproductive Technology database study, Fertil Steril 91:767, 2009.
876. **Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org; Practice Committee of the Society for Assisted Reproductive Technology**, Guidance on the limits to the number of embryos to transfer: a committee opinion, Fertil Steril 107:901, 2017.
877. **Pritts EA**, **Atwood AK**, Luteal phase support in infertility treatment: a meta-analysis of the randomized trials, Hum Reprod 17:2287, 2002.
878. **Beckers NG**, **Macklon NS**, **Eijkemans MJ**, **Ludwig M**, **Felberbaum RE**, **Diedrich K**, **Bustion S**, **Loumaye E**, **Fauser BC**, Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment, J Clin Endocrinol Metab 88:4186, 2003.
879. **Practice Committee of the American Society for Reproductive Medicine**, Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin, Fertil Steril 89:789, 2008.
880. **Hubayter ZR**, **Muasher SJ**, Luteal supplementation in in vitro fertilization: more questions than answers, Fertil Steril 89:749, 2008.
881. **Glujovsky D**, **Pesce R**, **Fiszbajn G**, **Sueldo C**, **Hart RJ**, **Ciapponi A**, Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes, Cochrane Database Syst Rev (1):CD006359, 2010.
882. **Barbosa MW**, **Silva LR**, **Navarro PA**, **Ferriani RA**, **Nastri CO**, **Martins WP**, Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials, Ultrasound Obstet Gynecol 48:161, 2016.
883. **Tournaye H**, **Sukhikh GT**, **Kahler E**, **Griesinger G**, A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal

support in in vitro fertilization, Hum Reprod 32:1019, 2017.
884. **van der Linden M**, **Buckingham K**, **Farquhar C**, **Kremer JA**, **Metwally M**, Luteal phase support for assisted reproduction cycles, Cochrane Database Syst Rev (7):CD009154, 2015.
885. **Kohls G**, **Ruiz F**, **Martinez M**, **Hauzman E**, **de la Fuente G**, **Pellicer A**, **Garcia-Velasco JA**, Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial, Fertil Steril 98:858, 2012.
886. **Pan SP**, **Chao KH**, **Huang CC**, **Wu MY**, **Chen MJ**, **Chang CH**, **Yang JH**, **Yang YS**, **Chen SU**, Early stop of progesterone supplementation after confirmation of pregnancy in IVF/ICSI fresh embryo transfer cycles of poor responders does not affect pregnancy outcome, PLoS One 13:e0201824, 2018.
887. **Vaisbuch E**, **de Ziegler D**, **Leong M**, **Weissman A**, **Shoham Z**, Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey, Reprod Biomed Online 28:330, 2014.
888. **Jee BC**, **Suh CS**, **Kim SH**, **Kim YB**, **Moon SY**, Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis, Fertil Steril 93:428, 2010.
889. **Ata B**, **Kucuk M**, **Seyhan A**, **Urman B**, Effect of high-dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles, J Reprod Med 55:485, 2010.
890. **Trounson A**, **Mohr L**, Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo, Nature 305:707, 1983.
891. **Practice Committee of American Society for Reproductive Medicine**, Ovarian hyperstimulation syndrome, Fertil Steril 90:S188, 2008.
892. **D'Angelo A**, **Amso N**, Embryo freezing for preventing ovarian hyperstimulation syndrome, Cochrane Database Syst Rev:CD002806, 2007.
893. **Kuwayama M**, Highly efficient vitrification for cryopreservation of human oocytes and embryos: the Cryotop method, Theriogenology 67:73, 2007.
894. **Vajta G**, **Nagy ZP**, **Cobo A**, **Conceicao J**, **Yovich J**, Vitrification in assisted reproduction: myths, mistakes, disbeliefs and confusion, Reprod Biomed Online 19(Suppl 3):1, 2009.
895. **Lin YP**, **Cassidenti DL**, **Chacon RR**, **Soubra SS**, **Rosen GF**, **Yee B**, Successful implantation of frozen sibling embryos is influenced by the outcome of the cycle from which they were derived, Fertil Steril 63:262, 1995.
896. **Pantos K**, **Stefanidis K**, **Pappas K**, **Kokkinopoulos P**, **Petroutsou K**, **Kokkali G**, **Stavrou D**, **Tzigounis V**, Cryopreservation of embryos, blastocysts, and pregnancy rates of blastocysts derived from frozen-thawed embryos and frozen-thawed blastocysts, J Assist Reprod Genet 18:579, 2001.
897. **Behr B**, **Gebhardt J**, **Lyon J**, **Milki AA**, Factors relating to a successful cryopreserved blastocyst transfer program, Fertil Steril 77:697, 2002.
898. **Senn A**, **Vozzi C**, **Chanson A**, **De Grandi P**, **Germond M**, Prospective randomized study of two cryopreservation policies avoiding embryo selection: the pronucleate stage leads to a higher cumulative delivery rate than the early cleavage stage, Fertil Steril 74:946, 2000.
899. **Oehninger S**, **Mayer J**, **Muasher S**, Impact of different clinical variables on pregnancy outcome following embryo cryopreservation, Mol Cell Endocrinol 169:73, 2000.
900. **Salumets A**, **Tuuri T**, **Makinen S**, **Vilska S**, **Husu L**, **Tainio R**, **Suikkari AM**, Effect of developmental stage of embryo at freezing on pregnancy outcome of frozen-thawed embryo transfer, Hum Reprod 18:1890, 2003.
901. **Kattera S**, **Shrivastav P**, **Craft I**, Comparison of pregnancy outcome of pronuclear- and multicellular-stage frozen-thawed embryo transfers, J Assist Reprod Genet 16:358, 1999.
902. **Rienzi L**, **Gracia C**, **Maggiulli R**, **LaBarbera AR**, **Kaser DJ**, **Ubaldi FM**, **Vanderpoel S**, **Racowsky C**, Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance, Hum Reprod Update 23:139, 2017.
903. **Li Z**, **Wang YA**, **Ledger W**, **Edgar DH**, **Sullivan EA**, Clinical outcomes following cryopreservation of blastocysts by vitrification or slow freezing: a population-based cohort study, Hum Reprod 29:2794, 2014.

904. **Mackens S**, **Santos-Ribeiro S**, **van de Vijver A**, **Racca A**, **Van Landuyt L**, **Tournaye H**, **Blockeel C**, Frozen embryo transfer: a review on the optimal endometrial preparation and timing, Hum Reprod 32:2234, 2017.
905. **Groenewoud ER**, **Cohlen BJ**, **Macklon NS**, Programming the endometrium for deferred transfer of cryopreserved embryos: hormone replacement versus modified natural cycles, Fertil Steril 109:768, 2018.
906. **Muasher SJ**, **Kruithoff C**, **Simonetti S**, **Oehninger S**, **Acosta AA**, **Jones GS**, Controlled preparation of the endometrium with exogenous steroids for the transfer of frozen-thawed pre-embryos in patients with anovulatory or irregular cycles, Hum Reprod 6:443, 1991.
907. **Simon A**, **Hurwitz A**, **Zentner BS**, **Bdolah Y**, **Laufer N**, Transfer of frozen-thawed embryos in artificially prepared cycles with and without prior gonadotrophin-releasing hormone agonist suppression: a prospective randomized study, Hum Reprod 13:2712, 1998.
908. **Remohi J**, **Gutierrez A**, **Cano F**, **Ruiz A**, **Simon C**, **Pellicer A**, Long oestradiol replacement in an oocyte donation programme, Hum Reprod 10:1387, 1995.
909. **Ghobara T**, **Gelbaya TA**, **Ayeleke RO**, Cycle regimens for frozen-thawed embryo transfer, Cochrane Database Syst Rev (7):CD003414, 2017.
910. **Santos-Ribeiro S**, **Polyzos NP**, **Lan VT**, **Siffain J**, **Mackens S**, **Van Landuyt L**, **Tournaye H**, **Blockeel C**, The effect of an immediate frozen embryo transfer following a freeze-all protocol: a retrospective analysis from two centres, Hum Reprod 31:2541, 2016.
911. **Lattes K**, **Checa MA**, **Vassena R**, **Brassesco M**, **Vernaeve V**, There is no evidence that the time from egg retrieval to embryo transfer affects live birth rates in a freeze-all strategy, Hum Reprod 32:368, 2017.
912. **Kulkarni AD**, **Jamieson DJ**, **Jones HW Jr**, **Kissin DM**, **Gallo MF**, **Macaluso M**, **Adashi EY**, Fertility treatments and multiple births in the United States, N Engl J Med 369:2218, 2013.
913. **Vahratian A**, **Schieve LA**, **Reynolds MA**, **Jeng G**, Live-birth rates and multiple-birth risk of assisted reproductive technology pregnancies conceived using thawed embryos, USA 1999-2000, Hum Reprod 18:1442, 2003.
914. **Wright V**, **Schieve LA**, **Vahratian A**, **Reynolds MA**, Monozygotic twinning associated with day 5 embryo transfer in pregnancies conceived after IVF, Hum Reprod 19:1831, 2004.
915. **Jain T**, **Missmer SA**, **Hornstein MD**, Trends in embryo-transfer practice and in outcomes of the use of assisted reproductive technology in the United States, N Engl J Med 350:1639, 2004.
916. **Pandey S**, **Shetty A**, **Hamilton M**, **Bhattacharya S**, **Maheshwari A**, Obstetric and perinatal outcomes in singleton pregnancies resulting from IVF/ICSI: a systematic review and meta-analysis, Hum Reprod Update 18:485, 2012.
917. **Helmerhorst FM**, **Perquin DA**, **Donker D**, **Keirse MJ**, Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies, BMJ 328:261, 2004.
918. **Jackson RA**, **Gibson KA**, **Wu YW**, **Croughan MS**, Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis, Obstet Gynecol 103:551, 2004.
919. **McDonald SD**, **Han Z**, **Mulla S**, **Murphy KE**, **Beyene J**, **Ohlsson A**, Preterm birth and low birth weight among in vitro fertilization singletons: a systematic review and meta-analyses, Eur J Obstet Gynecol Reprod Biol 146:138, 2009.
920. **McDonald SD**, **Murphy K**, **Beyene J**, **Ohlsson A**, Perinatal outcomes of singleton pregnancies achieved by in vitro fertilization: a systematic review and meta-analysis, J Obstet Gynaecol Can 27:449, 2005.
921. **McGovern PG**, **Llorens AJ**, **Skurnick JH**, **Weiss G**, **Goldsmith LT**, Increased risk of preterm birth in singleton pregnancies resulting from in vitro fertilization-embryo transfer or gamete intrafallopian transfer: a meta-analysis, Fertil Steril 82:1514, 2004.
922. **Henningsen AA**, **Gissler M**, **Skjaerven R**, **Bergh C**, **Tiitinen A**, **Romundstad LB**, **Wennerholm UB**, **Lidegaard O**, **Nyboe Andersen A**, **Forman JL**, **Pinborg A**, Trends in perinatal health after assisted reproduction: a Nordic study from the CoNARTaS group, Hum Reprod 30:710, 2015.
923. **Henningsen AA**, **Wennerholm UB**, **Gissler M**, **Romundstad LB**, **Nygren KG**, **Tiitinen A**, **Skjaerven R**, **Nyboe Andersen A**, **Lidegaard O**, **Forman JL**, **Pinborg A**, Risk of stillbirth and infant deaths after assisted reproductive technology: a Nordic study from the CoNARTaS group, Hum Reprod 29: 1090, 2014.

924. **Messerlian C**, **Maclagan L**, **Basso O**, Infertility and the risk of adverse pregnancy outcomes: a systematic review and meta-analysis, Hum Reprod 28:125, 2013.
925. **Declercq E**, **Luke B**, **Belanoff C**, **Cabral H**, **Diop H**, **Gopal D**, **Hoang L**, **Kotelchuck M**, **Stern JE**, **Hornstein MD**, Perinatal outcomes associated with assisted reproductive technology: the Massachusetts Outcomes Study of Assisted Reproductive Technologies (MOSART), Fertil Steril 103:888, 2015.
926. **Pinborg A**, **Wennerholm UB**, **Romundstad LB**, **Loft A**, **Aittomaki K**, **Soderstrom-Anttila V**, **Nygren KG**, **Hazekamp J**, **Bergh C**, Why do singletons conceived after assisted reproduction technology have adverse perinatal outcome? Systematic review and meta-analysis, Hum Reprod Update 19:87, 2013.
927. **Ginstrom Ernstad E**, **Bergh C**, **Khatibi A**, **Kallen KB**, **Westlander G**, **Nilsson S**, **Wennerholm UB**, Neonatal and maternal outcome after blastocyst transfer: a population-based registry study, Am J Obstet Gynecol 214:378.e1, 2016.
928. **Pinborg A**, **Henningsen AA**, **Loft A**, **Malchau SS**, **Forman J**, **Andersen AN**, Large baby syndrome in singletons born after frozen embryo transfer (FET): is it due to maternal factors or the cryotechnique? Hum Reprod 29:618, 2014.
929. **Martin AS**, **Chang J**, **Zhang Y**, **Kawwass JF**, **Boulet SL**, **McKane P**, **Bernson D**, **Kissin DM**, **Jamieson DJ; States Monitoring Assisted Reproductive Technology Collaborative**, Perinatal outcomes among singletons after assisted reproductive technology with single-embryo or double-embryo transfer versus no assisted reproductive technology, Fertil Steril 107:954, 2017.
930. **Wennerholm UB**, **Henningsen AK**, **Romundstad LB**, **Bergh C**, **Pinborg A**, **Skjaerven R**, **Forman J**, **Gissler M**, **Nygren KG**, **Tiitinen A**, Perinatal outcomes of children born after frozen-thawed embryo transfer: a Nordic cohort study from the CoNARTaS group, Hum Reprod 28:2545, 2013.
931. **Hansen M**, **Bower C**, The impact of assisted reproductive technologies on intra-uterine growth and birth defects in singletons, Semin Fetal Neonatal Med 19:228, 2014.
932. **Sutcliffe AG**, **Ludwig M**, Outcome of assisted reproduction, Lancet 370:351, 2007.
933. **Hansen M**, **Bower C**, **Milne E**, **de Klerk N**, **Kurinczuk JJ**, Assisted reproductive technologies and the risk of birth defects—a systematic review, Hum Reprod 20:328, 2005.
934. **Hansen M**, **Kurinczuk JJ**, **Milne E**, **de Klerk N**, **Bower C**, Assisted reproductive technology and birth defects: a systematic review and meta-analysis, Hum Reprod Update 19:330, 2013.
935. **Rimm AA**, **Katayama AC**, **Diaz M**, **Katayama KP**, A meta-analysis of controlled studies comparing major malformation rates in IVF and ICSI infants with naturally conceived children, J Assist Reprod Genet 21:437, 2004.
936. **Wen J**, **Jiang J**, **Ding C**, **Dai J**, **Liu Y**, **Xia Y**, **Liu J**, **Hu Z**, Birth defects in children conceived by in vitro fertilization and intracytoplasmic sperm injection: a meta-analysis, Fertil Steril 97:1331.e1, 2012.
937. **Boulet SL**, **Kirby RS**, **Reefhuis J**, **Zhang Y**, **Sunderam S**, **Cohen B**, **Bernson D**, **Copeland G**, **Bailey MA**, **Jamieson DJ**, **Kissin DM**, Assisted reproductive technology and birth defects among liveborn infants in Florida, Massachusetts, and Michigan, 2000-2010, JAMA Pediatr 170:e154934, 2016.
938. **Heisey AS**, **Bell EM**, **Herdt-Losavio ML**, **Druschel C**, Surveillance of congenital malformations in infants conceived through assisted reproductive technology or other fertility treatments, Birth Defects Res A Clin Mol Teratol 103:119, 2015.
939. **Hwang SS**, **Dukhovny D**, **Gopal D**, **Cabral H**, **Missmer S**, **Diop H**, **Declercq E**, **Stern JE**, Health of infants after art-treated, subfertile, and fertile deliveries, Pediatrics 142, 2018.
940. **Davies MJ**, **Moore VM**, **Willson KJ**, **Van Essen P**, **Priest K**, **Scott H**, **Haan EA**, **Chan A**, Reproductive technologies and the risk of birth defects, N Engl J Med 366:1803, 2012.
941. **Zhu JL**, **Basso O**, **Obel C**, **Bille C**, **Olsen J**, Infertility, infertility treatment, and congenital malformations: Danish national birth cohort, BMJ 333:679, 2006.
942. **Rimm AA**, **Katayama AC**, **Katayama KP**, A meta-analysis of the impact of IVF and ICSI on major malformations after adjusting for the effect of subfertility, J Assist Reprod Genet 28:699, 2011.
943. **Chang AS**, **Moley KH**, **Wangler M**, **Feinberg AP**, **Debaun MR**, Association between Beckwith-Wiedemann syndrome and assisted reproductive technology: a case series of 19 patients, Fertil Steril 83:349, 2005.

944. **Halliday J**, **Oke K**, **Breheny S**, **Algar E**, **Amor DJ**, Beckwith-Wiedemann syndrome and IVF: a case-control study, Am J Hum Genet 75:526, 2004.
945. **Lim D**, **Bowdin SC**, **Tee L**, **Kirby GA**, **Blair E**, **Fryer A**, **Lam W**, **Oley C**, **Cole T**, **Brueton LA**, **Reik W**, **Macdonald F**, **Maher ER**, Clinical and molecular genetic features of Beckwith-Wiedemann syndrome associated with assisted reproductive technologies, Hum Reprod 24:741, 2009.
946. **Orstavik KH**, **Eiklid K**, **van der Hagen CB**, **Spetalen S**, **Kierulf K**, **Skjeldal O**, **Buiting K**, Another case of imprinting defect in a girl with Angelman syndrome who was conceived by intracytoplasmic semen injection, Am J Hum Genet 72:218, 2003.
947. **Ludwig M**, **Katalinic A**, **Gross S**, **Sutcliffe A**, **Varon R**, **Horsthemke B**, Increased prevalence of imprinting defects in patients with Angelman syndrome born to subfertile couples, J Med Genet 42:289, 2005.
948. **Bowdin S**, **Allen C**, **Kirby G**, **Brueton L**, **Afnan M**, **Barratt C**, **Kirkman-Brown J**, **Harrison R**, **Maher ER**, **Reardon W**, A survey of assisted reproductive technology births and imprinting disorders, Hum Reprod 22:3237, 2007.
949. **Doornbos ME**, **Maas SM**, **McDonnell J**, **Vermeiden JP**, **Hennekam RC**, Infertility, assisted reproduction technologies and imprinting disturbances: a Dutch study, Hum Reprod 22:2476, 2007.
950. **Strawn EY, Jr.**, **Bick D**, **Swanson A**, Is it the patient or the IVF? Beckwith-Wiedemann syndrome in both spontaneous and assisted reproductive conceptions, Fertil Steril 94:754.e1, 2010.
951. **Ceelen M**, **van Weissenbruch MM**, **Roos JC**, **Vermeiden JP**, **van Leeuwen FE**, **Delemarre-van de Waal HA**, Body composition in children and adolescents born after in vitro fertilization or spontaneous conception, J Clin Endocrinol Metab 92:3417, 2007.
952. **Ceelen M**, **van Weissenbruch MM**, **Vermeiden JP**, **van Leeuwen FE**, **Delemarre-van de Waal HA**, Cardiometabolic differences in children born after in vitro fertilization: follow-up study, J Clin Endocrinol Metab 93:1682, 2008.
953. **Sakka SD**, **Loutradis D**, **Kanaka-Gantenbein C**, **Margeli A**, **Papastamataki M**, **Papassotiriou I**, **Chrousos GP**, Absence of insulin resistance and low-grade inflammation despite early metabolic syndrome manifestations in children born after in vitro fertilization, Fertil Steril 94:1693, 2010.
954. **Miles HL**, **Hofman PL**, **Peek J**, **Harris M**, **Wilson D**, **Robinson EM**, **Gluckman PD**, **Cutfield WS**, In vitro fertilization improves childhood growth and metabolism, J Clin Endocrinol Metab 92:3441, 2007.
955. **Scherrer U**, **Rimoldi SF**, **Rexhaj E**, **Stuber T**, **Duplain H**, **Garcin S**, **de Marchi SF**, **Nicod P**, **Germond M**, **Allemann Y**, **Sartori C**, Systemic and pulmonary vascular dysfunction in children conceived by assisted reproductive technologies, Circulation 125:1890, 2012.
956. **Wagenaar K**, **van Weissenbruch MM**, **Knol DL**, **Cohen-Kettenis PT**, **Delemarre-van de Waal HA**, **Huisman J**, Behavior and socioemotional functioning in 9-18-year-old children born after in vitro fertilization, Fertil Steril 92:1907, 2009.
957. **Wagenaar K**, **van Weissenbruch MM**, **van Leeuwen FE**, **Cohen-Kettenis PT**, **Delemarre-van de Waal HA**, **Schats R**, **Huisman J**, Self-reported behavioral and socioemotional functioning of 11- to 18-year-old adolescents conceived by in vitro fertilization, Fertil Steril 95:611, 2011.
958. **Golombok S**, **MacCallum F**, **Goodman E**, The "test-tube" generation: parent-child relationships and the psychological well-being of in vitro fertilization children at adolescence, Child Dev 72:599, 2001.
959. **Wagenaar K**, **van Weissenbruch MM**, **Knol DL**, **Cohen-Kettenis PT**, **Delemarre-van de Waal HA**, **Huisman J**, Information processing, attention and visual-motor function of adolescents born after in vitro fertilization compared with spontaneous conception, Hum Reprod 24:913, 2009.
960. **Levy-Shiff R**, **Vakil E**, **Dimitrovsky L**, **Abramovitz M**, **Shahar N**, **Har-Even D**, **Gross S**, **Lerman M**, **Levy I**, **Sirota L**, **Fish B**, Medical, cognitive, emotional, and behavioral outcomes in school-age children conceived by in-vitro fertilization, J Clin Child Psychol 27:320, 1998.
961. **Knoester M**, **Helmerhorst FM**, **Vandenbroucke JP**, **van der Westerlaken LA**, **Walther FJ**, **Veen S**, Cognitive development of singletons born after intracytoplasmic sperm injection compared with in vitro fertilization and natural conception, Fertil Steril 90:289, 2008.
962. **Abdel-Mannan O**, **Sutcliffe A**, I was born following ART: how will I get on at school? Semin Fetal Neonatal Med 19:245, 2014.

963. **Hargreave M**, **Jensen A**, **Toender A**, **Andersen KK**, **Kjaer SK**, Fertility treatment and childhood cancer risk: a systematic meta-analysis, Fertil Steril 100:150, 2013.
964. **Williams CL**, **Bunch KJ**, **Stiller CA**, **Murphy MF**, **Botting BJ**, **Wallace WH**, **Davies M**, **Sutcliffe AG**, Cancer risk among children born after assisted conception, N Engl J Med 369:1819, 2013.
965. **Sundh KJ**, **Henningsen AK**, **Kallen K**, **Bergh C**, **Romundstad LB**, **Gissler M**, **Pinborg A**, **Skjaerven R**, **Tiitinen A**, **Vassard D**, **Lannering B**, **Wennerholm UB**, Cancer in children and young adults born after assisted reproductive technology: a Nordic cohort study from the Committee of Nordic ART and Safety (CoNARTaS), Hum Reprod 29:2050, 2014.
966. **Buster JE**, **Bustillo M**, **Thorneycroft IH**, **Simon JA**, **Boyers SP**, **Marshall JR**, **Louw JA**, **Seed RW**, **Seed RG**, Non-surgical transfer of in vivo fertilised donated ova to five infertile women: report of two pregnancies, Lancet 2:223, 1983.
967. **Trounson A**, **Leeton J**, **Besanko M**, **Wood C**, **Conti A**, Pregnancy established in an infertile patient after transfer of a donated embryo fertilised in vitro, Br Med J (Clin Res Ed) 286:835, 1983.
968. **Lutjen P**, **Trounson A**, **Leeton J**, **Findlay J**, **Wood C**, **Renou P**, The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure, Nature 307:174, 1984.
969. **Sauer MV**, **Kavic SM**, Oocyte and embryo donation 2006: reviewing two decades of innovation and controversy, Reprod Biomed Online 12:153, 2006.
970. **Practice Committee of American Society for Reproductive Medicine; Practice Committee of Society for Assisted Reproductive Technology**, Recommendations for gamete and embryo donation: a committee opinion, Fertil Steril 99:47, 2013.
971. **Karnis MF**, **Zimon AE**, **Lalwani SI**, **Timmreck LS**, **Klipstein S**, **Reindollar RH**, Risk of death in pregnancy achieved through oocyte donation in patients with Turner syndrome: a national survey, Fertil Steril 80:498, 2003.
972. **Practice Committee of American Society for Reproductive Medicine**, Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome, Fertil Steril 90:S185, 2008.
973. **Navot D**, **Scott RT**, **Droesch K**, **Veeck LL**, **Liu HC**, **Rosenwaks Z**, The window of embryo transfer and the efficiency of human conception in vitro, Fertil Steril 55:114, 1991.
974. **Navot D**, **Bergh PA**, **Williams M**, **Garrisi GJ**, **Guzman I**, **Sandler B**, **Fox J**, **Schreiner-Engel P**, **Hofmann GE**, **Grunfeld L**, An insight into early reproductive processes through the in vivo model of ovum donation, J Clin Endocrinol Metab 72:408, 1991.
975. **Miles RA**, **Paulson RJ**, **Lobo RA**, **Press MF**, **Dahmoush L**, **Sauer MV**, Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study, Fertil Steril 62:485, 1994.
976. **Navot D**, **Anderson TL**, **Droesch K**, **Scott RT**, **Kreiner D**, **Rosenwaks Z**, Hormonal manipulation of endometrial maturation, J Clin Endocrinol Metab 68:801, 1989.
977. **Li TC**, **Cooke ID**, **Warren MA**, **Goolamallee M**, **Graham RA**, **Aplin JD**, Endometrial responses in artificial cycles: a prospective study comparing four different oestrogen dosages, Br J Obstet Gynaecol 99:751, 1992.
978. **Krasnow JS**, **Lessey BA**, **Naus G**, **Hall LL**, **Guzick DS**, **Berga SL**, Comparison of transdermal versus oral estradiol on endometrial receptivity, Fertil Steril 65:332, 1996.
979. **Tourgeman DE**, **Gentzchein E**, **Stanczyk FZ**, **Paulson RJ**, Serum and tissue hormone levels of vaginally and orally administered estradiol, Am J Obstet Gynecol 180:1480, 1999.
980. **Rosenwaks Z**, Donor eggs: their application in modern reproductive technologies, Fertil Steril 47:895, 1987.
981. **Bourgain C**, **Devroey P**, **Van Waesberghe L**, **Smitz J**, **Van Steirteghem AC**, Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure, Hum Reprod 5:537, 1990.
982. **Gonen Y**, **Casper RF**, **Jacobson W**, **Blankier J**, Endometrial thickness and growth during ovarian stimulation: a possible predictor of implantation in in vitro fertilization, Fertil Steril 52:446, 1989.

983. **Shapiro H**, **Cowell C**, **Casper RF**, The use of vaginal ultrasound for monitoring endometrial preparation in a donor oocyte program, Fertil Steril 59: 1055, 1993.
984. **Csapo AI**, **Pulkkinen MO**, **Wiest WG**, Effects of luteectomy and progesterone replacement therapy in early pregnant patients, Am J Obstet Gynecol 115:759, 1973.
985. **Sauer MV**, **Paulson RJ**, Oocyte donors: a demographic analysis of women at the University of Southern California, Hum Reprod 7:726, 1992.
986. **Mascarenhas M**, **Sunkara SK**, **Antonisamy B**, **Kamath MS**, Higher risk of preterm birth and low birth weight following oocyte donation: a systematic review and meta-analysis, Eur J Obstet Gynecol Reprod Biol 218:60, 2017.
987. **Blazquez A**, **Garcia D**, **Rodriguez A**, **Vassena R**, **Figueras F**, **Vernaeve V**, Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis, J Assist Reprod Genet 33:855, 2016.
988. **Masoudian P**, **Nasr A, de Nanassy J**, **Fung-Kee-Fung K**, **Bainbridge SA**, **El Demellawy D**, Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis, Am J Obstet Gynecol 214:328, 2016.

Chapter twenty nine

REFERENCES

1. **Donnez J**, **Dolmans MM**, Fertility preservation in women, N Engl J Med 377:1657, 2017.
2. **Salama M**, **Woodruff TK**, New advances in ovarian autotransplantation to restore fertility in cancer patients, Cancer Metastasis Rev 34:807, 2015.
3. **Donnez J**, **Dolmans MM**, **Pellicer A**, et al., Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation, Fertil Steril 99:1503, 2013.
4. **Imbert R**, **Moffa F**, **Tsepelidis S**, et al., Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis, Hum Reprod 29:1931, 2014.
5. **Donnez J**, **Jadoul P**, **Squifflet J**, et al., Ovarian tissue cryopreservation and transplantation in cancer patients, Best Pract Res Clin Obstet Gynaecol 24:87, 2010.
6. **Salama M**, **Isachenko V**, **Isachenko E**, **Rahimi G**, **Mallmann P**, Updates in preserving reproductive potential of prepubertal girls with cancer: systematic review, Crit Rev Oncol Hematol 103:10, 2016.
7. **Ward E**, **DeSantis C**, **Robbins A**, **Kohler B**, **Jemal A**, Childhood and adolescent cancer statistics, 2014, CA Cancer J Clin 64:83, 2014.
8. **Caburet S**, **Zavadakova P**, **Ben-Neriah Z**, et al., Genome-wide linkage in a highly consanguineous pedigree reveals two novel loci on chromosome 7 for non-syndromic familial Premature Ovarian Failure, PLoS One 7:e33412, 2012.
9. **Nelson LM**, Clinical practice. Primary ovarian insufficiency, N Engl J Med 360:606, 2009.
10. **Murk W**, **Seli E**, Fertility preservation as a public health issue: an epidemiological perspective, Curr Opin Obstet Gynecol 23:143, 2011.
11. **Raffi F**, **Metwally M**, **Amer S**, The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis, J Clin Endocrinol Metab 97:3146, 2012.
12. **Rienzi L**, **Gracia C**, **Maggiulli R**, et al., Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance, Hum Reprod Update 23:139, 2017.
13. **Mathews TJ**, **Hamilton BE**, Mean age of mothers is on the rise: United States, 2000-2014, NCHS Data Brief (232):1, 2016.
14. **Trounson A**, **Mohr L**, Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo, Nature 305:707, 1983.
15. **Steptoe PC**, **Edwards RG**, Birth after the reimplantation of a human embryo, Lancet 2:366, 1978.
16. **Chen C**, Pregnancy after human oocyte cryopreservation, Lancet 1:884, 1986.
17. **Matson PL**, **Graefling J**, **Junk SM**, **Yovich JL**, **Edirisinghe WR**, Cryopreservation of oocytes and embryos: use of a mouse model to investigate effects upon zona hardness and formulate treatment strategies in an in-vitro fertilization programme, Hum Reprod 12:1550, 1997.
18. **Porcu E**, **Fabbri R**, **Seracchioli R**, **Ciotti PM**, **Magrini O**, **Flamigni C**, Birth of a healthy female after intracytoplasmic sperm injection of cryopreserved human oocytes, Fertil Steril 68:724, 1997.
19. **Polak de Fried E**, **Notrica J**, **Rubinstein M**, **Marazzi A**, **Gomez Gonzalez M**, Pregnancy after human donor oocyte cryopreservation and thawing in association with intracytoplasmic sperm injection in a patient with ovarian failure, Fertil Steril 69:555, 1998.
20. **Ragni G**, **Allegra A**, **Anserini P**, et al., The 2004 Italian legislation regulating assisted reproduction technology: a multicentre survey on the results of IVF cycles, Hum Reprod 20:2224, 2005.
21. **Antinori M**, **Licata E**, **Dani G**, **Cerusico F**, **Versaci C**, **Antinori S**, Cryotop vitrification of human oocytes results in high survival rate and healthy deliveries, Reprod Biomed Online 14:72, 2007.
22. **Cao YX**, **Xing Q**, **Li L**, et al., Comparison of survival and embryonic development in human oocytes cryopreserved by slow-freezing and vitrification, Fertil Steril 92:1306, 2009.
23. **Fadini R**, **Brambillasca F**, **Renzini MM**, et al., Human oocyte cryopreservation: comparison between slow and ultrarapid methods, Reprod Biomed Online 19:171, 2009.

24. **Smith GD**, **Serafini PC**, **Fioravanti J**, et al., Prospective randomized comparison of human oocyte cryopreservation with slow-rate freezing or vitrification, Fertil Steril 94:2088, 2010.
25. **Cil AP**, **Seli E**, Current trends and progress in clinical applications of oocyte cryopreservation, Curr Opin Obstet Gynecol 25:247, 2013.
26. **Loren AW**, **Mangu PB**, **Beck LN**, et al., Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol 31:2500, 2013.
27. **Grifo JA**, **Noyes N**, Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients, Fertil Steril 93:391, 2010.
28. **Cobo A**, **Garcia-Velasco JA**, **Coello A**, **Domingo J**, **Pellicer A**, **Remohi J**, Oocyte vitrification as an efficient option for elective fertility preservation, Fertil Steril 105:755.e8, 2016.
29. **Pellicer A**, Fertility preservation: what is best—oocyte vitrification or tissue freezing? 24th World Congress on Controversies in Obstetrics, Gynecology & Infertility, Amsterdam, Netherlands, 2016.
30. **Wallace WH**, **Anderson RA**, **Irvine DS**, Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 6:209, 2005.
31. **Levine JM**, **Kelvin JF**, **Quinn GP**, **Gracia CR**, Infertility in reproductive-age female cancer survivors, Cancer 121:1532, 2015.
32. **Cil AP**, **Bang H**, **Oktay K**, Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis, Fertil Steril 100:492.e3, 2013.
33. **Cakmak H**, **Katz A**, **Cedars MI**, **Rosen MP**, Effective method for emergency fertility preservation: random-start controlled ovarian stimulation, Fertil Steril 100:1673, 2013.
34. **Reddy J**, **Oktay K**, Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer, Fertil Steril 98: 1363, 2012.
35. **Oktay K**, **Buyuk EL**, **Libertella N**, **Akar M**, **Rosenwaks Z**, Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation, J Clin Oncol 23:4347, 2005.
36. **Parrott DM**, The fertility of mice with orthotopic ovarian grafts derived from frozen tissue, J Reprod Fertil 1:230, 1960.
37. **Oktay K**, **Karlikaya GG**, **Aydin BA**, Ovarian cryopreservation and transplantation: basic aspects, Mol Cell Endocrinol 169:105, 2000.
38. **Donnez J**, **Dolmans MM**, **Demylle D**, et al., Live birth after orthotopic transplantation of cryopreserved ovarian tissue, Lancet 364:1405, 2004.
39. **Silber SJ**, Ovary cryopreservation and transplantation for fertility preservation, Mol Hum Reprod 18:59, 2012.
40. **Kolp LA**, **Hubayter Z**, Autotransplantation of cryopreserved ovarian tissue: a procedure with promise, risks, and a need for a registry, Fertil Steril 95:1879, 2011.
41. **Resetkova N**, **Hayashi M**, **Kolp LA**, **Christianson MS**, Fertility preservation for prepubertal girls: update and current challenges, Curr Obstet Gynecol Rep 2:218, 2013.
42. **Ernst E**, **Bergholdt S**, **Jorgensen JS**, **Andersen CY**, The first woman to give birth to two children following transplantation of frozen/thawed ovarian tissue, Hum Reprod 25:1280, 2010.
43. **Demeestere I**, **Simon P**, **Moffa F**, **Delbaere A**, **Englert Y**, Birth of a second healthy girl more than 3 years after cryopreserved ovarian graft, Hum Reprod 25:1590, 2010.
44. **Demeestere I**, **Simon P**, **Dedeken L**, et al., Live birth after autograft of ovarian tissue cryopreserved during childhood, Hum Reprod 30:2107, 2015.
45. **Silber S**, Ovarian tissue cryopreservation and transplantation: scientific implications, J Assist Reprod Genet 33:1595, 2016.
46. **Oliver D**, David Oliver: Why shouldn't hospitals challenge inspections? BMJ 351:h5320, 2015.
47. **Van der Ven H**, **Liebenthron J**, **Beckmann M**, et al., Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates, Hum Reprod 31:2031, 2016.
48. **Bedaiwy MA**, **El-Nashar SA**, **El Saman AM**, et al., Reproductive outcome after transplantation of ovarian

tissue: a systematic review, Hum Reprod 23:2709, 2008.
49. **Jensen AK**, **Macklon KT**, **Fedder J**, **Ernst E**, **Humaidan P**, **Andersen CY**, 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children, J Assist Reprod Genet 34:325, 2017.
50. **Martinez-Madrid B**, **Dolmans MM**, **Van Langendonckt A**, **Defrere S**, **Donnez J**, Freeze-thawing intact human ovary with its vascular pedicle with a passive cooling device, Fertil Steril 82:1390, 2004.
51. **Silber SJ**, **Grudzinskas G**, **Gosden RG**, Successful pregnancy after microsurgical transplantation of an intact ovary, N Engl J Med 359:2617, 2008.
52. **Mullen SF**, **Critser JK**, The science of cryobiology, Cancer Treat Res 138:83, 2007.
53. **Karlsson JO**, **Toner M**, Long-term storage of tissues by cryopreservation: critical issues, Biomaterials 17:243, 1996.
54. **Kawamura K**, **Cheng Y**, **Suzuki N**, et al., Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment, Proc Natl Acad Sci U S A 110:17474, 2013.
55. **Suzuki N**, **Yoshioka N**, **Takae S**, et al., Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency, Hum Reprod 30:608, 2015.
56. **Kuleshova L**, **Gianaroli L**, **Magli C**, **Ferraretti A**, **Trounson A**, Birth following vitrification of a small number of human oocytes: case report, Hum Reprod 14:3077, 1999.
57. **Amorim CA**, **Curaba M**, **Van Langendonckt A**, **Dolmans MM**, **Donnez J**, Vitrification as an alternative means of cryopreserving ovarian tissue, Reprod Biomed Online 23:160, 2011.
58. **Oktay K**, **Karlikaya G**, Ovarian function after transplantation of frozen, banked autologous ovarian tissue, N Engl J Med 342:1919, 2000.
59. **Meirow D**, **Levron J**, **Eldar-Geva T**, et al., Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy, N Engl J Med 353:318, 2005.
60. **Sonmezer M**, **Oktay K**, Orthotopic and heterotopic ovarian tissue transplantation, Best Pract Res Clin Obstet Gynaecol 24:113, 2010.
61. Suzuki N, Donnez J, editors. Gonadal tissue cryopreservation in fertility preservation. Tokyo: Springer; 2016 Jun 21.
62. **Oktay K**, Spontaneous conceptions and live birth after heterotopic ovarian transplantation: is there a germline stem cell connection? Hum Reprod 21:1345, 2006.
63. **Oktay K**, **Turkcuoglu I**, **Rodriguez-Wallberg KA**, Four spontaneous pregnancies and three live births following subcutaneous transplantation of frozen banked ovarian tissue: what is the explanation? Fertil Steril 95:804.e7, 2011.
64. **Demeestere I**, **Simon P**, **Emiliani S**, **Delbaere A**, **Englert Y**, Orthotopic and heterotopic ovarian tissue transplantation, Hum Reprod Update 15:649, 2009.
65. **Donnez J**, **Dolmans MM**, Transplantation of ovarian tissue, Best Pract Res Clin Obstet Gynaecol 28:1188, 2014.
66. **Stern CJ**, **Gook D**, **Hale LG**, et al., First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy, Hum Reprod 28:2996, 2013.
67. **Stern CJ**, **Gook D**, **Hale LG**, et al., Delivery of twins following heterotopic grafting of frozen-thawed ovarian tissue, Hum Reprod 29:1828, 2014.
68. **Eppig JJ**, **O'Brien MJ**, Development in vitro of mouse oocytes from primordial follicles, Biol Reprod 54:197, 1996.
69. **Eppig JJ**, **O'Brien MJ**, **Pendola FL**, **Watanabe S**, Factors affecting the developmental competence of mouse oocytes grown in vitro: follicle-stimulating hormone and insulin, Biol Reprod 59:1445, 1998.
70. **Eppig JJ**, **Hosoe M**, **O'Brien MJ**, **Pendola FM**, **Requena A**, **Watanabe S**, Conditions that affect acquisition of developmental competence by mouse oocytes in vitro: FSH, insulin, glucose and ascorbic acid, Mol Cell Endocrinol 163:109, 2000.
71. **O'Brien MJ**, **Pendola JK**, **Eppig JJ**, A revised protocol for in vitro development of mouse oocytes from primordial follicles dramatically improves their developmental competence, Biol Reprod 68:1682, 2003.
72. **McLaughlin M**, **Albertini DF**, **Wallace WHB**, **Anderson RA**, **Telfer EE**, Metaphase II oocytes from

human unilaminar follicles grown in a multi-step culture system, Mol Hum Reprod 24:135, 2018.
73. **Hsueh AJ**, **Kawamura K**, **Cheng Y**, **Fauser BC**, Intraovarian control of early folliculogenesis, Endocr Rev 36:1, 2015.
74. **Li J**, **Kawamura K**, **Cheng Y**, et al., Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci U S A 107:10280, 2010.
75. **Cordeiro CN**, **Christianson MS**, **Selter JH**, **Segars JH Jr**, In vitro activation: a possible new frontier for treatment of primary ovarian insufficiency, Reprod Sci 23:429, 2016.
76. **van Kasteren YM**, **Schoemaker J**, Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy, Hum Reprod Update 5:483, 1999.
77. **Prasath EB**, **Chan ML**, **Wong WH**, et al., First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient, Hum Reprod 29:276, 2014.
78. **Hourvitz A**, **Yerushalmi GM**, **Maman E**, et al., Combination of ovarian tissue harvesting and immature oocyte collection for fertility preservation increases preservation yield, Reprod Biomed Online 31:497, 2015.
79. **Lass A**, **Paul M**, **Margara R**, **Winston RM**, Women with one ovary have decreased response to GnRHa/HMG ovulation protocol in IVF but the same pregnancy rate as women with two ovaries, Hum Reprod 12:298, 1997.
80. **Bjelland EK**, **Wilkosz P**, **Tanbo TG**, **Eskild A**, Is unilateral oophorectomy associated with age at menopause? A population study (the HUNT2 Survey), Hum Reprod 29:835, 2014.
81. **Yasui T**, **Hayashi K**, **Mizunuma H**, et al., Factors associated with premature ovarian failure, early menopause and earlier onset of menopause in Japanese women, Maturitas 72:249, 2012.
82. **Andersen CY**, **Kristensen SG**, Novel use of the ovarian follicular pool to postpone menopause and delay osteoporosis, Reprod Biomed Online 31:128, 2015.
83. **Lobo RA**, What the future holds for women after menopause: where we have been, where we are, and where we want to go, Climacteric 17(Suppl 2):12, 2014.
84. **Lobo RA**, **Davis SR**, **De Villiers TJ**, et al., Prevention of diseases after menopause, Climacteric 17:540, 2014.
85. **Shikanov A**, **Zhang Z**, **Xu M**, et al., Fibrin encapsulation and vascular endothelial growth factor delivery promotes ovarian graft survival in mice, Tissue Eng Part A 17:3095, 2011.
86. **Oktay K**, **Bedoschi G**, **Pacheco F**, **Turan V**, **Emirdar V**, First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozen-banked ovarian tissue with a human extracellular matrix scaffold using robot-assisted minimally invasive surgery, Am J Obstet Gynecol 214:94.e1, 2016.
87. **Kniazeva E**, **Hardy AN**, **Boukaidi SA**, **Woodruff TK**, **Jeruss JS**, **Shea LD**, Primordial follicle transplantation within designer biomaterial grafts produce live births in a mouse infertility model, Sci Rep 5:17709, 2015.
88. **Rios PD**, **Kniazeva E**, **Lee HC**, et al., Retrievable hydrogels for ovarian follicle transplantation and oocyte collection, Biotechnol Bioeng 115;2075, 2018.
89. **Cakmak H**, **Seli E**, Gonadotropin-releasing hormone agonists, In: Seli E, Agarwal A, eds. Fertility Preservation, Springer, New York, 2012, p. 145.
90. **Oktay K**, **Nugent D**, **Newton H**, **Salha O**, **Chatterjee P**, **Gosden RG**, Isolation and characterization of primordial follicles from fresh and cryopreserved human ovarian tissue, Fertil Steril 67:481, 1997.
91. **McNatty KP**, **Heath DA**, **Lundy T**, et al., Control of early ovarian follicular development, J Reprod Fertil Suppl 54:3, 1999.
92. **Oktay K**, **Briggs D**, **Gosden RG**, Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles, J Clin Endocrinol Metab 82:3748, 1997.
93. **Blumenfeld Z**, **von Wolff M**, GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy, Hum Reprod Update 14:543, 2008.
94. **Kitajima Y**, **Endo T**, **Nagasawa K**, et al., Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5, Endocrinology 147:694, 2006.

95. **Saitta A**, **Altavilla D**, **Cucinotta D**, et al., Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women, Arterioscler Thromb Vasc Biol 21:1512, 2001.
96. **Hsueh AJ**, **Schaeffer JM**, Gonadotropin-releasing hormone as a paracrine hormone and neurotransmitter in extra-pituitary sites, J Steroid Biochem 23:757, 1985.
97. **Imai A**, **Sugiyama M**, **Furui T**, **Tamaya T**, **Ohno T**, Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage, Gynecol Obstet Invest 63:102, 2007.
98. **Torrealday S**, **Lalioti MD**, **Guzeloglu-Kayisli O**, **Seli E**, Characterization of the gonadotropin releasing hormone receptor (GnRHR) expression and activity in the female mouse ovary, Endocrinology 154:3877, 2013.
99. **Zhang Y**, **Xiao Z**, **Wang Y**, **Luo S**, **Li X**, **Li S**, Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients, PLoS One 8:e80444, 2013.
100. **Lambertini M**, **Moore HCF**, **Leonard RCF**, et al., Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data, J Clin Oncol 36:1981, 2018.
101. **Ben-Aharon I**, **Gafter-Gvili A**, **Leibovici L**, **Stemmer SM**, Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis, Breast Cancer Res Treat 122:803, 2010.
102. **Demeestere I**, **Brice P**, **Peccatori FA**, et al., No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial, J Clin Oncol 34:2568, 2016.
103. **Bedaiwy MA**, **Abou-Setta AM**, **Desai N**, et al., Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis, Fertil Steril 95:906.e1, 2011.
104. **Roness H**, **Kashi O**, **Meirow D**, Prevention of chemotherapy-induced ovarian damage, Fertil Steril 105:20, 2016.
105. **Vanacker J**, **Luyckx V**, **Dolmans MM**, et al., Transplantation of an alginate-matrigel matrix containing isolated ovarian cells: first step in developing a biodegradable scaffold to transplant isolated preantral follicles and ovarian cells, Biomaterials 33:6079, 2012.
106. **Luyckx V**, **Dolmans MM**, **Vanacker J**, et al., A new step toward the artificial ovary: survival and proliferation of isolated murine follicles after autologous transplantation in a fibrin scaffold, Fertil Steril 101:1149, 2014.
107. **Camboni A**, **Van Langendonckt A**, **Donnez J**, **Vanacker J**, **Dolmans MM**, **Amorim CA**, Alginate beads as a tool to handle, cryopreserve and culture isolated human primordial/primary follicles, Cryobiology 67:64, 2013.
108. **Callejo J**, **Salvador C**, **Gonzalez-Nunez S**, et al., Live birth in a woman without ovaries after autograft of frozen-thawed ovarian tissue combined with growth factors, J Ovarian Res 6:33, 2013.
109. **Abir R**, **Fisch B**, **Jessel S**, **Felz C**, **Ben-Haroush A**, **Orvieto R**, Improving posttransplantation survival of human ovarian tissue by treating the host and graft, Fertil Steril 95:1205, 2011.
110. **Soleimani R**, **Heytens E**, **Oktay K**, Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants, PLoS One 6:e19475, 2011.
111. **Herraiz S**, **Buigues A**, **Diaz-Garcia C**, et al., Fertility rescue and ovarian follicle growth promotion by bone marrow stem cell infusion, Fertil Steril 109:908.e2, 2018.

Chapter thirty

REFERENCES

1. **Malpas P**, A study of abortion sequence, J Obstet Gynaecol Br Emp 45:932, 1938.
2. **Eastman NJ**, Habitual abortion, In: Meigs JV, Sturgis S, eds. Progress in Gynecology, Vol. 1, Grune & Stratton, New York, 1946.
3. **Warburton D**, **Fraser FS**, Spontaneous abortion risks in man: data from reproductive histories collected in a medical genetics unit, Am J Hum Genet 16:1, 1964.
4. **Poland BJ**, **Miller JR**, **Jones DC**, **Trimble BK**, Reproductive counseling in patients who have had a spontaneous abortion, Am J Obstet Gynecol 127:685, 1977.
5. **Roman E**, Fetal loss rates and their relation to pregnancy order, J Epidemiol Community Health 38:29, 1984.
6. **Clifford K**, **Rai R**, **Regan L**, Future pregnancy outcome in unexplained recurrent first trimester miscarriage, Hum Reprod 12:387, 1997.
7. **Stirrat GM**, Recurrent miscarriage, Lancet 336:673, 1990.
8. **Lee RM**, **Silver RM**, Recurrent pregnancy loss: summary and clinical implications, Seminar Reprod Med 18:433, 2000.
9. **Christiansen OB**, **Nybo Andersen AM**, **Bosch E**, **Daya S**, **Delves PJ**, **Hviid TV**, **Kutteh WH**, **Laird SM**, **Li TC**, **van der Ven K**, Evidence-based investigations and treatments of recurrent pregnancy loss, Fertil Steril 83:821, 2005.
10. **Jacobs PA**, **Hassold TJ**, Chromosomal abnormalities: origin and etiology in abortions and live births, In: Vogel F, Sperling K, eds. Human Genetics, Springer-Verlag, Berlin, 1987, p. 233.
11. **Quenby S**, **Vince G**, **Farquharson R**, **Aplin J**, Recurrent miscarriage: a defect in nature's quality control? Hum Reprod 17:1959, 2002.
12. **Geller PA**, **Klier CM**, **Neugebauer R**, Anxiety disorders following miscarriage, J Clin Psychiatry 62:432, 2001.
13. **Neugebauer R**, **Kline J**, **Shrout P**, **Skodol A**, **O'Connor P**, **Geller PA**, **Stein Z**, **Susser M**, Major depressive disorder in the 6 months after miscarriage, JAMA 277:383, 1997.
14. **Gosden RG**, Maternal age: a major factor affecting the prospects and outcome of pregnancy, Ann N Y Acad Sci 442:45, 1985.
15. **Wilcox AJ**, **Weiberg CR**, **O'Connor JF**, **Baird DD**, **Schlatterer JP**, **Canfield RE**, **Armstrong EG**, **Nisula BC**, Incidence of early loss of pregnancy, N Engl J Med 319:189, 1988.
16. **Zinaman MJ**, **Clegg ED**, **Brown CC**, **O'Connor J**, **Selevan SG**, Estimates of human fertility and pregnancy loss, Fertil Steril 65:503, 1996.
17. **Edmonds DK**, **Lindsay KS**, **Miller JF**, **Williamson E**, **Wood PJ**, Early embryonic mortality in women, Fertil Steril 38:447, 1982.
18. **Regan L**, **Braude PR**, **Trembath PL**, Influence of past reproductive performance on risk of spontaneous abortion, Br Med J 299:541, 1989.
19. **Stirrat GM**, Recurrent miscarriage. II: Clinical associations, causes, and management, Lancet 336:728, 1990.
20. **Bulletti C**, **Flamigni C**, **Giacomucci E**, Reproductive failure due to spontaneous abortion and recurrent miscarriage, Hum Reprod Update 2:118, 1996.
21. **Maroulis GB**, Effect of aging on fertility and pregnancy, Semin Reprod Endocrinol 9:165, 1991.
22. **Stein ZA**, A woman's age: childbearing and childrearing, Am J Epidemiol 121:327, 1985.
23. **Hassold T**, **Chiu D**, Maternal age-specific rates of numerical chromosome abnormalities with special reference to trisomy, Hum Genet 70:11, 1985.
24. **Warburton D**, **Kline J**, **Stein Z**, **Strobino B**, Cytogenetic abnormalities in spontaneous abortions of recognized conceptions, In: Porter IH, ed. Perinatal Genetics: Diagnosis and Treatment, Academic Press, New York, 1986, p. 133.
25. **Nybo Andersen AM**, **Wohlfahrt J**, **Christens P**, **Olsen J**, **Melbye M**, Maternal age and fetal loss: population based register linkage study, Br Med J 320:1708, 2000.
26. **Warburton D**, Reproductive loss: how much is preventable? N Engl J Med 316:158, 1987.

27. **Goldstein SR**, Embryonic death in early pregnancy: a new look at the first trimester, Obstet Gynecol 84:294, 1994.
28. **Simpson JL**, **Mills JL**, **Holmes LB**, **Ober CL**, **Aarons J**, **Jovanovic L**, **Knopp RH**, Low fetal loss rates after ultrasound-proved viability in early pregnancy, JAMA 258:2555, 1987.
29. **Rosen GF**, **Silva PD**, **Patrizio P**, **Asch RH**, **Yee B**, Predicting pregnancy outcome by the observation of a gestational sac or of early fetal cardiac motion with transvaginal ultrasonography, Fertil Steril 54:260, 1990.
30. **van Leeuwen I**, **Branch DW**, **Scott JR**, First trimester ultrasonography findings in women with a history of recurrent pregnancy loss, Am J Obstet Gynecol 168:111, 1993.
31. **Laufer MR**, **Ecker JL**, **Hill JA**, Pregnancy outcome following ultrasound-detected fetal cardiac activity in women with a history of multiple spontaneous abortions, J Soc Gynecol Invest 1:138, 1994.
32. **Falco P**, **Milano V**, **Pilu G**, **David C**, **Grisolia G**, **Rizzo N**, **Bovicelli L**, Sonography of pregnancies with first-trimester bleeding and a viable embryo: a study of prognostic indicators by logistic regression analysis, Ultrasound Obstet Gynecol 7:165, 1996.
33. **Tannirandorn Y**, **Sangsawang S**, **Manotaya S**, **Uerpairojkit B**, **Samritpradit P**, **Charoenvidhya D**, Fetal loss in threatened abortion after embryonic/fetal heart activity, Int J Gynaecol Obstet 81:263, 2003.
34. **Nagy S**, **Bush M**, **Stone J**, **Lapinski RH**, **Gardo S**, Clinical significance of subchorionic and retroplacental hematomas detected in the first trimester of pregnancy, Obstet Gynecol 102:94, 2003.
35. **Laboda LA**, **Estroff JA**, **Benacerraf BR**, First trimester bradycardia. A sign of impending fetal loss, J Ultrasound Med 8:561, 1989.
36. **Deaton JL**, **Honoré GM**, **Huffman CS**, **Bauguess P**, Early transvaginal ultrasound following an accurately dated pregnancy: the importance of finding a yolk sac or fetal heart motion, Hum Reprod 12:2820, 1997.
37. **Boue J**, **Boue A**, **Lazar P**, Retrospective and prospective epidemiological studies of 1500 karyotyped spontaneous human abortions, Teratology 12:11, 1975.
38. **Guerneri S**, **Bettio D**, **Simoni G**, **Brambat B**, **Lanzani A**, **Fraccaro M**, Prevalence and distribution of chromosome abnormalities in a sample of first-trimester internal abortions, Hum Reprod 2:735, 1987.
39. **Simpson JL**, Genes, chromosomes, and reproductive failure, Fertil Steril 33:107, 1980.
40. **Goddijn M**, **Leschot NJ**, Genetic aspects of miscarriage, Baillieres Best Pract Res Clin Obstet Gynaecol 14:855, 2000.
41. **Yusuf RZ**, **Naeem R**, Cytogenetic studies of spontaneous miscarriages: a seven year study to compare significance of primary vs. secondary culture methods for assessment of fetal karyotype yield and maternal cell contamination, Early Pregnancy 5:121, 2001.
42. **Lomax B**, **Tang S**, **Separovic E**, **Phillips D**, **Hillard E**, **Thomson T**, **Kalousek DK**, Comparative genomic hybridization in combination with flow cytometry improves results of cytogenetic analysis of spontaneous abortions, Am J Hum Genet 66:1516, 2000.
43. **Fritz B**, **Hallermann C**, **Olert J**, **Fuchs B**, **Bruns M**, **Aslan M**, **Schmidt S**, **Coerdt W**, **Muntefering H**, **Rehder H**, Cytogenetic analyses of culture failures by comparative genomic hybridisation (CGH)—re-evaluation of chromosome aberration rates in early spontaneous abortions, Eur J Hum Genet 9:539, 2001.
44. **Philipp T**, **Philipp K**, **Reiner A**, **Beer F**, **Kalousek DK**, Embryoscopic and cytogenetic analysis of 233 missed abortions: factors involved in the pathogenesis of developmental defects of early failed pregnancies, Hum Reprod 18:1724, 2003.
45. **Ward KJ**, Genetic factors in recurrent pregnancy loss, Semin Reprod Med 18:425, 2000.
46. **Carr DH**, Chromosome studies in selected spontaneous abortions and early pregnancy loss, Obstet Gynecol 37:570, 1971.
47. **Stephenson MD**, **Awartani KA**, **Robinson WP**, Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study, Hum Reprod 17:446, 2002.
48. **Stern JJ**, **Dorfmann AD**, **Gutierrez-Najar AJ**, **Cerrillo M**, **Coulam CB**, Frequency of abnormal karyotypes among abortuses from women with and without a history of recurrent spontaneous abortion, Fertil Steril 65:250, 1996.
49. **Ogasawara M**, **Aoki K**, **Okada S**, **Suzumori K**, Embryonic karyotype of abortuses in relation to the number of previous miscarriages, Fertil Steril 73:300, 2000.

50. **Carp H**, **Toder V**, **Aviram A**, **Daniely M**, **Mashiach S**, **Barkai G**, Karyotype of the abortus in recurrent miscarriage, Fertil Steril 75:678, 2001.
51. **Tho PT**, **Byrd JR**, **McDonough PG**, Etiologies and subsequent reproductive performance of 100 couples with recurrent abortion, Fertil Steril 32:389, 1979.
52. **Harger JH**, **Archer DF**, **Marchese SG**, **Muracca-Clemens M**, **Garver KL**, Etiology of recurrent pregnancy losses and outcome of subsequent pregnancies, Obstet Gynecol 62:574, 1983.
53. **Stray-Pedersen B**, **Stray-Pedersen S**, Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion, Am J Obstet Gynecol 148:140, 1984.
54. **Portnoi M-F**, **Joye N**, **van den Akker J**, **Morlier G**, **Taillemite JL**, Karyotypes of 1142 couples with recurrent abortion, Obstet Gynecol 72:310, 1988.
55. **Plouffe L Jr**, **White EW**, **Tho ST**, **Sweet CS**, **Layman LC**, **Whitman GF**, **McDonough PG**, Etiologic factors of recurrent abortion and subsequent reproductive performance of couples: have we made any progress in the past 10 years? Am J Obstet Gynecol 167:313, 1992.
56. **Tulppala M**, **Palosuo T**, **Ramsay T**, **Miettinen A**, **Salonen R**, **Ylikorkala O**, A prospective study of 63 couples with a history of recurrent spontaneous abortions: contributing factors and outcome of subsequent pregnancies, Hum Reprod 8:7640, 1993.
57. **Fryns JP**, **Van Buggenhout G**, Structural chromosome rearrangements in couples with recurrent fetal wastage, Eur J Obstet Gynecol Reprod Biol 81:171, 1998.
58. **De Braekeleer M**, **Dao TN**, Cytogenetic studies in couples experiencing repeated pregnancy losses, Hum Reprod 5:519, 1990.
59. **Gardner RJM**, **Sutherland GR**, Autosomal reciprocal translocations. Chromosome Abnormalities and Genetic Counseling, Oxford University Press, New York, 1996, p. 59.
60. **Egozcue J**, **Blanco J**, **Anton E**, **Egozcue S**, **Sarrate Z**, **Vidal F**, Genetic analysis of sperm and implications of severe male infertility—a review, Placenta 24(Suppl 2): S62, 2003.
61. **Shi Q**, **Ko E**, **Barclay L**, **Hoang T**, **Rademaker A**, **Martin R**, Cigarette smoking and aneuploidy in human sperm, Mol Reprod Dev 59:417, 2001.
62. **Escudero T**, **Abdelhadi I**, **Sandalinas M**, **Munne S**, Predictive value of sperm fluorescence in situ hybridization analysis on the outcome of preimplantation genetic diagnosis for translocations, Fertil Steril 79 (Suppl 3):1528, 2003.
63. **Fraccaro M**, **Lindsten J**, **Ford CE**, **Iselius L**, The 11q;22q translocation: a European collaborative analysis of 43 cases, Hum Genet 56:21, 1980.
64. **Iselius L**, **Lindsten J**, **Aurias A**, **Fraccaro M**, **Bastard C**, **Bottelli AM**, **Bui TH**, **Caufin D**, **Dalpra L**, **Delendi N**, et al., The 11q;22q translocation: a collaborative study of 20 new cases and analysis of 110 families, Hum Genet 64:343, 1983.
65. **Zackai EH**, **Emanuel BS**, Site-specific reciprocal translocation, t(11;22) (q23;q11), in several unrelated families with 3:1 meiotic disjunction, Am J Med Genet 7:507, 1980.
66. **Teo SH**, **Tan M**, **Knight L**, **Yeo SH**, **Ng I**, Pericentric inversion 9—incidence and clinical significance, Ann Acad Med Singapore 24:302, 1995.
67. **Ferfouri F**, **Clement P**, **Gomes DM**, **Minz M**, **Amar E**, **Selva J**, **Vialard F**, Is classic pericentric inversion of chromosome 2 inv(2)(p11q13) associated with an increased risk of unbalanced chromosomes? Fertil Steril 92:1497, 2009.
68. **van den Boogaard E**, **Kaandorp SP**, **Franssen MT**, **Mol BW**, **Leschot NJ**, **Wouters CH**, **Van der Veen F**, **Korevaar JC**, **Goddijn M**, Consecutive or non-consecutive recurrent miscarriage: is there any difference in carrier status? Hum Reprod 25:1411, 2010.
69. **Barratt PJ**, **Juberg RC**, **Fritz MA**, **Holliday DJ**, Fetal death associated with a t(1;14) in three generations, Am J Med Genet Suppl 3:157, 1987.
70. **Pellestor F**, **Andreo B**, **Arnal F**, **Humeau C**, **Demaille J**, Maternal aging and chromosomal abnormalities: new data drawn from in vitro unfertilized human oocytes, Hum Genet 112:195, 2003.
71. **Angell R**, Mechanism of chromosome nondisjunction in human oocytes, Prog Clin Biol Res 393:13, 1995.
72. **Angell R**, First-meiotic-division nondisjunction in human oocytes, Am J Hum Genet 61:23, 1997.

73. **Kuliev A**, **Cieslak J**, **Ilkevitch Y**, **Verlinsky Y**, Chromosomal abnormalities in a series of 6,733 human oocytes in preimplantation diagnosis for age-related aneuploidies, Reprod Biomed Online 6:54, 2003.
74. **Nasmyth K**, Disseminating the genome: joining, resolving, and separating sister chromatids during mitosis and meiosis, Annu Rev Genet 35:673, 2001.
75. **Battaglia DE**, **Goodwin P**, **Klein NA**, **Soules MR**, Influence of maternal age on meiotic spindle assembly in oocytes from naturally cycling women, Hum Reprod 11:2217, 1996.
76. **Volarcik K**, **Sheean L**, **Goldfarb J**, **Woods L**, **Abdul-Karim FW**, **Hunt P**, The meiotic competence of in-vitro matured human oocytes is influenced by donor age: evidence that folliculogenesis is compromised in the reproductively aged ovary, Hum Reprod 13:154, 1998.
77. **Hassold T**, **Hunt P**, To err (meiotically) is human: the genesis of human aneuploidy, Nat Rev Genet 2:280, 2001.
78. **Trout SW**, **Seifer DB**, Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values? Fertil Steril 74:335, 2000.
79. **Hofmann GE**, **Khoury J**, **Thie J**, Recurrent pregnancy loss and diminished ovarian reserve, Fertil Steril 74:1192, 2000.
80. **Katz-Jaffe MG**, **Surrey ES**, **Minjarez DA**, **Gustofson RL**, **Stevens JM**, **Schoolcraft WB**, Association of abnormal ovarian reserve parameters with a higher incidence of aneuploid blastocysts, Obstet Gynecol 121(1):71, 2013. doi:http://10.1097/AOG.0b013e318278eeda.
81. **Shahine LK**, **Marshall L**, **Lamb JD**, **Hickok LR**, Higher rates of aneuploidy in blastocysts and higher risk of no embryo transfer in recurrent pregnancy loss patients with diminished ovarian reserve undergoing in vitro fertilization, Fertil Steril 106(5):1124, 2016. doi:10.1016/j.fertnstert.2016.06.016.
82. **Morin SJ**, **Patounakis G**, **Juneau CR**, **Neal SA**, **Scott RT Jr**, **Seli E**, Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance, Hum Reprod, 2018.
83. **Bishop LA**, **Richter KS**, **Patounakis G**, **Andriani L**, **Moon K**, **Devine K**, Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss in younger in vitro fertilization patients, Fertil Steril 108(6):980, 2017. doi:10.1016/j.fertnstert.2017.09.011.
84. **Treloar AE**, Menstrual cyclicity and the pre-menopause, Maturitas 3:249, 1981.
85. **van Noord PAH**, **Dubas JS**, **Dorland M**, **Boersma H**, **te Velde E**, Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors, Fertil Steril 68:95, 1997.
86. **Tibiletti MG**, **Testa G**, **Vegetti W**, **Alagna F**, **Taborelli M**, **Dalpra L**, **Bolis PF**, **Crosignani PG**, The idiopathic forms of premature menopause and early menopause show the same genetic pattern, Hum Reprod 14:2731, 1999.
87. **Vegetti W**, **Marozzi A**, **Manfredini E**, **Testa G**, **Alagna F**, **Nicolosi A**, **Caliari I**, **Taborelli M**, **Tibiletti MG**, **Dalpra L**, **Crosignani PG**, Premature ovarian failure, Mol Cell Endocrinol 161:53, 2000.
88. **Nikolaou D**, **Templeton A**, Early ovarian ageing: a hypothesis: detection and clinical relevance, Hum Reprod 18:1137, 2003.
89. **Kline J**, **Kinney A**, **Levin B**, **Warburton D**, Trisomic pregnancy and earlier age at menopause, Am J Hum Genet 67:395, 2000.
90. **Nasseri A**, **Mukherjee T**, **Grifo JA**, **Noyes N**, **Krey L**, **Copperman AB**, Elevated day 3 serum follicle stimulating hormone and/or estradiol may predict fetal aneuploidy, Fertil Steril 71:715, 1999.
91. **van Beresteijn ECH**, **Korevaar JC**, **Huijbregts PCW**, **Schouten EG**, **Burema J**, **Kok FJ**, Perimenopausal increase in serum cholesterol: a 10-year longitudinal study, Am J Epidemiol 137:383, 1993.
92. **van Montfrans JM**, **Dorland M**, **Oosterhuis GJ**, **van Vugt JM**, **Rekers-Mombarg LT**, **Lambalk CB**, Increased concentrations of follicle-stimulating hormone in mothers of children with Down's syndrome, Lancet 353:1853, 1999.
93. **van Montfrans JM**, **van Hooff MH**, **Martens F**, **Lambalk CB**, Basal FSH, estradiol and inhibin B concentrations in women with a previous Down's syndrome affected pregnancy, Hum Reprod 17:44, 2002.

94. **Freeman SB**, **Yang Q**, **Allran K**, **Taft LF**, **Sherman SL**, Women with a reduced ovarian complement may have an increased risk for a child with Down syndrome, Am J Hum Genet 66:1680, 2000.
95. **Sangha KK**, **Stephenson MD**, **Brown CJ**, **Robinson WP**, Extremely skewed X-chromosome inactivation is increased in women with recurrent spontaneous abortion, Am J Hum Genet 65:913, 1999.
96. **Lanasa MC**, **Hogge WA**, X chromosome defects as an etiology of recurrent spontaneous abortion, Semin Reprod Med 18:97, 2000.
97. **Uehara S**, **Hashiyada M**, **Sato K**, **Sato Y**, **Fujimori K**, **Okamura K**, Preferential X-chromosome inactivation in women with idiopathic recurrent pregnancy loss, Fertil Steril 76:908, 2001.
98. **Beever CL**, **Stephenson MD**, **Penaherrera MS**, **Jiang RH**, **Kalousek DK**, **Hayden M**, **Field L**, **Brown CJ**, **Robinson WP**, Skewed X-chromosome inactivation is associated with trisomy in women ascertained on the basis of recurrent spontaneous abortion or chromosomally abnormal pregnancies, Am J Hum Genet 72:399, 2003.
99. **Bagislar S**, **Ustuner I**, **Cengiz B**, **Soylemiez F**, **Akyerli CB**, **Ceylaner S**, **Ceylaner G**, **Acar A**, **Ozcelik T**, Extremely skewed X-chromosome inactivation patterns in women with recurrent spontaneous abortion, Aust N Z J Obstet Gynaecol 46:384, 2006.
100. **Hogge WA**, **Prosen TL**, **Lanasa MC**, **Huber HA**, **Reeves MF**, Recurrent spontaneous abortion and skewed X-inactivation: is there an association? Am J Obstet Gynecol 384:e1, 2007.
101. **Warburton D**, **Kline J**, **Kinney A**, **Yu CY**, **Levin B**, **Brown S**, Skewed X chromosome inactivation and trisomic spontaneous abortion: no association, Am J Hum Genet 85:179, 2009.
102. **Lanasa MC**, **Hogge WA**, **Kubik CJ**, **Ness RB**, **Harger J**, **Nagel T**, **Prosen T**, **Markovic N**, **Hoffman EP**, A novel X chromosome-linked genetic cause of recurrent spontaneous abortion, Am J Obstet Gynecol 185:563, 2001.
103. **Simpson JL**, **Rajkovic A**, Ovarian differentiation and gonadal failure, Am J Med Genet 89:186, 1999.
104. **Carrell DT**, **Wilcox AL**, **Lowy L**, **Peterson CM**, **Jones KP**, **Erickson L**, **Campbell B**, **Branch DW**, **Hatasaka HH**, Elevated sperm chromosome aneuploidy and apoptosis in patients with unexplained recurrent pregnancy loss, Obstet Gynecol 101:1229, 2003.
105. **Rubio C**, **Simon C**, **Blanco J**, **Vidal F**, **Minguez Y**, **Egozcue J**, **Crespo J**, **Remohi J**, **Pellicer A**, Implications of sperm chromosome abnormalities in recurrent miscarriage, J Assist Reprod Genet 16:253, 1999.
106. **Egozcue S**, **Blanco J**, **Vendrell JM**, **Garcia F**, **Veiga A**, **Aran B**, **Barri PN**, **Vidal F**, **Egozcue J**, Human male infertility: chromosome anomalies, meiotic disorders, abnormal spermatozoa and recurrent abortion, Hum Reprod Update 6:93, 2000.
107. **Shi Q**, **Martin RH**, Aneuploidy in human spermatozoa: FISH analysis in men with constitutional chromosomal abnormalities, and in infertile men, Reproduction 121:655, 2001.
108. **Pfeffer J**, **Pang MG**, **Hoegerman SF**, **Osgood CJ**, **Stacey MW**, **Mayer J**, **Oehninger S**, **Kearns WG**, Aneuploidy frequencies in semen fractions from ten oligoasthenoteratozoospermic patients donating sperm for intracytoplasmic sperm injection, Fertil Steril 72:472, 1999.
109. **Saxena P**, **Misro MM**, **Chaki SP**, **Chopra K**, **Roy S**, **Nandan D**, Is abnormal sperm function an indicator among couples with recurrent pregnancy loss? Fertil Steril 90:1854, 2008.
110. **Collodel G**, **Giannerini V**, **Antonio Pascarelli N**, **Federico MG**, **Comodo F**, **Moretti E**, TEM and FISH studies in sperm from men of couples with recurrent pregnant loss, Andrologia 41:352, 2009.
111. **Bhattacharya SM**, Hypo-osmotic swelling test and unexplained repeat early pregnancy loss, J Obstet Gynaecol Res 36:119, 2010.
112. **Shi Q**, **Martin RH**, Aneuploidy in human sperm: a review of the frequency and distribution of aneuploidy, effects of donor age and lifestyle factors, Cytogenet Cell Genet 90:219, 2000.
113. **Slama R**, **Werwatz A**, **Boutou O**, **Ducot B**, **Spira A**, **Hardle W**, Does male age affect the risk of spontaneous abortion? An approach using semiparametric regression, Am J Epidemiol 157:815, 2003.
114. **Levy B**, **Sigurjonsson S**, **Pettersen B**, **Maisenbacher MK**, **Hall MP**, **Demko Z**, **Lathi RB**, **Tao R**, **Aggarwal V**, **Rabinowitz M**, Genomic imbalance in products of conception: single-nucleotide polymorphism chromosomal microarray analysis, Obstet Gynecol 124(2 Pt 1):202, 2014.
115. **Bagheri H**, **Mercier E**, **Qiao Y**, **Stephenson MD**, **Rajcan-Separovic E**, Genomic characteristics of

miscarriage copy number variants, Mol Hum Reprod 21(8):655, 2015.
116. **Levi AJ**, **Raynault MF**, **Bergh PA**, **Drews MR**, **Miller BT**, **Scott RT Jr**, Reproductive outcome in patients with diminished ovarian reserve, Fertil Steril 76:666, 2001.
117. **Franssen MT**, **Korevaar JC**, **van der Veen F**, **Leschot NJ**, **Bossuyt PM**, **Goddijn M**, Reproductive outcome after chromosome analysis in couples with two or more miscarriages: index (corrected)-control study, Br Med J 332:759, 2006.
118. **Verlinsky Y**, **Ginsberg N**, **Lifchez A**, **Valle J**, **Moise J**, **Strom CM**, Analysis of the first polar body: preconception genetic diagnosis, Hum Reprod 5:826, 1990.
119. **Handyside AH**, **Lesko JG**, **Tarin JJ**, **Winston RML**, **Hughes MR**, Birth of a normal girl after in vitro fertilization and preimplantation diagnostic testing for cystic fibrosis, N Engl J Med 327:905, 1992.
120. **Handyside AH**, **Kontogianni EH**, **Hardy K**, **Winston RM**, Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification, Nature 344:768, 1990.
121. **Gianaroli L**, **Magli MC**, **Fiorentino F**, **Baldi M**, **Ferraretti AP**, Clinical value of preimplantation genetic diagnosis, Placenta 24(Suppl 2):S77, 2003.
122. **Voullaire L**, **Slater H**, **Williamson R**, **Wilton L**, Chromosome analysis of blastomeres from human embryos by using comparative genomic hybridization, Hum Genet 106:210, 2000.
123. **Wilton L**, **Voullaire L**, **Sargeant P**, **Williamson R**, **McBain J**, Preimplantation aneuploidy screening using comparative genomic hybridization or fluorescence in situ hybridization of embryos from patients with recurrent implantation failure, Fertil Steril 80:860, 2003.
124. **Wilton L**, **Williamson R**, **McBain J**, **Edgar D**, **Voullaire L**, Birth of a healthy infant after preimplantation confirmation of euploidy by comparative genomic hybridization, N Engl J Med 345:1537, 2001.
125. **Menten B**, **Swerts K**, **Delle Chiaie B**, **Janssens S**, **Buysse K**, **Phillippé J**, **Speleman F**, Array comparative genomic hybridization and flow cytometry analysis of spontaneous abortions and mors in utero samples, BMC Med Genet 10:89, 2009.
126. **Warren JE**, **Turok DK**, **Maxwell TM**, **Brothman AR**, **Silver RM**, Array comparative genomic hybridization for genetic evaluation of fetal loss between 10 and 20 weeks of gestation, Obstet Gynecol 114:1093, 2009.
127. **Maxwell SM**, **Colls P**, **Hodes-Wertz B**, **McCulloh DH**, **McCaffrey C**, **Wells D**, et al., Why do euploid embryos miscarry? A case-control study comparing the rate of aneuploidy within presumed euploid embryos that resulted in miscarriage or live birth using next-generation sequencing, Fertil Steril 106:1414, 2016.
128. **Munné S**, **Blazek J**, **Large M**, **Martinez-Ortiz PA**, **Nisson H**, **Liu E**, et al., Detailed investigation into the cytogenetic constitution and pregnancy outcome of replacing mosaic blastocysts detected with the use of high-resolution next-generation sequencing, Fertil Steril 108:62, 2017.
129. **Friedenthal J**, **Nybo Andersen AM**, **Bosch E**, **Daya S**, **Delves PJ**, **Hviid TV**, **Kutteh WH**, **Laird SM**, **Li TC**, **van der Ven K**, Next generation sequencing for preimplantation genetic screening improves pregnancy outcomes compared with array comparative genomic hybridization in single thawed euploid embryo transfer cycles, Fertil Steril 109:627, 2018. doi:10.1016/j.fertnstert.2017.12.017.
130. **Bielanska M**, **Tan SL**, **Ao A**, Chromosomal mosaicism throughout human preimplantation development in vitro: incidence, type, and relevance to embryo outcome, Hum Reprod 17:413, 2002.
131. **Ruangvutilert P**, **Delhanty JD**, **Serhal P**, **Simopoulou M**, **Rodeck CH**, **Harper JC**, FISH analysis on day 5 post-insemination of human arrested and blastocyst stage embryos, Prenat Diagn 20:552, 2000.
132. **Gonzalez-Merino E**, **Emiliani S**, **Vassart G**, **Van den Bergh M**, **Vannin AS**, **Abramowicz M**, **Delneste D**, **Englert Y**, Incidence of chromosomal mosaicism in human embryos at different developmental stages analyzed by fluorescence in situ hybridization, Genet Test 7:85, 2003.
133. **Magli MC**, **Jones GM**, **Gras L**, **Gianaroli L**, **Korman I**, **Trounson AO**, Chromosome mosaicism in day 3 aneuploid embryos that develop to morphologically normal blastocysts in vitro, Hum Reprod 15:1781, 2000.
134. **Munné S**, **Wells D**, Detection of mosaicism at blastocyst stage with the use of high-resolution next-generation sequencing, Fertil Steril 107:1085, 2017.
135. **Taylor TH**, **Gitlin SA**, **Patrick JL**, **Crain JL**, **Wilson JM**, **Griffin DK**, The origin, mechanisms, incidence and clinical consequences of chromosomal mosaicism in humans, Hum Reprod Update 20:571, 2014.

136. **Munné S**, **Velilla E**, **Colls P**, **Garcia Bermudez M**, **Vemuri MC**, **Steuerwald N**, et al., Self-correction of chromosomally abnormal embryos in culture and implications for stem cell production, Fertil Steril 84:1328, 2005.
137. **Besser AG**, **Mounts EL**, Counselling considerations for chromosomal mosaicism detected by preimplantation genetic screening, Reprod Biomed Online 34:369, 2017.
138. **Munne S**, Preimplantation genetic diagnosis and human implantation—a review, Placenta 24(Suppl 2):S70, 2003.
139. **Fragouli E**, **Alfarawati S**, **Daphnis DD**, **Goodall NN**, **Mania A**, **Griffiths T**, et al., Cytogenetic analysis of human blastocysts with the use of FISH, CGH and array-CGH: scientific data and technical evaluation, Hum Reprod 26:480, 2011.
140. **Greco E**, **Minasi MG**, **Fiorentino F**, Healthy babies born after intrauterine transfer of mosaic aneuploid blastocyst, N Engl J Med 373:2089, 2015.
141. **Mamas T**, **Gordon A**, **Brown A**, **Harper J**, **Sengupta S**, Detection of aneuploidy by array comparative genomic hybridization using cell lines to mimic a mosaic trophectoderm biopsy, Fertil Steril 97:943, 2012.
142. **Vera-Rodriguez M**, **Michel CE**, **Mercader A**, **Bladon AJ**, **Rodrigo L**, **Kokocinski F**, et al., Distribution patterns of segmental aneuploidies in human blastocysts identified by next-generation sequencing, Fertil Steril 105: 1047, 2016.
143. **Gleicher N**, **Vidali A**, **Braverman J**, **Kushnir VA**, **Barad DH**, **Hudson C**, **Wu YG**, **Wang Q**, **Zhang L**, **Albertini DF**; **International PGS Consortium Study Group**, Accuracy of preimplantation genetic screening (PGS) is compromised by degree of mosaicism of human embryos, Reprod Biol Endocrinol 14(1): 54, 2016.
144. **Spinella F**, **Fiorentino F**, **Biricik A**, **Bono S**, **Ruberti A**, **Cotroneo E**, **Baldi M**, **Cursio E**, **Minasi MG**, **Greco E**, Extent of chromosomal mosaicism influences the clinical outcome of in vitro fertilization treatments, Fertil Steril 109(1):77, 2018.
145. **Kushnir VA**, **Darmon SK**, **Barad DH**, **Gleicher N**, Degree of mosaicism in trophectoderm does not predict pregnancy potential: a corrected analysis of pregnancy outcomes following transfer of mosaic embryos, Reprod Biol Endocrinol 16(1):6, 2018. doi:10.1186/s12958-018-0322-5.
146. **Gianaroli L**, **Magli MC**, **Ferraretti AP**, The in vivo and in vitro efficiency and efficacy of PGD for aneuploidy, Mol Cell Endocrinol 183(Suppl 1):S13, 2001.
147. **Magli MC**, **Gianaroli L**, **Ferraretti AP**, Chromosomal abnormalities in embryos, Mol Cell Endocrinol 183(Suppl 1):S29, 2001.
148. **Magli MC**, **Gianaroli L**, **Munne S**, **Ferraretti AP**, Incidence of chromosomal abnormalities from a morphologically normal cohort of embryos in poor-prognosis patients, J Assist Reprod Genet 15:297, 1998.
149. **Delhanty JD**, **Harper JC**, **Ao A**, **Handyside AH**, **Winston RM**, Multicolour FISH detects frequent chromosomal mosaicism and chaotic division in normal preimplantation embryos from fertile patients, Hum Genet 99:755, 1997.
150. **Simon C**, **Rubio C**, **Vidal F**, **Gimenez C**, **Moreno C**, **Parrilla JJ**, **Pellicer A**, Increased chromosome abnormalities in human preimplantation embryos after in-vitro fertilization in patients with recurrent miscarriage, Reprod Fertil Dev 10:87, 1998.
151. **Vidal F**, **Gimenez C**, **Rubio C**, **Simon C**, **Pellicer A**, **Santalo J**, **Egozcue J**, FISH preimplantation diagnosis of chromosome aneuploidy in recurrent pregnancy wastage, J Assist Reprod Genet 15:310, 1998.
152. **Pellicer A**, **Rubio C**, **Vidal F**, **Minguez Y**, **Gimenez C**, **Egozcue J**, **Remohi J**, **Simon C**, In vitro fertilization plus preimplantation genetic diagnosis in patients with recurrent miscarriage: an analysis of chromosome abnormalities in human preimplantation embryos, Fertil Steril 71:1033, 1999.
153. **Pehlivan T**, **Rubio C**, **Rodrigo L**, **Remohi J**, **Pellicer A**, **Simon C**, Preimplantation genetic diagnosis by fluorescence in situ hybridization: clinical possibilities and pitfalls, J Soc Gynecol Investig 10:315, 2003.
154. **Rubio C**, **Simon C**, **Vidal F**, **Rodrigo L**, **Pehlivan T**, **Remohi J**, **Pellicer A**, Chromosomal abnormalities and embryo development in recurrent miscarriage couples, Hum Reprod 18:182, 2003.
155. **Gianaroli L**, **Magli MC**, **Ferraretti AP**, **Tabanelli C**, **Trombetta C**, **Boudjema E**, The role of preimplantation diagnosis for aneuploidies, Reprod Biomed Online 4(Suppl 3):31, 2002.

156. **Gianaroli L**, **Magli MC**, **Ferraretti AP**, **Munne S**, Preimplantation diagnosis for aneuploidies in patients undergoing in vitro fertilization with a poor prognosis: identification of the categories for which it should be proposed, Fertil Steril 72:837, 1999.
157. **Murugappan G**, **Ohno MS**, **Lathi RB**, Cost-effectiveness analysis of preimplantation genetic screening and in vitro fertilization versus expectant management in patients with unexplained recurrent pregnancy loss, Fertil Steril 103(5):1215, 2015. doi:org/10.1016/j.fertnstert.2015.02.012.
158. **Mersereau JE**, **Plunkett BA**, **Cedars MI**, Preimplantation genetic screening in older women: a cost-effectiveness analysis, Fertil Steril 90:592, 2008.
159. **Munne S**, **Fung J**, **Cassel MJ**, **Marquez C**, **Weier HU**, Preimplantation genetic analysis of translocations: case-specific probes for interphase cell analysis, Hum Genet 102:663, 1998.
160. **Munne S**, **Magli C**, **Bahce M**, **Fung J**, **Legator M**, **Morrison L**, **Cohert J**, **Gianaroli L**, Preimplantation diagnosis of the aneuploidies most commonly found in spontaneous abortions and live births: XY, 13, 14, 15, 16, 18, 21, 22, Prenat Diagn 18:1459, 1998.
161. **Munne S**, **Sandalinas M**, **Escudero T**, **Fung J**, **Gianaroli L**, **Cohen J**, Outcome of preimplantation genetic diagnosis of translocations, Fertil Steril 73: 1209, 2000.
162. **Otani T**, **Roche M**, **Mizuike M**, **Colls P**, **Escudero T**, **Munné S**, Preimplantation genetic diagnosis significantly improves the pregnancy outcome of translocation carriers with a history of recurrent miscarriage and unsuccessful pregnancies, Reprod Biomed Online 13:869, 2006.
163. **Garrisi JG**, **Colls P**, **Ferry KM**, **Zheng X**, **Garrisi MG**, **Munné S**, Effect of infertility, maternal age, and number of previous miscarriages on the outcome of preimplantation genetic diagnosis for idiopathic recurrent pregnancy loss, Fertil Steril 92:288, 2009.
164. **Fischer J**, **Colls P**, **Escudero T**, **Munné S**, Preimplantation genetic diagnosis (PGD) improves pregnancy outcome for translocation carriers with a history of recurrent losses, Fertil Steril 94:283, 2010.
165. **Homer HA**, **Li TC**, **Cooke ID**, The septate uterus: a review of management and reproductive outcome, Fertil Steril 73:1, 2000.
166. **Pellerito JS**, **McCarthy SM**, **Doyle MB**, **Glickman MG**, **DeCherney AH**, Diagnosis of uterine anomalies: relative accuracy of MR imaging, endovaginal sonography, and hysterosalpingography, Genitourin Radiol 183:795, 1992.
167. **Kelly SM**, **Sladkevicius P**, **Campbell S**, **Nargund G**, Investigation of the infertile couple: a one-stop ultrasound-based approach, Hum Reprod 16:2481, 2001.
168. **Becker E Jr**, **Lev-Toaff AS**, **Kaufman EP**, **Halpern EJ**, **Edelweiss MI**, **Kurtz AB**, The added value of transvaginal sonohysterography over transvaginal sonography alone in women with known or suspected leiomyoma, J Ultrasound Med 21:237, 2002.
169. **Leone FP**, **Lanzani C**, **Ferrazzi E**, Use of strict sonohysterographic methods for preoperative assessment of submucous myomas, Fertil Steril 79:998, 2003.
170. **Sylvestre C**, **Child TJ**, **Tulandi T**, **Tan SL**, A prospective study to evaluate the efficacy of two- and three-dimensional sonohysterography in women with intrauterine lesions, Fertil Steril 79:1222, 2003.
171. **Soares SR**, **Barbosa dos Reis MM**, **Camargos AF**, Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases, Fertil Steril 73:406, 2000.
172. **Fedele L**, **Bianchi S**, **Dorta M**, **Vignali M**, Intrauterine adhesions: detection with transvaginal US, Radiology 199:757, 1996.
173. **Salle B**, **Gaucherand P**, **de Saint Hilaire P**, **Rudigoz RC**, Transvaginal sonohysterographic evaluation of intrauterine adhesions, J Clin Ultrasound 27:131, 1999.
174. **Saleem SN**, MR imaging diagnosis of uterovaginal anomalies: current state of the art, Radiographics 23:13, 2003.
175. **Ghi T**, **Casadio P**, **Kuleva M**, **Perrone AM**, **Savelli L**, **Giunchi S**, **Meriggiola MC**, **Gubbini G**, **Pilu G**, **Pelusi C**, **Pelusi G**, Accuracy of three-dimensional ultrasound in diagnosis and classification of congenital uterine anomalies, Fertil Steril 92:808, 2009.
176. **Salim R**, **Regan L**, **Woelfer B**, **Backos M**, **Jurkovic D**, A comparative study of the morphology of

congenital uterine anomalies in women with and without a history of recurrent first trimester miscarriage, Hum Reprod 18:162, 2003.
177. **Clifford K**, **Rai R**, **Watson H**, **Regan L**, An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases, Hum Reprod 9:1328, 1994.
178. **Makino T**, **Umeuchi M**, **Nakada K**, **Nozawa S**, **Iizuka R**, Incidence of congenital uterine anomalies in repeated reproductive wastage and prognosis for pregnancy after metroplasty, Int J Fertil 37:167, 1992.
179. **Makino T**, **Hara T**, **Oka C**, **Toyoshima K**, **Sugi T**, **Iwasaki K**, **Umeuchi M**, **Iizuka R**, Survey of 1120 Japanese women with a history of recurrent spontaneous abortions, Eur J Obstet Gynecol Reprod Biol 44:123, 1992.
180. **Jurkovic D**, **Gruboeck K**, **Tailor A**, **Nicolaides KH**, Ultrasound screening for congenital uterine anomalies, Br J Obstet Gynaecol 104:1320, 1997.
181. **Ashton D**, **Amin HK**, **Richart RM**, **Neuwirth RS**, The incidence of asymptomatic uterine anomalies in women undergoing transcervical tubal sterilization, Obstet Gynecol 72:28, 1988.
182. **Simon C**, **Martinez L**, **Pardo F**, **Tortajada M**, **Pellicer A**, Mullerian defects in women with normal reproductive outcome, Fertil Steril 56:1192, 1991.
183. **Saravelos SH**, **Cocksedge KA**, **Li TC**, The pattern of pregnancy loss in women with congenital uterine anomalies and recurrent miscarriage, Reprod Biomed Online 20:416, 2010.
184. **Bohlmann MK**, **von Wolff M**, **Luedders DW**, **Beuter-Winkler P**, **Diedrich K**, **Hornemann A**, **Strowitzki T**, Hysteroscopic findings in women with two and with more than two first-trimester miscarriages are not significantly different, Reprod Biomed Online 21:230, 2010.
185. **Leible S**, **Munoz H**, **Walton R**, **Sabaj V**, **Cumsille F**, **Sepulveda W**, Uterine artery blood flow velocity waveforms in pregnant women with mullerian duct anomaly: a biologic model for uteroplacental insufficiency, Am J Obstet Gynecol 178:1048, 1998.
186. **Propst AM**, **Hill JA III**, Anatomic factors associated with recurrent pregnancy loss, Semin Reprod Med 18:341, 2000.
187. **Heinonen PK**, Unicornuate uterus and rudimentary horn, Fertil Steril 68:224, 1997.
188. **Sarto GE**, **Simpson JL**, Abnormalities of the Mullerian and Wolffian duct systems, Birth Defects Orig Artic Ser 14:37, 1978.
189. **Steinberg W**, Strassmann's metroplasty in the management of bipartite uterus causing sterility or habitual abortion, Obstet Gynecol Surv 10:400, 1955.
190. **Heinonen PK**, **Saarikoski S**, **Pystynen P**, Reproductive performance of women with uterine anomalies. An evaluation of 182 cases, Acta Obstet Gynecol Scand 61:157, 1982.
191. **Strassman EO**, Fertility and unification of the pregnant uterus, Fertil Steril 17:165, 1966.
192. **Patton PE**, **Novy MJ**, Reproductive potential of the anomalous uterus, Semin Reprod Endocrinol 6:217, 1988.
193. **Golan A**, **Langer R**, **Wexler S**, **Segev E**, **Niv D**, **David MP**, Cervical cerclage—its role in the pregnant anomalous uterus, Int J Fertil 35:164, 1990.
194. **Blum M**, Prevention of spontaneous abortion by cervical suture of the malformed uterus, Int Surg 62:213, 1977.
195. **Raga F**, **Bauset C**, **Remohi J**, **Bonilla-Musoles F**, **Simón C**, **Pellicer A**, Reproductive impact of congenital Müllerian anomalies, Hum Reprod 12:2277, 1997.
196. **Grimbizis GF**, **Camus M**, **Tarlatzis BC**, **Bontis JN**, **Devroey P**, Clinical implications of uterine malformations and hysteroscopic treatment results, Hum Reprod Update 7:161, 2001.
197. **Burchell RC**, **Creed F**, **Rasoulpour M**, **Whitcomb M**, Vascular anatomy of the human uterus and pregnancy wastage, Br J Obstet Gynaecol 85:698, 1978.
198. **Dabirashrafi H**, **Bahadori M**, **Mohammad K**, **Alavi M**, **Moghadami-Tabrizi N**, **Zandinejad K**, **Ghafari V**, Septate uterus: new idea on the histologic features of the septum in this abnormal uterus, Am J Obstet Gynecol 172:105, 1995.
199. **Candiani GB**, **Fedele L**, **Zamberletti D**, **De Virgiliis D**, **Carinelli S**, Endometrial patterns in malformed uteri, Acta Eur Fertil 14:311, 1983.
200. **Fedele L**, **Bianchi S**, **Marchini M**, **Mezzopane R**, **Di Nola G**, **Tozzi L**, Residual uterine septum of less than

1 cm after hysteroscopic metroplasty does not impair reproductive outcome, Hum Reprod 11:727, 1996.
201. **Kaufman RH**, **Adan E**, **Binder GL**, **Gerthoffer E**, Upper genital tract changes and pregnancy outcome in offspring exposed in utero to diethylstilbestrol, Am J Obstet Gynecol 137:299, 1980.
202. **Herbst AL**, **Ulfelder H**, **Poskanzer DC**, Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women, N Engl J Med 284:878, 1971.
203. **Goldberg JM**, **Falcone T**, Effect of diethylstilbestrol on reproductive function, Fertil Steril 72:1, 1999.
204. **Ludmir J**, **Landon MB**, **Gabbe SG**, **Samuels P**, **Mennuti MT**, Management of the diethylstilbestrol-exposed pregnant patient: a prospective study, Am J Obstet Gynecol 157:665, 1987.
205. **Levine RU**, **Berkowitz KM**, Conservative management and pregnancy outcome in diethylstilbestrol-exposed women with and without gross genital tract abnormalities, Am J Obstet Gynecol 169:1125, 1993.
206. **Buttram VC**, **Reiter RC**, Uterine leiomyomata: etiology, symptomatology and management, Fertil Steril 36:433, 1981.
207. **Li TC**, **Mortimer R**, **Cooke ID**, Myomectomy: a retrospective study to examine reproductive performance before and after surgery, Hum Reprod 14:1735, 1999.
208. **Bosteels J**, **Kasius J**, **Weyers S**, **Broekmans FJ**, **Mol BW**, **D'Hooghe TM**, Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities, Cochrane Database Syst Rev (2):CD009461, 2015. doi:10.1002/14651858.CD009461.pub3. Review.
209. **Vollenhoven BJ**, **Lawrence AS**, **Healy DL**, Uterine fibroids: a clinical review, Br J Obstet Gynaecol 97:285, 1990.
210. **Tal R**, **Segars JH**, The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy, Hum Reprod Update 20(2):194, 2014. doi:10.1093/humupd/dmt042. Review.
211. **Doherty LF**, **Taylor HS**, Leiomyoma-derived transforming growth factor-β impairs bone morphogenetic protein-2-mediated endometrial receptivity, Fertil Steril 103(3):845, 2015.
212. **Sinclair DC**, **Mastroyannis A**, **Taylor HS**, Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3, J Clin Endocrinol Metab 96(2):412, 2011.
213. **Styer AK**, **Jin S**, **Liu D**, **Wang B**, **Polotsky AJ**, **Christianson MS**, **Vitek W**, **Engmann L**, **Hansen K**, **Wild R**, **Legro RS**, **Coutifaris C**, **Alvero R**, **Robinson RD**, **Casson P**, **Christman GM**, **Christy A**, **Diamond MP**, **Eisenberg E**, **Zhang H**, **Santoro N**; **National Institute of Child Health and Human Development Reproductive Medicine Network**, Association of uterine fibroids and pregnancy outcomes after ovarian stimulation-intrauterine insemination for unexplained infertility, Fertil Steril 107(3):756, 2017.
214. **Farhi J**, **Ashkenazi J**, **Feldberg D**, **Dicker D**, **Orvieto R**, **Ben Rafael Z**, Effect of uterine leiomyomata on the results of in-vitro fertilization treatment, Hum Reprod 10:2576, 1995.
215. **Ramzy AM**, **Sattar M**, **Amin Y**, **Mansour RT**, **Serour GI**, **Aboulghar MA**, Uterine myomata and outcome of assisted reproduction, Hum Reprod 13:198, 1998.
216. **Jun SH**, **Ginsburg ES**, **Racowsky C**, **Wise LA**, **Hornstein MD**, Uterine leiomyomas and their effect on in vitro fertilization outcome: a retrospective study, J Assist Reprod Genet 18:139, 2001.
217. **Surrey ES**, **Lietz AK**, **Schoolcraft WB**, Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization-embryo transfer cycle outcome, Fertil Steril 75:405, 2001.
218. **Pritts EA**, **Parker WH**, **Olive DL**, Fibroids and infertility: an updated systematic review of the evidence, Fertil Steril 91(4):1215, 2009. doi:10.1016/j.fertnstert.2008.01.051. Epub 2008 Mar 12. Review.
219. **Goldenberg M**, **Sivan E**, **Sharabi Z**, **Bider D**, **Rabinovici J**, **Seidman DS**, Outcome of hysteroscopic resection of submucous myomas for infertility, Fertil Steril 64:714, 1995.
220. **Giatras K**, **Berkeley AS**, **Noyes N**, **Licciardi F**, **Lolis D**, **Grifo JA**, Fertility after hysteroscopic resection of submucous myomas, J Am Assoc Gynecol Laparosc 6:155, 1999.
221. **Varasteh NN**, **Neuwirth RS**, **Levin B**, **Keltz MD**, Pregnancy rates after hysteroscopic polypectomy and myomectomy in infertile women, Obstet Gynecol 94:168, 1999.
222. **Vercellini P**, **Maddalena S**, **De Giorgi O**, **Pesole A**, **Ferrari L**, **Crosignani PG**, Determinants of reproductive outcome after abdominal myomectomy for infertility, Fertil Steril 72:109, 1999.
223. **Fernandez H**, **Sefrioui O**, **Virelizier C**, **Gervaise A**, **Gomel V**, **Frydman R**, Hysteroscopic resection of

submucosal myomas in patients with infertility, Hum Reprod 16:1489, 2001.
224. **March CM**, Intrauterine adhesions, Obstet Gynecol Clin North Am 22:491, 1995.
225. **Al-Inany H**, Intrauterine adhesions. An update, Acta Obstet Gynecol Scand 80:986, 2001.
226. **Schenker JG**, **Margalioth EJ**, Intrauterine adhesions: an updated appraisal, Fertil Steril 37:593, 1982.
227. **Jensen PA**, **Stromme WB**, Amenorrhea secondary to puerperal curettage (Asherman's syndrome), Am J Obstet Gynecol 113:150, 1972.
228. **Feng ZC**, **Yang B**, **Shao J**, **Liu S**, Diagnostic and therapeutic hysteroscopy for traumatic intrauterine adhesions after induced abortions: clinical analysis of 365 cases, Gynaecol Endosc 8:95, 1999.
229. **Pistofidis GA**, **Dimitropoulos K**, **Mastrominas M**, Comparison of operative and fertility outcome between groups of women with intrauterine adhesions after adhesiolysis, J Am Assoc Gynecol Laparosc 3(Suppl):S40, 1996.
230. **Shaffer W**, Role of uterine adhesions in the cause of multiple pregnancy losses, Clin Obstet Gynecol 29:912, 1986.
231. **Goldenberg M**, **Sivan E**, **Sharabi Z**, **Mashiach S**, **Lipitz S**, **Seidman DS**, Reproductive outcome following hysteroscopic management of intrauterine septum and adhesions, Hum Reprod 10:2663, 1995.
232. **Petri M**, **Allbritton J**, Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort, J Rheumatol 20:650, 1993.
233. **Fausett MB**, **Branch DW**, Autoimmunity and pregnancy loss, Semin Reprod Endocrinol 18:379, 2000.
234. **Ginsberg JS**, **Brill-Edwards P**, **Johnston M**, **Denburg JA**, **Andrew M**, **Burrows RF**, **Bensen W**, **Cividino A**, **Long AA**, Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study, Blood 80:975, 1992.
235. **Lockshin MD**, **Druzin ML**, **Goei S**, **Qamar T**, **Magid MS**, **Jovanovic L**, **Ferenc M**, Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus, N Engl J Med 313:152, 1985.
236. **Ogasawara M**, **Aoki K**, **Hayashi Y**, A prospective study on pregnancy risk of antiphospholipid antibodies in association with systemic lupus erythematosus, J Reprod Immunol 28:159, 1995.
237. **Kleinman D**, **Katz VL**, **Kuller JA**, Perinatal outcomes in women with systemic lupus erythematosus, J Perinatol 18:178, 1998.
238. **Buchanan NM**, **Khamashta MA**, **Morton KE**, **Kerslake S**, **Baguley EA**, **Hughes GR**, A study of 100 high risk lupus pregnancies, Am J Reprod Immunol 28:192, 1992.
239. **Wilson WA**, **Gharavi AE**, **Koike T**, **Lockshin MD**, **Branch DW**, **Piette JC**, **Brey R**, **Derksen R**, **Harris EN**, **Hughes GR**, **Triplett DA**, **Khamashta MA**, International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop, Arthritis Rheum 42:1309, 1999.
240. **Lockshin MD**, **Sammaritano LR**, **Schwartzman S**, Validation of the Sapporo criteria for antiphospholipid syndrome, Arthritis Rheum 43:440, 2000.
241. **Triplett DA**, Antiphospholipid antibodies, Arch Pathol Lab Med 126:1424, 2002.
242. **Silver RM**, **Porter TF**, **van Leeuween I**, **Jeng G**, **Scott JR**, **Branch DW**, Anticardiolipin antibodies: clinical consequences of "low titers", Obstet Gynecol 87:494, 1996.
243. **Solano C**, **Lamuño M**, **Vargas A**, **Amezcua-Guerra LM**, Comparison of the 1999 Sapporo and 2006 revised criteria for the classification of the antiphospholipid syndrome, Clin Exp Rheumatol 27:914, 2009.
244. **Miyakis S**, **Lockshin MD**, **Atsumi T**, **Branch DW**, **Brey RL**, **Cervera R**, **Derksen RH**, **De Groot PG**, **Koike T**, **Meroni PL**, **Rebar G**, **Schoenfeld Y**, **Tincani A**, **Vlachoyiannopoulos PG**, **Krilis SA**, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost 4:295, 2006.
245. **Hill JA**, Sporadic and recurrent spontaneous abortion, Curr Probl Obstet Gynecol Fertil 17:114, 1994.
246. **Branch DW**, **Silver R**, **Pierangeli S**, **van Leeuwen I**, **Harris EN**, Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome, Obstet Gynecol 89:549, 1997.
247. **Lockwood CJ**, **Romero R**, **Feinberg RF**, **Clyne LP**, **Coster B**, **Hobbins JC**, The prevalence and biologic

significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population, Am J Obstet Gynecol 161:369, 1989.
248. **Pattison NS**, **Chamley LW**, **McKay EJ**, **Liggins GC**, **Butler WS**, Antiphospholipid antibodies in pregnancy: prevalence and clinical associations, Br J Obstet Gynaecol 100:909, 1993.
249. **Branch DW**, **Silver RM**, **Blackwell JL**, **Reading JC**, **Scott JR**, Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience, Obstet Gynecol 80:614, 1992.
250. **Cowchock FS**, **Reece EA**, **Balaban D**, **Branch DW**, **Plouffe L**, Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment, Am J Obstet Gynecol 166:1318, 1992.
251. **Lima F**, **Khamashta MA**, **Buchanan NM**, **Kerslake S**, **Hunt BJ**, **Hughes GR**, A study of sixty pregnancies in patients with the antiphospholipid syndrome, Clin Exp Rheumatol 14:131, 1996.
252. **Out HJ**, **Bruinse HW**, **Christiaens GC**, **van Vliet M**, **de Groot PG**, **Nieuwenhuis HK**, **Derksen RH**, A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies, Am J Obstet Gynecol 167:26, 1992.
253. **Branch DW**, **Dudley DJ**, **Mitchell MD**, **Creighton KA**, **Abbott TM**, **Hammond EH**, **Daynes RA**, Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss, Am J Obstet Gynecol 163:210, 1990.
254. **Blank M**, **Cohen J**, **Toder V**, **Shoenfeld Y**, Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies, Proc Natl Acad Sci U S A 88:3069, 1991.
255. **Chamley LW**, **Pattison NS**, **McKay EJ**, The effect of human anticardiolipin antibodies on murine pregnancy, J Reprod Immunol 27:123, 1994.
256. **Branch DW**, Immunologic disease and fetal death, Clin Obstet Gynecol 30:295, 1987.
257. **Oshiro BT**, **Silver RM**, **Scott JR**, **Yu H**, **Branch DW**, Antiphospholipid antibodies and fetal death, Obstet Gynecol 87:489, 1996.
258. **Harris EN**, **Asherson RA**, **Gharavi AE**, **Morgan SH**, **Derue G**, **Hughes GR**, Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody, Br J Haematol 59:227, 1985.
259. **Tulppala M**, **Viinikka L**, **Ylikorkala O**, Thromboxane dominance and prostacyclin deficiency in habitual abortion, Lancet 337:879, 1991.
260. **Rand JH**, **Wu XX**, **Andree HA**, **Lockwood CJ**, **Guller S**, **Scher J**, **Harpel PC**, Pregnancy loss in the antiphospholipid-antibody syndrome—a possible thrombogenic mechanism, N Engl J Med 337:154, 1997.
261. **Rand JH**, Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome, J Autoimmun 15:107, 2000.
262. **Erlendsson K**, **Steinsson K**, **Johannsson JH**, **Geirsson RT**, Relation of antiphospholipid antibody and placental bed inflammatory vascular changes to the outcome of pregnancy in successive pregnancies of 2 women with systemic lupus erythematosus, J Rheumatol 20:1779, 1993.
263. **Di Simone N**, **Di Nicuolo F**, **D'Ippolito S**, **Castellani R**, **Tersigni C**, **Caruso A**, **Meroni P**, **Marana R**, Antiphospholipid antibodies affect human endometrial angiogenesis, Biol Reprod 83(2):212, 2010.
264. **Regan L**, **Rai R**, Thrombophilia and pregnancy loss, J Reprod Immunol 55:163, 2002.
265. **Pijnenborg R**, **Bland JM**, **Robertson WB**, **Brosens I**, Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy, Placenta 4:397, 1983.
266. **Abrahams VM**, Mechanisms of antiphospholipid antibody-associated pregnancy complications, Thromb Res 124:521, 2009.
267. **Kwak-Kim J**, **Agcaoili MS**, **Aleta L**, **Liao A**, **Ota K**, **Dambaeva S**, **Beaman K**, **Kim JW**, **Gilman-Sachs A**, Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome, Am J Reprod Immunol 69(6):596, 2013. doi:10.1111/aji.12114.
268. **Kutteh WH**, Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone, Am J Obstet Gynecol 174:1584, 1996.
269. **Rai R**, **Cohen H**, **Dave M**, **Regan L**, Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid

antibodies), Br Med J 314:253, 1997.
270. **Tulppala M**, **Marttunen M**, **Söderström-Anttila V**, **Foudila T**, **Ailus K**, **Palosuo T**, **Ylikorkala O**, Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production, Hum Reprod 12:1567, 1997.
271. **Farquharson RG**, **Quenby S**, **Greaves M**, Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment, Obstet Gynecol 100:408, 2002.
272. **Laskin CA**, **Spitzer KA**, **Clark CA**, **Crowther MR**, **Ginsberg JSH, G A**, **Kingdom GA**, **Kingdom JC**, **Barrett J**, **Gent M**, Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial, J Rheumatol 36:279, 2009.
273. **Backos M**, **Rai R**, **Baxter N**, **Chilcott IT**, **Cohen H**, **Regan L**, Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin, Br J Obstet Gynaecol 106:102, 1999.
274. **Empson M**, **Lassere M**, **Craig J**, **Scott J**, Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant, Cochrane Database Syst Rev (2):CD002859, 2005.
275. **Ziakas PD**, **Pavlou M**, **Voulgarelis M**, Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis, Obstet Gynecol 115:1256, 2010.
276. **Clark P**, **Walker ID**, **Langhorne P**, **Crichton L**, **Thomson A**, **Greaves M**, **Whyte S**, **Greer IA**, **Scottish Pregnancy Intervention Study (SPIN) collaborators**, SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage, Blood 115:4162, 2010.
277. **Kaandorp SP**, **Goddijn M**, **van der Post JA**, **Hutten BA**, **Verhoeve HR**, **Hamulyá K**, **Mol BW**, **Folkeringa N**, **Nahuis M**, **Papatsonis DN**, **Büller HR**, **Van der Veen F**, **Middeldorp S**, Aspirin plus heparin or aspirin alone in women with recurrent miscarriage, N Engl J Med 362:1586, 2010.
278. **Laurent P**, **Dussarat GV**, **Bonal J**, **Jego C**, **Talard P**, **Bouchiat C**, **Cellarier G**, Low molecular weight heparins: a guide to their optimum use in pregnancy, Drugs 62:463, 2002.
279. **Bar J**, **Cohen-Sacher B**, **Hod M**, **Blickstein D**, **Lahav J**, **Merlob P**, Low-molecular-weight heparin for thrombophilia in pregnant women, Int J Gynaecol Obstet 69:209, 2000.
280. **Younis JS**, **Ohel G**, **Brenner B**, **Haddad S**, **Lanir N**, **Ben-Ami M**, The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation, Br J Obstet Gynaecol 107:415, 2000.
281. **Brenner B**, **Hoffman R**, **Blumenfeld Z**, **Weiner Z**, **Younis JS**, Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin, Thromb Haemost 83:693, 2000.
282. **Noble LS**, **Kutteh WH**, **Lashey N**, **Franklin RD**, **Herrada J**, Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin, Fertil Steril 83:684, 2005.
283. **Stephenson MD**, **Ballem PJ**, **Tsang P**, **Purkiss S**, **Ensworth S**, **Houlihan E**, **Ensom MH**, Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin, J Obstet Gynaecol Can 26:729, 2004.
284. **Laskin CA**, **Bombardier C**, **Hannah ME**, **Mandel FP**, **Ritchie JW**, **Farewell V**, **Farine D**, **Spitzer K**, **Fielding L**, **Soloninka CA**, **Yeung M**, Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss, N Engl J Med 337:148, 1997.
285. **Fawzy M**, **Shokeir T**, **El-Tatongy M**, **Warda O**, **El-Refaiey AA**, **Mosbah A**, Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study, Arch Gynecol Obstet 278:33, 2008.
286. **Hutton B**, **Sharma R**, **Fergusson D**, **Tinmouth A**, **Hebert P**, **Jamieson J**, **Walker M**, Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review, BJOG 114(2):134, 2007.
287. **Vaquero E**, **Lazzarin N**, **Valensise H**, **Menghini S**, **Di Pierro G**, **Cesa F**, **Romanini C**, Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin, Am J Reprod Immunol 45:174, 2001.
288. **Harris EN**, **Pierangeli SS**, Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss

in the antiphospholipid syndrome: a review, Scand J Rheumatol Suppl 107:97, 1998.
289. **Esplin MS**, **Branch DW**, **Silver R**, **Stagnaro-Green A**, Thyroid autoantibodies are not associated with recurrent pregnancy loss, Am J Obstet Gynecol 179:1583, 1998.
290. **Rushworth FH**, **Backos M**, **Rai R**, **Chilcott IT**, **Baxter N**, **Regan L**, Prospective pregnancy outcome in untreated recurrent miscarriers with thyroid autoantibodies, Hum Reprod 15:1637, 2000.
291. **Negro R**, **Mangieri T**, **Coppola L**, **Presicce G**, **Casavola EC**, **Gismondi R**, **Locorotondo G**, **Caroli P**, **Pezzarossa A**, **Dazzi D**, **Hassan H**, Levothyroxine treatment in thyroid peroxidase antibody-positive women undergoing assisted reproduction technologies: a prospective study, Hum Reprod 20:1529, 2005.
292. **Glinoer D**, **Riahi M**, **Grun JP**, **Kinthaert J**, Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders, J Clin Endocrinol Metab 79:197, 1994.
293. **Bustos D**, **Moret A**, **Tembutti M**, **Gorgorza S**, **Testa R**, **Ascione A**, **Prigoshin N**, Autoantibodies in Argentine women with recurrent pregnancy loss, Am J Reprod Immunol 55:201, 2006.
294. **Hanafusa N**, **Noiri E**, **Yamashita T**, **Kondo Y**, **Suzuki M**, **Watanabe Y**, **Kanai T**, **Miyashita E**, **Tsuno NH**, **Fujii T**, **Kozuma S**, **Takahashi K**, **Taketani Y**, **Nakao A**, **Fujita T**, Successful treatment by double filtrate plasmapheresis in a pregnant woman with the rare P blood group and a history of multiple early miscarriages, Ther Apher Dial 10:498, 2006.
295. **McIntyre JA**, **Faulk WP**, **Nichols-Johnson VR**, **Taylor CG**, Immunologic testing and immunotherapy in recurrent spontaneous abortion, Obstet Gynecol 67:169, 1986.
296. **Berke J**, **Johansen K**, The formation of HLA antibodies in pregnancy: the antigenicity of aborted and term fetuses, J Obstet Gyneacol Br Commonw 81:222, 1974.
297. **Coulam CB**, Immunologic tests in the evaluation of reproductive disorders: a critical review, Am J Obstet Gynecol 167:1844, 1992.
298. **Cowchock FS**, **Smith JB**, Predictors for live birth after unexplained spontaneous abortions: correlations between immunologic test results, obstetric histories, and outcome of next pregnancy without treatment, Am J Obstet Gynecol 167:1208, 1992.
299. **Beer AE**, **Quebbeman JF**, **Ayers JW**, **Haines RF**, Major histocompatibility complex antigens, maternal and paternal immune responses, and chronic habitual abortions in humans, Am J Obstet Gynecol 141:987, 1981.
300. **Rocklin RE**, **Kitzmiller JL**, **Garvoy MR**, Maternal-fetal relation. II. Further characterization of an immunologic blocking factor that develops during pregnancy, Clin Immunol Immunopathol 22:305, 1982.
301. **Sargent IL**, **Wilkins T**, **Redman CW**, Maternal immune responses to the fetus in early pregnancy and recurrent miscarriage, Lancet 2:1099, 1988.
302. **Porter TF**, **Scott JR**, Alloimmune causes of recurrent pregnancy loss, Semin Reprod Med 18:393, 2000.
303. **Ober C**, **Hyslop T**, **Elias S**, **Weitkamp LR**, **Hauck WW**, Human leukocyte antigen matching and fetal loss: results of a 10 year prospective study, Hum Reprod 13:33, 1998.
304. **Sbracia M**, **Mastrone M**, **Scarpellini F**, **Grasso JA**, Influence of histocompatibility antigens in recurrent spontaneous abortion couples and on their reproductive performances, Am J Reprod Immunol 35:85, 1996.
305. **Weitkamp LR**, **Ober C**, Ancestral and recombinant 16-locus HLA haplotypes in the Hutterites, Immunogenetics 49:491, 1999.
306. **Berger DS**, **Hogge WA**, **Barmada MM**, **Farrell RE**, Comprehensive analysis of HLA-G: implications for recurrent spontaneous abortions, Reprod Sci 17:331, 2010.
307. **Kolte AM**, **Steffensen R**, **Nielsen HS**, **Hvid TV**, **Christiansen OB**, Study of the structure and impact of human leukocyte antigen (HLA)-G-A, HLA-G-B, and HLA-G-DRB1 haplotypes in families with recurrent miscarriage, Hum Immunol 71:482, 2010.
308. **Clark DA**, **Vince G**, **Flanders KC**, **Hirte H**, **Starkey P**, CD56+ lymphoid cells in human first trimester pregnancy decidua as a source of novel transforming growth factor-beta 2-related immunosuppressive factors, Hum Reprod 9:2270, 1994.
309. **Kodama T**, **Hara T**, **Okamoto E**, **Kusunoki Y**, **Ohama K**, Characteristic changes of large granular lymphocytes that strongly express CD56 in endometrium during the menstrual cycle and early pregnancy, Hum Reprod 13:1036, 1998.
310. **Gendron RL**, **Baines MG**, Infiltrating decidual natural killer cells are associated with spontaneous abortion in

mice, Cell Immunol 113:261, 1988.
311. **de Fougerolles AR**, **Baines MG**, Modulation of the natural killer cell activity in pregnant mice alters the spontaneous abortion rate, J Reprod Immunol 11:147, 1987.
312. **Guimond MJ**, **Wang B**, **Croy BA**, Engraftment of bone marrow from severe combined immunodeficient (SCID) mice reverses the reproductive deficits in natural killer cell-deficient tg epsilon 26 mice, J Exp Med 187:217, 1998. https://doi.org/10.1084/jem.187.2.217
313. **Burke SD**, **Barrette VF**, **Bianco J**, **Thorne JG**, **Yamada AT**, **Pang SC**, **Adams MA**, **Croy BA**, Spiral arterial remodeling is not essential for normal blood pressure regulation in pregnant mice, Hypertension 55:729, 2010.
314. **Lima PD**, **Zhang J**, **Dunk C**, **Lye SJ**, **Croy BA**, Leukocyte driven-decidual angiogenesis in early pregnancy, Cell Mol Immunol 11(6):522, 2014.
315. **Starkey PM**, **Sargent IL**, **Redman CW**, Cell populations in human early pregnancy decidua: characterization and isolation of large granular lymphocytes by flow cytometry, Immunology 65:129, 1988.
316. **Lachapelle MH**, **Miron P**, **Hemmings R**, **Roy DC**, Endometrial T, B, and NK cells in patients with recurrent spontaneous abortion. Altered profile and pregnancy outcome, J Immunol 156:4027, 1996.
317. **Coulam CB**, **Goodman C**, **Roussev RG**, **Thomason EJ**, **Beaman KD**, Systemic CD56+ cells can predict pregnancy outcome, Am J Reprod Immunol 33:40, 1995.
318. **Beer AE**, **Kwak JY**, **Ruiz JE**, Immunophenotypic profiles of peripheral blood lymphocytes in women with recurrent pregnancy losses and in infertile women with multiple failed in vitro fertilization cycles, Am J Reprod Immunol 35:376, 1996.
319. **Yamamoto T**, **Takahashi Y**, **Kase N**, **Mori H**, Role of decidual natural killer (NK) cells in patients with missed abortion: differences between cases with normal and abnormal chromosome, Clin Exp Immunol 116:449, 1999.
320. **Gilman-Sachs A**, **DuChateau BK**, **Aslakson CJ**, **Wohlgemuth GP**, **Kwak JY**, **Beer AE**, **Beaman KD**, Natural killer (NK) cell subsets and NK cell cytotoxicity in women with histories of recurrent spontaneous abortions, Am J Reprod Immunol 41:99, 1999.
321. **Palmer EM**, **van Seventer GA**, Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals, J Immunol 158:2654, 1997.
322. **Asnagli H**, **Murphy KM**, Stability and commitment in T helper cell development, Curr Opin Immunol 13:242, 2001.
323. **O'Garra A**, **Arai N**, The molecular basis of T helper 1 and T helper 2 cell differentiation, Trends Cell Biol 10:542, 2000.
324. **Romagnani S**, Human TH1 and TH2 subsets: doubt no more, Immunol Today 12:256, 1991.
325. **Zammiti W**, **Mtiraoui N**, **Finan RR**, **Almawi WY**, **Mahjoub T**, Tumor necrosis factor alpha and lymphotoxin alpha haplotypes in idiopathic recurrent pregnancy loss, Fertil Steril 91:1903, 2009.
326. **Finan RR**, **Al-Irhayim Z**, **Mustafa FE**, **Al-Zaman I**, **Mohammed FA**, **Al-Khateeb GM**, **Madan S**, **Issa AA**, **Almawi WY**, Tumor necrosis factor-alpha polymorphisms in women with idiopathic recurrent miscarriage, J Reprod Immunol 84:186, 2010.
327. **Hill JA**, **Polgar K**, **Anderson DJ**, T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion, JAMA 273:1933, 1995.
328. **Hill JA**, **Polgar K**, **Harlow BL**, **Anderson DJ**, Evidence of embryo- and trophoblast-toxic cellular immune response(s) in women with recurrent spontaneous abortion, Am J Obstet Gynecol 166:1044, 1992.
329. **Yamada H**, **Polgar K**, **Hill JA**, Cell-mediated immunity to trophoblast antigens in women with recurrent spontaneous abortion, Am J Obstet Gynecol 170:1339, 1994.
330. **Yang H**, **Qiu L**, **Chen GP**, **Ye Z**, **Lü C**, **Lin Q**, Proportional change of CD4+ CD25+ regulatory T cells in decidua and peripheral blood in unexplained recurrent spontaneous abortion patients, Fertil Steril 89:656, 2008.
331. **Wang WJ**, **Hao CF**, **Wang WJ**, **Lin Y**, **Yin GJ**, **Bao SH**, **Qiu LH**, **Lin QD**, Increased prevalence of T helper 17 (Th17) cells in peripheral blood and decidua in unexplained recurrent spontaneous abortion patients, J Reprod Immunol 84:164, 2010.
332. **Hill JA**, T-helper 1-type immunity to trophoblast: evidence for a new immunological mechanism for recurrent

abortion in women, Hum Reprod 10(Suppl 2):114, 1995.
333. **Ecker JL**, **Laufer MR**, **Hill JA**, Measurement of embryotoxic factors is predictive of pregnancy outcome in women with a history of recurrent abortions, Obstet Gynecol 81:84, 1993.
334. **Jenkins C**, **Roberts J**, **Wilson R**, **MacLean MA**, **Shilito J**, **Walker JJ**, Evidence of a T(H) 1 type response associated with recurrent miscarriage, Fertil Steril 73:1206, 2000.
335. **Yang KM**, **Ntrivalas E**, **Cho HJ**, **Kim NY**, **Beaman K**, **Gilman-Sachs A**, **Kwak-Kim J**, Women with multiple implantation failures and recurrent pregnancy losses have increased peripheral blood T cell activation, Am J Reprod Immunol 63:370, 2010.
336. **Mei S**, **Tan JY**, **Chen HW**, **Chen Y**, **Zhang J**, Changes of CD4(+)CD25(high) regulatory T cells and FOXP3 expression in unexplained recurrent spontaneous abortion patients, Fertil Steril 94(6):2244, 2010.
337. **Toth B**, **Haufe T**, **Scholz C**, **Kuhn C**, **Friese K**, **Karamouti M**, **Makrigiannakis A**, **Jeschke U**, Placental interleukin-15 expression in recurrent miscarriage, Am J Reprod Immunol 64:402, 2010.
338. **Bombell S**, **McGuire W**, Cytokine polymorphisms in women with recurrent pregnancy loss: meta-analysis, Aust N Z J Obstet Gynaecol 48:147, 2008.
339. **Choi YK**, **Kwak-Kim J**, Cytokine gene polymorphisms in recurrent spontaneous abortions: a comprehensive review, Am J Reprod Immunol 60:91, 2008.
340. **Levrant S**, **Coulam CB**, **Jeyendran RS**, Interleukin 1 receptor antagonist gene polymorphisms are not risk factors for recurrent pregnancy loss: evaluation of couples, Am J Reprod Immunol 60:224, 2008.
341. **Dai MZ**, **Pan YQ**, **Chen XJ**, **Qian RJ**, **Chen DH**, **Cui TW**, **Lin A**, **Yan WH**, IL-1 receptor antagonist gene polymorphism in idiopathic recurrent spontaneous abortion in a Chinese Han population, Int J Immunogenet 35(5):393, 2010.
342. **Kwak JY**, **Gilman-Sachs A**, **Moretti M**, **Beaman KD**, **Beer AE**, Natural killer cell cytotoxicity and paternal lymphocyte immunization in women with recurrent spontaneous abortions, Am J Reprod Immunol 40:352, 1998.
343. **Ober C**, **Karrison T**, **Odem RR**, **Barnes RB**, **Branch DW**, **Stephenson MD**, **Baron B**, **Walker MA**, **Scott JR**, **Schreiber JR**, Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial, Lancet 354:365, 1999.
344. **Scott JR**, Immunotherapy for recurrent miscarriage, Cochrane Database Syst Rev (1):CD000112, 2003.
345. **Dwyer JM**, Intravenous therapy with gamma globulin, Adv Intern Med 32:111, 1987.
346. **Thornton CA**, **Ballow M**, Safety of intravenous immunoglobulin, Arch Neurol 50:135, 1993.
347. **Recurrent Miscarriage Immunotherapy Trialists Group**, Worldwide collaborative observational study and meta-analysis on allogenic leukocyte immunotherapy for recurrent spontaneous abortion, Am J Reprod Immunol 32:55, 1994.
348. **Porter TF**, **LaCoursiere Y**, **Scott JR**, Immunotherapy for recurrent miscarriage, Cochrane Database Syst Rev 19:CD000112, 2006.
349. **Scarpellini F**, **Sbracia M**, Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial, Hum Reprod 24:2702, 2009.
350. **Zafardoust S**, **Akhondi MM**, **Sadeghi MR**, **Mohammadzadeh A**, **Karimi A**, **Jouhari S**, **Ansaripour S**, Efficacy of intrauterine injection of granulocyte colony stimulating factor (G-CSF) on treatment of unexplained recurrent miscarriage: a pilot RCT study, J Reprod Infertil 18(4):379, 2017.
351. **Dahlback B**, Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism, Blood 85:607, 1995.
352. **Svensson PJ**, **Dahlbäck B**, Resistance to activated protein C as a basis for venous thrombosis, N Engl J Med 330:517, 1994.
353. **Poort SR**, **Rosendaal FR**, **Reitsma PH**, **Bertina RM**, A common genetic variation in the 3¢-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis, Blood 88:3698, 1996.
354. **Frosst P**, **Blom HJ**, **Milos R**, **Goyette P**, **Sheppard CA**, **Matthews RG**, **Boers GJ**, **den Heijer M**, **Kluijtmans LA**, **van den Heuvel LP**, et al., A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase, Nat Genet 10:111, 1995.

355. **Pauer HU**, **Burfeind P**, **Kostering H**, **Emons G**, **Hinney B**, Factor XII deficiency is strongly associated with primary recurrent abortions, Fertil Steril 80:590, 2003.
356. **Bertina RM**, **Koeleman BP**, **Koster T**, **Rosendaal FR**, **Dirven RJ**, **de Ronde H**, **van den Velden PA**, **Reitsma PH**, Mutation in blood coagulation factor V associated with resistance to activated protein C, Nature 369:64, 1994.
357. **Rey E**, **Kahn SR**, **David M**, **Shrier I**, Thrombophilic disorders and fetal loss: a meta-analysis, Lancet 361:901, 2003.
358. **Rai R**, **Backos M**, **Elgaddal S**, **Shlebak A**, **Regan L**, Factor V Leiden and recurrent miscarriage—prospective outcome of untreated pregnancies, Hum Reprod 17:442, 2002.
359. **Yenicesu GI**, **Cetin M**, **Ozdemir O**, **Cetin A**, **Ozen F**, **Yenicesu C**, **Yildiz C**, **Kocak N**, A prospective case-control study analyzes 12 thrombophilic gene mutations in Turkish couples with recurrent pregnancy loss, Am J Reprod Immunol 63:126, 2010.
360. **Gris JC**, **Ripart-Neveu S**, **Maugard C**, **Tailland ML**, **Brun S**, **Courtieu C**, **Biron C**, **Hoffet M**, **Hedon B**, **Mares P**, Retrospective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 77:1096, 1997.
361. **Rai R**, **Backos M**, **Baxter N**, **Chilcott I**, **Regan L**, Recurrent miscarriage—an aspirin a day? Hum Reprod 15:2220, 2000.
362. **Brenner B**, **Sarig G**, **Weiner Z**, **Younis J**, **Blumenfeld Z**, **Lanir N**, Thrombophilic polymorphisms are common in women with fetal loss without apparent cause, Thromb Haemost 82:6, 1999.
363. **Brenner B**, **Mandel H**, **Lanir N**, **Younis J**, **Rothbart H**, **Ohel G**, **Blumenfeld Z**, Activated protein C resistance can be associated with recurrent fetal loss, Br J Haematol 97:551, 1997.
364. **Kutteh WH**, **Park VM**, **Deitcher SR**, Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss, Fertil Steril 71:1048, 1999.
365. **Souza SS**, **Ferriani RA**, **Pontes AG**, **Zago MA**, **Franco RF**, Factor V leiden and factor II G20210A mutations in patients with recurrent abortion, Hum Reprod 14:2448, 1999.
366. **Holmes ZR**, **Regan L**, **Chilcott I**, **Cohen H**, The C677T MTHFR gene mutation is not predictive of risk for recurrent fetal loss, Br J Haematol 105:98, 1999.
367. **Rai R**, **Shlebak A**, **Cohen H**, **Backos M**, **Holmes Z**, **Marriott K**, **Regan L**, Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage, Hum Reprod 16:961, 2001.
368. **Preston FE**, **Rosendaal FR**, **Walker ID**, **Briet E**, **Berntorp E**, **Conard J**, **Fontcuberta J**, **Makris M**, **Mariani G**, **Noteboom W**, **Pabinger I**, **Legnani C**, **Scharrer I**, **Schulman S**, **van der Meer FJ**, Increased fetal loss in women with heritable thrombophilia, Lancet 348:913, 1996.
369. **Kupferminc MJ**, **Eldor A**, **Steinman N**, **Many A**, **Bar-Am A**, **Jaffa A**, **Fait G**, **Lessing JB**, Increased frequency of genetic thrombophilia in women with complications of pregnancy, N Engl J Med 340:9, 1999.
370. **Younis JS**, **Brenner B**, **Ohel G**, **Tal J**, **Lanir N**, **Ben-Ami M**, Activated protein C resistance and factor V Leiden mutation can be associated with first- as well as second-trimester recurrent pregnancy loss, Am J Reprod Immunol 43:31, 2000.
371. **Rai R**, **Regan L**, Thrombophilia and adverse pregnancy outcome, Semin Reprod Med 18:369, 2000.
372. **Dizon-Townson DS**, **Meline L**, **Nelson LM**, **Varner M**, **Ward K**, Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction, Am J Obstet Gynecol 177:402, 1997.
373. **Rees DC**, **Cox M**, **Clegg JB**, World distribution of factor V Leiden, Lancet 346:1133, 1995.
374. **Carp H**, **Dolitzky M**, **Inbal A**, Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia, J Thromb Haemost 1:433, 2003.
375. **Monien S**, **Ladecki O**, **Baumgarten S**, **Salama A**, **Dörner T**, **Kiesewetter H**, Use of heparin in women with early and late miscarriages with and without thrombophilia, Clin Appl Thromb Hemost 15:636, 2009.
376. **Abalovich M**, **Gutierrez S**, **Alcaraz G**, **Maccallini G**, **Garcia A**, **Levalle O**, Overt and subclinical hypothyroidism complicating pregnancy, Thyroid 12:63, 2002.
377. **Montoro M**, **Collea JV**, **Frasier D**, **Mestman J**, Successful outcome of pregnancy in women with hypothyroidism, Ann Intern Med 94:31, 1981.

378. **Roti E**, **Minelli R**, **Salvi M**, Clinical review 80: management of hyperthyroidism and hypothyroidism in the pregnant woman, J Clin Endocrinol Metab 81:1679, 1996.
379. **Wang S**, **Teng WP**, **Li JX**, **Wang WW**, **Shan ZY**, Effects of maternal subclinical hypothyroidism on obstetrical outcomes during early pregnancy, J Endocrinol Invest 35(3):322, 2012.
380. **Ashoor G**, **Maiz N**, **Rotas M**, **Jawdat F**, **Nicolaides KH**, Maternal thyroid function at 11 to 13 weeks of gestation and subsequent fetal death, Thyroid 20(9):989, 2010. doi:10.1089/thy.2010.0058.
381. **De Vivo A**, **Mancuso A**, **Giacobbe A**, **Moleti M**, **Maggio Savasta L**, **De Dominici R**, **Priolo AM**, **Vermiglio F**, Thyroid function in women found to have early pregnancy loss, Thyroid 20(6):633, 2010. doi:10.1089/thy.2009.0323.
382. **Cleary-Goldman J**, **Malone FD**, **Lambert-Messerlian G**, **Sullivan L**, **Canick J**, **Porter TF**, **Luthy D**, **Gross S**, **Bianchi DW**, **D'Alton ME**, Maternal thyroid hypofunction and pregnancy outcome, Obstet Gynecol 112(1):85, 2008. doi:10.1097/AOG.0b013e3181788dd7.
383. **Michalakis KG**, **Mesen TB**, **Brayboy LM**, **Yu B**, **Richter KS**, **Levy M**, **Widra E**, **Segars JH**, Subclinical elevations of thyroid-stimulating hormone and assisted reproductive technology outcomes, Fertil Steril 95(8):2634, 2011.
384. **Mandel SJ**, **Larsen PR**, **Seely EW**, **Brent GA**, Increased need for thyroxine during pregnancy in women with primary hypothyroidism, N Engl J Med 323:91, 1990.
385. **Kaplan MM**, Monitoring thyroxine treatment during pregnancy, Thyroid 2:147, 1992.
386. **Alexander EK**, **Marqusee E**, **Lawrence J**, **Jarolim P**, **Fischer GA**, **Larsen PR**, Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism, N Engl J Med 351:241, 2004.
387. **Mandel SJ**, **Spencer CA**, **Hollowell JG**, Are detection and treatment of thyroid insufficiency in pregnancy feasible? Thyroid 15:44, 2005.
388. **Mills JE**, **Simpson JL**, **Driscoll SG**, Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception, N Engl J Med 319:1617, 1988.
389. **Miodovnik M**, **Mimouni F**, **Siddiqi TA**, **Khoury J**, **Berk MA**, Spontaneous abortions in repeat diabetic pregnancies: a relationship with glycemic control, Obstet Gynecol 75:75, 1990.
390. **Greene MF**, Spontaneous abortions and major malformations in women with diabetes mellitus, Semin Reprod Endocrinol 17:127, 1999.
391. **Sutherland HW**, **Pritchard CW**, Increased incidence of spontaneous abortion in pregnancies complicated by maternal diabetes mellitus, Am J Obstet Gynecol 155:135, 1986.
392. **Regan L**, **Owen EJ**, **Jacobs HS**, Hypersecretion of luteinising hormone, infertility, and miscarriage, Lancet 336:1141, 1990.
393. **Tulppala M**, **Stenman U-H**, **Cacciatore B**, **Ylikorkala O**, Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women, Br J Obstet Gynaecol 100:348, 1993.
394. **Sagle M**, **Bishop K**, **Ridley N**, **Alexander FM**, **Michel M**, **Bonney RC**, **Beard RW**, **Franks S**, Recurrent early miscarriage and polycystic ovaries, Br Med J 297:1027, 1988.
395. **Homburg R**, **Armar NA**, **Eshel A**, **Adams J**, **Jacobs HS**, Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome, Br Med J 297:1024, 1988.
396. **Clifford K**, **Rai R**, **Watson H**, **Franks S**, **Regan L**, Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial, Br Med J 312:1508, 1996.
397. **Watson H**, **Kiddy DS**, **Hamilton-Fairley D**, **Scanlon MJ**, **Barnard C**, **Collins WP**, **Bonney RC**, **Franks S**, Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage, Hum Reprod 8:829, 1993.
398. **Moghetti P**, **Castello R**, **Negri C**, **Tosi F**, **Perrone F**, **Caputo M**, **Zanolin E**, **Muggeo M**, Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation, J Clin Endocrinol Metab 85:139, 2000.

399. **Nestler JE**, **Jakubowicz DJ**, **Evans WS**, **Pasquali R**, Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome, N Engl J Med 338:1876, 1998.
400. **Velázquez E**, **Acosta A**, **Mendoza SG**, Menstrual cyclicity after metformin therapy in polycystic ovary syndrome, Obstet Gynecol 90:392, 1997.
401. **Glueck CJ**, **Wang P**, **Fontaine R**, **Tracy T**, **Sieve-Smith L**, Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome, Metabolism 48:511, 1999.
402. **Glueck CJ**, **Wang P**, **Fontaine RN**, **Sieve-Smith L**, **Tracy T**, **Moore SK**, Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome, Metabolism 48:1589, 1999.
403. **Velazquez EM**, **Mendoza SG**, **Wang P**, **Glueck CJ**, Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome, Metabolism 46:454, 1997.
404. **Atiomo WU**, **Bates SA**, **Condon JE**, **Shaw S**, **West JH**, **Prentice AG**, The plasminogen activator system in women with polycystic ovary syndrome, Fertil Steril 69:236, 1998.
405. **Sampson M**, **Kong C**, **Patel A**, **Unwin R**, **Jacobs HS**, Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome, Clin Endocrinol (Oxf) 45:623, 1996.
406. **Glueck CJ**, **Phillips H**, **Cameron D**, **Sieve-Smith L**, **Wang P**, Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study, Fertil Steril 75:46, 2001.
407. **Glueck CJ**, **Wang P**, **Goldenberg N**, **Sieve-Smith L**, Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin, Hum Reprod 17:2858, 2002.
408. **Jakubowicz DJ**, **Iuorno MJ**, **Jakubowicz S**, **Roberts KA**, **Nestler JE**, Effects of metformin on early pregnancy loss in the polycystic ovary syndrome, J Clin Endocrinol Metab 87:524, 2002.
409. **Nawaz FH**, **Rizvi J**, Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovary syndrome, Gynecol Obstet Invest 69:184, 2010.
410. **Moll E**, **Bossuyt PM**, **Korevaar JC**, **Lambalk CB**, **van der Veen F**, Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial, Br Med J 332:1461, 2006.
411. **Legro RS**, **Barnhart HX**, **Schlaff WD**, **Carr BR**, **Diamond MP**, **Carson SA**, **Steinkampf MP**, **Coutifaris C**, **McGovern PG**, **Cataldo NA**, **Gosman GG**, **Nestler JE**, **Giudice LC**, **Leppert PC**, **Myers ER**; for the **Cooperative Multicenter Reproductive Medicine Network**, Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome, N Engl J Med 356:551, 2007.
412. **Zain MM**, **Jamaluddin R**, **Ibrahim A**, **Norman RJ**, Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial, Fertil Steril 91:514, 2009.
413. **Legro RS**, **Brzyski RG**, **Diamond MP**, **Coutifaris C**, **Schlaff WD**, **Casson P**, **Christman GM**, **Huang H**, **Yan Q**, **Alvero R**, **Haisenleder DJ**, **Barnhart KT**, **Bates GW**, **Usadi R**, **Lucidi S**, **Baker V**, **Trussell JC**, **Krawetz SA**, **Snyder P**, **Ohl D**, **Santoro N**, **Eisenberg E**, **Zhang H**; **NICHD Reproductive Medicine Network**, Letrozole versus clomiphene for infertility in the polycystic ovary syndrome, N Engl J Med 371(2):119, 2014. doi:10.1056/NEJMoa1313517.
414. **Homburg R**, Pregnancy complications in PCOS, Best Pract Res Clin Endocrinol Metab 20:281, 2006.
415. **Palomba S**, **Falbo A**, **Orio F Jr**, **Zullo F**, Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials, Fertil Steril 92:1646, 2009.
416. **Glueck CJ**, **Wang P**, **Kobayashi S**, **Phillips H**, **Sieve-Smith L**, Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome, Fertil Steril 77:520, 2002.
417. **Glueck CJ**, **Goldenberg N**, **Streicher P**, **Wang P**, Metformin and gestational diabetes, Curr Diab Rep 3:303,

2003.
418. **Glueck CJ**, **Goldenberg N**, **Wang P**, **Loftspring M**, **Sherman A**, Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy, Hum Reprod 19:510, 2004.
419. **Coetzee EJ**, **Jackson WP**, The management of non-insulin-dependent diabetes during pregnancy, Diabetes Res Clin Pract 1:281, 1985.
420. **Coetzee EJ**, **Jackson WP**, Metformin in management of pregnant insulin-independent diabetes, Diabetologia 16:241, 1979.
421. **Hellmuth E**, **Damm P**, **Molsted-Pedersen L**, Oral hypoglycaemic agents in 118 diabetic pregnancies, Diabet Med 17:507, 2000.
422. **Hughes RC**, **Rowan JA**, Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? Diabet Med 23:318, 2006.
423. **Mathur R**, **Alexander CJ**, **Yano J**, **Trivax B**, **Azziz R**, Use of metformin in polycystic ovary syndrome, Am J Obstet Gynecol 199:596, 2008.
424. **Tulchinsky D**, **Hobel CJ**, Plasma human and chorionic gonadotropin, estrogen, estradiol, estriol, progesterone and 17α-hydroxyprogesterone in human pregnancy, Am J Obstet Gynecol 117:884, 1973.
425. **Scott R**, **Navot D**, **Liu HC**, **Rosenwaks Z**, A human in vivo model for the luteoplacental shift, Fertil Steril 56:481, 1991.
426. **Csapo AI**, **Pulkkinen M**, Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence, Obstet Gynecol Surv 33:69, 1978.
427. **Csapo AL**, **Pulkkinen MO**, **Wiest WG**, Effects of luteectomy and progesterone replacement in early pregnant patients, Am J Obstet Gynecol 115:759, 1973.
428. **Schneider MA**, **Davies MC**, **Honour JW**, The timing of placental competence in pregnancy after oocyte donation, Fertil Steril 59:1059, 1993.
429. **Azuma K**, **Calderon I**, **Besanko M**, **Maclachlan V**, **Healy D**, Is the luteo-placental shift a myth? Analysis of low progesterone levels in successful ART pregnancies, J Clin Endocrinol Metab 77:195, 1993.
430. **Sultan KM**, **Davis OK**, **Liu H-C**, **Rosenwaks Z**, Viable term pregnancy despite "subluteal" serum progesterone levels in the first trimester, Fertil Steril 60:363, 1993.
431. **Mishell Jr DR**, **Thorneycroft IH**, **Nagata Y**, **Murata T**, **Nakamura RM**, Serum gonadotropin and steroid patterns in early human gestation, Am J Obstet Gynecol 117:631, 1973.
432. **Filicori M**, **Butler JP**, **Crowley WF**, Neuroendocrine regulation of the corpus luteum in the human: evidence for pulsatile progesterone secretion, J Clin Invest 73:1638, 1984.
433. **Murray MJ**, **Meyer WR**, **Zaino RJ**, **Lessey BA**, **Novotny DB**, **Ireland I**, **Fritz MA**, A critical reanalysis of the accuracy, reproducibility, and clinical utility of histologic endometrial dating: a systematic study of the secretory phase in normally cycling, fertile women, Fertil Steril 81:1333, 2004.
434. **Jones GES**, **Delfs E**, Endocrine patterns in term pregnancies following abortion, JAMA 146:1212, 1951.
435. **Stouffer RL**, **Hodgen GD**, **Ottobre AC**, **Christian CD**, Follicular fluid treatment during the follicular versus luteal phase of the menstrual cycle: effects on corpus luteum function, J Clin Endocrinol Metab 58:1027, 1984.
436. **DiZerega GS**, **Hodgen GD**, Luteal phase dysfunction infertility: a sequel to aberrant folliculogenesis, Fertil Steril 35:489, 1981.
437. **Strott CA**, **Cargille CM**, **Ross GT**, **Lipsett MB**, The short luteal phase, J Clin Endocrinol Metab 30:246, 1970.
438. **Sherman BM**, **Korenman SG**, Measurement of plasma LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the short luteal phase, J Clin Endocrinol Metab 38:89, 1974.
439. **Sheehan KL**, **Casper RF**, **Yen SS**, Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: a model for fertility control, Science 215:170, 1982.
440. **Quagliarello J**, **Weiss G**, Clomiphene citrate in the management of infertility associated with shortened luteal phases, Fertil Steril 31:373, 1979.
441. **Guzick DS**, **Zeleznik A**, Efficacy of clomiphene citrate in the treatment of luteal phase deficiency: quantity

versus quality of preovulatory follicles, Fertil Steril 54:206, 1990.
442. **Haas DM**, **Ramsey PS**, Progestogen for preventing miscarriage, Cochrane Database Syst Rev 16:CD003511, 2008.
443. **Witkin SS**, **Ledger WJ**, Antibodies to Chlamydia trachomatis in sera of women with recurrent spontaneous abortions, Am J Obstet Gynecol 167:135, 1992.
444. **Osser S**, **Persson K**, Chlamydial antibodies in women who suffer miscarriage, Br J Obstet Gynaecol 103:137, 1996.
445. **Quinn PA**, **Shewchuk AB**, **Shuber J**, **Lie KI**, **Ryan E**, **Sheu M**, **Chipman ML**, Serologic evidence of ureaplasma urealyticum infection in women with spontaneous pregnancy loss, Am J Obstet Gynecol 145:245, 1983.
446. **Donders GG**, **Van Bulck B**, **Caudron J**, **Londers L**, **Vereecken A**, **Spitz B**, Relationship of bacterial vaginosis and mycoplasmas to the risk of spontaneous abortion, Am J Obstet Gynecol 183:431, 2000.
447. **Ralph SG**, **Rutherford AJ**, **Wilson JD**, Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study, Br Med J 319:220, 1999.
448. **Oakeshott P**, **Hay P**, **Hay S**, **Steinke F**, **Rink E**, **Kerry S**, Association between bacterial vaginosis or chlamydial infection and miscarriage before 16 weeks' gestation: prospective community based cohort study, Br Med J 325:1334, 2002.
449. **Paavonen J**, **Kiviat N**, **Brunham RC**, **Stevens CE**, **Kuo CC**, **Stamm WE**, **Miettinen A**, **Soules M**, **Eschenbach DA**, **Holmes KK**, Prevalence and manifestations of endometritis among women with cervicitis, Am J Obstet Gynecol 152:280, 1985.
450. **Korn AP**, **Bolan G**, **Padian N**, **Ohm-Smith M**, **Schachter J**, **Landers DV**, Plasma cell endometritis in women with symptomatic bacterial vaginosis, Obstet Gynecol 85:387, 1995.
451. **Wiesenfeld HC**, **Hillier SL**, **Krohn MA**, **Amortegui AJ**, **Heine RP**, **Landers DV**, **Sweet RL**, Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease, Obstet Gynecol 100:456, 2002.
452. **Quinn PA**, **Shewchuk AB**, **Shuber J**, **Lie KI**, **Ryan E**, **Chipman ML**, **Nocilla DM**, Efficacy of antibiotic therapy in preventing spontaneous pregnancy loss among couples colonized with genital mycoplasmas, Am J Obstet Gynecol 145:239, 1983.
453. **Munday PE**, **Porter R**, **Falder PF**, **Carder JM**, **Holliman R**, **Lewis BV**, **Taylor-Robinson D**, Spontaneous abortion—an infectious aetiology? Br J Obstet Gynaecol 91:1177, 1984.
454. **Toth A**, **Lesser ML**, **Brooks-Toth CW**, **Feiner C**, Outcome of subsequent pregnancies following antibiotic therapy after primary or multiple spontaneous abortions, Surg Gynecol Obstet 163:243, 1986.
455. **Wacholder S**, **Chen BE**, **Wilcox A**, **Macones G**, **Gonzalez P**, **Befano B**, **Hildesheim A**, **Rodriguez AC**, **Solomon D**, **Herrero R**, **Schiffman M**; **CVT Group**, Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials, Br Med J 340:c712, 2010. doi:10.1136/bmj.c712.
456. **Harlap S**, **Shiono PH**, Alcohol, smoking, and incidence of spontaneous abortions in the first and second trimester, Lancet 2:173, 1980.
457. **Armstrong BG**, **McDonald AD**, **Sloan M**, Cigarette, alcohol, and coffee consumption and spontaneous abortion, Am J Public Health 82:85, 1992.
458. **Hughes EG**, **Brennan BG**, Does cigarette smoking impair natural or assisted fecundity, Fertil Steril 66:679, 1996.
459. **Himmelberger DU**, **Brown BW Jr**, **Cohen EN**, Cigarette smoking during pregnancy and the occurrence of spontaneous abortion and congenital abnormality, Am J Epidemiol 108:470, 1978.
460. **Hemminki K**, **Mutanen P**, **Saloniemi I**, Smoking and the occurrence of congenital malformations and spontaneous abortions: multivariate analysis, Am J Obstet Gynecol 145:61, 1983.
461. **Windham GC**, **Swan SH**, **Fenster L**, Parental cigarette smoking and the risk of spontaneous abortion, Am J Epidemiol 135:1394, 1992.
462. **Kline J**, **Stein ZA**, **Susser M**, **Warburton D**, Smoking: a risk factor for spontaneous abortion, N Engl J Med 297:793, 1977.

463. **Coste J**, **Job-Spira N**, **Fernandez H**, Risk factors for spontaneous abortion: a case-control study in France, Hum Reprod 6:1332, 1991.
464. **Gardella JR**, **Hill JA III**, Environmental toxins associated with recurrent pregnancy loss, Semin Reprod Med 18:407, 2000.
465. **Streissguth AP**, **Martin DC**, **Martin JC**, **Barr HM**, The Seattle longitudinal prospective study on alcohol and pregnancy, Neurobehav Toxicol Teratol 3: 223, 1981.
466. **Kline J**, **Shrout P**, **Stein Z**, **Susser M**, **Warburton D**, Drinking during pregnancy and spontaneous abortion, Lancet 2:176, 1980.
467. **Cavallo F**, **Russo R**, **Zotti C**, **Camerlengo A**, **Ruggenini AM**, Moderate alcohol consumption and spontaneous abortion, Alcohol 30:195, 1995.
468. **Srisuphan W**, **Bracken MB**, Caffeine consumption during pregnancy and association with late spontaneous abortion, Am J Obstet Gynecol 154:14, 1986.
469. **Kline J**, **Levin B**, **Silverman J**, **Kinney A**, **Stein Z**, **Susser M**, **Warburton D**, Caffeine and spontaneous abortion of known karyotype, Epidemiology 2:409, 1991.
470. **Infante-Rivard C**, **Fernandez A**, **Gauthier R**, **David M**, **Rivard GE**, Fetal loss associated with caffeine intake before and during pregnancy, JAMA 270:2940, 1993.
471. **Fenster L**, **Hubbard AE**, **Swan SH**, **Windham GC**, **Waller K**, **Hiatt RA**, **Benowitz N**, Caffeinated beverages, decaffeinated coffee, and spontaneous abortion, Epidemiology 8:515, 1997.
472. **Dlugosz L**, **Belanger K**, **Hellenbrand K**, **Holford TR**, **Leaderer B**, **Bracken MB**, Maternal caffeine consumption and spontaneous abortion: a prospective cohort study, Epidemiology 7:250, 1996.
473. **Rasch V**, Cigarette, alcohol, and caffeine consumption: risk factors for spontaneous abortion, Acta Obstet Gynecol Scand 82:182, 2003.
474. **Parazzini F**, **Chatenoud L**, **Di Cintio E**, **Mezzopane R**, **Surace M**, **Zanconato G**, **Fedele L**, **Benzi G**, Coffee consumption and risk of hospitalized miscarriage before 12 weeks of gestation, Hum Reprod 13:2286, 1998.
475. **Wen W**, **Shu XO**, **Jacobs DR Jr**, **Brown JE**, The associations of maternal caffeine consumption and nausea with spontaneous abortion, Epidemiology 12:38, 2001.
476. **McMartin KI**, **Chu M**, **Kopecky E**, **Einarson TR**, **Koren G**, Pregnancy outcome following maternal organic solvent exposure: a meta-analysis of epidemiologic studies, Am J Ind Med 34:288, 1998.
477. **Schnorr TM**, **Grajewski BA**, **Hornung RW**, **Thun MJ**, **Egeland GM**, **Murray WE**, **Conover DL**, **Halperin WE**, Video display terminals and the risk of spontaneous abortion, N Engl J Med 324:727, 1991.
478. **Lammer EJ**, **Chen DT**, **Hoar RM**, **Agnish ND**, **Benke PJ**, **Braun JT**, **Curry CJ**, **Fernhoff PM**, **Grix AW Jr**, et al., Retinoic acid embryopathy, N Engl J Med 313:837, 1985.
479. **Heidam LZ**, Spontaneous abortions among laboratory workers, J Epidemiol Community Health 38:36, 1984.
480. **Taskinen H**, **Lindbohm ML**, **Hemminki K**, Spontaneous abortions among women working in the pharmaceutical industry, Br J Ind Med 43:199, 1984.
481. **Belanger K**, **Leaderer B**, **Hellenbrand K**, **Holford TR**, **McSharry J**, **Power M-E**, **Bracken MB**, Spontaneous abortion and exposure to electric blankets and heated water beds, Epidemiology 9:36, 1998.
482. **Metwally M**, **Ong MKJ**, **Ledger WL**, **Li TC**, Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception? A meta-analysis of the evidence, Fertil Steril 90:714, 2008.
483. **Zhang BY**, **Wei YS**, **Niu JM**, **Li Y**, **Miao ZL**, **Wang ZN**, Risk factors for unexplained recurrent spontaneous abortion in a population from southern China, Int J Gynaecol Obstet 108:135, 2010.
484. **Metwally M**, **Saravelos SH**, **Ledger WL**, **Li TC**, Body mass index and risk of miscarriage in women with recurrent miscarriage, Fertil Steril 94:290, 2010.
485. **Goldenberg RL**, **Mayberry SK**, **Copper RL**, **Dubard MB**, **Hauth JC**, Pregnancy outcome following a second-trimester loss, Obstet Gynecol 81:444, 1993.
486. **Perino A**, **Vassiliadis A**, **Vucetich A**, **Colacurci N**, **Menato G**, **Cignitti M**, **Semprini AE**, Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study, Hum Reprod 12:2388, 1997.
487. **Fedele L**, **Acala B**, **Parazzini F**, **Ricciardiello O**, **Cantiani GB**, Ectopic pregnancy and recurrent

spontaneous abortion: two associated reproductive failures, Obstet Gynecol 73:206, 1989.

488. **Goldstein P**, **Berrier J**, **Rosen S**, **Sacks HS**, **Chalmers TC**, A meta-analysis of randomized control trials of progestational agents in pregnancy, Br J Obstet Gynaecol 96:265, 1989.
489. **Daya S**, Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials, Br J Obstet Gynaecol 96:275, 1989.
490. **Marzetti L**, **Boni T**, **Fazzio M**, **Giobbe M**, Current role of progesterone therapy in the prevention of spontaneous abortion and in the treatment of threatened abortion, Minerva Ginecol 52:515, 2000.

Chapter thirty one

KEY READINGS

1. **Collins FS**, **Green ED**, **Guttmacher AE**, **Guyer MS**; **on behalf of the U.S. National Human Genome Research Institute,** A vision for the future of genomics research. A blueprint for the genomic era, Nature 422:835, 2003.
2. **Croce CM**, Oncogenes and cancer, N Engl J Med 358:502, 2008.
3. **Espy MG**, Real-time PCR in clinical microbiology: applications for routine laboratory testing, Clin Microbiol Rev 19:165, 2006.
4. **Hardy B-J**, **Séguin B**, **Goodsaid F**, **Jimenez-Sanchez G**, **Singer PA**, **Daar A**, The next steps for genomic medicine: challenges and opportunities for the developing world, Nat Rev Genet (Suppl 1):S23, 2008.
5. **International HapMap Consortium**, A haplotype map of the human genome, Nature 437:1299, 2005.
6. **International Human Genome Sequencing Consortium**, Finishing the euchromatic sequence of the human genome, Nature 431:931, 2004.
7. **Pearson TA**, **Manolio TA**, How to interpret a genome-wide association study, JAMA 299:1335, 2008.

Chapter thirty two

REFERENCES

1. **Knapp VJ**, How old is endometriosis? Late 17th- and 18th-century European descriptions of the disease, Fertil Steril 72(1):10, 1999.
2. **Nezhat C**, **Nezhat F**, Endometriosis: ancient disease, ancient treatments, Fertil Steril 98(6 Suppl):S1, 2012.
3. **Sampson JA**, Perforating hemorrhagic cysts (chocolate cyst) of the ovary: their importance and especially their relation to pelvic adenomas of the endometrial type, Arch Surg 3:245, 1921.
4. **Macer ML**, **Taylor HS**, Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility, Obstet Gynecol Clin North Am 39(4):535, 2012.
5. **Bulun SE**, Endometriosis, N Engl J Med 360(3):268, 2009.
6. **Nnoaham KE**, **Hummelshoj L**, **Webster P**, **d'Hooghe T**, **de Cicco Nardone F**, **de Cicco Nardone C**, et al., Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries, Fertil Steril 96(2):366, 2011.
7. **Simoens S**, **Dunselman G**, **Dirksen C**, **Hummelshoj L**, **Bokor A**, **Brandes I**, et al., The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres, Hum Reprod 27(5):1292, 2012.
8. **Wheeler JM**, Epidemiology of endometriosis-associated infertility, J Reprod Med 34:41, 1989.
9. **Strathy JH**, **Molgaard CA**, **Coulam CB**, **Melton LJ III,** Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women, Fertil Steril 38:667, 1982.
10. **Chatman DL**, **Ward AB,** Endometriosis in adolescents, J Reprod Med 27:156, 1982.
11. **Goldstein DP**, **deCholnoky C**, **Emans SJ**, **Leventhal JM**, Laparoscopy in the diagnosis and management of pelvic pain in adolescents, J Reprod Med 24:251, 1989.
12. **Mahmood TA**, **Templeton A,** Prevalence and genesis of endometriosis, Hum Reprod 6:544, 1991.
13. **Sangi-Haghpeykar H**, **Poindexter AN** III, Epidemiology of endometriosis among parous women, Obstet Gynecol 85:983, 1995.
14. **Giudice LC**, Clinical practice. Endometriosis, N Engl J Med 362(25):2389, 2010.
15. **Cramer DW**, **Missmer SA**, The epidemiology of endometriosis, Ann N Y Acad Sci 955:11, 2002.
16. **D'Hooghe TM**, **Debrock S**, **Hill JA**, **Meuleman C**, Endometriosis and subfertility: is the relationship resolved? Semin Reprod Med 21:243, 2003.
17. **Giudice LC**, **Kao LC,** Endometriosis, Lancet 364:1789, 2004.
18. **Bulun SE**, Endometriosis, New Engl J Med 360:268, 2009.
19. **Kuohung W**, **Jones GL**, **Vitonis AF**, **Cramer DW**, **Kennedy SH**, **Thomas D**, **Hornstein MD**, Characteristics of patients with endometriosis in the United States and the United Kingdom, Fertil Steril 78:767, 2002.
20. **Hediger ML**, **Hartnett HJ**, **Louis GM**, Association of endometriosis with body size and figure, Fertil Steril 84:1366, 2005.
21. **Reese KA**, **Reddy S**, **Rock JA**, Endometriosis in an adolescent population: the emory experience, J Pediatr Adolesc Gynecol 9:125, 1996.
22. **Janssen EB**, **Rijkers AC**, **Hoppenbrouwers K**, **Meuleman C**, **D'Hooghe TM**, Prevalence of endometriosis diagnosed by laparoscopy in adolescents with dysmenorrhea or chronic pelvic pain: a systematic review, Hum Reprod Update 19(5):570, 2013.
23. **Huffman JW,** Endometriosis in young teen-age girls, Pediatr Ann 10:501, 1981.
24. **Punnonen R**, **Klemi PJ**, **Nikkanen V,** Postmenopausal endometriosis, Eur J Obstet Gynecol Reprod Biol 11:195, 1980.
25. **Djursing H**, **Petersen K**, **Weberg E**, Symptomatic postmenopausal endometriosis, Acta Obstet Gynecol Scand 60:529, 1981.
26. **Tan DA**, **Almaria MJG**, Postmenopausal endometriosis: drawing a clearer clinical picture, Climacteric 21(3):249, 2018.
27. **Missmer SA**, **Hankinson SE**, **Spiegelman D**, **Barbieri RL**, **Marshall LM**, **Hunter DJ**, Incidence of

laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors, Am J Epidemiol 160:784, 2004.
28. **Berube S**, **Marcoux S**, **Maheux R**, Characteristics related to the prevalence of minimal or mild endometriosis in infertile women. Canadian Collaborative Group on Endometriosis, Epidemiology 9:504, 1998.
29. **Shah DK**, **Correia KF**, **Vitonis AF**, **Missmer SA**, Body size and endometriosis: results from 20 years of follow-up within the Nurses' Health Study II prospective cohort, Hum Reprod 28:1783, 2013.
30. **Vitonis AF**, **Baer HJ**, **Hankinson SE**, **Laufer MR**, **Missmer SA**, A prospective study of body size during childhood and early adulthood and the incidence of endometriosis, Hum Reprod 25:1325, 2010.
31. **Ferrero S**, **Anserini P**, **Remorgida V**, **Ragni N**, Body mass index in endometriosis, Eur J Obstet Gynecol Reprod Biol 121:94, 2005.
32. **Shafrir AL**, **Farland LV**, **Shah DK**, **Harris HR**, **Kvaskoff M**, **Zondervan K**, et al., Risk for and consequences of endometriosis: a critical epidemiologic review, Best Pract Res Clin Obstet Gynaecol 51:1, 2018.
33. **Darrow SL**, **Vena JE**, **Batt RE**, **Zielezny MA**, **Michalek AM**, **Selman S**, Menstrual cycle characteristics and the risk of endometriosis, Epidemiology 4:135, 1993.
34. **Matorras R**, **Rodiquez F**, **Pijoan JI**, **Ramon O**, **Gutierrez de Teran G**, **Rodriguez-Escudero T**, Epidemiology of endometriosis in infertile women, Fertil Steril 63:34, 1995.
35. **Gruppos Italiano per lo Studio Dell'Endometriosi**, Risk factors for pelvic endometriosis in women with pelvic pain or infertility, Eur J Obstet Gynecol Reprod Biol 83:195, 1999.
36. **Moen MH**, Is a long period without childbirth a risk factor for developing endometriosis? Hum Reprod 6:1404, 1991.
37. **Zhou Y**, **Jorgensen EM**, **Gan Y**, **Taylor HS**, Cigarette smoke increases progesterone receptor and homeobox A10 expression in human endometrium and endometrial cells: a potential role in the decreased prevalence of endometrial pathology in smokers, Biol Reprod 84(6):1242, 2011.
38. **Rier S**, **Foster WG**, Environmental dioxins and endometriosis, Semin Reprod Med 21:145, 2003.
39. **Bruner-Tran KL**, **Osteen KG**, Dioxin-like PCBs and endometriosis, Syst Biol Reprod Med 56(2):132, 2010.
40. **Missmer SA**, **Hankinson SE**, **Spiegelman D**, **Barbieri RL**, **Michels KB**, **Hunter DJ,** In utero exposures and the incidence of endometriosis, Fertil Steril 82:1501, 2004.
41. **Giudice LC**, **Swiersz LM**, **Burney RO**, Endometriosis. In: Jameson JL, De Groot LJ, eds. Endocrinology, 6th ed, Elsevier, New York, 2010, p. 2356.
42. **Somigliana E**, **Viganò P**, **Parazzini F**, et al., Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence, Gynecol Oncol 101:331, 2006.
43. **Sampson JA**, Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity, Am J Obstet Gynecol 14:422, 1927.
44. **Olive DL**, **Henderson DY**, Endometriosis and müllerian anomalies, Obstet Gynecol 69:412, 1987.
45. **Burney RO**, **Giudice LC**, Pathogenesis and pathophysiology of endometriosis, Fertil Steril 98(3):511, 2012.
46. **Liu DTY**, **Hitchchock A**, Endometriosis: its association with retrograde menstruation, dysmenorrhea, and tubal pathology, Br J Obstet Gynaecol 93:859, 1986.
47. **Kruitwagen RFPM**, **Poels LG**, **Willemsen WNP**, **Jap PHK**, **Thomas CMG**, **Rolland R**, Endometrial epithelial cells in peritoneal fluid during the early follicular phase, Fertil Steril 55:297, 1991.
48. **Witz CA**, **Monotoya-Rodriguez IA**, **Schenken RS**, Whole explants of peritoneum and endometrium: a novel model of the early endometriosis lesion, Fertil Steril 71:56, 1999.
49. **Maas JW**, **Groothuis PG**, **Dunselman GA**, **de Goeij AF**, **Struijker-Boudier HA**, **Evers JL**, Development of endometriosis-like lesions after transplantation of human endometrial fragments onto the chick embryo chorioallantoic membrane, Hum Reprod 16:627, 2001.
50. **Cramer DW**, **Wilson E**, **Stillman RJ**, **Berger MJ**, **Belisle S**, **Schiff I**, **Albrecht B**, **Gibson M**, **Stadel BV**, **Schoenbaum SC**, The relation of endometriosis to menstrual characteristics, smoking and exercise, JAMA 355:1904, 1986.
51. **Jenkins S**, **Olive DL**, **Haney AF**, Endometriosis: pathogenetic implications of the anatomic distribution, Obstet Gynecol 67:335, 1986.

52. **Ishimura T**, **Masuzaki H**, Peritoneal endometriosis: endometrial tissue implantation as its primary etiologic mechanism, Am J Obstet Gynecol 165:210, 1991.
53. **Gruppos Italiano per lo Studio Dell'Endometriosi**, Prevalence and anatomical distribution of endometriosis in women with selected gynaecological conditions: results from a multicentric Italian study, Hum Reprod 9:1158, 1994.
54. **TeLinde R**, **Scott R**, Experimental endometriosis, Am J Obstet Gynecol 60:1147, 1950.
55. **Scott RB**, **TeLinde RW**, **Wharton LR Jr**, Further studies on experimental endometriosis, Am J Obstet Gynecol 66:1082, 1953.
56. **Lee B**, **Du H**, **Taylor HS**, Experimental murine endometriosis induces DNA methylation and altered gene expression in eutopic endometrium, Biol Reprod 80(1):79, 2009.
57. **Taylor HS**, **Alderman Iii M**, **D'Hooghe TM**, **Fazleabas AT**, **Duleba AJ**, Effect of simvastatin on baboon endometriosis, Biol Reprod 97(1):32, 2017.
58. **D'Hooghe TM**, **Bambra CS**, **Raeymaekers BM**, **De Jonge I**, **Lauweryns JM**, **Koninckx PR**, Intrapelvic injection of menstrual endometrium causes endometriosis in baboons (Papio cynocephalus and Papio anubis), Am J Obstet Gynecol 173:125, 1995.
59. **Ridley J**, **Edwards I**, Experimental endometriosis in the human, Am J Obstet Gynecol 76:783, 1958.
60. **Ferguson BR**, **Bennington JL**, **Haber SL**, Histochemistry of mucosubstances and histology of mixed mullerian pelvic lymph node glandular inclusions. Evidence for histogenesis by mullerian metaplasia of coelomic epithelium, Obstet Gynecol 33(5):617, 1969.
61. **Suginami H**, A reappraisal of the coelomic metaplasia theory by reviewing endometriosis occurring in unusual sites and instances, Am J Obstet Gynecol 165:214, 1991.
62. **Clark AH**, Endometriosis in a young girl, JAMA 136:690, 1948.
63. **Whitehouse HB**, Endometrioma invading the bladder removed from a patient who never menstruated, Proc R Soc Med 19:15, 1925.
64. **El-Mahgoub S**, **Yaseen S**, A positive proof for the theory of coelomic metaplasia, Am J Obstet Gynecol 137:137, 1980.
65. **Schifrin BS**, **Erez S**, **Moore JG**, Teen-age endometriosis, Am J Obstet Gynecol 116:973, 1973.
66. **Foster DC**, **Stern JL**, **Buscema J**, **Rock JA**, **Woodruff JD**, Pleural and parenchymal pulmonary endometriosis, Obstet Gynecol 58:552, 1981.
67. **Gruenwald P**, Origin of endometriosis from the mesenchyme of the coelomic walls, Am J Obstet Gynecol 44:470, 1942.
68. **Fujii S**, Secondary mullerian system and endometriosis, Am J Obstet Gynecol 165:219, 1991.
69. **Das Gupta S**, **Pal SK**, **Saha PK**, **Dawn CS**, Endometriosis in the thumb, J Indian Med Assoc 83:122, 1985.
70. **Gitelis S**, **Petasnick JP**, **Turner DA**, **Ghiselli RW**, **Miller AW III**, Endometriosis simulating a soft tissue tumor of the thigh: CT and MR evaluation, J Comput Assist Tomogr 9:573, 1985.
71. **Patel VC**, **Samuels H**, **Abeles E**, **Hirjibehedin PF**, Endometriosis at the knee. A case report, Clin Orthop 171:140, 1982.
72. **Oliker AJ**, **Harris AE**, Endometriosis of the bladder in a male patient, J Urol 106:858, 1971.
73. **Schrodt GR**, **Alcorn MO**, **Ibanez J**, Endometriosis of the male urinary system: a case report, J Urol 124:722, 1980.
74. **Martin JD Jr**, **Hauck AE**, Endometriosis in the male, Am Surg 51:426, 1985.
75. **Matsuura K**, **Ohtake H**, **Katabuchi H**, **Okamura H**, Coelomic metaplasia theory of endometriosis: evidence from in vivo studies and an in vitro experimental model, Gynecol Obstet Invest 47(Suppl 1):18, 1999.
76. **Redwine DB**, Was Sampson wrong?, Fertil Steril 78:686, 2002.
77. **Comiter CV**, Endometriosis of the urinary tract, Urol Clin North Am 29:625, 2002.
78. **Shah M**, **Tager D**, **Feller E**, Intestinal endometriosis masquerading as common digestive disorders, Arch Intern Med 155:977, 1995.
79. **Candiani GB**, **Vercellini P**, **Fedele L**, **Vendola N**, **Carinelli S**, **Scaglione V**, Inguinal endometriosis: pathogenetic and clinical implications, Obstet Gynecol 78:191, 1991.
80. **Zollner U**, **Girschick G**, **Steck T**, **Dietl J**, Umbilical endometriosis without previous pelvic surgery: a case

report, Arch Gynecol Obstet 267:258, 2003.
81. **Markham SM**, **Carpenter SE**, **Rock JA**, Extrapelvic endometriosis, Obstet Gynecol Clin North Am 16:193, 1989.
82. **Honore GM**, Extrapelvic endometriosis, Clin Obstet Gynecol 42:699, 1999.
83. **Javert CT**, Pathogenesis of endometriosis based on endometrial homeoplasia, direct extension, exfoliation and implantation, lymphatic and hematogenous metastasis. Including five case reports of endometrial tissue in pelvic lymph nodes, Cancer 2:399, 1949.
84. **Ueki M**, Histologic study of endometriosis and examination of lymphatic drainage in and from the uterus, Am J Obstet Gynecol 165:201, 1991.
85. **Ichimiya M**, **Hirota T**, **Muto M**, Intralymphatic embolic cells with cutaneous endometriosis in the umbilicus, J Dermatol 25:333, 1998.
86. **Moore JG**, **Binstock MA**, **Growdon WA**, The clinical implications of retroperitoneal endometriosis, Am J Obstet Gynecol 158:1291, 1988.
87. **Scholefield HJ**, **Sajjad Y**, **Morgan PR**, Cutaneous endometriosis and its association with caesarean section and gynaecological procedures, J Obstet Gynaecol 22:553, 2002.
88. **Taff L**, **Jones S**, Cesarean scar endometriosis. A report of two cases, J Reprod Med 47:50, 2002.
89. **Kanellos I**, **Kelpis T**, **Zaraboukas T**, **Betsis D**, Perineal endometriosis in episiotomy scar with anal sphincter involvement, Tech Coloproctol 5:107, 2001.
90. **Sasson IE**, **Taylor HS**, Stem cells and the pathogenesis of endometriosis, Ann N Y Acad Sci 1127:106, 2008.
91. **Chan RW**, **Schwab KE**, **Gargett CE**, Clonogenicity of human endometrial epithelial and stromal cells, Biol Reprod 70(6):1738, 2004.
92. **Du H**, **Taylor HS**, Contribution of bone marrow-derived stem cells to endometrium and endometriosis, Stem Cells 25(8):2082, 2007.
93. **Taylor HS**, Endometrial cells derived from donor stem cells in bone marrow transplant recipients, JAMA 292(1):81, 2004.
94. **Du H**, **Naqvi H**, **Taylor HS**, Ischemia/reperfusion injury promotes and granulocyte-colony stimulating factor inhibits migration of bone marrow-derived stem cells to endometrium, Stem Cells Dev 21(18):3324, 2012.
95. **Sakr S**, **Naqvi H**, **Komm B**, **Taylor HS**, Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment, Endocrinology 155(4):1489, 2014.
96. **Moridi I**, **Mamillapalli R**, **Cosar E**, **Ersoy GS**, **Taylor HS**, Bone marrow stem cell chemotactic activity is induced by elevated CXCl12 in endometriosis, Reprod Sci 24(4):526, 2017.
97. **Pluchino N**, **Mamillapalli R**, **Moridi I**, **Tal R**, **Taylor HS**, G-protein-coupled receptor CXCR7 is overexpressed in human and murine endometriosis, Reprod Sci 25(8):1168, 2018. doi:10.1177/1933719118766256.
98. **Wang X**, **Mamillapalli R**, **Mutlu L**, **Du H**, **Taylor HS**, Chemoattraction of bone marrow-derived stem cells towards human endometrial stromal cells is mediated by estradiol regulated CXCL12 and CXCR4 expression, Stem Cell Res 15(1):14, 2015.
99. **Barrier BF**, Immunology of endometriosis, Clin Obstet Gynecol 53:397, 2010.
100. **Sinaii N**, **Cleary SD**, **Ballweg ML**, **Nieman LK**, **Stratton P**, High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis, Hum Reprod 17:2715, 2002.
101. **Matorras R**, **Ocerin I**, **Unamuno M**, **Nieto A**, **Peiro E**, **Burgos J**, **Exposito A**, Prevalence of endometriosis in women with systemic lupus erythematosus and Sjogren's syndrome, Lupus 16:736, 2007.
102. **Pasoto SG**, **Abrao MS**, **Viana VS**, **Bueno C**, **Leon EP**, **Bonfa E**, Endometriosis and systemic lupus erythematosus: a comparative evaluation of clinical manifestations and serological autoimmune phenomena, Am J Reprod Immunol 53:85, 2005.
103. **Taylor PV**, **Maloney MD**, **Campbell JM**, **Skerrow SM**, **Nip MM**, **Parmar R**, **Tate G**, Autoreactivity in women with endometriosis, Br J Obstet Gynaecol 98:680, 1991.
104. **Mathur S**, **Chihal HJ**, **Homm RJ**, **Garza DE**, **Rust PF**, **Williamson HO**, Endometrial antigens involved in

the autoimmunity of endometriosis, Fertil Steril 50:860, 1988.
105. **Kennedy SH**, **Starkey PM**, **Sargent IL**, **Hicks BR**, **Barlow DH**, Antiendometrial antibodies in endometriosis measured by an enzyme-linked immunosorbent assay before and after treatment with danazol and nafarelin, Obstet Gynecol 75:914, 1990.
106. **Wild RA**, **Hirisave V**, **Podczaski ES**, **Coulam C**, **Shivers CA**, **Satyaswaroop PG**, Autoantibodies associated with endometriosis: can their detection predict presence of the disease?, Obstet Gynecol 77:927, 1991.
107. **Odukoya OA**, **Wheatcroft N**, **Weetman AP**, **Cooke ID**, The prevalence of endometrial immunoglobulin G antibodies in patients with endometriosis, Hum Reprod 10:1214, 1995.
108. **Pillai S**, **Zhou GX**, **Arnaud P**, **Jiang H**, **Butler WJ**, **Zhang H**, Antibodies to endometrial transferrin and alpha 2-Heremans Schmidt (HS) glycoprotein in patients with endometriosis, Am J Reprod Immunol 35:483, 1996.
109. **Randall GW**, **Gantt PA**, **Poe-Zeigler RL**, **Bergmann CA**, **Noel ME**, **Strawbridge WR**, **Richardson-Cox B**, **Hereford JR**, **Reiff RH**, Serum antiendometrial antibodies and diagnosis of endometriosis, Am J Reprod Immunol 58:374, 2007.
110. **Inagaki J**, **Sugiura-Ogasawara M**, **Nomizu M**, **Nakatsuka M**, **Ikuta K**, **Suzuki N**, **Kaihara K**, **Kobayashi K**, **Yasuda T**, **Shoenfeld Y**, **Aoki K**, **Matsuura E**, An association of IgG anti-laminin-1 autoantibodies with endometriosis in infertile patients, Hum Reprod 18:544, 2003.
111. **Herington JL**, **Bruner-Tran KL**, **Lucas JA**, **Osteen KG**, Immune interactions in endometriosis, Expert Rev Clin Immunol 7(5):611, 2011.
112. **Haney AF**, **Muscato JJ**, **Weinberg JB**, Peritoneal fluid cell populations in infertility patients, Fertil Steril 35:696, 1981.
113. **Halme J**, **Becker S**, **Hammond MG**, **Raj MH**, **Raj S**, Increased activation of pelvic macrophages in infertile women with mild endometriosis, Am J Obstet Gynecol 145:333, 1983.
114. **Olive DL**, **Weinberg JB**, **Haney AF**, Peritoneal macrophages and infertility: the association between cell number and pelvic pathology, Fertil Steril 44:772, 1985.
115. **Hill JA**, **Faris HM**, **Schiff I**, **Anderson DJ**, Characterization of leukocyte subpopulations in the peritoneal fluid of women with endometriosis, Fertil Steril 50:216, 1988.
116. **Lebovic DI**, **Mueller MD**, **Taylor RN**, Immunobiology of endometriosis, Fertil Steril 75:1, 2001.
117. **Sidell N**, **Han SW**, **Parthasarathy S**, Regulation and modulation of abnormal immune responses in endometriosis, Ann N Y Acad Sci 955:159, 2002.
118. **Bruner-Tran KL**, **Herington JL**, **Duleba AJ**, **Taylor HS**, **Osteen KG**, Medical management of endometriosis: emerging evidence linking inflammation to disease pathophysiology. Minerva Ginecol 65(2):199, 2013.
119. **Kikuchi Y**, **Ishikawa N**, **Hirata J**, **Imaizumi E**, **Sasa H**, **Nagata I**, Changes of peripheral blood lymphocyte subsets before and after operation of patients with endometriosis, Acta Obstet Gynecol Scand 72:157, 1993.
120. **Oosterlynck DJ**, **Cornillie FJ**, **Waer M**, **Vandeputte M**, **Koninckx PR**, Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium, Fertil Steril 56:45, 1991.
121. **Oosterlynck DJ**, **Meuleman C**, **Waer M**, **Vandeputte M**, **Koninckx PR**, The natural killer activity of peritoneal fluid lymphocytes is decreased in women with endometriosis, Fertil Steril 58:292, 1992.
122. **Ho HN**, **Chao KH**, **Chen HF**, **Wu MY**, **Yang YS**, **Lee TY**, Peritoneal natural killer cytotoxicity and CD25+ CD3+ lymphocyte subpopulation are decreased in women with stage III-IV endometriosis, Hum Reprod 10:2671, 1995.
123. **Wu MY**, **Yang JH**, **Chao KH**, **Hwang JL**, **Yang YS**, **Ho HN**, Increase in the expression of killer cell inhibitory receptors on peritoneal natural killer cells in women with endometriosis, Fertil Steril 74:1187, 2000.
124. **Maeda N**, **Izumiya C**, **Yamamoto Y**, **Oguri H**, **Kusume T**, **Fukaya T**, Increased killer inhibitory receptor KIR2DL1 expression among natural killer cells in women with pelvic endometriosis, Fertil Steril 77:297, 2002.
125. **Dmowski WP**, **Gebel HM**, **Braun DP**, The role of cell-mediated immunity in pathogenesis of endometriosis, Acta Obstet Gynecol Scand 159(Suppl):7, 1994.

126. **Witz CA**, **Montoya IA**, **Dey TD**, **Schenken RS**, Characterization of lymphocyte subpopulations and T cell activation in endometriosis, Am J Reprod Immunol 32:173, 1994.
127. **Seli E**, **Arici A**, Endometriosis: interaction of immune and endocrine systems, Semin Reprod Med 21:135, 2003.
128. **Nematian SE**, **Mamillapalli R**, **Kadakia TS**, **Majidi Zolbin M**, **Moustafa S**, **Taylor HS**, Systemic inflammation induced by microRNAs: rndometriosis-derived alterations in circulating microRNA 635-5p and Let-7b-5p regulate macrophage cytokine production, J Clin Endocrinol Metab 103(1):64, 2018.
129. **Lebovic DI**, **Bentzien F**, **Chao VA**, **Garrett EN**, **Meng YG**, **Taylor RN**, Induction of an angiogenic phenotype in endometriotic stromal cell cultures by interleukin-1beta, Mol Hum Reprod 6:269, 2000.
130. **Arici A**, **Tazuke SI**, **Attar E**, **Kliman HJ**, **Olive DL,** Interleukin-8 concentration in peritoneal fluid of patients with endometriosis and modulation of interleukin-8 expression in human mesothelial cells, Mol Hum Reprod 2:40, 1996.
131. **Vigano P**, **Gaffuri B**, **Somigliana E**, **Busacca M**, **Di Blasio AM**, **Vignali M**, Expression of intercellular adhesion molecule (ICAM)-1 mRNA and protein is enhanced in endometriosis versus endometrial stromal cells in culture, Mol Hum Reprod 4:1150, 1998.
132. **Witz CA**, Cell adhesion molecules and endometriosis, Semin Reprod Med 21:173, 2003.
133. **Ryan IP**, **Tseng JF**, **Schriock ED**, **Khorram O**, **Landers DV**, **Taylor RN**, Interleukin-8 concentrations are elevated in peritoneal fluid of women with endometriosis, Fertil Steril 63:929, 1995.
134. **Akoum A**, **Lawson C**, **McColl S**, **Villeneuve M**, Ectopic endometrial cells express high concentrations of interleukin (IL)-8 in vivo regardless of the menstrual cycle phase and respond to oestradiol by up-regulating IL-1-induced IL-8 expression in vitro, Mol Hum Reprod 7:859, 2001.
135. **Garcia-Velasco JA**, **Arici A**, Interleukin-8 stimulates the adhesion of endometrial stromal cells to fibronectin, Fertil Steril 72:336, 1999.
136. **Arici A**, **Seli E**, **Zeyneloglu HB**, **Senturk LM**, **Oral E**, **Olive DL**, Interleukin-8 induces proliferation of endometrial stromal cells: a potential autocrine growth factor, J Clin Endocrinol Metab 83:1201, 1998.
137. **Arici A**, Local cytokines in endometrial tissue: the role of interleukin-8 in the pathogenesis of endometriosis, Ann N Y Acad Sci 955:101, 2002.
138. **Jolicoeur C**, **Boutouil M**, **Drouin R**, **Paradis I**, **Lemay A**, **Akoum A**, Increased expression of monocyte chemotactic protein-1 in the endometrium of women with endometriosis, Am J Pathol 152:125, 1998.
139. **Akoum A**, **Jolicoeur C**, **Boucher A**, Estradiol amplifies interleukin-1-induced monocyte chemotactic protein-1 expression by ectopic endometrial cells of women with endometriosis, J Clin Endocrinol Metab 85:896, 2000.
140. **Hornung D**, **Ryan IP**, **Chao VA**, **Vigne JL**, **Schriock ED**, **Taylor RN**, Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells, J Clin Endocrinol Metab 82:1621, 1997.
141. **Arici A**, **Oral E**, **Attar E**, **Tazuke SI**, **Olive DL**, Monocyte chemotactic protein-1 concentration in peritoneal fluid of women with endometriosis and its modulation of expression in mesothelial cells, Fertil Steril 67:1065, 1997.
142. **Khorram O**, **Taylor RN**, **Ryan IP**, **Schall TJ**, **Landers DV**, Peritoneal fluid concentrations of the cytokine RANTES correlate with the severity of endometriosis, Am J Obstet Gynecol 169:1545, 1993.
143. **Akoum A**, **Lemay A**, **Brunet C**, **Hebert J**, Secretion of monocyte chemotactic protein-1 by cytokine-stimulated endometrial cells of women with endometriosis. Le groupe d'investigation en gynecologie, Fertil Steril 63:322, 1995.
144. **Akoum A**, **Lemay A**, **Brunet C**, **Hebert J**, Cytokine-induced secretion of monocyte chemotactic protein-1 by human endometriotic cells in culture. The Groupe d'Investigation en Gynecologie, Am J Obstet Gynecol 172:594, 1995.
145. **Boucher A**, **Mourad W**, **Mailloux J**, **Lemay A**, **Akoum A**, Ovarian hormones modulate monocyte chemotactic protein-1 expression in endometrial cells of women with endometriosis, Mol Hum Reprod 6:618, 2000.
146. **Zhang RJ**, **Wild RA**, **Ojago JM**, Effect of tumor necrosis factor-alpha on adhesion of human endometrial stromal cells to peritoneal mesothelial cells: an in vitro system. Fertil Steril 59:1196, 1993.

147. **Debrock S**, **De Strooper B**, **Vander Perre S**, **Hill JA**, **D'Hooghe TM**, Tumour necrosis factor-alpha, interleukin-6 and interleukin-8 do not promote adhesion of human endometrial epithelial cells to mesothelial cells in a quantitative in vitro model, Hum Reprod 21:605, 2006.
148. **Groothuis PG**, **Nap AW**, **Winterhager E**, **Grümmer R**, Vascular development in endometriosis, Angiogenesis 8(2):147, 2005.
149. **Taylor RN**, **Lebovic DI**, **Mueller MD**, Angiogenic factors in endometriosis, Ann N Y Acad Sci 955:89, 2002; discussion 118, 396–406.
150. **McLaren J**, **Prentice A**, **Charnock-Jones DS**, **Smith SK**, Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis, Hum Reprod 11:220, 1996.
151. **Shifren JL**, **Tseng JF**, **Zaloudek CJ**, **Ryan IP**, **Meng YG**, **Ferrara N**, et al., Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis, J Clin Endocrinol Metab 81:3112, 1996.
152. **Donnez J**, **Smoes P**, **Gillerot S**, **Casanas-Roux F**, **Nisolle M**, Vascular endothelial growth factor (VEGF) in endometriosis, Hum Reprod 13(6):1686, 1998.
153. **Kennedy S**, **Mardon H**, **Barlow D**, Familial endometriosis, J Assist Reprod Genet 12:32, 1995.
154. **Stefansson H**, **Einarsdottir A**, **Geirsson RT**, **Jonsdottir K**, **Sverrisdottir G**, **Gudnadottir VG**, **Gunnarsdottir S**, **Manolescu A**, **Gulcher J**, **Stefansson K**, Endometriosis is not associated with or linked to the GALT gene, Fertil Steril 76:1019, 2001.
155. **Stefansson H**, **Geirsson RT**, **Steinthorsdottir V**, **Jonsson H**, **Manolescu A**, **Kong A**, **Ingadottir G**, **Gulcher J**, **Stefansson K**, Genetic factors contribute to the risk of developing endometriosis, Hum Reprod 17:555, 2002.
156. **Hadfield RM**, **Yudkin PL**, **Coe CL**, **Scheffler J**, **Uno H**, **Barlow DH**, **Kemnitz JW**, **Kennedy SH**, Risk factors for endometriosis in the rhesus monkey (Macaca mulatta): a case-control study, Hum Reprod Update 3:109, 1997.
157. **Hadfield RM**, **Mardon JH**, **Barlow DH**, **Kennedy SH**, Endometriosis in monozygotic twins, Fertil Steril 68:941, 1997.
158. **Moen MH**, Endometriosis in monozygotic twins, Acta Obstet Gynecol Scand 73:59, 1994.
159. **Treloar SA**, **O'Connor DT**, **O'Connor VM**, **Martin NG**, Genetic influences on endometriosis in an Australian twin sample, Fertil Steril 71:701, 1999.
160. **Kennedy S**, **Hadfield R**, **Mardon H**, **Barlow D**, Age of onset of pain symptoms in non-twin sisters concordant for endometriosis, Hum Reprod 11:403, 1996.
161. **Coxhead D**, **Thomas EJ**, Familial inheritance of endometriosis in a British population: a case control study, J Obstet Gynaecol 13:42, 1993.
162. **Kennedy S**, **Hadfield R**, **Westbrook C**, **Weeks DE**, **Barlow D**, **Golding S**, Magnetic resonance imaging to assess familial risk in relatives of women with endometriosis, Lancet 352:1440, 1998.
163. **Moen MH**, **Magnus P**, The familial risk of endometriosis, Acta Obstet Gynecol Scand 72:560, 1993.
164. **Simpson JL**, **Elias S**, **Malinak LR**, **Buttram VC Jr**, Heritable aspects of endometriosis. I. Genetic studies, Am J Obstet Gynecol 137:327, 1980.
165. **Kennedy S**, Is there a genetic basis to endometriosis? Semin Reprod Endocrinol 15:309, 1997.
166. **Kennedy S**, Genetics of endometriosis: a review of the positional cloning approaches, Semin Reprod Med 21:111, 2003.
167. **Kao LC**, **Germeyer A**, **Tulac S**, **Lobo S**, **Yang JP**, **Taylor RN**, **Osteen K**, **Lessey BA**, **Giudice LC**, Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility, Endocrinology 144:2870, 2003.
168. **Burney RO**, **Talbi S**, **Hamilton AE**, **Vo KC**, **Nyegaard M**, **Nezhat CR**, **Lessey BA**, **Giudice LC**, Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis, Endocrinology 148:3814, 2007.
169. **Albertsen HM**, **Chettier R**, **Farrington P**, **Ward K**, Genome-wide association study link novel loci to endometriosis, PLoS One 8(3):e58257, 2013.
170. **Uno S**, **Zembutsu H**, **Hirasawa A**, **Takahashi A**, **Kubo M**, **Akahane T**, et al., A genome-wide association

study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. Nat Genet 42(8):707, 2010.

171. **Nyholt DR**, **Low SK**, **Anderson CA**, **Painter JN**, **Uno S**, **Morris AP**, et al., Genome-wide association meta-analysis identifies new endometriosis risk loci. Nat Genet 44(12):1355, 2012.
172. **Painter JN**, **Anderson CA**, **Nyholt DR**, **Macgregor S**, **Lin J**, **Lee SH**, et al., Genome-wide association study identifies a locus at 7p15.2 associated with endometriosis. Nat Genet 43(1):51, 2011.
173. **Pagliardini L**, **Gentilini D**, **Sanchez AM**, **Candiani M**, **Vigano P**, **Di Blasio AM**, Replication and meta-analysis of previous genome-wide association studies confirm vezatin as the locus with the strongest evidence for association with endometriosis, Hum Reprod 30(4):987, 2015.
174. **Pagliardini L**, **Gentilini D**, **Vigano P**, **Panina-Bordignon P**, **Busacca M**, **Candiani M**, et al., An Italian association study and meta-analysis with previous GWAS confirm WNT4, CDKN2BAS and FN1 as the first identified susceptibility loci for endometriosis, J Med Genet 50(1):43, 2013.
175. **Rahmioglu N**, **Nyholt DR**, **Morris AP**, **Missmer SA**, **Montgomery GW**, **Zondervan KT**, Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight genome-wide association and replication datasets, Hum Reprod Update 20(5):702, 2014.
176. **Zondervan KT**, **Rahmioglu N**, **Morris AP**, **Nyholt DR**, **Montgomery GW**, **Becker CM**, et al., Beyond endometriosis genome-wide association study: from genomics to phenomics to the patient, Semin Reprod Med 34(4):242, 2016.
177. **Grechukhina O**, **Petracco R**, **Popkhadze S**, **Massasa E**, **Paranjape T**, **Chan E**, et al., A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. EMBO Mol Med 4(3):206, 2012.
178. **Yoo JY**, **Kim TH**, **Fazleabas AT**, **Palomino WA**, **Ahn SH**, **Tayade C**, et al., KRAS Activation and over-expression of SIRT1/BCL6 contributes to the pathogenesis of endometriosis and progesterone resistance. Sci Rep 7(1):6765, 2017.
179. **Kim JJ**, **Taylor HS**, **Lu Z**, **Ladhani O**, **Hastings JM**, **Jackson KS**, et al., Altered expression of HOXA10 in endometriosis: potential role in decidualization, Mol Hum Reprod 13(5):323, 2007.
180. **Tseng JF**, **Ryan IP**, **Milam TD**, **Murai JT**, **Schriock ED**, **Landers DV**, **Taylor RN**, Interleukin-6 secretion in vitro is up-regulated in ectopic and eutopic endometrial stromal cells from women with endometriosis, J Clin Endocrinol Metab 81:1118, 1996.
181. **Noble LS**, **Simpson ER**, **Johns A**, **Bulun SE**, Aromatase expression in endometriosis, J Clin Endocrinol Metab 81:174, 1996.
182. **Noble LS**, **Takayama K**, **Zeitoun KM**, **Putman JM**, **Johns DA**, **Hinshelwood MM**, **Agarwal VR**, **Zhao Y**, **Carr BR**, **Bulun SE**, Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells, J Clin Endocrinol Metab 82:600, 1997.
183. **Lucidi RS**, **Witz CA**, **Chrisco M**, **Binkley PA**, **Shain SA**, **Schenken RS**, A novel in vitro model of the early endometriotic lesion demonstrates that attachment of endometrial cells to mesothelial cells is dependent on the source of endometrial cells, Fertil Steril 84:16, 2005.
184. **Gebel HM**, **Braun DP**, **Tambur A**, **Frame D**, **Rana N**, **Dmowski WP**, Spontaneous apoptosis of endometrial tissue is impaired in women with endometriosis, Fertil Steril 69:1042, 1998.
185. **Dmowski WP**, **Ding J**, **Shen J**, **Rana N**, **Fernandez BB**, **Braun DP**, Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis, Hum Reprod 16:1802, 2001.
186. **Garcia-Velasco JA**, **Arici A**, Apoptosis and the pathogenesis of endometriosis, Semin Reprod Med 21:165, 2003.
187. **Missmer SA**, **Hankinson SE**, **Spiegelman D**, **Barbieri RL**, **Malspeis S**, **Willett WC**, **Hunter DJ**, Reproductive history and endometriosis among premenopausal women, Obstet Gynecol 104:965, 2004.
188. **Zeitoun KM**, **Bulun SE**, Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target, Fertil Steril 72:961, 1999.
189. **Gurates B**, **Bulun SE**, Endometriosis: the ultimate hormonal disease, Semin Reprod Med 21:125, 2003.
190. **Bulun SE**, **Lin Z**, **Imir G**, **Amin S**, **Demura M**, **Yilmaz B**, **Martin R**, **Utsunomiya H**, **Thung S**, **Gurates B**, **Tamura M**, **Langoi D**, **Deb S**, Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment, Pharmacol Rev 57:359, 2005.

191. **Sun HS**, **Hsiao KY**, **Hsu CC**, **Wu MH**, **Tsai SJ**, Transactivation of steroidogenic acute regulatory protein in human endometriotic stromal cells is mediated by the prostaglandin EP2 receptor, Endocrinology 144:3934, 2003.
192. **Gurates B**, **Sebastian S**, **Yang S**, **Zhou J**, **Tamura M**, **Fang Z**, **Suzuki T**, **Sasano H**, **Bulun SE**, WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells, J Clin Endocrinol Metab 87:4369, 2002.
193. **Jabbour HN**, **Sales KJ**, **Smith OP**, **Battersby S**, **Boddy SC**, Prostaglandin receptors are mediators of vascular function in endometrial pathologies, Mol Cell Endocrinol 252:191, 2006.
194. **Funk CD**, Prostaglandins and leukotrienes: advances in eicosanoid biology, Science 294:1871, 2001.
195. **Wu MH**, **Wang CA**, **Lin CC**, **Chen LC**, **Chang WC**, **Tsai SJ**, Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells, J Clin Endocrinol Metab 90:286, 2005.
196. **Ota H**, **Igarashi S**, **Sasaki M**, **Tanaka T**, Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis, Hum Reprod 16:561, 2001.
197. **Tsai SJ**, **Wu MH**, **Lin CC**, **Sun HS**, **Chen HM**, Regulation of steroidogenic acute regulatory protein expression and progesterone production in endometriotic stromal cells, J Clin Endocrinol Metab 86:5765, 2001.
198. **Zeitoun K**, **Takayama K**, **Michael MD**, **Bulun SE**, Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element, Mol Endocrinol 13:239, 1999.
199. **Tamura M**, **Sebastian S**, **Yang S**, **Gurates B**, **Fang Z**, **Bulun SE**, Interleukin-1beta elevates cyclooxygenase-2 protein level and enzyme activity via increasing its mRNA stability in human endometrial stromal cells: an effect mediated by extracellularly regulated kinases 1 and 2, J Clin Endocrinol Metab 87:3263, 2002.
200. **Tamura M**, **Sebastian S**, **Yang S**, **Gurates B**, **Ferrer K**, **Sasano H**, **Okamura K**, **Bulun SE**, Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells. A paracrine effect mediated by prostaglandin E2 and nuclear factor-kappa B, J Biol Chem 277:26208, 2002.
201. **Tamura M**, **Sebastian S**, **Gurates B**, **Yang S**, **Fang Z**, **Bulun SE**, Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells, J Clin Endocrinol Metab 87:3504, 2002.
202. **Wu Y**, **Kajdacsy-Balla A**, **Strawn E**, **Basir Z**, **Halverson G**, **Jailwala P**, **Wang Y**, **Wang X**, **Ghosh S**, **Guo SW**, Transcriptional characterizations of differences between eutopic and ectopic endometrium, Endocrinology 147:232, 2006.
203. **Osteen KG**, **Bruner KL**, **Sharpe-Timms KL**, Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis, Semin Reprod Endocrinol 14:247, 1996.
204. **Sharpe-Timms KL**, **Cox KE**, Paracrine regulation of matrix metalloproteinase expression in endometriosis, Ann N Y Acad Sci 955:147, 2002.
205. **Osteen KG**, **Yeaman GR**, **Bruner-Tran KL**, Matrix metalloproteinases and endometriosis, Semin Reprod Med 21:155, 2003.
206. **Ulukus M**, **Ulukus EC**, **Seval Y**, **Zheng W**, **Arici A**, Expression of interleukin-8 receptors in endometriosis, Hum Reprod 20:794, 2005.
207. **Kao LC**, **Tulac S**, **Lobo S**, **Imani B**, **Yang JP**, **Germeyer A**, **Osteen K**, **Taylor RN**, **Lessey BA**, **Giudice LC**, Global gene profiling in human endometrium during the window of implantation, Endocrinology 143:2119, 2002.
208. **Brosens JJ**, **Hayashi N**, **White JO,** Progesterone receptor regulates decidual prolactin expression in differentiating human endometrial stromal cells, Endocrinology 140:4809, 1999.
209. **Fazleabas AT**, **Brudney A**, **Chai D**, **Langoi D**, **Bulun SE,** Steroid receptor and aromatase expression in baboon endometriotic lesions, Fertil Steril 80(Suppl 2):820, 2003.
210. **Casey ML**, **MacDonald PC**, **Andersson S**, 17 beta-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium, J Clin Invest 94:2135, 1994.
211. **Mustonen MV**, **Isomaa VV**, **Vaskivuo T**, **Tapanainen J**, **Poutanen MH**, **Stenback F**, **Vihko RK**, **Vihko**

PT, Human 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression and localization in term placenta and in endometrium during the menstrual cycle, J Clin Endocrinol Metab 83:1319, 1998.

212. **Cheng YH**, **Yin P**, **Xue Q**, **Yilmaz B**, **Dawson MI**, **Bulun SE**, Retinoic acid (RA) regulates 17beta-hydroxysteroid dehydrogenase type 2 expression in endometrium: interaction of RA receptors with specificity protein (SP) 1/SP3 for estradiol metabolism, J Clin Endocrinol Metab 93:1915, 2008.
213. **Tseng L**, **Gurpide E**, Estradiol and 20alpha-dihydroprogesterone dehydrogenase activities in human endometrium during the menstrual cycle, Endocrinology 94:419, 1974.
214. **Tseng L**, **Gurpide E**, Induction of human endometrial estradiol dehydrogenase by progestins, Endocrinology 97:825, 1975.
215. **Satyaswaroop PG**, **Wartell DJ**, **Mortel R**, Distribution of progesterone receptor, estradiol dehydrogenase, and 20 alpha-dihydroprogesterone dehydrogenase activities in human endometrial glands and stroma: progestin induction of steroid dehydrogenase activities in vitro is restricted to the glandular epithelium, Endocrinology 111:743, 1982.
216. **Yang S**, **Fang Z**, **Gurates B**, **Tamura M**, **Miller J**, **Ferrer K**, **Bulun SE**, Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2, Mol Endocrinol 15:2093, 2001.
217. **Lessey BA**, **Metzger DA**, **Haney AF**, **McCarty KS Jr**, Immunohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy, Fertil Steril 51:409, 1989.
218. **Vierikko P**, et al., Steroidal regulation of endometriosis tissue: lack of induction of 17 beta-hydroxysteroid dehydrogenase activity by progesterone, medroxyprogesterone acetate, or danazol, Fertil Steril 43:218, 1985.
219. **Cheng YH**, **Imir A**, **Fenkci V**, **Yilmaz MB**, **Bulun SE**, Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial 17beta-hydroxysteroid dehydrogenase type 2 gene and its transcriptional regulator Sp1: a mechanism for defective estradiol metabolism, Am J Obstet Gynecol 196:391.e1, 2007.
220. **Zeitoun K**, **Takayama K**, **Sasano H**, **Suzuki T**, **Moghrabi N**, **Andersson S**, **Johns A**, **Meng L**, **Putman M**, **Carr B**, **Bulun SE**, Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol, J Clin Endocrinol Metab 83:4474, 1998.
221. **Bulun SE**, **Cheng YH**, **Yin P**, **Imir G**, **Utsunomiya H**, **Attar E**, **Innes J**, **Julie Kim J**, Progesterone resistance in endometriosis: link to failure to metabolize estradiol, Mol Cell Endocrinol 248:94, 2006.
222. **Attia GR**, **Zeitoun K**, **Edwards D**, **Johns A**, **Carr BR**, **Bulun SE**, Progesterone receptor isoform A but not B is expressed in endometriosis, J Clin Endocrinol Metab 85:2897, 2000.
223. **Giangrande PH**, **Kimbrel EA**, **Edwards DP**, **McDonnell DP**, The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding, Mol Cell Biol 20(9):3102, 2000.
224. **Patel BG**, **Rudnicki M**, **Yu J**, **Shu Y**, **Taylor RN**, Progesterone resistance in endometriosis: origins, consequences and interventions, Acta Obstet Gynecol Scand 96(6):623, 2017.
225. **Prentice A**, **Randall BJ**, **Weddell A**, **McGill A**, **Henry L**, **Horne CH**, et al., Ovarian steroid receptor expression in endometriosis and in two potential parent epithelia: endometrium and peritoneal mesothelium, Hum Reprod 7(9):1318, 1992.
226. **Gonzalez-Ramos R**, **Van Langendonckt A**, **Defrere S**, **Lousse JC**, **Colette S**, **Devoto L**, et al., Involvement of the nuclear factor-kappaB pathway in the pathogenesis of endometriosis, Fertil Steril 94(6):1985, 2010.
227. **Guo SW**, Nuclear factor-kappab (NF-kappaB): an unsuspected major culprit in the pathogenesis of endometriosis that is still at large? Gynecol Obstet Invest 63(2):71, 2007.
228. **Jackson KS**, **Brudney A**, **Hastings JM**, **Mavrogianis PA**, **Kim JJ**, **Fazleabas AT**, The altered distribution of the steroid hormone receptors and the chaperone immunophilin FKBP52 in a baboon model of endometriosis is associated with progesterone resistance during the window of uterine receptivity, Reprod Sci 14:137, 2007.
229. **Aghajanova L**, **Velarde MC**, **Giudice LC**, The progesterone receptor coactivator Hic-5 is involved in the pathophysiology of endometriosis, Endocrinology 150:3863, 2009.

230. **Al-Sabbagh M**, **Lam EW**, **Brosens JJ**, Mechanisms of endometrial progesterone resistance, Mol Cell Endocrinol 25:208, 2012.
231. **Wu Y**, **Strawn E**, **Basir Z**, **Halverson G**, **Guo SW**, Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis, Epigenetics 1(2):106, 2006.
232. **Wu Y**, **Shi X**, **Guo S**, The knockdown of progesterone receptor isoform B (PR-B) promotes proliferation in immortalized endometrial stromal cells, Fertil Steril 90:1320, 2008.
233. **Wu Y**, **Strawn E**, **Basir Z**, **Halverson G**, **Guo SW**, Aberrant expression of deoxyribonucleic acid methyltransferases DNMT1, DNMT3A, and DNMT3B in women with endometriosis, Fertil Steril 87:24, 2007.
234. **Xue Q**, **Lin Z**, **Yin P**, **Milad MP**, **Cheng YH**, **Confino E**, **Reierstad S**, **Bulun SE**, Transcriptional activation of steroidogenic factor-1 by hypomethylation of the 5¢ CpG island in endometriosis, J Clin Endocrinol Metab 92:3261, 2007.
235. **Utsunomiya H**, **Cheng YH**, **Lin Z**, **Reierstad S**, **Yin P**, **Attar E**, **Xue Q**, **Imir G**, **Thung S**, **Trukhacheva E**, **Suzuki T**, **Sasano H**, **Kim JJ**, **Yaegashi N**, **Bulun SE**, Upstream stimulatory factor-2 regulates steroidogenic factor-1 expression in endometriosis, Mol Endocrinol 22:904, 2008.
236. **Xue Q**, **Lin Z**, **Cheng YH**, **Huang CC**, **Marsh E**, **Yin P**, **Milad MP**, **Confino E**, **Reierstad S**, **Innes J**, **Bulun SE**, Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis, Biol Reprod 77:681, 2007.
237. **Petracco R**, **Grechukhina O**, **Popkhadze S**, **Massasa E**, **Zhou Y**, **Taylor HS**, MicroRNA 135 regulates HOXA10 expression in endometriosis, J Clin Endocrinol Metab 96(12):E1925, 2011.
238. **Ghazal S**, **McKinnon B**, **Zhou J**, **Mueller M**, **Men Y**, **Yang L**, **Mueller M**, **Flannery C**, **Huang Y**, **Taylor HS**, H19 lncRNA alters stromal cell growth via IGF signaling in the endometrium of women with endometriosis, EMBO Mol Med 7(8):996, 2015.
239. **Practice Committee of the American Society for Reproductive Medicine**, Treatment of pelvic pain associated with endometriosis: a committee opinion, Fertil Steril 101(4):927, 2014.
240. **Porpora MG**, **Koninckx PR**, **Piazze J**, **Natili M**, **Colagrande S**, **Cosmi EV**, Correlation between endometriosis and pelvic pain, J Am Assoc Gynecol Laparosc 6:429, 1999.
241. **Donnez J**, **Nisolle M**, **Smoes P**, **Gillet N**, **Beguin S**, **Casanas-Roux F**, Peritoneal endometriosis and "endometriotic" nodules of the rectovaginal septum are two different entities, Fertil Steril 66:362, 1996.
242. **Anaf V**, **Simon P**, **El Nakadi I**, **Fayt I**, **Buxant F**, **Simonart T**, **Peny MO**, **Noel JC**, Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules, Hum Reprod 15:1744, 2000.
243. **Wang G**, **Tokushige N**, **Markham R**, **Fraser IS**, Rich innervation of deep infiltrating endometriosis, Hum Reprod 24:827, 2009.
244. **Tran LV**, **Tokushige N**, **Berbic M**, **Markham R**, **Fraser IS**, Macrophages and nerve fibres in peritoneal endometriosis, Hum Reprod 24:835, 2009.
245. **Gruppos Italiano per lo Studio Dell'Endometriosi**, Relationship between stage, site and morphological characteristics of pelvic endometriosis and pain, Hum Reprod 16:2668, 2001.
246. **Vercellini P**, **Fedele L**, **Aimi G**, **Pietropaolo G**, **Consonni D**, **Crosignani PG**, Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients, Hum Reprod 22(1):266, 2007.
247. **Bajaj P**, **Madsen H**, **Arendt-Nielsen L**, Endometriosis is associated with central sensitization: a psychophysical controlled study, J Pain 4:372, 2003.
248. **Li T**, **Mamillapalli R**, **Ding S**, **Chang H**, **Liu Z-W**, **Gao X-B**, **Taylor HS**, Endometriosis alters brain electrophysiology, gene expression and increases pain sensitization, anxiety, and depression in female mice, Biol Reprod 99 (2):349, 2018.
249. **Riley JL III**, **Robinson ME**, **Wise EA**, **Price DD**, A meta-analytic review of pain perception across the menstrual cycle, Pain 81:225, 1999.
250. **Takayama K**, **Zeitoun K**, **Gunby RT**, **Sasano H**, **Carr BR**, **Bulun SE**, Treatment of severe postmenopausal endometriosis with an aromatase inhibitor, Fertil Steril 69:709, 1998.
251. **Kubli-Garfias C**, Modulatory action of 5-reduced androgens and progestogens on the excitability of CNS and smooth muscle, J Steroid Biochem 27:631, 1987.

252. **Matorras R**, **Rodriguez F**, **Pijoan JI**, **Etxanojauregui A**, **Neyro JL**, **Elorriaga MA**, **Rodriguez-Escudero FJ**, Women who are not exposed to spermatozoa and infertile women have similar rates of stage I endometriosis, Fertil Steril 76:923, 2001.
253. **Olive DL**, **Stohs GF**, **Metzger DA**, **Franklin RR**, Expectant management and hydrotubations in the treatment of endometriosis-associated infertility, Fertil Steril 44:35, 1985.
254. **Garcia CF**, **Davis SS**, Pelvic endometriosis: infertility and pelvic pain, Am J Obstet Gynecol 129:740, 1977.
255. **Schenken RS**, **Malinak LR**, Conservative surgery versus expectant management for the infertile patient with mild endometriosis, Fertil Steril 37:183, 1982.
256. **Seibel M**, **Berger MJ**, **Weinstein FG**, **Taymor ML**, The effectiveness of danazol on subsequent fertility in minimal endometriosis, Fertil Steril 38:534, 1982.
257. **Portuondo JA**, **Echanojauregui AD**, **Herran C**, **Alijarte I**, Early conception in patients with untreated mild endometriosis, Fertil Steril 39:22, 1983.
258. **Hughes EG**, The effectiveness of ovulation induction and intrauterine insemination in the treatment of persistent infertility: a meta-analysis, Hum Reprod 12:1865, 1997.
259. **Tanbo T**, **Fedorcsak P**, Endometriosis-associated infertility: aspects of pathophysiological mechanisms and treatment options, Acta Obstet Gynecol Scand 96(6):659, 2017.
260. **Marcoux S**, **Maheux R**, **Berube S**, Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis, New Engl J Med 337:217, 1997.
261. **Jacobson TZ**, **Barlow DH**, **Koninckx PR**, **Olive D**, **Farquhar C**, Laparoscopic surgery for subfertility associated with endometriosis, Cochrane Database Syst Rev CD001398, 2002.
262. **AlKudmani B**, **Gat I**, **Buell D**, **Salman J**, **Zohni K**, **Librach C**, **Sharma P**, In vitro fertilization success rates after surgically treated endometriosis and effect of time interval between surgery and in vitro fertilization, J Minim Invasive Gynecol 25(1):99, 2018.
263. **Schenken RS**, **Asch RH**, **Williams RF**, **Hodgen GD**, Etiology of infertility in monkeys with endometriosis: luteinized unruptured follicles, luteal phase defects, pelvic adhesions, and spontaneous abortions, Fertil Steril 41:122, 1984.
264. **Hornstein MD**, **Barbieri RL**, **McShane PM**, Effects of previous ovarian surgery on the follicular response to ovulation induction in an in vitro fertilization program, J Reprod Med 34:277, 1989.
265. **Pal L**, **Shifren JL**, **Isaacson KB**, **Chang Y**, **Leykin L**, **Toth TL**, Impact of varying stages of endometriosis on the outcome of in vitro fertilization-embryo transfer, J Assist Reprod Genet 15:27, 1998.
266. **Toya M**, **Saito H**, **Ohta N**, **Saito T**, **Kaneko T**, **Hiroi M**, Moderate and severe endometriosis is associated with alterations in the cell cycle of granulosa cells in patients undergoing in vitro fertilization and embryo transfer, Fertil Steril 73:344, 2000.
267. **Holoch KJ**, **Lessey BA**, Endometriosis and infertility, Clin Obstet Gynecol 53(2):429, 2010.
268. **Morcos RN**, **Gibbons WE**, **Findley WE**, Effect of peritoneal fluid on in vitro cleavage of 2-cell mouse embryos: possible role in infertility associated with endometriosis, Fertil Steril 44(5):678, 1985.
269. **Lessey BA**, **Ilesanmi AO**, **Castelbaum AJ**, **Yuan L**, **Somkuti SG**, **Chwalisz K**, **Satyaswaroop PG**, Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the alpha1 integrin, J Steroid Biochem Mol Biol 59(1):31, 1996.
270. **Osteen KG**, **Keller NR**, **Feltus FA**, **Melner MH**, Paracrine regulation of matrix metalloproteinase expression in the normal human endometrium, Gynecol Obstet Invest 48(Suppl 1):2, 1999.
271. **Mohamed OA**, **Jonnaert M**, **Labelle-Dumais C**, **Kuroda K**, **Clarke HJ**, **Dufort D**, Uterine Wnt/beta-catenin signaling is required for implantation, Proc Natl Acad Sci U S A 102(24):8579, 2005.
272. **Hou X**, **Tan Y**, **Li M**, **Dey SK**, **Das SK**, Canonical Wnt signaling is critical to estrogen-mediated uterine growth, Mol Endocrinol 18(12):3035, 2004.
273. **Zanatta A**, **Rocha AM**, **Carvalho FM**, **Pereira RM**, **Taylor HS**, **Motta EL**, et al., The role of the Hoxa10/HOXA10 gene in the etiology of endometriosis and its related infertility: a review, J Assist Reprod Genet 27(12):701, 2010.
274. **Taylor HS**, **Bagot C**, **Kardana A**, **Olive D**, **Arici A**, HOX gene expression is altered in the endometrium of women with endometriosis, Hum Reprod 14(5):1328, 1999.

275. **Taylor HS**, **Arici A**, **Olive D**, **Igarashi P**, HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium, J Clin Invest 101(7):1379, 1998.
276. **Daftary GS**, **Troy PJ**, **Bagot CN**, **Young SL**, **Taylor HS**, Direct regulation of beta3-integrin subunit gene expression by HOXA10 in endometrial cells, Mol Endocrinol 16(3):571, 2002.
277. **Cakmak H**, **Taylor HS**, Molecular mechanisms of treatment resistance in endometriosis: the role of progesterone-hox gene interactions, Semin Reprod Med 28(1):69, 2010.
278. **Daftary GS**, **Taylor HS**, Endocrine regulation of HOX genes, Endocr Rev 27(4):331, 2006.
279. **Santamaria X**, **Massasa EE**, **Taylor HS**, Migration of cells from experimental endometriosis to the uterine endometrium, Endocrinology 153:5566, 2012.
280. **Hufnagel D**, **Li F**, **Cosar E**, **Krikun G**, **Taylor HS**, The role of stem cells in the etiology and pathophysiology of endometriosis, Semin Reprod Med 33(5):333, 2015.
281. **Lessey BA**, **Kim JJ**, Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why, Fertil Steril 108(1):19, 2017.
282. **Barnhart K**, **Dunsmoor-Su R**, **Coutifaris C**, Effect of endometriosis on in vitro fertilization, Fertil Steril 77:1148, 2002.
283. **Harb HM**, **Gallos ID**, **Chu J**, **Harb M**, **Coomarasamy A**, The effect of endometriosis on in vitro fertilisation outcome: a systematic review and meta-analysis, BJOG 120:1308, 2013.
284. **Brosens I**, Endometriosis and the outcome of in vitro fertilization, Fertil Steril 81:1198, 2004.
285. **Gibbons WE**, Management of endometriosis in fertility patients, Fertil Steril 81:1204, 2004.
286. **Senapati S**, **Sammel MD**, **Morse C**, **Barnhart KT**, Impact of endometriosis on in vitro fertilization outcomes: an evaluation of the Society for Assisted Reproductive Technologies Database, Fertil Steril 106(1):164, 2016.
287. **Society for Assisted Reproductive Technology,** https://www.sart.org
288. **Garcia-Velasco J**, **Arici A**, Is the endometrium or the oocyte/embryo affected in endometriosis? Hum Reprod 14(Suppl 2):77, 1999.
289. **Simon C**, **Gutierrez A**, **Vidal A**, **de los Santos MJ**, **Tarin JJ**, **Remohi J**, **Pellicer A**, Outcome of patients with endometriosis in assisted reproduction: results from in-vitro fertilization and oocyte donation, Hum Reprod 9:725, 1994.
290. **Sung L**, **Mukherjee T**, **Takeshige T**, **Bustillo M**, **Copperman AB**, Endometriosis is not detrimental to embryo implantation in oocyte recipients, J Assist Reprod Genet 14:152, 1997.
291. **Pellicer A**, **Oliveira N**, **Ruiz A**, **Remohi J**, **Simon C,** Exploring the mechanism(s) of endometriosis-related infertility: an analysis of embryo development and implantation in assisted reproduction, Hum Reprod 10(Suppl 2):91, 1995.
292. **Diaz I**, **Navarro J**, **Blasco L**, **Simon C**, **Pellicer A**, **Remohi J**, Impact of stage III-IV endometriosis on recipients of sibling oocytes: matched case-control study, Fertil Steril 74:31, 2000.
293. **Brizek CL**, **Schlaff S**, **Pellegrini VA**, **Frank JB**, **Worrilow KC**, Increased incidence of aberrant morphological phenotypes in human embryogenesis–an association with endometriosis, J Assist Reprod Genet 12:106, 1995.
294. **Garrido N**, **Pellicer A**, **Remohi J**, **Simon C**, Uterine and ovarian function in endometriosis, Semin Reprod Med 21:183, 2003.
295. **Guidice LC**, Genomics' role in understanding the pathogenesis of endometriosis, Semin Reprod Med 21:119, 2003.
296. **Groll M**, Endometriosis and spontaneous abortion, Fertil Steril 41:933, 1984.
297. **Wheeler JM**, **Johnston BM**, **Malinak LR**, The relationship of endometriosis to spontaneous abortion, Fertil Steril 39:656, 1983.
298. **Olive DL**, **Franklin RR**, **Gratkins LV**, The association between endometriosis and spontaneous abortion. A retrospective clinical study, J Reprod Med 27:333, 1982.
299. **Metzger DA**, **Olive DL**, **Stohs GF**, **Franklin RR**, Association of endometriosis and spontaneous abortion: effect of control group selection, Fertil Steril 45:18, 1986.
300. **FitzSimmons J**, **Stahl R**, **Gocial B**, **Shapiro SS**, Spontaneous abortion and endometriosis, Fertil Steril 47:696,

1987.
301. **Cosar E**, **Mamillapalli R**, **Ersoy GS**, **Cho S**, **Seifer B**, **Taylor HS**, Serum microRNAs as diagnostic markers of endometriosis: a comprehensive array-based analysis, Fertil Steril 106(02):402, 2016.
302. **Sinaii N**, **Plumb K**, **Cotton L**, **Lambert A**, **Kennedy S**, **Zondervan K**, **Stratton P**, Differences in characteristics among 1,000 women with endometriosis based on extent of disease, Fertil Steril 89:538, 2008.
303. **Ballard KD**, **Seaman HE**, **de Vries CS**, **Wright JT**, Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study—Part 1, Br J Obstet Gynaecol 115:1382, 2008.
304. **Husby GK**, **Haugen RS**, **Moen MH**, Diagnostic delay in women with pain and endometriosis, Acta Obstet Gynecol Scand 82:649, 2003.
305. **Mahmood TA**, **Templeton AA**, **Thomson L**, **Fraser C**, Menstrual symptoms in women with pelvic endometriosis, Br J Obstet Gynaecol 98:558, 1991.
306. **Davis GD**, **Thillet E**, **Lindemann J**, Clinical characteristics of adolescent endometriosis, J Adolesc Health 14:362, 1993.
307. **Koninckx PR**, **Meuleman C**, **Demeyere S**, **Lesaffre E**, **Cornillie FJ**, Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain, Fertil Steril 55:759, 1991.
308. **Fauconnier A**, **Chapron C**, **Dubuisson JB**, **Vieira M**, **Dousset B**, **Breart G**, Relation between pain symptoms and the anatomic location of deep infiltrating endometriosis, Fertil Steril 78:719, 2002.
309. **Chapron C**, **Barakat H**, **Fritel X**, **Dubuisson JB**, **Breart G**, **Fauconnier A**, Presurgical diagnosis of posterior deep infiltrating endometriosis based on a standardized questionnaire, Hum Reprod 20:507, 2005.
310. **Vercellini P**, **Trespidi L**, **De Giorgi O**, **Cortesi I**, **Parazzini F**, **Crosignani PG**, Endometriosis and pelvic pain: relation to disease stage and localization, Fertil Steril 65:299, 1996.
311. **Fedele L**, **Bianchi S**, **Bocciolone L**, **Di Nola G**, **Parazzini F**, Pain symptoms associated with endometriosis, Obstet Gynecol 79:767, 1992.
312. **Brenner C**, **Wohlgemuth S**, Scar endometriosis, Surg Gynecol Obstet 170:538, 1990.
313. **Wolf Y**, **Haddad R**, **Werbin N**, **Skornick Y**, **Kaplan O**, Endometriosis in abdominal scars: a diagnostic pitfall, Am Surg 62:1042, 1996.
314. **Azzena A**, **Litta P**, **Ferrara A**, **Perin D**, **Brotto M**, **Chiarelli S**, **Sandei F**, Rectosigmoid endometriosis: diagnosis and surgical management, Clin Exp Obstet Gynecol 25:94, 1998.
315. **Yantiss RK**, **Clement PB**, **Young RH**, Endometriosis of the intestinal tract: a study of 44 cases of a disease that may cause diverse challenges in clinical and pathologic evaluation, Am J Surg Pathol 25:445, 2001.
316. **Donnez J**, **Spada F**, **Squifflet J**, **Nisolle M**, Bladder endometriosis must be considered as bladder adenomyosis, Fertil Steril 74:1175, 2000.
317. **Redwine DB**, Diaphragmatic endometriosis: diagnosis, surgical management, and long-term results of treatment, Fertil Steril 77:288, 2002.
318. **Rychlik DF**, **Bieber EJ**, Thoracic endometriosis syndrome resembling pulmonary embolism, J Am Assoc Gynecol Laparosc 8:445, 2001.
319. **Fedele L**, **Bianchi S**, **Raffaelli R**, **Zanconato G**, **Zanette G**, Phantom endometriosis of the sciatic nerve, Fertil Steril 72:727, 1999.
320. **Taylor HS**, **Adamson GD**, **Diamond MP**, **Goldstein SR**, **Horne AW**, **Missmer SA**, **Snabes MC**, **Surrey E**, **Taylor RN**, An evidence-based approach to assessing surgical versus clinical diagnosis of symptomatic endometriosis, Int J Gynaecol Obstet 142(2):131, 2018.
321. **Taylor HS**, Clinicaldiagnosis of endometriosis and optimal medical therapy, Fertil Steril 108(5):759, 2017.
322. **American College of Obstetricians and Gynecologists**, ACOG Committee Opinion Number 310, April 2005. Endometriosis in adolescents, Obstet Gynecol 105:921, 2005.
323. **Matorras R**, **Rodriguez F**, **Pijoan JI**, **Soto E**, **Perez C**, **Ramon O**, **Rodriguez-Escudero F**, Are there any clinical signs and symptoms that are related to endometriosis in infertile women? Am J Obstet Gynecol 174:620, 1996.
324. **Ripps BA**, **Martin DC**, Correlation of focal pelvic tenderness with implant dimension and stage of endometriosis, J Reprod Med 37:620, 1992.

325. **Koninckx PR**, **Meuleman C**, **Oosterlynck D**, **Cornillie FJ**, Diagnosis of deep endometriosis by clinical examination during menstruation and plasma CA-125 concentration, Fertil Steril 65:280, 1996.
326. **Spaczynski RZ**, **Duleba AJ**, Diagnosis of endometriosis, Semin Reprod Med 21:193, 2003.
327. **Barbieri RL**, **Niloff JM**, **Bast RC Jr**, **Schaetzl E**, **Kistner RW**, **Knapp RC**, Elevated serum concentrations of CA-125 in patients with advanced endometriosis, Fertil Steril 45:630, 1986.
328. **Pittaway DE**, **Fayez JA**, The use of CA-125 in the diagnosis and management of endometriosis, Fertil Steril 46:790, 1986.
329. **Koninckx PR**, **Riittinen L**, **Seppala M**, **Cornillie FJ**, CA-125 and placental protein 14 concentrations in plasma and peritoneal fluid of women with deeply infiltrating pelvic endometriosis, Fertil Steril 57:523, 1992.
330. **Pittaway DE**, **Fayez JA**, Serum CA-125 antigen levels increase during menses, Am J Obstet Gynecol 156:75, 1987.
331. **Bon GG**, **Kenemans P**, **Dekker JJ**, **Hompes PG**, **Verstraeten RA**, **van Kamp GJ**, **Schoemaker J**, Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles, Hum Reprod 14:566, 1999.
332. **Mol BW**, **Bayram N**, **Lijmer JG**, **Wiegerinck MA**, **Bongers MY**, **van der Veen F**, **Bossuyt PM**, The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis, Fertil Steril 70:1101, 1998.
333. **Hirsch M**, **Duffy J**, **Davis CJ**, **Nieves Plana M**, **Khan KS**, Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis, BJOG 123(11):1761, 2016.
334. **Franssen AMHW**, **van der Heijden PFM**, **Thomas CMG**, **Doesburg WH**, **Willemsen WNP**, **Rolland R**, On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol, Fertil Steril 57:974, 1992.
335. **Chen FP**, **Soong YK**, **Lee N**, **Lo SK**, The use of serum CA-125 as a marker for endometriosis in patients with dysmenorrhea for monitoring therapy and for recurrence of endometriosis, Acta Obstet Gynecol Scand 77:665, 1998.
336. **Pittaway DE**, The use of serial CA-125 concentrations to monitor endometriosis in infertile women, Am J Obstet Gynecol 163:1032, 1990.
337. **Pittaway DE**, **Rondinone D**, **Miller KA**, **Barnes K**, Clinical evaluation of CA-125 concentrations as a prognostic factor for pregnancy in infertile women with surgically treated endometriosis, Fertil Steril 64:321, 1995.
338. **Iorio MV**, **Ferracin M**, **Liu CG**, **Veronese A**, **Spizzo R**, **Sabbioni S**, et al., MicroRNA gene expression deregulation in human breast cancer, Cancer Res 65:7065, 2005.
339. **Akao Y**, **Nakagawa Y**, **Naoe T**, MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 26:311, 2007.
340. **Yang H**, **Kong W**, **He L**, **Zhao JJ**, **O'Donnell JD**, **Wang J**, et al., MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN, Cancer Res 68:425, 2008.
341. **Small EM**, **Olson EN**, Pervasive roles of microRNAs in cardiovascular biology, Nature 469:336, 2011.
342. **Brest P**, **Lapaquette P**, **Souidi M**, **Lebrigand K**, **Cesaro A**, **Vouret-Craviari V**, et al., A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease, Nat Genet 43:242, 2011.
343. **Yang N**, **Kaur S**, **Volinia S**, **Greshock J**, **Lassus H**, **Hasegawa K**, et al., MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer, Cancer Res 68:10307, 2008.
344. **Marsh EE**, **Lin Z**, **Yin P**, **Milad M**, **Chakravarti D**, **Bulun SE**, Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium, Fertil Steril 89:1771, 2008.
345. **Mitchell PS**, **Parkin RK**, **Kroh EM**, **Fritz BR**, **Wyman SK**, **Pogosova-Agadjanyan EL**, et al., Circulating microRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci U S A 105:10513, 2008.
346. **Resnick KE**, **Alder H**, **Hagan JP**, **Richardson DL**, **Croce CM**, **Cohn DE**, The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform, Gynecol Oncol 112:55, 2009.

347. **Wang F**, **Zheng Z**, **Guo J**, **Ding X**, Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor, Gynecol Oncol 119:586, 2010.
348. **Cho S**, **Mutlu L**, **Grechukhina O**, **Taylor HS**, Circulating microRNAs as potential biomarkers for endometriosis, Fertil Steril 103(05):1252, 2015.
349. **Seifer BJ**, **Su D**, **Taylor HS**, Circulating miRNAs in murine experimental endometriosis, Reprod Sci 24(03):376, 2017.
350. **Alcázar JL**, **Laparte C**, **Jurado M**, **López-Garcia G**, The role of transvaginal ultrasonography combined with color velocity imaging and pulsed Doppler in the diagnosis of endometrioma, Fertil Steril 67:487, 1997.
351. **Patel MD**, **Feldstein VA**, **Chen DC**, **Lipson SD**, **Filly RA**, Endometriomas: diagnostic performance of US, Radiology 210:739, 1999.
352. **Mais V**, **Guerriero S**, **Ajossa S**, **Angiolucci M**, **Paoletti AM**, **Melis GB**, The efficiency of transvaginal ultrasonography in the diagnosis of endometrioma, Fertil Steril 60:776, 1993.
353. **Guerriero S**, **Ajossa S**, **Paoletti AM**, **Mais V**, **Angiolucci M**, **Melis GB**, Tumor markers and transvaginal ultrasonography in the diagnosis of endometrioma, Obstet Gynecol 88:403, 1996.
354. **Kennedy S**, **Bergqvist A**, **Chapron C**, **D'Hooghe T**, **Dunselman G**, **Greb R**, **Hummelshoj L**, **Prentice A**, **Saridogan E**, ESHRE guideline for the diagnosis and treatment of endometriosis, Hum Reprod 20:2698, 2005.
355. **Abrao MS**, **Goncalves MO**, **Dias JA Jr**, **Podgaec S**, **Chamie LP**, **Blasbalg R**, Comparison between clinical examination, transvaginal sonography and magnetic resonance imaging for the diagnosis of deep endometriosis, Hum Reprod 22:3092, 2007.
356. **Bazot M**, **Malzy P**, **Cortez A**, **Roseau G**, **Amouyal P**, **Darai E**, Accuracy of transvaginal sonography and rectal endoscopic sonography in the diagnosis of deep infiltrating endometriosis, Ultrasound Obstet Gynecol 30:994, 2007.
357. **Bazot M**, **Lafont C**, **Rouzier R**, **Roseau G**, **Thomassin-Naggara I**, **Darai E**, Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis, Fertil Steril 92:1825, 2009.
358. **Hudelist G**, **Oberwinkler KH**, **Singer CF**, **Tuttlies F**, **Rauter G**, **Ritter O**, **Keckstein J**, Combination of transvaginal sonography and clinical examination for preoperative diagnosis of pelvic endometriosis, Hum Reprod 24:1018, 2009.
359. **Hudelist G**, **Tuttlies F**, **Rauter G**, **Pucher S**, **Keckstein J**, Can transvaginal sonography predict infiltration depth in patients with deep infiltrating endometriosis of the rectum?, Hum Reprod 24:1012, 2009.
360. **Piketty M**, **Chopin N**, **Dousset B**, **Millischer-Bellaische AE**, **Roseau G**, **Leconte M**, **Borghese B**, **Chapron C**, Preoperative work-up for patients with deeply infiltrating endometriosis: transvaginal ultrasonography must definitely be the first-line imaging examination, Hum Reprod 24:602, 2009.
361. **Savelli L**, **Manuzzi L**, **Pollastri P**, **Mabrouk M**, **Seracchioli R**, **Venturoli S**, Diagnostic accuracy and potential limitations of transvaginal sonography for bladder endometriosis, Ultrasound Obstet Gynecol 34:595, 2009.
362. **Arrive L**, **Hricak H**, **Martin MC**, Pelvic endometriosis: MR imaging, Radiology 171:687, 1989.
363. **Togashi K**, **Nishimura K**, **Kimura I**, **Tsuda Y**, **Yamashita K**, **Shibata T**, **Nakano Y**, **Konishi J**, **Konishi I**, **Mori T**, Endometrial cysts: diagnosis with MR imaging, Radiology 180:73, 1991.
364. **Stratton P**, **Winkel C**, **Premkumar A**, **Chow C**, **Wilson J**, **Hearns-Stokes R**, **Heo S**, **Merino M**, **Nieman LK**, Diagnostic accuracy of laparoscopy, magnetic resonance imaging, and histopathologic examination for the detection of endometriosis, Fertil Steril 79:1078, 2003.
365. **Ascher SM**, **Agrawal R**, **Bis KG**, **Brown ED**, **Maximovich A**, **Markham SM**, **Patt RH**, **Semelka RC**, Endometriosis: appearance and detection with conventional and contrast-enhanced fat-suppressed spin-echo techniques, J Magn Reson Imaging 5:251, 1995.
366. **Kinkel K**, **Chapron C**, **Balleyguier C**, **Fritel X**, **Dubuisson JB**, **Moreau JF**, Magnetic resonance imaging characteristics of deep endometriosis, Hum Reprod 14:1080, 1999.
367. **Martin DC**, **Hubert GD**, **Vander Zwaag R**, **el-Zeky FA**, Laparoscopic appearances of peritoneal endometriosis, Fertil Steril 51:63, 1989.

368. **Stripling MC**, **Martin DC**, **Chatman DL**, **Zwaag RV**, **Poston WM**, Subtle appearance of pelvic endometriosis, Fertil Steril 49:427, 1988.
369. **Stegmann BJ**, **Sinaii N**, **Liu S**, **Segars J**, **Merino M**, **Nieman LK**, **Stratton P**, Using location, color, size, and depth to characterize and identify endometriosis lesions in a cohort of 133 women, Fertil Steril 89:1632, 2008.
370. **Jansen RPS**, **Russell P**, Nonpigmented endometriosis: clinical, laparoscopic and pathologic definition, Am J Obstet Gynecol 155:1154, 1986.
371. **Gustofson RL**, **Kim N**, **Liu S**, **Stratton P**, Endometriosis and the appendix: a case series and comprehensive review of the literature, Fertil Steril 86:298, 2006.
372. **Nisolle M**, **Paindaveine B**, **Bourdon A**, **Berliére M**, **Casanas-Roux F**, **Donnez J**, Histologic study of peritoneal endometriosis in infertile women, Fertil Steril 53:984, 1990.
373. **Moen MH**, **Halvorsen TB**, Histologic confirmation of endometriosis in different peritoneal lesions, Acta Obstet Gynecol Scand 71:337, 1992.
374. **Redwine DB**, Age-related evolution in color appearance of endometriosis, Fertil Steril 48:1062, 1987.
375. **Wiegerinck MA**, **Van Dop PA**, **Brosens I**, The staging of peritoneal endometriosis by the type of active lesion in addition to the revised American Fertility Society classification, Fertil Steril 60:461, 2001.
376. **Walter AJ**, **Hentz JG**, **Magtibay PM**, **Cornella JL**, **Magrina JF**, Endometriosis: correlation between histologic and visual findings at laparoscopy, Am J Obstet Gynecol 184:1407, 2001.
377. **Winkel CA**, Evaluation and management of women with endometriosis, Obstet Gynecol 102:397, 2003.
378. **Wykes CB**, **Clark TJ**, **Khan KS**, Accuracy of laparoscopy in the diagnosis of endometriosis: a systematic quantitative review, Br J Obstet Gynaecol 111:1204, 2004.
379. **Vercellini P**, **Vendola N**, **Bocciolone L**, **Rognoni MT**, **Carinelli SG**, **Candiani GB**, Reliability of the visual diagnosis of ovarian endometriosis, Fertil Steril 56:1198, 1991.
380. **Nezhat F**, **Nezhat C**, **Allan CJ**, **Metzger DA**, **Sears DL**, Clinical and histologic classification of endometriomas. Implications for a mechanism of pathogenesis, J Reprod Med 37:771, 1992.
381. **Candiani GB**, **Vercellini P**, **Fedele L**, Laparoscopic ovarian puncture for correct staging of endometriosis, Fertil Steril 53:994, 1990.
382. **Redwine DB**, Ovarian endometriosis: a marker for more extensive pelvic and intestinal disease, Fertil Steril 72:310, 1999.
383. **Nisolle M**, **Donnez J**, Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities, Fertil Steril 68:585, 1997.
384. **Donnez J**, **Nisolle M**, **Gillerot S**, **Smets M**, **Bassil S**, **Casanas-Roux F**, Rectovaginal septum adenomyotic nodules: a series of 500 cases, Br J Obstet Gynaecol 104:1014, 1997.
385. **American Fertility Society**, Classification of endometriosis, Fertil Steril 32:633, 1979.
386. **Buttram VC Jr**, Evolution of the revised American Fertility Society classification of endometriosis, Fertil Steril 43:347, 1985.
387. **American Society for Reproductive Medicine**, Revised American Society for Reproductive Medicine classification of endometriosis: 1996, Fertil Steril 67:817, 1997.
388. **Damario MA**, **Rock JA**, Classification of endometriosis, Semin Reprod Endocrinol 15:235, 1997.
389. **Guzick DS**, **Silliman NP**, **Adamson GD**, **Buttram VC Jr**, **Canis M**, **Malinak LR**, **Schenken RS**, Prediction of pregnancy in infertile women based on the American Society for Reproductive Medicine's revised classification of endometriosis, Fertil Steril 67:822, 1997.
390. **Adamson GD**, **Pasta DJ**, Endometriosis fertility index: the new, validated endometriosis staging system, Fertil Steril 94(5):1609–1615, 2010.
391. **Roberts CP**, **Rock JA**, The current staging system for endometriosis: does it help? Obstet Gynecol Clin North Am 30:115, 2003.
392. **Tuttlies F**, **Keckstein J**, **Ulrich U**, **Possover M**, **Schweppe KW**, **Wustlich M**, et al., ENZIAN-score, a classification of deep infiltrating endometriosis. (In German), Zentralbl Gynakol 127:275, 2005.
393. **Johnson NP**, **Hummelshoj L**, **Adamson GD**, **Keckstein J**, **Taylor HS**, **Abrao MS**, **Bush D**, **Kiesel L**, **Tamimi R**, **Sharpe-Timms KL**, **Rombauts L**, **Giudice LC**, World Endometriosis Society Sao Paulo

Consortium; World Endometriosis Society consensus on the classification of endometriosis, Hum Reprod 32(2):315, 2017.
394. **Mahmood TA**, **Templeton A**, The impact of treatment on the natural history of endometriosis, Hum Reprod 5:965, 1990.
395. **Gambone JC**, **Mittman BS**, **Munro MG**, **Scialli AR**, **Winkel CA**, Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process, Fertil Steril 78:961, 2002.
396. **Brown J**, **Crawford TJ**, **Allen C**, **Hopewell S**, **Prentice A**, Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis, Cochrane Database Syst Rev (1):CD004753, 2017.
397. **Kistner RW**, Management of endometriosis in the infertile patient, Fertil Steril 26:1151, 1975.
398. **Meresman GF**, **Vighi S**, **Buquet RA**, **Contreras-Ortiz O**, **Tesone M**, **Rumi LS**, Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis, Fertil Steril 74:760, 2000.
399. **Vercellini P**, **Somigliana E**, **Vigano P**, Endometriosis: current therapies and new pharmacological developments, Drugs 69:649, 2009.
400. **Vercellini P**, **Frontino G**, **De Giorgi O**, **Pietropaolo G**, **Pasin R**, **Crosignani PG**, Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen, Fertil Steril 80:560, 2003.
401. **Proctor ML**, **Roberts H**, **Farquhar CM**, Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea, Cochrane Database Syst Rev CD002120, 2001.
402. **Harada T**, **Momoeda M**, **Taketani Y**, **Hoshiai H**, **Terakawa N**, Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial, Fertil Steril 90:1583, 2008.
403. **Davis L**, **Kennedy SS**, **Moore J**, **Prentice A**, Modern combined oral contraceptives for pain associated with endometriosis, Cochrane Database Syst Rev CD001019, 2007.
404. **Olive DL**, Medical therapy of endometriosis, Semin Reprod Med 21:209, 2003.
405. **Moore J**, **Kennedy S**, **Prentice A**, Modern combined oral contraceptives for pain associated with endometriosis, Cochrane Database Syst Rev CD001019, 2000.
406. **Vercellini P**, **Fedele L**, **Pietropaolo G**, **Frontino G**, **Somigliana E**, **Crosignani PG**, Progestogens for endometriosis: forward to the past, Hum Reprod Update 9:387, 2003.
407. **Song JY**, **Fraser IS**, Effects of progestogens on human endometrium, Obstet Gynecol Surv 50:385, 1995.
408. **Bruner KL**, **Eisenberg E**, **Gorstein F**, **Osteen KG**, Progesterone and transforming growth factor-beta coordinately regulate suppression of endometrial matrix metalloproteinases in a model of experimental endometriosis, Steroids 64:648, 1999.
409. **Osteen KG**, **Igarashi TM**, **Bruner-Tran KL**, Progesterone action in the human endometrium: induction of a unique tissue environment which limits matrix metalloproteinase (MMP) expression, Front Biosci 8:d78, 2003.
410. **Vercellini P**, **Cortesi I**, **Crosignani PG**, Progestins for symptomatic endometriosis: a critical analysis of the evidence, Fertil Steril 68:393, 1997.
411. **Luciano AA**, **Turksoy RN**, **Carleo J**, Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis, Obstet Gynecol 72:323, 1988.
412. **Telimaa S**, **Puolakka J**, **Ronnberg L**, **Kauppila A**, Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis, Gynecol Endocrinol 1:13, 1987.
413. **Prentice A**, **Deary AJ**, **Bland E**, Progestagens and anti-progestagens for pain associated with endometriosis, Cochrane Database Syst Rev CD002122, 2000.
414. **Crosignani PG**, **Luciano A**, **Ray A**, **Bergqvist A**, Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain, Hum Reprod 21:248, 2006.
415. **Brown J**, **Kives S**, **Akhtar M**, Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev (3):CD002122, 2012.
416. **Muneyyirci-Delale O**, **Karacan M**, Effect of norethindrone acetate in the treatment of symptomatic endometriosis, Int J Fertil Womens Med 43:24, 1998.
417. **Schlaff WD**, **Dugoff L**, **Damewood MD**, **Rock JA**, Megestrol acetate for treatment of endometriosis, Obstet

Gynecol 75:646, 1990.
418. **Vercellini P**, **Aimi G**, **Panazza S**, **De Giorgi O**, **Pesole A**, **Crosignani PG**, A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study, Fertil Steril 72:505, 1999.
419. **Vercellini P**, **Frontino G**, **De Giorgi O**, **Aimi G**, **Zaina B**, **Crosignani PG**, Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study, Fertil Steril 80:305, 2003.
420. **Lockhat FB**, **Emembolu JO**, **Konje JC**, The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up, Hum Reprod 20:789, 2005.
421. **Petta CA**, **Ferriani RA**, **Abrao MS**, **Hassan D**, **Rosa ESJC**, **Podgaec S**, **Bahamondes L**, Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis, Hum Reprod 20:1993, 2005.
422. **Fedele L**, **Bianchi S**, **Zanconato G**, **Portuese A**, **Raffaelli R**, Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis, Fertil Steril 75:485, 2001.
423. **Abou-Setta AM**, **Houston B**, **Al-Inany HG**, **Farquhar C**, Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev (1):CD005072, 2013.
424. **Yisa SB**, **Okenwa AA**, **Husemeyer RP**, Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon), J Fam Plann Reprod Health Care 31:67, 2005.
425. **Walch K**, **Unfried G**, **Huber J**, **Kurz C**, **van Trotsenburg M**, **Pernicka E**, **Wenzl R**, Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis—a pilot study, Contraception 79:29, 2009.
426. **Strowitzki T**, **Marr J**, **Gerlinger C**, **Faustmann T**, **Seitz C**, Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial, Hum Reprod 25:633, 2010.
427. **Harada T**, et al., Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis: a randomized, double-blind, multicenter, controlled trial, Fertil Steril 91:675, 2009.
428. **Hayashi A**, et al., Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis, J Ovarian Res 5:31, 2010.
429. **H. Al Kadri**, **S. Hassan**, **H.M. Al-Fozan**, et al., Hormone therapy for endometriosis and surgical menopause, Cochrane Database Syst Rev (1):CD005997, 2009.
430. **Hirvonen E**, **Malkonen M**, **Manninen V**, Effects of different progestogens on lipoproteins during postmenopausal therapy, New Engl J Med 304:560, 1981.
431. **Fahraeus L**, **Sydsjo A**, **Wallentin L**, Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate, Fertil Steril 45:503, 1986.
432. **Cundy T**, **Farquhar CM**, **Cornish J**, **Reid IR**, Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women, J Clin Endocrinol Metab 81:1014, 1996.
433. **Meldrum DR**, Clinical management of endometriosis with luteinizing hormone-releasing hormone analogues, Semin Reprod Endocrinol 3:371, 1985.
434. **Lemay A**, **Sandow J**, **Bureau M**, **Maneux R**, **Fontaine J-Y**, **Merat P**, Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase, Fertil Steril 49:410, 1988.
435. **Brown J**, **Pan A**, **Hart RJ**, Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database of Systematic Reviews 12, 2010. Art. No.: CD008475. doi: 10.1002/14651858.CD008475.pub2.
436. **Hornstein MD**, **Surrey ES**, **Weisberg GW**, **Casino LA**, Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group, Obstet Gynecol 91:16, 1998.
437. **Dlugi AM**, **Miller JD**, **Knittle J**, Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group, Fertil Steril 54:419,

1990.
438. **Valimaki M**, **Nilsson CG**, **Roine R**, **Ylikorkala O**, Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis, J Clin Endocrinol Metab 69:1097, 1989.
439. **Burry KA**, **Patton PE**, **Illingworth DR**, Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol, Am J Obstet Gynecol 160:1454, 1989.
440. **Barbieri RL**, Hormone treatment of endometriosis: the estrogen threshold hypothesis, Am J Obstet Gynecol 166:740, 1992.
441. **Chwalisz K**, **Surrey E**, **Stanczyk FZ**, The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosi, Reprod Sci 19(6):563, 2012.
442. **Friedman AJ**, **Hornstein MD**, Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain, Fertil Steril 60:236, 1993.
443. **Surrey ES**, Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group, Fertil Steril 71:420, 1999.
444. **Hurst BS**, **Gardner SC**, **Tucker KE**, **Awoniyi CA**, **Schlaff WD**, Delayed oral estradiol combined with leuprolide increases endometriosis-related pain, JSLS 4:97, 2000.
445. **Surrey ES**, **Hornstein MD**, Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up, Obstet Gynecol 99:709, 2002.
446. **Surrey ES**, **Judd HL**, Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial, J Clin Endocrinol Metab 75:558, 1992.
447. **Makarainen L**, **Ronnberg L**, **Kauppila A**, Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis, Fertil Steril 65:29, 1996.
448. **Edmonds DK**, **Howell R**, Can hormone replacement therapy be used during medical therapy of endometriosis? Br J Obstet Gynaecol 101(Suppl 10):24, 1994.
449. **Kiilholma P**, **Tuimala R**, **Kivinen S**, **Korhonen M**, **Hagman E**, Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis, Fertil Steril 64:903, 1995.
450. **Moghissi KS**, **Schlaff WD**, **Olive DL**, **Skinner MA**, **Yin H**, Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis, Fertil Steril 69:1056, 1998.
451. **The Nafarelin European Endometriosis Trial Group**, Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up, Fertil Steril 57:514, 1992.
452. **Fedele L**, **Bianchi S**, **Bocciolone L**, **Di Nola G**, **Franchi D**, Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study, Fertil Steril 59:516, 1993.
453. **Vercellini P**, **Trespidi L**, **Colombo A**, **Vendola N**, **Marchini M**, **Crosignani PG**, A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis, Fertil Steril 60:75, 1993.
454. **Waller KG**, **Shaw RW**, Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up, Fertil Steril 59:511, 1993.
455. **Gerhard I**, **Schindler AE**, **Buhler K**, **Winkler U**, **Meinen K**, **Mancarella D**, **Hoffmann G**, **Schussler B**, **Kimmig R**, **Kranzfelder D**, Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study, Clin Ther 14(Suppl A):3, 1992.
456. **Henzl MR**, **Corson SL**, **Moghissi K**, **Buttram VC Jr**, **Berqvist C**, **Jacobson J**, Administration of nasal nafarelin as compared with oral danazol for endometriosis, N Engl J Med 318:485, 1988.
457. **Henzl MR**, **Kwei L**, Efficacy and safety of nafarelin in the treatment of endometriosis, Am J Obstet Gynecol 162:570, 1990.
458. **Rolland R**, **van der Heijden PF**, Nafarelin versus danazol in the treatment of endometriosis, Am J Obstet Gynecol 162:586, 1990.
459. **Kennedy SH**, **Williams IA**, **Brodribb J**, **Barlow DH**, **Shaw RW**, A comparison of nafarelin acetate and

danazol in the treatment of endometriosis, Fertil Steril 53:998, 1990.
460. **Shaw RW**, An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team, Fertil Steril 58:265, 1992.
461. **Regidor PA**, **Regidor M**, **Schmidt M**, **Ruwe B**, **Lubben G**, **Fortig P**, **Kienle E**, **Schindler AE**, Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis, Gynecol Endocrinol 15:202, 2001.
462. **Batioglu S**, **Celikkanat H**, **Ugur M**, **Mollamahmutoglu L**, **Yesilyurt H**, **Kundakci M**, The use of GnRH agonists in the treatment of endometriomas with or without drainage, J Pak Med Assoc 46:30, 1996.
463. **Prentice A**, **Deary AJ**, **Goldbeck-Wood S**, **Farquhar C**, **Smith SK**, Gonadotrophin-releasing hormone analogues for pain associated with endometriosis, Cochrane Database Syst Rev CD000346, 2000.
464. **Taylor HS** et al., Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist, N Engl J Med 377(1):28–40, 2017. doi: 10.1056/NEJMoa1700089. Epub 2017 May 19.
465. **Ng J** et al., Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women, JCEM 102(5), 2017.
466. **Surrey** et al., Long-term outcomes of elagolix in women with endometriosis: results from two extension studies, Obstetrics and Gynecology, 2018.
467. **Barbieri RL**, **Evans S**, **Kistner RW**, Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up, Fertil Steril 37:737, 1982.
468. **Barbieri RL**, **Canick JA**, **Makris A**, **Todd RB**, **Davies IJ**, **Ryan KJ**, Danazol inhibits steroidogenesis, Fertil Steril 28:809, 1977.
469. **Barbieri RL**, **Osathanondh R**, **Ryan KJ**, Danazol inhibition of steroidogenesis in the human corpus luteum, Obstet Gynecol 57:722, 1981.
470. **Floyd WS**, Danazol: endocrine and endometrial effects, Int J Fertil 25:75, 1980.
471. **McGinley R**, **Casey JH**, Analysis of progesterone in unextracted serum: a method using danazol [17 alpha-pregn-4-en-20-yno(2, 3-d) isoxazol-17-ol] a blocker of steroid binding to proteins, Steroids 33:127, 1979.
472. **Barbieri RL**, **Hornstein MD**, Medical therapy for endometriosis, In: Wilson EA, ed. Endometriosis, Alan R. Liss, Inc., New York, 1987, p. 111.
473. **Selak V**, **Farquhar C**, **Prentice A**, **Singla A**, Danazol for pelvic pain associated with endometriosis, Cochrane Database Syst Rev CD000068, 2007.
474. **Miller JD**, **Shaw RW**, **Casper RF**, **Rock JA**, **Thomas EJ**, **Dmowski WP**, **Surrey E**, **Malinak LR**, **Moghissi K**, Historical prospective cohort study of the recurrence of pain after discontinuation of treatment with danazol or a gonadotropin-releasing hormone agonist, Fertil Steril 70:293, 1998.
475. **Dmowski WP**, **Cohen MR**, Treatment of endometriosis with an antigonadotropin, Danazol. A laparoscopic and histologic evaluation, Obstet Gynecol 46:147, 1975.
476. **Buttram VC Jr**, **Reiter RC**, **Ward S**, Treatment of endometriosis with danazol: report of a 6-year prospective study, Fertil Steril 43:353, 1985.
477. **Wheeler JM**, **Knittle JD**, **Miller JD**; for the **Lupron Endometriosis Study Group**, Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety, Am J Obstet Gynecol 169:26, 1993.
478. **Buttram VC Jr**, **Belue JB**, **Reiter R**, Interim report a study of danazol for the treatment of endometriosis, Fertil Steril 37:478, 1982.
479. **Quagliarello J**, **Alba Greco M**, Danazol and urogenital sinus formation in pregnancy, Fertil Steril 43:939, 1985.
480. **Wardle PG**, **Whitehead MI**, **Mills RP**, Nonreversible and wide ranging vocal changes after treatment with danazol, Br Med J 287:946, 1983.
481. **Mercaitis PA**, **Peaper RE**, **Schwartz PA**, Effect of danazol on vocal pitch: a case study, Obstet Gynecol 65:131, 1985.
482. **Alvarado RG**, **Liu JY**, **Zwolak RM**, Danazol and limb-threatening arterial thrombosis: two case reports, J Vasc Surg 34:1123, 2001.
483. **Dmowski WP**, **Kapetanakis E**, **Scommegna A**, Variable effects of danazol on endometriosis at 4 low-dose

levels, Obstet Gynecol 59:408, 1982.
484. **Vercellini P**, **Trespidi L**, **Panazza S**, **Bramante T**, **Mauro F**, **Crosignani PG**, Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study, Fertil Steril 62:1136, 1994.
485. **Igarashi M**, **Iizuka M**, **Abe Y**, **Ibuki Y**, Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis, Hum Reprod 13:1952, 1998.
486. **Igarashi M**, A new therapy for pelvic endometriosis and uterine adenomyosis: local effect of vaginal and intrauterine danazol application, Asia Oceania J Obstet Gynaecol 16:1, 1990.
487. **Razzi S**, **Luisi S**, **Calonaci F**, **Altomare A**, **Bocchi C**, **Petraglia F**, Efficacy of vaginal danazol treatment in women with recurrence deeply infiltrating endometriosis, Fertil Steril 88:789, 2007.
488. **Okamura Y**, **Suzuki J**, **Honda R**, **Hoba T**, **Katabuchi H**, **Okamura O**, Clinical outcome of vaginal danazol suppository use in women with pelvic endometriosis. Fertil Steril 90(Suppl 1):S486, 2008.
489. **Bhattacharya SM**, **Tolasaria A**, **Khan B**, Vaginal danazol for the treatment of endometriosis-related pelvic pain, Int J Gynaecol Obstet 115:294, 2011.
490. **Ferrero S**, **Tramalloni D**, **Venturini PL**, **Remorgida V**, Vaginal danazol for women with rectovaginal endometriosis and pain symptoms persisting after insertion of a levonorgestrel-releasing uterine device, Int J Gynaecol Obstet 113:116, 2011. doi:10.1016/j.ijgo.2010.11.015.
491. **Mizutani T**, **Nishiyama S**, **Amakawa I**, **Watanabe A**, **Nakamuro K**, **Terada N**, Danazol concentrations in ovary, uterus, and serum and their effect on the hypothalamic-pituitary-ovarian axis during vaginal administration of a danazol suppository, Fertil Steril 63:1184, 1995.
492. **Attar E**, **Bulun SE**, Aromatase inhibitors: the next generation of therapeutics for endometriosis?, Fertil Steril 85:1307, 2006.
493. **Pavone ME**, **Bulun SE**, Aromatase inhibitors for the treatment of endometriosis. Fertil Steril 98(6):1370, 2012.
494. **Razzi S**, **Fava A**, **Sartini A**, **De Simone S**, **Cobellis L**, **Petraglia F**, Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman, Br J Obstet Gynaecol 111:182, 2004.
495. **Ailawadi RK**, **Jobanputra S**, **Kataria M**, **Gurates B**, **Bulun SE**, Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study, Fertil Steril 81:290, 2004.
496. **Shippen ER**, **West WJ Jr**, Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor, Fertil Steril 81:1395, 2004.
497. **Amsterdam LL**, **Gentry W**, **Jobanputra S**, **Wolf M**, **Rubin SD**, **Bulun SE**, Anastrozole and oral contraceptives: a novel treatment for endometriosis, Fertil Steril 84:300, 2005.
498. **Hefler LA**, **Grimm C**, **van Trotsenburg M**, **Nagele F**, Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study, Fertil Steril 84:1033, 2005.
499. **Fatemi HM**, **Al-Turki HA**, **Papanikolaou EG**, **Kosmas L**, **De Sutter P**, **Devroey P**, Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor, Reprod Biomed Online 11:455, 2005.
500. **Ferrero S**, **Venturini PL**, **Ragni N**, **Camerini G**, **Remorgida V**, Pharmacological treatment of endometriosis: experience with aromatase inhibitors, Drugs 69(8):943, 2009.
501. **Soysal S**, **Soysal ME**, **Ozer S**, **Gul N**, **Gezgin T**, The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial, Hum Reprod 19:160, 2004.
502. **Ferrero S**, **Camerini G**, **Seracchioli R**, **Ragni N**, **Venturini PL**, **Remorgida V**, Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis, Hum Reprod 24:3033, 2009.
503. **Ferrero S**, **Camerini G**, **Ragni N**, **Venturini PL**, **Biscaldi E**, **Seracchioli R**, et al., Letrozole and norethisterone acetate in colorectal endometriosis, Eur J Obstet Gynecol Reprod Biol 150:199, 2010.
504. **Remorgida V**, **Abbamonte HL**, **Ragni N**, **Fulcheri E**, **Ferrero S**, Letrozole and norethisterone acetate in rectovaginal endometriosis, Fertil Steril 88:724, 2007.
505. **Sasson IE**, **Taylor HS**, Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a

postmenopausal woman, Fertil Steril 92(3):1170.e1, 2009.
506. **Bedaiwy MA**, **Alfaraj S**, **Yong P**, **Casper R**, New developments in the medical treatment of endometriosis, Fertil Steril 107(3):555, 2017.
507. **Kettel LM**, **Murphy AA**, **Morales AJ**, **Ulmann A**, **Baulieu EE**, **Yen SS**, Treatment of endometriosis with the antiprogesterone mifepristone (RU486), Fertil Steril 65:23, 1996.
508. **Kettel LM**, **Murphy AA**, **Morales AJ**, **Yen SS**, Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486), Am J Obstet Gynecol 178:1151, 1998.
509. **Kulak J Jr**, **Fischer C**, **Komm B**, **Taylor HS**, Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology 152(8):3226, 2011.
510. **Naqvi H**, **Sakr S**, **Presti T**, **Krikun G**, **Komm B**, **Taylor HS**, Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model, Biol Reprod 90(6):121, 2014.
511. **Flores VA**, **Stachenfeld NS**, **Taylor HS**, Bazedoxifene-conjugated estrogens for treating endometriosis, Obstet Gynecol 132(2):475, 2018.
512. **Hill AM**, **Lessey B**, **Flores VA**, **Taylor HS**, Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis, Clin Case Rep 6(6):990, 2018.
513. **Flores VA**, **Vanhie A**, **Dang T**, **Taylor HS**, Precision medicine in endometriosis: progesterone receptor status in endometriosis. Journal of Clinical Endocrinology and Metabolism 103(12):4561–4568, 2018. PMID 30357380.
514. **Taylor HS**, **Osteen KG**, **Bruner-Tran KL**, Novel therapies targeting endometriosis, Reprod Sci 18:814, 2011.
515. **Laschke M**, **Menger M**, Anti-angiogenic treatment strategies for the therapy of endometriosis, Hum Reprod Update 18:682, 2012.
516. **Sahin C**, **Mamillapalli R**, **Yi KW**, **Taylor HS**, microRNA Let-7b: a novel treatment for endometriosis, J Cell Mol Med 22(11):5346, 2018.
517. **Crosignani PG**, **Vercellini P**, **Biffignandi F**, **Costantini W**, **Cortesi I**, **Imparato E,** Laparoscopy versus laparotomy in conservative surgical treatment for severe endometriosis, Fertil Steril 66:706, 1996.
518. **Bruhat MA**, **Mage G**, **Chapron C**, **Pouly JL**, **Canis M**, **Wattiez A**, Present day endoscopic surgery in gynecology, Eur J Obstet Gynecol Reprod Biol 41:4, 1991.
519. **Adamson GD**, **Pasta DJ**, Surgical treatment of endometriosis-associated infertility: meta-analysis compared with survival analysis, Am J Obstet Gynecol 171:1488, 1994.
520. **Adamson D**, Surgical management of endometriosis, Semin Reprod Med 21:223, 2003.
521. **Duffy JM**, **Arambage K**, **Correa FJ**, **Olive D**, **Farquhar C**, **Garry R**, et al., Laparoscopic surgery for endometriosis. Cochrane Database Syst Rev (4):CD011031, 2014
522. **Kodaman PH**, Current strategies for endometriosis management, Obstet Gynecol Clin North Am 42(1):87, 2015.
523. **Koninckx PR**, **Martin D**, Treatment of deeply infiltrating endometriosis, Curr Opin Obstet Gynecol 6:231, 1994.
524. **Vercellini P**, **Frontino G**, **Pietropaolo G**, **Gattei U**, **Daguati R**, **Crosignani PG**, Deep endometriosis: definition, pathogenesis, and clinical management, J Am Assoc Gynecol Laparosc 11:153, 2004.
525. **Ferrero S**, **Alessandri F**, **Racca A**, **Leone Roberti Maggiore U**, Treatment of pain associated with deep endometriosis: alternatives and evidence, Fertil Steril 104(4):771, 2015.
526. **Donnez J**, **Smets M**, **Jadoul P**, **Pirard C**, **Squifflet J**, Laparoscopic management of peritoneal endometriosis, endometriotic cysts, and rectovaginal adenomyosis, Ann N Y Acad Sci 997:274, 2003.
527. **Hart RJ**, **Hickey M**, **Maouris P**, **Buckett W**, Excisional surgery versus ablative surgery for ovarian endometriomata, Cochrane Database Syst Rev (2):CD004992, 2008.
528. **Hart RJ**, **Hickey M**, **Maouris P**, **Buckett W**, **Garry R**, Excisional surgery versus ablative surgery for ovarian endometriomata, Cochrane Database Syst Rev CD004992, 2005.
529. **Muzii L**, **Bellati F**, **Palaia I**, **Plotti F**, **Manci N**, **Zullo MA**, **Angioli R**, **Panici PB**, Laparoscopic stripping of endometriomas: a randomized trial on different surgical techniques. Part I: clinical results, Hum Reprod 20:1981, 2005.
530. **Raffi F**, **Metwally M**, **Amer S**, The impact of excision of ovarian endometrioma on ovarian reserve: a

systematic review and meta-analysis, J Clin Endocrinol Metab 97(9):3146, 2012.
531. **Reich H**, **Abrao MS**, Post-surgical ovarian failure after laparoscopic excision of bilateral endometriomas: is this rare problem preventable? Am J Obstet Gynecol 195:339, 2006.
532. **Wilson ML**, **Farquhar CM**, **Sinclair OJ**, **Johnson NP**, Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea, Cochrane Database Syst Rev CD001896, 2000.
533. **Candiani GB**, **Fedele L**, **Vercellini P**, **Bianchi S**, **Di Nola G**, Presacral neurectomy for the treatment of pelvic pain associated with endometriosis: a controlled study, Am J Obstet Gynecol 167:100, 1992.
534. **Chen FP**, **Soong YK**, The efficacy and complications of laparoscopic presacral neurectomy in pelvic pain, Obstet Gynecol 90:974, 1997.
535. **Candiani GB**, **Fedele L**, **Vercellini P**, **Bianchi S**, **Di Nola G**, Repetitive conservative surgery for recurrence of endometriosis, Obstet Gynecol 77:421, 1991.
536. **Sutton CJG**, **Pooley AS**, **Ewen SP**, **Haines P**, Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis, Fertil Steril 68:1070, 1997.
537. **Shakiba K**, **Bena JF**, **McGill KM**, **Minger J**, **Falcone T**, Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery, Obstet Gynecol 111:1285, 2008.
538. **Vercellini P**, **Vigano P**, **Somigliana E**, **Fedele L**, Endometriosis: pathogenesis and treatment, Nat Rev Endocrinol 10(5):261, 2014.
539. **Taylor E**, **Williams C**, Surgical treatment of endometriosis: location and patterns of disease at reoperation, Fertil Steril 93:57, 2010.
540. **Schweppe KW**, **Ring D**, Peritoneal defects and the development of endometriosis in relation to the timing of endoscopic surgery during the menstrual cycle, Fertil Steril 78:763, 2002.
541. **Namnoum AB**, **Hickman TN**, **Goodman SB**, **Gehlbach DL**, **Rock JA**, Incidence of symptom recurrence after hysterectomy for endometriosis, Fertil Steril 64:898, 1995.
542. **Matorras R**, **Elorriaga MA**, **Pijoan JI**, **Ramon O**, **Rodriguez-Escudero FJ,** Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who received hormone replacement therapy, Fertil Steril 77:303, 2002.
543. **Hickman TN**, **Namnoum AB**, **Hinton EL**, **Zacur HA**, **Rock JA**, Timing of estrogen replacement therapy following hysterectomy with oophorectomy for endometriosis, Obstet Gynecol 91:673, 1998.
544. **Rana N**, **Rotman C**, **Hasson HM**, **Redwine DB**, **Dmowski WP**, Ovarian remnant syndrome after laparoscopic hysterectomy and bilateral salpingo-oophorectomy for severe pelvic endometriosis, J Am Assoc Gynecol Laparosc 3:423, 1996.
545. **Clayton RD**, **Hawe JA**, **Love JC**, **Wilkinson N**, **Garry R**, Recurrent pain after hysterectomy and bilateral salpingo-oophorectomy for endometriosis: evaluation of laparoscopic excision of residual endometriosis, Br J Obstet Gynaecol 106:740, 1999.
546. **Dmowski WP**, **Radwanska E**, **Rana N**, Recurrent endometriosis following hysterectomy and oophorectomy: the role of residual ovarian fragments, Int J Gynaecol Obstet 26:93, 1988.
547. **Magtibay PM**, **Nyholm JL**, **Hernandez JL**, **Podratz KC**, Ovarian remnant syndrome, Am J Obstet Gynecol 193(6):2062, 2005.
548. **Furness S**, **Yap C**, **Farquhar C**, **Cheong YC**, Pre and post-operative medical therapy for endometriosis surgery, Cochrane Database Syst Rev (3):CD003678, 2004.
549. **Somigliana E**, **Vercellini P**, **Vigano P**, **Benaglia L**, **Busnelli A**, **Fedele L**, Postoperative medical therapy after surgical treatment of endometriosis: from adjuvant therapy to tertiary prevention. J Minim Invasive Gynecol, 21(3):328, 2014.
550. **Flower A**, **Liu JP**, **Lewith G**, **Little P**, **Li Q**, Chinese herbal medicine for endometriosis, Cochrane Database Syst Rev (5):CD006568, 2012.
551. **Hughes E**, **Brown J**, **Collins JJ**, **Farquhar C**, **Fedorkow DM**, **Vandekerckhove P**, Ovulation suppression for endometriosis, Cochrane Database Syst Rev CD000155, 2007.
552. **Sallam HN**, **Garcia-Velasco JA**, **Dias S**, **Arici A**, Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev (1):CD004635, 2006.

553. **Surrey ES**, **Silverberg KM**, **Surrey MW**, **Schoolcraft WB**, Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis, Fertil Steril 78(4):699, 2002.
554. **de Ziegler D**, **Gayet V**, **Aubriot FX**, Use of oral contraceptives in women with endometriosis before assisted reproduction treatment improves outcomes, Fertil Steril 94(7):2796, 2010.
555. **Gruppo Italiano per lo Studio Dell'Endometriosi**, Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomized trial, Hum Reprod 14:1332, 1999.
556. **Wood C**, **Maher P**, **Hill D**, Diagnosis and surgical management of endometriomas, Aust N Z J Obstet Gynaecol 32:161, 1992.
557. **Reich H**, **McGlynn F**, Treatment of ovarian endometriomas using laparoscopic surgical techniques, J Reprod Med 31:577, 1986.
558. **Donnez J**, **Nisolle M**, **Gillet N**, **Smets M**, **Bassil S**, **Casanas-Roux F**, Large ovarian endometriomas, Hum Reprod 11:641, 1996.
559. **Practice Committee of the American Society for Reproductive Medicine**; **Pfeifer S**, **Fritz M**, **Goldberg J**, **McClure R**, **Lobo R**, **Thomas M**, **Widra E**, **Schattman G**, **Licht M**, **Collins J**, **Cedars M**, **Racowsky C**, **Vernon M**, **Davis O**, **Barnhart K**, **Gracia C**, **Catherino W**, **Rebar R**, **Barbera AL**, Endometriosis and infertility: a committee opinion, Fertil Steril 98(3):591, 2012.
560. **Busacca M**, **Bianchi M**, **Agnoli B**, et al., Follow-up of laparoscopic treatment of stage IIIIV endometriosis, J Am Assoc Gynecol Laparosc 6:55, 1999.
561. **Soong YK**, **Chang FH**, **Chou HH**, et al., Life table analysis of pregnancy rates in women with moderate or severe endometriosis comparing danazol therapy after carbon dioxide laser laparoscopy plus electrocoagulation or laparotomy plus electrocoagulation versus danazol therapy only, J Am Assoc Gynecol Laparosc 4:225, 1997.
562. **Bianchi PH**, **Pereira RM**, **Zanatta A**, **Alegretti JR**, **Motta EL**, **Serafini PC**, Extensive excision of deep infiltrative endometriosis before in vitro fertilization significantly improves pregnancy rates, J Minim Invasive Gynecol 16:174, 2009.
563. **Farquhar C**, **Vandekerckhove P**, **Watson A**, **Vail A**, **Wiseman D**, Barrier agents for preventing adhesions after surgery for subfertility, Cochrane Database Syst Rev CD000475, 2000.
564. **Watson A**, **Vandekerckhove P**, **Lilford R**, Liquid and fluid agents for preventing adhesions after surgery for subfertility, Cochrane Database Syst Rev CD001298, 2003.
565. **Alderman MH III**, **Yoder N**, **Taylor HS**, The systemic effects of endometriosis, Semin Reprod Med 35(3):263, 2017.
566. **Goetz LG**, **Mamillapalli R**, **Taylor HS**, Low body mass index in endometriosis is promoted by hepatic metabolic gene dysregulation in mice, Biol Reprod 95(6):115, 2016.
567. **Mu F**, **Rich-Edwards J**, **Rimm EB**, **Spiegelman D**, **Missmer SA**, Endometriosis and risk of coronary heart disease, Circ Cardiovasc Qual Outcomes 9(3):257, 2016.
568. **Pluchino, Wenger**, **Petignat P**, **Tal R**, **Bolmont M**, **Taylor HS**, **Bianchi-Demicheli F**, Sexual function in endometriosis patients and their partners: effect of the disease and consequences of treatment, Hum Reprod Update 22(6):762, 2016.

Chapter thirty three

REFERENCES

1. **Graham H**, Eternal Eve, The History of Gynaecology & Obstetrics, Doubleday & Company, Inc., Garden City, 1951.
2. **Harbert WW**, A case of extra-uterine pregnancy, West J Med Surg 3:110, 1849.
3. **Parry JS**, Extra-uterine Pregnancy: Its Causes, Species, Pathological Anatomy, Clinical History, Diagnosis, Prognosis, and Treatment, H.C. Lea, Philadelphia, PA, 1876.
4. **Tait RL**, Five cases of extra-uterine pregnancy operated upon at the time of rupture, Br Med J I:1250, 1884.
5. **Goldner TE**, **Lawson HW**, **Xia Z**, **Atrash HK**, Surveillance for ectopic pregnancy—United States, 1970–1989, MMWR Surveill Summ 42:73, 1993.
6. **Centers for Disease Control and Prevention**, Ectopic pregnancy—United States, 1990–1992, MMWR Morb Mortal Wkly Rep 44:46, 1995.
7. **Stovall TG**, **Ling FW**, **Buster JE**, Outpatient chemotherapy of unruptured ectopic pregnancy, Fertil Steril 51:435, 1989.
8. **Ory SJ**, New options for diagnosis and treatment of ectopic pregnancy, JAMA 267:534, 1992.
9. **Carson SA**, **Buster JE**, Ectopic pregnancy, N Engl J Med 329:1174, 1993.
10. **Zane SB**, **Kieke BA Jr**, **Kendrick JS**, **Bruce C**, Surveillance in a time of changing health care practices: estimating ectopic pregnancy incidence in the United States, Matern Child Health J 6:227, 2002.
11. **Chang J**, **Elam-Evans LD**, **Berg CJ**, **Herndon J**, **Flowers L**, **Seed KA**, **Syverson CJ**, Pregnancy-related mortality surveillance—United States, 1991–1999, MMWR Surveill Summ 52:1, 2003.
12. **Barnhart KT**, Clinical practice. Ectopic pregnancy, N Engl J Med 361:379, 2009.
13. **Van Den Eeden SK**, **Shan J**, **Bruce C**, **Glasser M**, Ectopic pregnancy rate and treatment utilization in a large managed care organization, Obstet Gynecol 105:1052, 2005.
14. **Stovall TG**, **Ling FW**, **Andersen RN**, **Buster JE**, Improved sensitivity and specificity of a single measurement of serum progesterone over serial quantitative beta-human chorionic gonadotrophin in screening for ectopic pregnancy, Hum Reprod 7:723, 1992.
15. **Barnhart KT**, **Simhan H**, **Kamelle SA**, Diagnostic accuracy of ultrasound above and below the beta-hCG discriminatory zone, Obstet Gynecol 94:583, 1999.
16. **Storeide O**, **Veholmen M**, **Eide M**, **Bergsjo P**, **Sandvei R**, The incidence of ectopic pregnancy in Hordaland County, Norway 1976–1993, Acta Obstet Gynecol Scand 76:345, 1997.
17. **Nybo Andersen AM**, **Wohlfahrt J**, **Christens P**, **Olsen J**, **Melbye M**, Maternal age and fetal loss: population based register linkage study, Br Med J 320:1708, 2000.
18. **Barnhart KT**, **Sammel MD**, **Gracia CR**, **Chittams J**, **Hummel AC**, **Shaunik A**, Risk factors for ectopic pregnancy in women with symptomatic first-trimester pregnancies, Fertil Steril 86:36, 2006.
19. **American College of Obstetricians and Gynecologists**, ACOG Practice Bulletin No. 94: medical management of ectopic pregnancy, Obstet Gynecol 111:1479, 2008.
20. **Gaskins AJ**, **Missmer SA**, **Rich-Edwards JW**, **Williams PL**, **Souter I**, **Chavarro JE**, Demographic, lifestyle, and reproductive risk factors for ectopic pregnancy, Fertil Steril 110(7):1328, 2018. doi:10.1016/j.fertnstert.2018.08.022.
21. **Ankum WM**, **Mol BWJ**, **Van der Veen F**, **Bossuyt PMM**, Risk factors for ectopic pregnancy: a meta-analysis, Fertil Steril 65:1093, 1996.
22. **Bouyer J**, **Coste J**, **Shojaei T**, **Pouly JL**, **Fernandez H**, **Gerbaud L**, **Job-Spira N**, Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population-based study in France, Am J Epidemiol 157:185, 2003.
23. **Murray H**, **Baakdah H**, **Bardell T**, **Tulandi T**, Diagnosis and treatment of ectopic pregnancy, CMAJ 173:905, 2005.
24. **Skjeldestad FE**, **Hadgu A**, **Eriksson N**, Epidemiology of repeat ectopic pregnancy: a population-based prospective cohort study, Obstet Gynecol 91:129, 1998.
25. **Schoen JA**, **Nowak RJ**, Repeat ectopic pregnancy: a 16-year clinical survey, Obstet Gynecol 45:542, 1975.

26. **Hallatt JG**, Repeat ectopic pregnancy: a study of 123 consecutive cases, Am J Obstet Gynecol 122:520, 1975.
27. **Sandvei R**, **Bergsjo P**, **Ulstein M**, **Steier JA**, Repeat ectopic pregnancy. A twenty-year hospital survey, Acta Obstet Gynecol Scand 66:35, 1987.
28. **Seeber BE**, **Barnhart KT**, Suspected ectopic pregnancy, Obstet Gynecol 107:399, 2006.
29. **Yao M**, **Tulandi T**, Current status of surgical and nonsurgical management of ectopic pregnancy, Fertil Steril 67:421, 1997.
30. **Hajenius PJ**, **Mol F**, **Mol BW**, **Bossuyt PM**, **Ankum WM**, **van der Veen F**, Interventions for tubal ectopic pregnancy, Cochrane Database Syst Rev CD000324, 2007.
31. **Mol F**, **Mol BW**, **Ankum WM**, **van der Veen F**, **Hajenius PJ**, Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis, Hum Reprod Update 14:309, 2008.
32. **Job-Spira N**, **Fernandez H**, **Bouyer J**, **Pouly JL**, **Germain E**, **Coste J**, Ruptured tubal ectopic pregnancy: risk factors and reproductive outcome: results of a population-based study in France, Am J Obstet Gynecol 180:938, 1999.
33. **Svensson L**, **Mardh PA**, **Ahlgren M**, **Nordenskjold F**, Ectopic pregnancy and antibodies to Chlamydia trachomatis, Fertil Steril 44:313, 1985.
34. **Kihlstrom E**, **Lindgren R**, **Ryden G**, Antibodies to Chlamydia trachomatis in women with infertility, pelvic inflammatory disease and ectopic pregnancy, Eur J Obstet Gynecol Reprod Biol 35:199, 1990.
35. **Odland JO**, **Anestad G**, **Rasmussen S**, **Lundgren R**, **Dalaker K**, Ectopic pregnancy and chlamydial serology, Int J Gynaecol Obstet 43:271, 1993.
36. **Chow JM**, **Yonekura L**, **Richwald GA**, **Greenland S**, **Sweet RL**, **Schachter J**, The association between Chlamydia trachomatis and ectopic pregnancy: a matched-pair, case-control study, JAMA 263:3164, 1990.
37. **Hillis SD**, **Owens LM**, **Marchbanks PA**, **Amsterdam LF**, **Mac Kenzie WR**, Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease, Am J Obstet Gynecol 176:103, 1997.
38. **Westrom L**, **Joesoef R**, **Reynolds G**, **Hagdu A**, **Thompson SE**, Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results, Sex Transm Dis 19:185, 1992.
39. **Goldberg JM**, **Falcone T**, Effect of diethylstilbestrol on reproductive function, Fertil Steril 72:1, 1999.
40. **Kaufman RH**, **Adam E**, **Hatch EE**, **Noller K**, **Herbst AL**, **Palmer JR**, **Hoover RN**, Continued follow-up of pregnancy outcomes in diethylstilbestrol-exposed offspring, Obstet Gynecol 96:483, 2000.
41. **DeCherney AH**, **Cholst I**, **Naftolin F**, Structure and function of the fallopian tubes following exposure to diethylstilbestrol (DES) during gestation, Fertil Steril 36:741, 1981.
42. **Haney AF**, **Newbold RR**, **Fetter BF**, **McLachlan JA**, Paraovarian cysts associated with prenatal diethylstilbestrol exposure. Comparison of the human with a mouse model, Am J Pathol 124:405, 1986.
43. **Herbst AL**, **Ulfelder H**, **Poskanzer DC**, Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women, N Engl J Med 284:878, 1971.
44. **WHO Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Intrauterine Devices for Fertility Regulation**, A multinational case-control study of ectopic pregnancy, Clin Reprod Fertil 3:131, 1985.
45. **Franks AL**, **Beral V**, **Cates W Jr**, **Hogue CJ**, Contraception and ectopic pregnancy risk, Am J Obstet Gynecol 163:1120, 1990.
46. **Mol BW**, **Ankum WM**, **Bossuyt PM**, **Van der Veen F**, Contraception and the risk of ectopic pregnancy: a meta-analysis, Contraception 52:337, 1995.
47. **Furlong LA**, Ectopic pregnancy risk when contraception fails. A review, J Reprod Med 47:881, 2002.
48. **Edelman DA**, **Porter CW**, The intrauterine device and ectopic pregnancy, Contraception 36:85, 1987.
49. **Sivin I**, **el Mahgoub S**, **McCarthy T**, **Mishell DR Jr**, **Shoupe D**, **Alvarez F**, **Brache V**, **Jimenez E**, **Diaz J**, **Faundes A**, **Diaz MM**, **Coutinho E**, **Mattos CER**, **Diaz S**, **Pavez M**, **Stern J**, Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study, Contraception 42:361, 1990.

50. **Sivin I**, **Stern J**, **Coutinho E**, **Mattos CE**, **el Mahgoub S**, **Diaz S**, **Pavez M**, **Alvarez F**, **Brache V**, **Thevenin F**, **Diaz J**, **Faundes A**, **Diaz MM**, **McCarthy T**, **Mishell DR**, **Shoupe D**, Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS, Contraception 44:473, 1991.
51. **Sivin I**, **Stern J**; **International Committee for Contraception Research**, Health during prolonged use of levonorgestrel 20 mg/d and the copper TCu 380 Ag intrauterine contraceptive devices: a multicenter study, Fertil Steril 61:70, 1994.
52. **Andersson K**, **Odlind V**, **Rybo G**, Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial, Contraception 49:56, 1994.
53. **Cox M**, **Blacksell SE**, Clinical performance of the Nova-T380 IUD in routine use by the UK Family Planning and Reproductive Health Research Network: 12-month report, Br J Fam Plann 26:148, 2000.
54. **Cox M**, **Blacksell S**, Clinical performance of the levonorgestrel intra-uterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 12-month report, Br J Fam Plann 26:143, 2000.
55. **Backman T**, **Rauramo I**, **Huhtala S**, **Koskenvuo M**, Pregnancy during the use of levonorgestrel intrauterine system, Am J Obstet Gynecol 190:50, 2004.
56. **Ganacharya S**, **Bhattoa HP**, **Batar I**, Ectopic pregnancy among non-medicated and copper-containing intrauterine device users: a 10-year follow-up, Eur J Obstet Gynecol Reprod Biol 111:78, 2003.
57. **Peterson HB**, **Xia Z**, **Hughes JM**, **Wilcox LS**, **Tylor LR**, **Trussell J**; **for the U.S. Collaborative Review of Sterilization Working Group**, The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization, Am J Obstet Gynecol 174:1161, 1996.
58. **McCausland A**, High rate of ectopic pregnancy following laparoscopic tubal coagulation failure, Am J Obstet Gynecol 136:977, 1980.
59. **Chi I-c**, **Laufe LE**, **Atwed R**, Ectopic pregnancy following female sterilization procedures, Adv Plann Parenthood 16:52, 1981.
60. **Peterson HB**, **Xia Z**, **Hughes JM**, **Wilcox LS**, **Tylor LR**, **Trussell J**; **for the U.S. Collaborative Review of Sterilization Working Group**, The risk of ectopic pregnancy after tubal sterilization, N Engl J Med 336:762, 1997.
61. **Holt V**, **Chu J**, **Daling JR**, **Stergachis AS**, **Weiss NS**, Tubal sterilization and subsequent ectopic pregnancy, JAMA 266:242, 1991.
62. **Nielsen CL**, **Miller L**, Ectopic gestation following emergency contraceptive pill administration, Contraception 62:275, 2000.
63. **Jian Z**, **Linan C**, Ectopic gestation following emergency contraception with levonorgestrel, Eur J Contracept Reprod Health Care 8:225, 2003.
64. **Sheffer-Mimouni G**, **Pauzner D**, **Maslovitch S**, **Lessing JB**, **Gamzu R**, Ectopic pregnancies following emergency levonorgestrel contraception, Contraception 67:267, 2003.
65. **Grimes DA**, **Raymond EG**, Emergency contraception, Ann Intern Med 137:180, 2002.
66. **Shao EX**, **Hopper K**, **McKnoulty M**, **Kothari A**, A systematic review of ectopic pregnancy after hysterectomy, Int J Gynaecol Obstet 141(2):159, 2018. doi:10.1002/ijgo.12385.
67. **Thorburn J**, **Philipson M**, **Lindblom B**, Background factors of ectopic pregnancy. II. Risk estimation by means of a logistic model, Eur J Obstet Gynecol Reprod Biol 23:333, 1986.
68. **Yang CP**, **Chow WH**, **Daling JR**, **Weiss NS**, **Moore DE**, Does prior infertility increase the risk of tubal pregnancy?, Fertil Steril 48:62, 1987.
69. **Tuomivaara L**, **Kauppila A**, Ectopic pregnancy: a case-control study of aetiological risk factors, Arch Gynecol Obstet 243:5, 1988.
70. **Varma TR**, **Patel RH**, **Bhathenia RK**, Outcome of pregnancy after infertility, Acta Obstet Gynecol Scand 67:115, 1988.
71. **Nordenskjold F**, **Ahlgren M**, Risk factors in ectopic pregnancy. Results of a population-based case-control study, Acta Obstet Gynecol Scand 70:575, 1991.
72. **Fernandez H**, **Coste J**, **Job-Spira N**, Controlled ovarian hyperstimulation as a risk factor for ectopic pregnancy, Obstet Gynecol 78:656, 1991.

73. **Marcus SF**, **Brinsden PR**, Analysis of the incidence and risk factors associated with ectopic pregnancy following in-vitro fertilization and embryo transfer, Hum Reprod 10:199, 1995.
74. **Braude P**, **Rowell P**, Assisted conception. III—problems with assisted conception, Br Med J 327:920, 2003.
75. **Steptoe PC**, **Edwards RG**, Reimplantation of a human embryo with subsequent tubal pregnancy, Lancet 1:880, 1976.
76. **Clayton HB**, **Schieve LA**, **Peterson HB**, **Jamieson DJ**, **Reynolds MA**, **Wright VC**, Ectopic pregnancy risk with assisted reproductive technology procedures, Obstet Gynecol 107:595, 2006.
77. **Xing W**, **Ou J**, **Cai L**, Thawed embryo transfer and ectopic pregnancy: a meta-analysis, Arch Gynecol Obstet 297(6):1345, 2018. doi:10.1007/s00404-018-4724-6.
78. **Knutzen V**, **Stratton CJ**, **Sher G**, **McNamee PI**, **Huang TT**, **Soto-Albors C**, Mock embryo transfer in early luteal phase, the cycle before in vitro fertilization and embryo transfer: a descriptive study, Fertil Steril 57:156, 1992.
79. **Nazari A**, **Askari HA**, **Check JH**, **O'Shaughnessy A**, Embryo transfer technique as a cause of ectopic pregnancy in in vitro fertilization, Fertil Steril 60:919, 1993.
80. **Lesny P**, **Killick SR**, **Robinson J**, **Maguiness SD**, Transcervical embryo transfer as a risk factor for ectopic pregnancy, Fertil Steril 72:305, 1999.
81. **Reece EA**, **Petrie RH**, **Sirmans MF**, **Finster M**, **Todd WD**, Combined intrauterine and extrauterine gestations: a review, Am J Obstet Gynecol 146:323, 1983.
82. **Lemus JF**, Ectopic pregnancy: an update, Curr Opin Obstet Gynecol 12:369, 2000.
83. **Maymon R**, **Shulman A**, Controversies and problems in the current management of tubal pregnancy, Hum Reprod Update 2:541, 1996.
84. **Zhang B**, **Cui L**, **Tang R**, **Ding L**, **Yan L**, **Chen ZJ**, Reduced ectopic pregnancy rate on day 5 embryo transfer compared with day 3: a meta-analysis, PLoS One 12(1):e0169837, 2017. doi:10.1371/journal.pone.0169837.
85. **Centers for Disease Control and Prevention**, 2007 Assisted Reproductive Technology Success Rates. National Summary and Fertility Clinic Reports, Author, Atlanta, GA, 2009.
86. **van Seeters JAH**, **Chua SJ**, **Mol BWJ**, **Koks CAM**, Tubal anastomosis after previous sterilization: a systematic review, Hum Reprod Update 23(3):358, 2017. doi:10.1093/humupd/dmx003.
87. **Saraiya M**, **Berg CJ**, **Kendrick JS**, **Strauss LT**, **Atrash HK**, **Ahn YW**, Cigarette smoking as a risk factor for ectopic pregnancy, Am J Obstet Gynecol 178:493, 1998.
88. **Knoll M**, **Talbot P**, Cigarette smoke inhibits oocyte cumulus complex pick-up by the oviduct in vitro independent of ciliary beat frequency, Reprod Toxicol 12:57, 1998.
89. **Riveles K**, **Iv M**, **Arey J**, **Talbot P**, Pyridines in cigarette smoke inhibit hamster oviductal functioning in picomolar doses, Reprod Toxicol 17:191, 2003.
90. **Bouyer J**, **Saurel-Cubizolles MJ**, **Grenier C**, **Aussel L**, **Job-Spira N**, Ectopic pregnancy and occupational exposure of hospital personnel, Scand J Work Environ Health 24:98, 1998.
91. **Pisarska MD**, **Carson SA**, **Buster JE**, Ectopic pregnancy, Lancet 351:1115, 1998.
92. **Chow WH**, **Daling JR**, **Weiss NS**, **Moore DE**, **Soderstrom R**, Vaginal douching as a potential risk factor for tubal ectopic pregnancy, Am J Obstet Gynecol 153:727, 1985.
93. **Wolner-Hanssen P**, **Eschenbach DA**, **Paavonen J**, **Stevens CE**, **Kiviat NB**, **Critchlow C**, **DeRouen T**, **Koutsky L**, **Holmes KK**, Association between vaginal douching and acute pelvic inflammatory disease, JAMA 263:1936, 1990.
94. **Daling JR**, **Weiss NS**, **Schwartz SM**, **Stergachis A**, **Wang SP**, **Foy H**, **Chu J**, **McKnight B**, **Grayston JT**, Vaginal douching and the risk of tubal pregnancy, Epidemiology 2:40, 1991.
95. **Phillips RS**, **Tuomala RE**, **Feldblum PJ**, **Schachter J**, **Rosenberg MJ**, **Aronson MD**, The effect of cigarette smoking, Chlamydia trachomatis infection, and vaginal douching on ectopic pregnancy, Obstet Gynecol 79:85, 1992.
96. **Kendrick JS**, **Atrash HK**, **Strauss LT**, **Gargiullo PM**, **Ahn YW**, Vaginal douching and the risk of ectopic pregnancy among black women, Am J Obstet Gynecol 176:991, 1997.
97. **Zhang J**, **Thomas AG**, **Leybovich E**, Vaginal douching and adverse health effects: a meta-analysis, Am J

Public Health 87:1207, 1997.
98. **Monif GR**, The great douching debate: to douche, or not to douche, Obstet Gynecol 94:630, 1999.
99. **Banerjee A**, **Prateek S**, **Malik S**, **Dhingra D**, Genital tuberculosis in adolescent girls from low socioeconomic status with acute ectopic pregnancy presenting at a tertiary care hospital in urban Northern India: are we missing an opportunity to treat? Arch Gynecol Obstet 286(6):1477, 2012. doi:10.1007/s00404-012-2487-z.
100. **de Silva PS**, **Hansen HH**, **Wehberg S**, **Friedman S**, **Nørgård BM**, Risk of ectopic pregnancy in women with inflammatory bowel disease: a 22-year nationwide cohort study, Clin Gastroenterol Hepatol 16(1):83.e1, 2018. doi:10.1016/j.cgh.2017.06.054.
101. **Bolaji II**, **Oktaba M**, **Mohee K**, **Sze KY**, An odyssey through salpingitis isthmica nodosa, Eur J Obstet Gynecol Reprod Biol 184:73, 2015. doi:10.1016/j.ejogrb.2014.11.014.
102. **Breen JL**, A 21 year survey of 654 ectopic pregnancies, Am J Obstet Gynecol 106:1004, 1970.
103. **Bouyer J**, **Coste J**, **Fernandez H**, **Pouly JL**, **Job-Spira N**, Sites of ectopic pregnancy: a 10 year population-based study of 1800 cases, Hum Reprod 17:3224, 2002.
104. **Attar E**, Endocrinology of ectopic pregnancy, Obstet Gynecol Clin North Am 31:779, 2004.
105. **Green LK**, **Kott ML**, Histopathologic findings in ectopic tubal pregnancy, Int J Gynecol Pathol 8:255, 1989.
106. **Stock RJ**, Tubal pregnancy. Associated histopathology, Obstet Gynecol Clin North Am 18:73, 1991.
107. **Kutluay L**, **Vicdan K**, **Turan C**, **Batioglu S**, **Oguz S**, **Gokmen O**, Tubal histopathology in ectopic pregnancies, Eur J Obstet Gynecol Reprod Biol 57:91, 1994.
108. **Lopez HB**, **Micheelsen U**, **Berendtsen H**, **Kock K**, Ectopic pregnancy and its associated endometrial changes, Gynecol Obstet Invest 38:104, 1994.
109. **Senterman M**, **Jibodh R**, **Tulandi T**, Histopathologic study of ampullary and isthmic tubal ectopic pregnancy, Am J Obstet Gynecol 159:939, 1988.
110. **Budowick M**, **Johnson TR Jr**, **Genadry R**, **Parmley TH**, **Woodruff JD**, The histopathology of the developing tubal ectopic pregnancy, Fertil Steril 34:169, 1980.
111. **Dietl J**, **Buchholz F**, **Kindler PA**, Histopathology of tubal pregnancy, Int J Gynaecol Obstet 27:385, 1988.
112. **Cohen MA**, **Sauer MV**, Expectant management of ectopic pregnancy, Clin Obstet Gynecol 42:48, 1999.
113. **Coste J**, **Fernandez H**, **Joye N**, **Benifla J**, **Girard S**, **Marpeau L**, **Job-Spira N**, Role of chromosome abnormalities in ectopic pregnancy, Fertil Steril 74:1259, 2000.
114. **Burgoyne PS**, **Holland K**, **Stephens R**, Incidence of numerical chromosome anomalies in human pregnancy estimation from induced and spontaneous abortion data, Hum Reprod 6:555, 1991.
115. **Goddijn M**, **van der Veen F**, **Schuring-Blom GH**, **Ankum WM**, **Leschot NJ**, Cytogenetic characteristics of ectopic pregnancy, Hum Reprod 11:2769, 1996.
116. **Alsuleiman SA**, **Grimes EM**, Ectopic pregnancy: a review of 147 cases, J Reprod Med 27:101, 1982.
117. **Dart RG**, **Kaplan B**, **Varaklis K**, Predictive value of history and physical examination in patients with suspected ectopic pregnancy, Ann Emerg Med 33:283, 1999.
118. **Buckley RG**, **King KJ**, **Disney JD**, **Gorman JD**, **Klausen JH**, History and physical examination to estimate the risk of ectopic pregnancy: validation of a clinical prediction model, Ann Emerg Med 34:589, 1999.
119. **Taylor RN**, **Padula C**, **Goldsmith PC**, Pitfall in the diagnosis of ectopic pregnancy: immunocytochemical evaluation in a patient with false-negative serum beta-hCG levels, Obstet Gynecol 71:1035, 1988.
120. **Hochner-Celnikier D**, **Ron M**, **Goshen R**, **Azcut D**, **Amir G**, **Yagel S**, Rupture of ectopic pregnancy following disappearance of serum beta subunit of HCG, Obstet Gynecol 79:826, 1992.
121. **Maccato ML**, **Estrada R**, **Faro S**, Ectopic pregnancy with undetectable serum and urine beta-hCG levels and detection of beta-hCG in the ectopic trophoblast by immunocytochemical evaluation, Obstet Gynecol 81:878, 1993.
122. **Rotmensch S**, **Cole LA**, False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations, Lancet 355:712, 2000.
123. **Butler SA**, **Cole LA**, Use of heterophilic antibody blocking agent (HBT) in reducing false-positive hCG results, Clin Chem 47:1332, 2001.
124. **American College of Obstetricians and Gynecologists**, Avoiding inappropriate clinical decisions based on

false-positive human chorionic gonadotropin test results, Int J Gynaecol Obstet 80:231, 2003.
125. **Esfandiari N**, **Goldberg JM**, Heterophile antibody blocking agent to confirm false positive serum human chorionic gonadotropin assay, Obstet Gynecol 101:1144, 2003.
126. **Kadar N**, **Caldwell BV**, **Romero R**, A method of screening for ectopic pregnancy and its indications, Obstet Gynecol 58:162, 1981.
127. **Kadar N**, **Romero R**, Observations on the log human chorionic gonadotropin-time relationship in early pregnancy and its practical implications, Am J Obstet Gynecol 157:73, 1987.
128. **Fritz MA**, **Guo S**, Doubling time of human chorionic gonadotropin (hCG) in early normal pregnancy: relationship to hCG concentration and gestational age, Fertil Steril 47:584, 1987.
129. **Kadar N**, **Freedman M**, **Zacher M**, Further observations on the doubling time of human chorionic gonadotropin in early asymptomatic pregnancies, Fertil Steril 54:783, 1990.
130. **Pittaway DE**, **Reish RL**, **Wentz AC**, Doubling times of human chorionic gonadotropin increase in early viable intrauterine pregnancies, Am J Obstet Gynecol 152:299, 1985.
131. **Barnhart KT**, **Sammel MD**, **Rinaudo PF**, **Zhou L**, **Hummel AC**, **Guo W**, Symptomatic patients with an early viable intrauterine pregnancy: HCG curves redefined, Obstet Gynecol 104:50, 2004.
132. **Barnhart KT**, **Guo W**, **Cary MS**, **Morse CB**, **Chung K**, **Takacs P**, **Senapati S**, **Sammel MD**, Differences in serum human chorionic gonadotropin rise in early pregnancy by race and value at presentation, Obstet Gynecol 128(3):504, 2016.
133. **Silva C**, **Sammel MD**, **Zhou L**, **Gracia C**, **Hummel AC**, **Barnhart K**, Human chorionic gonadotropin profile for women with ectopic pregnancy, Obstet Gynecol 107:605, 2006.
134. **Barnhart K**, **Sammel MD**, **Chung K**, **Zhou L**, **Hummel AC**, **Guo W**, Decline of serum human chorionic gonadotropin and spontaneous complete abortion: defining the normal curve, Obstet Gynecol 104:975, 2004.
135. **Shepherd RW**, **Patton PE**, **Novy MJ**, **Burry KA**, Serial beta-hCG measurements in the early detection of ectopic pregnancy, Obstet Gynecol 75:417, 1990.
136. **Letterie GS**, **Hibbert M**, Serial serum human chorionic gonadotropin (hCG) levels in ectopic pregnancy and first trimester miscarriage, Arch Gynecol Obstet 263:168, 2000.
137. **Doubilet PM**, **Benson CB**, **Bourne T**, **Blaivas M**; **Society of Radiologists in Ultrasound Multispecialty Panel on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy**; **Barnhart KT**, **Benacerraf BR**, **Brown DL**, **Filly RA**, **Fox JC**, **Goldstein SR**, **Kendall JL**, **Lyons EA**, **Porter MB**, **Pretorius DH**, **Timor-Tritsch IE**, Diagnostic criteria for nonviable pregnancy early in the first trimester, N Engl J Med 369(15):1443, 2013. doi:10.1056/NEJMra1302417.
138. **Mol BW**, **van der Veen F**, **Hajenius PJ**, **Engelsbel S**, **Ankum WM**, **Hogerzeil HV**, **Hemrika DJ**, **Bossuyt PM**, Diagnosis of ectopic pregnancy after in vitro fertilization and embryo transfer, Fertil Steril 68:1027, 1997.
139. **Chung K**, **Sammel MD**, **Coutifaris C**, **Chalian R**, **Lin K**, **Castelbaum AJ**, **Freedman MF**, **Barnhart KT**, Defining the rise of serum HCG in viable pregnancies achieved through use of IVF, Hum Reprod 21:823, 2006.
140. **Dickey RP**, **Taylor SN**, **Lu PY**, **Sartor BM**, **Storment JM**, **Rye PH**, **Pelletier WD**, **Zender JL**, **Matulich EM**, Spontaneous reduction of multiple pregnancy: incidence and effect on outcome, Am J Obstet Gynecol 186:77, 2002.
141. **Goldstein SR**, **Wolfson R**, Endovaginal ultrasonographic measurement of early embryonic size as a means of assessing gestational age, J Ultrasound Med 13:27, 1994.
142. **Bradley WG**, **Fiske CE**, **Filly RA**, The double sac sign of early intrauterine pregnancy: use in exclusion of ectopic pregnancy, Radiology 143:223, 1982.
143. **Rossavik IK**, **Torjusen GO**, **Gibbons WE**, Conceptual age and ultrasound measurements of gestational sac and crown-rump length in in vitro fertilization pregnancies, Fertil Steril 49:1012, 1988.
144. **Hadlock FP**, **Shah YP**, **Kanon DJ**, **Lindsey JV**, Fetal crown-rump length: reevaluation of relation to menstrual age (5–18 weeks) with high-resolution real-time US, Radiology 182:501, 1992.
145. **Goldstein SR**, Significance of cardiac activity on endovaginal ultrasound in very early embryos, Obstet Gynecol 80:670, 1992.
146. **Levi CS**, **Lyons EA**, **Zheng XH**, **Lindsay DJ**, **Holt SC**, Endovaginal US: demonstration of cardiac activity in

embryos of less than 5.0 mm in crown-rump length, Radiology 176:71, 1990.
147. **Brown DL**, **Emerson DS**, **Felker RE**, **Cartier MS**, **Smith WC**, Diagnosis of early embryonic demise by endovaginal sonography, J Ultrasound Med 9:631, 1990.
148. **Condous G**, **Okaro E**, **Khalid A**, **Lu C**, **Van Huffel S**, **Timmerman D**, **Bourne T**, The accuracy of transvaginal ultrasonography for the diagnosis of ectopic pregnancy prior to surgery, Hum Reprod 20:1404, 2005.
149. **Kirk E**, **Papageorghiou AT**, **Condous G**, **Tan L**, **Bora S**, **Bourne T**, The diagnostic effectiveness of an initial transvaginal scan in detecting ectopic pregnancy, Hum Reprod 22:2824, 2007.
150. **Brown DL**, **Doubilet PM**, Transvaginal sonography for diagnosing ectopic pregnancy: positivity criteria and performance characteristics, J Ultrasound Med 13:259, 1994.
151. **Shapiro BS**, **Escobar M**, **Makuch R**, **Lavy G**, **DeCherney AH**, A model-based prediction for transvaginal ultrasonographic identification of early intrauterine pregnancy, Am J Obstet Gynecol 166:1495, 1992.
152. **Rowling SE**, **Langer JE**, **Coleman BG**, **Nisenbaum HL**, **Horii SC**, **Arger PH**, Sonography during early pregnancy: dependence of threshold and discriminatory values on transvaginal transducer frequency, Am J Roentgenol 172:983, 1999.
153. **Barnhart K**, **Mennuti MT**, **Benjamin I**, **Jacobson S**, **Goodman D**, **Coutifaris C**, Prompt diagnosis of ectopic pregnancy in an emergency department setting, Obstet Gynecol 84:1010, 1994.
154. **Shalev E**, **Yarom I**, **Bustan M**, **Weiner E**, **Ben-Shlomo I**, Transvaginal sonography as the ultimate diagnostic tool for the management of ectopic pregnancy: experience with 840 cases, Fertil Steril 69:62, 1998.
155. **Condous G**, **Lu C**, **Van Huffel SV**, **Timmerman D**, **Bourne T**, Human chorionic gonadotrophin and progesterone levels in pregnancies of unknown location, Int J Gynaecol Obstet 86:351, 2004.
156. **Kadar N**, **Bohrer M**, **Kemmann E**, **Shelden R**, The discriminatory human chorionic gonadotropin zone for endovaginal sonography: a prospective, randomized study, Fertil Steril 61:1016, 1994.
157. **Mol BW**, **Hajenius PJ**, **Engelsbel S**, **Ankum WM**, **van der Veen F**, **Hemrika DJ**, **Bossuyt PM**, Are gestational age and endometrial thickness alternatives for serum human chorionic gonadotropin as criteria for the diagnosis of ectopic pregnancy?, Fertil Steril 72:643, 1999.
158. **Fleischer AC**, **Pennell RG**, **McKee MS**, **Worrell JA**, **Keefe B**, **Herbert CM**, **Hill GA**, **Cartwright PS**, **Kepple DM**, Ectopic pregnancy: features at transvaginal sonography, Radiology 174:375, 1990.
159. **Sadek AL**, **Schiotz HA**, Transvaginal sonography in the management of ectopic pregnancy, Acta Obstet Gynecol Scand 74:293, 1995.
160. **Gamzu R**, **Almog B**, **Levin Y**, **Pauzner D**, **Lessing JB**, **Jaffa A**, **Bar-Am A**, The ultrasonographic appearance of tubal pregnancy in patients treated with methotrexate, Hum Reprod 17:2585, 2002.
161. **Gabrielli S**, **Romero R**, **Pilu G**, **Pavani A**, **Capelli M**, **Milano V**, **Bevini M**, **Bovicelli L**, Accuracy of transvaginal ultrasound and serum hCG in the diagnosis of ectopic pregnancy, Ultrasound Obstet Gynecol 2:110, 1992.
162. **Mol BW**, **Hajenius PJ**, **Engelsbel S**, **Ankum WM**, **Van der Veen F**, **Hemrika DJ**, **Bossuyt PM**, Serum human chorionic gonadotropin measurement in the diagnosis of ectopic pregnancy when transvaginal sonography is inconclusive, Fertil Steril 70:972, 1998.
163. **Spandorfer SD**, **Barnhart KT**, Endometrial stripe thickness as a predictor of ectopic pregnancy, Fertil Steril 66:474, 1996.
164. **Mehta TS**, **Levine D**, **McArdle CR**, Lack of sensitivity of endometrial thickness in predicting the presence of an ectopic pregnancy, J Ultrasound Med 18:117, 1999.
165. **Seeber B**, **Sammel M**, **Zhou L**, **Hummel A**, **Barnhart KT**, Endometrial stripe thickness and pregnancy outcome in first-trimester pregnancies with bleeding, pain or both, J Reprod Med 52:757, 2007.
166. **Gracia CR**, **Barnhart KT**, Diagnosing ectopic pregnancy: decision analysis comparing six strategies, Obstet Gynecol 97:464, 2001.
167. **Banerjee S**, **Aslam N**, **Zosmer N**, **Woelfer B**, **Jurkovic D**, The expectant management of women with early pregnancy of unknown location, Ultrasound Obstet Gynecol 14:231, 1999.
168. **Frates MC**, **Doubilet PM**, **Peters HE**, **Benson CB**, Adnexal sonographic findings in ectopic pregnancy and their correlation with tubal rupture and human chorionic gonadotropin levels, J Ultrasound Med 33(4):697, 2014.

doi:10.7863/ultra.33.4.697.
169. **Chambers S**, **Muir B**, **Haddad N**, Ultrasound evaluation of ectopic pregnancy including correlation with human chorionic gonadotropin levels, Br J Radiol 63:246, 1990.
170. **Emerson DS**, **Cartier MS**, **Altier LA**, **Felker RE**, **Smith WC**, **Stovall TG**, **Gray LA**, Diagnostic efficacy of endovaginal color Doppler flow imaging in an ectopic pregnancy screening program, Radiology 183:413, 1992.
171. **Pellerito JS**, **Taylor KJ**, **Quedens-Case C**, **Hammers LW**, **Scoutt LM**, **Ramos IM**, **Meyer WR**, Ectopic pregnancy: evaluation with endovaginal color flow imaging, Radiology 183:407, 1992.
172. **Kirchler HC**, **Seebacher S**, **Alge AA**, **Muller-Holzner E**, **Fessler S**, **Kolle D**, Early diagnosis of tubal pregnancy: changes in tubal blood flow evaluated by endovaginal color Doppler sonography, Obstet Gynecol 82:561, 1993.
173. **Atri M**, Ectopic pregnancy versus corpus luteum cyst revisited: best Doppler predictors, J Ultrasound Med 22:1181, 2003.
174. **Pellerito JS**, **Troiano RN**, **Quedens-Case C**, **Taylor KJ**, Common pitfalls of endovaginal color Doppler flow imaging, Radiographics 15:37, 1995.
175. **Kadar N**, **DeVore G**, **Romero R**, Discriminatory hCG zone: its use in the sonographic evaluation for ectopic pregnancy, Obstet Gynecol 58:156, 1981.
176. **Nyberg DA**, **Mack LA**, **Laing FC**, **Jeffrey RB**, Early pregnancy complications: endovaginal sonographic findings correlated with human chorionic gonadotropin levels, Radiology 167:619, 1988.
177. **Cacciatore B**, **Stenman UH**, **Ylostalo P**, Diagnosis of ectopic pregnancy by vaginal ultrasonography in combination with a discriminatory serum hCG level of 1000 IU/l (IRP), Br J Obstet Gynaecol 97:904, 1990.
178. **Paul M**, **Schaff E**, **Nichols M**, The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice, Am J Obstet Gynecol 183:S34, 2000.
179. **Seeber BE**, **Sammel MD**, **Guo W**, **Zhou L**, **Hummel A**, **Barnhart KT**, Application of redefined human chorionic gonadotropin curves for the diagnosis of women at risk for ectopic pregnancy, Fertil Steril 86:454, 2006.
180. **Chapa JB**, **Hibbard JU**, **Weber EM**, **Abramowicz JS**, **Verp MS**, Prenatal diagnosis of methotrexate embryopathy, Obstet Gynecol 101:1104, 2003.
181. **Goffman D**, **Cole DS**, **Bobby P**, **Garry DJ**, Failed methotrexate termination of pregnancy: a case report, J Perinatol 26:645, 2006.
182. **Seidahmed MZ**, **Shaheed MM**, **Abdulbasit OB**, **Al Dohami H**, **Babiker M**, **Abdullah MA**, **Abomelha AM**, A case of methotrexate embryopathy with holoprosencephaly, expanding the phenotype, Birth Defects Res A Clin Mol Teratol 76:138, 2006.
183. **Adam MP**, **Manning MA**, **Beck AE**, **Kwan A**, **Enns GM**, **Clericuzio C**, **Hoyme HE**, Methotrexate/misoprostol embryopathy: report of four cases resulting from failed medical abortion, Am J Med Genet A 123A:72, 2003.
184. **Addar MH**, Methotrexate embryopathy in a surviving intrauterine fetus after presumed diagnosis of ectopic pregnancy: case report, J Obstet Gynaecol Can 26:1001, 2004.
185. **Usta IM**, **Nassar AH**, **Yunis KA**, **Abu-Musa AA**, Methotrexate embryopathy after therapy for misdiagnosed ectopic pregnancy, Int J Gynaecol Obstet 99:253, 2007.
186. **Mol BW**, **van Der Veen F**, **Bossuyt PM**, Implementation of probabilistic decision rules improves the predictive values of algorithms in the diagnostic management of ectopic pregnancy, Hum Reprod 14:2855, 1999.
187. **Hajenius PJ**, **Mol BW**, **Ankum WM**, **van der Veen F**, **Bossuyt PM**, **Lammes FB**, Suspected ectopic pregnancy: expectant management in patients with negative sonographic findings and low serum hCG concentrations, Early Pregnancy 1:258, 1995.
188. **Ankum WM**, **van der Veen F**, **Hamerlynck JV**, **Lammes FB**, Suspected ectopic pregnancy. What to do when human chorionic gonadotropin levels are below the discriminatory zone, J Reprod Med 40:525, 1995.
189. **Kadar N**, **Romero R**, Further observations on serial human chorionic gonadotropin patterns in ectopic pregnancies and spontaneous abortions, Fertil Steril 50:367, 1988.

190. **Barnhart KT**, **Katz I**, **Hummel A**, **Gracia CR**, Presumed diagnosis of ectopic pregnancy, Obstet Gynecol 100:505, 2002.
191. **Cacciatore B**, **Ylostalo P**, **Stenman UH**, **Widholm O**, Suspected ectopic pregnancy: ultrasound findings and hCG levels assessed by an immunofluorometric assay, Br J Obstet Gynaecol 95:497, 1988.
192. **Hahlin M**, **Thorburn J**, **Bryman I**, The expectant management of early pregnancies of uncertain site, Hum Reprod 10:1223, 1995.
193. **Condous G**, **Kirk E**, **Lu C**, **Van Calster B**, **Van Huffel S**, **Timmerman D**, **Bourne T**, There is no role for uterine curettage in the contemporary diagnostic workup of women with a pregnancy of unknown location, Hum Reprod 21:2706, 2006.
194. **Banerjee S**, **Aslam N**, **Woelfer B**, **Lawrence A**, **Elson J**, **Jurkovic D**, Expectant management of early pregnancies of unknown location: a prospective evaluation of methods to predict spontaneous resolution of pregnancy, Br J Obstet Gynaecol 108:158, 2001.
195. **Mol BW**, **Van der Veen F**, Results of expectant management of women early pregnancy and unknown location, Ultrasound Obstet Gynecol 15:265; author reply 266, 2000.
196. **Hubinont CJ**, **Thomas C**, **Schwers JF**, Luteal function in ectopic pregnancy, Am J Obstet Gynecol 156:669, 1987.
197. **Wang L**, **Warnes GM**, **Kirby CA**, **Matthews CD**, **Norman RJ**, Luteal function associated with single, multiple and ectopic embryo implantation in natural cycles or after ovarian hyperstimulation for in-vitro fertilization/gamete intra-fallopian transfer, Hum Reprod 5: 476, 1990.
198. **Mantzavinos T**, **Phocas I**, **Chrelias H**, **Sarandakou A**, **Zourlas PA**, Serum levels of steroid and placental protein hormones in ectopic pregnancy, Eur J Obstet Gynecol Reprod Biol 39:117, 1991.
199. **Lower AM**, **Yovich JL**, **Hancock C**, **Grudzinskas JG**, Is luteal function maintained by factors other than chorionic gonadotrophin in early pregnancy?, Hum Reprod 8:645, 1993.
200. **Sauer MV**, **Anderson RE**, **Vermesh M**, **Stone BA**, **Paulson RJ**, Spontaneously resorbing ectopic pregnancy: preservation of human chorionic gonadotropin bioactivity despite declining steroid hormone levels, Am J Obstet Gynecol 161:1673, 1989.
201. **Kratzer PG**, **Taylor RN**, Corpus luteum function in early pregnancies is primarily determined by the rate of change of human chorionic gonadotropin levels, Am J Obstet Gynecol 163:1497, 1990.
202. **Klein M**, **Graf AH**, **Hutter W**, **Hacker GW**, **Beck A**, **Staudach A**, **Kiss H**, **Egarter C**, **Husslein P**, Proliferative activity in ectopic trophoblastic tissue, Hum Reprod 10:2441, 1995.
203. **Kiss H**, **Klein M**, **Egarter C**, **Graf AH**, **Hacker G**, **Hutter W**, **Czerwenka K**, **Husslein P**, Proliferative cell activity in correlation to human chorionic gonadotrophin release of trophoblast tissue of tubal pregnancy, Hum Reprod 12:383, 1997.
204. **Johnson MR**, **Riddle AF**, **Irvine R**, **Sharma V**, **Collins WP**, **Nicolaides KH**, **Grudzinskas JG**, Corpus luteum failure in ectopic pregnancy, Hum Reprod 8:1491, 1993.
205. **Alam V**, **Altieri E**, **Zegers-Hochschild F**, Preliminary results on the role of embryonic human chorionic gonadotrophin in corpus luteum rescue during early pregnancy and the relationship to abortion and ectopic pregnancy, Hum Reprod 14:2375, 1999.
206. **Stovall TG**, **Ling FW**, **Cope BJ**, **Buster JE**, Preventing ruptured ectopic pregnancy with a single serum progesterone, Am J Obstet Gynecol 160:1425, 1989.
207. **Mol BW**, **Lijmer JG**, **Ankum WM**, **van der Veen F**, **Bossuyt PM**, The accuracy of single serum progesterone measurement in the diagnosis of ectopic pregnancy: a meta-analysis, Hum Reprod 13:3220, 1998.
208. **Buckley RG**, **King KJ**, **Disney JD**, **Riffenburgh RH**, **Gorman JD**, **Klausen JH**, Serum progesterone testing to predict ectopic pregnancy in symptomatic first-trimester patients, Ann Emerg Med 36:95, 2000.
209. **Grosskinsky CM**, **Hage ML**, **Tyrey L**, **Christakos AC**, **Hughes CL**, hCG, progesterone, alpha-fetoprotein, and estradiol in the identification of ectopic pregnancy, Obstet Gynecol 81:705, 1993.
210. **Dart R**, **Dart L**, **Segal M**, **Page C**, **Brancato J**, The ability of a single serum progesterone value to identify abnormal pregnancies in patients with beta-human chorionic gonadotropin values less than 1,000 mIU/mL, Acad Emerg Med 5:304, 1998.
211. **Gelder MS**, **Boots LR**, **Younger JB**, Use of a single random serum progesterone value as a diagnostic aid

for ectopic pregnancy, Fertil Steril 55:497, 1991.
212. **McCord ML**, **Muram D**, **Buster JE**, **Arheart KL**, **Stovall TG**, **Carson SA**, Single serum progesterone as a screen for ectopic pregnancy: exchanging specificity and sensitivity to obtain optimal test performance, Fertil Steril 66:513, 1996.
213. **Perkins SL**, **Al-Ramahi M**, **Claman P**, Comparison of serum progesterone as an indicator of pregnancy nonviability in spontaneously pregnant emergency room and infertility clinic patient populations, Fertil Steril 73:499, 2000.
214. **Stovall TG**, **Ling FW**, **Carson SA**, **Buster JE**, Serum progesterone and uterine curettage in differential diagnosis of ectopic pregnancy, Fertil Steril 57:456, 1992.
215. **Lindahl B**, **Ahlgren M**, Identification of chorion villi in abortion specimens, Obstet Gynecol 67:79, 1986.
216. **Lipscomb GH**, **Stovall TG**, **Ling FW**, Nonsurgical treatment of ectopic pregnancy, N Engl J Med 343:1325, 2000.
217. **Ries A**, **Singson P**, **Bidus M**, **Barnes JG**, Use of the endometrial pipelle in the diagnosis of early abnormal gestations, Fertil Steril 74:593, 2000.
218. **Barnhart KT**, **Gracia CR**, **Reindl B**, **Wheeler JE**, Usefulness of pipelle endometrial biopsy in the diagnosis of women at risk for ectopic pregnancy, Am J Obstet Gynecol 188:906, 2003.
219. **Spandorfer SD**, **Menzin AW**, **Barnhart KT**, **LiVolsi VA**, **Pfeifer SM**, Efficacy of frozen-section evaluation of uterine curettings in the diagnosis of ectopic pregnancy, Am J Obstet Gynecol 175:603, 1996.
220. **Heller DS**, **Hessami S**, **Cracchiolo B**, **Skurnick JH**, Reliability of frozen section of uterine curettings in evaluation of possible ectopic pregnancy, J Am Assoc Gynecol Laparosc 7:519, 2000.
221. **Yonke N**, **Leeman LM**, First-trimester surgical abortion technique, Obstet Gynecol Clin North Am 40(4):647, 2013. doi:10.1016/j.ogc.2013.08.006.
222. Safe Abortion: Technical and Policy Guidance for Health Systems, World Health Organization, Geneva, 2012.
223. **Insogna IG**, **Farland LV**, **Missmer SA**, **Ginsburg ES**, **Brady PC**, Outpatient endometrial aspiration: an alternative to methotrexate for pregnancy of unknown location, Am J Obstet Gynecol 217(2):185.e1, 2017. doi:10.1016/j.ajog.2017.04.023.
224. ACOG Practice Bulletin No. 193: tubal ectopic pregnancy, Obstet Gynecol 131(3):e91, 2018.
225. **Gruber K**, **Gelven PL**, **Austin RM**, Chorionic villi or trophoblastic tissue in uterine samples of four women with ectopic pregnancies, Int J Gynecol Pathol 16:28, 1997.
226. **Condous G**, **Timmerman D**, **Goldstein S**, **Valentin L**, **Jurkovic D**, **Bourne T**, Pregnancies of unknown location: consensus statement, Ultrasound Obstet Gynecol 28:121, 2006.
227. **Ailawadi M**, **Lorch SA**, **Barnhart KT**, Cost-effectiveness of presumptively medically treating women at risk for ectopic pregnancy compared with first performing a dilatation and curettage, Fertil Steril 83:376, 2005.
228. **Cacciatore B**, **Stenman UH**, **Ylostalo P**, Early screening for ectopic pregnancy in high-risk symptom-free women, Lancet 343:517, 1994.
229. **Mol BW**, **Hajenius PJ**, **Ankum WM**, **Bossuyt PM**, **van der Veen F**, Screening for ectopic pregnancy in symptom-free women at increased risk, Obstet Gynecol 89:704, 1997.
230. **Mol BW**, **van der Veen F**, **Bossuyt PM**, Symptom-free women at increased risk of ectopic pregnancy: should we screen?, Acta Obstet Gynecol Scand 81:661, 2002.
231. **Nielsen S**, **Hahlin M**, Expectant management of first-trimester spontaneous abortion, Lancet 345:84, 1995.
232. **Chipchase J**, **James D**, Randomised trial of expectant versus surgical management of spontaneous miscarriage, Br J Obstet Gynaecol 104:840, 1997.
233. **Blohm F**, **Friden B**, **Platz-Christensen JJ**, **Milsom I**, **Nielsen S**, Expectant management of first-trimester miscarriage in clinical practice, Acta Obstet Gynecol Scand 82:654, 2003.
234. **Garcia AJ**, **Aubert JM**, **Sama J**, **Josimovich JB**, Expectant management of presumed ectopic pregnancies, Fertil Steril 48:395, 1987.
235. **Ylostalo P**, **Cacciatore B**, **Sjoberg J**, **Kaariainen M**, **Tenhunen A**, **Stenman U-H**, Expectant management of ectopic pregnancy, Obstet Gynecol 80:345, 1992.
236. **Shalev E**, **Peleg D**, **Tsabari A**, **Romano S**, **Bustan M**, Spontaneous resolution of ectopic tubal pregnancy: natural history, Fertil Steril 63:15, 1995.

237. **Trio D**, **Strobelt N**, **Picciolo C**, **Lapinski R**, **Ghidioni A**, Prognostic factors for successful expectant management of ectopic pregnancy, Fertil Steril 63:469, 1995.
238. **Korhonen J**, **Stenman UH**, **Ylostalo P**, Low-dose oral methotrexate with expectant management of ectopic pregnancy, Obstet Gynecol 88:775, 1996.
239. **Jurkovic D**, **Memtsa M**, **Sawyer E**, **Donaldson AN**, **Jamil A**, **Schramm K**, **Sana Y**, **Otify M**, **Farahani L**, **Nunes N**, **Ambler G**, **Ross JA**, Single-dose systemic methotrexate vs expectant management for treatment of tubal ectopic pregnancy: a placebo-controlled randomized trial, Ultrasound Obstet Gynecol 49(2):171, 2017. doi:10.1002/uog.17329.
240. **Tulandi T**, **Hemmings R**, **Khalifa F**, Rupture of ectopic pregnancy in women with low and declining serum beta-human chorionic gonadotropin concentrations, Fertil Steril 56:786, 1991.
241. **Rantala M**, **Mäkinen J**, Tubal patency and fertility outcome after expectant management of ectopic pregnancy, Fertil Steril 68:1043, 1997.
242. **Kenigsberg D**, **Porte J**, **Hull M**, **Spitz IM**, Medical treatment of residual ectopic pregnancy: RU 486 and methotrexate, Fertil Steril 47:702, 1987.
243. **Altaras M**, **Cohen I**, **Cordoba M**, **Ben-Nun I**, **Ben-Aderet N**, Treatment of an interstitial pregnancy with actinomycin D. Case report, Br J Obstet Gynaecol 95:1321, 1988.
244. **Aboulghar MA**, **Mansour RT**, **Serour GI**, Transvaginal injection of potassium chloride and methotrexate for the treatment of tubal pregnancy with a live fetus, Hum Reprod 5:887, 1990.
245. **Lang PF**, **Weiss PA**, **Mayer HO**, **Haas JG**, **Honigl W**, Conservative treatment of ectopic pregnancy with local injection of hyperosmolar glucose solution or prostaglandin-F2 alpha: a prospective randomised study, Lancet 336:78, 1990.
246. **Lindblom B**, **Hahlin M**, **Lundorff P**, **Thorburn J**, Treatment of tubal pregnancy by laparoscope-guided injection of prostaglandin F2 alpha, Fertil Steril 54:404, 1990.
247. **Gazvani MR**, **Emery SJ**, Mifepristone and methotrexate: the combination for medical treatment of ectopic pregnancy, Am J Obstet Gynecol 180:1599, 1999.
248. **Stovall TG**, **Ling FW**, Single-dose methotrexate: an expanded clinical trial, Am J Obstet Gynecol 168:1759, 1993.
249. **Alexander JM**, **Rouse DJ**, **Varner E**, **Austin JM Jr**, Treatment of the small unruptured ectopic pregnancy: a cost analysis of methotrexate versus laparoscopy, Obstet Gynecol 88:123, 1996.
250. **Barnhart K**, **Esposito M**, **Coutifaris C**, An update on the medical treatment of ectopic pregnancy, Obstet Gynecol Clin North Am 27:653, 2000.
251. **Creinin MD**, **Krohn MA**, Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion, Am J Obstet Gynecol 177:1444, 1997.
252. **Bleyer WA**, The clinical pharmacology of methotrexate: new applications of an old drug, Cancer 41:36, 1978.
253. **Kooi S**, **Kock HC**, A review of the literature on nonsurgical treatment in tubal pregnancies, Obstet Gynecol Surv 47:739, 1992.
254. **Glock JL**, **Johnson JV**, **Brumsted JR**, Efficacy and safety of single-dose systemic methotrexate in the treatment of ectopic pregnancy, Fertil Steril 62:716, 1994.
255. **Corsan GH**, **Karacan M**, **Qasim S**, **Bohrer MK**, **Ransom MX**, **Kemmann E**, Identification of hormonal parameters for successful systemic single-dose methotrexate therapy in ectopic pregnancy, Hum Reprod 10:2719, 1995.
256. **Ransom MX**, **Garcia AJ**, **Bohrer M**, **Corsan GH**, **Kemmann E**, Serum progesterone as a predictor of methotrexate success in the treatment of ectopic pregnancy, Obstet Gynecol 83:1033, 1994.
257. **Stika CS**, **Anderson L**, **Frederiksen MC**, Single-dose methotrexate for the treatment of ectopic pregnancy: Northwestern Memorial Hospital three-year experience, Am J Obstet Gynecol 174:1840, 1996.
258. **Lipscomb GH**, **McCord ML**, **Stovall TG**, **Huff G**, **Portera SG**, **Ling FW**, Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies, N Engl J Med 341:1974, 1999.
259. **Ory SJ**, **Villanueva AL**, **Sand PK**, **Tamura RK**, Conservative treatment of ectopic pregnancy with methotrexate, Am J Obstet Gynecol 154:1299, 1986.
260. **American College of Obstetricians and Gynecologists**, ACOG practice bulletin. Medical management of

tubal pregnancy. Number 3, December 1998. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists, Int J Gynaecol Obstet 65:97, 1999.
261. **Stovall TG**, **Ling FW**, **Gray LA**, Single-dose methotrexate for treatment of ectopic pregnancy, Obstet Gynecol 77:754, 1991.
262. **Buster JE**, **Pisarska MD**, Medical management of ectopic pregnancy, Clin Obstet Gynecol 42:23, 1999.
263. **Shalev E**, **Peleg D**, **Bustan M**, **Romano S**, **Tsabari A**, Limited role for intratubal methotrexate treatment of ectopic pregnancy, Fertil Steril 63:20, 1995.
264. **Lipscomb GH**, **Bran D**, **McCord ML**, **Portera JC**, **Ling FW**, Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate, Am J Obstet Gynecol 178:1354, 1998.
265. **Fernandez H**, **Pauthier S**, **Doumerc S**, **Lelaidier C**, **Olivennes F**, **Ville Y**, **Frydman R**, Ultrasound-guided injection of methotrexate versus laparoscopic salpingotomy in ectopic pregnancy, Fertil Steril 63:25, 1995.
266. **Barnhart KT**, **Gosman G**, **Ashby R**, **Sammel M**, The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens, Obstet Gynecol 101:778, 2003.
267. **Romero R**, **Copel JA**, **Kadar N**, **Jeanty P**, **Decherney A**, **Hobbins JC**, Value of culdocentesis in the diagnosis of ectopic pregnancy, Obstet Gynecol 65:519, 1985.
268. **Vermesh M**, **Graczykowski JW**, **Sauer MV**, Reevaluation of the role of culdocentesis in the management of ectopic pregnancy, Am J Obstet Gynecol 162:411, 1990.
269. **Menon S**, **Colins J**, **Barnhart KT**, Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review, Fertil Steril 87:481, 2007.
270. **American Society for Reproductive Medicine**, Medical treatment of ectopic pregnancy, Fertil Steril 90:S206, 2008.
271. **Sauer MV**, **Gorrill MJ**, **Rodi IA**, **Yeko TR**, **Greenberg LH**, **Bustillo M**, **Gunning JE**, **Buster JE**, Nonsurgical management of unruptured ectopic pregnancy: an extended clinical trial, Fertil Steril 48:752, 1987.
272. **Barnhart K**, **Hummel AC**, **Sammel MD**, **Menon S**, **Jain J**, **Chakhtoura N**, Use of "2-dose" regimen of methotrexate to treat ectopic pregnancy, Fertil Steril 87:250, 2007.
273. **American College of Obstetricians and Gynecologists**, Prevention of Rh D isoimmunization, In: Practice Bulletin, American College of Obstetricians and Gynecologists, Washington, 2017. (Replaces Practice Bulletin Number 4, May 1999). Available at https://www.acog.org:443/Clinical-Guidance-and-Publications/Practice-Bulletins/Committee-on-Practice-Bulletins-Obstetrics/Prevention-of-Rh-D-Alloimmunization
274. **Fung Kee Fung K**, **Eason E**, **Crane J**, **Armson A**, **De La Ronde S**, **Farine D**, **Keenan-Lindsay L**, **Leduc L**, **Reid GJ**, **Aerde JV**, **Wilson RD**, **Davies G**, **Desilets VA**, **Summers A**, **Wyatt P**, **Young DC**, Prevention of Rh alloimmunization, J Obstet Gynaecol Can 25:765, 2003.
275. **Jabara S**, **Barnhart KT**, Is Rh immune globulin needed in early first-trimester abortion? A review, Am J Obstet Gynecol 188:623, 2003.
276. **Natale A**, **Candiani M**, **Barbieri M**, **Calia C**, **Odorizzi MP**, **Busacca M**, Pre- and post-treatment patterns of human chorionic gonadotropin for early detection of persistence after a single dose of methotrexate for ectopic pregnancy, Eur J Obstet Gynecol Reprod Biol 117:87, 2004.
277. **Brown DL**, **Felker RE**, **Stovall TG**, **Emerson DS**, **Ling FW**, Serial endovaginal sonography of ectopic pregnancies treated with methotrexate, Obstet Gynecol 77:406, 1991.
278. **Fauconnier A**, **Mabrouk A**, **Salomon LJ**, **Bernard JP**, **Ville Y**, Ultrasound assessment of haemoperitoneum in ectopic pregnancy: derivation of a prediction model, World J Emerg Surg 2:23, 2007.
279. **Lipscomb GH**, **Puckett KJ**, **Bran D**, **Ling FW**, Management of separation pain after single-dose methotrexate therapy for ectopic pregnancy, Obstet Gynecol 93:590, 1999.
280. **Stovall TG**, **Ling FW**, **Gray LA**, **Carson SA**, **Buster JE**, Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases, Obstet Gynecol 77:749, 1991.
281. **Lipscomb GH**, **Givens VM**, **Meyer NL**, **Bran D**, Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy, Am J Obstet Gynecol 192:1844, 2005.
282. **Alleyassin A**, **Khademi A**, **Aghahosseini M**, **Safdarian L**, **Badenoosh B**, **Hamed EA**, Comparison of success rates in the medical management of ectopic pregnancy with single-dose and multiple-dose administration of methotrexate: a prospective, randomized clinical trial, Fertil Steril 85:1661, 2006.

283. **Yang C**, **Cai J**, **Geng Y**, **Gao Y**, Multiple-dose and double-dose versus single-dose administration of methotrexate for the treatment of ectopic pregnancy: a systematic review and meta-analysis, Reprod Biomed Online 34(4):383, 2017. doi:10.1016/j.rbmo.2017.01.004.
284. **Song T**, **Kim MK**, **Kim ML**, **Jung YW**, **Yun BS**, **Seong SJ**, Single-dose versus two-dose administration of methotrexate for the treatment of ectopic pregnancy: a randomized controlled trial, Hum Reprod 31(2):332, 2016. doi:10.1093/humrep/dev312.
285. **Hamed HO**, **Ahmed SR**, **Alghasham AA**, Comparison of double- and single-dose methotrexate protocols for treatment of ectopic pregnancy, Int J Gynaecol Obstet 116(1):67, 2012.
286. **Yuk JS**, **Lee JH**, **Park WI**, **Ahn HS**, **Kim HJ**, Systematic review and meta-analysis of single-dose and non-single-dose methotrexate protocols in the treatment of ectopic pregnancy, Int J Gynaecol Obstet 141(3):295, 2018. doi:10.1002/ijgo.12473.
287. **Hajenius PJ**, **Engelsbel S**, **Mol BW**, **Van der Veen F**, **Ankum WM**, **Bossuyt PM**, **Hemrika DJ**, **Lammes FB**, Randomised trial of systemic methotrexate versus laparoscopic salpingostomy in tubal pregnancy, Lancet 350:774, 1997.
288. **Sowter MC**, **Farquhar CM**, **Petrie KJ**, **Gudex G**, A randomised trial comparing single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured tubal pregnancy, Br J Obstet Gynaecol 108:192, 2001.
289. **Elito J Jr**, **Han KK**, **Camano L**, Values of beta-human chorionic gonadotropin as a risk factor for tubal obstruction after tubal pregnancy, Acta Obstet Gynecol Scand 84:864, 2005.
290. **Bernoux A**, **Job-Spira N**, **Germain E**, **Coste J**, **Bouyer J**, Fertility outcome after ectopic pregnancy and use of an intrauterine device at the time of the index ectopic pregnancy, Hum Reprod 15:1173, 2000.
291. **Job-Spira N**, **Bouyer J**, **Pouly JL**, **Germain E**, **Coste J**, **Aublet-Cuvelier B**, **Fernandez H**, Fertility after ectopic pregnancy: first results of a population-based cohort study in France, Hum Reprod 11:99, 1996.
292. **al-Nuaim L**, **Bamgboye EA**, **Chowdhury N**, **Adelusi B**, Reproductive potential after an ectopic pregnancy, Fertil Steril 64:942, 1995.
293. **Gruft L**, **Bertola E**, **Luchini L**, **Azzilonna C**, **Bigatti G**, **Parazzini F**, Determinants of reproductive prognosis after ectopic pregnancy, Hum Reprod 9:1333, 1994.
294. **Pouly JL**, **Chapron C**, **Manhes H**, **Canis M**, **Wattiez A**, **Bruhat MA**, Multifactorial analysis of fertility after conservative laparoscopic treatment of ectopic pregnancy in a series of 223 patients, Fertil Steril 56:453, 1991.
295. **Sultana CJ**, **Easley K**, **Collins RL**, Outcome of laparoscopic versus traditional surgery for ectopic pregnancies, Fertil Steril 57:285, 1992.
296. **Ory SJ**, **Nnadi E**, **Herrmann R**, **O'Brien PS**, **Melton LJ III**, Fertility after ectopic pregnancy, Fertil Steril 60:231, 1993.
297. **Ego A**, **Subtil D**, **Cosson M**, **Legoueff F**, **Houfflin-Debarge V**, **Querleu D**, Survival analysis of fertility after ectopic pregnancy, Fertil Steril 75:560, 2001.
298. **Gervaise A**, **Masson L**, **de Tayrac R**, **Frydman R**, **Fernandez H**, Reproductive outcome after methotrexate treatment of tubal pregnancies, Fertil Steril 82:304, 2004.
299. **Pektasides D**, **Rustin GJ**, **Newlands ES**, **Begent RH**, **Bagshawe KD**, Fertility after chemotherapy for ovarian germ cell tumours, Br J Obstet Gynaecol 94:477, 1987.
300. **Ayhan A**, **Ergeneli MH**, **Yuce K**, **Yapar EG**, **Kisnisci AH**, Pregnancy after chemotherapy for gestational trophoblastic disease, J Reprod Med 35:522, 1990.
301. **Keefe KA**, **Wald JS**, **Goldstein DP**, **Bernstein M**, **Berkowitz RS**, Reproductive outcome after methotrexate treatment of tubal pregnancies, J Reprod Med 43:28, 1998.
302. **Kung FT**, **Chang SY**, **Tsai YC**, **Hwang FR**, **Hsu TY**, **Soong YK**, Subsequent reproduction and obstetric outcome after methotrexate treatment of cervical pregnancy: a review of original literature and international collaborative follow-up, Hum Reprod 12:591, 1997.
303. **Oriol B**, **Barrio A**, **Pacheco A**, **Serna J**, **Zuzuarregui JL**, **Garcia-Velasco JA**, Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve, Fertil Steril 90:1579, 2008.
304. **Morlock RJ**, **Lafata JE**, **Eisenstein D**, Cost-effectiveness of single-dose methotrexate compared with

laparoscopic treatment of ectopic pregnancy, Obstet Gynecol 95:407, 2000.
305. **Nieuwkerk PT**, **Hajenius PJ**, **Van der Veen F**, **Ankum WM**, **Wijker W**, **Bossuyt PM**, Systemic methotrexate therapy versus laparoscopic salpingostomy in tubal pregnancy. Part II. Patient preferences for systemic methotrexate, Fertil Steril 70:518, 1998.
306. **Fernandez H**, **Yves Vincent SC**, **Pauthier S**, **Audibert F**, **Frydman R**, Randomized trial of conservative laparoscopic treatment and methotrexate administration in ectopic pregnancy and subsequent fertility, Hum Reprod 13:3239, 1998.
307. **Nieuwkerk PT**, **Hajenius PJ**, **Ankum WM**, **Van der Veen F**, **Wijker W**, **Bossuyt PM**, Systemic methotrexate therapy versus laparoscopic salpingostomy in patients with tubal pregnancy. Part I. Impact on patients' health-related quality of life, Fertil Steril 70:511, 1998.
308. **Cohen DR**, **Falcone T**, **Khalife S**, Methotrexate: local versus intramuscular, Fertil Steril 65:206, 1996.
309. **Schiff E**, **Shalev E**, **Bustan M**, **Tsafari A**, **Mashiach S**, **Winer E**, Pharmacokinetics of methotrexate after local tubal injection for conservative treatment of ectopic pregnancy, Fertil Steril 57:688, 1992.
310. **Doubilet PM**, **Benson CB**, **Frates MC**, **Ginsburg E**, Sonographically guided minimally invasive treatment of unusual ectopic pregnancies, J Ultrasound Med 23:359, 2004.
311. **Brumsted J**, **Kessler C**, **Gibson C**, **Nakajima S**, **Riddick DH**, **Gibson M**, A comparison of laparoscopy and laparotomy for the treatment of ectopic pregnancy, Obstet Gynecol 71:889, 1988.
312. **Silva PD**, A laparoscopic approach can be applied to most cases of ectopic pregnancy, Obstet Gynecol 72:944, 1988.
313. **Vermesh M**, **Silva PD**, **Rosen GF**, **Stein AL**, **Fossum GT**, **Sauer MV**, Management of unruptured ectopic gestation by linear salpingostomy: a prospective, randomized clinical trial of laparoscopy versus laparotomy, Obstet Gynecol 73:400, 1989.
314. **Lundorff P**, **Thorburn J**, **Hahlin M**, **Kallfelt B**, **Lindblom B**, Laparoscopic surgery in ectopic pregnancy. A randomized trial versus laparotomy, Acta Obstet Gynecol Scand 70:343, 1991.
315. **Lundorff P**, **Hahlin M**, **Kallfelt B**, **Thorburn J**, **Lindblom B**, Adhesion formation after laparoscopic surgery in tubal pregnancy: a randomized trial versus laparotomy, Fertil Steril 55:911, 1991.
316. **Murphy AA**, **Nager CW**, **Wujek JJ**, **Kettel LM**, **Torp VA**, **Chin HG**, Operative laparoscopy versus laparotomy for the management of ectopic pregnancy: a prospective trial, Fertil Steril 57:1180, 1992.
317. **Gray DT**, **Thorburn J**, **Lundorff P**, **Strandell A**, **Lindblom B**, A cost-effectiveness study of a randomised trial of laparoscopy versus laparotomy for ectopic pregnancy, Lancet 345:1139, 1995.
318. **Lundorff P**, **Thorburn J**, **Lindblom B**, Fertility outcome after conservative surgical treatment of ectopic pregnancy evaluated in a randomized trial, Fertil Steril 57:998, 1992.
319. **Ugur M**, **Yesilyurt H**, **Soysal S**, **Gokmen O**, Prophylactic vasopressin during laparoscopic salpingotomy for ectopic pregnancy, J Am Assoc Gynecol Laparosc 3:365, 1996.
320. **Fedele L**, **Bianchi S**, **Tozzi L**, **Zanconato G**, **Silvestre V**, Intramesosalpingeal injection of oxytocin in conservative laparoscopic treatment for tubal pregnancy: preliminary results, Hum Reprod 13:3042, 1998.
321. **Tulandi T**, **Guralnick M**, Treatment of tubal ectopic pregnancy by salpingotomy with or without tubal suturing and salpingectomy, Fertil Steril 55:53, 1991.
322. **Milad MP**, **Klein E**, **Kazer RR**, Preoperative serum hCG level and intraoperative failure of laparoscopic linear salpingostomy for ectopic pregnancy, Obstet Gynecol 92:373, 1998.
323. **Cheng X**, **Tian X**, **Yan Z**, **Jia M**, **Deng J**, **Wang Y**, **Fan D**, Comparison of the fertility outcome of salpingotomy and salpingectomy in women with tubal pregnancy: a systematic review and meta-analysis, PLoS One 11(3):e0152343, 2016. doi:10.1371/journal.pone.0152343.
324. **Sherman D**, **Langer R**, **Herman A**, **Bukovsky I**, **Caspi E**, Reproductive outcome after fimbrial evacuation of tubal pregnancy, Fertil Steril 47:420, 1987.
325. **Tuomivaara L**, **Kauppila A**, Radical or conservative surgery for ectopic pregnancy? A follow-up study of fertility of 323 patients, Fertil Steril 50:580, 1988.
326. **Bangsgaard N**, **Lund CO**, **Ottesen B**, **Nilas L**, Improved fertility following conservative surgical treatment of ectopic pregnancy, BJOG 110:765, 2003.
327. **Seifer DB**, Persistent ectopic pregnancy: an argument for heightened vigilance and patient compliance, Fertil

Steril 68:402, 1997.
328. **Kelly RW**, **Martin SA**, **Strickler RC**, Delayed hemorrhage in conservative surgery for ectopic pregnancy, Am J Obstet Gynecol 133:225, 1979.
329. **Seifer DB**, **Gutmann JN**, **Doyle MB**, **Jones EE**, **Diamond MP**, **DeCherney AH**, Persistent ectopic pregnancy following laparoscopic linear salpingostomy, Obstet Gynecol 76:1121, 1990.
330. **Seifer DB**, **Diamond MP**, **DeCherney AH**, Persistent ectopic pregnancy, Obstet Gynecol Clin North Am 18:153, 1991.
331. **Seifer DB**, **Gutmann JN**, **Grant WD**, **Kamps CA**, **DeCherney AH**, Comparison of persistent ectopic pregnancy after laparoscopic salpingostomy versus salpingostomy at laparotomy for ectopic pregnancy, Obstet Gynecol 81:378, 1993.
332. **Hajenius PJ**, **Mol BW**, **Ankum WM**, **van der Veen F**, **Bossuyt PM**, **Lammes FB**, Clearance curves of serum human chorionic gonadotrophin for the diagnosis of persistent trophoblast, Hum Reprod 10:683, 1995.
333. **DiMarchi JM**, **Kosasa TS**, **Kobara TY**, **Hale RW**, Persistent ectopic pregnancy, Obstet Gynecol 70:555, 1987.
334. **Nathorst-Boos J**, **Rafik Hamad R**, Risk factors for persistent trophoblastic activity after surgery for ectopic pregnancy, Acta Obstet Gynecol Scand 83:471, 2004.
335. **Goldstein JS**, **Ratts VS**, **Philpott T**, **Dahan MH**, Risk of surgery after use of potassium chloride for treatment of tubal heterotopic pregnancy, Obstet Gynecol 107:506, 2006.
336. **Graczykowski JW**, **Mishell DR Jr**, Methotrexate prophylaxis for persistent ectopic pregnancy after conservative treatment by salpingostomy, Obstet Gynecol 89:118, 1997.
337. **Spandorfer SD**, **Sawin SW**, **Benjamin I**, **Barnhart KT**, Postoperative day 1 serum human chorionic gonadotropin level as a predictor of persistent ectopic pregnancy after conservative surgical management, Fertil Steril 68:430, 1997.
338. **Hoppe DE**, **Bekkar BE**, **Nager CW**, Single-dose systemic methotrexate for the treatment of persistent ectopic pregnancy after conservative surgery, Obstet Gynecol 83:51, 1994.
339. **Gracia CR**, **Brown HA**, **Barnhart KT**, Prophylactic methotrexate after linear salpingostomy: a decision analysis, Fertil Steril 76:1191, 2001.
340. **Seifer DB**, **Silva PD**, **Grainger DA**, **Barber SR**, **Grant WD**, **Gutmann JN**, Reproductive potential after treatment for persistent ectopic pregnancy, Fertil Steril 62:194, 1994.
341. **Pisarska MD**, **Casson PR**, **Moise KJ Jr**, **DiMaio DJ**, **Buster JE**, **Carson SA**, Heterotopic abdominal pregnancy treated at laparoscopy, Fertil Steril 70:159, 1998.
342. **Barrenetxea G**, **Barinaga-Rementeria L**, **Lopez de Larruzea A**, **Agirregoikoa JA**, **Mandiola M**, **Carbonero K**, Heterotopic pregnancy: two cases and a comparative review, Fertil Steril 87:417 e9, 2007.
343. **Habana A**, **Dokras A**, **Giraldo JL**, **Jones EE**, Cornual heterotopic pregnancy: contemporary management options, Am J Obstet Gynecol 182:1264, 2000.
344. **Hsieh BC**, **Hwang JL**, **Pan HS**, **Huang SC**, **Chen CY**, **Chen PH**, Heterotopic Caesarean scar pregnancy combined with intrauterine pregnancy successfully treated with embryo aspiration for selective embryo reduction: case report, Hum Reprod 19:285, 2004.
345. **Shojai R**, **Chaumoitre K**, **Chau C**, **Panuel M**, **Boubli L**, **d'Ercole C**, Advanced combined abdominal and intrauterine pregnancy: a case report, Fetal Diagn Ther 22:128, 2007.
346. **Hassiakos D**, **Bakas P**, **Pistofidis G**, **Creatsas G**, Heterotopic pregnancy at 16 weeks of gestation after in-vitro fertilization and embryo transfer, Arch Gynecol Obstet 266:124, 2002.
347. **Tal J**, **Haddad S**, **Gordon N**, **Timor-Tritsch I**, Heterotopic pregnancy after ovulation induction and assisted reproductive technologies: a literature review from 1971 to 1993, Fertil Steril 66:1, 1996.
348. **Cheng PJ**, **Chueh HY**, **Qiu JT**, Heterotopic pregnancy in a natural conception cycle presenting as hematometra, Obstet Gynecol 104:1195, 2004.
349. **Clayton HB**, **Schieve LA**, **Peterson HB**, **Jamieson DJ**, **Reynolds MA**, **Wright VC**, A comparison of heterotopic and intrauterine-only pregnancy outcomes after assisted reproductive technologies in the United States from 1999 to 2002, Fertil Steril 87:303, 2007.
350. **Oyawoye S**, **Chander B**, **Pavlovic B**, **Hunter J**, **Gadir AA**, Heterotopic pregnancy: successful management

with aspiration of cornual/interstitial gestational sac and instillation of small dose of methotrexate, Fetal Diagn Ther 18:1, 2003.
351. **Salomon LJ**, **Fernandez H**, **Chauveaud A**, **Doumerc S**, **Frydman R**, Successful management of a heterotopic Caesarean scar pregnancy: potassium chloride injection with preservation of the intrauterine gestation: case report, Hum Reprod 18:189, 2003.
352. **Strohmer H**, **Obruca A**, **Lehner R**, **Egarter C**, **Husslein P**, **Feichtinger W**, Successful treatment of a heterotopic pregnancy by sonographically guided instillation of hyperosmolar glucose, Fertil Steril 69:149, 1998.
353. **Goldberg JM**, **Bedaiwy MA**, Transvaginal local injection of hyperosmolar glucose for the treatment of heterotopic pregnancies, Obstet Gynecol 107:509, 2006.
354. **Funamizu A**, **Fukui A**, **Fukuhara R**, **Kobayashi A**, **Chiba H**, **Matsumura Y**, **Ito A**, **Mizunuma H**, A case of bilateral tubal pregnancy, Gynecol Minim Invasive Ther 6(4):191, 2017. doi:10.1016/j.gmit.2017.05.003.
355. **Sugawara N**, **Sato R**, **Kato M**, **Manome T**, **Kimura Y**, **Araki Y**, **Araki Y**, Bilateral tubal pregnancies after a single-embryo transfer, Reprod Med Biol 16(4):396, 2017. doi:10.1002/rmb2.12053.
356. **Xu H**, A spontaneous bilateral tubal pregnancy: a case report, Medicine (Baltimore) 97(38):e12365, 2018.
357. **Atrash HK**, **Friede A**, **Hogue CJ**, Abdominal pregnancy in the United States: frequency and maternal mortality, Obstet Gynecol 69:333, 1987.
358. **Fisch B**, **Peled Y**, **Kaplan B**, **Zehavi S**, **Neri A**, Abdominal pregnancy following in vitro fertilization in a patient with previous bilateral salpingectomy, Obstet Gynecol 88:642, 1996.
359. **Rahman MS**, **Al-Suleiman SA**, **Rahman J**, **Al-Sibai MH**, Advanced abdominal pregnancy—observations in 10 cases, Obstet Gynecol 59:366, 1982.
360. **Lamina MA**, **Akinyemi BO**, **Fakoya TA**, **Shorunmu TO**, **Oladapo OT**, Abdominal pregnancy: a cause of failed induction of labour, Niger J Med 14:213, 2005.
361. **Varma R**, **Mascarenhas L**, **James D**, Successful outcome of advanced abdominal pregnancy with exclusive omental insertion, Ultrasound Obstet Gynecol 21:192, 2003.
362. **Morita Y**, **Tsutsumi O**, **Kuramochi K**, **Momoeda M**, **Yoshikawa H**, **Taketani Y**, Successful laparoscopic management of primary abdominal pregnancy, Hum Reprod 11:2546, 1996.
363. **Gerli S**, **Rossetti D**, **Baiocchi G**, **Clerici G**, **Unfer V**, **Di Renzo GC**, Early ultrasonographic diagnosis and laparoscopic treatment of abdominal pregnancy, Eur J Obstet Gynecol Reprod Biol 113:103, 2004.
364. **Zinger M**, **Rosenfeld D**, Failed treatment of abdominal pregnancy with methotrexate. A case report, J Reprod Med 46:392, 2001.
365. **Beddock R**, **Naepels P**, **Gondry C**, **Besserve P**, **Camier B**, **Boulanger JC**, **Gondry J**, [Diagnosis and current concepts of management of advanced abdominal pregnancy], Gynecol Obstet Fertil 32:55, 2004.
366. **Martin JN Jr**, **Sessums JK**, **Martin RW**, **Pryor JA**, **Morrison JC**, Abdominal pregnancy: current concepts of management, Obstet Gynecol 71:549, 1988.
367. **Oki T**, **Baba Y**, **Yoshinaga M**, **Douchi T**, Super-selective arterial embolization for uncontrolled bleeding in abdominal pregnancy, Obstet Gynecol 112:427, 2008.
368. **Rahaman J**, **Berkowitz R**, **Mitty H**, **Gaddipati S**, **Brown B**, **Nezhat F**, Minimally invasive management of an advanced abdominal pregnancy, Obstet Gynecol 103:1064, 2004.
369. **Cardosi RJ**, **Nackley AC**, **Londono J**, **Hoffman MS**, Embolization for advanced abdominal pregnancy with a retained placenta. A case report, J Reprod Med 47:861, 2002.
370. **Hallatt JG**, Primary ovarian pregnancy: a report of twenty-five cases, Am J Obstet Gynecol 143:55, 1982.
371. **Grimes HG**, **Nosal RA**, **Gallagher JC**, Ovarian pregnancy: a series of 24 cases, Obstet Gynecol 61:174, 1983.
372. **Sinha P**, **Wissa IM**, Ovarian pregnancy simulating a haemorrhagic corpus luteum, J Obstet Gynaecol 24:197, 2004.
373. **Adeniran A**, **Stanek J**, Ovarian pregnancy, Arch Pathol Lab Med 127:1635, 2003.
374. **Shamma FN**, **Schwartz LB**, Primary ovarian pregnancy successfully treated with methotrexate, Am J Obstet Gynecol 167:1307, 1992.
375. **Raziel A**, **Golan A**, Primary ovarian pregnancy successfully treated with methotrexate, Am J Obstet Gynecol 169:1362, 1993.

376. **Habbu J**, **Read MD**, Ovarian pregnancy successfully treated with methotrexate, J Obstet Gynaecol 26:587, 2006.
377. **Tulandi T**, **Al-Jaroudi D**, Interstitial pregnancy: results generated from the Society of Reproductive Surgeons Registry, Obstet Gynecol 103:47, 2004.
378. **Ackerman TE**, **Levi CS**, **Dashefsky SM**, **Holt SC**, **Lindsay DJ**, Interstitial line: sonographic finding in interstitial (cornual) ectopic pregnancy, Radiology 189:83, 1993.
379. **Timor-Tritsch IE**, **Monteagudo A**, **Matera C**, **Veit CR**, Sonographic evolution of cornual pregnancies treated without surgery, Obstet Gynecol 79:1044, 1992.
380. **Jansen RP**, **Elliott PM**, Angular intrauterine pregnancy, Obstet Gynecol 58:167, 1981.
381. **Lau S**, **Tulandi T**, Conservative medical and surgical management of interstitial ectopic pregnancy, Fertil Steril 72:207, 1999.
382. **Moon HS**, **Choi YJ**, **Park YH**, **Kim SG**, New simple endoscopic operations for interstitial pregnancies, Am J Obstet Gynecol 182:114, 2000.
383. **Moawad NS**, **Mahajan ST**, **Moniz MH**, **Taylor SE**, **Hurd WW**, Current diagnosis and treatment of interstitial pregnancy, Am J Obstet Gynecol 202:15, 2010.
384. **Jermy K**, **Thomas J**, **Doo A**, **Bourne T**, The conservative management of interstitial pregnancy, Br J Obstet Gynaecol 111:1283, 2004.
385. **Meyer WR**, **Mitchell DE**, Hysteroscopic removal of an interstitial ectopic gestation. A case report, J Reprod Med 34:928, 1989.
386. **Budnick SG**, **Jacobs SL**, **Nulsen JC**, **Metzger DA**, Conservative management of interstitial pregnancy, Obstet Gynecol Surv 48:694, 1993.
387. **Deruelle P**, **Lucot JP**, **Lions C**, **Robert Y**, Management of interstitial pregnancy using selective uterine artery embolization, Obstet Gynecol 106:1165, 2005.
388. **Ophir E**, **Singer-Jordan J**, **Oettinger M**, **Odeh M**, **Tendler R**, **Feldman Y**, **Fait V**, **Bornstein J**, Uterine artery embolization for management of interstitial twin ectopic pregnancy: case report, Hum Reprod 19:1774, 2004.
389. **Benifla JL**, **Fernandez H**, **Sebban E**, **Darai E**, **Frydman R**, **Madelenat P**, Alternative to surgery of treatment of unruptured interstitial pregnancy: 15 cases of medical treatment, Eur J Obstet Gynecol Reprod Biol 70:151, 1996.
390. **Weissman A**, **Fishman A**, Uterine rupture following conservative surgery for interstitial pregnancy, Eur J Obstet Gynecol Reprod Biol 44:237, 1992.
391. **Downey GP**, **Tuck SM**, Spontaneous uterine rupture during subsequent pregnancy following non-excision of an interstitial ectopic gestation, Br J Obstet Gynaecol 101:162, 1994.
392. **Ushakov FB**, **Elchalal U**, **Aceman PJ**, **Schenker JG**, Cervical pregnancy: past and future, Obstet Gynecol Surv 52:45, 1997.
393. **Vela G**, **Tulandi T**, Cervical pregnancy: the importance of early diagnosis and treatment, J Minim Invasive Gynecol 14:481, 2007.
394. **Karande VC**, **Flood JT**, **Heard N**, **Veeck L**, **Muasher SJ**, Analysis of ectopic pregnancies resulting from in-vitro fertilization and embryo transfer, Hum Reprod 6:446, 1991.
395. **Hofmann HM**, **Urdl W**, **Hofler H**, **Honigl W**, **Tamussino K**, Cervical pregnancy: case reports and current concepts in diagnosis and treatment, Arch Gynecol Obstet 241:63, 1987.
396. **Kung FT**, **Lin H**, **Hsu TY**, **Chang CY**, **Huang HW**, **Huang LY**, **Chou YJ**, **Huang KH**, Differential diagnosis of suspected cervical pregnancy and conservative treatment with the combination of laparoscopy-assisted uterine artery ligation and hysteroscopic endocervical resection, Fertil Steril 81:1642, 2004.
397. **Jurkovic D**, **Hacket E**, **Campbell S**, Diagnosis and treatment of early cervical pregnancy: a review and a report of two cases treated conservatively, Ultrasound Obstet Gynecol 8:373, 1996.
398. **Monteagudo A**, **Tarricone NJ**, **Timor-Tritsch IE**, **Lerner JP**, Successful transvaginal ultrasound-guided puncture and injection of a cervical pregnancy in a patient with simultaneous intrauterine pregnancy and a history of a previous cervical pregnancy, Ultrasound Obstet Gynecol 8:381, 1996.
399. **Cepni I**, **Ocal P**, **Erkan S**, **Erzik B**, Conservative treatment of cervical ectopic pregnancy with transvaginal

ultrasound-guided aspiration and single-dose methotrexate, Fertil Steril 81:1130, 2004.
400. **Mesogitis S**, **Pilalis A**, **Daskalakis G**, **Papantoniou N**, **Antsaklis A**, Management of early viable cervical pregnancy, Br J Obstet Gynaecol 112:409, 2005.
401. **Kirk E**, **Condous G**, **Haider Z**, **Syed A**, **Ojha K**, **Bourne T**, The conservative management of cervical ectopic pregnancies, Ultrasound Obstet Gynecol 27:430, 2006.
402. **Jeng CJ**, **Ko ML**, **Shen J**, Transvaginal ultrasound-guided treatment of cervical pregnancy, Obstet Gynecol 109:1076, 2007.
403. **Frates MC**, **Benson CB**, **Doubilet PM**, **Di Salvo DN**, **Brown DL**, **Laing FC**, **Rein MS**, **Osathanondh R**, Cervical ectopic pregnancy: results of conservative treatment, Radiology 191:773, 1994.
404. **Suzumori N**, **Katano K**, **Sato T**, **Okada J**, **Nakanishi T**, **Muto D**, **Suzuki Y**, **Ikuta K**, **Suzumori K**, Conservative treatment by angiographic artery embolization of an 11-week cervical pregnancy after a period of heavy bleeding, Fertil Steril 80:617, 2003.
405. **Hajenius PJ**, **Roos D**, **Ankum WM**, **Van der Veen F**, Are serum human chorionic gonadotropin clearance curves of use in monitoring methotrexate treatment in cervical pregnancy?, Fertil Steril 70:362, 1998.
406. **Lee CL**, **Wang CJ**, **Chao A**, **Yen CF**, **Soong YK**, Laparoscopic management of an ectopic pregnancy in a previous Caesarean section scar, Hum Reprod 14:1234, 1999.
407. **Rotas MA**, **Haberman S**, **Levgur M**, Cesarean scar ectopic pregnancies: etiology, diagnosis, and management, Obstet Gynecol 107:1373, 2006.
408. **Valley MT**, **Pierce JG**, **Daniel TB**, **Kaunitz AM**, Cesarean scar pregnancy: imaging and treatment with conservative surgery, Obstet Gynecol 91:838, 1998.
409. **Fylstra DL**, Ectopic pregnancy within a cesarean scar: a review, Obstet Gynecol Surv 57(8):537, 2002.
410. **Timor-Tritsch IE**, **Monteagudo A**, Unforeseen consequences of the increasing rate of cesarean deliveries: early placenta accreta and cesarean scar pregnancy. A review, Am J Obstet Gynecol 207(1):14, 2012. doi:10.1016/j.ajog.2012.03.007. Erratum in: Am J Obstet Gynecol 210(4):371, 2014.
411. **Ash A**, **Smith A**, **Maxwell D**, Caesarean scar pregnancy, Br J Obstet Gynaecol 114:253, 2007.
412. **Osborn DA**, **Williams TR**, **Craig BM**, Cesarean scar pregnancy: sonographic and magnetic resonance imaging findings, complications, and treatment, J Ultrasound Med 31(9):1449, 2012.
413. **Maymon R**, **Svirsky R**, **Smorgick N**, **Mendlovic S**, **Halperin R**, **Gilad K**, **Tovbin J**, Fertility performance and obstetric outcomes among women with previous cesarean scar pregnancy, J Ultrasound Med 30(9):1179, 2011.
414. **Ouyang Y**, **Li X**, **Yi Y**, **Gong F**, **Lin G**, **Lu G**, First-trimester diagnosis and management of cesarean scar pregnancies after in vitro fertilization-embryo transfer: a retrospective clinical analysis of 12 cases, Reprod Biol Endocrinol 13: 126, 2015.
415. **Graesslin O**, **Dedecker F Jr**, **Quereux C**, **Gabriel R**, Conservative treatment of ectopic pregnancy in a cesarean scar, Obstet Gynecol 105:869, 2005.
416. **Armstrong V**, **Hansen WF**, **Van Voorhis BJ**, **Syrop CH**, Detection of cesarean scars by transvaginal ultrasound, Obstet Gynecol 101:61, 2003.
417. **Ofili-Yebovi D**, **Ben-Nagi J**, **Sawyer E**, **Yazbek J**, **Lee C**, **Gonzalez J**, **Jurkovic D**, Deficient lower-segment Cesarean section scars: prevalence and risk factors, Ultrasound Obstet Gynecol 31:72, 2008.
418. **Calì G**, **Timor-Tritsch IE**, **Palacios-Jaraquemada J**, **Monteaugudo A**, **Buca D**, **Forlani F**, **Familiari A**, **Scambia G**, **Acharya G**, **D'Antonio F**, Outcome of cesarean scar pregnancy managed expectantly: systematic review and meta-analysis, Ultrasound Obstet Gynecol 51(2):169, 2018. doi:10.1002/uog.17568.
419. **Birch Petersen K**, **Hoffmann E**, **Rifbjerg Larsen C**, **Svarre Nielsen H**, Cesarean scar pregnancy: a systematic review of treatment studies, Fertil Steril 105(4):958, 2016. doi:10.1016/j.fertnstert.2015.12.130.
420. **Jurkovic D**, **Hillaby K**, **Woelfer B**, **Lawrence A**, **Salim R**, **Elson CJ**, First-trimester diagnosis and management of pregnancies implanted into the lower uterine segment Cesarean section scar, Ultrasound Obstet Gynecol 21:220, 2003.
421. **Sugawara J**, **Senoo M**, **Chisaka H**, **Yaegashi N**, **Okamura K**, Successful conservative treatment of a cesarean scar pregnancy with uterine artery embolization, Tohoku J Exp Med 206:261, 2005.
422. **Yang MJ**, **Jeng MH**, Combination of transarterial embolization of uterine arteries and conservative surgical

treatment for pregnancy in a cesarean section scar. A report of 3 cases, J Reprod Med 48:213, 2003.
423. **Chou MM**, **Hwang JI**, **Tseng JJ**, **Huang YF**, **Ho ES**, Cesarean scar pregnancy: quantitative assessment of uterine neovascularization with 3-dimensional color power Doppler imaging and successful treatment with uterine artery embolization, Am J Obstet Gynecol 190:866, 2004.
424. **Zhuang Y**, **Huang L**, Uterine artery embolization compared with methotrexate for the management of pregnancy implanted within a cesarean scar, Am J Obstet Gynecol 201:152 e1, 2009.
425. **Timor-Tritsch IE**, **Monteagudo A**, **Bennett TA**, **Foley C**, **Ramos J**, **Kaelin Agten A**, A new minimally invasive treatment for cesarean scar pregnancy and cervical pregnancy, Am J Obstet Gynecol 215(3):351.e1, 2016. doi:10.1016/j.ajog.2016.03.010.
426. **Timor-Tritsch IE**, **Monteagudo A**, **Kaelin Agten A**, Recap—minimally invasive treatment for cesarean scar pregnancy using a double-balloon catheter: additional suggestions to the technique, Am J Obstet Gynecol 217(4):496, 2017.
427. **Zosmer N**, **Fuller J**, **Shaikh H**, **Johns J**, **Ross JA**, Natural history of early first-trimester pregnancies implanted in cesarean scars, Ultrasound Obstet Gynecol 46(3):367, 2015. doi:10.1002/uog.14775.
428. **Timor-Tritsch IE**, **Monteagudo A**, **Cali G**, **Vintzileos A**, **Viscarello R**, **Al-Khan A**, **Zamudio S**, **Mayberry P**, **Cordoba MM**, **Dar P**, Cesarean scar pregnancy is a precursor of morbidly adherent placenta, Ultrasound Obstet Gynecol 44(3):346, 2014. doi:10.1002/uog.13426.
429. **Seow KM**, **Huang LW**, **Lin YH**, **Lin MY**, **Tsai YL**, **Hwang JL**, Cesarean scar pregnancy: issues in management, Ultrasound Obstet Gynecol 23:247, 2004.
430. **Seow KM**, **Hwang JL**, **Tsai YL**, **Huang LW**, **Lin YH**, **Hsieh BC**, Subsequent pregnancy outcome after conservative treatment of a previous cesarean scar pregnancy, Acta Obstet Gynecol Scand 83:1167, 2004.
431. **Ben Nagi J**, **Helmy S**, **Ofili-Yebovi D**, **Yazbek J**, **Sawyer E**, **Jurkovic D**, Reproductive outcomes of women with a previous history of Caesarean scar ectopic pregnancies, Hum Reprod 22:2012, 2007.
432. **Gao L**, **Huang Z**, **Zhang X**, **Zhou N**, **Huang X**, **Wang X**, Reproductive outcomes following cesarean scar pregnancy—a case series and review of the literature, Eur J Obstet Gynecol Reprod Biol 200:102, 2016. doi:10.1016/j.ejogrb.2016.02.039.
433. **Wang Q**, **Peng HL**, **He L**, **Zhao X**, Reproductive outcomes after previous cesarean scar pregnancy: follow up of 189 women, Taiwan J Obstet Gynecol 54(5):551, 2015.
434. **Rosen T**, Placenta accreta and cesarean scar pregnancy: overlooked costs of the rising cesarean section rate, Clin Perinatol 35:519, 2008.